FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Aghili, SM
   Shahjooie, F
   Moghadam, MA
   Khazaeipour, Z
   Vaseie, M
   Kia, M
AF Aghili, Seyed Mojtaba
   Shahjooie, Fahime
   Moghadam, Mohammad Afzali
   Khazaeipour, Zahra
   Vaseie, Mohammad
   Kia, Maryam
TI RELATIONSHIP BETWEEN THE DEGREE OF DEHYDRATION IN EMERGENCY MEDICINE
   RESIDENTS AT THE BEGINNING AND END OF CLINICAL SHIFTS WITH COGNITIVE
   PERFORMANCE, MOOD, AND ANXIETY AT EMAM KHOMEINI HOSPITAL (JUNE 2016
   UNTIL THE END OF THE SAME YEAR)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE dehydration; concentration; cognitive performance; mood; anxiet
ID MILD DEHYDRATION; RISK-FACTOR; HYDRATION; IMPAIRS; WORKERS; DRINK; HEAT
AB Study's background and aim: The physical condition of emergency department (ED) residents plays an important role in decision making for diagnosis and treatment of the patient, and any problem in their physical status may lead to irreparable medical errors; thus, an investigation in to dehydration and its effects on cognitive performance is needed.
   Materials and methods: A cross-sectional study was performed in 44 ED residents. Urine sample of all individuals were collected at the beginning and end of shifts. Residents' weight, weight changes, and vital signs were measured at the beginning and end of their shifts. Participants were asked about the amount of sleep acquired before and the amount of food and water intake during shifts. Mood and anxiety as well as cognitive behavior were assessed before and after shifts.
   Results: Urine specific gravity (P<0.001) increased significantly during a shift. Residents' weight (P=0.024) and percentage concentration of urine (P=0.001) were significantly lower after a shift than before a shift. Emergency crowding and percentage of concentration after a shift (P<0.001), emergency crowding and concentration changes (P<0.001), and also the amount of water intake and urine specific gravity after a shift (P=0.01) demonstrated significant negative correlations, while emergency crowding and urine specific gravity before (P<0.001) and after (P<0.001) a shift and also emergency crowding and urine specific gravity changes(P=0.024) demonstrated a significant positive correlations.
   Conclusions: It seems necessary that residents be much more conscientious about fluid intake during shifts and set aside some time to consume fluids in order to prevent impaired decision-making and decrease possible medical errors.
C1 [Aghili, Seyed Mojtaba; Moghadam, Mohammad Afzali] Univ Tehran Med Sci, Imam Khomeini Hosp, Emergency Dept, Emergency Med, Tehran, Iran.
   [Shahjooie, Fahime; Vaseie, Mohammad] Univ Tehran Med Sci, Imam Khomeini Hosp, Emergency Dept, Tehran, Iran.
   [Khazaeipour, Zahra] Univ Tehran Med Sci, Brain & Spinal Cord Injury Res Ctr, Neurosci Inst, Tehran, Iran.
   [Kia, Maryam] Univ Tehran Med Sci, Ziaeian Hosp, Internal Med Dept, Internal Med, Tehran, Iran.
RP Kia, M (corresponding author), Univ Tehran Med Sci, Ziaeian Hosp, Internal Med Dept, Internal Med, Tehran, Iran.
EM m-kia@tums.ac.ir
RI Shahjooie, Fahime/AAE-7008-2020; kia, maryam/ABE-2631-2020; Aghili,
   Seyed Mojtaba/J-9092-2017; Vaseie, Mohammad/AAH-2434-2019
OI Aghili, Seyed Mojtaba/0000-0003-2931-6159; 
CR Armstrong LE, 2012, J NUTR, V142, P382, DOI 10.3945/jn.111.142000
   Arnaud MJ, 2003, EUR J CLIN NUTR, V57, pS88, DOI 10.1038/sj.ejcn.1601907
   Baker LB, 2007, MED SCI SPORT EXER, V39, P976, DOI 10.1097/mss.0b013e3180471ff2
   Benton D, 2011, NUTRIENTS, V3, P555, DOI 10.3390/nu3050555
   Brake R., 2001, QUEENSL MIN IND OCC
   Clapp AJ, 2002, AIHAJ, V63, P190, DOI 10.1202/0002-8894(2002)063<0190:AROFRF>2.0.CO;2
   D'Anci KE, 2009, PERCEPT MOTOR SKILL, V109, P251, DOI 10.2466/PMS.109.1.251-269
   Dougherty KA, 2006, MED SCI SPORT EXER, V38, P1650, DOI 10.1249/01.mss.0000227640.60736.8e
   Ganio MS, 2011, BRIT J NUTR, V106, P1535, DOI 10.1017/S0007114511002005
   Gray Mikel, 2003, J Wound Ostomy Continence Nurs, V30, P126, DOI 10.1067/mjw.2003.117
   Hills P, 2002, PERS INDIV DIFFER, V33, P1073, DOI 10.1016/S0191-8869(01)00213-6
   Kalhoff H, 2003, EUR J CLIN NUTR, V57, pS81, DOI 10.1038/sj.ejcn.1601906
   Kavouras SA, 2002, CURR OPIN CLIN NUTR, V5, P519, DOI 10.1097/00075197-200209000-00010
   Kenefick RW, 2007, J AM COLL NUTR, V26, p597S, DOI 10.1080/07315724.2007.10719665
   Lawlor DA, 2006, AM J EPIDEMIOL, V163, P608, DOI 10.1093/aje/kwj085
   Lieberman HR, 2005, BIOL PSYCHIAT, V57, P422, DOI 10.1016/j.biopsych.2004.11.014
   Manz F, 2005, NUTR REV, V63, pS2, DOI [10.1111/j.1753-4887.2005.tb00150.x, 10.1301/nr.2005.jun.S2-S5]
   Maughan RJ, 2003, EUR J CLIN NUTR, V57, pS19, DOI 10.1038/sj.ejcn.1601897
   Mentes J, 2006, AM J NURS, V106, P40, DOI 10.1097/00000446-200606000-00023
   Niemann A., 2012, EFFECT INSTRUMENT TY
   SHARMA VM, 1986, ERGONOMICS, V29, P791, DOI 10.1080/00140138608968315
   Siener R, 2003, EUR J CLIN NUTR, V57, pS47, DOI 10.1038/sj.ejcn.1601901
   Stover B, 2007, ACSMS HEALTH FIT J, V11, P7, DOI 10.1249/01.FIT.0000262486.81937.4b
   Su SB, 2006, J OCCUP HEALTH, V48, P284, DOI 10.1539/joh.48.284
   Szinnai G, 2005, AM J PHYSIOL-REG I, V289, pR275, DOI 10.1152/ajpregu.00501.2004
NR 25
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 2
BP 591
EP 596
DI 10.19193/0393-6384_2018_2s_93
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7SD
UT WOS:000429274400007
DA 2022-07-14
ER

PT J
AU Akin, M
   Kurtulus, A
   Adanir, H
   Gelen, MT
AF Akin, Mete
   Kurtulus, Aziz
   Adanir, Haydar
   Gelen, Mustafa Tekinalp
TI ASSOCIATION OF HELICOBACTER PYLORI DENSITY WITH ENDOSCOPIC AND
   HISTOPATHOLOGICAL FINDINGS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Helicobacter pylori; dyspepsia; peptic ulcer; atrophy; intestinal
   metaplasia; Helicobacter pylori density
ID PEPTIC-ULCER; CHRONIC GASTRITIS; INFECTION; EPIDEMIOLOGY
AB Introduction: Helicobacter pylori (H. pylori) is a gram negative, unipolar, and spiral-shaped microaerophilic bacteria. Gastric colonization of H. pylori has been established as an etiological factor in chronic gastritis, peptic ulcers, atrophic gastritis, gastric adenocarcinoma, and lymphoma. Only a few studies have examined the effect of H. pylori density on clinical, endoscopic, and histopathological findings. The present study aims to investigate the association of H. pylori density with clinical and endoscopic findings as well as histopathological findings that are particularly observed in atrophy, intestinal metaplasia, and dysplasia.
   Materials and methods: This study included 105 patients that underwent upper gastrointestinal system endoscopy due to various indications. During endoscopy, biopsies were performed from gastric antrum and corpus and the density of H. pylori was assessed with histopathological examination. Patients were categorized as mild, moderate, and severe density groups according to Sydney classification. Furthermore, these groups were compared in terms of endoscopy indications, endoscopic findings, and histopathological features.
   Results: H. pylori density was mild in 59 (56%) patients, moderate in 23 (22%) patients, and severe in 23 (22%) patients. The most common indication for endoscopy was dyspeptic complaints. There was no significant difference between the groups in terms of dyspepsia or other endoscopy indications (p > 0.05). The most frequent endoscopic finding was gastritis. Regarding endoscopic findings, only erosive gastritis was found to be significantly more frequent in the moderate and severe H. pylori density groups compared to the mild density group (p=0.03). There was no difference between the groups regarding atrophy, intestinal metaplasia, or dysplasia (p > 0.05).
   Conclusion: Our results indicate that H. pylori density does not have significant effect on patients' symptoms or endoscopic and histopathological findings.
C1 [Akin, Mete; Adanir, Haydar] Akdeniz Univ, Sch Med, Dept Gastroenterol, Antalya, Turkey.
   [Kurtulus, Aziz] Akdeniz Univ, Sch Med, Dept Internal Med, Antalya, Turkey.
   [Gelen, Mustafa Tekinalp] Akdeniz Univ, Sch Med, Dept Pathol, Antalya, Turkey.
RP Akin, M (corresponding author), Akdeniz Univ Hosp, Dept Internal Med, Antalya, Turkey.
CR Braden B, 1997, DIGEST DIS SCI, V42, P2120, DOI 10.1023/A:1018886905516
   Chey WD, 1999, AM J GASTROENTEROL, V94, P1522, DOI 10.1111/j.1572-0241.1999.1137_r.x
   Cohen H, 2000, GASTROENTEROL CLIN N, V29, P775, DOI 10.1016/S0889-8553(05)70146-1
   Everhart JE, 2000, GASTROENTEROL CLIN N, V29, P559, DOI 10.1016/S0889-8553(05)70130-8
   Fareed R, 2000, J Pak Med Assoc, V50, P148
   Fischbach W, 2005, HELICOBACTER, V10, P34, DOI 10.1111/j.1523-5378.2005.00338.x
   FONTHAM ETH, 1995, AM J GASTROENTEROL, V90, P1094
   Go MF, 2000, GASTROENTEROL CLIN N, V29, P649, DOI 10.1016/S0889-8553(05)70136-9
   Gurel S, 1998, ENDOSKOPI DERGISI, V9, P134
   Kadanali A, 2004, KLIMIK DERGISI, V17, P146
   MEGRAUD F, 1993, GASTROENTEROL CLIN N, V22, P73
   Morgner A, 2000, GASTROENTEROL CLIN N, V29, P593, DOI 10.1016/S0889-8553(05)70132-1
   Nai Gisele Alborghetti, 2007, Arq. Gastroenterol., V44, P240, DOI 10.1590/S0004-28032007000300012
   Nguyen TL, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-114
   Ozaydin N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1215
   Ozdil K, 2010, HEPATO-GASTROENTEROL, V57, P1563
   Shah Dharmesh K, 2015, Trop Gastroenterol, V36, P101
   Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542
   Tokunaga Y, 1998, J AM COLL SURGEONS, V186, P659, DOI 10.1016/S1072-7515(98)00128-8
   Topal Derya, 2004, Turk J Gastroenterol, V15, P149
   Watari J, 2014, WORLD J GASTROENTERO, V20, P5461, DOI 10.3748/wjg.v20.i18.5461
   Windsor HM, 2000, GASTROENTEROL CLIN N, V29, P633, DOI 10.1016/S0889-8553(05)70135-7
   Wong CS, 2013, J SURG RES, V182, P219, DOI 10.1016/j.jss.2012.10.046
   Yamaoka Y, 1999, GUT, V45, P804, DOI 10.1136/gut.45.6.804
NR 24
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 663
EP 668
DI 10.19193/0393-6384_2018_3_102
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000007
DA 2022-07-14
ER

PT J
AU Albu, A
   Bondor, CI
   Fodor, D
AF Albu, Adriana
   Bondor, Cosmina I.
   Fodor, Daniela
TI RISK FACTORS ASSOCIATED WITH ARTERIAL STIFFNESS IN ELDERLY NON-DIABETIC
   WOMEN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE arterial stiffness; cardiovascular risk; abdominal obesity; C-reactive
   protein; elderly
ID C-REACTIVE PROTEIN; AORTIC STIFFNESS; HEALTHY POPULATION; METABOLIC
   SYNDROME; ENDOTHELIAL-CELLS; ABDOMINAL OBESITY; BODY-COMPOSITION;
   OLDER-ADULTS; FOLLOW-UP; HYPERTENSION
AB Background: Elderly women have increased arterial stiffness but the precise mechanism that induces vascular alterations is not known. Classical cardiovascular risk factors and systemic inflammation may play a role in this process, but the major determinants in elderly women have not yet been established. The aim of this study was to evaluate the correlation between classical cardiovascular risk factors, C-reactive protein and aortic pulse wave velocity (PWV) in elderly non-diabetic women, without overt cardiovascular disease.
   Methods: Aortic PWV was measured non-invasively using an oscillometric device in 104 elderly women, mean age 69.7 +/- 6.4 years. Laboratory parameters of lipid and glucose metabolism and high sensitive C-reactive protein (hsCRP) were also evaluated.
   Results: Aortic PWV independently correlated with hsCRP (beta=0.22, p=0.01), systolic blood pressure (beta=0.23, p=0.009), abdominal circumference (beta=0.24, p=0.007) and age (beta=0.18, p=0.03). Aortic PWV was increased in hypertensive compared with normotensive subjects (10.3 +/- 2.3 vs. 9.0 +/- 1.6, p=0.006) and in obese compared to non-obese women (10.7 +/- 1.9 vs. 9.6 +/- 2.2, p=0.01).
   Conclusion: In elderly non-diabetic women, age, abdominal obesity, systolic blood pressure and hsCRP, are the most important determinants of aortic PWV. Body weight loss, efficient control of blood pressure and decrease in systemic inflammation may reduce arterial stiffness in this high cardiovascular risk population.
C1 [Albu, Adriana; Fodor, Daniela] Iuliu Hatieganu Univ Med & Pharm, Dept Internal Med 2, 2-4 Clinicilor Str, Cluj Napoca, Romania.
   [Bondor, Cosmina I.] Iuliu Hatieganu Univ Med & Pharm, Med Informat & Biostat Dept, Cluj Napoca, Romania.
RP Albu, A (corresponding author), Iuliu Hatieganu Univ Med & Pharm, Dept Internal Med 2, 2-4 Clinicilor Str, Cluj Napoca, Romania.
RI Bondor, Cosmina Ioana/V-8815-2019; albu, adriana/D-4480-2016
CR Alecu C, 2006, J HUM HYPERTENS, V20, P749, DOI 10.1038/sj.jhh.1002072
   Araujo F, 2004, INT J CARDIOL, V97, P433, DOI 10.1016/j.ijcard.2003.10.027
   Assuncao LGS, 2012, BRAZ J MED BIOL RES, V45, P1284, DOI 10.1590/S0100-879X2012007500154
   Baulmann J, 2008, J HYPERTENS, V26, P523, DOI 10.1097/HJH.0b013e3282f314f7
   Boutouyrie P, 2002, HYPERTENSION, V39, P10, DOI 10.1161/hy0102.099031
   Budimir D, 2012, MED SCI MONITOR, V18, pCR65, DOI 10.12659/MSM.882457
   Chahal HS, 2007, J PATHOL, V211, P173, DOI 10.1002/path.2110
   Charakida M, 2012, J AM COLL CARDIOL, V60, P2643, DOI 10.1016/j.jacc.2012.08.1017
   Corden B, 2013, HYPERTENSION, V61, P1322, DOI 10.1161/HYPERTENSIONAHA.113.01177
   Coutinho T, 2014, CAN J CARDIOL, V30, P756, DOI 10.1016/j.cjca.2014.03.020
   Fantin F, 2010, J HYPERTENS, V28, P333, DOI 10.1097/HJH.0b013e328333d23c
   Ford LB, 2010, J HYPERTENS, V28, pE223
   Genuth S, 2003, DIABETES CARE, V26, P3160
   Horvath IG, 2010, J HYPERTENS, V28, P2068, DOI 10.1097/HJH.0b013e32833c8a1a
   Jia GH, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00231
   Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58
   Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254
   Lavie CJ, 2009, AM J MED SCI, V338, P486, DOI 10.1097/MAJ.0b013e3181c61b66
   Lechleitner M, 2008, GERONTOLOGY, V54, P253, DOI 10.1159/000161734
   Lee HY, 2010, CIRC J, V74, P2257, DOI 10.1253/circj.CJ-10-0910
   Mackey RH, 2002, AM J HYPERTENS, V15, P16, DOI 10.1016/S0895-7061(01)02228-2
   Mahmud A, 2005, HYPERTENSION, V46, P1118, DOI 10.1161/01.HYP.0000185463.27209.b0
   Mattace-Raso FUS, 2004, ATHEROSCLEROSIS, V176, P111, DOI 10.1016/j.atherosclerosis.2004.04.014
   Park JB, 2010, 23 SCI M INT SOC HYP
   Park S, 2012, YONSEI MED J, V53, P258, DOI 10.3349/ymj.2012.53.2.258
   Pasceri V, 2000, CIRCULATION, V102, P2165
   Recio-Rodriguez JI, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-3
   Safar ME, 2013, J AM COLL CARDIOL, V61, P12, DOI 10.1016/j.jacc.2012.01.088
   Scuteri A, 2012, ATHEROSCLEROSIS, V221, P189, DOI 10.1016/j.atherosclerosis.2011.11.045
   Strandberg TE, 2000, ARTERIOSCL THROM VAS, V20, P1057, DOI 10.1161/01.ATV.20.4.1057
   Sutton-Tyrrell K, 2001, HYPERTENSION, V38, P429, DOI 10.1161/01.HYP.38.3.429
   Trachet B, 2010, ANN BIOMED ENG, V38, P876, DOI 10.1007/s10439-010-9945-1
   Venugopal SK, 2002, CIRCULATION, V106, P1439, DOI 10.1161/01.CIR.0000033116.22237.F9
   Vermeersch SJ, 2008, J HYPERTENS, V26, P1411, DOI 10.1097/HJH.0b013e3282ffac00
   Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061
   Weisbrod RM, 2013, HYPERTENSION, V62, P1105, DOI 10.1161/HYPERTENSIONAHA.113.01744
   Won KB, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/1758-5996-7-3
   Woodard GA, 2011, MENOPAUSE, V18, P1291, DOI 10.1097/gme.0b013e31821f81c2
   Zieman SJ, 2005, ARTERIOSCL THROM VAS, V25, P932, DOI 10.1161/01.ATV.0000160548.78317.29
NR 39
TC 2
Z9 2
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 625
EP 630
DI 10.19193/0393-6384_2018_3_96
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000001
DA 2022-07-14
ER

PT J
AU Amato, A
   Messina, G
   Contro, V
   Sacco, A
   Proia, P
AF Amato, Alessandra
   Messina, Giuseppe
   Contro, Valentina
   Sacco, Alessia
   Proia, Patrizia
TI TOTAL GENETIC SCORE: AN INSTRUMENT TO IMPROVE THE PERFORMANCE IN THE
   ELITE ATHLETES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE genetics analysis; polymorphism; performance demands; basketball; soccer
ID ENDURANCE CAPACITY; SOCCER PLAYERS; PPARA GENE; STRENGTH; GENOTYPE;
   ACTN3; ASSOCIATION; GLY482SER; VARIANTS; ACE
AB Introduction: The purpose of this study was to demonstrate the effectiveness of the TGS calculation method to identify genetic athletic predisposition in two groups of basketball and soccer players based on genetics analysis.
   Through the genetic profile we calculated, by an algorithm, the TGS (Total Genetic Score) in both groups; this idea comes from the concept that it's better to personalized workout based on athlete genetic profile. Identifying specifically performance demands (based on the metabolism system used during performance, aerobic or anaerobic) and paying attention to the performance-enhancing genes and their polymorphisms, is important focus it in order to build personalized and successful training for every single athlete.
   Materials and methods: We considered two groups of professional athletes: 21 basketball players and 21 soccer players both involved in professional championships. For the genetic analysis a saliva sample was taken from athletes, and the polymorphisms were analysed: ACE; ACTN3; CK-MM; PPAR alpha; PPAR gamma C1; NRF2 A/G; NRF2 C/T. Each genotype was scored from 0 to 2 depending on whether they were more related to resistance or power activity. The sum of these scores generates the total TGS for each athlete and was compared both for resistance and power.
   Results: Our results indicate that professional basketball players have a power-related TGS higher than the resistance-related conversely the football players, that have a resistance-related TGS greater than power-related one.
   Conclusion: TGS can be a useful tool to identify the genetic predisposition of the athlete starting from the genetic analysis of some PEPs, regardless of the type and number of genes analysed.
C1 [Amato, Alessandra; Messina, Giuseppe; Contro, Valentina; Sacco, Alessia; Proia, Patrizia] Univ Palermo, Dipartimento Sci Psicol Pedag & Formaz, Palermo, Italy.
RP Messina, G (corresponding author), Univ Palermo, Dipartimento Sci Psicol Pedag & Formaz, Palermo, Italy.
EM giuseppe.messina17@unipa.it
OI Proia, Patrizia/0000-0002-0326-5560
CR Ahmetov II, 2013, J PHYSIOL SCI, V63, P79, DOI 10.1007/s12576-012-0233-8
   Alves Cleber Rene, 2018, J RENIN-ANGIO-ALDO S, P1
   Amato A., 2017, Human Movement, V18, P12
   Bianco A., 2016, ASIAN J SPORTS MED, V7
   Bruni F, 2010, J BIOL CHEM, V285, P3939, DOI 10.1074/jbc.M109.044305
   Charlier R, 2017, PHYSIOL GENOMICS, V49, P160, DOI 10.1152/physiolgenomics.00085.2016
   Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564
   Contro V, 2018, EUR J TRANSL MYOL, V28, P87, DOI 10.4081/ejtm.2018.7186
   Egorova ES, 2014, J SPORT SCI, V32, P1286, DOI 10.1080/02640414.2014.898853
   Fedotovskaia O N, 2012, Fiziol Cheloveka, V38, P105
   He Z, 2007, INT J SPORTS MED, V28, P717, DOI 10.1055/s-2007-964913
   Hughes DC, 2011, J SPORT SCI, V29, P1425, DOI 10.1080/02640414.2011.597773
   Jones N, 2016, BIOL SPORT, V33, P117, DOI 10.5604/20831862.1198210
   Lopez-Leon S, 2016, BIOL SPORT, V33, P3, DOI 10.5604/20831862.1180170
   Lucia A, 2005, J APPL PHYSIOL, V99, P344, DOI 10.1152/japplphysiol.00037.2005
   Ma F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054685
   Maciejewska A, 2012, J SPORT SCI, V30, P101, DOI 10.1080/02640414.2011.623709
   Ostrander EA, 2009, ANNU REV GENOM HUM G, V10, P407, DOI 10.1146/annurev-genom-082908-150058
   Patti A, 2016, J PHYS THER SCI, V28, P72, DOI 10.1589/jpts.28.72
   Proia P, 2012, J SPORT MED PHYS FIT, V52, P102
   Proia P, 2014, OPEN ACCESS J SPORTS, V5, P273, DOI 10.2147/OAJSM.S68333
   Rankinen T, 2010, MED SCI SPORT EXER, V42, P835, DOI 10.1249/MSS.0b013e3181d86cec
   Wang G, 2013, MED SCI SPORT EXER, V45, P892, DOI 10.1249/MSS.0b013e31827c501f
   Yang N, 2003, AM J HUM GENET, V73, P627, DOI 10.1086/377590
NR 24
TC 3
Z9 3
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1857
EP 1862
DI 10.19193/0393-6384_2018_6_287
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400038
DA 2022-07-14
ER

PT J
AU Ao, JP
AF Ao, Jinping
TI SPORTS INJURIES CHARACTERISTIC OF FEMALE GYMNASTS AND EFFECT OF ITS
   PSYCHOLOGICAL STRESS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Female gymnasts; Special sports injury; Psychological stress; Treatment
   effect
AB Targeting at sports injuries which often occur in female gymnasts in training and competition process, lead to game loss and even impact athletes' career, this paper included 2,000 female gymnasts from Eastern and Western countries in the study, conducted a survey analysis on the relevance between main types of sports injuries, treatment method and psychological stress, and analyzed stress coping behaviors of different athletes with retrospective analysis of patients. The results show that psychological stress is a major cause of sports injuries among female gymnasts, and there is a big difference in stress coping psychology of different athletes, which shows that athletes should be arranged with appropriate amount of exercise training and maintain relaxed, joyful mood to improve competitive ability of female gymnasts.
C1 [Ao, Jinping] Cent China Normal Univ, Sch Phys Educ, Wuhan 430079, Hubei, Peoples R China.
RP Ao, JP (corresponding author), Cent China Normal Univ, Sch Phys Educ, Wuhan 430079, Hubei, Peoples R China.
EM sevenaojinping@sina.com
CR Awan UA, 2017, PAK J PHARM SCI, V30, P729
   Balkhair KS, 2016, SAUDI J BIOL SCI, V23, pS32, DOI 10.1016/j.sjbs.2015.09.023
   Billen J, 2017, SAUDI J BIOL SCI, V24, P830, DOI 10.1016/j.sjbs.2016.06.007
   Carcu-Dobrin M, 2017, SAUDI PHARM J, V25, P397, DOI 10.1016/j.jsps.2016.09.007
   Chen J., 2012, CHIN SPORT COACHES, V18, P54
   Li D., 2014, SPORTS WORLD, V21, P136
   Liu Y, 2012, SCI TECHNOL INFORM, V45, P278
   Lu Y., 2012, J NAN SPORT I, V19, P154
   Lu Z., 2014, CHINA SCH PHYS ED, V24, P82
   Peng WX, 2017, SAUDI J BIOL SCI, V24, P103, DOI 10.1016/j.sjbs.2016.08.013
   Shi H., 2012, B SPORT SCI TECHNOL, V15, P126
   Sultan MT, 2015, PAK J PHARM SCI, V28, P589
   Wang Y., 2013, B SPORT SCI TECHNOL, V34, P127
   Xie YZ, 2018, SAUDI J BIOL SCI, V25, P234, DOI 10.1016/j.sjbs.2017.08.006
   Yang AM, 2017, J ALLOY COMPD, V695, P915, DOI 10.1016/j.jallcom.2016.10.188
   Zhang Y, 2012, MOD SOC, V23, P7
   Zheng L., 2013, J SHANDONG I PHYS ED, V12, P67
   Zhou C., 2013, PSYCHO TECHNOL APPL, V18, P49
NR 18
TC 0
Z9 0
U1 2
U2 13
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1557
EP 1560
DI 10.19193/0393-6384_2018_3s_240
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400016
DA 2022-07-14
ER

PT J
AU Ascione, A
   Belfiore, P
   Di Palma, D
AF Ascione, Antonio
   Belfiore, Patrizia
   Di Palma, Davide
TI SPORTS PROGRAM TO PROMOTE THE WELLBEING OF PEOPLE WITH DISABILITIES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Disability; Sports Program; Psycho-physical Wellbeing; Swimming;
   Pedagogical Aspects
ID SYSTEM
AB Introduction: It has investigated the possibility of achieving both an increase in athletic performance, that in the level of health and psycho-physical well-being by a group of athletes with disabilities through sports activities.
   Materials and methods: 8 disabled athletes have followed a pedagogical sports program characterized by the swimming trainings and socio-relational meetings for a period of 5 months with two series of evaluations at predetermined intervals.
   Results: It was found that there was a drop out equal to 0 and all the disabled athletes involved have recorded improvements both in the field of sports, that in social and psycho-physical.
   Conclusions: A suitable program of sporting activities, also meant in its socio-pedagogical meaning, is capable of generating multiple benefits in respect of disabled people.
C1 [Ascione, Antonio; Belfiore, Patrizia; Di Palma, Davide] Parthenope Univ, Dept Sport Sci & Wellness, Naples, Italy.
RP Belfiore, P (corresponding author), Parthenope Univ Naples, Naples, Italy.
EM patrizia.belfiore@uniparthenope.it
OI Di Palma, Davide/0000-0001-8224-5797
CR Apalone G, 2005, QUESTIONARIO STATO S
   Beyer R., 2009, J YOUTH SPORTS, V4
   Liow D.K., 1996, ADAPT PHYS ACT Q, V13, P372, DOI [10.1123/apaq.13.4.372, DOI 10.1123/APAQ.13.4.372]
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P641, DOI 10.19193/0393-6384_2017_4_095
   Messina G, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/639280
   Muscogiuri G, 2014, ENDOCR RES, V39, P137, DOI 10.3109/07435800.2014.952018
   Orio F, 2013, MINERVA ENDOCRINOL, V38, P305
   Orio F, 2013, E SPEN J, V8, P200
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   ORNSTEIN LJ, 1983, MED SCI SPORT EXER, V15, P110, DOI 10.1249/00005768-198315020-00102
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Petralia MC, 2018, ACTA MEDICA MEDITERR, V34, P107, DOI 10.19193/0393-6384_2018_1_18
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Shapiro DR, 2014, J SPORT MANAGEMENT, V28
   Tafuri D., 2017, SPORT SCI, V10, P70
   2011, WORLD REP DIS, P1
NR 22
TC 13
Z9 13
U1 0
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1261
EP 1263
DI 10.19193/0393-6384_2018_5_194
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700016
DA 2022-07-14
ER

PT J
AU Ascione, A
   Belfiore, P
   Di Palma, D
AF Ascione, Antonio
   Belfiore, Patrizia
   Di Palma, Davide
TI SPORT AS A PSYCHO-SOCIAL SUPPORT IN DISABILITY THROUGH THE POSITIVE
   STIMULATION OF SELF-EFFICACY AND RESILIENCE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Self Efficacy; Resilience; Sport; Disability
AB Sport is a key element in disability, it is a context of great support that often welcomes and receives important changes in how every subject can read and understand his special condition.
   Therefore, given its characteristics, sport can contribute to enhancing and supporting psychological aspects that are fundamental to the life of the disabled, improving his development and enhancing what he feels he is able to achieve.
   Taking care of one's own physical and psychological well-being through sport allows reversing a life pattern from within, by creating new opportunities for growth through greater awareness, more intense quality of the relationships, and an important acquisition of new resources. Convincing and redefining positively, by experiencing and evaluating one's own limits as resources and qualities, supports the disabled and who revolves around his world, accepting difficulties and,facing the issues under a different light.
C1 [Ascione, Antonio; Belfiore, Patrizia; Di Palma, Davide] Parthenope Univ, Via Medina 40, Naples, Italy.
RP Belfiore, P (corresponding author), Parthenope Univ, Via Medina 40, Naples, Italy.
EM patrizia.belfiore@uniparthenope.it
OI Di Palma, Davide/0000-0001-8224-5797
CR Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Bandura A., 2000, AUTOEFFICACIA TEORIA
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   Malaguti E., 2005, EDUCARSI RESILIENZA
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Petralia MC, 2018, ACTA MEDICA MEDITERR, V34, P107, DOI 10.19193/0393-6384_2018_1_18
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Short D., 2004, SPERANZA RESILIENZA
   Tafuri D., 2017, SPORT SCI, V10, P70
   Tortorella D, 2016, PREPARARSI VIA PSICO
   Zimmerman J, ELSEVIER J, V25, P89
NR 19
TC 0
Z9 0
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1517
EP 1520
DI 10.19193/0393-6384_2018_3s_232
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400009
DA 2022-07-14
ER

PT J
AU Avci, DK
AF Avci, Dilek Kusaslan
TI RELATIONSHIP BETWEEN HBA1C AND VARIOUS FACTORS THAT AFFECT THE
   ADAPTATION OF THE PATIENTS TO THE TREATMENT IN PATIENTS WITH DIABETES
   MELLITUS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Diabetes Mellitus; HbA1c; Adaptation; Treatment
ID GLYCEMIC CONTROL; HEALTH; DISTRESS; BEHAVIOR; QUALITY; SUPPORT; FAMILY;
   CARE
AB Introduction: We aimed to investigate the relationship between HbA1c and various factors that affect the adaptation of the patients to the treatment in patients with Diabetes Mellitus.
   Material and methods: The method was based on semi-structured questionnaires. A total of 458 patients diagnosed with Diabetes Mellitus was selected by simple random sampling method. Data assessment for independent samples was performed by one-way analysis of variance (ANOVA) and Chi-Square test. Correlation analyses were carried out by the Spearman correlation analysis and Pearson correlation analysis.
   Results: The mean HbA1c (9.28 +/- 1.88) was found to be significantly high in married individuals who say that they feel uncomfortable for being warned related to treatment by their partners (p<0.001). It was found that the rate of blaming themselves, their families, their partners or other people was significantly high in females, compared to the males when they have difficulty in adaptation to diet (%34.7; p=0.012), exercise(%30.6; p=0.003) or drug therapy (%12.9; p<0.001).
   Conclusion: It is necessary to evaluate the diabetic individuals multidiciplinary. In the struggle of the individual which began with the diagnosis of diabetes, evaluation of the emotional reactions that they could experience in addition to considering physical problems could increase the adaptation to the disease and treatment.
C1 [Avci, Dilek Kusaslan] Yuzuncu Yil Univ, Med Fac, Dept Family Med, Van, Turkey.
RP Avci, DK (corresponding author), Yuzuncu Yil Univ, Med Fac, Dept Family Med, Van, Turkey.
CR Berkman LF, 2000, SOC SCI MED, V51, P843, DOI 10.1016/S0277-9536(00)00065-4
   Choi S, 2009, WESTERN J NURS RES, V31, P347, DOI 10.1177/0193945908328472
   Cohen S, 2004, AM PSYCHOL, V59, P676, DOI 10.1037/0003-066X.59.8.676
   DuVal TM, 2011, J GEN INTERN MED, V26, pS205
   Egede LE, 2012, CURR PSYCHIAT REP, V14, P15, DOI 10.1007/s11920-011-0240-0
   Gunn KL, 2012, HEALTH SOC CARE COMM, V20, P591, DOI 10.1111/j.1365-2524.2012.01073.x
   Holt RIG, 2013, DIABETIC MED, V30, P789, DOI 10.1111/dme.12242
   Ilias I, 2001, PSYCHOL REP, V88, P929, DOI 10.2466/pr0.2001.88.3.929
   International Diabetes Federation, IDF DIAB ATL
   Jones A, 2016, PRIM CARE DIABETES, V10, P83, DOI 10.1016/j.pcd.2015.03.008
   Kirk Julienne K, 2011, N C Med J, V72, P345
   Lau D. C., 2010, PRIM CARE DIABETES, V4, P24, DOI 10.1016/S1751-9918(10)60006-X
   Liu H, 2016, J GERONTOL B-PSYCHOL, V71, P1070, DOI 10.1093/geronb/gbw061
   Patel Y, 2016, CLIN NUTR, P1
   Peyrot M, 1999, J HEALTH SOC BEHAV, V40, P141, DOI 10.2307/2676370
   Rahman NAA, 2008, INT MED J, V15, P29
   Schiotz ML, 2012, DIABETIC MED, V29, P654, DOI 10.1111/j.1464-5491.2011.03485.x
   Sinclair AJ, 2010, DIABETIC MED, V27, P1055, DOI 10.1111/j.1464-5491.2010.03066.x
   Souza RAP, 2011, LAT AM J PHARM, V30, P860
   Thaneerat T, 2009, ASIAN BIOMED, V3, P383
   UMBERSON D, 1992, SOC SCI MED, V34, P907, DOI 10.1016/0277-9536(92)90259-S
   Venkataraman K, 2012, J COMMUN HEALTH, V37, P653, DOI 10.1007/s10900-011-9496-x
   Vogelsang DA, 2011, AM DIAB ASS
   Wazaify Mayyada, 2011, Complement Ther Clin Pract, V17, P71, DOI 10.1016/j.ctcp.2011.02.002
   Whisman MA, 2014, HEALTH PSYCHOL, V33, P832, DOI 10.1037/hea0000064
   Zhou HH, 2017, PSYCHIAT RES, V252, P45, DOI 10.1016/j.psychres.2017.02.049
NR 26
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1207
EP 1212
DI 10.19193/0393-6384_2018_5_185
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700007
DA 2022-07-14
ER

PT J
AU Aytac, E
   Akpinar, CK
AF Aytac, Emrah
   Akpinar, Cetin Kursad
TI THE RELATIONSHIP BETWEEN DIAGNOSIS AND SEVERITY OF ISCHEMIC STROKE AND
   SERUM UROTENSIN-II LEVELS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE urotensin-II; ischemic stroke; severity; cardioembolic stroke
ID INCREASED EXPRESSION; ATHEROSCLEROSIS; RECEPTOR; ARTERIES; DISEASE
AB Introduction: Introduction: Urotensin-II is an extremely potent, widespread vasopressor and increased serum urotensin-II level is associated to many disorders including congestive heart failure, hypertension, coronary artery diseases, diabetes mellitus and metabolic syndromes. In this study we aimed to investigate whether there is a relationship between serum urotensin-II level and etiology and severity of stroke in patients with ischemic cerebrovascular disease.
   Materials and methods: The study included 20 patients experienced acute ischemic cerebrovascular event (study group) and 20 healthy individuals (control group). Venous blood samples were drawn from patients who experienced acute ischemic stroke within prior 12 hours and urotensin-II measurements were performed by ELISA kits using sandwich enzyme-linked sorbent immunoassay method.
   Results: No significant difference was observed in serum urotensin-II levels between study and control groups. In the analysis of ischemic stroke subgroups, urotensin-II level was found to be significantly higher in patients with cardioembolic stroke. In addition, a positive correlation was detected between urotensin-II level and high National Institutes of Health Stroke Scale (NIHSS) score at presentation.
   Conclusion: This is the first study analysing urotensin-II levels in stroke, concluding that urotensin-II could be a relevant parameter for assessment of etiology and severity of stroke.
C1 [Aytac, Emrah; Akpinar, Cetin Kursad] Firat Univ, Sch Med, Dept Neurol, TR-23100 Elazig, Turkey.
   [Akpinar, Cetin Kursad] Samsun Training & Res Hosp, Dept Neurol, Samsun, Turkey.
RP Aytac, E (corresponding author), Firat Univ, Sch Med, Dept Neurol, TR-23100 Elazig, Turkey.
RI AYTAC, EMRAH/X-1420-2018
CR Bottrill FE, 2000, BRIT J PHARMACOL, V130, P1865, DOI 10.1038/sj.bjp.0703513
   Bousette N, 2004, ATHEROSCLEROSIS, V176, P117, DOI 10.1016/j.atherosclerosis.2004.03.023
   Chatzikonstantinou A, 2012, J NEUROL, V259, P653, DOI 10.1007/s00415-011-6234-3
   Cohen JD, 2007, J MANAGE CARE PHARM, V13, pS6
   Douglas SA, 2000, TRENDS CARDIOVAS MED, V10, P229, DOI 10.1016/S1050-1738(00)00069-4
   Guidolin D, 2010, PEPTIDES, V31, P1219, DOI 10.1016/j.peptides.2010.03.022
   Gurkas E, 2017, INTERV NEURORADIOL, V23, P166, DOI 10.1177/1591019916682358
   Jegou S, 2006, J COMP NEUROL, V495, P21, DOI 10.1002/cne.20845
   Maguire JJ, 2004, PEPTIDES, V25, P1767, DOI 10.1016/j.peptides.2004.01.028
   Onan D, 2004, TRENDS ENDOCRIN MET, V15, P175, DOI 10.1016/j.tem.2004.03.007
   Ong KL, 2005, CARDIOVASC DRUG THER, V19, P65, DOI 10.1007/s10557-005-6899-x
   Papadopoulos P, 2008, PEPTIDES, V29, P764, DOI 10.1016/j.peptides.2007.09.012
   Suguro T, 2008, CLIN SCI, V115, P327, DOI 10.1042/CS20080014
   Watson AM, 2004, PEPTIDES, V25
   WOLF PA, 1998, STROKE PATHOPHYSIOLO, P3
NR 15
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 345
EP 348
DI 10.19193/0393-6384_2018_2_54
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400008
DA 2022-07-14
ER

PT J
AU Ba, HJ
   Lin, Q
   Cai, JY
   Lu, C
   Sun, J
   Ma, LT
AF Ba, Huajun
   Lin, Qun
   Cai, Jianyong
   Lu, Chuan
   Sun, Jun
   Ma, Lianting
TI EVALUATION OF CEREBRAL PERFUSION AND CEREBRAL HEMODYNAMICS CHANGES IN
   PATIENTS WITH SYMPTOMATIC CAROTID ARTERY STENOSIS BEFORE AND AFTER
   STENTING BY DSA PARAMETRIC IMAGING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Symptomatic carotid artery stenosis; Stenting; Cerebral perfusion;
   Cerebral hemodynamics; DSA parametric imaging
ID DISEASE; TRANSPLANTATION; STROKE
AB Objective: Investigating the DSA parametric imaging's value of application in evaluating the changes of cerebral perfusion and cerebral hemodynamics changes before and after stenting in subjects having symptomatic carotid artery stenosis.
   Patients and methods: From March 2006 to March 2017, 30 patients admitted to our hospital with unilateral carotid artery bifurcation stenosis were selected as the subjects. After stenting treatment, the effect of carotid artery stenting on intracranial blood flow was quantitatively evaluated according to the comparisons before and after stenting by using the iFLOW post processing technique with DSA scan.
   Results: After operation, the brain peak value and the max slope rates of time - gray scale curves of ipsilateral operation in brain of the subjects were considerably more when compared to those prior to operation (P<0.05), and the time to peak, mean transit time and circulation time of ipsilateral operation were significantly decreased (P<0.05). After operation, the peak value, time of appearance of peak, the time to peak, mean transit time and circulation time of contralateral operation in brain of patients were significantly higher than those of before operation, and there was a considerable variation with probability less than 0.01. After operation, the peak value of posterior circulation was considerably less compared to that before operation with probability less than 0.05, however, the time of appearance of peak, the time to peak, mean transit time and circulation time were significantly higher than before operation, the difference was significant (P<0.05).
   Conclusion: The evaluation of cerebral hemodynamics changes after stenting, by using the post processing function of iFLOW, according to the quantitative comparison of blood flow velocity in the same part of intracranial vessels before and after operation, is accurate and reliable.
C1 [Ba, Huajun] Southern Med Univ, 1023 Shatai Nan Rd, Guangzhou 510515, Guangdong, Peoples R China.
   [Ma, Lianting] Southern Med Univ, Guangzhou Mil Command, Wuhan Gen Hosp, Dept Neurosurg, 627 Wuluo Rd, Wuhan 430070, Hubei, Peoples R China.
   [Ba, Huajun; Lin, Qun; Cai, Jianyong; Lu, Chuan; Sun, Jun] Wenzhou Cent Hosp, Dept Neurosurg, 32 Dajian Rd, Wenzhou 325000, Peoples R China.
RP Ma, LT (corresponding author), Southern Med Univ, Guangzhou Mil Command, Wuhan Gen Hosp, Dept Neurosurg, 627 Wuluo Rd, Wuhan 430070, Hubei, Peoples R China.
EM mlt1937@163.com
CR Badheka AO, 2015, AM J CARDIOL, V116, P132, DOI 10.1016/j.amjcard.2015.03.053
   Balasubramaian A, 2015, J STROKE, V17, P127, DOI 10.5853/jos.2015.17.2.127
   Chen H, 2015, STROKE, V46, P961, DOI 10.1161/STROKEAHA.114.008015
   Chen LG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130991
   Chen Y. F., 2017, SCI REPORTS, V7
   Chen Z, 2009, TOP STROKE REHABIL, V16, P330, DOI 10.1310/tsr1605-330
   Chit A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133606
   Cronberg C N, 2015, ACTA RADIOL, V44, P59
   Crozier S, 2015, J GENET COUNS, V24, P29, DOI 10.1007/s10897-014-9755-y
   Du SD, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000388
   Ishiguro T, 2015, NEUROL MED-CHIR, V55, P830, DOI 10.2176/nmc.oa.2014-0398
   Korn A, 2015, CLIN NEURORADIOL, V25, P33, DOI 10.1007/s00062-013-0276-0
   Lee MJ, 2015, STROKE, V46, P2800, DOI 10.1161/STROKEAHA.115.009828
   Lin CJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003529
   Liu B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120146
   Martelli CMT, 2015, VALUE HEALTH, V9, pA668
   Mundiyanapurath S, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0576-5
   Netuka D, 2016, ACTA NEUROCHIR, V158, P1
   Norman FF, 2015, FUTURE MICROBIOL, V10, P69, DOI 10.2217/fmb.14.105
   Obrenovic-Kircanski B, 2016, ACTA MEDICA MEDITERR, V32, P63
   Ohana M, 2015, J CARDIOVASC SURG, V56, P287
   Paneque M, 2015, J GENET COUNS, V24, P1
   Pulitano C, 2015, LIVER TRANSPLANT, V21, P162, DOI 10.1002/lt.24043
   Song IU, 2015, NUCL MED COMMUN, V36, P1049, DOI 10.1097/MNM.0000000000000354
   Sung RS, 2015, AM J TRANSPLANT, V15, P2808, DOI 10.1111/ajt.13459
   Yang HT, 2015, J THORAC DIS, V7, P1227, DOI 10.3978/j.issn.2072-1439.2015.05.13
   Young JY, 2016, INT J CARDIOVAS IMAG, V32, P19, DOI 10.1007/s10554-015-0757-0
NR 27
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 463
EP 468
DI 10.19193/0393-6384_2018_2_74
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400028
DA 2022-07-14
ER

PT J
AU Bademler, S
   Sari, M
   Ucuncu, MZ
   Serilmez, M
   Karabulut, S
AF Bademler, Suleyman
   Sari, Murat
   Ucuncu, Muhammet Zubeyr
   Serilmez, Murat
   Karabulut, Senem
TI CLINICAL SIGNIFICANCE OF SERUM INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) AND
   INSULIN-LIKE GROWTH BINDING PROTEIN-3 (IGFBP-3) IN PATIENTS WITH GASTRIC
   CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Gastric cancer; serum; IGF-1; IGFBP-3
ID FACTOR RECEPTOR; EXPRESSION; SYSTEM; RISK
AB Introduction: Early diagnosis reduces mortality in gastric adenocarcinoma (GC). However, there are no markers that can be used to allow early diagnosis. The aim of the present study was to investigate clinical utility of insulin-like growth factor-1 (IGF-1) and insulin-like growth-binding protein-3 (IGFBP-3) in the diagnosis of GC.
   Materials and methods: Hundred and fifteen patients with histopathologically confirmed diagnosis of GC and 53 age- and sex-matched healthy controls were included in our study at Istanbul University Institute of Oncology. Serum IGF-1 and IGFBP-3 levels were determined using enzyme-linked immunosorbent assay (ELISA).
   Results: The mean age of the patients was 61 (range: 32-89) years. At the end of the median 11-month follow-up period, 75% (n=86) of the patients died. Serum IGF-1 and IGFBP-3 levels were significantly lower in the patient group than those in the control group (p=0.001). The sensitivity and specificity for IGF-1 were found to be 62.61% and 68.52%, respectively. The sensitivity and specificity, for IGFBP-3 were found to be 73.91% and 62.96%, respectively. Serum IGFBP-3 levels were significantly higher in younger patients compared to those in older patients (p=0.009). The median survival was 14 +/- 3.3 months (95% Cl= 7.620.4). 3-year survival rate was 25.6% (95% CI=15.4-35.8). Large T status, high N status and metastasis were found to have a prognostic role on survival (p=0.05, p=0.05, and p=0.003, respectively). Serum IGF-1 and IGFBP-3 concentrations had no prognostic role on survival (p=0.72, p=0.41, respectively).
   Conclusion: in our study, we showed that serum IGF-1 and IGFBP-3 levels could be used for early diagnosis of GC. We found that these two biomarkers have good sensitivity and specificity in clinical practice.
C1 [Bademler, Suleyman] Istanbul Univ, Inst Oncol, Dept Surg, Istanbul, Turkey.
   [Sari, Murat; Karabulut, Senem] Istanbul Univ, Inst Oncol, Dept Med Oncol, Istanbul, Turkey.
   [Ucuncu, Muhammet Zubeyr] Istanbul Gelisim Univ, Inst Hlth Sci, Dept Gen Surg, Istanbul, Turkey.
   [Serilmez, Murat] Istanbul Univ, Inst Oncol, Dept Basic Oncol, Istanbul, Turkey.
RP Karabulut, S (corresponding author), Istanbul Univ, Inst Oncol, Dept Med Oncol, Istanbul, Turkey.
EM drsenemkarabulut@gmail.com
RI karabulut, senem/AAT-3594-2020; Sari, Murat/AAD-4420-2019; Bademler,
   Süleyman/AAY-4675-2020; Serilmez, Murat/V-6153-2018; ucuncu, Muhammed
   zubeyr/B-3397-2018
OI Sari, Murat/0000-0003-0596-1559; Serilmez, Murat/0000-0001-8502-2505;
   ucuncu, Muhammed zubeyr/0000-0003-4638-1059
CR Abdel-Rahman O, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0431-8
   Baxter RC, 2001, J CLIN PATHOL-MOL PA, V54, P145, DOI 10.1136/mp.54.3.145
   Douglas JB, 2010, CANCER EPIDEM BIOMAR, V19, P2298, DOI 10.1158/1055-9965.EPI-10-0400
   Ennishi D, 2011, CANCER SCI, V102, P2231, DOI 10.1111/j.1349-7006.2011.02062.x
   Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3
   Gryko M, 2014, POL J PATHOL, V65, P135, DOI 10.5114/PJP.2014.42678
   Ikoma N, 2018, GASTRIC CANCER, V21, P74, DOI 10.1007/s10120-017-0743-4
   Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215
   Kuang RG, 2013, TURK J GASTROENTEROL, V24, P99, DOI 10.4318/tjg.2013.0571
   Lee Dae-Yeol, 1997, Journal of Korean Medical Science, V12, P32
   Li HM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0576-5
   Matsubara J, 2008, ONCOLOGY-BASEL, V74, P76, DOI 10.1159/000139127
   Miller BS, 2005, CANCER RES, V65, P10123, DOI 10.1158/0008-5472.CAN-05-2752
   Ning SF, 2018, J CANCER, V9, P494, DOI 10.7150/jca.21562
   Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387
   Wang HB, 2011, PATHOL RES PRACT, V207, P169, DOI 10.1016/j.prp.2010.12.009
   Weroha SJ, 2012, ENDOCRIN METAB CLIN, V41, P335, DOI 10.1016/j.ecl.2012.04.014
   Xue M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081423
NR 18
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 2055
EP 2060
DI 10.19193/0393-6384_2018_6_320
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400071
DA 2022-07-14
ER

PT J
AU Barcellona, M
   Giustino, V
   Messina, G
   Battaglia, G
   Fischetti, F
   Palma, A
   Iovane, A
AF Barcellona, Matteo
   Giustino, Valerio
   Messina, Giuseppe
   Battaglia, Giuseppe
   Fischetti, Francesco
   Palma, Antonio
   Iovane, Angelo
TI EFFECTS OF A SPECIFIC TRAINING PROTOCOL ON POSTUROGRAPHIC PARAMETERS OF
   A TAEKWONDO ELITE ATHLETE AND IMPLICATIONS ON INJURY PREVENTION: A CASE
   STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE taekwondo; balance; postural control; training
ID BALANCE; STRATEGIES; POSTURE; QUIET; ANKLE
AB Introduction: Taekwondo elite athletes should have excellent qualities in several aspects of fitness, as well as peculiar postural characteristics in terms of balance and postural control, to achieve the best possible results during competitions. Moreover, it is known that taekwondo shows high risk of injury. The aim of this case study is to evaluate the effects of a specific training protocol on posturographic parameters of a taekwondo elite athlete in order to prevent the risk of injury.
   Materials and methods: The specific training protocol provided 2 months of general strength conditioning, which included pre-conditioning in the first 2 weeks, physical training to improve explosive strength, balance and postural control and athletic training to improve the combat technique. The experimental design included three assessment times: the pre-test (T-0), the intermediate-test (T-1) and the post-test (T-2). Each test provided the same evaluations: anthropometric measurements, cervical ROM assessment and posturographic evaluation.
   Results: Stabilometric parameters showed a good balance and postural control both in T-0 and T-2. Baropodometric parameters showed a physiological load pressure distribution between the left and the right foot in T-0 (left foot 54% - right foot 46%) as well as in T-2 (left foot 45% - right foot 55%). The left forefoot-rearfoot ratio pressure showed no differences between T-0 and T-2 (p>0.05); we found an improvement on the right forefoot-rearfoot ratio (p<0.05). Cervical range of motion evaluation showed no significant variations from T-0 to T-2 (p>0.05) on rotation and lateral bending movements; we found an improvement on the extension movement from T-0 to T-2 (p<0.05), while the flexion movement decreased (p>0.05).
   Conclusion: The presented case study showed that the experimental protocol improved the postural parameters of this taekwondo elite athlete. We believe that other athletes may adopt this protocol in order to improve own sports performance and to prevent injuries.
C1 [Barcellona, Matteo; Battaglia, Giuseppe; Palma, Antonio] Univ Palermo, Sport & Exercise Sci Res Unit, Palermo, Italy.
   [Giustino, Valerio; Messina, Giuseppe; Iovane, Angelo] Univ Palermo, Posturol & Biomech Lab Res Unit, Palermo, Italy.
   [Giustino, Valerio; Messina, Giuseppe] Posturalab Italia Res Inst, Palermo, Italy.
   [Messina, Giuseppe; Battaglia, Giuseppe; Palma, Antonio; Iovane, Angelo] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Battaglia, Giuseppe; Palma, Antonio] CONI Sicilia, Reg Sports Sch, Sicily, Italy.
   [Fischetti, Francesco] Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy.
RP Messina, G (corresponding author), Via Giovanni Pascoli 6, Palermo, Italy.
EM giuseppe.messina17@unipa.it
RI Giustino, Valerio/AAR-6788-2021; Messina, Giuseppe/N-7298-2019;
   Battaglia, Giuseppe/AAV-3916-2020
OI Giustino, Valerio/0000-0002-4575-8021; Messina,
   Giuseppe/0000-0003-2774-4950; Battaglia, Giuseppe/0000-0002-7758-7175;
   Francesco, Fischetti/0000-0001-8616-5372
CR Alexandrov AV, 2001, BIOL CYBERN, V84, P435, DOI 10.1007/PL00007987
   Baldini A, 2013, AVIAT SPACE ENVIR MD, V84, P823, DOI 10.3357/ASEM.3541.2013
   Battaglia G, 2016, ACTA MEDICA MEDITERR, V32, P1589, DOI 10.19193/0393-6384_2016_5_135
   Battaglia G, 2010, AGING CLIN EXP RES, V22, P406, DOI [10.3275/6713, 10.1007/BF03337736]
   Bellafiore M, 2011, AGING CLIN EXP RES, V23, P378, DOI [10.3275/7354, 10.1007/BF03337762]
   Bianco A, 2016, J SPORTS MED, V7
   Bianco A, 2014, J INT SOC SPORT NUTR, V11, DOI 10.1186/1550-2783-11-30
   Cho Kang Ok, 2013, J Lifestyle Med, V3, P54
   Creath R, 2005, NEUROSCI LETT, V377, P75, DOI 10.1016/j.neulet.2004.11.071
   Gorgy O, 2008, J SPORT SCI, V26, P629, DOI 10.1080/02640410701670401
   GURFINKEL VS, 1995, NEUROSCIENCE, V68, P229, DOI 10.1016/0306-4522(95)00136-7
   Hamaoui A, 2014, GAIT POSTURE, V39, P333, DOI 10.1016/j.gaitpost.2013.07.131
   Hrysomallis C, 2007, SPORTS MED, V37, P547, DOI 10.2165/00007256-200737060-00007
   Ji M, 2016, J PHYS THER SCI, V28, P231, DOI 10.1589/jpts.28.1544
   Kazemi Mohsen, 2009, J Can Chiropr Assoc, V53, P144
   Lystad RP, 2015, BIOL SPORT, V32, P213, DOI 10.5604/20831862.1150303
   Lystad RP, 2009, J SCI MED SPORT, V12, P614, DOI 10.1016/j.jsams.2008.09.013
   McLeod TCV, 2009, J SPORT REHABIL, V18, P465, DOI 10.1123/jsr.18.4.465
   Neto HP, 2015, J BODYW MOV THER, V19, P429, DOI 10.1016/j.jbmt.2014.09.007
   Runge CF, 1999, GAIT POSTURE, V10, P161, DOI 10.1016/S0966-6362(99)00032-6
   Thomas E, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010244
   van Dijk GP, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00010
   Verhagen E, 2004, AM J SPORT MED, V32, P1385, DOI 10.1177/0363546503262177
   Winter DA, 1998, J NEUROPHYSIOL, V80, P1211, DOI 10.1152/jn.1998.80.3.1211
   Yoon SD, 2015, J PHYS THER SCI, V27, P509, DOI 10.1589/jpts.27.509
NR 25
TC 4
Z9 4
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1533
EP 1538
DI 10.19193/0393-6384_2018_3s_236
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400013
DA 2022-07-14
ER

PT J
AU Barone, A
   Ascione, A
   Tafuri, D
AF Barone, Augusto
   Ascione, Antonio
   Tafuri, Domenico
TI SPORT MEDICINE AND DISABILITY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Sport Medicine; Athlete; Disability; Inclusion
AB The sports medical examination of the disabled subject represents an important moment in the doctor-athlete relationship, more than in the case of a non-disabled subject; the person's expectations (together with his family's ones) are confronted, in fact, with the pathology the subject carries in a different context from the rehabilitation setting, from the perspective of the access to the sports universe which, at any level, can represent an excellent tool for growth and affirmation, as well as a stumulus to the set up of inclusive processes towards the disabled athlete.
C1 [Ascione, Antonio; Tafuri, Domenico] Univ Naples Parthenope, Naples, Italy.
   [Barone, Augusto; Tafuri, Domenico] CONI Reg Sports Sch, Rome, Italy.
RP Ascione, A (corresponding author), Univ Naples Parthenope, Naples, Italy.
EM antonio.ascione@uniparthenope.it
CR Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   ICD 10 Version, 2016, INT STAT CLASS DIS R
   ICF. International Classification of Functioning, 2002, INT CLASS FUNCT DIS
   LUCKASSON R, 1992, MENTAL RETARDATION D
   Nicoletti R, 2007, IL CONTROLLO MOTORIO
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Petralia MC, 2018, ACTA MEDICA MEDITERR, V34, P107, DOI 10.19193/0393-6384_2018_1_18
   Porciani M, 1995, SPORT HANDICAP
   Raimondi P, 2006, TEORIA METODOLOGIA D
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Tafuri D., 2017, SPORT SCI, V10, P70
   1996, DSM 4 DIAGNOSTIC STA
NR 20
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1529
EP 1532
DI 10.19193/0393-6384_2018_3s_235
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400012
DA 2022-07-14
ER

PT J
AU Basile, MS
   Coco, M
   Buscemi, A
   Petralia, MC
AF Basile, Maria Sofia
   Coco, Marinella
   Buscemi, Andrea
   Petralia, Maria Cristina
TI BRIEF REVIEW ON THE HISTORICAL EVOLUTION OF KINEMATICS AND ITS
   APPLICATION IN CLINICAL PRACTICE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE kinematics; walking; human movement
AB Walking is one of the basics of human movement.
   Once learned, walking becomes an acquired skill, therefore we are able to move automatically without thinking.
   Over centuries, advances in science and technology have led to the study of human walking mechanisms.
   Brief review on the historical evolution of kinematics and its application in clinical practice
C1 [Basile, Maria Sofia; Coco, Marinella; Petralia, Maria Cristina] Univ Catania, Dept Biomed Biotechnol Sci, Catania, Italy.
   [Petralia, Maria Cristina] Univ Catania, Dept Educ Sci, Catania, Italy.
   [Buscemi, Andrea] Horus Social Cooperat, Ragusa, Italy.
   [Buscemi, Andrea] Ctr Studies Osteopathy, Dept Res, Catania, Italy.
RP Coco, M (corresponding author), Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
EM marinella.coco@gmail.com
RI Petralia, Maria/AAE-6337-2019; Basile, Maria Sofia/AAC-3393-2019; Coco,
   Marinella/AAC-8750-2020
OI Basile, Maria Sofia/0000-0002-4811-4694; Petralia, Maria
   Cristina/0000-0002-9643-1045
CR Buscemi A, 2016, ACTA MEDICA MEDITERR, V32, P953, DOI 10.19193/0393-6384_2016_4_115
   Coco M., 2018, SPORT SCI HLTH, V14, P547, DOI [10.1007/s11332-018-0458-x, DOI 10.1007/S11332-018-0458-X]
   Coco M, 2013, PERCIAVALLE CURA VOL
   Coco M, 2017, NEUROL SCI, V38, P1865, DOI 10.1007/s10072-017-3014-6
   Fenn WO, 1935, J PHYSIOL-LONDON, V85, P277, DOI 10.1113/jphysiol.1935.sp003318
   Musumeci G, 2014, ACTA HISTOCHEM, V116, P61, DOI 10.1016/j.acthis.2013.05.006
   Perciavalle V, 2017, NEUROL SCI, V38, P451, DOI 10.1007/s10072-016-2790-8
   Perciavalle V, 2016, PHYSICIAN SPORTSMED, V44, P403, DOI 10.1080/00913847.2016.1222852
   Petralia MC, 2018, SPORT SCI HLTH, V14, P455, DOI [10.1007/s11332-018-0431-8, DOI 10.1007/S11332-018-0431-8]
   SAUNDERS JBDM, 1953, J BONE JOINT SURG AM, V35-A, P543, DOI 10.2106/00004623-195335030-00003
   SCHERB R, 1945, SCHWEIZ MED WSCHR, V75, P1077
   Scherb R., 1927, BEILAGEHEFT Z ORTHOP, V48, P462
   Schwartz RP, 1932, J BONE JOINT SURG, V14, P783
NR 13
TC 2
Z9 2
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 911
EP 913
DI 10.19193/0393-6384_2018_4_138
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500001
DA 2022-07-14
ER

PT J
AU Bavykina, IA
   Miroshnichenko, LA
   Zvyagin, AA
   Burkovsky, VL
AF Bavykina, Irina A.
   Miroshnichenko, Lidiya A.
   Zvyagin, Alexandr A.
   Burkovsky, Victor L.
TI AMARANTH PRODUCTS IN THE GLUTEN-FREE DIET AND THEIR IMPACT ON PATIENTS'
   PHYSICAL DEVELOPMENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE gluten intolerance; gluten-free diet; amaranth products; physical
   growth; children
ID QUALITY-OF-LIFE; CELIAC-DISEASE; CHILDREN
AB Introduction: The article is devoted to the problem of gluten intolerance. In recent years, amaranth products have been considered an alternative source of gluten-free products due to low content of prolamins.
   Objective: To evaluate physical growth in children following gluten : free diet after introduction of new amaranth products into their diet, and to study the influence of amaranth products on the adherence to ,gluten-free diet. Materials and methods. The study included 37 children, aged 1-17, with gluten intolerance, who followed gluten free diet six months and more. Their physical development was assessed according to WHO criteria, and their parents reported adherence to gluten-free diet using a specially designed questionnaire. The patients were examined before and after amaranth product introduction into their diets.
   Results: The research demonstrated that 73% of patients (n=27) strictly followed ,gluten-free diet. 18.9% of children violated the diet rarely, 8.1% frequently violated the diet for a long time. Pathologically low height was diagnosed in 21.5% of children; 5.4% were tall, 59.5% of children were of medium height, 8.1% of children were shorter than medium, 5.4% were higher than medium. Lower body mass was diagnosed in 37.8% of patients, excess body mass was observed in 8.1%; 54.1% of patients had regular (normal?) body mass value. 100% of families included in the study became interested in the option to expand the diet of a child with gluten free products made from amaranth. Regular amaranth product consumption resulted in the increased number of children following strict gluten : free diet (up to 83.8%) and improved physical growth parameters.
   Conclusion: Amaranth products consumption facilitated adherence to gluten free diet, improved nutrition quality, reduced psycho-emotional over strain in children due to the opportunity to vary their diet by new gluten free amaranth products.
C1 [Bavykina, Irina A.; Zvyagin, Alexandr A.] Voronezh State Med Univ, Voronezh, Russia.
   [Miroshnichenko, Lidiya A.] OOO Russkaya Oliva, Voronezh, Russia.
   [Burkovsky, Victor L.] Voronezh State Tech Univ, Voronezh, Russia.
RP Bavykina, IA (corresponding author), 10 Studencheskaya St, Voronezh 394036, Russia.
EM i-bavikina@yandex.ru
FU Russian Federation [MK-114.2017.7]
FX The study was carried out with the financial support of the grant of the
   President of the Russian Federation for young Russian scientists -
   candidates of sciences No. MK-114.2017.7.
CR Bavykina I A, 2017, Vopr Pitan, V86, P91, DOI 10.24411/0042-8833-2017-00038
   Bavykina I. A., 2015, VOPROSY PRAKTICHESKO, V10, P20
   Bavykina I. A., 2016, VOPR DETSK DIET, V14, P40
   Bianco Antonino, 2018, SUSTAINABILITY, V10, P1847
   Caselato-Sousa VM, 2012, FOOD SCI, V77, P93
   Czaja-Bulsa G, 2015, CLIN NUTR, V34, P189, DOI 10.1016/j.clnu.2014.08.012
   Halmos EP, 2018, ALIMENT PHARM THER, V48, P78, DOI 10.1111/apt.14791
   Marchese A, 2013, EUR J INTERN MED, V24, P87, DOI 10.1016/j.ejim.2012.09.015
   Mooney Peter D, 2014, BMJ-BRIT MED J, V348, P1561
   Ortega FB, 2008, INT J OBESITY, V32, P1, DOI 10.1038/sj.ijo.0803774
   Oxentenko AS, 2015, CLIN GASTROENTEROL H, V13, P1396, DOI 10.1016/j.cgh.2014.07.024
   Pacheco GG, 2014, ARCH ARGENT PEDIATR, V112, P457, DOI [10.1590/S0325-00752014000500012, 10.5546/aap.2014.457]
   Arce MFP, 2018, NUTR HOSP, V35, P25, DOI 10.20960/nh.919
   Almagro JR, 2017, J CLIN NURS, V26, P1119, DOI 10.1111/jocn.13584
   Sainsbury K, 2018, APPETITE, V125, P356, DOI 10.1016/j.appet.2018.02.023
   Samasca Gabriel, 2014, Gastroenterol Hepatol Bed Bench, V7, P139
   Singh P, 2015, NATL MED J INDIA, V28, P176
   Subbotina O. A., 2013, Voprosy Pitaniya, V82, P34
   Szakacs Z, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187526
   Theethira TG, 2014, EXPERT REV GASTROENT, V8, P123, DOI 10.1586/17474124.2014.876360
   Usta M., 2014, IRAN J PEDIATR, V24, P1
   Zis P, 2018, NUTRIENTS, V10
   Zuccotti G, 2013, J HUM NUTR DIET, V26, P436, DOI 10.1111/jhn.12026
   Zviagin A. A, 2015, VOPR DETSK DIET, V13, P37
   Zvyagin A. A., 2015, Pediatriya (Moscow), V94, P141
   Zvyagin A.A., 2015, VOPROSY DETSKOY DIET, V13, P46
NR 26
TC 0
Z9 0
U1 0
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 2001
EP 2006
DI 10.19193/0393-6384_2018_6_312
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400063
DA 2022-07-14
ER

PT J
AU Bayan, K
   Celen, MK
   Dal, T
   Ayaz, C
   Tekin, R
   Akdemir, I
   Sari, T
   Gunal, O
   Efe, SC
AF Bayan, Kadim
   Celen, Mustafa Kemal
   Dal, Tuba
   Ayaz, Celal
   Tekin, Recep
   Akdemir, Irem
   Sari, Tugba
   Gunal, Ozgur
   Efe, Savas Cumali
TI OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN
   HCV PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hepatitis C; treatment; genotype
ID C VIRUS GENOTYPES; CHRONIC HEPATITIS-C; INFECTION; ABT-450/R-OMBITASVIR;
   RIBAVIRIN; TURKEY; EFFICACY; PROVINCE
AB Introduction: Achieving sustained virologic response (SVR) is critical in HCV patients. In current study, we aimed to investigate the efficacy and safety of DAA (OBV/PTV/r + DSV +/- RBV) treatment regimen in patients with HCV.
   Materials and method: A total of 57 adults with HCV infection who initiated treatment DAA were included in this study. Baseline, 4 weeks and 12 weeks data including clinical characteristics, laboratory results and adverse events (AEs) were recorded.
   Results: One patient left treatment at the second week. The majority of patients were female 33 (57.9 %) and HCV GT1b (80.7%). Of the patients, 43 (75.4 %) patients were treatment experienced with pegylated interferon +/- RBV and 14 (25.6%) patients were naive. Ten (17.5%) patients had liver cirrhosis, 3 patients renal insufficiency, 7 patients diabetes mellitus, and 6 patients hypertension. Mean baseline ALT and HCV RNA levels was 48.58 +/- 25.8 U/L and 2857661 +/- 7231938 IU/ml, respectively. At the end of the week 4, one patient had >15 IU/mL HCVRNA level, HCVRNA was negative in remaining patients and mean ALT levels was 34.7 +/- 17.01 U/L. Three (5.3%) patient had AEs. At the end of the week 12, HCVRNA was negative in all patients, mean ALT levels was 29.3 +/- 12.2 U/L, 8 (14%) patients had AEs.
   Conclusion: DAA was a safe and effective therapy with 100% SVR rate and low treatment discontinuation rate (1.7 %) in patients with HCV GT1, GT1a and GT1b. This was well tolerated and efficient treatment aproach in patients with liver cirrhosis, renal insufficiency, diabetes mellitus, and hypertension.
C1 [Bayan, Kadim] Diyarbakir Sultan Hosp, Dept Gastroenterol, Diyarbakir, Turkey.
   [Celen, Mustafa Kemal; Ayaz, Celal; Tekin, Recep] Dicle Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Diyarbakir, Turkey.
   [Dal, Tuba] Ankara Yildirim Beyazit Univ, Sch Med, Dept Med Microbiol, Ankara, Turkey.
   [Akdemir, Irem] Batman Reg State Hosp, Dept Infect Dis & Clin Microbiol, Batman, Turkey.
   [Sari, Tugba] Turkish Natl Publ Hlth Agcy, Ankara, Turkey.
   [Gunal, Ozgur] Samsun Training & Educ Hosp, Dept Infect Dis & Clin Microbiol, Samsun, Turkey.
   [Efe, Savas Cumali] Batman Reg State Hosp, Dept Gastroenterol, Batman, Turkey.
RP Dal, T (corresponding author), Ankara Yildirim Beyazit Univ, Med Fac, Dept Med Microbiol, Ankara, Turkey.
RI Gunal, Ozgur/V-6314-2019; Sari, Tugba/A-5204-2018; Kalkan, İrem
   Akdemir/ABI-7558-2020; gunal, ozgur/I-7882-2014
OI Gunal, Ozgur/0000-0002-7744-4123; Kalkan, İrem
   Akdemir/0000-0001-5136-9148; Sari, Tugba/0000-0003-3204-2371
CR AbbVie Ltd (United Kingdom), 2016, EU SUMM PROD CHAR SM
   Aktas E, 2010, MIKROBIYOL BUL, V44, P647
   Alter MJ, 2007, WORLD J GASTROENTERO, V13, P2436, DOI 10.3748/wjg.v13.i17.2436
   Altindis M, 2016, BIOTECHNOL BIOTEC EQ, V30, P335, DOI 10.1080/13102818.2015.1093430
   Altuglu I, 2008, INT J INFECT DIS, V12, P239, DOI 10.1016/j.ijid.2007.07.003
   Antaki N, 2010, LIVER INT, V30, P342, DOI 10.1111/j.1478-3231.2009.02188.x
   Ayaz C, 2008, WORLD J GASTROENTERO, V14, P255, DOI 10.3748/wjg.14.255
   Bostan N, 2010, CRIT REV MICROBIOL, V36, P91, DOI 10.3109/10408410903357455
   Centers for Disease Control and Prevention, 2015, HEP C INF HLTH PROF
   Dayan S, 2013, J INFECT DEV COUNTR, V7, P665, DOI 10.3855/jidc.2835
   Dubuisson J, 2007, WORLD J GASTROENTERO, V13, P2406, DOI 10.3748/wjg.v13.i17.2406
   Feld JJ, 2016, J HEPATOL, V64, P301, DOI 10.1016/j.jhep.2015.10.005
   Feld JJ, 2014, NEW ENGL J MED, V370, P1594, DOI 10.1056/NEJMoa1315722
   Ferenci P, 2014, NEW ENGL J MED, V370, P1983, DOI 10.1056/NEJMoa1402338
   Jubin R, 2001, CURR OPIN MOL THER, V3, P278
   Kalayci R, 2010, MIKROBIYOL BUL, V44, P237
   Marascio N, 2012, J PATHOG, V2012, DOI 10.1155/2012/631095
   Pockros PJ, 2016, GASTROENTEROLOGY, V150, P1590, DOI 10.1053/j.gastro.2016.02.078
   Poordad F, 2014, NEW ENGL J MED, V370, P1973, DOI 10.1056/NEJMoa1402869
   Reker C, 2014, INT J INFECT DIS, V25, P104, DOI 10.1016/j.ijid.2014.02.003
   Rigat K, 2010, ANTIVIR RES, V88, P197, DOI 10.1016/j.antiviral.2010.08.014
   Saglik I, 2014, MIKROBIYOL BUL, V48, P429
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Sunbul M, 2014, WORLD J GASTROENTERO, V20, P5427, DOI 10.3748/wjg.v20.i18.5427
   Tezcan S, 2013, MIKROBIYOL BUL, V47, P332, DOI 10.5578/mb.4063
   Welzel TM, 2017, J VIRAL HEPAT
   Zeuzem S, 2014, NEW ENGL J MED, V370, P1604, DOI 10.1056/NEJMoa1401561
NR 27
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 71
EP 75
DI 10.19193/0393-6384_2018_1_12
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600012
DA 2022-07-14
ER

PT J
AU Belfiore, P
   Di Palma, D
   Ascione, A
AF Belfiore, Patrizia
   Di Palma, Davide
   Ascione, Antonio
TI ADAPTED PHYSICAL ACTIVITY (APA) FOR THE TUTELAGE OF PATIENTS WITH TYPE
   II DIABETES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Type II Diabetes; Adapted Physical Activity; Economic sustainability;
   Budget Impact Analysis
ID LIFE-STYLE; EXERCISE; GLUCOSE; PREVENTION; PREVALENCE; MELLITUS
AB Introduction: Diabetes is one of the major public health problems because a great proportion of the healthcare expenditure has been spent on the treatment of its associated morbidity and mortality.
   Methods: A Budget Impact Analysis (BIA) was carried out from the healthcare management perspective to evaluate the economic sustainability and the aspects of tutelage deriving from the introduction of a structured program of APA for diabetics in Campania.
   Results: The results of the projection show at the end of the five years a possible saving of 27,205,286 euros, distributed among the three cost items.
   Conclusion: This study testify the importance of Adapted Physical Activity (APA) to obtain an optimal healthcare management and to tutelage effective services for the health and wellbeing of individuals.
C1 [Belfiore, Patrizia; Di Palma, Davide; Ascione, Antonio] Parthenope Univ, Dept Sport Sci & Wellness, Naples, Italy.
RP Di Palma, D (corresponding author), Univ Naples Parthenope, Dept Movement & Wellbeing Sci, Naples, Italy.
EM davide.dipalma@uniparthenope.it
OI Di Palma, Davide/0000-0001-8224-5797
CR AMD (Associazione Medici Diabetologi) SID (Societa Italiana di Diabetologia), 2009, STAND IT CUR DIAB ME
   Associazione Medici Diabetologi (AMD) Societa Italiana di Diabetologia (SID), 2014, STAND IT CUR DIAB ME
   Belfiore P, 2015, POLITICHE SANITARIE, V16, P244
   Centers for Disease Control and Prevention, 1996, JAMA-J AM MED ASSOC, V276, P522, DOI DOI 10.1001/JAMA.1996.03540070018010
   Chen L, 2012, NAT REV ENDOCRINOL, V8, P228, DOI 10.1038/nrendo.2011.183
   Consoli A, 2013, ITALIANBAROMETERDIAB
   Creviston T, 2001, NURS CLIN N AM, V36, P243
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X
   Eriksson JG, 1999, SPORTS MED, V27, P381, DOI 10.2165/00007256-199927060-00003
   Galle F, 2015, BENEFICI ATTIVITA FI
   Galle F, 2017, DIABETES THER, V8, P875, DOI 10.1007/s13300-017-0283-2
   Grimaccia F, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/1744-8603-10-58
   Herman WH, 2012, DIABETES CARE, V35, P943, DOI 10.2337/dc12-0298
   Istituto Nazionale di Statistica, 2014, ANN STAT IT 2014
   Istituto Nazionale di Statistica, 2010, ANN STAT IT
   Ivy J L, 1999, Exerc Sport Sci Rev, V27, P1
   Lauro R, 2015, ITALIAN BAROMETER DI, P35
   Liguori G, 2014, EVIDENZE SCI ATTIVIT, P104
   Marcellusi A, 2016, EUR J HEALTH ECON, V17, P139, DOI 10.1007/s10198-014-0660-y
   Marchesini G, 2014, DIABETE MA QUANTO CI
   Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z
   Tudor-Locke CE, 2000, CAN J APPL PHYSIOL, V25, P466, DOI 10.1139/h00-031
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   Wallberg-Henriksson H, 1998, SPORTS MED, V25, P25, DOI 10.2165/00007256-199825010-00003
   Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351
NR 25
TC 14
Z9 14
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1257
EP 1260
DI 10.19193/0393-6384_2018_5_193
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700015
DA 2022-07-14
ER

PT J
AU Belfiore, P
   Di Palma, D
   Ascione, A
AF Belfiore, Patrizia
   Di Palma, Davide
   Ascione, Antonio
TI HEALTH PROMOTION. HEALTH PROTECTION AND SPORT IN THE SCHOOL
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE health promotion; health protection; sport activity; physical education
ID INCREASING PHYSICAL-ACTIVITY; AFTER-SCHOOL; EDUCATION; CHILDREN;
   STUDENTS; PROGRAM; YOUTH
AB Introduction: Sport activity contributes to improve physical conditions and to promote health. However, its importance is often overlooked. It is not always adequately treated in schools.
   Materials and methods: An anonymous questionnaire was administered to 500 students. Demographic data and information about sport activity were also collected.
   Results: A total of 450 (90% response rate) questionnaires were completed. The 90 % of the sample reported current practice of sport. Sport was considered significant by 65% of the students. The relationship between sport and health promotion is important for 55% of the students.
   Conclusions: Sport activity is very important for health promotion. For this reason it is decisive the role it plays in the ,for/nation of students in schools. It is an important link between health promotion and health protection.
C1 [Belfiore, Patrizia; Di Palma, Davide; Ascione, Antonio] Parthenope Univ, Via Medina 40, Naples, Italy.
RP Di Palma, D (corresponding author), Parthenope Univ, Via Medina 40, Naples, Italy.
EM davide.dipalma@uniparthenope.it
OI Di Palma, Davide/0000-0001-8224-5797
CR Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   CDC, 2008, PHYS ACT GUID AM
   Dale D, 2000, RES Q EXERCISE SPORT, V71, P240, DOI 10.1080/02701367.2000.10608904
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   Dobbins M, 2013, COCHRANE DB SYST REV, V2, P1361
   Ford P, 2012, EUR J SPORT SCI, V12, P515, DOI 10.1080/17461391.2011.577241
   Galle F, 2015, SPORT SCI HLTH, V11, P109, DOI [DOI 10.1007/S11332-014-0216-7, 10.1007/s11332-014-0216-7]
   Galle F, 2017, GERIATR GERONTOL INT, V17, P1421, DOI 10.1111/ggi.12879
   Gidlow C, 2008, J SPORT SCI, V26, P1411, DOI 10.1080/02640410802277445
   Hardman K, 2001, INT SPORT STUD, V23, P68
   Hardman K., 2008, HUMAN MOVEMENT, V9, P5, DOI DOI 10.2478/V10038-008-0001-Z
   Hobin EP, 2010, J SCHOOL HEALTH, V80, P445, DOI 10.1111/j.1746-1561.2010.00526.x
   Hohepa M, 2006, J ADOLESCENT HEALTH, V39, P328, DOI 10.1016/j.jadohealth.2005.12.024
   Jago R, 2004, PREV MED, V39, P157, DOI 10.1016/j.ypmed.2004.01.014
   Morgan CF, 2007, RES Q EXERCISE SPORT, V78, P407, DOI 10.5641/193250307X13082505158507
   Morin P, 2013, J SCHOOL HEALTH, V83, P597, DOI 10.1111/josh.12071
   Morton KL, 2016, OBES REV, V17, P142, DOI 10.1111/obr.12352
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Sport Science, V9, P24
   Pommier J, 2011, GLOB HEALTH PROMOT, V18, P34, DOI 10.1177/1757975910393585
   Sacchetti R, 2013, J SCHOOL HEALTH, V83, P639, DOI 10.1111/josh.12076
   School Sport Canada, 2013, SSC
   Tang KC, 2009, HEALTH PROMOT INT, V24, P68, DOI 10.1093/heapro/dan037
   Trost SG, 2008, MED SCI SPORT EXER, V40, P622, DOI 10.1249/MSS.0b013e318161eaa5
   Tudor-Locke C, 2009, RES Q EXERCISE SPORT, V80, P164, DOI 10.1080/02701367.2009.10599550
   US Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU
   US National Physical Activity Plan Alliance, 2010, PUBL HLTH NAT PHYS A
   World Health Organization, 2010, GLOB STRAT DIET PHYS
   World Health Organization, 2011, GLOBAL RECOMMENDATIO
NR 31
TC 1
Z9 1
U1 2
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1483
EP 1486
DI 10.19193/0393-6384_2018_3s_225
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400002
DA 2022-07-14
ER

PT J
AU Belfiore, P
   Di Palma, D
   Ascione, A
AF Belfiore, Patrizia
   Di Palma, Davide
   Ascione, Antonio
TI SPORT, PHYSICAL ACTIVITY AND BREAST CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Sport; Physical Activity; Breast cancer
ID RANDOMIZED CONTROLLED-TRIAL; SURVIVORS; PROTEINS; PROGRAM; INSULIN;
   PEOPLE
AB Introduction. Breast cancer is a big problem in Italy and in the world. Many women are affected. It absorbs many economic resources because it tends to develop complications. Sport and physical activity have positive effects on the pathology and its complications.
   Methods: Number of cases and costs were compared in the presence and absence of physical activity.
   Results: Our results support the idea that physical activity protects against breast cancer.
   Conclusion: This study demonstrates the importance of physical activity and sport in the management of breast cancer and its complications.
C1 [Belfiore, Patrizia; Di Palma, Davide; Ascione, Antonio] Parthenope Univ, Dept Sport Sci & Wellness, Naples, Italy.
RP Di Palma, D (corresponding author), Parthenope Univ, Naples, Italy.
EM davide.dipalma@uniparthenope.it
OI Di Palma, Davide/0000-0001-8224-5797
CR Ancelle-Park R, 2012, J MED SCREEN, V19, P5, DOI 10.1258/jms.2012.012077
   Arrospide A, 2015, REV ESP SALUD PUBLIC, V89, P93, DOI 10.4321/S1135-57272015000100010
   Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Baeten SA, 2011, BREAST J, V17, P548, DOI 10.1111/j.1524-4741.2011.01135.x
   Belfiore P, 2016, IG SANITA PUBBL, V72, P32
   Belfiore P, 2018, J SPORT MED PHYS FIT, V58, P1867, DOI 10.23736/S0022-4707.17.07749-0
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Biller-Andorno N, 2014, NEW ENGL J MED, V370, P1965, DOI 10.1056/NEJMp1401875
   Campbell Anna, 2005, Eur J Oncol Nurs, V9, P56, DOI 10.1016/j.ejon.2004.03.007
   Canadian Partnership Against Cancer, 2013, REP EV IND WORK GROU
   Carles M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-192
   Crowley SA, 2003, EFFECT STRUCTURED EX, P127
   Del Turco MR, 2010, EUR J CANCER, V46, P2344, DOI 10.1016/j.ejca.2010.06.119
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1479, DOI 10.19193/0393-6384_2018_3s_224
   Fairey AS, 2003, CANCER EPIDEM BIOMAR, V12, P721
   Friedenreich CM, 2008, BRIT J SPORT MED, V42, P636, DOI 10.1136/bjsm.2006.029132
   Galle F, 2017, GERIATR GERONTOL INT, V17, P1421, DOI 10.1111/ggi.12879
   Hoyle M, 2010, MED DECIS MAKING, V30, P426, DOI 10.1177/0272989X09353946
   Lee Sandra, 2006, J Natl Cancer Inst Monogr, P79, DOI 10.1093/jncimonographs/lgj011
   Liguori G, 2017, CLIN CHEM LAB MED, V55, P32, DOI 10.1515/cclm-2016-0371
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Sport Science, V9, P24
   Rue M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-326
   Schmitz KH, 2005, CANCER EPIDEM BIOMAR, V14, P1672, DOI 10.1158/1055-9965.EPI-04-0736
NR 25
TC 0
Z9 0
U1 7
U2 13
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1869
EP 1872
DI 10.19193/0393-6384_2018_6_289
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400040
DA 2022-07-14
ER

PT J
AU Berber, I
   Sahin, I
   Gorgel, A
   Cagin, YF
   Bag, HG
   Berber, NK
AF Berber, Ilhami
   Sahin, Idris
   Gorgel, Ahmet
   Cagin, Yasir Furkan
   Bag, Harika Gozukara
   Berber, Nurcan Kirici
TI EFFECTS OF RENAL REPLACEMENT THERAPY ON FIBROMYALGIA SYNDROME IN
   PATIENTS WITH CHRONIC KIDNEY DISEASE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Chronic kidney disease; fibromyalgia; hemodialysis; continuous
   ambulatory peritoneal dialysis
ID PREVALENCE; POPULATION; TURKEY
AB Introduction: Although musculoskeletal disorders are among the major complications of chronic kidney disease (CKD), there are scarce data to investigate fibromyalgia syndrome (FMS) in these patients. We aimed to investigate the prevalence of FMS in the patients with CKD.
   Material and methods: A total of 289 (119 predialysis (PD), 85 hemodialysis (HD), 85 continuous ambulatory peritoneal dialysis (CAPD)) patients were included. Diagnosis of FMS was based on American College of Rheumatology (ACR) 1990 FMS criteria.
   Results: Mean age was 52 +/- 16 years (range 18-89 years). One-hundred-sixty-four (56.7%) of them were male. A total of 46 patients (10 male/36 female) (15.9%) were diagnosed FMS. The prevalence of FMS was 28.8% in females and 6.1% in males. Compared to males, females had a significantly higher rate of FMS (p<0.001). The prevalence of FMS was 19.3% in PD group, 17.6% in the CAPD group, and 9.4% in the HD group. Although the frequency of FMS was lower in HD group compared to both the PD and the CAPD groups, the differences were not statistically significant (for HD vs PD, p=0.052; for HD vs CAPD, p=0.113). In PD group, hemoglobin (Hb) levels were significantly higher in patients with FMS than without FMS. Parathormone (PTH) levels were significantly lower in CAPD patients with FMS than without FMS. Although the prevalence of FMS was increased in PD and CAPD patients, this increase did not reach statistical significance. FMS was markedly more prevalent in female patients. While the Hb level was lower in the PD patients with FMS, PTH level was lower in the CAPD patients diagnosed with FMS.
   Conclusions: Our study demonstrated that the rate of FMS was higher in PD and CAPD patients compared to HD patients, although our results did not reach statistical significance. Among the entire demographic and laboratory parameters, female gender was found to be significant risk factor for development of FMS. Future multicenter studies which have large sample size are clearly needed to determine other factors related to development of FMS in patients with CKD.
C1 [Berber, Ilhami] Malatya Educ Res Hosp, Dept Hematol, Malatya, Turkey.
   [Sahin, Idris] Inonu Univ, Fac Med, Dept Internal Med, Nephrol Div, Malatya, Turkey.
   [Gorgel, Ahmet] Gozde Acad Hosp, Dept Endocrinol, Malatya, Turkey.
   [Cagin, Yasir Furkan] Malatya Educ Res Hosp, Dept Gastroenterol, Malatya, Turkey.
   [Bag, Harika Gozukara] Inonu Univ, Fac Med, Dept Biostat, Malatya, Turkey.
   [Berber, Nurcan Kirici] Malatya Educ Res Hosp, Dept Chest Med, Malatya, Turkey.
RP Berber, I (corresponding author), Malatya Educ Res Hosp, TR-44280 Malatya, Turkey.
EM drilhamiberber@hotmail.com
RI Sahin, Idris/AAS-4390-2020; Bag, Harika Gozde Gozukara/ABG-7588-2020;
   BERBER, Ilhami/ABI-6231-2020; görgel, ahmet/Q-3139-2019; Cagin, Yasir
   Furkan/ABI-2709-2020
OI Sahin, Idris/0000-0002-8683-3737; Bag, Harika Gozde
   Gozukara/0000-0003-1208-4072; BERBER, Ilhami/0000-0003-3312-8476; Cagin,
   Yasir Furkan/0000-0002-2538-857X
CR Avila-Diaz M, 2006, PERITON DIALYSIS INT, V26, P78
   Bagis S, 2013, RHEUMATOL INT, V33, P167, DOI 10.1007/s00296-011-2334-8
   Bardin T, 2003, CURR OPIN RHEUMATOL, V15, P48, DOI 10.1097/00002281-200301000-00009
   Couto CI, 2008, HEMODIAL INT, V12, P66, DOI 10.1111/j.1542-4758.2008.00243.x
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Ferrari R, 1996, Curr Opin Rheumatol, V8, P71
   Kart-Koseoglu H, 2005, RHEUMATOL INT, V25, P270, DOI 10.1007/s00296-003-0431-z
   McCarberg BH, 2012, AM J THER, V19, P357, DOI 10.1097/MJT.0b013e3181ff7bee
   Sahin I, 2009, RENAL FAILURE, V31, P920, DOI 10.3109/08860220903219265
   Sakarya ST, 2011, CLIN RHEUMATOL, V30, P1039, DOI 10.1007/s10067-011-1697-2
   Suk JH, 2012, EXP CLIN ENDOCR DIAB, V120, P401, DOI 10.1055/s-0032-1309008
   Suleymanlar G, 2011, NEPHROL DIAL TRANSPL, V26, P1862, DOI 10.1093/ndt/gfq656
   Topbas M, 2005, SCAND J RHEUMATOL, V34, P140, DOI 10.1080/03009740510026337
   WOLFE F, 1995, J RHEUMATOL, V22, P151
   WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104
   WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203
   Yanova D, 2007, HIPPOKRATIA, V11, P199
   Yuceturk TE, NEPHROL DIAL TRANSPL, V2205, P2485
NR 18
TC 2
Z9 2
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 337
EP 343
DI 10.19193/0393-6384_2018_2_53
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400007
DA 2022-07-14
ER

PT J
AU Bertozzi, G
   Di Battista, B
   Cascio, O
   Albano, GD
   Montana, A
   Maglietta, F
   Cipolloni, L
   Monda, V
   Messina, A
   Salerno, M
AF Bertozzi, Giuseppe
   Di Battista, Benedetta
   Cascio, Orazio
   Albano, Giuseppe Davide
   Montana, Angelo
   Maglietta, Francesca
   Cipolloni, Luigi
   Monda, Vincenzo
   Messina, Antonietta
   Salerno, Monica
TI A LETHAL DRIPPING FROM THE NECK: A CASE REPORT AND MINI REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE carotid blowout syndrome; head-and-neck cancers; post-actinic
   arteriopathy; autopsy
ID CAROTID BLOWOUT SYNDROME; IRRADIATION; HEAD; EXPRESSION; MANAGEMENT;
   MIGRAINE; INCREASE; ARTERY; STRESS; REGION
AB Post-actinic arteriopathy is one of the most devastating complications associated with therapy for head-and-neck cancers. We report a case of 67-year-old man presented to local emergency ward with left side neck blood dripping who died in a few hours before any diagnoses and treatment could be realized. Autoptic dissection found a 0,4cm length interruption in left internal carotid artery wall, within a fibrotic scar, which comprise the carotid sinus and its bifurcation. An injection and pumping proof with the water to simulate blood flow was conducted and demonstrated water jar from the left wall carotid artery injury. A diagnosis of acute carotid blowout syndrome was posed as cause of death.
C1 [Bertozzi, Giuseppe; Di Battista, Benedetta; Albano, Giuseppe Davide; Salerno, Monica] Univ Foggia, Sect Forens Pathol, Dept Clin & Expt Med, Foggia, Italy.
   [Cascio, Orazio; Montana, Angelo; Maglietta, Francesca] Univ Catania, Dept Adv Med Surg Sci & Technol GF Ingrassi, Catania, Italy.
   [Cipolloni, Luigi] Univ Roma La Sapienza, Dept Anat Histol Forens & Orthopaed Sci, Rome, Italy.
   [Monda, Vincenzo; Messina, Antonietta] Univ Campania Luigi Vanvitelli, Sect Human Physiol, Dept Expt Med, Naples, Italy.
RP Salerno, M (corresponding author), Univ Foggia, Sect Forens Pathol, Dept Clin & Expt Med, Osped Colonnello Avanzo, Viale Aviatori 1, I-71100 Foggia, Italy.
EM monica.salerno@unifg.it
RI Messina, Antonietta/AHH-2383-2022; MESSINA, ANTONIETTA/K-9366-2016;
   SALERNO, MONICA/AAC-1321-2019; Cipolloni, Luigi/AAS-2680-2020; Bertozzi,
   Giuseppe/AAS-9882-2020
OI Messina, Antonietta/0000-0001-8343-432X; SALERNO,
   MONICA/0000-0002-6410-3960; Bertozzi, Giuseppe/0000-0002-8179-1072;
   Maglietta, Francesca/0000-0001-7240-5902; Monda,
   Vincenzo/0000-0002-6083-5814
CR Becker M, 1997, RADIOGRAPHICS, V17, P5, DOI 10.1148/radiographics.17.1.9017796
   Bramanti V, 2015, J NEUROSCI RES, V93, P521, DOI 10.1002/jnr.23506
   Bramanti V, 2012, NEUROCHEM RES, V37, P2795, DOI 10.1007/s11064-012-0873-3
   Bramanti V, 2008, CLIN EXP HYPERTENS, V30, P798, DOI 10.1080/10641960802563576
   Cacopardo B, 2013, BMC SURG, V13, DOI 10.1186/1471-2482-13-S2-S50
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Cerretani D, 2011, PHARMACOL RES, V64, P517, DOI 10.1016/j.phrs.2011.08.002
   Chaloupka JC, 1999, AM J NEURORADIOL, V20, P1069
   Chaloupka JC, 1996, AM J NEURORADIOL, V17, P843
   Chang FC, 2008, J VASC SURG, V47, P936, DOI 10.1016/j.jvs.2007.12.030
   Chen KC, 2015, HEAD NECK-J SCI SPEC, V37, P794, DOI 10.1002/hed.23671
   CHUNG TS, 1994, J COMPUT ASSIST TOMO, V18, P533, DOI 10.1097/00004728-199407000-00003
   Cianci P, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0857-x
   Conomv JP, 1975, CANCER, V35, P1537
   Dorresteijn LDA, 2005, EUR J CANCER, V41, P1026, DOI 10.1016/j.ejca.2005.01.020
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   ESPOSITO M, 2013, NEUR, V9, DOI DOI 10.2147/NDT.S42182
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Forlano I, 2011, ANN ITAL CHIR, V82, P405
   Gianicolo ME, 2010, CARDIOVASC ULTRASOUN, V8, DOI 10.1186/1476-7120-8-8
   Gleysteen J, 2016, OTOLARYNG CLIN N AM, V49, P829, DOI 10.1016/j.otc.2016.02.001
   Loong HH, 2008, HEMATOL ONCOL CLIN N, V22, P1267, DOI 10.1016/j.hoc.2008.08.012
   Luo CB, 2006, EUR ARCH OTO-RHINO-L, V263, P644, DOI 10.1007/s00405-006-0028-8
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Muzaffar K, 2000, LARYNGOSCOPE, V110, P1811, DOI 10.1097/00005537-200011000-00007
   Neri V, 2013, ANN ITAL CHIR, V84, P47
   Neri V, 2009, ANN ITAL CHIR, V80, P363
   Neri V, 2009, PANCREAS, V38, P717, DOI 10.1097/MPA.0b013e3181a83087
   Okamura H, 2002, ORL J OTO-RHINO-LARY, V64, P226, DOI 10.1159/000058030
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Pomara C, 2012, CURR MED CHEM, V19, P5647, DOI 10.2174/092986712803988811
   Pomara C, 2008, CLIN TOXICOL, V46, P322, DOI 10.1080/15563650701419011
   Pomara C, 2016, J CELL PHYSIOL, V231, P1385, DOI 10.1002/jcp.25272
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2013, FORENSIC SCI INT, V231, P142, DOI 10.1016/j.forsciint.2013.04.006
   Turillazzi E, 2008, VIRCHOWS ARCH, V453, P209, DOI 10.1007/s00428-008-0632-7
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6
   Woodward WA, 2008, CANCER-AM CANCER SOC, V112, P268, DOI 10.1002/cncr.23172
   Zidar N, 1997, J LARYNGOL OTOL, V111, P988, DOI 10.1017/S0022215100139167
NR 57
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 203
EP 207
DI 10.19193/0393-6384_2018_1_33
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600033
DA 2022-07-14
ER

PT J
AU Bianco, A
   Sahin, FN
   Kizilyalli, M
   Genchi, R
   Basile, M
   Silva, C
   Loureiro, N
   Demetriou, Y
   Beckmann, J
   Pajaujiene, S
   Zuoziene, IJ
   Gomez-Lopez, M
   Sanchez, GFL
   Rada, A
   Ribeiro, A
   Castro, JD
   Alesi, M
AF Bianco, Antonino
   Sahin, Fatma Nese
   Kizilyalli, Meltem
   Genchi, Rosario
   Basile, Michele
   Silva, Carlos
   Loureiro, Nuno
   Demetriou, Yolanda
   Beckmann, Juergen
   Pajaujiene, Simona
   Zuoziene, Ilona Judita
   Gomez-Lopez, Manuel
   Lopez Sanchez, Guillermo Felipe
   Rada, Ante
   Ribeiro, Ana
   Castro, Jorge De Almeida
   Alesi, Marianna
TI PHYSICAL FITNESS AND MOTOR COORDINATION MONITORING DURING ENRICHED SPORT
   ACTIVITIES IN A SAMPLE OF CHILDREN LIVING IN EUROPE. THE ESA PROGRAM
SO ACTA MEDICA MEDITERRANEA
LA English
DT Letter
DE ESA Program; Physical Activity; Cognitive Functions; Executive Functions
ID PRESCHOOL-CHILDREN; PREFIT BATTERY; ADOLESCENTS; RELIABILITY
C1 [Bianco, Antonino; Alesi, Marianna] Univ Palermo, Dept Psychol Pedag & Educ Sci, Viale Sci,Ed 15, I-90128 Palermo, Italy.
   [Sahin, Fatma Nese; Kizilyalli, Meltem] Ankara Univ, Fac Sport Sci, Dept Sport & Hlth, Golbasi Yerleskesi Spor Bilimleri Fak, TR-06830 Golbasi Ankara, Turkey.
   [Bianco, Antonino; Genchi, Rosario; Basile, Michele; Alesi, Marianna] Palermo Univ, Sport Ctr CUS Palermo, Via Altofonte 80, I-90129 Palermo, Italy.
   [Silva, Carlos; Loureiro, Nuno] Escola Super Desporto Rio Maior IPSantarem, Av Dr Mario Soares, P-20413 Rio Maior, Portugal.
   [Demetriou, Yolanda; Beckmann, Juergen] Tech Univ Munich, Sch Sport & Hlth Sci, Uptown Munich Campus D,Georg Brauchle Ring 60-62, D-80992 Munich, Germany.
   [Pajaujiene, Simona; Zuoziene, Ilona Judita] Lithuanian Sports Univ, Dept Coaching Sci, Sporto 6, LT-44221 Kaunas, Lithuania.
   [Gomez-Lopez, Manuel; Lopez Sanchez, Guillermo Felipe] Univ Murcia, Fac Sports Sci, Dept Phys Act & Sport, Calle Argentina 19, Murcia 30720, Spain.
   [Rada, Ante] Univ Split, Fac Kinesiol, Teslina 6, Split 21000, Croatia.
   [Ribeiro, Ana; Castro, Jorge De Almeida] Escola Profiss Aveiro, Rua Dr Francisco Ferreira Neves Apartado 567 Baro, P-3800510 Aveiro, Portugal.
RP Bianco, A (corresponding author), Palermo Univ, Sport Ctr CUS Palermo, Via Altofonte 80, I-90129 Palermo, Italy.; Bianco, A (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Via Giovanni Pascoli, I-90128 Palermo, Italy.
RI KIZILYALLI, Meltem/AAD-6016-2020; Bianco, Antonino/AAB-8023-2020;
   Loureiro, Nuno/AAL-8870-2020; Gomez-Lopez, Manuel/I-4101-2012; Rada,
   Ante/D-6382-2017; Sánchez, Guillermo Felipe López/K-8703-2015; Alesi,
   Marianna/R-9650-2019; Bianco, Antonino/AAI-7451-2020; SAHIN, FATMA
   NESE/AAG-9096-2020; Demetriou, Yolanda/AAT-1258-2020; Gómez-López,
   Manuel/L-8894-2019; Marques da Silva, Carlos Manuel/N-4098-2014
OI KIZILYALLI, Meltem/0000-0001-9071-9868; Loureiro,
   Nuno/0000-0002-6558-1956; Rada, Ante/0000-0003-4216-6917; Sánchez,
   Guillermo Felipe López/0000-0002-9897-5273; Bianco,
   Antonino/0000-0001-8334-6581; SAHIN, FATMA NESE/0000-0002-8777-5807;
   Demetriou, Yolanda/0000-0001-6781-1295; Gómez-López,
   Manuel/0000-0002-4595-3994; Marques da Silva, Carlos
   Manuel/0000-0003-4327-5744; Beckmann, Juergen/0000-0001-7238-4646;
   Pajaujiene, Simona/0000-0001-5306-4188
CR Alesi M, 2017, J FUNCTIONAL MORPHOL, V2, P1
   Bianco A, 2015, INT J OCCUP MED ENV, V28, P445, DOI 10.13075/ijomeh.1896.00393
   Cadenas-Sanchez C, 2016, J SCI MED SPORT, V19, P910, DOI 10.1016/j.jsams.2016.02.003
   Catley MJ, 2013, BRIT J SPORT MED, V47, P98, DOI 10.1136/bjsports-2011-090218
   [EU Commission Social SEWETO], 2014, SPORT PHYS ACT
   Faigenbaum AD, 2017, ACTA PAEDIAT
   Faigenbaum AD, 2016, BRIT J SPORT MED, V50, DOI 10.1136/bjsports-2015-094621
   Kao SC, 2017, MED SCI SPORT EXER, V49, P500, DOI 10.1249/MSS.0000000000001132
   Ortega FB, 2015, SPORTS MED, V45, P533, DOI 10.1007/s40279-014-0281-8
   Stracciolini A, 2013, PHYSICIAN SPORTSMED, V41, P94, DOI 10.3810/psm.2013.02.2003
   Wouters M, 2017, RES DEV DISABIL, V61, P77, DOI 10.1016/j.ridd.2016.12.016
NR 11
TC 2
Z9 2
U1 2
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 11
EP 12
DI 10.19193/0393-6384_2018_1_1
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600001
DA 2022-07-14
ER

PT J
AU Bing, LL
   Yu, FY
   Yu, WJ
   Xie, YR
AF Bing, Leilei
   Yu, Fengyun
   Yu, Wenjuan
   Xie, Yanrong
TI THE EXPRESSION AND ROLE OF C-C CHEMOKINE RECEPTOR TYPE 5 IN TYPE II
   DIABETES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE type II diabetes; C-C chemokine receptor type 5; inflammatory response;
   PI3K/Akt/mTOR pathway
ID NONCOMMUNICABLE DISEASES; ASSOCIATION; MELLITUS; TIME; CCR5
AB To investigate the expression and role of C-C chemokine receptor type 5 (CCR5) in the course of type II diabetes and the possible mechanism. 120 specific pathogen free level male SD rats were randomly divided into model group, control group and C-C chemokine receptor type 5 antibody (CCR5Ab) group. Sampling was performed at week 4, 8 and 12. Levels of glycosylated hemoglobin (GHb), HDL, LDL, fasting blood TG and Insulin (Ins) were measured by ELISA or automatic biochemical analyzer, and Insulin sensitivity (IS) and Insulin resistance (IR) index were calculated. CCR5 expression was detected by Western blot and RT-PCR. Levels of IL-6, TNF-alpha, IL-10 and C-reactionprotein in serum were detected by ELISA. Western blot was used to detect the expression levels of PI3K/Akt/mTOR pathway related proteins. Compared with control group, indexes including body weight, levels of GHb, LDL, TG, Ins and IR, expression levels of CCR5, IL-6, TNF-alpha and C-reaction protein (CRP), and ratios of PI3K/Akt, P-PI3K/ and PmTOR/mTOR were significantly increased (p < 0.05), but IS level, HDL level and expression level of IL-10 were significantly decreased in model group. However, CCR5Ab treatment significantly reduced those changes to different extents at different time points. CCR5Ab can improve diabetes by reducing body's inflammatory response, and the mechanism of function is possible related to PI3K/Akt/mTOR pathway.
C1 [Bing, Leilei; Yu, Fengyun; Yu, Wenjuan; Xie, Yanrong] Yantai Hosp Tradit Chinese Med, Dept Endocrinol, 39 Xingfu Rd, Yantai 264001, Shandong, Peoples R China.
RP Xie, YR (corresponding author), Yantai Hosp Tradit Chinese Med, Dept Endocrinol, 39 Xingfu Rd, Yantai 264001, Shandong, Peoples R China.
EM Yanrong_Xie2017@126.com
CR Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011
   Andrade-Cetto A, 2008, J ETHNOPHARMACOL, V116, P27, DOI 10.1016/j.jep.2007.10.031
   [Anonymous], 2014, DIABETES CARE, V37, pS5, DOI 10.2337/dc14-S005
   Barmania F, 2013, APPL TRANSL GENOM, V2, P3, DOI 10.1016/j.atg.2013.05.004
   Belalcazar LM, 2014, FASEB J, V28
   Crume TL, 2016, ANN EPIDEMIOL, V26, P631, DOI 10.1016/j.annepidem.2016.07.014
   Donath MY, 2014, NAT REV DRUG DISCOV, V13, P465, DOI 10.1038/nrd4275
   Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925
   Gross JL, 2011, ANN INTERN MED, V154, P672, DOI 10.7326/0003-4819-154-10-201105170-00007
   Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492
   Inzucchi SE, 2015, DIABETOLOGIA, V58, P429, DOI 10.1007/s00125-014-3460-0
   Islam SMS, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/s12992-014-0081-9
   Kahn SE, 2014, LANCET, V383, P1068, DOI 10.1016/S0140-6736(13)62154-6
   Larsen CM, 2009, DIABETES CARE, V32, P1663, DOI 10.2337/dc09-0533
   Ling C, 2009, DIABETES, V58, P2718, DOI 10.2337/db09-1003
   Matsushita K, 2014, ANESTHESIOLOGY, V120, P1491, DOI 10.1097/ALN.0000000000000190
   Porat S, 2011, CELL METAB, V13, P440, DOI 10.1016/j.cmet.2011.02.012
   Potvin S, 2008, BIOL PSYCHIAT, V63, P801, DOI 10.1016/j.biopsych.2007.09.024
   Rahim HFA, 2014, LANCET, V383, P356, DOI 10.1016/S0140-6736(13)62383-1
   Ribback S, 2015, ONCOTARGET, V6, P13036, DOI 10.18632/oncotarget.3675
   Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303
   Viner R, 2017, LANCET, V389, P2252, DOI 10.1016/S0140-6736(17)31371-5
   Wang Fang, 2008, J Tradit Chin Med, V28, P101
   Yadav AK, 2014, J DIABETES, V6, P547, DOI 10.1111/1753-0407.12128
   Yin XY, 2017, DIABETES RES CLIN PR, V128, P127, DOI 10.1016/j.diabres.2017.04.002
   Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8
NR 26
TC 1
Z9 1
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 669
EP 675
DI 10.19193/0393-6384_2018_3_103
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000008
DA 2022-07-14
ER

PT J
AU Bisio, P
   Savino, F
   Tafuri, D
   Quarto, M
AF Bisio, Paolo
   Savino, Federica
   Tafuri, Domenico
   Quarto, Maria
TI MEASUREMENTS OF NOISE LEVEL IN A PAINT FACTORY: A CASE STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE occupational noise exposure; sound pressure level; noise risk
AB Introduction: Hearing loss, arterial hypertension, stress, sleep disturbance, and impaired cognitive performance.
   Material and methods: The occupational noise exposure study was carried out at paint factory after the acoustic remediation action. The equivalent continuous A-weighted sound pressure level was done according to Italian legislation on occupational safety and UNI 9432:2011 standard; The daily cumulative noise exposure dose was evaluated for each group of workers with different work tasks.
   Results: The equivalent continuous A-Freighted sound pressure levels were lower than 85 dB that is the which is the value above which the Italian law requires the use of personal protection device. The results obtained show that all the workers ,grouped for work tasks fall into the classes of non-significant (ICA = 0) or low (ICA = 1) noise risk.
   Conclusion: The study showed that the implementation of acoustic reclamation, if well designed, can significantly reduce worker exposure to noise.
C1 [Bisio, Paolo] Univ Genoa, Dept Hlth Sci, Genoa, Italy.
   [Bisio, Paolo] Univ Naples Federico II, ASL AL Prevent & Protect Off, Naples, Italy.
   [Savino, Federica] Univ Naples Federico II, Sch Med Phys, Naples, Italy.
   [Tafuri, Domenico] Parthenope Univ, Dept Sport Sci & Wellness, Naples, Italy.
   [Quarto, Maria] Univ Naples Federico II, Adv Biomed Sci Dept, Naples, Italy.
RP Quarto, M (corresponding author), Univ Napoli Federico II, Naples, Italy.
EM maria.quarto@unina.it
OI Quarto, Maria/0000-0003-0119-2393; Savino, Federica/0000-0001-5733-4325;
   BISIO, PAOLO LUIGI/0000-0003-3138-4812
CR Beutel ME, 2016, PLOS ONE, DOI [10.1371/journal.pone.0155357.t001, DOI 10.1371/JOURNAL.PONE.0155357.T001]
   Bisio P, 2017, GEAM-GEOING AMBIENT, P37
   Chen S, 2017, BMC PUBLIC HEALTH, V17, P1
   Choi SW, 2005, AM J IND MED, V48, P293, DOI 10.1002/ajim.20214
   INAIL, 2015, VAL RISCH RUM
   Jalilian H, 2018, NEUROTOXICOLOGY, V69, P242, DOI 10.1016/j.neuro.2017.12.005
   Kerns E, 2018, AM J IND MED, V61, P477, DOI 10.1002/ajim.22833
   Munzel T, 2018, J AM COLL CARDIOL, V71, P688, DOI 10.1016/j.jacc.2017.12.015
   Quarto M, 2014, RADIAT PROT DOSIM, V158, P442, DOI 10.1093/rpd/nct255
NR 9
TC 0
Z9 0
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1879
EP 1882
DI 10.19193/0393-6384_2018_6_291
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400042
DA 2022-07-14
ER

PT J
AU Bivona, G
   Agnello, L
   Butera, D
   Ciaccio, M
AF Bivona, Giulia
   Agnello, Luisa
   Butera, Daniela
   Ciaccio, Marcello
TI CLINICAL UTILITY OF HFABP IN ACUTE MYOCARDIAL INFARCTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE AMI; HFABP; chest pain; diagnosis; rule-out
ID ACID-BINDING PROTEIN; ACUTE CORONARY SYNDROME; CARDIAC TROPONIN-T;
   LONG-TERM MORTALITY; EARLY-DIAGNOSIS; EMERGENCY-DEPARTMENT; PROGNOSTIC
   VALUE; CIRCULATING LEVELS; H-FABP; EXCLUSION
AB Assessing chest pain patients presenting to the emergency area (EA) is still a clinical challenge, as acute myocardial infarction (AMI) diagnosis is not adjudicated in the majority of patients. New ,generation high sensitivity troponin assays (hs-cTn) still present some limitations, thus, novel biomarkers to early rule-in and rule- out myocardial infarction in chest pain patients presenting to the EA are sought after. Among all, heart- type fatty acid binding protein (h-FABP) has been largely investigated. Studies performed on HFABP in these patients present marked heterogeneity. However, it can be stated that HFABP is clearly not a reliable marker for AMI diagnosis, neither as a stand-alone test nor in combination with hs-cTn. More interventional trials are needed and more homogeneous studies are required to understand whether HFABP can add incremental value in rule- out AMI and risk stratify chest pain patients, however, available data may not encourage going on investigating.
C1 [Bivona, Giulia; Agnello, Luisa; Butera, Daniela; Ciaccio, Marcello] Univ Palermo, Dept Biopathol & Med Biotechnol, Sect Clin Biochem & Clin Mol Med, Palermo, Italy.
   [Ciaccio, Marcello] Univ Hosp Paolo Giaccone Palermo, Dept & UOC Lab Med, Palermo, Italy.
RP Ciaccio, M (corresponding author), Univ Palermo, Dept Med Biotechnol & Biopathol, Via Vespro,129, I-90127 Palermo, Italy.
EM marcello.ciaccio@unipa.it
CR Abbasi Walid Ahmad, 2017, J Ayub Med Coll Abbottabad, V29, P107
   Agnelli G, 2001, AM HEART J, V141, P190, DOI 10.1067/mhj.2001.112404
   Agnello L, 2017, SCAND J CLIN LAB INV, V77, P428, DOI 10.1080/00365513.2017.1335880
   Agnello L, 2017, CLIN BIOCHEM, V50, P797, DOI 10.1016/j.clinbiochem.2017.04.018
   Alhadi HA, 2004, QJM-INT J MED, V97, P187, DOI 10.1093/qjmed/hch037
   Bivona G, 2018, CLIN BIOCHEM, V58, P1, DOI 10.1016/j.clinbiochem.2018.04.021
   Bivona G, 2016, ARCH MED RES, V47, P521, DOI 10.1016/j.arcmed.2016.12.009
   Body R, 2017, EMERG MED J, V34, P349, DOI 10.1136/emermed-2016-205983
   Body R, 2014, HEART, V100, P1462, DOI 10.1136/heartjnl-2014-305564
   Body R, 2011, RESUSCITATION, V82, P1041, DOI 10.1016/j.resuscitation.2011.03.015
   Cappellini Fabrizio, 2013, Acute Card Care, V15, P83, DOI 10.3109/17482941.2013.841947
   Collinson PO, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17150
   Collinson P, 2014, HEART, V100, P140, DOI 10.1136/heartjnl-2013-304716
   Cubranic Z, 2012, BIOCHEM MEDICA, V22, P225
   Cullen LA, 2017, CLIN CHEM, V63, P129, DOI 10.1373/clinchem.2016.254730
   Daly MJ, 2011, J ELECTROCARDIOL, V44, P432, DOI 10.1016/j.jelectrocard.2011.03.001
   Dupuy AM, 2015, AM J EMERG MED, V33, P326, DOI 10.1016/j.ajem.2014.11.012
   Freund Y, 2012, AM J EMERG MED, V30, P1378, DOI 10.1016/j.ajem.2011.10.001
   Gami Bhakti N, 2015, J Clin Diagn Res, V9, pBC22, DOI 10.7860/JCDR/2015/11006.5451
   Garcia-Valdecasas S, 2011, ACTA CARDIOL, V66, P315, DOI 10.1080/AC.66.3.2114131
   Gerede DM, 2015, CARDIOVASC J AFR, V26, P204, DOI 10.5830/CVJA-2015-028
   Haltern G, 2010, AM J CARDIOL, V105, P1, DOI 10.1016/j.amjcard.2009.08.645
   Ishii J, 1997, CLIN CHEM, V43, P1372
   Jones JD, 2017, CURR CARDIOL REV, V13, P189, DOI 10.2174/1573403X13666170116121451
   Kilcullen N, 2007, J AM COLL CARDIOL, V50, P2061, DOI 10.1016/j.jacc.2007.08.021
   Kitamura M, 2013, J CARDIOL, V62, P336, DOI 10.1016/j.jjcc.2013.06.005
   Laugaudin G, 2016, EUR HEART J-ACUTE CA, V5, P354, DOI 10.1177/2048872615585518
   Leung YK, 2017, J EMERG MED, V53, P287, DOI 10.1016/j.jemermed.2017.05.006
   Li CJ, 2010, ACTA PHARMACOL SIN, V31, P307, DOI 10.1038/aps.2010.2
   Liou K, 2015, ANN CLIN BIOCHEM, V52, P370, DOI 10.1177/0004563214553277
   Martin-Reyes R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152816
   McCann CJ, 2009, AM J CARDIOL, V103, P22, DOI 10.1016/j.amjcard.2008.08.026
   McMahon CG, 2012, AM J EMERG MED, V30, P267, DOI 10.1016/j.ajem.2010.11.022
   Nichols M, 2014, EUR HEART J, V35, P2950, DOI 10.1093/eurheartj/ehu299
   Niizeki T, 2007, CIRC J, V71, P1452, DOI 10.1253/circj.71.1452
   Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603
   Reichlin T, 2009, NEW ENGL J MED, V361, P858, DOI 10.1056/NEJMoa0900428
   Reiter M, 2013, HEART, V99, P708, DOI 10.1136/heartjnl-2012-303325
   Reiter M, 2011, EUR HEART J, V32, P1379, DOI 10.1093/eurheartj/ehr033
   Richards AM, 2015, AM J CARDIOL, V115, p48B, DOI 10.1016/j.amjcard.2015.01.041
   Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320
   Schernthaner C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008396
   Schoenenberger AW, 2016, EUR HEART J-ACUTE CA, V5, P185, DOI 10.1177/2048872615571256
   Thygesen K, 2012, CIRCULATION, V126, P2020, DOI 10.1161/CIR.0b013e31826e1058
   Viswanathan K, 2010, J AM COLL CARDIOL, V55, P2590, DOI 10.1016/j.jacc.2009.12.062
   Vupputuri Anjith, 2015, Indian Heart J, V67, P538, DOI 10.1016/j.ihj.2015.06.035
   Wang HL, 2018, JCPSP-J COLL PHYSICI, V28, P56, DOI 10.29271/jcpsp.2018.01.56
   Wang J, 2017, J GERIATR CARDIOL, V14, P135, DOI 10.11909/j.issn.1671-5411.2017.02.008
   Willemsen RTA, 2015, EUR J GEN PRACT, V21, P156, DOI 10.3109/13814788.2015.1013934
   Xu LQ, 2018, HEART LUNG CIRC, V27, P503, DOI 10.1016/j.hlc.2017.03.165
   Young JM, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0089-y
   Zinellu A, 2011, CLIN CHEM LAB MED, V49, P897, DOI 10.1515/CCLM.2011.121
NR 52
TC 0
Z9 0
U1 1
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1621
EP 1625
DI 10.19193/0393-6384_2018_6_250
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400001
DA 2022-07-14
ER

PT J
AU Bivona, G
   Agnello, L
   Butera, D
   Ciaccio, M
AF Bivona, Giulia
   Agnello, Luisa
   Butera, Daniela
   Ciaccio, Marcello
TI THE IMMUNOLOGICAL IMPLICATIONS OF THE NEW VITAMIN D METABOLISM
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE vitamin D; metabolism; immune response; CYP450
ID AUTOIMMUNE-DISEASES; RECEPTOR; CELLS
AB Vitamin D is actually a neurohormone whose pleiotropic activities encompass regulation of calcium-phosphate metabolism, cell proliferation and immunomodulation. Starting from a cutaneous compound, 2 hydroxylation steps are required to produce the active form of vitamin D3, named calcitriol [1, 25-(OH)2-cholecalciferol]. The second hydroxylation step may occur at different tissues and cell types, including kidney, lung, prostate, brain, immune cells and placenta. Based on the advancing knowledge of Cytochrome P450 functions, a new conception of Vitamin D metabolism emerged. It implies that, depending on the site where the second hydroxylation step occurs, the active hormone can act as a calcium-phosphorus-homeostasis regulator, or an immune system modulator, or a cell proliferation and differentiation regulator. A detailed description of new Vitamin D metabolism and Vitamin D regulation of immune response is provided in this review.
C1 [Bivona, Giulia; Agnello, Luisa; Butera, Daniela; Ciaccio, Marcello] Univ Palermo, Dept Biopathol & Med Biotechnol, Sect Clin Biochem & Clin Mol Med, Palermo, Italy.
   [Ciaccio, Marcello] Univ Hosp Paolo Giaccone Palermo, Dept & UOC Lab Med, Palermo, Italy.
RP Ciaccio, M (corresponding author), Univ Palermo, Dept Med Biotechnol & Biopathol, Via Vespro,129, I-90127 Palermo, Italy.
EM marcello.ciaccio@unipa.it
CR Agmon-Levin N, 2013, CLIN REV ALLERG IMMU, V45, P256, DOI 10.1007/s12016-012-8342-y
   Agnello L, 2017, BIOCHEM GENET, V55, P183, DOI 10.1007/s10528-016-9783-4
   Anaya JM, 2018, CURR OPIN RHEUMATOL, V30, P350, DOI 10.1097/BOR.0000000000000498
   Antico A, 2012, AUTOIMMUN REV, V12, P127, DOI 10.1016/j.autrev.2012.07.007
   Baeke F, 2010, CURR OPIN PHARMACOL, V10, P482, DOI 10.1016/j.coph.2010.04.001
   Bivona G, 2017, ANN CLIN LAB SCI, V47, P508
   Bivona G, 2016, CLIN CHIM ACTA, V458, P115, DOI 10.1016/j.cca.2016.04.026
   Caruso A, 2014, PHARMACOGN PERS MED, V7, P117, DOI 10.2147/PGPM.S55548
   Fernandes de Abreu D A, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS265, DOI 10.1016/j.psyneuen.2009.05.023
   Giulia B, 2015, CLIN CHIM ACTA, V451, P215, DOI 10.1016/j.cca.2015.09.031
   Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382
   Kang SY, 2018, J CLIN NEUROSCI, V50, P294, DOI 10.1016/j.jocn.2018.01.047
   Khanal RC, 2008, J CELL BIOCHEM, V105, P1109, DOI 10.1002/jcb.21913
   Kim D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091949
   Mizwicki MT, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.275re4
   Rosen Y, 2016, SCAND J RHEUMATOL, V45, P439, DOI 10.3109/03009742.2016.1151072
   Shoenfeld Y, 2018, AUTOIMMUN REV, V17, P19, DOI 10.1016/j.autrev.2017.11.004
   Szodoray P, 2008, SCAND J IMMUNOL, V68, P261, DOI 10.1111/j.1365-3083.2008.02127.x
   Toubi E, 2010, ISR MED ASSOC J, V12, P174
   Veldman CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334, DOI 10.1006/abbi.1999.1605
   Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106
   Yang CY, 2013, CLIN REV ALLERG IMMU, V45, P217, DOI 10.1007/s12016-013-8361-3
NR 22
TC 0
Z9 0
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1627
EP 1629
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400002
DA 2022-07-14
ER

PT J
AU Bo, S
   Xiao, L
   Shi, JJ
AF Bo, Shi
   Xiao, Li
   Shi Jingjing
TI EFFECT OF MEDICATED SERUM OF CURCUMAE RADIX EXTRACT ON TGF-Beta 1
   SECRETION AND RECEPTOR T Beta-R I, T Beta-R II MRNA EXPRESSION IN HSC-T6
   CELLS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Medicated serum of Yujin extract; Hepatic stellate cells-T6 cells;
   Transforming growth factor-beta(1)
ID HEPATIC STELLATE CELLS; LIVER FIBROSIS; STRATEGIES; TIMPS
AB Introduction: To study the effect of medicated serum of Curcumae Radix (Yujin) extract on the secretion of transforming growth factor-beta 1 (TGF-beta 1) and expression of receptor T beta-RI, T beta-R. mRNA in rat hepatic stellate-T6 cells(HSC-T6).
   Materials and methods: Twenty SD rats were randomly divided into 4 groups: high (16.2 g Kg(-1)), medium (8.1 g Kg(-1)), low dose Yujin group (4.05 g Kg(-1)), and blank control group (with equal volume of 0.9% saline). Yujin extract or 0.9% saline were administered daily by gavage to rats for 3d, after once administration of full-day dose for 1h on the fourth day, ether anaesthesia was given, and blood was taken from abdominal aortic in asepsis condition to prepare medicated serum; HSC-T6 cells were divided into 5 groups, respectively high, medium and low dose medicated serum of Yujin groups, blank control serum group and negative control group (with equal volume of PBS to replace rat serum). Take 10% concentration of medicated serum, to be reacted with each group of HSC-T6 cells for 48 h. The levels of TGF-beta 1 secreted by HSC-T6 cells were detected by ELISA; the expression of T beta-RI and T beta-RII mRNA was analyzed by RT-PCR.
   Results: Compared with the blank control group, medicated serum of Yujin extract could not inhibit secretion of TGF-beta 1 and expression of T beta-R II mRNA, but had a significant inhibitory effect on expression of T beta-RI mRNA (P < 0.01). Compared with the negative control group, rat serum group could significantly increase content of TGF-beta 1, and increased expression of T beta-RI and T beta-RII mRNA.
   Discussion: Medicated serum of Yujin extract can affect TGF-beta 1 signal pathway conduction of HSC-T6 cells, which may be one of the molecular mechanisms that inhibit proliferation of HSC-T6 cells.
C1 [Bo, Shi; Shi Jingjing] Henan Univ Chinese Med, Sch Pharm, Zhengzhou, Henan, Peoples R China.
   [Xiao, Li] Henan Univ Chinese Med, Clin Med Coll 2, Zhengzhou, Henan, Peoples R China.
RP Shi, JJ (corresponding author), Henan Univ Chinese Med, Sch Pharm, Zhengzhou, Henan, Peoples R China.
EM 709759390@qq.com
FU Colleges and Universities in Henan Province [15A360031]
FX This paper is one of phase achievements in key scientific research
   project (No. 15A360031) of Colleges and Universities in Henan Province
   in 2015.
CR Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282
   Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   Chen JM, 2016, J GUANGDONG PHARM U, V32, P390
   Chen YL, 2010, CHIN J DIFFIC COMPL, V9, P19
   Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8
   Friedman SL, 2013, NAT REV GASTRO HEPAT, V10, P71, DOI 10.1038/nrgastro.2012.256
   Friedman SL, 2004, HEPATOLOGY, V40, P1041, DOI 10.1002/hep.20476
   Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner
   Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003
   Huang J., 2013, CHINESE J EXPT TRADI, V19, P283
   Kim KH, 2006, BIOCHEM BIOPH RES CO, V343, P1072, DOI 10.1016/j.bbrc.2006.03.087
   Lewindon PJ, 2002, AM J PATHOL, V160, P1705, DOI 10.1016/S0002-9440(10)61117-0
   Liu P, 2012, CHIN J INTEGR MED, V18, P398, DOI 10.1007/s11655-012-1030-1
   Liu XJ, 2006, PHARM RES-DORDR, V23, P82, DOI 10.1007/s11095-005-9043-5
   Omenetti A, 2011, J HEPATOL, V54, P366, DOI 10.1016/j.jhep.2010.10.003
   Popov Y, 2009, HEPATOLOGY, V50, P1294, DOI 10.1002/hep.23123
   Presser LD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056367
   Rockey Don C, 2006, Clin Liver Dis, V10, P459, DOI 10.1016/j.cld.2006.08.017
   Shek FW, 2004, EUR J GASTROEN HEPAT, V16, P123, DOI 10.1097/00042737-200402000-00001
   Sohrabpour AA, 2012, ALIMENT PHARM THER, V36, P824, DOI 10.1111/apt.12044
   Sun Lei, 2012, J PHARM PRACTICE, V30, P88
   Tacke F, 2012, EXPERT REV GASTROENT, V6, P67, DOI [10.1586/EGH.11.92, 10.1586/egh.11.92]
   Wu J. Y., 2000, CHINESE PHARMACOL B, V16, P118
   Zhao XM, 2010, CHIN J COMP MED, V20, P35
NR 24
TC 1
Z9 1
U1 1
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 113
EP 117
DI 10.19193/0393-6384_2018_1_19
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600019
DA 2022-07-14
ER

PT J
AU Borisovich, MA
   Aleksandrovna, IS
   Mikhailovna, LY
   Gennadievna, TL
   Akylbekovna, TA
   Moraru, D
   Chesca, A
AF Borisovich, Marchenko Alexandr
   Aleksandrovna, Ivasenko Svetlana
   Mikhailovna, Laryushina Yelena
   Gennadievna, Turgunova Lyudmila
   Akylbekovna, Turmukhambetova Anar
   Moraru, Dan
   Chesca, Antonella
TI RELATIONSHIP BETWEEN TRIMETHYLAMINE N-OXIDE AND TOTAL CARDIOVASCULAR
   RISK IN THE POPULATION OF CENTRAL KAZAKHSTAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE TMAO; total cardiovascular risk; cardiomarkers; Central Kazakhstan
ID PROGNOSTIC VALUE; DISEASE; MORTALITY; HEALTH
AB Aim: To investigate relationship between the level of trimethylamine N-oxide (TMAO) and total cardiovascular risk (CVR) among the population of Central Kazakhstan.
   Materials and methods: The cross-sectional investigation of urban and rural population of the Karaganda region was carried out. A total of 1,235 residents of the Karaganda region aged 18 to 65 were examined. In addition to calculating the total cardiovascular risk on the Systemic Coronary Risk Evalution (SCORE) scale, questionnaires, general laboratory tests, the level of TMAO was determined by the high performance liquid chromatography with mass-selective mass spectrometry (HPLC-MS/MS).
   Results: There was a strong direct relationship between the level of TMAO and the total CVR in men (r = 0.907, p < 0.001), a moderate direct relationship in women (r = 0.559, p < 0.001). According to the results of the binary logistic regression, the OR for men is 4.348 (95% CI 1.684; 11.227, p < 0.005), the OR for women is 1.624 (95% CI 1.408; 1.837, < 0.001).
   Conclusion: Thus, the relationship between elevated titers of TMAO and high total cardiovascular risk showed common pathogenetic mechanisms in its development and confirmed the diagnostic and prognostic significance of these indicators among the population of the Central Kazakhstan.
C1 [Borisovich, Marchenko Alexandr; Aleksandrovna, Ivasenko Svetlana; Mikhailovna, Laryushina Yelena; Gennadievna, Turgunova Lyudmila; Akylbekovna, Turmukhambetova Anar] Karaganda State Med Univ, Karaganda, Kazakhstan.
   [Chesca, Antonella] Transilvania Univ Brasov, Brasov, Romania.
   [Moraru, Dan; Chesca, Antonella] Clin Hosp Pneumophtysiol Brasov, Brasov, Romania.
RP Chesca, A (corresponding author), Clin Hosp Pneumophtysiol Brasov, Brasov, Romania.
RI Marchenko, Alexandr/P-5367-2017
OI Marchenko, Alexandr/0000-0002-0325-7659
CR Beard JR, 2016, GERONTOLOGIST, V56, pS163, DOI 10.1093/geront/gnw037
   Blacher J, 2010, J HUM HYPERTENS, V24, P19, DOI 10.1038/jhh.2009.34
   Blesso CN, 2015, NUTRIENTS, V7, P2731, DOI 10.3390/nu7042731
   Bruzzone G, 2016, CURR PHARM DESIGN, V22, P5676, DOI 10.2174/1381612822666160822143753
   Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3
   Dudina A, 2011, EUR J CARDIOV PREV R, V18, P731, DOI 10.1177/1741826711412039
   Ezzati M, 2015, NAT REV CARDIOL, V12, P508, DOI 10.1038/nrcardio.2015.82
   Kotseva K, 2016, EUR J PREV CARDIOL, V23, P636, DOI 10.1177/2047487315569401
   Lim S, 2013, INT J CARDIOL, V166, P8, DOI 10.1016/j.ijcard.2012.03.127
   Marchenko A. B., 2016, B KARAGANGA U, V84, P107
   Messner B, 2014, ARTERIOSCL THROM VAS, V34, P509, DOI 10.1161/ATVBAHA.113.300156
   Moran AE, 2014, GLOB HEART, V9, P3, DOI 10.1016/j.gheart.2014.03.1220
   Mottillo S, 2010, J AM COLL CARDIOL, V56, P1113, DOI 10.1016/j.jacc.2010.05.034
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   Perrone V, 2016, CLINICOECONOMIC OUTC, V8, P649, DOI 10.2147/CEOR.S107992
   Shah AD, 2015, LANCET DIABETES ENDO, V3, P105, DOI 10.1016/S2213-8587(14)70219-0
   Shah PK, 2014, CURR CARDIOL REP, V16, DOI 10.1007/s11886-014-0547-7
   Tang WHW, 2014, J AM COLL CARDIOL, V64, P1908, DOI 10.1016/j.jacc.2014.02.617
   Tang WHW, 2013, NEW ENGL J MED, V368, P1575, DOI 10.1056/NEJMoa1109400
   Tilg H, 2016, NEW ENGL J MED, V374, P2494, DOI 10.1056/NEJMcibr1604458
   Wang ZN, 2014, EUR HEART J, V35, P904, DOI 10.1093/eurheartj/ehu002
NR 21
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 59
EP 63
DI 10.19193/0393-6384_2018_1_10
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600010
DA 2022-07-14
ER

PT J
AU Fernandez, SC
   Iglesias, MEL
   Liria, IC
   Fernandez, RJ
   Vazquez, RR
   Vallejo, RBD
AF Cabrera Fernandez, Susana
   Losa Iglesias, Marta Elena
   Corral Liria, Inmaculada
   Jimenez Fernandez, Raquel
   Rodriguez Vazquez, Rocio
   de Bengoa Vallejo, Ricardo Becerro
TI ATTITUDES TOWARDS SEXUALITY IN ELDERS LIVING ALONE IN A SAMPLE OF
   NON-INSTITUTIONALIZED PEOPLE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Aging; Sexuality; Sexual Behavior; Sex; Attitudes
ID BEHAVIOR
AB Introduction: One of the inherent aspects to humans is sexuality. Those age 65 and older are in a vulnerable position when discussing sexuality due to their concern over society's perception of them. The objectives of this study were to evaluate older persons' attitudes toward sexuality in people over 65 years old and determine whether associations exist between these attitudes.
   Material and methods: We conducted a cross-sectional survey of attitudes and knowledge about affective and sexual behaviors among older people who attended two senior centers in Madrid, Spain. Sixty-seven participants from 65 to 95 years old responded. A self-administered questionnaire about sexuality developed by Corominas and colleagues we collected (cronbach's a of 0.85).
   Results: Participants tended to talk with others about sexuality, and this was especially so for men and those aged 65 to 80 years. Women and men and participants of all ages generally did not consider it indecent for older persons to show interest in sex. Men were less bothered by being naked in front of their partners than women were.
   Conclusion: Those over age 65 remain interested in sex; women and men think different about their level of comfort at being naked in front of a partner and their desire to receive sexual information; younger participants were more likely to talk about sex than older ones.
C1 [Cabrera Fernandez, Susana; Losa Iglesias, Marta Elena; Corral Liria, Inmaculada; Jimenez Fernandez, Raquel; Rodriguez Vazquez, Rocio; de Bengoa Vallejo, Ricardo Becerro] Univ Rey Juan Carlos, Fac Ciencias Salud, Avda Atenas S-N, Alcorcon Madrid 28922, Spain.
RP Iglesias, MEL (corresponding author), Univ Rey Juan Carlos, Fac Ciencias Salud, Avda Atenas S-N, Alcorcon Madrid 28922, Spain.
EM marta.losa@urjc.es
RI Iglesias, Marta E Losa/B-8830-2009; de Bengoa Vallejo, Ricardo
   Becerro/P-4153-2019
OI Iglesias, Marta E Losa/0000-0001-7588-2069; 
CR Blümel M Juan Enrique, 2004, Rev. chil. obstet. ginecol., V69, P118
   Boudet R., 2010, MEDISAN, V14, P447
   Cerruti S, 1990, SEXUALIDAD HUMANA AS
   Chirinos de Cova M A, 1992, Rev Cubana Enferm, V8, P50
   Corominas C, 1995, REV ENFERM, V5, P6
   Esere MO, 2008, AFR HEALTH SCI, V8, P120
   Fong J, 2002, MEDISAN, V6, P69
   FRIEDMAN HL, 1992, J ADOLESCENT HEALTH, V13, P345, DOI 10.1016/1054-139X(92)90026-8
   Gazquez JJ, 2009, EUR J EDUC PSYCHOL, V2, P263, DOI 10.30552/ejep.v2i3.27
   Kalra Gurvinder, 2011, Indian J Psychiatry, V53, P300, DOI 10.4103/0019-5545.91902
   Leyva-Moral Juan Manuel, 2008, Index Enferm, V17, P124, DOI 10.4321/s1132-12962008000200010
   Montoya Juárez Rafael, 2004, Index Enferm, V13, P70, DOI 10.4321/s1132-12962004000200017
   Moreno P, 2001, EDUCACION SEXUAL GUI
   Olivera C, 2010, HUMANIDADES MED, V10
   Organizacion Panamericana de la Salud, 2001, ASP CLIN AT ENV
   Orihuela J, 2001, REV CUB MED GEN INTE, V17, P546
   Perez V., 2008, REV CUBANA MED GEN I, V24
   PFEIFFER E, 1972, AM J PSYCHIAT, V128, P1262, DOI 10.1176/ajp.128.10.1262
   Rodrigues M, 2010, ENFERMERIA GLOBAL, V9
   Saiz D, 1998, ANALES PSICOLOGIA, V14, P3
   Valdes M., 2009, REV HABANERA CIENCIA, V8
   Valle Hernández María, 2012, Rev Ciencias Médicas, V16, P38
   Wong L, 2010, REV MEDICA ELECT, V32
   Yan E, 2011, CULT HEALTH SEX, V13, P983, DOI 10.1080/13691058.2011.605471
NR 24
TC 0
Z9 0
U1 3
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 197
EP 202
DI 10.19193/0393-6384_2018_1_32
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600032
DA 2022-07-14
ER

PT J
AU Calik, B
   Diniz, G
AF Calik, Bulent
   Diniz, Gulden
TI GASTROINTESTINAL STROMAL TUMOR: SINGLE-CENTER EXPERIENCE WITH REVIEW OF
   THE LITERATURE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Gastrointestinal stromal tumor; stromal tumor; follow-up; long term
ID LYMPH-NODE METASTASIS; C-KIT; GIST; MALIGNANCY; THERAPY
AB Objective: Gastrointestinal stromal tumors (GISTs) are the commonest mesenchymal tumors and these tumors stand for 0.2% of all gastrointestinal tumors. This study aimed to present the pathological and histological features, our clinical practice with surgical treatment, and the outcomes of GIST diagnosed in our center.
   Materials and methods: A retrospective study of 48 consecutive patients with GIST treated at our institution from June 2008 to September 2015 was performed. Information regarding age, gender, tumor location, size, procedure performed, postoperative complications, and long-term follow-up were collected from the patient charts. Immunohistochemistry studies were performed to corroborate the diagnosis. The mitotic count was performed on 50 HPFs (50 consecutive high-power fields), with a wide-field ocular microscope.
   Results: The most common primary site was stomach in 18 patients, followed by small intestine in 15. Among the study group, four patients presented with recurrent disease either isolated recurrence or metastasis. Surgery was performed in all patients. Three patients had a R2 resection and the rest of the patients had tumor-free margins (R0 resection). In our cohort we had 13 patients who received adjuvant imatinib. A variety of surgical procedures was performed. The tumor size varied from 0.8 to 22 cm. The mean follow-up period was 54.0 +/- 1.4 months. During the follow-up period, four patients had recurrence. One patient had metastasis during the follow-up. Six patients died due to GIST, four patients died due to other disease.
   Conclusion: This study highlights the changing presentation and treatment approach, as well as the outcomes achievable for GIST tumors. These results are valuable for understanding the clinical and pathological characteristics of patients with GIST, who are diagnosed, treated and followed up in Turkey.
C1 [Calik, Bulent] Saglik Bilimleri Univ, Tepecik Training & Res Hosp, Dept Gen Surg, Izmir, Turkey.
   [Diniz, Gulden] Saglik Bilimleri Univ, Tepecik Training & Res Hosp, Dept Pathol, Izmir, Turkey.
RP Calik, B (corresponding author), Gaziler St 468, Izmir, Turkey.
EM calikbulentdr@yahoo.com
CR Alvarado-Cabrero I, 2007, ANN DIAGN PATHOL, V11, P39, DOI 10.1016/j.anndiagpath.2006.03.014
   Dogusoy GB, 2012, TURK J GASTROENTEROL, V23, P203, DOI 10.4318/tjg.2012.0342
   DeMatteo RP, 2002, ANN SURG ONCOL, V9, P831, DOI 10.1007/BF02557518
   Eisenberg BL, 2004, ANN SURG ONCOL, V11, P465, DOI 10.1245/ASO.2004.09.011
   Hou YY, 2009, HISTOL HISTOPATHOL, V24, P737, DOI 10.14670/HH-24.737
   Jie GN, 2011, CLIN NUCL MED, V36, P678, DOI 10.1097/RLU.0b013e318219ad31
   Joensuu H, 2006, ANN ONCOL, V17, pX280, DOI 10.1093/annonc/mdl274
   MAZUR MT, 1983, AM J SURG PATHOL, V7, P507, DOI 10.1097/00000478-198309000-00001
   Miettinen M, 2003, AM J SURG PATHOL, V27, P625, DOI 10.1097/00000478-200305000-00006
   Miettinen M, 2001, VIRCHOWS ARCH, V438, P1, DOI 10.1007/s004280000338
   Miettinen M, 2002, HUM PATHOL, V33, P478, DOI 10.1053/hupa.2002.124123
   Rammohan Ashwin, 2013, World J Gastrointest Oncol, V5, P102, DOI 10.4251/wjgo.v5.i6.102
   Riddle ND, 2011, CANCER CONTROL, V18, P152, DOI 10.1177/107327481101800302
   Steigen SE, 2009, APMIS, V117, P73, DOI 10.1111/j.1600-0463.2008.00020.x
   Tokunaga M, 2011, HEPATO-GASTROENTEROL, V58, P1224, DOI 10.5754/hge10018
   Tran T, 2005, AM J GASTROENTEROL, V100, P162, DOI 10.1111/j.1572-0241.2005.41007.x
   Van den Abbeele AD, 2007, J NATL COMPR CANC S2, V5, P1, DOI DOI 10.1093/ANNONC/MDP310
   Wardelmann E, 2006, Verh Dtsch Ges Pathol, V90, P73
   Wong NACS, 2011, HISTOPATHOLOGY, V59, P807, DOI 10.1111/j.1365-2559.2011.03812.x
NR 19
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1967
EP 1970
DI 10.19193/0393-6384_2018_6_306
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400057
DA 2022-07-14
ER

PT J
AU Canakci, E
   Karatas, A
   Noyan, T
   Ayhan, BS
AF Canakci, Ebru
   Karatas, Ahmet
   Noyan, Tevfik
   Ayhan, Burhanettin Sertac
TI CAN ACUTE KIDNEY INJURY BE DIAGNOSED USING BIOMARKERS IN INTENSIVE CARE
   PATIENTS?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE KIM-1; Cystatin C; NGAL; IL-18; APACHE II score; intensive care unit
ID ACUTE-RENAL-FAILURE; HOSPITALIZED-PATIENTS; RIFLE CRITERIA; MULTICENTER;
   DEFINITION; MORTALITY; THERAPY; UNIT
AB Introduction: and Objective: Recent clinical trials have examined several biomarkers, which are suggested to allow an early diagnosis of AKI. Considering that the ,following molecules will allow an early diagnosis of AKI, we examined neutrophil gelatinase-associated lipocalin (NGAL), interleukin (IL-18), cystatin C (Cys-C), and kidney injury molecule-1 (KIM-1) in the urine samples and compared the levels of these molecules with the serum creatinine levels.
   Material and method: 27 patients who developed AKI and 27 patients who did not develop AKI, were included in the study. AKI and non-AKI groups namely , according to the RIFLE criteria. The urine samples from the patients were collected on the 1st, 3rd, and 7th days to study the levels of NGAL, IL-18, cystatin C, and KIM-1 as the biomarkers.
   Results: A significant difference was observed between the AKI and the non-AKI groups in terms of the APACHE II scores (p<0.001). A moderately negative and significant correlation at the level of p<0.05 was determined between the APACHE II scores and the day of ARE development (p=0.041, r=-0.403). As regards to the biomarker levels, we studied, statistically significant differences were identified in the AKI and non-AKI groups in the IL-18 levels on all of the three days which the tests were performed (p=0.042, p=0.008, p<0.0001 respectively). However, Cys-C levels measured on the 1st, 3rd, and 7th days were not statistically significantly different in the AKI or non-AKI groups (p=0.625, p= 0.074, p=0.061 respectively).
   Conclusion: NGAL can be a valuable biomarker to detect the development of AKI in the early phase in ICU admissions. NGAL and KIM-1 can be consecutively used for the early diagnosis of AKI. IL-18 can be used for the early diagnosis of AKI and it is a valuable biomarker.
C1 [Canakci, Ebru] Ordu Univ, Dept Anesthesiol & Reanimat, Fac Med, Ordu, Turkey.
   [Karatas, Ahmet] Ordu Univ, Div Nephrol, Dept Internal Med, Fac Med, Ordu, Turkey.
   [Noyan, Tevfik; Ayhan, Burhanettin Sertac] Ordu Univ, Dept Med Biochem, Fac Med, Ordu, Turkey.
RP Canakci, E (corresponding author), Ordu Univ, Dept Anesthesiol & Reanimat, Fac Med, Training & Res Hosp, Nefs I Bucak St, Ordu, Turkey.
EM canakciebru@gmail.com
RI NOYAN, Tevfik/ABI-5254-2020; Canakci, Ebru/AAO-6761-2020
OI NOYAN, Tevfik/0000-0002-7733-0177; 
CR Abernethy VE, 2002, CRIT CARE CLIN, V18, P203, DOI 10.1016/S0749-0704(01)00002-1
   Abosaif NY, 2005, AM J KIDNEY DIS, V46, P1038, DOI 10.1053/j.ajkd.2005.08.033
   Andreucci M, 2016, INT J NEPHROL RENOV, V9, P205, DOI 10.2147/IJNRD.S105124
   Arsalan Mani, 2018, Proc (Bayl Univ Med Cent), V31, P171, DOI 10.1080/08998280.2017.1416235
   Bagshaw SM, 2008, NEPHROL DIAL TRANSPL, V23, P1203, DOI 10.1093/ndt/gfm744
   Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872
   Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003
   Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740
   Cho YS, 2018, BIOMARKERS, V23, P487, DOI 10.1080/1354750X.2018.1452048
   de Mendonca A, 2000, INTENS CARE MED, V26, P915, DOI 10.1007/s001340051281
   Devarajan P, 2006, J AM SOC NEPHROL, V17, P1503, DOI 10.1681/ASN.2006010017
   Endre ZH, 2011, KIDNEY INT, V79, P1119, DOI 10.1038/ki.2010.555
   Jelinek MJ, 2018, CTS-CLIN TRANSL SCI, V11, P420, DOI 10.1111/cts.12547
   Kellum John A, 2002, Curr Opin Crit Care, V8, P509, DOI 10.1097/00075198-200212000-00005
   Lippi I, 2018, VET RES COMMUN, V42, P95, DOI 10.1007/s11259-018-9711-7
   Nejat M, 2012, KIDNEY INT, V81, P1254, DOI 10.1038/ki.2012.23
   Ostermann M, 2007, CRIT CARE MED, V35, P1837, DOI 10.1097/01.CCM.0000277041.13090.0A
   Schrier RW, 2004, J CLIN INVEST, V114, P5, DOI 10.1172/JC1200422353
   Soni SS, 2009, BLOOD PURIFICAT, V28, P165, DOI 10.1159/000227785
   Sterling M, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26538
   Uchino S, 2006, CRIT CARE MED, V34, P1913, DOI 10.1097/01.CCM.0000224227.70642.4F
   Vaidya VS, 2008, ANNU REV PHARMACOL, V48, P463, DOI 10.1146/annurev.pharmtox.48.113006.094615
   Waikar SS, 2009, J AM SOC NEPHROL, V20, P672, DOI 10.1681/ASN.2008070669
   Wang CA, 2017, EXP THER MED, V14, P6047, DOI 10.3892/etm.2017.5317
NR 24
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 2023
EP 2029
DI 10.19193/0393-6384_2018_6_316
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400067
DA 2022-07-14
ER

PT J
AU Celebi, A
   Avlagi, GK
   Ozdemir, A
   Koc, DO
   Gurler, M
   Ekizoglu, I
   Altay, M
AF Celebi, Aslan
   Avlagi, Gokalp Kurthan
   Ozdemir, Abbas
   Koc, Deniz Ogutmen
   Gurler, Mujgan
   Ekizoglu, Ismail
   Altay, Murat
TI EFFECTS OF HEPATITIS C SEROPOSITIVITY ON ERYTHROPOIETIN REQUIREMENT IN
   END-STAGE RENAL FAILURE PATIENTS RECEIVING HEMODIALYSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hemodialysis; hepatitis c; anemia; erythropoietin
ID VIRUS-INFECTION; KIDNEY-DISEASE; ANEMIA; PREVALENCE; HEMOGLOBIN;
   HEMATOCRIT; ABSENCE; UNITS
AB Background: Anemia and hepatitis C virus (HCV) infection are common problems encountered in patients with chronic renal failure (CRF). It has been reported that anemia is less common in HCV (+) hemodialysis patients because of increased endogenous erythropoietin (EPO) production. The present study is aimed to investigate the relation between anemia, EPO requirement, and HCV infection in CRF patients receiving hemodialysis.
   Methods: Medical records of the patients who had received hemodialysis for CRF between January 2013 and January 2014 in two private hemodialysis centers were retrospectively reviewed.
   Results: The mean age of the 52 patients included in the study was 59.50 +/- 14.28 years and 55.8% of them were females. There were 22 HCV (+) and 30 HCV (-) patients. There was no difference between HCV (+) and HCV (-) groups in terms of age and gender.
   Conclusion: HCV (+) patients had lower EPO requirement and ferritin levels, but higher total iron binding capacity and hemoglobin levels than that of HCV (-) patients.
C1 [Celebi, Aslan; Ozdemir, Abbas; Koc, Deniz Ogutmen; Ekizoglu, Ismail] Gaziosmanpasa Taksim Educ & Training Res Hosp, Dept Internal Med, Istanbul, Turkey.
   [Avlagi, Gokalp Kurthan] Istanbul Educ & Training Res Hosp, Dept Internal Med, Istanbul, Turkey.
   [Gurler, Mujgan] Abant Izzet Baysal Univ, Dept Internal Med, Bolu, Turkey.
   [Altay, Murat] Buyukcekmece Govt Hosp, Dept Internal Med, Istanbul, Turkey.
RP Celebi, A (corresponding author), Gaziosmanpasa Taksim Educ & Training Res Hosp, Dept Internal Med, Istanbul, Turkey.
OI Ozdemir, Ali/0000-0002-8087-9654
CR Alsaran KA, 2009, RENAL FAILURE, V31, P349, DOI 10.1080/08860220902835855
   Altintepe L, 2004, CLIN NEPHROL, V61, P347
   Ansari Iqra, 2014, Arab J Nephrol Transplant, V7, P13
   Caliskan Y, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-56
   Debenito JM, 2014, J MANAG CARE SPEC PH, V20, P15
   Di Iorio B, 2007, INT J ARTIF ORGANS, V30, P325, DOI 10.1177/039139880703000408
   ESCHBACH JW, 1985, KIDNEY INT, V28, P1, DOI 10.1038/ki.1985.109
   Fabrizi F, 2013, KIDNEY INT, V84, P874, DOI 10.1038/ki.2013.264
   Fabrizi F, 2012, CONTRIB NEPHROL, V176, P42, DOI 10.1159/000332379
   Galperim B, 2010, BRAZ J INFECT DIS, V14, P422, DOI 10.1590/S1413-86702010000400020
   Harmankaya O, 2002, RENAL FAILURE, V24, P639, DOI 10.1081/JDI-120013968
   Hayat Amir, 2008, Patient Prefer Adherence, V2, P195
   Khurana A, 2008, HEMODIAL INT, V12, P94, DOI 10.1111/j.1542-4758.2008.00248.x
   KLASSEN DK, 1990, AM J MED, V89, P684, DOI 10.1016/0002-9343(90)90190-O
   Leung N, 2013, SEMIN HEMATOL, V50, P207, DOI 10.1053/j.seminhematol.2013.06.002
   Lin YL, 2008, NEPHROLOGY, V13, P289, DOI 10.1111/j.1440-1797.2008.00937.x
   Marinaki S, 2015, WORLD J HEPATOL, V7, P548, DOI 10.4254/wjh.v7.i3.548
   Mohamed WZ, 2010, SAUDI J KIDNEY DIS T, V21, P548
   Sahin I, 2003, CLIN NEPHROL, V60, P401
   Saifan C, 2013, INT J NEPHROL RENOV, V6, P121, DOI 10.2147/IJNRD.S44656
   Saune K, 2011, NEPHROL DIAL TRANSPL, V26, P2309, DOI 10.1093/ndt/gfq696
   Tang Sydney, 2005, Hemodial Int, V9, P169, DOI 10.1111/j.1492-7535.2005.01129.x
   Vallet-Pichard A, 2013, CLIN RES HEPATOL GAS, V37, P340, DOI 10.1016/j.clinre.2013.03.005
   Verdalles U, 2011, BLOOD PURIFICAT, V32, P69, DOI 10.1159/000323095
   Wan QJ, 2014, INT UROL NEPHROL, V46, P1651, DOI 10.1007/s11255-013-0581-1
   Yu YC, 2014, WORLD J HEPATOL, V6, P419, DOI 10.4254/wjh.v6.i6.419
   Zumrutdal A, 2012, Indian J Nephrol, V22, P415, DOI 10.4103/0971-4065.106031
NR 27
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 453
EP 456
DI 10.19193/0393-6384_2018_2_72
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400026
DA 2022-07-14
ER

PT J
AU Cetiner, M
   Cam, M
   Kabay, SC
   Aydin, HE
   Ayas, S
   Temel, O
   Zorlu, Y
AF Cetiner, Mustafa
   Cam, Mustafa
   Kabay, Sibel Canbaz
   Aydin, Hasan Emre
   Ayas, Selahattin
   Temel, Ozge
   Zorlu, Yasar
TI ISCHAEMIC STROKE AETIOLOGY, RISK FACTORS AND CLINICAL OUTCOMES IN YOUNG
   PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Ischaemic stroke in young patients; risk factors; causes of stroke;
   clinical outcomes
ID ATRIAL-FIBRILLATION; WESTERN NORWAY; ADULTS; AGE; POPULATION;
   RECURRENCE; REGISTRY; TRENDS
AB Objective: Recent years, the incidence of stroke has increased in patients aged below 50 years. We aimed to determine the aetiological subtypes of stroke and distribution of the risk factors and share clinical outcomes of patients with ischaemic stroke aged below 50 years.
   Material and methods: The data of patients aged 50 years or younger, who were hospitalized in the department of neurology at Dumlupinar University Faculty of Medicine with the diagnosis of ischaemic stroke and who were followed up in the outpatient stroke clinic, were retrospectively reviewed. Demographic characteristics of the patients and the risk factors for stroke were recorded (Hypertension, diabetes mellitus, heart diseases, hyperlipidaemia, smoking and alcohol consumption, oral contraceptive use and regular medication and migraine). The patients were grouped according to the Trial of ORG 10172 in Acute Stroke Treatment classification. Patients were divided into two groups as below 45 years and 45 and older for statistical analysis
   Results: Of the patients, 37 (50%) were male, and 37 (50%) were female, and the mean age was 41.14 +/- 6.99 (17-49) years. In total patient population, 25 patients (33.8%) had cardioembolic stroke, 16 (21.6%) had stroke due to unknown causes, 14 (18.9%) had stroke due to other reasons, 12 (16.2%) had stroke due to atherosclerosis of large arteries and 7 (9.5%) had stroke due to lacunar infarction. Smoking (n = 37, 50%), cardiac diseases (n = 28, 38%), hyperlipidaemia (n = 24, 32.4%), obesity (n = 18, 24.3%), hypertension (n = 17, 23%) were the most common risk factors.
   Conclusion: The present study found that the risk factors observed in young stroke patients, particularly in patients aged below 50 years, were not remarkably different than the widely recognized risk factors, and congenital and genetic causes were more common in patients aged below 45 years.
C1 [Cetiner, Mustafa; Kabay, Sibel Canbaz; Ayas, Selahattin; Temel, Ozge] Dumlupinar Univ, Fac Med, Dept Neurol, Eryigit Sokak 24 Ladin Sitesi A Blok K 3,D-13, Kutahya, Turkey.
   [Aydin, Hasan Emre] Dumlupinar Univ, Fac Med, Dept Neurosurg, Kutahya, Turkey.
   [Cam, Mustafa] Denizli State Hosp, Dept Neurol, Denizli, Turkey.
   [Zorlu, Yasar] Izmir Tepecik Educ & Res Hosp, Neurol Clin, Izmir, Turkey.
RP Cetiner, M (corresponding author), Dumlupinar Univ, Fac Med, Dept Neurol, Eryigit Sokak 24 Ladin Sitesi A Blok K 3,D-13, Kutahya, Turkey.
RI ayas, selahattin/O-4160-2015; Aydin, Hasan Emre/AAA-4657-2021; ÇETİNER,
   MUSTAFA/AAG-6811-2021
OI Aydin, Hasan Emre/0000-0002-8932-1542; 
CR Acar A, 2012, DUZCE TIP DERGISI, V14, P32
   ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Adamson Joy, 2004, J Stroke Cerebrovasc Dis, V13, P171, DOI 10.1016/j.jstrokecerebrovasdis.2004.06.003
   Barlas NY, 2013, EUR J NEUROL, V20, P1431, DOI 10.1111/ene.12228
   Bejot Y, 2014, J NEUROL NEUROSUR PS, V85, P509, DOI 10.1136/jnnp-2013-306203
   Cerrato P, 2004, CEREBROVASC DIS, V18, P154, DOI 10.1159/000079735
   Dash D, 2014, J STROKE, V16, P173, DOI 10.5853/jos.2014.16.3.173
   Demir CF, 2007, TURK KLIN TIP BILIM, V27, P791
   Dharmasaroja PA, 2011, J STROKE CEREBROVASC, V20, P247, DOI 10.1016/j.jstrokecerebrovasdis.2010.01.004
   Ghandehari K, 2006, ACTA NEUROL SCAND, V113, P121, DOI 10.1111/j.1600-0404.2005.00515.x
   Griffiths D, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/209370
   Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7
   Kissela BM, 2012, NEUROLOGY, V79, P1781, DOI 10.1212/WNL.0b013e318270401d
   Kittner SJ, 2013, NEUROLOGY, V80, P1272, DOI 10.1212/WNL.0b013e31828ab3a4
   Kristensen B, 1997, STROKE, V28, P1702, DOI 10.1161/01.STR.28.9.1702
   Kwon SU, 2000, ACTA NEUROL SCAND, V101, P19, DOI 10.1034/j.1600-0404.2000.00004.x
   Lee TH, 2002, STROKE, V33, P1950, DOI 10.1161/01.STR.0000021409.16314.16
   Leys D, 2002, NEUROLOGY, V59, P26, DOI 10.1212/WNL.59.1.26
   Li F, 2017, EUR NEUROL, V77, P115, DOI 10.1159/000455093
   Maaijwee NAMM, 2014, NAT REV NEUROL, V10, P315, DOI 10.1038/nrneurol.2014.72
   Naess H, 2002, STROKE, V33, P2105, DOI 10.1161/01.STR.0000023888.43488.10
   Nayak SD, 1997, NATL MED J INDIA, V10, P107
   Nedeltchev K, 2005, J NEUROL NEUROSUR PS, V76, P191, DOI 10.1136/jnnp.2004.040543
   O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3
   Ozer IS, 2015, TURK J NEUROL, V21, P159, DOI 10.4274/tnd.68725
   Prefasi D, 2013, EUR J NEUROL, V20, P1367, DOI 10.1111/ene.12187
   Prefasi D, 2016, J THROMB THROMBOLYS, V42, P272, DOI 10.1007/s11239-016-1336-5
   Putaala J, 2009, STROKE, V40, P1195, DOI 10.1161/STROKEAHA.108.529883
   Renna R, 2014, J STROKE CEREBROVASC, V23, pE221, DOI 10.1016/j.jstrokecerebrovasdis.2013.10.008
   Rutten-Jacobs LCA, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-109
   Sanak D, 2015, EUR NEUROL, V73, P158, DOI 10.1159/000369793
   Simonetti BG, 2015, J NEUROL, V262, P2025, DOI 10.1007/s00415-015-7805-5
   Waje-Andreassen U, 2013, EUR J NEUROL, V20, P818, DOI 10.1111/ene.12073
   Wu TY, 2012, NEW ZEAL MED J, V125, P47
NR 34
TC 0
Z9 0
U1 3
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1019
EP 1025
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500018
DA 2022-07-14
ER

PT J
AU Cetinkaya, I
   Polat, M
AF Cetinkaya, Ismail
   Polat, Mumin
TI EVALUATION OF TOTAL ANTIOXIDANT (TAS) AND TOTAL OXIDANT (TOS) PARAMETERS
   IN LIVER, KIDNEY AND BRAIN TISSUES OF RATS WHICH ARE APPLIED JWH-200
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE TAS; TOS; Synthetic Cannabinoid; Rat
ID SYNTHETIC CANNABINOID USE; CASE SERIES; CANNABIMIMETIC INDOLES;
   MYOCARDIAL-INFARCTION; SPICE PRODUCTS; ACUTE TOXICITY; RECEPTOR;
   PHARMACOLOGY; K2; INTOXICATION
AB Synthetic cannabinoids (SC) have recently announced their name as substances which are misused among young adults. Death is commonly observed, since they cause serious toxicity. These effects often cause central nervous system damage . The end result of the use of synthetic cannabinoids is the circulatory and respiratory system as well as the central nervous system. Sudden changes in respiratory rate, rise in heart beat and expansion in blood vessels are significant symptoms. The aim of this study is to reveal changes in Total Antioxidant Level (TAS) and Total Oxidant Level (TOS) parameters in liver, kidney and brain tissues in order to obtain information about the predicted damages caused by synthetic drugs in tissues and organs. In our study, 20 male Wistar albino rats at least 8 weeks old were used. The rats were divided into two groups, experiment and control group, while the difference between the weights of the rats was adjusted to be statistically insignificant (p = 0.231) by two sample t tests. Experimental ,group rats were implemented as infra peritoneal the mixture of 0.5 ml / kg Ethanol, 4.5 ml / kg Dextrose, 5 mg / kg JWH-200. No implementation was applied to the control group. Decapitation was perforated under ,general anesthesia 8 hours after this implementation. TAS and TOS parameters were studied by taking and preparing liver, kidney and brains of both groups. Oxidative stress indexes were determined by measuring from the organs taken from the experimental and control groups with a spectrophotometer. The difference between the two groups was considered statistically insignificant (p > 0.05). Liver TOS level was determined higher in the experimental group in comparison with control ,group. In our study, renal TAS findings were determined lower in the experimental ,group than in the control group. In our study, oxidative stress is formed because of the high levels of antioxidant levels of kidney. It is thought that the use of synthetic cannabinoids in different systems, depending on the dose, can also affect the urinary system and the kidneys at the same time.
C1 [Cetinkaya, Ismail] Mehmet Akif Ersoy Univ, Hlth Sci Inst Lab & Expt Anim, Burdur, Turkey.
   [Polat, Mumin] Mehmet Akif Ersoy Univ, Fac Hlth Sci, Burdur, Turkey.
RP Polat, M (corresponding author), Mehmet Akif Ersoy Univ, Fac Hlth Sci, Dept Emergency & Disaster Management, TR-15100 Burdur, Turkey.
EM mpolat@mehmetakif.edu.tr
FU Mehmet Akif Ersoy University Scientific Research Projects Coordination
   Unit [0373-YL-16]
FX This study was supported by Mehmet Akif Ersoy University Scientific
   Research Projects Coordination Unit (Project number; 0373-YL-16).
CR Alhadi S, 2013, J MED TOXICOL, V9, P199, DOI 10.1007/s13181-013-0288-9
   Auwarter V, 2009, J MASS SPECTROM, V44, P832, DOI 10.1002/jms.1558
   Bachs L, 2001, FORENSIC SCI INT, V124, P200, DOI 10.1016/S0379-0738(01)00609-0
   Brents LK, 2014, DRUG METAB REV, V46, P72, DOI 10.3109/03602532.2013.839700
   Brents LK, 2012, BIOCHEM PHARMACOL, V83, P952, DOI 10.1016/j.bcp.2012.01.004
   Castaneto MS, 2014, DRUG ALCOHOL DEPEN, V144, P12, DOI 10.1016/j.drugalcdep.2014.08.005
   Castellanos D, 2011, J ADOLESCENT HEALTH, V49, P347, DOI 10.1016/j.jadohealth.2011.08.002
   Degenhardt L, 2011, DRUG ALCOHOL DEPEN, V117, P85, DOI 10.1016/j.drugalcdep.2010.11.032
   Ergul DF, 2015, TURK J ANAESTHESIOL, V43, P347, DOI 10.5152/TJAR.2015.05668
   Every-Palmer S, 2011, DRUG ALCOHOL DEPEN, V117, P152, DOI 10.1016/j.drugalcdep.2011.01.012
   Every-Palmer S, 2010, ADDICTION, V105, P1859, DOI 10.1111/j.1360-0443.2010.03119.x
   Evren C, 2013, DUNSEN ADAM, V26, P1, DOI 10.5350/DAJPN20132601001
   Fattore L, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00060
   Gunderson EW, 2012, AM J ADDICTION, V21, P320, DOI 10.1111/j.1521-0391.2012.00240.x
   Gurdal F, 2013, J FORENSIC LEG MED, V20, P667, DOI 10.1016/j.jflm.2013.03.041
   Harris CR, 2013, J EMERG MED, V44, P360, DOI 10.1016/j.jemermed.2012.07.061
   Hermanns-Clausen M, 2013, ADDICTION, V108, P534, DOI 10.1111/j.1360-0443.2012.04078.x
   Hoyte CO, 2012, ANN EMERG MED, V60, P435, DOI 10.1016/j.annemergmed.2012.03.007
   Huffman JW, 2005, CURR MED CHEM, V12, P1395, DOI 10.2174/0929867054020864
   Huffman JW, 2003, BIOORGAN MED CHEM, V11, P539, DOI 10.1016/S0968-0896(02)00451-0
   HUFFMAN JW, 1994, BIOORG MED CHEM LETT, V4, P563, DOI 10.1016/S0960-894X(01)80155-4
   Hurst D, 2011, AM J PSYCHIAT, V168, P1119, DOI 10.1176/appi.ajp.2011.11010176
   Jerry J, 2012, CLEV CLIN J MED, V79, P258, DOI 10.3949/ccjm.79a.11147
   Juknat Ana, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P289, DOI 10.1515/jbcpp-2015-0071
   Krylatov AV, 2007, BIOL BULL+, V34, P28, DOI 10.1134/S1062359007010049
   Liu CS, 2015, CNS DRUGS, V29, P615, DOI 10.1007/s40263-015-0270-y
   Mir A, 2011, PEDIATRICS, V128, pE1622, DOI 10.1542/peds.2010-3823
   Muller H, 2010, SCHIZOPHR RES, V118, P309, DOI 10.1016/j.schres.2009.12.001
   Nakajima J, 2011, FORENSIC TOXICOL, V29, P95, DOI 10.1007/s11419-011-0108-3
   Orhan S, 2017, TURK J INTENS CARE, V15, P141, DOI 10.4274/tybd.65487
   Pertwee RG, 1999, CURR MED CHEM, V6, P635
   Schneir AB, 2011, J EMERG MED, V40, P296, DOI 10.1016/j.jemermed.2010.10.014
   Seely KA, 2012, PROG NEURO-PSYCHOPH, V39, P234, DOI 10.1016/j.pnpbp.2012.04.017
   Sheikh IA, 2014, AM J CASE REP, V15, P584, DOI 10.12659/AJCR.891399
   Sherpa D, 2015, J COMMUNITY HOSP INT, V5, DOI 10.3402/jchimp.v5.27540
   Teske J, 2010, J CHROMATOGR B, V878, P2659, DOI 10.1016/j.jchromb.2010.03.016
   Tomiyama K, 2011, TOXICOL LETT, V207, P12, DOI 10.1016/j.toxlet.2011.08.021
   Vandrey R, 2012, DRUG ALCOHOL DEPEN, V120, P238, DOI 10.1016/j.drugalcdep.2011.07.011
   Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32
   Vardakou I, 2010, TOXICOL LETT, V197, P157, DOI 10.1016/j.toxlet.2010.06.002
   Wood DM, 2012, THER DRUG MONIT, V34, P363, DOI 10.1097/FTD.0b013e31825b954b
   Zhao A, 2015, CASE REP NEPHRO, P235
   Zimmermann US, 2009, DTSCH ARZTEBL INT, V106, P464, DOI 10.3238/arztebl.2009.0464
   Zubrzycki M, 2014, J PHYSIOL PHARMACOL, V65, P171
NR 44
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 2007
EP 2011
DI 10.19193/0393-6384_2018_6_313
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400064
DA 2022-07-14
ER

PT J
AU Cetinkol, Y
   Aladal, M
   Unal, N
   Bayramoglu, G
   Ahmetbayik, S
   Dogan, M
   Durmaz, S
   Gunes, H
   Ozlemkalayci, H
   Cetinonarer, P
   Mengeloglu, Z
   Milletli, F
   Ozdemir, M
   Yula, E
   Keremcalgin, M
   Yanik, K
AF Cetinkol, Yeliz
   Aladal, Murat
   Unal, Nevzat
   Bayramoglu, Gulcin
   Ahmetbayik, Seyit
   Dogan, Metin
   Durmaz, Suleyman
   Gunes, Hayati
   Ozlemkalayci, Hacer
   Cetinonarer, Pelin
   Mengeloglu, Zafer
   Milletli, Fikriye
   Ozdemir, Metin
   Yula, Erkan
   Keremcalgin, M.
   Yanik, Keramettin
TI COMPARISON OF FUSIDIC ACID SUSCEPTIBILITY OF STAPHYLOCOCCI: A
   MULTICENTER STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Thalasemia trait; iron deficiency anemia; differentiating index
ID ANTIMICROBIAL RESISTANCE; AUREUS STRAINS
AB Introduction: The increasing antibiotic resistance of staphylococci, an important factor among societal and hospital-sourced infection factors, reduces the treatment choices available. Fusidic acid (FA), the use of which has recently come to the agenda again, is thought to form a new alternative treatment for staphylococci infections. The aim of our study is to identify the FA resistance situation at certain centers compared to generally increasing antibiotic resistance, to present epidemiological data on new antibiotherapy methods and to aid in treatment planning.
   Materials and methods: With this aim we determined and compared the susceptibility of 2018 Staphylococcus aureus and 5242 Coagulase negative Staphylococci strains obtained at 11 centers in different regions of our country against FA, oxacillin, penicillin, trimethoprim-sulfamethoxazole and ciprofloxacin.
   Results: The Coagulase negative Staphylococci strains were determined to be more resistant to all antibiotics compared to S. aureus strains. When the means of all centers are examined, FA resistance was found in 7.1% of S. aureus strains and 55.1% of Coagulase negative Staphylococci strains. Of all antibiotics for both S. aureus and Coagulase negative Staphylococci strains the antibiotic that strains were most susceptible to was trimethoprim-sulfamethoxazole, while the antibiotic that most were resistant to was penicillin.
   Conclusion: In light of these findings, with high susceptibility of 92.9% for S. aureus strains to FA, it appears to be a good alternative treatment choice for S. aureus infections. Due to high resistance rates of methicillin-resistant Coagulase negative Staphylococci sourced infections, before treatment it is necessary to perform an antibiotic susceptibility test. We believe that broader scale and more comprehensive studies will provide guidance in planning treatment.
C1 [Cetinkol, Yeliz; Keremcalgin, M.] Ordu Univ, Sch Med, Dept Med Microbiol, Ordu, Turkey.
   [Aladal, Murat] Agri State Hosp, Dept Med Microbiol, Agri, Turkey.
   [Unal, Nevzat; Ahmetbayik, Seyit] Adana Numune Training & Res Hosp, Dept Med Microbiol, Adana, Turkey.
   [Bayramoglu, Gulcin] Karadeniz Tech Univ, Sch Med, Dept Med Microbiol, Trabzon, Turkey.
   [Dogan, Metin] Necmeddin Erbakan Univ, Sch Med, Dept Med Microbiol, Konya, Turkey.
   [Durmaz, Suleyman] Konya Numune Training & Res Hosp, Dept Med Microbiol, Konya, Turkey.
   [Gunes, Hayati] Namik Kemal Univ, Sch Med, Dept Med Microbiol, Tekirdag, Turkey.
   [Ozlemkalayci, Hacer; Yula, Erkan] Ordu State Hosp, Dept Med Microbiol, Ordu, Turkey.
   [Cetinonarer, Pelin] Katip Celebi Univ, Sch Med, Dept Med Microbiol, Izmir, Turkey.
   [Mengeloglu, Zafer] Izzet Baysal Training & Res Hosp, Dept Med Microbiol, Bolu, Turkey.
   [Milletli, Fikriye] Ahi Evran Univ, Training & Res Hosp, Dept Med Microbiol, Kirsehir, Turkey.
   [Ozdemir, Metin] Gazi State Hosp, Dept Med Microbiol, Samsun, Turkey.
   [Yanik, Keramettin] Ondokuz Mayis Univ, Sch Med, Dept Med Microbiol, Samsun, Turkey.
RP Cetinkol, Y (corresponding author), Ordu Univ, Training & Res Hosp, Bucak Mah Nefsi Bucak Cad, Ordu, Turkey.
RI ÇETİNKOL, YELİZ/AGX-6363-2022; Bayramoglu, Gulcin/AAR-2120-2020; Dogan,
   Metin/A-5751-2019
OI Dogan, Metin/0000-0003-3471-4768; Unal, Nevzat/0000-0001-5121-3100
CR Champion EA, 2014, PEDIATR PULM, V49, P230, DOI 10.1002/ppul.22815
   den Heijer CDJ, 2014, FUTURE MICROBIOL, V9, P737, DOI [10.2217/fmb.14.36, 10.2217/FMB.14.36]
   Deveci O, 2011, J MICROBIOL INFECT D, V1, P22
   Ehsan Muhammad Murad, 2014, J Ayub Med Coll Abbottabad, V26, P137
   Ertem G. T., 2013, Turkiye Klinikleri tip Bilimleri Dergisi, V33, P1381
   Gordon NC, 2014, J CLIN MICROBIOL, V52, P1182, DOI 10.1128/JCM.03117-13
   Lim KT, 2014, T ROY SOC TROP MED H, V108, P112, DOI 10.1093/trstmh/trt111
   Moghadam SO, 2014, J INFECT DEV COUNTR, V8, P1511, DOI 10.3855/jidc.5514
   Nergiz S, 2012, TURK KLIN TIP BILIM, V32, P1668, DOI 10.5336/medsci.2011-27892
   Ozturk F, 2005, ANKEM DERG, V19, P135
   Sahm DF, 2013, ANTIMICROB AGENTS CH, V57, P4535, DOI 10.1128/AAC.00206-13
   Salah LA, 2015, ACTA DERM-VENEREOL, V95, P532, DOI 10.2340/00015555-1996
   Unal S., 2009, ANKEM DERG, V23, P1
   Vindel A, 2014, J ANTIMICROB CHEMOTH, V69, P2913, DOI 10.1093/jac/dku232
   Vremera T, 2012, MED-SURG J, V116, P1171
   Yildiz O, 2014, ANN CLIN MICROB ANTI, V13, DOI 10.1186/s12941-014-0044-2
NR 16
TC 1
Z9 1
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 397
EP 402
DI 10.19193/0393-6384_2018_2_63
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400017
DA 2022-07-14
ER

PT J
AU Cevik, C
   Tekir, O
   Kaya, A
AF Cevik, Celalettin
   Tekir, Ozlem
   Kaya, Aysenur
TI STROKE PATIENTS 'QUALITY OF LIFE AND COMPLIANCE WITH THE TREATMENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Stroke; quality of life; adherence; rehabilitation
ID RANDOMIZED CONTROLLED-TRIAL; GLOBAL BURDEN; SYSTEMATIC ANALYSIS; CHRONIC
   DISEASES; REGIONAL BURDEN; ADHERENCE; MEDICATION; DEPRESSION; MORTALITY;
   REHABILITATION
AB Objective: The aim of this study was to determirte adherence with treatment, quality of life and related factors in, patients who were hospitalized and diagnosed with stroke at least six months before their hospitalization?
   Material and methods: The data of this cross-sectional study were collected through face-to face interviews held with 140 patients who were diagrtosed with stroke at least six months ago, hospitalized in Balikesir Atatiirk State Hospital Neurology Department between October 2015 and October-2016 and then discharged from the hospital.
   Results. In the study, the Stroke-Specific Quality of Life Scale (SSQOL) was used, and the participants were asked whether they complied with the treatment regularly. The participants' mean scores were 2.29 +/- 0.83 for the SSQOL scale. The mean scores for the SSQOL scale were higher in the married participants in those krtowledgeable of stroke, in those who received rehabilitation, in non-smokers, in those who had hemiplegia and in those who were able to carry out physical activities independently(p<0.05). Of the participants, 67.1% stated that they complied with their treatment. According to the logistic regression model, compliance with the treatment was 2.03 times higher in the participants with secondary and higher education (95.0% CI: 1.10-5.34), 5.27 times higher in the participants residing in a city (95.0% Cl: 1.25-12.22), 7.30 times higher in the participants having stroke diagnosis for 6-11 months (95.0% Cl 5.38-10.43).
   Conclusion: It was concluded that two-thirds of the participants complied with their daily treatments regularly and the mean scores they obtained from the SSQOL were lower than the average score to be 'obtained from the scale.
C1 [Cevik, Celalettin; Tekir, Ozlem; Kaya, Aysenur] Balikesir Univ, Sch Hlth, Dept Nursing, Publ Hlth, Balikesir, Turkey.
RP Cevik, C (corresponding author), Balikesir Univ, Sch Hlth, Dept Nursing, Balikesir, Turkey.
EM celalettincevik@balikesir.edu.tr
RI , celalettin/J-3513-2019
OI , celalettin/0000-0002-1123-6196
CR Arif H, 2007, NEUROL INDIA, V55, P130
   Barak S, 2014, PHYS THER, V94, P101, DOI 10.2522/ptj.20120473
   Barker-Collo S, 2015, NEUROEPIDEMIOLOGY, V45, P203, DOI 10.1159/000441103
   Bashir S., 2017, PAKISTAN J NEUROLOGI, V12, P38
   Bushnell CD, 2011, NEUROLOGY, V77, P1182, DOI 10.1212/WNL.0b013e31822f0423
   Chen CM, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0314-5
   Durmaz B., 2006, TURKISH J PHYS MED R, V52, P45
   Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4
   Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0
   Hacihasanoglu R, 2011, J CLIN NURS, V20, P692, DOI 10.1111/j.1365-2702.2010.03534.x
   Hankey GJ, 2013, LANCET GLOB HEALTH, V1, pE239, DOI 10.1016/S2214-109X(13)70095-0
   Hashim S, 2014, P INT C SCI TECHN SO
   Heikinheimo T, 2015, MALAWI MED J, V27, P50, DOI 10.4314/mmj.v27i2.4
   Huang YH, 2013, AM J OCCUP THER, V67, P54, DOI 10.5014/ajot.2013.004820
   Jaracz K, 2003, ACTA NEUROL SCAND, V107, P324, DOI 10.1034/j.1600-0404.2003.02078.x
   Kamal AK, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0471-5
   Khan SH, 2011, STROKE, V42, pE404, DOI 10.1161/STROKEAHA.111.613356
   Lin EHB, 2012, ANN FAM MED, V10, P6, DOI 10.1370/afm.1343
   Marini S, 2017, NEUROCRIT CARE, P1
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   Michaelsen SM, 2013, MOTRIZ, V19, P746, DOI 10.1590/S1980-65742013000400012
   Muus I, 2010, SCAND J CARING SCI, V24, P211, DOI 10.1111/j.1471-6712.2009.00705.x
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   Noto T, 2002, JAIDS-J ACQ IMM DEF, V51, P8123
   O'Carroll RE, 2013, ANN BEHAV MED, V46, P358, DOI 10.1007/s12160-013-9515-5
   Owolabi MO, 2013, ACTA NEUROL SCAND, V128, P311, DOI 10.1111/ane.12126
   Robinson RG, 2016, AM J PSYCHIAT, V173, P221, DOI 10.1176/appi.ajp.2015.15030363
   Senocak O, 2008, J NEUROL SCI-TURK, V25, P164
   Sprigg N, 2012, J STROKE CEREBROVASC, V21, P587, DOI 10.1016/j.jstrokecerebrovasdis.2011.01.007
   Thrift AG, 2014, INT J STROKE, V9, P6, DOI 10.1111/ijs.12245
   van Mierlo ML, 2014, INT J STROKE, V9, P341, DOI 10.1111/ijs.12149
   Visser MM, 2015, ARCH PHYS MED REHAB, V96, P1492, DOI 10.1016/j.apmr.2015.04.007
   Viswanathan M, 2012, ANN INTERN MED, V157, P785, DOI 10.7326/0003-4819-157-11-201212040-00538
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
   Yont GH, 2012, INT NURS REV, V59, P274, DOI 10.1111/j.1466-7657.2011.00962.x
NR 35
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 839
EP 846
DI 10.1919/0393-6384_2018_3_127
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000032
DA 2022-07-14
ER

PT J
AU Chang, XX
AF Chang, Xiaoxiao
TI CORRELATION BETWEEN SERUM FERRITIN AND PREMATURE CORONARY ARTERY DISEASE
   IN MIDDLE-AGED MALE PATIENTS WITH 5 YEARS OF FOLLOW-UP
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Atherosclerosis; Coronary artery disease; Serum ferritin; Iron overload;
   Follow-up
ID CAROTID ATHEROSCLEROSIS; CARDIOVASCULAR-DISEASE; IRON STORES;
   ASSOCIATION; RISK; ANGIOGRAPHY; HEMOGLOBIN; SEVERITY
AB Purpose: To investigate the correlation between serum ferritin levels and clinical outcomes of premature coronary artery disease (PCAD) in middle-aged male patients.
   Methods: A total of 420 middle-aged male patients with PCAD were recruited with case-control method for this study. The patients were grouped into two based on the cut off serum ferritin (SF >= 200 ng/m: overload group (SF >= 200 ng/ml) and control group (SF < 200 ng/ml). Differences between the incidence of major adverse cerebral cardiovascular events (MACCE), carotid atherosclerotic plaques, and survival rate were analyzed.
   Results: In one-year follow-up, there were no significant differences (p > 0.05) in the incidence of atherosclerotic plaques, MACCE and survival rate between the two groups. However, in a 3-year ,follow-up, there was significant difference < 0.05) in atherosclerotic plaques between the two groups, but the differences in MACCE and survival rate were not significant (p > 0.05). In a,follow-up spanning 5 years, there were significant differences (p < 0.05) between atherosclerotic plaques and MACCE.
   Conclusions: High serum ferritin level and iron overload have a positive association with PCAD in middle-aged male patients.
C1 [Chang, Xiaoxiao] Shanghai Jiguang Polytech Coll, Sch Nursing, Shanghai, Peoples R China.
RP Chang, XX (corresponding author), Shanghai Jiguang Polytech Coll, Sch Nursing, Shanghai, Peoples R China.
EM zo1269@163.com
CR Aranda N, 2016, EUR J CLIN INVEST, V46, P520, DOI 10.1111/eci.12625
   Aursulesei V, 2014, MED-SURG J, V118, P901
   Baharvand Maryam, 2014, Biomed J, V37, P331, DOI 10.4103/2319-4170.132888
   Berdoukas V, 2015, FREE RADICAL BIO MED, V88, P3, DOI 10.1016/j.freeradbiomed.2015.07.019
   Catalin T, 2012, BMC CARDIOVASC DISOR, V12, P1
   Cippa PE, 2014, AM J MED, V127, DOI 10.1016/j.amjmed.2014.03.016
   DePalma RG, 2013, VASCULAR, V21, P233, DOI 10.1177/1708538113478776
   Erdal M, 2014, ANATOL J CARDIOL, V14, P150, DOI 10.5152/akd.2014.4739
   Gill D, 2017, ARTERIOSCL THROM VAS, V37, P1788, DOI [10.1161/ATVBAHA.117.309757, 10.1161/atvbaha.117.309757]
   Grammer TB, 2014, ATHEROSCLEROSIS, V236, P292, DOI 10.1016/j.atherosclerosis.2014.07.002
   Howe LD, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004827
   Hung MY, 2013, INT J MED SCI, V10, P255, DOI 10.7150/ijms.5383
   Inci MF, 2013, ULTRASOUND Q, V29, P125, DOI 10.1097/RUQ.0b013e318291580e
   Iqbal MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067981
   Jankovic N, 2015, AM J CLIN NUTR, V102, P745, DOI 10.3945/ajcn.114.095117
   Jankowska EA, 2015, INT J CARDIOL, V182, P517, DOI 10.1016/j.ijcard.2014.10.006
   Kim TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090105
   Lapenna D, 2018, CLIN EXP MED, V18, P119, DOI 10.1007/s10238-017-0470-5
   Ma H, 2015, BRIT J NUTR, V114, P1064, DOI 10.1017/S0007114515001944
   McSorley ST, 2016, TRANSL RES, V176, P119, DOI 10.1016/j.trsl.2016.05.004
   Moschonis G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/423263
   Novo S, 2012, G ITAL CARDIOL, V13, P118, DOI 10.1714/1021.11145
   Park HB, 2015, EUR RADIOL, V25, P3073, DOI 10.1007/s00330-015-3698-z
   Pilote L, 2000, J CLIN EPIDEMIOL, V53, P809, DOI 10.1016/S0895-4356(99)00234-6
   Polak JF, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001492
   Pollock A, 2015, SOC SCI MED, V131, P221, DOI 10.1016/j.socscimed.2014.06.035
   Pourmoghaddas A, 2014, ARYA ATHEROSCLER, V10, P32
   Rajapurkar MM, 2012, AM J CARDIOL, V109, P438, DOI 10.1016/j.amjcard.2011.09.032
   Schreiner Florentine, 2016, Praxis (Bern 1994), V105, P543, DOI 10.1024/1661-8157/a002338
   Veselova TN, 2017, KARDIOLOGIYA, V57, P42, DOI 10.18565/cardio.2017.1.42-47
   Zhao Shui-Ping, 2016, Chronic Dis Transl Med, V2, P7, DOI 10.1016/j.cdtm.2016.04.001
   Zhou Y, 2014, INTERN MED J, V44, P846, DOI 10.1111/imj.12508
   Zhou YP, 2012, CLIN BIOCHEM, V45, P1336, DOI 10.1016/j.clinbiochem.2012.06.013
NR 33
TC 0
Z9 0
U1 1
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1991
EP 1996
DI 10.19193/0393-6384_2018_6_310
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400061
DA 2022-07-14
ER

PT J
AU Chen, C
   Wang, CH
   Gao, YZ
   Du, YJ
   Liu, H
AF Chen, Cao
   Wang, Chunhui
   Gao, Yuanze
   Du, Yongjun
   Liu, Hua
TI RETROSPECTIVE ANALYSIS ON CLINICAL FEATURE AND TREATMENT STRATEGY OF
   LUMBAR BRUCELLOSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE lumbar vertebra; bacterium burger; focal clearance; bone; graft fusion
AB Objective: discuss clinical feature and treatment strategy of lumbar brucellosis to improve the diagnosis and treatment of this disease.
   Methods: retrospective analysis on clinical features, signs and auxiliary examination results of 35 patients with lumbar brucellosis admitted to our department between January, 2012 and August, 2015 was performed, through visual analogue pain scale (VAS), spine Japanese Orthopaedic Association (JOA) Score and X-ray films and MRI imaging observation after 8 expectant treatments and 27 operative treatments, the clinical effect of patients was assessed.
   Result: 35 patients all had contact history of flocks and herds, medical history of significant fever with night sweat and repeated lumbago, among which, 18 patients had medical history of significant joint pain of four limbs. Imaging examination showed the lesions of all patients were distributed in lumbar vertebra and sacral vertebra, bone destruction was mild, which are common in moth-eaten destruction and hyperostosis osteosclerosis around the diseased vertebra, some patients had significant stenosis of intervertebral space and formation of small amount of abscess around diseased vertebra. Laboratory examination showed > 1:200 in brucella agglutination test, RBPT showed positive, erythrocyte sedimentation rate was increased basically, and white blood cell examination showed normal. The symptoms of all patients were significantly improved after treatment, the effect was satisfied, average VAS score was 8.6 before treatment and 1.7 in the latest follow-up after treatment, average spine function JOA score was 7.4 before treatment and 15.2 in the latest follow-up after treatment.
   Conclusion: lumbar brucellosis has the distinctive imaging features and epidemiological characteristics, the diagnosis rate can be increased through contact history, clinical feature, laboratory examination and imaging examination in early stage and the satisfied effect can be obtained by using appropriate treatment method.
C1 [Chen, Cao; Gao, Yuanze; Du, Yongjun; Liu, Hua] PLA, Dept Orthoped, Hosp 474, Urumqi 830013, Xinjiang, Peoples R China.
   [Wang, Chunhui] Shihezi Peoples Hosp, Dept Orthoped, Shihezi 832002, Xinjiang, Peoples R China.
RP Liu, H (corresponding author), Peoples Liberat Army, Hosp 474, Urumqi, Peoples R China.
EM 27988132@qq.com
CR Bozgeyik Z, 2008, EUR J RADIOL, V67, P153, DOI 10.1016/j.ejrad.2007.07.002
   Cao Jihuai, 2013, RADIOLOGIC PRACTICE, V4, P196
   Katonis P, 2006, CLIN ORTHOP RELAT R, P66, DOI 10.1097/01.blo.0000203455.59393.9a
   Ozdemir HM, 2003, SPINE, V28, P474, DOI 10.1097/00007632-200303010-00012
   Wang Jia, 2008, J PATHOGEN BIOL, V2, P149
   Yang Xinming, 2012, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V26, P266
   [杨新明 YANG Xinming], 2008, [中国地方病学杂志, Chinese Journal of Endemiology], V27, P699
   Yang Xinming, 2008, J PRACTICAL MED, V24, P1632
   Yang Xinming, 2011, SPINAL DIS, P271
   Zhao Guangmin, 2007, CHINESE J SPINE SPIN, V6, P437
NR 10
TC 0
Z9 0
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1711
EP 1716
DI 10.19193/0393-6384_2018_6_261
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400012
DA 2022-07-14
ER

PT J
AU Chen, S
   Xiao, R
AF Chen, Sheng
   Xiao, Rui
TI SURFACE MORPHOLOGY OF ISTHMIC LUMBAR SPONDYLOLISTHESIS IN BADMINTON
   ATHLETES AND DEGENERATIVE SPONDYLOLISTHESIS PATIENTS WITH SPINE PELVIS
   SAGITTAL PLANE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Lumbar vertebra; Isthmic spondylolisthesis; Degenerative
   spondylolisthesis; Spine pelvis sagittal morphology; Exploration
ID ASSOCIATION
AB To research on specific clinical features of isthmic lumbar spondylolisthesis in badminton athletes and explore the morphological study of degenerative spondylolisthesis patients with spine pelvic sagittal plane. In order to further study the characteristics of morphology, 1,100 patients with isthmic lumbar spondylolisthesis and degenerative spondylolisthesis, receiving clinic treatment by a hospital from January 2009 to February 2016, were randomly selected as the research object and all of them have complete image data. Patients were divided into spondylolysis group (550) and degeneration group (550). The relative spine and pelvic sagittal index of two groups of patients were collected, mainly covering the following aspects: inclination of pelvis, pelvic incidence angle and lumbar lordosis angle and so on. At the same time, the following parts of two groups were measured: angle of lumbar spondylolisthesis, spondylolisthesis rate, spondylolisthesis distance to analyze comparatively the above patients with these indicators. The results show that the angle of lumbar lordosis, thoracic posterior lobe and spondylolysis angle of the group of patients was significantly higher than that of degeneration group, meeting P < 0.05, which has statistical significance. The patients in the degeneration group were superior to spondylolysis group in vertical distance of sagittal axial. The comparison between two groups of patients does not exist statistical significance in following aspects: namely morphological parameters of the pelvis, pelvic tilt angle, sacral inclination angle and lumbar spondylolisthesis rate and so forth. Therefore, we can draw the conclusion that the isthmic lumbar spondylolisthesis of badminton players is similar to degenerative spondylolisthesis in pelvic morphology, but the former has larger thoracic kyphosis, lumbar lordosis and spondylolisthesis angle than the latter.
C1 [Chen, Sheng] Chengdu Univ, Sch Phys Educ, Chengdu 610106, Peoples R China.
   [Xiao, Rui] Sichuan Univ, Coll Literature & Journalism, Chengdu 610064, Peoples R China.
RP Chen, S (corresponding author), Chengdu Univ, Phys Educ 1Sch, Chengdu 610106, Sichuan, Peoples R China.
EM 787345913@qq.com
CR Aldahmash BA, 2016, SAUDI J BIOL SCI, V23, P311, DOI 10.1016/j.sjbs.2015.09.027
   Ali MA, 2016, SAUDI J BIOL SCI, V23, P229, DOI 10.1016/j.sjbs.2015.02.010
   Bich GA, 2017, SAUDI J BIOL SCI, V24, P851, DOI 10.1016/j.sjbs.2016.05.010
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P127, DOI 10.1016/j.sjbs.2016.09.005
   [何守玉 He Shouyu], 2015, [中国矫形外科杂志, Orthopedic Journal of China], V23, P77
   [何守玉 He Shouyu], 2014, [中国脊柱脊髓杂志, Chinese Journal of Spine and Spinal Cord], V24, P109
   Jin Wang, 2016, CHINESE J TISSUE ENG, V22, P3322
   Kos M, 2015, ACTA MEDICA MEDITERR, V31, P219
   Liang LI, 2013, CHINESE J REPARATIVE, V11, P1338
   Song HM, 2015, ACTA MEDICA MEDITERR, V31, P303
   Taheri M, 2017, ACTA MEDICA MEDITERR, V33, P597, DOI 10.19193/0393-6384_2017_4_088
   Turhan Iyidir O, 2017, TURK J MED SCI, V47, P1751, DOI 10.3906/sag-1610-139
   Uluocak N, 2016, ACTA MEDICA MEDITERR, V32, P1029, DOI 10.19193/0393-6384_2016_4_127
   Wang Y, 2015, ACTA MEDICA MEDITERR, V31, P981
   Yang AM, 2017, J ALLOY COMPD, V695, P915, DOI 10.1016/j.jallcom.2016.10.188
   Yang YS, 2018, IEEE INSTRU MEAS MAG, V21, P34, DOI 10.1109/MIM.2018.8278808
   Yong Liu, 2013, CHINESE J SPINE SPIN, V23, P307
NR 18
TC 0
Z9 0
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1583
EP 1587
DI 10.19193/0393-6384_2018_3s_246
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400022
DA 2022-07-14
ER

PT J
AU Chen, T
   Wang, ZH
AF Chen, Tao
   Wang, Zhanhua
TI EVALUATION OF THE INFLUENCE OF ACUPOINTS SELECTION ON GHRELIN AND GHSR
   EXPRESSION IN GASTRIC FUNDUS TISSUE OF DGP RATS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Acupoints compatibility; Acupoints selection; Diabetic gastroparesis;
   Acupuncture therapy
ID RECEPTOR; MOTILITY
AB Objective: To investigate the influence of acupoint selection on ghrelin and GHSR expressions in the gastric fundus of rats with diabetic gastroparesis (DGP).
   Methods: Sixty male SPF SD rats were given adaptive feeding for one week and were randomly divided into a blank control group, a model group, Zusanli and Zhongwan (ZZ) group, Zusanli and Neiguan group (ZN), as well as Zusanli and non-meridian acupoint (ZNA) group, with 12 rats in each group. Except for the blank group, the other 48 rats were used to establish a DGP model by using streptozotocin. Acupuncture therapy was performed from the end of the tenth week for an additional four weeks. Then the rats were sacrificed and the sera and gastric fundus tissues were collected. Serum ghrelin content was assayed with ELISA kits. The expression of ghrelin positive cells in the gastric fundus tissue was determined by immunohistochemistry, while the expression of ghrelin and GHSR mRNA in the gastric fundus tissue was determined by real-time polymerase chain reaction (RT-PCR).
   Results: Compared with the control group, the feed intake and the expression of ghrelin and GHSR mRNA in the gastric fundus tissue in the model group was significantly increased, while small intestinal propulsion rate, serum ghrelin content, and the gray value of the gastric fundus were significantly decreased (p < 0.05). Compared with the model group, the expression of ghrelin and GHSR mRNA in the gastric fundus tissue, small intestinal propulsion rate, serum ghrelin content, and gray value of the gastric fundus were significantly increased (p < 0.05). Feed intake was significantly higher in the ZN and the ZNA groups (p < 0.05), and the expressions of ghrelin and GHSR mRNA in the gastric fundus tissue were significantly increased (p < 0.05) but the serum ghrelin content in ZN group was significantly decreased (p < 0.05).
   Conclusions: These results suggest that improvement of gastrointestinal motility in DGP by acupuncture therapy is associated with serum ghrelin content and GHSR expression in the gastric fundus. They also indicate that the effect of treatment with local acupoints compatibility is better than that of distal acupoints compatibility, and that acupoint selection according to location or outcome is a key factor that influences acupoints compatibility.
C1 [Chen, Tao] Gansu Prov Hosp Rehabil Ctr, Lanzhou 730000, Gansu, Peoples R China.
   [Wang, Zhanhua] Lanzhou Petrochem Gen Hosp, Dept Lab, Lanzhou 730060, Gansu, Peoples R China.
RP Wang, ZH (corresponding author), Lanzhou Petrochem Gen Hosp, Dept Lab, Lanzhou 730060, Gansu, Peoples R China.
EM ij0738@163.com
CR Bazhanov N, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0284-5
   Chen CY, 2010, J CHIN MED ASSOC, V73, P225, DOI 10.1016/S1726-4901(10)70048-4
   Espelund U, 2005, J CLIN ENDOCR METAB, V90, P741, DOI 10.1210/jc.2004-0604
   Jing Qi, 2014, Zhong Yao Cai, V37, P1415
   Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230
   Li ZR., 2007, EXPT ACUPUNCTURE SCI, V2nd Edition, P255
   Lin GH, 2016, EXP THER MED, V11, P2489, DOI 10.3892/etm.2016.3185
   Lin Ya-ping, 2015, Zhen Ci Yan Jiu, V40, P290
   Lund A, 2014, EUR J INTERN MED, V25, P407, DOI 10.1016/j.ejim.2014.03.005
   Ma H, 2013, BIOMED ENVIRON SCI, V26, P155, DOI 10.3967/0895-3988.2013.03.001
   O'Grady G, 2015, GASTROENTEROL CLIN N, V44, P169, DOI 10.1016/j.gtc.2014.11.013
   Phillips LK, 2015, NAT REV ENDOCRINOL, V11, P112, DOI 10.1038/nrendo.2014.202
   Poitras P, 2009, REGUL PEPTIDES, V155, P24, DOI 10.1016/j.regpep.2009.04.007
   Sakurazawa N, 2013, NEUROSCI LETT, V541, P204, DOI 10.1016/j.neulet.2013.02.006
   Schubert ML, 2009, CURR OPIN GASTROEN, V25, P529, DOI 10.1097/MOG.0b013e328331b62a
   Shi Yunzhou, 2015, Zhongguo Zhen Jiu, V35, P1025
   SUM w Katowicach Patofizjologii Z, 2013, J COVER
   Tack Jan, 2014, Curr Treat Options Gastroenterol, V12, P468, DOI 10.1007/s11938-014-0034-7
   Tang M, 2013, PEDIATR DIABETES, V14, P239, DOI 10.1111/pedi.12039
   Tong J, 2014, DIABETES, V63, P407, DOI 10.2337/db13-1764
   Xu L, 2013, EUR J PHARMACOL, V718, P219, DOI 10.1016/j.ejphar.2013.08.030
   Yang CG, 2013, MOL MED REP, V7, P83, DOI 10.3892/mmr.2012.1157
   Zhang Guo-xue, 2014, Zhongguo Zhen Jiu, V34, P987
   Zhang Hui, 2015, Zhen Ci Yan Jiu, V40, P104
   Zheng Jiatai, 2015, Zhongguo Zhen Jiu, V35, P719
   Zhou Li, 2016, Zhongguo Zhong Xi Yi Jie He Za Zhi, V36, P322
NR 26
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 893
EP 900
DI 10.19193/0393-6384_2018_3_137
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000041
DA 2022-07-14
ER

PT J
AU Chen, X
   Tang, CH
   Cao, YL
   Lin, GJ
   Zhao, HL
   Deng, L
AF Chen, Xi
   Tang, Chenghai
   Cao, Yilin
   Lin, Gaojuan
   Zhao, Huiling
   Deng, Lian
TI EXPRESSION OF NESTIN IN CERVICAL CARCINOMA AND ITS CLINICAL SIGNIFICANCE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Cervical neoplasms; N-cadherin; Cisplatin chemotherapy;
   Immunohistochemistry
ID STEM-CELL MARKERS; ASSOCIATION; PROGRESSION; MMP-9; CD44
AB Objective: Cervical cancer has become the second most common malignancy of women in the world with its high incidence, high invasiveness, high metastasis, and ,gradual rejuvenation. The prognosis of patients with cervical cancer has closely related to its stage. For invasive metastasis, the prognosis is relatively poor, and the prognosis of those with limited tumor is relatively good.
   Methods: At present, the treatment of cancer is gradually becoming an era of individualized treatment, which emphasizes systemic therapy. Detection of specific tumor molecular markers is an important basis for identifying individual differences in tumor patients, and it is the premise and basis for individualized treatment of tumors. This paper has selected suitable drugs for patients.
   Results: This paper has also randomly selected pathological specimens of 80 newly diagnosed cervical cancer patients with pathologically confirmed and complete clinical data in our hospital as the study group. Immunohistochemistry has used to detect the expression of nesting in cervical cancer tissue and to investigate its expression in cervical cancer. 60 patients are selected and pathological specimens of newly diagnosed cervical cancer patients were divided into two groups according to the efficacy of chemotherapy: chemotherapy effective ,group and chemotherapy ineffective group, 30 cases in each group. The nestin expression level of interstitial markers has compared between the two groups.
   Conclusions: Through the comparison of nestin expression levels of interstitial markers between the two groups. This paper provides personalized predictive indicators for patients with personalized adjuvant chemotherapy, worthy of clinical application.
C1 [Chen, Xi; Tang, Chenghai; Cao, Yilin; Lin, Gaojuan; Zhao, Huiling; Deng, Lian] Nanxishan Hosp, Dept Oncol, Guilin 541002, Guangxi Zhuang, Peoples R China.
RP Chen, X (corresponding author), Nanxishan Hosp, Dept Oncol, Guilin 541002, Guangxi Zhuang, Peoples R China.
EM cenxi800@163.com
FU Guangxi Zhuang Autonomous Region Department of Health [z2014184]
FX Thanks to the Guangxi Zhuang Autonomous Region Department of Health for
   funding the research funded by self-financing. Title: Relationship
   between nestin expression in cervical cancer and chemotherapy efficacy
   (Contract No.: z2014184).
CR Ahir Bhavesh K, 2017, Genes Cancer, V8, P453, DOI 10.18632/genesandcancer.130
   Aurello P, 2017, AM J SURG, V213, P748, DOI 10.1016/j.amjsurg.2016.05.022
   Bi YL, 2016, J SURG ONCOL, V113, P144, DOI 10.1002/jso.24124
   Chen L, 2016, ONCOTARGET, V7, P20041, DOI 10.18632/oncotarget.7884
   Chi HC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091903
   Conner JR, 2015, ADV ANAT PATHOL, V22, P149, DOI 10.1097/PAP.0000000000000069
   de la Pena S, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/285906
   Hauff SJ, 2014, OTOLARYNGOL HEAD NEC, V151
   Hu JW, 2017, AER ADV ENG RES, V126, P1
   Hu J, 2017, ONCOTARGET, V8, P28463, DOI 10.18632/oncotarget.15307
   Huang CF, 2014, J ORAL PATHOL MED, V43, P492, DOI 10.1111/jop.12159
   Incesu Z, 2013, INDIAN J EXPT BIOL, V51
   Jia LF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108435
   Lawicki S, 2016, ONCOTARGETS THER, V9, P911, DOI 10.2147/OTT.S99959
   Lee KH, 2015, ONCOTARGET, V6, P3240, DOI 10.18632/oncotarget.3087
   Lv DL, 2017, MOL NEUROBIOL, V54, P727, DOI 10.1007/s12035-016-9689-5
   Macpherson IR, 2014, J CELL SCI 18, V127
   Onisim A, 2015, ANGIOGENESIS, V27, P40
   Ravindran G, 2015, CLIN ORAL INVEST, V19, P1251, DOI 10.1007/s00784-014-1341-z
   Sal V, 2017, J OBSTET GYNAECOL RE, V43, P371, DOI 10.1111/jog.13220
   Schmidt LH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177146
   Schoolmeester JK, 2017, AM J SURG PATHOL, V41, P622, DOI 10.1097/PAS.0000000000000796
   Singh N, 2015, DRUG DISCOV TODAY, V20, P578, DOI 10.1016/j.drudis.2014.11.013
   Skoda J, 2016, TUMOR BIOL, V37, P9535, DOI 10.1007/s13277-016-4837-0
   Taucher V, 2016, CELL ONCOL, V39, P295, DOI 10.1007/s13402-016-0275-7
   Tokar Tomas, 2018, Oncotarget, V9, P9137, DOI 10.18632/oncotarget.24070
   Verbovsek U, 2015, SEMIN CANCER BIOL, V35, P71, DOI 10.1016/j.semcancer.2015.08.010
   Vishnoi K, 2015, MULTITARGETED APPROA, P377
   Wu L, 2017, FEBS J
   Yu J, 2016, INT J CLIN EXP PATHO, V9, P5445
   Zhang XW, 2016, ONCOTARGET, V7, P9815, DOI 10.18632/oncotarget.6890
   Zhao Wenxiu, 2017, Cancer Transl Med, V3, P87, DOI 10.4103/ctm.ctm_69_16
   Zhong BL, 2015, ONCOTARGET, V6, P22970, DOI 10.18632/oncotarget.4042
NR 33
TC 0
Z9 0
U1 1
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1685
EP 1695
DI 10.19193/0393-6384_2018_6_258
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400009
DA 2022-07-14
ER

PT J
AU Chen, YW
   Shi, WJ
   Li, YP
   Gao, XM
   Zhang, MY
   Ren, GL
AF Chen, Ya-Wei
   Shi, Wen-Ju
   Li, Yu-Peng
   Gao, Xiu-Mei
   Zhang, Mei-Yan
   Ren, Guang-Li
TI DEVELOPMENT OF SPONTANEOUS RENAL HEMORRHAGE ASSOCIATED WITH ACUTE
   PANCREATITIS IN A PATIENT ON HEMODIALYSIS FOR CHRONIC RENAL FAILURE: A
   CASE REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Spontaneous renal hemorrhage; Wunderlich syndrome; hemodialysis; acute
   pancreatitis
ID DIALYSIS PATIENTS; DISEASE; RUPTURE
AB Objective: We present one rare case of spontaneous renal hemorrhage(SRH) in a 32-year-old woman with systemic lupus erythematosus(SLE) undergoing maintenance HD, and she subsequently developed acute pancreatitis(AP). These complicated illnesses she suffered brings us into question whether there is a causal relationship between SHR and AP in HD patient.
   Methods: A CT scan of the abdomen supported the evidence of renal hemorrhage. In view of the markedly raised pancreatic enzymes and CT findings, the acute pancreatitis was also diagnosed.
   Results: Multi-factors lead to the development of the disease. The factors such as anticoagulation used during HD, uraemia-associated functional platelet abnormalities, immunosuppression (corticosteroid), intimal arterial fibrosis and hypertension often combine to cause SRH. Other possibilities can be considered for the mechanism of AP: SHPT, gastrointestinal hormones and immunological condition.
   Conclusion: SRH and AP are both potentially life threatening condition in patients with end-stage renal disease(ESRD). A detailed understanding of pathophysiological processes and immunological aspects in patients is the basis for the development of therapeutic strategies that will provide significant reductions in morbidity and mortality.
C1 [Chen, Ya-Wei; Shi, Wen-Ju; Gao, Xiu-Mei; Zhang, Mei-Yan; Ren, Guang-Li] Chinese PLA 254 Hosp, Nephrol Dept, Huangwei Rd, Tianjin 300142, Peoples R China.
   [Li, Yu-Peng] Tianjin Med Univ, Metab Dis Hosp, 66 TongAn Rd, Tianjin, Peoples R China.
   [Li, Yu-Peng] Tianjin Endocrinol Inst, 66 TongAn Rd, Tianjin, Peoples R China.
RP Chen, YW (corresponding author), Chinese PLA 254 Hosp, Nephrol Dept, Huangwei Rd, Tianjin 300142, Peoples R China.
CR Bensalah K, 2003, EUR UROL, V44, P111, DOI 10.1016/S0302-2838(03)00213-6
   Ergun T, 2012, EUR J RADIOL, V81, P13, DOI 10.1016/j.ejrad.2010.10.012
   Golay V, 2012, RENAL FAILURE, V34, P1338, DOI 10.3109/0886022X.2012.718951
   Griesche-Philippi J, 2010, CLIN NEPHROL, V74, P457
   Hou SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071801
   Khan AS, 2010, J PANCREAS, V11, P545
   Kumar Santosh, 2013, J Emerg Trauma Shock, V6, P276, DOI 10.4103/0974-2700.120374
   Lankisch PG, 2008, NEPHROL DIAL TRANSPL, V23, P1401, DOI 10.1093/ndt/gfm769
   Minkov GA, 2015, PANCREAS, V44, P713, DOI 10.1097/MPA.0000000000000329
   Nahm AM, 2001, NEPHROL DIAL TRANSPL, V16, P1506, DOI 10.1093/ndt/16.7.1506
   Nasir Kiran, 2012, Arab J Nephrol Transplant, V5, P87
   PADILLA B, 1994, MEDICINE, V73, P8, DOI 10.1097/00005792-199401000-00002
   ROYSE VL, 1987, ARCH INTERN MED, V147, P537, DOI 10.1001/archinte.147.3.537
   STEINBERG W, 1994, NEW ENGL J MED, V330, P1198, DOI 10.1056/NEJM199404283301706
   Tarrass F, 2007, NEPHROL DIAL TRANSPL, V22, P280, DOI 10.1093/ndt/gfl617
   Tomino T, 2014, SURG TODAY, V44, P690, DOI 10.1007/s00595-013-0673-7
   Tonolini M, 2015, INSIGHTS IMAGING, V6, P693, DOI 10.1007/s13244-015-0439-4
   Vincenzo DP, 2015, ACTA MEDICA MEDITERR, V31, P437
   Zhang JQ, 2002, J UROLOGY, V167, P1593
NR 19
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 65
EP 69
DI 10.19193/0393-6384_2018_1_11
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600011
DA 2022-07-14
ER

PT J
AU Chen, YW
   Chen, W
   Zeng, Y
   Xie, XH
AF Chen, Yawei
   Chen, Wen
   Zeng, Yuan
   Xie, Xiaohua
TI ALDOSTERONE INDUCES IL-8 PRODUCTION IN HUMAN MONONUCLEAR MACROPHAGE
   THROUGH MINERALOCORTICOID RECEPTOR AND TOLL-LIKE RECEPTOR-4
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE mineralocorticoid receptor; aldosterone; TLR4; genomic
ID INFLAMMATION; DYSFUNCTION; EXPRESSION; KIDNEY; SPIRONOLACTONE;
   ACTIVATION; HEART
AB Stress and inflammation contribute to increased morbidity and mortality associated with activation of the rennin-angiotensin-aldosterone system (RAAS), learnt from our previous trauma researches. Because aldosterone has been implicated in the stimulation of cytokines production in various tissues, we investigated whether it would affect IL-8 production in cultures of human mononuclear macrophage. We first demonstrated that treatment with 10 to 10(4) nM aldosterone leads to a significant increase in IL-8 secretion and mRNA levels in a time-dependent manner. Pretreatment of cells with the mineralocorticoid receptor (MR) antagonist spironolactone and anti-Toll-like receptor 4 (anti-TLR4) antibody inhibited IL-8 production in aldosterone-treated cultures. We also demonstrated that aldosterone increases IL-8 production by time dependent manner. We further discovered that aldosterone could regulate the protein expression of MR and TLR4. Thus, we have demonstrated for the first time that (lidos(crone, which stimulates IL-8 production through the MR-dependent pathway, also maybe a novel endogenous ligand to TLR4.
C1 [Chen, Yawei] PLA 254th Hosp, Tianjin 300142, Peoples R China.
   [Chen, Wen; Zeng, Yuan; Xie, Xiaohua] Chinese Peoples Liberat Army Gen Hosp, Dept Comprehens Surg 1, South Bldg, Beijing 100853, Peoples R China.
RP Xie, XH (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Comprehens Surg 1, South Bldg, Beijing 100853, Peoples R China.
EM n4xxh@126.com
FU Chines Army key program Found in science and technology [06G117]
FX This work was supported by the Chines Army key program Found in science
   and technology (06G117).
CR Antonov YV, 2016, CLIN EXP HYPERTENS, V38, P415, DOI 10.3109/10641963.2015.1116546
   Briet M, 2016, HYPERTENSION, V67, P897, DOI 10.1161/HYPERTENSIONAHA.115.07074
   Briet M, 2013, J VASC RES, V50, P89, DOI 10.1159/000345243
   Briet M, 2010, NAT REV NEPHROL, V6, P261, DOI 10.1038/nrneph.2010.30
   Brown NJ, 2008, HYPERTENSION, V51, P161, DOI 10.1161/HYPERTENSIONAHA.107.095489
   EISEN C, 1994, CELL MOL BIOL, V40, P351
   Eissler R, 2011, HYPERTENS RES, V34, P551, DOI 10.1038/hr.2010.270
   Gekle M, 1998, J PHYSIOL-LONDON, V511, P255, DOI 10.1111/j.1469-7793.1998.255bi.x
   Goulopoulou S, 2016, PHARMACOL REV, V68, P142, DOI 10.1124/pr.114.010090
   Grossmann C, 2009, MOL CELL ENDOCRINOL, V308, P53, DOI 10.1016/j.mce.2009.02.005
   Libby P, 2002, NATURE, V420, P868, DOI [10.1038/nature01323, 10.1161/ATVBAHA.108.179705]
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Maguire M, 2005, IMMUNOLOGY, V115, P231, DOI 10.1111/j.1365-2567.2005.02155.x
   McCarthy CG, 2015, CARDIOVASC RES, V107, P119, DOI 10.1093/cvr/cvv137
   Miura R, 2006, J PHARMACOL SCI, V101, P256, DOI 10.1254/jphs.SC0060049
   Miyata K, 2005, J AM SOC NEPHROL, V16, P2906, DOI 10.1681/ASN.2005040390
   Moreth K, 2014, MATRIX BIOL, V35, P143, DOI 10.1016/j.matbio.2014.01.010
   Murakami M, 2016, BIOCHEM BIOPH RES CO, V476, P614, DOI 10.1016/j.bbrc.2016.06.007
   Nagai Y, 2005, HYPERTENSION, V46, P1039, DOI 10.1161/01.HYP.0000174593.88899.68
   Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207
   Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001
   Rocha R, 2002, AM J PHYSIOL-HEART C, V283, pH1802, DOI 10.1152/ajpheart.01096.2001
   Stribos EGD, 2015, MOL IMMUNOL, V64, P82, DOI 10.1016/j.molimm.2014.11.003
   Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9
   Urbach V, 2001, J PHYSIOL-LONDON, V537, P267, DOI 10.1111/j.1469-7793.2001.0267k.x
   Yang SH, 2001, INFECT IMMUN, V69, P2045, DOI 10.1128/IAI.69.4.2045-2053.2001
   Zhang Y, 2015, PLOS ONE, V10, P797
   Zhang YD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142456
NR 28
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1631
EP 1639
DI 10.19193/0393-6384_2018_6_252
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400003
DA 2022-07-14
ER

PT J
AU Chen, ZH
AF Chen, Zhenghong
TI SURFACE ELECTROMYOGRAPHY AND MUSCLE TESTING TECHNOLOGY FOR TREATMENT OF
   SHOULDER JOINT SPORTS INJURY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Surface electromyography and isokinetic muscle testing technology;
   Shoulder joint injury; Clinical effect
ID STRENGTH
AB Shoulder joint injury is one of the most common in various sports. If treated improperly, athletes' body health and sports career will be adversely affected. In order to provide more scientific and intuitive guidance basis for clinical treatment of shoulder joint injury, an in-depth analysis on clinical effect of surface electromyography and muscle testing technology for treatment of shoulder joint injury was carried out. In this study, 1,200 shoulder joint injury patients were selected as observation group research objects; 500 athletes without sports injury were additionally selected as control group research objects. Both groups received surface electromyography and isokinetic muscle testing, with test results of the two groups compared. The results of surface electromyography and isokinetic muscle testing showed significant differences between observation group and control group patients' shoulder joint in angular velocity, abduction supraspinatus, infraspinatus IEMG. Difference between the groups P <0.05, with significant statistical significance. It can thus be concluded that after athletes have shoulder joint injury, muscles, joints of associated parts will undergo obvious changes. With surface electromyography and isokinetic muscle testing technology, full and accurate assessment of changed muscle function, status can be made, thereby providing valuable basis for treatment of shoulder joint injury. Therefore, surface electromyography and isokinetic muscle testing technology have significant clinical value in diagnosis of shoulder joint injuries.
C1 [Chen, Zhenghong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rehabil Med, Guangzhou 510080, Guangdong, Peoples R China.
RP Chen, ZH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Rehabil Med, Guangzhou 510080, Guangdong, Peoples R China.
EM czlion@163.com
FU TAO-HONG-SI-WUTANG on physical fitness and fatigue recovery of athletes
   [0082704132154]
FX The physical effects of TAO-HONG-SI-WUTANG on physical fitness and
   fatigue recovery of athletes (No. 0082704132154).
CR Abdel-Warith AWA, 2016, SAUDI J BIOL SCI, V23, P404, DOI 10.1016/j.sjbs.2015.11.010
   Al-Hazmi AS, 2016, SAUDI J BIOL SCI, V23, P288, DOI 10.1016/j.sjbs.2015.04.007
   Bassi P, 2017, SAUDI PHARM J, V25, P32, DOI 10.1016/j.jsps.2015.06.003
   Billen J, 2017, SAUDI J BIOL SCI, V24, P830, DOI 10.1016/j.sjbs.2016.06.007
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P1370, DOI 10.1016/j.sjbs.2016.12.016
   Halici U, 2015, ACTA MEDICA MEDITERR, V31, P807
   Kaur G, 2017, PAK J PHARM SCI, V30, P789
   Lei XW, 2015, J COASTAL RES, P265, DOI 10.2112/SI73-047.1
   Sandri A. B. A., 2015, ASIAN PAC J SURG ONC, V1, P113
   Shahid B, 2015, PAK J PHARM SCI, V28, P95
   Shen Y, 2017, POL MARIT RES, V24, P95, DOI 10.1515/pomr-2017-0110
   Smithers BM, 2015, ASIAN PAC J SURG ONC, V1, P125
   Wroblewska K, 2015, SAUDI PHARM J, V23, P407, DOI 10.1016/j.jsps.2014.11.009
   Wu K, 2015, J COASTAL RES, P521, DOI 10.2112/SI73-091.1
   Yang AM, 2017, RESULTS PHYS, V7, P1046, DOI 10.1016/j.rinp.2017.02.027
   Zhang M, 2015, J COASTAL RES, P304, DOI 10.2112/SI73-053.1
NR 17
TC 0
Z9 0
U1 4
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1539
EP 1543
DI 10.19193/0393-6384_2018_3s_237
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400014
DA 2022-07-14
ER

PT J
AU Cheng, YS
   Zhou, J
   Zhou, YH
AF Cheng, Yanshuang
   Zhou, Jing
   Zhou, Yuhong
TI COMPARISON OF THE APPLICATION EFFECTS OF FLEXIBLE MANAGEMENT AND ROUTINE
   NURSING IN HEPATOBILIARY SURGICAL NURSING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Routine nursing; Flexible management; Hepatobiliary surgery; Application
   effect; Comparison and analysis
ID MOLECULAR-STRUCTURES; DRUGS
AB Objective: This study aimed to observe and analyze the application effects of flexible management and routine nursing in hepatobiliary surgical nursing.
   Methods: A total of 180 cases who underwent the treatment in the Department of Hepatobiliary Surgery in our hospital, were enrolled as the research subjects in this study. They were divided equally into the control group (90 cases, routine nursing mode) and the research group (90 cases, routine nursing mode plus flexible management scheme). The nursing effects in the two groups were observed and the following indexes were compared: the overall satisfaction of patients on nursing work, the nursing quality in both groups, the satisfaction of nurses on work, the incidence rate of nurses' error and the complaint rate in nursing service.
   Results: The overall nursing satisfaction of patients and satisfaction of nurses on work in the research group were significantly higher than those of patients and nurses in control group (P < 0.05). The nurses' nursing quality was evaluated by the Assessment Criteria of Nursing Quality formulated by our hospital in which the results showed that the nurses' nursing quality in research group was better than the control group (P < 0.05). Moreover, both patients' complaint rate in nursing service and incidence rate of nurses' error in the research group were distinctly lower as compared with the control group (P < 0.05).
   Conclusions: During the nursing period of patients with hepatobiliary surgery, the flexible management scheme can significantly enhanced patients' overall nursing satisfaction as well as the satisfaction of nurses on work, which are conducive to promote the harmonious degree of relationship between nurses and patients.
C1 [Cheng, Yanshuang] Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary Surg, Beijing 100853, Peoples R China.
   [Zhou, Jing] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China.
   [Zhou, Yuhong] Chinese Peoples Liberat Army Gen Hosp, Dept Surg, Beijing 100853, Peoples R China.
RP Zhou, YH (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Surg, Beijing 100853, Peoples R China.
FU Key Research and Development Project of Hainan Province [SQ2016SHFZ0113]
FX This study was supported by a grant from the Key Research and
   Development Project of Hainan Province (Grant No: SQ2016SHFZ0113).
CR Balkhair KS, 2016, SAUDI J BIOL SCI, V23, pS83, DOI 10.1016/j.sjbs.2015.10.029
   Cahill G., 2015, ASIAN PAC J SURG ONC, V1, P27
   Cahill T., 2015, ASIAN PAC J SURG ONC, V1, P47
   Din AJM, 2016, SAUDI J BIOL SCI, V23, pS69, DOI 10.1016/j.sjbs.2015.10.022
   Dobson P. R., 2015, ASIAN PAC J SURG ONC, V1, P59
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   Ghoneum M, 2015, ASIAN PAC J SURG ONC, V1, P73
   Kocak MZ, 2017, BIOMED RES-INDIA, V28, P3009
   Lu Y, 2015, WORLD LATEST MED INF, V14, P206
   Luo N, 2013, TODAY NURSE, V13, P71
   Ocek L, 2017, ACTA MEDICA MEDITERR, V33, P601, DOI 10.19193/0393-6384_2017_4_089
   Peng JP, 2016, SAUDI PHARM J, V24, P279, DOI 10.1016/j.jsps.2016.04.020
   Qin LM, 2016, GUIDE CHINA MED, V11, P221
   Shakeel S, 2016, PAK J PHARM SCI, V29, P2349
   Xia YH, 2016, J BAOTOU MED COLL, V22, P135
   Ying J., 2016, J TRADITIONAL CHINES
   Yung K. W., 2015, ASIAN PAC J SURG ONC, V1, P1
NR 19
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 221
EP 225
DI 10.19193/0393-6384_2018_1s_36
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100001
DA 2022-07-14
ER

PT J
AU Chisari, G
   Rampello, L
   Borzi, AM
   Chisari, LM
   Chisari, CG
AF Chisari, Giuseppe
   Rampello, Luigi
   Borzi, Antonio Maria
   Chisari, Laura Maria
   Chisari, Clara Grazia
TI THE EFFECTS OF BLOOD GLUCOSE REGULATION ON THE MICROBIOTA OCULAR IN TYPE
   II DIABETIC SUBJECTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE type 2 diabetics; the eye surface; ocular microbiota
ID SOFT-TISSUE INFECTIONS; AMNIOTIC MEMBRANE USE; RISK-FACTORS; SURFACE;
   SKIN
AB The authors studied the effects of blood glucose regulation on the microbiota ocular in type II diabetic subjects. 30 type II diabetic subjects were considered for at least 2 years and subdivided into three groups A, B and C based on the A1c (HbA1c) glycemic hemoglobin assay. The group "A" includes 10 subjects with HbA1c < 7.5%, in the group called "B" there are 10 subjects with the same ocular but with HbA1c range between 7.5 and 9.5 and 10 were included in group C, 10 diabetic subjects with HbA1c > 9.5%. All patients in the three groups were considered the following parameters: Schirmer I test, Schirmer II Test, time to break the tear film (BUT, sec)
   and conjunctival buffer for aerobic and anaerobic bacteria research. The cultivation examinations showed a positivity for the tests in group A of 5, group B of 7 and group C of 7 bacteriological examinations. In the group A we found a total of 4 mono microbial and 1 poly microbial finds, mono microbial group B 4 and 7 poly microbial, and mono microbial and 3 poly microbial C 3 groups. Our data show that there is a close relationship between the concentration of glucose in the blood and its modification of the ocular microbiota.
C1 [Chisari, Giuseppe; Chisari, Laura Maria] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Rampello, Luigi; Chisari, Clara Grazia] Univ Catania, Dept Dept Med Surg Sci & Adv Technol GF Ingrassia, Catania, Italy.
   [Borzi, Antonio Maria] Univ Catania, Res Ctr Great Senescence, Catania, Italy.
RP Chisari, LM (corresponding author), Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
RI Borzì, Antonio Maria/X-8685-2018
OI Borzì, Antonio Maria/0000-0001-6984-308X; chisari, clara
   grazia/0000-0003-1607-543X; CHISARI, Giuseppe/0000-0002-0492-2171
CR Aiello FC, 2017, CURR DIABETES REV, V13, P50, DOI 10.2174/1573399812666151123104352
   Azuara-Blanco A, 1999, BRIT J OPHTHALMOL, V83, P399, DOI 10.1136/bjo.83.4.399
   Chisari CG, 2015, ACTA MEDICA MEDITERR, V31, P1217
   Chisari CG, 2014, ACTA MEDICA MEDITERR, V30, P249
   Chisari EM, 2017, ACTA MEDICA MEDITERR, V10, P384
   Chisari EM, 2016, ACTA MEDICA MEDITERR, V32, P1577
   Chisari G, 2017, CLIN TER, V168, pE181, DOI [10.7417/CT.2017.2002, 10.7417/T.2017.2002]
   Chisari G, 2017, CURR CLIN PHARM, V12, P1574
   Chisari G, 2016, ACTA MEDICA MEDITERR, V32, P463
   Chisari G, 2017, ACTA MEDICA MEDITERR, V33, P431, DOI 10.19193/0393-6384_2017_3_063
   Chisari G, 2015, ACTA MEDICA MEDITERR, V31, P1057
   Chisari G, 2013, ACTA MEDICA MEDITERR, V29, P369
   Chisari G, 2011, ACTA MEDICA MEDITERR, V27, P73
   Jaaskelainen IH, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.01.002
   Jenkins TC, 2014, INFECT CONT HOSP EP, V35, P1241, DOI 10.1086/678056
   Lipsky BA, 2010, DIABETOLOGIA, V53, P914, DOI 10.1007/s00125-010-1672-5
   Lo V, 2009, INT J DERMATOL, V48, P935, DOI 10.1111/j.1365-4632.2009.04173.x
   Malaguarnera G, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1115-z
   Malaguarnera G, 2013, ANTI-CANCER AGENT ME, V13, P1406, DOI 10.2174/18715206113136660349
   Malaguarnera M, 2015, AM J TRANSL RES, V7, P2510
   Malaguarnera M, 2013, ACTA MEDICA MEDITERR, V29, P791
   Mamede AC, 2012, CELL TISSUE RES, V349, P447, DOI 10.1007/s00441-012-1424-6
   Pannuzzo G, 2016, J NEUROSCI RES, V94, P1318, DOI 10.1002/jnr.23761
   Reggio E, 2017, J NEUROL, V264, P494, DOI 10.1007/s00415-016-8364-0
   Ridolfo AL, 2016, J INFECT PUBLIC HEAL, V6, P24
   Russo A, 2016, NAT PROD COMMUN, V11, P275
   Stevens DL, 2014, CLIN INFECT DIS, V59, P147, DOI [10.1093/cid/ciu444, 10.1093/cid/ciu296]
   Stock SJ, 2007, AM J OBSTET GYNECOL, V196, P255, DOI 10.1016/j.ajog.2006.10.908
   Zervos MJ, 2012, J CLIN MICROBIOL, V50, P238, DOI 10.1128/JCM.05817-11
NR 29
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 215
EP 220
DI 10.19193/0393-6384_2018_1_35
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600035
DA 2022-07-14
ER

PT J
AU Choi, JW
   Lee, MH
   Fujii, T
   Fujii, N
AF Choi, Jong Weon
   Lee, Moon Hee
   Fujii, Tatsuyoshi
   Fujii, Noriyoshi
TI ASSOCIATION OF AUGMENTED HEMOGLOBIN F PRODUCTION WITH ERYTHROPOIETIN AND
   TOTAL OXYGEN CONCENTRATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE fetal hemoglobin; erythropoietin; total oxygen concentration; diabetes
   mellitus
ID OBSTRUCTIVE SLEEP-APNEA; FETAL-HEMOGLOBIN; HB-F; HYPOXIA; ADULT;
   EXPRESSION; PROTEIN
AB Objective: Elevated hemoglobin F (HbF) level has been reported in diabetic patients; however, the reason for the raised HbF synthesis is unclear. The aim of this study was to investigate whether enhanced HbF production is associated with erythropoietin (EPO) level and total oxygen concentration (ctO(2)) in patients with diabetes.
   Methods: Glycated hemoglobin (HbA1c), HbF, EPO, oxygen saturation (sO(2)), and renal parameters were measured in type 2 diabetic patients. The ctO(2) was calculated using sO(2), partial pressure of oxygen, and Hb sub-fractions.
   Results: Serum EPO concentration was significantly higher in patients with HbF > 1.0% than in those with HbF <= 1.0% (13.9 IU/L versus 8.5 IU/L, p < 0.001). Median ctO(2) level was significantly lower in the elevated HbF group than in the non-elevated HbF group (12.0 vol% versus 16.5 vol%, p < 0.001). The HbF concentration was closely associated with EPO and ctO(2) levels after adjusting for potential confounders [r = 0.306 and r = -0.257, respectively, p < 0.001]. In a multivariate logistic regression analysis, a decreased ctO(2) level (< 11.2 vol%) was significantly associated with enhanced HbF production [odds ratio, 1.47 (95% CI, 1.023.07), p = 0.009]. In a receiver operating characteristic curve, the diagnostic ability of EPO and ctO(2) to identify HbF > 1.0% in diabetics was superior to that of HbA1c [0.743 (95% CI, 0.636-0.850) and 0.677 (95% CI, 0.569-0.784) versus 0.570 (95% CI, 0.4460.694); respectively, p < 0.001].
   Conclusion: An increased EPO level seems to play an important role in the enhanced HbF production of diabetics in conjunction with a decreased ctO(2) level.
C1 [Choi, Jong Weon] Inha Univ, Coll Med, Dept Lab Med, 27 Inhang Ro, Incheon 22332, South Korea.
   [Lee, Moon Hee] Inha Univ, Coll Med, Dept Internal Med, Incheon, South Korea.
   [Fujii, Tatsuyoshi; Fujii, Noriyoshi] Univ Tsukuba, Sch Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan.
RP Choi, JW (corresponding author), Inha Univ, Coll Med, Dept Lab Med, 27 Inhang Ro, Incheon 22332, South Korea.
EM jwchoi@inha.ac.kr
FU Inha University Hospital
FX This study was supported by a research grant from Inha University
   Hospital.
CR Ang SH, 2015, CLIN CHIM ACTA, V439, P202, DOI 10.1016/j.cca.2014.10.019
   Baranowska-Jazwiecka Anna Iza, 2016, Pediatr Endocrinol Diabetes Metab, V22, P48, DOI 10.18544/PEDM-22.02.0050
   BARD H, 1975, J CLIN INVEST, V55, P395, DOI 10.1172/JCI107943
   Catrina SB, 2004, DIABETES, V53, P3226, DOI 10.2337/diabetes.53.12.3226
   Choi JW, 2011, ANN CLIN LAB SCI, V41, P224
   DIEM P, 1993, DIABETOLOGIA, V36, P129, DOI 10.1007/BF00400693
   KILPATRICK ES, 1993, CLIN CHEM, V39, P833
   KOSKINEN LK, 1994, DIABETES CARE, V17, P828, DOI 10.2337/diacare.17.8.828
   Lambers Heerspink HJ, 2008, AM J EPIDEMIOL, V168, P897, DOI 10.1093/aje/kwn209
   Lecube A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004692
   Lee MH, 2009, ACTA HAEMATOL-BASEL, V122, P247, DOI 10.1159/000253593
   Lee MH, 2011, CLIN CHIM ACTA, V412, P1600, DOI 10.1016/j.cca.2011.05.013
   Leong A, 2018, CURR OPIN GENET DEV, V50, P79, DOI 10.1016/j.gde.2018.02.008
   MULLIS P, 1989, DIABETOLOGIA, V32, P227, DOI 10.1007/BF00285288
   Peltier AC, 2007, SLEEP MED, V8, P149, DOI 10.1016/j.sleep.2006.06.010
   PEMBREY ME, 1973, LANCET, V1, P1350
   Peters A, 1998, BLOOD, V91, P691, DOI 10.1182/blood.V91.2.691.691_691_694
   Risso A, 2012, BLOOD CELL MOL DIS, V48, P147, DOI 10.1016/j.bcmd.2011.12.004
   ROCHETTE J, 1994, BLOOD REV, V8, P213, DOI 10.1016/0268-960X(94)90109-0
   Rohlfing Curt L, 2008, Am J Clin Pathol, V129, P811, DOI 10.1309/YFVTUD0GHJF7D16H
   Sada K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158619
   SIGGAARDANDERSEN O, 1988, SCAND J CLIN LAB INV, V48, P7
   STAMATOYANNOPOULOS G, 1985, ANN NY ACAD SCI, V445, P188, DOI 10.1111/j.1749-6632.1985.tb17188.x
   Stockmann C, 2006, CLIN EXP PHARMACOL P, V33, P968, DOI 10.1111/j.1440-1681.2006.04474.x
   Tsuchikura S, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-7
   Williams A, 2007, SLEEP BREATH, V11, P69, DOI 10.1007/s11325-007-0106-1
   WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801
   WOOD WG, 1975, BLOOD, V46, P671
   YATSCOFF RW, 1983, CLIN CHEM, V29, P543
NR 29
TC 1
Z9 1
U1 1
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1051
EP 1058
DI 10.19193/0393-6384_2018_4_161
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500024
DA 2022-07-14
ER

PT J
AU Cicek, M
   Deveci, O
   Cengiz, Z
   Bilden, A
   Bilik, OA
AF Cicek, Mutalip
   Deveci, Ozcan
   Cengiz, ZeynepTas
   Bilden, Alican
   Bilik, Ozge Alkan
TI DOES NEUTROPHIL / LYMPHOCYTE RATIO CONTRIBUTE TO DIAGNOSTICS IN PATIENTS
   WITH FASCIOLIASIS?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Fascioliasis; neutrophil/lymphocyte ratio; contribution to diagnosis
ID INFLAMMATORY MARKER; INFECTION; HEPATICA; CANCER; STAGE
AB Introduction: Fasciolia sp. is a trematode causes infection by settling in the liver bile ducts of domestic animal and human liver. Fascioliasis is a parasite disease that might have changes in liver parenchyma and in bile ducts. Many inflammatory reactions occur during the settlement of larvae and mature parasites into the liver. The neutrophil/lymphocyte ratio (NLR) has become a prominent marker of underlying inflammation. The objective of the present study is to investigate the relationship between the hematological parameters in patients with fascioliasis.
   Materials and methods: The diagnosis of fascioliasis was based on patient history, clinical and laboratory findings, radiological imaging (ultrasound), stool examination and IgG antibody titer determination by ELISA. Clinical and laboratory data were collected for 56 patients with fascioliasis, and diagnosed with serological and radiological imaging. 56 healthy volunteers were selected for the control group. Stool and blood samples were collected from patients with fascioliasis for serologic, biochemical, hematologic tests and ova examination. Total leukocyte, neutrophil, eosinophil and lymphocyte counts were recorded and NLR was calculated. ELISA antibody cut off titer value of patients with fascioliasis was 10> positive.
   Results: We compared neutrophil/lymphocyte ratio, eosinophil/lymphocyte ratio, the relation of eosinophilia and IgG antibody titers between two groups (patient and control groups). There was no statistically significant difference between patients and healthy controls neither based on age and gender nor NLR. According to these findings, NLR can not be considered as a diagnostic marker in fascioliasis.
   Conclusion: As a result, it was determined that NLR is not a crucial indicator of inflammation in parasitic fascioliasis. Extensive studies are need to be done to clarify the correlation between NLR and progression of other parasitic diseases.
C1 [Cicek, Mutalip] Ahi Evran Univ, Fac Med, Dept Med Microbiol, Kirsehir, Turkey.
   [Deveci, Ozcan] Elazig Med Pk Hosp, Dept Clin Microbiol & Infect Dis, Elazig, Turkey.
   [Cengiz, ZeynepTas] Yuzuncu Yil Univ, Fac Med, Dept Med Parasitol, Van, Turkey.
   [Bilden, Alican; Bilik, Ozge Alkan] Dicle Univ, Fac Med, Dept Med Microbiol, Diyarbakir, Turkey.
RP Deveci, O (corresponding author), Elazig Med Pk Hosp, Dept Clin Microbiol & Infect Dis, Elazig, Turkey.
CR Abakay O, 2015, INFLAMMATION, V38, P691, DOI 10.1007/s10753-014-9978-y
   Abdel-Razik A, 2015, ACTA GASTRO-ENT BELG, V78, P386
   Ahsen A, 2013, INFLAMMATION, V36, P1357, DOI 10.1007/s10753-013-9675-2
   Berasain P, 2000, EXP PARASITOL, V94, P99, DOI 10.1006/expr.1999.4479
   Duffy BK, 2006, AM J CARDIOL, V97, P993, DOI 10.1016/j.amjcard.2005.10.034
   Dusak A, 2012, J CLIN IMAG SCI, V2, DOI 10.4103/2156-7514.92372
   Garcia LS, 2007, DIAGNOSTIC MED PARAS, P432
   Graziosi L, 2015, AM J SURG, V209, P333, DOI 10.1016/j.amjsurg.2014.06.014
   Karahocagil MK, 2011, ACTA TROP, V118, P177, DOI 10.1016/j.actatropica.2008.08.013
   Maguire JH, 2005, PRINCIPLES PRACTICE, P3276
   Marcos L, 2006, T ROY SOC TROP MED H, V100, P158, DOI 10.1016/j.trstmh.2005.05.016
   Markell EK, 1986, MED PARASITOLOGY, V6th, P169
   Mas-Coma S, 2005, INT J PARASITOL, V35, P1255, DOI 10.1016/j.ijpara.2005.07.010
   Nakano K, 2014, ANTICANCER RES, V34, P3819
   Olt S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/210502
   Sarraf KM, 2009, J THORAC CARDIOV SUR, V137, P425, DOI 10.1016/j.jtcvs.2008.05.046
   Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
   Turkmen K, 2013, HEMODIAL INT, V17, P391, DOI 10.1111/hdi.12040
   van Wolfswinkel ME, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-101
   Yang Meng, 2015, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V27, P471, DOI 10.3760/cma.j.issn.2095-4352.2015.06.011
NR 20
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 955
EP 958
DI 10.19193/0393-6384_2018_4_145
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500008
DA 2022-07-14
ER

PT J
AU Cilekar, M
   Arslan, RS
   Akici, M
   Yilmaz, S
AF Cilekar, Murat
   Arslan, Ramazan Serdar
   Akici, Murat
   Yilmaz, Sezgin
TI UNUSUAL PERFORATIONS FOLLOWING ERCP PROCEDURE: AN EXPLORATORY LITERATURE
   SEARCH AND THE LESSONS LEARNED FROM THREE CASE STUDIES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Unusual perforations; ERCP; stent; trietz; duodenum
ID ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; COMPLICATIONS;
   MANAGEMENT
AB Introduction: ERCP procedure has severe risk of related complications that is about 5%-10%. The most feared complication of ERCP is perforation since it has highest mortality rate. The most common localization of perforation after ERCP is peripapillary area. However unusual anatomical localizations of perforations can also be seen. While most of the juxtapapillary perforations can be managed by non-operative measures, unusual per/orations usually require early surgical interventions.
   Patients and methods
   Case 1: An 86 year-old woman was referred to our centre with cholelithiasis and choledocholithiasis. During ERCP procedure, supracrural gastric perforation was detected in huge type III hiatal hernia by visualizing intraperitoneal cavity.
   Case 2: A 53 year-old woman was interned for stern removal. ERCP was performed for removing the stent, however the patient had developed severe peritonitis 36 hours after the procedure. An urgent operation performed and a perforation around the Trietz ligament was detected.
   Case 3: A 77 year-old woman was referred for choledocholithiasis. During ERCP there were large stones in biliary system that can not be removed endoscopically, so a temporary plastic biliary stem was inserted. Despite the stent placement, clinical condition of the patients has not improved and septic condition was developed due to extensive peritonitis.
   Conclusion: Although the clinical presentaions are similar to each other, it seems that the mortality rate of unusual perforations are quite higher than that of juxtapapillary perforations. The delay of surgical treatment in unusual perforations results in doubling the mortality rate. So every effort should be delineated to determine the perforation site and surgical treatment should be considered preferentially especially in first 24 hour.
C1 [Cilekar, Murat; Akici, Murat; Yilmaz, Sezgin] Afyon Kocatepe Univ, Gen Surg Dept, Fac Med, TR-03020 Afyon, Turkey.
   [Arslan, Ramazan Serdar] Banaz State Hosp, Gen Surg Dept, TR-64520 Banaz, Usak, Turkey.
RP Cilekar, M (corresponding author), Afyon Kocatepe Univ, Gen Surg Dept, Fac Med, TR-03020 Afyon, Turkey.
EM drmsurgeryx@hotmail.com
CR Alfieri S, 2013, SURG ENDOSC, V27, P2005, DOI 10.1007/s00464-012-2702-9
   Enns R, 2002, ENDOSCOPY, V34, P293, DOI 10.1055/s-2002-23650
   Huang J, 2014, SURG LAPARO ENDO PER, V24, pE101, DOI 10.1097/SLE.0b013e318293c4b6
   Kochar R, 2012, ENDOSCOPY, V44, pE238, DOI 10.1055/s-0032-1308930
   Kwon CI, 2013, CLIN ENDOSC, V46, P251, DOI 10.5946/ce.2013.46.3.251
   Lee D. W. H., 2001, Hong Kong Medical Journal, V7, P445
   Loperfido S, 1998, GASTROINTEST ENDOSC, V48, P1, DOI 10.1016/S0016-5107(98)70121-X
   MICKISCH O, 1992, Z GASTROENTEROL, V30, P428
   Miller R, 2013, AM J SURG, V206, P180, DOI 10.1016/j.amjsurg.2012.07.050
   Salminen P, 2008, SURG ENDOSC, V22, P1965, DOI 10.1007/s00464-007-9711-0
   Stapfer M, 2000, ANN SURG, V232, P191, DOI 10.1097/00000658-200008000-00007
   Wu Hao M, 2006, HPB (Oxford), V8, P393, DOI 10.1080/13651820600700617
   Yilmaz S, 2017, TURK J SURG, DOI [10.5152/turksurg.2017.3808, DOI 10.5152/TURKSURG.2017.3808]
   Yilmaz S, 2015, WORLD J GASTRO SURG, V7, P15, DOI 10.4240/wjgs.v7.i2.15
NR 14
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 2013
EP 2016
DI 10.19193/0393-6384_2018_6_314
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400065
DA 2022-07-14
ER

PT J
AU Colak, B
   Kirazli, H
   Ece, I
   Yormaz, S
   Sahin, M
AF Colak, Bayram
   Kirazli, Halil
   Ece, Ilhan
   Yormaz, Serdar
   Sahin, Mustafa
TI COMPARISION OF VACUUM-ASISTED CLOSURE AND INTRALESIONAL EPIDERMAL GROWTH
   FACTOR IN THE TREATMENT OF DIABETIC FOOT WOUNDS PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Growth factor; diabetic foot; negative pressure; wound
ID PROSPECTIVE RANDOMIZED-TRIAL; LOWER-EXTREMITY ULCERS; ASSISTED CLOSURE;
   CELL-PROLIFERATION; THERAPY; INFECTIONS; PRESSURE
AB Introduction: Diabetes mellitus (DM) is a common public health problem all over the world with serious complications. The mortality rate is 40% within 5 years in patients with major amputation due to diabetic foot wounds (DFW). Therefore, a nonsurgical but effective treatment method is needed for the treatment of DFW. In this study, we aimed to compare the results of intralesional epidermal growth factor (EGF) injection and negative pressure wound therapy (NPWT) for the treatment of DFW.
   Materials and methods: The medical records of patients who were treated for DFW with EGF or NPWT between February 2017 and December 2017 were retrospectively reviewed. Patients demographics, wound characteristics, allergic reactions and treatment responses were evaluated.
   Results: Amongst 42 patients, 20 patients were treated with the injection of EGF and 22 patients treated with NPWT. The duration of diabetes was higher in EGF group when compared to the NPWT group without a statistically significance (EGF: 20,7 years, NPWT: 16,9 years). According to the Wagner-Meggitt classification, the grade of the wounds was comparable in both groups. A complete response were obtained in 17 (85%) patients and 50% wound closure was achieved in the other patients in EGF group. In the NPWT group complete response rate was 45.4%. No major amputation was performed in any patient. In NPWT group, 13 (59%) of wouds were closed with split-thickness skin graft, only 3 patients (15%) of the EGF group were required a skin graft. The main advers affect of the EGF injection was an elevated fasting blood glucose level. In both groups, A decreased HbA1c levels were found after the wound treatment.
   Conclusion: Both administration of intralesional EGF and NPWT are safe, effective and non-surgical methods for the treatment of DFW. NPWT is seems to be a more effective treatment modality for infected wounds.
C1 [Colak, Bayram; Kirazli, Halil; Ece, Ilhan; Yormaz, Serdar; Sahin, Mustafa] Selcuk Univ, Fac Med, Dept Gen Surg, Konya, Turkey.
RP Colak, B (corresponding author), Selcuk Univ, Fac Med, Dept Gen Surg, Konya, Turkey.
EM bayro.99@gmail.com
RI Ece, ilhan/AAR-9923-2020; Sahin, Mustafa/AAH-3394-2019
OI Ece, ilhan/0000-0002-6966-7036; Sahin, Mustafa/0000-0002-4718-0083
CR Acosta Jorge Berlanga, 2006, Int Wound J, V3, P232, DOI 10.1111/j.1742-481X.2006.00237.x
   Aragon-Sanchez J, 2011, DIABETES RES CLIN PR, V94, pE83, DOI 10.1016/j.diabres.2011.09.009
   Arslan M., 2003, TURKIYE KLINIKLERI J, V1
   Berlanga J, 2008, World patent WO, Patent No. [PCT/ CU2002/ 000011, 2002000011]
   Berlanga J, 2013, MEDICC REV, V15, P11, DOI 10.37757/MR2013V15.N1.4
   Berlanga-Acosta J, 2001, GUT, V48, P803, DOI 10.1136/gut.48.6.803
   Berlanga-Acosta J, 2009, INT WOUND J, V6, P331, DOI 10.1111/j.1742-481X.2009.00622.x
   Boulton AJM, 2005, LANCET, V366, P1719, DOI 10.1016/S0140-6736(05)67698-2
   Bozkurt F, 2012, KONURALP TIP DERG, V4, P15
   CINZA A M, 1991, Biotecnologia Aplicada, V8, P166
   Clouse ME, 1974, AM J RADIOL, V121, P34
   COHEN S, 1962, J BIOL CHEM, V237, P1555
   Degim Z, 2011, INT WOUND J, V8, P343, DOI 10.1111/j.1742-481X.2011.00795.x
   Demiraslan H, 2008, TURKIYE KLINIKLERI J, V1
   Ertugrul BM, 2015, DIABET FOOT ANKLE, V6, DOI 10.3402/dfa.v6.28419
   Ertugrul MB, 2004, KLIMIK DERGISI, V17, P3
   Fabian TS, 2000, AM SURGEON, V66, P1136
   Fernandez-Montequin Jose I, 2007, Int Wound J, V4, P333
   Fernandez-Montequin JI, 2009, INT WOUND J, V6, P67, DOI 10.1111/j.1742-481X.2008.00561.x
   Frykberg RG, 2003, AM J SURG, V186, p44S, DOI 10.1016/j.amjsurg.2003.10.008
   Greene AK, 2006, ANN PLAS SURG, V56, P418, DOI 10.1097/01.sap.0000202831.43294.02
   Jacobs S, 2009, J PLAST RECONSTR AES, V62, P1331, DOI 10.1016/j.bjps.2008.03.024
   Jeffcoate WJ, 2003, LANCET, V361, P1545, DOI 10.1016/S0140-6736(03)13169-8
   Joseph E, 2000, WOUNDS, V12, P60
   Lipsky BA, 2004, CLIN INFECT DIS, V39, P885, DOI 10.1086/383271
   Lone AM, 2014, DIABET FOOT ANKLE, V5, DOI 10.3402/dfa.v5.23345
   Markuson M, 2009, ADV SKIN WOUND CARE, V22, P365, DOI 10.1097/01.ASW.0000358639.45784.cd
   Martson WA, 2003, DIABETES CARE, V26, P1701
   McEnery KW, 1993, DIABETIC FOOT, P341
   Moisidis E, 2004, PLAST RECONSTR SURG, V114, P917, DOI 10.1097/01.PRS.0000133168.57199.E1
   Monteiro-Soares M, 2014, DIABETES-METAB RES, V30, P610, DOI 10.1002/dmrr.2535
   Morykwas MJ, 1997, ANN PLAS SURG, V38, P553, DOI 10.1097/00000637-199706000-00001
   Moues CM, 2004, WOUND REPAIR REGEN, V12, P11, DOI 10.1111/j.1067-1927.2004.12105.x
   Ortegon MM, 2004, DIABETES CARE, V27, P901, DOI 10.2337/diacare.27.4.901
   Pedowitz WJ, 1997, FOOT ANKLE CLIN, V2, P89
   Ravari Hassan, 2013, J Cutan Aesthet Surg, V6, P17, DOI 10.4103/0974-2077.110091
   Reiber GE, 1996, DIABETIC MED, V13, pS6, DOI 10.1002/dme.1996.13.s1.6
   Reiber GE, 1999, DIABETES CARE, V22, P157, DOI 10.2337/diacare.22.1.157
   Robson M. C., 2005, Journal of Applied Research, V5, P35
   Rooh-Ul-Muqim, 2003, J Ayub Med Coll Abbottabad, V15, P39
   Saxena V, 2004, PLAST RECONSTR SURG, V114, P1086, DOI 10.1097/01.prs.0000135330.51408.97
   Schaper NC, 2004, DIABETES-METAB RES, V20, pS90, DOI 10.1002/dmrr.464
   Slovenkai MP, 1998, MED CLIN N AM, V82, P949, DOI 10.1016/S0025-7125(05)70031-6
   Tentolouris N, 2004, DIABETES CARE, V27, P1598, DOI 10.2337/diacare.27.7.1598
   Veves A, 2001, DIABETES CARE, V24, P290, DOI 10.2337/diacare.24.2.290
   Wagner F W Jr, 1981, Foot Ankle, V2, P64
   Yera-Alos IB, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-44
NR 47
TC 0
Z9 0
U1 2
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1245
EP 1252
DI 10.19193/0393-6384_2018_5_191
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700013
DA 2022-07-14
ER

PT J
AU Cupido, F
   La Mantia, I
   Di Carlo, F
   D'Alessi, S
AF Cupido, Francesco
   La Mantia, Ignazio
   Di Carlo, Francesco
   D'Alessi, Simona
TI VERTIGO AND OSTEOPOROSIS: THE CORRELATION BETWEEN NUTRITIONAL INTAKE OF
   VITAMIN D AND INCIDENCE OF RECURRING BENIGN PAROXYSMAL POSITIONAL
   VERTIGO IN SUBJECTS WITH HYPOVITAMINOSIS D
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Benign paroxysmal positional vertigo; vitamin D; hypovitaminosis D
ID OSTEOPENIA
AB Introduction: Benign paroxysmal positional vertigo (BPPV) is the most common peripheral cause of vertigo. It can be defined as transient vertigo induced by rapid changes in head position associated with a characteristic paroxysmal positional nystagmus. The aim of this study is to evaluate the association between the serum calcium and vitamin D levels in osteoporotic patients affected by recurrent BPPV.
   Materials and Methods: Calcium and 25-hydroxy-vitamin D levels were evaluated in peripheral venous serum samples of 40 BPPV patients.
   Results: The reduction of serum vitamin D levels is present in 16 of BPPV patients with recurrence. After nutritional intake of vitamin D there was a decline of the vertiginous crisis recurrence.
   Conclusion: Our findings suggested that the administration of vitamin D dietary supplements can improve, reduce and even eliminate the BPPV vertiginous crisis.
C1 [Cupido, Francesco] Univ Palermo, AOUP Paolo Giaccone, Dept Surg Oncol & Stomatol Disciplines, Palermo, Italy.
   [La Mantia, Ignazio] Dept Adv Med Surg & Technol Sci GF Ingrassia, Catania, Italy.
   [Di Carlo, Francesco; D'Alessi, Simona] ENT Studio Cupido Gianfranco & Francesco, Palermo, Italy.
RP Cupido, F (corresponding author), Univ Palermo, AOUP Paolo Giaccone, Dept Surg Oncol & Stomatol Disciplines, Palermo, Italy.
EM cicciocupido@yahoo.it
CR BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371
   Buki B, 2013, MED HYPOTHESES, V80, P201, DOI 10.1016/j.mehy.2012.11.029
   Consensus development conference, AM J MED, V90, P107
   Jeong SH, 2009, NEUROLOGY, V72, P1069, DOI 10.1212/01.wnl.0000345016.33983.e0
   Jeong SH, 2013, J NEUROL, V260, P832, DOI 10.1007/s00415-012-6712-2
   Kim JS, 2014, NEW ENGL J MED, V370, P1138, DOI 10.1056/NEJMcp1309481
   Oghalai JS, 2000, OTOLARYNG HEAD NECK, V122, P630, DOI 10.1016/S0194-5998(00)70187-2
   Parham K, 2013, LARYNGOSCOPE, V123, P2834, DOI 10.1002/lary.24162
   Parnes LS, 2003, CAN MED ASSOC J, V169, P681
   Vibert D, 2003, ANN OTO RHINOL LARYN, V112, P885, DOI 10.1177/000348940311201010
   von Brevern M, 2007, J NEUROL NEUROSUR PS, V78, P710, DOI 10.1136/jnnp.2006.100420
   Walther LE, 2007, J VESTIBUL RES-EQUIL, V17, P89
NR 12
TC 1
Z9 1
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 951
EP 954
DI 10.19193/0393-6384_2018_4_144
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500007
DA 2022-07-14
ER

PT J
AU Cusano, P
   Iovino, S
   Tafuri, D
AF Cusano, Pampilio
   Iovino, Salvatore
   Tafuri, Domenico
TI NEW TECHNOLOGIES IN THE ASSESSMENT OF THE EXPLOSIVE STRENGTH IN FOOTBALL
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Muscle Strength; Counter-Movement Jump; Powersprint; Assessment
ID SOCCER PLAYERS; RELIABILITY; TESTS; POWER; AGILITY; FITNESS; SPORTS;
   SPEED
AB Introduction: The assessment of the athlete's conditional abilities is a key performance index in sports games. In the football field, we proposed a correlation of gender differences in strength abilities of both female and male athletes.
   Materials and methods: The experimentation was carried out on two groups of, footballer athletes of the same age and of different genders. The Bosco's Test, more specifically the Counter Movement Jump, was employed as a reference model, through a recently introduced tool called Chronojump, and a new test model, called Powersprint, considering both them as performance indexes for two groups of athletes, in order to study the athlete's explosive-elastic muscle strength.
   Results: The male gender registered a higher muscle strength expression in both tests.
   Discussion: The assessment of the lower limbs strength is closely linked to the sports practice of football. The Powersprint tool can be employed for analyzing athletes' motor abilities.
C1 [Cusano, Pampilio; Iovino, Salvatore; Tafuri, Domenico] Parthenope Univ, Via Medina 40, Naples, Italy.
RP Tafuri, D (corresponding author), Parthenope Univ, Via Medina 40, Naples, Italy.
EM domenicotafuri@inwind.it
CR Akubat I, 2012, J SPORT SCI, V30, P1473, DOI 10.1080/02640414.2012.712711
   Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Bangsbo J., 1993, ACTA PHYSL SCANDIN S, V619, P1
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   BOSCO C, 1983, EUR J APPL PHYSIOL O, V50, P273, DOI 10.1007/BF00422166
   Castagna C, 2006, J STRENGTH COND RES, V20, P320, DOI 10.1519/00124278-200605000-00015
   de Blas X, 2012, RICYDE-REV INT CIENC, V8, P334, DOI 10.5232/ricyde2012.03004
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   Gabbett TJ, 2008, J STRENGTH COND RES, V22, P174, DOI 10.1519/JSC.0b013e31815ef700
   Hopkins WG, 2001, SPORTS MED, V31, P211, DOI 10.2165/00007256-200131030-00005
   Hopkins WG., 2004, SPORTSCIENCE, V8, P1, DOI DOI 10.1097/00005768-199804000-00026
   Kawamori N, 2014, J STRENGTH COND RES, V28, P2738, DOI 10.1519/JSC.0b013e3182915ed4
   Lockie RG, 2013, J SPORT SCI MED, V12, P88
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Pasquarelli BN, 2010, REV ANDALUZA MED DEP, V3
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Sands WA, 2004, J STRENGTH COND RES, V18, P810
   Sheppard JM, 2006, J SPORT SCI, V24, P919, DOI 10.1080/02640410500457109
   Svensson M, 2005, J SPORT SCI, V23, P601, DOI 10.1080/02640410400021294
   Tafuri D., 2017, SPORT SCI, V10, P70
   TIROSH E, 1990, AM J DIS CHILD, V144, P1083, DOI 10.1001/archpedi.1990.02150340027018
NR 26
TC 0
Z9 0
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1525
EP 1528
DI 10.19193/0393-6384_2018_3s_234
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400011
DA 2022-07-14
ER

PT J
AU Dag, NC
   Dag, H
   Dizdarer, G
AF Dag, Nevin Cetin
   Dag, Huseyin
   Dizdarer, Gulsen
TI AN EVALUATION OF HEADACHE AND ASSOCIATED TRIGGER FACTORS IN CHILDREN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Children; headache; migraine; trigger factors
ID UNPROVOKED SEIZURES; REFRACTIVE ERRORS; SCHOOL-CHILDREN; MIGRAINE;
   PREVALENCE; ADOLESCENTS; EPIDEMIOLOGY; DIAGNOSIS; CRITERIA; EPILEPSY
AB Introduction: Headaches are a common symptom in children and adolescents that can negatively affect their quality of life. Children who have a headache, generally present to pediatric, and pediatric neurology outpatient clinics with an inability to maintain social activities and often are absent from school. This study aimed to determine the etiology and trigger factors of headaches and the sociodemographic characteristics of children with headaches.
   Materials and methods: The sample of 500 pediatric patients who presented with headaches to the pediatric neurology outpatient clinic of Tepecik Training and Research Hospital between 2004 and 2009, and who had complete ,file records, were retrospectively evaluated in this study. The headache classification of patients was performed in accordance with the criteria of the International Classification of Headache Disorders (ICHD-11, 2004).
   Results: The sample consisted of 500 patients in total including 299 females (59.8%) and 202 males (40.2%) between the ages of 2 and 14. The mean age of the patients recruited for the study was 11 +/- 2.7. The most common cause of headache in children was migraine (43%),followed by tension-type headache and sinusitis as the most common causes. The most common trigger factor in children was stress, at 66.4%. Other common trigger factors included hunger and sleep deprivation.
   Conclusion: A headache in children is a complaint that affects the quality of life both in children and parents, and raises concern that there might be a worse underlying condition. Therefore, imaging should be used in selected patients along with a detailed history and physical examination. Hence, it is important to use the updated ICHD criteria as a guide in clinical practices.
C1 [Dag, Nevin Cetin; Dizdarer, Gulsen] Minist Hlth, Tepecik Training & Res Hosp, Dept Pediat, Izmir, Turkey.
   [Dag, Huseyin] Minist Hlth, Istanbul Okmeydani Training & Res Hosp, Dept Pediat, Istanbul, Turkey.
RP Dag, H (corresponding author), Minist Hlth, Istanbul Okmeydani Training & Res Hosp, Dept Pediat, Istanbul, Turkey.
EM huseyindag2003@gmail.com
CR Abu-Arafeh I, 2010, DEV MED CHILD NEUROL, V52, P1088, DOI 10.1111/j.1469-8749.2010.03793.x
   Akyol A, 2007, CEPHALALGIA, V27, P781, DOI 10.1111/j.1468-2982.2007.01343.x
   Alehan Fusun, 2003, Cocuk Sagligi ve Hastaliklari Dergisi, V46, P38
   ANDERMANN F, 1987, EPILEPSY RES, V1, P213, DOI 10.1016/0920-1211(87)90028-3
   Barea LM, 1996, CEPHALALGIA, V16, P545, DOI 10.1046/j.1468-2982.1996.1608545.x
   Bener A, 2000, HEADACHE, V40, P152, DOI 10.1046/j.1526-4610.2000.00021.x
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Bugdayci R, 2005, PEDIATR INT, V47, P316, DOI 10.1111/j.1442-200x.2005.02051.x
   Ceylan Isin, COCUKLUK CAGI VE ADO, P10
   Ekiciveark B., 2011, JOPP DERG, V3, P74
   Fukui PT, 2008, ARQ NEURO-PSIQUIAT, V66, P494, DOI 10.1590/S0004-282X2008000400011
   Gil-Gouveia R, 2002, HEADACHE, V42, P256, DOI 10.1046/j.1526-4610.2002.02077.x
   Harle DE, 2006, OPTOMETRY VISION SCI, V83, P82, DOI 10.1097/01.opx.0000200680.95968.3e
   HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x
   Hendricks TJW, 2007, OPTOMETRY VISION SCI, V84, P137, DOI 10.1097/OPX.0b013e318031b649
   Hernandez-Latorre MA, 2000, CEPHALALGIA, V20, P573, DOI 10.1046/j.1468-2982.2000.00083.x
   Hershey AD, 2005, HEADACHE, V45, P1288, DOI 10.1111/j.1526-4610.2005.00260.x
   Hoque Md Azharul, 2012, Oman Med J, V27, P383, DOI 10.5001/omj.2012.95
   Kelman L, 2006, HEADACHE, V46, P942, DOI 10.1111/j.1526-4610.2006.00443.x
   Lateef TM, 2009, J CHILD NEUROL, V24, P536, DOI 10.1177/0883073808327831
   Ludvigsson P, 2006, ANN NEUROL, V59, P210, DOI 10.1002/ana.20745
   Maytal J, 1997, NEUROLOGY, V48, P602, DOI 10.1212/WNL.48.3.602
   Ozge A, 2002, CEPHALALGIA, V22, P791, DOI 10.1046/j.1468-2982.2002.00467.x
   Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x
   Spierings ELH, 2001, HEADACHE, V41, P554, DOI 10.1046/j.1526-4610.2001.041006554.x
   Spiri D, 2014, ITAL J PEDIATR, V40, DOI 10.1186/s13052-014-0092-4
   Turkdogan D, 2006, HEADACHE, V46, P461, DOI 10.1111/j.1526-4610.2006.00377.x
   WOBERBINGOL C, 1995, CEPHALALGIA, V15, P13, DOI 10.1046/j.1468-2982.1995.1501013.x
   Yilmaz Deniz, 2016, TURKIYE COCUK HAST D, V3, P162
   Yilmaz M, 2013, ACTA MEDICA MEDITERR, V29, P419
   Yilmaz U, 2014, EUR J PAEDIATR NEURO, V18, P163, DOI 10.1016/j.ejpn.2013.11.003
   Zencir M, 2004, HEADACHE, V44, P780, DOI 10.1111/j.1526-4610.2004.04145.x
   Zwart JA, 2004, CEPHALALGIA, V24, P373, DOI 10.1111/j.1468-2982.2004.00680.x
NR 33
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2179
EP 2184
DI 10.19193/0393-6384_2018_4s_333
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900013
DA 2022-07-14
ER

PT J
AU De Vita, T
   Rosa, R
   Napolitano, F
AF De Vita, Tiziana
   Rosa, Roberta
   Napolitano, Felicia
TI PET-THERAPY AS AN INNOVATIVE INTERVENTION TOOL IN THE AUTISM SPECTRUM
   DISORDER MOTOR DEFICITS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Autism; Pet-Therapy; Motor Disorder
ID EARLY-DIAGNOSIS; CHILDREN; DOGS
AB The DSM-5 defines the Autism Spectrum Disorder (ASD) us a neurodevelopmental disorder, characterized by persistent communication and social interaction deficits, and by the presence of a repertoire of stereotyped and repetitive behaviors, interests or activities((1)). The DSM-5((1)) has grouped a series of previously separate disorders into a single name, that of autism spectrum disorder, and has reduced the triad of impairments described in DSM-IV(2) - social behavior deficit, language deficit, repetitive behavior and restricted interests- in two categories: social communication difficulties and repetitive or restrictive behavior.
   In the literature there are indications showing how, from a clinical point of view, ASD includes motor deficits such as difficulties in movement organization((3)), and difficulties related to anticipatory control and action planning skills((4)).
C1 [De Vita, Tiziana; Rosa, Roberta] Univ Basilicata, Potenza, Italy.
   [Napolitano, Felicia] Parthenope Univ, Via Medina 40, Naples, Italy.
RP De Vita, T (corresponding author), Univ Basilicata, Potenza, Italy.
EM tittidevita@libero.it
CR American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, V5
   American Psychiatric Association [APA], 1994, AM PSYCHIATR ASSOC, V4th
   BAUMAN M. L., 1992, MOVEMENT DISORDERS N, V1, P658
   Boria S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005596
   Campolo D, 2008, IEEE ENG MED BIO, P4875, DOI 10.1109/IEMBS.2008.4650306
   Fabbro F, 2016, NEUROSCIENZE DALLA F
   Fournier KA, 2010, J AUTISM DEV DISORD, V40, P1227, DOI 10.1007/s10803-010-0981-3
   Gonzalez DA, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00023
   Grandgeorge M, 2011, ANN I SUPER SANITA, V47, P397, DOI 10.4415/ANN_11_04_12
   Handlin L, 2011, ANTHROZOOS, V24, P301, DOI 10.2752/175303711X13045914865385
   Herbert MR, 2004, ANN NEUROL, V55, P530, DOI 10.1002/ana.20032
   Hughes C, 1996, J AUTISM DEV DISORD, V26, P99, DOI 10.1007/BF02276237
   Leary MR, 1996, MENT RETARD, V34, P39
   Levinson BM, 1962, MENTAL HYGIENE
   REDEFER LA, 1989, J AUTISM DEV DISORD, V19, P461, DOI 10.1007/BF02212943
   Sams MJ, 2006, AM J OCCUP THER, V60, P268, DOI 10.5014/ajot.60.3.268
   Solomon O, 2010, ETHOS, V38, P143, DOI 10.1111/j.1548-1352.2010.01085.x
   Teitelbaum O, 2004, P NATL ACAD SCI USA, V101, P11909, DOI 10.1073/pnas.0403919101
   Teitelbaum P, 1998, P NATL ACAD SCI USA, V95, P13982, DOI 10.1073/pnas.95.23.13982
NR 19
TC 0
Z9 0
U1 4
U2 23
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1503
EP 1506
DI 10.19193/0393-6384_2018_3s_229
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400006
DA 2022-07-14
ER

PT J
AU Demirel, U
   Yalniz, M
   Orhan, C
   Tunc, N
   Sahin, A
   Tuzcu, M
   Sahin, K
   Ozercan, IH
   Bahcecioglu, IH
AF Demirel, Ulvi
   Yalniz, Mehmet
   Orhan, Cemal
   Tunc, Nurettin
   Sahin, Abdurrahman
   Tuzcu, Mehmet
   Sahin, Kazim
   Ozercan, Ibrahim Hanifi
   Bahcecioglu, Ibrahim Halil
TI THE EFFECTS OF ALLOPURINOL ON REDOX SENSITIVE TRANSCRIPTION FACTORS,
   PRO-INFLAMMATORY CYTOKINES AND HEME OXYGENASE-1 IN ACETIC ACID-INDUCED
   COLITIS IN RATS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Oxidative Stress; Allopurinol; Acetic Acid; Colitis; Redox Sensitive
   Transcription Factors
ID TNBS-INDUCED COLITIS; NF-KAPPA-B; BOWEL-DISEASE; COLONIC INFLAMMATION;
   ACTIVATOR PROTEIN-1; OXIDATIVE DAMAGE; METABOLITES; INDUCTION; CURCUMIN;
   LIVER
AB Introduction: Oxidative stress plays an important role in pathophysiology of inflammatory bowel diseases. We aimed to investigate the effects of antioxidant allopurinol (AP) and the potential mechanisms leading amelioration upon acetic acid induced colitis.
   Materials and methods: Twenty-eight rats were divided in four groups. Control rats received 1 mL of NaCl (0.9%). In the AA group rats received 1 mL of 5% (v/v) acetic acid. The rats in the AAAP group received 1 mL of 5% (v/v) acetic acid. Additionally these rats received 100 mg/kg AP. AP group rats received only 100 mg/kg AP. Histopathological, biochemical and western blot analysis were done.
   Results: In the AA group, colonic injury scores, malondialdehyde (MDA), NF-kappa B p65, TNF alpha, COX2, AP-1 and IL-6 levels were significantly higher than in the control group (P<0.05). In the AAAP treatment group the colonic injury scores, MDA, NF-kappa B p65, TNFa, COX2, AP-1 and IL-6 levels significantly decreased when compared to the AA treated rats (P<0.05). The expression of HO-1 in the AAAP group significantly increased when compared to the AA treated rats (P<0.05).
   Conclusion: Intra colonic acetic acid instillation causes severe intestinal injury accompanied to increased oxidative stress. AP treatment ameliorates this injury by overcoming oxidative stress and regulating cellular redox balance in favor of antioxidant defense mechanisms probably via manipulation of redox sensitive transcription factors.
C1 [Demirel, Ulvi; Yalniz, Mehmet; Tunc, Nurettin; Sahin, Abdurrahman; Bahcecioglu, Ibrahim Halil] Firat Univ, Sch Med, Dept Gastroenterol, Elazig, Turkey.
   [Orhan, Cemal; Sahin, Kazim] Firat Univ, Dept Anim Nutr, Fac Vet Sci, Elazig, Turkey.
   [Tuzcu, Mehmet] Firat Univ, Dept Biol, Fac Sci, Elazig, Turkey.
   [Ozercan, Ibrahim Hanifi] Firat Univ, Sch Med, Dept Pathol, Elazig, Turkey.
RP Demirel, U (corresponding author), Univ Mah,Yunus Emre Blv 20, TR-23200 Elazig, Turkey.
RI Orhan, Cemal/Q-2086-2015; tunc, Nurettin/G-3282-2018; Sahin,
   Abdurrahman/C-1200-2019; ÖZERCAN, ibrahim Hanifi/W-7883-2018; Yalnız,
   Mehmet/G-6767-2015; Sahin, Kazim/D-5625-2009; Tuzcu, Mehmet/H-2953-2018
OI Orhan, Cemal/0000-0003-4138-7689; tunc, Nurettin/0000-0002-9723-4510;
   Sahin, Abdurrahman/0000-0001-5477-9492; ÖZERCAN, ibrahim
   Hanifi/0000-0002-8781-8838; Yalnız, Mehmet/0000-0001-7776-4154; Sahin,
   Kazim/0000-0001-9542-5244; Tuzcu, Mehmet/0000-0002-1329-3143
CR Ancha HR, 2009, DIGEST DIS SCI, V54, P758, DOI 10.1007/s10620-008-0438-0
   AUGUSTIN AJ, 1994, INVEST OPHTH VIS SCI, V35, P3897
   Ban KC, 2011, MOL CELL BIOCHEM, V347, P191, DOI 10.1007/s11010-010-0628-x
   Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901
   Erbil Y, 2007, J GASTROEN HEPATOL, V22, P1852, DOI 10.1111/j.1440-1746.2007.04838.x
   Farombi EO, 2008, FOOD CHEM TOXICOL, V46, P1279, DOI 10.1016/j.fct.2007.09.095
   Farombi EO, 2006, J BIOCHEM MOL BIOL, V39, P479
   GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2
   Grus FH, 2001, EUR J OPHTHALMOL, V11, P252, DOI 10.1177/112067210101100307
   Gue M, 1997, AM J PHYSIOL-GASTR L, V272, pG84, DOI 10.1152/ajpgi.1997.272.1.G84
   Iseri SO, 2009, J GASTROEN HEPATOL, V24, P1142, DOI 10.1111/j.1440-1746.2009.05797.x
   Jun CD, 2006, INFLAMM BOWEL DIS, V12, P619, DOI 10.1097/01.ibd.0000225340.99108.8a
   Kang G, 2004, J PHARMACOL SCI, V94, P325, DOI 10.1254/jphs.94.325
   Karatepe M, 2004, LC GC N AM, V22, P362
   KESHAVARZIAN A, 1992, J LAB CLIN MED, V120, P778
   KESHAVARZIAN A, 1992, GASTROENTEROLOGY, V103, P177, DOI 10.1016/0016-5085(92)91111-G
   KESHAVARZIAN A, 1990, GUT, V31, P786, DOI 10.1136/gut.31.7.786
   Kruidenier L, 2003, J PATHOL, V201, P17, DOI 10.1002/path.1408
   Kruidenier L, 2003, J PATHOL, V201, P28, DOI 10.1002/path.1409
   Lu YB, 2005, J IMMUNOL, V175, P5423, DOI 10.4049/jimmunol.175.8.5423
   Millar AD, 1996, GUT, V39, P407, DOI 10.1136/gut.39.3.407
   Moriyama I, 2008, LAB INVEST, V88, P652, DOI 10.1038/labinvest.2008.38
   Pawa S, 2004, BBA-MOL BASIS DIS, V1688, P210, DOI 10.1016/j.bbadis.2003.12.004
   Romagnali M, 2010, FREE RADICAL BIO MED, V49, P171, DOI 10.1016/j.freeradbiomed.2010.03.024
   Sapalidis Konstantinos, 2013, J Emerg Trauma Shock, V6, P203, DOI 10.4103/0974-2700.115346
   SCHWARTZ MC, 1995, AM J RESP CELL MOL, V12, P434, DOI 10.1165/ajrcmb.12.4.7695923
   Sengul N, 2011, DIGEST DIS SCI, V56, P707, DOI 10.1007/s10620-010-1362-7
   Sparrow MP, 2007, CLIN GASTROENTEROL H, V5, P209, DOI 10.1016/j.cgh.2006.11.020
   Sparrow MP, 2005, ALIMENT PHARM THER, V22, P441, DOI 10.1111/j.1365-2036.2005.02583.x
   Ukil A, 2003, BRIT J PHARMACOL, V139, P209, DOI 10.1038/sj.bjp.0705241
NR 30
TC 1
Z9 1
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 119
EP 126
DI 10.19193/0393-6384_2018_1_20
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600020
DA 2022-07-14
ER

PT J
AU Demiroglu, M
AF Demiroglu, Murat
TI FUNCTIONAL OUTCOMES OF PROXIMAL ROW CARPECTOMY AND POSTERIOR
   INTEROSSEOUS NEURECTOMY IN DEGENERATIVE ARTHRITIS OF THE WRIST
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Proximal row carpectomy; posterior interosseous nerve denervation;
   degenerative arthritis of the wrist
ID SCAPHOID EXCISION; KIENBOCKS-DISEASE; FOLLOW-UP; ARTHRODESIS; FUSION
AB Introduction: Degenerative wrist arthritis can develop from osteoarthritis, rheumatoid arthritis, posttraumatic arthritis. Common symptoms of degenerative wrist arthritis are pain and stiffness. Though, there is no cure for arthritis at the present time, there have been many treatment options to help recover pain and stiffness.
   The aim of this study was to determine the contribution of posterior interosseous nerve denervation and proximal row carpectomy to the improvement of pain and functional condition of patients who developed degenerative arthritis of the wrist.
   Materials and methods: The differences in the preoperative and postoperative 1st month, 6th month and 1st year VAS (Visual analogue scale) values of 9 patients, who underwent the same surgical procedure between January 2014 and June 2016, were recorded. The preoperative and postoperative 3rd-month and the 1st-year Quick DASH (The Disabilities of the Arm, Shoulder and Hand Score) scores were determined and the mean value was obtained. The range of the wrist motion was evaluated preoperatively and postoperatively.
   Results: The postoperative follow-up period was 22 (15-42) months. One (11%) patient developed postoperative pin site infection, which regressed with local dressing and oral antibiotherapy. One (11%) patient developed complex regional pain syndrome. A significant decrease was obtained in the mean postoperative VAS scores compared to the preoperative VAS scores (p < 0.01). The difference was 3.67. A significant improvement was obtained between the mean values of preoperative and postoperative Quick DASH scores (p < 0,01). The difference in Quick DASH score was 46%.
   Conclusion: We concluded that proximal row carpectomy along with posterior interosseous nerve neurectomy is movement-preserving surgery and that it is effective for pain control in patients with degenerative arthritis of the wrist and also advanced Kienbock's disease.
C1 [Demiroglu, Murat] Medeniyet Univ Gortepe EAH, Orthopaed, Istanbul, Turkey.
RP Demiroglu, M (corresponding author), Medeniyet Univ Gortepe EAH, Orthopaed, Istanbul, Turkey.
CR Akkaya N, 2012, EKLEM HAST CERRAHISI, V23, P122
   Ali Mir H, 2012, Hand (N Y), V7, P72, DOI 10.1007/s11552-011-9368-y
   ALLENDE BT, 1988, INT ORTHOP, V12, P201, DOI 10.1007/BF00547164
   Blankenhorn BD, 2007, J HAND SURG-AM, V32A, P37, DOI 10.1016/j.jhsa.2006.10.014
   Buluc L, 2015, ACTA ORTHOP TRAUMATO, V49, P641, DOI 10.3944/AOTT.2015.14.0346
   Chim H, 2012, J WRIST SURG, V1, P141, DOI 10.1055/s-0032-1329547
   Cohen MS, 2001, J HAND SURG-AM, V26A, P94, DOI 10.1053/jhsu.2001.20160
   CRABBE WA, 1964, J BONE JOINT SURG BR, V46, P708, DOI 10.1302/0301-620X.46B4.708
   Della Santa DR, 2010, CHIR MAIN, V29, P224, DOI 10.1016/j.main.2010.06.001
   DELLON AL, 1985, J HAND SURG-AM, V10A, P527, DOI 10.1016/S0363-5023(85)80077-0
   DiDonna ML, 2004, J BONE JOINT SURG AM, V86A, P2359, DOI 10.2106/00004623-200411000-00001
   Ertem K, 2016, EKLEM HAST CERRAHISI, V27, P132, DOI 10.5606/ehc.2016.28
   Gummesson C, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-44
   Ilyas Asif M, 2010, Tech Hand Up Extrem Surg, V14, P136, DOI 10.1097/BTH.0b013e3181d44526
   INGLIS AE, 1977, J BONE JOINT SURG AM, V59, P460, DOI 10.2106/00004623-197759040-00004
   Jacobs R, 2008, J HAND SURG-EUR VOL, V33E, P768, DOI 10.1177/1753193408092490
   Jebson PJL, 2003, J HAND SURG-AM, V28A, P561, DOI 10.1016/S0363-5023(03)00248-X
   JORGENSEN EC, 1969, J BONE JOINT SURG AM, VA 51, P1104, DOI 10.2106/00004623-196951060-00005
   Kilic A, 2006, EKLEM HAST CERRAHISI, V17, P56
   Kwon BC, 2009, J BONE JOINT SURG BR, V91B, P1601, DOI 10.1302/0301-620X.91B12.22335
   Mandarano LG, 2015, ACTA ORTOP BRAS, V23, P311, DOI 10.1590/1413-785220152306150054
   Marin-Braun F, 1992, Ann Chir Main Memb Super, V11, P283, DOI 10.1016/S0753-9053(05)80472-7
   Mulford JS, 2009, J HAND SURG-EUR VOL, V34E, P256, DOI 10.1177/1753193408100954
   Nakamura R, 1998, J HAND SURG-BRIT EUR, V23B, P741, DOI 10.1016/S0266-7681(98)80087-9
   Nanavati VN, 2009, J HAND SURG-AM, V34A, P251, DOI 10.1016/j.jhsa.2008.10.030
   Patterson RW, 2010, J HAND SURG-AM, V35A, P52, DOI 10.1016/j.jhsa.2009.10.014
   TOMAINO MM, 1994, J HAND SURG-AM, V19A, P134, DOI 10.1016/0363-5023(94)90237-2
   Vanden Berge Dennis J, 2017, Hand (N Y), V12, P535, DOI 10.1177/1558944717692093
   Wall LB, 2013, J HAND SURG-AM, V38A, P1498, DOI 10.1016/j.jhsa.2013.04.028
   Wall LB, 2013, HAND CLIN, V29, P69, DOI 10.1016/j.hcl.2012.08.022
   Weiss ND, 2011, J HAND SURG-AM, V36A, P577, DOI 10.1016/j.jhsa.2011.01.009
   Zhu YL, 2010, J HAND SURG-EUR VOL, V35E, P43, DOI 10.1177/1753193409344527
   Zinberg EM, 2014, J HAND SURG-AM, V39, P1055, DOI 10.1016/j.jhsa.2014.03.032
NR 33
TC 0
Z9 0
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 631
EP 636
DI 10.19193/0393-6384_2018_3_97
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000002
DA 2022-07-14
ER

PT J
AU Deng, YH
   Liu, LX
   Ma, XL
   Jian, WY
   Zhao, Y
AF Deng Yong-Hong
   Liu Li-Xia
   Ma Xiao-Li
   Jian Wen-Yuan
   Zhao Ying
TI EFFECTS OF HIGH GLUCOSE ON VEGF-B AND ITS RECEPTOR AND CELL PATHWAYS IN
   RPE AND HREC
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE RPE; HREC; VEGF-B; Cell pathways
ID GROWTH
AB Objective: To investigate the effects of high glucose on VEGF-B and its receptors and cell pathways in RPE and HREC.
   Methods: RPE and HREC cells were cultured in 5.5 mmol/L, glucose (control group) and 40.0 mmol/L glucose (high glucose group), respectively, according to the different culture conditions. The expression of the VEGF-B protein in RPE and HREC cells, and the expression of VEGFR-1 (Flt-1), NP-1 and cell pathway-related molecules including Erk, p-Erk, Akt, p-Akt, Src, p-Src of the two groups were recorded and compared.
   Results: The expression of VEGF-B, Flt-1, Erk, p-Erk, Akt and p-Akt in RPE and HREC cells of the high glucose group was significantly higher than that of the control group (P<0.05). All indicators showed a trend to increase to start (6-24 h) and then decreased (> 24h). The expression of NP-1, Src and p-Src in the high glucose group was not significantly different from that in the control group (P>0.05).
   Conclusion: High glucose can stimulate the expression of VEGF-B in RPE and HREC cells. A high level of VEGF-B is associated with Flt-1 specificity, which will activate Erk and Akt molecules in downstream cell pathways and promote retinal neovascularisation, therefore protecting the retina from high glucose damage.
C1 [Deng Yong-Hong; Jian Wen-Yuan; Zhao Ying] Chengdu Univ Tradit Chinese Med, 37 Shi Er Qiao Rd, Chengdu 610075, Sichuan, Peoples R China.
   [Liu Li-Xia] Henan Vocat Coll Nursing, Dept Basic Med Sci, Anyang 455000, Henan, Peoples R China.
   [Ma Xiao-Li] Sichuan KeLun Biotech Biopharmaceut Co LTD, 666 Xinhua Ave, Chengdu 611138, Sichuan, Peoples R China.
RP Zhao, Y (corresponding author), Chengdu Univ Tradit Chinese Med, 37 Shi Er Qiao Rd, Chengdu 610075, Sichuan, Peoples R China.
EM fk1243@163.com
CR Gao HT, 2018, CHIN J FRONT MED SCI
   Huang DL, 2015, SHANDONG BINZHOU MED, P22
   Invernizzi A, 2018, OPHTHALMOLOGY, V125, P237, DOI 10.1016/j.ophtha.2017.08.039
   Kim SH, 2015, PHYTOTHER RES, V29, P1910, DOI 10.1002/ptr.5480
   Kwanbunjan K, 2018, BMC ENDOCR DISORD, V18, DOI 10.1186/s12902-018-0254-2
   Lankhorst S, 2017, HYPERTENSION, V69, P919, DOI 10.1161/HYPERTENSIONAHA.116.08565
   Li FL, 2017, MED SCI MONITOR, V23, P5139, DOI 10.12659/MSM.907207
   Li HH, 2018, ONCOL LETT, V16, P353, DOI 10.3892/ol.2018.8656
   Li L, 2015, ADV CARDIOVASC DIS, V36, P210
   Li LF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172571
   Liu W, 2017, CHINA MED ENG
   [娄菲菲 Lou Feifei], 2017, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V23, P1074
   [马旭梁 Ma Xuliang], 2011, [材料工程, Journal of Materials Engineering], P6
   Mousavi SH, 2018, RES PHARM SCI, V13, P121, DOI 10.4103/1735-5362.223794
   [邵琚 Shao Jun], 2016, [中华眼底病杂志, Chinese Journal of Ocular Fundus Diseases], V32, P159
   Tseng SC, 2017, J AGR FOOD CHEM, V65, P2670, DOI 10.1021/acs.jafc.6b04800
   Wojciechowska J, 2016, EXP CLIN ENDOCR DIAB, V124, P263, DOI 10.1055/s-0042-100910
   Zafar MI, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20171089
   Zhan YZ, 2016, ENVIRON TOXICOL PHAR, V41, P39, DOI 10.1016/j.etap.2015.10.008
   Zhang DM, 2017, MED RECAPITULATE, V23, P417
NR 20
TC 0
Z9 0
U1 1
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1923
EP 1929
DI 10.19193/0393-6384_2018_6_299
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400050
DA 2022-07-14
ER

PT J
AU Di Palma, D
   Ascione, A
   Belfiore, P
AF Di Palma, Davide
   Ascione, Antonio
   Belfiore, Patrizia
TI EXPERIMENTAL APPROACH OF WATER POLO TRAINING TO IMPROVE PSYCHO-PHYSICAL
   CONDITIONS OF DISABLED ATHLETES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Sport Disability; Psycho-physical Wellbeing; Water polo Training;
   Experimental Approach; Didactic-Pedagogical Aspects
ID SYSTEM
AB Introduction: Disability is an enormous sanitary and social criticality and this study examines the possibility, through sports activities, to pursue both an increase in athletic performance, that in the level of health and well-being by a group of disabled athletes.
   Materials and methods: 10 disabled athletes have been subjected to a series of experimental programs of water polo training for 8 months and have carried out two series of evaluations at the beginning and at the end of this period of sporting activity.
   Results: There have been improvements both as regards the skills from a sporting point of view, both as regards the level of psycho-physical wellbeing for all disabled people.
   Conclusions: The sports activity, if managed in performant way, is able to lead to a benefit athletic and to an improvement of the quality of life for the people with disability.
C1 [Di Palma, Davide; Ascione, Antonio; Belfiore, Patrizia] Parthenope Univ, Dept Sport Sci & Wellness, Naples, Italy.
RP Ascione, A (corresponding author), Parthenope Univ, Naples, Italy.
EM antonio.ascione@uniparthenope.it
CR Alexander M, 2010, RES REV, V16
   Apalone G, 2005, QUESTIONARIO STATO S
   Bampouras TM, 2009, J STRENGTH COND RES, V23, P336, DOI 10.1519/JSC.0b013e3181876ad0
   Beyer R., 2009, J YOUTH SPORTS, V4
   Kung SP, 2014, SPORT MANAG REV, V17, P8, DOI 10.1016/j.smr.2013.08.009
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P641, DOI 10.19193/0393-6384_2017_4_095
   Messina G, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/639280
   Muscogiuri G, 2014, ENDOCR RES, V39, P137, DOI 10.3109/07435800.2014.952018
   Orio F, 2013, MINERVA ENDOCRINOL, V38, P305
   Orio F, 2013, E SPEN J, V8, P200
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Petralia MC, 2018, ACTA MEDICA MEDITERR, V34, P107, DOI 10.19193/0393-6384_2018_1_18
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Shapiro DR, 2014, J SPORT MANAGEMENT, V28
   Tafuri D., 2017, SPORT SCI, V10, P70
   Well B, 2008, WATER POLO TRAINING
   2011, WORLD REP DIS, P1
NR 24
TC 12
Z9 12
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1253
EP 1256
DI 10.19193/0393-6384_2018_5_192
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700014
DA 2022-07-14
ER

PT J
AU Di Palma, D
   Ascione, A
   Belfiore, P
AF Di Palma, Davide
   Ascione, Antonio
   Belfiore, Patrizia
TI EDUCATIONAL SPORT FOR THE HEALTH WELLBEING OF PEOPLE WITH AUTISM
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Autism; Educational Sport; Wellness; Inclusion; Health
AB Objective: For a person with autism, motor activity represents an important opportunity for the development of functional skills as it supports those areas that are most affected by the disorder; in this case, we speak of the communication, social interaction, emotional and educational area. Through sport we can redefine those that, by definition, are described as deficits or limitations of persons with autism, channeling them towards a path that is useful and constructive for their health and well-being state. Different types of sports lead .specifically to significant support and aid for the different aspects of this disorder, contributing at the same time to enhancing the residual skills of these subjects.
C1 [Di Palma, Davide; Ascione, Antonio; Belfiore, Patrizia] Parthenope Univ, Via Medina 40, Naples, Italy.
RP Ascione, A (corresponding author), Parthenope Univ, Via Medina 40, Naples, Italy.
EM antonio.ascione@uniparthenope.it
OI Di Palma, Davide/0000-0001-8224-5797
CR Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Bahrami F, 2016, J AUTISM DEV DISORD, V46, P978, DOI 10.1007/s10803-015-2643-y
   Bahrami F, 2012, RES DEV DISABIL, V33, P1183, DOI 10.1016/j.ridd.2012.01.018
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Caputo G, 2015, TERAPIA MULTISISTEMI
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina G, NEUROLOGY RESERARCH, V2013, P1, DOI [10.1155/2013/639280, DOI 10.1155/2013/639280.]
   Muscogiuri G, 2014, ENDOCR RES, V39, P137, DOI 10.3109/07435800.2014.952018
   Oriel KN, 2011, PEDIATR PHYS THER, V23, P187, DOI 10.1097/PEP.0b013e318218f149
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Petralia MC, 2018, ACTA MEDICA MEDITERR, V34, P107, DOI 10.19193/0393-6384_2018_1_18
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Schultheis S.F., 2000, FOCUS AUTISM OTHER D, V15, P159, DOI [10.1177/108835760001500306, DOI 10.1177/108835760001500306]
   Tafuri D., 2017, SPORT SCI, V10, P70
NR 21
TC 2
Z9 2
U1 5
U2 17
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1479
EP 1482
DI 10.19193/0393-6384_2018_3s_224
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400001
DA 2022-07-14
ER

PT J
AU Di Palma, D
   Belfiore, P
   Ascione, A
AF Di Palma, Davide
   Belfiore, Patrizia
   Ascione, Antonio
TI PROMOTE EDUCATIONAL DEVELOPMENT OF STUDENTS WITH SLD IN THE SCHOOL AND
   UNIVERSITY: THE ROLE OF SPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Sport; Specific Learning Disorders (SLD); Didactic-Educational Contexts
   School; University
ID LEARNING-DISABILITIES; CHILDREN; PEOPLE
AB This research work aims to identify and analyze a performing educational and social strategy able to deal with the critical aspects relating to Specific Learning Disorders (SLD) in the main scholastic contexts such as School and University. In this regard, a set of key determinants has been suggested to define and develop operational management solutions at different educational levels and identifies in the sporting activity a tool of universal support able to achieve multiple benefits for supporting students with SLD.
C1 [Di Palma, Davide; Belfiore, Patrizia; Ascione, Antonio] Parthenope Univ, Dept Sport Sci & Wellness, Naples, Italy.
RP Belfiore, P (corresponding author), Parthenope Univ, Naples, Italy.
EM patrizia.belfiore@uniparthenope.it
OI Di Palma, Davide/0000-0001-8224-5797
CR Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Bollani A, 2017, PSICOL CLIN SVILUPP, V21, P329, DOI 10.1449/87542
   Capuano A., 2013, BES DSA SCUOLA QUALI
   Cornoldi C., 2007, DIFFICOLTA DISTURBI
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1479, DOI 10.19193/0393-6384_2018_3s_224
   Ghidoni E., 2015, GIOVANI ADULTI CON D
   KAVALE KA, 1991, LEARN DISABILITY Q, V14, P257, DOI 10.2307/1510662
   Morlini I., 2017, STUDIO INCIDENZA DIS, P5
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Polloway E. A., 2015, TEACHING STUDENTS SP
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Razuk M, 2014, RES DEV DISABIL, V35, P1988, DOI 10.1016/j.ridd.2014.03.045
   Tafuri D., 2017, SPORT SCI, V10, P70
   Tressoldi P. E., 1996, DIAGNOSI DISTURBI AP
   Turnbull A., 1995, EXCEPTIONAL LIVES SP
   Vuijk PJ, 2011, J LEARN DISABIL-US, V44, P276, DOI 10.1177/0022219410378446
   Westendorp M, 2011, RES DEV DISABIL, V32, P2773, DOI 10.1016/j.ridd.2011.05.032
NR 24
TC 0
Z9 0
U1 1
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1873
EP 1877
DI 10.19193/0393-6384_2018_6_290
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400041
DA 2022-07-14
ER

PT J
AU Dispenza, F
   Lorusso, F
   Gallina, S
   Martines, F
AF Dispenza, Francesco
   Lorusso, Francesco
   Gallina, Salvatore
   Martines, Francesco
TI LARYNGEAL INVOLVEMENT IN RELAPSING POLYCHONDRITIS: CASE REPORT AND
   REVIEW OF LITERATURE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE dyspnoea; tracheotomy; laryngo-tracheal malacia; relapsing
   polychondritis; autoimmune disease
ID COMPLICATIONS; MANIFESTATIONS
AB Relapsing polychondritis is a rare multisystem autoimmune disease of unknown origin characterised by recurrent episodes of inflammation and progressive destruction of the cartilaginous structures and connective tissue of the whole body.
   The diagnosis of relapsing polychondritis is difficult.
   We present a review of the literature and describe a case of 49-year old woman.
   Her symptoms began in June 2004 with sore throat, dysphonia, pain in the thoracic wall and some joints, a slightly raised temperature and cough. The objective picture was immediately apparent after carrying out a high definition neck-thorax computed tomography and a laryngoscopy with fiber optics, which showed considerable laryngo-tracheal damage.
   As can be seen the diagnosis of RP today remains very difficult. The delay in diagnosis of our patient was considerable as described in literature and now estimated to be about 2.9 years. Perhaps an ENT examination would have hastened the diagnosis.
C1 [Dispenza, Francesco] Ist Euro Mediterraneo Sci & Tecnol, Palermo, Italy.
   [Lorusso, Francesco] AUOP Paolo Giaccone, UO Otorinolaringoiatria, Palermo, Italy.
   [Gallina, Salvatore; Martines, Francesco] Univ Palermo, Bio Ne C Dept, Palermo, Italy.
RP Lorusso, F (corresponding author), Via Isidoro La Lumia n 80, I-90139 Palermo, Italy.
OI Dispenza, Francesco/0000-0002-5844-9762; MARTINES,
   Francesco/0000-0002-8616-4481
CR Cabibi D, 2013, PATHOLOGICA, V105, P11
   CASSELMAN JW, 1988, AM J ROENTGENOL, V150, P355, DOI 10.2214/ajr.150.2.355
   Chang Shu-Jen, 2005, J Chin Med Assoc, V68, P279
   DAHLQVIST A, 1983, ACTA OTO-LARYNGOL, V96, P355, DOI 10.3109/00016488309132907
   DALY JF, 1966, ARCHIV OTOLARYNGOL, V84, P570
   DAMIANI JM, 1979, LARYNGOSCOPE, V89, P929
   Daniel L, 2001, NEPHRON, V87, P190, DOI 10.1159/000045912
   De Stefano A, 2010, OTORINOLARINGOLOGIA, V60, P155
   Ernst A, 2009, CHEST, V135, P1024, DOI 10.1378/chest.08-1180
   Frances C, 2001, MEDICINE, V80, P173, DOI 10.1097/00005792-200105000-00003
   GAFFNEY RJ, 1992, J LARYNGOL OTOL, V106, P63, DOI 10.1017/S002221510011864X
   Gallina S, 2015, ACTA OTORHINOLARYNGO, V35, P15
   GIBSON GJ, 1974, THORAX, V29, P726, DOI 10.1136/thx.29.6.726
   Gungor F, 1997, CLIN NUCL MED, V22, P264
   HANSLIK T, 1994, CLIN EXP RHEUMATOL, V12, P539
   Jaksch-Wartenhorst R., 1923, POLYCHONDROPATHIA WI, V6, P93
   Lee CC, 2006, AM J EMERG MED, V24, P750, DOI 10.1016/j.ajem.2006.02.016
   LUTHRA HS, 2003, RHEUMATOLOGY, P1747
   Martines F, 2003, ACTA MEDICA MEDITERR, V19, P183
   MCADAM LP, 1976, MEDICINE, V55, P193, DOI 10.1097/00005792-197605000-00001
   MICHET CJ, 1986, ANN INTERN MED, V104, P74, DOI 10.7326/0003-4819-104-1-74
   Narozny W, 2001, Acta Otorhinolaryngol Belg, V55, P227
   OHANLAN M, 1976, ARTHRITIS RHEUM, V19, P191, DOI 10.1002/art.1780190210
   PORT JL, 1993, COMPUT MED IMAG GRAP, V17, P119, DOI 10.1016/0895-6111(93)90053-P
   Sato M, 2010, ANN NUCL MED
   Spraggs PDR, 1997, LARYNGOSCOPE, V107, P936, DOI 10.1097/00005537-199707000-00020
   TERATO K, 1990, ARTHRITIS RHEUM, V33, P1493, DOI 10.1002/art.1780331006
   Trentham DE, 1998, ANN INTERN MED, V129, P114, DOI 10.7326/0003-4819-129-2-199807150-00011
   YANG CL, 1993, ARCH DERMATOL RES, V285, P245, DOI 10.1007/BF00371591
NR 29
TC 1
Z9 1
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 295
EP 300
DI 10.19193/0393-6384_2018_2_47
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400001
DA 2022-07-14
ER

PT J
AU Doaei, S
   Malmir, H
   Kalantari, N
   Majidi, N
   Gholamalizadeh, M
   Shahvegharasl, Z
   Elahi, R
AF Doaei, S.
   Malmir, H.
   Kalantari, N.
   Majidi, N.
   Gholamalizadeh, M.
   Shahvegharasl, Z.
   Elahi, R.
TI BODY MASS INDEX (BMI) WAS ASSOCIATED WITH MENTAL HEALTH, BUT IT HAD NO
   ASSOCIATION WITH SELF-ESTEEM IN IRANIAN GIRLS: A CASE-CONTROL STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Body Mass Index; Mental Health; self-esteem; Adolescent Girls
AB Introduction: Overweight and obesity are known as one of the major problems in girls' physical and mental health. This study aimed to evaluate the association between body mass index (BMI) with mental health and self-esteem in Iranian girls.
   Methods: In this case-control study, 160 girls (47 obese or overweight as the case group and 113 normal weight as the control group) aged 13 to 18 years old were recruited. Adolescents' height and weight were measured according to international standards, and BMI was calculated. Mental health status and self-esteem were measured using the validated general health questionnaire (GHQ) and the Rosenberg self-esteem questionnaire, respectively. Comparison of the variables was performed using chi-square test.
   Results: The mean BMI in the case group was 26.73 Kg/m2 and in the control group was 20.13 Kg/m2. 78% of cases and 21% of controls had mental disorders which significantly differed from each other (P < 0.001). Moreover, 31% of cases and 24% of controls had sufficient self-esteem. However, this difference was not statistically significant.
   Conclusion: Mental health disorders in obese girls were much higher than normal weight girls. However, there was not a significant association between obesity and self-esteem. It seems that obesity is not associated with the reduced self-esteem of Iranian girls. Further longitudinal studies with larger participants were required to achieve the psychological effects of obesity in Iranian girls.
C1 [Doaei, S.] North Khorasan Univ Med Sci, Nat Prod & Med Plants Res Ctr, Bojnurd, Iran.
   [Malmir, H.] Univ Tehran Med Sci, Fac Nutr Sci, Tehran, Iran.
   [Kalantari, N.] Shahid Beheshti Univ Med Sci, Fac Nutr Sci & Food Technol, Dept Publ Hlth Nutr, Tehran, Iran.
   [Majidi, N.] Shahid Beheshti Univ Med Sci, Fac Nutr Sci & Food Technol, Tehran, Iran.
   [Doaei, S.; Gholamalizadeh, M.] Shahid Beheshti Univ Med Sci, Canc Res Ctr, Student Res Comm, Tehran, Iran.
   [Shahvegharasl, Z.] Tabriz Univ Med Sci, Fac Nutr Sci, Tabriz, Iran.
   North Khorasan Univ Med Sci, Hlth Sch, Dept Publ Hlth, Bojnurd, Iran.
   [Doaei, S.; Elahi, R.] Univ Shahrekord, Fac Vet Med, Shahrekord, Iran.
RP Gholamalizadeh, M (corresponding author), Shahid Beheshti Univ Med Sci, Canc Res Ctr, Student Res Comm, Tehran, Iran.
EM gholamalizadeh@sbmu.ac.ir
RI Doaei, Saeid/X-6425-2018; kalantari, naser/AAA-2857-2022
OI Doaei, Saeid/0000-0002-2532-7478; 
FU Student Research Committee of Shahid Beheshti University of Medical
   Sciences in Tehran [8182]
FX This study was supported by the Student Research Committee of Shahid
   Beheshti University of Medical Sciences in Tehran (Code 8182). We
   acknowledge all the university staff and the study participants for
   their excellent cooperation.
CR Boroujeni SS, 2016, J SPORT MANAGEMENT M, V11, P133
   Doaei Saeid, 2015, Iran J Psychiatry, V10, P278
   Javanmard GH, 2013, PROCD SOC BEHV, V84, P47, DOI 10.1016/j.sbspro.2013.06.507
   Kalantari N, 2016, BRIT J MED MED RES, V14, P1
   Kalantari N, 2017, INT J PREVENTIVE MED, V8, DOI 10.4103/ijpvm.IJPVM_306_16
   Kalantari Naser, 2016, Iran J Psychiatry, V11, P43
   Kiviruusu O, 2016, INT J BEHAV MED, V23, P355, DOI 10.1007/s12529-015-9529-4
   Kourakos Michael, 2017, Asian Pac J Cancer Prev, V18, P1991
   Mailey E, 2012, MENT HEALTH PHYS ACT, V5, P76, DOI DOI 10.1016/J.MHPA.2012.01.001
   Makinen M, 2015, CHILD ADOL PSYCH MEN, V9, DOI 10.1186/s13034-015-0038-7
   Ozmen D, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-80
   Que Min, 2007, Zhonghua Liu Xing Bing Xue Za Zhi, V28, P460
   SHAPURIAN R, 1987, PERCEPT MOTOR SKILL, V65, P27, DOI 10.2466/pms.1987.65.1.27
   Tabacchi G, 2014, PUBLIC HEALTH NUTR, V17, P2700, DOI 10.1017/S1368980013003157
NR 14
TC 2
Z9 2
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1015
EP 1017
DI 10.19193/0393-6384_2018_4_154
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500017
DA 2022-07-14
ER

PT J
AU Dong, Q
   Zhang, YG
   Tian, W
AF Dong, Qiang
   Zhang, Yin-Guang
   Tian, Wei
TI THE EFFECT OF PFNA MINIMALLY INVASIVE INTERNAL FIXATION ON THE
   POSTOPERATIVE SLIPPAGE OF FIXING NEEDLE IN ELDERLY PATIENTS WITH FEMORAL
   INTERTROCHANTERIC FRACTURE AND THE CHANGE OF RESET IMAGE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE PFNA minimally invasive internal fixation; Elderly femoral
   iritertrochariteric fracttire; fixing needle slippage; Reset image
ID PERCUTANEOUS COMPRESSION PLATE; SLIDING HIP SCREW; FEMUR FRACTURES;
   RISK-FACTORS; MANAGEMENT; NAIL
AB Objective: To compare the effect of PFNA minimally invasive internal fixation and Gamma nail internal fixation on the posto- perative slippage of fixing needle in aged subjects with femoral intertrochanteric fracture and the change of reset image.
   Patients and methods: Patients who were treated in our hospital from January 2015 to April 2016, about one hundred seventy eighty of them, having femoral intertrochanteric fracture were chosen as the subjects. As per a random number table, they were divi- ded into two groups- Group A and Group B. A group of patients with PFNA minimally invasive internal fixation, B group of patients with Gamma nail internal fixation. The clinical efficacy, hip joint function, slippage of fixing needle and reset image were evaluated in both groups.
   Results: Compared to the control group, it was observed that Group As effective rate was greater by a significant amount (P <0.05). Compared to Group B, the operation time, discharge time and healing time were much lesser (P <0.05). The bleeding volume in group A was significantly less than that in group B (P < 0.05). In the amount of fixing needle slippage between the two groups, no main variations were found (P > 0.05). Six months after operation, the Group A patients TAD lagged behind group B patients, and the collodiaphysial angle of group A was higher than that of group B, statistically, there was much variation (P < 0.05). In the inci- dence of complications such as infection, femoral fracture, nonunion, coxa varus and dysfunction, there was not much variation between the two groups (P > 0.05).
   Conclusion: The two kinds of internal fixation both have good clinical curative effects on the elderly femoral intertrochanteric fracture, however, the PFNA minimally invasive internal fixation is more effective, with smaller changes of postoperative TAD and collodiaphysial angle.
C1 [Dong, Qiang; Zhang, Yin-Guang; Tian, Wei] Tianjin Hosp, Dept Traumatol, 406 Jiefang South Rd, Tianjin 300211, Peoples R China.
RP Dong, Q (corresponding author), Tianjin Hosp, Dept Traumatol, 406 Jiefang South Rd, Tianjin 300211, Peoples R China.
EM 381245249@qq.com
CR Anglen JO, 2008, J BONE JOINT SURG AM, V90A, P700, DOI 10.2106/JBJS.G.00517
   Atkinson K, 2005, PHYSIOTHERAPY ORTHOP, P237
   Bansal R, 2005, INJURY, V36, P984, DOI 10.1016/j.injury.2004.11.017
   [陈魏(综述) Chen Wei], 2014, [中国矫形外科杂志, Orthopedic Journal of China], V22, P723
   Cheng T, 2012, J TRAUMA ACUTE CARE, V72, P1435, DOI 10.1097/TA.0b013e318247252a
   Chinzei N, 2015, CLIN ORTHOP SURG, V7, P291, DOI 10.4055/cios.2015.7.3.291
   Crespo E, 2012, EUR J TRAUMA EMERG S, V38, P443, DOI 10.1007/s00068-012-0181-2
   Finsen V, 2004, CLIN ORTHOP RELAT R, P173, DOI 10.1097/01.blo.0000111886.01667.79
   Hou Guo-Jin, 2013, Beijing Da Xue Xue Bao Yi Xue Ban, V45, P738
   Hsueh KK, 2010, INT ORTHOP, V34, P1273, DOI 10.1007/s00264-009-0866-2
   Huang HJ, 2014, INT J CLIN EXP MED, V7, P3687
   [蒋正武 Jiang Zhengwu], 2014, [中国现代医学杂志, China Journal of Modern Medicine], V24, P101
   Langford J, 2011, J ORTHOP TRAUMA, V25, P191, DOI 10.1097/BOT.0b013e3181ecfcba
   Li Y., 2013, CHONGQING MED, V10, P1172
   McCormack R, 2013, INJURY, V44, P1904, DOI 10.1016/j.injury.2013.06.017
   Mirjalili Mohammad Raza, 2016, ACTA MEDICA MEDITERR, P1203
   Miyamoto RG, 2008, J AM ACAD ORTHOP SUR, V16, P596, DOI 10.5435/00124635-200810000-00005
   Sbiyaa M, 2016, PAN AFR MED J, V23, DOI 10.11604/pamj.2016.23.57.7965
   Schmidt-Rohlfing B, 2013, J ORTHOP TRAUMA, V27, P312, DOI 10.1097/BOT.0b013e3182703730
   Seyhan M, 2015, J ORTHOP SCI, V20, P1053, DOI 10.1007/s00776-015-0750-4
   Streubel PN, 2013, J ORTHOP TRAUMA, V27, P22, DOI 10.1097/BOT.0b013e318251930d
   Wilson JD, 2011, BRIT J RADIOL, V84, P375, DOI 10.1259/bjr/29690721
   [向川 Xiang Chuan], 2013, [中国矫形外科杂志, Orthopedic Journal of China], V21, P1384
   Yang SL, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700810
   Zhang JH, 2005, ORTHOPEDIC J CHINA, V15, P577
   冯涛, 2012, [中国老年学杂志, Chinese Journal of Gerontology], V32, P218
NR 26
TC 1
Z9 1
U1 2
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 831
EP 837
DI 10.19193/0393-6384_2018_3_127
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000031
DA 2022-07-14
ER

PT J
AU Dong, YL
   Huang, CP
   Li, J
AF Dong, Yan-lei
   Huang, Cui-ping
   Li, Juan
TI THE INHIBITIVE EFFECTS OF ORIDONIN ON CISPLATIN-RESISTANT OVARIAN CANCER
   CELLS VIA INDUCING CELL APOPTOSIS AND INHIBITING ADAM17
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Ovarian cancer; oridonin; cisplatin; drug resistance; cell apoptosis
ID IN-VIVO; ASSOCIATION; EXPRESSION; RUBESCENS; EFFICACY; GROWTH
AB Background: Cisplatin is the first generation chemotherapy medium based on platinum, nonetheless, the large-scale utilization of cisplatin naturally causes defenses against drugs, which is a key barrier to cancer chemotherapy. Oridonin is a diterpenoid sperated from Rabdosia rubescens with potent anticancer activity. Our research's purpose is to find the function of oridonin to reverse the cisplatin-immunity in ovarian cancer cells of human.
   Methods: The impact of oridonin on rapid growth was assessed through MTT examination,. In addition, cell movement and incursion were assessed through transwell movement as well as incursion examination in cisplatin-resistant ovarian cancer cells. Cell apoptosis was examined by moving cytometry. Xenografted nude mice is used to examine the inhibitive impact of oridonin in vivo. Furthermore, real-time PCR and western blot detected the appearance of ADAM17.
   Results: There was a synergic antitumor effect in middle of cisplatin and oridonin on cisplatin-resistant cells of ovarian cancer in vitro as well as in vivo. Furthermore, the amalgamation of cisplatin and oridonin synergetic induced apoptosis. Furthermore, the combination treatment not only inhibited cancer cell migration and invasion, but more significantly, decreased the expression of ADAM17 protein. More importantly, ADAM17 attenuated the suppressive effect of oridonin.
   Conclusion: Our outcome shows that the synergic impact between both agents is probably caused by the impediment of ADAM17 and the resulting increased apoptosis.
C1 [Dong, Yan-lei; Huang, Cui-ping] Shandong Univ, Dept Gynaecol, Hosp 2, 247 Beiyuan St, Jinan, Shandong, Peoples R China.
   [Li, Juan] Shandong Univ, Dept Imaging, Hosp 2, Jinan, Shandong, Peoples R China.
RP Huang, CP (corresponding author), Shandong Univ, Dept Gynaecol, Hosp 2, 247 Beiyuan St, Jinan, Shandong, Peoples R China.
EM huang982007@163.com
CR Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Gallo D, 2006, INT J GYNECOL CANCER, V16, P222, DOI 10.1111/j.1525-1438.2006.00304.x
   Gao FH, 2012, INT J MOL MED, V29, P649, DOI 10.3892/ijmm.2012.895
   Gao FH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-610
   Huang HL, 2012, MOL CANCER THER, V11, P1155, DOI 10.1158/1535-7163.MCT-12-0066
   Ikezoe T, 2005, MOL CANCER THER, V4, P578, DOI 10.1158/1535-7163.MCT-04-0277
   Joo WD, 2009, J GYNECOL ONCOL, V20, P96, DOI 10.3802/jgo.2009.20.2.96
   Karam AK, 2009, GYNECOL ONCOL, V114, P246, DOI 10.1016/j.ygyno.2009.02.022
   Kim HS, 2009, J CANCER RES CLIN, V135, P1513, DOI 10.1007/s00432-009-0598-0
   Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x
   Leung CH, 2005, MOL PHARMACOL, V68, P286, DOI 10.1124/mol.105.012765
   Musiani D, 2014, J PROTEOME RES, V13, P4970, DOI 10.1021/pr500651n
   Ozga M, 2015, PALLIAT SUPPORT CARE, P1
   Qi XL, 2012, INT J NANOMED, V7, P1793, DOI 10.2147/IJN.S29483
   Redman Charles, 2011, Practitioner, V255, P27
   Shou ZX, 2012, ANN SURG, V256, P1014, DOI 10.1097/SLA.0b013e3182592f56
   Song T, 2013, CANCER CHEMOTH PHARM, V72, P653, DOI 10.1007/s00280-013-2241-7
   Walters Haygood Christen L, 2014, World J Stem Cells, V6, P441, DOI 10.4252/wjsc.v6.i4.441
   Wang SP, 2013, AM J CHINESE MED, V41, P177, DOI 10.1142/S0192415X13500134
   Wang YY, 2014, ANTI-CANCER DRUG, V25, P1192, DOI 10.1097/CAD.0000000000000154
   Ye HY, 2014, MAT SCI ENG C-MATER, V45, P609, DOI 10.1016/j.msec.2014.06.002
   Yoshida H, 2013, ANTICANCER RES, V33, P1409
   Zafrakas M, 2014, FRONT SURG, V1, DOI 10.3389/fsurg.2014.00014
   Zhang HY, 2012, J CANCER RES THER, V8, P226, DOI 10.4103/0973-1482.98975
   Zhen T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003562
   Zheng XG, 2012, MOL CARCINOGEN, V51, P150, DOI 10.1002/mc.20772
   Zhou GB, 2007, BLOOD, V109, P3441, DOI 10.1182/blood-2006-06-032250
NR 28
TC 1
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 819
EP 825
DI 10.19193/0393-6384_2018_3_125
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000029
DA 2022-07-14
ER

PT J
AU Du, F
   Liu, DS
   He, G
   Chen, DG
AF Du, Fei
   Liu, Daishun
   He, Gang
   Chen, Daigang
TI EFFECT OF SIMVASTATIN ON SERUM GAMMA-GLUTAMYLTRANSFERASE AND C-REACTIVE
   PROTEIN IN PATIENT WITH ACUTE EXACERBATION CHRONIC OBSTRUCTIVE PULMONARY
   DISEASE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE simvastatin; chronic obstructive pulmonary disease; gamma-glutamyl
   transferase; C-reactive protein
ID STATIN USE; CARDIOVASCULAR-DISEASE; REDUCTASE INHIBITOR; METABOLIC
   SYNDROME; OXIDATIVE STRESS; LUNG-FUNCTION; COPD; RISK; THERAPY; DECLINE
AB Objective: Retrospective studies have shown that statins decrease the rate and severity of exacerbations, the rate of hospitalization, and mortality in chronic obstructive pulmonary disease(COPD). To explore the effect of simvastatin on serum gamma-glutamyl transferase (GGT) and C-reactive protein (CRP) on patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).
   Methods: 60 cases with AECOPD were randomly divided into the treatment group and control group. In addition to routine comprehensive treatment in both groups, additional 20mg Simvastatin was given to the treatment group by per os, once per night for two weeks. We observed the change of GGT activity and serum CRP concentration before and after treated in the two groups. Meanwhile, the pulmonary function measurements were performed.
   Results: There were no significant differences in the pulmonary function: forced expiratory volume in one second(FEV1), forced vital capacity(FVC), forced vital capacity rate of one second(FEV1/FVC), peak expiratory flow(PEF), residual volume(RV) and residual volume to total lung capacity(RV/TLC) and the serum GGT and CRP levels between the two groups before treatment. The control group showed no significant changes in any parameters before and after two-week treatment. The pulmonary function in the treatment group after two week treatment significantly improved compared with those before treatment and the control group, but the serum GGT activity and CRP levels significantly decreased.
   Conclusions: Simvastatin may reduce the decline in pulmonary function and decrease the levels of serum GGT and CRP of patients with AECOPD. Improvement in pulmonary function may be related to it.
C1 [Du, Fei; Liu, Daishun; He, Gang; Chen, Daigang] First Peoples Hosp Zun Yi, Dept Resp Med, Zunyi Gui Zhou 563000, Zhejiang, Peoples R China.
RP Du, F (corresponding author), First Peoples Hosp Zun Yi, Dept Resp Med, Zunyi Gui Zhou 563000, Zhejiang, Peoples R China.
EM fei632@163.com
FU Technology Division of ZunYi [[2013]02]
FX Technology Division of ZunYi NO. [2013]02
CR Alexeeff SE, 2007, AM J RESP CRIT CARE, V176, P742, DOI 10.1164/rccm.200705-656OC
   Balk EM, 2003, ANN INTERN MED, V139, P670, DOI 10.7326/0003-4819-139-8-200310210-00011
   Bellosta S, 1998, ARTERIOSCL THROM VAS, V18, P1671, DOI 10.1161/01.ATV.18.11.1671
   Biljak VR, 2013, COLLEGIUM ANTROPOL, V37, P221
   Boros PW, 2012, POL ARCH MED WEWN, V122, P73, DOI 10.20452/pamw.1177
   Chopra V, 2009, CHEST, V136, P1381, DOI 10.1378/chest.09-0941
   Criner GJ, 2014, NEW ENGL J MED, V370, P2201, DOI 10.1056/NEJMoa1403086
   Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847
   Ermis H, 2013, POL ARCH MED WEWN, V123, P85, DOI 10.20452/pamw.1617
   Ferns GAA, 2003, ATHEROSCLEROSIS, V169, P349, DOI 10.1016/S0021-9150(03)00191-6
   GLOD Executive Committee, GLOBAL STRATEGY DIAG
   Grundy SM, 2007, ARTERIOSCL THROM VAS, V27, P4, DOI 10.1161/01.ATV.0000253905.13219.4b
   Holme J, 2010, COPD, V7, P126, DOI 10.3109/15412551003631733
   Hothersall E, 2006, THORAX, V61, P729, DOI 10.1136/thx.2005.057976
   Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9
   Jean JC, 2002, AM J PHYSIOL-LUNG C, V283, pL766, DOI 10.1152/ajplung.00250.2000
   Jialal I, 2001, CIRCULATION, V103, P1933
   John ME, 2015, INT J CHRONIC OBSTR, V10, P211, DOI 10.2147/COPD.S76061
   Johnson BA, 2003, AM J RESP CRIT CARE, V167, P1271, DOI 10.1164/rccm.200205-410OC
   Kinlay S, 2003, CIRCULATION, V108, P1560, DOI 10.1161/01.CIR.0000091404.09558.AF
   Kruger P, 2013, AM J RESP CRIT CARE, V187, P743, DOI 10.1164/rccm.201209-1718OC
   Kurian KC, 2006, J CARD FAIL, V12, P473, DOI 10.1016/j.cardfail.2006.02.001
   Lahousse L, 2013, PULM PHARMACOL THER, V26, P212, DOI 10.1016/j.pupt.2012.10.008
   Lawes CMM, 2012, PRIM CARE RESP J, V21, P35, DOI 10.4104/pcrj.2011.00095
   Lee DH, 2005, ATHEROSCLEROSIS, V178, P327, DOI 10.1016/j.atherosclerosis.2004.08.027
   Lee DH, 2004, FREE RADICAL RES, V38, P535, DOI 10.1080/10715760410001694026
   Lee DS, 2007, ARTERIOSCL THROM VAS, V27, P127, DOI 10.1161/01.ATV.0000251993.20372.40
   Mammen MJ, 2012, POL ARCH MED WEWN, V122, P54, DOI 10.20452/pamw.1134
   Maneechotesuwan K, 2015, CHEST, V6, P14
   Mortensen EM, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-45
   Ou XM, 2009, RESPIROLOGY, V14, P734, DOI 10.1111/j.1440-1843.2009.01549.x
   Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256
   Prasad K, 2006, CARDIOVASC DRUG REV, V24, P33, DOI 10.1111/j.1527-3466.2006.00033.x
   Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805
   Wang MT, 2013, AM J MED, V126, P598, DOI 10.1016/j.amjmed.2013.01.036
   Wang YJ, 2014, INT J CLIN EXP PATHO, V7, P8553
NR 36
TC 2
Z9 2
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1221
EP 1226
DI 10.19193/0393-6384_2018_5_187
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700009
DA 2022-07-14
ER

PT J
AU Egin, S
   Gokcek, B
   Yesiltas, M
   Hot, S
   Kamali, S
   Isil, RG
   Tok, H
   Karahan, SR
AF Egin, Seracettin
   Gokcek, Berk
   Yesiltas, Metin
   Hot, Semih
   Kamali, Sedat
   Isil, Riza Gurhan
   Tok, Hasan
   Karahan, Servet Rustu
TI THE FACTORS AFFECTING SURVIVAL IN OPEN ABDOMEN DUE TO SURGICAL ABDOMINAL
   SEPSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Abdominal sepsis; Open abdomen; Vacuum-assisted closure; Negative
   pressure therapy
ID COMPARTMENT SYNDROME; MANAGEMENT; GUIDELINES; SOCIETY; CLOSURE
AB Introduction: In the literature, there are studies comparing open abdomen technique and primary closure technique in terms of survival and other results in patients with surgical abdominal sepsis. There are no studies investigating the factors affecting survival in patients treated with open abdominal technique alone. These factors should be investigated retrospectively in open abdomen patients. We aimed to investigate the factors of survival in patients with severe intraabdominal sepsis treated with vacuum-assisted closure systems for open abdomen. We hypothesized that use of open abdomen with vacuum-assisted closure systems was reduced mortality in patients with severe intraabdominal sepsis.
   Materials and methods: We retrospectively reviewed 40 open abdomen patients performed vacuum-assisted closure for severe intraabdominal sepsis. Alive and mortal groups were evaluated in terms of age, gender, body mass index, etiology of surgical abdominal sepsis, Apache II score, Mannheim peritonitis index score, Bjorck classification, fascia score, abdominal defect size, stoma and fistula presence, and vacuum-assisted closure treatment duration. It was evaluated whether any of these parameters was effective on survival.
   Results: Mean age and body mass index were significantly elevated in the mortal group compared with the alive group. A significant difference with regard to Bjorck classification was detected between the alive and mortal groups. In Bjorck 1 and 2, mortality rates were 36.8% and 31.3%, respectively, while in Bjorck 4, mortality was 100%. The presence and ope of fistula were statistically significant for mortality. None of the other parameters were statistically significant for mortality.
   Discussion: The studies of the last twelve years showed that the open abdomen technique with the temporary abdominal wall closure using negative pressure dressing methods gave positive results. The 42.5% mortality rate in our study is much lower than the mortality rate for abdominal sepsis patients in the literature. Our study indicated that the management of open abdomen and negative pressure therapy was possible to increase the survival in patients with surgical abdominal sepsis.
C1 [Egin, Seracettin; Gokcek, Berk; Yesiltas, Metin; Hot, Semih; Kamali, Sedat; Isil, Riza Gurhan; Tok, Hasan; Karahan, Servet Rustu] Saglik Bilimleri Univ, Okmeydani Educ & Res Hosp, Darulaceze Cad 25, TR-34384 Istanbul, Turkey.
RP Egin, S (corresponding author), Saglik Bilimleri Univ, Okmeydani Educ & Res Hosp, Darulaceze Cad 25, TR-34384 Istanbul, Turkey.
EM seracettin_egin@hotmail.com
RI Hot, Semih/ADG-3811-2022; Yeşiltaş, Metin/Q-8190-2019; Yeşiltaş,
   Metin/R-3639-2018; eğin, seracettin/AAR-8417-2020
OI Hot, Semih/0000-0001-9623-356X; Yeşiltaş, Metin/0000-0002-2080-1572;
   Yeşiltaş, Metin/0000-0002-2080-1572; eğin,
   seracettin/0000-0002-4090-5205
CR Adkins AL, 2004, AM SURGEON, V70, P137
   Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002
   Balogh Z, 2003, J TRAUMA, V54, P848, DOI 10.1097/01.TA.0000070166.29649.F3
   Bjorck M, 2009, WORLD J SURG, V33, P1154, DOI 10.1007/s00268-009-9996-3
   CHRISTOU NV, 1993, ARCH SURG-CHICAGO, V128, P193
   Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI [10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]
   Dellinger RP, 2008, INTENS CARE MED, V34, P783, DOI [10.1007/s00134-008-1040-9, 10.1007/s00134-007-0934-2]
   Demetriades D, 2012, INT WOUND J, V9, P17, DOI 10.1111/j.1742-481X.2012.01018.x
   Diaz JJ, 2010, J TRAUMA, V68, P1425, DOI 10.1097/TA.0b013e3181da0da5
   Hanisch Ernst, 2011, J Intensive Care Med, V26, P27, DOI 10.1177/0885066610384058
   Kaplan M, 2005, WOUNDS S1, V17, pS1
   Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z
   Kubiak BD, 2010, SHOCK, V34, P525, DOI 10.1097/SHK.0b013e3181e14cd2
   Moore LJ, 2011, J TRAUMA, V70, P672, DOI 10.1097/TA.0b013e31820e7803
   Plaudis Haralds, 2012, Ann Intensive Care, V2 Suppl 1, pS23, DOI 10.1186/2110-5820-2-S1-S23
   Rausei Stefano, 2014, Surg Technol Int, V25, P68
   Robledo Felipe A, 2007, Surg Infect (Larchmt), V8, P63, DOI 10.1089/sur.2006.8.016
   Sartelli M, 2015, WORLD J EMERG SURG, V10, DOI 10.1186/s13017-015-0032-7
   Sartelli M, 2014, WORLD J EMERG SURG, V9, DOI 10.1186/1749-7922-9-22
   Terzi C, 2014, INT WOUND J, V11, P17, DOI 10.1111/iwj.12288
   van Hensbroek PB, 2009, WORLD J SURG, V33, P199, DOI 10.1007/s00268-008-9867-3
   Vargo D, 2009, AM SURGEON, V75, pS1
   Verdam FJ, 2011, WORLD J SURG, V35, P2348, DOI 10.1007/s00268-011-1210-8
NR 23
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 2031
EP 2036
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400068
DA 2022-07-14
ER

PT J
AU Ergonul, E
   Baskurt, F
   Yilmaz, ND
   Baskurt, Z
   Asci, H
   Koc, S
   Temel, UB
AF Ergonul, Esin
   Baskurt, Ferdi
   Yilmaz, Nilufer Demiral
   Baskurt, Zeliha
   Asci, Halil
   Koc, Sukran
   Temel, Ugur Burak
TI RELIABILITY AND VALIDITY OF THE READINESS FOR INTERPROFESSIONAL LEARNING
   SCALE (RIPLS) IN TURKISH SPEAKING HEALTH CARE STUDENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Interprofessional education; RIPLS; Turkish; Psychometrics; Evaluation
ID EDUCATION; VERSION
AB Objectives: The purpose of the study was to provide psychometric evaluation of the Turkish version of the Readiness for Interprofessional Learning Scale (RIPLS).
   Material and methods: This cross-sectional study was carried out with 213 students at the Faculty of Medicine, Faculty of Dentistry and Faculty of Health Sciences. The construct validity of the Turkish version of the scale was analyzed with confirmatory factor analysis (CFA). To determine the reliability of the scale, the Cronbach's alpha coefficient was calculated. In addition, for the assessment of the discrimination of each item on the scale, the top and bottom 27 % from the groups that received the lowest and highest scores from the scale were compared.
   Results: Standardized coefficients determined with the CFA in the Turkish version of the scale ranged between 0.34 and 0.85 in the students (Except for Item 18). The explained variance values for the items other than item 18 ranged from 0.11 to 0.72. t-values of all the factor loadings were significant. According to the reliability studies of the RIPLS, the internal consistency of Cronbach's Alpha was 0.85 for the overall scale. The t-test results showed that all the items significantly discriminated between students of high and low performance (t: 99.57; p=0.01).
   Conclusion: As a result, it can be said that the validity and reliability study of the RIPLS administered to Turkish healthcare students indicated that the scale was capable of measuring the Turkish-speaking students' readiness for interprofessional education.
C1 [Ergonul, Esin] Dokuz Eylul Univ, Fac Med, Dept Med Educ, Izmir, Turkey.
   [Ergonul, Esin] Dokuz Eylul Univ, Vocat Sch Hlth Serv, Izmir, Turkey.
   [Baskurt, Ferdi; Baskurt, Zeliha] Suleyman Demirel Univ, Fac Hlth Sci, Dept Phys Therapy & Rehabil, Isparta, Turkey.
   [Yilmaz, Nilufer Demiral] Ege Univ, Dept Med Educ, Fac Med, Izmir, Turkey.
   [Asci, Halil] Suleyman Demirel Univ, Dept Pharmacol, Fac Med, Isparta, Turkey.
   [Koc, Sukran] Suleyman Demirel Univ, Dept Midwifery, Fac Hlth Sci, Isparta, Turkey.
   [Temel, Ugur Burak] Suleyman Demirel Univ, Fac Dent, Isparta, Turkey.
RP Baskurt, F (corresponding author), Suleyman Demirel Univ, Fac Hlth Sci, Dept Phys Therapy & Rehabil, Isparta, Turkey.
RI Ergonul, Esin/Q-2657-2019
CR Accreditation Council for Graduate Medical Education, ACGME COMM PROGR REQ
   Artino AR, 2014, MED TEACH, V36, P463, DOI 10.3109/0142159X.2014.889814
   Baumgartner H., 1996, INT J RES MARK, V13, P139, DOI [https://doi.org/10.1016/0167-8116(95)00038-0, DOI 10.1016/0167-8116(95)00038-0]
   Byrne BM, 1999, J CROSS CULT PSYCHOL, V30, P555, DOI 10.1177/0022022199030005001
   CHIC Working Group, 2012, INV QUANT TOOLS MEAS
   Frye AW, 2012, MED TEACH, V34, pE288, DOI 10.3109/0142159X.2012.668637
   Gjersing L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-13
   Guitard, 2010, JPHYSICAL THERAPY ED, V24, P19, DOI [10.1097/00001416-201010000-00005, DOI 10.1097/00001416-201010000-00005]
   Hall P, 2005, J INTERPROFESSION S1, V19, P188, DOI DOI 10.1080/13561820500081745
   Hean S, 2012, MED TEACH, V34, pE78, DOI 10.3109/0142159X.2012.650740
   Hooper D, 2008, STRUCTURAL EQUATION
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Interprofessional Education Collaborative, 2016, COR COMP INT COLL PR
   Kenny Gerard, 2002, Nurs Stand, V17, P33
   Kline R.B, 2011, PRINCIPLES PRACTICE
   Lauffs M, 2008, MED EDUC, V42, P405, DOI 10.1111/j.1365-2923.2008.03017.x
   MacCallum RC, 2000, ANNU REV PSYCHOL, V51, P201, DOI 10.1146/annurev.psych.51.1.201
   Mahler C, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-145
   McFadyen A K, 2005, J Interprof Care, V19, P595
   National Medical Education Accreditation Board, 2018, UND MED ED STAND
   National Nurse Education Accreditation Board, 2013, UND NURS ED STAND
   Norgaard B, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0591-7
   Parsell G, 1999, MED EDUC, V33, P95, DOI 10.1046/j.1365-2923.1999.00298.x
   Reeves S, 2016, MED TEACH, V38, P656, DOI 10.3109/0142159X.2016.1173663
   Simin D, 2010, SRP ARK CELOK LEK, V138, P480, DOI 10.2298/SARH1008480S
   Tyastuti D, 2014, J INTERPROF CARE, V28, P426, DOI 10.3109/13561820.2014.907778
   Walsh Claire L, 2005, Nurse Educ Pract, V5, P230, DOI 10.1016/j.nepr.2004.12.004
   World Health Organization (WHO), 2010, FRAM ACT INT ED COLL
NR 28
TC 3
Z9 3
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 797
EP 803
DI 10.19193/0393-6384_2018_3_122
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000042
DA 2022-07-14
ER

PT J
AU Etemad, Z
   Nikbakht, H
   Azarbayjani, MA
   Gholami, M
AF Etemad, Zaher
   Nikbakht, Hojatollah
   Azarbayjani, Mohammad Ali
   Gholami, Mandana
TI EFFECT OF DIFFERENT REST INTERVAL LENGTHS OF RESISTANCE EXERCISE ON SOME
   ATHEROSCLEROSIS MARKERS AND INFLAMMATORY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Resistance training; Rest interval; CRP; Homocysteine
ID ADIPOSE-TISSUE
AB The purpose of this study was to determine the effects of two resistance exercise (RE) protocols with different rest intervals between sets on homocysteine and CRP In Sedentary Men. For this purpose, 30 untrained males voluntarily participated in the research and were randomly assigned to one of two resistance exercise groups: a) a shorter inter-set rest interval of 90 second (RI-90; n=10); or b) a longer rest interval of 180 second (RI-180; n=10) and control group (10 people).
   Resistance exercise in both groups consisted of bench press; pull down curls with pulleys, biceps and triceps workout with a barbell, squat using (hack squat machine), "lat" pull down and sit-ups, which were performed with 50% of one repetition maximum in the first session and with 85% of one repetition maximum on the last session and in 8-12 repetitions in 3 sets.
   Before and after 8 weeks training period blood sampling were collected from the antecubital vein preexercise. Indndent and paired T Tests were used to analyze data in a meaningful level (p<0.05). Results showed thepeat there is statistically significant reduction in CRP, homocysteine levels after 8 weeks of resistance training with different rest intervals in the experimental group compared to the control group (p<0.05).
   In general, we can say that the difference between rest periods in resistance training can be an important factor in changes in serum levels of homocysteine and CRP are important. These exercises might probably decrease the risk of cardiovascular disease.
C1 [Etemad, Zaher; Nikbakht, Hojatollah] Islamic Azad Univ, Sci & Res Branch, Exercise Physiol, Tehran, Iran.
   [Azarbayjani, Mohammad Ali] Islamic Azad Univ, Dept Exercise Physiol, Tehran Cent Branch, Tehran, Iran.
   [Gholami, Mandana] Islamic Azad Univ, Dept Exercise Physiol, Sci & Res Branch, Tehran, Iran.
RP Nikbakht, H (corresponding author), Islamic Azad Univ, Sci & Res Branch, Exercise Physiol, Tehran, Iran.
EM hojnik1937@yahoo.com
RI etemad, zaher/ABB-1926-2021
OI Azarbayjani, Mohammad Ali/0000-0002-3502-7487
CR Abramson JL, 2002, ARCH INTERN MED, V162, P1286, DOI 10.1001/archinte.162.11.1286
   Bruun JM, 2006, AM J PHYSIOL-ENDOC M, V290, pE961, DOI 10.1152/ajpendo.00506.2005
   Brzycki M., 1993, J PHYS EDUC RECREAT, V64, P88, DOI [DOI 10.1080/07303084.1993.10606684, 10.1080/07303084.1993.10606684]
   de Salles BF, 2009, SPORTS MED, V39, P765, DOI 10.2165/11315230-000000000-00000
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   Fleck S. J., 2014, DESIGNING RESISTANCE, p4E
   Hammouda Omar, 2012, Asian J Sports Med, V3, P239, DOI 10.5812/asjsm.34544
   Hudson MB, 2008, MED SCI SPORT EXER, V40, P542, DOI [10.1249/MSS.0b013e31815daf89, 10.1249/mss.0b013e31815daf89]
   JACKSON AS, 1978, BRIT J NUTR, V40, P497, DOI 10.1079/BJN19780152
   Joubert L. M., 2008, PROQUEST
   Mann DL, 2014, BRAUNWALDS HEART DIS
   Mayhew DL, 2005, J STRENGTH COND RES, V19, P16
   Neuman JC, 2013, NUTR RES, V33, P487, DOI 10.1016/j.nutres.2013.04.008
   Panic N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083138
   Paziraei M., INTERACTIVE EFFECT A
   Siri W.E., 1961, TECHNIQUES MEASURING, P223
   Stefani GP, 2014, J INT SOC SPORT NUTR, V11, DOI 10.1186/1550-2783-11-11
   Swift DL, 2012, MED SCI SPORT EXER, V44, P1028, DOI 10.1249/MSS.0b013e31824526cc
   Talebi-Garakani E, 2013, ENDOCRINE, V43, P564, DOI 10.1007/s12020-012-9786-9
NR 19
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 2
BP 555
EP 559
DI 10.19193/0393-6384_2018_2s_88
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7SD
UT WOS:000429274400002
DA 2022-07-14
ER

PT J
AU Fan, LC
   Zhou, LC
AF Fan Lichao
   Zhou Lichun
TI EXPRESSION AND MECHANISM OF ACTION OF JAK-STAT SIGNAL PASSAGE
   TRANSDUCING PROTEINS IN A RAT MODEL OF CEREBRAL ISCHEMIA REPERFUSION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Cerebral ischemia reperfusion; JAK-STAT signal passage; p-JAK2; p-STAT3
AB Objective: To study the expression and mechanism of action of JAK-STAT signal passage transducing proteins JAK2 and STAT3 in a rat cerebral ischemia reperfusion models.
   Methods: Wistar rats (100) were divided into a sham-operation group and a model group with 50 rats in either group, to build cerebral ischemia reperfusion models of rats. After the models have been set up successfully, reperfusion injury was induced, and brain tissues were taken at 2 h, 1 day, 3 days, 7 days and 21 days, and subjected to Western blot and immunofluorescence to determine changes in expressions of p-JAK2 and p-STAT3.
   Results: There were significant differences in the expressions of p-JAK2 and p-STAT3 between the model group and the pseudo-operation group within the same periods (p < 0.05). These expressions were highest in the model group at day 1.
   Conclusion: These results indicate that the expressions of p-JAK2 and p-STAT3 are highly enhanced after cerebral ischemia reperfusion. Thus, abnormal activation of JAK2-STAT3 signal transduction passage may be one of the mechanisms involved in nerve cell apoptosis after cerebral ischemia and reperfusion injury.
C1 [Fan Lichao; Zhou Lichun] Capital Med Univ, Beijing Chao Yang Hosp, Dept Neurol, Jingxi Campus, Beijing, Peoples R China.
RP Zhou, LC (corresponding author), 5 Jingyuan Rd, Beijing 100043, Peoples R China.
EM tuitgdby38697@163.com
CR Funamoto K, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00340
   He Wei, 2015, PHARM CLIN RES, V23, P164
   HOWARDJONES N, 1985, WHO CHRON, V39, P51
   Liu H, 2017, BIOSCI TRENDS
   Liu J, 2017, EXP THER MED, V14, P939, DOI 10.3892/etm.2017.4622
   [刘荣 Liu Rong], 2011, [神经解剖学杂志, Chinese Journal of Neuroanatomy], V27, P617
   Pan Q, 2016, J NANCHANG U CHEM, V56, P88
   Shi P, 2017, NEURAL REGEN RES, V12, P925, DOI 10.4103/1673-5374.208574
   [王莉安 WANG Li-an], 2009, [中国药学杂志, Chinese Pharmaceutical Journal], V44, P1862
   Wang RL, 2017, AGING DIS, V8, P410, DOI 10.14336/AD.2016.1209
   Yang JW, 2017, EXP THER MED, V14, P1163, DOI 10.3892/etm.2017.4614
NR 11
TC 0
Z9 0
U1 1
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1097
EP 1100
DI 10.19193/0393-6384_2018_4_168
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500031
DA 2022-07-14
ER

PT J
AU Fan, L
   Meng, HY
   Yang, YS
   Shi, KY
   Liu, DN
   Meng, FB
AF Fan, Lin
   Meng, Heyu
   Yang, Yushuang
   Shi, Kaiyao
   Liu, Dongna
   Meng, Fanbo
TI CLINICAL SIGNIFICANCE OF DOWNREGULATED PROTEIN KINASE C IOTA (PRKCI)
   GENE IN PERIPHERAL LEUKOCYTES OF PATIENTS WITH ACUTE MYOCARDIAL
   INFARCTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Acute myocardial infarction; PRKCI gene; RNA; PRKCI protein; molecular
   labeling
ID CORONARY-ARTERY-DISEASE; STIMULATED GLUCOSE-TRANSPORT; ALLELIC VARIANTS;
   PCSK9 INHIBITORS; CELLS; EXPRESSION; CLOPIDOGREL; RISK; POLYMORPHISMS;
   TRANSLOCATION
AB Introduction: It has been accepted that gene play a role in the evolution of acute myocardial infarction (AMI). We found protein kinase C iota (PRKCI) gene had different expression in the peripheral leukocytes of patients with AMI through gene chip.
   Materials and methods: 20 AMI patients were randomly selected and set as the AMI group, and 20 healthy people were selected as the control group. The clinical data of all study subjects were recorded. 6 ml of venous blood was sampled from both two groups for ribonucleic acid (RNA) and protein extraction; reverse transcriptionpolymerase chain reaction (RT-PCR) and Western blot were then performed to detect the expression of PRKCI gene using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin as the internal reference, respectively.
   Results: There existed significant differences in low-density lipoprotein (LDL-ch) and high-density lipoprotein (HDL-ch) between the two groups. At the RNA level, the relative expression of PRKCI gene in the AMI group to the control group was 0.62 +/- 0.11 (P=0.032); at the protein level, the PRKCI protein expression in the AMI group was also significantly reduced than the control group.
   Conclusions: The low expression of PRKCI gene takes part in the development of AMI. PRKCI gene may be used as a molecular marker for the diagnosis of AMI, even treated as a therapeutic target for the clinical diagnosis and treatment of AMI patients.
C1 [Fan, Lin; Yang, Yushuang; Shi, Kaiyao; Liu, Dongna; Meng, Fanbo] Jilin Univ, China Japan Union Hosp, Dept Cardiovasc Med, 126 Xiantai St, Jilin 130033, Jilin, Peoples R China.
   [Fan, Lin] Soochow Univ, Affiliated Hosp 1, Echocardiog Dept, Suzhou 215006, Peoples R China.
   [Meng, Heyu] Yanbian Univ, Med Coll, Yanji 133000, Peoples R China.
RP Meng, FB (corresponding author), Jilin Univ, China Japan Union Hosp, Dept Cardiovasc Med, 126 Xiantai St, Jilin 130033, Jilin, Peoples R China.
EM docfanbomeng@126.com
FU Excellent Talent Projects in New Century of Ministry of Education;
   Projects of Jilin Provincial Science and Technology Department
   [20090734]; Projects of Jilin Provincial Department of Finance [2012009]
FX This study was funded by the Excellent Talent Projects in New Century of
   Ministry of Education (2008), Projects of Jilin Provincial Science and
   Technology Department in 2009 (20090734), and Projects of Jilin
   Provincial Department of Finance in 2012 (2012009), and special
   acknowledgements should be given to Professor Zhihui Zhao and his
   research team for their technical guidance.
CR Abid K, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/792679
   Albert CJ, 1999, AM J PHYSIOL-HEART C, V276, pH642, DOI 10.1152/ajpheart.1999.276.2.H642
   Almontashiri NAM, 2015, CIRCULATION, V132, P1969, DOI 10.1161/CIRCULATIONAHA.114.015023
   Baine MJ, 2012, CANCER BIOMARK, V11, P1, DOI 10.3233/CBM-2012-0260
   Bandyopadhyay G, 2000, ENDOCRINOLOGY, V141, P4120, DOI 10.1210/en.141.11.4120
   Bandyopadhyay G, 2004, MOL ENDOCRINOL, V18, P373, DOI 10.1210/me.2003-0087
   Broeckel U, 2002, NAT GENET, V30, P210, DOI 10.1038/ng827
   Fan L, 2015, J AM COLL CARDIOL, V66, pC5, DOI 10.1016/j.jacc.2015.06.044
   Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015
   Gremmel T, 2013, INT J CARDIOL, V166, P126, DOI 10.1016/j.ijcard.2011.10.010
   Gu XD, 2015, CHINESES LAB DIAGNOS, V6, P977
   Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842
   Hu KL, 1996, CIRC RES, V78, P492, DOI 10.1161/01.RES.78.3.492
   Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6
   Khademi Khadijeh Golabgir, 2016, Iranian Biomedical Journal, V20, P122, DOI 10.7508/ibj.2016.02.008
   Korkor MT, 2011, INT J MED SCI, V8, P168, DOI 10.7150/ijms.8.168
   LIU YG, 1994, J MOL CELL CARDIOL, V26, P661, DOI 10.1006/jmcc.1994.1078
   Luscher TF, 2015, EUR HEART J, V36, P2965, DOI 10.1093/eurheartj/ehv576
   McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447
   NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0
   Qaseem A, 2012, ANN INTERN MED, V157, P729, DOI 10.7326/0003-4819-157-10-201211200-00010
   Rehman KU, 2015, EXP THER MED, V10, P309, DOI 10.3892/etm.2015.2493
   Schunkert H, 2010, EUR HEART J, V31, P918, DOI 10.1093/eurheartj/ehq038
   SPEECHLYDICK ME, 1994, CIRC RES, V75, P586, DOI 10.1161/01.RES.75.3.586
   Takahashi P, 2014, GENE, V539, P213, DOI 10.1016/j.gene.2014.01.075
   Varenhorst C, 2009, EUR HEART J, V30, P1744, DOI 10.1093/eurheartj/ehp157
   Wang M, 2015, GENE, V571, P245, DOI 10.1016/j.gene.2015.06.070
   Whayne TF, 2016, AM J CARDIOVASC DRUG, V16, P83, DOI 10.1007/s40256-015-0150-3
   Zeng Q, 2013, CAN J CARDIOL, V29, P940, DOI 10.1016/j.cjca.2012.11.028
   Zhang Y, 2015, CYTOKINE, V76, P356, DOI 10.1016/j.cyto.2015.06.015
NR 30
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 313
EP 319
DI 10.19193/0393-6384_2018_2_50
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400004
DA 2022-07-14
ER

PT J
AU Fan, SY
   Fan, SH
   Wu, WJ
AF Fan, Shuying
   Fan, Shaohua
   Wu, Wenjing
TI USEFULNESS OF A NOVEL THREE DIMENTIONAL ELECTROCARDIOGRAPHY SYSTERM IN
   PATIENTS WITH PRIOR MYOCARDIAL INFARCTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE myocardial infarction; prior; 3-dimensional; Electrocardiography; 3D;
   ECG
AB Introduction: This study aims to understand the usefulness of a novel noninvasive 3-dimensional electrocardiography system (3D-ECG) in the diagnosis of prior myocardial infarction.
   Material and methods: 212 patients with more than 1 month history of acute myocardial infarction were selected as prior myocardial infarction group (PMI). 88 patients without myocardial infarction were selected as control group (NPMI). Electrocardiograph and 3D-ECG were applied on all patients in order.
   Results: Comparison between 3D-ECG and ECG was accomplished in 212 prior myocardial patients and 88 non myocardial patients. 3D-ECG correctly diagnosed prior myocardial infarction in 210 of 212 (99%)PMI and non myocardial infarction in 84 of 88 (95%) NPMI, while ECG diagnosed prior myocardial infarction in 132 of 212 (62%) PMI and non myocardial infarction in 84 of 88 (95%) NPMI. 3D-ECG misdiagnosed prior myocardial infarction in 2 of 212 (0.9%) PMI and non myocardial infarction in 4 of 88 (4.5%) NPMI while ECG misdiagnosed prior myocardial infarction in 80 of 212 (37.7%) PMI and non myocardial infarction in 84 of 88 (4.5%) NPMI.
   Discussion: The study shows a high success rate of 3D-ECG in accurately diagnosing the prior myocardial infarction comparing with ECG and its application to diagnose prior myocardial infarction is under the way.
C1 [Fan, Shuying; Wu, Wenjing] China Japan Friendship Hosp, Dept Cardiol, Beijing 100029, Peoples R China.
   [Fan, Shaohua] Shandong Univ, Jinan Cent Affiliated Hosp, Dept Crit Care Med, Jinan 250013, Shandong, Peoples R China.
RP Fan, SY (corresponding author), China Japan Friendship Hosp, Dept Cardiol, Beijing 100029, Peoples R China.
CR Bonakdar H, 2016, ANATOL J CARDIOL, V16, P106, DOI 10.5152/akd.2015.5887
   Dubois R, 2016, IEEE J TRANSL ENG HE, V5
   George E B, 1964, YB MED, V309
   Haissaguerre M, 2016, J PHYSIOL-LONDON, V594, P2387, DOI 10.1113/JP270617
   Iglesias DS, 2017, IEEE J TRANSL ENG HE, V5, DOI 10.1109/JTEHM.2016.2634006
   Janousek O, 2010, PHYSIOL RES, V59, pS51, DOI 10.33549/physiolres.932013
   Reddy K, 2015, WORLD J CARDIOL, V7, P243, DOI 10.4330/wjc.v7.i5.243
   Richardson WJ, 2015, COMPR PHYSIOL, V5, P1877, DOI 10.1002/cphy.c140067
   Shah AJ, 2014, J ATR FIBRILLATION, V7, P31
   Shah AJ, 2013, J AM COLL CARDIOL, V62, P889, DOI 10.1016/j.jacc.2013.03.082
NR 10
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1833
EP 1836
DI 10.19193/0393-6384_2018_6_282
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400033
DA 2022-07-14
ER

PT J
AU Fan, Y
   Jiang, H
AF Fan, Ying
   Jiang, Hong
TI SAFFLOWERINHIBITSCOXSACKIEVIRUS B3 INFECTION OF MYOCARDIAL MICROVASCULAR
   ENDOTHELIAL CELLSVIA THE TOLL-LIKE RECEPTOR 4/NUCLEAR FACTOR KAPPA B
   SIGNALING PATHWAY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Safflower yellow B; Coxsackievirus B3; Toll-like receptor 4/Nuclear
   factor kappa B; Myocarditis
ID SAFFLOWER OIL; INJURY; ACID
AB Introduction: Infections caused by different pathogens can lead to cardiovascular diseases such as acute/chronic myocarditis. Coxsackievirus B3 (CVB3) is the most common causative agent of myocarditis, which can result in dilated cardiomyopathy. Here we investigated the mechanism by which safflower yellow B (SYB) inhibitsthe CVB3 infection of myocardial microvascular endothelial cells.
   Materials and methods: CVB3 infected myocardial microvascular endothelial cells was detected by TCID50. The CVB3 activated the TLR4/NF-&B pathway in myocardial microvascular endothelial cells was detected by Western blotting. And the which safflower yellow B (SYB) inhibitsthe CVB3 infection of myocardial microvascular endothelial cells was detected by Western blotting.
   Results: SYB inhibited CVB3 infection via the toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-kappa B) signaling pathway. Furthermore, the median tissue culture infective dose of CVB3 was higher in infected cells than in thosetreated with SYB.
   Conclusion: We showed that SYB inhibited the CVB3 infection of myocardial microvascular endothelial cellsviathe TLR4/NF kappa B signaling pathway. These findings may lead to new insights on the treatment of CVB3-induced myocarditis by SYB.
C1 [Fan, Ying; Jiang, Hong] Wuhan Univ, Renmin Hosp, Wuhan, Hubei, Peoples R China.
RP Jiang, H (corresponding author), Wuhan Univ, Renmin Hosp, Wuhan, Hubei, Peoples R China.
EM hongjiangwh@126.com
CR Avlas O., 2016, EXP CELL RES
   Bouin A, 2016, EMERG INFECT DIS, V22, P1488, DOI 10.3201/eid2208.160186
   Camas N, 2006, HEREDITAS, V143, P55, DOI 10.1111/j.2006.0018-0661.01914.x
   Chen P., 2016, J DIFFER EQU, V2016, P1, DOI DOI 10.1061/(ASCE)GT.1943-5606.0001598
   Compes E, 2006, ALLERGY, V61, P1239, DOI 10.1111/j.1398-9995.2006.01138.x
   Damsky WE, 2016, PEDIATR DERMATOL, V33, pE140, DOI 10.1111/pde.12769
   Freitas MS, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01003
   Jiang Y, 2015, INTERVIROLOGY, V58, P343, DOI 10.1159/000442588
   Laxmivandana R, 2016, J GEN VIROL, V97, P694, DOI 10.1099/jgv.0.000391
   Lee YS, 2009, INT J MOL SCI, V10, P292, DOI 10.3390/ijms10010292
   Li DD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140218
   Li RY, 2016, PHYTOMEDICINE, V23, P1012, DOI 10.1016/j.phymed.2016.06.010
   Liu CC, 2016, ANTIVIR RES, V129, P58, DOI 10.1016/j.antiviral.2016.02.008
   Ma ZY, 2016, INT J MOL MED, V37, P603, DOI 10.3892/ijmm.2016.2462
   Minami A, 2002, BRIT J NUTR, V87, P157, DOI 10.1079/BJN2001496
   Muller HDHD, 2016, BMC ORAL HEALTH, V17, DOI 10.1186/s12903-016-0229-5
   Norris LE, 2009, AM J CLIN NUTR, V90, P468, DOI 10.3945/ajcn.2008.27371
   Plociennikowska A., 2016, J LEUKOC BIOL
   Qi M, 2016, PHARMACOL RES, V111, P509, DOI 10.1016/j.phrs.2016.07.016
   Raina SN, 2005, J HERED, V96, P424, DOI 10.1093/jhered/esi041
   Smilde BJ, 2016, INT J CARDIOL, V216, P58, DOI 10.1016/j.ijcard.2016.04.144
   Wang Y, 2016, MBIO, V7, DOI 10.1128/mBio.00119-16
   Yamazaki T, 2007, HEPATOLOGY, V46, P1779, DOI 10.1002/hep.21934
   Yu Y., 2016, SPRINGERPLUS, V5, P1, DOI DOI 10.7554/
   Zhu HS, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0418-x
NR 25
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 367
EP 371
DI 10.19193/0393-6384_2018_2_57
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400011
DA 2022-07-14
ER

PT J
AU Fang, B
   Ye, DL
   Li, H
AF Fang Bao
   Ye Deli
   Li Heng
TI CORRELATION BETWEEN CHANGES IN SERUM TNF-A, IL-6 AND CRP, AND SEVERITY
   OF CRANIOCEREBRAL INJURY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Dynamic Changes; TNF-A; IL-6; CRP Of Serum; Craniocerebral injury
ID NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; INFLAMMATION; BRAIN
AB Objective: To study correlations between changes in serum TNF-alpha, IL-6 and CRP in craniocerebral injury patients, and severity of craniocerebral injury.
   Methods: A total of 120 craniocerebral injury patients were classified as slight, moderate, and severe, according to degree of craniocerebral injury, with 46, 38 and 36 cases, respectively. The control group comprised 35 healthy volunteers who were physically examined in our hospital. Serum levels of TNF-alpha, IL-6 and CRP as a function of time (1 day, 3 days, and 7 days) after craniocerebral injury, were monitored with ELISA kits.
   Results: Serum levels of TNF-alpha, IL-6 and CRP in the slight, moderate and severe craniocerebral injury patients at the three time intervals after injury were significantly higher than corresponding values in the control group (p < 0.05). Serum TNF-alpha, IL-6 and CRP levels in severe injury group were significantly higher than their levels in the slight and moderate groups on days 1, 3 and 7 after injury, and their levels in the slight craniocerebral injury group were lower than in the medium group at the same time points (p < 0.05). Serum levels of TNF-alpha, IL-6 and CRP levels at the three time points after injury had positive correlations with degree of injury
   Conclusion: These results indicate that craniocerebral injury patients have elevated serum TNF-alpha, IL-6 and CRP levels, which levels vary in direct proportion to the severity of injury.
C1 [Fang Bao] Zhejiang Kaihua Clin Lab Ctr, Kaihua, Zhejiang, Peoples R China.
   [Ye Deli] Zhejiang Prov Peoples Hosp, 158 Shang Tang Rd, Hangzhou 310014, Zhejiang, Peoples R China.
   [Li Heng] Changchun Univ Tradit Chinese Med, Affiliated Hosp, Dept Pediat, Changchun, Jilin, Peoples R China.
RP Ye, DL (corresponding author), Zhejiang Prov Peoples Hosp, 158 Shang Tang Rd, Hangzhou 310014, Zhejiang, Peoples R China.
EM jz1349@163.com
CR Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7
   Keller CW, 2011, J BIOL CHEM, V286, P3970, DOI 10.1074/jbc.M110.159392
   Krakauer Teresa, 2004, Current Drug Targets - Inflammation and Allergy, V3, P317
   Liang M, 2013, CHINESE J PRACTICAL, V16, P3
   Lin ZJ, 2010, SHANDONG MED J, V50, P81
   Lumsden JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020775
   Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575
   Pearson TA, 2009, AM J CARDIOL, V103, P369, DOI 10.1016/j.amjcard.2008.09.090
   Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6
   Vermeij JD, 2013, J NEUROTRAUM, V30, P2073, DOI 10.1089/neu.2013.3060
   Weaver-Mikaere L, 2013, DEV NEUROSCI-BASEL, V35, P461, DOI 10.1159/000354862
   Xie CJ, 2014, CHINESE J NEUROSURG, V13, P200
   Zhao WH, 2013, CHIN J PRACT NERVOUS, V16, P22
   Zhu Tao, 2004, Chin J Traumatol, V7, P32
   Zhu XL, 2011, SURG HUANG JIASI, P829
NR 15
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1121
EP 1124
DI 10.19193/0393-6384_2018_4_172
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500035
DA 2022-07-14
ER

PT J
AU Fayyaz, N
   Mohebbi, M
   Milani, E
AF Fayyaz, Nasrin
   Mohebbi, Mohebbat
   Milani, Elnaz
TI EFFECT OF GERMINATION ON NUTRIENTS, MINERAL, PHYTIC ACID AND ENZYME
   ACTIVITY OF MUNG BEAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE mung bean; germination; response surface methodology (RSM); phytic acid;
   enzyme activity
ID IN-VITRO IRON; ANTINUTRITIONAL FACTORS; PROTEIN DIGESTIBILITY; CALCIUM;
   WHEAT; ZINC; ANTINUTRIENTS; FERMENTATION; ANTIOXIDANT; SOAKING
AB Background and objective: temperatures ( 10, 22.5 and 35 degrees C) to determine the changes in their chemical composition, enzyme activity, as well as minerals and phytic acid content. The results show a significant increase in germination temperature, total protein, and fat content (p <= 0.05). The optimum condition for germination of mung bean was defined as soaking for 48h, followed by germination at 35 degrees C for 3 days. Under this condition, the predicted values for crude protein, ash, fat and crude fiber contents were 31.93, 3.976, 1 and 5% dry basis, respectively. Mineral contents of mung bean increased during germination. It can be concluded that sprouting improved the nutritional worth of the mung bean in terms of more nutrients content, less phytic acid content as well as increase in enzyme activity and protein content.
C1 [Fayyaz, Nasrin; Milani, Elnaz] Ferdowsi Univ Mashhad, Fac Agr, Dept Food Sci Ind, Int Campus, Mashhad, Iran.
   [Mohebbi, Mohebbat] ACECR, Food Sci & Technol Res Inst, Food Proc Dept, Mashhad Iran, Iran.
RP Mohebbi, M (corresponding author), Ferdowsi Univ Mashhad, Fac Agr, Dept Food Sci Ind, Int Campus, Mashhad, Iran.
EM m-mohebbi@um.ac.ir
RI mohebbi, mohebbat/P-4802-2015
OI mohebbi, mohebbat/0000-0002-3475-3049
CR AKPAPUNAM MA, 1985, QUAL PLANT, V35, P353, DOI 10.1007/BF01091780
   Anjum NA, 2011, RUSS J PLANT PHYSL+, V58, P92, DOI 10.1134/S1021443710061019
   [Anonymous], J AGR FOOD CHEM, V24, P1126
   Barros M, 2010, BRAZ J CHEM ENG, V27, P15, DOI 10.1590/S0104-66322010000100002
   Barry V., 2002, J AOAC INT, V85, P5
   Caraban A., 2012, EUR R DEV
   CHUNG TY, 1998, PLANT FOOD HUM NUTR, V39, P267
   Dongyan T., 2014, CHEM CENTRAL J, V8, P4
   Dost K, 2006, ANAL CHIM ACTA, V558, P22, DOI 10.1016/j.aca.2005.11.035
   El-Adawy T.A., 2003, PLANT FOOD HUM NUTR, V58, P1, DOI [10.1023/B:QUAL.0000040339.48521.75, DOI 10.1023/B:QUAL.0000040339.48521.75]
   Eyzaguirre RZ, 2006, J SCI FOOD AGR, V86, P1391, DOI 10.1002/jsfa.2527
   Firestone D, 1990, OFFICIAL METHODS ANA
   Ghavidel RA, 2007, LWT-FOOD SCI TECHNOL, V40, P1292, DOI 10.1016/j.lwt.2006.08.002
   Gokmen V, 2007, CEREAL CHEM, V84, P290, DOI 10.1094/CCHEM-84-3-0290
   Gujral HS, 2011, INT J FOOD PROP, V14, P1366, DOI 10.1080/10942911003672167
   Johnson R., 2007, COLLBY J RES METH, V9, P11
   Jung G. H., 2005, KOREAN J FOOD PRESER, V4, P538
   Kanatt SR, 2011, FOOD RES INT, V44, P3182, DOI 10.1016/j.foodres.2011.08.022
   Kaushik G, 2010, MEDITERR J NUTR META, V3, P39, DOI 10.1007/s12349-009-0079-7
   Khatoon N, 2006, FOOD CHEM, V97, P115, DOI 10.1016/j.foodchem.2005.03.007
   Khattak A. B., 2008, American Journal of Food Technology, V3, P24
   Kim S. D., 1993, INT J FOOD SCI NUTR, V51, P301
   Lee YR, 2007, FOOD SCI BIOTECHNOL, V16, P1006
   Liang JF, 2008, FOOD CHEM, V110, P821, DOI 10.1016/j.foodchem.2008.02.064
   LUKOW OM, 1984, CEREAL CHEM, V61, P336
   Luo YW, 2014, CYTA-J FOOD, V12, P22, DOI 10.1080/19476337.2013.782071
   Luo YW, 2013, CYTA-J FOOD, V11, P318, DOI 10.1080/19476337.2012.757756
   Luo YW, 2013, CYTA-J FOOD, V11, P43, DOI 10.1080/19476337.2012.681705
   MARSH SJ, 1988, J SCI FOOD AGR, V45, P175, DOI 10.1002/jsfa.2740450209
   Min L, 2001, SHANGHAI J TRAD CHIN, V5, P18
   Mosaddegh Mehrjardi M. H., 2014, J FOOD QUALITY HAZAR, V1, P29
   Mousavi Babak, 2014, WHEAT CONDITIONING B, P84156
   Mubarak AE, 2005, FOOD CHEM, V89, P489, DOI 10.1016/j.foodchem.2004.01.007
   Nonogaki H., 2010, PLANT SCI, DOI [10.1016/PlantScience.02.010, DOI 10.1016/PLANTSCIENCE.02.010]
   OBIZOBA IC, 1991, PLANT FOOD HUM NUTR, V41, P21, DOI 10.1007/BF02196378
   Park D. Y., 1986, KOREAN J FOOD SCI TE, V18, P162
   Rahman M. M., 2007, Bangladesh Journal of Scientific and Industrial Research, V42, P213
   Rose DJ, 2006, J AM OIL CHEM SOC, V83, P415, DOI 10.1007/s11746-006-1220-0
   SATTAR A, 1989, FOOD CHEM, V34, P111, DOI 10.1016/0308-8146(89)90079-4
   Shah SA, 2011, AFR J AGR RES, V6, P5091
   Singh H, 2001, J FOOD ENG, V47, P23, DOI 10.1016/S0260-8774(00)00094-7
   SURREY K, 1964, PLANT PHYSIOL, V39, P65, DOI 10.1104/pp.39.1.65
   Sweta Kumari, 2014, Australian Journal of Crop Science, V8, P1168
   Urbano G, 2005, NUTRITION, V21, P230, DOI 10.1016/j.nut.2004.04.025
   Vidal-Valverde C, 2003, J SCI FOOD AGR, V83, P298, DOI 10.1002/jsfa.1309
NR 45
TC 4
Z9 4
U1 9
U2 29
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 2
BP 597
EP 605
DI 10.19193/0393-6384_2018_2s_94
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7SD
UT WOS:000429274400008
DA 2022-07-14
ER

PT J
AU Fazeli, A
   Aminkhandaghi, M
   Rezvani, MS
   Karami, M
AF Fazeli, Ahmadreza
   Aminkhandaghi, Maghsoud
   Rezvani, Mahmood Saeedy
   Karami, Morteza
TI THE NATURE OF IDEOLOGY AND EXPLANATION OF ITS IMPLICATIONS FOR
   CURRICULUM
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE nature; ideology; curriculum; curriculum ideology
AB Ideology is as major influence on the social implications of the social sciences, particularly education system and curriculum in each country. The aim of this study was to determine the nature of ideology and its semantics implies that the curriculum is. Definitions of ideology is discussed, examined and analyzed their nature and in terms of genus and three general categories, picked up the scientific or epistemological, social withdrawal or sociological and cultural perceptions were divided. the basic principles of curriculum and originally known books such as efficiency, control and predict the exact purpose of the center is, the accurate prediction purposes, logically organize content and other elements of the curriculum is effective. Based on the social conception of ideology, an important source of design and curriculum development is community and community needs and curriculum are designed around social issues. The basic objective of the curriculum preparing students for life in society, labor market and interact constructively with others. Based on the cultural perception of the nature of ideology, culture and customs curriculum according to design and develop the culture of each region and environment, in other words, context-based and position-based curriculum is being completely that not all of the objectives, content and other elements of the curriculum was designed and developed. The curriculum and its elements can not be determined in advance but only a general framework curriculum is determined and this type of curriculum requires teachers with academic and professional qualifications high level that they can play a role in programming.
C1 [Fazeli, Ahmadreza] Ferdowsi Univ Mashhad, Curriculum Studies, Mashhad, Iran.
   [Aminkhandaghi, Maghsoud; Rezvani, Mahmood Saeedy; Karami, Morteza] Ferdowsi Univ Mashhad, Fac Educ & Psychol, Curriculum Studies, Mashhad, Iran.
RP Aminkhandaghi, M (corresponding author), Ferdowsi Univ Mashhad, Fac Educ & Psychol, Curriculum Studies, Mashhad, Iran.
EM aminkhandaghi@ferdowsi.um.ac.ir
RI Rahimian, Yaser/ABC-9678-2021; Rezvani, Mahmood Saeedy/AAA-5189-2021
OI Rezvani, Mahmood Saeedy/0000-0001-9553-9380
CR Akarsu B., 2012, EUROPEAN J PHYS ED, V3, P36
   Alexander HA, 2005, J MORAL EDUC, V34, P1, DOI 10.1080/03057240500049216
   Alipour M., 2002, ANAL CONCEPT IDEOLOG
   Duncan G., 1987, UNDERSTANDING IDEOLO, P659
   Eisner E.W., 1994, ED IMAGINATION
   Ferreira S., 2008, 5 INT BAS BERNST S C
   Larrain J., 1979, CONCEPT IDEOLOGY
   Littledyke M., 1996, CURRICULUM STUDIES, V4, P119, DOI DOI 10.1080/0965975960040107
   MCCARTHY ED, 1994, SOCIOL QUART, V35, P415, DOI 10.1111/j.1533-8525.1994.tb01736.x
   Mehrmohammadi M., 2009, CURRICULUM PERSPECTI
   Musgrave P. W., 1972, MELBOURNE STUDIES ED, P124
   Musgrove F., 1987, CURRICULUM STUDIES, V2, P99
   SARGENT LT, 2009, CONT POLITICAL IDEOL
   Ssentamu P. N., 2014, TUNING J HIGHER ED, V2, P129
   Tohidfam M., 2002, ROTATION IDEOLOGY
   Van Dijk T.A., 1998, IDEOLOGY MULTIDISCIP
   Walton D., 2009, STUDIES LOGIC GRAMMA, V16, P245
   Yerli A. H., 2008, THESIS
   [No title captured]
NR 19
TC 0
Z9 0
U1 6
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 2
BP 549
EP 553
DI 10.19193/0393-6384_2018_2s_87
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7SD
UT WOS:000429274400001
DA 2022-07-14
ER

PT J
AU Feng, Z
   Wu, WN
   Zhang, QZ
   Wei, JQ
   Gu, R
   Wang, Y
AF Feng Zhen
   Wu Weina
   Zhang Qingzhu
   Wei Junqiang
   Gu Rui
   Wang Yan
TI EXPRESSION OF STIM1 AND ONTOGENETIC DIFFERENTIATION-RELATED FACTORS IN
   BONE MARROW STROMAL STEM CELLS OF POST-MENOPAUSAL OSTEOPOROSIS PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Post-menopausal osteoporosis; Borte marrow stromal stem cells; Stromal
   interaction molecule-1; Ca(2+)channel
ID MANAGEMENT; BMSCS
AB Objective: To study the expressions of stromal interaction molecule-1 (STIM1) and other ontogenetic differentiation-related factors in bone marrow stromal stem cells (BMSCs) of post-menopausal osteoporosis patients.
   Methods: Bone marrow stromal stem cells (BMSCs) from post-menopausal osteoporosis patients were cultured in the presence of osteogenic induction for 14 days. Ca2+ concentration and Ca2+ release activated Ca2+ channel (CRAC) were analyzed using Fluo-3 staining before and after osteogenic induction, respectively. In addition, the expressions of STIM1 and other osteogenic differentiation-related factors (ALP, OPN, and OCN) were measured by quantitative real time PCR. Total RNA was extracted from cultures at the start of osteogenic induction and after 7 and 14 days. The BMSCs were stained for alkaline phosphatase (ALP) on day 7.
   Results: BMSCs were successfully cultured after 14-day osteogenic induction. The expressions of STIM1 and other osteogenic differentiation related factors (ALP, OPN, and OCN) were lower than those in normal control (p < 0.05). Similarly, when compared with the normal control cells, ALP staining was significantly reduced in post-menopausal osteoporosis. The expression of STIM1 was reduced after 14-day osteogenic induction, and Ca2+ concentration was significantly reduced in BMSCs of osteoporosis patients (p < 0.05).
   Conclusion: These results suggest that STIM1 in BMSCs contribute to post-menopausal osteoporosis. This could provide a new research direction on therapeutic strategy for osteoporosis.
C1 [Feng Zhen; Zhang Qingzhu; Wei Junqiang; Wang Yan] Chengde Med Univ, Affiliated Hosp, Traumat Orthoped, Chengde, Hebei, Peoples R China.
   [Wu Weina] Chengde Med Univ, Affiliated Hosp, Dept Radiol, Chengde, Hebei, Peoples R China.
RP Wang, Y (corresponding author), Chengde Med Univ, Affiliated Hosp, Dept Radiol, Chengde, Hebei, Peoples R China.; Wang, Y (corresponding author), Chengde Med Coll, South Wing Hosp, Chengde City 067000, Hebei, Peoples R China.
EM afvvf0@163.com
CR Abouzaripour M, 2016, CELL J, V17, P701
   Andreopoulou P, 2015, ANNU REV MED, V66, P329, DOI 10.1146/annurev-med-070313-022841
   Hannafon F, 2014, J GERONTOL NURS, V40, P10, DOI 10.3928/00989134-20140204-01
   Hashimoto Ryota, 2010, Ann Vasc Dis, V3, P117, DOI 10.3400/avd.AVDoa01008
   Liu ST, 2017, SCI REP-UK, V7, DOI 10.1038/srep46731
   Migliaccio S, 2013, AGING CLIN EXP RES, V25, pS117, DOI 10.1007/s40520-013-0106-x
   Pan HH, 2017, COLLOID SURFACE B, V152, P344, DOI 10.1016/j.colsurfb.2017.01.039
   Qian DH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00629-3
   Shu QM, 2017, ONCOTARGET, V8, P28431, DOI 10.18632/oncotarget.16085
   TANG Y, 2017, SCI REP, V7
   Wang YJ, 2017, CHEM-BIOL INTERACT, V271, P39, DOI 10.1016/j.cbi.2017.04.024
   Wilkins CH, 2005, AM J MED, V118, P1190, DOI 10.1016/j.amjmed.2005.06.046
   Xue JJ, 2017, ACS APPL MATER INTER, V9, P12299, DOI 10.1021/acsami.7b00882
   Yang F, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12422
   Zhao Q, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172954
NR 15
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 853
EP 857
DI 10.19193/0393-6384_2018_3_129
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000034
DA 2022-07-14
ER

PT J
AU Feola, A
   Giugliano, P
   La Sala, F
   Buonomo, C
   Della Pietra, B
AF Feola, Alessandro
   Giugliano, Pasquale
   La Sala, Francesco
   Buonomo, Carmela
   Della Pietra, Bruno
TI FATAL HEMORRHAGE FROM ARTERIOVENOUS DIALYSIS ACCESS SITE: A CASE REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hemodialysis; Cronic Kidney Disease; fatal vascular access hemorrhage
AB Introduction: Surgical arteriovenous fistula is necessary to hemodialysis in order to have a continuous access to circulation. Complications related to a vascular access are aneurysms, vascular steal syndrome, venous hypertension, bleeding, infections and neurological disorders. The breakthrough bleeding of the fistula is a rare, but fatal, complication.
   Case presentation: The Authors describe the case of a 53-year-old woman, suffering from cronic kidney disease (stage 5) with lateral arteriovenous fistula between the brachial artery and the median basilic vein, died after hemorrhage for rupture of the fistula. Autopsy revealed traumatic mechanism as genesis of fatal bleeding.
   Conclusion: In case of fatal breakthrough bleeding of the fistula the forensic pathologist has to determine whether it is accidental event or otherwise to assess eventually liability in determining death.
C1 [Feola, Alessandro] Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.
   [Giugliano, Pasquale; Buonomo, Carmela] AORN St Anna & San Sebastiano, Via Palasciano, I-81100 Caserta, Italy.
   [La Sala, Francesco; Della Pietra, Bruno] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via L Armanni 5, I-80138 Naples, Italy.
RP Feola, A (corresponding author), Via Montpellier 1, I-00133 Rome, Italy.
EM alessandro.feola@icloud.com
RI Feola, Alessandro/AAI-4601-2020
OI Feola, Alessandro/0000-0002-9666-2636; Giugliano,
   Pasquale/0000-0002-3633-8893
CR Ball LK, 2013, NEPHROL NURS J, V40, P297
   Byard Roger W, 2007, Forensic Sci Med Pathol, V3, P128, DOI 10.1007/s12024-007-0003-8
   Conte G, 2014, G ITAL NEFROL, V31, P1
   Ellingson KD, 2012, KIDNEY INT, V82, P686, DOI 10.1038/ki.2012.185
   Fragkouli Kleio, 2012, BMC Res Notes, V5, P488, DOI 10.1186/1756-0500-5-488
   Harber M. P., 2014, PRACTICAL NEPHROLOGY
   Hill NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158765
   HODDE L A, 1992, Journal of Emergency Medicine, V10, P317, DOI 10.1016/0736-4679(92)90339-U
   Lazarides MK, 2007, J VASC SURG, V45, P420, DOI 10.1016/j.jvs.2006.10.035
   Murtagh FE, 2010, J PAIN SYMPTOM MANAG, V40, P342, DOI 10.1016/j.jpainsymman.2010.01.021
   National Kidney Foundation, 2006, UPD CLIN PRACT GUID
   Salahi H, 2006, TRANSPL P, V38, P1261, DOI 10.1016/j.transproceed.2006.02.066
   Stolic R, 2013, MED PRIN PRACT, V22, P220, DOI 10.1159/000343669
   Tattersall J, 2011, NEPHROL DIAL TRANSPL, V26, P2082, DOI 10.1093/ndt/gfr168
NR 14
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 159
EP 162
DI 10.19193/0393-6384_2018_1_26
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600026
DA 2022-07-14
ER

PT J
AU Fu, JD
   Wang, H
   Wang, L
   Li, Y
   Zhang, YG
AF Fu, Jin-Dong
   Wang, Hui
   Wang, Ling
   Li, Yao
   Zhang, Yuguo
TI A RARE MULTISYSTEM LANGERHANS CELL HISTIOCYTOSIS PRESENTED WITH
   SCLEROSING CHOLANGITIS: CASE REPORT AND LITERATURE REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Langerhans cell histiocytosis; Sclerosing cholongitis; Skin; Lung; Nail
ID PEDIATRIC LIVER-TRANSPLANTATION; ADULT PATIENT; JAUNDICE; DISEASE
AB Introduction: Langerhans cell histiocytosis is a rare disease with unknown etiology. It occurs more in children and also in adults and involves one or more organs such as skin, bone, lung, hypothalamus, posterior pituitary gland, lymph nodes and other tissues. But liver involvement is rarely reported and pathological manifestation of sclerosing chlongitis is rare.
   Metholds: We reported a case of langerhans cell histocytosis with multisystem involvement including skin, lungs, thyroid gland, rare liver, nails and possible spleen in a young adult man.
   Results: Though he developed cholestasis and came to liver disease center firstly, he was diagnosed by infiltration of Langerhans cell in the skin and thyroid gland biopsy, with pathological manifestation of sclerosing cholongitis in liver biopsy.
   Conclusion: It is a rare case with multi-organ involved.
C1 [Fu, Jin-Dong; Wang, Hui; Wang, Ling] MD Peoples Hosp Rizhao, 126 Taian RoadDonggang Dist, Rizhao 276826, Shandong, Peoples R China.
   [Li, Yao; Zhang, Yuguo] Hebei Med Univ, Hosp 3, Ziqiang Rd, Shijiazhuang 050051, Hebei, Peoples R China.
RP Wang, H (corresponding author), MD Peoples Hosp Rizhao, 126 Taian RoadDonggang Dist, Rizhao 276826, Shandong, Peoples R China.
CR Abla O, 2010, CANCER TREAT REV, V36, P354, DOI 10.1016/j.ctrv.2010.02.012
   Braier J, 2002, MED PEDIATR ONCOL, V38, P178, DOI 10.1002/mpo.1306
   Caputo R, 2004, DERMATOLOGY, V209, P335, DOI 10.1159/000080864
   Chang Karen L., 2008, V142, P383
   Desrame J, 2005, GASTROEN CLIN BIOL, V29, P300, DOI 10.1016/S0399-8320(05)80767-5
   Dina Ion, 2006, J Gastrointestin Liver Dis, V15, P57
   DIPALO S, 1988, TUMORI, V74, P593, DOI 10.1177/030089168807400518
   Doganci T, 2004, INT J DERMATOL, V43, P673, DOI 10.1111/j.1365-4632.2004.02160.x
   Feola A, 2017, ACTA MEDICA MEDITERR, V33, P55, DOI 10.19193/0393-6384_2017_1_008
   Gey T, 2004, REV MAL RESPIR, V21, P997
   GRANOT E, 1994, EUR J GASTROEN HEPAT, V6, P275, DOI 10.1097/00042737-199403000-00015
   Griffiths W, 2006, J HEPATOL, V44, P829, DOI 10.1016/j.jhep.2005.12.024
   Hadzic N, 2000, TRANSPLANTATION, V70, P815, DOI 10.1097/00007890-200009150-00019
   Kaplan KJ, 1999, MODERN PATHOL, V12, P370
   LEBLANC A, 1981, GASTROENTEROLOGY, V80, P134
   NEVEU I, 1990, ARCH FR PEDIATR, V47, P197
   Pagnoux C, 2003, REV MED INTERNE, V24, P324, DOI 10.1016/S0248-8663(03)00063-8
   PIROVINO M, 1988, LIVER, V8, P293
   RAMOS FJ, 1987, AM J MED, V82, P191, DOI 10.1016/0002-9343(87)90419-0
   Sampathkumar Sujatha, 2002, Endocr Pract, V8, P217
   Satter EK, 2008, PEDIATR DERMATOL, V25, P291, DOI 10.1111/j.1525-1470.2008.00669.x
   THOMPSON HH, 1984, GUT, V25, P526, DOI 10.1136/gut.25.5.526
   WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303
   ZANDI P, 1995, HEPATOLOGY, V21, P129, DOI 10.1002/hep.1840210122
NR 24
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 43
EP 46
DI 10.19193/0393-6384_2018_1_7
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600007
DA 2022-07-14
ER

PT J
AU Fu, N
   Liao, HW
   Fu, N
   Wen, L
   Zhou, X
   Peng, MJ
   Zhang, Q
   Cheng, JP
   Yang, XF
AF Fu, Nian
   Liao, Hong-Wu
   Fu, Nian
   Wen, Luo
   Zhou, Xu
   Peng, Meng-Jie
   Zhang, Qiao
   Cheng, Jing-Ping
   Yang, Xue-Feng
TI CYCLOOXYGENASE-2 SHORT HAIRPIN RNA IMPROVES HEPATIC FIBROSIS BY
   REGULATING THE TGFBL/SMADS SIGNAL TRANSDUCTION PATHWAY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE COX-2; Short hairpin RNA; Hepatic fibrosis; Transforming growth
   factor-beta; Smads
ID INDUCED LIVER-INJURY; STELLATE CELLS; TGF-BETA; RATS; INFLAMMATION;
   CELECOXIB
AB Cyclooxygenase-2 (COX-2) has been involved the initiation and development of hepatic fibrosis and Cirrhosis. however the mechanism within has still remained unclear. At the same time, the results of COX-2 inhibitors in experimental liver fibrosis were controversial and its side effects would limit their clinical applications. Gene silencing using short hairpin RNAs (shRNAs) is a novel and promising technology for therapeutic applications of various diseases such as hepatic fibrosis that involves upregulation of several genes. This aim of this study was to investigate the antifibrotic effects of COX-2 short hairpin RNAs(COX-2 shRNA) and whether through TGF-beta 1/smads signaling pathway to takes part in antifibrotic effects. Forty Sprague-Dawley rats were randomly divided into four groups. The rats was induced hepatic fibrosis by carbon tetrachloride(CCl4) and high fat diet for 12 weeks together with or without COX-2shRNA, and hepatic steatosis, necroinflammatory activity and fibrosis were evaluated semiquantitatively by HE dyeing and MASSON Staining according to the METAVIR scoring system. Detecting the serum cerealthirdtransaminase (ALT), aspartate transaminase (AST), total cholesterol (TC), triglycerides (TG) levels to investigate protective role of COX-2 shRNA and it whether cause damage to the liver. The mRNA and protein expression of COX-2, TGF-beta 1 and Smad1-5 were determined by reverse transcription (RT)-PCR analysis or immunohistochemistry. The results of this study found that prevention with COX-2shRNA significantly attenuated the liver steatosis, inflammatory and fibrosis, moreover, markedly reduced COX-2, TGF-beta 1/Smad1-5 mRNA and protein expression and the levels of ALT, AST, TC, TG in hepatic fibrosis rats received COX-2shRNA. These data suggest COX-2shRNA was a novel antifibrotic agent and possible through regulating the expression of COX-2 and TGF beta 1/Smads signalling pathway to improves hepatic fibrosis.
C1 [Fu, Nian; Liao, Hong-Wu; Fu, Nian; Wen, Luo; Zhou, Xu; Peng, Meng-Jie; Zhang, Qiao; Yang, Xue-Feng] Univ South China, Affiliated Nanhua Hosp, Dept Gastroenterol, Hengyang 421002, Peoples R China.
   [Cheng, Jing-Ping] China Resourses & WISCO Gen Hosp, Dept Gastroenterol Hlth Care Ctr Cadres, Wuhan 430080, Peoples R China.
RP Yang, XF (corresponding author), Univ South China, Affiliated Nanhua Hosp, Dept Gastroenterol, Hengyang 421002, Peoples R China.; Cheng, JP (corresponding author), China Resourses & WISCO Gen Hosp, Dept Gastroenterol Hlth Care Ctr Cadres, Wuhan 430080, Peoples R China.
EM 404178516@qq.com; yxf9988@126.com
FU National Natural Science Foundation of China [81373465]
FX The National Natural Science Foundation of China, Foundation Number:
   81373465
CR Bonniaud P, 2005, J IMMUNOL, V175, P5390, DOI 10.4049/jimmunol.175.8.5390
   Ekor M, 2013, DRUG CHEM TOXICOL, V36, P1, DOI 10.3109/01480545.2011.642380
   George J, 2007, GENE THER, V14, P790, DOI 10.1038/sj.gt.3302929
   Gressner AM, 2006, J CELL MOL MED, V10, P76, DOI 10.1111/j.1582-4934.2006.tb00292.x
   Lacroix I, 2004, FUND CLIN PHARMACOL, V18, P201, DOI 10.1111/j.1472-8206.2004.00224.x
   Latella G, 2009, LIVER INT, V29, P997, DOI 10.1111/j.1478-3231.2009.02011.x
   Leitao HS, 2017, RADIOLOGY, V283, P98, DOI 10.1148/radiol.2016151570
   Munoz-Felix JM, 2013, CYTOKINE GROWTH FACT
   Shen H, 2007, J CELL PHYSIOL, V212, P764, DOI 10.1002/jcp.21074
   Sysa P, 2009, DNA CELL BIOL, V28, P425, DOI 10.1089/dna.2009.0884
   Tu CT, 2007, J GASTROEN HEPATOL, V22, P877, DOI 10.1111/j.1440-1746.2007.04867.x
   Wen SL, 2014, J GASTROEN HEPATOL, V29, P1932, DOI 10.1111/jgh.12641
   Xu FY, 2016, J HISTOCHEM CYTOCHEM, V64, P157, DOI 10.1369/0022155415627681
   Yue HY, 2010, GUT, V59, P236, DOI 10.1136/gut.2008.174904
   Zan YL, 2013, BIOCHEM BIOPH RES CO, V435, P391, DOI 10.1016/j.bbrc.2013.04.098
NR 15
TC 0
Z9 0
U1 1
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 495
EP 498
DI 10.19193/0393-6384_2018_2_80
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GC0AJ
UT WOS:000429437100001
DA 2022-07-14
ER

PT J
AU Gallai, B
   Tripi, G
   Lavano, F
   Salerno, M
   Lavano, SM
   Romano, P
   Cerroni, F
   Russo, D
   Cerron, F
   D'Oro, L
   Franco, S
   Picciocchi, E
   Geraci, D
   Chisari, MG
   Polito, AN
   Sorrentino, M
   Magliulo, RM
   Di Folco, A
   Parisi, L
   Testa, D
   Murabito, P
   Marotta, R
AF Gallai, Beatrice
   Tripi, Gabriele
   Lavano, Francesco
   Salerno, Margherita
   Lavano, Serena Marianna
   Romano, Palmira
   Cerroni, Francesco
   Russo, Daniela
   Cerronia, Francesco
   D'Oro, Lucrezia
   Franco, Sabrina
   Picciocchi, Elisabetta
   Geraci, Diego
   Chisari, Mario Giuseppe
   Polito, Anna Nunzia
   Sorrentino, Michele
   Magliulo, Rosaria Martina
   Di Folco, Annabella
   Parisi, Lucia
   Testa, Davide
   Murabito, Paolo
   Marotta, Rosa
TI EATING AND FEEDING DISORDERS IN PEDIATRIC AGE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE anorexia nervosa; feeding troubles; eating disorders
ID SLEEP-APNEA SYNDROME; MONOSYMPTOMATIC NOCTURNAL ENURESIS; AUTISM
   SPECTRUM DISORDERS; WEIGHT-LOSS PROGRAM; QUALITY-OF-LIFE; CHILDHOOD
   MIGRAINE; KETOGENIC DIET; PARENTAL STRESS; OBESE CHILDREN; OREXIN SYSTEM
AB Eating and feeding disorders are common in pediatric. age and may be important to discover and recover the early symptoms in order to optimize the treatment and management.
C1 [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Lavano, Francesco; Lavano, Serena Marianna; Marotta, Rosa] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Cerroni, Francesco; Cerronia, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Di Folco, Annabella; Parisi, Lucia; Testa, Davide] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [D'Oro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Franco, Sabrina; Geraci, Diego] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, I-95123 Catania, Italy.
   [Picciocchi, Elisabetta] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Chisari, Mario Giuseppe] INPS, Catania, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Sorrentino, Michele] NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp, Castel Volturno, CE, Italy.
   [Magliulo, Rosaria Martina] Ctr Studi Scoliosi SRL, Naples, Italy.
RP Parisi, L (corresponding author), Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Cerroni, Francesco/0000-0003-3024-5482; Murabito,
   Paolo/0000-0002-2662-1898; Marotta, Rosa/0000-0003-0515-5952
CR Albenzio M, 2018, J DAIRY SCI, V101, P4842, DOI 10.3168/jds.2017-13104
   Albenzio M, 2016, J DAIRY SCI, V99, P5032, DOI 10.3168/jds.2015-10704
   Albenzio M, 2017, NUTRIENTS IN DAIRY AND THEIR IMPLICATIONS FOR HEALTH AND DISEASE, P435, DOI 10.1016/B978-0-12-809762-5.00034-6
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   BRYANTWAUGH R, 1995, J CHILD PSYCHOL PSYC, V36, P191, DOI 10.1111/j.1469-7610.1995.tb01820.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00188
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2017, EUR J PHYS REHAB MED, V53, P643, DOI 10.23736/S1973-9087.16.04037-5
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Gallelli Luca, 2017, Microrna, V6, P152, DOI 10.2174/2211536606666170913152821
   Gigante E, 2018, ACTA MEDICA MEDITERR, V34, P1295, DOI 10.19193/0393-6384_2018_5_199
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P769, DOI 10.19193/0393-6384_2017_5_113
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P729, DOI 10.19193/0393-6384_2017_5_107
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P737, DOI 10.19193/0393-6384_2017_5_108
   Matricardi S, 2018, ACTA NEUROL SCAND, V137, P575, DOI 10.1111/ane.12902
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSL, V8
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Smirni D, 2018, J NERV MENT DIS, V206, P628, DOI 10.1097/NMD.0000000000000853
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P1271, DOI 10.19193/0393-6384_2018_5_196
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2018, ACTA NEUROL SCAND, V138, P523, DOI 10.1111/ane.13006
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 91
TC 0
Z9 0
U1 2
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2125
EP 2133
DI 10.19193/0393-6384_2018_4s_327
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900007
DA 2022-07-14
ER

PT J
AU Gao, BL
   Zhang, XJ
   Hao, WL
   Fan, QY
   Li, CH
   Yang, ST
AF Gao, Bu-Lang
   Zhang, Xue-Jing
   Hao, Wei-Li
   Fan, Qiong-Ying
   Li, Cong-Hui
   Yang, Song-Tao
TI ENDOVASCULAR TREATMENT OF CAROTID-CAVERNOUS FISTULAS WITH LONG-TERM
   FOLLOW-UP: FROM BALLOON DEPLOYMENT TO STENT-GRAFT PARENT ARTERY
   RECONSTRUCTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Direct carotid-cavernous fistula; Endovascular treatment; Detachable
   balloon; Covered stent; Follow-up
ID COVERED STENT; ARTERIOVENOUS-MALFORMATIONS; INTRACRANIAL VASCULATURE;
   DETACHABLE BALLOONS; PSEUDOANEURYSMS; MANAGEMENT; PLACEMENT;
   IMPLANTATION; ASSOCIATION; EXPERIENCE
AB Introduction: The long-term effect of endovascular treatment for traumatic direct carotid-cavernous fistulas (CCF) and this study served this purpose with the focus on the initial balloon deployment to stent-graft parent artery reconstruction.
   Materials and methods: Between 1999 and 2012, 32 patients with traumatic direct CCFs were treated endovascularly at our institution and retrospectively analyzed. All patients had cerebral angiography for the diagnosis of CCF. Treatment modalities included balloon occlusion of the CCF, sacrifice of the ipsilateral internal carotid artery (ICA) with detachable balloons, coil embolization of the CCF and secondary pseudoaneurysms, and covered-stent reconstruction of the parent artery.
   Results: All patients were successfully managed endovascularly. Three patients were initially treated with ICA sacrifice, 19 with detachable balloons or coils, and the remaining 10 with a covered stent. At angiographic follow-up (2-24 months), four (21.1%) of the 19 patients treated with detachable balloons and coils developed a pseudoaneurysm after occlusion of the CCF, and four (21.1%) patients recurred and were retreated with ICA sacrifice in three and coil embolization in one. In total, 29 embolization procedures were performed for the 19 patients with detachable balloons or coils, and six (27.3%) patients experienced permanent ICA occlusion before the application of the covered stent. Of 10 patients with covered stents, four patients initially failed detachable balloon deployment. Clinical follow-up (12-72 months) revealed complete occlusion of all the CCFs with no recurrence of CCF symptoms and signs.
   Conclusion: Traumatic direct CCFs can be successfully managed endovascularly with increasingly better effects from detachable balloons to covered stent reconstruction of ICA.
C1 [Gao, Bu-Lang; Zhang, Xue-Jing; Hao, Wei-Li; Fan, Qiong-Ying] Hebei Med Univ, Shijiazhuang Hosp 1, Dept Med Res, 36 Fanxi Rd, Shijiazhuang 050011, Hebei, Peoples R China.
   [Gao, Bu-Lang; Li, Cong-Hui; Yang, Song-Tao] Hebei Med Univ, Shijiazhuang Hosp 1, Dept Neurosurg, Shijiazhuang, Hebei, Peoples R China.
RP Gao, BL (corresponding author), Hebei Med Univ, Shijiazhuang Hosp 1, Dept Med Res, 36 Fanxi Rd, Shijiazhuang 050011, Hebei, Peoples R China.
CR Andrade G, 2013, INTERV NEURORADIOL, V19, P445, DOI 10.1177/159101991301900407
   Archondakis E, 2007, AM J NEURORADIOL, V28, P342
   Bavinzski G, 1997, NEURORADIOLOGY, V39, P81, DOI 10.1007/s002340050371
   Briganti F, 2009, INTERV NEURORADIOL, V15, P185, DOI 10.1177/159101990901500208
   Cantarella G, 2015, ACTA MEDICA MEDITERR, V31, P1019
   Fattahi TT, 2003, J CRANIOFAC SURG, V14, P240, DOI 10.1097/00001665-200303000-00020
   Gemmete JJ, 2010, CURR TREAT OPTION N, V12, P43, DOI 10.1007/s11940-009-0051-3
   Gomez F, 2007, AM J NEURORADIOL, V28, P1762, DOI 10.3174/ajnr.A0636
   Gupta AK, 2006, NEURORADIOLOGY, V48, P831, DOI 10.1007/s00234-006-0132-x
   HIGASHIDA RT, 1989, AM J ROENTGENOL, V153, P577, DOI 10.2214/ajr.153.3.577
   Joshi KC, 2016, CLIN NEUROL NEUROSUR, V149, P46, DOI 10.1016/j.clineuro.2016.06.008
   Klisch J, 2003, NEUROSURGERY, V53, P836, DOI 10.1227/01.NEU.0000083551.26295.AB
   Klisch J, 2003, NEUROSURGERY, V53, P56
   Lang M, 2016, J NEUROSURG, P1
   Layton KF, 2004, AM J NEURORADIOL, V25, P1760
   LEWIS AI, 1995, NEUROSURGERY, V36, P239, DOI 10.1227/00006123-199502000-00001
   Li MH, 2007, AM J NEURORADIOL, V28, P1579, DOI 10.3174/ajnr.A0668
   Li MH, 2006, NEURORADIOLOGY, V48, P841, DOI 10.1007/s00234-006-0127-7
   Luo CB, 2004, J TRAUMA, V56, P1214, DOI 10.1097/01.TA.0000131213.93205.57
   Lv XL, 2008, INTERV NEURORADIOL, V14, P435, DOI 10.1177/159101990801400409
   Maras D, 2006, CARDIOVASC INTER RAD, V29, P958, DOI 10.1007/s00270-005-0367-7
   Meijer FJA, 2009, INTERV NEURORADIOL, V15, P191, DOI 10.1177/159101990901500209
   Moron FE, 2005, AM J NEURORADIOL, V26, P1399
   Ng SH, 1999, J TRAUMA, V47, P1156, DOI 10.1097/00005373-199912000-00033
   Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458
   Remonda L, 2004, AM J NEURORADIOL, V25, P611
   SERBINENKO FA, 1974, J NEUROSURG, V41, P125, DOI 10.3171/jns.1974.41.2.0125
   TSAI FY, 1983, AM J NEURORADIOL, V4, P357
   Tu YK, 1997, NEUROSURGERY, V41, P798, DOI 10.1097/00006123-199710000-00006
   Wang C, 2009, AM J NEURORADIOL, V30, P1342, DOI 10.3174/ajnr.A1583
   Wang W, 2011, J CLIN NEUROSCI, V18, P24, DOI 10.1016/j.jocn.2010.06.008
   Wang YL, 2012, INTERV NEURORADIOL, V18, P172, DOI 10.1177/159101991201800208
   Yu JS, 2008, CHINESE MED J-PEKING, V121, P1558, DOI 10.1097/00029330-200808020-00011
NR 33
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 91
EP 98
DI 10.19193/0393-6384_2018_1_16
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600016
DA 2022-07-14
ER

PT J
AU Gao, BL
   Zhang, XJ
   Fan, QY
   Hao, WL
   Li, CH
   Yang, ST
AF Gao, Bu-Lang
   Zhang, Xue-Jing
   Fan, Qiong-Ying
   Hao, Wei-Li
   Li, Cong-Hui
   Yang, Song-Tao
TI LONG-TERM OUTCOME OF THE ENTERPRISE STENT IN THE TREATMENT OF
   WIDE-NECKED CEREBRAL ANEURYSMS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Intracranial stenting; Wide-necked aneurysm; Vascular reconstruction
   device; Endovascular treatment
ID ASSISTED COIL EMBOLIZATION; INTRACRANIAL ANEURYSMS; NEUROFORM STENT;
   OCCLUSION; RESTENOSIS; EXPERIENCE; RECONSTRUCTION; STENOSIS
AB Introduction: The long-term results of intracranial aneurysms treated with the Enterprise stent is not known. This study was to investigate the safety and long-term outcome of the Enterprise stent in the treatment of wide-necked intracranial aneurysms.
   Materials and methods: Sixty-eight patients harboring 78 intracranial aneurysms were treated with the Enterprise stent-assisted embolization with or without coiling. Angiographic data and clinical outcomes before and after stenting and at follow-up were retrospectively evaluated.
   Results: Seventy-seven Enterprise stents were successfully deployed in the desired position (100%). Seven procedure-related complications (10.3%) occurred including thrombosis formation in two patients, coil protrusion in two and stent dislocation in three. Twelve aneurysms were treated with stent deployment alone. Sixty-six aneurysms were treated with stent-assisted coiling, resulting in complete occlusion in 46 aneurysms (69.7%), near complete in 15 (22.7%) and incomplete in 5 (7.6%). At follow-up of 12-55 months (mean 38), progressive thrombosis occurred in 23 (71.9%) aneurysms, and aneurysm regrowth in 11 cases (18.0%). Stenting significantly (P<0.05) increased the parent artery diameters to 3.72 +/- 0.09 mm at point B and 3.43 +/- 0.1mm at D. At the last angiographic follow-up, the artery diameter was significantly (P<0.05) decreased to 3.45 +/- 0.2 mm at point B and 3.03 +/- 0.14 mm at D, with a medium asymptomatic in-stent stenosis in six patients (8.8%).
   Conclusion: The Enterprise stent reconstruction of the parent artery for treating intracranial aneurysms is safe and effective with long-term asymptomatic instent stenosis.
C1 [Gao, Bu-Lang] Shijiazhuang First Hosp, Dept Med Res, Shijiazhuang 050011, Hebei, Peoples R China.
   [Gao, Bu-Lang] Shijiazhuang First Hosp, Dept Neurosurg, Shijiazhuang 050011, Hebei, Peoples R China.
RP Gao, BL (corresponding author), Shijiazhuang First Hosp, Dept Med Res, Shijiazhuang 050011, Hebei, Peoples R China.; Gao, BL (corresponding author), Shijiazhuang First Hosp, Dept Neurosurg, Shijiazhuang 050011, Hebei, Peoples R China.
FU National Natural Scientific Funding of China [81271575]
FX This work was supported by the National Natural Scientific Funding of
   China (Grant number 81271575).
CR Bendok BR, 2007, NEUROSURGERY, V61, P835, DOI 10.1227/01.NEU.0000298913.24625.26
   Benitez RP, 2004, NEUROSURGERY, V54, P1359, DOI 10.1227/01.NEU.0000124484.87635.CD
   Benndorf G, 2006, NEUROSURGERY S2, V58, DOI DOI 10.1227/01.NEU.0000205287.06739.E1
   Biondi A, 2007, NEUROSURGERY, V61, P460, DOI 10.1227/01.NEU.0000290890.62201.A9
   Broadbent LP, 2003, AM J NEURORADIOL, V24, P1819
   Chalouhi N, 2013, STROKE, V44, P1348, DOI 10.1161/STROKEAHA.111.000641
   Colby GP, 2012, J NEUROINTERV SURG, V4, P116, DOI 10.1136/jnis.2011.004911
   Costa MA, 2005, CIRCULATION, V111, P2257, DOI 10.1161/01.CIR.0000163587.36485.A7
   Costa MA, 2000, AM J CARDIOL, V85, P135, DOI 10.1016/S0002-9149(99)00655-4
   DUSSAILLANT GR, 1995, J AM COLL CARDIOL, V26, P720, DOI 10.1016/0735-1097(95)00249-4
   Ebrahimi N, 2007, AM J NEURORADIOL, V28, P823
   Fiorella D, 2005, NEUROSURGERY, V56, P1191, DOI 10.1227/01.NEU.0000159645.86823.AF
   Fiorella D, 2004, NEUROSURGERY, V54, P6, DOI 10.1227/01.NEU.0000097194.35781.EA
   Fiorella D, 2005, NEUROSURGERY, V56, P201
   Fiorella D, 2006, NEUROSURGERY, V59, P291, DOI 10.1227/01.NEU.0000223650.11954.6C
   Fiorella D, 2006, NEUROSURGERY, V59, P34, DOI 10.1227/01.NEU.0000219853.56553.71
   Gao B, 2014, J NEUROINTERV SURG
   Gentric JC, 2013, AM J NEURORADIOL, V34, P1203, DOI 10.3174/ajnr.A3379
   GEREMIA G, 1994, AM J NEURORADIOL, V15, P1223
   Geremia G, 2000, AM J NEURORADIOL, V21, P739
   Gu DQ, 2013, J CLIN NEUROSCI, V20, P238, DOI 10.1016/j.jocn.2012.01.053
   Herweh C, 2016, CLIN NEURORADIO 0927
   Hoit DA, 2005, NEUROSURGERY, V57, P1228, DOI 10.1227/01.NEU.0000176026.12709.BC
   Izar B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024875
   Kim DJ, 2010, ACTA NEUROCHIR, V152, P423, DOI 10.1007/s00701-009-0522-z
   King B, 2014, J NEUROINTERV SURG
   Lawson MF, 2011, NEUROSURGERY, V69, P598, DOI 10.1227/NEU.0b013e3182181c2b
   Lee JI, 2013, NEUROL MED-CHIR, V53, P310, DOI 10.2176/nmc.53.310
   Lee YJ, 2005, NEURORADIOLOGY, V47, P680, DOI 10.1007/s00234-005-1402-8
   Lylyk P, 2005, J NEUROSURG, V102, P235, DOI 10.3171/jns.2005.102.2.0235
   Maldonado IL, 2011, AM J NEURORADIOL, V32, P131, DOI 10.3174/ajnr.A2245
   Pelz DM, 1998, AM J NEURORADIOL, V19, P1541
   Peng TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092407
   Piotin M, 2010, STROKE, V41, P110, DOI 10.1161/STROKEAHA.109.558114
   Serra A, 2017, ACTA MEDICA MEDITERR, V33, P869, DOI 10.19193/0393-6384_2017_5_129
   Song J, 2016, ACTA NEUROCHIR, V158, P803, DOI 10.1007/s00701-016-2721-8
   Vinuela F, 1997, J NEUROSURG, V86, P475, DOI 10.3171/jns.1997.86.3.0475
   Weber W, 2007, NEURORADIOLOGY, V49, P555, DOI 10.1007/s00234-007-0232-2
   Welt FGP, 2002, ARTERIOSCL THROM VAS, V22, P1769, DOI 10.1161/01.ATV.0000037100.44766.5B
   Workman MJ, 2002, AM J NEURORADIOL, V23, P1568
   Zenteno MA, 2005, NEUROSURGERY, V57, P208, DOI 10.1227/01.NEU.0000163683.64511.24
NR 41
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 99
EP 105
DI 10.19193/0393-6384_2018_1_17
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600017
DA 2022-07-14
ER

PT J
AU Gao, XY
   Xi, M
   Chen, YB
   Xin, GD
AF Gao, Xiao-Ying
   Xi, Ming
   Chen, Yan-Bing
   Xin, Guang-Da
TI CHANGES OF THE LEVELS OF PCT AND CRP IN URINARY TRACT INFECTION OF ELDER
   PATIENTS AND THEIR CLINICAL SIGNIFICANCE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Elder patients; urinary tract; PCT; CRP
ID COMMUNITY-ACQUIRED PNEUMONIA; GUIDELINES; MANAGEMENT; DIAGNOSIS
AB Objective: To analyze the changes of procalcitonin (PCT) and C-reactive protein (CRP) levels in urinary tract infection o elder patients and its clinical significance.
   Methods: Randomly, we selected a total of 68 elder patients with urinary tract infection. 32 patients with upper urinary tract infection were enrolled into the Group 1, 36 with lower urinary tract infection into the Group II, and 30 healthy subjects who attended the physical examinations into the control ,group. White blood cell count of blood and urine, PCT and CRP were determined for all patients, and comparison of the levels of PCT and CRP before and after treatment and the correlation analysis between the levels of PCT and CRP were carried out for patients in the observation group.
   Results: In two observation ,groups, white blood cell counts of blood and urine and levels of PCT and CRP were higher than those in the control ,group, while the levels of PCT and CRP in Group 1 were higher than those in Group II (p<0.05); after active treatment, significant decreases were identified in levels of PCT and CRP in observation groups (p<0.05); Pearson correlation analysis showed positive correlation between PCT and CRP (r=0.73, p<0.01).
   Conclusion: Levels of PCT and CRP are sensitive indicators for diagnosis and auxiliary diagnosis of urinary tract infection of elder patients, and conduces to guiding the clinical medication, which are worthy being promoted in clinical practice.
C1 [Gao, Xiao-Ying] Tangshan Gongren Hosp, Dept Nephrol, Tangshan 063000, Hebei, Peoples R China.
   [Xi, Ming] Southern Med Univ, Huadu Dist Peoples Hosp, Dept Urol, Guangzhou 510800, Guangdong, Peoples R China.
   [Chen, Yan-Bing] Nanchang Univ, Affiliated Hosp 1, Dept Nephrol, Nanchang 330100, Jiangxi, Peoples R China.
RP Xin, GD (corresponding author), Jilin Univ, China Japan Union Hosp, Dept Nephrol, 126 Xiantai Ave, Changchun 130033, Jilin, Peoples R China.
EM guangdaxin75@163.com
CR Capelastegul A, 2006, EUR RESPIR J, V27, P151, DOI 10.1183/09031936.06.00062505
   Hooton TM, 2010, CLIN INFECT DIS, V50, P625, DOI 10.1086/650482
   Juthani-Mehta M, 2009, J AM GERIATR SOC, V57, P963, DOI 10.1111/j.1532-5415.2009.02227.x
   Kruger S, 2008, EUR RESPIR J, V31, P349, DOI 10.1183/09031936.00054507
   Lutters M, 2008, COCHRANE DB SYST REV, V3
   Nicolle LE, 2001, J INFECT DIS, V183, pS5, DOI 10.1086/318844
   Rao G, 2009, J ANTIMICROB CHEMOTH, V63, P5, DOI 10.1093/jac/dkn458
   Schuetz P, 2012, CURR OPIN CRIT CARE, V18, P341, DOI 10.1097/MCC.0b013e328354b2c8
   Sundqvist M, 2009, J ANTIMICROB CHEMOTH, V64, P227, DOI 10.1093/jac/dkp181
   Tal S, 2005, J INFECTION, V50, P296, DOI 10.1016/j.jinf.2004.04.004
   Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, pE1, DOI 10.1111/j.1469-0691.2011.03672.x
NR 11
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1843
EP 1846
DI 10.19193/0393-6384_2018_6_284
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400035
DA 2022-07-14
ER

PT J
AU Ge, HL
   Cao, FJ
   Sun, GJ
   Shi, XY
   Jia, FB
AF Ge, Hongliang
   Cao, Fengjun
   Sun, Guanjun
   Shi, Xiuyun
   Jia, Fubao
TI RELATED RESEARCH ON HEMORRHAGIC TRANSFORMATION CAUSES DETERIORATION
   AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE ISCHEMIC STROKE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Acute ischemic stroke; Thrombolytic therapy; GOS score; Glutamic acid;
   Serum complement C3
AB Object: To investigate hemorrhagic transformation caused by thrombolytic therapy in acute ischemic stroke patients whether can cause disturbance of consciousness and other deterioration.
   Methods: Selecting the medical records of acute ischemic stroke patients admitted to Neurology Emergency department in our hospital to retrospectively analysis. The experimental group was 100 patients treated with thrombolytic therapy and hemorrhagic transformation occurred, and the control group was 100 patients treated with thrombolytic therapy and hemorrhagic transformation no occurred. The PT, APPT, FBG indicators of patients before and utter thrombolytic therapy were tested, and the serum glutamic acid and serum complement C3 levels were measured after thrombolytic therapy. Then the follow-up work was carried out, and prognostic status of the patients were evaluated by the GOS scoring system.
   Results: The levels of PT, APPT, FBG of patients in the experimental group was significantly higher than that of the control group (p<0.05). The serum glutamic acid and serum complement C3 levels of patients in the experimental group was higher than that of the control group (p<0.05). When the GOS score was 4-5, the number of patients in the experimental group was significantly lower than that of the control group, and when the GOS score was 1-3, the number of patients in the experimental group was significantly higher than that of the control group (p<0.05).
   Conclusion: Hemorrhagic transformation in acute ischemic stroke patients after thrombolytic therapy will reduce the patient's prognosis, and seriously threaten the patient's quality of life. We should strictly control the occurrence of the related danger when patients are treated with thrombolytic therapy.
C1 [Ge, Hongliang; Cao, Fengjun; Sun, Guanjun; Jia, Fubao] Shanxian Cent Hosp, Dept Internal Neurol, Shanxian 274300, Peoples R China.
   [Shi, Xiuyun] Shanxian Cent Hosp, Dept Test, Shanxian 274300, Peoples R China.
RP Jia, FB (corresponding author), Shanxian Cent Hosp, Dept Internal Neurol, Shanxian 274300, Peoples R China.
EM jfb2001@163.com
CR Ayromlou H, 2014, IRAN RED CRESCENT ME, V16, DOI 10.5812/ircmj.11284
   Demchuk AM, 2012, DRUGS, V72, P1833, DOI 10.2165/11635740-000000000-00000
   Garcia-Caldentey J, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/923676
   Levine S R, 2015, THROMBOLYTIC THERAPY, P27
   Magnusson KR, 2015, NEUROSCIENCE, V300, P128, DOI 10.1016/j.neuroscience.2015.05.016
   Mishra NK, 2010, STROKE, V41, P2840, DOI 10.1161/STROKEAHA.110.586206
   Mohajeri MH, 2015, NUTRITION, V31, P261, DOI 10.1016/j.nut.2014.06.016
   Ringleb A, 2007, J NEUROL NEUROSUR PS, V78, P690, DOI 10.1136/jnnp.2006.105890
   Szpetnar M, 2016, CURR ISS PHARM MED S, V29, P151, DOI 10.1515/cipms-2016-0031
   Wahlgren N, 2017, J INTERN MED, V281, P273, DOI 10.1111/joim.12576
   Zerna C, 2016, CIRC RES, V118, P1425, DOI 10.1161/CIRCRESAHA.116.307005
   Zhai YK, 2015, J TELEMED TELECARE, V21, P123, DOI 10.1177/1357633X15571357
   Zhao GJ, 2017, J CLIN NEUROSCI, V40, P175, DOI 10.1016/j.jocn.2017.01.001
   Zhao H, 2015, CHINESE J HLTH LAB T
NR 14
TC 1
Z9 1
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1793
EP 1797
DI 10.19193/0393-6384_2018_6_275
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400026
DA 2022-07-14
ER

PT J
AU Gigante, E
   Picciocchi, E
   Valenzano, A
   Cibelli, G
   Ruberto, V
   Cantone, D
   Moretto, E
   Di Sarno, AD
   Longobardi, T
   Iennaco, D
   Messina, M
   Nascivera, N
   Pisanelli, D
   Polito, AN
   Marsala, G
   Costa, V
   Mosca, L
   Dell'Orco, S
AF Gigante, Elena
   Picciocchi, Elisabetta
   Valenzano, Anna
   Cibelli, Giuseppe
   Ruberto, Valentina
   Cantone, Daniela
   Moretto, Enrico
   Di Sarno, Alfonso Davide
   Longobardi, Teresa
   Iennaco, Daniela
   Messina, Martina
   Nascivera, Nicole
   Pisanelli, Daniela
   Polito, Anna Nunzia
   Marsala, Gabriella
   Costa, Vania
   Mosca, Luciana
   Dell'Orco, Sivia
TI THE EFFECTS OF THE ENDOCRINE DISRUPTORS AND OF THE HALOGENS ON THE
   FEMALE REPRODUCTIVE SYSTEM AND ON EPIGENETICS: A BRIEF REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Bisphenol A; embryonic development; endocrine disruptors; epigenetic;
   female reproductive system; halogens; Metal; Polybrominated Diphenyl
   Ethers; Phthalates; Pesticide
ID BISPHENOL-A; POLYCHLORINATED-BIPHENYLS; HYPERTHERMIC REACTIONS;
   INHIBITOR DEVELOPMENT; CHILDHOOD MIGRAINE; CEREBRAL INJECTION; OXIDATIVE
   STRESS; ITALIAN PATIENTS; EXPOSURE; CHILDREN
AB Introduction: An endocrine-disrupting chemical (EDC) is defined as "an exogenous chemical or a mixture of chemicals that interfere with any aspect of the hormonal action". Endocrine systems are a physiological interface with the environment and genetic-environmental interactions are disrupted by EDCs. Today, there are almost 1000 chemicals reported to have endocrine effects: the prevalence of EDC in our environment and in our bodies represents a major global health challenge. This review gathers the studies that have investigated the correlations between exposure to EDC and pathologies of the female reproductive system and fetal development.
   Methods: A PubMed research was conducted using the keywords, their variants, and their combinations (BPA, DES, MXC, pesticides, phthalates, plasticizers, PCBs, dioxins, ovaries, oocytes, ovaries, fallopian tubes, follicles, vagina, uterus, fibroids, fertility, infertility, puberty, polycystic ovary syndrome, premature ovarian failure, birth, preterm birth, birth outcome, steroid, hormone, female, girl and menopause).
   Results: The endocrine system plays a central role in all vertebrates and regulates critical biological functions such as metabolism, development, reproduction, and behavior. Epidemiological studies link EDCs with reproductive effects, neuro-behavioral and neurodevelopment alterations, metabolic syndrome, bone disorders, immune disorders, and cancers in humans. Human investigations confirm the results of the studies carried out on animal showing associations with many additional effects on health, including asthma, learning and behavior problems, premature puberty, infertility, breast and prostate cancer, Parkinson's disease, obesity and other diseases.
   Conclusions: It is important to undertake research with follow-up methodologies and/or longitudinal studies to detect the extent of exposure of pregnant women to EDCs and halogenated substances and the effects of such exposure on brain development. A future research hypothesis may consider the effect that these substances have on neuro-development and, more specifically, how EDCs are involved in pathogenic disorders such as autism spectrum disorders (ASD). In addition, a scientific study could be performed on the correlations between this type of substance and the inconveniences found in the field of executive frontal functions.
C1 [Gigante, Elena; Moretto, Enrico; Di Sarno, Alfonso Davide; Longobardi, Teresa; Iennaco, Daniela; Messina, Martina; Nascivera, Nicole; Costa, Vania; Mosca, Luciana; Dell'Orco, Sivia] SiPGI Postgrad Sch Integrated Gestalt Psychothera, DM 12-10-2007,Via V Veneto 240, I-80058 Naples, Italy.
   [Picciocchi, Elisabetta; Valenzano, Anna; Cibelli, Giuseppe; Ruberto, Valentina; Pisanelli, Daniela] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa dei Fiori Acerra, Naples, Italy.
   [Cantone, Daniela] Univ Campania Luigi Vanvitelli, Dept Psychol, Naples, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Marsala, Gabriella] Osped Riuniti Foggia, Azienda Osped Univ, Foggia, Italy.
RP Gigante, E (corresponding author), SiPGI Postgrad Sch Integrated Gestalt Psychothera, DM 12-10-2007,Via V Veneto 240, I-80058 Naples, Italy.
EM gigantelena@gmail.com
RI Moretto, Enrico/AFV-4935-2022; Cibelli, Giuseppe/AAC-2635-2019
OI MORETTO, ENRICO/0000-0002-1726-7866; CIBELLI,
   GIUSEPPE/0000-0002-5371-2584; MOSCA, LUCIA LUCIANA/0000-0001-9090-094X
CR Albenzio M, 2013, J DAIRY SCI, V96, P2781, DOI 10.3168/jds.2012-6218
   Bafunno V, 2012, HAEMOPHILIA, V18, P1003, DOI 10.1111/j.1365-2516.2012.02882.x
   Bafunno V, 2010, HAEMOPHILIA, V16, P469, DOI 10.1111/j.1365-2516.2009.02150.x
   Bafunno V, 2014, THROMB RES, V134, P1135, DOI 10.1016/j.thromres.2014.08.028
   Bafunno V, 2013, J ALLERGY CLIN IMMUN, V132, P748, DOI 10.1016/j.jaci.2013.04.006
   Bertozzi G, 2018, MOL NEUROBIOL, V55, P5548, DOI 10.1007/s12035-017-0774-1
   Boucher O, 2012, ENVIRON HEALTH PERSP, V120, P608, DOI 10.1289/ehp.1103828
   Bramanti V, 2016, J NEUROSCI RES, V94, P90, DOI 10.1002/jnr.23678
   Braun JM, 2011, PEDIATRICS, V128, P873, DOI 10.1542/peds.2011-1335
   Braun JM, 2014, ENVIRON HEALTH PERSP, V122, P513, DOI 10.1289/ehp.1307261
   Brieno-Enriquez MA, 2016, FERTIL STERIL, V106, P871, DOI 10.1016/j.fertnstert.2016.07.1100
   Bukvic N, 2010, AM J MED GENET A, V152A, P1730, DOI 10.1002/ajmg.a.33437
   Canestraro M, 2010, CANCER GENET CYTOGEN, V199, P110, DOI 10.1016/j.cancergencyto.2010.02.010
   Cantone D, 2012, REV LATINOAM PSICOPA, V15, P42, DOI 10.1590/S1415-47142012000100004
   Cantone D, 2012, RIV PSICHIATR, V47, P246, DOI 10.1708/1128.12448
   Caroprese M, 2012, SMALL RUMINANT RES, V102, P177, DOI 10.1016/j.smallrumres.2011.07.010
   Caroprese M, 2010, J DAIRY SCI, V93, P2395, DOI 10.3168/jds.2009-2604
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Caserta D, 2014, REPROD BIOL ENDOCRIN, V12, DOI 10.1186/1477-7827-12-37
   Cerretani D, 2011, PHARMACOL RES, V64, P517, DOI 10.1016/j.phrs.2011.08.002
   Chieffi S, 2017, FRONT PHYSL, V8
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Cordier S, 2015, ENVIRON RES, V138, P271, DOI 10.1016/j.envres.2015.02.021
   Csaba G, 2015, ORVOSI HETILAP, V156, P1120, DOI 10.1556/650.2015.30187
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Eladak S, 2015, FERTIL STERIL, V103, P11, DOI 10.1016/j.fertnstert.2014.11.005
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2014, CHEMOSPHERE, V94, P62, DOI 10.1016/j.chemosphere.2013.09.013
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Galimberti S, 2007, J CHEMOTHERAPY, V19, P315, DOI 10.1179/joc.2007.19.3.315
   Giesbrecht GF, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0259-8
   Goodyer CG, 2017, ENVIRON HEALTH PERSP, V125, DOI [10.1289/EHP522, 10.1289/ehp522]
   Lin XG, 2017, BIOSENS BIOELECTRON, V91, P104, DOI 10.1016/j.bios.2016.12.024
   Macejova Dana, 2016, Endocr Regul, V50, P154, DOI 10.1515/enr-2016-0018
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maldonato NM, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00447
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina G, 2015, AFRICAN J PSYCHIAT S, V18
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda M, 2008, PEPTIDES, V29, P120, DOI 10.1016/j.peptides.2007.10.016
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda V, 2017, FRONT PHYSL, V8
   Monteagudo C, 2016, CHEMOSPHERE, V156, P135, DOI 10.1016/j.chemosphere.2016.04.103
   Moscatelli F, 2015, BIOL MED, V7
   Moscatelli F, 2016, PLOS ONE, V11
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Perez-Albaladejo E, 2017, TOXICOL IN VITRO, V38, P41, DOI 10.1016/j.tiv.2016.11.003
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Petito A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156601
   Piacentino D, 2015, CURR NEUROPHARMACOL, V13, P101, DOI 10.2174/1570159X13666141210222725
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Pomara C, 2012, CURR MED CHEM, V19, P5647, DOI 10.2174/092986712803988811
   Pomara C, 2009, RADIOL MED, V114, P1367, DOI 10.1007/s11547-009-0435-1
   Pomara C, 2008, CLIN TOXICOL, V46, P322, DOI 10.1080/15563650701419011
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santacroce R, 2008, BLOOD COAGUL FIBRIN, V19, P197, DOI 10.1097/MBC.0b013e3282f234ab
   Santacroce R, 2009, GENET TEST MOL BIOMA, V13, P573, DOI 10.1089/gtmb.2009.0015
   Santillo A, 2009, INT DAIRY J, V19, P655, DOI 10.1016/j.idairyj.2009.06.011
   Santillo A, 2009, J DAIRY SCI, V92, P1330, DOI 10.3168/jds.2008-1598
   Sen A, 2016, ENDOCRINOLOGY, V157, P3366, DOI 10.1210/en.2016-1450
   Sevi A, 2003, APPL ANIM BEHAV SCI, V83, P41, DOI 10.1016/S0168-1591(03)00088-1
   Sheikh IA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151444
   Shelton JF, 2014, ENVIRON HEALTH PERSP, V122, P1103, DOI 10.1289/ehp.1307044
   Simon V, 2017, ENDOCRINOLOGY, V158, P3200, DOI 10.1210/en.2017-00374
   Sperandeo R, 2016, SMART INNOV SYST TEC, V54, P293, DOI 10.1007/978-3-319-33747-0_29
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Sperandeo R, 2016, INT CONF COGN INFO, P43, DOI 10.1109/CogInfoCom.2016.7804522
   Swan SH, 2010, INT J ANDROL, V33, P259, DOI 10.1111/j.1365-2605.2009.01019.x
   Tassinari R, 2015, J PEDIATR ENDOCR MET, V28, P1369, DOI 10.1515/jpem-2015-0116
   Trasande L, 2015, J CLIN ENDOCR METAB, V100, P1245, DOI 10.1210/jc.2014-4324
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2005, INT J CARDIOL, V104, P152, DOI 10.1016/j.ijcard.2004.10.051
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2008, INT J LEGAL MED, V122, P173, DOI 10.1007/s00414-007-0208-0
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Turillazzi E, 2013, FORENSIC SCI INT, V231, P142, DOI 10.1016/j.forsciint.2013.04.006
   Turillazzi E, 2008, VIRCHOWS ARCH, V453, P209, DOI 10.1007/s00428-008-0632-7
   Uzumcu M, 2012, REPROD DOMEST ANIM, V47, P338, DOI 10.1111/j.1439-0531.2012.02096.x
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Won H, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00019
   Ziv-Gal A, 2016, FERTIL STERIL, V106, P827, DOI 10.1016/j.fertnstert.2016.06.027
NR 101
TC 5
Z9 5
U1 1
U2 36
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1295
EP 1303
DI 10.19193/0393-6384_2018_5_199
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700021
DA 2022-07-14
ER

PT J
AU Gokmen, S
   Avdal, EU
   Uran, BNO
AF Gokmen, Sibel
   Avdal, Elif Unsal
   Uran, Berna Nilgun Ozgursoy
TI INVESTIGATION OF THE EFFECT OF DIABETIC NEUROPATHIC PAIN ON DEPRESSION
   AND QUALITY OF LIFE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE diabetetes; neuropathic pain; depression; life quality
ID LEEDS ASSESSMENT; SYMPTOMS; SCALE; TURKEY; RISK
AB Introduction and aim: One of the most common and long-lasting complications in uncontrolled diabetes is diabetic neuropathy. The aim of this study was to investigate the effect of diabetic neuropathic pain on depression and quality of life.
   Material and methods: The study was designed as cross-sectional and descriptive study and was conducted between February and April of 2016 with 40 diabetic individuals diagnosed with diabetic neuropathy. Data were collected using the Diabetes Individual Identification Form, Leeds Assessment of Neuropathic Symptom and Signs Scale, Beck's Depression Inventory and the EORTC QLQ-C30 Quality of Life Questionnaire. Verbal and written consent was obtained and the data were analyzed with the SPSS program.
   Results: 25 women and 15 men participated in this study. It was determined that 50% of the individuals participating in the study had had diabetes for 6-10 years, 55% had received insulin treatment and 25% had only received oral anti-diabetic (OAD) treatment. The mean score for the LANSS pain scale of diabetic subjects was 9.83, the mean score for the BECK's Depression Inventory was 18.03 and the mean score for the EORTC Quality of Life Questionnaire was 612. The correlation coefficient between the LANSS pain scale and the EORTC Quality of Life Questionnaire was significant for individuals with diabetic neuropathic pain. There was a positive correlation between the two scales (r=0.671, p=0.000 <alpha=0.05.). There was a positive but weak relationship between the LANSS Pain Scale and the BECK Depression Inventory, while no significant relationship was found between the BECK Depression Inventory and the EORTC Quality of Life Questionnaire for individuals with neuropathic pain (r=0.097, p=0.551>alpha=0.05.) rs=0.312, p=0.050 =alpha=0.05).
   Conclusion: Diabetic neuropathic pain seriously affects the quality of life and increases susceptibility to psychological problems such as depression. When using a patient-specific treatment approach for diabetes, taking into account the data on depression and quality of life will increase the patient's participation in the treatment process and the success of the treatment.
C1 [Gokmen, Sibel] Izmir Katip Celebi Univ, Ataturk Res Hosp, Izmir, Turkey.
   [Avdal, Elif Unsal; Uran, Berna Nilgun Ozgursoy] Izmir Katip Celebi Univ, Fac Hlth Sci, Izmir, Turkey.
RP Avdal, EU (corresponding author), Izmir Katip Celebi Univ, Fac Hlth Sci, Izmir, Turkey.
RI AVDAL, ELİF UNSAL/ABE-9593-2021
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   American Diabetes Association (ADA), 2015, DIABETES CARE, V38, P8
   Bahar A., 2006, ANADOLU PSIKIYATR DE, V7, P18
   Bai JW, 2017, J DIABETES COMPLICAT, V31, P1318, DOI 10.1016/j.jdiacomp.2017.05.002
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004
   Bennett M, 2001, PAIN, V92, P147, DOI 10.1016/S0304-3959(00)00482-6
   Beser N, 2003, CU NURS SCH J, V7, P47
   Blackburn-Munro G, 2001, J NEUROENDOCRINOL, V13, P1009, DOI 10.1046/j.0007-1331.2001.00727.x
   Cragg JJ, 2015, NEUROEPIDEMIOLOGY, V44, P130, DOI 10.1159/000377726
   Dziemidok P, 2016, PSYCHIATR POL, V50, P407, DOI 10.12740/PP/OnlineFirst/42352
   Fishbain DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006
   Grundy Scott M., 2002, Circulation, V105, P2231, DOI 10.1161/01.CIR.0000013952.86046.DD
   Gul HL, 2015, THESIS, P32
   Gulseren L, 2001, TURKISH J PSYCHIAT, V12, P89
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   HIBBARD JH, 1983, SOC SCI MED, V17, P129, DOI 10.1016/0277-9536(83)90246-0
   Hisli N., 1989, GUVENIRLIGI, V7, P3
   International Diabetes Federation (IDF) , 2013, DIABETES ATLAS, V6th
   Irem A., 2007, THESIS, P33
   Kayahan M, 2007, DAHILI VE CERRAHI KL, P45
   Marks JB, 2000, J DIABETES COMPLICAT, V14, P108, DOI 10.1016/S1056-8727(00)00065-9
   Noh JH, 2005, DIABETES RES CLIN PR, V69, P243, DOI 10.1016/j.diabres.2004.10.009
   Satman I, 2002, DIABETES CARE, V25, P1551, DOI 10.2337/diacare.25.9.1551
   Satman I, 2013, EUR J EPIDEMIOL, V28, P169, DOI 10.1007/s10654-013-9771-5
   Sonmez B, 2013, TURK AILE HEK DERG, P119
   T. C. Saglik Bakanligi Turkiye Halk Sagligi Kurumu, 2014, TURK DIYAB PROGR 201
   Turhan H., 2007, THESIS, P45
   Turkiye Endokrin ve Metabolizma Dernegi (TEMD), 2014, DIAB MELL VE KOMPL T
   Yucel A, 2004, J PAIN, V5, P427, DOI 10.1016/j.jpain.2004.07.001
   Yuksel S., 2007, THESIS, P45
NR 30
TC 0
Z9 0
U1 1
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 643
EP 650
DI 10.19193/0393-6384_2018_3_99
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000004
DA 2022-07-14
ER

PT J
AU Gong, LH
   Cai, YT
   Liu, Y
AF Gong Li-Hong
   Cai Yu-Ting
   Liu Yi
TI EVALUATION OF ANTI-TUMOR EFFECT OF SAPOSHNIKOVIA POLYSACCHARIDE BEFORE
   AND AFTER SULFATION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Saposhnikovia polysaccharide; Sulfation; K562 cells; Anti-tumor;
   Antioxidant
ID CELLS
AB Objective: This study was conceived and designed in order to evaluate the inhibitory effect of ultrasonic Saposhnikovia polysaccharide (USPS) on the proliferation of K562 leukemia cells in vitro, and also to examine its antioxidant activity.
   Methods: USPS was sulfated by chlorosulfonic acid-pyridine method to obtain the sulfated USPS derivative (S-USPS), and MTT assay was used to determine their inhibitory effects on the growth of K562 cells at various doses (25 ug/ml, 50 ug/ml, 100 ug/ml, 200 ug/ml, 400 ug/ml, 800 ug/ml). Total reducing power of USPS and S-USPS and their scavenging capacity on hydroxyl radical (center dot OH) and superoxide anion (O2-(center dot)) were determined.
   Results: Results from MTT assay showed that USPS and S-USPS inhibited the proliferation of K562 cells in vitro in a time-and dose-dependent manner; 800 ug/ml S-USPS / USPS mixture controlled the growth of K562 cells at 72 h, but S-USPS had higher inhibitory effect than USPS. In addition, the total reducing power, as well as superoxide anion and hydroxyl radical scavenging capacities of S-USPS were significantly higher than the corresponding values for USPS (p < 0.05).
   Conclusion: Sulfated Saposhnikovia polysaccharide possesses in vitro anti-tumor and anti-oxidant activities. Thus, research on modification of Saposhnikovia polysaccharide may be useful in cancer therapy.
C1 [Gong Li-Hong; Cai Yu-Ting; Liu Yi] Mudanjiang Med Univ, Dept Pharm, Mudanjiang 157011, Heilongjiang, Peoples R China.
RP Liu, Y (corresponding author), Mudanjiang Med Univ, Dept Pharm, Mudanjiang 157011, Heilongjiang, Peoples R China.
EM nxwmi1@163.com
FU Heilongjiang Provincial Health and Family Planning Commission [2017-367]
FX This research project was supported by Heilongjiang Provincial Health
   and Family Planning Commission (2017-367).
CR Chawathe S S, 2015, THEOR PRACT OBJ SYST, V5, P143
   Dou HX, 2009, CHIN MED, V26, P15
   Geng YM, 2017, CHIN PHARM, V20, P1188
   Guo J, 2016, INT J BIOL MACROMOL, V93, P829, DOI 10.1016/j.ijbiomac.2016.08.083
   Huang GL, 2016, CURR DRUG TARGETS, V17, P1799, DOI 10.2174/1389450117666160502151004
   Jia XW, 2017, INT J MED MUSHROOMS, V19, P355, DOI [10.1615/IntJMedMushrooms.v19.i4.60, 10.1615/intjmedmushrooms.v19.i4.60]
   Jiang Y, 2012, STEM CELLS, V30, P599, DOI 10.1002/stem.1053
   LI L, 1999, J BEIJING U TCM, V22, P38
   [刘培勋 Liu Peixun], 2005, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V21, P35
   Sanchez C, 2017, SYN SYST BIOTECHNO, V2, P13, DOI 10.1016/j.synbio.2016.12.001
   Tian SY, 2017, J FOOD DRUG ANAL, V25, P766, DOI 10.1016/j.jfda.2016.08.012
   Yan EK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111906
   Yang JM, 2016, JILIN J TRADIT CHIN, V36, P513
   Yu M, 2017, SAUDI PHARM J, V25, P464, DOI 10.1016/j.jsps.2017.04.007
   Zheng C, 2017, REHABIL MED, V27, P33
   [周林珠 Zhou Linzhu], 2002, [中国生化药物杂志, Chinese Journal of Biochemical Pharmaceutics], V23, P210
   张泽庆, 2009, [中草药, Chinese Traditional and Herbal Drugs], V40, P1208
NR 17
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 997
EP 1001
DI 10.19193/0393-6384_2018_4_151
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500014
DA 2022-07-14
ER

PT J
AU Goret, CC
   Goret, NE
   Ozkan, OF
   Kilic, G
AF Goret, Ceren Canbey
   Goret, Nuri Emrah
   Ozkan, Omer Faruk
   Kilic, Guray
TI CLINICOPATHOLOGICAL ANALYSES OF PANCREAS SPECIMENS IN 49 CONSECUTIVE
   PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Whipple procedure; Distal pancreatectomy; Pancreas pathology;
   Pancreatitis
ID NEEDLE-ASPIRATION BIOPSY; CYSTIC LESIONS; ADENOCARCINOMA;
   PANCREATICODUODENECTOMY; CARCINOMA; DIAGNOSIS; OUTCOMES; AMPULLA; VATER;
   EUS
AB Objective: Pancreaticoduodenectomy (Whipple) and distal pancreatectomy (DP) operations are the preferred methods for indications ranging from benign inflammatory conditions to malignant neoplasia. Pathological examination of both Whipple and DP materials requires special attention to correctly evaluate many important prognostic factors. In this study, we aimed to present the pathology results of 49 Whipple and DP materials evaluated retrospectively.
   Materials and method: Patients were evaluated in the Istanbul Ekin Private Pathology Laboratory between January 2010 and January 2016, operated in Canakkale Onsekiz Mart University, General Surgery Clinic between January 2016 and August 2017, and Canakkale State Hospital, General Surgery Clinic between January 2012 and January 2018. A total of 49 Whipple procedure and DP materials, both benign and malignant, were included in the study taking into consideration the age, sex, tumor size, surgical margin status, tumor localization, lymphovascular invasion, perineural invasion, number of lymph nodes, and presence/absence of metastatic lymph nodes.
   Results: Out of the 49 cases, 12 (24.5%) underwent DP and 37 (75.5%) pancreaticoduodenectomy (Whipple). 27 (55.1%) cases were male and 22 (44.9%) were female, and the mean age was 61.4 years. 8 (16.3%) cases were benign and 41 (83.7%) were malignant. Of the 41 malignant cases, 17 were female and 24 were male; the mean age was 61.4 years. In terms of tumor localization, 6 (% 14.6) tumors were localized to the ampulla, 8 (% 19.5) to the pancreas distal, 2 (% 4.9) to the duodenum, and 25 (% 61) to the pancreas head. In 33 (% 80.5) cases, the surgical margin was intact. In 18 (% 43.9) cases, metastasis was present.
   Conclusion: In pancreatic carcinoma cases that are treated with either Whipple or DP, macroscopy should be assessed pathologically, and the entire piece should be diligently sampled. By doing so, parameters fundamentally affecting the survey, such as tumor type and lymph node status, will be evaluated more accurately. In addition, rate of resection in benign lesions can be slightly reduced by performing FNAB with ERCP or EUS to the masses detected by imaging in the preoperative period.
C1 [Goret, Ceren Canbey] Hlth Sci Univ, Sancaktepe Res & Educ Hosp, Dept Surg Pathol, TR-34000 Istanbul, Turkey.
   [Goret, Nuri Emrah] Hlth Sci Univ, Kartal Res & Educ Hosp, Dept Gen Surg, Istanbul, Turkey.
   [Ozkan, Omer Faruk] Hlth Sci Univ, Umraniye Res & Educ Hosp, Dept Gen Surg, Istanbul, Turkey.
   [Kilic, Guray] Private Ekin Pathol, Dept Surg Pathol, Istanbul, Turkey.
RP Goret, CC (corresponding author), Hlth Sci Univ, Sancaktepe Res & Educ Hosp, Dept Surg Pathol, TR-34000 Istanbul, Turkey.
CR Adsay NV, 2014, AM J SURG PATHOL, V38, P480, DOI 10.1097/PAS.0000000000000165
   Atalay FO, 2015, ACTA MEDICA MEDITERR, V31, P383
   Bottger TC, 1999, WORLD J SURG, V23, P164
   Foroughi Forough, 2012, Gastroenterol Hepatol Bed Bench, V5, P179
   GORET CC, 2017, HAYDARPASA NUMUNE ME, V57, P107
   Iannuzzi C, 1993, ANN ITAL CHIR, V64, P305
   Iannuzzi Carlo, 1993, Annali Italiani di Chirurgia, V64, P301
   Kalogeraki A, 2016, ROM J INTERN MED, V54, P24, DOI 10.1515/rjim-2016-0002
   Karabulut M, 2017, ACTA MEDICA MEDITERR, V33, P613, DOI 10.19193/0393-6384_2017_4_091
   Karabulut S, 2016, ACTA MEDICA MEDITERR, V32, P1035, DOI 10.19193/0393-6384_2016_4_128
   Karoumpalis I, 2016, ANN GASTROENTEROL, V29, P155, DOI 10.20524/aog.2016.0007
   Kavanagh DO, 2008, THESCIENTIFICWORLDJO, V8, P1156, DOI 10.1100/tsw.2008.147
   Kilic MO, 2016, J TURGUT OZAL MED CE, V23, P306
   Lee YN, 2017, CANCER MED-US, V6, P582, DOI 10.1002/cam4.1034
   Lillemoe KD, 1999, ANN SURG, V229, P693, DOI 10.1097/00000658-199905000-00012
   Marcy M, 2002, ANN PATHOL, V22, P314
   Napolitano L, 2001, Ann Ital Chir, V72, P61
   Napolitano L, 2001, ANN ITAL CHIR, V72, P65
   Qiao QL, 2007, WORLD J SURG, V31, P137, DOI 10.1007/s00268-006-0213-3
   Tiberio G., 1997, Annali Italiani di Chirurgia, V68, P643
   van Roest MHG, 2008, ANN SURG, V248, P97, DOI 10.1097/SLA.0b013e31817b6609
   Whipple AO, 1935, ANN SURG, V102, P763, DOI 10.1097/00000658-193510000-00023
   Yeo CJ, 1997, ANN SURG, V226, P248, DOI 10.1097/00000658-199709000-00004
NR 23
TC 2
Z9 2
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1041
EP 1045
DI 10.19193/0393-6384_2018_4_159
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500022
DA 2022-07-14
ER

PT J
AU Grieco, M
   Salerno, M
   Tripi, G
   Lavano, F
   Romano, P
   Russo, D
   Lavano, SM
   Testa, D
   Cerroni, F
   Marotta, R
   Ro, LD
   Sorrentino, M
   Di Folco, A
   Magliulo, RM
   Gallai, B
   Marsala, G
   Montana, A
   Franco, S
   Geraci, D
   Chisari, MG
   Picciocchi, E
   Cibelli, G
   Valenzano, A
   Polito, AN
   Murabito, P
   Giugliano, P
   Parisi, L
AF Grieco, Maria
   Salerno, Margherita
   Tripi, Gabriele
   Lavano, Francesco
   Romano, Palmira
   Russo, Daniela
   Lavano, Serena Marianna
   Testa, Davide
   Cerroni, Francesco
   Marotta, Rosa
   Ro, Lucrezia D'Oro
   Sorrentino, Michele
   Di Folco, Annabella
   Magliulo, Rosaria Martina
   Gallai, Beatrice
   Marsala, Gabriella
   Montana, Angelo
   Franco, Sabrina
   Geraci, Diego
   Chisari, Mario Giuseppe
   Picciocchi, Elisabetta
   Cibelli, Giuseppe
   Valenzano, Anna
   Polito, Anna Nunzia
   Murabito, Paolo
   Giugliano, Pasquale
   Parisi, Lucia
TI A BRIEF REVIEW ABOUT ANXIETY AND AGGRESSIVE BEHAVIOR IN PEDIATRIC AGE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE pediatric anxiety; aggressive behaviour; pediatric age
ID MONOSYMPTOMATIC NOCTURNAL ENURESIS; CHILDHOOD ABSENCE EPILEPSY;
   SLEEP-APNEA SYNDROME; QUALITY-OF-LIFE; HYPERTHERMIC REACTIONS; OXIDATIVE
   STRESS; HEME OXYGENASE-1; OBESE CHILDREN; OPEN-LABEL; MIGRAINE
AB Anxiety can be considered a normal experience of the human being and as such also of the child. It manifests itself in different ways according to the level of development: in the smaller the child, the more anxiety is expressed with manifestations that involve the whole organism, becoming evident either with motor excitement or with physical discomfort. As the psychic apparatus is structured, anxiety is experienced as an inner phenomenon and is experienced as an unpleasant state. Fortunately, we are all a bit anxious, even if there are some people who are more, others less.
C1 [Grieco, Maria] Presidio Riabilitaz Diocleziano, Naples, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorder, St Benoit La Foret, France.
   [Lavano, Francesco; Lavano, Serena Marianna; Marotta, Rosa] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Testa, Davide; Di Folco, Annabella; Parisi, Lucia] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Ro, Lucrezia D'Oro] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Sorrentino, Michele] NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp Castel Volturno CE, Castel Volturno, Italy.
   [Magliulo, Rosaria Martina] Ctr Scoliosi SRL, Naples, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Osped Riuniti Foggia, Struttura Complessa Farm, Foggia, Italy.
   [Montana, Angelo; Franco, Sabrina; Geraci, Diego] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, Catania, Italy.
   [Cibelli, Giuseppe] INPS, Catania, Italy.
   [Picciocchi, Elisabetta; Cibelli, Giuseppe; Valenzano, Anna] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Murabito, Paolo] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
   [Giugliano, Pasquale] UOC Med Legale, Syracuse, Italy.
   [Giugliano, Pasquale] Azienda Osped St Anna & San Sebastiano Caserta, Caserta, Italy.
RP Parisi, L (corresponding author), Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
RI Cibelli, Giuseppe/AAC-2635-2019; Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; CIBELLI,
   GIUSEPPE/0000-0002-5371-2584; Cerroni, Francesco/0000-0003-3024-5482;
   Murabito, Paolo/0000-0002-2662-1898
CR Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSL, V8
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2017, EUR J PHYS REHAB MED, V53, P643, DOI 10.23736/S1973-9087.16.04037-5
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Gallelli Luca, 2017, Microrna, V6, P152, DOI 10.2174/2211536606666170913152821
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Li Volti G, 2004, BIOCHEM BIOPH RES CO, V315, P517, DOI 10.1016/j.bbrc.2004.01.090
   Matricardi S, 2018, ACTA NEUROL SCAND, V137, P575, DOI 10.1111/ane.12902
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSL, V8
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Moscatelli F, 2016, PLOS ONE, V24
   Moscatelli F, 2015, BIOL MED, V7
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Rizzo M, 2015, J CLIN ENDOCR METAB, V100, P603, DOI 10.1210/jc.2014-2291
   Santillo A, 2009, INT DAIRY J, V19, P655, DOI 10.1016/j.idairyj.2009.06.011
   Santillo A, 2009, J DAIRY SCI, V92, P1330, DOI 10.3168/jds.2008-1598
   Smirni D, 2018, J NERV MENT DIS, V206, P628, DOI 10.1097/NMD.0000000000000853
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2005, INT J CARDIOL, V104, P152, DOI 10.1016/j.ijcard.2004.10.051
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2018, ACTA NEUROL SCAND, V138, P523, DOI 10.1111/ane.13006
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 98
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2071
EP 2079
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900001
DA 2022-07-14
ER

PT J
AU Grieco, M
   Salerno, M
   Tripi, G
   Lavano, F
   Romano, P
   Russo, D
   Lavano, SM
   Cerroni, F
   Marotta, R
   D'oro, L
   Franco, S
   Picciocchi, E
   Geraci, D
   Chisari, MG
   Marsala, G
   Polito, AN
   Sorrentino, M
   Magliulo, RM
   Di Folco, A
   Parisi, L
   Testa, D
   Murabito, P
   Giugliano, P
   Gallai, B
AF Grieco, Maria
   Salerno, Margherita
   Tripi, Gabriele
   Lavano, Francesco
   Romano, Palmira
   Russo, Daniela
   Lavano, Serena Marianna
   Cerroni, Francesco
   Marotta, Rosa
   D'oro, Lucrezia
   Franco, Sabrina
   Picciocchi, Elisabetta
   Geraci, Diego
   Chisari, Mario Giuseppe
   Marsala, Gabriella
   Polito, Anna Nunzia
   Sorrentino, Michele
   Magliulo, Rosaria Martina
   Di Folco, Annabella
   Parisi, Lucia
   Testa, Davide
   Murabito, Paolo
   Giugliano, Pasquale
   Gallai, Beatrice
TI PSYCHOPATHOLOGICAL AND PSYCHODYNAMIC HYPOTHESES FOR PEDIATRIC STUTTERING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE pediatric stuttering; psychodynamic hypotheses; anxiety disorders
ID AUTISM SPECTRUM DISORDERS; MONOSYMPTOMATIC NOCTURNAL ENURESIS; PRIMARY
   CILIARY DYSKINESIA; SLEEP-APNEA SYNDROME; WEIGHT-LOSS PROGRAM;
   QUALITY-OF-LIFE; BEHAVIORAL-DISORDERS; CHILDHOOD MIGRAINE; SOCIAL
   ANXIETY; OREXIN SYSTEM
AB Stuttering is a common language alteration in pediatric age consisting in repetitions and blocks, which entail a break in the rhythm and melody of the speech. According to the WHO it is a disorder of the rhythm?! of the word, the subject knows precisely what he would like to .ray, but at the same time he is not able to say it. It is a great inconvenience for those affected, also because the slowing down of speaking is not about thought or cognitive skills.
C1 [Grieco, Maria] Univ Palermo, Presidio Riabilitaz Diocleziano, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Lavano, Francesco; Lavano, Serena Marianna; Marotta, Rosa] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Romano, Palmira; Cerroni, Francesco] Ctr Riabilitaz LARS, Sarno, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Di Folco, Annabella; Parisi, Lucia; Testa, Davide] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [D'oro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Franco, Sabrina; Geraci, Diego] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, I-95123 Catania, Italy.
   [Picciocchi, Elisabetta] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Chisari, Mario Giuseppe] INPS, Catania, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Struttura Complessa Farm, Osped Riuniti Foggia, Foggia, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp Castel Volturno CE, NICU, Preterm & High Risk Newborn Neurodev Follow Serv, Castel Volturno, Italy.
   [Magliulo, Rosaria Martina] Ctr Scoliosi SRL, Naples, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Giugliano, Pasquale] Azienda Osped St Anna & San Sebastiano Caserta, UOC Med Legale, Caserta, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
RP Parisi, L (corresponding author), Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; Murabito, Paolo/0000-0002-2662-1898;
   Cerroni, Francesco/0000-0003-3024-5482
CR Albenzio M, 2018, J DAIRY SCI, V101, P4842, DOI 10.3168/jds.2017-13104
   Albenzio M, 2016, J DAIRY SCI, V99, P5032, DOI 10.3168/jds.2015-10704
   Albenzio M, 2017, NUTRIENTS IN DAIRY AND THEIR IMPLICATIONS FOR HEALTH AND DISEASE, P435, DOI 10.1016/B978-0-12-809762-5.00034-6
   Alm PA, 2014, J FLUENCY DISORD, V40, P5, DOI 10.1016/j.jfludis.2014.01.004
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00188
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Craig A, 2014, J FLUENCY DISORD, V40, P35, DOI 10.1016/j.jfludis.2014.01.001
   Craig-McQuaide A, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00884
   Cruz C, 2018, REV NEUROLOGIA, V66, P59, DOI 10.33588/rn.6602.2017151
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Garcia-Barrera MA, 2015, J FLUENCY DISORD, V44, P1, DOI 10.1016/j.jfludis.2015.03.002
   Gigante E, 2018, ACTA MEDICA MEDITERR, V34, P1295, DOI 10.19193/0393-6384_2018_5_199
   Iverach L, 2017, AM J SPEECH-LANG PAT, V26, P540, DOI 10.1044/2016_AJSLP-16-0033
   Iverach L, 2014, J FLUENCY DISORD, V40, P69, DOI 10.1016/j.jfludis.2013.08.003
   Jones R, 2014, SEMIN SPEECH LANG, V35, DOI 10.1055/s-0034-1371755
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Mawson AR, 2016, EUR NEUROL, V76, P244, DOI 10.1159/000452215
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSL, V8
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Neef NE, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0579-4
   Neumann K, 2017, DTSCH ARZTEBL INT, V114, P383, DOI 10.3238/arztebl.2017.0383
   Nippold MA, 2018, LANG SPEECH HEAR SER, V49, P4, DOI 10.1044/2017_LSHSS-17-0066
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perez HR, 2016, CAN FAM PHYSICIAN, V62, P479
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Sasisekaran J, 2014, SEMIN SPEECH LANG, V35, DOI 10.1055/s-0034-1371754
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Smith KA, 2014, J FLUENCY DISORD, V40, P22, DOI 10.1016/j.jfludis.2014.01.003
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P1271, DOI 10.19193/0393-6384_2018_5_196
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Ward D, 2013, J FLUENCY DISORD, V38, P134, DOI 10.1016/j.jfludis.2013.02.007
   Yairi E, 2013, J FLUENCY DISORD, V38, P66, DOI 10.1016/j.jfludis.2012.11.002
NR 98
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2171
EP 2178
DI 10.19193/0393-6384_2018_4s_332
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900012
DA 2022-07-14
ER

PT J
AU Gu, TS
   Li, B
AF Gu Tieshu
   Li Bo
TI THE APPLICATION OF PTCD IN PATIENT WITH MALIGNANT OBSTRUCTIVE JAUNDICE
   CAUSED BY LOW-GRADE PANCREATIC CANCER:A CASE REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Pancreatic Cancer; Obstructive Jaundice; PTCD; Palliative treatment
AB Introduction: Pancreatic cancer is a type of high-grade malignant tumor of digestive tract, which is difficult to diagnose and treat. The obstructive jaundice induced by pancreatic cancer may lead to hepatic failure and accelerated progress of disease. On this basis, percutaneous transhepaticcholangial drainage (PTCD) and biliary tract external drainage (BTED) can relieve the symptoms of obstructive jaundice induced by pancreatic cancer, and improve patients' disease condition their quality of life.
   Materials and method: In this research, the selected pancreatic cancer patient (who had been misdiagnosed to take gall-bladder. jejunum side to side anastomosis + jejuntan-jejuntan side to side anastomosis internal drainage rather than take pancreaticoduodenectomy, and refused to take surgical treatment again) suffered the complication of obstructive jaundice andserious infection. interventional therapies with PTCD and BTED were performed to relieve the symptoms of obstructive jaundice and control the infection.
   Results: Through implementing interventional treatment of complications of pancreatic cancer, patients' life quality was improved and their life time was prolonged.
   Discussion:We believe interventional therapy is a safe and effective Conservative treatment through this case study.
C1 [Gu Tieshu; Li Bo] Hebei Med Univ, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China.
RP Li, B (corresponding author), Hebei Med Univ, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China.
EM 68309175@qq.com
CR Baterdene Namsrai, 2016, Korean J Hepatobiliary Pancreat Surg, V20, P137, DOI 10.14701/kjhbps.2016.20.3.137
   Bonnel DH, 2012, AM J SURG, V203, P675, DOI 10.1016/j.amjsurg.2012.02.001
   Choi JH, 2017, GASTROINTEST ENDOSC, V85, P357, DOI 10.1016/j.gie.2016.07.067
   [范恒伟 Fan Hengwei], 2014, [中华肝胆外科杂志, Chinese Journal of Hepatobiliary Surgery], V20, P92
   Fu Yi, 2014, TUMOR IMAGING, V23, P286
   Garcarek J, 2012, ADV CLIN EXP MED, V21, P621
   Hong HP, 2013, KOREAN J RADIOL, V14, P789, DOI 10.3348/kjr.2013.14.5.789
   Hwang SI, REAPPRAISAL PERCUTAN
   Kubo K, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0531-3
   Liu Yuting, 2015, CHINESE J DIGESTIVE, P270
   [牛洪涛 NIU Hongtao], 2011, [中华放射学杂志, Chinese Journal of Radiology], V45, P964
   Song GW, 2012, AM J SURG, V203, P675, DOI [10.1016/j.amjsurg.2012.02.001, DOI 10.1016/J.AMJSURG.2012.02.001]
   Xu Chuan, 2015, Asian Pac J Cancer Prev, V16, P2543
   Yamabe A, 2016, CLIN J GASTROENTEROL, V9, P324, DOI 10.1007/s12328-016-0673-4
   Yan T., 2014, THESIS
   Zhao Jun Kang, J HEPATOPANCREATOBIL, V25, P432
NR 16
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1837
EP 1842
DI 10.19193/0393-6384_2018_6_283
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400034
DA 2022-07-14
ER

PT J
AU Gulsen, M
   Atici, E
   Aytar, A
   Sahin, FN
AF Gulsen, Mustafa
   Atici, Emine
   Aytar, Aydan
   Sahin, Fatma Nese
TI EFFECTS OF TRACTION THERAPY IN ADDITION TO CONVENTIONAL PHYSIOTHERAPY
   MODALITIES ON PAIN AND FUNCTIONALITY IN PATIENTS WITH LUMBAR DISC
   HERNIATION: RANDOMIZED CONTROLLED STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Lumbar Disc; Hernia; Traction
ID LOW-BACK-PAIN; INTERVERTEBRAL DISC; TURKISH VERSION; DISABILITY;
   VALIDATION
AB The aim of this study is to investigate the effects of traction therapy in addition to conventional physiotherapy modalities on pain and functionality in patients with chronic lumbar disc herniation. Patients (n=210, mean age=48.20 +/- 13.07 years, mean height=167.2 +/- 9.34 and mean weight= 74.86 +/- 13.47) were diagnosed with lumbar disc hernia through a clinical evaluation and an MRI and were graded as "protrusion or bulging lumbar herniation" according to the Macnab Classification. Patients were then randomly divided into 3 groups: the first group (n=70) underwent a hot pack (HP), Transcutaneous Electrical Nerve Stimulation (TENS), ultrasounds (US) and home exercise (HE); the second group (n=75) underwent additional traction therapy compared to the first group and the third group (n=65) was given only home exercise. Sociodemographic and clinical characteristics of patients were recorded. All assessments were done before and after the treatments (4th week). Pain and functional status of patients were evaluated. There were no significant differences between the groups (p>0.05) except for pain score (p<0.05). Comparing within groups showed improvements in all parameters after treatment (p<0.05). Although there was a significant difference between group 1 and group 3, group 2 and group 3 in pain scores (p< 0.05), there was no significant difference found for other outcome measures.It was observed that in all treatment groups, there was a significant reduction of pain and functional impairment. Traction therapy wasn't more effective than other treatments for patients with lumbar disc herniation. As a clinical outcome not only physiotherapy modalities are effective, but also specific home exercises could be considered as a form of treatment for patients with lumbar disc hernia.
C1 [Gulsen, Mustafa] Baskent Univ, Vocat Sch Hlth, Dept Therapy & Rehabil, Ankara, Turkey.
   [Atici, Emine] Okan Univ, Dept Phys Therapy & Rehabil, Fac Hlth Sci, Istanbul, Turkey.
   [Aytar, Aydan] Baskent Univ, Dept Phys Therapy & Rehabil, Fac Hlth Sci, Ankara, Turkey.
   [Sahin, Fatma Nese] Ankara Univ, Fac Sport Sci, Ankara, Turkey.
RP Gulsen, M (corresponding author), Baskent Univ Baglica, Dept Therapy & Rehabil, Vocat Sch Hlth Sci, Ankara, Turkey.
EM mgulsen81@hotmail.com
RI Atıcı, Emine/AAL-5444-2020; SAHIN, FATMA NESE/AAG-9096-2020
OI SAHIN, FATMA NESE/0000-0002-8777-5807
CR Azimi Parisa, 2018, J Spine Surg, V4, P102, DOI 10.21037/jss.2018.03.11
   Boos N, 2000, SPINE, V25, P1484, DOI 10.1097/00007632-200006150-00006
   CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9
   Choi J, 2015, J PHYS THER SCI, V27, P481, DOI 10.1589/jpts.27.481
   Chow DHK, 2017, MUSCULOSKEL SCI PRAC, V29, P78, DOI 10.1016/j.msksp.2017.03.007
   Jung O, 2000, EFFECTS TRADITIONAL
   Klineberg Eric, 2015, Instr Course Lect, V64, P405
   Kreiner DS, 2014, SPINE J, V14, P180, DOI 10.1016/j.spinee.2013.08.003
   Kucukdeveci AA, 2001, SPINE, V26, P2738, DOI 10.1097/00007632-200112150-00024
   Leventoglu F, 2004, EGE FIZ TIP REH DERG, V10, P23
   MACNAB I, 1971, J BONE JOINT SURG AM, VA 53, P891, DOI 10.2106/00004623-197153050-00004
   Mathews J A, 1975, Rheumatol Rehabil, V14, P222, DOI 10.1093/rheumatology/14.4.222
   Thomas E, 2018, INT J SPORTS MED, V39, P243, DOI 10.1055/s-0044-101146
   Yakut E, 2004, SPINE, V29, P581, DOI 10.1097/01.BRS.0000113869.13209.03
   Yang HS, 2014, J PHYS THER SCI, V26, P1049, DOI 10.1589/jpts.26.1049
NR 15
TC 3
Z9 3
U1 0
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 2017
EP 2021
DI 10.19193/0393-6384_2018_6_315
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400066
DA 2022-07-14
ER

PT J
AU Gunes, H
   Aksu, E
   Nacar, H
   Kerkutluoglu, M
   Tatlisu, MA
AF Gunes, Hakan
   Aksu, Ekrem
   Nacar, Huseyin
   Kerkutluoglu, Murat
   Tatlisu, Mustafa Adem
TI INCREASED SOLUBLE ST2 LEVEL PREDICTS LENGTH OF STAY IN PATIENTS WITH
   ACUTE HEART FAILURE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Heart failure; ST2 levels; Length of stay; Biomarkers
ID LONG-TERM MORTALITY; ELDERLY-PATIENTS; CARE; HOSPITALIZATION;
   ASSOCIATION; DIAGNOSIS; EPIDEMIOLOGY; POPULATION; GUIDELINES; BIOMARKER
AB Introduction: The increased length of stay of patients with acute heart failure increases costs and morbidity. The association of soluble suppression of tumorigenicity-2 (ST2) levels with mortality and morbidity in patients with heart failure has been established. We investigated the relationship between ST2 levels in patients with acute decompensated heart failure and the length of stay.
   Materials and methods: This study included 143 patients who were hospitalized for acute decompensated heart failure. The average length of stay was 4 days. Patients were divided into 2 groups: group 1 consisted of patients who stayed 4 days or less; group 2 consisted of patients who stayed more than 4 days.
   Results: The serum ST2 levels were greater in the group 2 as compared to the group 1 (32 ng/mL (3-68 ng/mL) versus 47 ng/mL (9-298 ng/mL) (P < 0.001). The optimal cutoff level of ST2 in the prediction of length of stay was > 39 U/mL, with a specificity of 95.8% and a sensitivity of 96% (area under the curve, 0.979; 95% confidence interval [CI], 0.953-0.992). In the multivariate logistic regression model, ST2 levels of > 35 U/mL on admission (OR=10.750, 95% CI: 4.218-27.395, p<0.001), were also associated with a longer length of stay after adjustment for variables was found to be statistically significant in univariate analysis and correlated with ST2 levels.
   Conclusion: In our study, the ST2 levels were found to be an independent marker for the length of stay in patients with acute decompensated heart failure.
C1 [Gunes, Hakan; Aksu, Ekrem; Kerkutluoglu, Murat] Sutcu Imam Univ, Dept Cardiol, Kahramanmaras, Turkey.
   [Nacar, Huseyin] Adiyaman Univ Training & Res Hosp, Dept Cardiol, Adiyaman, Turkey.
   [Tatlisu, Mustafa Adem] Texas A&M Univ, Texas A&M Inst Preclin Studies, College Stn, TX 77843 USA.
RP Gunes, H (corresponding author), Kahramanmaras Sutcu Imam Univ, Sch Med, Dept Cardiol, Kahramanmaras, Turkey.
EM drhakangunes83@hotmail.com
RI Kerkütlüoğlu, Murat/AAA-6780-2021; TATLISU, Mustafa A/H-5340-2018
OI Kerkütlüoğlu, Murat/0000-0003-1007-0574; TATLISU, Mustafa
   A/0000-0003-1058-7194
CR Ahmad T, 2012, NAT REV CARDIOL, V9, P347, DOI 10.1038/nrcardio.2012.37
   Ark HYV, 2015, EUR J HLTH SCI, V1, P1
   Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165
   Chaudhry SI, 2007, CIRCULATION, V116, P1549, DOI 10.1161/CIRCULATIONAHA.107.690768
   Cowie MR, 2000, HEART, V83, P505, DOI 10.1136/heart.83.5.505
   Dickstein K, 2008, EUR J HEART FAIL, V10, P933, DOI 10.1016/j.ejheart.2008.08.005
   Felker GM, 2013, CIRC-HEART FAIL, V6, P1172, DOI 10.1161/CIRCHEARTFAILURE.113.000207
   Formiga F, 2008, EUR J INTERN MED, V19, P198, DOI 10.1016/j.ejim.2007.09.007
   Goldsmith Steven R, 2006, Curr Cardiol Rep, V8, P204, DOI 10.1007/s11886-006-0035-9
   Gul I, 2017, ANATOL J CARDIOL, V18, P200, DOI 10.14744/AnatolJCardiol.2017.7741
   Kaya H, 2017, TEX HEART I J, V44, P22, DOI 10.14503/THIJ-15-5626
   Kovesdy CP, 2012, CIRCULATION, V125, P677, DOI 10.1161/CIRCULATIONAHA.111.065391
   Ky B, 2011, CIRC-HEART FAIL, V4, P180, DOI 10.1161/CIRCHEARTFAILURE.110.958223
   Lu J, 2010, CLIN CHIM ACTA, V411, P1825, DOI 10.1016/j.cca.2010.07.014
   Bonilla-Palomas JL, 2014, J CARD FAIL, V20, P350, DOI 10.1016/j.cardfail.2014.01.016
   Manzano-Fernandez S, 2011, AM J CARDIOL, V107, P259, DOI 10.1016/j.amjcard.2010.09.011
   McMurray JJV, 2014, NEW ENGL J MED, V371, P993, DOI 10.1056/NEJMoa1409077
   Mueller C, 2006, AM HEART J, V151, P845, DOI 10.1016/j.ahj.2005.06.046
   Mueller T, 2008, CLIN CHEM, V54, P752, DOI 10.1373/clinchem.2007.096560
   Ni HY, 1998, ARCH INTERN MED, V158, P1231, DOI 10.1001/archinte.158.11.1231
   Rami K, 2013, EXPERT REV CARDIOVAS, V11, P1125, DOI 10.1586/14779072.2013.827466
   Rehman SU, 2008, J AM COLL CARDIOL, V52, P1458, DOI 10.1016/j.jacc.2008.07.042
   Rich MW, 1997, J AM GERIATR SOC, V45, P968, DOI 10.1111/j.1532-5415.1997.tb02968.x
   Sahin S, 2012, ANATOL J CARDIOL, V12, P123, DOI 10.5152/akd.2012.038
   Verdugo FJ, 2014, REV MED CHILE, V142, P61, DOI 10.4067/S0034-98872014000100010
   Weinberg EO, 2003, CIRCULATION, V107, P721, DOI 10.1161/01.CIR.0000047274.66749.FE
   Whellan DJ, 2011, J CARD FAIL, V17, P649, DOI 10.1016/j.cardfail.2011.04.005
   Whellan DJ, 2010, CIRC-CARDIOVASC QUAL, V3, P33, DOI 10.1161/CIRCOUTCOMES.109.854760
   Wojtczak-Soska K, 2014, KARDIOL POL, V72, P725, DOI 10.5603/KP.a2014.0085
   Yucel O, 2017, HERZ
   Zannad F, 2011, NEW ENGL J MED, V364, P11, DOI 10.1056/NEJMoa1009492
NR 31
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1469
EP 1474
DI 10.19193/0393-6384_2018_5_223
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700045
DA 2022-07-14
ER

PT J
AU Guo, CY
   Sun, YX
   Zheng, WW
   Zhan, YQ
   Wang, K
   Yu, SQ
   Zhu, WW
   Li, KQ
   Lu, C
AF Guo, Chenyu
   Sun, Yongxu
   Zheng, Wenwen
   Zhan, Yiqiang
   Wang, Ke
   Yu, Shengqiang
   Zhu, Weiwei
   Li, Kangqi
   Lu, Congxiao
TI EFFECTS OF TACROLIMUS TROUGH CONCENTRATIONS ON LONG-TERM OUTCOMES OF
   KIDNEY TRANSPLANT RECIPIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Tacrolimus; Kidney transplantation; Allograft function; Clinical
   parameters; Chinese kidney transplant recipients
ID RENAL-TRANSPLANTATION; ACUTE REJECTION; BLOOD-CONCENTRATIONS;
   RANDOMIZED-TRIAL; WHOLE-BLOOD; MULTICENTER; THERAPY; ANEMIA; LIVER;
   FK506
AB In order to investigate the impact of tacrolimus trough concentrations (TTC) on long-term outcome for Chinese kidney transplant recipients, the corresponding information of ninety six Chinese kidney transplant recipients were collected in the following-up period after surgery. TTC were subdivided into four groups according to TTC range (Group I: <= 6 ng/mL, Group II: 6-10 ng/mL, Group III: 10-15 ng/mL, and Group IV: >15 ng/mL), and then the clinical data of each group were analyzed. The correlations of daily doses of tacrolimus, TTC, and clinical parameters were evaluated by the method of univariate factor analysis. Based on the results, the appropriate range of TTC for Chinese kidney transplant recipients might be 6-15 ng/mL. Compared with the ranges of <= 6 ng/mL and >15 ng/mL, the patients whose TTC were maintained in the range of 6-15 ng/mL had better allograft function and low risks of moderate/severe anemia and infection. The main clinical parameters significantly affecting daily doses of tacrolimus and TTC were also provided. The result of our study might be useful for guiding clinical monitoring of tacrolimus. Furthermore, it could provide astrong support for the clinical treatment forkidney transplant recipients.
C1 [Guo, Chenyu; Sun, Yongxu; Zheng, Wenwen; Zhu, Weiwei; Li, Kangqi; Lu, Congxiao] Yuhuangding Hosp, Dept Pharm, 20 Yuhuangding Dong Rd, Yantai, Shandong, Peoples R China.
   [Zhan, Yiqiang] Fudan Univ, Inst Clin Epidemiol, Sch Publ Hlth, Shanghai, Peoples R China.
   [Wang, Ke; Yu, Shengqiang] Yuhuangding Hosp, Dept Urol, Yantai, Peoples R China.
RP Lu, C (corresponding author), Yuhuangding Hosp, Dept Pharm, 20 Yuhuangding Dong Rd, Yantai, Shandong, Peoples R China.
EM shgcy@vip.qq.com
FU Yantai science and technology development planning, China [2014WS011]
FX This study was supported by a grant from Yantai science and technology
   development planning, China (2014WS011)
CR BACKMAN L, 1994, TRANSPLANTATION, V57, P519
   Borobia AM, 2009, THER DRUG MONIT, V31, P436, DOI 10.1097/FTD.0b013e3181a8f02a
   Bottiger Y, 1999, BRIT J CLIN PHARMACO, V48, P445
   Bowman LJ, 2008, EXPERT OPIN PHARMACO, V9, P635, DOI 10.1517/14656566.9.4.635
   Choukroun G, 2012, J AM SOC NEPHROL, V23, P360, DOI 10.1681/ASN.2011060546
   Ekberg H, 2007, NEW ENGL J MED, V357, P2562, DOI 10.1056/NEJMoa067411
   Heinze G, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4018
   Hu RH, 2000, TRANSPL P, V32, P1689, DOI 10.1016/S0041-1345(00)01413-5
   Hummel AD, 2011, TRANSPL P, V43, P1343, DOI 10.1016/j.transproceed.2011.02.029
   Iwamoto H, 2014, TRANSPL P, V46, P496, DOI 10.1016/j.transproceed.2013.12.043
   Jones H, 2012, TRANSPLANTATION, V93, P923, DOI 10.1097/TP.0b013e31824b36fa
   Laskow DA, 1996, TRANSPLANTATION, V62, P900, DOI 10.1097/00007890-199610150-00005
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Margreiter R, 2002, LANCET, V359, P741, DOI 10.1016/S0140-6736(02)07875-3
   O'Seaghdha C, 2009, CLIN TRANSPLANT, V23, P462, DOI 10.1111/j.1399-0012.2009.01021.x
   Pascual J, 2006, TRANSPLANTATION, V82, P55, DOI 10.1097/01.tp.0000225806.80890.5e
   Rodriguez-Peralvarez M, 2013, J HEPATOL, V58, P262, DOI 10.1016/j.jhep.2012.09.019
   Sanders-Pinheiro H, 2012, TRANSPL P, V44, P2381, DOI 10.1016/j.transproceed.2012.07.137
   Staatz C, 2001, NEPHROL DIAL TRANSPL, V16, P1905, DOI 10.1093/ndt/16.9.1905
   Stratta P, 2012, EUR J CLIN PHARMACOL, V68, P671, DOI 10.1007/s00228-011-1150-0
   TANAKA H, 1987, TRANSPLANT P, V19, P11
   Tang L, 2002, CELL BIOL INT, V26, P75, DOI 10.1006/cbir.2001.0812
   Undre NA, 1998, TRANSPL P, V30, P1261, DOI 10.1016/S0041-1345(98)00234-6
   Vanrenterghem Y, 2005, AM J TRANSPLANT, V5, P87, DOI 10.1111/j.1600-6143.2004.00638.x
   Velickovic-Radovanovic R, 2012, GENDER MED, V9, P471, DOI 10.1016/j.genm.2012.10.003
   Velickovic-Radovanovic R, 2011, GENDER MED, V8, P23, DOI 10.1016/j.genm.2011.01.003
   Venkataramanan R, 2001, J CLIN PHARMACOL, V41, P542, DOI 10.1177/00912700122010429
   Vicari-Christensen M, 2009, PROG TRANSPLANT, V19, P277, DOI 10.7182/prtr.19.3.22u4114wn0l01140
   Wallemacq P, 2009, THER DRUG MONIT, V31, P139, DOI 10.1097/FTD.0b013e318198d092
   Webster AC, 2005, BMJ-BRIT MED J, V331, P810, DOI 10.1136/bmj.38569.471007.AE
   Wolbold R, 2003, HEPATOLOGY, V38, P978, DOI 10.1053/jhep.2003.50393
NR 31
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 725
EP 732
DI 10.19193/0393-6384_2018_3_112
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000017
DA 2022-07-14
ER

PT J
AU Guo, RM
   Mo, HL
   Jiang, JM
   Wu, ZJ
   Liu, C
   Meng, XH
   You, Q
   Wang, ZQ
   Wu, K
AF Guo, Runmin
   Mo, Hailiang
   Jiang, Jiamei
   Wu, Zijun
   Liu, Chang
   Meng, Xuehui
   You, Qiong
   Wang, Zhiqiang
   Wu, Keng
TI ELEVATED SERUM APURINIC/APYRIMIDINIC ENDONUCLEASE 1 WITH DNA REPAIR
   DYSFUNCTION IN DIABETIC CARDIOMYOPATHY PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Diabetic cardiomyopathy; High glucose; Apurinic/Apyrimidinic
   Endonuclease 1; Apoptosis
ID GLOBAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; REACTIVE OXYGEN; FACTOR-I;
   DAMAGE; MELLITUS; GENE; MECHANISMS; APE1/REF-1; APOPTOSIS
AB Background: This study is aimed at evaluating whether DNA repair protein Apurinic/Apyrimidinic Endonuclease 1 (APE1) correlates with diabetic cardiomyopathy(DCM).
   Methods: 32 patients with DCM, 62 DM patients and 60 control subjects were enrolled. 8-OHdG (a marker of oxidative DNA damage) were measured in serum. Expression and DNA repair enzyme activity of APE1 were tested by ELISA kit and modified methods respectively. Cardiac diastolic and systolic function in patients were measured using echocardiography.
   Results: The 8-OHdG levels were higher than those of controls. Serum APE1 in DCM patients were elevated and its DNA repair activity was markedly reduced.
   Conclusions: Expression and DNA repair enzyme activity of APE1 were closely associated with heart function in DCM patients. Our results suggest that DNA repair deficiency of APE1 might be involved in cardiac injuries under diabetic context.
C1 [Guo, Runmin; Mo, Hailiang; Jiang, Jiamei; Wu, Zijun; Liu, Chang; You, Qiong; Wu, Keng] Guangdong Med Univ, Affiliated Hosp, Dept Cardiol, 57 Renmin Ave, Zhanjiang 524001, Guangdong, Peoples R China.
   [Wang, Zhiqiang] Guangdong Med Univ, Affiliated Hosp, Clin Res Ctr, 57 Renmin Ave, Zhanjiang 524001, Guangdong, Peoples R China.
   [Meng, Xuehui] Zhejiang Hosp, Healthcare Reform Res Dept, Dev Ctr, 216 Qingchun Rd, Hangzhou 310006, Zhejiang, Peoples R China.
   [Wang, Zhiqiang] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA.
RP Wu, K (corresponding author), Guangdong Med Univ, Affiliated Hosp, Dept Cardiol, 57 Renmin Ave, Zhanjiang 524001, Guangdong, Peoples R China.; Wang, ZQ (corresponding author), Guangdong Med Univ, Affiliated Hosp, Clin Res Ctr, 57 Renmin Ave, Zhanjiang 524001, Guangdong, Peoples R China.; Wang, ZQ (corresponding author), Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA.
EM zhi2050@163.com; wukeng1245@hotmail.com
FU China Natural Science Foundation [81670348]; Guangdong Provincial
   Natural Science Foundation [2016A030313678, 2015A030310359,
   2016A030310359]; Guangdong Provincial Medical Science Research Fund
   [A2016143]; Zhanjiang Municipal Financial Fund [2015C01006, 2014A01033];
   Science and Technology Project
FX These studies were supported by grants from China Natural Science
   Foundation(81670348), Guangdong Provincial Natural Science Foundation
   (2016A030313678; 2015A030310359; 2016A030310359), Guangdong Provincial
   Medical Science Research Fund (A2016143) and Science and Technology
   Project supported by Zhanjiang Municipal Financial Fund (2015C01006,
   2014A01033).
CR Al-Aubaidy HA, 2011, EUR J ENDOCRINOL, V164, P899, DOI 10.1530/EJE-11-0053
   [Anonymous], 2015, CURR EYE RES, V40, P378
   Aonuma T, 2016, STEM CELL TRANSL MED, V5, P1067, DOI 10.5966/sctm.2015-0281
   Bukhari SA, 2015, PAK J PHARM SCI, V28, P483
   Choi Sunga, 2016, Chonnam Med J, V52, P75, DOI 10.4068/cmj.2016.52.2.75
   Dandamudi S, 2014, J CARD FAIL, V20, P304, DOI 10.1016/j.cardfail.2014.02.007
   Jin SA, 2015, KOREAN CIRC J, V45, P364, DOI 10.4070/kcj.2015.45.5.364
   Kawase M, 1999, STROKE, V30, P441, DOI 10.1161/01.STR.30.2.441
   Lirussi L, 2016, ONCOTARGET, V7, P26293, DOI 10.18632/oncotarget.8477
   Liu Q, 2014, J DIABETES INVEST, V5, P623, DOI 10.1111/jdi.12250
   Merecz A, 2015, ADV MED SCI-POLAND, V60, P220, DOI 10.1016/j.advms.2015.04.001
   Mishra M, 2016, INVEST OPHTH VIS SCI, V57, P4035, DOI 10.1167/iovs.16-19073
   Naganuma T, 2010, AM J HYPERTENS, V23, P186, DOI 10.1038/ajh.2009.221
   Sengupta S, 2012, J HYPERTENS, V30, P917, DOI 10.1097/HJH.0b013e3283525124
   Stetler RA, 2016, P NATL ACAD SCI USA, V113, pE3558, DOI 10.1073/pnas.1606226113
   Stetler RA, 2010, P NATL ACAD SCI USA, V107, P3204, DOI 10.1073/pnas.1000030107
   Taniguchi N, 2016, ARCH BIOCHEM BIOPHYS, V595, P72, DOI 10.1016/j.abb.2015.11.024
   Wang WX, 2015, FREE RADICAL RES, V49, P1199, DOI 10.3109/10715762.2015.1033416
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 20
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1907
EP 1914
DI 10.19193/0393-6384_2018_6_296
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400047
DA 2022-07-14
ER

PT J
AU Guo, TW
   Zhu, BY
   Wu, QG
AF Guo, Taiwei
   Zhu, Bingyang
   Wu, Qingguo
TI CLINICAL OBSERVATION OF TREATMENT OF BADMINTON PLAYER WITH ELBOW JOINT
   DISLOCATION COMBINED WITH ULNAR CORONOID PROCESS FRACTURE BY OPEN
   REDUCTION AND INTERNAL FIXATION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE badminton player; elbow joint dislocation; ulnar coronoid process
   fracture; open reduction and internal fixation
AB Objective: To observe and analyze the effect of open reduction and internal fixation on badminton players with elbow joint dislocation combined with ulnar coronoid process fracture.
   Methods: A total of 180 badminton players with elbow joint dislocation and ulnar coronoid process fracture treated in our hospital were selected as the research objects and randomly divided into two groups: the reference group treated with traditional Kirschner wire tension band fixation and the research ,group treated with open reduction and internal fixation. Treatment effect of two groups was observed and compared.
   Results: By comparing good rates of treatment in both ,groups, the research group (93.33%) was significantly superior to the reference group (75.56%), P <0.05, statistically significant. By comparing incidence of complications between the two groups, the research group had significantly lower incidence (6.67%) than the reference group (22.22%), P <0.05, statistically significant. In addition, in terms of overall treatment satisfaction scale, the research group had higher satisfaction (97.78%) than the reference group (82.22%), P <0.05, statistically significant.
   Conclusion: For badminton players with elbow joint dislocation combined with ulnar coronoid process fracture, open reduction and internal fixation is an effective treatment means.
C1 [Guo, Taiwei; Zhu, Bingyang; Wu, Qingguo] Yangzhou Univ, Sch Phys Educ, Yangzhou 225009, Jiangsu, Peoples R China.
RP Guo, TW (corresponding author), Yangzhou Univ, Sch Phys Educ, Yangzhou 225009, Jiangsu, Peoples R China.
EM licewhet@163.com
CR Akay G, 2017, TURK J MED SCI, V47, P1715, DOI 10.3906/sag-1607-127
   Al-Aqeedi Rafid, 2017, HEART VIEWS, V12, P369
   Chbani B, 2015, CHIR MAIN, V31, P230
   Esim O, 2018, SAUDI PHARM J, V26, P53, DOI 10.1016/j.jsps.2017.10.013
   Khan A, 2018, PAK J PHARM SCI, V31, P31
   Khan SK, 2016, J MED CASE REPORTS, V12, P128
   Liu Junqiang, 2016, PUBLIC MED FORUM MAG, V20, P4213
   Luo Xiaoming, 2016, TIBETAN MED, V37, P9
   Peng Jinyang, 2017, TRADITIONAL CHINESE, V30, P28
   Qin JH, 2018, SAUDI J BIOL SCI, V25, P47, DOI 10.1016/j.sjbs.2016.08.002
   Shen YF, 2017, POL MARIT RES, V24, P102, DOI 10.1515/pomr-2017-0111
   Vinz H., 2016, Z ORTHOP UNFALL, V150, P98
   Vinz H, 2012, Z FUER ORTHOPAEDIE U, V150, P308
   Xie YZ, 2018, SAUDI J BIOL SCI, V25, P234, DOI 10.1016/j.sjbs.2017.08.006
   [徐铁锋 Xu Tiefeng], 2014, [中国现代医学杂志, China Journal of Modern Medicine], V24, P83
   Yang Guoyong, 2016, CHINESE J SPORTS MED, V35, P132
NR 16
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1571
EP 1574
DI 10.19193/0393-6384_2018_3s_243
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400019
DA 2022-07-14
ER

PT J
AU He, Q
   He, SZ
   Su, YS
   Wang, P
   Xiang, ST
   Su, W
   Mao, CW
AF He, Qian
   He, Shi-Zhen
   Su, Yun-Shan
   Wang, Peng
   Xiang, Shu-Tiang
   Su, Wei
   Mao, Chong-Wen
TI THE CORRELATION BETWEEN DIFFERENT HRCT PHENOTYPES AND SMOKING INDEX AND
   GOLD GRADUATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Chronic obstructive pulmonary disease; HRCT; Computer tomography;
   Phenotype; Pulmonary function
ID CLINICAL PHENOTYPES; COPD; FUTURE
AB Objective: This study aims to investigate the smoking index and lung function changes of chronic obstructive pulmonary disease (COPD) patients with different HRCT manifestations.
   Methods: A retrospective analysis was conducted on the pulmonary function of 56 patients. These patients were divided into three groups: phenotype A (Airway type), phenotype E (Emphysema type), and phenotype M (Mix type). Pulmonary function test (PFT) and high-resolution computed tomography (HRCT) were performed within three days. The imaging classification of patients was based on emphysema and bronchiectasis, which was assessed on HRCT images. Furthermore, the clinical characteristics and Global Initiative for Chronic Obstructive Lung Disease (GOLD) graduation among the different phenotypes were analyzed.
   Results: The smoking index of phenotype A, phenotype E and phenotype M was 359.47 +/- 114.24, 468.00 +/- 119.42 and 400.7 +/- 136.87, respectively, and the difference in smoking index among these three phenotypes was statistically significant (P<0.001). In phenotype A, the GOLD grade was mild in five patients, moderate in 21 patients, severe in four patients, and critically severe in one patient. In phenotype E, the GOLD grade was mild in one patient, moderate in two patients, severe in six patients, and critically severe in two cases. In phenotype M, GOLD grade was mild in one patient, moderate in three patients, severe in eight patients and critically severe in two patients. The difference in GOLD grades among these different phenotypes was statistically significant (P=0.006).
   Conclusion: Smoking is one of the risk factors that lead to emphysema. Patients with phenotype M had emphysema and bronchial wall thickening at the same time. Furthermore, these patients had the most severe airflow limitation, severe and critically severe GOLD grades, and the most obvious lung function damage in the middle and late stages of the disease.
C1 [He, Qian; He, Shi-Zhen; Su, Yun-Shan; Wang, Peng; Xiang, Shu-Tiang; Su, Wei; Mao, Chong-Wen] Kunming Med Univ, Affiliated Hosp 4, Peoples Hosp Yunnan Prov 2, Dept Radiol, Kunming 650000, Yunnan, Peoples R China.
RP Xiang, ST (corresponding author), Kunming Med Univ, Dept Radiol, Peoples Hosp Yunnan Prov 2, 176 Qingnian St, Kunming 650000, Yunnan, Peoples R China.; Xiang, ST (corresponding author), Kunming Med Univ, Affiliated Hosp 4, 176 Qingnian St, Kunming 650000, Yunnan, Peoples R China.
CR Agusti A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-122
   [Anonymous], 2016, GLOB STRAT DIAGN MAN
   Bai Yu, 2015, Zhonghua Jie He He Hu Xi Za Zhi, V38, P356
   Burgel PR, 2015, ANN AM THORAC SOC, V12, P289, DOI 10.1513/AnnalsATS.201501-011ED
   Fan L, 2014, CLIN RESPIR J, V8, P45, DOI 10.1111/crj.12033
   Fujimoto K, 2006, RESPIROLOGY, V11, P731, DOI 10.1111/j.1440-1843.2006.00930.x
   Han MK, 2010, AM J RESP CRIT CARE, V182, P598, DOI 10.1164/rccm.200912-1843CC
   Kim V, 2011, CHEST, V140, P626, DOI 10.1378/chest.10-2948
   Ley-Zaporozhan J, 2010, J MAGN RESON IMAGING, V32, P1340, DOI 10.1002/jmri.22376
   Izquierdo-Alonso JL, 2013, RESP MED, V107, P724, DOI 10.1016/j.rmed.2013.01.001
   Matsuoka S, 2010, RADIOGRAPHICS, V30, P55, DOI 10.1148/rg.301095110
   Miravitlles M, 2012, ARCH BRONCONEUMOL, V48, P86, DOI 10.1016/j.arbres.2011.10.007
   de Oca MM, 2012, EUR RESPIR J, V40, P28, DOI 10.1183/09031936.00141611
   Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102, DOI 10.1164/ajrccm.162.3.9907120
   Provinciali M, 2011, CURR OPIN PULM MED, V17, pS3, DOI 10.1097/01.mcp.0000410742.90463.1f
   Tan WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058932
   The Spanish COPD Guidelines(GESEPOC), 2011, ARCHRONCONENMOL, V7, P379
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Woodruff PG, 2015, LANCET, V385, P1789, DOI 10.1016/S0140-6736(15)60693-6
NR 19
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1031
EP 1036
DI 10.19193/0393-6384_2018_4_157
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500020
DA 2022-07-14
ER

PT J
AU He, Q
   Liu, Y
   Yang, NN
   Guan, YS
AF He, Qing
   Liu, Yang
   Yang, Ning-Ning
   Guan, Yong-Song
TI CURRENT STATUS OF TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION FOR
   HEPATOCELLULAR CARCINOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Transcatheter arterial chemoembolization; Embolization agents;
   Hepatocellular carcinoma; Combination therapy; Treatment outcome
ID DRUG-ELUTING BEADS; COLORECTAL LIVER METASTASES; TRANSARTERIAL
   CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; PROGNOSTIC-FACTORS; OILY
   CHEMOEMBOLIZATION; THERMAL ABLATION; FREE SURVIVAL; ANIMAL-MODEL; DC
   BEAD
AB Hepatocellular carcinoma (HCC) is a lethal disease that kills hundreds of thousands of people each year worldwide. Transcatheter arterial chemoembolization (TACE) is a widely used approach in clinical practice to treat HCC. Many patients with unresectable HCC benefited from this technique. Now, TACE has evolved into the first choice among non-surgical HCC's for its minimally invasive nature and definite therapeutic effects. However, this technique was beset with relative high incidence of complications plus low cure rate. For optimal TACE's antitumor effect, many efforts have been made in varies aspects of TACE procedure including alterative contrast agent, combination therapies, newly developed embolizing agents and evaluation techniques et al. Therefore, this paper reviews recent advances in TACE for HCC, highlighting newly developed embolization agents and TACE-based integrated therapies in an attempts to improve local curability which may help to get closer to ultimate success of HCC treatment.
C1 [He, Qing; Yang, Ning-Ning; Guan, Yong-Song] Sichuan Univ, West China Hosp, Dept Oncol, 37 Guoxuexiang St, Chengdu 610041, Sichuan, Peoples R China.
   [Liu, Yang] Sichuan Univ, West China Hosp, Dept Psychiat, Chengdu 610041, Sichuan, Peoples R China.
RP He, Q (corresponding author), Sichuan Univ, West China Hosp, Dept Oncol, 37 Guoxuexiang St, Chengdu 610041, Sichuan, Peoples R China.
CR Bastian P, 1998, EUR J PHARM BIOPHARM, V46, P243, DOI 10.1016/S0939-6411(98)00047-2
   Bilbao JI, 2008, J VASC INTERV RADIOL, V19, P1625, DOI 10.1016/j.jvir.2008.07.014
   Bonomo G, 2010, CARDIOVASC INTER RAD, V33, P552, DOI 10.1007/s00270-009-9752-y
   Brown DB, 2005, J VASC INTERV RADIOL, V16, P1661, DOI 10.1097/01.RVI.0000182160.26798.A2
   Chan SL, 2016, CANCER TREAT REV, V45, P77, DOI 10.1016/j.ctrv.2016.02.008
   Choe DH, 1997, INVEST RADIOL, V32, P260, DOI 10.1097/00004424-199705000-00002
   Chu KF, 2014, NAT REV CANCER, V14, P199, DOI 10.1038/nrc3672
   Dumortier J, 2006, DIGEST LIVER DIS, V38, P125, DOI 10.1016/j.did.2005.10.025
   Edeline J, 2015, LIVER CANCER, V4, P16, DOI 10.1159/000343878
   Facciorusso A, 2016, DIG LIVER DIS
   Favoulet P, 2001, ANTI-CANCER DRUG, V12, P801, DOI 10.1097/00001813-200111000-00003
   Gerunda GE, 2000, LIVER TRANSPLANT, V6, P619, DOI 10.1053/jlts.2000.8312
   Gomaa AI, 2015, WORLD J HEPATOL, V7, P673, DOI 10.4254/wjh.v7.i4.673
   He Q, 2013, WORLD J GASTROENTERO, V19, P9104, DOI 10.3748/wjg.v19.i47.9104
   He Q, 2012, WORLD J GASTROENTERO, V18, P6861, DOI 10.3748/wjg.v18.i46.6861
   He Q, 2011, WORLD J GASTROENTERO, V17, P2353, DOI 10.3748/wjg.v17.i18.2353
   Hong K, 2006, CLIN CANCER RES, V12, P2563, DOI 10.1158/1078-0432.CCR-05-2225
   Hsu KF, 2012, EUR J RADIOL, V81, P466, DOI 10.1016/j.ejrad.2010.12.058
   Hucke F, 2014, J HEPATOL, V60, P118, DOI 10.1016/j.jhep.2013.08.022
   Hui Yang, 2015, Hepatogastroenterology, V62, P1002
   Huo YR, 2015, JAMA ONCOL, V1, P756, DOI 10.1001/jamaoncol.2015.2189
   Jordan O, 2010, J VASC INTERV RADIOL, V21, P1084, DOI 10.1016/j.jvir.2010.02.042
   Kan Zuxing, 2008, Semin Intervent Radiol, V25, P77, DOI 10.1055/s-2008-1076685
   Kaseb Ahmed O, 2013, Recent Results Cancer Res, V190, P247, DOI 10.1007/978-3-642-16037-0_16
   Kekez D, 2014, TUMORI J, V100, P499, DOI 10.1700/1660.18160
   Kettenbach J, 2008, CARDIOVASC INTER RAD, V31, P468, DOI 10.1007/s00270-007-9280-6
   Kim DY, 2016, HEPATOL INT, V10, P883, DOI 10.1007/s12072-016-9722-9
   Kim JH, 2011, ANN SURG ONCOL, V18, P1624, DOI 10.1245/s10434-011-1673-8
   Kim JW, 2014, AM J GASTROENTEROL, V109, P1234, DOI 10.1038/ajg.2014.152
   Kim JH, 2017, CLIN MOL HEPATOL, V23, P42, DOI 10.3350/cmh.2016.0058
   Kokabi N, 2014, ABDOM IMAGING, V39, P969, DOI 10.1007/s00261-014-0127-8
   Kudo M, 2010, JPN J CLIN ONCOL, V40, pi19, DOI 10.1093/jjco/hyq123
   Lammer J, 2010, CARDIOVASC INTER RAD, V33, P41, DOI 10.1007/s00270-009-9711-7
   Lencioni R, 2012, CARDIOVASC INTER RAD, V35, P980, DOI 10.1007/s00270-011-0287-7
   Li JH, 2016, AM J CANCER RES, V6, P2109
   Livraghi T, 2000, RADIOLOGY, V214, P761, DOI 10.1148/radiology.214.3.r00mr02761
   Llovet JM, 2008, J HEPATOL, V48, pS20, DOI 10.1016/j.jhep.2008.01.022
   Loffroy R, 2013, QUANT IMAG MED SURG, V3, P196, DOI 10.3978/j.issn.2223-4292.2013.08.05
   Lopez-Benitez R, 2009, CARDIOVASC INTER RAD, V32, P615, DOI 10.1007/s00270-009-9568-9
   Lubienski A, 2004, ROFO-FORTSCHR RONTG, V176, P1794, DOI 10.1055/s-2004-813669
   Luo J, 2011, ANN SURG ONCOL, V18, P413, DOI 10.1245/s10434-010-1321-8
   Marelli L, 2007, CARDIOVASC INTER RAD, V30, P6, DOI 10.1007/s00270-006-0062-3
   Maruyama H, 2016, J GASTROENTEROL, V51, P21
   MATSUI O, 1993, RADIOLOGY, V188, P79, DOI 10.1148/radiology.188.1.8390073
   Minami Y, 2015, ONCOLOGY-BASEL, V89, P27, DOI 10.1159/000440628
   MONDAZZI L, 1994, HEPATOLOGY, V19, P1115, DOI 10.1016/0270-9139(94)90857-5
   Moreno-Luna LE, 2013, CARDIOVASC INTER RAD, V36, P714, DOI 10.1007/s00270-012-0481-2
   Morimoto M, 2010, CANCER-AM CANCER SOC, V116, P5452, DOI 10.1002/cncr.25314
   N'Kontchou G, 2009, HEPATOLOGY, V50, P1475, DOI 10.1002/hep.23181
   Nakamoto Y, 2011, CLIN EXP IMMUNOL, V163, P165, DOI 10.1111/j.1365-2249.2010.04246.x
   NAKAMURA H, 1989, RADIOLOGY, V170, P783, DOI 10.1148/radiology.170.3.2536946
   Nowicki Miroslaw L, 2014, Med Sci Monit, V20, P1353, DOI 10.12659/MSM.890480
   O'Suilleabhain CB, 2003, BRIT J SURG, V90, P325, DOI 10.1002/bjs.4045
   Okusaka T, 2012, INVEST NEW DRUG, V30, P2015, DOI 10.1007/s10637-011-9776-4
   Oliveri RS, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004787.pub2
   Onizuka H, 2017, ABDOM RADIOL, V42, P2544, DOI 10.1007/s00261-017-1168-6
   Pung LL, 2017, J VASC INTERV RADIOL, V28, P334, DOI 10.1016/j.jvir.2016.11.037
   Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006
   Rossi S, 1999, TUMORI, V85, P128
   Sahani DV, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-51
   Salem R, 2011, GASTROENTEROLOGY, V140, P497, DOI 10.1053/j.gastro.2010.10.049
   Shibata T, 2009, RADIOLOGY, V252, P905, DOI 10.1148/radiol.2523081676
   Shin SW, 2009, KOREAN J RADIOL, V10, P425, DOI 10.3348/kjr.2009.10.5.425
   Sieghart W, 2013, HEPATOLOGY, V57, P2261, DOI 10.1002/hep.26256
   Siskin GP, 2003, J VASC INTERV RADIOL, V14, P89, DOI 10.1097/01.RVI.000052296.26939.4c
   Song MJ, 2013, EUR J NUCL MED MOL I, V40, P865, DOI 10.1007/s00259-013-2366-2
   Sueyoshi E, 2015, J VASC SURG, V61, P298, DOI 10.1016/j.jvs.2014.07.088
   Takaki H, 2007, J VASC INTERV RADIOL, V18, P856, DOI 10.1016/j.jvir.2007.04.022
   Takaki S, 2012, CARDIOVASC INTER RAD, V35, P544, DOI 10.1007/s00270-011-0224-9
   Tang Y, 2006, J CONTROL RELEASE, V116, pE55, DOI 10.1016/j.jconrel.2006.09.047
   Tsurusaki M, 2015, LIVER CANCER, V4, P165, DOI 10.1159/000367739
   Vaidya Sandeep, 2008, Semin Intervent Radiol, V25, P204, DOI 10.1055/s-0028-1085930
   Varela M, 2007, J HEPATOL, V46, P474, DOI 10.1016/j.jhep.2006.10.020
   Vogl TJ, 2007, EUR RADIOL, V17, P1025, DOI 10.1007/s00330-006-0372-5
   Wang DX, 2014, RADIOLOGY, V272, P587, DOI 10.1148/radiol.14131311
   Wang YXJ, 2015, CHINESE J CANCER RES, V27, P96, DOI 10.3978/j.issn.1000-9604.2015.03.03
   Wu Lu, 2016, Anticancer Agents Med Chem, V16, P1155
   Xu HX, 2005, CLIN RADIOL, V60, P1018, DOI 10.1016/j.crad.2005.04.009
   Xu XH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/901642
   Xue TC, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-60
   Yamasaki T, 2002, CANCER-AM CANCER SOC, V95, P2353, DOI 10.1002/cncr.10966
   Yuan J, 2012, QUANT IMAGING MED SU, V2, P21, DOI [10.3978/j.issn.2223-4292.2012.01.06, 10.3978/j.issn.2223-4292.2012.11.04]
NR 82
TC 0
Z9 0
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 531
EP 542
DI 10.19193/0393-6384_2018_2_85
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400038
DA 2022-07-14
ER

PT J
AU Heidar, Z
   Bahramzadeh, S
   Motevasselian, M
   Nazari, BA
AF Heidar, Zahra
   Bahramzadeh, Sarah
   Motevasselian, Mahtab
   Nazari, Behnaz Amir
TI THE RELATIONSHIP BETWEEN BODY MASS INDEX (BMI) AND SERUM ANTI-MULLERIAN
   HORMONE (AMH) LEVELS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ovarian reserve; Anti-Mullerian Hormone (AMH); IVF candidate; infertile
   women
ID ASSISTED REPRODUCTIVE TECHNOLOGY; IN-VITRO FERTILIZATION;
   ANTIMULLERIAN-HORMONE; OVARIAN RESERVE; MENSTRUAL-CYCLE; AGE WOMEN;
   OBESITY; OVERWEIGHT
AB Background and objective: Reduced ovarian reserve is associated with a decrease in quality and quantity of oocytes and thus adverse effects in IVF cycles. Anti-Mullerian Hormone (AMH) has been accepted as a prognostic marker of ovarian reserve. The relationship between BMI and serum AMH levels has not been well documented. The main purpose of this study is to determine the relationship between BMI and AMH level in IVF candidate infertile women referred to an infertility clinic.
   Materials and methods: through a cross-sectional study, IVF candidates were recruited. BMI and serum AMH were measured. Then, stimulation of ovulation began on days 3-4. Patients were assigned to three groups with poor ovarian response (<= 3 oocytes), adequate ovarian response (4-12 oocytes) and excessive ovarian response (>12 oocytes) based on the number of oocytes retrieved.
   Results: The results of linear regression showed no significant relationship between AMH levels and BMI (P = 0.8). Only in overweight individuals, the likelihood of forming an oocyte was 10% higher than those with normal BMI, and this relationship was not observed for obese subjects (P = 0.3). In obese people, there is no relationship between AMH levels and poor and excessive ovarian responses.
   Discussion and conclusion: this study showed that AMH does not correlate with BMI. In obese infertile women, AMH is not an appropriate indicator of ovarian response.
C1 [Heidar, Zahra; Bahramzadeh, Sarah; Motevasselian, Mahtab; Nazari, Behnaz Amir] Shahid Beheshti Univ Med Sci, IRHRC, Tehran, Iran.
RP Bahramzadeh, S (corresponding author), Shahid Beheshti Univ Med Sci, IRHRC, Tehran, Iran.
EM sarah.bahramzadeh@hotmail.com
RI Heidar, zahra/AAC-4809-2019
CR Anderson RA, 2012, MATURITAS, V71, P28, DOI 10.1016/j.maturitas.2011.11.008
   Baraldi E, 2011, REPROD BIOMED ONLINE, V22, P341
   Buyuk E, 2011, FERTIL STERIL, V95, P2364, DOI 10.1016/j.fertnstert.2011.03.081
   Chang HJ, 2010, FERTIL STERIL, V94, P343, DOI 10.1016/j.fertnstert.2009.02.022
   Derman Seth G, 2003, Curr Womens Health Rep, V3, P375
   Dobbelsteyn CJ, 2001, INT J OBESITY, V25, P652, DOI 10.1038/sj.ijo.0801582
   Freeman EW, 2007, FERTIL STERIL, V87, P101, DOI 10.1016/j.fertnstert.2006.05.074
   Hamdine O, 2015, HUM REPROD, V30, P170, DOI 10.1093/humrep/deu266
   Hazout A, 2004, FERTIL STERIL, V82, P1323, DOI 10.1016/j.fertnstert.2004.03.061
   Hehenkamp WJK, 2006, J CLIN ENDOCR METAB, V91, P4057, DOI 10.1210/jc.2006-0331
   Heidar Z, 2015, J ENDOCRINOL INVEST
   Kupka MS, 2011, GYNECOL ENDOCRINOL, V27, P144, DOI 10.3109/09513590.2010.487617
   La Marca A, 2006, HUM REPROD, V21, P3103, DOI 10.1093/humrep/del291
   Maheshwari A, 2007, HUM REPROD UPDATE, V13, P433, DOI 10.1093/humupd/dmm017
   Malhotra N, 2013, ARCH GYNECOL OBSTET, V287, P161, DOI 10.1007/s00404-012-2528-7
   Meden-Vrtovec H, 2004, Clin Exp Obstet Gynecol, V31, P5
   Nardo LG, 2007, GYNECOL ENDOCRINOL, V23, P486, DOI 10.1080/09513590701532815
   Neeta S, 2013, J OBSTET GYN INDIA, V63, P268, DOI 10.1007/s13224-012-0318-6
   Organization WH., 1998, OB PREV MAN GLOB EP
   Popkin BM, 1998, NUTR REV, V56, P106
   Shaw CM, 2011, FERTIL STERIL, V95, P2718, DOI 10.1016/j.fertnstert.2011.05.051
   Skalba P, 2011, EUR J OBSTET GYN R B, V158, P254, DOI 10.1016/j.ejogrb.2011.06.006
   Steiner AZ, 2010, CONTRACEPTION, V81, P245, DOI 10.1016/j.contraception.2009.10.004
   Streuli I, 2008, FERTIL STERIL, V90, P395, DOI 10.1016/j.fertnstert.2007.06.023
   Su HI, 2008, MENOPAUSE, V15, P857, DOI 10.1097/gme.0b013e318165981e
   van Rooij IAJ, 2005, FERTIL STERIL, V83, P979, DOI 10.1016/j.fertnstert.2004.11.029
   Zhang D, 2010, GYNECOL ENDOCRINOL, V26, P325, DOI 10.3109/09513591003632100
NR 27
TC 1
Z9 1
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 329
EP 335
DI 10.19193/0393-6384_2018_2_52
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400006
DA 2022-07-14
ER

PT J
AU Hismiogullari, AA
   Hismiogullari, SE
   Sel, T
   Kilic, O
   Rahman, K
AF Hismiogullari, Adnan Adil
   Hismiogullari, Sahver Ege
   Sel, Tevhide
   Kilic, Oktay
   Rahman, Khalid
TI EFFECT OF TAURODEHYDROCHOLIC ACID ON THE HEPATIC EXPRESSION OF ABCG5 AND
   ABCG8 AND BILIARY PARAMETERS IN THE FISTULA RAT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Taurodehyroxycholic acid; Abcg5 transporter; Abcg8 transporter; bile;
   biliary cholesterol
ID PLASMA-MEMBRANE ENZYMES; CHOLESTEROL SECRETION; LIPID SECRETION;
   BILE-SALTS; DIETARY-CHOLESTEROL; GALLSTONE DISEASE; PHOSPHOLIPIDS;
   DIOSGENIN; MECHANISM; EXCRETION
AB Introduction: Biliary secretion of phospholipids and cholesterol is mainly dependent on bile-salt secretion although the exact mechanisms involved are not clearly defined.
   Aims: This study was to investigate the effect of oral administration of taurodehydrocholic acid (TDHC) on cholesterol metabolism.
   Materials and methods: TDHC was administered orally at a concentration of 10mM twice a day to rats for 7 days in order to mimic the in vivo situation in gallstone patients on bile salt therapy. Bile duct was cannulated and bile was collected for 30 mins on ice and subjected to analysis for total cholesterol, total bilirubin, alkaline phosphatase (ALP) and Gamma glutamyl transferase (GGT). Liver samples were subjected to real time PCR and the gene expression of the adenosine triphosphate-binding cassette transporter heterodimer Abcg5/g8 was determined.
   Results: TDHC significantly increased the expression of Abcg5 whilst the level of Abcg8 was significantly decreased. No changes in biliary cholesterol, ALP and GGT were observed, however the total bilirubin was significantly increased in the bile of TDHC administered rats.
   Conclusions: Increased expression of Abcg5 may be one mechanism by which TDHC stimulates the secretion of biliary cholesterol.
C1 [Hismiogullari, Adnan Adil] Univ Balikesir, Sch Med, Dept Med Biochem, Balikesir, Turkey.
   [Hismiogullari, Sahver Ege] Univ Balikesir, Sch Vet Med, Dept Pharmacol & Toxicol, Balikesir, Turkey.
   [Sel, Tevhide] Univ Ankara, Sch Vet Med, Dept Biochem, Ankara, Turkey.
   [Kilic, Oktay] Univ Balikesir, Sch Med, Dept Psychol, Balikesir, Turkey.
   [Rahman, Khalid] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Liverpool L3 3AF, Merseyside, England.
RP Hismiogullari, AA (corresponding author), Balikesir Univ, Sch Med, Cagis Yerleskesi, TR-10145 Balikesir, Turkey.
CR BALINT JA, 1971, J LAB CLIN MED, V77, P122
   BARNWELL SG, 1983, BIOCHEM J, V210, P549, DOI 10.1042/bj2100549
   BARNWELL SG, 1984, BIOCHEM J, V220, P723, DOI 10.1042/bj2200723
   BARNWELL SG, 1983, BIOCHEM J, V216, P107, DOI 10.1042/bj2160107
   BOOKER ML, 1989, GASTROENTEROLOGY, V97, P1261, DOI 10.1016/0016-5085(89)91697-1
   Buch S, 2007, NAT GENET, V39, P995, DOI 10.1038/ng2101
   Crawford JM, 1996, COMP BIOCHEM PHYS B, V115, P341, DOI 10.1016/S0305-0491(96)00181-2
   Dikkers A, 2013, HEPATOLOGY, V58, P293, DOI 10.1002/hep.26316
   Dikkers A, 2010, WORLD J GASTROENTERO, V16, P5936, DOI 10.3748/wjg.v16.i47.5936
   Gilat T, 1996, BBA-REV BIOMEMBRANES, V1286, P95, DOI 10.1016/0304-4157(96)00005-6
   Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200
   HARDISON WG, 1972, AM J PHYSIOL, V222, P61, DOI 10.1152/ajplegacy.1972.222.1.61
   Hazard SE, 2007, PFLUG ARCH EUR J PHY, V453, P745, DOI 10.1007/s00424-005-0040-7
   Hismiogullari AA, 2007, TURK J GASTROENTEROL, V18, P65
   Kamisako T, 2003, HEPATOL RES, V26, P348, DOI 10.1016/S1386-6346(03)00153-0
   Katsika D, 2010, J INTERN MED, V268, P279, DOI 10.1111/j.1365-2796.2010.02249.x
   Kimura Y, 2002, HEPATOLOGY, V36, P1227, DOI 10.1053/jhep.2002.36157
   Kosters A, 2005, HEPATOLOGY, V41, P141, DOI 10.1002/hep.20540
   MONTET JC, 1978, DIGESTION, V17, P346, DOI 10.1159/000198128
   NERVI F, 1988, J CLIN INVEST, V82, P1818, DOI 10.1172/JCI113797
   OMAILLE ERL, 1986, Q J EXP PHYSIOL CMS, V71, P475, DOI 10.1113/expphysiol.1986.sp003006
   RAHMAN K, 1987, BIOCHEM J, V245, P531, DOI 10.1042/bj2450531
   Rahman K, 1986, ENTEROHERTIC CIRCULA
   Robins SJ, 1997, J CLIN INVEST, V99, P380, DOI 10.1172/JCI119170
   Salen G, 2004, CIRCULATION, V109, P966, DOI 10.1161/01.CIR.0000116766.31036.03
   SCHERSTEN T, 1979, BIOL EFFECTS BILE AC, P53
   SOMJEN GJ, 1990, BIOCHIM BIOPHYS ACTA, V1042, P28, DOI 10.1016/0005-2760(90)90052-Y
   VERKADE HJ, 1995, HEPATOLOGY, V21, P1174
   White DA, 1973, FORM FUNCTION PHOSPH, P441
   Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI0216001, 10.1172/JCI200216001]
NR 30
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 33
EP 38
DI 10.19193/0393-6384_2018_1_5
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600005
DA 2022-07-14
ER

PT J
AU Hu, J
AF Hu, Jiang
TI TRACE ANALYSIS OF THERAPEUTIC EFFECT OF NON-SURGICAL REHABILITATION
   METHOD IN TREATING SIMPLE POSTERIOR CRUCIATE LIGAMENT RUPTURE OF
   BASKETBALL PLAYER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Female gymnasts; Special sports injury; Psychological stress; Treatment
   effect
ID DRUGS
AB Introduction: During basketball training period, simple Posterior Cruciate Ligament (PCL) rupture is not often occurred, however the therapeutic methods for such injury have long been a controversial topic. In this research, non-surgical rehabilitation treatment was applied for basketball player with PLC rupture, and followed investigations of therapeutic effects were performed.
   Method: In this work, 50 basketball players with simple PCL rupture, who had been treated in our hospital from Apr 2012 to Apr 2016, were selected as research objects, and all the selected basketball players were injured due to basketball reason. For all the selected players, a 5-stage non-surgical rehabilitation scheme with gradually increased load was applied. The ,first stage began from the 1st day to the 5th day since got injured; the second stage started from the 6th day to the 20th day since got injured; the third stage started from the 21st day to the 25th day since got injured; the fourth stage began from the 26th day to the 30th day since got injured; and the last stage started from one month later since gut injured, during which injured players were allowed to train with their team, in the hope of maintaing their physical strengths by gradually increasing exercise amount. From the 38th to the 78th day since ,got injured, KT2 test was performed to test the stress levels of quadriceps femoris of their both legs.
   Results: Through rehabilitation treatment, injured players can return to basketball training after averagely 38 days since get injured, morevoer the quadriceps,femoris strength of injured leg can recover to around 102% level of that of the non-injured leg. At the first test, the ratio between injured knee strength and non-injured knee strength was 0.52:1, can then increased to 0.96:1 at the 14th day since got injured. After returing to basketball training, knee joint injuries did not reappear, the therapeutic effect was ideal and the satisfaction degree on the treatment was high.
   Conclusion: Regarding simple PCL rupture of basketball player, non-surgical rehabilitation treatment can achieve ideal therapeutic effect, promote the function recovery of knee joint , significantly reduce and eliminate symptoms of knee joint, and accelerate the recovery as soon as possible.
C1 [Hu, Jiang] Shihezi Univ, Sch Phys Educ, Shihezi 832000, Peoples R China.
RP Hu, J (corresponding author), Shihezi Univ, Sch Phys Educ, Shihezi 832000, Peoples R China.
EM 214099889@qq.com
CR Ahmad Z, 2016, SAUDI J BIOL SCI, V23, P741, DOI 10.1016/j.sjbs.2016.07.001
   Attari Z, 2016, SAUDI PHARM J, V24, P57, DOI 10.1016/j.jsps.2015.03.008
   Duzer S, 2017, ACTA MEDICA MEDITERR, V33, P637, DOI 10.19193/0393-6384_2017_4_094
   Gao Shijun, 2011, CHINESE J ORTHOPAEDI, V31
   Gao Shijun, 2010, J HEBEI MED U
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Hazra M, 2015, SAUDI PHARM J, V23, P429, DOI 10.1016/j.jsps.2015.01.007
   Ibrahim S, 2016, SAUDI J BIOL SCI, V23, pS56, DOI 10.1016/j.sjbs.2015.10.024
   Jiang Bole, 2006, CHINESE J CLIN REHAB, V10, P17
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P667, DOI 10.19193/03936384_2017_4_100
   Moty SGA, 2016, SAUDI PHARM J, V24, P119, DOI 10.1016/j.jsps.2013.12.016
   Ofori-Kwakye K, 2016, SAUDI PHARM J, V24, P82, DOI 10.1016/j.jsps.2015.03.005
   Peng WX, 2017, SAUDI J BIOL SCI, V24, P103, DOI 10.1016/j.sjbs.2016.08.013
   Teixeira MC, 2017, SAUDI PHARM J, V25, P231, DOI 10.1016/j.jsps.2016.06.004
   Turhan Iyidir O, 2017, TURK J MED SCI, V47, P1751, DOI 10.3906/sag-1610-139
   Wroblewska K, 2015, SAUDI PHARM J, V23, P407, DOI 10.1016/j.jsps.2014.11.009
   Yang AM, 2017, J ALLOY COMPD, V695, P915, DOI 10.1016/j.jallcom.2016.10.188
   王晓琨, 2012, [中国老年学杂志, Chinese Journal of Gerontology], V32, P439
NR 18
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1561
EP 1564
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400017
DA 2022-07-14
ER

PT J
AU Huang, CB
   Wan, L
   Liu, J
   Liu, L
AF Huang Chuanbing
   Wan Lei
   Liu Jian
   Liu Lei
TI XINFENG CAPSULE IMPROVES ANGIOGENESIS BY REGULATING PTEN-PI3K / AKT
   PATHWAY AND PLATELET ACTIVATION IN ADJUVANT INDUCES ARTHRITIS RATS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Adjuvant arthritis; Platelet particles; Vascular hyperplasia; PTEN-PI3K
   / AKT pathway; Xinfeng capsule
ID RHEUMATOID-ARTHRITIS; IN-VITRO; MICROPARTICLES; AGGREGATION; MIGRATION
AB Objective: To observe the effect of Xinfeng capsule (XFC) on the expression of PTEN-PI3K / AKT pathway in platelet microparticles and platelet cell protein in adjuvant arthritis (AA) rats.
   Methods: The AA model was established by Freund's complete adjuvant. The rats were dosed on the 12th day after inflammation. Forty rats were randomly divided into normal control (NC) group, model control (MC) group, XFC group, tripterygium wilfordii (TPT) group. After administration for 30 days, MVD, platelet parameters, platelet microparticles (CD61 + CD41 + PMPs), VEGF, ES, VEGF / ES, PTEN, PI3K, AKT, P-AKT, BAD were observed.
   Results: Compared with NC group, the expressions of MVD, CD61 + CD41 + PMP, PLT, PCT, VEGF and VEGF mRNA in MC group were significantly lower than those in NC group, and ES mRNA was elevated. Expression of PTEN, BAD protein decreased, and PI3K, AKT, P-AKT protein increased. Compared with MC group, the expression of MVD, CD61 + CD41 + PMPs, platelet parameters PLT and PCT decreased in XFC group, the expression of VEGF, VEGF mRNA decreased, the expression of ES mRNA in peripheral blood ES and synovial blood vessel increased, ES mRNA decreased. PTEN, BAD protein expression increased, PI3K, AKT, P-AKT protein decreased. Compared with TPT group, expression of CD61 + CD41 + PMPs decreased in XFC group. Expression of PI3K, P-AKT protein decreased, and BAD increased (P < 0.01, P < 0.05).
   Conclusion: The abnormal expression of PMPs can break the balance of VEGF and inhibit the growth of vascular smooth muscle cells, resulting in the abnormal proliferation of synovial microvessels. XFC can significantly inhibit the proliferation of synovial tissue in AA rats. The mechanism may be through up-regulating the expression of PTEN, inhibiting the activation of PI3K / AKT pathway, up-regulating Bad, regulating the balance of VEGF / ES, inhibiting platelet release and improving angiogenesis.
C1 [Huang Chuanbing; Wan Lei; Liu Jian; Liu Lei] Anhui Univ Chinese Med, Affiliated Hosp 1, Hefei 230031, Anhui, Peoples R China.
RP Liu, L (corresponding author), Anhui Univ Chinese Med, Affiliated Hosp 1, Hefei 230031, Anhui, Peoples R China.
EM yxwanlei@163.com
FU National Natural Science Foundation [81473672]; Anhui University Natural
   Science Research Project [KJ2017A281]; Anhui Province Natural Science
   Foundation [1208085MH180]; Anhui Provincial Department of Health in
   Chinese medicine research project [2012zy28]; Anhui University of
   Chinese Medicine exploratory research projects; Anhui Provincial Key
   Laboratory of Modern Traditional Chinese Medicine Internal Medicine
   Application Foundation and Development Research [1606c08238]; Anhui
   Provincial Natural Science Foundation of China [1508085QH159]
FX This work was supported by grants from the National Natural Science
   Foundation Project (81473672). Anhui University Natural Science Research
   Project (KJ2017A281). Anhui Province Natural Science Foundation
   (1208085MH180); Anhui Provincial Department of Health in 2012 Chinese
   medicine research project (2012zy28); Anhui University of Chinese
   Medicine exploratory research projects. Anhui Provincial Key Laboratory
   of Modern Traditional Chinese Medicine Internal Medicine Application
   Foundation and Development Research (1606c08238). Anhui Provincial
   Natural Science Foundation of China (1508085QH159).
CR Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928
   Falanga A, 2012, THROMB RES, V129, pS132, DOI 10.1016/S0049-3848(12)70033-6
   Flaumenhaft R, 2010, SEMIN THROMB HEMOST, V36, P881, DOI 10.1055/s-0030-1267042
   Fleitas T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047365
   Genc H, 2018, TOXICOL IN VITRO, V47, P238, DOI 10.1016/j.tiv.2017.12.004
   Guilbert C, 2017, J BIOMECH, V61, P26, DOI 10.1016/j.jbiomech.2017.06.044
   Hu L, 2017, STEM CELL RES, V20, P14, DOI 10.1016/j.scr.2017.02.003
   Little RD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06581-6
   Mause SF, 2010, CIRCULATION, V122, P495, DOI 10.1161/CIRCULATIONAHA.109.909473
   Moghaddam F, 2016, ARTIF CELL NANOMED B, V44, P1702, DOI 10.3109/21691401.2015.1089251
   Olumuyiwa-Akeredolu OOO, 2015, RHEUMATOL INT, V35, P1955, DOI 10.1007/s00296-015-3300-7
   Ortega KF, 2017, CHEM-EUR J, V23, P12443, DOI 10.1002/chem.201702248
   Pan DM, 2018, INT IMMUNOPHARMACOL, V55, P174, DOI 10.1016/j.intimp.2017.12.011
   Pisetsky DS, 2012, RHEUMATOLOGY, V51, P1737, DOI 10.1093/rheumatology/kes028
   Rk Zong, 2011, ZHONG XI YI JIE HE Z, V9, P1347
   Rother S, 2017, ACS APPL MATER INTER, V9, P9539, DOI 10.1021/acsami.7b01300
   Shevchenko AV, 2017, TERAPEVT ARKH, V89, P60, DOI 10.17116/terarkh201789560-64
   Sun XT, 2017, FEBS OPEN BIO, V7, P1899, DOI 10.1002/2211-5463.12326
   Szekanecz Z, 2009, AUTOIMMUNITY, V42, P563, DOI 10.1080/08916930903143083
   Ta HT, 2017, BIOMATERIALS, V134, P31, DOI 10.1016/j.biomaterials.2017.04.037
   Weng Z, 2010, BLOOD, V116, P2579, DOI 10.1182/blood-2010-03-277236
   Wenwen W, 2017, PLOS ONE, V12
   Yun F, 2013, INT J CLIN EXP PATHO, V6, P2112
   Zhang J, 2017, ONCOTARGET, V8, P73529, DOI 10.18632/oncotarget.19867
   Zhang W, 2015, MOL IMMUNOL, V67, P532, DOI 10.1016/j.molimm.2015.07.033
   Zhu X, 2017, BIOSCI MICROB FOOD H, V36, P45, DOI 10.12938/bmfh.16-016
NR 26
TC 0
Z9 0
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 773
EP 779
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000023
DA 2022-07-14
ER

PT J
AU Huang, HT
   Ding, SG
   Yu, XQ
   Wang, F
   Zhong, CJ
AF Huang, Hai-Tao
   Ding, Sheng-Guang
   Yu, Xiao-Qiang
   Wang, Fei
   Zhong, Chong-Jun
TI SWIMMING EXERCISE TRAINING ATTENUATE CARDIAC INFARCTION SIZE VIA
   DOWN-REGULATING MIRNA-146A
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE miRNA-146a; swimming exercise training; acute myocardial infarction;
   apoptosis
ID ACUTE MYOCARDIAL-INFARCTION; ALL-CAUSE MORTALITY; HEART-FAILURE;
   ISCHEMIA-REPERFUSION; RAT MODEL; APOPTOSIS; ELEVATION; DYSFUNCTION;
   PROTECTS; DISEASE
AB Objective: To observe the effect of swimming exercise on the infarct size, and the differential expression of miRNA in infarcted myocardium. The protective mechanism of miRNA-146a was also investigated in this study.
   Methods: Acute myocardial infarction (AMI) model was constructed on rats with swimming exercise pretreatment. TTC stain was used to evaluate the myocardiac infarct area. The differential expression of miRNA in infarcted myocardium was tested by miRNA sequencing. RT-PCR was used to verify the expression of miRNA-146a. Apoptosis was tested by flow-cytometry and caspase-3 activity assay. One-way ANOVA and t-test analyses were utilized to identify differences between groups.
   Results: Physiological myocardial hypertrophy was induced by swimming exercise. Heart weight/body weight and Heart weight/tibia length in swimming group were significantly more than that in control group (p<0.05). The cardiac infarction area was significant less in swimming exercise group compared to sedentary group (p<0.01). The expression of miRNA-146a was down-regulated significantly in the infarcted myocardium with swimming exercise (p<0.05). MiRNA-146a mimics could induce the apoptosis in anoxial cardiac myocytes (p<0.05, compared with normal and miRNA-146a inhibitor group). Caspase-3 activity was strongest when the anoxial cardiac myocytes treated with miRNA-146a mimic. Overexpression of in cardiac myocytes increase caspase-3 activity followed by promoting apoptosis (p<0.05, compared with normal and miRNA-146a inhibitor group).
   Conclusions: Swimming exercise can attenuate cardiac infarction area in rat AMI model. Down-regulating of miRNA-146a by swimming exercise can repress apoptosis by inhibiting Caspase-3 activity.
C1 [Huang, Hai-Tao; Ding, Sheng-Guang; Yu, Xiao-Qiang; Wang, Fei; Zhong, Chong-Jun] Nantong First Peoples Hosp, Dept Thorac & Cardiovasc Surg, Nantong 226001, Jiangsu, Peoples R China.
RP Zhong, CJ (corresponding author), Nantong Univ, Affiliated Hosp 2, 6 North Haier Lane Rd, Nantong 226001, Peoples R China.
EM zhongcjnt@126.com
FU Nantong science and technology project of Nantong Science and Technology
   Bureau [MS22016046]
FX Foundation: supported by the Nantong science and technology project of
   Nantong Science and Technology Bureau (project number: MS22016046)
CR Beygui F, 2013, INT J CARDIOL, V167, P73, DOI 10.1016/j.ijcard.2011.11.076
   Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205
   Bostrom P, 2010, CELL, V143, P1072, DOI 10.1016/j.cell.2010.11.036
   Calvert JW, 2011, CIRC RES, V108, P1448, DOI 10.1161/CIRCRESAHA.111.241117
   Dayan A, 2005, ANN CLIN LAB SCI, V35, P73
   Dong SM, 2009, J BIOL CHEM, V284, P29514, DOI 10.1074/jbc.M109.027896
   Huang W, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.12
   Hwee DT, 2015, J PHARMACOL EXP THER, V353, P159, DOI 10.1124/jpet.114.222224
   Kasama S, 2011, HEART, V97, P817, DOI 10.1136/hrt.2010.215459
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Kwak HB, 2006, FASEB J, V20, P791, DOI 10.1096/fj.05-5116fje
   Kwak HB, 2011, FASEB J, V25, P1106, DOI 10.1096/fj.10-172924
   Montalescot G, 2014, EUR HEART J, V35, P2295, DOI 10.1093/eurheartj/ehu164
   Nicholson CK, 2013, J MOL CELL CARDIOL, V64, P1, DOI 10.1016/j.yjmcc.2013.08.002
   Pang LR, 2017, ONCOL LETT, V14, P7745, DOI 10.3892/ol.2017.7242
   Pina IL, 2013, AM J CARDIOL, V112, P971, DOI 10.1016/j.amjcard.2013.05.033
   Solomon SD, 2011, EUR HEART J, V32, P1227, DOI 10.1093/eurheartj/ehq522
   Tu YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075872
   Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061
   Wang XH, 2013, CARDIOVASC RES, V97, P432, DOI 10.1093/cvr/cvs356
   White HD, 2008, LANCET, V372, P570, DOI 10.1016/S0140-6736(08)61237-4
   Wu ZW, 2015, GENET MOL RES, V14, P18703, DOI 10.4238/2015.December.28.19
NR 22
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1377
EP 1382
DI 10.19193/0393-6384_2018_5_210
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700032
DA 2022-07-14
ER

PT J
AU Huang, SY
   Ma, HS
   Zhang, JZ
   Shao, W
   Li, DH
AF Huang, Shaoyan
   Ma, Huashan
   Zhang, Jianzhong
   Shao, Wei
   Li, Donghua
TI COMPARISON ABOUT THE VASCULAR LEAKAGE OF HYDROXYETHYL STARCH 130/0.4
   (VOLUVEN) AMONG CHD CHILDREN OF DIFFERENT AGES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hydroxyethyl Starch; Children; Colloid Osmotic Pressure; Concentration
   Determination; Acute Hemodilution
ID ACUTE KIDNEY INJURY; VOLUME REPLACEMENT; CARDIAC-SURGERY; NORMOVOLEMIC
   HEMODILUTION; INFLAMMATORY RESPONSE; RESUSCITATION; ASSOCIATION;
   VOLUNTEERS; ALBUMIN; SAFETY
AB Background: To compare the vascular leakage of hydroxyethyl starch 130/0.4 (Voluven) after acute hemodilution among different ages of children with congenital heart disease (CHD).
   Methods: 40 CHD children were divided into two groups: Group A (2 <= age <= 6, n=20) and Group B (6 <= age <= 12, n=20). The children's blood volume was calculated according to the blood volume formula. The indexes of plasma colloid osmotic pressure (PCOP), plasma Voluven concentration and hemoglobin (HGB) were measured with central venous blood prior to the transfusion of Voluven (T0), 15 min after the transfusion (T1), and 30 min after the transfusion (T2) respectively. The urine generated between the start of transfusion and 30 min after the completion of transfusion was kept to measure Voluven concentration in urine.
   Results: The dilatation proportion is about 100%. In comparison with T0, HGB of the two groups lowers at T1 and T2 (P < 0.05) and the difference of HGB between the two groups has no statistical significance (P > 0.05). Compared with T0, PCOP in Group B increases at T1 and T2 (P < 0.05) while the difference of PCOP in Group A at T1 and T2 has no statistical significance (P > 0.05). Comparison between the two groups shows that the plasma Voluven concentration of Group B at T1 and T2 is higher than that of Group A (P < 0.05). The difference between Group A and Group B has no statistical significance (P > 0.05) in urine Voluven concentration.
   Conclusion: There is a more obvious vascular leakage of Voluven in the group of low-age children.
C1 Yantaishan Hosp, Dept Oncol, Yantai 264000, Shandong, Peoples R China.
   [Ma, Huashan] Dongying City Peoples Hosp, Dept Anesthesia, Dongying 257000, Shandong, Peoples R China.
   [Zhang, Jianzhong; Shao, Wei] Yantaishan Hosp, Dept Anesthesia, Yantai 264000, Shandong, Peoples R China.
   [Li, Donghua] Binzhou Med Univ Hosp, Dept Anesthesia, 661 Huanghe 2 Rd, Binzhou 256600, Shandong, Peoples R China.
RP Li, DH (corresponding author), Binzhou Med Univ Hosp, Dept Anesthesia, 661 Huanghe 2 Rd, Binzhou 256600, Shandong, Peoples R China.
EM M18153529929@163.com
FU key research and development plan in shandong province [2018GSF118054]
FX This work was supported by key research and development plan in shandong
   province (No. 2018GSF118054
CR Antonelli M, 2012, INTENS CARE MED, V38, P1560, DOI 10.1007/s00134-012-2644-7
   Dieterich HJ, 2006, CRIT CARE MED, V34, P1775, DOI 10.1097/01.CCM.0000218814.77568.BC
   Drobin D, 1999, ANESTHESIOLOGY, V90, P81, DOI 10.1097/00000542-199901000-00013
   Haynes Gary R, 2014, J Pharm Pract, V27, P17, DOI 10.1177/0897190013504960
   Jacob M, 2003, ANAESTHESIST, V52, P896, DOI 10.1007/s00101-003-0557-0
   Jacob M, 2006, ANESTHESIOLOGY, V104, P1223, DOI 10.1097/00000542-200606000-00018
   Kataria A, 2015, NAT REV NEPHROL, V11, P610, DOI 10.1038/nrneph.2015.94
   Laliberte BD, 2014, J CLIN ANESTH, V26, P402, DOI 10.1016/j.jclinane.2014.03.001
   Lang K, 2003, CAN J ANAESTH, V50, P1009, DOI 10.1007/BF03018364
   Li LX, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0815-y
   Lissauer ME, 2011, AM J SURG, V202, P53, DOI 10.1016/j.amjsurg.2010.05.002
   Mizzi Anna, 2011, Anesthesiol Clin, V29, P547, DOI 10.1016/j.anclin.2011.05.012
   Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759
   PEREL P., 2013, COCHRANE DB SYST REV, V28
   Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242
   Rehm M, 2004, ANESTHESIOLOGY, V100, P1211, DOI 10.1097/00000542-200405000-00025
   Rioux JP, 2009, CRIT CARE MED, V37, P1293, DOI 10.1097/CCM.0b013e31819cc1a0
   Van der Linden P, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0830-z
   Van der Linden P, 2013, ANESTHESIOLOGY, V119, P1296, DOI 10.1097/ALN.0b013e3182a6b387
   Waitzinger Josef, 2003, Drugs R D, V4, P149, DOI 10.2165/00126839-200304030-00002
   Wang PF, 2009, INT IMMUNOPHARMACOL, V9, P347, DOI 10.1016/j.intimp.2008.12.014
   Wiedermann CJ, 2004, WIEN KLIN WOCHENSCHR, V116, P583, DOI 10.1007/s00508-004-0237-3
   Wilkes NJ, 2002, ANESTH ANALG, V94, P538, DOI 10.1097/00000539-200203000-00011
   Xue FS, 2015, ANESTHESIOLOGY, V123, P481, DOI 10.1097/ALN.0000000000000718
   Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430
NR 25
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1227
EP 1232
DI 10.19193/0393-6384_2018_5_188
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700010
DA 2022-07-14
ER

PT J
AU Huzmeli, C
   Candan, F
   Bagci, G
   Bagci, B
   Akkaya, L
   Seker, A
   Kayatas, M
AF Huzmeli, Can
   Candan, Ferhan
   Bagci, Gokhan
   Bagci, Binnur
   Akkaya, Lale
   Seker, Ayse
   Kayatas, Mansur
TI VITAMIN D RECEPTOR TAQI POLYMORPHISM IS ASSOCIATED WITH HIGHER IMMUNE
   RESPONSE TO HEPATITIS B VACCINATION IN TURKISH DIALYSIS PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hemodialysis; peritoneal dialysis; vitamin D receptor; chronic kidney
   disease; vitamin D; polymorphism
ID RENAL-FAILURE PATIENTS; HEMODIALYSIS-PATIENTS; INFECTIOUS-DISEASES;
   VIRUS INFECTION; CHRONIC KIDNEY; D DEFICIENCY; SCHEDULES; ALPHA; GENE
AB Introduction: We aimed to investigate the possible role of vitamin D receptor (VDR) gene TaqI, ApaI and FokI polymorphisms in immune response to Hepatitis B virus (HBV) vaccination in dialysis patients.
   Methods: A total of 200 patients included in the study. Genotyping was done by using PCR-RFLP method.
   Results: TaqI TC genotype was 2.15 times higher in responders compared to non-responders (OR: 2.15 95% CI: 1.12-4.15, p: 0.021). TaqI CC genotype was found to be 2.80 times higher in responders compared to non-responders (OR: 2.80, 95% CI: 1.09-7.16, p: 0.031). When TC and CC genotype were evaluated together, they were found to be 2.31 times higher in responders (OR: 2.31, 95% CI: 1.26-4.24, p: 0.006). Carrying the C allele was found 1.92 times higher in responders compared to non-responders (OR: 1.92, 95% CI: 1.21-3.03, p: 0.005). No statistical significance was found between responders and non-responders in terms of FokI and ApaI genotype and allele frequencies (p > 0.05).
   Conclusion: Results of the present study demonstrate that carrying TC and CC genotype and C allele of VDR TaqI polymorphism have showed higher vaccination response while carrying TT genotype and T allele showed lower vaccination response in dialysis patients.
C1 [Huzmeli, Can; Candan, Ferhan; Akkaya, Lale; Seker, Ayse; Kayatas, Mansur] Cumhuriyet Univ, Dept Nephrol, Fac Med, Sivas, Turkey.
   [Bagci, Gokhan] Cumhuriyet Univ, Dept Med Genet, Fac Med, Sivas, Turkey.
   [Bagci, Binnur] Cumhuriyet Univ, Dept Nutr & Dietet, Fac Hlth Sci, Sivas, Turkey.
RP Huzmeli, C (corresponding author), Cumhuriyet Univ, Div Nephrol, Dept Internal Med, Fac Med, TR-58140 Sivas, Turkey.
RI Bagci, Gokhan/AAE-3124-2021; Ertan, Asli/AAE-6201-2021
OI Bagci, Gokhan/0000-0003-4554-2391; bagci, binnur/0000-0003-1323-3359
FU Scientific Research Project Fund of Cumhuriyet University [T-594]
FX This work was supported by the Scientific Research Project Fund of
   Cumhuriyet University under the project number 'T-594'
CR Ahmadi F, 2012, HEPAT MON, V12, P344, DOI 10.5812/hepatmon.6438
   Al Saran K, 2014, SAUDI J KIDNEY DIS T, V25, P185, DOI 10.4103/1319-2442.124572
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Brown CM, 2011, RENAL FAILURE, V33, P276, DOI 10.3109/0886022X.2011.559300
   Cordova E, 2017, ANN IG MED PREV COMU, V29, P27, DOI 10.7416/ai.2017.2129
   Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev
   Fabrizi F, 2006, ALIMENT PHARM THER, V23, P1105, DOI 10.1111/j.1365-2036.2006.02877.x
   Fabrizi F, 2012, DIGEST DIS SCI, V57, P1366, DOI 10.1007/s10620-011-1987-1
   Fernandez E, 1996, NEPHROL DIAL TRANSPL, V11, P1559, DOI 10.1093/oxfordjournals.ndt.a027613
   Grzegorzewska AE, 2014, EXPERT REV VACCINES, V13, P1395, DOI 10.1586/14760584.2014.962521
   Hashemi B, 2011, HEPAT MON, V11, P816, DOI 10.5812/kowsar.1735143X.751
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Jhorawat R, 2016, INDIAN J GASTROENTER, V35, P67, DOI 10.1007/s12664-016-0621-8
   Kazemi Arababadi M, 2009, J BABOL U MED SCI, V11, P19
   Lin SY, 2011, VACCINE, V29, P3738, DOI 10.1016/j.vaccine.2011.03.049
   McNulty CAM, 2005, VACCINE, V23, P4142, DOI 10.1016/j.vaccine.2005.03.020
   Hoan NX, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1836-0
   Roozbeh J, 2005, ASAIO J, V51, P242, DOI 10.1097/01.MAT.0000161935.66158.97
   Sadarangani SP, 2015, EXPERT REV VACCINES, V14, P1427, DOI 10.1586/14760584.2015.1082426
   Suneetha PV, 2006, J HEPATOL, V44, P856, DOI 10.1016/j.jhep.2006.01.028
   Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8
   White JH, 2008, INFECT IMMUN, V76, P3837, DOI 10.1128/IAI.00353-08
   Yamshchikov AV, 2009, ENDOCR PRACT, V15, P438, DOI 10.4158/EP09101.ORR
   Zitt E, 2012, VACCINE, V30, P931, DOI 10.1016/j.vaccine.2011.11.086
NR 24
TC 2
Z9 2
U1 1
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 791
EP 796
DI 10.19193/0393-6384_2018_3_121
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000026
DA 2022-07-14
ER

PT J
AU Icacan, OC
   Yokus, O
   Sametoglu, F
   Gedik, H
AF Icacan, Ozan Cemal
   Yokus, Osman
   Sametoglu, Fettah
   Gedik, Habip
TI SERUM VITAMIN D VALUES OF ACUTE LEUKEMIA CASES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Vitamin D; acute leukemia; acute myeloid leukemia; acute lymphoblastic
   leukemia; body-mass index
ID 25-HYDROXYVITAMIN D; D DEFICIENCY; PROGNOSIS
AB Objective: It was aimed to investigate the serum vitamin D (Vit D) levels of acute leukemia cases and compare their levels with those of healthy people to evaluate the relationship between acute leukemia and serum Vit D level.
   Material and method: In this retrospective, case-control study, the vitamin levels of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients who were followed-up and treated between 2012 and 2016 at the hematology clinic of Ministry of Health Istanbul Training and Research Hospital were evaluated in order to compare with the vit D levels of healthy individuals who were taken as control group in the same period.
   Results: In the study, 29 patients with AML, 17 patients with ALL and 50 healthy controls were included. There was a statistically significant difference between Vit D levels of patients group and control group (p= 0.001). The Vit D level of control group was statistically higher than those of ALL and AML patients. (p = 0.005; p = 0.001, respectively). In the subgroup analysis, there was a significant difference between Vit D levels of both ALL (p = 0.005) and AML (p: 0.001) patient groups and Vit D levels of control group. However, there was no statistical significance between Vit D levels of AML and ALL patients (p = 0.524).
   Conclusion: Vit D levels of patients with acute leukemia were found to be lower than those of healthy controls. In case patients with hematological malignancy have Vit D deficit, especially in the case of serious deficiencies, the replacement therapy should be administered. Prospective randomized controlled trials on multiple cases of acute leukemia are needed to clarify the effects of Vit D deficiency on disease progression and survival.
C1 [Icacan, Ozan Cemal; Sametoglu, Fettah] Istanbul Training & Res Hosp, Minist Hlth, Dept Internal Dis, Istanbul, Turkey.
   [Yokus, Osman] Istanbul Training & Res Hosp, Minist Hlth, Dept Hematol, Istanbul, Turkey.
   [Gedik, Habip] Bakirkoy Dr Sadi Konuk Training & Res Hosp, Minist Hlth, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
RP Gedik, H (corresponding author), Bakirkoy Sadi Konuk Egitim & Arastirma Hastanesi, Infeksiyon Hastaliklari & Klin Mikrobiyol Klin, Istanbul, Turkey.
EM habipgedik@yahoo.com
RI Gedik, Habip/ABI-3946-2020; Yokus, Osman/ABF-5160-2020
OI Gedik, Habip/0000-0002-8406-2254; 
CR Alagol F, 2000, J ENDOCRINOL INVEST, V23, P173, DOI 10.1007/BF03343702
   Aypak C, 2013, HASEKI TIP B, V954, P95
   Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358
   Guo J, 2014, CELL PHYSIOL BIOCHEM, V33, P1087, DOI 10.1159/000358678
   Lee Hun Ju, 2014, CANCER, V120, P521
   Lim U, 2009, INT J CANCER, V124, P979, DOI 10.1002/ijc.23984
   Naz A, 2013, PAK J MED SCI, V29, P10, DOI 10.12669/pjms.291.2764
   Ng AC, 2009, AM J HEMATOL, V84, P397, DOI 10.1002/ajh.21412
   PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748
   Rajakumar K, 2007, AM J PUBLIC HEALTH, V97, P2121, DOI 10.2105/AJPH.2006.091736e
   Rajakumar K, 2008, OBESITY, V16, P90, DOI 10.1038/oby.2007.23
   Thomas X, 2011, HEMATOLOGY, V16, P278, DOI 10.1179/102453311X13085644679908
   Wang W, 2015, CELL PHYSIOL BIOCHEM, V35, P1999, DOI 10.1159/000374007
NR 13
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1883
EP 1887
DI 10.19193/0393-6384_2018_6_292
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400043
DA 2022-07-14
ER

PT J
AU Ilgin, D
   Karaali, HK
   Ozcan, O
   Arslan, S
   Arslan, T
   Gunduz, T
   Limoncu, ME
AF Ilgin, Duygu
   Karaali, Hayriye Kul
   Ozcan, Ozlem
   Arslan, Serdar
   Arslan, Tugba
   Gunduz, Turan
   Limoncu, Mehmet Emin
TI INVESTIGATION OF HAND HYGIENE KNOWLEDGE LEVEL OF PHYSIOTHERAPY AND
   REHABILITATION STUDENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE hygiene guidelines; healthcare students; healthcare associated
   infections
ID MEDICAL-STUDENTS; NOSOCOMIAL INFECTION; INFORMATION; BELIEFS
AB Introduction: Increasing health care students' awareness about the hand hygiene (HH) during the pre-graduation period becomes an important requirement for providing both patient's safety and the healthcare student's safety by preventing healthcare associated infections (HCAIs). Although it has been emphasized that rehabilitation clinics are important places to be taken into consideration in the transmission of HCAIs, the number of studies about the students from department of physiotherapy and rehabilitation (DPR) are limited. Thus, our research was done to examine the HH knowledge level of students of DPR.
   Materials and methods: This cross-sectional study was done by 191 volunteers from a total of 209 first and second-year students. We recorded the sociodemographic characteristics. Based on the suggestions commented in the Center for Disease Control and Prevention Guideline for HH in Health Care Settings, HH knowledge levels were assessed using face to face interview technique.
   Results: The average correct answer rate to the questions about the HH knowledge level was 69.49%. The level of knowledge about the importance of HH was good, but the correct response rates for terminology and alcohol-based handrub were less than 50%.
   Conclusions: Since DPR students form an important ring in the therapy chain, so in the development of educational programs for the students of DPR, it is very important to improve their knowledge level especially about terminology and alcohol-based handrub techniques.
C1 [Ilgin, Duygu; Karaali, Hayriye Kul; Ozcan, Ozlem] Manisa Celal Bayar Univ, Dept Physiotherapy & Rehabil, Fac Hlth Sci, Manisa, Turkey.
   [Arslan, Serdar] Necmettin Erbakan Univ, Dept Physiotherapy & Rehabil, Fac Hlth Sci, Konya, Turkey.
   [Arslan, Tugba] Pamukkale Univ, Hlth Sci Inst, Denizli, Turkey.
   [Gunduz, Turan; Limoncu, Mehmet Emin] Manisa Celal Bayar Univ, Manisa Hlth Serv Vocat Sch, Manisa, Turkey.
RP Ilgin, D (corresponding author), Manisa Celal Bayar Univ, Fac Hlth Sci, Dept Physiotherapy & Rehabil, Uncubozkoy Hlth Campus, Yunusemre Manisa, Turkey.
RI ILGIN, DUYGU/ABD-6345-2020; Ilgın, Duygu/AAA-1543-2021
CR Al Kadi Azzam, 2012, Interdiscip Perspect Infect Dis, V2012, P679129
   Al-Naggar R, 2013, INT MED J MALAYS, V12, P11
   Ariyaratne M, 2015, SRI LANKAN J INFECT, V3, P15, DOI [10.4038/sljid.v3i1.4761, DOI 10.4038/SLJID.V3I1.4761]
   Bello AI, 2011, INT J GEN MED, V4, P571, DOI 10.2147/IJGM.S16720
   Boyce JM, 2002, INFECT CONT HOSP EP, V23, pS3, DOI 10.1086/503164
   Costers M, 2012, EUROSURVEILLANCE, V17, P20161
   Cruz JP, 2016, J INFECT PUBLIC HEAL, V9, P485, DOI 10.1016/j.jiph.2015.11.010
   Graf K, 2011, AM J INFECT CONTROL, V39, P885, DOI 10.1016/j.ajic.2010.08.025
   Herbert Verena G, 2013, Interdiscip Perspect Infect Dis, V2013, P802930, DOI 10.1155/2013/802930
   Ibeneme S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5841805
   Ibrahim AA, 2016, ADV MED EDUC PRACT, V7, P505, DOI 10.2147/AMEP.S109830
   Kalata NL, 2013, MALAWI MED J, V25, P50
   Mahmood SE, 2015, INT J COMMUNITY MED, V2, P466
   Mann CM, 2006, J HOSP INFECT, V64, P366, DOI 10.1016/j.jhin.2006.06.030
   Martinez J, 2014, CIENC CUID SAUDE, V13, P455, DOI DOI 10.4025/CIENCCUIDSAUDE.V13I3.19118
   Nair SS, 2014, PREVENTIVE MED, V2014
   O'Brien D, 2009, J HOSP INFECT, V73, P171, DOI 10.1016/j.jhin.2009.07.006
   Ojulong J, 2013, Afr Health Sci, V13, P1071, DOI 10.4314/ahs.v13i4.30
   Opara PI, 2009, NIGERIAN HLTH J, V9, P14
   Pittet D, 1999, ARCH INTERN MED, V159, P821, DOI 10.1001/archinte.159.8.821
   Preposi Cruz J, 2015, GENDER DIFFERENCES H, DOI [10.3396/ijic.v11i4.029.15, DOI 10.3396/IJIC.V11I4.029.15, 10.3396/IJIC.v11i4.029.15]
   Rossini A, 2013, AM J INFECT CONTROL, V41, P560, DOI 10.1016/j.ajic.2012.10.023
   Sax H, 2001, J HOSP INFECT, V48, P27, DOI 10.1053/jhin.2001.0961
   Serel S, 2015, TURK J PHYSIOTHER R, V26, P14
   Shinde MB, 2014, INT J SCI RES, V3, P311
   Snow M, 2006, AM J INFECT CONTROL, V34, P18, DOI 10.1016/j.ajic.2005.05.009
   Tavolacci MP, 2008, INFECT CONT HOSP EP, V29, P642, DOI 10.1086/588683
   Thakker Vaishnavi S, 2015, J Family Med Prim Care, V4, P582, DOI 10.4103/2249-4863.174298
   Van De Mortel TF, 2012, J ADV NURS, V68, P569, DOI 10.1111/j.1365-2648.2011.05758.x
   van de Mortel TF, 2010, AM J INFECT CONTROL, V38, P75, DOI 10.1016/j.ajic.2009.05.006
   Ward DJ, 2010, J ADV NURS, V66, P1533, DOI 10.1111/j.1365-2648.2010.05332.x
   Yaembut N, 2016, J SURG EDUC, V73, P400, DOI 10.1016/j.jsurg.2015.12.007
NR 32
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 749
EP 757
DI 10.19193/0393-6384_2018_3_115
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000020
DA 2022-07-14
ER

PT J
AU Illeez, OG
   Ozkan, FU
   Aktas, I
AF Illeez, Ozge Gulsum
   Ozkan, Feyza Unlu
   Aktas, Ilknur
TI PARAMETERS OF TOTAL BLOOD COUNT; MIGHT THEY BE INDICATORS OF
   INFLAMMATION IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Ankylosing spondylitis; inflammation; rheumatoid arthritis;
   neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; mean platelet
   volume
ID NEUTROPHIL-TO-LYMPHOCYTE; ERYTHROCYTE SEDIMENTATION-RATE; MEAN PLATELET
   VOLUME; DISEASE-ACTIVITY; POOR-PROGNOSIS; RATIO; CRITERIA; INDEXES;
   MARKERS; SHOW
AB Introduction: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic inflammatory disorders. Inflammation is the probable underlying cause of disability. Platelet indices and complete blood compounds such as neutrophils and leukocytes are used to assess inflammation. This study investigated the relation between inflammation and the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), mean platelet volume (MPV) and platelet distribution width (PDW) in RA and AS.
   Materials and methods: 425 subjects aged 17-89 (mean 44.64 +/- 14.07), 225 (52.9%) female and 200 (47.1%) male, were included in this retrospective study. One hundred five subjects had RA, 216 had AS, and 104 were healthy. RA was diagnosed based on 2010 ACR/EULAR Classification Criteria and AS according to Modified New York Criteria. RA disease activity was determined using DAS28 scores and AS disease activity using BASDAI.
   Results: Hemoglobin values in patients with RA were statistically significantly lower compared to the control group (p=0.001), while ESR, CRP, NLR and PLR values were higher (p=0.001, p=0.001, p=0.001, and p=0.040). No difference was determined in MPV or PDW (p>0.05). Hemoglobin, ESR, CRP and NLR values in AS patients were significantly higher than in the control group (p=0.001, p=0.001, p=0.006, and p=0.001), while PDW values were lower (p=0.027; p<0.05). No difference was determined in PLR or MPV values (p>0.05). No correlation was determined between disease activity indices and NLR, PLR, MPV, PDW.
   Conclusion: Being cost-effective and easily calculated, NLR and PLR in RA and NLR in AS can be used together with ESR and CRP or as inflammation markers when these are unavailable.
C1 [Illeez, Ozge Gulsum; Ozkan, Feyza Unlu; Aktas, Ilknur] Univ Hlth Sci, Fatih Sultan Mehmet Training & Res Hosp, Dept Phys Med & Rehabil, Istanbul, Turkey.
RP Illeez, OG (corresponding author), E5 Karayolu Uzeri, TR-34752 Istanbul, Turkey.
EM ozgeilleez@hotmail.com
RI ozkan, feyza unlu/AAC-4013-2019; AKTAŞ, İLKNUR/AAC-3173-2021
CR Acet H, 2015, ANATOL J CARDIOL, V15, P648, DOI 10.5152/akd.2014.5592
   Ahbap E, 2016, CLIN NEPHROL, V85, P199, DOI 10.5414/CN108584
   Akin F, 2015, ANATOL J CARDIOL, V15, P218, DOI 10.5152/akd.2014.5263
   Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   Bozan N, 2016, EUR ARCH OTO-RHINO-L, V273, P3663, DOI 10.1007/s00405-016-3980-y
   Celikbilek A, 2014, J CLIN LAB ANAL, V28, P27, DOI 10.1002/jcla.21639
   Cho KM, 2017, ONCOTARGET, V8, P2329, DOI 10.18632/oncotarget.13731
   Choi JW, 2004, CLIN CHIM ACTA, V341, P117, DOI 10.1016/j.cccn.2003.11.013
   Eyuboglu M, 2016, ANGIOLOGY, V67, P195, DOI 10.1177/0003319715593224
   Fu HT, 2015, CLIN LAB, V61, P269, DOI 10.7754/Clin.Lab.2014.140927
   GARRETT S, 1994, J RHEUMATOL, V21, P2286
   Gasparyan AY, 2010, RHEUMATOL INT, V30, P1125, DOI 10.1007/s00296-009-1345-1
   Gunay E, 2014, INFLAMMATION, V37, P374, DOI 10.1007/s10753-013-9749-1
   Isik M, 2014, EUR J RHEUMATOL, V1, P144, DOI 10.5152/eurjrheumatol.2014.140023
   Karatas MB, 2016, ACTA CARDIOL SIN, V32, P313, DOI 10.6515/ACS20151013A
   Kayhan F, 2017, PSYCHIAT RES, V247, P332, DOI 10.1016/j.psychres.2016.11.016
   Kisacik B, 2008, JOINT BONE SPINE, V75, P291, DOI 10.1016/j.jbspin.2007.06.016
   Mercan R, 2016, J CLIN LAB ANAL, V30, P597, DOI 10.1002/jcla.21908
   Miao G, 2002, ARCH MED RES, V33, P506, DOI 10.1016/S0188-4409(02)00385-5
   Nurden AT, 2011, THROMB HAEMOSTASIS, V105, pS13, DOI 10.1160/THS10-11-0720
   Pietrzyk Lukasz, 2016, Asian Pac J Cancer Prev, V17, P4433
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Sahin A, 2016, W INDIAN MED J, V65, P165, DOI 10.7727/wimj.2014.202
   Sari I, 2015, KARDIOL POL, V73, P1310, DOI 10.5603/KP.a2015.0098
   Sevinc MM, 2016, J BUON, V21, P1153
   Sezgin M, 2017, CLIN HEMORHEOL MICRO, V65, P1, DOI 10.3233/CH-162067
   Shi LH, 2017, ONCOTARGET, V8, P18792, DOI 10.18632/oncotarget.13320
   Talukdar M, 2017, J CLIN DIAGN RES, V11, pEC01, DOI DOI 10.7860/JCDR/2017/23524.913024
   Tecer D, 2016, BIOMARK MED, V10, P967, DOI 10.2217/bmm-2016-0148
   Tekeoglu I, 2016, INT J RHEUM DIS, V19, P1078, DOI 10.1111/1756-185X.12805
   Uslu AU, 2015, INT J RHEUM DIS, V18, P731, DOI 10.1111/1756-185X.12582
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
NR 32
TC 7
Z9 7
U1 2
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1751
EP 1756
DI 10.19193/0393-6384_2018_6_268
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400019
DA 2022-07-14
ER

PT J
AU Iorio, S
   Badino, P
   Aliverti, M
   Gorini, I
AF Iorio, Silvia
   Badino, Paola
   aliverti, Massimo
   Gorini, Ilaria
TI A CRITICAL NOTE BY ABELE DE BLASIO (1902) ON THE ARCHAEO ANTHROPOLOGICAL
   CONJECTURES OF LUIGI PALMIERI (1872)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Archaeo-anthropology; ancient tombs; craniometric measurements; 1872 /
   1902
AB This paper offers a description and explanation of a criticism written by Abel De Blasio in 1902 on the archaeological and anthropological conjectures that Luigi Palmieri had made in the past. In a note presented in 1872 at the Academy of Sciences of Naples, regarding some ancient tombs discovered by chance near the Observatory on Mount Vesuvius, Palmieri presented interpretative observations that were unacceptable for specialists in anthropological studies and funerary archaeology.
C1 [Iorio, Silvia] Sapienza Univ Rome, Unit Hist Med, Dept Mol Med, Rome, Italy.
   [Badino, Paola; Gorini, Ilaria] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.
   [aliverti, Massimo] Univ Insubria, Varese, Italy.
RP Gorini, I (corresponding author), Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.
EM ilaria.gorini@uninsubria.it
OI iorio, silvia/0000-0001-9741-7838
CR [Anonymous], 1902, RIV MENS PSICH FOR A, P394
   Badino Paola, 2017, Acta Biomed, V88, P97, DOI 10.23750/abm.v88i1.5379
   Borgo M, 2017, ACTA MEDICA MEDITERR, V33, P95, DOI 10.19193/0393-6384_2017_1_015
   Caldarini C, 2015, BONES ORTHOPAEDIC PA, P3
   Lazzati AMB, 2015, INT J OSTEOARCHAEOLO
   Licata M, 2015, SKELETAL RADIOL, P323
   Licata M, 2017, J FORENSIC LEG MED, V51, P74, DOI 10.1016/j.jflm.2017.07.023
   Licata M, 2016, ACTA MEDICA MEDITERR, V32, P1569, DOI 10.19193/0393-6384_2016_5_131
   Licata M, 2014, ACTA MEDICA MEDITERR, V30, P555
   Riva E, 2014, ROMA, V80, P611
NR 10
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 390
EP 391
DI 10.19193/0393-6384_2018_2_61
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400015
DA 2022-07-14
ER

PT J
AU Iosip, A
   Pop, D
   Sitar-Taut, A
   Niculescu, I
   Caloian, B
   Zdrenghea, D
   Zdrenghea, M
AF Iosip, Adriana
   Pop, Dana
   Sitar-Taut, Adela
   Niculescu, Ioana
   Caloian, Bogdan
   Zdrenghea, Dumitru
   Zdrenghea, Mihnea
TI NT-PRO-BNP AND URIC ACID LEVELS CORRELATE IN PATIENTS WITH COPD AND
   HEART FAILURE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Heart failure; COPD; NT-ProBNP; Uric Acid
ID CARDIOVASCULAR-DISEASE; EUROPEAN-SOCIETY; ASSOCIATION HFA; TASK-FORCE;
   CORONARY; EXACERBATIONS; HYPERURICEMIA; GUIDELINES; OXYPURINOL;
   DIAGNOSIS
AB Introduction: Chronic obstructive pulmonary disease (COPD) is a frequent comorbidity in heart failure (HF) patients, increasing their mortality. Early detection of prognostic markers for the two diseases can be extremely useful. The present study aims to investigate the correlation between uricemia and N-terminal Brain Natriuretic Peptide (NT-pro-BNP) in patients with both HF and COPD, the latter condition being known as an aggravating factor for HF.
   Materials and methods: A total of 101 patients with HF were enrolled. All patients were evaluated through clinical history, physical examination, cardiovascular risk factors, chest X ray, pulmonary function tests, echocardiography and their serum uric acid (UA) and NT-pro-BNP levels (on the first day of admission) were determined.
   Results: We noticed a significant correlation between NT-pro-BNP and uric acid levels (r=0.409, p=0.0001). Correlation was present in both sexes, with a higher prevalence in men (r=0.43, p=0.0034) than in women (r=0.38, p=0.012). By looking only at COPD patients, the correlation between NT-pro-BNP and uric acid persisted (r=0.47, p=0.010). Comparing the two genders, in COPD patients the correlation was stronger in women (r=0.57, p=0.031) than in men (r=0.40, p=NS). In non-COPD patients, correlation between NT-pro-BNP and uric acid levels was also positive and statistically significant (r=0.41, p=0.0013). By gender, correlation was stronger in women (r=0.56, p=0.0014) than in men (r=0.18, p=NS).
   Conclusion: Even though NT-pro-BNP values were lower in COPD patients, we found a direct correlation between NT- proBNP and uric acid in both COPD and non-COPD patients, and both findings can be regarded as potential contributors to a negative course of HF.
C1 [Iosip, Adriana; Pop, Dana; Sitar-Taut, Adela; Niculescu, Ioana; Caloian, Bogdan; Zdrenghea, Dumitru; Zdrenghea, Mihnea] Univ Med & Pharm Iuliu Hatieganu, Cluj Napoca, Romania.
RP Pop, D (corresponding author), Clin Rehabil Hosp, Cardiol Dept, Viilor St 46-50,2nd Floor,Room 222, Cluj Napoca, Cluj Cty, Romania.
EM pop67dana@gmail.com
RI Zdrenghea, Mihnea/V-3373-2019
OI Zdrenghea, Mihnea/0000-0002-9461-987X
CR Amann M, HEART FAIL REV
   Anker SD, 2003, CIRCULATION, V107, P1991, DOI 10.1161/01.CIR.0000065637.10517.A0
   Aryal S, 2013, TRANSL RES, V162, P208, DOI 10.1016/j.trsl.2013.04.003
   Baldus S, 2005, FREE RADICAL BIO MED, V39, P1184, DOI 10.1016/j.freeradbiomed.2005.06.004
   Bardin T, 2014, CURR OPIN RHEUMATOL, V26, P186, DOI 10.1097/BOR.0000000000000028
   Bartziokas K, 2014, EUR RESPIR J, V43, P43, DOI 10.1183/09031936.00209212
   Blanco I, 2016, RESPIROLOGY, V21, P984, DOI 10.1111/resp.12772
   Burke MA, 2007, HEART FAIL REV, V12, P23, DOI 10.1007/s10741-007-9002-9
   Cappola TP, 2001, CIRCULATION, V104, P2407, DOI 10.1161/hc4501.098928
   Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003
   Curkendall SM, 2006, ANN EPIDEMIOL, V16, P63, DOI 10.1016/j.annepidem.2005.04.008
   Domej W, 2014, INT J CHRONIC OBSTR, V9, P1207, DOI 10.2147/COPD.S51226
   Garcia-Pachon E, 2007, LUNG, V185, P21, DOI 10.1007/s00408-006-0076-2
   Ghaemi-Oskouie F, 2011, CURR RHEUMATOL REP, V13, P160, DOI 10.1007/s11926-011-0162-1
   Glantzounis GK, 2005, CURR PHARM DESIGN, V11, P4145, DOI 10.2174/138161205774913255
   Hageman GJ, 2003, FREE RADICAL BIO MED, V35, P140, DOI 10.1016/S0891-5849(03)00237-5
   Hare JM, 2008, J AM COLL CARDIOL, V51, P2301, DOI 10.1016/j.jacc.2008.01.068
   Harzand Arash, 2012, Congest Heart Fail, V18, P179, DOI 10.1111/j.1751-7133.2011.00262.x
   Horsfall LJ, 2014, THORAX, V69, P1021, DOI 10.1136/thoraxjnl-2014-205271
   Kojima S, 2005, AM J CARDIOL, V96, P489, DOI 10.1016/j.amjcard.2005.04.007
   McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104
   Nicks ME, 2011, COPD, V8, P264, DOI 10.3109/15412555.2011.579202
   Paulus WJ, 2013, J AM COLL CARDIOL, V62, P263, DOI 10.1016/j.jacc.2013.02.092
   Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128
   Tamariz Leonardo, 2011, Congest Heart Fail, V17, P25, DOI 10.1111/j.1751-7133.2011.00200.x
   Tse HN, 2014, INT J CHRONIC OBSTR, V9, P825, DOI 10.2147/COPD.S51057
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Zdrenghea M, 2016, CARDIOVASC J AFR, V27, P1
   Zhang X, 2015, INT J CHRONIC OBSTR, V10, P2519, DOI 10.2147/COPD.S87202
NR 29
TC 0
Z9 0
U1 0
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 189
EP 195
DI 10.19193/0393-6384_2018_1_31
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600031
DA 2022-07-14
ER

PT J
AU Isiklar, A
   Karsidag, K
AF Isiklar, A.
   Karsidag, K.
TI ASSOCIATION BETWEEN THALASSEMIA TRAIT AND INSULIN RESISTANCE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Insulin resistance; thalassemia minor; thalassemia trait
ID ALPHA-THALASSEMIA; BETA-THALASSEMIA; IRON-DEFICIENCY; SERUM FERRITIN;
   DIFFERENTIATION; METABOLISM; CODAM
AB Introduction: One of the subjects discussed in the patients with thalassemia major and thalassemia intermedia is whether excess iron deposition in the liver causes insulin resistance or not. As well, patient group with thalassemia trait (minor) is considered as iron deficiency anemia erroneously in daily practice and this group is subjected to excess iron treatment unnecessarily. In this study, if unnecessary iron load in the patients with thalassemia minor had any effect on insulin resistance was assessed.
   Materials and methods: A two-hour oral glucose tolerance test (OGTT) was performed in 30 thalassemia carrier patients and 30 gender-age-history matched healthy individuals. Glucose and insulin levels were measured at time zero, 30, 60, 90 and 120 minutes. Homeostasis model assessment of insulin resistance (HOMA-IR), whole-body insulin sensitivity index (WBISI), were calculated and the association between acute phase reactant C-reactive protein (CRP) and insulin resistance was investigated.
   Results: There was no significant difference between study group and control group with respect to age, gender and body mass index (BMI) parameters. Insulin resistance (IR) parameters were compared within two groups and no statistical significance was determined. Groups were classified in two subgroups according to BMI value: Subgroups with BMI > 25 kg/m(2) and subgroups with BMI < 25 kg/m(2). When considered with respect to same BMI values, there was no difference between patient and control groups regarding glucose metabolism parameters and CRP levels. Insulin resistance was more evident inherently regarding BMI difference.
   Conclusion: It was concluded that glucose metabolisms in patients with thalassemia trait did not show difference compared to BMI-matched healthy individuals. Detecting insulin resistance to be increased in both groups as BMI increased was suggestive of main factor causing disturbances in glucose metabolism in the patients thalassemia trait was obesity.
C1 [Isiklar, A.] Univ Hlth Sci, Fatih Sultan Mehmet Training & Res Hosp, Istanbul, Turkey.
   [Karsidag, K.] Istanbul Univ, Istanbul Sch Med, Istanbul, Turkey.
RP Isiklar, A (corresponding author), E5 Highway, TR-34752 Atasehir, Turkey.
EM aysunisiklar@gmail.com
RI Karşıdağ, Kubilay/AAD-7442-2020
OI Isiklar, Aysun/0000-0003-2690-3067
CR [Anonymous], 2009, TURKIYE ENDOKRINOLOJ
   Apostol T, 2007, EUROPEAN J HEMATOLOG, P1600
   BESSMAN JD, 1979, BLOOD, V53, P288, DOI 10.1182/blood.V53.2.288.288
   Bolu SE, 2006, TURKIYE KLIN J INT M, V2, P8
   Bonora E, 1998, DIABETES CARE, V21, P221, DOI 10.2337/diacare.21.2.221
   DORMER P, 1978, BRIT J HAEMATOL, V38, P5
   ENGLAND JM, 1973, LANCET, V1, P449, DOI 10.1016/S0140-6736(73)91878-3
   Fernandez-Real JM, 1998, DIABETES CARE, V21, P62, DOI 10.2337/diacare.21.1.62
   FINCH CA, 1970, MEDICINE, V49, P17, DOI 10.1097/00005792-197001000-00002
   Ford ES, 1999, DIABETES CARE, V22, P1978, DOI 10.2337/diacare.22.12.1978
   Iwasaki T, 2005, DIABETES CARE, V28, P2486, DOI 10.2337/diacare.28.10.2486
   James M, 1999, METHODS MOL MED, P81
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Karaaslan T., 1997, THESIS
   KATTAMIS C, 1972, J MED GENET, V9, P154, DOI 10.1136/jmg.9.2.154
   Krentz AJ, 1996, BMJ-BRIT MED J, V313, P1385, DOI 10.1136/bmj.313.7069.1385
   Leila JN., 2011, AM J HEM
   Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462
   Medici F, 1999, DIABETOLOGIA, V42, P146, DOI 10.1007/s001250051132
   MELIS MA, 1983, BLOOD, V62, P226
   MENTZER WC, 1973, LANCET, V1, P882
   MERKEL PA, 1988, NEW ENGL J MED, V318, P809, DOI 10.1056/NEJM198803313181303
   MOI P, 1988, BLOOD, V72, P530
   Nathan DG., 1976, CIBA FDN S
   Reaven G, 2003, TIP 2 DIYABET SORULA, P54
   Tong PCY, 2002, DIABETES CARE, V25, P1480, DOI 10.2337/diacare.25.8.1480
   Van Campenhout A, 2006, DIABETES-METAB RES, V22, P444, DOI 10.1002/dmrr.635
   WALFORD DM, 1977, BRIT J HAEMATOL, V35, P347, DOI 10.1111/j.1365-2141.1977.tb00593.x
   WICKRAMASINGHE S N, 1970, British Journal of Haematology, V19, P719, DOI 10.1111/j.1365-2141.1970.tb07017.x
   Wickramsinghe SN, 1973, BRIT J HAEMATOL, V25, P15
   Wlazlo N, 2015, ACTA DIABETOL, V52, P337, DOI 10.1007/s00592-014-0646-3
   Wlazlo N, 2013, DIABETES CARE, V36, P309, DOI 10.2337/dc12-0505
NR 32
TC 1
Z9 1
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 321
EP 327
DI 10.19193/0393-6384_2018_2_51
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400005
DA 2022-07-14
ER

PT J
AU Isler, Y
   Ozdinc, S
   Kaya, H
AF Isler, Yesim
   Ozdinc, Serife
   Kaya, Halil
TI CAN NGAL BE USED AS AN EARLY MARKER OF CONTRAST-INDUCED NEPHROPATHY IN
   EMERGENCY DEPARTMENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE acute renal failure; computerized tomography; contrast-induced
   nephropathy; Neutrophil Gelatinase-Associated Lipocalin (NGAL)
ID GELATINASE-ASSOCIATED LIPOCALIN; ACUTE KIDNEY INJURY; ANGIOPLASTY; RISK
AB Aim: The objective of this study was to indicate the importance of the level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) against Serum Creatinine (SCr) for the early diagnosis of acute renal failure (ARF) related to contrast agent.
   Methods: 60 voluntary patients admitted to the emergency department for various reasons who had underwent contrast-enhanced computerized tomography scans were included in the study. Blood samples for NGAL, creatinine were taken . from the peripheral veins of the patients; pre exposure (0 hours) and post exposure to contrast agent on the 4th and 24th hours were examined for contrast computed tomography.
   Results: NGAL value was measured 4 hours after the administration of the contrast agent in our study and was significantly increased (p<0.05), however the creatinine value did not show a statistically significant change (p>0.05). When NGAL values were considered in relation to age, a significant increase was observed in patients over sixty years of age (p<0.05). There was no statistically significant difference between the groups based on the creatinine values (p>0.05).
   Conclusion: It was determined in the present study that NGAL indicates more significant results in comparison with creatinine with regard to the early diagnosis of contrast-induced nephropathy which can develop in patients who underwent a contrast-enhanced tomography scan. It is believed that NGAL can be the reagent which replaces creatinine in future studies for the early diagnosis of contrast-induced nephropathy particularly for patients aged 60 and above. Further investigations are required for clarifying the role of NGAL values in the early diagnosis of Contrast-Induced Nephropathy after contrast-enhanced computed tomography in Emergency Department.
C1 [Isler, Yesim; Kaya, Halil] Saglik Bilimleri Univ, Bursa Training & Res Hosp, Dept Emergency Med, Bursa, Turkey.
   [Ozdinc, Serife] Afyon Kocatepe Univ, Med Fac, Dept Emergency Med, Afyon, Turkey.
RP Kaya, H (corresponding author), Saglik Bilimleri Univ, Yuksek Ihtisas Training & Res Hosp, Dept Emergency Med, Fac Med, Bursa, Turkey.
EM drhalilkaya@gmail.com
RI Kaya, Halil/ABH-5489-2020
OI Kaya, Halil/0000-0003-2005-6100
CR Alharazy SM, 2014, ANGIOLOGY, V65, P216, DOI 10.1177/0003319712474947
   Andreoli SP, 2009, PEDIATR NEPHROL, V24, P253, DOI 10.1007/s00467-008-1074-9
   Bachorzewska-Gajewska H, 2007, KIDNEY BLOOD PRESS R, V30, P408, DOI 10.1159/000109102
   Bachorzewska-Gajewska H, 2007, NEPHROL DIAL TRANSPL, V22, P295, DOI 10.1093/ndt/gfl408
   Borregaard N, 2006, BIOMETALS, V19, P211, DOI 10.1007/s10534-005-3251-7
   Cruz DN, 2010, INTENS CARE MED, V36, P444, DOI 10.1007/s00134-009-1711-1
   Devarajan P, 2008, SCAND J CLIN LAB INV, V68, P89, DOI 10.1080/00365510802150158
   Haase M, 2009, AM J KIDNEY DIS, V54, P1012, DOI 10.1053/j.ajkd.2009.07.020
   Hawkins R, 2011, KOREAN J LAB MED, V31, P72, DOI 10.3343/kjlm.2011.31.2.72
   Iakovou Ioannis, 2003, J Invasive Cardiol, V15, P18
   McCullough PA, 2008, NEPHRON PHYSIOL, V109, pP61, DOI 10.1159/000142938
   Mueller C, 2002, ARCH INTERN MED, V162, P329, DOI 10.1001/archinte.162.3.329
   Sadat U., 2013, ISRN RADIOL, V2013, DOI DOI 10.5402/2013/496438
   Schillinger M, 2001, J ENDOVASC THER, V8, P609, DOI 10.1583/1545-1550(2001)008<0609:PRFABA>2.0.CO;2
   Schmidt-Ott KM, 2006, CURR OPIN NEPHROL HY, V15, P442, DOI 10.1097/01.mnh.0000232886.81142.58
   Solomon R, 2008, CLIN J AM SOC NEPHRO, V3, P1242, DOI 10.2215/CJN.03470708
   Solomon R, 2007, NEPHROL DIAL TRANSPL, V22, P1812, DOI 10.1093/ndt/gfm207
   Soni SS, 2010, INT UROL NEPHROL, V42, P141, DOI 10.1007/s11255-009-9608-z
   Tepel M, 2006, CIRCULATION, V113, P1799, DOI 10.1161/CIRCULATIONAHA.105.595090
   Wagener G, 2006, ANESTHESIOLOGY, V105, P485, DOI 10.1097/00000542-200609000-00011
   Yildiz Alaattin, 2003, Anadolu Kardiyol Derg, V3, P104
NR 21
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1889
EP 1894
DI 10.19193/0393-6384_2018_6_293
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400044
DA 2022-07-14
ER

PT J
AU Jamalmohammadi, A
   Tabibi, SJ
   Riahi, L
   Farahani, MMM
AF Jamalmohammadi, Ali
   Tabibi, Seyed Jamaledin
   Riahi, Leila
   Farahani, Mahmoud Mahmoudi Majdabadi
TI COMPARATIVE STUDY OF FINANCING MECHANISM OF EMERGENCY MEDICAL SERVICE IN
   THE FORM OF INTEGRATED MANAGEMENT OF PRE-HOSPITAL AND HOSPITAL EMERGENCY
   IN SELECTED COUNTRIES AND IRAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Financing; Emergency Medical Service; Integrated management
ID INTERNATIONAL EMS SYSTEMS
AB Background and objective: Organizing medical services in emergency and payment systems of costs associated with these services is quite different in different countries. In recent years, many countries have attempted to reform in this area to be reduced the number of false visits to the emergency department and utilization of medical services in pre-hospital and hospital emergency to be done reasonably and properly.
   Methods: This research is a descriptive study and with comparative approach. Developed countries in different parts of the world on the basis of having accepted models of service delivery and availability of information were selected. Information about mechanism of payment of costs of emergency care in the countries studied is collected and then on the basis of comparative tables, factors affecting the pattern of payment of costs of emergency care in the form of integrated management of pre-hospital and hospital emergency of studied countries were extracted.
   Results: A significant difference can be observed between the number of visits to emergency departments for every 1,000 people in selected countries and Iran; Iran and Australia has the largest number of outpatients to emergency departments and has the largest number of patients admitted in the emergency departments but the proportion of patients admitted in all visits to the emergency department is slightly higher than other countries; there are multiple payment mechanisms for those involved in providing emergency medical services. In addition, payment systems to pre-hospital and hospital emergency in a country often have different mechanisms.
   Conclusion: Despite the lack of financial and human resources in the health system of Iran, to meet the expectations of patients needing emergency care, we need to reform emergency services and this action requires a reorganization of pre-hospital emergency and upgrade the emergency department at the hospital and enjoying budget resources of outpatient care in pre-hospital emergency to pay for treatment of outpatients outside of hospital emergency department using effective approaches on improving payment mechanism in pre-hospital and hospital emergency in Iran.
C1 [Jamalmohammadi, Ali] Islamic Azad Univ, Dept Hlth Serv Adm, Sci & Res Branch, Hlth Serv Management, Tehran, Iran.
   [Tabibi, Seyed Jamaledin; Riahi, Leila; Farahani, Mahmoud Mahmoudi Majdabadi] Islamic Azad Univ, Dept Hlth Serv Adm, Sci & Res Branch, Tehran, Iran.
RP Tabibi, SJ (corresponding author), Islamic Azad Univ, Dept Hlth Serv Adm, Sci & Res Branch, Tehran, Iran.
EM alijamalmohammdi@yahoo.com; sjtabibi@yahoo.com
CR Adnet F, 2004, RESUSCITATION, V63, P7, DOI 10.1016/j.resuscitation.2004.04.001
   [Anonymous], 2003, PLAN SIT AN EM DEP H
   [Anonymous], 2004, AM COLL EM PHYS REP
   [Anonymous], 2015, GEN POL HLTH SYST
   Asadi Farkhonde, 2003, IMPROVE PERFORMANCE
   Azami Saber, 2013, HLTH J ARDABIL, V3, P7
   Bahadori Mohammad Karim, 2007, SH INVESTIGATING STR
   Baruni M., 2004, COMP STUDY METHODS F
   Cobelas C, 2001, QUALITY MANAGEMENT E
   Karimi Iraj, 2005, J HLTH ADM, V8, P15
   Keshavarz Hasani, 2012, PLANNING COORDINATIO
   Kobusingye OC, 2005, B WORLD HEALTH ORGAN, V83, P626
   Masoumi Habib, 2015, PREHOSPITAL URGENCIE
   Masumi Gh, 2003, HOSP EMERGENCY DEP I
   Papaspyrou E, 2004, RESUSCITATION, V63, P255, DOI 10.1016/j.resuscitation.2004.06.009
   Pozner CN, 2004, RESUSCITATION, V60, P239, DOI 10.1016/j.resuscitation.2003.11.004
   Quentin Wilm, 2016, ORG PAYMENT EMERGENC
   Rajabpour Vand, 1998, COMP STUDY PUBLIC HL
   Safdari Reza, 2010, J MED PURIFICATION, P41
   Siddiqui AA, J COLL PHYS SURG PAK
   VanRooyen MJ, 1999, J EMERG MED, V17, P691, DOI 10.1016/S0736-4679(99)00065-7
NR 21
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 2
BP 569
EP 573
DI 10.19193/0393-6384_2018_2s_90
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7SD
UT WOS:000429274400004
DA 2022-07-14
ER

PT J
AU Jenaabadi, H
AF Jenaabadi, Hossein
TI EFFICACY OF ANGER MANAGEMENT TRAINING ON ANGER DECREASE OF AND BLOOD
   PRESSURE REACTIVITY AMONG PATIENTS WITH HYPERTENSION IN ZAHEDAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Anger Management Training; Blood Pressure; Anger
AB Background and objective: This study aimed to examine the impact of anger management training on anger and blood pressure among patients with hypertension in Zahedan. Using a simple random sampling method, a total of 30 subjects was selected among patients referred to hospitals in Zahedan and was randomly assigned into two groups: an experimental group and a control group. Measurement tool used in the current study was Spielberger State-Trait Anger Expression Inventory-2 (1999). Moreover, the subjects' levels of blood pressure were measured. The present study followed a pretest, posttest, and follow-up quasi-experimental design with a control group. The subjects assigned to the experimental group took part in 10 sessions of anger management training. Pretest, posttest, and one-month follow-up were conducted on both groups. Data was analyzed using univariate and multivariate analyses of covariance. Results demonstrated that anger management training was effective in reducing systolic blood pressure and anger among the patients with hypertension in the experimental group. In addition, results of the follow-up showed stability of the impacts of anger management training on systolic blood pressure and anger among the patients in the experimental group.
C1 [Jenaabadi, Hossein] Univ Sistan & Baluchestan, Dept Psychol, Zahedan, Iran.
RP Jenaabadi, H (corresponding author), Univ Sistan & Baluchestan, Dept Psychol, Zahedan, Iran.
EM hjenaabadi@ped.usb.ac.ir
RI Jenaabadi, Hossein/CAG-0698-2022
OI Jenaabadi, Hossein/0000-0002-4373-9353
CR Aghaei E., 2013, PSYCHOL HEALTH, V2, P57
   Argyle M., 2001, PSYCHOL HAPPINESS
   Bagheri N., 2006, THESIS
   Bagherian R., 2010, J PSYCHIAT CLIN PSYC, V52, P272
   Bahrami M., 2013, J CLIN PSYCHOL, V3, P79
   Buehler C, 2006, J MARRIAGE FAM, V68, P109, DOI 10.1111/j.1741-3737.2006.00237.x
   Dahlen E R, 2001, ANGER MANAGEMENT EMP
   Davydov DM, 2012, INT J PSYCHOPHYSIOL, V85, P212, DOI 10.1016/j.ijpsycho.2012.04.011
   Eysenck M., 1990, ALWAYS BE HAPPY
   Feindler E. L., 2005, J FAMILY VIOLENCE, V4, P26
   Haghdust Ali Akbar, 2006, J KERMAN U MED SCI, V13, P64
   Hergenhahn B. V., 2003, INTRO LEARNING THEOR
   Lau B. V. K., 2001, HONG KONG PRACTITION, V23, P258
   McCraty R, 1999, INTEGR PHYS BEH SCI, V34, P246, DOI 10.1007/BF02688693
   Navid A., 2006, THESIS
   Navidi A., 2008, IRANIAN J PSYCHIAT C, V14, P394
   Navidi M., 2006, J GONABAD U MED SCI, V1, P66
   Seifzadeh M., 2009, THESIS
   Smith, 2002, STRESS MANAGEMENT CO
   Spielberger CD., 1999, STAXI 2 STATE TRAIT
   Stern S. B., 1999, AM J FAM THER, V27, P341
   World Health Organization, 2006, CAUS DEATH, P120
NR 22
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 2
BP 607
EP 612
DI 10.19193/0393-6384_2018_2s_95
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7SD
UT WOS:000429274400009
DA 2022-07-14
ER

PT J
AU Jia, BH
   Chen, Y
   Li, XY
   Huang, M
   Shang, MS
   Liu, N
   Wu, LL
   Yan, ZJ
AF Jia, Baohui
   Chen, Yi
   Li, Xiangyang
   Huang, Min
   Shang, Mingsheng
   Liu, Ning
   Wu, Lili
   Yan, Zhijie
TI PROTECTIVE EFFECTS OF NICOTINE AGAINST SEPSIS IN MICE AFTER A CLP VIA
   ACTIVATING CHOLINERGIC ANTI-INFLAMMATORY PATHWAY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Nicotine; Cholinergic anti-inflammatory pathway; Sepsis; Tumor necrosis
   factor; Interleukine-1 beta
ID PROINFLAMMATORY CYTOKINES; MORTALITY
AB Objective: To investigate the effects of nicotine on sepsis in mice.
   Methods: Sepsis was induced in female Kunming mice with cecal ligation and puncture operation (CLP). The experiment group were administered nicotine (400 mu g/kg) 30 minutes before and three times daily for 3 days after sepsis induction. Survival of mice was observed up to 7 days after CLP in a total of 65 mice. In a separate experiment, the severity of the sepsis was evaluated and lung and liver histopathological examinations were performed (n=18). In the third experiment (n=120), we examined the temporal levels of proinflammatory cytokines (TNF-alpha and IL-1 beta) in mouse plasma corresponding to varying doses (40-400 mu g/kg) of nicotine administered.
   Results: Nicotine (400 mu g/kg) significantly increased the survival rate of CLP mice compared to those of the control group (56.7% vs. 20%; P<0.01). It could attenuate sepsis severity (15.00 +/- 3.58 in experiment group vs. 21.00 +/- 2.37 in CLP group; P<0.05) and decrease the lung wet/dry weight ratio (2.30 +/- 1.03 vs. 2.71 +/- 1.58 in CLP group; P<0.05). It could also ameliorate hepatic and lung damage. Six hours after administration, nicotine (400 mu g/kg) significantly decreased the serum levels of TNF-alpha (531.79 +/- 8.14 vs. 731.11 +/- 42.56 in CLP group; P<0.01) and IL-1 beta (245.19 +/- 35.03 vs. 556.12 +/- 7.08 in CLP group; P<0.01).
   Conclusions: Nicotine has protective effects against sepsis in mice, and it could be attributed to its activation of cholinergic anti-inflammatory pathway to inhibit the production of inflammatory cytokines.
C1 [Jia, Baohui; Liu, Ning] Zhengzhou Railway Technol Vocat Coll, Zhengzhou 450052, Henan, Peoples R China.
   [Chen, Yi; Huang, Min; Shang, Mingsheng; Wu, Lili; Yan, Zhijie] Nanchang Univ, Hosp 4, Dept Crit Care Med, Nanchang 330003, Jiangxi, Peoples R China.
   [Li, Xiangyang] Zhengzhou Univ, Zhengzhou Cent Hosp, Zhengzhou 450052, Henan, Peoples R China.
RP Jia, BH (corresponding author), Zhengzhou Railway Technol Vocat Coll, Zhengzhou 450052, Henan, Peoples R China.
EM bhjia@126.com
CR Bonaz B, 2016, J PHYSIOL-LONDON, V594, P5781, DOI 10.1113/JP271539
   Di Giovangiulio M, 2016, MOL MED, V22, P464, DOI 10.2119/molmed.2016.00062
   Halpin DMG, 2016, RESP MED, V114, P1, DOI 10.1016/j.rmed.2016.02.012
   Inci A, 2016, ACTA MEDICA MEDITERR, V32, P249
   [贾宝辉 Jia Baohui], 2013, [中国急救医学, Chinese Journal of Critical Care Medicine], V33, P168
   [贾宝辉 Jia Baohui], 2012, [中国现代医学杂志, China Journal of Modern Medicine], V22, P17
   Jing F, 2016, EXP THER MED, V12, P1048, DOI 10.3892/etm.2016.3372
   Kanashiro A, 2016, PHARM RES, V117, P1
   Lee W, 2015, INFLAMMATION, V38, P1911, DOI 10.1007/s10753-015-0171-8
   Leite FB, 2013, BRAIN RES, V1507, P74, DOI 10.1016/j.brainres.2013.02.036
   Maria C, 2014, PLOS ONE, V9
   Ruiz Stephanie, 2016, Intensive Care Med Exp, V4, P22, DOI 10.1186/s40635-016-0096-z
   Savran Y, 2016, ACTA MEDICA MEDITERR, V32, P17
   Tracey K J, 2009, US, Patent No. [US7572446(P), 7572446]
   Willenberg I, 2016, INFLAMM RES, V65, P133, DOI 10.1007/s00011-015-0897-7
   Zabrodskii PF, 2015, B EXP BIOL MED+, V159, P740, DOI 10.1007/s10517-015-3063-x
   Zabrodskii PF, 2012, B EXP BIOL MED+, V152, P600, DOI 10.1007/s10517-012-1585-z
NR 17
TC 2
Z9 2
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 139
EP 144
DI 10.19193/0393-6384_2018_1_23
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600023
DA 2022-07-14
ER

PT J
AU Jia, BQ
   Li, H
   Cha, N
   Bao, WH
   Zhao, RG
   Sun, SR
AF Jia, Baoqing
   Li, Hui
   Cha, Nier
   Bao, Wenhua
   Zhao, Ruigang
   Sun, Shengrong
TI INHIBITION OF AQUAPORIN 5 SUPPRESSES PROLIFERATION, MIGRATION, AND
   INVASION OF BREAST CANCER CELLS BY MODULATING MAPK SIGNALING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE AQP-5; MAPK; invasion; MMP-2; MMP
ID PALMOPLANTAR KERATODERMA; PROSTATE-CANCER; COLON-CANCER; P38 MAPK; AQP5;
   EXPRESSION; INVOLVEMENT; SURVIVAL; PROTEIN; RISK
AB Introduction: Despite all clinical available therapies for breast cancer, new targets and specific drugs are still under intensive investigation and development. Here we sought to explore the potential role of Aquaporin 5 (AQP-5) in breast cancer metastasis and clarify the involvement of MAPK pathway via specific inhibition.
   Methods: In vitro culture MCF-7 breast cancer cell lines. AQP-5 targeting siRNA was designed with software and synthesized to suppress AQP-5 expression. Cells were transfected with either sham, scramble or AQP-5 siRNA. In addition, specific inhibitor SB203580 was employed to block MAPK pathway. Cell growth was monitored by CCK-8 proliferation assay. The change of MAPK pathway factors were determined by western blotting. Invasion capacity was evaluated by trans-well assay. And extracellular matrix protease activities of MMP-2, 9 were measured by Gelatin Zymography.
   Results: Both transcript and protein of AQP-5 were efficiently decreased by siRNA. Cell proliferation was significantly suppressed upon AQP-5 knockdown. Phosphorylation but not the total protein of p38 was elevated. Knockdown of AQP-5 impaired invasion of MCF-7 in trans-well assay and reduced MMP-2, 9 enzymatic activities in gelatin zymogram, which could be reversed by simultaneous treatment with SB203580.
   Conclusions: Suppression the expression of AQP-5 inhibits proliferation, migration and invasion of breast cancer cell line MCF-7 via activation of MAPK pathway. This effect was counteracted by MAPK specific inhibitor SB203580, which suggested the predominant role of MAPK pathway in mediating tumor suppression in this setting.
C1 [Jia, Baoqing; Sun, Shengrong] Wuhan Univ, Renmin Hosp, Dept Breast & Thyroid Surg, 95 Zhangzhidong Rd, Wuhan 430060, Hubei, Peoples R China.
   [Li, Hui] Inner Mongolia Peoples Hosp, Dept Oncol, Inner Mongolia, Peoples R China.
   [Cha, Nier; Bao, Wenhua; Zhao, Ruigang] Inner Mongolia Peoples Hosp, Dept Breast Surg, Inner Mongolia, Peoples R China.
RP Sun, SR (corresponding author), Wuhan Univ, Renmin Hosp, Dept Breast & Thyroid Surg, 95 Zhangzhidong Rd, Wuhan 430060, Hubei, Peoples R China.
EM shengrongsun886@126.com
CR Blaydon DC, 2013, AM J HUM GENET, V93, P330, DOI 10.1016/j.ajhg.2013.06.008
   Cao X, 2014, J INVEST DERMATOL, V134, P284, DOI 10.1038/jid.2013.302
   Chae YK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002162
   Criscitiello C, 2015, PROG TUMOR RES, V42, P30, DOI 10.1159/000437183
   Gomes LR, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-26
   Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026
   Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/S0140-6736(16)31891-8, 10.1016/s0140-6736(16)31891-8]
   Jung H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027938
   Kang BW, 2015, ONCOLOGY-BASEL, V88, P369, DOI 10.1159/000369073
   Kasimir-Bauer S, 2009, MOL MED REP, V2, P645, DOI 10.3892/mmr_00000151
   Kim ES, 2004, INT J ONCOL, V25, P1375
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee SJ, 2017, ONCOLOGY-BASEL, V92, P153, DOI 10.1159/000452715
   Lee SJ, 2014, ANN SURG ONCOL, V21, P375, DOI 10.1245/s10434-013-3317-7
   Li JP, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-284
   Liu XB, 2006, J BIOL CHEM, V281, P15485, DOI 10.1074/jbc.M600549200
   Ohashi Y, 2003, AM J OPHTHALMOL, V136, P291, DOI 10.1016/S0002-9394(03)00203-4
   Pust A, 2016, HUM PATHOL, V48, P102, DOI 10.1016/j.humpath.2015.09.026
   Shan T, 2014, ONCOL REP, V32, P1564, DOI 10.3892/or.2014.3377
   Shi XM, 2014, TUMOR BIOL, V35, P7035, DOI 10.1007/s13277-014-1956-3
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Turkoz FP, 2013, BREAST, V22, P344, DOI 10.1016/j.breast.2012.08.005
   Wang D, 2009, J MED INVESTIG, V56, P350, DOI 10.2152/jmi.56.350
   Watanabe T, 2009, J PHYSIOL SCI, V59, P113, DOI 10.1007/s12576-008-0017-3
   Williams LA, 2016, CANCER CAUSE CONTROL, V27, P259, DOI 10.1007/s10552-015-0703-4
   Yan CX, 2014, J OVARIAN RES, V7, DOI 10.1186/s13048-014-0078-2
   Zhang T, 2012, MED ONCOL, V29, P1998, DOI 10.1007/s12032-011-0095-6
NR 27
TC 1
Z9 1
U1 1
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1397
EP 1403
DI 10.19193/0393-6384_2018_5_213
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700035
DA 2022-07-14
ER

PT J
AU Jia, FB
   Sun, GJ
   Cao, FJ
   Shi, XY
   Ge, HL
AF Jia, Fubao
   Sun, Guanjun
   Cao, Fengjun
   Shi, Xiuyun
   Ge, Hongliang
TI ANALYSIS OF THE RISK FACTORS OF HEMORRHAGIC TRANSFORMATION IN PATIENTS
   WITH NON-THROMBOLYTIC ISCHEMIC STROKE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ischemic stroke; non thrombolytic therapy; hemorrhagic transformation
ID THERAPY
AB The purpose of this article is to explore the risk factors associated with non-thrombolytic hemorrhagic transformation in patients with acute ischemic stroke. It also provides a clinical prevention and treatment method for hemorrhagic transformation, which provides a theoretical basis for the risk assessment of patients in the future. A retrospective analysis method was used to analyze 60 patients who failed to respond to thrombolysis or were not willing to accept thrombolytic therapy in our emergency department of Neurology in January 2016 - January 2017. Hemorrhagic transformation was used as a sign, which was divided into hemorrhagic transformation, group and non-hemorrhagic transformation group. There were 30 patients in each group. The basic information, clinical indicators and imaging data of patients' medical records were collected. After that, SPSS 20 software was used for statistical analysis. Logistic regression analysis showed that the ficctors of the difference were statistic-ally significant for a total of 5. They are the infarction area (OR=3.48, CI: 1.41-8.86, P=0.006); NIHSS score (OR=1.068, CI: 1.014-1.128, P=0.009), high blood lipids (OR=2.78, CI: 1.36-5.62, P=0.009), diabetes mellitus (OR=1.062, CI: 0.967-1.284, P=0.006), urine protein (OR=2.12, CI: 1.68-3.06, P=0.000). It can be concluded that NIHSS score, infarct area, hyperlipidemia, diabetes, and urine protein are independent factors of hemorrhagic transformation.
C1 [Jia, Fubao; Sun, Guanjun; Cao, Fengjun; Ge, Hongliang] Shanxian Cent Hosp, Dept Internal Neurol, Shanxian 274300, Peoples R China.
   [Shi, Xiuyun] Shanxian Cent Hosp, Dept Test, Shanxian 274300, Peoples R China.
RP Ge, HL (corresponding author), Shanxian Cent Hosp, Dept Internal Neurol, Shanxian 274300, Peoples R China.
EM Ps21805@163.com
CR Chaudhry SA, 2016, NEUROL-CLIN PRACT, V6, P22, DOI 10.1212/CPJ.0000000000000212
   Cucchiara B, 2009, STROKE, V40, P3067, DOI 10.1161/STROKEAHA.109.554386
   [黄银辉 Huang Yinhui], 2013, [中国神经精神疾病杂志, Chinese Journal of Nervous and Mental Diseases], V39, P581
   Kim EY, 2005, AM J NEURORADIOL, V26, P1050
   Lee J Y, 2005, REOCCLUSION HEMORRHA
   Mehta T, 2017, NEUROL RES, V39, P1
   Merino Zamorano C, 2015, EP2887069[P], Patent No. 2887069
   Rodriguez-Gonzalez R, 2013, ATHEROSCLEROSIS, V226, P165, DOI 10.1016/j.atherosclerosis.2012.10.072
   Tan S, 2014, J NEUROL, V261, P905, DOI 10.1007/s00415-014-7297-8
   Wan Jin-ping, 2014, Zhejiang Da Xue Xue Bao Yi Xue Ban, V43, P36
   Wei H, 2015, CHIN J CONT NEUROL N, V15, P126
   Zhang PL, 2015, EUR REV MED PHARMACO, V19, P1001
   Zhao W, 2015, PRACTICAL J CARDIAC
   Zhuan X U, 2015, J APOPLEXY NERVOUS D
NR 14
TC 0
Z9 0
U1 1
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1771
EP 1775
DI 10.19193/0393-6384_2018_6_271
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400022
DA 2022-07-14
ER

PT J
AU Jiang, K
   Wang, C
   Yan, SL
AF Jiang Kun
   Wang Chao
   Yan Silei
TI EFFECT OF COMBINATION OF METHYLPREDNISOLONE AND AZITHROMYCIN ON
   PEDIATRIC MYCOPLASMA PNEUMONIA AND ITS EFFECTS ON PROCALCITONIN, HS-CRP,
   CARDIAC TROPONIN AND IL-2
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Pediatric mycoplasma pneumonia; Methylprednisolone; Azithromycin
ID RESISTANCE; CHILDREN
AB Objectives: To investigate the curative effect of treatment with combination of methylprednisolone and azithromycin on pediatric mycoplasmal pneumonia and its effect on procalcitonin (PCT), high sensitivity C-reactive protein (hs-CRP), cardiac troponin and IL-2.
   Methods: A total of 100 cases of children diagnosed with mycoplasma pneumonia and treated in our hospital from March 2014 to March 2017 were randomly divided into control group and observation group (50 cases in each group). The control group was treated with azithromycin, while the observation group was treated with methylprednisolone combined with azithromycin. Hospital stays, treatment time, clinical symptoms, symptom disappearance time, incidence of adverse reactions, and effect of clinical treatment in the two groups were analyzed statistically. At the same time, the concentrations of PCT, hs-CRP, cardiac troponin and IL-2 in serum of the two groups were determined and analyzed before and after treatment, using magnetic particle chemiluminescence (quantitative).
   Results: The total treatment effectiveness in the observation group was 96%, which was significantly higher than 84% in the control group (p < 0.05). Fever cessation time, disappearance time of cough and hales, hospital stays and healing time in the observation group were all significantly shorter than those in the control group (p < 0.05). The incidence of nausea, vomiting, abdominal pain, diarrhea, rash, injection site pain and liver function impairment in the observation group were lower than those in the control group (p < 0.05). The levels of PCT, hs-CRP, cardiac troponin in both groups decreased after treatment, while the IL-2 increased. There was a significant difference between values before and after treatment (p < 0.05). The degrees of changes jn PCT, hs-CRP, cardiac troponin and IL-2 in the observation group before and after treatment were significantly higher than those in the control group. After treatment, the concentrations of PCT, hs-CRP and cardiac troponin in the observation group were lower than those in the control group, and the concentration of IL-2 in the observation group was higher than that in the control group (p < 0.05).
   Conclusion: Compared with azithromycin, combination of methylprednisolone and azithromycin in the treatment of children with mycoplasma pneumoniae has better clinical efficiency and safety, lower inflammation and better immune balance.
C1 [Jiang Kun; Wang Chao; Yan Silei] Shanghai Childrens Hosp, 24,1400 Beijing West Rd, Shanghai, Peoples R China.
   [Jiang Kun; Wang Chao; Yan Silei] Shanghai Jiao Tong Univ, Affiliated Childrens Hosp, Dept Resp Med, Shanghai, Peoples R China.
RP Jiang, K (corresponding author), Shanghai Childrens Hosp, 24,1400 Beijing West Rd, Shanghai, Peoples R China.
EM mvqxd6@163.com
CR Chen Lili, 2014, Zhonghua Er Ke Za Zhi, V52, P172
   [邓银灿 Deng Yincan], 2014, [上海交通大学学报. 医学版, Journal of Shanghai Jiaotong University .Medical Science], V34, P1372
   Di Marco E, 2014, METHODS MOL BIOL, V1160, P99, DOI 10.1007/978-1-4939-0733-5_9
   Gao RN, 2009, J PEDIAT PHARM, V15, P18
   Hantz S, 2012, J CLIN MICROBIOL, V50, P3402, DOI 10.1128/JCM.01248-12
   Hou JW, 2012, MOD J INT TRADI CHIN, V21, P2548
   Huang L, 2014, CHIN MED SCI, V4, P56
   Lee KY, 2006, PEDIATR PULM, V41, P263, DOI 10.1002/ppul.20374
   Liu KY, 2015, PEDIAT EMERG MED CHI, V22, P56
   Ma HX, 2011, ANHUI MED J, V32, P498
   Mulholland S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004875.pub4
   Onozuka D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095447
   Peng W, 2014, INFECT INFLAMM REPAI, V15, P221
   [齐烨 QI Ye], 2011, [实用儿科临床杂志, Journal of Applied Clinical Pediatrics], V26, P1141
   Sauteur PMM, 2014, CURR OPIN INFECT DIS, V27, P220, DOI 10.1097/QCO.0000000000000063
   Sorensen MG, 2007, BIOMARKERS, V12, P266, DOI 10.1080/13547500601070842
   Sun LF, 2003, CHONGQING MED, V32, P389
   Wu Yue-Jin, 2014, Zhongguo Dang Dai Er Ke Za Zhi, V16, P401
   Zhang Lijie, 2009, Critical Reviews in Biomedical Engineering, V37, P1
NR 19
TC 0
Z9 0
U1 0
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 805
EP 809
DI 10.19193/0393-6384_2018_3_123
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000027
DA 2022-07-14
ER

PT J
AU Jiao, HX
   Hu, JH
   Lu, WQ
AF Jiao, Hong-Xin
   Hu, Jian-Hua
   Lu, Wen-Qing
TI REHABILITATION TREATMENT BY EAR SQUEEZE WITH WAIST EXERCISE FOR ACUTE
   LOW BACK PAIN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE auricular acupressure; waist exercise; acute lower-back pain; semen
   coicis; junction point of antihelical crura; anesthetic effects
ID EPIDEMIOLOGY; TRIAL; CARE
AB Objective: This study aims to evaluate the treatment effects of auricular point acupressure with waist exercise in the rehabilitation of patients with simple acute lower-back pain.
   Methods: Acupressure of semen coicis at the junction point of the antihelical crura of each auricular with waist exercise was employed to treat patients with acute lower-back pain between the period of 2006 to 2014. The visual analogue scale (VAS) on pain was used to evaluate the effects of the treatment.
   Results: This study included 210 patients (82 males/128 females, mean age: 47.5 years, disease duration: four hours to three weeks). After the first office-visit treatments, acute pain and the limited movement of all patients (n=210) were significantly relieved. Most of these cases recovered and returned to work after one week of self-treatment. Among the 193 cases that were followed-up, low-back pain disappeared after one, two and three weeks of treatments in 110 (57%), 60 (31%) and 14 (7.3%) cases, respectively. Furthermore, nine (4.7%) cases became chronic low-back pain, in which acute low-back pain occurred within two weeks of their first office-visit and treatment.
   Conclusion: Auricular point acupressure with waist exercise is an effective treatment for acute low-back pain rehabilitation. Early treatment ascertains better rehabilitative effects. This treatment would most likely replace the dislocated spine joints and stimulate endogenous anesthetic effects.
C1 [Jiao, Hong-Xin; Hu, Jian-Hua; Lu, Wen-Qing] Second Peoples Hosp Kunshan, Dept Orthopaed, 142 Zhongshan Rd, Kunshan 215300, Jiangsu, Peoples R China.
RP Jiao, HX (corresponding author), Second Peoples Hosp Kunshan, Dept Orthopaed, 142 Zhongshan Rd, Kunshan 215300, Jiangsu, Peoples R China.
CR Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4
   Cramer GD, 2002, SPINE, V27, P2459, DOI 10.1097/00007632-200211150-00008
   Cramer GD, 2013, J MANIP PHYSIOL THER, V36, P203, DOI 10.1016/j.jmpt.2013.04.003
   Fassoulaki A, 2007, ANESTH ANALG, V104, P312, DOI 10.1213/01.ane.0000250911.43942.4e
   Golob AL, 2014, MED CLIN N AM, V98, P405, DOI 10.1016/j.mcna.2014.01.003
   HADLER NM, 1987, SPINE, V12, P703, DOI 10.1097/00007632-198709000-00012
   Hoy D, 2010, BEST PRACT RES CL RH, V24, P769, DOI 10.1016/j.berh.2010.10.002
   Kent Peter M, 2005, Chiropr Osteopat, V13, P13, DOI 10.1186/1746-1340-13-13
   Lidgren L, 2003, B WORLD HEALTH ORGAN, V81, P629
   Luo XM, 2004, SPINE, V29, P79, DOI 10.1097/01.BRS.0000105527.13866.0F
   McIntosh G., 2011, BMJ CLIN EVIDENCE, V2011
   Neviaser A, 2013, J BONE JOINT SURG AM, V95A, P1896, DOI 10.2106/JBJS.M.00958
   Patel AT, 2000, AM FAM PHYSICIAN, V61, P1779
   Patrick N, 2014, MED CLIN N AM, V98, P777, DOI 10.1016/j.mcna.2014.03.005
   Suen Lorna K P, 2007, Complement Ther Clin Pract, V13, P63, DOI 10.1016/j.ctcp.2006.10.005
   WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002
   WHEELER AH, 1995, SPINE, V20, P375, DOI 10.1097/00007632-199502000-00023
   Wu H, 1997, J Tradit Chin Med, V17, P26
   Zhou B., 2010, PAIN NECK SHOULDERS
NR 19
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1105
EP 1110
DI 10.19193/0393-6384_2018_4_170
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500033
DA 2022-07-14
ER

PT J
AU Jin, F
   Liang, W
AF Jin, Fang
   Liang, Wang
TI COMPARISON OF ANTEROLATERAL THIGH FLAP, PECTORALIS MAJOR MYOCUTANEOUS
   FLAP AND FREE FOREARM FLAP IN THE SURGICAL REPAIR OF ORO-MAXILLOFACIAL
   DEFECTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Anterolateral thigh flap; pectoralis major myocutaneous flap; free
   forearm flap; Oro-maxillofacial region defects
ID RECONSTRUCTION; MORBIDITY
AB Objective: To investigate and compare the effectiveness of treatment with anterolateral thigh flap, pectoralis major myocutaneous flap and free forearm flap in the repair of oro-maxillofacial region soft tissue defects.
   Methods: Patients (117) with oro-maxillofacial region soft tissue defects treated with skin flap repair in oral and maxillofacial surgery of our hospital from September 2015 to August 2017 were selected for the study. Out of this number, 47 patients received anterolateral thigh flap repair, 40 patients received pectoralis major myocutaneous flap repair, and 30 patients underwent forearm flap repair. The post-operative repair effect, adverse reactions and satisfaction with the curative effect were assessed and compared in the three groups.
   Results: There was no significant difference in the number of different flap sources between groups (p > 0.05). The success scores of transplantation in the three groups (95.74%, 92.5%, and 90%, respectively) did not differ significantly (p > 0.05). The observed adverse reactions were infection, hematocele, effusion, and skin flap necrosis, with total incidence of 14.89%, 12.5%, 20%, and there was no significant difference between groups (p > 0.05). in addition, no significant differences were seen between the three groups with respect to total satisfaction of the repair effect (p > 0.05).
   Conclusion: The use of anterolateral thigh flap, pectoralis major myocutaneous flap and free forearm flap have good clinical effects in the repair of oro-maxillofacial region soft tissue defects, and the choice of skin flap is extensive. These findings are worthy of clinical promotion and application.
C1 [Jin, Fang] Nanjing Med Univ, Huaian Peoples Hosp 1, Nanjing, Jiangsu, Peoples R China.
   [Liang, Wang] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Shanghai, Peoples R China.
RP Jin, F (corresponding author), Nanjing Med Univ, Huaian Peoples Hosp 1, Nanjing, Jiangsu, Peoples R China.
EM hgnqqslb29140@163.com
CR Aggarwal A, 2017, INDIAN J PLAST SURG, V50, P91, DOI 10.4103/ijps.IJPS_158_16
   Chuan Xu Da, 1984, J ANATOMY CLIN APPL, V2, P158
   Dewey EH, 2017, AM J OTOLARYNG, V38, P618, DOI 10.1016/j.amjoto.2017.07.004
   Hirai E, 2017, J ORAL MAXIL SURG, V75, DOI 10.1016/j.joms.2017.03.035
   Jeong EC, 2017, J CRANIOFAC SURG, V28, pe438, DOI 10.1097/SCS.0000000000003618
   Numajiri T, 2017, PRS-GLOB OPEN, V5, DOI 10.1097/GOX.0000000000001448
   Pancholi Mayank, 2016, Ann Maxillofac Surg, V6, P219, DOI 10.4103/2231-0746.200320
   Rahpeyma A, 2016, J CRANIOFAC SURG, V27, P2190, DOI 10.1097/SCS.0000000000003094
   Shroff SS, 2017, J MAXILLOFAC ORAL SU, V16, P101, DOI 10.1007/s12663-016-0930-6
   Simon-Sanz E, 2016, INDIAN J PLAST SURG, V49, P422, DOI 10.4103/0970-0358.197246
   SONG YG, 1984, BRIT J PLAST SURG, V37, P149, DOI 10.1016/0007-1226(84)90002-X
   Takayama Y, 2016, J CRANIOFAC SURG, V27, P2055, DOI 10.1097/SCS.0000000000002969
   Tao Wang, 2015, MODERN BIOMEDICAL ME, V15, P6064
   Watfa W, 2017, J SEX MED, V14, P1277, DOI 10.1016/j.jsxm.2017.08.003
   Yang B, 2017, J CRANIO MAXILL SURG, V45, P347, DOI 10.1016/j.jcms.2016.12.012
NR 15
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 759
EP 764
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000021
DA 2022-07-14
ER

PT J
AU Jin, LF
   Hua, YF
   Cao, HH
   Zhang, M
AF Jin, Lifang
   Hua, Yunfen
   Cao, Huanhuan
   Zhang, Ming
TI EX VIVO ISOLATION AND EXPANSION OF RABBIT MESENCHYMAL STEM CELLS IN
   DEFINED SERUM-FREE MEDIA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Mesenchymal stem cells; Serum-free medium; Expansion; Differentiation;
   Rabbit
ID THERAPY POSITION STATEMENT; BONE-MARROW; INTERNATIONAL-SOCIETY;
   PERIPHERAL-BLOOD; DIFFERENTIATION; CULTURE
AB Introduction: Mesenchymal stem cells (MSCs) derived from rabbit bone marrow are routinely investigated in cardiovascular and orthopedic models for regenerative medicine. However, classical media used for generating MSCs are typically augmented with ill-defined supplements, such as fetal bovine serum, which increases safety concerns as well as inconsistency in MSC generation. We tested three commercial serum-free media for the generation and expansion of rabbit MSCs (rbMSCs). Materials and methods: RbMSCs were separated by adherent tissue culture and cultured in serum-free or serum-containing media. Cultured cells were characterized by phase contrast microscopy, cell-proliferation, flow cytometry, and qPCR analyses.
   Results: MesenCult (R) XF medium supported the generation and expansion of rbMSCs, whereas StemPro (R) hMSC and BD Mosaic hMSC media did not propagate freshly isolated rbMSCs. At passage 5, total cell yields for serum-containing and MesenCult (R) XF media were 4.0 +/- 0.16 x 108 and 1.9 +/- 0.28 x 109, and cumulative population doublings were 11.5 +/- 0.12 and 13.08 +/- 0.19, respectively. Colony formation efficiencies in MesenCult (R) XF were 21 to 26%, whereas those in serum-containing medium were 14 to 17%. Flow cytometry showed that rbMSCs in MesenCult (R) XF were positive for CD29, CD44 and CD73, and negative for CD34 and CD45. After corresponding differentiation, rbMSCs from MesenCult (R) XF could differentiate into adipogenic, osteogenic and chondrogenic lineages. qPCR analysis demonstrated that cells cultured in serum-free media had higher differentiation potentials than those cultured in serum-containing media.
   Discussion: rbMSCs were efficiently generated and expanded in MesenCult (R) XF, while maintaining the necessary characteristics attributed to MSCs for potential therapeutic use.
C1 [Jin, Lifang] Shaoxing Univ, Coll Life Sci, Shaoxing, Zhejiang, Peoples R China.
   [Jin, Lifang; Hua, Yunfen; Cao, Huanhuan; Zhang, Ming] Hangzhou Precis Med Res Ctr, Hangzhou, Zhejiang, Peoples R China.
RP Zhang, M (corresponding author), Hangzhou Precis Med Res Ctr, Hangzhou, Zhejiang, Peoples R China.
EM zhangming_ls@zju.edu.cn
FU Zhejiang Province Science and Technology Project of China [2013C33189]
FX This work was supported by research grants from the Zhejiang Province
   Science and Technology Project of China [grant number 2013C33189].
CR Al-Saqi SH, 2015, CELL TISSUE BANK, V16, P181, DOI 10.1007/s10561-014-9463-8
   Amini AR, 2012, J ORTHOP RES, V30, P1507, DOI 10.1002/jor.22097
   Bakhtina A, 2014, IN VITRO CELL DEV-AN, V50, P251, DOI 10.1007/s11626-013-9702-5
   Boo L, 2011, J MATER SCI-MATER M, V22, P1343, DOI 10.1007/s10856-011-4294-7
   Chase LG, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt8
   Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698
   Crapnell K, 2013, EXP CELL RES, V319, P1409, DOI 10.1016/j.yexcr.2013.04.004
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Esmaeli A, 2016, INT J REPROD BIOMED, V14, P567
   Fu WL, 2012, TISSUE ENG PT A, V18, P1793, DOI [10.1089/ten.tea.2011.0530, 10.1089/ten.TEA.2011.0530]
   Gupta R, 2007, J SHOULDER ELB SURG, V16, p149S, DOI 10.1016/j.jse.2007.05.002
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Hudson JE, 2011, STEM CELLS DEV, V20, P77, DOI 10.1089/scd.2009.0497
   Javorkova E, 2018, BIOMED PHARMACOTHER, V97, P402, DOI 10.1016/j.biopha.2017.10.114
   Jin LF, 2014, ANIM CELLS SYST, V18, P228, DOI 10.1080/19768354.2014.929026
   Lapi S, 2008, BMC RES NOTES, V28, P1
   Lee MS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081779
   Lin CB, 2015, IN VITRO CELL DEV-AN, V51, P1102, DOI 10.1007/s11626-015-9933-8
   Mapara Manjeet, 2012, Dent Res J (Isfahan), V9, P111, DOI 10.4103/1735-3327.92960
   Nadri S, 2007, INT J DEV BIOL, V51, P723, DOI 10.1387/ijdb.072352ns
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Swamynathan P, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt477
   Tan SL, 2013, J ANAT, V222, P437, DOI 10.1111/joa.12032
   Wang ND, 2014, CYTOTECHNOLOGY, V66, P119, DOI 10.1007/s10616-013-9544-8
   Yanni AE, 2004, LAB ANIM-UK, V38, P246, DOI 10.1258/002367704323133628
NR 25
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 811
EP 817
DI 10.19193/0393-6384_2018_3_124
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000028
DA 2022-07-14
ER

PT J
AU Jin, YT
   Chen, S
   Zhu, ZY
   Wu, LT
   Xuan, LH
AF Jin Yu-Tong
   Chen Shan
   Zhu Zheng-Yang
   Wu Ling-Tao
   Xuan Li-Hua
TI TLR-NF-KB SIGNALING PATHWAY-BASED INVESTIGATION ON THE INFLUENCE OF
   ACUPOINT APPLICATION OF RAW AND FRIED WHITE MUSTARD SEED PLASTERS ON
   NASAL MUCOSA IN RATS WITH ALLERGIC RHINITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Acupoint application; Toll-like receptor; TLR-NF-kappa B pathway;
   Allergic rhinitis
ID CHRONIC RHINOSINUSITIS; EPITHELIUM; EXPRESSION
AB Objective: To investigate the expression of TLR-NF-kappa B signaling pathway in nasal mucosa of rats with allergic rhinitis (AR) and the effect of therapy with acupoint application of raw and fried white mustard seed plasters on it.
   Methods: A total of 50 Wistar rats were randomly divided into the normal group, the model group, the fluticasone propionate group, the raw white mustard seed plaster group and the fried white mustard seed plaster group, with 10 rats in each group. OVA hen ovalbumin was used to prepare rat models of AR, and they were treated by intranasal administration with fluticasone propionate and acupoint application therapy respectively, and behavioral scoring was performed before and after treatment. After treatment, rats in different groups were treated with HE staining to observe the shape of nasal mucosa. The expression of TLR4 and NF-kappa B mRNA in the nasal mucosa was detected by the reverse transcriptase polymerase chain reaction (RT-PCR) and the expression quantities of TLR4 and NF-kappa B in nasal mucosa were determined by Western blotting (WB).
   Results: Behavioral scores, the mRNA and protein expression of TLR4 and NF-kappa B in the nasal mucosa of the model group were significantly higher than those in the normal group (P<0.05). HE staining showed that the nasal mucosa of rats in the model group was destroyed obviously, a large number of eosinophils and other inflammatory cells infiltrated. After treatment, behavioral scores, mRNA and protein expression quantities of TLR4 and NF-kappa B in the fluticasone propionate group, the raw white mustard seed plaster group and the fried white mustard seed plaster group were significantly lower than those in the model group (P<0.05). HE staining showed that inflammatory cell infiltration was significantly decreased, and the curative effect was more significant in the raw white mustard seed plaster group than in the fluticasone propionate group or the fried white mustard seed plaster group (P<0.05), but there was no significant difference between the fried white mustard seed plaster group and the fluticasone propionate group (P<0.05).
   Conclusion: The acupoint application can reduce the expression of TLR4 and NF-kappa B mRNA and proteins and relieve nasal inflammatory symptoms through regulating the TLR-NF-kappa B signaling pathway in nasal mucosa of rats, thus treating allergic rhinitis (AR). besides, the effects of raw white mustard seed plaster are more significant than fried white mustard seed plaster.
C1 [Jin Yu-Tong; Zhu Zheng-Yang; Wu Ling-Tao] Zhejiang Chinese Med Univ, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   [Chen Shan; Xuan Li-Hua] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Hangzhou 310006, Zhejiang, Peoples R China.
RP Xuan, LH (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Hangzhou 310006, Zhejiang, Peoples R China.
EM xlh1083@163.com
FU key science and technology projects of Zhejiang Province [2014C03046-2]
FX Supported by The key science and technology projects of Zhejiang
   Province (No. 2014C03046-2)
CR Aryan Z, 2014, INT ARCH ALLERGY IMM, V164, P46, DOI 10.1159/000362553
   Chen Jing, 2012, Zhongguo Zhen Jiu, V32, P31
   Chen Z, 2017, EXPT THERAPEUTIC MED, V13
   Fransson M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-100
   Imai A, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00327
   Li XR, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1400-x
   Lin Yong-kai, 2014, Zhongguo Zhen Jiu, V34, P967
   Liu Guoling, 2014, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V30, P721
   Melvin TAN, 2013, AM J RHINOL ALLERGY, V27, P30, DOI 10.2500/ajra.2013.27.3834
   Renkonen J, 2015, APMIS, V123, P716, DOI 10.1111/apm.12408
   SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6
   Shin JH, 2017, ALLERGY ASTHMA IMMUN, V9, P237, DOI 10.4168/aair.2017.9.3.237
   Wang Hao, 2013, Zhongguo Zhen Jiu, V33, P789
   Wee JH, 2017, ALLERGY ASTHMA IMMUN, V9, P61, DOI 10.4168/aair.2017.9.1.61
   Wei Y, 2014, J ALLERGY CLIN IMMUN, V133, P420, DOI 10.1016/j.jaci.2013.09.052
   Wen C Y Z, 2015, EVID-BASED COMPL ALT, V2015
   Wen DY, 2006, J PHARMACOL EXP THER, V317, P989, DOI 10.1124/jpet.105.097584
   Xie Yilin, 2015, Zhongguo Zhen Jiu, V35, P1215
   Zhao Jiandong, 2008, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V22, P57
NR 19
TC 1
Z9 1
U1 1
U2 15
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1461
EP 1467
DI 10.19193/0393-6384_2018_5_222
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700044
DA 2022-07-14
ER

PT J
AU Jing, W
   Ling, T
AF Jing, Wang
   Ling, Tang
TI ECG ANALYSIS OF 40 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ECG analysis; Systemic lupus erythematosus
ID DISEASE; SLE
AB Objective: To determine and analyze the ECG patterns of 40 patients with systemic lupus erythematosus (SLE).
   Methods: Clinical data of 40 patients with SLE managed in Zhangye People's Hospital from April 2015 to November 2016 were analyzed, but with particular attention to features of their ECGs.
   Results: Twenty three cases (57.5%) of the 40 patients with SLE had clinical symptoms of heart injury. The average time the SLE patients with heart injury had been suffering from the disease before admission into the hospital was significantly (p < 0.05) longer than that of non-heart injury patients. There were 15 cases (37.5%) with abnormal ECG, 12 cases (30.0%) with ST-T change, 8 cases (20.0%) with arrhythmia, and 5 cases (12.5%) with low limb lead voltage. There were 2 cases of death out of the 40 patients, consisting of one male and one female. The cause of death in one of them was heart failure, while the other death was due to uremia with acute pulmonary edema.
   Conclusion: Changes in ECG of SLE patients is common and should be an important parameter that physicians should routinely examine for SLE cases with heart injury, in order to achieve improved prognosis of the patients' = condition.
C1 [Jing, Wang] Hexi Univ Gansu Prov, Zhangye Peoples Hosp, Dept Dermatol, Zhangye 734000, Gansu, Peoples R China.
   [Ling, Tang] Hexi Univ Gansu Prov, Zhangye Peoples Hosp, Dept Funct, Zhangye, Gansu, Peoples R China.
RP Jing, W (corresponding author), Hexi Univ Gansu Prov, Zhangye Peoples Hosp, Dept Dermatol, Zhangye 734000, Gansu, Peoples R China.
EM dp1321@163.com
CR Aringer M, 2003, ARTHRITIS RES THER, V5, P172, DOI 10.1186/ar770
   Badiu E, 1985, ANGIOLOGY, V36, P431
   [陈太波 Chen Taibo], 2003, [中华风湿病学杂志, Chinese Journal of Rheumatology], V7, P220
   Cui Jing, 2013, Zhonghua Nei Ke Za Zhi, V52, P383
   [董睿 Dong Rui], 2013, [中国全科医学, Chinese General Practice], V16, P1759
   Jiang M., 1998, RHEUMATOLOGY, P846
   Manzi S, 1997, AM J EPIDEMIOL, V145, P408
   Sekigawa I, 2003, CLIN EXP RHEUMATOL, V21, P683
   STURFELT G, 1992, MEDICINE, V71, P216, DOI 10.1097/00005792-199207000-00004
   [唐晓艳 Tang Xiaoyan], 2014, [中华实用儿科临床杂志, Chinese Journal of Applied Clinical Pediatrics], V29, P1451
   Wu ZH, 2016, J CHIN IMMUNOL NEURO, V23, P377
NR 11
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1151
EP 1154
DI 10.19193/0393-6384_2018_4_177
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500040
DA 2022-07-14
ER

PT J
AU Kaplan, NB
   Harputluoglu, H
   Dikilitas, M
   Elkiran, ET
   Temelli, O
AF Kaplan, Nihal Bozdag
   Harputluoglu, Hakan
   Dikilitas, Mustafa
   Elkiran, Emin Tamer
   Temelli, Oztun
TI POSTERIOR REVERSIBLE LEUKOENCEPHALOPATHY SYNDROME DEVELOPING SECONDARY
   TO SUNITINIB THERAPY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Posterior reversible encephalopathy syndrome; sunitinib; early diagnosis
AB Posterior reversible encephalopathy syndrome (PRES) is characterized by vasogenic edema occurring generally in parietal and occipital areas of the brain as a result of different etiologic causes and it is diagnosed by means of clinical and radiologic assessment. Sunitinib is an orally administered tyrosine kinase inhibitor used in the treatment of renal cell carcinoma with its antiangiogenic and antitumor effects. Fatigue, nausea-vomiting, diarrhea, hypertension, cardiotoxicity, hypothyroidism, neutropenia, and skin toxicity are among common side effects associated with sunitinib therapy. The current report presents a female patient with metastatic papillary renal cell cancer who developed posterior reversible encephalopathy syndrome as determined by means of clinical and radiologic assessment at 8 months of sunitinib therapy and who completely recovered with antihypertensive, antiepileptic, and antiedema therapy.
C1 [Kaplan, Nihal Bozdag] Sisli Hamidiye Etfal Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey.
   [Harputluoglu, Hakan; Dikilitas, Mustafa; Elkiran, Emin Tamer] Inonu Univ, Fac Med, Dept Med Oncol, Malatya, Turkey.
   [Temelli, Oztun] Inonu Univ, Fac Med, Dept Radiat Oncol, Malatya, Turkey.
RP Kaplan, NB (corresponding author), Sisli Hamidiye Etfal Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey.
RI harputluoglu, hakan/ABI-6451-2020; temelli, Oztun/ABE-6986-2020;
   Elkıran, Emin Tamer/ABI-8192-2020
OI harputluoglu, hakan/0000-0001-8537-5941; Elkıran, Emin
   Tamer/0000-0001-6681-7249
CR Agarwala SS, 2010, ONCOLOGIST, V15, P236, DOI 10.1634/theoncologist.2009-0141
   Covarrubias DJ, 2002, AM J NEURORADIOL, V23, P1038
   Crona DJ, 2015, INVEST NEW DRUG, V33, P751, DOI 10.1007/s10637-014-0193-3
   Foerster R, 2013, CASE REP ONCOL, V6, P204, DOI 10.1159/000350742
   Fugate JE, 2010, MAYO CLIN PROC, V85, P427, DOI 10.4065/mcp.2009.0590
   Glusker P, 2006, NEW ENGL J MED, V354, P980
   Govindan R, 2006, J CLIN ONCOL, V24, P4848, DOI 10.1200/JCO.2006.07.7404
   Hadj J.O, 2012, ONCOLOGY LETT, P1293
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Kim CAK, 2014, INVEST NEW DRUG, V32, P1036, DOI 10.1007/s10637-014-0113-6
   Lee VH, 2008, ARCH NEURO, V165, P205
   LINEHAN WM, 2001, CANC PRINCIPLES PRAC
   Martin G, 2007, J CLIN ONCOL, V25, P3559, DOI 10.1200/JCO.2007.12.8710
   Medioni J, 2007, TARGET ONCOL, V2, P193, DOI 10.1007/s11523-007-0050-9
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Ozcan C, 2006, NEW ENGL J MED, V354, P981
   Padhy BM, 2011, BRIT J CLIN PHARMACO, V71, P777, DOI 10.1111/j.1365-2125.2010.03893.x
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI [10.3322/caac.21254, 10.1001/jamaoto.2014.2530, 10.3322/caac.21208, 10.1136/bmj.g1502]
   van der Veldt AAM, 2010, DISCOV MED, V10, P394
NR 19
TC 0
Z9 0
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 39
EP 42
DI 10.19193/0393-6384_2018_1_6
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600006
DA 2022-07-14
ER

PT J
AU Karaca, F
   Afsar, CU
AF Karaca, Feryal
   Afsar, Cigdem Usul
TI THE EFFECT OF PRETREATMENT NEUTROPHIL/LYMPHOCYTE RATIO AND
   PLATELET/LYMPHOCYTE RATIO ON PATHOLOGICAL RESPONSE AND SURVIVAL IN
   PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE rectal cancer; locally advanced; survival; NLR; PLR
ID TO-LYMPHOCYTE RATIO; COLORECTAL-CANCER; ULCERATIVE-COLITIS;
   INFLAMMATION; NEUTROPHILS; TUMOR
AB Introduction: Rectal carcinoma is one of the leading causes of cancer death today. In our study, we retrospectively reviewed 357 patients with locally advanced rectal cancer who applied to our hospital between 2009 and 2016.
   Materials and methods: Chemoradiotherapy (CRT) was applied to the patients before surgery. The ratio of neutrophil/lymphocyte (NLR) and platelet/lymphocyte (PLR) were examined at the diagnosis in relation to pathological response and surveillance. The Kaplan-Meier method was used for estimating the survival function from lifetime data. In addition, Cox regression model was also used to explore the relationship between the survival of a patient and several explanatory variables.
   Results: As the tumor diameter increases, the NLR increases, p value is < 0.01 and statistically significant. NLRs were not different between the tumors of T1 and T2, but for T3 and T4 tumors it was higher and more different than others (T3 = 7.0186, T4 = 12.4391). NLR was higher in patients with surgical border continuity, p = 0.01 and statistically significant. A decrease of 1 unit of NLR would increase the likelihood of a pathological good response (1/0.962) by 1.04 fold. PLR, however, is not statistically significant; it has been observed that a decrease in the 1-unit PLR tends to increase the likelihood of a good response (1/0.996) in the pathological stage by 1.004 fold. While the patients who received partial response to the treatment were living at 59 months, the patients who received good response were living at 71 months. Although p value was 0.383, a 12-month median difference in life expectancy was significant.
   Conclusion: It has been shown that high NLR in colorectal cancer and many other cancers is a negative prognostic factor. However, there are few articles evaluating the NLR and PLR only for rectum cancer. As in other cancers, a high PLR is associated with a pathological response in rectal cancer and poor prognosis.
C1 [Karaca, Feryal] Hlth Sci Univ, Adana Numune Educ & Res Hosp, Dept Radiat Oncol, Adana, Turkey.
   [Afsar, Cigdem Usul] Acibadem Mehmet Ali Aydinlar Univ, Dept Internal Med & Med Oncol, Istanbul, Turkey.
RP Afsar, CU (corresponding author), Acibadem Mehmet Ali Aydinlar Univ, Acibadem Bakirkoy Hosp, Dept Internal Med & Med Oncol, Zeytinlik Mah Halit Ziya Usakligil Cad 1, TR-34140 Istanbul, Turkey.
EM cigdemusul@yahoo.com
RI Afsar, Cigdem Usul/C-3436-2015; Afsar, Cigdem Usul/AAA-6103-2021
OI Afsar, Cigdem Usul/0000-0002-3764-7639; Afsar, Cigdem
   Usul/0000-0002-3764-7639
CR Alexandrakis MG, 2003, AM J CLIN ONCOL-CANC, V26, P135, DOI 10.1097/00000421-200304000-00007
   Azab B, 2014, CANCER BIOMARK, V14, P303, DOI 10.3233/CBM-140416
   Buttner S, 2017, ACTA CHIR BELG, V117, P181, DOI 10.1080/00015458.2017.1279872
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   de Martino M, 2013, J UROLOGY, V190, P1999, DOI 10.1016/j.juro.2013.06.082
   Fridlender ZG, 2012, CARCINOGENESIS, V33, P949, DOI 10.1093/carcin/bgs123
   Graziosi L, 2015, AM J SURG, V209, P333, DOI 10.1016/j.amjsurg.2014.06.014
   Guthrie GJK, 2013, CRIT REV ONCOL HEMAT, V88, P218, DOI 10.1016/j.critrevonc.2013.03.010
   Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261
   Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Moody GA, 1996, EUR J GASTROEN HEPAT, V8, P1179, DOI 10.1097/00042737-199612000-00009
   Proctor MJ, 2011, EUR J CANCER, V47, P2633, DOI 10.1016/j.ejca.2011.03.028
   Roxburgh CSD, 2014, BRIT J CANCER, V110, P1409, DOI 10.1038/bjc.2014.90
   Seril DN, 2003, CARCINOGENESIS, V24, P353, DOI 10.1093/carcin/24.3.353
   Shibutani M, 2013, ANTICANCER RES, V33, P3291
   Tazzyman S, 2009, INT J EXP PATHOL, V90, P222, DOI 10.1111/j.1365-2613.2009.00641.x
   Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
NR 17
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1383
EP 1390
DI 10.19193/0393-6384_2018_5_211
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700033
DA 2022-07-14
ER

PT J
AU Karimi, A
   Sadoughi, F
   Majdzadeh, R
AF Karimi, Afsaneh
   Sadoughi, Farahnaz
   Majdzadeh, Reza
TI ESSENTIAL REVISIONS IN THE MATERNAL MORTALITY SURVEILLANCE SYSTEM:
   LESSONS LEARNED FROM A QUALITATIVE STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Public Health; Evaluation Studies; Information Storage and Retrieval
ID ICD-MM CLASSIFICATION; IRAN; DEATH
AB Background: Iran has been able to achieve the MDG 5, but continued success in this direction seems to be difficult due to changes in the country's family planning policy, which is to increase the population. Therefore, it is important to determine the status of the Iranian Maternal Mortality Surveillance System (IMMSS) to identify its pros and cons and to try to improve its quality; this is the aim of this study.
   Methods: Using the content analysis approach, this qualitative study was conducted in 2016. It had two stages: the review of all related documents and the interviews of 15 key informants. The data were analyzed through framework analysis and the results were presented using a descriptive method.
   Results: The implementation of various programs, interventions to improve maternal health and the achievement of the MDG 5 were found to be the most important strengths of the IMMSS. There are several weaknesses in the system, including a lack of clear information about morbidities caused by pregnancy and birth, repeated maternal deaths due to similar causes and the lack of a system evaluation at the provincial level.
   Conclusions: We found that the IMMSS is useful. However, certain measures are recommended to improve the system performance quality. These are, for example, the establishment of a system for the surveillance of maternal morbidities and high-risk mothers, and the evaluation of a maternal mortality surveillance system at the provincial level.
C1 [Karimi, Afsaneh] Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Hlth Informat Management Dept, Tehran, Iran.
   [Sadoughi, Farahnaz] Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Hlth Management & Econ Res Ctr, 6 Rashidi Yasemi St,Vali E Ast St Vanak Sq, Tehran, Iran.
   [Majdzadeh, Reza] Tehran Univ Med Sci, KURC, Tehran, Iran.
   [Majdzadeh, Reza] Tehran Univ Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran.
RP Sadoughi, F (corresponding author), Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Hlth Management & Econ Res Ctr, 6 Rashidi Yasemi St,Vali E Ast St Vanak Sq, Tehran, Iran.
RI Karimi, Afsaneh/J-9367-2017; sadoughi, farahnaz/B-7605-2018
OI Karimi, Afsaneh/0000-0003-3728-4513; sadoughi,
   farahnaz/0000-0002-7452-0864
FU Iran University of Medical Sciences [IUMS/SHMIS-2015/18]
FX This study was part of a PhD thesis supported by the Iran University of
   Medical Sciences (IUMS/SHMIS-2015/18). The authors would like to thank
   all the participants.
CR Agampodi S, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-17
   Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7
   Ameh CA, 2014, BJOG-INT J OBSTET GY, V121, P32, DOI 10.1111/1471-0528.12987
   Bayati M, 2016, MED J ISLAM REPUB IR, V30, P415
   Camacho A, 2012, INT J GYNECOL OBSTET, V119, pS193
   Emamiafshar N, 2006, NATL MATERNAL MORTAL
   German R R, 2001, MMWR Recomm Rep, V50, P1
   Hajizadeh S, 2014, ARCH IRAN MED, V17, P198, DOI 0141703/AIM.0011
   Iran's Ministry of Health Maternal Health department, 2013, REP PERF ACH NAT MAT
   Iran's Ministry of Health Maternal Health department, 2014, REP PERF ACH NAT MAT
   Iran's Ministry of Health Maternal Health department, 2015, REP PERF ACH NAT MAT
   Iran's Ministry of Health Maternal Health department, 2011, REP PERF ACH NAT MAT
   Islamic Parliament Research Center of the Islamic Republic of Iran, 2009, REL FREE ACC INF LAW
   Lankarani Kamran Bagheri, 2013, Med J Islam Repub Iran, V27, P42
   Maternal Health department, 2016, NAT MAT MORT SURV SY
   Moazzeni MS, 2013, MATERN CHILD HLTH J, V17, P577, DOI 10.1007/s10995-012-1043-6
   Mohammadi M, 2015, J APPL SOCIOLOGY, V26, P159
   Mullen SM, 2014, 2014 CSTE ANN C
   Nasiri S., 2017, Razi Journal of Medical Sciences, V24, P73
   Owolabi H, 2014, BJOG-INT J OBSTET GY, V121, P95, DOI 10.1111/1471-0528.12998
   Sadoughi F, 2016, GLOBAL J HLTH SCI, V9, P128
   Sadoughi Farahnaz, 2017, Electron Physician, V9, P4914, DOI 10.19082/4914
   Sajedinejad S, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0087-y
   Soltani H, 2015, MIDWIFERY, V31, P271, DOI 10.1016/j.midw.2014.11.009
   Statistical Center of Iran, 2017, SEL GEN POP HOUS CEN
   Tajik P, 2012, INT J PREVENTIVE MED, V3, P116
   Tran T, 2011, MATERN CHILD HLTH J, V15, P955, DOI 10.1007/s10995-010-0564-0
   World Health Organization, 2013, MAT DEATH SURV RESP
   World Health Organization (WHO), 2012, WHO APPL ICD 10 DEAT
   Yazdizadeh B, 2014, INT J PREVENTIVE MED, V5, P624
   Zolala F, 2012, SINGAP MED J, V53, P684
   Zolala F, 2011, INT J PREVENTIVE MED, V2, P88
NR 32
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1111
EP 1119
DI 10.19193/0393-6384_2018_4_171
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500034
DA 2022-07-14
ER

PT J
AU Kole, MT
   Dag, H
   Dikker, O
   Arica, V
   Ozturkcu, Y
   Kandemir, I
   Dogan, M
   Gedik, H
AF Kole, Mehmet Tolga
   Dag, Huseyin
   Dikker, Okan
   Arica, Vefik
   Ozturkcu, Yusuf
   Kandemir, Ibrahim
   Dogan, Murat
   Gedik, Habip
TI THE EVALUATION OF MEAN PLATELET VOLUME OF CHILDREN WITH ADENOID
   HYPERTROPHY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Adenoids; Mean Platelet Volume; Child
ID RESPIRATORY-TRACT INFECTIONS; OTITIS-MEDIA; VALUES
AB Objective: We aimed to compare the platelet distribution width (PDW) and platelet parameters (PLT), particularly MPV values of children who were diagnosed with adenoid hypertrophy at the pediatric clinic with those of healthy children to investigate a relationship between adenoid hypertrophy and MPV values.
   Material and method: This prospective, cross-sectional study was conducted at the department of pediatrics, Health Sciences University, Ministry of Health Okmeydam Training and Research Hospital between January 2012 and December 2014. The PLT and PDW values as well as MPV of children who were diagnosed with adenoid hypertrophy were compared with those of healthy children.
   Results: In this study, 120 children with adenoid hypertrophy and 120 healthy children were evaluated. The age range of participants was between 3 years and 16 years, and the mean age was 9.13 +/- 2.94 rears. The mean MPV value in children with adenoid hypertrophy (10.88 +/- 1.15 fL) was statistically significantly higher than that in the control group (9.84 +/- 1.04 fL). While the mean platelet distribution width value in the adenoid hypertrophy group was statistically significantly higher than that of the control group, there was no statistically significant difference between the mean platelet counts of both groups.
   Conclusion: MPV, PLT, and PDW values did not differ significantly in children with adenoid hypertrophy compared to healthy children. MPV values were determined significantly higher in children with adenoid hypertrophy when compared with healthy children. Children with adenoid hypertrophy should be followed up in terms of cardiovascular disease on the long view.
C1 [Kole, Mehmet Tolga; Dag, Huseyin; Arica, Vefik; Dogan, Murat] Hlth Sci Univ, Okmeydani Training & Res Hosp, Dept Pediat, Istanbul, Turkey.
   [Dikker, Okan] Hlth Sci Univ, Okmeydani Training & Res Hosp, Dept Med Biochem, Istanbul, Turkey.
   [Ozturkcu, Yusuf] Hlth Sci Univ, Okmeydani Training & Res Hosp, Dept Otolaryngol Head & Neck Surg, Istanbul, Turkey.
   [Kandemir, Ibrahim] Istanbul Univ, Istanbul Med Fac Hosp, Dept Pediat, Istanbul, Turkey.
   [Gedik, Habip] Hlth Sci Univ, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
RP Gedik, H (corresponding author), Hlth Sci Univ, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
EM habipgedik@yahoo.com
RI Gedik, Habip/ABI-3946-2020
OI Gedik, Habip/0000-0002-8406-2254
CR Abdel-Aziz M, 2011, J CRANIOFAC SURG, V22, P1401, DOI 10.1097/SCS.0b013e31821cc334
   Bath PMW, 1996, BLOOD COAGUL FIBRIN, V7, P157, DOI 10.1097/00001721-199603000-00011
   Bentivegna D, 2012, ACTA MEDICA MEDITERR, V28, P287
   Cengiz C, 2013, PAK J MED SCI, V29, P569, DOI 10.12669/pjms.292.2715
   Dogu F, 2002, ANKARA U TIP FAKULTE, V55, P291
   Eder K, 2009, INFLAMM RES, V58, P727, DOI 10.1007/s00011-009-0060-4
   Elzey BD, 2003, IMMUNITY, V19, P9, DOI 10.1016/S1074-7613(03)00177-8
   Ferrara P., 2011, OTORINOLARINGOLOGIA, V61, P11
   Flad HD, 2010, CELL MOL LIFE SCI, V67, P2363, DOI 10.1007/s00018-010-0306-x
   Hunelshausen PV, 2007, CIRC RES, V100, P27
   KENNA MA, 2000, NELSON TXB PEDIAT, P1267
   Kucur C, 2014, J CRANIOFAC SURG, V25, pE29, DOI 10.1097/SCS.0b013e3182a2eddd
   Martines F, 2016, BRAZ J OTORHINOLAR, V82, P215, DOI 10.1016/j.bjorl.2015.04.002
   Mucia M, 2015, ACTA MEDICA MEDITERR, V31, P419
   Onder S, 2014, INT J PEDIATR OTORHI, V78, P1449, DOI 10.1016/j.ijporl.2014.06.001
   Rosen CL, 2000, NELSON TXB PEDIAT, P1268
   Sagit M, 2012, J CRANIOFAC SURG, V23, P974, DOI 10.1097/SCS.0b013e31824e2c08
   Sandhaus LM, 2002, AM J CLIN PATHOL, V118, P787
   Sokucu SN, 2014, PULM MED, V2014, DOI 10.1155/2014/754839
   Tuncel T, 2012, ALLERGOL IMMUNOPATH, V40, P104, DOI 10.1016/j.aller.2011.03.007
   Varol E, 2010, SCAND J CLIN LAB INV, V70, P497, DOI 10.3109/00365513.2010.520733
   Vizioli L, 2009, INT J CLIN PRACT, V63, P1509, DOI 10.1111/j.1742-1241.2009.02070.x
NR 22
TC 1
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1665
EP 1669
DI 10.19193/0393-6384_2018_6_255
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400006
DA 2022-07-14
ER

PT J
AU Koseoglu, H
   Alisik, M
   Solakoglu, T
   Tahtaci, M
   Erel, O
   Ersoy, O
AF Koseoglu, Huseyin
   Alisik, Murat
   Solakoglu, Tevfik
   Tahtaci, Mustafa
   Erel, Ozcan
   Ersoy, Osman
TI COPEPTIN MAY NOT INCREASE IN MILD ACUTE PANCREATITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Acute pancreatitis; Arginine vasopressin; Copeptin
ID PLASMA COPEPTIN; ATLANTA CLASSIFICATION; VASOPRESSIN PRECURSOR;
   PROGNOSIS; SEVERITY; MORTALITY; PEPTIDE; SEPSIS; RULE
AB Introduction: Arginine vasopressin (AVP), a hormone of the hypothalamic-pituitary-adrenal axis, is stimulated by endogenous stress. Copeptin is a glycopeptide derived from a pre-pro-hormone, which directly mirrors AVP levels. Copeptin has been shown to be elevated in various infectious and noninfectious diseases, and in acute pancreatitis. The present study aimed to examine copeptin in mild acute pancreatitis patients and to investigate it as a severity index.
   Materials and methods: This prospective study included 32 patients admitted to the hospital with mild acute pancreatitis, and 30 healthy volunteers. Independent sample t test and Pearson's correlation test were used for statistical evaluation.
   Results: Serum copeptin level was 0.539 +/- 0.076 ng/mL in mild acute pancreatitis patients and was not statistically significantly different than the control group (0.544 +/- 0.061 ng/mL). On correlation analysis serum copeptin level was not associated with the known prognosis factors.
   Conclusion: Previous studies have found that copeptin may be used as a prognostic factor, but our study could not find an increase in mild acute pancreatitis patients or a correlation between copeptin level and other known prognostic factors. Further studies are needed to use copeptin in diagnosis or prognosis prediction in acute pancreatitis.
C1 [Koseoglu, Huseyin] Ankara Ataturk Educ & Res Hosp, Dept Gastroenterol, Bilkent, Turkey.
   [Alisik, Murat] Ankara Ataturk Educ & Res Hosp, Dept Clin Biochem, Bilkent, Turkey.
   [Solakoglu, Tevfik] Corlu State Hosp, Dept Gastroenterol, Corlu, Turkey.
   [Tahtaci, Mustafa; Ersoy, Osman] Yildirim Beyazit Univ, Dept Gastroenterol, Fac Med, Ankara, Turkey.
   [Erel, Ozcan] Yildirim Beyazit Univ, Dept Clin Biochem, Fac Med, Ankara, Turkey.
RP Koseoglu, H (corresponding author), Univ Mh Bilkent, Ataturk Egitim & Arastirma Hastanesi, Ankara Ataturk Educ & Res Hosp, Dept Gastroenterol, Cad 1, Bilkent, Turkey.
EM huseyinko@yahoo.com
RI Ertan, Asli/AAE-6201-2021; Alisik, Murat/O-6114-2019; EREL,
   Ozcan/U-1008-2019; koseoglu, huseyin/A-2449-2017
OI Alisik, Murat/0000-0003-0434-3206; EREL, Ozcan/0000-0002-2996-3236; 
CR Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779
   Chen YH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000638
   Choi KS, 2015, SCI REP-UK, V5, DOI 10.1038/srep11665
   Dobsa L, 2013, BIOCHEM MEDICA, V23, P172, DOI 10.11613/BM.2013.021
   Hamada T, 2013, J GASTROENTEROL, V48, P1384, DOI 10.1007/s00535-013-0765-6
   Isman FK, 2013, AM J EMERG MED, V31, P690, DOI 10.1016/j.ajem.2012.12.016
   Jochberger S, 2009, CRIT CARE MED, V37, P476, DOI 10.1097/CCM.0b013e3181957532
   Katan M, 2008, CRIT CARE, V12, DOI 10.1186/cc6799
   Kruger S, 2007, INTENS CARE MED, V33, P2069, DOI 10.1007/s00134-007-0895-5
   Moreno JP, 2013, LIVER INT, V33, P843, DOI 10.1111/liv.12175
   Morgenthaler NG, 2008, TRENDS ENDOCRIN MET, V19, P43, DOI 10.1016/j.tem.2007.11.001
   Ray P, 2012, AM J EMERG MED, V30, P440, DOI 10.1016/j.ajem.2011.12.008
   Reichlin T, 2009, J AM COLL CARDIOL, V54, P60, DOI 10.1016/j.jacc.2009.01.076
   Sang G, 2014, PEPTIDES, V51, P4, DOI 10.1016/j.peptides.2013.10.019
   Stoiser B, 2006, EUR J CLIN INVEST, V36, P771, DOI 10.1111/j.1365-2362.2006.01724.x
   Struck J, 2005, PEPTIDES, V26, P2500, DOI 10.1016/j.peptides.2005.04.019
   Szinnai G, 2007, J CLIN ENDOCR METAB, V92, P3973, DOI 10.1210/jc.2007-0232
   Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218
   Vege SS, 2009, AM J GASTROENTEROL, V104, P710, DOI 10.1038/ajg.2008.77
   Zweifel C, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-34
NR 20
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1327
EP 1330
DI 10.19193/0393-6384_2018_5_203
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700025
DA 2022-07-14
ER

PT J
AU Koyuncuer, A
AF Koyuncuer, Ali
TI CORRELATION OF HER2 STATUS WITH HORMONE RECEPTORS ESTROGEN, PROGESTERONE
   RECEPTORS AND HISTOPATHOLOGIC FEATURES IN INVASIVE BREAST CARCINOMAS: A
   STUDY ON 117 CONSECUTIVE PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Breast; Cancer; Estrogen; HER2; Progesteron
ID CANCER SUBTYPES; SURVIVAL
AB Objective: Nowadays, Estrogen Receptor (ER), Progesteron Receptor (PgR) and HER2 Receptor are commonly used markers in breast cancer (BC). Multi factorial features, chemical or molecular variety of conditions significant differences ethnic group or racial predilection.
   Methods: A total of 117 patients suffering from primary malignant invasive BCs was evaluated. ER, PgR and HER2 conditions are evaluated by the immunohistochemistry method as a routine for all cases of BC, where paraffin blocks of the cancer are exist.
   Results: Although the mean age at the time of diagnosis was 51years, >= 40 years of age comprised 96 (82.1%) of cases, 96 (82.1%) were observed invasive breast carcinoma no special type, mean diameter of tumor size 22.2 millimeters, the majority of breast carcinomas cases (47%) have a histologic grade 2, predominantly pathologic stage; pT1c: 43 (36.8%), most positive lymph node; pN1a: 22 (18.8%) identified. There was strong positive staining in ER, PgR and HER2 37.6%, 19.7%, and 21.4% of the cases, respectively. Triple negativity cases was found 25.67%. The presence of tumor size was associated with lymph-vascular invasion and lymph nodes status (P = 0.01, 0.044, P < 0.05).A significant relationship was found between positive ER staining and lymph-node status (P = 0.013). A significant relationship was found between positive HER2 staining and lymph-vascular invasion and tumor focality (P = 0.041, 0.044).
   Conclusion: These results show highly different disease, it varies amongst racial or ethnic predilatation. No statistically significant correlation was found between ER and PgR expression and HER2 staining. No association was found between the HER2 expression and histologic types, histologic grade, tumor size, lymph node status.
C1 [Koyuncuer, Ali] Hatay State Hosp, Dept Pathol, Antakya, Turkey.
RP Koyuncuer, A (corresponding author), Hatay State Hosp, Dept Pathol, Antakya, Turkey.
EM alikoyuncuer@hotmail.com
RI Koyuncuer, Ali/I-7999-2014
OI Koyuncuer, Ali/0000-0002-0994-1275
CR ALLEGRA JC, 1979, CANCER TREAT REP, V63, P1271
   Almasri NM, 2005, BREAST CANCER RES, V7, pR598, DOI 10.1186/bcr1200
   Bhagat VM, 2012, NAT J MED RES, V2, P295
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Chariyalertsak S, 1998, ASIAN PAC J ALLERGY, V16, P161
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Desai SB, 2000, BREAST, V9, P267, DOI 10.1054/brst.2000.0134
   Fan Y, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002066
   Hefti MM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3462
   Hoda SA, 2014, BREAST, P435
   Keshgegian AA, 1996, ARCH PATHOL LAB MED, V120, P970
   Kumar V, 2015, ROBBINS COTRAN PATHO, P1043
   Lal P, 2005, AM J CLIN PATHOL, V123, P541, DOI 10.1309/YMJ3A83TB39MRUT9
   Mudduwa LKB, 2009, INDIAN J PATHOL MICR, V52, P159, DOI 10.4103/0377-4929.48906
   Nappi O, 2008, EJC SUPPL, V6, P1, DOI 10.1016/j.ejcsup.2008.06.011
   Nordenskjold A, 2016, BREAST CANCER RES TR, V160, P313, DOI 10.1007/s10549-016-4007-5
   Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825
   Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948
   Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006
   REDKAR AA, 1992, INDIAN J MED RES-B, V96, P1
   Stefano R, 2004, ANN NY ACAD SCI, V1028, P463, DOI 10.1196/annals.1322.055
   STEWART JF, 1983, EUR J CANCER CLIN ON, V19, P1381, DOI 10.1016/0277-5379(93)90007-R
   Tewari M, 2007, BREAST, V16, P540, DOI 10.1016/j.breast.2007.05.005
   Wild C.P., 2014, IARC WORLD CANC REPO
   Zafrani B, 2000, HISTOPATHOLOGY, V37, P536, DOI 10.1046/j.1365-2559.2000.01006.x
NR 25
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1943
EP 1948
DI 10.19193/0393-6384_2018_6_302
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400053
DA 2022-07-14
ER

PT J
AU La Mantia, I
   Grillo, C
   Andaloro, C
AF La Mantia, Ignazio
   Grillo, Calogero
   Andaloro, Claudio
TI SHORT-TERM USE OF OCCLUSAL SPLINT IN PATIENTS WITH SLEEP BRUXISM: A
   CASE-CONTROLLED STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE sleep bruxism; occlusal splint; migraine; masticatory muscle
ID ELECTROMYOGRAPHIC RECORDING DEVICE; MANDIBULAR ADVANCEMENT APPLIANCE;
   OF-THE-LITERATURE; TEMPOROMANDIBULAR DISORDERS; NOCTURNAL BRUXISM;
   HEADACHES; SYMPTOMS; ASSOCIATION; PREVALENCE; ADULTS
AB Objectives: The efficacy of the occlusal splint to reduce sleep bruxism (SB), remains a controversial issue.
   This study aimed to investigate the effect of a short-term occlusal splint therapy in patients with SB, evaluating both the nocturnal electromyographic (EMG) activity of the temporalis muscle through a portable EMG recording device and the migraine SB-related severity and discomfort.
   Materials and methods: Sixty patients with SB were randomized into 2 equal groups, a group treated with an occlusal splint and an untreated control group for a study period of two weeks. EMG activity during sleep was recorded from the right side of anterior temporalis muscle with a portable electromyographic recording device.
   Outcomes of interest were the differences in bruxism activity (number of EMG events/hour) Bruxism length (Second/event) and migraine disability score (MIDAS) between the two groups.
   Results: After the 2-weeks study period the bruxism activity and length decreased significantly (p = 0.006 and p = 0.037, respectively) as well as the MIDAS grading (p < 0.05) in the treatment group compared with control group.
   Conclusion: Our results suggest that the short-term use of occlusal splint therapy is effective in reducing both SB activity and migraine SB-related discomfort, with a positive and rapid relaxing action of the masticatory muscles.
C1 [La Mantia, Ignazio; Grillo, Calogero] GF Ingrassia Univ Catania, Dept Med Sci Surg & Adv Technol, Via Santa Sofia 78, I-95123 Catania, Italy.
   [Andaloro, Claudio] Santa Marta & Santa Venera Hosp, ENT Unit, Catania, Italy.
RP La Mantia, I (corresponding author), GF Ingrassia Univ Catania, Dept Med Sci Surg & Adv Technol, Via Santa Sofia 78, I-95123 Catania, Italy.
RI Andaloro, Claudio/J-7079-2019
OI Andaloro, Claudio/0000-0003-0274-6247
CR American Academy of Sleep Medicine, 2014, AM ACAD SLEEP MED
   Andaloro C, 2017, MINERVA GASTROENTERO, V63, P307, DOI 10.23736/S1121-421X.17.02403-5
   Balasubramaniam R., 2014, J DENT SLEEP MED, V1, DOI [10.15331/jdsm.3736, DOI 10.15331/JDSM.3736, DOI 10.15331/jdsm.3736]
   Carra MC, 2013, SLEEP MED, V14, P656, DOI 10.1016/j.sleep.2013.03.009
   Daif ET, 2012, ACTA ODONTOL SCAND, V70, P72, DOI 10.3109/00016357.2011.597776
   Dube C, 2004, J DENT RES, V83, P398, DOI 10.1177/154405910408300509
   Fernandes G, 2013, J OROFAC PAIN, V27, P14, DOI 10.11607/jop.921
   Frati F, 2014, J INVEST ALLERG CLIN, V24, P352
   Goncalves DAG, 2010, HEADACHE, V50, P231, DOI 10.1111/j.1526-4610.2009.01511.x
   Grillo C, 2004, ACTA MEDICA MEDITERR, V20, P155
   Harada T, 2006, J ORAL REHABIL, V33, P482, DOI 10.1111/j.1365-2842.2005.01576.x
   HOLMGREN K, 1993, J PROSTHET DENT, V69, P293, DOI 10.1016/0022-3913(93)90109-2
   Hosoya H, 2014, SLEEP BREATH, V18, P837, DOI 10.1007/s11325-014-0953-5
   Jagger Robert, 2008, Evid Based Dent, V9, P23, DOI 10.1038/sj.ebd.6400569
   Koyano K, 2005, INT J PROSTHODONT, V18, P293
   La Mantia I, 2017, EMBJ, V12, P144
   La Mantia I, 2017, AM J RHINOL ALLERGY
   Landry-Schonbeck A, 2009, INT J PROSTHODONT, V22, P251
   Lavigne GJ, 2001, J SLEEP RES, V10, P237, DOI 10.1046/j.1365-2869.2001.00261.x
   Lobbezoo F, 2006, J ORAL REHABIL, V33, P293, DOI 10.1111/j.1365-2842.2006.01609.x
   Macedo CR, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005514.pub2
   Manfredini D, 2013, J ORAL REHABIL, V40, P631, DOI 10.1111/joor.12069
   Manfredini D, 2015, J ORAL REHABIL, V42, P862, DOI 10.1111/joor.12322
   Manfredini D, 2013, J OROFAC PAIN, V27, P99, DOI 10.11607/jop.921
   Matsumoto H, 2015, J ORAL REHABIL, V42, P251, DOI 10.1111/joor.12251
   Mitrirattanakul S, 2002, J DENT RES, V81, pA130
   Miyawaki S, 2003, SLEEP, V26, P888, DOI 10.1093/sleep/26.7.888
   Savabi O, 2007, QUINTESSENCE INT, V38, P129
   Shetty Shilpa, 2010, J Indian Prosthodont Soc, V10, P141, DOI 10.1007/s13191-011-0041-5
   Stapelmann Henrike, 2008, BMC Oral Health, V8, P22, DOI 10.1186/1472-6831-8-22
   Stuginski-Barbosa J, 2016, SLEEP BREATH, V20, P695, DOI 10.1007/s11325-015-1283-y
   Troeltzsch M, 2011, J PROSTHET DENT, V105, P410, DOI 10.1016/S0022-3913(11)60084-X
   Yap Adrian U, 2016, J Conserv Dent, V19, P383, DOI 10.4103/0972-0707.190007
   Yap AUJ, 1998, J ORAL REHABIL, V25, P64
NR 34
TC 1
Z9 1
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 301
EP 305
DI 10.19193/0393-6384_2018_2_48
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400002
DA 2022-07-14
ER

PT J
AU La Mantia, I
   Cupido, F
   Andaloro, C
AF La Mantia, Ignazio
   Cupido, Francesco
   Andaloro, Claudio
TI VOCAL FUNCTION EXERCISES AND VOCAL HYGIENE COMBINED TREATMENT APPROACH
   AS A METHOD OF IMPROVING VOICE QUALITY IN IRRADIATED PATIENTS FOR
   LARYNGEAL CANCERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE voice therapy; laryngeal cancer; radiotherapy
ID RANDOMIZED CLINICAL-TRIAL; EARLY GLOTTIC CANCER; RADIATION-THERAPY;
   CARCINOMA; RADIOTHERAPY; DISORDERS; TEACHERS; EFFICACY; REHABILITATION;
   OUTCOMES
AB Introduction: Despite the negative effects of radiation therapy on voice quality is well documented in literature few studies have focused on the efficacy of voice therapy in the irradiated laryngeal cancers population. The purpose of this study was to investigate the efficacy of an evidence-based voice therapy, known as Vocal Function Exercises (VFE) in a combined approach with Vocal Hygiene (VH) in improving vocal function in patients who have been irradiated for laryngeal cancers and compared to the results of VH alone treatment.
   Materials and methods: A prospective, randomized and controlled study involved patients with primary laryngeal cancer treated with curatively intended radiotherapy. Study group (10 patients) was treated with VFE+VH approach and control group (9 patients) was treated with a VH alone therapy; both interventions started one month following radiotherapy completion and lasted for 6 weeks. Voice Handicap Index (VHI) scores, laryngeal stroboscopy, high-speed laryngeal imaging, acoustic analysis, aerodynamic analysis, auditory-perceptual measures through the Grade, Roughness, Breathiness, Asthenia, Strain (GRBAS) rating scale and impact on Health-Related Quality of Life (HRQL) through the EORTC Quality of Life Questionnaire Head and Neck module (EORTC QLQ-H&N35) were evaluated at baseline and post-intervention.
   Results: VFE+VH combined approach shows better and statistically significant improvement after vocal intervention when compared to VH alone group for VHI (p=0.023), GRBAS (p=0.038), MPT (p<0.001), jitter (p=0.015), NMWA (p=0.011), NGG (p=0.026) and EORTC QLQ-H& N35 (p=0.047).
   Conclusions: The current investigation demonstrated that the VFE+VH combined approach was effective in improving the vocal function in irradiated patients with laryngeal cancers.
C1 [La Mantia, Ignazio] Univ Catania, Dept Med Sci Surg & Adv Technol, Catania, Italy.
   [Cupido, Francesco] Univ Palermo, Dept Surg & Oncol Disciplines, Palermo, Italy.
   [Andaloro, Claudio] Santa Marta & Santa Venera Hosp, Ear Nose & Throat Unit, Catania, Italy.
RP La Mantia, I (corresponding author), Dept Med Sci Surg & Adv Technol, Via Santa Sofia 78, I-95123 Catania, Italy.
RI Andaloro, Claudio/J-7079-2019
OI Andaloro, Claudio/0000-0003-0274-6247
CR Angadi V, 2017, ANN OTO RHINOL LARYN, V126, P483, DOI 10.1177/0003489417702922
   Bergstrom L, 2016, LARYNGOSCOPE, V126, P2029, DOI 10.1002/lary.25919
   Frati F, 2014, J INVEST ALLERG CLIN, V24, P352
   Grillo C., 2017, OTORINOLARINGOL, V67, P75
   Grillo C, 2004, ACTA MEDICA MEDITERR, V20, P155
   Hirano M, 1981, PSYCHOACOUSTIC EVALU
   Hocevar-Boltezar I, 2009, RADIOTHER ONCOL, V93, P524, DOI 10.1016/j.radonc.2009.09.014
   HONG WK, 1993, CANCER RES, V53, P5113
   Jacobson BH, 1997, AM J SPEECH-LANG PAT, V6, P66, DOI [10.1044/1058-0360.0603.66, DOI 10.1044/1058-0360.0603.66]
   Kobayashi T, 2017, AURIS NASUS LARYNX, V44, P86, DOI 10.1016/j.anl.2016.04.005
   La Mantia I, 2017, EGYPTIAN J EAR NOSE, V18, P247
   Lazarus CL, 2009, CURR OPIN OTOLARYNGO, V17, P172, DOI 10.1097/MOO.0b013e32832af12f
   Lim H. J., 2009, PHONETICS SPEECH SCI, V1, P37, DOI DOI 10.1016/j.jvoice.2017.08.031
   MCGUIRT WF, 1994, ARCH OTOLARYNGOL, V120, P951
   McMullen CA, 2011, J SPEECH LANG HEAR R, V54, P845, DOI 10.1044/1092-4388(2010/10-0127)
   Metcalfe CW, 2013, J CRANIOMAXILLOFAC S, V41, P641
   Pasa G, 2007, LOGOP PHONIATR VOCO, V32, P128, DOI 10.1080/14015430701207774
   Remmelts AJ, 2013, EUR ARCH OTO-RHINO-L, V270, P2079, DOI 10.1007/s00405-013-2460-x
   Roy N, 2003, J SPEECH LANG HEAR R, V46, P670, DOI 10.1044/1092-4388(2003/053)
   Roy N, 2001, J SPEECH LANG HEAR R, V44, P286, DOI 10.1044/1092-4388(2001/023)
   Ruotsalainen JH, 2007, COCHRANE DB SYST REV
   Sauder C, 2010, ANN OTO RHINOL LARYN, V119, P460, DOI 10.1177/000348941011900706
   STEMPLE JC, 1994, J VOICE, V8, P271, DOI 10.1016/S0892-1997(05)80299-1
   Tae K, 2011, CLIN EXP OTORHINOLAR, V4, P101, DOI 10.3342/ceo.2011.4.2.101
   Tamura E, 2003, LARYNGOSCOPE, V113, P910, DOI 10.1097/00005537-200305000-00025
   Tuomi L, 2014, INT J RADIAT ONCOL, V89, P964, DOI 10.1016/j.ijrobp.2014.04.030
   van Gogh CDL, 2006, CANCER-AM CANCER SOC, V106, P95, DOI 10.1002/cncr.21578
   van Gogh CDL, 2012, J VOICE, V26, P398, DOI 10.1016/j.jvoice.2011.06.002
   Zotti P, 2000, QUAL LIFE RES, V9, P1147, DOI 10.1023/A:1016674507150
NR 29
TC 2
Z9 2
U1 2
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 517
EP 523
DI 10.19193/0393-6384_2018_2_83
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400036
DA 2022-07-14
ER

PT J
AU La Mantia, I
   Cupido, F
   Castro, V
   Andaloro, C
AF La Mantia, Ignazio
   Cupido, Francesco
   Castro, Veronica
   Andaloro, Claudio
TI OLFACTORY FUNCTION IN CHRONIC RHINITIS SUBTYPES: ANY DIFFERENCES?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Olfaction disorders; Rhinitis; Allergic; Rhinitis; Vasomotor
ID ALLERGIC RHINITIS; DYSFUNCTION; IMPACT; SMELL; SENSE
AB Introduction: Olfactory dysfunction is a common problem in rhinological disease, but it has been few evaluated among patients with different chronic rhinitis subtypes. The aim of this study was to assess olfactory function in patients with allergic rhinitis (AR), non-allergic rhinitis (NAR) and mixed rhinitis (MR).
   Materials and methods: A total of 122 patients with AR, NAR, and MR were included in the study. Sniffin' Sticks test was applied to all groups. The study groups were compared in terms of odor scores and an association between olfactory dysfunction and rhinitis grading, according to ARIA (Allergic Rhinitis and its Impact on Asthma) criteria, was also investigated.
   Results: A significant difference was observed between NAR patients and the two other study groups with respect to all odor scores. TDI (Threshold, Discrimination, Identification) score, for overall olfactory function, resulted significantly lower in NAR patients than that in the other two groups (P=0.038). Conversely, no significant difference was observed between patients with AR and MR. Consistent with ARIA classification, NAR patients suffered mostly from persistent symptoms, whereas, AR patients generally suffered by intermittent symptoms, as well as MR patients, but this last with a significative higher presence of patients with persistent symptoms, when compared to AR group (P<0.05). A significative association was also observed between lower TDI scores and presence of persistent rhinitis symptomatology (P<0.001).
   Conclusions: Impaired olfaction is a feature more evident in NAR patients when compared to the other rhinitis subtype and it was much more affected by longer duration of rhinitis symptomatology rather than severity.
C1 [La Mantia, Ignazio; Castro, Veronica] Univ Catania, Dept Med Sci Surg & Adv Technol, Catania, Italy.
   [Cupido, Francesco] Univ Palermo, Dept Surg & Oncol Disciplines, Palermo, Italy.
   [Andaloro, Claudio] Santa Marta & Santa Venera Hosp, Ear Nose & Throat Unit, Catania, Italy.
RP La Mantia, I (corresponding author), Dept Med Sci Surg & Adv Technol, Via Santa Sofia 78, I-95123 Catania, Italy.
RI Andaloro, Claudio/J-7079-2019
OI Andaloro, Claudio/0000-0003-0274-6247
CR Apter AJ, 1999, ARCH OTOLARYNGOL, V125, P1005, DOI 10.1001/archotol.125.9.1005
   Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0
   Becker S, 2012, ACTA OTO-LARYNGOL, V132, P763, DOI 10.3109/00016489.2012.656764
   Bernstein JA, 2010, ALLERGY ASTHMA PROC, V31, P365, DOI 10.2500/aap.2010.31.3380
   Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891
   Bramerson A, 2004, LARYNGOSCOPE, V114, P733
   Ciprandi G, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0185-x
   Dinc ME, 2017, ACTA OTO-LARYNGOL, V137, P71, DOI 10.1080/00016489.2016.1211318
   Doty RL, 2001, LARYNGOSCOPE, V111, P409, DOI 10.1097/00005537-200103000-00008
   Frati F, 2014, J INVEST ALLERG CLIN, V24, P352
   Greiwe J, 2016, IMMUNOL ALLERGY CLIN, V36, P289, DOI 10.1016/j.iac.2015.12.006
   Grillo C, 2004, ACTA MEDICA MEDITERR, V20, P155
   Guilemany JM, 2009, LARYNGOSCOPE, V119, P233, DOI 10.1002/lary.20075
   Guss J, 2009, ORL-J OTO-RHIN-LARYN, V71, P268, DOI 10.1159/000242429
   Higo R, 1996, Nihon Jibiinkoka Gakkai Kaiho, V99, P1648
   Hummel T, 2005, ACTA OTO-LARYNGOL, V125, P116, DOI 10.1080/00016480410022787
   Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39
   La Mantia I, 2017, EMBJ, V12, P144
   La Mantia I, 2017, AM J RHINOL ALLERGY, V31, P364, DOI 10.2500/ajra.2017.31.4482
   La Mantia I, 2017, EURASIAN J MED, V49, P220, DOI 10.5152/eurasianjmed.2017.17257
   La Mantia I, 2017, INT J PEDIATR OTORHI, V98, P103, DOI 10.1016/j.ijporl.2017.04.044
   Lee CH, 2008, CLIN EXP OTORHINOLAR, V1, P196, DOI 10.3342/ceo.2008.1.4.196
   Mann S. S., 2002, Indian Journal of Physiology and Pharmacology, V46, P186
   Rezvani M, 2007, ANN ALLERG ASTHMA IM, V99, P571, DOI 10.1016/S1081-1206(10)60389-4
   Rydzewski B, 2000, ACTA OTO-LARYNGOL, V120, P323
   Simola M, 1998, ALLERGY, V53, P190, DOI 10.1111/j.1398-9995.1998.tb03869.x
   SnowJr JB, 1997, TASTE SMELL DISORDER, P1
   Stuck BA, 2015, J ALLERGY CLIN IMMUN, V136, P1460, DOI 10.1016/j.jaci.2015.08.003
   Tran NP, 2011, ALLERGY ASTHMA IMMUN, V3, P148, DOI 10.4168/aair.2011.3.3.148
NR 29
TC 6
Z9 6
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 525
EP 529
DI 10.19193/0393-6384_2018_2_84
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400037
DA 2022-07-14
ER

PT J
AU Lan, LX
   Zhou, Q
   Yang, XH
AF Lan, Lixin
   Zhou, Quan
   Yang, Xiaohui
TI PREPARATION OF LIPOSOME ENCAPSULATED PROTEIN DRUGS AND CONTROL OF
   INFLUENCING FACTORS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Liposome; Protein drug encapsulating; Preparation and influencing
   factors; Analysis and exploration
AB Objective: Liposome was firstly measuredby electron microscopy in 1965, and was firstly used as drug carrier in 1971. In the lastfew decades, the related studies were mainly focused on using liposome as the carrier of small molecule chemical drugs. In recent years, with the continuous development of biopharmaceutical technology, the studies on using liposome as the carrier of the protein drugs are constantly deepened. The application of protein drugs in clinical diagnosis or treatment shall take account of two aspects, namely whether there are sufficient drugs for the organism to intake and use, and the second aspects is whether the protein drug delivery is targeted and efficient. Based on this, this paper probed into the previous studies that were carried out in recent years on the liposomes for encapsulating protein drugs. Hence, this study summarized the characteristics of liposome from different preparation methods, and explored the goodpreparation methods to improve the drug entrapment efficiency as well as the excellentdetection method. Thus, this investigation is providing the theoretical basis up to some extent for the industrial production of protein drug liposomes.
C1 [Lan, Lixin; Zhou, Quan; Yang, Xiaohui] Hunan Chem Vocat Technol Coll, Dept Pharmaceut & Biol Engn, Zhuzhou 412004, Peoples R China.
RP Lan, LX (corresponding author), Hunan Chem Vocat Technol Coll, Dept Pharmaceut & Biol Engn, Zhuzhou 412004, Peoples R China.
EM hnhyllx@126.com
CR Alharbi SA, 2016, SAUDI J BIOL SCI, V23, P268, DOI 10.1016/j.sjbs.2015.06.020
   El-Jakee JK, 2016, SAUDI J BIOL SCI, V23, P48, DOI 10.1016/j.sjbs.2015.06.011
   Liu Weilin, 2013, STRUCTURE DIGESTION
   Nowak R, 2016, SAUDI J BIOL SCI, V23, P15, DOI 10.1016/j.sjbs.2015.01.017
   Qin HP, 2016, SAUDI PHARM J, V24, P265, DOI 10.1016/j.jsps.2016.04.015
   Xiao Weiyun, 2013, PREPARATION HCPT INC
   Zhang J, 2016, SAUDI PHARM J, V24, P312, DOI 10.1016/j.jsps.2016.04.003
   Zhang Jianjun, 2016, STUDY ADOPTION NOVEL
   Zhang Shuihua, 2006, PROGR PHARM SCI, V12, P17
   Zhaona, 2016, PRELIMINARY STUDY PR
   Zheng Z, 2016, SAUDI J BIOL SCI, V23, P372, DOI 10.1016/j.sjbs.2015.04.001
   Zhou R, 2015, J COASTAL RES, P600, DOI 10.2112/SI73-104.1
NR 12
TC 0
Z9 0
U1 5
U2 20
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 227
EP 231
DI 10.19193/0393-6384_2018_1s_37
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100002
DA 2022-07-14
ER

PT J
AU Latino, F
   D'Andria, A
   Tafuri, D
AF Latino, Francesca
   D'Andria, Antonio
   Tafuri, Domenico
TI BADMINTON PLAYER REATHLETIZATION AFTER ACHILLES TENDON RUPTURE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Training Program; Achilles Tendon rupture; Badminton
ID MUSCLE FUNCTION; MANAGEMENT
AB Introduction: The purpose of this study is to introduce an example of a criteria-driven progression through the return-to-sport phase of rehabilitation,following Achilles Tendon reconstruction.
   Case presentation: In this study the Authors present the case of a 28-years-old man, professional Badminton players, who had Achilles Tendon rupture during practice. So, the Authors describe recovery program necessary to get back to competitive sport.
   Conclusion: To ensure a successful return to sport following Achilles Tendon re-constructionis necessary to formulate an accurate training program. The training program should be personalised, gradual and editable.
C1 [Latino, Francesca; D'Andria, Antonio; Tafuri, Domenico] Parthenope Univ, Via Medina 40, Naples, Italy.
RP Tafuri, D (corresponding author), Parthenope Univ Naples, Naples, Italy.
EM domenicotafuri@inwind.it
OI Latino, Francesca/0000-0003-0302-6145
CR Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Carbonetto G, 2008, DA OLIMPIA A PECHINO
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   Doral MN, 2010, OPEN ACCESS J SPORTS, V1, P233, DOI 10.2147/OAJSM.S10670
   GILLIES H, 1970, J BONE JOINT SURG AM, VA 52, P337, DOI 10.2106/00004623-197052020-00015
   Gulati V, 2015, WORLD J ORTHOP, V6, P380, DOI 10.5312/wjo.v6.i4.380
   HAGGMARK T, 1986, ORTHOPEDICS, V9, P160
   Jafari A., 2014, International Journal of Basic Sciences and Applied Research, V3, P40
   Jafari A, 2014, INT J BASIC SCI APPL, V3, P40
   KENDAL FP, 2005, MUSCLES TESTING FUNC
   Lanzetta A, 1996, MALATTIE ORTOPEDICHE
   Leppilahti J, 1996, INT J SPORTS MED, V17, P619, DOI 10.1055/s-2007-972905
   LIPSCOMB P R, 1956, Minn Med, V39, P731
   Mahmudieh B, 2013, GLOBAL J SCI ENG TEC
   Martini F, 2012, HUMAN ANATOMY
   Moller M, 2002, SCAND J MED SCI SPOR, V12, P9, DOI 10.1034/j.1600-0838.2002.120103.x
   Myerson M S, 1999, Instr Course Lect, V48, P219
   Ooi CH, 2009, J SPORT SCI, V27, P1591, DOI 10.1080/02640410903352907
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Perrone V, 2009, GIOT, V35, P129
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Tafuri D., 2017, SPORT SCI, V10, P70
   WREDMARK T, 1992, Scandinavian Journal of Medicine and Science in Sports, V2, P139
   Yung Patrick Shu-Hang, 2007, Res Sports Med, V15, P133, DOI 10.1080/15438620701405263
NR 31
TC 0
Z9 0
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1493
EP 1497
DI 10.19193/0393-6384_2018_3s_227
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400004
DA 2022-07-14
ER

PT J
AU Latino, F
   Cassese, FP
   Tafuri, D
AF Latino, Francesca
   Cassese, Francesco Peluso
   Tafuri, Domenico
TI BADMINTON: FROM COMPETITIVE MOTOR ACTIVITY TO INCLUSIVE DIDACTICS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Badminton; Para-Badminton; Competitiveness; Inclusion
AB The purpose of this article is to examine how disabled sport, expecially Badminton, could be a means of integration and cooperation, and the way the disabled could have the equal possibilities for training in a professional context. According to researchers, Badminton is associated with emotional and psychophysical benefits, as well as with an educative function. Furthermore, participation in Badminton activities facilitates skills and behaviour across various setting.
   In conclusion, this study investigates how Badminton is an important activity to improve physical and mental conditions. In fact, it increases self-confidence and removes depression associated with disability.
C1 [Latino, Francesca; Tafuri, Domenico] Parthenope Univ, Via Medina 40, Naples, Italy.
   [Cassese, Francesco Peluso] Cusano Univ Telemat Rome, Rome, Italy.
RP Tafuri, D (corresponding author), Parthenope Univ, Via Medina 40, Naples, Italy.
EM domenicotafuri@inwind.it
RI CASSESE, FRANCESCO PELUSO/A-4303-2016
OI CASSESE, FRANCESCO PELUSO/0000-0002-6798-3668; Latino,
   Francesca/0000-0003-0302-6145
CR Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Badminton England, 2012, DIS STRAT STRAT VIS
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Bernardi M, 1996, 3 PAR C WORLD C DIS
   Brasile F. M., 1990, ADAPTED PHYSICAL ACT, V7, P3, DOI DOI 10.1123/APAQ.7.1.3
   Canevaro A., 2003, DIVERSABILITA STORIE
   Carbonetto G, 2008, DA OLIMPIA A PECHINO
   CHIN MK, 1995, BRIT J SPORT MED, V29, P153, DOI 10.1136/bjsm.29.3.153
   DE ANNA L., 2007, INTEGRAZIONE SCOLAST
   De Pauw KP, 2005, ENCICLOPEDYA WORLD S, V2, P460
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   Dias R, 1995, SCI SPORTS RACKET
   Fitzgerald H, 2009, INT STUD PHYS EDUC Y, P1
   GARDNER H., 2005, EDUCAZIONE SVILUPPO
   Ghirlanda S., 2003, SPORT TUTTI SPAZIO D
   Gosh AK, 2003, INDIAN J MED RES, V98, P232
   Ooi CH, 2009, J SPORT SCI, V27, P1591, DOI 10.1080/02640410903352907
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Petralia MC, 2018, ACTA MEDICA MEDITERR, V34, P107, DOI 10.19193/0393-6384_2018_1_18
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Reilly T, 1995, SCI RACKET SPORT
   Schmidt R. A., 2000, APPRENDIMENTO MOTORI
   Sherrill C., ADAPTED PHYS ACTIVIT, V16, P206
   Tafuri D., 2017, SPORT SCI, V10, P70
   Tweedy SM, 2011, BRIT J SPORTS MED, V45
   WEISS MR, 1992, J SPORT EXERCISE PSY, V14, P177, DOI 10.1123/jsep.14.2.177
NR 32
TC 0
Z9 0
U1 1
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1521
EP 1524
DI 10.19193/0393-6384_2018_3s_233
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400010
DA 2022-07-14
ER

PT J
AU Lavan, F
   Testa, D
   Lavan, SM
   Marotta, R
   Tripi, G
   Salerno, M
   Romano, P
   Di Folco, A
   Gallai, B
   Russo, D
   D'Oro, L
   Sorrentno, M
   Magliulo, RM
   Cerroni, F
   Marsala, G
   Montana, A
   Franco, S
   Geraci, D
   Chisari, MG
   Picciocchi, E
   Polito, AN
   Murabito, P
   Parisi, L
AF Lavan, Francesco
   Testa, Davide
   Lavan, Serena Marianna
   Marotta, Rosa
   Tripi, Gabriele
   Salerno, Margherita
   Romano, Palmira
   Di Folco, Annabella
   Gallai, Beatrice
   Russo, Daniela
   D'Oro, Lucrezia
   Sorrentno, Michele
   Magliulo, Rosaria Martina
   Cerroni, Francesco
   Marsala, Gabriella
   Montana, Angelo
   Franco, Sabrina
   Geraci, Diego
   Chisari, Mario Giuseppe
   Picciocchi, Elisabetta
   Polito, Anna Nunzia
   Murabito, Paolo
   Parisi, Lucia
TI VISUOSPATIAL SKILLS IN CHILDREN AFFECTED BY PRIMARY NOCTURNAL ENURESIS:
   REHABILITATIVE PROPOSALS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE nocturnal enuresis; rehabilitation; visuospatial skills
ID SLEEP-APNEA SYNDROME; CHILDHOOD ABSENCE EPILEPSY; WEIGHT-LOSS PROGRAM;
   QUALITY-OF-LIFE; HYPERTHERMIC REACTIONS; OBESE CHILDREN; SELF-CONCEPT;
   OREXIN-A; MIGRAINE; ADOLESCENTS
AB The sphincterial control problems in childhood are very common, with relevant comorbidities (i.e.: difficulty in academic performance, sleep disturbances, minor neurological signs) involved in the complex process of maturation and learning, such as to cause a great deal of discomfort and related disorders in affected subjects.
   Enuresis is characterized by the involuntary urination in the absence of a physical disorder, socially unacceptable in places and at one stage of life where such control is acquired by the majority of subjects (about 5 years). The present study aims to evaluate the visuospatial skills in children affected by primary monosymptomatic nocturnal enuresis (PMNE). 31 PMNE children (16 males and 15 females) (mean age 10.87, SD +/- 1.68) and 61 healthy children (32 males, 29 females) (mean age 11.03, SD +/- 1.85, p = 0687) were evaluated for visuomotor skills with the Visual-Motor Integration Scale (VMI). PMNE subjects show a worse performance on average to VMI, especially in the total visual-motor integration test. This finding emphasizes the importance of a framework for global and more complex than is commonly implemented, across the border but framing the subject of enuretic symptoms in a more global perspective.
C1 [Lavan, Francesco; Lavan, Serena Marianna; Marotta, Rosa] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Testa, Davide; Di Folco, Annabella; Parisi, Lucia] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [D'Oro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Sorrentno, Michele] Pineta Grande Hosp, NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
   [Magliulo, Rosaria Martina] Ctr Scoliosi SRL, Naples, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Marsala, Gabriella] Osped Riuniti Foggia, Azienda Ospedal Univ, Struttura Complessa Farm, Foggia, Italy.
   [Montana, Angelo; Franco, Sabrina; Geraci, Diego] Univ Catania, Dept Med Surg & Adv Technol Sci GE Ingrassia, Catania, Italy.
   [Chisari, Mario Giuseppe] INPS, Catania, Italy.
   [Picciocchi, Elisabetta] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
RP Parisi, L (corresponding author), Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Cerroni, Francesco/0000-0003-3024-5482; Murabito,
   Paolo/0000-0002-2662-1898; Marotta, Rosa/0000-0003-0515-5952
CR American Psychiatric Association American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th
   Beery K.E., 1989, DEV TEST VISUAL MOTO
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Bosson S, 2002, ARCH DIS CHILD, V87, P188, DOI 10.1136/adc.87.3.188
   Butler RJ, 1998, J CHILD PSYCHOL PSYC, V39, P453, DOI 10.1017/S0021963098002224
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Dai Xiao-Mei, 2007, Zhongguo Dang Dai Er Ke Za Zhi, V9, P433
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, PRIMARY NOCTURNAL EN
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Gallelli Luca, 2017, Microrna, V6, P152, DOI 10.2174/2211536606666170913152821
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   MacPhersona SE, 2017, NEUROPSYCHOLOGIA, V96, P19, DOI 10.1016/j.neuropsychologia.2016.12.028
   Matricardi S, 2018, ACTA NEUROL SCAND, V137, P575, DOI 10.1111/ane.12902
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSIOL, P8
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Moscatelli F, 2016, PLOS ONE, V24
   Moscatelli F, 2015, BIOL MED, V7
   Neveus T, 2006, J UROLOGY, V176, P314, DOI 10.1016/S0022-5347(06)00305-3
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Sarici S. Umit, 2003, International Urology and Nephrology, V35, P381
   Smirni D, 2018, J NERV MENT DIS, V206, P628, DOI 10.1097/NMD.0000000000000853
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Smirni D, 2017, NEUROPSYCHOLOGIA, V102, P109, DOI 10.1016/j.neuropsychologia.2017.06.006
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Testa D, 2017, AGING CLIN EXP RES, V29, pS191, DOI 10.1007/s40520-016-0647-x
   Testa D, 2016, OPEN MED-WARSAW, V11, P208, DOI 10.1515/med-2016-0040
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Touchette E, 2005, ARCH PEDIAT ADOL MED, V159, P1129, DOI 10.1001/archpedi.159.12.1129
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2005, INT J CARDIOL, V104, P152, DOI 10.1016/j.ijcard.2004.10.051
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2018, ACTA NEUROL SCAND, V138, P523, DOI 10.1111/ane.13006
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   von Gontard A, 2006, DEV MED CHILD NEUROL, V48, P744, DOI 10.1017/S0012162206001599
   Yu B, 2011, J PAEDIATR CHILD H, V47, P429, DOI 10.1111/j.1440-1754.2010.02000.x
NR 100
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2161
EP 2170
DI 10.19193/0393-6384_2018_4s_331
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900011
DA 2022-07-14
ER

PT J
AU Leng, XK
AF Leng, Xinke
TI ANKLE JOINT INJURY OF MARTIAL ARTS ROUTINE ATHLETES AND COUNTERMEASURE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Martial Arts; Athletes; Routine; Ankle joint; Injury; Cause;
   Countermeasure
ID MOLECULAR-STRUCTURES; DRUGS
AB Purpose: To analyze the ,factor causing ankle joint injury of Martial Arts Routine Athletes and propose related countermeasure.
   Method: analyzing the data of 2,600 martial art athletes with ankle joint injuries who received by various hospitals from Feb, 2013 to Aug, 2015. From the angle of exercise physiology and theories of sport training, this paper conducted effective analysis of the factors causing ankle joint injury of Martial Arts Routine Athletes according to the specific, feature of martial art athlete and implemented corresponding countermeasures, so as to effectively avoid the occurrence of ankle joint injuries, improve technical level of martial arts athlete, and guarantee their health.
   Results: The injured location of martial arts athlete is dominated by ankle joint, and the most significant cause is due to nonstandard movement, incorrect skill, lack of self-protection awareness, and fear of the movement.
   Conclusion: in the process of training or competition, it is easy to cause ankle joint injury, which is mainly due to nonstandard movement and insufficiency of self-protection awareness. Therefore, it suggest improve self-protection awareness of athletes, so as to help them over fear mentality and guarantee their health.
C1 [Leng, Xinke] Hunan Univ, Coll Phys Educ, Changsha 410028, Hunan, Peoples R China.
RP Leng, XK (corresponding author), Hunan Univ, Coll Phys Educ, Changsha 410028, Hunan, Peoples R China.
EM 37162107@qq.com
CR Biyuan Mou, 2012, J HUBEI SPORTS SCI, V10, P611
   Chen Fang, 2014, B SPORT SCI TECHNOLO, V17
   Chenyan Wu, 2010, LEGEND BIOGRAPHY LIT, V12
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P1355, DOI 10.1016/j.sjbs.2016.09.010
   Hong B, 2017, PAK J PHARM SCI, V30, P809
   Hongli Lin, 2014, CONT SPORTS TECHNOLO, V26, P9
   Huiting Liu, 2014, SPORTS WORLD ACAD ED, V17, P79
   Iqbal O, 2017, PAK J PHARM SCI, V30, P49
   Peng WX, 2017, SAUDI J BIOL SCI, V24, P399, DOI 10.1016/j.sjbs.2015.10.026
   Rulei Zhang, 2015, SICHUAN SPORTS SCI, V9, P59
   Sheng Chen, 2010, J FUJIAN NORMAL U NA, V23, P119
   Siddiqui SZ, 2017, PAK J PHARM SCI, V30, P675
   Wan Haiguang, 2015, CONT SPORTS TECHNOLO, V9, P22
   Xueda Yang, 2015, CHINESE J TISSUE ENG, V23, P2366
   Zuhui Liu, 2014, J BEIJING SPORT U, V25
NR 17
TC 0
Z9 0
U1 1
U2 12
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1579
EP 1582
DI 10.19193/0393-6384_2018_3s_245
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400021
DA 2022-07-14
ER

PT J
AU Li, C
   Xia, JY
   Wan, Q
AF Li, Cheng
   Xia, Ji-Yi
   Wan, Qin
TI INTERACTION OF THE NRF2/ARE AND IRS-PI3K/AKT PATHWAYS IN PANCREATIC B
   CELLS AND THE UNDERLYING MECHANISMS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Nrf2/ARE pathway; IRS-PI3K/AKT pathway; IRS-PI3K/AKT-Nrf2/ARE complex
   pathway; pancreatic B cell; oxidative stress; chronic inflammation
ID ACTIVATION; PROTECTION; STRESS
AB Introduction: In pancreatic B cells, the insulin-signaling IRS-PI3K/AKT pathway and the anti-oxidative stress PI3K/AKTNrf2/ARE are cross-linked by a PI3K/AKT pathway. This study aims to observe the presence of the IRS-PI3K/AKT-Nrf2/ARE complex pathway in pancreatic B cells.
   Materials and methods: A rat model of type 2 diabetes was developed, and the rats were fed a high-sugar, high-fat diet supplemented with 1% tBHQ, an activator of the Nrf2/ARE pathway, for 8 weeks. Then, various indicators of oxidative stress and inflammatory response were measured in the serum and pancreatic tissues, and the fluorescence and protein expressions of Nrf2, IRS-2, pIRS-2, AKT and p-AKT in the islet cells were determined.
   Results: Oxidative stress and inflammation of the pancreatic B cells decreased the protein expressions of Nrf2, IRS-2, p-IRS-2, AKT, and p-AKT, and interfered with signal transduction in the IRS-PI3K/AKT-Nrf2/ARE pathway. Activation of the Nrf2/ARE pathway increased the expressions of the above proteins by increasing anti-oxidative stress and anti-inflammatory responses and promoting signal transduction in the IRS-PI3K/AKT pathway.
   Conclusions: There may exist a complex IRS-PI3K/AKT-Nrf2/ARE pathway for signal transduction in pancreatic B cells. This pathway is likely to play an important role in maintaining a relatively stable environment in the pancreatic B cells.
C1 [Li, Cheng; Wan, Qin] Southwest Med Univ, Affiliated Hosp, Dept Endocrinol, Luzhou, Sichuan, Peoples R China.
   [Li, Cheng] Rongchang Dist Peoples Hosp, Dept Endocrinol, Rongchang, Chongqing Provi, Peoples R China.
   [Xia, Ji-Yi] Southwest Med Univ, Res Ctr Drug & Funct Food, Luzhou, Sichuan, Peoples R China.
RP Wan, Q (corresponding author), Southwest Med Univ, Affiliated Hosp, 25 Taiping St, Luzhou 646000, Sichuan, Peoples R China.
EM wanqin3@163.com
FU Ministry of Science and Technology [2016YFC0901200, 2016YFC0901205]
FX This work is supported by the grants 2016YFC0901200 and 2016YFC0901205
   from the Ministry of Science and Technology.
CR Buelna-Chontal M, 2013, CELL SIGNAL, V25, P2548, DOI 10.1016/j.cellsig.2013.08.007
   Cho HY, 2013, OXID MED CELLLONGEV, V2013
   Elanchezhian R, 2012, CHEM-BIOL INTERACT, V200, P1, DOI 10.1016/j.cbi.2012.08.017
   Giudice A, 2010, METHODS MOL BIOL, V647, P37, DOI 10.1007/978-1-60761-738-9_3
   Hsu YY, 2012, EUR J PHARM SCI, V46, P415, DOI 10.1016/j.ejps.2012.03.004
   Kumar H, 2014, NAT PROD REP, V31, P109, DOI 10.1039/c3np70065h
   Lingohr MK, 2006, J BIOL CHEM, V281, P15884, DOI 10.1074/jbc.M600356200
   Nouhi F, 2011, NEUROCHEM RES, V36, P870, DOI 10.1007/s11064-011-0417-2
   Perez-Rojas JM, 2011, FOOD CHEM TOXICOL, V49, P2631, DOI 10.1016/j.fct.2011.07.008
   Williamson TP, 2012, NEUROTOXICOLOGY, V33, P272, DOI 10.1016/j.neuro.2012.01.015
   Wu KC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044686
NR 11
TC 1
Z9 1
U1 3
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1079
EP 1084
DI 10.19193/0393-6384_2018_4_165
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500028
DA 2022-07-14
ER

PT J
AU Li, F
   Wang, JZ
   Cao, F
   Chen, H
   Wang, WB
AF Li, Feng
   Wang, Jingzhong
   Cao, Feng
   Chen, Hui
   Wang, Wanbi
TI QUALITY CONTROL OF LOWER LIMB ARTERY IMAGING BY 320-SLICE SPIRAL CT AND
   ITS EFFECT IN ARTERIAL STENOSIS ASSESSMENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE 320-slice spiral CT; Lower limb artery imaging; Arterial stenosis
   assessment; Quality control
ID WATER; SYSTEM
AB Objective: This study aims to evaluate specific effect of 320-slice spiral CT in assessment of lower limb arterial stenosis, analyze the specific factors affecting imaging quality of lower limb artery by 320-slice spiral CT and propose effective countermeasures.
   Methods: The 400 patients receiving 320-slice spiral CT of lower limb arterial imaging examination in our hospital from March 2014 to March 2016 were included in the study. The differences in relevant parameters of general data, clinical manifestation and scanning were analyzed, the specific factors affecting lower limb artery imaging quality were analyzed; According to the standard of spiral CT imaging, arterial stenosis of the patients was divided into 4 levels by considering ,general data, respectively less than 50%, 50%-75%, 76% -99%, occlusion. The specific of feet of lower limb artery imaging by 320 - slice spiral CT under different grades of arterial stenosis was analyzed.
   Results: As can be seen from the imaging results, the higher the level of arterial stenosis is, the higher the sensitivity and specificity of 320-slice spiral CT in evaluation of lower limb artery imaging is, especially sensitivity. There are significant differences between the different levels (P <0.05); The imaging quality of lower limb artery by 320 - slice spiral CT is affected by such factors as contrast agent velocity, contrast agent concentration, contrast agent dose, delay time, scanning parameters, vascular calcification, patient age and reconstruction technique (P <0.05).
   Conclusion: Lower limb artery imaging by 320 - slice spiral CT has a high sensitivity and specificity, which enjoys great value in clinical application.
C1 [Li, Feng; Wang, Jingzhong; Cao, Feng; Chen, Hui; Wang, Wanbi] Hubei Univ Arts & Sci, Affiliated Hosp, Xiangyang Cent Hosp, Radiol Dept, Xiangyang 441021, Peoples R China.
RP Cao, F (corresponding author), Hubei Univ Arts & Sci, Affiliated Hosp, Xiangyang Cent Hosp, Radiol Dept, Xiangyang 441021, Peoples R China.
EM caof77210@163.com
FU Research project of Heilongjiang Provincial Health Bureau [2014-007]
FX Research project of Heilongjiang Provincial Health Bureau; Application
   of 640 slice CT low dose scanning technique in abdominal and lower
   extremity arterial imaging (No. 2014-007).
CR Balkhair KS, 2016, SAUDI J BIOL SCI, V23, pS32, DOI 10.1016/j.sjbs.2015.09.023
   Ganeshpurkar A, 2017, SAUDI PHARM J, V25, P149, DOI 10.1016/j.jsps.2016.04.025
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Guowei Ye, COMP ANAL 4 IMAGING
   Huang HQ, 2015, J COASTAL RES, P698, DOI 10.2112/SI73-120.1
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P667, DOI 10.19193/03936384_2017_4_100
   Mohammed MJ, 2017, SAUDI J BIOL SCI, V24, P737, DOI 10.1016/j.sjbs.2017.01.050
   Obeidat HR, 2015, SAUDI PHARM J, V23, P455, DOI 10.1016/j.jsps.2014.11.003
   Peng WX, 2016, SAUDI J BIOL SCI, V23, P348, DOI 10.1016/j.sjbs.2015.10.027
   Wang L.-L., 2010, CHINESE MED EQUIPMEN, V31, P13
   Wei Li, 2009, J HAINAN MED U, V15, P1018
   Wei Xia, 2014, CHINESE J MED IMAGIN, V10, P842
   Wu K, 2015, J COASTAL RES, P521, DOI 10.2112/SI73-091.1
   Zhang J, 2015, J COASTAL RES, P652, DOI 10.2112/SI73-113.1
   Zhang M, 2015, J COASTAL RES, P304, DOI 10.2112/SI73-053.1
   Zhang XY, 2015, J COASTAL RES, P9, DOI 10.2112/SI73-003.1
   Zhao N, 2015, J COASTAL RES, P220, DOI 10.2112/SI73-039.1
   [周淑琴 Zhou Shuqin], 2013, [中华放射医学与防护杂志, Chinese Journal of Radiological Medicine and Protection], V33, P318
NR 18
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1937
EP 1941
DI 10.19193/0393-6384_2018_6_301
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400052
DA 2022-07-14
ER

PT J
AU Li, GZ
   Zhai, GS
   Tao, H
   Cao, JM
   Wang, XL
   Chen, ZS
   Li, M
   Huang, KM
   Guo, JQ
AF Li, Gaozhong
   Zhai, Guangsheng
   Tao, Hong
   Cao, Jingmei
   wang, Xiulian
   Chen, Zhaosheng
   Li, Min
   Huang, Kunming
   Guo, Jianqiang
TI STUDY ON PROTECTING EFFECTS OF PARTHENOLIDE ON HEPATIC INJURY IN RATS
   WITH SEVERE ACUTE PANCREATITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Severe acute pancreatitis; parthenolide; TNF-alpha; IL-6; NF-kappa B
ID NF-KAPPA-B; MULTIPLE ORGAN INJURY; NECROTIZING PANCREATITIS;
   INFLAMMATORY MEDIATORS; OXIDATIVE STRESS; TNF-ALPHA; MECHANISMS;
   DRAINAGE; EFFICACY; ACTIVATION
AB Objective: Our study was designed to investigate the protective effects of parthenolide on hepatic injury in rats with severe acute pancreatitis (SAP).
   Methods: The SAP rat models were prepared and randomly devided into five groups, the model control group, parthenolide treated group with different doses of parthenolide, and the sham operated group. The levels of AMY, ALT, AST, IL-6 and TNF-alpha in serum, NF-kappa B expression and hepatic pathological changes in all groups were detected.
   Results: The levels of AMY, ALT, AST, IL-6 and TNF-alpha in serum and expression levels of NF-kappa B were lower in parthenolide treated groups than that in model control group. The model control group showed obviously pathological changes compared with sham group, while the administration of parthenolide dose-dependently inhibited the changes. C
   Conclusion: Parthenolide demonstrated a well curative capability on rats with SAP.
C1 [Li, Gaozhong; Chen, Zhaosheng; Guo, Jianqiang] Shandong Univ, Hosp 2, Dept Gastroenterol, 247 Beiyuan St, Jinan 250033, Shandong, Peoples R China.
   [Li, Gaozhong; Cao, Jingmei; wang, Xiulian; Li, Min; Huang, Kunming] Zibo Cent Hosp, Dept Gastroenterol, 54 West Gongqingtuan Rd, Zibo 255036, Shandong, Peoples R China.
   [Zhai, Guangsheng] Zibo Cent Hosp, Dept Radiotherapy, 54 West Gongqingtuan Rd, Zibo 255036, Shandong, Peoples R China.
   [Tao, Hong] Zibo Cent Hosp, Div Clin Skill Training Ctr, 54 West Gongqingtuan Rd, Zibo 255036, Shandong, Peoples R China.
RP Guo, JQ (corresponding author), Shandong Univ, Hosp 2, Dept Gastroenterol, 247 Beiyuan St, Jinan 250033, Shandong, Peoples R China.
CR Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781
   Beger HG, 2007, WORLD J GASTROENTERO, V13, P5043, DOI 10.3748/wjg.v13.i38.5043
   Bhatia M, 2000, J PATHOL, V190, P117
   Bruennler T, 2008, WORLD J GASTROENTERO, V14, P725, DOI 10.3748/wjg.14.725
   Buter A, 2002, BRIT J SURG, V89, P298, DOI 10.1046/j.0007-1323.2001.02025.x
   Cappell MS, 2008, MED CLIN N AM, V92, P889, DOI 10.1016/j.mcna.2008.04.013
   Dai Y, 2010, BRIT J HAEMATOL, V151, P70, DOI 10.1111/j.1365-2141.2010.08319.x
   Dambrauskas Z, 2010, WORLD J GASTROENTERO, V16, P1845, DOI 10.3748/wjg.v16.i15.1845
   Gunduz E, 2014, ACTA MEDICA MEDITERR, V30, P1285
   Horvath K, 2010, ARCH SURG-CHICAGO, V145, P817, DOI 10.1001/archsurg.2010.178
   Johnson CD, 2001, GUT, V48, P62, DOI 10.1136/gut.48.1.62
   Kaplan A, 2015, ACTA MEDICA MEDITERR, V31, P1253
   Kim H, 2000, FREE RADICAL BIO MED, V29, P674, DOI 10.1016/S0891-5849(00)00368-3
   Kim H, 2008, GUT LIVER, V2, P74, DOI 10.5009/gnl.2008.2.2.74
   KNIGHT DW, 1995, NAT PROD REP, V12, P271, DOI 10.1039/np9951200271
   Lee JH, 2012, EUR J PHARMACOL, V687, P28, DOI 10.1016/j.ejphar.2012.04.048
   Lese Mihaela, 2005, Chirurgia (Bucur), V100, P445
   Levin M, 2012, HEADACHE, V52, P76, DOI 10.1111/j.1526-4610.2012.02234.x
   Magni P, 2012, PHYTOTHER RES, V26, P1405, DOI 10.1002/ptr.3732
   Muhs BE, 2003, J SURG RES, V109, P110, DOI 10.1016/S0022-4804(02)00084-7
   Nam YJ, 2015, N-S ARCH PHARMACOL, V388, P921, DOI 10.1007/s00210-015-1132-3
   Payne CM, 2007, CARCINOGENESIS, V28, P215, DOI 10.1093/carcin/bgl139
   Ramudo L, 2005, J PATHOL, V206, P9, DOI 10.1002/path.1747
   Rau BM, 2006, CLIN GASTROENTEROL H, V4, P1053, DOI 10.1016/j.cgh.2006.05.030
   Shrivastava P, 2010, WORLD J GASTROENTERO, V16, P3995, DOI 10.3748/wjg.v16.i32.3995
   Surbatovic M, 2013, J CLIN GASTROENTEROL, V47, P637, DOI 10.1097/MCG.0b013e31828a6cfc
   Tapia PC, 2006, MED HYPOTHESES, V66, P832, DOI 10.1016/j.mehy.2005.09.009
   van Baal MC, 2011, BRIT J SURG, V98, P18, DOI 10.1002/bjs.7304
   Wang MT, 2015, NAT PROD RES, V29, P1092, DOI 10.1080/14786419.2014.981541
   Werner J, 2005, GUT, V54, P426, DOI 10.1136/gut.2003.035907
   Zerem E, 2011, DIGEST LIVER DIS, V43, P478, DOI 10.1016/j.dld.2011.02.020
   Zhang QH, 2001, CHINESE MED J-PEKING, V114, P738
   Zhang XP, 2008, DIGEST DIS SCI, V53, P581, DOI 10.1007/s10620-007-9868-3
   Zhang XP, 2007, WORLD J GASTROENTERO, V13, P4566, DOI 10.3748/wjg.v13.i34.4566
   Zhang XP, 2007, WORLD J GASTROENTERO, V13, P717, DOI 10.3748/wjg.v13.i5.717
   Zhang XF, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/546097
NR 36
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 489
EP 494
DI 10.19193/0393-6384_2018_2_79
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400033
DA 2022-07-14
ER

PT J
AU Li, GJ
   Peng, MJ
   Wu, XB
   Liao, HW
   Zhang, L
   Li, Y
   Yang, XF
   Chen, H
AF Li, Guo-Juan
   Peng, Meng-Jie
   Wu, Xiao-Bing
   Liao, Hong-Wu
   Zhang, Li
   Li, Ying
   Yang, Xue-Feng
   Chen, Hong
TI CYCLOOXYGENASE-2 SHORT HAIRPIN RNA LIMITS NONALCOHOLICFATTY LIVER
   DISEASE BY INDUCING LIVER CELL AGING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE non-alcoholic fatty liver; COX-2; cell aging
ID INDUCED SENESCENCE; IN-VIVO; HEPATOCYTE; PROGRESSION
AB Cyclooxygenase-2 (COX-2) has been involved the initiation and development of nonalcoholic fatty liver disease (NAFLD), however the mechanism within has still remained unclear. This aim of this study was observe the effects of COX-2 short hairpin RNA (COX-2 shRNA) on the liver cell aging in rats with NAFLD induced by a high-fat diet. 48 SD rats divided randomly into four group (n = 12). The rats was induced NAFLD by high fat diet for 12 weeks together with or without COX-2shRNA. Liver fat degeneration and fibrosis was evaluated by Oil red O, HE and MASSON Staining according to the METAVIR scoring system, and liver tissue cell aging by beta-galactose glucoside enzyme staining, COX-2 and a- SMA mRNA expression of liver tissue by real-time fluorescent quantitative PCR. The serum cerealthirdtransaminase (ALT), aspartate transaminase (AST), total cholesterol (TC), trigly-cerides (TG) levels was investigate by enzyme-linked immunosorbent assay (ELISA). The results of this study found liver steatosis degree, liver tissue lipid variable area and liver fibrosis in rats with COX-2shRNA significantly attenuated, and the serum levels of ALT, AST, TC, TG in rats with COX-2shRNA significantly improved. These data suggest COX-2shRNA limits the development of NAFLD through inducing liver cell aging.
C1 [Li, Guo-Juan; Chen, Hong] Southern Med Univ Guangzhou, Zhujiang Hosp, Dept Endocrinol & Metab, Guangzhou 510515, Guangdong, Peoples R China.
   [Li, Guo-Juan; Peng, Meng-Jie; Wu, Xiao-Bing; Liao, Hong-Wu; Zhang, Li; Li, Ying; Yang, Xue-Feng] Univ South China, Affiliated Nanhua Hosp, Dept Gastroenterol, Hengyang 421002, Peoples R China.
RP Chen, H (corresponding author), Southern Med Univ Guangzhou, Zhujiang Hosp, Dept Endocrinol & Metab, Guangzhou 510515, Guangdong, Peoples R China.; Yang, XF (corresponding author), Univ South China, Affiliated Nanhua Hosp, Dept Gastroenterol, Hengyang 421002, Peoples R China.
EM yxf9988@126.com; chenhong123@smu.edu.cn
FU National Natural Science Foundation of China [81373465]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81373465).
CR Aravinthan A, 2014, CELL CYCLE, V13, P1489, DOI 10.4161/cc.28471
   Aravinthan A, 2013, J HEPATOL, V58, P549, DOI 10.1016/j.jhep.2012.10.031
   Chen J, 2011, MOL MED REP, V4, P811, DOI 10.3892/mmr.2011.501
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Kim SR, 2008, MECH AGEING DEV, V129, P706, DOI 10.1016/j.mad.2008.09.003
   Kong XN, 2012, HEPATOLOGY, V56, P1150, DOI 10.1002/hep.25744
   Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x
   Serra MP, 2014, INT J RADIAT BIOL, V90, P876, DOI 10.3109/09553002.2014.922714
   Serra MP, 2012, HEPATOLOGY, V56, P760, DOI 10.1002/hep.25698
   Wan JH, 2014, AM J PATHOL, V184, P1763, DOI 10.1016/j.ajpath.2014.02.014
   Wiemann SU, 2002, FASEB J, V16, P935, DOI 10.1096/fj.01-0977com
   Zdanov S, 2009, BIOGERONTOLOGY, V10, P291, DOI 10.1007/s10522-008-9204-0
NR 14
TC 0
Z9 0
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 409
EP 413
DI 10.19193/0393-6384_2018_2_65
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400019
DA 2022-07-14
ER

PT J
AU Li, H
   Cao, YD
   Hou, R
   Liu, ZY
AF Li, Huan
   Cao, Yingdong
   Hou, Rui
   Liu, Zhiyan
TI CLINICAL NURSING ANALYSIS OF PATIENTS ACCEPTINGRADICAL ESOPHAGECTOMY
   FOLLOWED BY LEAVING A DUODENAL FEEDING TUBE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE radical esophagectomy; duodenal feeding tube; comprehensive nursing mode
AB Purpose: to observe and analyze the nursing strategy of radical esophagectomy followed by leaving a duodenal feeding tube.
   Method: 160 patients who had been treated with radical esophagectomy in our hospital were selected as research objects, and randomly divided into control group and research group, each containing 80 patients. All selected patients had a duodenal feeding tube left in their body after radical esophagectomy. The patients in control group were applied with conventional nursing mode, while patients in research group were applied with comprehensive nursing mode. The nursing effect of two groups were observed and compared.
   Result: the adverse reaction rate in research group was lower than that in control group, P<0. 05; the quality of life and overall nursing satisfactory in research group were significantly higher than that in control group, p<0. 05.
   Conclusion: The application of radical esophagectomy followed by leaving a duodenal feeding tube can significantly improve overall treatment effect and increase the quality of life of patients.
C1 [Li, Huan; Cao, Yingdong; Hou, Rui] Zhengzhou Univ, Sias Int Univ, Nursing Sch, Xinzheng 451150, Peoples R China.
   [Liu, Zhiyan] Zhengzhou Univ, Canc Hosp, Zhengzhou 450008, Henan, Peoples R China.
RP Liu, ZY (corresponding author), Zhengzhou Univ, Canc Hosp, Zhengzhou 450008, Henan, Peoples R China.
EM Zhanghaiyu0805@163.com
CR Akay G, 2017, TURK J MED SCI, V47, P1715, DOI 10.3906/sag-1607-127
   Ammar MH, 2017, SAUDI J BIOL SCI, V24, P80, DOI 10.1016/j.sjbs.2016.05.011
   Jiao Wenjie, 2016, BMC CANCER, V8, P123
   Kumar PKP, 2016, PAK J PHARM SCI, V29, P1279
   Lv Jin, 2017, WORLD J GASTROENTERO, V16, P228
   Lv MX, 2017, INDIAN J PHARM SCI, V79, P893, DOI 10.4172/pharmaceutical-sciences.1000305
   Peng WX, 2016, SAUDI J BIOL SCI, V23, P348, DOI 10.1016/j.sjbs.2015.10.027
   Pouliquen X, 2016, FRENCH ASS SURG RES, V10, P561
   Qin Miaomiao, 2016, WORLD LATEST MED INF, V16, P317
   Wang M, 2018, J CLEAN PROD, V179, P12, DOI 10.1016/j.jclepro.2018.01.096
   Xiang Yunlian, 2016, HLTH PEOPLE, V10, P272
   Yang Xiaoning, 2017, E JURNAL CLIN NURSIN, V2, P148
   Zhong Jian, 2014, CONT MED FORUM, V12, P81
   Zhou Yong, 2013, WORLD J GASTROENTERO, V19, P220
   孙国玉, 2016, [中国循证儿科杂志, Chinese Journal of Evidence Based Pediatrics], V11, P235
NR 15
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1971
EP 1974
DI 10.19193/0393-6384_2018_6_307
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400058
DA 2022-07-14
ER

PT J
AU Li, HR
   Bai, JL
   Xu, R
   Kong, Y
AF Li, Hui-Rong
   Bai, Ji-Li
   Xu, Rui
   Kong, Yan
TI CORRELATION BETWEEN SURVIVIN OVEREXPRESSION AND CLINICO-PATHOLOGICAL
   FEATURES OF INVASIVE CERVICAL CANCER: A META-ANALYSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Survivin; Cervical cancer; Invasiveness; Clinical pathology;
   Meta-analysis
ID EXPRESSION; CELLS
AB Objective: To systematically evaluate the correlation between overexpression of survivin and clinicopathological features of invasive cervical cancer.
   Methods: EMBASE, Medline, PubMed, Wan Fang, and VIP databases from 2001 were searched for published case-control studies on invasive clinical pathologies associated with cervical cancer as they relate to the overexpression of survivin. The data were screened and collected independently by two reviewers, and thereafter subjected to meta-analysis using RevMan5.2 analysis software version after assessing risk of bias.
   Results: Meta-analysis of 21 included articles showed that the clinical pathology features of invasive cervical cancer were generally accompanied by survivin overexpression; the expression of survivin in lymph node metastasis tissue was higher than that in non-metastasis lymph tissue, and the depth of invasive infiltration was higher than that in superficial layer. Moreover, survivin expression was significantly higher in the cervical cancer group than in the CIN group, and also higher in clinical stage. than in clinical stage.. There was a positive correlation between survivin and the clinical features of symptoms [OR = 5.52, 95 % CI = 4.09, 7.46; p < 0.00001].
   Conclusion: High expression of survivin is consistent with clinical pathology of invasive cervical cancer, and the intensity of expression is positively correlated with the degree of pathological features.
C1 [Li, Hui-Rong; Kong, Yan] Shandong Prov Third Hosp, Dept Obstet & Gynecol, Jinan 250000, Shandong, Peoples R China.
   [Bai, Ji-Li; Xu, Rui] Third Peoples Hosp Lixia Dist Jinan City, Dept Obstet & Gynecol, Jinan 250100, Shandong, Peoples R China.
RP Bai, JL (corresponding author), Third Peoples Hosp Lixia Dist Jinan City, Dept Obstet & Gynecol, Jinan 250100, Shandong, Peoples R China.
EM ldaky1@163.com
CR Cao XQ, 2014, ASIAN PAC J CANCER P, V15, P5271, DOI 10.7314/APJCP.2014.15.13.5271
   Fei Xin-xiong, 2013, J CLIN EXPT MED, V12, P778
   Groner B, 2014, BIODRUGS, V28, P27, DOI 10.1007/s40259-013-0058-x
   Gu Yi-bo, 2015, MED INNOV CHINA, V12, P149
   Jin A., 2016, CHONGQING MED, V45, P2244
   Li Miao, 2011, J MOD ONCOL, V19, P1396
   Lu Dan, 2013, MATERN CHILD HLTH J, V28, P4722
   Ma Shou-ye, 2015, MED RECAPITULATE, V21, P1597
   Meng Xue-mei, 2015, MED PHARM J CHINESE, V5, P56
   Mi Zhe-tao, 2010, CANC RES CLIN, V8, P36
   Mobahat M, 2014, INT J MOL SCI, V15, P2494, DOI 10.3390/ijms15022494
   Modepalli N, 2016, J CLIN DIAGN RES, V10, pEC1, DOI 10.7860/JCDR/2016/21741.8716
   Nasu S, 2002, ANTICANCER RES, V22, P1839
   Shi Zheng-zheng, 2009, J CHIN PHYS, V11, P1018
   Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509
   Wang Hui-juan, 2013, QINGDAO MED J, V45, P13
   Wang JJ, 2010, INT J GYNECOL CANCER, V20, P500, DOI 10.1111/IGC.0b013e3181c5ddfa
   Wang Qiu-lan, 2010, MATERN CHILD HLTH J, V25, P1405
   Wang Ying-jian, 2011, CHIN J LAB DIAGN, V15, P2132
   Xie Ping, 2015, CHIN J CLIN RES, V28, P293
   Xuan Zhang-biao, 2011, J MED RES, V40, P133
   Xue Y, 2011, EUR J OBSTET GYN R B, V159, P204, DOI 10.1016/j.ejogrb.2011.06.038
   Yang Chao-hui, 2016, CHINESE J HLTH LAB T, V26, P2743
   Yang JunWen, 2015, Maternal and Child Health Care of China, V30, P614
   Yu J, 2016, INT J CLIN EXP PATHO, V9, P5445
   Zhang Bao-hua, 2004, J PRACT MED, V20, P384
   Zhang Wen-yuan, 2013, J CLIN ONCOL, V19, P605
   Zhe Yan, 2013, CANC RES PREV TREAT, V40, P83
   Zhou XL, 2015, GENET MOL RES, V14, P17059, DOI 10.4238/2015.December.16.6
   Zhou Xing, 2014, CANC RES CLIN, V26, P243
   Zhu Hua, 2010, J PRACT OBSTET GYNEC, V26, P57
NR 31
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1091
EP 1096
DI 10.19193/0393-6384_2018_4_167
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500030
DA 2022-07-14
ER

PT J
AU Li, J
   Li, GZ
   Li, XZ
   Yuan, L
AF Li, Jie
   Li, Guozhen
   Li, Xiaozheng
   Yuan, Li
TI THE CLINICAL EFFECT AND SAFETY ANALYSIS OF DEZOCINE COMBINED WITH LOW
   CONCENTRATION ROPIVACAINE IN UPPER LIMB SURGERIES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE dezocine; ropivacaine; low concentration; brachial plexus nerve block;
   operation; safety; clinical effect
ID BRACHIAL-PLEXUS BLOCK; ANALGESIA; TRIAL
AB Objective: To research the clinical effect of Dezocine combined with low concentration Ropivacaine in upper limb surgeries, and analyze its safety.
   Method: 240 patients who had upper limb surgeries were randomly divided into two groups, research group and control group. Each group had 120 patients. Patients in control group were treated with low concentration Ropivacaine. Patients in research group were treated with low concentration Ropivacaine combined with Dezocine. Difference analysis of the two groups was conducted with anesthesia effect, VAS grading, and adverse reactions.
   Results: The acting time of anesthesia in research group was significantly shorter than that in control group. The difference had statistical significance (P < 0.05). Sensory block and analgesic time in research group were significantly longer than that in control group, and the difference had statistical significance (P < 0.05). VAS grading of research group 2h, 4h, 8h after the operation was significantly lower than that in control group, and the difference had statistical significance (P < 0.05). The adverse reaction rate in research group (0.83%) was significantly lower than that in control group (13.33%), and the difference had a statistical significance (P < 0.05). In addition, patients in both groups did not have retention of urine, skin itch, respiratory depression, or any other severe adverse reaction.
   Conclusion: mixed solution of Dezocine and low concentration Ropivacaine had a quick anesthetic effect, long anesthesia and analgesic time, low adverse reaction rate and high clinic safety.
C1 [Li, Jie; Li, Guozhen; Li, Xiaozheng] Shanxian Cent Hosp, Dept Anesthesiol, Shanxian 274300, Peoples R China.
   [Yuan, Li] Qingdao Univ, Dept Anesthesiol, Affiliated Hosp, Qingdao 266000, Peoples R China.
RP Li, J (corresponding author), Care of Sun CM, Dept Lab, Yantai Yuhuangding Hosp, Yantai 264000, Peoples R China.
EM yimaoli76@163.com
CR Abdallah FW, 2016, ANESTHESIOLOGY, V124, P683, DOI 10.1097/ALN.0000000000000983
   Badiger Santoshi V, 2017, Anesth Essays Res, V11, P140, DOI 10.4103/0259-1162.186865
   Barsagade W, 2016, COMP STUDY ROPIVACAI, V7, P543
   Cao J, 2016, CHINA PRACTICAL MED
   Chinnappa Jithendra, 2017, J Anaesthesiol Clin Pharmacol, V33, P81, DOI 10.4103/0970-9185.202196
   Das B, 2016, REV ESP ANEST REANIM, V63, P135, DOI 10.1016/j.redar.2015.04.012
   Eman A, 2014, ACTA MEDICA MEDITERR, V30, P481
   Kavrut ON, 2017, J ANESTH, P1
   Lina A N, 2014, MED J CHINESE PEOPLE
   Pang Z, 2015, CHINA MODERN MED, V66, P335
   Rashmi H D, 2017, Anesth Essays Res, V11, P134, DOI 10.4103/0259-1162.181431
   Saied N N, 2016, PAIN MED, P1
   Watanabe K, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006457
   Wiegel M, 2017, REGION ANESTH PAIN M, V42, P310, DOI 10.1097/AAP.0000000000000573
   Xiao Z J, 2016, J CLIN MED LIT, V7, P455
   Zhu Z., 2015, CHINA MODERN MED, V66, P341
   Zhu Z., 2015, CHINA MODERN MED
NR 17
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 469
EP 473
DI 10.19193/0393-6384_2018_2_75
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400029
DA 2022-07-14
ER

PT J
AU Li, J
   Wang, ST
AF Li, Jing
   Wang, Shitao
TI STRENGTH TRAINING ON EXERCISE-INDUCED SKELETAL MUSCLE INJURY IN TRACK
   AND FIELD SPORTS AND MECHANISM ANALYSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Strength training; Exercise-induced muscle injury in track and field
   sports; Eccentric exercise; Biomechanical property
AB This paper mainly observed the influence of eccentric contraction strength training on the structure, serum ck, and biomechanical property of muscle of track and field athlete under different tensions, analyzed the internal relation between exercise-induced muscle injury and mechanical factors. In this paper, the research method was to establish a dynamic and quantitative test model for testing muscle strength training and the biomechanical property of an alive rat, and conducted cyclical eccentric strength training for ankle joint dorsal muscle group of SD male rats under two groups of different applied loads. According to the research results, it can be seen that after eccentric movement, the difference in terms of structure, serum ck, biomechanical property of rat muscle between high tension group and low tension group was not of statistic significance, P>0.05. It can conclude that the high tension, which was resulted by eccentric contraction, was the primary factor to cause exercise-induced muscle injury.
C1 [Li, Jing] Jilin Sport Univ, Sch Sports Human Sci, Changchun 130022, Peoples R China.
   [Wang, Shitao] Jilin Sport Univ, Sch Sports & Arts, Changchun 130022, Peoples R China.
RP Wang, ST (corresponding author), Jilin Sport Univ, Sch Sports & Arts, Changchun 130022, Peoples R China.
EM wst-0223@163.com
FU Jilin Social Science Fund Project - Research on the health industry of
   the elderly [2017M16]
FX Jilin Social Science Fund Project - Research on the health industry of
   the elderly (No. 2017M16).
CR Alanazi K, 2016, SAUDI J BIOL SCI, V23, P87, DOI 10.1016/j.sjbs.2015.09.008
   Amr AEGE, 2017, PAK J PHARM SCI, V30, P833
   Bassi P, 2017, SAUDI PHARM J, V25, P32, DOI 10.1016/j.jsps.2015.06.003
   Cahill T., 2015, ASIAN PAC J SURG ONC, V1, P47
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P1355, DOI 10.1016/j.sjbs.2016.09.010
   Jin QG, 2010, CHIN SPORTS SCI, V30, P76
   Kos M, 2015, ACTA MEDICA MEDITERR, V31, P219
   [赖桂华 Lai Guihua], 2015, [中国临床解剖学杂志, Chinese Journal of Clinical Anatomy], V33, P545
   Lee R., 2015, ASIAN PAC J SURG ONC, V1, P39
   Shahid B, 2015, PAK J PHARM SCI, V28, P95
   Sharma M, 2015, SAUDI PHARM J, V23, P675, DOI 10.1016/j.jsps.2015.02.013
   Song HM, 2015, ACTA MEDICA MEDITERR, V31, P303
   Wang Dapeng, 2016, CHINESE J TISSUE ENG, V20, P273
   Wang M, 2018, J CLEAN PROD, V179, P12, DOI 10.1016/j.jclepro.2018.01.096
   Wang YM, 2017, SAUDI J BIOL SCI, V24, P837, DOI 10.1016/j.sjbs.2016.12.004
   Zhang M, 2015, J COASTAL RES, P304, DOI 10.2112/SI73-053.1
   Zhang Yipeng, 2013, RES INTEGRATED TRADI, V5, P228
   Zhen-Ying Zhang, 2007, Shengli Xuebao, V59, P643
NR 18
TC 0
Z9 0
U1 2
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1565
EP 1569
DI 10.19193/0393-6384_2018_3s_242
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400018
DA 2022-07-14
ER

PT J
AU Li, J
   Wang, AL
   Song, L
   Zhao, JG
AF Li, Jing
   Wang, Aili
   Song, Lu
   Zhao, Jiguang
TI EXPRESSION AND CLINICAL SIGNIFICANCE OF AEG-1, E-CA AND IGFBP-3 IN
   ESOPHAGEAL CANCER PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Esophageal carcinoma; AEG-1; E-ca; IGFBP-3; Treatment
ID IGF-I; METAANALYSIS
AB Purpose: To investigate the expressions of astrocytic upregulation gene-1 (AEG-1), cadherin (E-ca) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with esophageal cancer, and their clinical significance in diagnosis, treatment, and prediction of prognosis.
   Methods: A total of 160 patients were used for this study, and they were divided into two groups: esophageal carcinoma group and Para-cancerous (control) group. There were 80 patients in the esophageal carcinoma group which comprised 58 males and 22 females within the age range 28 - 70 years (mean age = 49.26 +/- 15.32 years). The para-cancerous group consisted of 80 patients with adjacent tumor-free tissue samples within the same period. They were confirmed by clinical pathology. Specimens from the patients were subjected to immunohistochemistry and Western blotting.
   Results: The positive expressions of AEG-1 and IGFBP-3 in patients with esophageal carcinoma were significantly higher < 0.05) than those of corresponding para-cancerous tissue. The positive expression of E-ca was significantly lower (p < 0.05) than that of the corresponding para-cancerous tissue. The positive expressions of the three genes were not correlated with sex, age, site of tumor and tumor pathology type, but were related to the degree of tumor differentiation, depth of invasion, clinical stage and lymph node metastasis.
   Conclusion: The expressions of AEG-1, E-ca and IGFBP-3 in patients with esophageal cancer can provide important reference values for the early diagnosis and treatment of the disease, and improve its prognosis.
C1 [Li, Jing; Wang, Aili; Song, Lu; Zhao, Jiguang] 6 Peoples Hosp Qingdao, Dept Clin Lab, Qingdao, Peoples R China.
RP Zhao, JG (corresponding author), 6 Peoples Hosp Qingdao, Dept Clin Lab, Qingdao, Peoples R China.
EM vk1214@163.com
CR Benham-Pyle BW, 2015, SCIENCE, V348, P1024, DOI 10.1126/science.aaa4559
   Cai X, 2001, CHIN MED J, V81, P625
   Chinese Medical Association Digestive Endoscopy Branch, 2016, CHIN J DIG ENDOSC, V1, P3
   Dai Y, 2016, MOD ONCOL, V24, P3691
   Gao ZQ, 2016, SHANGHAI MED U, V9, P563
   He Y T, 2017, Zhonghua Zhong Liu Za Zhi, V39, P315, DOI 10.3760/cma.j.issn.0253-3766.2017.04.016
   Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103
   Liu HY, 2012, CANCER BIOMARK, V11, P115, DOI 10.3233/CBM-2012-0268
   Mayo J.C., 2017, J PINEAL RES, V62
   Pezzi N, 2016, MOL IMMUNOL, V77, P157, DOI 10.1016/j.molimm.2016.08.003
   Qin Y, 2017, J CLIN EXP PATHOLOGY, V33, P832
   Sarkar D, 2013, ADV CANCER RES, V120, P193, DOI 10.1016/B978-0-12-401676-7.00007-3
   Teumer Alexander, 2016, Aging Cell, V15, P811, DOI 10.1111/acel.12490
   Torre S. B. D., 2017, Nutrients, V9, DOI 10.3390/nu9010076
   Travis RC, 2016, CANCER RES, V76, P2288, DOI 10.1158/0008-5472.CAN-15-1551
   [王澜 Wang Lan], 2016, [中华放射肿瘤学杂志, Chinese Journal of Radiation Oncology], V25, P565
   Wang Y, 2017, MOD ONCOL MED, V25, P2164
   Ye Y, 2016, J ANHUI MED U, V51, P231
   Yin X, 2017, J NEUROSCI RES, V95, P2086, DOI 10.1002/jnr.24044
   [周志国 Zhou Zhiguo], 2015, [肿瘤防治研究, Cancer Research on Prevention and Treatment], V42, P772
NR 20
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1671
EP 1676
DI 10.19193/0393-6384_2018_6_256
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400007
DA 2022-07-14
ER

PT J
AU Li, J
   Liu, CB
   Wang, C
   Du, LJ
   Dong, XC
   Guo, Y
   Gao, F
   Liu, HW
   Chen, L
   Li, JJ
AF Li, Jun
   Liu, Changbin
   Wang, Chong
   Du, Liangjie
   Dong, Xuechao
   Guo, Yun
   Gao, Feng
   Liu, Hongwei
   Chen, Liang
   Li, Jianjun
TI TRANSFERRING LATERAL HEAD OF GASTROCNEMIUS MUSCLE FOR TREATMENT OF DEEP
   PERONEAL NERVE INJURIES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE gastrocnemius muscle; peronal nerve injure; nerve transposition
   operation; reconstruction
ID TIBIAL NERVE; MANAGEMENT; REPAIR
AB Objective: To clarify the effect of transferring lateral head of gastrocnemius muscle on the treatment of deep peroneal nerve injuries in rats.
   Methods: Thirty-two rats were randomly divided into sham group, control group with injury of the deep peroneal nerve, the neural anastomosis group and the nerve transfer group. We measured walking tracks analysis, electrophysiology, wet weight and creatine phosphokinase of anterior tibial muscle, and the branching pattern, length, diameter of motor branches of the tibial nerve in the proximal leg, the maximum dissected length of the common fibular nerve to the proximal and the diameter of deep fibular nerve.
   Results: After the intra-neural dissection of the common fibular nerve, the lateral head of gastrocnemius muscle was long enough for direct nerve suture with the deep fibular division without tension. After 12w of surgery, peroneal nerve function index, compound muscle action potential, wet weight and creatine phosphokinase of anterior tibial muscle in the nerve transfer group were higher than them in the control group, but there was no significant difference of them when compare with the neural anastomosis group.
   Conclusion: Transferring lateral head of gastrocnemius muscle for treatment of deep peroneal nerve injuries in rats is effective.
C1 [Li, Jun; Liu, Changbin; Wang, Chong; Du, Liangjie; Dong, Xuechao; Guo, Yun; Gao, Feng; Liu, Hongwei; Chen, Liang; Li, Jianjun] Capital Med Univ, Sch Rehabil Med, Beijing, Peoples R China.
   [Li, Jun; Liu, Changbin; Wang, Chong; Du, Liangjie; Dong, Xuechao; Guo, Yun; Gao, Feng; Liu, Hongwei; Chen, Liang; Li, Jianjun] Beijing Boai Hosp, China Rehabil Res Ctr, Dept Spinal & Neural Funct Reconstruct, Beijing, Peoples R China.
   [Li, Jun; Liu, Changbin; Wang, Chong; Du, Liangjie; Dong, Xuechao; Guo, Yun; Gao, Feng; Liu, Hongwei; Chen, Liang; Li, Jianjun] China Rehabil Res Ctr, Inst Rehabil Sci China, Beijing, Peoples R China.
   [Li, Jun; Liu, Changbin; Wang, Chong; Du, Liangjie; Dong, Xuechao; Guo, Yun; Gao, Feng; Liu, Hongwei; Chen, Liang; Li, Jianjun] Beijing Inst Brain Disorders, Ctr Neural Injury & Repair, Beijing, Peoples R China.
   [Li, Jun; Liu, Changbin; Wang, Chong; Du, Liangjie; Dong, Xuechao; Guo, Yun; Gao, Feng; Liu, Hongwei; Chen, Liang; Li, Jianjun] Beijing Key Lab Neural Injury & Rehabil, Beijing, Peoples R China.
RP Li, JJ (corresponding author), Capital Med Univ, Beijing Key Lab Neural Injury & Rehabil,Beijing I, China Rehabil Res Ctr,Inst Rehabil Sci China,Ctr, Sch Rehabil Med,Beijing Boai Hosp,China Rehabil R, 10 Jiaomen Bei Lu, Beijing 100068, Peoples R China.
CR Bodily KD, 2004, CLIN ANAT, V17, P201, DOI 10.1002/ca.10189
   Eser F, 2009, NEUROL INDIA, V57, P434, DOI 10.4103/0028-3886.55614
   FU SY, 1995, J NEUROSCI, V15, P3886
   Gousheh J, 2002, PLAST RECONSTR SURG, V109, P994, DOI 10.1097/00006534-200203000-00030
   Gousheh J, 2008, PLAST RECONSTR SURG, V121, P878, DOI 10.1097/01.prs.0000299286.67932.88
   HARE GMT, 1992, PLAST RECONSTR SURG, V89, P251, DOI 10.1097/00006534-199202000-00009
   Kemp SWP, 2010, EUR J NEUROSCI, V31, P1074, DOI 10.1111/j.1460-9568.2010.07130.x
   Kim DH, 2004, J NEUROSURG, V101, P8, DOI 10.3171/jns.2004.101.1.0008
   Kline DG, 1998, J NEUROSURG, V89, P13, DOI 10.3171/jns.1998.89.1.0013
   Midha R, 2005, NEUROSURGERY, V57, P1289, DOI 10.1227/01.NEU.0000187480.38170.EC
   Moorman CD, 2009, J FOOT ANKLE SURG, V48, P466, DOI 10.1053/j.jfas.2009.02.012
   Rochkind S, 2013, INT REV NEUROBIOL, V109, P99, DOI 10.1016/B978-0-12-420045-6.00004-3
   Stewart John D, 2008, Pract Neurol, V8, P158, DOI 10.1136/jnnp.2008.149393
   Wang Y, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0034-4
   White CP, 2012, CAN J PLAST SURG, V20, P24, DOI 10.1177/229255031202000104
   Won YH, 2016, NEUROL SCI, P1
NR 16
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1071
EP 1078
DI 10.19193/0393-6384_2018_4_164
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500027
DA 2022-07-14
ER

PT J
AU Li, W
   Feng, CC
   He, XL
   Wu, Y
   Wu, J
   Hu, XK
   Zhao, SZ
AF Li, Wei
   Feng, Chenchen
   He, Xiaoli
   Wu, Yan
   Wu, Juan
   Hu, Xiaokun
   Zhao, Shuzhen
TI APPLICATION OF THE ICF CHECKLIST IN THE CHINESE SYSTEMIC LUPUS
   ERYTHEMATOSUS PATIENTS: A CROSS-SECTIONAL STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ICF; systemic lupus erythematosus; function
ID QUALITY-OF-LIFE; INTERNATIONAL CLASSIFICATION; DISEASE-ACTIVITY; SOCIAL
   SUPPORT; RHEUMATOID-ARTHRITIS; RELEVANT CONCEPTS; REPORTED FATIGUE;
   SLEEP DISORDERS; LINKING RULES; HEALTH
AB Systemic lupus erythematosus (SLE) has wide damages on people's function. Thorough explore of problems will benefit SLE patient's needs determination, resources allocation, rehabilitation and outcomes assessment. Therefore, there was a need for an instrument that can conduct a comprehensive investigation of SLE people's experienced problems. To identify SLE patients' function, disability and health problems and to provide references for the future development of SLE core sets. A cross-sectional study was conducted in the rheumatology outpatient in one general hospital in China. 100 SLE patients' function, disability and health problems were collected using expanded ICF checklist. Descriptive analysis was performed to summarize the data. Of the 150 categories, 55 categories were relevant to at least 20% of the patients, 28 from body functions and structures component, 14 from activities and participation component and 13 from environmental factors component. The mostly referred problems were fatiguability (96%) in body functions, joints (76%) in body structures. The most restricted activity was remunerative employment (71%), and patients' mostly important facilitator was immediate family (47%), mostly referred barrier was light (96%). In conclusion, a large variety of problems were identified, reflecting the complexity of the lived experiences of SLE patients, and intervention should be taken based on those relevant categories. And this study also can serve as a reference for future development of SLE core set.
C1 [Li, Wei; Feng, Chenchen; He, Xiaoli; Wu, Yan; Wu, Juan; Hu, Xiaokun; Zhao, Shuzhen] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Zhao, SZ (corresponding author), Sichuan Univ, West China Hosp, Outpatient Dept, 37 Guoxue Lane, Chengdu 610041, Sichuan, Peoples R China.
EM ssszszzsz@126.com
CR Anic F, 2014, CROAT MED J, V55, P514, DOI 10.3325/cmj.2014.55.514
   Askanase A, 2012, SOC WORK HEALTH CARE, V51, P576, DOI 10.1080/00981389.2012.683369
   Barbasio C, 2015, COMPR PSYCHIAT, V63, P88, DOI 10.1016/j.comppsych.2015.09.004
   Bauernfeind B, 2009, ARTHRIT RHEUM-ARTHR, V61, P21, DOI 10.1002/art.24165
   Bickenbach J., 2012, ICF CORE SETS MANUAL
   BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
   Brennan KAM, 2016, QUAL LIFE RES, V25, P1227, DOI 10.1007/s11136-015-1151-z
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Chen HH, 2017, CLIN RHEUMATOL, V36, P133, DOI 10.1007/s10067-016-3471-y
   Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263
   Cieza A, 2002, J REHABIL MED, V34, P205, DOI 10.1080/165019702760279189
   Cieza A, 2019, DISABIL REHABIL, V41, P574, DOI 10.3109/09638288.2016.1145258
   Cleanthous S, 2012, LUPUS, V21, P465, DOI 10.1177/0961203312436863
   Garcia-Carrasco M, 2012, LUPUS, V21, P1219, DOI 10.1177/0961203312456749
   Gladman D, 1996, ARTHRITIS RHEUM, V39, P363, DOI 10.1002/art.1780390303
   Gradinger F, 2011, J SLEEP RES, V20, P445, DOI 10.1111/j.1365-2869.2010.00888.x
   Kasitanon N, 2013, LUPUS, V22, P1353, DOI 10.1177/0961203313507355
   KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022
   Kuhn A, 2015, DTSCH ARZTEBL INT, V112, P423, DOI 10.3238/arztebl.2015.0423
   Leong KP, 2005, RHEUMATOLOGY, V44, P1267, DOI 10.1093/rheumatology/keh605
   Leuchten N, 2014, ARTHRIT CARE RES, V66, P1895, DOI 10.1002/acr.22372
   LIANG MH, 1989, ARTHRITIS RHEUM, V32, P1107, DOI 10.1002/anr.1780320909
   Mazzoni D, 2011, LUPUS, V20, P1117, DOI 10.1177/0961203311412994
   Mazzoni D, 2016, ANXIETY STRESS COPIN, V29, P542, DOI 10.1080/10615806.2015.1134785
   McElhone K, 2007, ARTHRIT RHEUM-ARTHR, V57, P972, DOI 10.1002/art.22881
   Mirbagher L., 2014, INT J RHEUM DIS, V19, P305, DOI 10.1111/1756-185x.12418
   Nowicka-Sauer K, 2007, CLIN RHEUMATOL, V26, P1523, DOI 10.1007/s10067-007-0619-9
   Oner FC, 2015, SPINE, V40, P1371, DOI 10.1097/BRS.0000000000001009
   Palagini L, 2014, LUPUS, V23, P115, DOI 10.1177/0961203313518623
   Pons-Estel GJ, 2010, SEMIN ARTHRITIS RHEU, V39, P257, DOI 10.1016/j.semarthrit.2008.10.007
   Schmeding A, 2013, BEST PRACT RES CL RH, V27, P363, DOI 10.1016/j.berh.2013.07.009
   Selb M, 2015, EUR J PHYS REHAB MED, V51, P105
   Shariati-Sarabi Z, 2013, CLIN EXP RHEUMATOL, V31, P69
   Stamm TA, 2007, ARTHRIT RHEUM-ARTHR, V57, P1287, DOI 10.1002/art.23013
   Sterling KL, 2014, LUPUS, V23, P124, DOI 10.1177/0961203313511554
   Stucki G, 2004, ANN RHEUM DIS, V63, P40, DOI 10.1136/ard.2004.028233
   Stucki G, 2004, J REHABIL MED, V36, P5, DOI 10.1080/16501960410022300
   SYMMONS DPM, 1988, Q J MED, V69, P927
   Tsutsui H, 2015, CLIN EXP NEPHROL, V19, P254, DOI 10.1007/s10157-014-0983-0
   Ustun B, 2004, J REHABIL MED, V36, P7, DOI 10.1080/16501960410015344
   Vina ER, 2013, JCR-J CLIN RHEUMATOL, V19, P7, DOI 10.1097/RHU.0b013e31827cd20d
   W. World Health Organisation, 2001, INT CLASS FUNCT DIS
   Weigl M, 2004, J REHABIL MED, V36, P12, DOI 10.1080/16501960410015443
   World Health Organization, 2001, ICF CHECKL VERS 2 1A
   Yilmaz-Oner S, 2016, CLIN RHEUMATOL, V35, P617, DOI 10.1007/s10067-015-2930-1
   Zheng Y, 2009, CLIN RHEUMATOL, V28, P265, DOI 10.1007/s10067-008-1033-7
   Zochling J, 2006, CLIN EXP RHEUMATOL, V24, P239
   ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 49
TC 0
Z9 0
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1281
EP 1288
DI 10.19193/0393-6384_2018_5_197
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700019
DA 2022-07-14
ER

PT J
AU Li, X
   Yang, YJ
   Zheng, J
   Li, Y
   Lin, DN
   Cai, YP
AF Li, Xia
   Yang, Yujie
   Zheng, Jing
   Li, Ye
   Lin, Denan
   Cai, Yunpeng
TI ASSESSMENT OF APPROPRIATENESS OF DRUG USAGE IN CHINESE HYPERTENSIVE
   PATIENTS AND HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE hypertension; type 2 diabetes; drug; SBP; DBP
ID BLOOD-PRESSURE; AMERICAN SOCIETY; PREVALENCE; AWARENESS; MANAGEMENT;
   STATEMENT; ADULTS; AGE; COMMUNITY; COUNTRIES
AB Background: Hypertension remains a major global public health problem. The objective of this study was to evaluate the appropriateness of drug usage in Chinese hypertensive patients.
   Methodology: Patients data with drug usage were collected from Shenzhen in China. Student' t test was used to compare the diastolic blood pressure (DBP) and systolic blood pressure (SBP) differences.
   Results: A total of 58,971 hypertensive patients and 12,732 hypertensive patients with type 2 diabetes were studied. The abnormal DBP (mean: 81 mmHg) and SBP (mean: above 130 mmHg) observed in two groups indicated both populations were correctly diagnosed with hypertension. Those hypertensive patients with type 2 diabetes got significant higher SBP (mean: 133 mmHg), suggesting they were more severe. After a period of at least 3 years follow up investigations, the SBP of patients with only hypertension dropped to a mean value of 129 mmHg. Hypertensive patients with type 2 diabetes also showed significant SBP decreasing changes, with the mean of SBP around 130 mmHg. The DBP of two groups decreased to the normal range after 3 years (mean: around 79 mmHg).
   Significance: These results supported the reasonability of current drug usage and had extensive applicability for other hypertensive patients' treatment.
C1 [Li, Xia; Yang, Yujie; Li, Ye; Cai, Yunpeng] Chinese Acad Sci, Shenzhen Inst Adv Technol, Res Ctr Biomed Informat Technol, Shenzhen, Peoples R China.
   [Zheng, Jing; Lin, Denan] Shenzhen Hlth Informat Ctr, Shenzhen, Peoples R China.
RP Cai, YP (corresponding author), Chinese Acad Sci, Shenzhen Inst Adv Technol, Res Ctr Biomed Informat Technol, Shenzhen, Peoples R China.; Lin, DN (corresponding author), Shenzhen Hlth Informat Ctr, Shenzhen, Peoples R China.
EM ldn308@163.com; yp.cai@siat.ac.cn
RI Li, Xia/X-3897-2019; Cai, Yunpeng/O-8823-2018
OI Li, Xia/0000-0002-6068-5182; 
FU National High-tech R&D Program (863 Program) of China [SS2015AA020109];
   Science and Technology Planning Project of Guangdong Province
   [2015B010129012]; National Natural Science Foundation of China
   [31501065]
FX This work was supported by National High-tech R&D Program (863 Program)
   of China (SS2015AA020109), Science and Technology Planning Project of
   Guangdong Province (2015B010129012), and the National Natural Science
   Foundation of China (31501065).
CR Ahmed H, 2012, JACC-CARDIOVASC INTE, V5, P758, DOI 10.1016/j.jcin.2012.01.027
   Amer Diabet Assoc, 2016, DIABETES CARE, V39, pS60, DOI 10.2337/dc16-S011
   [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004, 10.2337/dc12-s011]
   Beckett NS, 2008, NEW ENGL J MED, V358, P1887, DOI 10.1056/NEJMoa0801369
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   DANNENBERG AL, 1987, JAMA-J AM MED ASSOC, V257, P1477, DOI 10.1001/jama.257.11.1477
   Dubey RK, 2002, CARDIOVASC RES, V53, P688, DOI 10.1016/S0008-6363(01)00527-2
   Emdin CA, 2015, JAMA-J AM MED ASSOC, V313, P603, DOI 10.1001/jama.2014.18574
   Green JB, 2015, NEW ENGL J MED, V373, P232, DOI 10.1056/NEJMoa1501352
   Hajjar I, 2003, JAMA-J AM MED ASSOC, V290, P199, DOI 10.1001/jama.290.2.199
   Holman RR, 2014, LANCET, V383, P2008, DOI 10.1016/S0140-6736(14)60794-7
   Huri HZ, 2013, BMC ENDOCR DISORD, V13, DOI 10.1186/1472-6823-13-2
   Larsen RN, 2014, NUTR METAB CARDIOVAS, V24, P976, DOI 10.1016/j.numecd.2014.04.011
   Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
   Lloyd-Sherlock P, 2014, INT J EPIDEMIOL, V43, P116, DOI 10.1093/ije/dyt215
   Munger MA, 2010, DRUG AGING, V27, P871, DOI 10.2165/11538650-000000000-00000
   Rapsomaniki E, 2014, LANCET, V383, P1899, DOI 10.1016/S0140-6736(14)60685-1
   Rosendorff C, 2015, HYPERTENSION, V65, P1372, DOI 10.1161/HYP.0000000000000018
   Salehi N, 2016, ACTA MEDICA MEDITERR, V32, P927
   Sorlie PD, 2014, AM J HYPERTENS, V27, P793, DOI 10.1093/ajh/hpu003
   Tikkanen I, 2015, DIABETES CARE, V38, P420, DOI 10.2337/dc14-1096
   Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003
   Vijan S, 2003, ANN INTERN MED, V138, P593, DOI 10.7326/0003-4819-138-7-200304010-00018
   Wang JW, 2014, AM J HYPERTENS, V27, P1355, DOI 10.1093/ajh/hpu053
   Wang YF, 2004, ARCH INTERN MED, V164, P2126, DOI 10.1001/archinte.164.19.2126
   Weber MA, 2014, J HYPERTENS, V32, P3, DOI [10.1111/jch.12237, 10.1097/HJH.0000000000000065]
   Wolf-Maier K, 2004, HYPERTENSION, V43, P10, DOI 10.1161/01.HYP.0000103630.72812.10
   Wolz M, 2000, AM J HYPERTENS, V13, P103, DOI 10.1016/S0895-7061(99)00241-1
   Wu YF, 2008, CIRCULATION, V118, P2679, DOI 10.1161/CIRCULATIONAHA.108.788166
   Xue BJ, 2005, AM J PHYSIOL-HEART C, V288, pH2177, DOI 10.1152/ajpheart.00969.2004
NR 30
TC 0
Z9 0
U1 2
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 153
EP 158
DI 10.19193/0393-6384_2018_1_25
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600025
DA 2022-07-14
ER

PT J
AU Li, XL
   Xu, PC
AF Li Xiaoli
   Xu Pengcheng
TI EFFECT OF SERUM TH1/TH2 CYTOKINE IMBALANCE ON THE OCCURRENCE AND
   DEVELOPMENT OF VARIOUS TYPES OF CHRONIC GLOMERULONEPHRITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Chronic glomerulonephritis; Th1/Th2 cytokine; Interferon-gamma;
   Interleukin-10
ID TH1
AB Objective: To study the effect of changes in serum cytokine Th1/Th2, interferon-gamma (IFN-gamma) and interleukin-10 (IL-10) on the occurrence and development of various forms of chronic glomerulonephritis (CGN) in patients.
   Methods: Venous blood was collected from 9 patients with IgA mesangio-proliferative glomerulonephritis (IgA nephropathy), 18 patients with non-IgA mesangio-proliferative glomerulonephritis (non-IgA MsPGN), 7 patients with membranous nephropathy (MN), 6 patients with focal segmental sclerosing glomerulonephritis (FSGS), 14 patients with chronic renal failure, and 20 healthy people. Serum IFN-gamma and IL-10 were assayed by double antibody sandwich ELISA, and 24-h urinary protein and serum creatinine excretion were measured using turbidimetry and picric acid colorimetry, respectively.
   Results: There were significant elevations in blood levels of IFN-gamma in patients with IgA nephropathy and non-IgA MsPGN, but the levels of IFN-gamma in patients with MN were decreased. The IFN-gamma of non-IgA MsPGN patients was positively correlated with 24 h urinary protein excretion. The levels of IL-10 in patients with IgA nephropathy, non-IgA MsPGN, FSGC and CRF were significantly decreased. In CRF patients, IL-10 was negatively associated with serum creatinine.
   Conclusion: Serum IFN-gamma plays a role in the improvement of immunologic injury in mesangio-proliferative glomerulonephritis which is related to development of proteinuria. The occurrence and development of CGN and CRF are closely linked to decreases in IL-10 levels. Thus, imbalance in serum Th1/Th2 cytokines has certain correlation with clinical indices of these conditions.
C1 [Li Xiaoli; Xu Pengcheng] Tianjin Med Univ, Gen Hosp, Kidney Internal Med Dept, Tianjin, Peoples R China.
RP Xu, PC (corresponding author), Tianjin Med Univ, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.
RI Xu, Pengcheng/J-1429-2012
OI Xu, Pengcheng/0000-0001-8651-208X
CR [Anonymous], 2002, CLIN EXP IMMUNOL, V128, P36
   Fan XH, 1997, INFLAMMATION, V21, P105, DOI 10.1023/A:1027399027170
   Fan XZ, 2005, J CLIN NEPHROL, V5, P281
   Hagiwara E, 2001, Ryumachi, V41, P888
   Holdsworth SR, 1999, KIDNEY INT, V55, P1198, DOI 10.1046/j.1523-1755.1999.00369.x
   Kitching AR, 2002, CLIN EXP IMMUNOL, V128, P36, DOI 10.1046/j.1365-2249.2002.01793.x
   Li YH, 2010, CHIN MOD DOCTOR, V48, P111
   Liping M A, 2016, J TRADIA CHIN INTERN, V48, P56
   Liu Y, 2012, MOD MED HEAL, V28, P1478
   Lucey DR, 1996, CLIN MICROBIOL REV, V9, P532, DOI 10.1128/CMR.9.4.532
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   Ortega L.M., 2010, INT J INTERFERON CYT, V2, P49
   Tipping PG, 2005, CLIN EXP IMMUNOL, V142, P207, DOI 10.1111/j.1365-2249.2005.02842.x
   Wang HY, 1996, NEPHROLOGY, P595
   Wang HZ, 2011, CHIN MOD DOCTOR, V49, P102
   Yang Y., 2012, PICA PROG INTELL COM, V1, P50
   Yano N, 1997, J CLIN IMMUNOL, V17, P396, DOI 10.1023/A:1027368308453
   Ye RG, 2004, INTERNAL MED, P494
NR 18
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1059
EP 1063
DI 10.19193/0393-6384_2018_4_162
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500025
DA 2022-07-14
ER

PT J
AU Li, Y
   Fan, XQQ
   Fan, Q
   Wang, FS
   Li, JZ
   Yang, Q
AF Li, Yang
   Wu, Xiu-Qin
   Fan, Qi
   Wang, Fu-Shun
   Li, Jian-Zhong
   Yang, Qing
TI A STUDY ON THE CORRELATION OF COGNITIVE DYSFUNCTION AFTER STROKE WITH
   THE LEVELS OF VILIP-1 AND HS-CRP IN SERUM
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Stroke; cognitive dysfunction; VILIP-1; hs-CRP
ID C-REACTIVE PROTEIN; DEMENTIA
AB Objective: To investigate the variations in levels of visinin-like protein-1 (VILIP-1 ) and high sensitive C-reaction protein (hs-CRP) in cognitive dysfunction after stroke and the clinical significance.
   Methods: A total of 110 patients with ischemic stroke (Stroke group) were divided into two groups according to the MoCA scale at 3 months after attack, i.e. the cognitive dysfunction (n=53) and normal cognition group (n=57); at the same time, 50 subjects who attended the physical examination were enrolled in the control group. General data of patients were collected from patients, including gender, age, education years, disease history and biochemical indexes, and enzyme-linked immunosorbent assay was carried out to detect the levels of VILIP-1 in and immuno-scatter turbidmetry to detect the levels of hs-CRP in serum of all groups.
   Results: In 110 stroke patients, there were 53 with cognitive dysfunction (48.18%). In the stroke group, the level of VILIP-1 was higher than that in the control group [(449.20 +/- 100.77) ng.L-1 vs. (332.78 +/- 92.13) ng.L-1; t=6.95, p<0.001]. In the cognitive dysfunction group, the level of VILIP-1 was higher than that in the normal cognition group [( 530.72 +/- 72.05 ) ng.L-1 vs. (373.41 +/- 50.00) ng.L-1; t=12.965, p<0.001]. Significant increases were identified in HIHSS score and hs-CRP in the cognitive dysfunction group in comparison with the levels of normal cognition group, and the difference had statistical significance (p<0.01), suggesting that the level of hs-CRP goes up against the severity in cognitive dysfunction with aggravation in nerve functions.
   Conclusion: After stroke, VILIP-1 is increased in patients with cognitive dysfunction, suggesting that it can serve as a predictor for cognitive dysfunction after stroke; hypertension and the level of VILIP-1 in serum are independent risk factors of cognitive dysfunction after stroke, indicative of the importance of antihypertensive therapy. In light of the close correlation between hs-CRP and cognitive dysfunction after. stroke, it can be used to evaluate the severity of cognitive dysfunction of patients.
C1 [Li, Yang] Nanjing Forest Police Coll, Sch Management, Psychol Ctr, Nanjing 210023, Jiangsu, Peoples R China.
   [Wu, Xiu-Qin] Nanjing Univ Chinese Med, Hanlin Coll, Nanjing 225300, Jiangsu, Peoples R China.
   [Fan, Qi; Wang, Fu-Shun; Li, Jian-Zhong] Nanjing Univ Chinese Med, Sch Psychol, Nanjing 210023, Jiangsu, Peoples R China.
   [Yang, Qing] Hosp Jilin Univ, Blood Transfus Dept 2, 71 Xinmin St, Changchun 30000 1, Jilin, Peoples R China.
RP Yang, Q (corresponding author), Hosp Jilin Univ, Blood Transfus Dept 2, 71 Xinmin St, Changchun 30000 1, Jilin, Peoples R China.
EM 13844056540@163.com
FU science foundation of Jiangsu Province [BK20151565]; postdoctoral
   science research, dominant discipline of Jiangsu Province (integrated
   traditional Chinese and western medicine of NJUTCM) [2014-2017:145189]
FX project supported by science foundation of Jiangsu Province
   (BK20151565); project supported by postdoctoral science research,
   dominant discipline of Jiangsu Province (integrated traditional Chinese
   and western medicine of NJUTCM) (2014-2017:145189)
CR Andin U, 2005, DEMENT GERIATR COGN, V19, P222, DOI 10.1159/000083801
   Groblewska M, 2015, J ALZHEIMERS DIS, V47, P17, DOI 10.3233/JAD-150060
   Hinkle JL, 2002, J NEUROSCI NURS, V34, P91
   Jin Ya-Ping, 2006, Alzheimers Dement, V2, P171, DOI 10.1016/j.jalz.2006.03.006
   Kester MI, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0142-1
   Kuo HK, 2005, LANCET NEUROL, V4, P371, DOI 10.1016/S1474-4422(05)70099-5
   Leys D, 2005, LANCET NEUROL, V4, P752, DOI 10.1016/S1474-4422(05)70221-0
   Melis F, 1996, NEUROSCIENCE, V74, P155, DOI 10.1016/0306-4522(96)00109-1
   Merino JG, 2002, STROKE, V33, P2261
   O Caoimh R, 2014, J ALZHEIMERS DIS, V40, P595
   Rebaud S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093948
   Schmidt R, 2002, ANN NEUROL, V52, P168, DOI 10.1002/ana.10265
   Tang QP, 2014, TOP STROKE REHABIL, V21, P120, DOI 10.1310/tsr2102-120
   Tarawneh R, 2015, JAMA NEUROL, V72, P656, DOI 10.1001/jamaneurol.2015.0202
   Verma S, 2004, CIRCULATION, V109, P2058, DOI 10.1161/01.CIR.0000127577.63323.24
   Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066
   Webb AJS, 2014, STROKE, V45, P3337, DOI 10.1161/STROKEAHA.114.006309
NR 17
TC 1
Z9 1
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1895
EP 1899
DI 10.19193/0393-6384_2018_6_294
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400045
DA 2022-07-14
ER

PT J
AU Liang, CC
   Wang, HK
   Ke, Y
   Ji, WJ
AF Liang Cancan
   Wang Haikun
   Ke Yue
   Ji Wenjing
TI EXPRESSIONS OF TLR4 AND MYD88, AND THEIR CORRELATION WITH
   CLINICO-PATHOLOGICAL FEATURES IN PATIENTS WITH COLORECTAL CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE TLR4; MyD88; Colorectal cancer; Clinico-pathological features; Prognosis
ID ACTIVATION
AB Purpose: To investigate the expressions of TLR4 and MyD88, and their correlations with clinicopathological features in patients with colorectal cancer.
   Methods: A total of 234 patients were selected for this study and divided into two groups of 117 patients each, namely: study group (patients with colorectal cancer over a period of two years) and control (patients with normal intestinal mucosal tissues). They consisted of 68 males and 49 females aged between 29 and 67 years (mean age = 52 years). Patients in the study group were staged using TNM staging criteria for colorectal cancer. Immunohistochemistry was used to determine the degree of expressions of Toll-like receptor 4 (TLR4) and myeloid differentiation factor (MyD88) in colorectal cancer and normal mucosal tissues. The relationship between the expressions of TLR4 and MyD88, and clinical characteristics and prognosis was also assessed.
   Results: The expressions of TLR4 and MyD88 in colorectal cancer tissues were significantly higher (p < 0.05), when compared to control, and were positively correlated with TNM staging, liver metastasis and vascular invasion. Patients with low expressions of TLR4 and MyD88 had significantly longer (p < 0.05) survival time than those with high expressions, and the expressions of TLR4 and MyD88, and TNM staging had significant impact (p < 0.05) on the prognosis of colorectal cancer.
   Conclusion: There is a positive correlation between the expressions of TLR4 and MyD88, and clinic-pathological features such as TNM staging, metastasis, and vascular invasion of patients with colorectal cancer.
C1 [Liang Cancan; Ke Yue; Ji Wenjing] Xinjiang Med Univ, Dept Digest Internal Med, Affiliated Hosp 2, Xinjiang 830000, Peoples R China.
   [Wang Haikun] Xinjiang Med Univ, Dept Digest Internal Med, Affiliated Hosp 1, Xinjiang 830000, Peoples R China.
RP Liang, CC (corresponding author), Xinjiang Med Univ, Dept Digest Internal Med, Affiliated Hosp 2, Xinjiang 830000, Peoples R China.
EM fe1229@163.com
CR Cho JS, 2014, CLIN EXP ALLERGY, V133, P1038
   Echizen K, 2016, CANCER SCI, V107, P391, DOI 10.1111/cas.12901
   Haruki K, 2015, ANIMAL SCI J, V79, P11
   He AQ, 2016, INFLAMMATION, V39, P172, DOI 10.1007/s10753-015-0236-8
   Li DaoJuan, 2015, Cancer Research on Prevention and Treatment, V42, P305
   Li G, 2016, INT J MOL MED, V37, P99, DOI 10.3892/ijmm.2015.2410
   Markowitz SD, 2016, NEW ENGL J MED, V362, P1246
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Sun L., 2016, INTEGR CANC SCI THER, V3, P432
   Wang JQ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00367
   [伍振辉 Wu Zhenhui], 2017, [国际药学研究杂志, Journal of International Pharmaceutical Research], V44, P396
   Zheng Q, 2018, J CELL MOL MED
   [周少龙 Zhou Shaolong], 2015, [中华神经医学杂志, Chinese Journal of Neuromedicine], V14, P563
   江宁红(综述), 2015, [实用妇产科杂志, Journal of Practical Obstetrics and Gynecology], V31, P338
   姚宏伟, 2010, [中华外科杂志, Chinese Journal of Surgery], V48, P1601
NR 15
TC 0
Z9 0
U1 2
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1777
EP 1781
DI 10.19193/0393-6384_2018_6_272
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400023
DA 2022-07-14
ER

PT J
AU Liang, CC
   Wang, HK
   Ke, Y
   Ji, WJ
AF Liang Cancan
   Wang Haikun
   Ke Yue
   Ji Wenjing
TI EXPRESSIONS OF TLR4 AND MYD88, AND THEIR CORRELATION WITH
   CLINICO-PATHOLOGICAL FEATURES IN PATIENTS WITH COLORECTAL CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE TLR4; MyD88; Colorectal cancer; Clinico-pathological features; Prognosis
ID ACTIVATION
AB Purpose: To investigate the expressions of TLR4 and MyD88, and their correlations with clinicopathological features in patients with colorectal cancer.
   Methods: A total of 234 patients were selected for this study and divided into two groups of 117 patients each, namely: study group (patients with colorectal cancer over a period of two years) and control (patients with normal intestinal mucosal tissues). They consisted of 68 males and 49 females aged between 29 and 67 years (mean age = 52 years). Patients in the study group were staged using TNM staging criteria for colorectal cancer Immunohistochemistry was used to determine the degree of expressions of Toll-like receptor 4 (71R4) and myeloid differentiation factor (MyD88) in colorectal cancer and normal mucosal tissues. The relationship between the expressions of TLR4 and MyD88, and clinical characteristics and prognosis was also assessed..
   Results: The expressions of TLR4 and MyD88 in colorectal cancer tissues were significantly higher (p < 0.05), when compared to control, and were positively correlated with TIVM staging, liver metastasis and vascular invasion. Patients with low expressions of T1124 and MyD88 had significantly longer (p < 0.05) survival time than those with high expressions, and the expressions of TLR4 and MyD88, and TNM staging had significant impact (p < 0.05) on the prognosis of colorectal cancer.
   Conclusion: There is a positive correlation between the expressions of TLR4 and MyD88, and clinic-pathological features such as TAM staging, metastasis, and vascular invasion of patients with colorectal cancer.
C1 [Liang Cancan; Ke Yue; Ji Wenjing] Xinjiang Med Univ, Dept Digest Internal Med, Affiliated Hosp 2, Xinjiang 830000, Peoples R China.
   [Wang Haikun] Xinjiang Med Univ, Dept Digest Internal Med, Affiliated Hosp 1, Xinjiang 830000, Peoples R China.
RP Liang, CC (corresponding author), Xinjiang Med Univ, Dept Digest Internal Med, Affiliated Hosp 2, Xinjiang 830000, Peoples R China.
EM fe1229@163.com
CR Cho JS, 2014, CLIN EXP ALLERGY, V133, P1038
   Echizen K, 2016, CANCER SCI, V107, P391, DOI 10.1111/cas.12901
   Haruki K, 2015, ANIMAL SCI J, V79, P11
   He AQ, 2016, INFLAMMATION, V39, P172, DOI 10.1007/s10753-015-0236-8
   Li DaoJuan, 2015, Cancer Research on Prevention and Treatment, V42, P305
   Li G, 2016, INT J MOL MED, V37, P99, DOI 10.3892/ijmm.2015.2410
   Markowitz SD, 2016, NEW ENGL J MED, V362, P1246
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Sun L., 2016, INTEGR CANC SCI THER, V3, P432
   Wang JQ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00367
   [伍振辉 Wu Zhenhui], 2017, [国际药学研究杂志, Journal of International Pharmaceutical Research], V44, P396
   Zheng Q, 2018, J CELL MOL MED
   [周少龙 Zhou Shaolong], 2015, [中华神经医学杂志, Chinese Journal of Neuromedicine], V14, P563
   江宁红(综述), 2015, [实用妇产科杂志, Journal of Practical Obstetrics and Gynecology], V31, P338
   姚宏伟, 2010, [中华外科杂志, Chinese Journal of Surgery], V48, P1601
NR 15
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1931
EP 1936
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400051
DA 2022-07-14
ER

PT J
AU Lin, FC
   Feng, WX
   Huang, DH
   Wu, YC
AF Lin, Facai
   Feng, Weixing
   Huang, Dehong
   Wu, Yunchuan
TI CHANGES OF SERUM IL-6 AND TNF-A AND THEIR RELATIONSHIPS WITH DEPRESSION
   SEVERITY IN PATIENTS WITH POST-STROKE DEPRESSION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE post-stroke depression; cytokine; interleukin-6; tumor necrosis
   factor-alpha; depression severity
ID INFLAMMATORY CYTOKINES; HYPOTHESIS; STROKE
AB Objective: To observe the changes of serum interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha) in patients with post-stroke depression (PSD), so as to explore their relationships with the depression severity of patients with PSD.
   Methods: A total of 92 patients diagnosed with PSD were selected and divided into mild, moderate and severe depression groups according to Hamilton Depression Scale (HAMD) scores. The expressions of serum IL-6 and TNF-alpha were detected, the relationships between the levels and normal level of serum IL-6 and TNF-alpha were compared, and the difference of serum IL-6 and TNF-alpha in patients with different-degree PSD were analyzed.
   Results: The levels of IL-6 and TNF-alpha were markedly higher in all groups than normal levels, and there were significant differences (P<0.01), which were the lowest in mild depression group and the highest in severe depression group, but there was insignificant difference among different groups (P>0.05).
   Conclusion: Serum IL-6 and TNF-alpha are in close association with the occurrence of PSD, which increase evidently along with the depression severity. However, there is insignificant relationship between the increase range of IL-6 and TNF-alpha and the depression severity.
C1 [Lin, Facai; Wu, Yunchuan] Nanjing Univ Chinese Med, Sch Clin Med 2, Nanjing 210023, Jiangsu, Peoples R China.
   [Feng, Weixing] Univ Chinese Med, Affiliated Hosp Shaanxi, Xianyang, Peoples R China.
   [Huang, Dehong] Guangzhou Hosp TCM, Dept Neurol, Guangzhou, Guangdong, Peoples R China.
RP Wu, YC (corresponding author), Nanjing Univ Chinese Med, Sch Clin Med 2, Nanjing 210023, Jiangsu, Peoples R China.
FU State Clinical Research Base of TCM; Second Batch of Professional Skill
   Scientific and Research Special Project [JDZX2015127]; Jiangsu Natural
   Science Foundation Youth Project [BK20171070]; Nanjing Scientific
   Development Planned Project [201402057]
FX State Clinical Research Base of TCM, The Second Batch of Professional
   Skill Scientific and Research Special Project(No. JDZX2015127); Jiangsu
   Natural Science Foundation Youth Project (No. BK20171070); Nanjing
   Scientific Development Planned Project (No. 201402057).
CR ang XM, 2011, J INT NEUROLOGY NEUR, V38, P280
   Anisman H, 2008, PROG NEUROBIOL, V85, P1, DOI 10.1016/j.pneurobio.2008.01.004
   Duan PX, 2011, CHIN J INTEGRATED ME, V9, P104
   Ghose SS, 2001, STROKE, V32, P364
   Kang HJ, 2016, PSYCHONEUROENDOCRINO, V72, P156, DOI 10.1016/j.psyneuen.2016.07.001
   Lin FC, 2014, J INT TRANSL MED, V2, P336
   [刘丹 Liu Dan], 2013, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V28, P47
   MAES M, 1995, PROG NEURO-PSYCHOPH, V19, P11, DOI 10.1016/0278-5846(94)00101-M
   Miao Y, 2007, ZHONG GUO KANG FU YI, V22, P696
   Munire Husaiyin, 2014, CHINESE J GERONTOLOG, V34, P6937
   Pascoe MC, 2011, INT J STROKE, V6, P128, DOI 10.1111/j.1747-4949.2010.00565.x
   Pucak ML, 2006, INT REV PSYCHIATR, V17, P477, DOI 10.1080/02646830500381757
   Spalletta G, 2006, MOL PSYCHIATR, V11, P984, DOI 10.1038/sj.mp.4001879
   Su JA, 2012, GEN HOSP PSYCHIAT, V34, P35, DOI 10.1016/j.genhosppsych.2011.09.020
   Tan Y, 2017, INT J CLIN EXP MED, V10, P1259
   Tang X, 2015, J NANTONG U MED SCI, V35, P401
   Williams LS, 2004, AM J PSYCHIAT, V161, P1090, DOI 10.1176/appi.ajp.161.6.1090
   Zhang XF, 2016, J HUAZHONG U SCI-MED, V36, P732, DOI 10.1007/s11596-016-1653-0
NR 18
TC 0
Z9 0
U1 1
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 403
EP 407
DI 10.19193/0393-6384_2018_2_64
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400018
DA 2022-07-14
ER

PT J
AU Liu, HX
AF Liu, Huixia
TI EFFECT OF HIGH-QUALITY NURSING SERVICE APPLIED TO ELDERLY PATIENTS WITH
   CEREBRAL INFARCTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE high-quality nursing service; senile cerebral infarction; nursing effect
ID EXTRACT
AB Objective: Since different nursing models applied to the elderly patients with cerebral infarction can get different effects, the paper explores the effect ofhigh-quality nursing service applied in the treatment for elderly patients with cerebral infarction.
   Methods: 120 elderly patients with cerebral infarction were randomly divided into two groups, namelyresearch group and reference group, both of which have 60 cases of patients respectively. The two groups of patients were given different nursing. The research groupreceived high-quality nursing, while the reference group only received routine nursing. The overall nursing effect of the two groups of patients were observed and compared.
   Results: Based on the comparison of the neurologic impairment degree of patients before and after operation, the MESSS score obtained by the research group after The MESSS score obtained by the research group after operation was significantly higher than that of the control group (P < 0.05); according to the Fugl-Meyer assessment(FMA) of extremity function disturbance, the research group had a better result than the reference group, with statistical significance (P < 0.05); as for the patients'daily life ability assessed with Barthelr index (MBI), the results showed that the daily life ability of the research group was significantly higher than that of the reference group (P < 0.05); the self-made nursing satisfaction questionnaire was adopted for survey and the results showed that theresearch grouphad a higher score than the reference group (P < 0.05).
   Conclusion: the high-quality nursing applied to patients with cerebral infarction can obtain good effect, thus it is worthy to be used in clinical practice nursing care.
C1 [Liu, Huixia] Third Peoples Hosp, CT Room, Shijiazhuang 050000, Hebei, Peoples R China.
RP Liu, HX (corresponding author), Third Peoples Hosp, CT Room, Shijiazhuang 050000, Hebei, Peoples R China.
EM 240870138@qq.com
CR Aldahlawi AM, 2016, SAUDI J BIOL SCI, V23, P101, DOI 10.1016/j.sjbs.2015.05.003
   Ali MA, 2016, SAUDI J BIOL SCI, V23, P229, DOI 10.1016/j.sjbs.2015.02.010
   [Anonymous], 2014, J HLTH ACAD EDITION, V7, P235
   Chensu, 2016, CLIN MED RES PRACTIC, V16, P158
   Hashem A, 2016, SAUDI J BIOL SCI, V23, P272, DOI 10.1016/j.sjbs.2015.11.002
   Hu Li, 2016, CHINESE J FEMALE HLT, V12, P106
   Hyun TK, 2016, SAUDI J BIOL SCI, V23, P181, DOI 10.1016/j.sjbs.2015.02.008
   Nowak R, 2016, SAUDI J BIOL SCI, V23, P15, DOI 10.1016/j.sjbs.2015.01.017
   Suxin, 2015, J QIQIHAR MED COLL, V18, P435
   Zhang Haiyan, 2016, CONT MED SCI, V22, P89
NR 10
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 279
EP 283
DI 10.19193/0393-6384_2018_1s_46
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100011
DA 2022-07-14
ER

PT J
AU Liu, J
   Yu, Q
AF Liu, Jie
   Yu, Qing
TI EFFECTS OF VALPROATE AND ADIPONECTIN ON BONE MINERAL DENSITY IN RATS
   WITH DIABETIC NEPHROPATHY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE diabetic nephropathy rats; bone mineral density; adiponectin; AdipoR1;
   osteoprotegerin
ID KIDNEY-DISEASE
AB Objective: This study aims to observe the effects of valproate and adiponectin on AdipoR1 and OPG expression in bone tissues of rats with diabetic nephropathy (DN), and investigate the protective (fleet of sodium valproate on osteoporosis caused by elevated adiponectin levels.
   Methods: The Wistar rat DN model was established. The DN model rats were randomly divided into three ,groups, and a control group was assigned at the same time. Twelve weeks later, rats were sacrificed; and 24-hour urine volume, blood glucose, blood urea nitrogen, creatinine, blood calcium, blood phosphorus and ALP were determined. Furthermore, plasma adiponectin in rats were measured by ELISA, 24-hour urinary albumin was determined by the immunoturbidimetric method, bone tissue structure was detected under a light microscope (LM), bone mineral density was determined by the dual energy X-ray method, and the expression of AdipoR1 and OPG in rat bone tissues were detected by immunohistochemical method.
   Results: AdipoR1 expression in rat bone tissues increased, and OPG expression decreased in the APN group. Furthermore, in the APN group, blood calcium and ALP expression significantly increased compared with the normal group (P<0.05). After the intervention of VPA, AdipoR1 expression in bone tissues decreased, the expression of OPG increased, and APN, calcium and ALP expression significantly decreased, compared with the APN group (P<0.05).
   Conclusion: Adiponectin may be involved in the development of DN osteoporosis. Sodium valproate may improve osteoporosis in DN rats through the inhibition of APN formation and the increasing of OPG.
C1 [Liu, Jie; Yu, Qing] Henan Univ, Huaihe Hosp, Dept Image, Kaifeng 475001, Peoples R China.
RP Yu, Q (corresponding author), Henan Univ, Dept Image, Huaihe Hosp, Package North Rd 8, Gulou Dist 475001, Kaifeng, Peoples R China.
EM qing_yudoc@163.com
CR Amemiya N, 2013, CLIN EXP NEPHROL, V17, P411, DOI 10.1007/s10157-012-0723-2
   Aoki A, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-11
   Bacchetta J, 2009, NEPHROL DIAL TRANSPL, V24, P3120, DOI 10.1093/ndt/gfp262
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Bozic B, 2010, J CARD FAIL, V16, P301, DOI 10.1016/j.cardfail.2009.12.015
   Galovicova A, 2012, Vnitr Lek, V58, P825
   Jin XG, 2013, KIDNEY INT, V83, P604, DOI 10.1038/ki.2012.408
   Kacso IM, 2012, SCAND J CLIN LAB INV, V72, P333, DOI 10.3109/00365513.2012.668928
   Kanazawa I, 2012, CURR MED CHEM, V19, P5481, DOI 10.2174/092986712803833146
   Lei Z, 2005, ZHONGGUO SHI YAN DON, V13, P163
   [刘幼硕 Liu Yaoshuo], 2008, [中华老年医学杂志, Chinese Journal of Geriatrics], V27, P114
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Markaki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052350
   Napoli Nicola, 2014, INT J ENDOCRINOL, V2014, P690
   Piccinin MA, 2014, ADIPOCYTE, V3, P263, DOI 10.4161/adip.32215
   Qiao LP, 2006, ENDOCRINOLOGY, V147, P865, DOI 10.1210/en.2005-1030
   Tunc I, 2000, J STORED PROD RES, V36, P161, DOI 10.1016/S0022-474X(99)00036-3
   Wu N, 2010, CLIN CHIM ACTA, V411, P771, DOI 10.1016/j.cca.2010.02.064
   Wu YY, 2015, INT J ORAL SCI, V7, P63, DOI 10.1038/ijos.2015.2
   [周银娥 Zhou Yine], 2012, [实用儿科临床杂志, Journal of Applied Clinical Pediatrics], V27, P1521
NR 21
TC 0
Z9 0
U1 2
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1677
EP 1683
DI 10.19193/0393-6384_2018_6_257
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400008
DA 2022-07-14
ER

PT J
AU Liu, JL
   Gao, XL
   Hou, CZ
   Zhu, L
   Xu, H
AF Liu, Jing-li
   Gao, Xiao-lin
   Hou, Cong-zhe
   Zhu, Lin
   Xu, Hui
TI DIAGNOSTIC SIGNIFICANCE OF CHANGES IN SERUM HUMAN EPIDIDYMIS EPITHELIAL
   SECRETORY PROTEIN 4 AND CARBOHYDRATE ANTIGEN 125 IN ENDOMETRIAL
   CARCINOMA PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Endometrial carcinoma; Serum human epididymal epithelial secretory
   protein 4; Carbohydrate antigen 125; Histological types
ID OVARIAN-CANCER; PROGNOSTIC ROLE; HE-4; CA125; BIOMARKER; MARKER
AB Objective: To study changes in serum human epididymis epithelial secretory protein 4(HE4) and carbohydrate antigen 125(CA125) in endometrial carcinoma (EC) patients, and the diagnostic significance of these changes.
   Methods: A total of 40 cases of EC patients were assigned to the EC group, 20 patients with endometrial hyperplasia were in the endometrial hyperplasia group, while 30 healthy subjects were in the control group. Changes in HE4 and CA125 levels in the three groups were analyzed before and after operation using ELISA. Positive expressions and sensitivity indicators were used to determine efficiency and relationship between the changes in serum HE4 and CA125, and histological grades and surgical staging.
   Results: Before operation, serum HE4 and CA125 levels in the EC group were significantly higher than those in the endometrial hyperplasia and control groups (p < 0.05). Serum HE4 and CA125 levels of endometrial hyperplasia group were significantly higher than those of the control group (p < 0.05), and the sensitivity of the combination of HE4 and CA125 in the diagnosis of EC was significantly higher than that of either marker alone (p < 0.05). Serum HE4 and CA125 levels in EC 7 days after operation were significantly lower than those before operation (p < 0.05). Analyses of histological types showed that the highest positive expression of HE4 was pathological grade 3 (G3) while the lowest positive expression of HE4 was G1 (p < 0.05); G3 was significantly higher than G2 (p < 0.05). In analyses of surgical stages, the highest positive expressions of HE4 and CA125 were stage., and the lowest were stage I (p < 0.05); stage. was significantly higher than stage.(p < 0.05). Serum HE4 and CA125 levels in the recurrence group at 18 and 24 months after operation were significantly higher than those in non-recurrence group (p < 0.05).
   Conclusion: Combined determination of serum HE4 and CA125 in the diagnosis of EC has high sensitivity. This has important clinical value for early diagnosis, and is useful for guiding operation and prognosis.
C1 [Liu, Jing-li; Gao, Xiao-lin; Hou, Cong-zhe; Zhu, Lin; Xu, Hui] Shandong Univ, Dept Obstet & Gynecol, Hosp 2, Jinan 250012, Shandong, Peoples R China.
RP Xu, H (corresponding author), Shandong Univ, Dept Obstet & Gynecol, Hosp 2, Jinan 250012, Shandong, Peoples R China.
EM xanhn6@163.com
CR Bian J, 2017, TECHNOL CANCER RES T, V16, P435, DOI 10.1177/1533034616666644
   [杨彩虹 Caihong YANG], 2011, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V38, P516
   Calis P, 2016, GYNECOL OBSTET INVES, V81, P518, DOI 10.1159/000444321
   Dong Dongli, 2017, SHANDONG MED J, V57, P73
   Fang YY., 2015, ANHUI MED J, V09, P1068
   Jiang T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1260-7
   Kalogera E, 2012, GYNECOL ONCOL, V124, P270, DOI 10.1016/j.ygyno.2011.10.025
   Knific T, 2017, GYNECOL ONCOL, V147, P126, DOI 10.1016/j.ygyno.2017.07.130
   Lewin SN, 2010, OBSTET GYNECOL, V116, P1141, DOI 10.1097/AOG.0b013e3181f39849
   Li X., 2015, BIOMED RES INT, V2015, P1, DOI DOI 10.1155/2015/824710
   Liu XG, 2015, ONCOTARGETS THER, V8, P1239, DOI 10.2147/OTT.S81853
   LUO Shu-ling, 2016, CHIN J LAB DIAGNOSIS, V20, P1490
   Modarres-Gilani M, 2017, CANCER BIOMARK, V20, P135, DOI 10.3233/CBM-160529
   Mutz-Dehbalaie I, 2012, GYNECOL ONCOL, V126, P186, DOI 10.1016/j.ygyno.2012.04.022
   Nagy B, 2016, CHEST, V150, P661, DOI 10.1016/j.chest.2016.04.006
   Nikolaou M, 2014, J BUON, V19, P198
   Soochit A, 2015, GYNECOL ONCOL, V137, P114, DOI 10.1016/j.ygyno.2015.01.284
   Stiekema A, 2015, GYNECOL ONCOL, V136, P562, DOI 10.1016/j.ygyno.2014.12.037
   Zamani Narges, 2015, J Family Reprod Health, V9, P177
   Zheng LE, 2016, OPEN MED-WARSAW, V11, P125, DOI 10.1515/med-2016-0024
NR 20
TC 1
Z9 1
U1 2
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 785
EP 789
DI 10.19193/0393-6384_2018_3_120
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000025
DA 2022-07-14
ER

PT J
AU Liu, K
AF Liu, Kun
TI EFFECT OF BUSHEN JIANPI HUOXUE RECIPE ON TIBIAL STRESS INJURIES IN
   RABBITS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Bushen Jianpi Huoxue Recipe; tibial stress injury in rabbit running
AB The study was aimed to study the preventive effect of Bushen Jianpi Huoxue recipe on tibial stress injury in rabbits. In this research, seventy mature male rabbits were divided randomly and equally into 7 groups with each group containing 10 rabbits. All the mature male rabbits were participated in the passive running and jumping before they undergone the radio nuclide bone imaging and tibial X-ray findings. The histological and electron microscopic changes were observed, and each of the parathyroid hormone (PTH), osteocalcin (BGP) and testosterone concentration (T) was measured. After 2 weeks of continuous stimulation, the trends of stress injury in osteocytes, serum parathyroid hormone and osteocalcin have increased, while serum testosterone is showing an obvious decreasing trend. After three to four weeks, the X-ray, radionuclide bone imaging, histology, and blood biochemistry were carried out on the rabbits. The results showed stress injuries have occurred in the rabbits. In the two medication groups, the X-ray and nuclide bone showed the formation of new bone in the cortex; osteoblastic phase existed in bone cells; serum parathyroid hormone decreased significantly; while serum osteocalcin and blood testosterone level of the rabbits were higher as compared to exercise group in the same week. It can be concluded that Bushen Jianpi Huoxue recipe can be used to treat the tibial stress injury in rabbits effectively by stimulating the new bone formation and enhance the blood testosterone level.
C1 [Liu, Kun] Soochow Univ, Sch Phys Educ, Suzhou 215021, Peoples R China.
   [Liu, Kun] Jiangxi Univ Tradit Chinese Med, PE Dept, Nanchang 330004, Jiangxi, Peoples R China.
RP Liu, K (corresponding author), Soochow Univ, Sch Phys Educ, Suzhou 215021, Peoples R China.; Liu, K (corresponding author), Jiangxi Univ Tradit Chinese Med, PE Dept, Nanchang 330004, Jiangxi, Peoples R China.
EM liuk0791@163.com
CR Attari Z, 2016, SAUDI PHARM J, V24, P57, DOI 10.1016/j.jsps.2015.03.008
   Balkhair KS, 2016, SAUDI J BIOL SCI, V23, pS83, DOI 10.1016/j.sjbs.2015.10.029
   Cankilic MY, 2017, BIOMED RES-INDIA, V28, P3108
   Chen You-xue, 2008, Zhong Xi Yi Jie He Xue Bao, V6, P738, DOI 10.3736/jcim20080715
   Ding X. Q., 2012, EFFECTS JUMPING BONE
   El-Jakee JK, 2016, SAUDI J BIOL SCI, V23, P48, DOI 10.1016/j.sjbs.2015.06.011
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   Hazra M, 2015, SAUDI PHARM J, V23, P429, DOI 10.1016/j.jsps.2015.01.007
   Moty SGA, 2016, SAUDI PHARM J, V24, P119, DOI 10.1016/j.jsps.2013.12.016
   Ofori-Kwakye K, 2016, SAUDI PHARM J, V24, P82, DOI 10.1016/j.jsps.2015.03.005
   Oliveira MTA, 2016, SAUDI J BIOL SCI, V23, P34, DOI 10.1016/j.sjbs.2015.02.001
   Sharma V, 2017, ARAB J CHEM, V10, P509, DOI 10.1016/j.arabjc.2014.08.019
   Sui Y. H., 2014, EFFECT BUSHEN YIQI H
   Sun LX, 2016, SAUDI J BIOL SCI, V23, P66, DOI 10.1016/j.sjbs.2015.10.005
   Wroblewska K, 2015, SAUDI PHARM J, V23, P407, DOI 10.1016/j.jsps.2014.11.009
   Xia J. Y., 2014, CLIN OBSERVATION BUS
   Yu X. M., 2014, EFFECT YIQI BUSHEN H
NR 18
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 233
EP 237
DI 10.19193/0393-6384_2018_1s_38
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100003
DA 2022-07-14
ER

PT J
AU Liu, LM
AF Liu, Lamei
TI EFFECTS OF TRANSITIONAL CARE ON FUNCTIONAL EXERCISE: COMPLIANCE AND
   HEALTH STATUS OF STROKE PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Transitional care; stroke; functional exercise; health status
ID RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY; MENTAL-HEALTH;
   OLDER-ADULTS; SURVIVORS; OUTCOMES; INTERVENTION; DISABILITY; INFECTION;
   ADHERENCE
AB Background: Stroke is the leading cause of morbidity, mortality, and disability among adults in China. There are more than 2 million new stroke patients every year, more than 1.8 million deaths from stroke each year, and a 75% disability rate among survivors. After hospital treatment, transitional care could help ensure improved patient care and outcomes and reduce medical costs and readmission rates. Nevertheless, the intervention effect of transitional care on the functional exercise compliance and health status of stroke patients has not been reported in mainland China.
   Objectives: To examine the effectiveness of a nurse-led transitional care model on the functional exercise compliance and health status of Chinese stroke patients.
   Methods: The sample comprised 40 Chinese stroke patients. The intervention group (n = 20) received one month of nurse-led transitional care intervention, which included discharge assessment and a personalized transitional care plan and health education for the patients based on the results of the assessment, followed by 1 month of individual guidance (home visits and telephone follow-up). The control group (n = 20) received routine instructions at discharge, including instructions on functional exercise, daily care, dietary guidance, psychological care, and medication guidance. Functional exercise compliance and health status were monitored in both groups before the intervention and one, three, and six months after the end of transitional care to evaluate the intervention out-comes.
   Results: No significant between-group differences were observed in functional exercise compliance or health status before the intervention was conducted. One month after the intervention, functional exercise compliance and health status were significantly improved in the intervention group, with significant between-group differences in all but one dimension: social functioning. Three months after the intervention, functional exercise compliance and four dimensions of health status - physical functioning (PF), role limitations due to physical health problems (RP), general health perceptions (GH), and mental health (MH) - were significantly improved in the intervention group compared with the control group. Six months after the intervention, only the active advice-seeking of functional exercise compliance and the GH of health status were significantly improved in the intervention group compared with the control group.
   Conclusion: A nurse-led transitional care intervention effectively improved the early functional exercise compliance and health status of stroke patients. However, the intervention effect decreased with time after the intervention, and the long-term effect was not ideal.
C1 [Liu, Lamei] Zhengzhou Univ, Sch Nursing, Dept Clin Teaching & Res, 100 Sci Ave, Zhengzhou 450000, Henan, Peoples R China.
RP Liu, LM (corresponding author), Zhengzhou Univ, Sch Nursing, Dept Clin Teaching & Res, 100 Sci Ave, Zhengzhou 450000, Henan, Peoples R China.
FU Henan Province Medical and Academic Technological Leaders Overseas
   Training Program [2011027]; Zhengzhou University School of Nursing
   "Emerging Nursing Discipline" Priority Program
FX This research was financially supported by the Henan Province Medical
   and Academic Technological Leaders Overseas Training Program (2011027)
   and the Zhengzhou University School of Nursing "Emerging Nursing
   Discipline" Priority Program, which the authors greatly appreciate.
CR Altfeld S, 2012, GENERATIONS, V36, P98
   ANDRESEN E, 1997, ASSESSING HLTH STATU
   Bettger JP, 2012, BETTGER TRANSITIONAL
   Coleman EA, 2004, J AM GERIATR SOC, V52, P1817, DOI 10.1111/j.1532-5415.2004.52504.x
   Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822
   Droste Dirk W, 2004, Bull Soc Sci Med Grand Duche Luxemb, P17
   Himi N, 2016, J STROKE CEREBROVASC, V25, P2987, DOI 10.1016/j.jstrokecerebrovasdis.2016.08.017
   Hirschman Karen B, 2015, Online J Issues Nurs, V20, P1
   Inc S, 2011, IBM SPSS STAT WINDOW
   Inoue A, 2017, J STROKE CEREBROVASC, V26, P741, DOI 10.1016/j.jstrokecerebrovasdis.2016.10.009
   Ji Y, 2009, J PRACTICAL MED, V25, P311
   Jones F, 2005, BRIT J HEALTH PSYCH, V10, P359, DOI 10.1348/135910704X24798
   Kinoshita S, 2015, J STROKE CEREBROVASC, V24, P1019, DOI 10.1016/j.jstrokecerebrovasdis.2014.12.026
   Kranciukaite-Butylkiniene D, 2009, MED LITH, V45, P896, DOI 10.3390/medicina45110115
   Liu-Ambrose T, 2015, J STROKE CEREBROVASC, V24, P130, DOI 10.1016/j.jstrokecerebrovasdis.2014.08.012
   Lui KC, 2009, HONG KONG PHYSIOTHER, V27, P30, DOI 10.1016/S1013-7025(10)70006-3
   Miller CM, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0679-9
   Mora K, 2017, J AM ASSOC NURSE PRA, V29, P773, DOI 10.1002/2327-6924.12509
   Munyombwe T, 2014, QUAL LIFE RES, V23, P2267, DOI 10.1007/s11136-014-0681-0
   Naylor MD, 2014, J COMP EFFECT RES, V3, P245, DOI [10.2217/CER.14.14, 10.2217/cer.14.14]
   Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x
   Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613
   Nicholson SL, 2014, DISABIL REHABIL, V36, P1857, DOI 10.3109/09638288.2013.874506
   Ostwald SK, 2016, AGING HLTH, V4, P241
   Prlic N, 2012, ACTA CLIN CROAT, V51, P601
   Puhr MI, 2015, J NEUROSCI NURS, V47, P223, DOI 10.1097/JNN.0000000000000143
   Sandberg K, 2016, ARCH PHYS MED REHAB, V97, P1244, DOI 10.1016/j.apmr.2016.01.030
   [盛晗 Sheng Han], 2016, [中华护理杂志, Chinese Journal of Nursing], V51, P712
   Shim R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010064
   Tang Y, 2007, CHINESE J REHABILITA, V13, P69
   van Exel J, 2003, COST EFFECT RESOUR A, V1, P1
   Vellone E, 2010, Ann Ig, V22, P469
   Wong FKY, 2015, HEALTH SOC CARE COMM, V23, P619, DOI 10.1111/hsc.12177
   Xu X., 2014, CHINESE J PRACTICAL, V17, P123
   张振香, 2012, [中国老年学杂志, Chinese Journal of Gerontology], V32, P3976
NR 35
TC 0
Z9 0
U1 5
U2 16
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 959
EP 965
DI 10.19193/0393-6384_2018_4_146
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500009
DA 2022-07-14
ER

PT J
AU Liu, M
   Gao, BH
   Lv, BQ
   Qin, CL
   Kou, GN
AF Liu, Meng
   Gao, Bing-Hong
   Lv, Bing-Qiang
   Qin, Chun-Li
   Kou, Guang-Ning
TI CITRUS FRUIT INTAKE DECREASES THE RISK OF INCIDENT TYPE 2 DIABETES: A
   SYSTEMATIC REVIEW AND META-ANALYSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Citrus fruits; TypeIIdiabetes; Risk; Meta-analysis; women
ID CORONARY-HEART-DISEASE; VEGETABLE CONSUMPTION; DIETARY FIBER;
   INSULIN-RESISTANCE; NUTRITIONAL EPIDEMIOLOGY; OXIDATIVE STRESS;
   MELLITUS; HEALTH; COHORT; WOMEN
AB Objective: Increasing total fruit consumption is often used in the management of typeII diabetes. However, so far we are not know the orange whether effective reduce the incidence of typeIIdiabetes so the target of this study was to review and conduct quantitative analyses of the results from expected cohort researches which assessed the correlation between the citrus ingestion and the risk of typeII diabetes.
   Materials and methods: The research team identified the pertinent studies by a systematical search in PubMed, Embase, Science Direct and Cochrane Library up to May 2017. Furthermore, the reseachers also used the random-effect model to combine the study-specific results and the subgroup analyses. Sensitivity analyses were also carried out. Researchers used the funnel plot of beg for estimating publication bias. Publication bias was estimated by using Begg's funnel plot.
   Results: This study selected a total 13 prospective studies that included 415462 participants from eight publications. The combined relative risk (RR) of type II diabetes for the highest versus the lowest category of the citrus fruit intake were 0.85 (95% CI, 0.78-0.92; p = 0.0001) for the incidence of all typeII diabetes events, and the correlation of subgroup analysis with sex, region, duration of follow-up, amount of cases and study quality was highly consistent with the overall data. For female subjects, there are exsit significant protective associations that between the citrus intake and the type II diabetes risk (RR, 0.83; 95% CI, 0.73-0.93; p = 0.000). The studies with follow-up were longer than 10 years (RR, 0.81; 95% CI, 0.73-0.89; p = 0.001). No publication bias was found.
   Conclusions: These results indicate that the consumption of citrusis inversely correlated with the risk of typeIIdiabetes, especially for female.
C1 [Kou, Guang-Ning] Southwest Univ, Coll Hort & Landscape Architecture, Chongqing, Peoples R China.
   [Liu, Meng; Lv, Bing-Qiang; Qin, Chun-Li] Chongqing Adm Sport, Chongqing Inst Sport Sci, Chongqing, Peoples R China.
   [Kou, Guang-Ning] Chongqing Southwest Inst Fruit Nutr, Chongqing, Peoples R China.
   [Liu, Meng; Lv, Bing-Qiang; Qin, Chun-Li; Kou, Guang-Ning] Lab Phys Fitness Evaluat & Performance Monitoring, Chongqing, Peoples R China.
   [Gao, Bing-Hong; Kou, Guang-Ning] Shanghai Sport Univ, Shanghai, Peoples R China.
RP Kou, GN (corresponding author), Southwest Univ, Coll Hort & Landscape Architecture, Chongqing, Peoples R China.; Kou, GN (corresponding author), Chongqing Southwest Inst Fruit Nutr, Chongqing, Peoples R China.; Kou, GN (corresponding author), Lab Phys Fitness Evaluat & Performance Monitoring, Chongqing, Peoples R China.
EM kouguangning@sina.com
FU Chongqing program for production of late maturing Citrus fruits
   [20184-4]; Chongqing sports bureau RD project [A2017014]; Fundamental
   Research Funds for the Central Universities [XDJK2017D087]
FX This work was financially supported by Chongqing program for production
   of late maturing Citrus fruits (20184-4); Chongqing sports bureau R&D
   project (A2017014); Fundamental Research Funds for the Central
   Universities (XDJK2017D087).
CR Alwan A, 2011, GLOBAL STATUS REPORT ON NONCOMMUNICABLE DISEASES 2010, P9
   Boeing H, 2013, EUR J CLIN NUTR, V67, P424, DOI 10.1038/ejcn.2013.47
   Carter Patrice, 2010, BMJ, V341, pc4229, DOI 10.1136/bmj.c4229
   Ceriello A, 2004, ARTERIOSCL THROM VAS, V24, P816, DOI 10.1161/01.ATV.0000122852.22604.78
   Chen LW, 2012, DIABETES CARE, V35, P1079, DOI 10.2337/dc11-2105
   Cooper AJ, 2012, EUR J CLIN NUTR, V66, P1082, DOI 10.1038/ejcn.2012.85
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X
   Dauchet L, 2006, J NUTR, V136, P2588, DOI 10.1093/jn/136.10.2588
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gillies CL, 2007, BMJ-BRIT MED J, V334, P299, DOI 10.1136/bmj.39063.689375.55
   Gordon MH, 1996, NAT PROD REP, V13, P265, DOI 10.1039/np9961300265
   Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002
   Hamer M, 2007, J HYPERTENS, V25, P2361, DOI 10.1097/HJH.0b013e3282efc214
   Harding AH, 2008, ARCH INTERN MED, V168, P1493, DOI 10.1001/archinte.168.14.1493
   He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0
   Holt EM, 2009, J AM DIET ASSOC, V109, P414, DOI 10.1016/j.jada.2008.11.036
   Keogh RH, 2013, STAT MED, V32, P3838, DOI 10.1002/sim.5803
   Kurotani K, 2013, BRIT J NUTR, V109, P709, DOI 10.1017/S0007114512001705
   Lattimer JM, 2010, NUTRIENTS, V2, P1266, DOI 10.3390/nu2121266
   Li J, 2014, EUR REV MED PHARMACO, V18, P1778
   Li S, 2017, EUR REV MED PHARMACO, V21, P3490
   Li SS, 2015, ENDOCRINE, V48, P454, DOI 10.1007/s12020-014-0351-6
   Liese AD, 2003, AM J CLIN NUTR, V78, P965, DOI 10.1093/ajcn/78.5.965
   Liu SM, 2004, DIABETES CARE, V27, P2993, DOI 10.2337/diacare.27.12.2993
   Liu SM, 2003, AM J CLIN NUTR, V78, P920, DOI 10.1093/ajcn/78.5.920
   Meyer KA, 2000, AM J CLIN NUTR, V71, P921
   Montonen J, 2005, EUR J CLIN NUTR, V59, P441, DOI 10.1038/sj.ejcn.1602094
   Muraki I, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5001
   Mursu J, 2014, AM J CLIN NUTR, V99, P328, DOI 10.3945/ajcn.113.069641
   NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306
   Pereira MA, 2004, ARCH INTERN MED, V164, P370, DOI 10.1001/archinte.164.4.370
   Roza JM, 2007, ALTERN THER HEALTH M, V13, P44
   Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101
   Villegas R, 2008, J NUTR, V138, P574, DOI 10.1093/jn/138.3.574
   Waterman C, 2015, MOL NUTR FOOD RES, V59, P1013, DOI 10.1002/mnfr.201400679
NR 35
TC 1
Z9 1
U1 1
U2 14
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1743
EP 1749
DI 10.19193/0393-6384_2018_6_267
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400018
DA 2022-07-14
ER

PT J
AU Liu, QY
   Li, JF
   Liang, X
AF Liu, Qi-yu
   Li, Jian-feng
   Liang, Xun
TI COMPARISON OF THE CLINICAL EFFICACY BETWEEN THE EARLY ENTERAL NUTRITION
   AND PARENTERAL NUTRITION ON PATIENTS AFTER LIVER TRANSPLANTATION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Liver transplantation; EN; PN
ID BACTERIAL; DISEASE; IMPACT
AB Objective: To investigate the clinical efficacy of early enteral nutrition (EN) on patients after liver transplantation.
   Methods: For 55 patients who received the liver transplantation, EN (n=27, Group EN) or parenteral nutrition (n=28, Group PN) was respectively provided for nutrition support within 48 h after operation. The levels of indicators, like serum albumin (ALB), alanine aminotransferase (ALT), aspartic transaminase (AST), prealbumin (PA), lymphocyte count (LC) and total bilirubin (TBIL), were measured at 1st and 9th days after operation, and the results were compared between two groups. Besides, we also compared the incidence of infection, mechanical ventilation duration, length of stay in intensive care unit (ICU) and postoperative length of stay in hospital within 2 weeks after operation between the two groups.
   Results: Differences in comparison of the laboratory indicators at the 1st day after operation showed no statistical significance (p>0.05), but when it came to the 9th day after operation, the levels of ALB, PA and LC in Group EN were significantly higher than those in the Group PN (p<0.05); comparisons of the remaining indicators between the two groups showed that the differences had no statistical significance, but were significantly decreased when compared with the levels at the 1st day after operation. Within 2 weeks after operation, the incidence rate of infection in the group EN was significantly lower than that in the Group PN (p<0.05), and the levels of IgA and IgM in the Group EN were higher than those in the Group PN (p<0.05). Comparisons of the mechanical ventilation duration and length of stay in ICU also showed that the differences were not statistically significant (p>0.05). However, after operation, the length of stay in hospital in the Group EN was significantly shorter than that in the Group PN (p<0.05).
   Conclusion: EN support should be provided for patients who received the liver transplantation as early as possible, which can effectively improve the nutrition status and immunological function of patients, and significantly reduce the incidence rate, thus accelerating the postoperative recovery.
C1 [Liu, Qi-yu] Kunming Med Univ, Peoples Hosp Kunming 1, Ganmei Affiliated Hosp, Kunming, Yunnan, Peoples R China.
   [Li, Jian-feng] First Peoples Hosp Wenling, Dept Gen Surg, Taizhou, Zhejiang, Peoples R China.
RP Liang, X (corresponding author), JiangSu Collge Nursing, Dept Special Nursing, 9 Ave Sci & Technol, Huaian, Jiangsu, Peoples R China.
EM liangxun_w@126.com
CR Dhaliwal R, 2014, NUTR CLIN PRACT, V29, P29, DOI 10.1177/0884533613510948
   Ikegami T, 2012, J AM COLL SURGEONS, V214, P288, DOI 10.1016/j.jamcollsurg.2011.12.001
   Jiang ZM, 1999, JPEN-PARENTER ENTER, V23, pS62, DOI 10.1177/014860719902300516
   Lochs H, 1999, Curr Opin Clin Nutr Metab Care, V2, P345, DOI 10.1097/00075197-199907000-00017
   MAYNARD ND, 1991, BRIT MED J, V303, P1007, DOI 10.1136/bmj.303.6809.1007
   Merli M, 2010, LIVER INT, V30, P208, DOI 10.1111/j.1478-3231.2009.02135.x
   Mtiller M J, 1994, CLIN NUTR, V13, P145
   Patel R, 2001, LIVER TRANSPLANT, V7, P752, DOI 10.1053/jlts.2001.0070752
   Singh N, 1998, Semin Gastrointest Dis, V9, P136
   Stickel F, 2008, NUTR REV, V66, P47, DOI 10.1111/j.1753-4887.2007.00005.x
   Garcia-Rodriguez MT, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0232-3
   Torre-Cisneros J, 2002, EUR J CLIN MICROBIOL, V21, P385, DOI 10.1007/s10096-002-0725-1
   Vieira PM, 2013, NUTR HOSP, V28, P1615, DOI 10.3305/nh.2013.28.5.6563
   WADE JJ, 1995, HEPATOLOGY, V21, P1328, DOI 10.1002/hep.1840210517
   WILMORE DW, 1988, SURGERY, V104, P917
   Windsor ACJ, 1998, GUT, V42, P431, DOI 10.1136/gut.42.3.431
NR 16
TC 3
Z9 2
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 859
EP 863
DI 10.19193/0393-6384_2018_3_131
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000035
DA 2022-07-14
ER

PT J
AU Liu, W
   Zhao, P
   Li, Q
   Wang, Q
   Cheng, Y
   Zhu, XD
AF Liu, Wei
   Zhao, Peng
   Li, Qi
   Wang, Qian
   Cheng, Yan
   Zhu, Xiaodong
TI THE TOXIC EFFECT OF ROTENONE ON THE MESENCEPHALIC ASTROCYTES AND
   DOPAMIN-ERGIC NEURON MICROENVIRONMENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Parkinson's disease (PD); astrocvte; rotenone; GSH; LDH; GDNF
ID PARKINSONS-DISEASE; NEUROTROPHIC FACTOR; SUBSTANTIA-NIGRA; GDNF; RAT;
   NEUROPROTECTION; APOPTOSIS; STRIATUM; CULTURES; DEATH
AB In the present study, we applied the mitochondrial complex 1 inhibitor rotenone to in vitro cultured astrocytes and examined the changes in lactate dehydrogenase (LDH) activity and the glutathione (GSH) level to determine whether glycolysis was elevated by the resulting dysfunction in oxidative phosphorylation, enhancement cif oxygen free radical production and reduction in GSH in the astrocytes. Glial cell line-derived neurotrophic factor (GDNF) has a protective effect on dopaminergic neurons. Western blot was performed to examine whether GDNF expression was altered after rotenone treatment. After short-term exposure cif astrocvtes (11 h Ito low dose cif rotenone (20, 30, and 40 nM), LDH activity was increased in all rotenone treatment groups compared to the control group and there was significant difference in LDH activity between the rotenone treatment groups and the control group. Additionally, the 40 nM group displayed a decreased GSH level, whereas the other two groups did not significantly differ from the control group. GDNF expression was decreased in all rotenone treatment groups compared to the control group and there was significant difference in GDNF expression between the rotenone treatment ,croups and the control, croup and the group treated with 40nM rotenone showed more significant difference than the others After the dopaminergic neurons were treated with 50 mu M 6-OHDA and the supernatant cif astrocyte treated with different rotenone concentration for 24 hours, the cell viability of the groups treated with different concentration of rotenone has distinguished difference than control group. As the increase of the rotenone's concentration, the cell viability treated with rotenone decreased. The above results demonstrated that rotenone treatment damaged the astrocytes that constituted the midbrain microenvironment. As a result, the production of oxygen free radicals was increased, the GSH and GDNF level was reduced, thus damaging dopaminergic neurons.
C1 [Liu, Wei; Zhao, Peng; Li, Qi; Cheng, Yan; Zhu, Xiaodong] Tianjin Med Univ, Dept Neurol, Gen Hosp, Tianjin 300052, Peoples R China.
   [Wang, Qian] Tianjin Med Univ, Tianjin Neurol Inst, Dept Neuropathol, Gen Hosp, Tianjin 300052, Peoples R China.
   [Wang, Qian] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin 300052, Peoples R China.
   [Wang, Qian] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China.
RP Zhu, XD (corresponding author), Tianjin Med Univ, Dept Neurol, Gen Hosp, Tianjin 300052, Peoples R China.
EM zxd3516@163.com
FU Tianjin Municipal Science and Technology Commission Foundation
   [15JCYBJC50000]
FX This study was supported by Tianjin Municipal Science and Technology
   Commission Foundation Grants 15JCYBJC50000
CR Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Connor B, 1999, GENE THER, V6, P1936, DOI 10.1038/sj.gt.3301033
   Giasson BI, 2000, NAT NEUROSCI, V3, P1227, DOI 10.1038/81737
   Jaumotte JD, 2016, EUR J NEUROSCI, V44, P1691, DOI 10.1111/ejn.13252
   LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557
   Marchetti B, 2013, EUR J NEUROSCI, V37, P1550, DOI 10.1111/ejn.12166
   MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890
   McNaught KSP, 2000, NEUROSCI LETT, V285, P61, DOI 10.1016/S0304-3940(00)00982-4
   McNaught KSP, 1999, J NEUROCHEM, V73, P2469, DOI 10.1046/j.1471-4159.1999.0732469.x
   Mytilineou C, 1999, J NEUROCHEM, V73, P112, DOI 10.1046/j.1471-4159.1999.0730112.x
   Revishchin A, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0271-x
   Rosenblad C, 2000, EXP NEUROL, V161, P503, DOI 10.1006/exnr.1999.7296
   Rossi D, 2015, PROG NEUROBIOL, V130, P86, DOI 10.1016/j.pneurobio.2015.04.003
   Seaton TA, 1997, BRAIN RES, V777, P110
   Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001
   Vanacore N, 2002, NEUROL SCI, V23, pS119, DOI 10.1007/s100720200098
   Zhao YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106867
NR 17
TC 0
Z9 0
U1 2
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1799
EP 1804
DI 10.19193/0393-6384_2018_6_276
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400027
DA 2022-07-14
ER

PT J
AU Liu, Y
   Liu, HF
   Wei, JW
   Zhang, CX
   Wang, DC
AF Liu, Yang
   Liu, Haifei
   Wei, Jianwei
   Zhang, Cunxin
   Wang, Dechun
TI CPN-9 PROTECTS RABBIT NUCLEUS PULPOSUS CELLS FROM XANTHURENIC
   ACID-INDUCED CYTOTOXICITY BY ACTIVATING THE NRF2/ARE PATHWAY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Rabbit nucleus pulposus cells; Xanthurenic acid; Cytotoxicity; CPN-9;
   Nrf2/ARE pathway
ID KYNURENINE PATHWAY; DEATH
AB Xanthurenic acid as the metabolite of tryptophan can induce the cytotoxicity and damage of nucleus pulposus cells. In addition, it was reported that N-(4-(2-pyridyl)(1,3-thiazol-2-yl))-2-(2,4,6-trimethylphenoxy) acetamide (CPN-9) played a pivotal role in oxidative stress-induced cell death by activating the Nrf2/ARE pathway. Therefore, it was of significance to investigate on mechanism of CPN-9 resisting xanthurenic acid-induced cytotoxicity. Cells used in this research were isolated from rabbit nucleus pulposus, analyzed by the growth curve and staining identifications. Hematoxylin eosin staining, toluidine blue, immunohistochemistry and immunofluorescent staining were performed to observe the cellular morphology. Furthermore, cell proliferative and apoptosis activities were detected by CCK-8 methods and AV-PI double-staining, respectively. Simultaneously, the expressions of Nrf2, ATF3, HO-1 and NQO1 were measured by western blot in this investigation. By analysis of growth curve plotting, cells isolated from nucleus pulposus growed in pattern of "S" in 1-5 generation. Staining observations revealed that nucleus pulposus cells were not only triangular, polygonal and short spindle shaped, but also cell nucleus was relatively large. The CCK-8 research demonstrated that xanthurenic acid had adverse effects on cell proliferative activity. Simultaneously, CPN-9(<= 40 mu M) resisted the impairments induced by xanthurenic acid and exerted protective effect on proliferative activity, consistent with the apoptosis results. Furtherly, the expressions of Nrf2, ATF3, HO-1 and NQO1 were elevated by injection of CPN-9. CPN-9 protects rabbit nucleus pulposus cells against xanthurenic acid-induced cytotoxicity by activating the Nrf2/ARE pathway.
C1 [Liu, Yang; Liu, Haifei; Wei, Jianwei; Wang, Dechun] Qingdao Univ, 308 Ningxia Rd, Qingdao 266061, Peoples R China.
   [Liu, Yang] Zhucheng Peoples Hosp, Joint Surg, Zhucheng, Weifang, Peoples R China.
   [Zhang, Cunxin] Jining 1 Peoples Hosp Univ, Emergency Trauma Surg, Jining, Peoples R China.
RP Wang, DC (corresponding author), Qingdao Univ, 308 Ningxia Rd, Qingdao 266061, Peoples R China.
EM dechunwang123@aliyun.com
FU Natural Science Foundation of China [21472104]
FX Natural Science Foundation of China (No. 21472104).
CR Arkesteijn ITM, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0569-6
   Chen Z, 2016, ONCOTARGET, V7, P19272, DOI 10.18632/oncotarget.8189
   Ding F, 2012, APOPTOSIS, V17, P579, DOI 10.1007/s10495-012-0708-3
   Haruki H, 2016, J BIOL CHEM, V291, P652, DOI 10.1074/jbc.C115.680488
   Hwang PY, 2015, CELL MOL BIOENG, V8, P1
   Jang M, 2016, MOL NEUROBIOL, V53, P2619, DOI 10.1007/s12035-015-9230-2
   Kanno T, 2012, FREE RADICAL BIO MED, V53, P2028, DOI 10.1016/j.freeradbiomed.2012.09.010
   Li CQ, 2009, P NATL ACAD SCI USA, V106, P14547, DOI 10.1073/pnas.0907539106
   LIPSON SJ, 1981, SPINE, V6, P194, DOI 10.1097/00007632-198105000-00002
   Malina H Z, 2001, BMC Physiol, V1, P7, DOI 10.1186/1472-6793-1-7
   Murakami K, 2006, BIOMETALS, V19, P429, DOI 10.1007/s10534-005-4528-6
   Nikitczuk KP, 2010, NANO LIFE, V1, P239, DOI 10.1142/S1793984410000171
   Notarangelo FM, 2016, J NEUROCHEM, V136, P804, DOI 10.1111/jnc.13455
   Roussel G, 2016, NEUROSCIENCE, V329, P226, DOI 10.1016/j.neuroscience.2016.05.006
   Shao L, 2010, HETEROATOM CHEM, V19, P2
   Song H, 2011, INT IMMUNOPHARMACOL, V11, P932, DOI 10.1016/j.intimp.2011.02.005
   Wang QX, 2015, FRONT BIOSCI-LANDMRK, V20, P1116, DOI 10.2741/4363
   Wu B, 2016, BIOMED PHARMACOTHER, V84, P754, DOI 10.1016/j.biopha.2016.09.077
   Xing HY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145183
NR 19
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1419
EP 1427
DI 10.19193/0393-6384_2018_5_216
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700038
DA 2022-07-14
ER

PT J
AU LouXin, BM
   Fangxiaoyan, MMS
AF LouXin, BaiMing
   Fangxiaoyan, MiaoMingsan
TI EFFECT OF ARCTIIN ON RAT HYPERURICEMIA MODEL
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hyperuricemic nephropathy; Animal model; Adenine; Ethambutol
AB Objective: To observe the effect of urchin on rat hyperuricemia model, and to explore the intervention effect and mechanism of arctiin on hyperuricemic nephropathy.
   Methods: Adopt the method of adenine and ethambutol joint application to establish the rat model of hyperuricemia.
   Conclusion: Arctiin can significantly reduce serum uric acid(UA), creatine (Cr), Urea nitrog en (BUN), Tumor necrosis factor-alpha (TNF-alpha), Mononuclear chemotactic protein -1 (MCP-1) level, xanthine oxidase (XOD) activity, the level of cyclooxygenase -2 (COX-2) in the renal tissue homogenate,and it can significantly reduce the degree of pathological injury of the thymus, spleen and kidney tissue. Results: Arctiin is effective for the treatment of hvperuricemia.
C1 [LouXin, BaiMing; Fangxiaoyan, MiaoMingsan] Henan Univ Tradit Chinese Med Zhengzhou, Zhengzhou 450046, Henan, Peoples R China.
RP LouXin, BM (corresponding author), Henan Univ Tradit Chinese Med Zhengzhou, Zhengzhou 450046, Henan, Peoples R China.
CR [陈星华 Chen Xinghua], 2012, [中国全科医学, Chinese General Practice], V15, P3083
   Chen yanming, 2017, BEIJING U CHINESE ME
   di Laio, 2016, AGR U SHENYANG
   Du xiaorang, 2012, J CHANGCHUN U TRADIT, V28, P264
   Li juan, 2012, J CLIN RATIONAL DRUG, V5, P120
   Li X, 2016, J CHEM, V2016, P1, DOI DOI 10.1016/J.CHEM0SPHERE.2016.01.074
   Liu yonggui, 2015, MODERN MED CLIN, V30, P345
   Wang tian, 2011, HEBEI J TRADITIONAL, V33, P466
   Wei wanchuan, 2014, BEIJING U CHINESE ME
   Wu weigang, 2014, ZHEJIANG J TRADITION, V49, P323
   Yu shuyan, 2014, HENAN COLL TRADITION
   Zeng xiaoyan, 2014, CHINESE WILD PLANT R, V33, P6
NR 12
TC 1
Z9 1
U1 12
U2 25
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1739
EP 1742
DI 10.19193/0393-6384_2018_6_266
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400017
DA 2022-07-14
ER

PT J
AU Lu, H
   Lu, YQ
   Zhu, FF
AF Lu Hui
   Lu Yiqun
   Zhu Fenfen
TI ANALYSIS OF THE EFFECT OF PEER SUPPORT ON THE LIFE QUALITY OF PATIENTS
   WITH TYPE 2 DIABETIC NEPHROPATHY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Type 2 diabetic nephropathy; Patients; Peer support; Quality of life
AB Objective: To investigate and analyze the effect of peer support on the quality of life of patients with type 2 diabetic nephropathy.
   Methods: One hundred and eighty (180) cases of patients with type 2 diabetic nephropathy diagnosed and treated in The First Affiliated Hospital of Soochow University, China, from February 2014 to October 2016 were selected and divided into study and control groups by lot. The control group was given routine treatment only, while the study group received additional intervention and peer support. After 6 months of intervention, the scores in diabetic clinical indicators, behavioral indicators and the overall quality of life in the two groups of patients were evaluated.
   Results: There was no significant difference in FPG, HbA1c, TAG, TC and other indicators as well as scores in various functions and overall quality of life before and after the intervention in the control group (p > 0.05). FPG, HbA1c, TG, TC and other indicators after intervention in the study group were significantly higher than their levels before intervention. FPG, HbA1c, TG, TC and other indicators as well as scores in various functions and overall quality of life after the intervention in the study group were also significantly higher than those of the control group (p < 0.05). There was no significant difference in the scores obtained in evaluation of diabetes-related problems and the WHO happiness index, before and after the intervention in the control group (p > 0.05). The scores in diabetes related problems of the study group were significantly lower than those before the intervention, while the scores in the WHO happiness index were all significantly higher than those before the intervention (p < 0.05). However, after intervention, the scores in diabetes-related problems in the study group were significantly lower than those of the control group, while the scores in the WHO happiness index were all significantly higher than those of the control group (p < 0.05).
   Conclusion: Peer support influence various clinical indices in type 2 diabetic nephropathy patients. It improves their psychological states, increases their self - management ability and sense of happiness. In addition, peer support improves quality of life of the patients, and so could be recommended for wider clinical application.
C1 [Lu Hui; Zhu Fenfen] Soochow Univ, Affiliated Hosp 1, Suzhou Vocat Hlth Coll, Dept Clin Med Sci Nursing,Int Nursing, Suzhou, Peoples R China.
   [Lu Yiqun] Soochow Univ, Affiliated Hosp 1, Dept Endocrinol, Suzhou, Peoples R China.
RP Lu, H (corresponding author), 28 Kehua Rd, Suzhou, Jiangsu, Peoples R China.
EM fb1349@163.com
CR Aihua Song, 2014, NURS RES, V28, P4518
   Browning C, 2011, CHINESE GEN MED, V14, P345
   Browning C, 2011, CHINE GEN MED, V14, P3189
   Chinese Diabetes Society, 2014, CHINESE J ENDOCRINOL, V30, P26
   Dennis CL, 2003, INT J NURS STUD, V40, P321, DOI 10.1016/S0020-7489(02)00092-5
   Duncan I, 2011, DIABETES EDUCATOR, V37, P638, DOI 10.1177/0145721711416256
   Hongchang Li, 2016, J TAISHAN MED COLL, V37, P306
   Jieqiong Xia, 2011, CHINESE J MODERN NUR, V17, P1109
   Udell JA, 2015, DIABETES CARE, V38, P696, DOI 10.2337/dc14-1850
   Wei Wei, 2015, CHINESE MODERN MED A, V9, P261
   Xiaojia Zhang, 2015, CHIN J NURSING, V50, P313
   Xiue Liao, 2014, NURS RES, V28, P503
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   Yufang Jiang, 2016, NURS RES, V30, P1660
   Yungu Liu, 2013, INT J NURSING, V32, P136
NR 15
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1155
EP 1159
DI 10.19193/0393-6384_2018_4_178
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500041
DA 2022-07-14
ER

PT J
AU Luping
   Bo, S
AF LuPing
   Bo, Shi
TI EFFECT OF BAICALEIN ON PCNA EXPRESSION DURING THE DEVELOPMENT OF MURINE
   FORESTOMACH CARCINOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Baicalein; Murine fore-stomach carcinoma; Proliferating cellular nuclear
   antigen (PCNA); Dynamic animal models
ID CELLS; APOPTOSIS; EXTRACTS; RADIX
AB Introduction: To investigate the effect of baicalein on Proliferating cellular nuclear antigen (PCNA) expression in dynamic process of murine fore-stomach carcinoma.
   aterials and methods: Dynamic animal models of murine fore-stomach carcinoma were established with the equal volume mixing (abbreviated as NSEE) of Sacrosine-ehylester-hydrochlorid and Sodium nitrite as a mutagen. 90 NIH mice (SPF) was divided into blank control group, the negative control group, high (1000mg kg(-1)), medium (500mg kg(-1)) and low (200mg kg(-1)) dose groups with baicalein (dissolved with 0.5% sodium carboxymethyl cellulose solution). In the experiment, all group were treated with NSEE, twice a week for six weeks by gavage, without the blank group (with equal volume of 0.9% saline). Meanwhile, all interventional groups with Baicalein were treated with baicalein solution by gavage once a day. The fore-stomach tissues were taken on 28th, 5 6th and 84th day for pathological observation. The PCNA expression in the fore-stomach tissues was observed by immunohistochemistry.
   Results: Compared with the blank control group, for interventional group, fore-stomach tissues was gradually evolves from hyperplastic lesions to atypical hyperplasia, or even carcinoma in situ, and the PCNA expression in the negative control group increases significantly (P < 0.01) by immunohistochemistry. Compared with the negative control group, the situation is the slightest in high dose group by pathological sections at 84d, the experimental results by immunohistochemistry showed that PCNA expression of high, medium and low dose baicalein intervention groups was significantly different from that of model group (P < 0.01), but there was no significant difference among the groups.
   Conclusion: High, medium and low doses of baicalein can significantly inhibit NSEE-induced fore-stomach cancer carcinogenesis in mice, which may be related to down-regulation of PCNA expression.
C1 [LuPing; Bo, Shi] Henan Univ Chinese Med, Sch Pharm, Zhengzhou, Henan, Peoples R China.
RP Bo, S (corresponding author), Henan Univ Chinese Med, Sch Pharm, Zhengzhou, Henan, Peoples R China.
EM xiaosehanfeng@126.com
FU Foundation for University Key Teacher by Henan Province [2014GGJS-070]
FX This paper is one of phase achievements in key scientific research
   project (No. 2014GGJS-070) of Foundation for University Key Teacher by
   Henan Province in 2014.
CR Chen CH, 2000, NUTR CANCER, V38, P287, DOI 10.1207/S15327914NC382_19
   Fei SJ, 2003, CHINA ONCOLOGY, V13, P17
   KIMURA Y, 1981, CHEM PHARM BULL, V29, P2308
   Lee HZ, 2005, ANTICANCER RES, V25, P959
   Lin CC, 1996, AM J CHINESE MED, V24, P31, DOI 10.1142/S0192415X96000050
   Liu Mei, 2014, Chinese Journal of Immunology, V30, P353
   Lu YJ, 2011, J AGR FOOD CHEM, V59, P10934, DOI 10.1021/jf202741x
   Ma XC, 2016, MED J W CHINA, V28, P430
   Ma Z, 2005, BLOOD, V105, P3312, DOI 10.1182/blood-2004-10-3915
   Miocinovic R, 2005, INT J ONCOL, V26, P241
   Song HJ, 2015, CHINA MED PHARM, V5, P28
   Wang Qizhang, 2005, SURG ESOPHAGUS, P87
   Wang Shijie, 2008, CARCINOMA ESOPHAGUS, V1, P8
   Xiang M, 2012, J MODERN ONCOLOGY, V20, P1098
   Yang Y, 2017, J SE U MED SCI EDI, V36, P155
   Zhang HB, 2013, ONCOL LETT, V5, P722, DOI 10.3892/ol.2012.1069
   Zhang HX, 2005, J HENAN NORMAL U NAT, V34, P116
NR 17
TC 0
Z9 0
U1 1
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 543
EP 546
DI 10.19193/0393-6384_2018_2_86
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GC0AJ
UT WOS:000429437100002
DA 2022-07-14
ER

PT J
AU Ma, JH
   Li, SW
AF Ma Junhong
   Li Shengwen
TI DECREASED EXPRESSION OF THE SPECKLE-TYPE POZ PROTEIN IS ASSOCIATED WITH
   POOR PROGNOSIS IN BLADDER CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE SPOP; Tumor suppressor; bladder cancer
ID UROTHELIAL CARCINOMA; SOMATIC MUTATIONS; UBIQUITIN LIGASE; SPOP;
   PROSTATE; RECEPTOR; GENE; COMPLEX; DAXX
AB Introduction: Bladder cancer is one of the most common malignancies in the genitourinary system, and the incidence tends to increase year by year. Despite tremendous progress in diagnosis and traditional treatment, the prognosis of patients, especially locally advanced or muscle-invasive bladder cancer remains poor. Currently many molecular biomarkers are considered to be assoisated with the occurrence of bladder cancer. The Speckle-type POZ protein, SPOP, is an E3 ubiquitin ligase adaptor, and it is found to inhibit oncogenic signaling in other cancers. However, the molecular mechanisms in bladder cancer are less reported.
   Methods: In this study, we characterized the expression of SPOP in 46 pairs of bladder cancer tissues and adjacent tissues by immunohistochemical staining and Western blotting. The relationship between SPOP expression and clinicalpathologic factors was analyzed. Transfected bladder cancer cell lines T24 were used in cell viability, migration and wound healing assays to investigate the role of tumor suppression mechanism.
   Results: Immunohistochemical staining of SPOP can be detected in bladder cancer tissues but much less than adjacent bladder tissues (P < 0.01). High SPOP expression is negatively correlated with lymph node metastasis, poor histological differentiation, and tumor malignancy according to TAM staging. In vitro inhibition of SPOP markedly promoted cell viability, migration and invasion in vitro in bladder cancer cell lines. Likewise, overexpression of SPOP inhibited cell viability; migration and proliferation.
   Conclusions: Our findings indicate that SPOP might act as a tumor suppressor and may have potential use as novel biomarker of bladder cancer, and can provide an alternative strategy for developing therapeutic agents of bladder cancer in future.
C1 [Ma Junhong; Li Shengwen] Tsinghua Univ, Affiliated Hosp 1, Dept Urol, 6 Jiuxianqiao 1St, Beijing 100016, Peoples R China.
RP Ma, JH (corresponding author), Tsinghua Univ, Affiliated Hosp 1, Dept Urol, 6 Jiuxianqiao 1St, Beijing 100016, Peoples R China.
EM majh_1@163.com
CR An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013
   Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279
   Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744
   Cheng L, 2009, MODERN PATHOL, V22, pS70, DOI 10.1038/modpathol.2009.1
   Ding DC, 2015, INT J ONCOL, V46, P333, DOI 10.3892/ijo.2014.2729
   Ferlay J, 2013, GLOBOCAN 2012 V1 0 C
   Geng C, 2013, P NATL ACAD SCI USA, V110, P6997, DOI 10.1073/pnas.1304502110
   Grignon DJ, 2009, MODERN PATHOL, V22, pS60, DOI 10.1038/modpathol.2008.235
   Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256
   Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102
   Huang Y, 2015, TUMOUR BIOL
   Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208
   Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8
   Kim MS, 2013, APMIS, V121, P626, DOI 10.1111/apm.12030
   Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200
   La M, 2004, BIOCHEM BIOPH RES CO, V320, P760, DOI 10.1016/j.bbrc.2004.06.022
   Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455
   Li C, 2011, ONCOGENE, V30, P4350, DOI 10.1038/onc.2011.151
   Li GQ, 2014, CANCER CELL, V25, P455, DOI 10.1016/j.ccr.2014.02.007
   Luo JH, 2008, INT J CANCER, V122, P2554, DOI 10.1002/ijc.23399
   Matsushita K, 2011, INT J UROL, V18, P616, DOI 10.1111/j.1442-2042.2011.02809.x
   Nagai Y, 1997, FEBS LETT, V418, P23, DOI 10.1016/S0014-5793(97)01340-9
   Netto GJ, 2012, NAT REV UROL, V9, P41, DOI 10.1038/nrurol.2011.193
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Theurillat JPP, 2014, SCIENCE, V346, P85, DOI 10.1126/science.1250255
   Vinnedge LMP, 2011, ONCOGENE, V30, P2741, DOI 10.1038/onc.2011.2
   Zeng CY, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0075-8
   Zhao Q, 2012, INT J CLIN EXP PATHO, V5, P422
   Zhao W, 2014, J BIOL CHEM, V289, P11219, DOI 10.1074/jbc.M113.535989
   Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022
NR 30
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1981
EP 1990
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400060
DA 2022-07-14
ER

PT J
AU Mahmoud, SAA
   Atoum, MF
   Al-Hourani, HM
   Bateineh, S
   Abderrahman, S
   Alzoughool, F
AF Mahmoud, Sameer Ahmed Al Haj
   Atoum, Manar Fayiz
   Al-Hourani, Huda Mustafa
   Bateineh, Sajedah
   Abderrahman, Salim
   Alzoughool, Foad
TI VITAMIN D DEFICIENCY AND RS731236(TAQ1) VITAMIN D RECEPTOR GENE
   POLYMORPHISM AS POSSIBLE RISK FACTORS FOR RHEUMATOID ARTHRITIS AND
   OSTEOARTHRITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE osteoarthritis; rheumatoid arthritis; serum 25-hydroxyvitamin D
ID 25-HYDROXYVITAMIN D; JORDANIANS; CLASSIFICATION; METAANALYSIS;
   ASSOCIATION; DISEASES; BSMI; APAI; TAQI
AB Introduction: Epidemiological evidence indicates a significant association between vitamin D deficiency and an increased incidence of autoimmune diseases. The role of vitamin D and the vitamin D receptor (VDR) on rheumatic arthritis (RA) and osteoarthritis (OA) health has recently been placed in the spotlight. The aim of this study is to investigate any association between circulating vitamin D level and rs731236 (Taq1) vitamin D receptor gene polymorphism among Jordanian Rheumatic arthritis and osteoarthritis patients.
   Methods: this study enrolled one hundred and eighty four RA patients, one hundred and fifty four OA patients and two hundred healthy Jordanians from Prince Hamzah Hospital/Amman (2013-2015). 25-hydroxyvitamin D (25 (OH) D) level was determined by competitive immunoassay. DNA was extracted from whole blood for all samples and control, PCR was amplified using specific primers, rs731236 (Taq1) VDR restriction digestion was carried out for Taq1 genotyping
   Results: 25 (OH) D level was statistically lower among RA and OA patients (12.03 +/- 3.21, 11.88 +/- 4.63 ng/mL,) compared to the healthy controls (21.32 +/- 3.12 and 21.51 +/- 3.46 ng/mL; respectively). 25 (OH) D within rs731236(Taq1) VDR TT genotype among RA patients (11.67 +/- 3.24) was statistically lower than its control (21.23 +/- 3.43). Statistical difference was found in 25 (OH) D level within TT genotype among the OA patients (12.63 +/- 4.31 ng/mL) compared to its control (21.41 +/- 3.32 ng/mL).
   Conclusion: This study showed that there is statistically significant decrease in the mean vitamin D level among both RA and OA patients compared to control, and rs731236(Taq1)VDR TT genotype may be a possible risk factors for both RA and OA.
C1 [Mahmoud, Sameer Ahmed Al Haj] Hashemite Univ, Fac Med, Zarqa, Jordan.
   [Atoum, Manar Fayiz; Bateineh, Sajedah; Alzoughool, Foad] Hashemite Univ, Fac Allied Hlth Sci, Dept Med Lab Sci, Zarqa, Jordan.
   [Al-Hourani, Huda Mustafa] Hashemite Univ, Fac Allied Hlth Sci, Clin Nutr & Dietet, Zarqa, Jordan.
   [Abderrahman, Salim] Hashemite Univ, Fac Sci, Dept Biol & Biotechnol, Zarqa, Jordan.
RP Atoum, MF (corresponding author), Hashemite Univ, Fac Allied Hlth, Dept Med Lab Sci, Zarqa, Jordan.
EM manar@hu.edu.jo
RI Mahmoud, Sameer Alhaj/AAA-3971-2020; Atoum, Manar Fayiz/AEN-1598-2022
OI ALZOUGHOOL, FOAD/0000-0001-5772-3830
FU Hashemite University, Zarqa, Jordan [27/2011]
FX All this work is supported and carried out at the Hashemite University,
   Zarqa, Jordan Grant number: (27/2011)
CR Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   Alkan G, 2017, J BACK MUSCULOSKELET, V30, P897, DOI 10.3233/BMR-160589
   Atoum MF, 2017, BREAST CANCER-TARGET, V9, P45, DOI 10.2147/BCTT.S125652
   Atoum Manar Fayiz, 2015, Asian Pac J Cancer Prev, V16, P2227
   Atoum MF, 2014, ASIAN PAC J CANCER P, V15, P7337, DOI 10.7314/APJCP.2014.15.17.7337
   Balato A, 2013, ARCH DERMATOL RES, V305, P255, DOI 10.1007/s00403-013-1327-8
   Barg A, 2013, FOOT ANKLE CLIN, V18, P411, DOI 10.1016/j.fcl.2013.06.001
   Cao YL, 2013, RHEUMATOLOGY, V52, P1323, DOI 10.1093/rheumatology/ket132
   Castillo EC, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/156563
   Chandrashekara S, 2017, INT J RHEUM DIS, V20, P825, DOI 10.1111/1756-185X.12770
   Cutolo M, 2011, AUTOIMMUN REV, V11, P84, DOI 10.1016/j.autrev.2011.08.003
   Glover TL, 2012, ARTHRITIS RHEUM-US, V64, P3926, DOI 10.1002/art.37687
   Hussien YM, 2013, MOL BIOL REP, V40, P3675, DOI 10.1007/s11033-012-2443-9
   HUSTMYER FG, 1993, HUM MOL GENET, V2, P487, DOI 10.1093/hmg/2.4.487
   Lee YH, 2016, CLIN EXP RHEUMATOL, V34, P827
   Levin GP, 2012, JAMA-J AM MED ASSOC, V308, P1898, DOI 10.1001/jama.2012.17304
   Liu HF, 2014, EXP BIOL MED, V239, P559, DOI 10.1177/1535370213514920
   Mallah EM, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-8
   Sabbagh Z, 2013, NUTRIENTS, V5, P2268, DOI 10.3390/nu5072268
   Tetlow LC, 2001, OSTEOARTHR CARTILAGE, V9, P423, DOI 10.1053/joca.2000.0408
   Wang X, 2017, OSTEOARTHR CARTILAGE, V25, P1304, DOI 10.1016/j.joca.2017.02.804
   Ishikawa LLW, 2017, CLIN REV ALLERG IMMU, V52, P373, DOI 10.1007/s12016-016-8577-0
   Yazici D, 2013, MINERVA ENDOCRINOL, V38, P195
   Zheng ZH, 2016, AM J CLIN EXP IMMUNO, V5, P48
NR 24
TC 3
Z9 3
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 209
EP 213
DI 10.19193/0393-6384_2018_1_34
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600034
DA 2022-07-14
ER

PT J
AU Mai, XC
   Ding, L
   Xu, YF
   Ceng, P
   Tao, D
AF Mai, Xuan-cheng
   Ding, Lei
   Xu, Yong-fang
   Ceng, Peng
   Tao, Dan
TI EFFECTS OF SPERM MORPHOLOGY AND TOTAL MOTILE SPERMATOZOA NUMBER ON THE
   RATE OF PREGNANCY THROUGH ARTIFICIAL INSEMINATION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Sperm morphology; total motile spermatozoa number; IUI; clinical
   pregnancy rate
ID INTRAUTERINE INSEMINATION
AB Objective: To investigate correlation of pregnancy rate through intrarauterine insemination (IUI) with the ratio of normal sperm and total motile spermatozoa number (A and B).
   Methods: A retrospective study was carried out with the IUI data of 330 cycles between January 1st and August 31st in 2017 to compare the effects of the ratio of normal sperm and total motile spermatozoa number (A and B) on the pregnancy rates of IUI.
   Results: a) For patients with normal sperm ratio less than 6%, their clinical pregnancy rate of IUI was significantly different from those with normal sperm ratio between 6% and 10%, or not less than 10% (p<0.05); b) during the treatment cycle, the clinical pregnancy rates of patients whose total motile spermatozoa numbers were not less than 10x106 and those whose total motile spermatozoa numbers were less than 10x106 were 21.6% and 9.2% before and after ovulation, and the difference had statistical significance (p<0.05); for those whose total motile spermatozoa numbers before ovulation were not less than 10x106, and after ovulation were less than 10x106, their pregnancy rate was 14.8%, which was also significantly different from those rates above (p<0.05).
   Conclusion: a) A high clinical pregnancy rate can be attained in IUI for those whose ratio of normal sperm is not less than 6%; b) IUI requires that seminal fluid should contain at least 10x106 sperms in total motile spermatozoa number, and the inseminations before and after ovulation are similar in importance.
C1 [Mai, Xuan-cheng; Ding, Lei; Xu, Yong-fang; Ceng, Peng; Tao, Dan] First Peoples Hosp Yunnan Prov, Dept Reprod Med, Kunming, Yunnan, Peoples R China.
RP Tao, D (corresponding author), Kunming Univ Sci & Technol, Fac Environm Sci & Engn, Dept Ophthalmol, Kunming Childrens Hosp, 288 Qian Xing Rd, Kunming, Yunnan, Peoples R China.
EM taodan1975@163.com
CR Bonnet R, 2004, ATLAS HUMAN SPERM MO, P27
   Guven S, 2008, J REPROD MED, V53, P257
   Lee RKK, 2002, INT J ANDROL, V25, P277, DOI 10.1046/j.1365-2605.2002.00355.x
   MACLEOD J, 1951, FERTIL STERIL, V2, P394
   Merviel P, 2010, FERTIL STERIL, V93, P79, DOI 10.1016/j.fertnstert.2008.09.058
   Nuojua-Huttunen S, 1999, HUM REPROD, V14, P698, DOI 10.1093/humrep/14.3.698
   Van Voorhis BJ, 2001, FERTIL STERIL, V75, P661, DOI 10.1016/S0015-0282(00)01783-0
   Wainer R, 2004, HUM REPROD, V19, P2060, DOI 10.1093/humrep/deh390
   Wiser A, 2012, REPROD BIOMED ONLINE, V24, P170, DOI 10.1016/j.rbmo.2011.11.007
   Yavuz A, 2013, IRAN J REPROD MED, V11, P227
NR 10
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 883
EP 887
DI 10.19193/0393-6384_2018_3_135
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000039
DA 2022-07-14
ER

PT J
AU Mal-Amir, MD
   Jahangirnejad, M
   Mandegari, M
   Rajaei, E
   Nokhostin, F
AF Mal-Amir, Dargahi M.
   Jahangirnejad, M.
   Mandegari, M.
   Rajaei, E.
   Nokhostin, F.
TI COMPARISON OF PERIODONTAL PARAMETERS IN OSTEOPENIC AND OSTEOPOROTIC
   PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Osteopenic; Osteoporotic; Periodontal Parameters
ID BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; DISEASE; ASSOCIATION; RISK
AB Introduction: Osteoporosis is a bone disease, which is common in ageing people. In addition, periodontal disease is seen in the elderly population. The loss of bone structures is a common feature of both diseases. The aim of this study is an evaluation of the relationship between osteoporosis and periodontal disease.
   Material and methods: The cross-sectional study was done in 2016 in 78 patients who referred to a bone densitometry center of the Golestan hospital in Ahwaz-Iran. Patients divided into three study groups include healthy, osteopenic and osteoporotic (each group consists of 26 patients). Dual X-ray Absorption was used for evaluation of osteoporosis and for evaluation of dental criteria, five factors include number of teeth, periodontal pocket depth, clinical attachment loss, place Index and bleeding on probing were determined. For Comparison SPSS software, ANOVA, and chi-square (x(2)) was used.
   Results: Mean age of patients was 49.31 +/- 12.78 include 15 men and 63 women. According to results, number of teeth (p<0.01), periodontal pocket depth (p=0.000) and clinical attachment loss (p=0.001) have a significant relationship with osteoporosis while a significant relationship between bleeding on probing and osteoporosis is not observed.
   Conclusion: Results indicate that osteoporosis is not the causative agent of periodontal disease. However, due to its impact on clinical attachment loss it can be considered as a risk factor for periodontal disease.
C1 [Jahangirnejad, M.] Ahvaz Jundishapur Univ Med Sci, Dept Periodontol, Ahvaz, Iran.
   [Mandegari, M.] Ahvaz Jundishapur Univ Med Sci, Res Comm, Ahvaz, Iran.
   [Rajaei, E.] Ahvaz Jundishapur Univ Med Sci, Dept Rheumatol, Ahvaz, Iran.
   [Nokhostin, F.] Ahvaz Jundishapur Univ Med Sci, Internal Med, Ahvaz, Iran.
   [Mal-Amir, Dargahi M.] Ahvaz Jundishapur Univ Med Sci, Internal Dept, Pulmonol, Ahvaz, Iran.
RP Rajaei, E (corresponding author), Ahvaz Jundishapur Univ Med Sci, Dept Rheumatol, Ahvaz, Iran.
EM elhamrj@gmail.com
RI Rajaei, Elham/AAD-1682-2020
OI Dargahi-Malamir, Mehrdad/0000-0002-4449-3359
CR Adams D F, 1992, Curr Opin Dent, V2, P33
   Al Habashneh R, 2010, J PERIODONTOL, V81, P1613, DOI 10.1902/jop.2010.100190
   Anwar RB, 2007, J DENT RES, V86, P52, DOI 10.1177/154405910708600108
   Bergstrom J, 2000, J CLIN PERIODONTOL, V27, P61, DOI 10.1034/j.1600-051x.2000.027001061.x
   Carranza FA, 2015, CLIN PERIODONTOLOGY, P454
   Chapple ILC, 2009, J AM DENT ASSOC, V140, P178, DOI 10.14219/jada.archive.2009.0131
   Cole R., 2008, FEMALE PATIENT, V33
   Esfahanian V, 2014, J ISFAHAN DENT SCH, V10, P353
   Flemmig T F, 1999, Ann Periodontol, V4, P32, DOI 10.1902/annals.1999.4.1.32
   Gharibdost F., 2002, OSTEOPROSIS, P217
   Haghighati F., 2006, J TEHRAN U MED SCI, P20
   Healt-care, WHAT AR SYMPT OST
   Javid AZ, 2014, J HUM NUTR DIET, V27, P523, DOI 10.1111/jhn.12184
   Khorsand A., 2005, J TEHRAN U MED SCI
   Lai Yu-Lin, 2004, J Chin Med Assoc, V67, P387
   Lalla E, 2007, J CLIN PERIODONTOL, V34, P294, DOI 10.1111/j.1600-051X.2007.01054.x
   Mattson John S, 2002, Compend Contin Educ Dent, V23, P1001
   Mellado-Valero A, 2010, MED ORAL PATOL ORAL, V15, pE52, DOI 10.4317/medoral.15.e52
   MICHALOWICZ BS, 1991, J PERIODONTOL, V62, P293, DOI 10.1902/jop.1991.62.5.293
   Michalowicz BS, 2000, J PERIODONTOL, V71, P1699, DOI 10.1902/jop.2000.71.11.1699
   Nishida M, 2000, J PERIODONTOL, V71, P1057, DOI 10.1902/jop.2000.71.7.1057
   Pilgram TK, 2002, J PERIODONTOL, V73, P298, DOI 10.1902/jop.2002.73.3.298
   Sculley DV, 2003, CLIN SCI, V105, P167, DOI 10.1042/CS20030031
   Sultan N, 2011, MED ORAL PATOL ORAL, V16, pE440, DOI 10.4317/medoral.16.e440
   Taguchi A, 2005, MENOPAUSE, V12, P144, DOI 10.1097/00042192-200512020-00007
   van der Velden U, 2005, PERIODONTOL 2000, V39, P13, DOI 10.1111/j.1600-0757.2005.00127.x
   Vishwanath S B, 2011, Indian J Dent Res, V22, P270, DOI 10.4103/0970-9290.84303
   WAHNER HW, 1994, EVALUATION OSTEOPORO
   White SC, 2002, DENTOMAXILLOFAC RAD, V31, P84, DOI 10.1038/sj.dmfr.4600674
   Yoshihara A, 2004, J CLIN PERIODONTOL, V31, P680, DOI 10.1111/j.1600-051X.2004.00548.x
NR 30
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1289
EP 1293
DI 10.19193/0393-6384_2018_5_198
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700020
DA 2022-07-14
ER

PT J
AU Maldonato, MN
   Sperandeo, R
   Dell'Orco, S
   Iennaco, D
   Cerroni, F
   Romano, P
   Salerno, M
   Maltese, A
   Roccella, M
   Parisi, L
   Tripi, G
   Moscatelli, F
   Sessa, F
   Monica, S
   Cibelli, G
   Messina, G
   Monda, M
   Chieffi, S
   Villano, I
   Monda, V
   Messina, A
   Ruberto, M
   Marsala, G
   Valenzano, A
   Marotta, R
AF Maldonato, Mauro N.
   Sperandeo, Raffaele
   Dell'Orco, Silvia
   Iennaco, Daniela
   Cerroni, Francesco
   Romano, Palmira
   Salerno, Margherita
   Maltese, Agata
   Roccella, Michele
   Parisi, Lucia
   Tripi, Gabriele
   Moscatelli, Fiorenzo
   Sessa, Francesco
   Monica, Salerno
   Cibelli, Giuseppe
   Messina, Giovanni
   Monda, Marcellino
   Chieffi, Sergio
   Villano, Ines
   Monda, Vincenzo
   Messina, Antonietta
   Ruberto, Maria
   Marsala, Gabriella
   Valenzano, Anna
   Marotta, Rosa
TI MIND, BRAIN AND ALTERED STATES OF CONSCIOUSNESS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Consciousness; global workspace; time; memory; mid-brain; alterated
   states
ID ACUTE BILIARY PANCREATITIS; SLEEP-APNEA SYNDROME; NEURAL OSCILLATIONS;
   CHILDHOOD MIGRAINE; VEGETATIVE STATE; DISORDERS; CHILDREN; COMA;
   SYNCHRONY; AURA
AB The consciousness is the expression of an enormous and complex variety of neurobiological events, phenomenological and psychological that, from the early stages of development, prepare the emergence soil of the Self. It is a complex of tangible and intangible characters distinct from one another - neural infrastructure, awareness, temporality, qualitative subjectivity, intentionality - to such an extent as to seem welded faces of the same prism. Consciousness is not a simple function of the mind, but its organization. In this paper we intend to show how its order is not strictly hierarchical, but sustained by multiple horizontal levels, each of which in a structural and functional continuum with several emerging phenomena. The same distinction between quantitative aspects (surveillance) and qualitative (content of consciousness) of consciousness is founded on the premise that the supervision is regulated by widespread in projection systems of the brain stem, hypothalamus and thalamus; while the content of consciousness depends on the cortical activity, and particularly from the associative areas of the cortex connected between them. The so-called disturbances of consciousness (vegetative state, the minimally conscious state, a coma, the Locked in syndrome) suggests the existence of an alteration of a common underlying system. Although the current heterogeneity of the data makes it impossible to attribute with certainty whether positive or negative about the alleged absence of consciousness in the individual patient, the search is deriving significant benefits from the accumulation of neuroimaging evidence in paintings like coma, general anesthesia, sleep, epilepsy and somnambulism. In this sense, it seems increasingly urgent a deeper understanding of the neural correlates during sleep or general anesthesia, as well as the relationships between neural processes and altered states of consciousness generated by pharmacological manipulations.
C1 [Maldonato, Mauro N.; Iennaco, Daniela] Univ Naples Federico II, Naples, Italy.
   [Sperandeo, Raffaele] SIPGI Scuola Specializzaz Psicoterapia Gestalt In, Genoa, Italy.
   [Maldonato, Mauro N.; Sperandeo, Raffaele; Dell'Orco, Silvia] Univ Basilicata, Potenza, Italy.
   [Cerroni, Francesco; Romano, Palmira] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Naples, Italy.
   [Marotta, Rosa] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Salerno, Margherita; Maltese, Agata; Roccella, Michele; Parisi, Lucia; Tripi, Gabriele] Univ Palermo, Dept Psychol & Pedag Sci, Child Neuropsychiat, Palermo, Italy.
   [Moscatelli, Fiorenzo; Sessa, Francesco; Monica, Salerno; Cibelli, Giuseppe; Messina, Giovanni; Valenzano, Anna] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Monda, Marcellino; Chieffi, Sergio; Villano, Ines; Monda, Vincenzo; Messina, Antonietta] Univ Campania Luigi Vanvitelli, Dept Expt Med, Sect Human Physiol, Naples, Italy.
   [Monda, Marcellino; Chieffi, Sergio; Villano, Ines; Monda, Vincenzo; Messina, Antonietta] Univ Campania Luigi Vanvitelli, Unit Dietet & Sports Med, Naples, Italy.
   [Ruberto, Maria] Ctr CRD, Naples, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Struttura Complessa Farm, Foggia, Italy.
RP Valenzano, A (corresponding author), Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
EM anna.valenzano@unifg.it
RI Sessa, Francesco/G-1754-2018; Messina, Giovanni/AAE-8668-2022; Cibelli,
   Giuseppe/AAC-2635-2019; Messina, Antonietta/AHH-2383-2022; Moscatelli,
   Fiorenzo/ABC-9536-2020; MALDONATO, NELSON MAURO/AAG-3791-2021; Marotta,
   Rosa/AAG-1453-2020; MESSINA, ANTONIETTA/K-9366-2016
OI Sessa, Francesco/0000-0003-0357-8791; Messina,
   Giovanni/0000-0002-0011-867X; Messina, Antonietta/0000-0001-8343-432X;
   MALDONATO, NELSON MAURO/0000-0002-6401-2305; Sperandeo,
   Raffaele/0000-0002-8892-179X; VILLANO, INES/0000-0002-1755-358X; TRIPI,
   Gabriele/0000-0001-7088-9325; Moscatelli, Fiorenzo/0000-0003-1274-0332;
   Monda, Vincenzo/0000-0002-6083-5814; Cerroni,
   Francesco/0000-0003-3024-5482; CIBELLI, GIUSEPPE/0000-0002-5371-2584;
   Monda, Marcellino/0000-0002-7184-218X
CR [Anonymous], 2006, 2 NATURE BRAIN SCI H
   [Anonymous], 1950, PRINCIPLES PSYCHOL
   [Anonymous], 1996, J NERV MENT DIS, V184, P445
   [Anonymous], 2001, TRAUMATIC RELATIONSH
   [Anonymous], 2014, CONSCIOUSNESS BRAIN
   Avola R, 2004, CLIN EXP HYPERTENS, V26, P323, DOI 10.1081/CEH-120034137
   Baars BJ, 2003, TRENDS NEUROSCI, V26, P671, DOI 10.1016/j.tins.2003.09.015
   Batthyany A., 2009, BATTHYANY AVSHALOM E
   Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5
   Blumenfeld H, 2003, NEUROSCIENTIST, V9, P301, DOI 10.1177/1073858403255624
   Bramanti V, 2012, NEUROCHEM RES, V37, P2795, DOI 10.1007/s11064-012-0873-3
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2017, FRONT PSYCHIATRY, P8
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Cerretani D, 2011, PHARMACOL RES, V64, P517, DOI 10.1016/j.phrs.2011.08.002
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00231
   Cianci P, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0857-x
   Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119
   Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019
   Damasio A, 2013, NAT REV NEUROSCI, V14, P143, DOI 10.1038/nrn3403
   Dehaene S, 2003, P NATL ACAD SCI USA, V100, P8520, DOI 10.1073/pnas.1332574100
   Demertzi Athena, 2008, Expert Rev Neurother, V8, P1719, DOI 10.1586/14737175.8.11.1719
   Duzel E, 2010, CURR OPIN NEUROBIOL, V20, P143, DOI 10.1016/j.conb.2010.01.004
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito T, 2016, DRUG DES DEV THER, V10, P2939, DOI 10.2147/DDDT.S106440
   Fiorelli A, 2017, ANN THORAC SURG, V103, P216, DOI 10.1016/j.athoracsur.2016.10.055
   Flodstrom John H, 1978, PHENOMENOLOGICAL STU
   Foote B, 2006, AM J PSYCHIAT, V163, P623, DOI 10.1176/appi.ajp.163.4.623
   Forlano I, 2011, ANN ITAL CHIR, V82, P405
   Frith C, 1999, TRENDS COGN SCI, V3, P105, DOI 10.1016/S1364-6613(99)01281-4
   Giacino JT, 2005, NEUROPSYCHOL REHABIL, V15, P166, DOI 10.1080/09602010443000498
   Hogan RE, 2003, AM J PSYCHIAT, V160, P1740, DOI 10.1176/appi.ajp.160.10.1740
   Jones EG, 2001, TRENDS NEUROSCI, V24, P595, DOI 10.1016/S0166-2236(00)01922-6
   Kelly S., 2003, COMMUNICATION   0509
   Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028
   Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X
   Laureys S, 2008, NAT CLIN PRACT NEURO, V4, P544, DOI 10.1038/ncpneuro0887
   LIBET B, 1983, BRAIN, V106, P623, DOI 10.1093/brain/106.3.623
   Maldonato M., 2015, ARCHIPELAGO CONSCIOU
   Mathalon DH, 2015, JAMA PSYCHIAT, V72, P840, DOI 10.1001/jamapsychiatry.2015.0483
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/639280
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Asian J Sports Med, V7, pe26841, DOI 10.5812/asjsm.26841
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Neri V, 2013, ANN ITAL CHIR, V84, P47
   Neri V, 2009, ANN ITAL CHIR, V80, P363
   Neri V, 2009, PANCREAS, V38, P717, DOI 10.1097/MPA.0b013e3181a83087
   O'Nuallain S. O, 2009, J COGN SCI, V4, P46
   Oken BS, 2006, CLIN NEUROPHYSIOL, V117, P1885, DOI 10.1016/j.clinph.2006.01.017
   Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166
   Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X
   PLUM F, 1991, NORMAL ALTERED STATE, V0009, P00359, DOI DOI 10.1007/978-1-4615-6622-9
   Pockett S, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00377
   Pomara C, 2012, CURR MED CHEM, V19, P5647, DOI 10.2174/092986712803988811
   Pomara C, 2008, CLIN TOXICOL, V46, P322, DOI 10.1080/15563650701419011
   Pomara C, 2016, J CELL PHYSIOL, V231, P1385, DOI 10.1002/jcp.25272
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Precenzano F, 2017, ACTA MEDICA MEDITERR, P33
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Ragguett RM, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2631
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Salomone F, 2014, TRANSL RES, V163, P593, DOI 10.1016/j.trsl.2013.12.001
   Siegel M, 2008, NEURON, V60, P709, DOI 10.1016/j.neuron.2008.09.010
   Sperandeo R, 7 IEEE INT C COGN IN
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Thompson E, 2001, TRENDS COGN SCI, V5, P418, DOI 10.1016/S1364-6613(00)01750-2
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2013, FORENSIC SCI INT, V231, P142, DOI 10.1016/j.forsciint.2013.04.006
   Turillazzi E, 2010, HISTOL HISTOPATHOL, V25, P1539, DOI 10.14670/HH-25.1539
   Turillazzi E, 2008, VIRCHOWS ARCH, V453, P209, DOI 10.1007/s00428-008-0632-7
   Uhlhaas PJ, 2010, NAT REV NEUROSCI, V11, P100, DOI 10.1038/nrn2774
   Vacchiano G, 2012, J ROY ARMY MED CORPS, V158, P338, DOI 10.1136/jramc-158-04-15
   Van Quyen ML, 2003, J PHYSIOL-PARIS, V97, P629, DOI 10.1016/j.jphysparis.2004.01.019
   Varela F. J, 1996, J CONSCIOUSNESS STUD, V3, P330
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Vyshka G, 2014, BMJ CASE REP
   Ward LM, 2003, TRENDS COGN SCI, V7, P553, DOI 10.1016/j.tics.2003.10.012
   Weiner WJ SL, 1999, EMERGENT URGENT NEUR
   Yarrow K, 2005, J PSYCHOPHYSIOL, V19, P232, DOI 10.1027/0269-8803.19.3.232
   Zeki S, 2003, TRENDS COGN SCI, V7, P214, DOI 10.1016/S1364-6613(03)00081-0
NR 94
TC 25
Z9 25
U1 0
U2 31
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 357
EP 366
DI 10.19193/0393-6384_2018_2_56
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400010
DA 2022-07-14
ER

PT J
AU Maltese, A
   Salerno, M
   Cerroni, F
   Romano, P
   Di Folco, A
   Di Filippo, T
   Tripi, G
AF Maltese, Agata
   Salerno, Margherita
   Cerroni, Francesco
   Romano, Palmira
   Di Folco, Annabella
   Di Filippo, Teresa
   Tripi, Gabriele
TI THE TRANSCRANIAL STIMULATION WITH DIRECT CURRENTS (TDCS): AN HISTORICAL
   AND CONCEPTUAL MINIREVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Transcranial Stimulation with Direct Currents; non invasive brain
   stimulation; tDCS
ID HUMAN MOTOR CORTEX; MAGNETIC STIMULATION; CHILDHOOD MIGRAINE; PREFRONTAL
   CORTEX; HEALTHY-SUBJECTS; PARIETAL CORTEX; VISUAL-SEARCH; CHILDREN;
   SLEEP; AURA
AB Transcranial Stimulation with Direct Currents (tDCS) is a method for non invasive brain stimulation created to induce functional changes in cerebral cortex. tDCS consists of application on the scalp of electrodes providing a low intensity direct current influencing neuronal functions. tDCS is not the only neurostimulation method for neuroscience clinical practice and research and can be used for treat many different clinical conditions such as migraine prevention, autism spectrum disorders (ASD), cerebral palsy rehabilitation, post-traumatic brain injury neuropsychological disorders.
C1 [Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Cerroni, Francesco; Romano, Palmira] Univ Campania Luigi Vanvitelli, Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Caserta, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325; Cerroni,
   Francesco/0000-0003-3024-5482
CR Andrade SM, 2017, J NEUROL SCI, V378, P225, DOI 10.1016/j.jns.2017.05.007
   Bracco M, 2017, NEUROPSYCHOLOGIA, V101, P30, DOI 10.1016/j.neuropsychologia.2017.05.006
   Bracco M, 2017, NEUROSCI LETT, V641, P45, DOI 10.1016/j.neulet.2017.01.027
   Cambiaghi M, 2018, J NEUROL, V265, P2466, DOI 10.1007/s00415-018-8739-5
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Duarte NDC, 2018, PEDIATR PHYS THER, V30, P67, DOI 10.1097/PEP.0000000000000467
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Havrda M, 2015, EARLY SCI MED, V20, P265, DOI 10.1163/15733823-00203P03
   Kim HJ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/1372946
   Lewis PM, 2016, NEUROSCIENTIST, V22, P406, DOI 10.1177/1073858416646707
   MacPhersona SE, 2017, NEUROPSYCHOLOGIA, V96, P19, DOI 10.1016/j.neuropsychologia.2016.12.028
   Mangano GR, 2015, NEUROPSYCHOLOGIA, V70, P196, DOI 10.1016/j.neuropsychologia.2015.03.002
   Mangano GR, 2014, VISION RES, V97, P74, DOI 10.1016/j.visres.2014.02.002
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Muszkat D, 2016, J CHILD ADOL PSYCHOP, V26, P590, DOI 10.1089/cap.2015.0172
   Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x
   de Amorim RLO, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00164
   Oliveri M, 2010, NEUROPSYCHOLOGIA, V48, P1003, DOI 10.1016/j.neuropsychologia.2009.11.024
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Priori A, 1998, NEUROREPORT, V9, P2257, DOI 10.1097/00001756-199807130-00020
   Przeklasa-Muszynska A, 2017, PHARMACOL REP, V69, P714, DOI 10.1016/j.pharep.2017.02.019
   Rosenkranz K, 2000, NEUROSCI LETT, V296, P61, DOI 10.1016/S0304-3940(00)01621-9
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Sanchez-Kuhn A, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0361-8
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Smirni D, 2017, NEUROPSYCHOLOGIA, V102, P109, DOI 10.1016/j.neuropsychologia.2017.06.006
   Smirni D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144838
   Steinberg H, 2013, PSYCHOL MED, V43, P669, DOI 10.1017/S0033291712002929
   Turriziani P, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00062
   Turriziani P, 2010, NEUROIMAGE, V52, P348, DOI 10.1016/j.neuroimage.2010.04.007
   Turriziani P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005319
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
NR 52
TC 1
Z9 1
U1 1
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 697
EP 702
DI 10.19193/0393-6384_2018_3_107
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000012
DA 2022-07-14
ER

PT J
AU Maltese, A
   Cerroni, F
   Romano, P
   Russo, D
   Salerno, M
   Gallai, B
   Marotta, R
   Lavano, SM
   Lavano, F
   Tripi, G
AF Maltese, Agata
   Cerroni, Francesco
   Romano, Palmira
   Russo, Daniela
   Salerno, Margherita
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Serena Marianna
   Lavano, Francesco
   Tripi, Gabriele
TI RETRACTED: THE COMPLEX COGNITIVE SYSTEM OF EXECUTIVE FUNCTIONING: A
   CONCEPTUAL REVIEW (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review; Retracted Publication
DE SAS; executive functioning; cognition
ID TRANSCRANIAL MAGNETIC STIMULATION; AUTISM SPECTRUM DISORDER;
   BEHAVIORAL-DISORDERS; CHILDHOOD MIGRAINE; HEALTHY-SUBJECTS; CHILDREN;
   ADOLESCENTS; THERAPY; CORTEX; AURA
AB Every day we are faced with a variety of situations that require the use of cognitive processes different, such as recognizing and memorizing stimuli, understanding and producing statements, solving problems. In recent decades, cognitive psychology and neuropsychology have made considerable advances in description of these processes and how they can be disrupted as a result of an injury to the nervous system central. However, it is clear that our adaptation to the environment is not limited to perceiving, reading, and speaking. A fundamental aspect of mental life is represented by the need to continuously modulate the use of these cognitive resources to contingent needs according to our goals and goals. It is this type of problem that refers to the expression executive functions (EFs). During developmental age Efs change consistently and since age of 8 years many Efs are similar to adults.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Cerroni, Francesco; Romano, Palmira; Russo, Daniela] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Serena Marianna; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Cerroni, Francesco/0000-0003-3024-5482; TRIPI,
   Gabriele/0000-0001-7088-9325; Marotta, Rosa/0000-0003-0515-5952
CR Auvin S, 2012, EUR J PEDIATR, V171, P1695, DOI 10.1007/s00431-012-1813-6
   Boccia G, 2006, CEPHALALGIA, V26, P1214, DOI 10.1111/j.1468-2982.2006.01196.x
   Bracco M, 2017, NEUROPSYCHOLOGIA, V101, P30, DOI 10.1016/j.neuropsychologia.2017.05.006
   Bracco M, 2017, NEUROSCI LETT, V641, P45, DOI 10.1016/j.neulet.2017.01.027
   Carey CE, 2018, J AM ACAD CHILD PSY, V57, P146, DOI 10.1016/j.jaac.2018.01.003
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Cirino PT, 2018, NEUROPSYCHOLOGY, V32, P176, DOI 10.1037/neu0000427
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Ishihara T, 2018, EUR J SPORT SCI, V18, P741, DOI 10.1080/17461391.2018.1444792
   Kouklari EC, 2018, RES DEV DISABIL, V76, P12, DOI 10.1016/j.ridd.2018.02.015
   MacPhersona SE, 2017, NEUROPSYCHOLOGIA, V96, P19, DOI 10.1016/j.neuropsychologia.2016.12.028
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1257, DOI 10.19193/0393-6384_2017_2s_194
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Mangano GR, 2015, NEUROPSYCHOLOGIA, V70, P196, DOI 10.1016/j.neuropsychologia.2015.03.002
   Mangano GR, 2014, VISION RES, V97, P74, DOI 10.1016/j.visres.2014.02.002
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Oliveri M, 2010, NEUROPSYCHOLOGIA, V48, P1003, DOI 10.1016/j.neuropsychologia.2009.11.024
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Smirni D, 2017, NEUROPSYCHOLOGIA, V102, P109, DOI 10.1016/j.neuropsychologia.2017.06.006
   Smirni D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144838
   Sonney J, 2019, J ASTHMA, V56, P179, DOI 10.1080/02770903.2018.1441870
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Turriziani P, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00062
   Turriziani P, 2010, NEUROIMAGE, V52, P348, DOI 10.1016/j.neuroimage.2010.04.007
   Turriziani P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005319
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Zelazo PD, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00208
NR 52
TC 0
Z9 0
U1 4
U2 14
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 915
EP 920
DI 10.19193/0393-6384_2018_4_139
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500002
DA 2022-07-14
ER

PT J
AU Maltese, A
   Cerroni, F
   Romano, P
   Russo, D
   Salerno, M
   Gallai, B
   Marotta, R
   Lavano, SM
   Lavano, F
   Tripi, G
AF Maltese, Agata
   Cerroni, Francesco
   Romano, Palmira
   Russo, Daniela
   Salerno, Margherita
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Serena Marianna
   Lavano, Francesco
   Tripi, Gabriele
TI RETRACTED: TECHNOLOGY, EDUCATIONAL CHALLENGES: SERIOUS GAME AND
   REHABILITATION (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE Serious games; virtual reality; electronic devices
ID TRANSCRANIAL MAGNETIC STIMULATION; AUTISM SPECTRUM DISORDERS;
   BEHAVIORAL-DISORDERS; CHILDHOOD MIGRAINE; HEALTHY-SUBJECTS; CHILDREN;
   ADOLESCENTS; STRESS; SLEEP; BRAIN
AB During child neurodevelopment, parenting plays the key role for accompanying children trough the evolutionary path, taking into account the various risks and dangers that may occur. Actually, certain delays or developmental disturbances may be considered as the consequence of incorrect parenting behavior. In this perspective the use of electronic devices may be observed seriously.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Cerroni, Francesco; Romano, Palmira; Russo, Daniela] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Serena Marianna; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI TRIPI, Gabriele/0000-0001-7088-9325; Cerroni,
   Francesco/0000-0003-3024-5482; Marotta, Rosa/0000-0003-0515-5952
CR Auvin S, 2012, EUR J PEDIATR, V171, P1695, DOI 10.1007/s00431-012-1813-6
   Boccia G, 2006, CEPHALALGIA, V26, P1214, DOI 10.1111/j.1468-2982.2006.01196.x
   Bracco M, 2017, NEUROPSYCHOLOGIA, V101, P30, DOI 10.1016/j.neuropsychologia.2017.05.006
   Bracco M, 2017, NEUROSCI LETT, V641, P45, DOI 10.1016/j.neulet.2017.01.027
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto M, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00295
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Fisher Paul G, 2017, J Pediatr, V191, P1, DOI 10.1016/j.jpeds.2017.10.020
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1189, DOI 10.19193/0393-6384_2017_2s_185
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Horowitz-Kraus T, 2018, ACTA PAEDIATR, V107, P685, DOI 10.1111/apa.14176
   Kenney EL, 2017, J PEDIATR-US, V182, P144, DOI 10.1016/j.jpeds.2016.11.015
   MacPhersona SE, 2017, NEUROPSYCHOLOGIA, V96, P19, DOI 10.1016/j.neuropsychologia.2016.12.028
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1257, DOI 10.19193/0393-6384_2017_2s_194
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Mangano GR, 2015, NEUROPSYCHOLOGIA, V70, P196, DOI 10.1016/j.neuropsychologia.2015.03.002
   Mangano GR, 2014, VISION RES, V97, P74, DOI 10.1016/j.visres.2014.02.002
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Monda V, 2018, MOL NEUROBIOL, V55, P6362, DOI 10.1007/s12035-017-0865-z
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Nelissen S, 2018, INFORM COMMUN SOC, V21, P375, DOI 10.1080/1369118X.2017.1281993
   Ogelman HG, 2018, EARLY CHILD DEV CARE, V188, P168, DOI 10.1080/03004430.2016.1208190
   Oliveri M, 2010, NEUROPSYCHOLOGIA, V48, P1003, DOI 10.1016/j.neuropsychologia.2009.11.024
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisano S, 2018, CLIN DRUG INVEST, V38, P457, DOI 10.1007/s40261-018-0627-3
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Smirni D, 2017, NEUROPSYCHOLOGIA, V102, P109, DOI 10.1016/j.neuropsychologia.2017.06.006
   Smirni D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144838
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Turriziani P, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00062
   Turriziani P, 2010, NEUROIMAGE, V52, P348, DOI 10.1016/j.neuroimage.2010.04.007
   Turriziani P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005319
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
NR 68
TC 0
Z9 0
U1 3
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 921
EP 927
DI 10.19193/0393-6384_2018_4_140
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500003
DA 2022-07-14
ER

PT J
AU Maltese, A
   Cerroni, F
   Romano, P
   Russo, D
   Salerno, M
   Gallai, B
   Marotta, R
   Lavano, SM
   Lavano, F
   Tripi, G
AF Maltese, Agata
   Cerroni, Francesco
   Romano, Palmira
   Russo, Daniela
   Salerno, Margherita
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Serena Marianna
   Lavano, Francesco
   Tripi, Gabriele
TI RETRACTED: THE CEREBRAL LOCALIZATION OF EXECUTIVE FUNCTIONS (Retracted
   Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE Executive Functions; frontal lobes; cortical areas; neuropsychology
ID AUTISM SPECTRUM DISORDERS; BEHAVIORAL-DISORDERS; MATERNAL STRESS;
   DEVELOPMENTAL DYSLEXIA; CHILDHOOD MIGRAINE; PARENTAL STRESS; OREXIN
   SYSTEM; CHILDREN; ADOLESCENTS; THERAPY
AB Executive Functions (EFs) are a complex neuropsychological tool that can lead all action of daily-life indipendently from age. The attempt to associate specific regions of the central nervous system (CNS) with specific sensory functions, motor and cognitive skills is one of the most recurring themes in the history of neuroscience. The concept of cerebral localization of mental activities started from the formulations of beginning phrenologists in Nineteenth century, passing through the holistic conceptions and antilocalization that marked some periods of the Twentieth century, until the beginning of the new millennium, characterized by the enormous popularity of the techniques of functional neuroimaging and the success of research programs aiming to create a real functional cartography of the human cerebral cortex.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Cerroni, Francesco; Romano, Palmira; Russo, Daniela] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Serena Marianna; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Cerroni, Francesco/0000-0003-3024-5482; Marotta,
   Rosa/0000-0003-0515-5952; TRIPI, Gabriele/0000-0001-7088-9325
CR [Anonymous], 2013, CURRENT TOPICS TOXIC, V9, P21
   Burgess PW, 2017, J INT NEUROPSYCH SOC, V23, P755, DOI 10.1017/S1355617717000704
   Capovilla G, 2004, EPILEPSIA, V45, P887, DOI 10.1111/j.0013-9580.2004.457erratum.x
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto M, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00295
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Craik FIM, 2018, CAN J EXP PSYCHOL, V72, P141, DOI 10.1037/cep0000143
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2018, ACTA MEDICA MEDITERR, V34, P697, DOI 10.19193/0393-6384_2018_3_107
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1257, DOI 10.19193/0393-6384_2017_2s_194
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Matricardi S, 2018, ACTA NEUROL SCAND, V137, P575, DOI 10.1111/ane.12902
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00259
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Monda V, 2018, MOL NEUROBIOL, DOI [10.1007/s12035-017-0865-zM, DOI 10.1007/S12035-017-0865-ZM]
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Monda V, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00695
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisano S, 2018, CLIN DRUG INVEST, V38, P457, DOI 10.1007/s40261-018-0627-3
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Salmon DP, 2013, NEUROLOGY, V80, P2174, DOI 10.1212/WNL.0b013e318296ea38
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Smirni D, 2018, NEUROL SCI, V39, P1391, DOI 10.1007/s10072-018-3433-z
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096
   Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695
   Tafuri D, 2015, BIOL MED, V7
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 69
TC 0
Z9 0
U1 2
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 929
EP 935
DI 10.19193/0393-6384_2018_4_141
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500004
DA 2022-07-14
ER

PT J
AU Maltese, A
   Cerroni, F
   Romano, P
   Russo, D
   Salerno, M
   Gallai, B
   Marotta, R
   Lavano, SM
   Lavano, F
   Tripi, G
AF Maltese, Agata
   Cerroni, Francesco
   Romano, Palmira
   Russo, Daniela
   Salerno, Margherita
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Serena Marianna
   Lavano, Francesco
   Tripi, Gabriele
TI RETRACTED: ANXIETY DISORDERS IN DEVELOPMENTAL AGE (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE social phobia; Separation anxiety
ID TRANSCRANIAL MAGNETIC STIMULATION; AUTISM SPECTRUM DISORDERS;
   BEHAVIORAL-DISORDERS; CHILDHOOD MIGRAINE; HEALTHY-SUBJECTS; CHILDREN;
   ADOLESCENTS; THERAPY; AURA; STRESS
AB Anxiety disorders represent the more common psychiatric disorder in developmental age and it is estimated that a third of adolescents satisfy the criteria for an anxiety disorder at the age of 18.
   Many researches show that the disorders of anxiety in childhood are associated with anxiety disorders in adulthood, depressive disorders and use of psychoactive substances.
   Suffering from anxiety disorders, such as specific phobia, agoraphobia, social anxiety or panic disorder, represents a strong predictor for the development of other psychiatric disorders
   consequential. In the literature the debate on the weight of environmental factors and genetic factors in determining the development of anxiety disorders is ongoing.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Cerroni, Francesco; Romano, Palmira; Russo, Daniela] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Serena Marianna; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI TRIPI, Gabriele/0000-0001-7088-9325; Marotta, Rosa/0000-0003-0515-5952;
   Cerroni, Francesco/0000-0003-3024-5482
CR Bracco M, 2017, NEUROPSYCHOLOGIA, V101, P30, DOI 10.1016/j.neuropsychologia.2017.05.006
   Bracco M, 2017, NEUROSCI LETT, V641, P45, DOI 10.1016/j.neulet.2017.01.027
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   de Lijster JM, 2018, J AFFECT DISORDERS, V230, P108, DOI 10.1016/j.jad.2018.01.008
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1189, DOI 10.19193/0393-6384_2017_2s_185
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Kaliebe K, 2018, CHILD ADOL PSYCH CL, V27, pXIII, DOI 10.1016/j.chc.2017.12.001
   MacPhersona SE, 2017, NEUROPSYCHOLOGIA, V96, P19, DOI 10.1016/j.neuropsychologia.2016.12.028
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1257, DOI 10.19193/0393-6384_2017_2s_194
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Mangano GR, 2015, NEUROPSYCHOLOGIA, V70, P196, DOI 10.1016/j.neuropsychologia.2015.03.002
   Mangano GR, 2014, VISION RES, V97, P74, DOI 10.1016/j.visres.2014.02.002
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Oliveri M, 2010, NEUROPSYCHOLOGIA, V48, P1003, DOI 10.1016/j.neuropsychologia.2009.11.024
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Pearcey S, 2018, J AFFECT DISORDERS, V229, P469, DOI 10.1016/j.jad.2017.12.078
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Smirni D, 2017, NEUROPSYCHOLOGIA, V102, P109, DOI 10.1016/j.neuropsychologia.2017.06.006
   Smirni D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144838
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Suveg C, 2018, J ABNORM CHILD PSYCH, V46, P569, DOI 10.1007/s10802-017-0319-0
   Turriziani P, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00062
   Turriziani P, 2010, NEUROIMAGE, V52, P348, DOI 10.1016/j.neuroimage.2010.04.007
   Turriziani P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005319
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Wissemann K, 2018, CHILD PSYCHIAT HUM D, V49, P814, DOI 10.1007/s10578-018-0797-5
NR 60
TC 0
Z9 0
U1 0
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 937
EP 943
DI 10.19193/0393-6384_2018_4_142
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500005
DA 2022-07-14
ER

PT J
AU Maltese, A
   Cerroni, F
   Romano, P
   Russo, D
   Salerno, M
   Gallai, B
   Marotta, R
   Lavano, SM
   Lavano, F
   Tripi, G
AF Maltese, Agata
   Cerroni, Francesco
   Romano, Palmira
   Russo, Daniela
   Salerno, Margherita
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Serena Marianna
   Lavano, Francesco
   Tripi, Gabriele
TI RETRACTED: DIGITAL NATIVES: LUCKY OR JELLIED? (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE digital natives; Millennial Generation; media devices
ID TRANSCRANIAL MAGNETIC STIMULATION; AUTISM SPECTRUM DISORDERS;
   BEHAVIORAL-DISORDERS; CHILDHOOD MIGRAINE; CHILDREN; ADOLESCENTS; AURA;
   THERAPY; STRESS; CORTEX
AB The technology now seems to have involved not only the world of adults, but also and especially that of children, becoming a form of communication and rapid interaction and widespread dissemination. Some parents start to worry about a possible technological dependency, given the hours spent by the youngest, called digital children, in front of computer, smartphones and tablets. A decade ago, the sociologist Mark Prensky spoke of digital natives, that is the first generation of children grew up with consoles, videogames and computers while today we are witnessing an evolution of this concept in the third generation of digital, appeared approximately with the arrival of iPad and tablet and is constantly evolving in a technology with wi-fi, app (programs designed for smartphones) and touchscreen.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Cerroni, Francesco; Romano, Palmira; Russo, Daniela] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Serena Marianna; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; TRIPI, Gabriele/0000-0001-7088-9325;
   Cerroni, Francesco/0000-0003-3024-5482
CR Bracco M, 2017, NEUROPSYCHOLOGIA, V101, P30, DOI 10.1016/j.neuropsychologia.2017.05.006
   Bracco M, 2017, NEUROSCI LETT, V641, P45, DOI 10.1016/j.neulet.2017.01.027
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   de Wet C, 2015, SCOT MED J, V60, P152, DOI 10.1177/0036933015597177
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1189, DOI 10.19193/0393-6384_2017_2s_185
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Katz VS, 2017, PEDIATRICS, V140, pS132, DOI 10.1542/peds.2016-1758R
   MacPhersona SE, 2017, NEUROPSYCHOLOGIA, V96, P19, DOI 10.1016/j.neuropsychologia.2016.12.028
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1257, DOI 10.19193/0393-6384_2017_2s_194
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Mangano GR, 2015, NEUROPSYCHOLOGIA, V70, P196, DOI 10.1016/j.neuropsychologia.2015.03.002
   Mangano GR, 2014, VISION RES, V97, P74, DOI 10.1016/j.visres.2014.02.002
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Oliveri M, 2010, NEUROPSYCHOLOGIA, V48, P1003, DOI 10.1016/j.neuropsychologia.2009.11.024
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Paudel S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014585
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Prensky M, 2001, DIGITAL NATIVES DIGI, V9
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Smirni D, 2017, NEUROPSYCHOLOGIA, V102, P109, DOI 10.1016/j.neuropsychologia.2017.06.006
   Smirni D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144838
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Turriziani P, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00062
   Turriziani P, 2010, NEUROIMAGE, V52, P348, DOI 10.1016/j.neuroimage.2010.04.007
   Turriziani P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005319
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Velasco HF, 2015, J PEDIAT-BRAZIL, V91, P183, DOI 10.1016/j.jped.2014.07.007
NR 60
TC 0
Z9 0
U1 1
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 945
EP 950
DI 10.19193/0393-6384_2018_4_143
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500006
DA 2022-07-14
ER

PT J
AU Maltese, A
   Cerroni, F
   Romano, P
   Russo, D
   Salerno, M
   Gallai, B
   Marotta, R
   Lavano, SM
   Lavano, F
   Tripi, G
AF Maltese, Agata
   Cerroni, Francesco
   Romano, Palmira
   Russo, Daniela
   Salerno, Margherita
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Serena Marianna
   Lavano, Francesco
   Tripi, Gabriele
TI RETRACTED: A MINIREVIEW ABOUT PRETERM BIRTH AND MAIN SPECIFIC
   NEURODEVELOPMENTAL DISORDERS (Retracted article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review; Retracted Publication
DE neurodevelopmental disorders; specific learning disorders; sensorial
   disability; very low birth weight
ID AUTISM SPECTRUM DISORDER; BEHAVIORAL-DISORDERS; CHILDHOOD MIGRAINE;
   CHILDREN; ADOLESCENTS; THERAPY; AURA; STRESS; SLEEP
AB The preterm birth interrupts the physiological processes that allow the development of the Nervous System and of the body apparatus. Preterm children present a multi-organ dysfunction inversely proportional to the gestational age, leading to respiratory, cardiovascular, haematological, metabolic, infectious, and neurological problems.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Cerroni, Francesco; Romano, Palmira; Russo, Daniela] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Serena Marianna; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] Childhood Psychiat Serv Neurodev Disorders, Ch Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; Cerroni,
   Francesco/0000-0003-3024-5482
CR Arpino Carla, 2005, Ann Ist Super Sanita, V41, P229
   Arpino C, 2010, CHILD NERV SYST, V26, P1139, DOI 10.1007/s00381-010-1125-y
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00295
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Ferreira C, 2017, CODAS, V29, DOI 10.1590/2317-1782/20172015285
   Fumagalli M, 2015, J MATERN-FETAL NEO M, V28, P2280, DOI 10.3109/14767058.2013.796168
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1257, DOI 10.19193/0393-6384_2017_2s_194
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Plomgaard AM, 2016, PEDIATR RES, V79, P466, DOI 10.1038/pr.2015.239
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Sirgiovanni I, 2014, PEDIATR RADIOL, V44, P289, DOI 10.1007/s00247-013-2826-7
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
NR 41
TC 0
Z9 0
U1 3
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1171
EP 1176
DI 10.19193/0393-6384_2018_5_179
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700001
DA 2022-07-14
ER

PT J
AU Maltese, A
   Cerroni, F
   Romano, P
   Russo, D
   Salerno, M
   Gallai, B
   Marotta, R
   Lavano, SM
   Lavano, F
   Tripi, G
AF Maltese, Agata
   Cerroni, Francesco
   Romano, Palmira
   Russo, Daniela
   Salerno, Margherita
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Serena Marianna
   Lavano, Francesco
   Tripi, Gabriele
TI RETRACTED: AUGMENTATIVE AND ALTERNATIVE COMMUNICATION (AAC) IN
   NEURODEVELOPMENTAL DISORDERS: A MINIREVIEW (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review; Retracted Publication
DE augmentative and alternative communication; devices with voice output;
   Functional Communication training
ID TRANSCRANIAL MAGNETIC STIMULATION; AUTISM SPECTRUM DISORDER;
   BEHAVIORAL-DISORDERS; CHILDHOOD MIGRAINE; CHILDREN; ADOLESCENTS;
   THERAPY; STRESS; SYSTEM; CORTEX
AB Children with neurodevelopmental disorders such as Autism Spectrum Disorders (ASD), cerebral palsy or severe motor speech disorders may beneficiate of augmentative and alternative communication (AAC) systems that may improve the developing language and the communication abilities. The term AAC tend to include each form of communication supplementing or replacing the natural speech production.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Cerroni, Francesco; Romano, Palmira; Russo, Daniela] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Serena Marianna; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] Childhood Psychiat Serv Neurodev Disorders, Ch Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; Cerroni,
   Francesco/0000-0003-3024-5482
CR An SN, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0165-5
   Borg S, 2015, STUD HEALTH TECHNOL, V217, P811, DOI 10.3233/978-1-61499-566-1-811
   Bracco M, 2017, NEUROPSYCHOLOGIA, V101, P30, DOI 10.1016/j.neuropsychologia.2017.05.006
   Bracco M, 2017, NEUROSCI LETT, V641, P45, DOI 10.1016/j.neulet.2017.01.027
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00295
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Ferreira C, 2017, CODAS, V29, DOI 10.1590/2317-1782/20172015285
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Ganz JB, 2017, AUGMENT ALTERN COMM, V33, P224, DOI 10.1080/07434618.2017.1373855
   MacPhersona SE, 2017, NEUROPSYCHOLOGIA, V96, P19, DOI 10.1016/j.neuropsychologia.2016.12.028
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1257, DOI 10.19193/0393-6384_2017_2s_194
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Mandak K, 2018, AUGMENT ALTERN COMM, V34, P130, DOI 10.1080/07434618.2018.1438513
   Mangano GR, 2015, NEUROPSYCHOLOGIA, V70, P196, DOI 10.1016/j.neuropsychologia.2015.03.002
   Mangano GR, 2014, VISION RES, V97, P74, DOI 10.1016/j.visres.2014.02.002
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Mohan V, 2019, DISABIL REHABIL-ASSI, V14, P75, DOI 10.1080/17483107.2017.1413144
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   O'Neill T, 2017, SEMIN SPEECH LANG, V38, P313, DOI 10.1055/s-0037-1604278
   Oliveri M, 2010, NEUROPSYCHOLOGIA, V48, P1003, DOI 10.1016/j.neuropsychologia.2009.11.024
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Romski M A, 1999, ASHA, V41, P38
   ROMSKI MA, 1994, AM J MENT RETARD, V98, P527
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Smirni D, 2017, NEUROPSYCHOLOGIA, V102, P109, DOI 10.1016/j.neuropsychologia.2017.06.006
   Smirni D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144838
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Thiemann-Bourque K, 2016, J SPEECH LANG HEAR R, V59, P1133, DOI 10.1044/2016_JSLHR-L-15-0313
   Turriziani P, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00062
   Turriziani P, 2010, NEUROIMAGE, V52, P348, DOI 10.1016/j.neuroimage.2010.04.007
   Turriziani P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005319
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Zink AG, 2018, PEDIATR DENT, V40, P18
NR 59
TC 0
Z9 0
U1 8
U2 22
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1181
EP 1187
DI 10.19193/0393-6384_2018_5_181
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700003
DA 2022-07-14
ER

PT J
AU Maltese, A
   Romano, P
   Cerroni, F
   Russo, D
   Salerno, M
   Gallai, B
   Marotta, R
   Lavano, SM
   Lavano, F
   Tripi, G
AF Maltese, Agata
   Romano, Palmira
   Cerroni, Francesco
   Russo, Daniela
   Salerno, Margherita
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Serena Marianna
   Lavano, Francesco
   Tripi, Gabriele
TI RETRACTED: EXECUTIVE FUNCTIONS REHABILITATION PROPOSAL: A TAILORED
   INTERVENTION (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE Executive Functions; tailored-chid rehabilitation; cognitive-behavioral
   training
ID AUTISM SPECTRUM DISORDER; BEHAVIORAL-DISORDERS; CHILDHOOD MIGRAINE;
   CHILDREN; ADOLESCENTS; THERAPY; AURA; PRETERM; STRESS; SLEEP
AB Executive functions (EFs) are cognitive processes that allow the development of intentional behaviors e requiring the ability to formulate goals and objectives, capacity for initiative, to anticipate the consequences of actions, to organize behavior and monitor it and adapt it based on the context. Patients with EFs deficiencies exhibit specific disorders of planning, regulation and correction intentional conduct and cognitive activity, while they have no problem in the execution of usual action sequences.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Romano, Palmira; Cerroni, Francesco; Russo, Daniela] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Serena Marianna; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] Childhood Psychiat Serv Neurodev Disorders, Ch Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; Cerroni,
   Francesco/0000-0003-3024-5482
CR Arpino Carla, 2005, Ann Ist Super Sanita, V41, P229
   Arpino C, 2010, CHILD NERV SYST, V26, P1139, DOI 10.1007/s00381-010-1125-y
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00295
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Fumagalli M, 2015, J MATERN-FETAL NEO M, V28, P2280, DOI 10.3109/14767058.2013.796168
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1257, DOI 10.19193/0393-6384_2017_2s_194
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Plomgaard AM, 2016, PEDIATR RES, V79, P466, DOI 10.1038/pr.2015.239
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Sirgiovanni I, 2014, PEDIATR RADIOL, V44, P289, DOI 10.1007/s00247-013-2826-7
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
NR 39
TC 1
Z9 1
U1 3
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1189
EP 1194
DI 10.19193/0393-6384_2018_5_182
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700004
DA 2022-07-14
ER

PT J
AU Maltese, A
   Cerroni, F
   Romano, P
   Russo, D
   Salerno, M
   Gallai, B
   Marotta, R
   Lavano, SM
   Lavano, F
   Tripi, G
AF Maltese, Agata
   Cerroni, Francesco
   Romano, Palmira
   Russo, Daniela
   Salerno, Margherita
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Serena Marianna
   Lavano, Francesco
   Tripi, Gabriele
TI THE MAIN SEQUELAE OF PRETERM BIRTH: FOCUS ON NEURODEVELOPMENTAL
   DISORDERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE preterm birth; periventricular leukomalacia; Neonatal Intensive Care
   Unit
ID AUTISM SPECTRUM DISORDERS; BEHAVIORAL-DISORDERS; CHILDHOOD MIGRAINE;
   CHILDREN; ADOLESCENTS; THERAPY; STRESS; AURA; HEMORRHAGE; SLEEP
AB Preterm birth is a traumatic event that interrupts the physiological processes that allow the development of the Nervous System and the body systems, resulting in a multi-organ dysfunction, of an entity in inverse proportion to the gestational age, which causes respiratory, cardiovascular, metabolic, infectious endocrine problems. and neurological. In particular, at a neurological level, in the most serious cases, for macroscopic lesions of the Central Nervous System, there is the risk of incurring in evolutionary Disabilities (Infantile Cerebral Palsy etc.); but in the absence of severe damage, since the birth occurs at a critical moment of the cerebral development in which the cortex is being organized, it is possible to establish minor deficits, arising from alterations in neural connectivity.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Cerroni, Francesco; Romano, Palmira; Russo, Daniela] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Serena Marianna; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] Childhood Psychiat Serv Neurodev Disorders, Ch Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; Cerroni,
   Francesco/0000-0003-3024-5482
CR Arpino Carla, 2005, Ann Ist Super Sanita, V41, P229
   Arpino C, 2010, CHILD NERV SYST, V26, P1139, DOI 10.1007/s00381-010-1125-y
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00295
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Fumagalli M, 2015, J MATERN-FETAL NEO M, V28, P2280, DOI 10.3109/14767058.2013.796168
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1257, DOI 10.19193/0393-6384_2017_2s_194
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Plomgaard AM, 2016, PEDIATR RES, V79, P466, DOI 10.1038/pr.2015.239
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Sirgiovanni I, 2014, PEDIATR RADIOL, V44, P289, DOI 10.1007/s00247-013-2826-7
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
NR 39
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1195
EP 1200
DI 10.19193/0393-6384_2018_5_183
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700005
DA 2022-07-14
ER

PT J
AU Maltese, A
   Gallai, B
   Marotta, R
   Lavano, F
   Lavano, SM
   Tripi, G
   Romano, P
   D'Oro, L
   Salerno, M
AF Maltese, Agata
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Tripi, Gabriele
   Romano, Palmira
   D'Oro, Lucrezia
   Salerno, Margherita
TI RETRACTION: NEUROSCIENCES AND ATTACHMENT THEORY: A BRIEF REVIEW
   (Retraction of Vol 33, Pg 1249, 2017)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Retraction
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Romano, Palmira] Ctr LARS, Sarno, Italy.
   [D'Oro, Lucrezia] Ctr Relax, Benevento, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Maltese, A (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
CR Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1249, DOI 10.19193/0393-6384_2017_2s_193
NR 1
TC 0
Z9 0
U1 1
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
AR 1249
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HF1IM
UT WOS:000453919900003
DA 2022-07-14
ER

PT J
AU Maltese, A
   Gallai, B
   Romano, P
   D'Oro, L
   Marotta, R
   Lavano, F
   Lavano, SM
   Tripi, G
   Salerno, M
AF Maltese, Agata
   Gallai, Beatrice
   Romano, Palmira
   D'Oro, Lucrezia
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Tripi, Gabriele
   Salerno, Margherita
TI RETRACTION: THE DYNAMIC MATURATIVE MODEL FOR ATTACHMENT (Retraction of
   Vol 33, Pg 1265, 2017)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Retraction
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Romano, Palmira] Ctr LARS, Sarno, Italy.
   [D'Oro, Lucrezia] Ctr Relax, Benevento, Italy.
   [Marotta, Rosa; Lavano, Francesco; Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Maltese, A (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
CR Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1265, DOI 10.19193/0393-6384_2017_2s_195
NR 1
TC 0
Z9 0
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
AR 1265
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HF1IM
UT WOS:000453919900004
DA 2022-07-14
ER

PT J
AU Maltese, A
   Romano, P
   D'Oro, L
   Gallai, B
   Marotta, R
   Lavano, F
   Lavano, SM
   Tripi, G
   Salerno, M
AF Maltese, Agata
   Romano, Palmira
   D'Oro, Lucrezia
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Tripi, Gabriele
   Salerno, Margherita
TI RETRACTION: ANGER IN CHILDREN: A MINIREVIEW (Retraction of Vol 33, Pg
   1233, 2017)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Retraction
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Romano, Palmira] Ctr LARS, Sarno, Italy.
   [D'Oro, Lucrezia] Ctr Relax, Benevento, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco; Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Maltese, A (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
CR Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1233, DOI 10.19193/0393-6384_2017_2s_191
NR 1
TC 0
Z9 0
U1 1
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
AR 1233
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HF1IM
UT WOS:000453919900001
DA 2022-07-14
ER

PT J
AU Maltese, A
   Gallai, B
   Romano, P
   D'Oro, L
   Marotta, R
   Lavano, F
   Lavano, SM
   Tripi, G
   Salerno, M
AF Maltese, Agata
   Gallai, Beatrice
   Romano, Palmira
   D'Oro, Lucrezia
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Tripi, Gabriele
   Salerno, Margherita
TI RETRACTION: MOTION SICKNESS IN CHILDHOOD MIGRAINE (Retraction of Vol 33,
   Pg 1241, 2017)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Retraction
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Romano, Palmira] Ctr LARS, Sarno, Italy.
   [D'Oro, Lucrezia] Ctr Relax, Benevento, Italy.
   [Marotta, Rosa; Lavano, Francesco; Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Maltese, A (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
CR Al-Twaijri WA, 2002, PEDIATR NEUROL, V26, P365, DOI 10.1016/S0887-8994(01)00416-7
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P1241, DOI 10.19193/0393-6384_2017_2s_192
NR 2
TC 0
Z9 0
U1 2
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
AR 1241
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HF1IM
UT WOS:000453919900002
DA 2022-07-14
ER

PT J
AU Maniaci, G
   La Cascia, C
   Ferraro, L
   Picone, F
   Sideli, L
   Seminerio, F
   Scaglione, A
   La Barbera, D
   Cannizzaro, C
AF Maniaci, Giuseppe
   La Cascia, Caterina
   Ferraro, Laura
   Picone, Francesca
   Sideli, Lucia
   Seminerio, Fabio
   Scaglione, Alessandra
   La Barbera, Daniele
   Cannizzaro, Carla
TI THE EFFICACY OF A FUNCTIONAL THERAPY PROGRAM FOR GAMBLING DISORDER: A
   PILOT STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Gambling disorder treatment; Functional Therapy; body-oriented therapy;
   treatment outcome
AB Background: Despite the great progress achieved by treatment approaches for Gambling Disorder (GD) the relevance of studying efficacious therapies still remains high. This pilot study aims at the evaluation of the efficacy of a standardized protocol based on Functional theory for GD. Functional Therapy (FT) is an integrated body-mind therapy.
   Methods: Twenty-eight pathological gamblers completed the FT protocol consisted in 16 sessions, two times a week for a total duration of two months, in an individual setting. No one of the patients was taking any psychopharmacological therapy. Psychological assessment both at baseline (T0) and at the end of the treament (T1) includes the South Oaks Gambling Screen, the PG-Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS), State-Trait Anxiety Inventory (STAI), the Beck Depression Inventory II version (BDI-II), the Barrat Impulsiveness Scale 11th version (BIS-11) and the Measurement of Psychological Stress (MSP).
   Results: a significant reduction of GD (gambling frequency, duration, money inserted, and expenditure) in pathological gamblers was revealed together with a significant reduction of depression, anxiety, impulsivity and perceived stress.
   Conclusions: the structured FT program for GD highlights a strong improvement in gambling behavior, in reducing impulsivity, depression, anxiety and perceived stress, thus obtaining a good compliance and a few dropout.
C1 [Maniaci, Giuseppe; La Cascia, Caterina; Ferraro, Laura; Sideli, Lucia; Seminerio, Fabio; Scaglione, Alessandra; La Barbera, Daniele] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy.
   [Picone, Francesca] ASP Palermo, Dept Pathol Addict, Palermo, Italy.
   [Cannizzaro, Carla] Giuseppe DAlessandro Univ Palermo, Dept Sci Hlth Promot & Mother & Child Care, Palermo, Italy.
RP Maniaci, G (corresponding author), Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy.
EM giuseppemaniaci@icloud.com
RI Ferraro, Laura/AAG-3724-2020; La Cascia, Caterina/U-7743-2017; La
   Barbera, Daniele/AAX-5591-2020
OI Ferraro, Laura/0000-0002-1205-2356; La Cascia,
   Caterina/0000-0002-2078-0214; La Barbera, Daniele/0000-0002-9506-4546
CR Achab S, 2011, CURR PHARM DESIGN, V17, P1389, DOI 10.2174/138161211796150774
   American Psychiatric Association American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th
   Beck A.T., 1996, BECK DEPRESSION INVE
   BERGER BG, 1988, RES Q EXERCISE SPORT, V59, P148, DOI 10.1080/02701367.1988.10605493
   Cavallaro A, 2016, ACTA MEDICA MEDITERR, V32, P903, DOI 10.19193/0393-6384_2016_4_108
   Chambless DL, 2001, ANNU REV PSYCHOL, V52, P685, DOI 10.1146/annurev.psych.52.1.685
   Cowlishaw S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008937.pub2
   Di Nuovo S, 2000, MISURARE STRESS LINE
   Dunn K., 2012, J GAMBL STUD, V12, P1
   Gambling Serpelloni G., 2013, GIOCO AZZARDO PROBLE
   Hodgins DC, 2004, PSYCHOL ADDICT BEHAV, V18, P293, DOI 10.1037/0893-164X.18.3.293
   Ledgerwood DM, 2006, CLIN PSYCHOL REV, V26, P216, DOI 10.1016/j.cpr.2005.11.008
   Leeman RF, 2012, PSYCHOPHARMACOLOGY, V219, P469, DOI 10.1007/s00213-011-2550-7
   LESIEUR HR, 1987, AM J PSYCHIAT, V144, P1184
   Lupi M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/537306
   Lushene, MANUAL STATE TRAIT A
   Malathi A., 1999, Indian Journal of Physiology and Pharmacology, V43, P218
   Maniaci G, 2018, J GAMBL STUD, V34, P147, DOI 10.1007/s10899-017-9685-3
   Maniaci G, 2017, PSYCHIAT RES, V257, P540, DOI 10.1016/j.psychres.2017.08.003
   Maniaci G, 2017, J GAMBL STUD, V33, P633, DOI 10.1007/s10899-016-9636-4
   Maniaci G, 2015, INT J MENT HEALTH AD, V13, P728, DOI 10.1007/s11469-015-9550-5
   Murugesan R., 2000, Indian Journal of Physiology and Pharmacology, V44, P207
   Netz Y, 2003, J PSYCHOL, V137, P405, DOI 10.1080/00223980309600624
   Nower L, 2013, ADDICTION, V108, P789, DOI 10.1111/add.12012
   Pallanti S, 2005, J GAMBL STUD, V21
   Perciavalle V, 2017, NEUROL SCI, V38, P451, DOI 10.1007/s10072-016-2790-8
   Perrella R, 2017, MEDITERR J CLIN PSYC, V5, DOI 10.6092/2282-1619/2017.5.1662
   Petry NM, 2014, J GAMBL STUD, V30, P493, DOI 10.1007/s10899-013-9370-0
   Plescia F, 2015, ACTA MEDICA MEDITERR, V31, P813
   Raju P S, 1997, J Altern Complement Med, V3, P291, DOI 10.1089/acm.1997.3.291
   Rash CJ, 2014, PSYCHOL RES BEHAV MA, V7, P285, DOI 10.2147/PRBM.S40883
   Rispoli L, 2008, BASIC EXPERIENCE DEV
   Rispoli L., 2016, CORPO PSICOTERAPIA O
   Rosenberg O, 2013, PSYCHIAT RES, V206, P111, DOI 10.1016/j.psychres.2012.09.045
   Rosenthal R J, 1994, J Gambl Stud, V10, P21, DOI 10.1007/BF02109777
   Smith DP, 2015, BEHAV RES THER, V69, P100, DOI 10.1016/j.brat.2015.04.008
   Stinchfield R, 2002, ADDICT BEHAV, V27, P1, DOI 10.1016/S0306-4603(00)00158-1
   Telles S, 1993, Indian J Med Sci, V47, P235
   Toneatto T, 2008, AM J ADDICTION, V17, P298, DOI 10.1080/10550490802138830
   Viets VCL, 1997, CLIN PSYCHOL REV, V17, P689, DOI 10.1016/S0272-7358(97)00031-7
NR 40
TC 5
Z9 5
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1447
EP 1452
DI 10.19193/0393-6384_2018_5_220
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700042
DA 2022-07-14
ER

PT J
AU Marella, GL
   Solinas, M
   Feola, A
   Raschella, F
   Caggiano, B
   Marsella, LT
   Romigi, A
AF Marella, Gian Luca
   Solinas, Matteo
   Feola, Alessandro
   Raschella, Francesco
   Caggiano, Bartolo
   Marsella, Luigi T.
   Romigi, Andrea
TI COMPLEX REGIONAL PAIN SYNDROME INDUCED BY EXTRAVASATION OF PROPOFOL
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Complex Regional Pain Syndrome; Causalgia; Reflex Sympathetic Dystrophy;
   Medico-legal evaluation
ID SYNDROME TYPE-I
AB Introduction: Complex Regional Pain Syndrome (CRPS) is a chronic disabling painful pathological condition that persists long after the initial injury to the affected limb, triggering characterized by constant pain, allodynia, hyperalgesia, edema, trophic changes, vasomotor dysregulation, and motor deficiency. Usually, the cause is a physical, chemical, or mechanical injury; other times no apparent cause can be identified that could justify the disease. Aspecific continuing pain is the symptomatology, which is not specific and appears disproportionate to any inciting the initial traumatic event.
   Case presentation: A 36-year-old woman with a history of dysphagia, heartburn, abdominal pain and persistent cough underwent to EGDS with the suspect of a hiatal hernia. During the induction phase of anesthesia by intravenous administration of Propofol, an intravenous anesthetic agent, the extravasation of this drug occurred in the upper right limb tissue. Ten months later further EMG/NCS showed an antalgic reduction of the voluntary recruitment pattern lacking peripheral neuropathy signs. Continuing pain disproportionate to the incidental event, allodynia, temperature asymmetry and alteration of the skin color at the right arm lacking evidence of nerve lesions, confirmed the diagnosis of complex regional pain syndrome type 2.
   Conclusion: In case of CPRS, the forensic pathologist has to determine the cause in order to prevent a medical malpratice claim, and also it is useful to well known the clinical features to evaluate a state of permanent invalidity. Difficult diagnosis plays a crucial role in the onset of the high disability that the disease causes if it is not recognized on time. The causes of CPRS may be the consequences of a medical error (in the specific case the extravasation of an irritant substance, Propofol) and from subsequent diagnostic delay a very debilitating morbid picture can occurs. For medico-legal purposes, it becomes essential to know the syndrome, and especially to diagnose it in a short time.
C1 [Marella, Gian Luca] Univ Roma Tor Vergata, Dept Expt Med & Surg, I-00133 Rome, Italy.
   [Solinas, Matteo] Univ Modena & Reggio Emilia, Dept Diagnost Clin & Publ Hlth Med, Via Pozzo 71, I-41124 Modena, Italy.
   [Feola, Alessandro; Raschella, Francesco; Caggiano, Bartolo; Marsella, Luigi T.] Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.
   [Romigi, Andrea] IRCCS Neuromed, Via Atinense 18, Pozzilli, Is, Italy.
RP Marella, GL (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Sect Legal Med, Via Montpellier 1, I-00133 Rome, Italy.
EM glmarella@gmail.com
RI Romigi, Andrea/AAE-5228-2020; Feola, Alessandro/AAI-4601-2020
OI Romigi, Andrea/0000-0002-4505-2600; Feola,
   Alessandro/0000-0002-9666-2636; Marella, Gian Luca/0000-0002-1160-2061;
   Marsella, Luigi Tonino/0000-0002-7005-7526
CR Abdi S., 2017, COMPLEX REGIONAL PAI
   [Anonymous], 2010, PAIN MED, V11, P1257
   Bruehl S, 1999, PAIN, V81, P147, DOI 10.1016/S0304-3959(99)00011-1
   Bussa M, 2015, ACTA ANAESTH SCAND, V59, P685, DOI 10.1111/aas.12489
   Eberle T, 2009, NEUROLOGY, V72, P505, DOI 10.1212/01.wnl.0000341930.35494.66
   GALER BS, 2001, BONICAS MANAGEMENT P, P388
   Harden RN, 2013, PAIN MED, V14, P180, DOI 10.1111/pme.12033
   Harden RN, 1999, PAIN, V83, P211, DOI 10.1016/S0304-3959(99)00104-9
   Hooshmand H., 1993, BONICAS MANAGEMENT P
   Merskey H, CLASSIFICATION CHRON, P210
   Pittman DM, 1997, AM FAM PHYSICIAN, V56, P2265
   Sandroni P, 2003, PAIN, V103, P199, DOI 10.1016/S0304-3959(03)00065-4
   Sethna NF, 2007, PAIN, V131, P153, DOI 10.1016/j.pain.2006.12.028
   Subedi A, 2011, KOREAN J PAIN, V24, P112, DOI 10.3344/kjp.2011.24.2.112
   Wuppenhorst N, 2010, CLIN J PAIN, V26, P182, DOI 10.1097/AJP.0b013e3181c20207
NR 15
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 373
EP 376
DI 10.19193/0393-6384_2018_2_58
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400012
DA 2022-07-14
ER

PT J
AU Masrour, MJ
   Azad, Z
AF Masrour, Mojgan Javedani
   Azad, Zahra
TI A COMPARISON OF THE EFFECTS OF HUMAN CHORIONIC GONADOTROPIN AND OXYTOCIN
   ON OVULATION IN PCOS PATIENTS FROM 2015 UNTIL 2018
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Oxytocin; Human Chorionic Gonadotropin; Polycystic Ovary Syndrome
ID POLYCYSTIC-OVARY-SYNDROME; N-ACETYL-CYSTEINE; CUMULUS/LUTEAL CELLS;
   BIOLOGICAL ASPECT; GENE-EXPRESSION; GNRH ANTAGONIST; RECEPTOR; WOMEN;
   HYPERSTIMULATION; EMBRYOGENESIS
AB Background and objective: Polycystic Ovary Syndrome [PCOS] is regarded as the most prevalent endocrine disorder and is often (but not always) featured by ovulatory dysfunction resulting in amenorrhea or oligo (Rotterdam 2003 consensus). The current study is carried out to compare the effects of oxytocin and chorionic gonadotropin (HCG) in inducting pregnancy and ovulation in women afflicted with the polycystic ovary syndrome.
   Even though clomiphene is still regarded as the major treatment in patients afflicted with the polycystic ovary syndrome, the failure of ovulation in clomiphene-resistant women is considered as a significant and serious clinical topic.
   Materials and methods: In a prospective research, 150 infertile clomiphene-resistant patients admitted to Akbarabadi hospital in Tehran from 2015 until 2018 were parted into three groups at random and received (100 mg clomiphene-citrate + 8 units of oxytocin), (100mg clomiphene-citrate + 10000 units of HCG) and (100mg clomiphene-citrate + 8 units of oxytocin and 10000 units of HCG). The treatment progress was determined by the number and size of Mlicles imaged using Transvaginal ultrasonography. To verify ovulation, the progesterone serum concentration was estimated. The rates of biochemical pregnancy and ovulation were compared in the mentioned three groups.
   Results: 150 patients went through the study. There was no major difference among the groups regarding the ovulation rate or the number of follicles [p>0.05], neither was there any significant side effects observed in any groups.
   Conclusion: Based on the findings of the current study, it can be concluded that because there is no difference in ovulation, OT can play a role in human ovulation either separately or coactively with other ovulatory mechanisms, and that the secretion of OT may be controlled by progesterone and ovarian estradiol. Moreover, the findings suggest that in clomiphene-resistance patients, OT might perform some role in regulating luteolysis.
C1 [Masrour, Mojgan Javedani; Azad, Zahra] Iran Univ Med Sci, Shahid Akbarabadi Hosp, Res & Clin Ctr Gynecol & Fertil, Tehran, Iran.
RP Masrour, MJ (corresponding author), Iran Univ Med Sci, Shahid Akbarabadi Hosp, Res & Clin Ctr Gynecol & Fertil, Tehran, Iran.
EM javedani46@yahoo.com
CR Abedi Gh, 2011, WORLD APPL SCI J, V12, P939
   Amer Soc Reprod Med, 2013, FERTIL STERIL, V99, P63, DOI 10.1016/j.fertnstert.2012.09.023
   Azziz R, 2004, J CLIN ENDOCR METAB, V89, P2745, DOI 10.1210/jc.2003-032046
   Balen A., 2004, OBSTET GYNAECOL, V6, P66
   Bayram N, 2001, COCHRANE DB SYST REV
   CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27, DOI 10.1210/jcem-64-1-27
   Collins J, 2001, SEMIN REPROD MED, V19, P279, DOI 10.1055/s-2001-18047
   Copland JA, 2002, BIOL REPROD, V66, P1230, DOI 10.1095/biolreprod66.5.1230
   Davar R, 2011, IRAN J REPROD MED, V9, P31
   Daya S, 2000, CURR OPIN OBSTET GYN, V12, P227, DOI 10.1097/00001703-200006000-00010
   DIAMANTIKANDARA.E, 2008, EXPERT REV MOL MED, V10
   Dyer SJ, 2002, HUM REPROD, V17, P1680, DOI 10.1093/humrep/17.7.1680
   Einspanier A, 1995, ADV EXP MED BIOL, V395, P517
   Einspanier A, 1997, BIOL REPROD, V57, P16, DOI 10.1095/biolreprod57.1.16
   Elghblawi Ebtisam, 2007, Br J Nurs, V16, P1118
   Elnashar A, 2007, FERTIL STERIL, V88, P406, DOI 10.1016/j.fertnstert.2006.11.173
   Evands, 2003, HUMAN REPROD, V18, P1428
   Farzadi Laya, 2006, J MED TABRIZ U MED S, V12, P29
   Fauser BC, 2002, J CLIN ENDOCR METAB, V87, P709, DOI 10.1210/jc.87.2.709
   Fulghesu AM, 2002, FERTIL STERIL, V77, P1128, DOI 10.1016/S0015-0282(02)03133-3
   Furuya K, 1995, ADV EXP MED BIOL, V395, P523
   FURUYA K, 1994, HORM RES, V41, P41, DOI 10.1159/000183942
   Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629
   Homburg R, 2008, BEST PRACT RES CL OB, V22, P261, DOI 10.1016/j.bpobgyn.2007.07.009
   Hrabovszky E, 1998, ENDOCRINOLOGY, V139, P2600, DOI 10.1210/en.139.5.2600
   Humaidan P, 2011, HUM REPROD UPDATE, V7, P510
   Johnson NP, 2003, HUM REPROD, V18, P947, DOI 10.1093/humrep/deg260
   Karimzadeh MA, 2010, FERTIL STERIL, V94, P216, DOI 10.1016/j.fertnstert.2009.02.078
   Leila Roshangar PH, 2001, IRAN J REPROD MED, V7, P19
   MAAS S, 1992, J CLIN ENDOCR METAB, V74, P306, DOI 10.1210/jc.74.2.306
   Malkawi H Y, 2003, J Obstet Gynaecol, V23, P289, DOI 10.1080/01443610310000100123
   Mass S, 1992, J CLIN ENDOCR METAB, V71, P306
   McEwen B. B, 2004, ADV PHARMACOL, V50, P650
   Melli Manizheh Sayyah, 2009, AFRICAN J PHARM PHAR, V1, P2992
   Melli Manizheh Sayyah, 2007, J MED SCI, V7, P9921
   Melo AS, 2010, HUM REPROD, V25, P2124, DOI 10.1093/humrep/deq162
   Moll E, 2006, BRIT MED J, V332, P1485, DOI 10.1136/bmj.38867.631551.55
   Morreale HFE, 2008, EXPERT OPIN PHARMACO, V9, P2995, DOI 10.1517/14656560802559932
   Nandanwar Y S, 1999, J Postgrad Med, V45, P79
   Odetti P, 2003, DIABETES, V52, P499, DOI 10.2337/diabetes.52.2.499
   Orio F, 2008, Minerva Ginecol, V60, P39
   Pieper GM, 1998, J CARDIOVASC PHARM, V32, P101, DOI 10.1097/00005344-199807000-00016
   Schuering Andreas N., 2008, Gynaekologisch-Geburtshilfliche Rundschau, V48, P9, DOI 10.1159/000111465
   Setji TL, 2007, AM J MED, V120, P128, DOI 10.1016/j.amjmed.2006.06.029
   SHALEV E, 1995, HUM REPROD, V10, P2541, DOI 10.1093/oxfordjournals.humrep.a135741
   singh Sima Mehtotra Urmila, LUCKNOW INDIA EFFECT
   Speroff Leon, 2011, FERTIL STERIL, V75, P1111
   Survey E. S, 2000, FERTIL STERIL, V73, P667
   Tarlatzis BC, 2008, HUM REPROD, V23, P462, DOI 10.1093/humrep/dem426
   Wadhwa L, 2016, J OBSTET GYN INDIA, V66, P459, DOI 10.1007/s13224-015-0833-3
   Wang SP, 2013, SEMIN REPROD MED, V31, P365, DOI 10.1055/s-0033-1348895
NR 51
TC 1
Z9 1
U1 5
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1757
EP 1763
DI 10.19193/0393-6384_2018_6_269
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400020
DA 2022-07-14
ER

PT J
AU Masrour, MJ
   Ashtary, F
AF Masrour, Mojgan Javedani
   Ashtary, Fatemeh
TI THE STUDY OF NATURAL VERSUS HORMONE REPLACEMENT THERAPY CYCLES IN FROZEN
   EMBRYO TRANSFER IN INFERTILE COUPLES ON PREGNANCY OUTCOME: A DOUBLE
   BLIND RANDOMIZED CONTROL TRIAL
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Endometrium thickness; Pregnancy outcome; Hormonal cycle; natural cycle
AB Background: The present Randomized controlled trial (RCT) was conducted to evaluate reproductive outcomes of frozen embryo transfer (FET) during hormonally intervened cycle and also during physiological condition.
   Methods: The present RCT was conducted on 200 couples (240 cycle) with male-originated infertility aged 19 to 39 years at the Infertility Clinic of Shahid Akbar Abadi hospital, Tehran. The Participants were randomly allocated into two group; the natural cycle (n=115 cycle) and hormonal cycle (n=125 cycle). The hormonal group was received 4-6 mg of oral estradiol on the third day of their cycles; while controls received placebo. Transvaginal ultrasound was used for evaluation of endometrial thickness and when the thickness was reached to8 mm, embryo transfer was planned. Chemical and clinical pregnancy were considered to be the primary and secondary outcomes, respectively.
   Results: A total of 28 cycles were cancelled in both groups; 15 cycles (8.3 percent) in the natural group and 13 cycles (7.6 percent) in the hormonal group. Inter-groups statistical analysis showed that serum levels of FSH, LH and estradiol were not statistically different between the study groups (P>0.05). On the other hand, chemical clinical pregnancy rate (hormone receiving group: 32.7% and control group: 33.3%) and clinical pregnancy rate (hormone receiving group: 34.5% and control group: 26.4%) statistically were not different between the groups (P>0.05).
   Conclusion: The study results showed there is not any statistical significant difference between the study groups from point of view of chemical and clinical pregnancy rate. There is still a controversy whether one is superior over the other, so further studies are needed.
C1 [Masrour, Mojgan Javedani; Ashtary, Fatemeh] Iran Univ Med Sci, Shahid Akbarabadi Hosp, Res & Clin Ctr Gynecol & Fertil, Moulavi St, Tehran, Iran.
RP Masrour, MJ (corresponding author), Iran Univ Med Sci, Shahid Akbarabadi Hosp, Res & Clin Ctr Gynecol & Fertil, Moulavi St, Tehran, Iran.
EM javedani46@yahoo.com
CR Casper RF, 2016, FERTIL STERIL, V105, P867, DOI 10.1016/j.fertnstert.2016.01.006
   Fox C, 2016, FERTIL STERIL, V105, P873, DOI 10.1016/j.fertnstert.2016.02.018
   Gelbaya TA, 2006, FERTIL STERIL, V85, P603, DOI 10.1016/j.fertnstert.2005.09.015
   Ghobara T, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003414.pub3
   Givens CR, 2009, REPROD BIOMED ONLINE, V19, P380, DOI 10.1016/S1472-6483(10)60172-1
   HARLOW CR, 1988, ENDOCRINOLOGY, V122, P2780, DOI 10.1210/endo-122-6-2780
   Imudia AN, 2013, FERTIL STERIL, V99, P168, DOI 10.1016/j.fertnstert.2012.08.060
   Levron J, 2014, GYNECOL ENDOCRINOL, V30, P494, DOI 10.3109/09513590.2014.900032
   Ly KD, 2010, CURR WOMENS HEALTH R, V6, P200, DOI 10.2174/157340410792007073
   Morozov V, 2007, J ASSIST REPROD GEN, V24, P119, DOI 10.1007/s10815-006-9100-y
   Mounce G, 2015, FERTIL STERIL, V4
   QUEENAN JT, 1994, FERTIL STERIL, V62, P545
   Schild RL, 2001, FERTIL STERIL, V75, P361, DOI 10.1016/S0015-0282(00)01695-2
   SCHMIDT CL, 1989, FERTIL STERIL, V52, P609
   Sills ES, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-7
   Wang AM, 2011, GYNECOL ENDOCRINOL, V27, P251, DOI 10.3109/09513590.2010.487584
   Xiao ZN, 2012, SYST BIOL REPROD MED, V58, P107, DOI 10.3109/19396368.2011.646047
   ZEILMAKER GH, 1984, FERTIL STERIL, V42, P293
   Zheng Y, 2014, AM J TRANSL RES, V6, P85
NR 19
TC 2
Z9 2
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1765
EP 1769
DI 10.19193/0393-6384_2018_6_270
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400021
DA 2022-07-14
ER

PT J
AU Merdin, A
AF Merdin, Alparslan
TI SUGGESTION OF NEW FORMULAE TO BE USED IN DISTINGUISHING BETA THALASEMIA
   TRAIT FROM IRON DEFICIENCY ANEMIA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Thalasemia trait; iron deficiency anemia; discrimination index
ID DIFFERENTIATION; INDEXES
AB Introduction: Clinical findings of thalasemia trait is similar with iron deficiency anemia. It is important to discriminate both from each other. Because treatment approaches are different for the each entities. But, it is not always possible to reach enough laboratory sufficiency for discriminating the two entities everywhere. Some pratical and easy formulae could help for the discrimination in such insufficient technical possibilities.
   Materials and method: 40 patients included in the study. The formula (RDW(Red blood cell distribution width) X RBC(Red blood cell count) X HGB(Hemoglobin))/MCV(Mean corpuscular volume) was evaluated for the discrimination of the two entities. The formula log(10) (MCH(Mean corpuscular hemoglobin) X MCHC(Mean corpuscular hemoglobin concentration) X RDW / RBC) was also evaluated for the differentiation of these two entities. The latter formula was identified as "Alparslan index''. These formulae were compared with the well known indices such as Mentzer index. Youden Index was calculated for each index for comparing the reliability and validity of the indices.
   Results: The study showed no difference between the compared indices according to the sensitivity. Youden Index were found 94,73 for the Alparslan Index and 89,96 for the Mentzer Index.
   Discussion: There are many formulae and indices to help have an opinion for the discrimination of beta thalasemia trait from IDA(Iron deficiency anemia). Simply calculable valid formulae could be more commonly and easily used according to the complex calculation formulae. RDWI(Red Blood Cell Distribution Width Index) was found to provide more reliability than Mentzer Index in the study. In the study, Alparslan Index and RDWI were also found to provide same reliability according to Youden Index.
C1 [Merdin, Alparslan] Univ Hlth Sci Ankara, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Hematol Clin, Ankara, Turkey.
   [Merdin, Alparslan] Univ Hlth Sci Ankara, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Bone Marrow Transplantat Unit, Ankara, Turkey.
RP Merdin, A (corresponding author), Zerdalilik Mahallesi, Muratpasa Antalya, Turkey.
EM Alparslanmerdin@yahoo.com
CR Demir A, 2002, PEDIATR INT, V44, P612, DOI 10.1046/j.1442-200X.2002.01636.x
   GREEN R, 1989, BLOOD CELLS, V15, P481
   Jayabose S, 1999, J PEDIAT HEMATOL ONC, V21, P314
   MENTZER WC, 1973, LANCET, V1, P882
   Ntaios G, 2007, ANN HEMATOL, V86, P487, DOI 10.1007/s00277-007-0302-x
   Sirdah M, 2008, INT J LAB HEMATOL, V30, P324, DOI 10.1111/j.1751-553X.2007.00966.x
   SRIVASTAVA PC, 1973, LANCET, V2, P154
   Vehapoglu A, 2014, ANEMIA, V2014, DOI 10.1155/2014/576738
   YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
NR 9
TC 2
Z9 2
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 393
EP 395
DI 10.19193/0393-6384_2018_2_62
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400016
DA 2022-07-14
ER

PT J
AU Merdin, FA
   Merdin, A
AF Merdin, Fatma Avci
   Merdin, Alparslan
TI IS THERE ANY RELATION BETWEEN IRON DEFICIENCY ANEMIA AND LIPID PROFILE
   IN WOMEN AGED 18-45 YEARS OLD?: A UNICENTER RETROSPECTIVE STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Iron deficiency; anemia; lipid profile; relation
ID RAT; PLASMA
AB Introduction: Iron deficiency anemia (IDA) is commonly seen among premenopausal women with anemia. Iron is a vital nutrient that plays a role in some metabolic pathways. This study aims to determine whether there is a relationship between iron deficiency anemia and lipid profile by comparing serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol levels in patients with IDA and healthy controls.
   Materials and methods: The study included 56 female patients admitted to the Internal Medicine Outpatient Unit of University of Health Sciences Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital between 15 October 2016 and 30 June 2017. All 56 patients were diagnosed with iron deficiency anemia. Patients with certain diseases that may affect lipid profile such as hypertension, diabetes mellitus, and thyroid diseases, as well as those using medications that could affect serum cholesterol levels were not included in the study. Besides, patients with known infectious or inflammatory diseases were excluded from the study. The study also included 37 healthy women as control group. All of 37 healthy women were admitted to outpatient unit for routine tests and they had no known illnesses, either anemia or any known clinical condition that could affect their lipid levels. All of 37 healthy women and all of 56 female patients were 18-45 years old. Serum triglyceride, total cholesterol, HDL cholesterol, LDL cholesterol, iron, and ferritin levels, and hemogram parameters were evaluated retrospectively on the electronic patient file system.
   Results: The triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol levels were compared between the two groups, and there were no statistically significant differences between the two groups in terms of triglyceride and HDL cholesterol levels (p>0.05). However, there was a statistically significant difference between the two groups with regard to total cholesterol levels (Z=-2.245; p=0.025). There was a statistically significant difference between the two groups with respect to LDL cholesterol levels (Z=-1.998; p=0.046). LDL cholesterol levels of patients with iron-deficiency anemia were found to be significantly higher than those of the control group. The mean age of the patients with iron deficiency anemia was also found to be significantly higher than that of the control group (Z=-2.925, p=0.003).
   Conclusion: It should be kept in mind that LDL cholesterol levels might be affected in patients with iron deficiency anemia.
C1 [Merdin, Fatma Avci] Univ Hlth Sci Ankara, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Internal Med Clin, Ankara, Turkey.
   [Merdin, Alparslan] Univ Hlth Sci Ankara, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Hematol Clin, Ankara, Turkey.
   [Merdin, Alparslan] Univ Hlth Sci Ankara, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Bone Marrow Transplantat Unit, Ankara, Turkey.
RP Merdin, FA (corresponding author), Dr Abdurrahman Yurtaslan Ankara Oncol Educ & Res, Mehmet Akif Ersoy Mahallesi,13 Cadde,56, Ankara, Turkey.
EM fatma_avci.md@hotmail.com
RI Ertan, Asli/AAE-6201-2021; Merdin, Alparslan/AAD-8751-2022
CR AMINE EK, 1971, J NUTR, V101, P1575, DOI 10.1093/jn/101.11.1575
   Balder JW, 2017, J CLIN LIPIDOL, V11, P1055, DOI 10.1016/j.jacl.2017.05.007
   BRISTOWCRAIG HE, 1994, INT J VITAM NUTR RES, V64, P324
   Choi JW, 2001, ANN CLIN LAB SCI, V31, P151
   CUNNANE SC, 1987, J NUTR, V117, P1514, DOI 10.1093/jn/117.9.1514
   Davis MR, 2012, GENES NUTR, V7, P415, DOI 10.1007/s12263-011-0278-y
   OHIRA Y, 1980, J NUTR SCI VITAMINOL, V26, P375, DOI 10.3177/jnsv.26.375
   Ozdemir A, 2007, AM J MED SCI, V334, P331, DOI 10.1097/MAJ.0b013e318145b107
   SHERMAN AR, 1978, J NUTR, V108, P152
   Shirvani M, 2017, CASP J INTERN MED, V8, P305, DOI 10.22088/cjim.8.4.305
   Turkiye Endokrinoloji ve Metabolizma Dernegi, 2017, LIP MET BOZ TAN TED
   Verma Udit, 2010, J Indian Med Assoc, V108, P555
   World Health Organization, 1968, WHO TECHN REP SER, V405
   Yang S, 2015, CLIN LAB, V61, P1463, DOI 10.7754/Clin.Lab.2015.150202
NR 14
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1949
EP 1952
DI 10.19193/0393-6384_2018_6303
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400054
DA 2022-07-14
ER

PT J
AU Messina, A
   Picciocchi, E
   Monda, V
   Valenzano, A
   Cibelli, G
   Ruberto, V
   Pisanelli, D
   Polito, AN
   Marsala, G
   Di Palma, A
   Barone, AV
   Monda, M
   Ruberto, M
   Gallai, B
   Tripi, G
   Lavan, F
   Salerno, M
   Lavano, SM
   Romano, P
   Cerroni, F
   Russo, D
   Doro, L
   Sorrentino, M
   Magliulo, RM
   Di Folco, A
   Parisi, L
   Testa, D
   Marotta, R
   Messina, G
AF Messina, Antonietta
   Picciocchi, Elisabetta
   Monda, Vincenzo
   Valenzano, Anna
   Cibelli, Giuseppe
   Ruberto, Valentina
   Pisanelli, Daniela
   Polito, Anna Nunzia
   Marsala, Gabriella
   Di Palma, Antonella
   Barone, Antonia Vanessa
   Monda, Marcellino
   Ruberto, Maria
   Gallai, Beatrice
   Tripi, Gabriele
   Lavan, Francesco
   Salerno, Margherita
   Lavano, Serena Marianna
   Romano, Palmira
   Cerroni, Francesco
   Russo, Daniela
   Doro, Lucrezia
   Sorrentino, Michele
   Magliulo, Rosaria Martina
   Di Folco, Annabella
   Parisi, Lucia
   Testa, Davide
   Marotta, Rosa
   Messina, Giovanni
TI BENEFICIAL EFFECTS OF PASTA DURING PREGNANCY: THE POSITIVE EFFECTS OF
   MEDITERRANEAN DIET
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Pregnancy; Diet; Mediterranean diet; Pasta; Nutrition
ID SLEEP-APNEA SYNDROME; CARDIOVASCULAR-DISEASE; HYPERTHERMIC REACTIONS;
   CEREBRAL INJECTION; OXIDATIVE STRESS; ITALIAN PATIENTS; CHILDREN;
   MUTATION; GENE; MIGRAINE
AB Pregnancy is a physiological state during which the woman's body undergoes profound modifications. During this time, every woman must be nourished in such a way as to maintain herself in good health and at the same time allovt , the fetal tissues to form and develop in the best way.
   Proper nutrition is one of the fundamental prerequisites for the normal evolution of both pregnancy and fetal growth: the quantity and quality of food and drinks must be scrupulously controlled.
   Contrariwise, it is important to avoid the excess calories and macronutrients. In filet, during pregnancy, it may be just as harmful as their shortage, e.specially in overweight and obese women, jar which the risk of miscarriage, gestational diabetes, fetal growth disorders and preeclampsia increases.
   The pasta constitutes the foundation of the Mediterranean diet food. The dough can be seen, therefore, so it represents an excellent ally of the diet from a nutritional point of view. The nutritional values of the pasta change depending on the type, based on the fact that the dough is traditional or integral semolina. It also contains vitamin B and has an abundance of minerals, among which potassium.
   The pasta is an easily digestible food, ensuring energy ready to use (such as all carbohydrates); moreover, it possesses a great satiating power. In case of overweight, however, it is possible to reduce the number of carbohydrates in the diet, taking care not to make them ever miss.
   In conclusion, the consumption of pasta is very important during pregnancy: a diet without carbohydrates can be dangerous for all physiological pathways.
C1 [Messina, Antonietta; Monda, Vincenzo; Monda, Marcellino] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.
   [Picciocchi, Elisabetta; Valenzano, Anna; Cibelli, Giuseppe; Ruberto, Valentina; Pisanelli, Daniela; Di Palma, Antonella; Barone, Antonia Vanessa; Messina, Giovanni] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Marsala, Gabriella] Azienda Ospedaliero Univ, Osped Riuniti Foggia, Struttura Complessa Farm, Foggia, Italy.
   [Ruberto, Maria] CDR Santa Maria Pozzo, Somma Vesuviana, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Lavan, Francesco; Lavano, Serena Marianna; Marotta, Rosa] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Di Folco, Annabella; Parisi, Lucia; Testa, Davide] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Doro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Sorrentino, Michele] NICU Preterm & High Risk Newborn Neurodev Follow, Volturno, CE, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp Castel, Volturno, CE, Italy.
   [Magliulo, Rosaria Martina] Ctr Studi Scoliosi SRL, Naples, Italy.
RP Monda, V (corresponding author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.
EM vincenzo.monda@unicampania.it
RI Messina, Antonietta/AHH-2383-2022; Cibelli, Giuseppe/AAC-2635-2019;
   Marotta, Rosa/AAG-1453-2020; Messina, Giovanni/AAE-8668-2022; MESSINA,
   ANTONIETTA/K-9366-2016
OI Messina, Antonietta/0000-0001-8343-432X; Messina,
   Giovanni/0000-0002-0011-867X; Monda, Marcellino/0000-0002-7184-218X;
   Monda, Vincenzo/0000-0002-6083-5814; CIBELLI,
   GIUSEPPE/0000-0002-5371-2584; Cerroni, Francesco/0000-0003-3024-5482;
   Marotta, Rosa/0000-0003-0515-5952
FU Pastificio Di Martino Gaetano F. lli Spa
FX Thanks to Pastificio Di Martino Gaetano & F. lli Spa for non-conditioned
   financial support for research projects in Nutrition Physiology
CR Albenzio M, 2013, J DAIRY SCI, V96, P2781, DOI 10.3168/jds.2012-6218
   Bach-Faig A, 2011, PUBLIC HEALTH NUTR, V14, P2274, DOI 10.1017/S1368980011002515
   Bafunno V, 2010, HAEMOPHILIA, V16, P469, DOI 10.1111/j.1365-2516.2009.02150.x
   Bafunno V, 2014, THROMB RES, V134, P1135, DOI 10.1016/j.thromres.2014.08.028
   Bafunno V, 2013, J ALLERGY CLIN IMMUN, V132, P748, DOI 10.1016/j.jaci.2013.04.006
   Bertozzi G, 2018, MOL NEUROBIOL, V55, P5548, DOI 10.1007/s12035-017-0774-1
   Bramanti V, 2016, J NEUROSCI RES, V94, P90, DOI 10.1002/jnr.23678
   Bruce KD, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-013-0446-0
   Bukvic N, 2010, AM J MED GENET A, V152A, P1730, DOI 10.1002/ajmg.a.33437
   Canestraro M, 2010, CANCER GENET CYTOGEN, V199, P110, DOI 10.1016/j.cancergencyto.2010.02.010
   Caroprese M, 2012, SMALL RUMINANT RES, V102, P177, DOI 10.1016/j.smallrumres.2011.07.010
   Caroprese M, 2010, J DAIRY SCI, V93, P2395, DOI 10.3168/jds.2009-2604
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Catalano P, 2015, INT J OBESITY, V39, P642, DOI 10.1038/ijo.2015.15
   Cerretani D, 2011, PHARMACOL RES, V64, P517, DOI 10.1016/j.phrs.2011.08.002
   Chatzi L, 2017, PEDIATR OBES, V12, P47, DOI 10.1111/ijpo.12191
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Cleveland LE, 2000, J AM COLL NUTR, V19, p331S, DOI 10.1080/07315724.2000.10718969
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Dominguez LJ, 2017, CURR OPIN CLIN NUTR, V20, P61, DOI 10.1097/MCO.0000000000000337
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Esposito M, 2014, CHEMOSPHERE, V94, P62, DOI 10.1016/j.chemosphere.2013.09.013
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Galimberti S, 2007, J CHEMOTHERAPY, V19, P315, DOI 10.1179/joc.2007.19.3.315
   Gabarra AG, 2017, NUTR HOSP, V34, P490, DOI 10.20960/nh.937
   Gutierrez-Bedmar M, 2017, CIRC J, V81, P1183, DOI 10.1253/circj.CJ-17-0032
   Muros JJ, 2017, NUTRITION, V35, P87, DOI 10.1016/j.nut.2016.11.002
   Koutelidakis AE, 2018, INT J FOOD SCI NUTR, V69, P84, DOI 10.1080/09637486.2017.1330403
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina G., 2015, BIOL MED ALIGARH, V7, P1, DOI [10.4172/0974-8369.1000240, DOI 10.4172/0974-8369.1000240]
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda M, 2008, PEPTIDES, V29, P120, DOI 10.1016/j.peptides.2007.10.016
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda V, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00695
   Moscatelli F, 2015, BIOL MED, V7
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159846
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parlapani E, 2019, J MATERN-FETAL NEO M, V32, P1084, DOI 10.1080/14767058.2017.1399120
   Pellegrino PL, 2007, AM J CARDIOL, V99, P1737, DOI 10.1016/j.amjcard.2007.01.056
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Petito A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156601
   Piacentino D, 2015, CURR NEUROPHARMACOL, V13, P101, DOI 10.2174/1570159X13666141210222725
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Pomara C, 2012, CURR MED CHEM, V19, P5647, DOI 10.2174/092986712803988811
   Pomara C, 2009, RADIOL MED, V114, P1367, DOI 10.1007/s11547-009-0435-1
   Pomara C, 2008, CLIN TOXICOL, V46, P322, DOI 10.1080/15563650701419011
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Santacroce R, 2008, BLOOD COAGUL FIBRIN, V19, P197, DOI 10.1097/MBC.0b013e3282f234ab
   Santacroce R, 2009, GENET TEST MOL BIOMA, V13, P573, DOI 10.1089/gtmb.2009.0015
   Santillo A, 2009, INT DAIRY J, V19, P655, DOI 10.1016/j.idairyj.2009.06.011
   Santillo A, 2009, J DAIRY SCI, V92, P1330, DOI 10.3168/jds.2008-1598
   Sevi A, 2003, APPL ANIM BEHAV SCI, V83, P41, DOI 10.1016/S0168-1591(03)00088-1
   Smirni D, 2018, NEUROL SCI, V39, P1391, DOI 10.1007/s10072-018-3433-z
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Tong TYN, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0677-4
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2005, INT J CARDIOL, V104, P152, DOI 10.1016/j.ijcard.2004.10.051
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2008, INT J LEGAL MED, V122, P173, DOI 10.1007/s00414-007-0208-0
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Turillazzi E, 2013, FORENSIC SCI INT, V231, P142, DOI 10.1016/j.forsciint.2013.04.006
   Turillazzi E, 2008, VIRCHOWS ARCH, V453, P209, DOI 10.1007/s00428-008-0632-7
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 97
TC 0
Z9 0
U1 5
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2107
EP 2114
DI 10.19193/0393-6384_2018_4s_325
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900005
DA 2022-07-14
ER

PT J
AU Mi, Z
AF Mi, Zhan
TI CLINICAL EFFICACY OBSERVATION OF MASSAGE MANIPULATION FOR GYMNASTS'
   ANKLE SPRAIN AND CONTUSION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Massage; Ankle joint; Skeletal injury; Ligament injury; Clinical
   efficacy
AB To fully define clinical effects of massage manipulation for gymnasts' ankle sprain and contusion, and find new method for gymnasts injury, this paper makes retrospective analysis of treatment materials of 1,200 Gymnasts' ankle sprain and contusion. According to different treatment methods, they are divided into observation group and control group, respectively 800 cases, 400 cases. Injury patients in observation group were treated with traditional Chinese massage manipulation, while injury patients in control group received conventional western way of treatment. Used drugs are Voltaren, to be administered in external application. Half a month after treatment, ankle injury symptoms and recovery of ankle function before and after treatment were compared and effect evaluation was done from such dimensions as ankle injury pain, joint swelling, joint tenderness, joint dysfunction. The results show that after massage manipulation, ankle symptoms and functional activity index scores of injury patients in observation group are significantly reduced. Compared with the situation before treatment, improved difference significantly P<0.05, statistically significant. In comparison of indexes of the two groups, ankle junction recovery of observation group patients is obviously better than that of control group patients, differences between the two groups P <0.05, with statistically significant differences. Therefore, the results of this study Ally confirm that treatment of Gymnasts' ankle sprain and contusion with massage manipulation can effectively improve patients' ankle function, and help patients relieve pain, with good therapeutic effect and high clinical value.
C1 [Mi, Zhan] Changan Univ, Dept Phys Educ, Xian 710064, Shaanxi, Peoples R China.
RP Mi, Z (corresponding author), Changan Univ, Dept Phys Educ, Xian 710064, Shaanxi, Peoples R China.
EM 345035663@qq.com
CR Banjar A, 2017, TURK J MED SCI, V47, P211, DOI 10.3906/sag-1510-105
   Bich GA, 2017, SAUDI J BIOL SCI, V24, P851, DOI 10.1016/j.sjbs.2016.05.010
   Bo Chen, 2012, CHINESE J TRADITIONA, V9
   Bo Chen, 2012, SHANGHAI J TRADITION, V12, P56
   Dilci A, 2017, TURK J MED SCI, V47, P1757, DOI 10.3906/sag-1705-108
   Feiyue Li, 2014, CHINESE J TRADITIONA, V14
   Fu HL, 2017, WATER-SUI, V9, DOI 10.3390/w9110846
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P1355, DOI 10.1016/j.sjbs.2016.09.010
   Jianbang Tang, 2011, J GUANGZHOU U TRADIT, V17, P232
   Kumar R, 2016, SAUDI J BIOL SCI, V23, P243, DOI 10.1016/j.sjbs.2015.03.006
   Li S, 2013, ACTA OCEANOL SIN, V32, P8, DOI 10.1007/s13131-013-0326-0
   Pinhui Xie, 2011, JIANGXI J TRADITIONA, V21, P69
   Shi Yanpeng, 2014, J OPT, V16, P1
   Valiee S, 2016, ACTA MEDICA MEDITERR, V32, P1021
   Xiangyang Zhai, 2011, J CHINESE MED, V8, P376
   Yang AM, 2017, J ALLOY COMPD, V695, P915, DOI 10.1016/j.jallcom.2016.10.188
   Yingzhi Li, 2014, J LIAONING U TRADITI, V23, P80
   Zhongsheng Gou, 2013, CHINESE MED HERALD, V8, P2080
NR 18
TC 0
Z9 0
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1589
EP 1592
DI 10.19193/0393-6384_2018_3s_247
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400023
DA 2022-07-14
ER

PT J
AU Mismar, A
   Aladaileh, M
   Obeidat, F
   Al-Qudah, M
   Albsoul, N
   Alimoglu, O
AF Mismar, Ayman
   Aladaileh, Mohammad
   Obeidat, Firas
   Al-Qudah, Mohammad
   Albsoul, Nader
   Alimoglu, Orhan
TI CHANGING HISTOPATHOLOGICAL TRENDS OF PAROTID TUMORS: 25 YEARS OF
   EXPERIENCE OF 160 CASES FROM A SINGLE INSTITUTION IN JORDAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Parotid; Warthin's; Pleomorphic; Demography; Relative incidence
ID SALIVARY-GLAND TUMORS; POPULATION; NEOPLASMS; FEATURES
AB Background: Benign parotid tumors show a variable behavior. Our aim is to study the features of parotid neoplasms in a recent time interval and to compare it with our previous results.
   Materials and methods: The records of 160 patients who underwent parotidectomy at Jordan University Hospital from January 1990 to September 2014 were reviewed. A comparison of histopathological features between two interval periods (19902006 & 2007-2014) was done.
   Results: The most common benign neoplasm was pleomorphic adenoma (46.6-50) %, followed by Warthin's tumor (16-29) %. Warthin tumours represented 29% of benign parotid tumors in 2007-2014 interval while it was 16 % in 1990-2006 interval with a significant difference statistically (p value 0.049).
   Conclusion: Warthin's tumor was seen more than expected, it exceeds the reports from other countries and our own report ten years ago giving the impression that it does not only vary geographically but also changes with time.
C1 [Mismar, Ayman; Aladaileh, Mohammad; Obeidat, Firas; Al-Qudah, Mohammad; Albsoul, Nader] Univ Jordan, Fac Med, Dept Gen Surg, Amman, Jordan.
   [Alimoglu, Orhan] Medeniyet Univ, Fac Med, Gen Surg, Istanbul, Turkey.
RP Mismar, A (corresponding author), Univ Jordan, Fac Med, Dept Surg, POB 13024, Amman 11942, Jordan.
EM aymanmismarr@yahoo.com
RI Mismar, Ayman/AAN-3570-2021; Alimoglu, Orhan/I-1972-2019
CR Al Sarraj Y, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.583
   Albsoul N, 2013, ACTA MEDICA MEDITERR, V29, P483
   Altinay S, 2014, ASIAN PAC J CANCER P, V15, P5701, DOI 10.7314/APJCP.2014.15.14.5701
   Alves FA, 2002, ARCH OTOLARYNGOL, V128, P1400, DOI 10.1001/archotol.128.12.1400
   Araya J, 2015, MED ORAL PATOL ORAL, V20, pE532, DOI 10.4317/medoral.20337
   Bradley PJ, 2013, BRIT J ORAL MAX SURG, V51, P399, DOI 10.1016/j.bjoms.2012.10.002
   Buchner A, 2007, J ORAL PATHOL MED, V36, P207, DOI 10.1111/j.1600-0714.2007.00522.x
   de Oliveira FA, 2009, HEAD NECK PATHOL, V3, P271, DOI 10.1007/s12105-009-0139-9
   Derin Serhan, 2015, Asian Pac J Cancer Prev, V16, P3539
   ELGAZAYE.MM, 1964, BRIT J CANCER, V18, P649, DOI 10.1038/bjc.1964.74
   Ezeanolue B C, 1999, West Afr J Med, V18, P179
   Fomete B, 2015, ANN AFR MED, V14, P148, DOI 10.4103/1596-3519.152071
   Ito FA, 2005, INT J ORAL MAX SURG, V34, P533, DOI 10.1016/j.ijom.2005.02.005
   Jaafari-Ashkavandi Zohreh, 2014, J Dent Res Dent Clin Dent Prospects, V8, P15, DOI 10.5681/joddd.2014.003
   Jansisyanont P, 2002, INT J ORAL MAX SURG, V31, P257, DOI 10.1054/ijom.2002.0223
   Lawal Ahmed O, 2013, J Clin Exp Dent, V5, pe218, DOI 10.4317/jced.51143
   LOYOLA AM, 1995, ORAL ONCOL, V31B, P197
   Luksic I, 2012, J CRANIO MAXILL SURG, V40, pE75, DOI 10.1016/j.jcms.2011.05.002
   Masanja M I, 2003, East Afr Med J, V80, P429
   Ochicha O, 2009, INDIAN J PATHOL MICR, V52, P473, DOI 10.4103/0377-4929.56121
   Pinkston JA, 1999, OTOLARYNG HEAD NECK, V120, P834, DOI 10.1016/S0194-5998(99)70323-2
   Przewozny T, 2004, EUR ARCH OTO-RHINO-L, V261, P369, DOI 10.1007/s00405-003-0698-4
   Ramdass MJ, 2015, MOL CLIN ONCOL, V3, P167, DOI 10.3892/mco.2014.437
   Satko I, 2000, J CRANIO MAXILL SURG, V28, P56, DOI 10.1054/jcms.1999.0092
   Shashinder S, 2009, Med J Malaysia, V64, P31
   SPIRO RH, 1986, HEAD NECK SURG, V8, P177, DOI 10.1002/hed.2890080309
   Taghavi N, 2016, TURK J PATHOL, V32, P35, DOI 10.5146/tjpath.2015.01336
   Tian Z, 2010, INT J ORAL MAX SURG, V39, P235, DOI 10.1016/j.ijom.2009.10.016
   Ungari C, 2008, EUR REV MED PHARMACO, V12, P321
   VARGAS Pablo Agustin, 2002, REV HOSP CLIN, V57
   Vuhahula Edda A M, 2004, Afr Health Sci, V4, P15
   Zhu SB, 2015, ARCH PATHOL LAB MED, V139, P55, DOI 10.5858/arpa.2014-0167-RA
NR 32
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 437
EP 441
DI 10.19193/0393-6384_2018_2_69
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400023
DA 2022-07-14
ER

PT J
AU Mnedla, S
   Bragazzi, NL
   Chiorri, C
   Elloumi, A
   Briki, W
AF Mnedla, Sofiene
   Bragazzi, Nicola Luigi
   Chiorri, Carlo
   Elloumi, Ali
   Briki, Walid
TI VALIDATION OF THE ARABIC-TUNISIAN VERSION OF THE FRENCH COMPETITIVE
   STATE ANXIETY INVENTORY-2 REVISED (CSAI-2R): INSIGHTS FROM AN
   EXPLORATORY FACTOR ANALYSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE competitive anxiety; sport psychology; Arabic language; scale
   validation; parallel analysis (PA); exploratory factor analysis (EFA);
   item analysis
ID DIMENSIONS; INTENSITY
AB Aim: The Competitive State Anxiety Inventory-2 Revised (CSAI-2R) is one of the most frequently used instruments when quantitatively investigating competitive state anxiety in the field of sport psychology research. The purpose of the present study was to validate the Arabic-Tunisian version of the French CSAI-2R questionnaire and to evaluate its validity and reliability.
   Materials and methods: Out of an initial list of 490 subjects, participants of the present validation study were 304 Tunisian football players (81 males [26.6%]; mean age 21.58 years (SD = 2.40 years, range 16-31) of different levels (international level: 34 [11.2%]; national level: 238 [78.3%]; regional level: 32 [10.5%]) that volunteered to participate in the study. Data were collected and analyzed in terms of reliability and validity using correlations, reliability, parallel analysis and exploratory factor analysis.
   Results: The 2-factor solution accounted for 48%, 47% and 56% of variance for the Direction, Frequency, and Intensity scales, respectively. The 3-factor solution accounted for 60%, 57% and 64% of variance for the Direction, Frequency, and Intensity scales, respectively. Although the 3-factor solution explained an additional, substantial proportion of variance with respect to the 2-factor solution, the factor structure did not replicate well across scales. Conversely, in 2-factor solution, if items 1, 2, 15, and 16 were excluded, the pattern of loadings was exactly the same for all scales. Hence, we concluded that the 2-factor solution should be retained, as it provided a measurement model for the Arabic-Tunisian CSAI-2R items that was constant across scales.
   Conclusion: The Arabic-Tunisian version of the French CSAI-2R in its original version has failed to demonstrate robust and sound psychometric properties. Its reduced version represents a first attempt that can be henceforth used in the Arab world, even if further investigations should enable to improve its psychometric properties.
C1 [Mnedla, Sofiene] Mannouba Univ, Dept Educ Sci, Higher Inst Sport & Phys Educ Ksar Said, Manouba, Tunisia.
   [Bragazzi, Nicola Luigi] Univ Genoa, Dept Hlth Sci DISSAL, Sch Publ Hlth, I-16132 Genoa, Italy.
   [Bragazzi, Nicola Luigi] Univ Genoa, IRCCS San Martino IST, Dept Neurosci DINOGMI, Sect Psychiat, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.
   [Chiorri, Carlo] Univ Genoa, Dept Educ Sci, Genoa, Italy.
   [Elloumi, Ali] Univ Paris 05, Lab Tech & Enjeux Corps, Paris, France.
   [Briki, Walid] Qatar Univ, Coll Arts & Sci, Sport Sci Program, Doha, Qatar.
RP Mnedla, S (corresponding author), Mannouba Univ, Dept Educ Sci, Higher Inst Sport & Phys Educ Ksar Said, Manouba, Tunisia.; Mnedla, S (corresponding author), Tunis Univ, Fac Humanities & Social Sci, Dept Educ Sci, Tunis, Tunisia.
RI Bragazzi, Nicola Luigi/G-1672-2011
OI Bragazzi, Nicola Luigi/0000-0001-8409-868X; Briki,
   Walid/0000-0002-6298-811X
CR Asparouhov T, 2009, STRUCT EQU MODELING, V16, P397, DOI 10.1080/10705510903008204
   Benjamini Y, 2000, J EDUC BEHAV STAT, V25, P60, DOI 10.3102/10769986025001060
   BUJA A, 1992, MULTIVAR BEHAV RES, V27, P509, DOI 10.1207/s15327906mbr2704_2
   Gaudreau P, 2002, PSYCHOL SPORT EXERC, V3, P1, DOI 10.1016/S1469-0292(01)00017-6
   Genz A., 2016, PACKAGE MVTNORM
   Hambleton RK., 2009, ADAPTING ED PSYCHOL
   HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447
   JONES G, 1992, PERCEPT MOTOR SKILL, V74, P467, DOI 10.2466/PMS.74.2.467-472
   Martens R., 1990, COMPETITIVE ANXIETY, P127
   Martinent G, 2010, PSYCHOL SPORT EXERC, V11, P51, DOI 10.1016/j.psychsport.2009.05.001
   MORRIS LW, 1981, J EDUC PSYCHOL, V73, P541, DOI 10.1037/0022-0663.73.4.541
   Muthen B., 1998, MPLUS USERS GUIDE
   Nunnally J, 1994, PSYCHOMETRIC THEORY
   SWAIN A, 1993, J SPORT SCI, V11, P533, DOI 10.1080/02640419308730024
   VALLERAND RJ, 1989, CAN PSYCHOL, V30, P662, DOI 10.1037/h0079856
   Woodman T, 2005, J SPORT EXERCISE PSY, V27, P382, DOI 10.1123/jsep.27.3.382
   Woodman T, 2003, J SPORT SCI, V21, P443, DOI 10.1080/0264041031000101809
   Woodman T., 2001, HDB SPORT PSYCHOL, V2nd, P290
NR 18
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 377
EP 382
DI 10.19193/0393-6384_2018_2_59
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400013
DA 2022-07-14
ER

PT J
AU Mo, JG
   Tang, CX
   Wang, XT
   Lu, WS
   Tong, H
   Zhang, CY
   Zhang, GZ
AF Mo, Jinggang
   Tang, Caixi
   Wang, Xiaotao
   Lu, Weisheng
   Tong, Hui
   Zhang, Chunye
   Zhang, Guozhi
TI HISTOPATHOLOGICAL ANALYSIS OF DUCTULAR REACTION IN RABBIT LIVER AFTER
   CHRONIC EXPOSURE OF CHROMIUM (VI)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Cr(VI); Histopathology; Ductular Reaction; Liver; Rabbit
ID PROGENITOR CELLS; STEM-CELLS; RATS; FIBROSIS; CYTOTOXICITY; INDUCTION;
   TOXICITY; INSIGHTS; DISEASES; STRESS
AB Exposure to hexavalent chromium [Cr(VI)] results in hepatocellular damage. However, no research addresses the response of ductules cells, which harbor hepatic stem/progenitor cells, in Cr(VI) induced liver injury. The main goal of this study is to clarify the toxic effect of Cr(VI) on liver histopathological changes including hepatocellular damage and biliary ductular reaction after 3 months exposure in adult rabbits. Twenty four male and female rabbits were allotted randomly to three groups including control, low and moderate dose of Cr(VI) (fed with 0, 0.35 and 2.09 mg/kg/day Cr(VI), respectively). H&E and immunohistochemistry staining were utilized to analyze changes in the structure of the liver. Histopathological results showed that Cr(VI) exposure resulted in hepatocellular damage in a dose dependent manner. Ductular reaction was observable at the portal area as well as canal of Herings as determined by CK7 and CK19. In addition, low dose of Cr(VI) exposure generated more CK-positive cells compared to control and moderate dose of Cr(VI) exposure. Correspondingly, cholangiofibrosis was accompanied by an increase in the bile duct proliferation. To our knowledge, this is the first report that ductular reaction play an important role in the degree of damage and recovery that the liver undergoes following Cr(VI) intoxication.
C1 [Mo, Jinggang] Taizhou Cent Hosp, Dept Hepatobiliary Surg, Taizhou, Zhejiang, Peoples R China.
   [Tang, Caixi] Zhuzhou Cent Hosp, Hepatobiliary & Pancreat Splen Surg, Zhuzhou, Hunan, Peoples R China.
   [Wang, Xiaotao; Lu, Weisheng; Zhang, Guozhi] North China Univ Sci & Technol, Affiliated Hosp, Dept Gen Surg, Tangshan 063000, Hebei, Peoples R China.
   [Tong, Hui; Zhang, Chunye] Hangzhou Singclean Med Prod Co Ltd, Hangzhou, Zhejiang, Peoples R China.
RP Zhang, GZ (corresponding author), North China Univ Sci & Technol, Affiliated Hosp, Dept Gen Surg, Tangshan 063000, Hebei, Peoples R China.
EM Zhanggz5136@163.com
FU Zhejiang Province Science and Technology Project of China [2013C33189]
FX This work was supported by research grants from Zhejiang Province
   Science and Technology Project of China [grant number 2013C33189].
CR Agamy E, 2012, TOXICOL PATHOL, V40, P1128, DOI 10.1177/0192623312448936
   [Anonymous], [No title captured]
   Blazka ME, 1996, TOXICOL PATHOL, V24, P181, DOI 10.1177/019262339602400206
   Cardinale V, 2012, NAT REV GASTRO HEPAT, V9, P231, DOI 10.1038/nrgastro.2012.23
   Collins BJ, 2010, TOXICOL SCI, V118, P368, DOI 10.1093/toxsci/kfq263
   DeFlora S, 1997, CARCINOGENESIS, V18, P531, DOI 10.1093/carcin/18.3.531
   Egyed-Zsigmond I, 2010, ROM J MORPHOL EMBRYO, V51, P265
   Fausto N, 2004, HEPATOLOGY, V39, P1477, DOI 10.1002/hep.20214
   Grappone C, 1999, J HEPATOL, V31, P100, DOI 10.1016/S0168-8278(99)80169-X
   Haouem S, 2013, J TOXICOL PATHOL, V26, P359, DOI 10.1293/tox.2013-0025
   Hickling KC, 2010, TOXICOL PATHOL, V38, P213, DOI 10.1177/0192623309357945
   Jin Li-Fang, 2013, Zoological Research, V34, pE93
   Kolacinski Z, 1999, J TOXICOL-CLIN TOXIC, V37, P785
   Lanthier N, 2013, ACTA GASTRO-ENT BELG, V76, P3
   Libbrecht L, 2002, SEMIN CELL DEV BIOL, V13, P389, DOI 10.1016/S1084952102001258
   Loubieres Y, 1999, J TOXICOL-CLIN TOXIC, V37, P333, DOI 10.1081/CLT-100102431
   Mitsuishi M, 2015, J TOXICOL PATHOL, V28, P1, DOI 10.1293/tox.2014-0021
   Osheroff MR, 2013, INT J TOXICOL, V32, p59S, DOI 10.1177/1091581813487564
   PASCALE LR, 1952, JAMA-J AM MED ASSOC, V149, P1385, DOI 10.1001/jama.1952.02930320025008
   Pozniak KN, 2017, AM J PATHOL, V187, P2744, DOI 10.1016/j.ajpath.2017.08.024
   Saxena R, 2004, SEMIN LIVER DIS, V24, P43
   Sell S, 1998, HEPATOLOGY, V27, P317, DOI 10.1002/hep.510270202
   Soudani N, 2013, ENVIRON TOXICOL, V28, P11, DOI 10.1002/tox.20692
   Stout MD, 2009, ENVIRON HEALTH PERSP, V117, P716, DOI 10.1289/ehp.0800208
   Theise ND, 2007, GASTROENTEROLOGY, V133, P350, DOI 10.1053/j.gastro.2007.05.040
   TSAPAKOS MJ, 1983, CANCER RES, V43, P5662
   Turanyi E, 2010, HISTOPATHOLOGY, V57, P607, DOI 10.1111/j.1365-2559.2010.03668.x
   Velma V, 2013, BIOMARK INSIGHTS, V8, P43, DOI 10.4137/BMI.S11456
   Witt KL, 2013, TOXICOL PATHOL, V41, P326, DOI 10.1177/0192623312469856
   Zhang YJ, 2017, TOXICOL IN VITRO, V41, P232, DOI 10.1016/j.tiv.2017.03.003
   Zhong XL, 2017, J OCCUP MED TOXICOL, V12, DOI 10.1186/s12995-017-0161-x
NR 31
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1213
EP 1219
DI 10.19193/0393-6384_2018_5_186
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700008
DA 2022-07-14
ER

PT J
AU Moeini, A
   Pishvaee, MS
   Dezfuli, M
AF Moeini, Alireza
   Pishvaee, Mir Saman
   Dezfuli, Mostafa
TI STUDY OF CULTURAL AND SOCIAL INDICATORS OF UNIVERSITIES AND HIGHER
   EDUCATION INSTITUTIONS OF THE ISLAMIC REPUBLIC OF IRAN BASED ON THE
   UPSTREAM DOCUMENTS OF THE COUNTRY BY THE COMBINATION OF BSC AND KPI
   METHOD AND THEIR RANKING USING AHP TECHNIQUE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Performance Measurement; Key Performance Indicators; Balanced Score Card
   (BSC); Multi-criteria Decision Technique; Analytical Hierarchy Process;
   Universities and Higher Education Institutions
ID RESPONSIBILITY
AB Background and objective: The purpose of this article is to develop a functional model in the form of a balanced scorecard and multi-criteria decision-making techniques in order to find the most important criteria and key indicators for assessing the performance of universities and institutions of higher education and their ranking.
   Method of measurement: This research is a descriptive-survey study that consisted of 20 experts who consisted of 10 faculty members and 10 faculty members. Data collection tools were four separate questionnaires completed by a group of experts and experts.
   Results: The results of this study showed that strengthening the culture and increasing the financial index and attracting credits is the most important key indicator and financial and human resources criteria are the most important criteria for assessing universities and higher education institutions.
   Conclusion: Based on this research, key criteria and indicators were identified and ranked to assess the cultural and social performance of universities through a group of experts.
C1 [Moeini, Alireza; Pishvaee, Mir Saman] Univ Sci & Technol Iran, Fac Ind, Tehran, Iran.
   [Dezfuli, Mostafa] Univ Sci & Technol Iran, Ind Engn, Tehran, Iran.
RP Moeini, A (corresponding author), Univ Sci & Technol Iran, Fac Ind, Tehran, Iran.
EM alijamalmohammdi@yahoo.com
RI moini, alireza/S-9310-2018; Pishvaee, Mir Saman/H-3450-2018
OI Pishvaee, Mir Saman/0000-0001-6389-6308
CR Ahmad J, 2012, SOC RESPONSIB J, V8, P77, DOI 10.1108/17471111211196584
   BARR PS, 1992, STRATEGIC MANAGE J, V13, P15, DOI 10.1002/smj.4250131004
   Bevan S., 2004, ACHIEVING HIGH PERFO
   Bhattacharya CB, 2004, CALIF MANAGE REV, V47, P9, DOI 10.2307/41166284
   Bronn P. S., 2001, INT J ADVERT, V20, P207, DOI DOI 10.1080/02650487.2001.11104887
   Brown E, 2009, ACME, V8, P474
   Carroll AB., 1979, ACAD MANAGE REV, V4, P497, DOI DOI 10.5465/AMR.1979.4498296
   Hossain Mohammed, 2007, Corporate Social Responsibility and Environmental Management, V14, P274, DOI 10.1002/csr.154
   Nejati M, 2011, AFR J BUS MANAGE, V5, P440
   Sobhani FA, 2009, CORP SOC RESP ENV MA, V16, P167, DOI 10.1002/csr.193
NR 10
TC 2
Z9 2
U1 1
U2 23
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 2
BP 575
EP 581
DI 10.19193/0393-6384_2018_2s_91
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7SD
UT WOS:000429274400005
DA 2022-07-14
ER

PT J
AU Moshtaghie, M
   Kaboli, M
   Salehi, M
AF Moshtaghie, Minoo
   Kaboli, Mohammad
   Salehi, Mansour
TI GEOMETRIC MORPHOMETRIC ANALYSIS OF HEAD SHAPE IN A SPOTTED WHIP SNAKE
   (HEMORRHOIS RAVERGIERI) IN DIFFERENT HABITATS OF IRAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE geometric morphometric; Hemorrhois ravergieri; head shape; habitat
ID LIZARD ANOLIS-CAROLINENSIS; SEXUAL SIZE DIMORPHISM; BODY-SIZE;
   MORPHOLOGICAL VARIATION; CRANIAL DESIGN; BITE-FORCE; EVOLUTION;
   PERFORMANCE; PATTERNS; CONSEQUENCES
AB Morphological patterns of existing variation and investigative concept related to diversity can be very important in understanding the evolution of morphology. It is known that phylogenetic history, size and ecology can all promote the evolution of morphological variation; however, some methods have been recently developed to analyze these aspects for particular body structures. Spotted whip snake Hemorrhois ravergieri appears to have the widest distribution of the Hemorrhois snake genus, especially in Iran. Morphological difference resulting from habitat can occur in several populations of H. ravergieri. Some studies have studied the relation between morphology and habitat use, revealing that motion is the main facilitator of this evolutionary relationship. Now, we consider intraspecific ecomorphological in three habitat types. Geometric morphometric analyses can provide a more detailed image of head shape in three directions (dorsal, lateral and ventral) on three types of habitat: north-west of Iran, north-east of Iran and central Zagros of Iran. Adult specimens were selected and characteristics of head were analyzed, along with body and head size for understanding the proximate mechanisms, which might be involved. The morphological variation between H. ravergieri indicated that variation in size and head dimensions between species and sexes are highly significant in habitat. Males and females differed in head characters and body size; especially, males were found to exhibit a disproportionate increase in head size and dimensions. H. ravergieri from north-east and central Zagros are smaller, than those living in north-west are. The results revealed that considering the previous findings on the populations, the morphological differences were probably not caused by competition between the populations; instead, these traits could be attributed to the natural selection.
C1 [Moshtaghie, Minoo] Islamic Azad Univ, Dept Environm & Energy, Sci & Res Branch, Tehran, Iran.
   [Kaboli, Mohammad] Univ Tehran, Fac Nat Resources, Dept Environm, Tehran, Iran.
   [Salehi, Mansour] Isfahan Univ Med Sci, Sch Med, Dept Genet & Mol Biol, Esfahan, Iran.
RP Kaboli, M (corresponding author), Univ Tehran, Fac Nat Resources, Dept Environm, Tehran, Iran.
EM mkaboli@ut.ac.ir
CR Adams DC, 2004, ITAL J ZOOL, V71, P5, DOI 10.1080/11250000409356545
   Adams DC, 2013, HYSTRIX, V24, P7, DOI 10.4404/hystrix-24.1-6283
   ANDREWS RM, 1994, COPEIA, P613, DOI 10.2307/1447177
   Barros FC, 2011, J EVOLUTION BIOL, V24, P2423, DOI 10.1111/j.1420-9101.2011.02372.x
   Bookstein, BIOMETRICS 1978 INT, P154
   Brown JH, 2000, SFI S SCI C, P1
   Bruner E, 2005, ACTA ZOOL-STOCKHOLM, V86, P245, DOI 10.1111/j.1463-6395.2005.00206.x
   Cardini A, 2009, ZOOL J LINN SOC-LOND, V157, P197, DOI 10.1111/j.1096-3642.2009.00508.x
   CARPENTER GC, 1995, HERPETOLOGICAL MONOGRAPHS, NO 9, 1995, P88
   Claude J, 2003, BIOL J LINN SOC, V79, P485, DOI 10.1046/j.1095-8312.2003.00198.x
   Collar DC, 2011, EVOLUTION, V65, P2664, DOI 10.1111/j.1558-5646.2011.01335.x
   COOPER WE, 1989, AM NAT, V133, P729, DOI 10.1086/284948
   DRYDEN IL, 1998, STAT SHAPE ANAL VOLU
   Fathnia B, 2011, IRANIAN J ANIMAL BIO, V6
   Ghazikhanloo A, 2013, J ANIMAL ENV, V4, P57
   Goodman RM, 2013, INTEGR ZOOL, V8, P184, DOI 10.1111/1749-4877.12041
   Gvozdik L, 2003, J ZOOL, V259, P7, DOI 10.1017/S0952836902003308
   Herrel A, 2001, J EXP ZOOL, V290, P101, DOI 10.1002/jez.1039
   Herrel A, 2007, INTEGR COMP BIOL, V47, P107, DOI 10.1093/icb/icm014
   Husak JF, 2006, COPEIA, P301, DOI 10.1643/0045-8511(2006)6[301:BPPDIM]2.0.CO;2
   Huyghe K, 2009, BIOL J LINN SOC, V96, P13, DOI 10.1111/j.1095-8312.2008.01103.x
   Kaliontzopoulou A, 2008, BIOL J LINN SOC, V93, P111
   Kaliontzopoulou A, 2007, J MORPHOL, V268, P152, DOI 10.1002/jmor.10494
   Kikukawa Nobuto, 2012, Current Herpetology, V31, P97, DOI 10.5358/hsj.31.97
   Klingenberg CP, 2012, J EVOLUTION BIOL, V25, P115, DOI 10.1111/j.1420-9101.2011.02410.x
   Klingenberg CP, 1998, EVOLUTION, V52, P1363, DOI 10.1111/j.1558-5646.1998.tb02018.x
   Pyron RA, 2013, BMC EVOL BIOL, V13, DOI 10.1186/1471-2148-13-93
   Rice WR, 2001, J EVOLUTION BIOL, V14, P685, DOI 10.1046/j.1420-9101.2001.00319.x
   Rohlf F. J, 2004, TPSDIG DIGITIZE LAND
   ROHLF FJ, 1990, SYST ZOOL, V39, P40, DOI 10.2307/2992207
   Rohlf FJ., 2003, TPSSMALL THIN PLATE
   Schaerlaeken V, 2012, J EXP ZOOL PART A, V317A, P371, DOI 10.1002/jez.1730
   Schaetti Beat, 2010, Bulletin of Zoological Nomenclature, V67, P44
   Schatti B, 1985, NEUES KONZEPT COLUBE
   Schweiger M, 1991, HERPETOFAUNA, V13, P70
   Shirai LT, 2010, J EXP ZOOL PART B, V314B, P663, DOI 10.1002/jez.b.21367
   Thompson GG, 2008, AUST J ZOOL, V56, P351, DOI 10.1071/ZO08030
   Tollis M, 2014, GENETICA, V142, P59, DOI 10.1007/s10709-013-9754-1
   Wallach V., 2014, SNAKES WORLD CATALOG
   Watkins GG, 1996, ECOLOGY, V77, P1473, DOI 10.2307/2265544
   Zelditch ML, 2012, GEOMETRIC MORPHOMETRICS FOR BIOLOGISTS: A PRIMER, 2ND EDITION, P1
NR 41
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 2
BP 583
EP 589
DI 10.19193/0393-6384_2018_2s_92
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7SD
UT WOS:000429274400006
DA 2022-07-14
ER

PT J
AU Nezakati, A
   Valiee, S
   Roshani, D
   Seidi, J
AF Nezakati, Aram
   Valiee, Sina
   Roshani, Daem
   Seidi, Jamal
TI THE COMPARISON OF EFFECT OF ABDOMINAL MASSAGE AND CHEWING SUGAR-FREE GUM
   ON THE INCIDENCE AND SEVERITY OF CONSTIPATION IN MALE PATIENTS
   UNDERGOING SKELETAL TRACTION OF LOWER LIMBS: A SINGLE-BLIND CLINICAL
   TRIAL
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Constipation; Massage; Chewing gum; fractures; Iran
ID POSTOPERATIVE BOWEL ACTIVITY; SURGERY; ILEUS; EFFICACY
AB Background: Constipation is a common problem among orthopedic patients, and it is followed by some complications. There are several ways to prevent constipation.
   Objectives: The present study aims to investigate the comparison of effect of abdominal massage and chewing sugar-free gum on the incidence and severity of constipation in male patients undergoing skeletal traction of lower limbs.
   Methods: The present study was conducted as single-blind clinical trial in Besat Hospital of Sanandaj, Iran, 2017. Ninty three male patients undergoing skeletal traction were randomly selected by using sealed envelopes with the capability of replacing the envelopes. They were then divided into three groups: sugar-free chewing gum group, abdominal massage group, and control group. After seven days of intervention, the patients' rate of incidence and severity of constipation was measured based on Rome Ill questionnaire. The data were then analyzed using Kolmogorov Smirnov test and chi-squared test using SPSS-23.
   Results: The incidence rate of constipation in sugar-free chewing gum group, abdominal massage group, and control group was 23.7%, 37.3%, and 39% respectively. The findings indicated that the incidence of constipation in sugar-free chewing gum group as well abdominal massage group was much less than that of the control group, and this statistical difference was significant (P=0.034). With respect to the severity of constipation, no significant difference was observed between the intervention group and control group (p=0.947).
   Conclusion: The present study indicated that chewing sugar free gum and conducting abdominal massage would be effective as a complementary and non-pharmacological method in reducing the incidence rate of constipation.
C1 [Nezakati, Aram] Kurdistan Univ Med Sci, Student Res Comm, Sanandaj, Iran.
   [Valiee, Sina; Seidi, Jamal] Kurdistan Univ Med Sci, Clin Care Res Ctr, Sanandaj, Iran.
   [Roshani, Daem] Kurdistan Univ Med Sci, Res Inst Hlth Dev, Social Determinants Hlth Res Ctr, Sanandaj, Iran.
RP Seidi, J (corresponding author), Kurdistan Univ Med Sci, Clin Care Res Ctr, Sanandaj, Iran.
EM jamal.seidi@muk.ac.ir
RI Valiee, Sina/M-5269-2015; Roshani, Daem/Q-2935-2016
OI Valiee, Sina/0000-0002-5419-1004; Roshani, Daem/0000-0003-4746-1114
FU Research and Technology Deputy of Kurdistan University of Medical
   Sciences, Sanandaj
FX The present study is the result of a master thesis in medical surgical
   nursing titled "the comparison of effect of abdominal massage and
   chewing sugar-free gum on the incidence and severity of constipation in
   male patients undergoing skeletal traction of lower limbs". The Research
   and Technology Deputy of Kurdistan University of Medical Sciences,
   Sanandaj, Iran is greatly appreciated for the financial supports they
   provide for the present study.
CR Abdollahi AA, 2011, ARAK MED U J, V13, P38
   Bonventre S, 2014, MINERVA CHIR, V69, P47
   Choi H, 2014, ASIA-PAC J CLIN ONCO, V10, P53, DOI 10.1111/ajco.12113
   Choopani R, 2017, J EVIDENCE BASED COM
   Ergul B, 2014, SAUDI J GASTROENTERO, V20, P356, DOI 10.4103/1319-3767.145325
   Foroutan, 2015, PHYS TREATMENTS SPEC, V4, P177
   Ge BJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006501
   Huang R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090193
   Khan F, 2017, ANN PHYS REHABILITAT
   Kira I, 2016, JPN J NURS SCI, V13, P95, DOI 10.1111/jjns.12090
   Krogh K, 2017, UNITED EUR GASTROENT, V5, P465, DOI 10.1177/2050640616663439
   Lee JT, 2016, BIOL RES NURS, V18, P167, DOI 10.1177/1099800415592966
   Lee TH, 2015, J NEUROGASTROENTEROL, V21, P121, DOI 10.5056/jnm14077
   Liu Q, 2017, INT J SURG, V47, P107, DOI 10.1016/j.ijsu.2017.07.107
   McClurg D, 2016, PARKINSONS DIS-US, V2016, DOI 10.1155/2016/4842090
   McClurg D, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1890-y
   McGraw T, 2016, CLIN EXP GASTROENTER, V9, DOI 10.2147/CEG.S111693
   MCMILLAN SC, 1989, CANCER NURS, V12, P183, DOI 10.1097/00002820-198906000-00012
   Murata S, 2017, J CLIN BIOCHEM NUTR, V60, P121, DOI 10.3164/jcbn.16-52
   Park KS, 2017, J NEUROGASTROENTEROL, V23, P569, DOI 10.5056/jnm17033
   Sendir M, 2012, GASTROENTEROL NURS, V35, P106, DOI 10.1097/SGA.0b013e31824d2945
   Seyyedrassoli A, 2016, INT J MED RES HEALTH, V5, P33
   Somi Mohammad Hossein, 2015, J Tradit Complement Med, V5, P153, DOI 10.1016/j.jtcme.2014.07.001
   Soufi-Afshar I, 2016, CASP J INTERN MED, V7, P19
   Tekgunduz KS, 2014, ITAL J PEDIATR, V40, DOI 10.1186/s13052-014-0089-z
   Turan N, 2016, GASTROENTEROL NURS, V39, P48, DOI 10.1097/SGA.0000000000000202
   Wong WK, 2015, CHIN MED-UK, V10, DOI 10.1186/s13020-015-0064-7
   박정희, 2016, [Korean Journal of Adult Nursing, 성인간호학회지], V28, P637, DOI 10.7475/kjan.2016.28.6.637
NR 28
TC 1
Z9 1
U1 1
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1787
EP 1792
DI 10.19193/0393-6384_2018_6_274
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400025
DA 2022-07-14
ER

PT J
AU Ni, Z
   Zhuo, H
   Yang, Q
   OuYang, S
   Lin, W
AF Ni, Zhao
   Zhuo, Hui
   Yang, Qing
   OuYang, Song
   Lin, Wei
TI EXPRESSIONS AND CLINICAL SIGNIFICANCE OF PSA, ALP AND ASSOCIATED
   INDICATORS IN SERUM OF PROSTATE CANCER PATIENTS WITH OSSEOUS METASTASIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Prostate cancer; osseous metastasis; prostate specific antigen;
   prostate-specific antigen density
ID ANTIGEN; PARAMETERS
AB Objective: To investigate the correlations of ALP, PSA and associated indicators (fPSA, fPSA/tPSA and PSAD) and osseous metastasis in prostate cancer, and the predictive value of these indicators for diagnosis of osseous metastasis of prostate cancer.
   Methods: A retrospective study was conducted for 167 prostate cancer patients who were confirmed by needle biopsy of prostate gland or postoperative pathologic examination between September 2014 and August 2017. Osseous metastasis was diagnosed through ECT, X-ray, CT/MRI or bone biopsy, and we analyzed the correlations of ALP, PSA, fPSA, fPSA/tPSA and PSAD with the osseous metastasis of prostate cancer and their diagnostic value for osseous metastasis.
   Results: In 183 patients, there were 114 with osseous metastasis (62.3%) and 69 with non-osseous metastasis (37.7%). In the osseous metastasis group, the levels of ALP, PSA and PSAD were significantly higher than those in the non-osseous metastasis group (p<0.01), while the difference in comparison of fPSA/tPSA between two groups showed no statistical significance (p>0.05). In patients with PSA>50 ng/m, the incidence rate of osseous metastasis was significantly higher than that in those with PSA in concentrations between 20 and 50 ng/mL, 10 and 20 ng/mL and not higher than 10 ng/mL (p<0.05); for patients with ALP larger than 90 U/L, incidence of osseous metastasis was significantly elevated in comparison with that in patients with ALP in concentration not higher than 90 U/L (p<0.05); the rate of osseous metastasis in patients with PSAD>0.4 ng/ml/cm(3) was significantly higher than that in those with PSAD <= 0.4 ng/ml/cm(3). With ALP>90 UIL, PSA>50 ng/mL and PSAD>0.4 ng/ml/cm(3) as critical values, we analyzed the predictive values of ALP, PSA, PSAD, PSA+ALP, PSA+PSAD and PSA+PSAD+ALP in diagnosis of osseous metastasis in prostate cancer, and the results revealed that combined application of these indicators is more effective for positive and negative predictions in comparison with the single indicator, and combination of PSA+PSAD+ALP showed optimal outcomes in sensitivity (100%), specificity (79.17%), positive predictive value (91.38%) and negative predictive value (100%).
   Conclusion: ALP, PSA and PSAD are the reliable indicators for evaluating the osseous metastasis in prostate cancer patients, while the combination of PSA, PSAD and ALP is conducive to prediction of prostate cancer. PSA<50 ng/mL, PSAD<0.4 ng/ml/cm(3) and ALP<90 U/L can help physicians to rule out the osseous metastasis.
C1 [Ni, Zhao; OuYang, Song] Shihezi Univ Shihezi, Med Coll, Affiliated Hosp 1, Dept Urol, Xinjiang 832008, Peoples R China.
   [Zhuo, Hui] 3rd Hosp Chengdu, Dept Urol, Chengdu 610031, Sichuan, Peoples R China.
   [Yang, Qing] Jilin Univ, Dept Blood Transfus, Hosp 1, Changchun 130000, Jilin, Peoples R China.
RP Lin, W (corresponding author), Shanghai Changning Matern & Infant Hlth Inst, Androl Dept, 773 Wuyi Rd, Shanghai 200051, Peoples R China.
EM shlinwei123@163.com
OI Ou-Yang, Song/0000-0001-7962-2811
CR CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x
   CHYBOWSKI FM, 1991, J UROLOGY, V145, P313, DOI 10.1016/S0022-5347(17)38325-8
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5
   Maeda H, 1998, Int J Urol, V5, P343, DOI 10.1111/j.1442-2042.1998.tb00364.x
   Patel PH, 2008, ANN PHARMACOTHER, V42, P91, DOI 10.1345/aph.1K429
   Sakai Iori, 2004, Int J Clin Oncol, V9, P64, DOI 10.1007/s10147-003-0365-1
   SEMJONOW A, 1995, UROLOGE A, V34, P290
   Stokkel MPM, 1998, INT J BIOL MARKER, V13, P70, DOI 10.1177/172460089801300202
   Talbot A, 2004, NUCL MED COMMUN, V25, P318
   Wymenga LFA, 2001, BJU INT, V88, P226, DOI 10.1046/j.1464-410x.2001.02275.x
   Yahara J, 2003, BJU INT, V92, P379, DOI 10.1046/j.1464-410X.2003.04362.x
NR 12
TC 0
Z9 0
U1 0
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1815
EP 1820
DI 10.19193/0393-6384_2018_6_279
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400030
DA 2022-07-14
ER

PT J
AU Niu, XH
   Chen, HY
AF Niu Xiao-Hua
   Chen Hong-Yuan
TI EFFECT OF INULICIN ON EXPRESSIONS OF COX-2 AND INOS GENES IN THE
   HIPPOCAMPUS OF AB-INDUCED ALZHEIMER'S DISEASE MODEL RATS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Inulicin; Alzheimer's disease; Cycloxygenase-2; Inducible nitric oxide
   synthase
AB Objective: To investigate the effect of inulicin on expressions of COX-2 and iNOS genes in the hippocampus of A beta-induced Alzheimer's disease (AD) model rats.
   Methods: A total of 60 rats were randomly divided into three groups of 20 rats each based on their weight. Group 1 was the blank control, group 2 the model and group 3 the experimental. AD models were established by injecting A beta 25 similar to 35 into the brain of the rats in the model and experimental groups respectively. In addition, the rats in the experimental group were administered inulicin via gavage, once a day. These three groups were maintained for 21 days. After the 21 days period, immunohistochemistry and Western blot were used for proving that the production of COX-2 and iNOS proteins occured in the hippocampus of the rats, and RTPCR was used to amplify the levels of COX-2 and iNOS mRNA molecules.
   Results: The transcription of the mRNA molecules, and their translation into proteins, of COX-2 and iNOS in the hippocampus of the rats in the model group were significantly greater (p < 0.05) than those of the blank control group. The transcription of the mRNA molecules, and their translation into proteins, of COX-2 and iNOS in the hippocampus of the rats in the experimental group administered inulicin were significantly lower than those of the model group (p < 0.05).
   Conclusion: Inulicin inhibits the expressions of COX-2 and iNOS genes in the hippocampus of A beta-induced Alzheimer's disease model rats. This suggests that inulicin plays anti -inflammatory role in the brain and this may be the mechanism by which it brings about amelioration in AD condition.
C1 [Niu Xiao-Hua; Chen Hong-Yuan] Chongqing Three Gorges Med Coll, Chongqing Engn Res Ctr Antitumor Nat Drugs, Chongqing, Peoples R China.
RP Chen, HY (corresponding author), Chongqing Baian Star Rd Wanzhou Dist 366 Dam, Chongqing 404020, Peoples R China.
EM tf1346@163.com
CR Frost GR, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170228
   Galati C, 2017, BEILSTEIN J NANOTECH, V8, P2446, DOI 10.3762/bjnano.8.243
   Gejl M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17718-y
   Khalaji N, 2017, BASIC CLIN NEUROSCI, V8, P5, DOI 10.15412/J.BCN.03080101
   Larsson SC, 2017, BMJ-BRIT MED J, V6, P5359
   Park S, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/6512520
   Shi J, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2040-5
   Tifratene K, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0256-8
   [王英杰 WANG Yingjie], 2008, [中国新药杂志, Chinese Journal New Drugs], V17, P1318
   Wang YJ, 2008, EXPT STUDY INULICIN
   Zhang JZ, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00395
   王英杰, 2009, [中国老年学杂志, Chinese Journal of Gerontology], V29, P956
NR 12
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 975
EP 979
DI 10.19193/0393-6384_2018_4_148
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500011
DA 2022-07-14
ER

PT J
AU Oztekin, C
   Oztekin, A
   Tastan, K
   Ozmen, GG
   Pektas, SD
AF Oztekin, Coskun
   Oztekin, Aynure
   Tastan, Kenan
   Ozmen, Gulsen Gul
   Pektas, Suzan Demir
TI THE ASSOCIATION BETWEEN VERRUCA VULGARIS AND VITAMIN D: IS THERE A
   CASUAL LINK?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Verruca Vulgaris; Vitamin D; Human Papilloma Virus; Serum
ID D DEFICIENCY; EXPRESSION; INDUCTION; INJECTION; DEFENSE; IMPACT; WARTS
AB Introduction: Verruca vulgaris is a well-known skin lesion caused by human papillomavirus. There are topical, local invasion and immune therapy options for verruca vulgaris. The role of vitamin D levels in patients with verruca vulgaris is not clear. We investigated the serum vitamin D levels in patients with verruca vulgaris.
   Materials and methods: Fifty-five patients with verruca vulgaris (Group I) and 60 healthy controls (Group II) included in the study. The characteristics of verruca vulgaris (duration, clinical type, the number of lesions, family history) and demographics of the participants were recorded. Serum 25-hydroxycholecalciferol levels were measured using electrochemiluminescence binding method.
   Results: After covariance analysis, we found no statistically significant difference between the groups in terms of mean age (23.38 +/- 4.68 years in Group I versus 27.35 +/- 8.14 years in Group II). Other baseline characteristics were not significantly different between the groups (p > 0.05 for all). The mean duration of verruca vulgaris was 12 (4-18) years and the most common sites were hand (26 patients, 47.3%) and foot (23 patients, 41.8%). Serum vitamin D levels were 8.35 +/- 6.03 ng/ml in Group I and 18.08 +/- 10.01 ng/ml in Group II. There was a statistically significant difference between the groups in terms of serum vitamin D levels (p < 0.001).
   Conclusion: In this study, vitamin D levels in patients with verruca vulgaris were found to be decreased compared to healthy controls. Low vitamin D levels may play an etiological role in the development of verruca vulgaris.
C1 [Oztekin, Coskun] Hitit Univ, Sch Med, Dept Family Med, Corum, Turkey.
   [Oztekin, Aynure] Hitit Univ, Sch Med, Dept Dermatol, Corum, Turkey.
   [Tastan, Kenan] Ataturk Univ, Sch Med, Dept Family Med, Erzurum, Turkey.
   [Ozmen, Gulsen Gul] Ali Osman Sonmez Onkol State Hosp, Dept Biochem, Bursa, Turkey.
   [Pektas, Suzan Demir] Mugla Sitki Kocman Univ, Sch Med, Dept Dermatol, Mugla, Turkey.
RP Oztekin, C (corresponding author), Hitit Univ, Sch Med, Dept Family Med, Corum, Turkey.
CR Aktas H, 2016, J CUTAN MED SURG, V20, P118, DOI 10.1177/1203475415602841
   Beard JA, 2011, J CLIN VIROL, V50, P194, DOI 10.1016/j.jcv.2010.12.006
   Bhat YJ, 2017, INDIAN J DERMATOL, V62, P407, DOI 10.4103/ijd.IJD_677_16
   Bikle DD, 2007, CURR OPIN RHEUMATOL, V19, P383, DOI 10.1097/BOR.0b013e32818e9d58
   Bucak IH, 2016, PEDIATR INT, V58, P270, DOI 10.1111/ped.12809
   Caccamo D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030892
   Conner K, 2002, J AM ACAD DERMATOL, V47, P347, DOI 10.1067/mjd.2002.122190
   Elenius V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172350
   Hansdottir S, 2008, J IMMUNOL, V181, P7090, DOI 10.4049/jimmunol.181.10.7090
   Hansdottir S, 2010, J IMMUNOL, V184, P965, DOI 10.4049/jimmunol.0902840
   Hoseinzadeh E, 2018, FOOD CHEM TOXICOL, V113, P241, DOI 10.1016/j.fct.2018.01.052
   Kranjec C, 2016, CURR OPIN VIROL, V20, P129, DOI 10.1016/j.coviro.2016.08.011
   Labandeira J, 2005, PEDIATR DERMATOL, V22, P375, DOI 10.1111/j.1525-1470.2005.22425.x
   Lucas RM, 2017, J AOAC INT, V100, P1225, DOI 10.5740/jaoacint.17-0082
   Meyer-Hoffert U, 2008, J EUR ACAD DERMATOL, V22, P1050, DOI 10.1111/j.1468-3083.2008.02675.x
   Raghukumar S, 2017, J CUTAN MED SURG, V21, P320, DOI 10.1177/1203475417704180
   Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027
   Schramm S, 2017, ENDOCRINE, V56, P658, DOI 10.1007/s12020-017-1292-7
   Wang GS, 2014, PHARMACEUTICALS-BASE, V7, P545, DOI 10.3390/ph7050545
   Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909
NR 20
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1047
EP 1050
DI 10.19193/0393-6384_2018_4_160
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500023
DA 2022-07-14
ER

PT J
AU Padros, C
   Cantadori, E
   Fuste, E
   Vinuesa, T
   Vinas, M
AF Padros, Carolina
   Cantadori, Erica
   Fuste, Ester
   Vinuesa, Teresa
   Vinas, Miguel
TI DIABETIC FOOT INFECTION IN SPAIN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Diabetic foot; Nursing cares; Staphylococcus; Pseudomonas; antibiotic
   treatment
ID OUTCOMES; RISK
AB Introduction: The associated complications of diabetes mellitus significantly impair the quality of life of affected patients. The disease leads to a wide variety of complications; among them foot ulcers are common being the most frequent cause of hospitalization of diabetic patients. Moreover, foot ulcers predict disability, morbidity, and mortality in diabetic patients in addition to incurring considerable healthcare costs. We investigate the bacteria involved in diabetic foot ulcers infection and record the evolution and epidemiological data of a group of patients.
   Materials and methods: The study population consisted of prospectively enrolled diabetic patients who attended two hospitals in Barcelona: one specializing in foot care (Hospital Podologic of the University of Barcelona) and the other a tertiary referral hospital (Hospital de Sant Pau). A comparison of microbiological results and their dependence on the sampling method (swab or punch) was done.
   Results: Diabetic Foot Syndrome was more prevalent in males than in females and more prevalent in patients with type 2 than type 1 diabetes. It becomes apparent that individuals living alone (singles, widowers and widows, etc.) tend to request medical assistance later or perhaps they take less attention to their feet, thus percentage of singles increased with the severity. Relatives and nursing care seem to play a relevant role in the evolution and prognosis of diabetic foot ulcers.
   Conclusion: Relatives and nursing care seem to play a crucial role in the evolution and prognosis of diabetic foot ulcers. Pseudomonas and Staphylococcus were the most frequent bacteria infecting ulcers. The use of ciprofloxacin should be discouraged since resistance accounted up to a 40%.
C1 [Padros, Carolina; Cantadori, Erica; Fuste, Ester; Vinuesa, Teresa; Vinas, Miguel] Univ Barcelona, IDIBELL Fac Med & Hlth Sci, Dept Pathol & Expt Therapeut, Barcelona, Spain.
   [Padros, Carolina] Univ Barcelona, IDIBELL Fac Med & Hlth Sci, Dept Clin Sci, Barcelona, Spain.
   [Fuste, Ester] Univ Barcelona, IDIBELL Fac Med & Hlth Sci, Dept Publ Hlth Mental Hlth & Perinatal Nursing, Barcelona, Spain.
RP Vinas, M (corresponding author), Dept Pathol & Expt Therapeut, Barcelona, Spain.
RI Domínguez, Ester Fusté/J-3648-2015; Domínguez, Ester Fusté/X-2975-2019;
   Aumedes, Teresa Vinuesa/C-2986-2015
OI Domínguez, Ester Fusté/0000-0002-3561-9765; Domínguez, Ester
   Fusté/0000-0002-3561-9765; Aumedes, Teresa Vinuesa/0000-0002-3536-4109
FU Fibrodress project; NSFA - Programa Nacional de Salud y Farmacia
   [IPT-2012-0602-300000]
FX This work was financed by the Fibrodress project. NSFA - Programa
   Nacional de Salud y Farmacia IPT-2012-0602-300000
CR Al-Rubeaan K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124446
   Bauer A. W., 1966, TECH B REG MED TECH, V36, P49
   Fan LF, 2013, CAN J DIABETES, V37, P195, DOI 10.1016/j.jcjd.2013.03.020
   Herrera-Rangel A, 2014, J DIABETES RES, V2014, DOI 10.1155/2014/787202
   JEFFCOATE WJ, 1993, DIABETIC MED, V10, P676, DOI 10.1111/j.1464-5491.1993.tb00144.x
   Kawamoto KR, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0629-7
   Lin W, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0333-z
   Lipsky BA, 2004, CLIN INFECT DIS, V39, P885, DOI 10.1086/383271
   Missoni Emilija Mlinaric, 2006, Acta Med Croatica, V60, P43
   Radji M, 2014, DIABETES METAB SYND, V8, P221, DOI 10.1016/j.dsx.2014.09.006
   Ramsey SD, 1999, DIABETES CARE, V22, P382, DOI 10.2337/diacare.22.3.382
   Seghieri G, 2017, CURR DIABETES REV, V13, P148, DOI 10.2174/1573399812666160517115756
   Valizadeh Reza, 2016, Osong Public Health Res Perspect, V7, P296
   Vidal-Perez R, 2010, REV ESP CARDIOL, V63, P170, DOI 10.1016/S0300-8932(10)70035-X
   Wat N, 2016, HONG KONG MED J, V22, P589, DOI 10.12809/hkmj164869
   Wrobel JS, 2003, DIABETES CARE, V26, P3042, DOI 10.2337/diacare.26.11.3042
NR 16
TC 1
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 651
EP 656
DI 10.19193/0393-6384_2018_3_100
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000005
DA 2022-07-14
ER

PT J
AU Pajaujiene, S
   Dabasinskiene, L
   Santos-Rocha, R
AF Pajaujiene, Simona
   Dabasinskiene, Laura
   Santos-Rocha, Rita
TI HEALTH PROMOTION PROGRAM FOR IMPROVING WOMEN'S BODY COMPOSITION AND
   ACTIVE LIFESTYLE IN POSTPARTUM: A PILOT STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE postpartum care; preventive healthcare; lifestyle; exercise; physical
   activity; body composition
ID PHYSICAL-ACTIVITY; MATERNAL OBESITY; PREGNANCY; WEIGHT; IMPACT
AB Introduction: The purpose was to design a healthy lifestyle promotion program for postpartum women aiming at improving women's body composition and active lifestyle, and to analyze its feasibility regarding the methods and acceptability. It is important to understand which interventions focused on the reduction of weight gained during pregnancy are the safest, and the most effective.
   Methods: A pilot study was carried out in a Hospital setting. Twenty-nine women were involved in the study. A healthy lifestyle promotion program for postpartum women including, visual materials of an exercise program, and physical activity and healthy diet recommendations after delivery, was designed. Women after 2 days after delivery were invited to participate in the study by following recommendations on lifestyle. After two and six month's postpartum, women were asked to come back to the Obstetrics Department for individual control (health variables), lifestyle (diet and exercise) and anthropometric measurements (body composition). Data analysis consisted of the qualitative analysis regarding the feasibility of the program, and on the quantitative analysis regarding the changes of the outcome variables from 2 to 6 months postpartum.
   Results: The pilot study was feasible and most of the participants were satisfied with it. The materials were built by health and exercise professionals, and were easily put in practice. The setting was appropriate, and the intervention was combined with the usual care of postpartum women in a hospital setting, supervised by a midwife. The pilot intervention resulted in positive changes in body composition (i.e., 71.1 +/- 10.8 to 62.6 +/- 10.1 kg; and significant reduction of most girths and skin folds' measurements), and physical activity level of women (12.1 +/- 1.6 to 23.5 +/- 2.5 metabolic equivalent) within 6 months after delivery.
   Discussion: This pilot study supports the research hypothesis that a healthy lifestyle promotion program may positively affect the changes in the body composition and physical activity level of women after childbirth. A protocol study for a randomised control study will be developed in first place.
C1 [Pajaujiene, Simona] Lithuanian Sports Univ, Dept Coaching Sci, Kaunas, Lithuania.
   [Dabasinskiene, Laura] Vilnius Univ Hosp Santaros Clin, Obstet Dept, Vilnius, Lithuania.
   [Santos-Rocha, Rita] Polytech Inst Santarem, Sport Sci Sch Rio Maior, Santarem, Portugal.
   [Santos-Rocha, Rita] Univ Lisbon, Fac Human Kinet, Interdisciplinary Ctr Study Human Performance, Lisbon, Portugal.
RP Santos-Rocha, R (corresponding author), Escola Super Desporto Rio Maior, Av Dr Mario Soares 110, P-2040413 Rio Maior, Portugal.
EM ritasantosrocha@esdrm.ipsantarem.pt
RI Santos-Rocha, Rita/AAF-3774-2020; Santos-Rocha, Rita A/L-4317-2014
OI Santos-Rocha, Rita/0000-0001-7188-8383; Santos-Rocha, Rita
   A/0000-0001-7188-8383
CR Adegboye ARA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005627.pub3
   American College of Sports Medicine, 2017, ACSMS GUIDELINES EXE
   Blum JW, 2004, MATERN CHILD HEALT J, V8, P163, DOI 10.1023/B:MACI.0000037649.24025.2c
   Chasan-Taber L, 2004, MED SCI SPORT EXER, V36, P1750, DOI 10.1249/01.MSS.0000142303.49306.0D
   Chasan-Taber L, 2011, MED SCI SPORT EXER, V43, P195, DOI 10.1249/MSS.0b013e318202a02c
   Choi SK, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-6
   Comm Obstet Practice, 2015, OBSTET GYNECOL, V126, pe135, DOI 10.1097/AOG.0000000000001214
   Cramp AG, 2010, MATERN CHILD HLTH J, V14, P343, DOI 10.1007/s10995-009-0462-5
   EuropeActive, 2016, EUROPEACTIVE STAND E
   Fell DB, 2009, MATERN CHILD HLTH J, V13, P597, DOI 10.1007/s10995-008-0404-7
   Godin G., 1997, MED SCI SPORT EXER, V29, pS36, DOI DOI 10.1097/00005768-199706001-00009
   Jones G, 2017, PILOT FEASIBILITY ST, V4, P3
   Kernot J, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-518
   Kinnunen TI, 2007, NUTR J, V6, DOI 10.1186/1475-2891-6-21
   Leddy Meaghan A, 2008, Rev Obstet Gynecol, V1, P170
   Lietuvos statistikos departamentas, 2015, LIET GYV SVEIK 2014
   Medairos R, 2016, J PHYS ACT HEALTH, V6, P1
   Mottola MF, 2013, NUTR REV, V71, pS31, DOI 10.1111/nure.12064
   Myatt L., 2010, MATERNAL FETAL NUTR
   Norton K, 2004, ANTHROPOMETRICA TXB, P25
   Paoli A, 2015, CLIN PHYSIOL FUNCT I, V35, P1, DOI 10.1111/cpf.12136
   Paoli A, 2012, AM J CARDIOL, V109, P305, DOI 10.1016/j.amjcard.2011.10.011
   Ruager-Martin R, 2010, EARLY HUM DEV, V86, P715, DOI 10.1016/j.earlhumdev.2010.08.007
   Saligheh M, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0908-x
   Schmitt NM, 2007, INT J OBESITY, V31, P1642, DOI 10.1038/sj.ijo.0803655
   Siri W.E., 1961, TECHNIQUES MEASURING, P223
   Tenenbaum-Gavish K, 2013, FETAL DIAGN THER, V34, P1, DOI 10.1159/000350170
   The American College of Nurse-Midwives, 2014, J MIDWIFERY WOM HEAL, V59, P473
   Torris C, 2013, BREASTFEED MED, V8, P8, DOI 10.1089/bfm.2012.0048
   Tripette J, 2014, MED SCI SPORT EXER, V46, P472, DOI 10.1249/MSS.0000000000000136
   Walker LO, 2007, JOGNN-J OBST GYN NEO, V36, P490, DOI 10.1111/J.1552-6909.2007.00179.x
   WHO, 2014, OB OV
   WILMORE JH, 1970, AM J CLIN NUTR, V23, P267
NR 33
TC 0
Z9 0
U1 0
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1365
EP 1375
DI 10.19193/0393-6384_2018_5_209
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700031
DA 2022-07-14
ER

PT J
AU Pan, XD
   Tang, LM
   Wang, LX
   Sun, LF
   Kong, WQ
AF Pan, Xiao-dong
   Tang, Lu-ming
   Wang, Lin-xia
   Sun, Lai-fang
   Kong, Wan-quan
TI STUDY ON THE CORRELATION BETWEEN TLRS SIGNALLING PATHWAY-MEDIATED IRAK-M
   GENE AND SEPSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE TLR signalling pathway; IRAK-M gene; sepsis; diagnosis
AB Objective: To explore the correlation between the interleukin-1 receptor-associated kinase M (IRAK-M) gene mediated by the Toll-like receptor (TLR) signalling pathway and sepsis.
   Methods: In this study, 68 patients with sepsis treated in our hospital from February 2014 to February 2015 were selected as the study objects (observation group), and 68 normal individuals were selected as the control group. The relationship between IRAK-M gene mediation by the TLR signalling pathway and sepsis was studied by fluorescence quantitative PCR, enzyme-linked immunosorbent assay (ELISA), Western blotting and immunohistochemistry.
   Results: The mRNA expression levels of TLRs and IRAK-M in blood of patients with sepsis were remarkably increased, with significant differences compared to the normal group (P<0.05). The protein expression levels of TLRs and IRAK-M in the blood of the observation group and control group were detected by ELISA and Western blotting. This study found that the expression of TLRs and the IRAK-M protein in the blood of patients from the observation group (0.96 mu g/L, 7.3 mu g/L) was significantly higher than in the control group (0.32 mu g/L, 0.54 mu g/L) and there was a significant difference between the two groups (P<0.05). The immunohistochemical results of the observation group and the control group showed that expression of the IRAK-M gene in the pathological site of the patients in the observation group was significantly increased; the number of positive cells (94.3%) was significantly higher than that in the control group (18.4%) (P<0.05 ).
   Conclusion: The IRAK-M gene may be involved in the pathogenesis of sepsis in severely burned patients through the TLR signalling pathway.
C1 [Tang, Lu-ming] Wenzhou Med Univ, Affiliated Hosp 2, Dept Emergency, Wenzhou 325027, Zhejiang, Peoples R China.
   [Tang, Lu-ming] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Zhejiang, Peoples R China.
RP Tang, LM (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Emergency, Wenzhou 325027, Zhejiang, Peoples R China.; Tang, LM (corresponding author), Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Zhejiang, Peoples R China.
EM dv1276@163.com
CR Barbera B A, 2016, PLOS ONE, V11
   Cheng Y, 2017, MOL BIOL CELL, V28, P201, DOI 10.1091/mbc.E16-02-0126
   Chu Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04354-9
   Donadio ME, 2014, PEDIATR NEPHROL, V29, P1545, DOI 10.1007/s00467-014-2807-6
   Itzhak VB, 2018, AM J CARDIOL
   Kawasaki Y, 2017, PEDIATR INT, V59, P41, DOI 10.1111/ped.13074
   Lo J, 2018, J IMMUNOL RES, V2018, P1
   Long HK, 2016, CELL, V167, P1170, DOI 10.1016/j.cell.2016.09.018
   Roland CL, 2016, ANN SURG ONCOL, V23, P2220, DOI 10.1245/s10434-016-5115-5
   Shen PC, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1268-9
   Tirandaz N, 2017, APPL THERM ENG, V112, P1566, DOI 10.1016/j.applthermaleng.2016.09.113
   Vahed SZ, 2017, CLIN BIOCHEM, V50, P32, DOI 10.1016/j.clinbiochem.2016.08.007
   Wang Y, 2017, CHIN CONTINUING MED
   Wolf D, 2017, BIOL BLOOD MARROW TR, V23
   Yu DH, 2018, LEARN MEMORY, V25, P183, DOI 10.1101/lm.046557.117
   Yujuan D, 2013, MOL CANCER RES, V11, P1051
   Zhu Yun, 2017, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V29, P684, DOI 10.3760/cma.j.issn.2095-4352.2017.08.003
NR 18
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1809
EP 1814
DI 10.19193/0393-6384_2018_6_278
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400029
DA 2022-07-14
ER

PT J
AU Pavlova, M
   Velev, V
   Dobreva, E
   Asseva, G
   Ivanov, IN
   Tomova, I
   Kantardjiev, T
AF Pavlova, Maria
   Velev, Valeri
   Dobreva, Elina
   Asseva, Galina
   Ivanov, Ivan N.
   Tomova, Ivelina
   Kantardjiev, Todor
TI ADVANTAGES OF EVA GREEN REAL-TIME MPCR WITH CULTURE AND
   IMMUNOCHROMATOGRAPHIC METHODS FOR DIFFERENTIATING C. JEJUNI / COLI
   DIRECTLY FROM FECES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Campylobacter; diarrhea; mPCR
ID CAMPYLOBACTER; INFECTION; BULGARIA
AB Objective: To develop and optimize a rapid molecular method for diagnosing campylobacteriosis directly from a clinical fecal sample and at the same time determining the most common causing agents - C. jejuni/coli.
   Materials and methods: 40 clinical fecal samples of hospitalized patients in the Pediatric Clinic of Infectious Diseases - Sofia were tested, the patients aged between 0 and 7 years and with diarrheal syndrome. The clinical samples were tested using a rapid immunochromatographic test (ICT) (CerTest Biotec). All positive samples were tested for confirmation by culturing in a microaerophilic atmosphere at 42 degrees C and subsequently the isolates were biochemically differentiated. The Eva Green real-time mPCR reaction of a direct fecal sample was conducted using the "IQ5TM Real-Time PCR System" apparatus.
   Results: Out of 40 clinical fecal samples which were ICT positive, 20 strains were isolated by culture - 18 of C. jejuni and 2 of C. coli. The Eva Green real-time mPCR reaction also reported 20 positive samples for Campylobacter - 18 out of which were of C. jejuni and 2 of C. coli. All other samples were negative for Campylobacter spp. The analytical sensitivity and specificity of the mPCR method were 100%.
   Discussion: We developed and optimized the Eva Green real-time mPCR for detection and species differentiation of C. jejuni/coli directly from a clinical fecal sample. This analysis ensures the faster and more reliable detection of bacterial cells when compared to the conventional culture methods using biochemical differentiation.
C1 [Pavlova, Maria; Dobreva, Elina; Asseva, Galina; Ivanov, Ivan N.; Kantardjiev, Todor] Natl Ctr Infect & Parasit Dis, Sofia, Bulgaria.
   [Velev, Valeri; Tomova, Ivelina] Med Univ Sofia, Dept Infect Dis & Parasitol, Sofia, Bulgaria.
RP Velev, V (corresponding author), Med Univ Sofia, Bulv G Sofiiski 1, Sofia, Bulgaria.
RI Velev, Valeri/AAX-3241-2020
OI Velev, Valeri/0000-0003-0161-6993; Pavlova, Maria/0000-0003-2116-6264
CR Asseva G, 2012, EUR J CLIN MICROBIOL, V31, P3217, DOI 10.1007/s10096-012-1688-5
   Boyanova L, 2004, DIAGN MICR INFEC DIS, V49, P71, DOI 10.1016/j.diagmicrobio.2003.12.004
   Center of Disease Control, 2008, CAMPYLOBACTER
   Daskalov H, 2012, TURK J VET ANIM SCI, V36, P539, DOI 10.3906/vet-1102-788
   Sahin O, 2015, AVIAN DIS, V59, P185, DOI 10.1637/11072-032315-Review
   Stoicheva M, MEDICART, V3, P23
NR 6
TC 1
Z9 1
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1027
EP 1030
DI 10.19193/0393-6384_2018_4_156
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500019
DA 2022-07-14
ER

PT J
AU Pennacchio, S
   Tripi, G
   Salerno, M
   Russo, DA
   Lavano, SM
   Cerroni, F
   Marotta, R
   Romano, P
   Gallai, B
   Giugliano, P
   Murabito, P
   Sorrentino, M
   Magliulo, RM
   D'oro, L
   Di Folco, A
   Testa, D
   Marsala, G
   Geraci, D
   Chisari, MG
   Picciocchi, E
   Lavano, F
   Marotta, R
   Parisi, L
   Ruberto, M
AF Pennacchio, Stefano
   Tripi, Gabriele
   Salerno, Margherita
   Russo, Daniel A.
   Lavano, Serena Marianna
   Cerroni, Francesco
   Marotta, Rosa
   Romano, Palmira
   Gallai, Beatrice
   Giugliano, Pasquale
   Murabito, Paolo
   Sorrentino, Michele
   Magliulo, Rosaria Martina
   D'oro, Lucrezia
   Di Folco, Annabella
   Testa, Davide
   Marsala, Gabriella
   Geraci, Diego
   Chisari, Mario Giuseppe
   Picciocchi, Elisabetta
   Lavano, Francesco
   Marotta, Rosa
   Parisi, Lucia
   Ruberto, Maria
TI ANIMALS-ASSISTED THERAPY: A BRIEF REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE animals-assisted therapy; neurodevelopmental disorders; dogs
ID MONOSYMPTOMATIC NOCTURNAL ENURESIS; CHILDHOOD ABSENCE EPILEPSY;
   SLEEP-APNEA SYNDROME; QUALITY-OF-LIFE; HYPERTHERMIC REACTIONS; CHILDREN;
   MIGRAINE; ADOLESCENTS; DISORDERS; WEIGHT
AB In rehabilitative setting, the presence of animals can be considered as an important stimulus for verbal and social communication, and for mood regulation. Interaction with an animal is beneficial for children's development and numerous psychological tests have revealed that growing up with pets has a beneficial effect on children's self-esteem and self-confidence, can improve empathy, a sense of responsibility and cognitive development, as well as social status within the peer group.
C1 [Pennacchio, Stefano] Medh Ctr Srl, Campania, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disor, St Benoit La Foret, France.
   [Salerno, Margherita; Di Folco, Annabella; Testa, Davide; Parisi, Lucia] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Russo, Daniel A.] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Lavano, Serena Marianna; Marotta, Rosa] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Romano, Palmira; Lavano, Francesco; Marotta, Rosa] Ctr Riabilitaz LARS, Sarno, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Giugliano, Pasquale] UOC Med Legale, Azienda Osped St Anna & San Sebastiano di Caser, Viterbo, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp, NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
   [Magliulo, Rosaria Martina] Ctr Scoliosi SRL, Naples, Italy.
   [D'oro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Marsala, Gabriella; Chisari, Mario Giuseppe] Azienda Osped Univ, Osped Riuniti Foggia, Struttura Complessa Farm, Foggia, Italy.
   [Geraci, Diego] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, I-95123 Catania, Italy.
   INPS, Catania, Italy.
   [Picciocchi, Elisabetta; Lavano, Francesco] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Ruberto, Maria] CDR Santa Maria del Pozzo, Somma Vesuviana, Italy.
RP Parisi, L (corresponding author), Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Cerroni, Francesco/0000-0003-3024-5482; Murabito,
   Paolo/0000-0002-2662-1898; Marotta, Rosa/0000-0003-0515-5952
CR Bachi K, 2017, CLIN CHILD PSYCHOL P, V22, P3, DOI 10.1177/1359104516672549
   Ballarini G., 2005, ANIMALI AMICI SALUTE
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Braun Carie, 2009, Complement Ther Clin Pract, V15, P105, DOI 10.1016/j.ctcp.2009.02.008
   Butler RJ, 1998, J CHILD PSYCHOL PSYC, V39, P453, DOI 10.1017/S0021963098002224
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSL, V8
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Charry-Sanchez JD, 2018, J DEV BEHAV PEDIATR, V39, P580, DOI 10.1097/DBP.0000000000000594
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Dimitrijevic I, 2009, PSYCHIAT DANUB, V21, P236
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Gallelli Luca, 2017, Microrna, V6, P152, DOI 10.2174/2211536606666170913152821
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Marchesini R., 2015, PET THERAPY MANUALE
   Martin F, 2002, WESTERN J NURS RES, V24, P657, DOI 10.1177/019394502320555403
   Matricardi S, 2018, ACTA NEUROL SCAND, V137, P575, DOI 10.1111/ane.12902
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSL, V8
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Moscatelli F, 2016, PLOS ONE, V24
   Moscatelli F, 2015, BIOL MED, V7
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P481, DOI 10.19193/0393-6384_2017_3_071
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Smirni D, 2018, J NERV MENT DIS, V206, P628, DOI 10.1097/NMD.0000000000000853
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Smirni D, 2017, NEUROPSYCHOLOGIA, V102, P109, DOI 10.1016/j.neuropsychologia.2017.06.006
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Testa D, 2017, AGING CLIN EXP RES, V29, pS191, DOI 10.1007/s40520-016-0647-x
   Testa D, 2016, OPEN MED-WARSAW, V11, P208, DOI 10.1515/med-2016-0040
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2005, INT J CARDIOL, V104, P152, DOI 10.1016/j.ijcard.2004.10.051
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2018, ACTA NEUROL SCAND, V138, P523, DOI 10.1111/ane.13006
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Yap E, 2017, COMPLEMENT THER CLIN, V26, P47, DOI 10.1016/j.ctcp.2016.11.009
NR 96
TC 0
Z9 0
U1 5
U2 15
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2089
EP 2095
DI 10.19193/0393-6384_2018_4s_323
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900003
DA 2022-07-14
ER

PT J
AU Persolja, M
   Markic, M
   Blatnik, D
   Palese, A
AF Persolja, Melita
   Markic, Mirko
   Blatnik, Dragica
   Palese, Alvisa
TI PATIENT SATISFACTION WITH NURSING CARE DELIVERED IN MEDICAL UNITS IN
   POST-TRANSITIONAL COUNTRY: A CORRELATIONAL STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE evidence-based healthcare management; medical units; nursing service
   hospital; nursing care; patient satisfaction post-transitional country
ID QUALITY; TIME; PREDICTORS; PERCEPTION; SPEND; HOME
AB Introduction: There is limited evidence on the relationship between patients' satisfaction with nursing care and some variables in medical units in post-transitional countries.
   Materials and methods: This correlational study design was aimed at discovering correlations, if any, between the patient satisfaction with nursing care and nursing care activities. The study was performed in a Slovenian medical hospital, and variables were collected at (1) the ward level (patients cared pr on a daily basis; number of hours/patients a day), (2) nursing care level, by observing nursing activities at 10-minute intervals; and (3) at the patient level, by administering the Patient Perception of Hospital Experience with Nursing tool.
   Results: A total of 218 patients were involved, and their satisfaction with nursing care was high (average=4.42, Sd=0.53). On average, 80 patients were cared for per day at the unit level by ensuring around 3.6 hours of nursing care; 7,732 activities were performed by 43 nursing personnel, and only a third (n=2,842, 36.8%) of all nursing activities were performed in contact with the patient. Patient satisfaction was significantly negatively correlated with the number of patients cared for at the unit level on a daily basis (p<0.000). On the contrary, it was positively correlated (p<0.000) with the amount of care hours/patient/day, and with some direct care activities (p<0.000).
   Conclusions: To ensure patient satisfaction, more nurses should deal with the increased number of patients admitted in the medical units. It is recommended to increase the amount of nursing care offered by registered nurses, given that the competences acquired at the academic level can affect the environment and the caring processes and, thereby, the patients' satisfaction.
C1 [Persolja, Melita] Univ Primorska, Nova Gorica Unit, Fac Hlth Sci, Koper, Slovenia.
   [Markic, Mirko] Univ Primorska, Fac Management, Koper, Slovenia.
   [Blatnik, Dragica] Izola Gen Hosp, Izola, Slovenia.
   [Palese, Alvisa] Univ Udine, Dept Med Sci, Udine, Italy.
RP Palese, A (corresponding author), Univ Udine, Dept Med Sci, Udine, Italy.
EM alvisa.palese@uniud.it
RI Palese, Alvisa/J-9427-2015
OI Palese, Alvisa/0000-0002-3508-844X
FU European Union under the European Social Fund; Ministry of Education,
   Science and Sport of the Republic of Slovenia
FX This research was not funded. The article was carried under the
   operation Mobility of Slovene higher education teachers 2017 - 2018 in
   the frame of the "Operativni program za izvajanje evropske kohezijske
   politike v obdobju 2014-2020, co-financed by the European Union under
   the European Social Fund and the Ministry of Education, Science and
   Sport of the Republic of Slovenia.
CR Aiken Linda H, 2012, BMJ, V344, pe1717, DOI 10.1136/bmj.e1717
   Al Qahtani M, 2015, WORLD FAM MED, V13, P13, DOI 10.5742/MEWFM.2015.92665
   Al-Abri Rashid, 2014, Oman Med J, V29, P3, DOI 10.5001/omj.2014.02
   Albreht T, 2016, HLTH SYSTEMS TRANSIT, V18, P1, DOI DOI 10.1136/BMJSPCARE-2015-001031
   Atallah MA, 2013, INT J NURS PRACT, V19, P584, DOI 10.1111/ijn.12102
   Attree M, 2001, J ADV NURS, V33, P456, DOI 10.1046/j.1365-2648.2001.01689.x
   Ausserhofer D, 2014, BMJ QUAL SAF, V23, P126, DOI 10.1136/bmjqs-2013-002318
   Berg Gina M, 2012, J Trauma Nurs, V19, P104, DOI 10.1097/JTN.0b013e3182562997
   Butler M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007019.pub2
   Casati M, 2017, ASSIST INFERM RIC, V36, P179, DOI 10.1702/2817.28484
   Chang AM, 1988, J NURS MANAGE, V6, P155
   Davidson R, 1988, EU J CANC CARE, V14, P83
   Dellefield ME, 2012, GERIATR NURS, V33, P256, DOI 10.1016/j.gerinurse.2012.01.003
   DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743
   Dozier AM, 2001, RES NURS HEALTH, V24, P506, DOI 10.1002/nur.10007
   England, 2014, SAFER STAFFING GUIDE
   Field A, 2009, DISCOVERING STAT USI, V3rd
   Hajdinjak G, 2012, MODERN NURSING CARE
   Ham HS, 2015, NURS RES PRACT, V2015, DOI 10.1155/2015/749754
   Hauke J, 2011, QUAEST GEOGR, V30, P87, DOI 10.2478/v10117-011-0021-1
   Hockenberry JM, 2016, ILR REV, V69, P890, DOI 10.1177/0019793916642760
   HOFFMAN FM, 1986, J NURS ADMIN, V16, P17
   JINKS AM, 2000, J NURS MANAGE, V8, P273
   Kalisch BJ, 2011, J NURS SCHOLARSHIP, V43, P82, DOI 10.1111/j.1547-5069.2010.01375.x
   Kostovich Carol T, 2016, J Appl Meas, V17, P476
   Kraska RA, 2017, HEALTH EXPECT, V20, P593, DOI 10.1111/hex.12485
   Laal M, 2013, PROCD SOC BEHV, V84, P243, DOI 10.1016/j.sbspro.2013.06.543
   McCambridge J, 2014, J CLIN EPIDEMIOL, V67, P267, DOI 10.1016/j.jclinepi.2013.08.015
   McCloskey JC, 1996, NURS ECON, V14, P22
   Munyisia EN, 2011, J ADV NURS, V67, P1908, DOI 10.1111/j.1365-2648.2011.05633.x
   Murgic L, 2015, BMC MED ETHICS, V16, DOI 10.1186/s12910-015-0059-z
   Negarandeh R, 2016, ASIAN NURS RES KOREA, V8, P282
   NIPH, REC DAT HLTH PROF NE
   Palese A, 2017, SCAND J CARING SCI, V31, P768, DOI 10.1111/scs.12396
   Papastavrou E, 2014, BMC NURS, V13, DOI 10.1186/1472-6955-13-26
   Penque Sue, 2015, Nurs Manage, V46, P38, DOI 10.1097/01.NUMA.0000462367.98777.40
   Sermeus W, 2011, BMC NURS, V10, DOI 10.1186/1472-6955-10-6
   Skela-Savic B., 2016, OBZORNIK ZDRAVSTVENE, V50, P4, DOI [10.14528/snr.2016.50.1.94, DOI 10.14528/SNR.2016.50.1.94]
   Staniszewska S, 1988, NURS STAND, V12, P34
   Sulmasy DP, 2003, MED CARE, V41, P458, DOI 10.1097/00005650-200304000-00002
   World Health Organization, PROC TRANSL AD INSTR
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Zorec M, 2001, SLOV NURS REV, V35, P181
NR 43
TC 2
Z9 2
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 2045
EP 2054
DI 10.19193/0393-6384_2018_6_319
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400070
DA 2022-07-14
ER

PT J
AU Petralia, MC
   Coco, M
   Maci, T
   Minissale, C
   De Pasquale, C
   D'Orto, G
   Basile, MS
   Donato, E
   Maniaci, M
   Commodari, E
   Di Nuovo, S
   Perciavalle, V
   Di Corrado, D
   Guarnera, M
   Pirrone, C
   Castellano, S
   Platania, S
   Ramaci, T
   Bellomo, M
   Maggio, C
   Sehili, A
   Coco, LSG
   Napolitano, S
   Ascione, A
   Perciavalle, V
   Buscemi, A
AF Petralia, Maria Cristina
   Coco, Marinella
   Maci, Tiziana
   Minissale, Chiara
   De Pasquale, Concetta
   D'Orto, Gianluca
   Basile, Maria Sofia
   Donato, Ezio
   Maniaci, Mario
   Commodari, Elena
   Di Nuovo, Santo
   Perciavalle, Vincenzo
   Di Corrado, Donatella
   Guarnera, Maria
   Pirrone, Concetta
   Castellano, Sabrina
   Platania, Silvia
   Ramaci, Tiziana
   Bellomo, Maria
   Maggio, Claudio
   Sehili, Amel
   Coco, Lucio Salvatore Giovanni
   Napolitano, Salvatore
   Ascione, Antonio
   Perciavalle, Valentina
   Buscemi, Andrea
TI SUCCESSFULLY AGING. CHOICE OF LIFE OR LIFE THAT CHOICES?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE sport; physical activity; digit ratio; personality
ID BLOOD LACTATE LEVELS; DIGIT RATIO; EXCITABILITY; PERSONALITY; EXERCISE;
   STRESS
AB Introduction: Doing regular physical activity offers a great deal of positive physiological and psychological effects, such as a decrease in cardiovascular diseases, osteoporosis and hypertension.
   Today, more than ever, physical activity is particularly relevant in people's life, as it can be seen by the great number of people who registers in gyms, and by the growing importance given to wellness/fitness and the striving to physical "perfection". It is known that a good perception of his own body allows the individual to positively influence his self-esteem, his self-efficacy and his mood.
   There are not age limitations to enroll in sport clubs and in the last twenty years many seniors have begun to enroll in sport clubs and to frequent them assiduously.
   Materials and methods: In the present research, we asked ourselves if for a sample of seniors, going regularly to a sport club is linked to a concept of health or to different variables
   We went to a prestigious Sicilian gym and we documented ourselves about the age of the people enrolled in the structure; we examined a sample of seniors frequenting the structure both on personality and self-perception variables, and on the natural predisposition to confront emergencies (digit radio).
   Results: The Big Five - 10 items show that the female group is more open to experience while the male sample shows higher values for consciousness and extroversion. 44% of the female sample and 52% of the male sample obtained mean self-efficacy values. Values obtained from the sample show a statistically relevant difference (P<<0,0001) between real figure and ideal figure; these values reveal that the sample is not satisfied of his body. Results obtained from the entire sample show a slight level of overweight with a BMI of 25,91 (+/- 3,5). While the ratio 2D: 4D is correlated for both groups conscientiously.
   Conclusion: Results leads us to observe, firstly, the growing number of seniors enrolled at the gym, secondary, that the choice to frequent a sport club is mostly linked to an aesthetic canon imposed by modern society and not to a concept of health. To the question "Choice of life or life that choices?" that we asked ourselves at the beginning of this work we can answer with slight bitterness that often is the life that choices. In any age, mediatic conditioning is very strong; we should continue to make physical activity with the awareness that it represents life and health for our body, becoming sometimes a true elixir of life.
C1 [Petralia, Maria Cristina; Coco, Marinella; Basile, Maria Sofia; Perciavalle, Vincenzo; Castellano, Sabrina; Platania, Silvia] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Petralia, Maria Cristina; Commodari, Elena; Di Nuovo, Santo; Pirrone, Concetta; Castellano, Sabrina; Perciavalle, Valentina] Univ Catania, Dept Educ Sci, Catania, Italy.
   [Maci, Tiziana] Alzheimer Ctr Psychogeriatry, Dept Mental Hlth ASP Catania 3, Catania, Italy.
   [Minissale, Chiara; De Pasquale, Concetta; D'Orto, Gianluca; Maggio, Claudio; Sehili, Amel; Coco, Lucio Salvatore Giovanni] Univ Catania, Catania, Italy.
   [Donato, Ezio; Maniaci, Mario] Virgin Act Catania, Catania, Italy.
   [Di Corrado, Donatella; Guarnera, Maria; Ramaci, Tiziana; Bellomo, Maria] Kore Univ, Dept Human & Social Sci, Enna, Italy.
   [Napolitano, Salvatore; Ascione, Antonio] Univ Naples Parthenope, Dept Phys Educ & Wellness, Naples, Italy.
   [Buscemi, Andrea] Horus Cooperat Social, Ragusa, Italy.
RP Coco, M (corresponding author), Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
EM marinella.coco@unict.it
RI Di Nuovo, Santo/K-7760-2019; Basile, Maria Sofia/AAC-3393-2019;
   Petralia, Maria/AAE-6337-2019; Coco, Marinella/AAC-8750-2020; Platania,
   silvia/F-4869-2017; Di Corrado, Donatella/K-3757-2019; Di Corrado,
   Donatella/H-3726-2019; de pasquale, concetta/AAG-8431-2020; RAMACI,
   TIZIANA/AAD-3672-2019; Ascione, Antonio/I-9473-2018
OI Di Nuovo, Santo/0000-0001-6086-7624; Basile, Maria
   Sofia/0000-0002-4811-4694; Di Corrado, Donatella/0000-0001-8223-6671; de
   pasquale, concetta/0000-0003-4692-0980; RAMACI,
   TIZIANA/0000-0002-0745-2013; Platania, Silvia/0000-0002-7324-4466;
   Ascione, Antonio/0000-0003-4466-1807; Petralia, Maria
   Cristina/0000-0002-9643-1045
CR Alagona G, 2009, NEUROSCI LETT, V450, P111, DOI 10.1016/j.neulet.2008.11.064
   Bouchard C, PHYS ACTIVITY FITNES
   Buscemi A, 2016, ACTA MEDICA MEDITERR, V32, P953, DOI 10.19193/0393-6384_2016_4_115
   Coco M, 2013, SOMATOSENS MOT RES
   Coco M, 2017, NEUROL SCI, V38, P1865, DOI 10.1007/s10072-017-3014-6
   Coco M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002978
   Coco M, 2015, MOL MED REP, V11, P2135, DOI 10.3892/mmr.2014.2898
   Coco M, 2014, SOMATOSENS MOT RES, V31, P35, DOI 10.3109/08990220.2013.834816
   Coco M, 2013, SOMATOSENS MOT RES, V30, P90, DOI 10.3109/08990220.2013.769949
   Coco M, 2011, SOMATOSENS MOT RES, V28, P19, DOI 10.3109/08990220.2011.598268
   Coco M, 2009, BRAIN RES, V1302, P205, DOI 10.1016/j.brainres.2009.09.032
   de Bruijn GJ, 2009, J SPORT EXERCISE PSY, V31, P724, DOI 10.1123/jsep.31.6.724
   Donia M, 2012, ONCOL REP, V28, P682, DOI 10.3892/or.2012.1840
   Fallon Elizabeth A, 2005, Body Image, V2, P62
   Gosling SD, 2003, J RES PERS, V37, P504, DOI 10.1016/S0092-6566(03)00046-1
   Kern L, 2010, ENCEPHALE, V36, P212, DOI 10.1016/j.encep.2009.06.007
   Magnano Paola, 2013, COMPAETENZE TRASVERS
   Mijatovic S, 2010, FREE RADICAL BIO MED, V48, P1090, DOI 10.1016/j.freeradbiomed.2010.01.026
   Paul SN, 2006, BRIT J SPORT MED, V40, P981, DOI 10.1136/bjsm.2006.027193
   Perciavalle V, 2013, SOMATOSENS MOT RES
   Perciavalle V, 2017, NEUROL SCI, V38, P451, DOI 10.1007/s10072-016-2790-8
   Perciavalle V, 2016, PHYSICIAN SPORTSMED, V44, P403, DOI 10.1080/00913847.2016.1222852
   Perciavalle V, 2015, NEUROL SCI, V36, P2129, DOI 10.1007/s10072-015-2329-4
   Perciavalle V, 2015, NEUROL SCI, V36, P1597, DOI 10.1007/s10072-015-2210-5
   Perciavalle V, 2014, PERCEPT MOTOR SKILL, V118, P940, DOI 10.2466/19.50.PMS.118k27w8
   Perciavalle V, 2014, PERCEPT MOTOR SKILL, V118, P733, DOI 10.2466/29.30.PMS.118k22w1
   Perciavalle V, 2014, SOMATOSENS MOT RES, V31, P1, DOI 10.3109/08990220.2013.796924
   Perciavalle V, 2013, MOL MED REP, V7, P1733, DOI 10.3892/mmr.2013.1426
   Schilder P., 1950, IMAGE APPEARANCE HUM
   WALLER BF, 1992, CLIN CARDIOL, V15, P851, DOI 10.1002/clc.4960151111
NR 30
TC 16
Z9 16
U1 2
U2 17
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 107
EP 111
DI 10.19193/0393-6384_2018_1_18
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600018
DA 2022-07-14
ER

PT J
AU Polito, AN
   Picciocchi, E
   Geraci, D
   Chisari, MG
   Marsala, G
   Sorrentino, M
   Tripi, G
   Salerno, M
   Russo, D
   Lavano, SM
   Cerroni, F
   Romano, P
   Marotta, R
   Lavano, F
   Magliulo, RM
   D'Oro, L
   Di Folco, A
   Parisi, L
   Testa, D
   Murabito, P
   Salerno, M
   Gallai, B
AF Polito, Anna Nunzia
   Picciocchi, Elisabetta
   Geraci, Diego
   Chisari, Mario Giuseppe
   Marsala, Gabriella
   Sorrentino, Michele
   Tripi, Gabriele
   Salerno, Margherita
   Russo, Daniela
   Lavano, Serena Marianna
   Cerroni, Francesco
   Romano, Palmira
   Marotta, Rosa
   Lavano, Francesco
   Magliulo, Rosaria Martina
   D'Oro, Lucrezia
   Di Folco, Annabella
   Parisi, Lucia
   Testa, Davide
   Murabito, Paolo
   Salerno, Monica
   Gallai, Beatrice
TI MOTOR SKILLS IN CHILDREN WITH PRIMARY HEADACHE: A PILOT CASE-CONTROL
   STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE primary headaches; migraine without aura; motor skills
ID HYPERTHERMIC REACTIONS; DEPRESSIVE SYMPTOMS; CHILDHOOD MIGRAINE;
   OXIDATIVE STRESS; HEME OXYGENASE-1; MATERNAL STRESS; OREXIN SYSTEM;
   SLEEP; MULTICENTER; THERAPY
AB Background: Headache is the most common painful manifestation in the developmental age, often accompanied by severe disability such as scholastic absenteeism, low quality of academic performance and compromised emotional functioning. The aim of the study is to evaluate praxis abilities in a population of children without aural migraine.
   Materials and methods: The test population consists of 10 subjects without migraine without aura (MwA), (8 Males) (mean age 8.40, SD +/- 1.17) and 11 healthy children (7 Males) (mean age 8.27; SD +/- 1.10; p = 0.800).
   All subjects underwent evaluation of motor coordination skills through the Battery for Children Movement Assessment (MABC).
   Results: The two groups (10 MwA vs 11 Controls) were similar for age (8.40 +/- 1.17 vs 8.27 +/- 1.10; p = 0.800), sex (p = 0. 730), and BMI (p = 0.204). The migraine subjects show an average worse performance than the Movement ABC; specifically, migraineurs show significantly higher total score values (31.00 +/- 23.65 vs 4.72 +/- 2.61; p = 0.001), manual dexterity (12.10 +/- 11.20 vs 2.04 +/- 2.65; p = 0.009) and balance (14.85 +/- 10.08 vs. 1.04 +/- 1.05; p <0.001). The mean percentile of migraine performance is significantly reduced compared to controls (9.00 +/- 3.82 vs 51.00 +/- 24.34, p <0.001) (Table 1).
   Conclusion: Migraine can alter many cognitive and executive functions such as motor skills in developmental age.
C1 [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Picciocchi, Elisabetta] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Geraci, Diego; Salerno, Monica] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, I-195123 Catania, Italy.
   [Chisari, Mario Giuseppe] INPS, Catania, Italy.
   [Marsala, Gabriella] Osped Riuniti Foggia, Azienda Osped Univ, Struttura Complessa Farm, Foggia, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp, NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Di Folco, Annabella; Parisi, Lucia; Testa, Davide] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Lavano, Serena Marianna; Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Magliulo, Rosaria Martina] Ctr Scoliosi SRL, Naples, Italy.
   [D'Oro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
RP Parisi, L (corresponding author), Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020; SALERNO, MONICA/AAC-1321-2019
OI SALERNO, MONICA/0000-0002-6410-3960; Cerroni,
   Francesco/0000-0003-3024-5482; Marotta, Rosa/0000-0003-0515-5952;
   Murabito, Paolo/0000-0002-2662-1898
CR Albenzio M, 2018, J DAIRY SCI, V101, P4842, DOI 10.3168/jds.2017-13104
   Albenzio M, 2016, J DAIRY SCI, V99, P5032, DOI 10.3168/jds.2015-10704
   Albenzio M, 2017, NUTRIENTS IN DAIRY AND THEIR IMPLICATIONS FOR HEALTH AND DISEASE, P435, DOI 10.1016/B978-0-12-809762-5.00034-6
   Ambrosini A, 1999, NEUROSCI LETT, V276, P201, DOI 10.1016/S0304-3940(99)00820-4
   Brighina F, 2011, EUR J PAIN, V15, P928, DOI 10.1016/j.ejpain.2011.03.012
   Brighina F, 2009, CEREBELLUM, V8, P260, DOI 10.1007/s12311-008-0090-4
   Capovilla G, 2004, EPILEPSIA, V45, P887, DOI 10.1111/j.0013-9580.2004.457erratum.x
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00295
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00983
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Cuvellier JC, 2009, J HEADACHE PAIN, V10, P447, DOI 10.1007/s10194-009-0158-7
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Dodick D, 2007, HEADACHE, V47, P1210, DOI 10.1111/j.1526-4610.2007.00889.x
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2017, EUR J PHYS REHAB MED, V53, P643, DOI 10.23736/S1973-9087.16.04037-5
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli Luca, 2017, Microrna, V6, P17, DOI 10.2174/2211536606666170104130101
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Gigante E, 2018, ACTA MEDICA MEDITERR, V34, P1295, DOI 10.19193/0393-6384_2018_5_199
   Henderson S. E., 1992, MOVEMENT ASSESSMENT
   Kernick D, 2009, CEPHALALGIA, V29, P3, DOI 10.1111/j.1468-2982.2008.01693.x
   Kirby Amanda, 2011, J Fam Health Care, V21, P29
   Lateef TM, 2009, J CHILD NEUROL, V24, P536, DOI 10.1177/0883073808327831
   Li Volti G, 2004, BIOCHEM BIOPH RES CO, V315, P517, DOI 10.1016/j.bbrc.2004.01.090
   Mathew NT, 2011, HEADACHE, V51, P84, DOI 10.1111/j.1526-4610.2011.01955.x
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Monda V, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00695
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Rizzo M, 2015, J CLIN ENDOCR METAB, V100, P603, DOI 10.1210/jc.2014-2291
   Rossi P, 2005, HEADACHE, V45, P561, DOI 10.1111/j.1526-4610.2005.05110.x
   Salamone F, 2012, WORLD J GASTROENTERO, V18, P3862, DOI 10.3748/wjg.v18.i29.3862
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Shields KG, 2006, NEUROBIOL DIS, V23, P491, DOI 10.1016/j.nbd.2006.04.003
   Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Smits-Engelsman BC, 1998, MOVEMENT ASSESSMENT
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P1271, DOI 10.19193/0393-6384_2018_5_196
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Testa D, 2017, AGING CLIN EXP RES, V29, pS191, DOI 10.1007/s40520-016-0647-x
   Testa D, 2016, OPEN MED-WARSAW, V11, P208, DOI 10.1515/med-2016-0040
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Viggiano E, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00150
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 100
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2143
EP 2150
DI 10.19193/0393-6384_2018_4s_329
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900009
DA 2022-07-14
ER

PT J
AU Provenzano, S
   Santangelo, OE
   Catalano, R
   Marchese, V
   Bonanno, V
   La Placa, S
   Cernigliaro, A
   Mattina, F
   Firenze, A
AF Provenzano, Sandro
   Santangelo, Omar Enzo
   Catalano, Rosanna
   Marchese, Valentina
   Bonanno, Valentina
   La Placa, Simona
   Cernigliaro, Achille
   Mattina, Francesca
   Firenze, Alberto
TI DETERMINANTS ASSOCIATED WITH OBESITY AND PHYSICAL ACTIVITY IN THE PUBLIC
   AND PRIVATE SCHOOLS OF THE CITY OF PALERMO
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Surveys and Questionnaires; Students; Adolescent Behavior; Sicily; Body
   Weight; Physical Activity
ID QUALITY-OF-LIFE; SEDENTARY BEHAVIOR; AGED CHILDREN; ADOLESCENTS;
   OVERWEIGHT; HEALTH; TELEVISION; EXERCISE; FAMILY; EAT
AB Introduction: Obesity is a medical condition associated with premature death and it is a risk factor for many chronic diseases. In this context, performing a regular physical activity promotes a healthy lifestyle, with significant health benefits. The aim of the study was to investigate behaviors that increase the risk of obesity and the determinants that encourage physical activity among adolescents.
   Materials and methods: The HBSC (Health Behavior in School-aged Children) questionnaire was administered to students in Palermo's private and public schools. For the sampling of public schools the protocol of the HBSC Surveillance System was followed; for the private ones it was opportunistic.
   Results: Private school students are more likely to exercise more than 3 days per week (OR 1.58) and are more likely to exercise more than 2 times a week (OR 2.08). Obese students in private schools in Palermo are more likely to perform physical activity for less than 3 days a week (OR 3.52) and a higher risk of not having breakfast (OR 10.11) and a snack between main meals (OR 3.82) every day. For all the schools examined, it emerged that obese subjects are more likely not to consume fruit (OR 3.13), to stay more than 6 hours a day in front of PCs and video games (OR 3.24) and more than 2 hours a day in front of TV (OR 3.79). Male students are more likely to perform physical activity for more than 3 days per week (OR 1.48) and intense physical activity at least 2 times per week (OR 1.76)
   Conclusions: It is necessary to intervene early with training on school and family in order to promote correct and responsible food choices and increase the level of physical activity among students. Therefore prevention interventions must be an integral part of coherent strategies based on tests of agreed effectiveness in order to minimize the risk linked to the development of diseases.
C1 [Provenzano, Sandro; Santangelo, Omar Enzo; Catalano, Rosanna; Marchese, Valentina; Bonanno, Valentina; La Placa, Simona; Firenze, Alberto] Univ Study Palermo, Dept Sci Hlth Promot & Mother & Child Care GD Ale, Palermo, Italy.
   [La Placa, Simona] Polyclin Univ Hosp P Giaccone, Palermo, Italy.
   [Cernigliaro, Achille] Reg Hlth Author, Dept Hlth Serv & Epidemiol Observ, Palermo, Sicilian Region, Italy.
   [Mattina, Francesca] Local Hlth Unit Palermo, Dept Prevent Food Hyg Surveillance & Nutr Prevent, Palermo, Italy.
RP Firenze, A (corresponding author), Dipartimento Sci Promoz Salute & Materno Infantil, Via Vespro 129, I-90127 Palermo, Italy.
EM alberto.firenze@unipa.it
RI Santangelo, Omar Enzo/T-9659-2019; Cernigliaro, Achille/AAP-8092-2020
OI Santangelo, Omar Enzo/0000-0003-2017-3665; Provenzano,
   Sandro/0000-0001-7179-7246
CR Alfermann D, 2000, INT J SPORT PSYCHOL, V31, P47
   Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1
   [Anonymous], 2014, CALCULATE YOUR BMI
   Bar-on ME, 2001, PEDIATRICS, V107, P423, DOI 10.1542/peds.107.2.423
   Boreham C, 2001, J SPORT SCI, V19, P915, DOI 10.1080/026404101317108426
   Centers for Disease Control SHAPE America, 2017, PHYS ACTIVITY
   Crespo CJ, 2001, ARCH PEDIAT ADOL MED, V155, P360, DOI 10.1001/archpedi.155.3.360
   Fox KR, 2000, INT J SPORT PSYCHOL, V31, P228
   Friedlander SL, 2003, ARCH PEDIAT ADOL MED, V157, P1206, DOI 10.1001/archpedi.157.12.1206
   Haines J, 2007, OBESITY, V15, P2748, DOI 10.1038/oby.2007.327
   HBSC Italia, 2014, HLTH BEH SCH AG CHIL
   Mainvil LA, 2009, AM J HEALTH PROMOT, V23, P210, DOI 10.4278/ajhp.061221154
   Ministero della Salute Repubblica Italiana, 2012, DOSS ALC GUAD SAL
   Mond J, 2011, J ADOLESCENT HEALTH, V48, P373, DOI 10.1016/j.jadohealth.2010.07.022
   Nelson MC, 2006, PEDIATRICS, V118, pE1627, DOI 10.1542/peds.2006-0926
   Pearson N, 2009, PUBLIC HEALTH NUTR, V12, P267, DOI 10.1017/S1368980008002589
   Provincia autonoma di Bolzano-Alto Adige, 2010, IND SPORT SCOL
   Santangelo OE, 2018, RIV PSICHIA IN PRESS, V53
   Schor EL, 2003, PEDIATRICS, V111, P1541
   Sjoberg RL, 2005, PEDIATRICS, V116, pE389, DOI 10.1542/peds.2005-0170
   Sonneville KR, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-81
   StataCorp, 2015, STAT REL 14 STAT SOF
   Strauss RS, 2003, ARCH PEDIAT ADOL MED, V157, P746, DOI 10.1001/archpedi.157.8.746
   Swallen KC, 2005, PEDIATRICS, V115, P340, DOI 10.1542/peds.2004-0678
   Troiano RP, 2001, J NUTR, V131, p451S, DOI 10.1093/jn/131.2.451S
   Vieno A, 2005, EPIDEMIOL PSICHIAT S, V14, P100, DOI 10.1017/S1121189X00006308
   Who, 2000, IS BIRDTH
   World Health Organization, 2004, GLOB STRAT DIET
   World Health Organization, 2011, GLOBAL RECOMMENDATIO
NR 29
TC 2
Z9 2
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 443
EP 448
DI 10.19193/0393-6384_2018_2_70
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400024
DA 2022-07-14
ER

PT J
AU Puscas, DM
   Tache, S
AF Puscas, Dina Magdalena
   Tache, Simona
TI CHANGES IN REDOX HOMEOSTASIS AND HISTOPATHOLOGY IN EXPERIMENTAL
   LYMPHEDEMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE lymphedema; physical activity; antioxidants; breast cancer
ID OXIDATIVE STRESS; BREAST-CANCER; ANTIOXIDANT ACTIVITY;
   PHENOLIC-COMPOUNDS; EXERCISE; THERAPY; RECOVERY; EXTRACT; SURGERY; WOMEN
AB Objective: Lymphedema is one of the major long-term conditions related to breast cancer treatment. Active exercise stimulates musculoskeletal contractions, which may be considered a major pumping mechanism for lymphatic and venous drainage. Active exercise plays a key role in developing new pathways for lymphatic vessels and promoting lymphangiogenesis. The effect of physical activity on redox balance is extremely complex and it is influenced by age, sex, and training level, as well as by the intensity and duration of the exercise. During intense physical activity, free radicals are produced and oxidative stress is induced. In our study, we evaluated the efficacy of antioxidant supplementation and an intense physical activity program on redox homeostasis and the histopathological changes in animals with induced lymphedema, performing intense physical activity, with and without antioxidant supplementation.
   Methods: 50 Wistar female rats were randomized in five groups: group I: witness; group II: induced lymphedema; group III: induced lymphedema and a daily physical activity program, group IV: induced lymphedema and antioxidant supplementation; group V: induced lymphedema, a daily physical activity program and antioxidant supplementation.
   Results: After surgery for removal of axillary lymph nodes, right anterior limb volume of all subjects from the study increased significantly. Redox homeostasis was improved after antioxidant supplementation by the decrease of the oxidative stress. Lymphedema was significantly reduced. Histopathological examination revealed that physical activity has led to a reduction in the number of lymphatic capillaries and lymphatic vessel expansion. Antioxidant supplementation reduced significantly the inflammation and lymphatic dilatation after lymphadenectomy.
   Conclusions: Moderate physical activity has antioxidant effects, while intensive effort's effect is pro oxidant. Cellular redox balance is dependent on antioxidants. Antioxidant supplementation attenuates significantly the pro oxidant effect in subjects with induced lymphedema, even in subjects with intense physical activity. Reducing the oxidative stress or strengthening the antioxidative defense mechanism could supplement the complex physical therapy in chronic lymphedema.
C1 [Puscas, Dina Magdalena; Tache, Simona] Iuliu Hatieganu Univ Med & Pharm Cluj Napoca, Dept Physiotherapy, Cluj Napoca, Romania.
RP Puscas, DM (corresponding author), 8 Babes St, Cluj Napoca 400012, Romania.
EM dina.puscas@yahoo.com
CR Akinbo DB, 2018, CANC BIOMARK
   Andrisic L, 2018, REDOX BIOL, V14, P47, DOI 10.1016/j.redox.2017.08.009
   BENOIT JN, 1992, AM J PHYSIOL, V262, pG199, DOI 10.1152/ajpgi.1992.262.2.G199
   Bicego D, 2006, PHYS THER, V86, P1398, DOI 10.2522/ptj.20050328
   Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931
   Borek C., 2017, J RESTOR MED, V6, P53
   Brenke R, 1996, J LYMPHOL, V20, P31
   Buldus CF, 2012, THESIS
   Casanova E, 2008, PLANT FOOD HUM NUTR, V63, P93, DOI 10.1007/s11130-008-0073-0
   Chang TC, 2013, PHARM BIOL, V51, P573, DOI 10.3109/13880209.2012.749923
   COLTON T, 1974, STAT MED, P211
   CONTI M, 1991, CLIN CHEM, V37, P1273
   Cooke JP, 2012, CIRCULATION, V125, P853, DOI 10.1161/CIRCULATIONAHA.111.083477
   da Silva AO, 2014, J ETHNOPHARMACOL, V154, P319, DOI 10.1016/j.jep.2014.03.017
   Damstra RJ, 2009, BRIT J SURG, V96, P859, DOI 10.1002/bjs.6658
   Delanian S, 2004, RADIOTHER ONCOL, V73, P119, DOI 10.1016/j.radonc.2004.08.021
   Ewertz M, 2011, ACTA ONCOL, V50, P187, DOI 10.3109/0284186X.2010.533190
   FOLDI M, 1994, LYMPHOLOGY, V27, P1
   de Oliveira MMF, 2014, PHYSIOTHER THEOR PR, V30, P384, DOI 10.3109/09593985.2013.876695
   Ghasemnezhad M, 2011, J FUNCT FOODS, V3, P44, DOI 10.1016/j.jff.2011.02.002
   Hecht F, 2016, TUMOR BIOL, V37, P4281, DOI 10.1007/s13277-016-4873-9
   Hominickn D, 2018, ELIFE, V7, DOI 10.7554/eLife.34323
   HU ML, 1994, METHOD ENZYMOL, V233, P380
   Hwang JH, 1999, LYMPHOLOGY, V32, P15
   Ismail Amin Jr, 2002, Malays J Nutr, V8, P167
   Kasseroller R G, 2000, Am J Ther, V7, P273, DOI 10.1097/00045391-200007040-00008
   Lane K, 2005, SPORTS MED, V35, P461, DOI 10.2165/00007256-200535060-00001
   Luis A, 2011, NAT PROD COMMUN, V6, P1863
   Ly CL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010171
   Marin A, 2004, J AGR FOOD CHEM, V52, P3861, DOI 10.1021/jf0497915
   Materska M, 2005, J AGR FOOD CHEM, V53, P1750, DOI 10.1021/jf035331k
   Mendez U, 2012, AM J PHYSIOL-HEART C, V303, pH1107, DOI 10.1152/ajpheart.00522.2012
   Milkovic L, 2014, CURR PHARM DESIGN, V20, P6529, DOI 10.2174/1381612820666140826152822
   Morry J, 2017, REDOX BIOL, V11, P240, DOI 10.1016/j.redox.2016.12.011
   Murakami A, 2008, CANCER LETT, V269, P315, DOI 10.1016/j.canlet.2008.03.046
   Nayanatara A.K., 2005, THAI J PHARM SCI, V18, P3
   Pingitore A, 2015, NUTRITION, V31, P916, DOI 10.1016/j.nut.2015.02.005
   Puscas DM, 2017, EUR PROC SOC BEHAV, V23, P1648, DOI 10.15405/epsbs.2017.05.02.202
   Puscas DM, 2017, EUR PROC SOC BEHAV, V23, P69, DOI 10.15405/epsbs.2017.05.02.10
   Rehecho S, 2011, LWT-FOOD SCI TECHNOL, V44, P875, DOI 10.1016/j.lwt.2010.11.035
   Rockson SG, 2017, J AM HEART ASSOC, V1
   Secom, 2015, CAT PROD
   Shih YCT, 2009, J CLIN ONCOL, V27, P2007, DOI 10.1200/JCO.2008.18.3517
   Siems WG, 2002, QJM-INT J MED, V95, P803, DOI 10.1093/qjmed/95.12.803
   Smykla A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/767106
   Stoilova I, 2007, FOOD CHEM, V102, P764, DOI 10.1016/j.foodchem.2006.06.023
   Wang J, 2008, INT J BIOL MACROMOL, V42, P127, DOI 10.1016/j.ijbiomac.2007.10.003
   Waris G, 2006, J CARCINOG, V5, P14, DOI [10.1186/1477-3163-5-14, DOI 10.1186/1477-3163-5-14]
   Zancan KC, 2002, J SUPERCRIT FLUID, V24, P57, DOI 10.1016/S0896-8446(02)00013-X
   ZAWIEJA DC, 1993, LYMPHOLOGY, V26, P135
NR 50
TC 1
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1317
EP 1325
DI 10.19193/0393-6384_2018_5_202
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700024
DA 2022-07-14
ER

PT J
AU Qi, P
   Chen, H
   Lu, SY
   Yin, ZG
   Lin, J
AF Qi, Ping
   Chen, Hao
   Lu, Shun-yu
   Yin, Zhi-guo
   Lin, Jun
TI SYNTHESIS OF SOME NEW 2(3H)-BENZOXAZOLONE AND THEIR ANTIHEPATODAMAGE
   ACTIVITY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE 4-Hydroxy-2(3H)-Benzoxazolone; Liver injury Carbon tetrachloride
AB The synthesis, characterization and pharmacological activities of a new series of 4-Hydroxy-2(3H)-benzoxazolone are described.CCl4-induced acute liver injury model in mice was determined by serum alanine aminol ransferase(ALT). Among the synthesized compounds, compound 4-hydroxy-2(3H)-benzoxazolone, 4-Acetyl-2(3H)-benzoxazolone, 3-4-Acetoxy-2(3H)-benzoxazolone was found to be the most promising compound for antihepatis.
C1 [Qi, Ping; Yin, Zhi-guo] Ankang Municipal Ctr Hosp, Dept Pharm, Ankang 725000, Shanxi, Peoples R China.
   [Chen, Hao] Ankang Municipal Ctr Hosp, Dept Endocrinol, Ankang 725000, Shanxi, Peoples R China.
   [Lu, Shun-yu] Guangxi Med Univ, Dept Pharmacol, 22 Double Rd, Nanning 530021, Guangxi, Peoples R China.
RP Lin, J (corresponding author), Guangxi Med Univ, Dept Pharmacol, 22 Double Rd, Nanning 530021, Guangxi, Peoples R China.
EM 2541289288@qq.com
FU Guangxi medical University.Research Center Fund [2012 AM4019]
FX This study was supported by the Guangxi medical University.Research
   Center Fund (Project number: 2012 AM4019).
CR Babu BH, 2002, J ETHNOPHARMACOL, V79, P27, DOI 10.1016/S0378-8741(01)00347-6
   Gerova MS, 2017, PHOSPHORUS SULFUR, V192, P905, DOI 10.1080/10426507.2017.1321645
   Gokhan-Kelekci N, 2009, J ENZYM INHIB MED CH, V24, P29, DOI 10.1080/14756360701841772 
   Itoh A, 2010, BIOL PHARM BULL, V33, P983, DOI 10.1248/bpb.33.983
   Linpeng, 1995, ECOLOGY EC USE MANGR, P19
   Pengxing Longshengjing, 2006, W CHINA J PHARM SCI, V21, P14
   Yuan Liping, 2009, MODERN AGROCHEMICALS, V8, P15
NR 7
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1805
EP 1808
DI 10.19193/0393-6384_2018_6_277
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400028
DA 2022-07-14
ER

PT J
AU Qin, YZL
   Zhang, CM
AF Qin, Ying Zhang Lei
   Zhang, Changming
TI CLINICAL VALUE OF COMBINING F-18-FDG PET/CT SCANNING WITH SERUM LEVELS
   OF CYFRA211 AND HIF-1AFOR EARLY DETECTION OF LUNG CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE 18F-FDG PET/CT; Cyfra21-1; HIF-1 alpha; lung cancer
AB Objective: To explore the value of combining 2-Fluoro-2-Deoxy-D-Glucopyranose (18F-FDG) (Positron emission tomography/computer tomography, PET/CT) scanning with serum levels of (Cytokeratin 19 fragment antigen), Cyfra21-1 and (hypoxia inducible factor-1 alpha, HIF-1 alpha) afor early detection of lung cancer.
   Method: A total of 80 treatment-free patients with lung cancer confirmed through imaging, chemical pathology diagnosis and cytology in our hospital from January 2015 to December 2016 were placed in the early lung cancer group, while 25 others with benign lung diseases who reported in our hospital during the same period were placed in the control group. Serum levels of Cyfra21-1 and HIF-1 alpha in both groups were quantified, and then 18F-FDG PET/CT scanning was done, so as to evaluate the clinical significance of both methods in early diagnosis of lung cancer. In a third approach, tissue levels of deoxyglucose and serum levels of Cyfra21-1 and HIF-1 alpha were determined simultaneously using 18F-FDG PET/CT scanning.
   Results: The scan revealed that the standard uptake value (SUV) of 80 patients with early lung cancer (10.51 +/- 4.23) was significantly higher than that of the control group (P < 0.01). Levels of Cyfra21-1 and HIF-1 alpha were also significantly higher than in the control group (P < 0.01), and also significantly higher in patients with squamous cell carcinoma than in those with adenocarcinoma or small cell carcinoma (P < 0.05). However, there were no significant differences in Cyfra21-1 and HIF-1 alpha levels among adenocarcinoma, small cell carcinoma and unclassified cancerpatients (P>0.05). The sensitivity, specificity, and accuracy of Cyfra21-1 independently determined were 60.53%, 90.34%, and 80.52%, respectively, while those of HIF-1 alpha were 49.56%, 84.91%, and 65.23% respectively. The sensitivity, specificity, and accuracy of 18F-FDG PET/CT independently determined were 88.75%, 90.57%, and 90.05% respectively, while those of 18F-FDG PET/CT determined jointly with Cyfra21-1 and HIF-1 alpha were 97.04%, 98.62%, and 98.75%, respectively. There was statistical difference between the values of the independent and combined determinations (P < 0.05).
   Conclusion: The technique of combining 18F-FDG PET/CT scanning with determination of serum Cyfra21-1 and HIF-1 alpha levels is a considerably improved, accurate and sensitive approach for diagnosis of early stages of lung cancer.
C1 [Qin, Ying Zhang Lei; Zhang, Changming] Liaocheng Peoples Hosp, Dept Imaging, Liaocheng, Peoples R China.
RP Zhang, CM (corresponding author), 67 Dongchang Rd, Liaocheng City, Peoples R China.
EM or4363@163.com
CR [Anonymous], 2015, MODERN JOURNINTEGRTR, V24, P87
   [Anonymous], 2014, JOURNINNER MONGOLIA, V36, P555
   Bonafe F, 2015, MED HYPOTHESES, V84, P227, DOI 10.1016/j.mehy.2015.01.001
   Hang X, 2013, JOURNJ CAPITMEDUNIV, V34, P49
   Liu S, 2008, J MED THEORY PRACT, V21, P215
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Seemann F., 2012, COMP BIOCH PHYSL
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230
   STRAUSS GM, 1994, HEMATOL ONCOL CLIN N, V8, P507, DOI 10.1016/S0889-8588(18)30166-7
   Takahashi R, 2012, CLIN CANCER RES, V18, P220, DOI 10.1158/1078-0432.CCR-11-0868
   Tremblay A, 2016, CHEST, V148, p547A
   [王俊起 WANG Junqi], 2009, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V36, P868
   Wang Y, 2015, AIMS MATER SCI, V2, P448, DOI 10.3934/matersci.2015.4.448
   Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12
   Wu J, 2014, CHIN JOURNPRACTI MED, V41, P77
   Zhu L. Y, 2005, CHINA J MOD MED
NR 17
TC 1
Z9 1
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 183
EP 187
DI 10.19193/0393-6384_2018_1_30
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600030
DA 2022-07-14
ER

PT J
AU Qin, YJ
   Zhan, ZJ
   Xu, ZY
   Gao, KQ
   Ren, XL
   Wang, XL
AF Qin, Yujing
   Zhan, Zhijia
   Xu, Zhiyan
   Gao, Kequn
   Ren, Xiulan
   Wang, Xiaolei
TI MIR-449A DEPRESS THE GROWTH OF ENDOMETRIAL CARCINOMA CELLS BY REGULATING
   NOTCH1 SIGNALING PATHWAY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE miR-449a; endometrial carcinoma; HEC-1A cell; Notch1 pathway
ID QUALITY-OF-LIFE; MICRORNA CLUSTER; GASTRIC-CANCER; INVASION;
   PROLIFERATION; EXPRESSION; PHENOTYPE; APOPTOSIS
AB Objective: The aim of the study is to investigate the effect of miR-449a on endometrial cancer (EC) cells by regulating Notch1 signaling pathway, and to provide a theoretical basis for the clinical application of miRNA in the gene diagnosis and molecular biology therapy of endometrial carcinoma.
   Method: The experiment was divided into 3 groups, control group, negative control group and miR-449a transfection group. The expression of miR-449a mRNA was detected by RT-PCR. The cell proliferation, invasion, migration and apoptosis rate were detected. The mRNA and protein expression of Notch1, CBF1, HES1, p27 were detected by RT-PCR and Western blot, respectively.
   Result: Compared with the blank control group and negative control group, the miR-449a mRNA expression level in miR-449a transfection group was significantly higher (p < 0.05), and the transfection efficiency was high. The proliferation, the invasive ability and the migration ability of HEC-1A cells in miR-449a transfection group was significantly lower (p < 0.05). The apoptosis rate of HEC-1A cells in miR-449a transfection group was significantly increased(p < 0.05) and the mRNA expression and the protein of NOTCH1, CBF1 and HES1 in miR-449a transfection group was significantly lower than that in blank control group and negative control group, and the expression of p27 mRNA was significantly increased (p < 0.05).
   Conclusion: The effect of miR-449a on the growth of endometrial cancer cells is regulated by the Notch1 signaling pathway.
C1 [Qin, Yujing; Zhan, Zhijia; Gao, Kequn; Ren, Xiulan; Wang, Xiaolei] Qingdao Univ, Weihai Municiple Hosp 2, Dept Obstet & Gynecol, 51 Guangming Rd, Weihai 264200, Shandong, Peoples R China.
   [Xu, Zhiyan] Qingdao Univ, Weihai Municiple Hosp 2, Weihai, Shandong, Peoples R China.
RP Wang, XL (corresponding author), Qingdao Univ, Weihai Municiple Hosp 2, Dept Obstet & Gynecol, 51 Guangming Rd, Weihai 264200, Shandong, Peoples R China.
EM weihwxl@163.com
CR [Anonymous], 2014, GEN INF END CANC, P22
   AUTorre LA, 2015, CA CANC J CLIN GLOBA, V65, P87
   Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Collins BJ, 2004, SEMIN CANCER BIOL, V14, P357, DOI 10.1016/j.semcancer.2004.04.015
   Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172
   Gao YT, 2015, FEBS LETT, V589, P207, DOI 10.1016/j.febslet.2014.12.002
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   International Agency for Research on Cancer, 2014, WORLD CANC REPORT 20
   Ito T, 2000, DEVELOPMENT, V127, P3913
   Jang SG, 2014, INT J GYNECOL CANCER, V24, P1558, DOI 10.1097/IGC.0000000000000267
   Jeon HS, 2012, LUNG CANCER, V76, P171, DOI 10.1016/j.lungcan.2011.10.012
   Jurcevic S, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0088-6
   Kheir TB, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-29
   Konno Y, 2014, ONCOTARGET, V5, P6049, DOI 10.18632/oncotarget.2157
   Kumar P, ONCOTARGET
   Li Q, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0435-5
   Liang Y, 2015, DISASTER MED PUBLIC, V9, P111, DOI 10.1017/dmp.2015.7
   Liang Y, 2014, SOC INDIC RES, V119, P943, DOI 10.1007/s11205-013-0525-2
   Liang Y, 2015, SOC INDIC RES, V120, P277, DOI 10.1007/s11205-014-0585-y
   Liang Y, 2015, SOC INDIC RES, V120, P835, DOI 10.1007/s11205-014-0620-z
   Liu SY, 2016, AM J TRANSL RES, V8, P2609
   Liu YL, 2016, ONCOTARGET, V7, P13491, DOI 10.18632/oncotarget.4821
   Lize M, 2010, CELL CYCLE, V9, P4579, DOI 10.4161/cc.9.22.13870
   Niu M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2253-x
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   Shi J, 2015, INT J CLIN EXP PATHO, V8, P13387
   Shi W, 2016, ONCOTARGET, V7, P18906, DOI 10.18632/oncotarget.7753
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Tagawa H, 2005, LEUKEMIA, V19, P2013, DOI 10.1038/sj.leu.2403942
   Taichman DB, 2002, DEV DYNAM, DOI [10.1038/cdd.2009.188, DOI 10.1038/CDD.2009.188]
   Tsikouras P, 2013, EUR J OBSTET GYN R B, V169, P1, DOI 10.1016/j.ejogrb.2013.01.018
   Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x
   Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754
   You JC, 2015, AM J CANCER RES, V5, P2730
   Zhang H, 2015, CELL MOL BIOL, V61, P96
NR 38
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1411
EP 1418
DI 10.19193/0393-6384_2018_5_215
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700037
DA 2022-07-14
ER

PT J
AU Qiu, DH
   Zhao, N
AF Qiu Donghao
   Zhao Ning
TI LOW MOLECULAR WEIGHT HEPARIN CALIUM COMBINED WITH SHENYANKANGFU TABLET
   FOR THE TREATMENT OF PRIMARY NEPHROTIC SYNDROME
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hypercoagulable State; Primary nephrotic syndrome; Shenyankangfu tablet;
   Low molecular weight heparin calium
ID UNFRACTIONATED HEPARIN
AB Objective: To study the clinical effects of Shenyankangfu tablet combined with low molecular weight heparin calium for primary nephrotic syndrome PNS).
   Methods: 90 PNS patients treated from May 2013 to May 2014 in our hospital were selected and randomly divided into experimental group and control group, 45 cases each group. The experimental group patients were treated with Shenyankangfu tablet combined with low molecular weight heparin calium while the control group patients were just treated with low molecular weight heparin calium, two groups patients were treated for 2 months. The clinical effects and clinical index like triglyceride, total cholesterol, serum creatinine, serum albumin, urine protein quantification in the two groups were compared before and after surgery, as well as the coagulation indicators of two groups were observed.
   Result: The effective rate of experimental group (88.9%) was significantly higher than that of control group (66.7%) (P < 0.05); the index like triglyceride, total cholesterol, serum creatinine, serum albumin, urine protein quantification of experimental group was significantly better than that of control group (P < 0.05); the coagulation indicators like D-dimer (D-D), fibrinogen (Fib), prothrombin time (PT), activated partial thromboplastin time (APTT) of experimental group was significantly better than that of control group (P < 0.05).
   Conclusion: For PNS patients, Shenyankangfu tablet combined with low molecular weight heparin calium has an obvious clinical effect and can significantly improve the hypercoagulable state and renal functions. It is worthy of clinical promotion.
C1 [Qiu Donghao] Han Nationality, Jiashan, Zhejiang, Peoples R China.
   [Zhao Ning] Han Nationality, Shaoxing, Zhejiang, Peoples R China.
RP Qiu, DH (corresponding author), Care of Ming W, Shangcheng Huansha Rd 261, Hangzhou, Zhejiang, Peoples R China.
EM linken_linn@aliyun.com
CR ALHENCGELAS M, 1995, NEPHRON, V71, P149
   Ayar Y, 2016, ACTA MEDICA MEDITERR, V32, P1723
   Brieger D B, 2015, J AM COLL CARDIOL, V373, P1882
   Cui HF, 2013, GUIDE CHINA MED, V24, P172
   Fujinaga S, 2015, PEDIATR NEPHROL, V10, P159
   Gao M, 2011, CHINA PRACTICAL MED, V06, P153
   Grimpel YI, 2011, PLACENTA, V32, pS55, DOI 10.1016/j.placenta.2010.11.019
   Kou J, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-479
   Ravani P, 2015, J AM SOC NEPHROL, V15, P159
   Semenov AN, 2007, RUSS J INORG CHEM+, V52, P645, DOI 10.1134/S0036023607040316
   SHAUGHNESSY SG, 1995, BLOOD, V86, P1368, DOI 10.1182/blood.V86.4.1368.bloodjournal8641368
   Sun YM, 2012, CHINA PRACTICAL MED, V7, P172
   Valgimigli M, 2015, NEW ENGL J MED, V373, P997, DOI 10.1056/NEJMoa1507854
   Wang H, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-165
   Wu JW, 2010, CHINESE PEDIAT EMERG, V17, P173
   Xu CW, 2012, CHINESE J BIOCH PHAR, V33, P289
NR 16
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 485
EP 488
DI 10.19193/0393-6384_2018_2_78
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400032
DA 2022-07-14
ER

PT J
AU Qu, MW
   Zhang, LH
AF Qu Mingwei
   Zhang Lihua
TI EFFECT OF THZ1 ON PROLIFERATION AND APOFTOSIS OF HUMAN GLIOMA CELL LINE
   U373-MG
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE THZ1; Glioma; Proliferation; Apoptosis
AB Objective: The purpose of this study was to investigate the effect of THZ1 on proliferation and apoptosis of human glioma U373-MG cells.
   Methods: The study involved three sets of cells namely, experimental group, blank control group and DMSO group. The experimental group was treated with THZ1 at different concentrations, and cell proliferation was determined by MTT assay, while cell cycle and apoptosis analyses were assessed by flow cytometry. The expression of caspase-3/7 was determined by Western blot.
   Results: The rate of cell growth in the experimental group began to slow down from the third day in a time- and dose-dependent manner. The rate of growth of this group of cells was statistically significant when compared with blank control group and DMSO group (p < 0.05). Cell cycle determination showed that THZ1 arrested U373-MG cells in G1 phase, with relatively small number of cells in the S phase. This observation suggests that THZ1 blocks the proliferation of tumor cells by inhibiting cell cycle progression. Besides, THZ1 promoted the apoptosis of U373-MG cells and it probably accomplished this by increasing the activity of caspase-3/7 related apoptosis.
   Conclusion: Results from the present study indicate that THZ1 can inhibit the proliferation of human glioma U373-MG cells, block cell cycle progression and promote apoptosis.
C1 [Qu Mingwei; Zhang Lihua] Cangzhou Cent Hosp, Dept Neurol, Cangzhou 061000, Hebei, Peoples R China.
RP Zhang, LH (corresponding author), Cangzhou Cent Hosp, Dept Neurol, Cangzhou 061000, Hebei, Peoples R China.
EM 874878927@qq.com
CR Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504
   Balakrishnan A, 2016, WORLD J GASTROENTERO, V22, P2159, DOI 10.3748/wjg.v22.i7.2159
   Dante RA, 2014, PLANTA, V239, P493, DOI 10.1007/s00425-013-1990-1
   Farina FM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.291
   Greenall SA, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.33
   Hu WM, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000979
   Lu JX, CHIN J PRAC NERV DIS, V015, P48
   Peyressatre M, 2015, CANCERS, V7, P179, DOI 10.3390/cancers7010179
   Qiao DH, 2013, MOL CELL BIOL, V33, P4408, DOI 10.1128/MCB.00238-13
   Strickland M, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00043
   Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069
   Wang J, 2016, TRANSL ONCOL, V9, P548, DOI 10.1016/j.tranon.2016.08.007
   Xu YJ, 2017, J MOD ONCO, V25, P185
   Zhi TL, 2017, AM J CANCER RES, V7, P982
NR 14
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 871
EP 875
DI 10.19193/0393-6384_2018_3_133
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000037
DA 2022-07-14
ER

PT J
AU Quarto, M
   Savino, F
   Molisso, V
AF Quarto, Maria
   Savino, Federica
   Molisso, Vittoria
TI SPECIFIC LEARNING DISORDERS AND COMPENSATORY TOOLS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Specific Learning Disorder (SLD); Resilience; Physics; Compensatory
   Tools
AB Introduction: People with Specific Learning Disorders face many difficulties in their school experiences and in life, with consequences on learning, psychological implications and negative school paths undertaken. Behind the SLD label there are very different frameworks: characteristics that also affect the way to face and manage one's own life, including difficulties; it needs to get a wider vision and recognize early warning bells to intervene with individualized paths.
C1 [Quarto, Maria; Savino, Federica] Univ Naples Federico II, Naples, Italy.
   [Molisso, Vittoria] Parthenope Univ, Naples, Italy.
RP Quarto, M (corresponding author), Univ Naples Federico II, Naples, Italy.
EM maria.quarto@unina.it
OI Quarto, Maria/0000-0003-0119-2393; Savino, Federica/0000-0001-5733-4325
CR AID Associazione Italiana Dislessia Comitato Promotore Consensus Conference, DIST EV SPEC APPR RA
   Anaut M., 2003, RESILIENCE SURMONTER
   Andolfi M, 2009, MANUALE PSICOLOGIA R
   Aurilio R, 2015, APPRENDERLA PRATICAR
   BEER FP, MECH MAT
   Campbell F.C., 2008, ELEMENTS METALLURGY
   Cornoldi C., 2017, DISTURBI DIFFICOLTA
   Cyrulnik, 2005, COSTRUIRE RESILIENZA
   Di Palma D, 2016, SPECIAL NEEDS INCLUS
   Lucangeli D., 2012, DISCALCULIA DIFFICOL
   Malagoli Togliatti M, 2014, INDIVIDUO SISTEMA MA
   Malaguti E., 2005, COME AFFRONTARE CRIS
   Short D, 2014, SPERANZA RESILIENZA
NR 13
TC 1
Z9 1
U1 2
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1513
EP 1515
DI 10.19193/0393-6384_2018_3s_231
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400008
DA 2022-07-14
ER

PT J
AU Rampello, L
   Rampello, L
   Malaguarnera, G
   Chisari, EM
   Arcidiacono, A
   Zappia, M
AF Rampello, Luigi
   Rampello, Liborio
   Malaguarnera, Giulia
   Chisari, Eleonora Margherita
   Arcidiacono, Antonio
   Zappia, Mario
TI DIFFERENTIAL DIAGNOSIS OF THE MAIN TRANSIENT GLOBAL AMNESIAS ATYPICAL
   CASE REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE transient epileptic amnesia; transient global amnesia; transient
   ischemic attack
ID OF-THE-LITERATURE; VASCULAR DEMENTIA; EPILEPTIC AMNESIA; FOLLOW-UP;
   DEPRESSION; PROGNOSIS; EVOLUTION; ANATOMY; ATTACK
AB Objective: Memory is one of man's most important cognitive functions. Various diseases can affect memory function and yield specific memory impairments. One of these conditions, transient global amnesia, is a peculiar type of memory loss with hallmark characteristics. However, the pathophysiological explanation for transient global amnesia remains controversial
   Methods: Starting with the most significant data from the literature, we describe the most important features needed for diagnosing the three main clinical conditions that could mimic transient global amnesia. Then, we describe a retrospective series of cases of transient global amnesia.
   Results: Among the cases observed, we focus on a case of transient global amnesia with features that distinguish it from the cases reported in the literature.
   Conclusion: This paper describes the key features of transient global amnesia, discusses the main differential diagnoses from similar conditions and proposes a pathogenetic interpretation consistent with all of the hallmarks of the disorder (amnesia duration, lack of specific neuroradiological and electroencephalo-graphic correlates or impaired sensitivity or motility, reversibility and benign prognosis of the amnesic episodes, and rare recurrence).
C1 [Rampello, Luigi; Rampello, Liborio; Zappia, Mario] Univ Catania, Neurosci Sect, GF Ingrassia Dept, Via Santa Sofia 78, I-95123 Catania, Italy.
   [Malaguarnera, Giulia] Univ Catania, Res Ctr, Great Senescence, I-95123 Catania, Italy.
   [Chisari, Eleonora Margherita] Univ Catania, Dept Educ, I-95123 Catania, Italy.
   [Arcidiacono, Antonio] Univ Catania, Biometec Dept, Via Santa Sofia 78, I-95123 Catania, Italy.
RP Rampello, L (corresponding author), Univ Catania, Dipartimento GF Ingrassia, Sez Neurosci, Via Santa Sofia 78, I-95123 Catania, Italy.
RI Zappia, Mario/AAB-7800-2019
FU University of Catania [21040104]
FX Financial support was provided by the University of Catania (code
   21040104)
CR Bartolomei F, 2004, NEUROLOGY, V63, P858, DOI 10.1212/01.WNL.0000137037.56916.3F
   Bartsch T, 2007, ANN NEUROL, V62, P475, DOI 10.1002/ana.21189
   Bartsch T, 2010, LANCET NEUROL, V9, P205, DOI 10.1016/S1474-4422(09)70344-8
   Bettermann K, 2006, ARCH NEUROL-CHICAGO, V63, P1336, DOI 10.1001/archneur.63.9.1336
   Butler CR, 2008, BRAIN, V131, P2243, DOI 10.1093/brain/awn127
   Caplan L., 1985, HDB CLIN NEUROLOGY, V1, P205
   Cataudella E, 2012, ACTA MEDICA MEDITERR, V28, P245
   Di Filippo M, 2007, NEUROLOGY, V69, P493, DOI 10.1212/01.wnl.0000271085.87627.72
   Dohring J, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00287
   FISHER CM, 1964, ACTA NEUROL SCAND, V40, P7
   GANDOLFO C, 1992, EUR NEUROL, V32, P52, DOI 10.1159/000116787
   HODGES JR, 1990, J NEUROL NEUROSUR PS, V53, P834, DOI 10.1136/jnnp.53.10.834
   HODGES JR, 1990, BRAIN, V113, P639, DOI 10.1093/brain/113.3.639
   Malaguarnera M, 2008, DIGEST DIS SCI, V53, P3018, DOI 10.1007/s10620-008-0238-6
   Malaguarnera M, 2011, SCAND J GASTROENTERO, V46, P750, DOI 10.3109/00365521.2011.565067
   Malaguarnera M, 2011, METAB BRAIN DIS, V26, P281, DOI 10.1007/s11011-011-9260-z
   Manahan-Vaughan D, 2003, NEUROPHARMACOLOGY, V44, P17, DOI 10.1016/S0028-3908(02)00342-8
   MERRIAM AE, 1992, PSYCHOSOMATICS, V33, P109, DOI 10.1016/S0033-3182(92)72029-5
   MILLER JW, 1987, NEUROLOGY, V37, P733, DOI 10.1212/WNL.37.5.733
   Quinette P, 2006, BRAIN, V129, P1640, DOI 10.1093/brain/awl105
   Rampello L, 2005, J NEUROL, V252, P1045, DOI 10.1007/s00415-005-0811-2
   Rampello L, 2004, PSYCHOPHARMACOLOGY, V173, P73, DOI 10.1007/s00213-003-1698-1
   Rampello L, 2000, CNS DRUGS, V13, P35, DOI 10.2165/00023210-200013010-00004
   Rampello L, 2016, J NEUROL SCI, V369, P354, DOI 10.1016/j.jns.2016.08.048
   Ricceri R, 2013, ACTA MEDICA MEDITERR, V29, P99
   Schmidtke K, 1998, EUR NEUROL, V40, P9, DOI 10.1159/000007948
   Schreiber SJ, 2005, J NEUROL NEUROSUR PS, V76, P509, DOI 10.1136/jnnp.2004.043844
   STILLHARD G, 1990, J NEUROL NEUROSUR PS, V53, P339, DOI 10.1136/jnnp.53.4.339
   Vuilleumier P, 1996, NEUROLOGY, V46, P1036, DOI 10.1212/WNL.46.4.1036
   Weon YC, 2008, AM J NEURORADIOL, V29, P1324, DOI 10.3174/ajnr.A1105
   Winbeck K, 2005, J NEUROL NEUROSUR PS, V76, P438, DOI 10.1136/jnnp.2004.042432
   Zelante G, 2012, ACTA MEDICA MEDITERR, V28, P45
   Zeman AZJ, 1998, J NEUROL NEUROSUR PS, V64, P435, DOI 10.1136/jnnp.64.4.435
   ZORZON M, 1995, STROKE, V26, P1536, DOI 10.1161/01.STR.26.9.1536
NR 34
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 685
EP 690
DI 10.19193/0393-6384_2018_3_105
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000010
DA 2022-07-14
ER

PT J
AU Rampello, L
   Rampello, L
   Chisari, CG
   Malaguarnera, M
   Arcidiacono, A
   Vecchio, I
   Scuderi, R
   Zappia, M
AF Rampello, Luigi
   Rampello, Liborio
   Chisari, Clara Grazia
   Malaguarnera, Michele
   Arcidiacono, Antonio
   Vecchio, Ignazio
   Scuderi, Rosario
   Zappia, Mario
TI AFTER THE SWEET COMES THE BITTER. TIME TO HALT THE DIABETIC NEUROPATHY
   EPIDEMIC
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE diabetes; diabetic neuropathy; diabetic complications; diabetic
   prevention; diabetic therapy
ID DISCOID LUPUS-ERYTHEMATOSUS; OCULAR SURFACE; POPULATION; PREVALENCE;
   DIAGNOSIS; RISK
AB Diabetes is the leading cause of neuropathy in industrialized countries and possibly worldwide. The most common form is distal symmetrical polyneuropathy. Diabetes affects the nerves even before being recognized. The disease continues to expand in parallel with the incorrect lifestyle habits typical of modern society. The cardinal symptoms of peripheral nervous system diseases may be indicative of motor, sensory, autonomic and trophic lesions. Diabetic neuropathy also has significant economic costs to society. The high rate of diabetic neuropathy causes substantial morbidity from recurrent infections of the lower limbs, ulceration and amputation. Electromyographic examination of the distal muscles of the lower extremities may reveal acute and chronic denervation. Some alterations of the paraspinal muscles, such as spontaneous activity, are similar to those of disease in the spinal nerve roots.
C1 [Rampello, Luigi; Rampello, Liborio; Chisari, Clara Grazia; Zappia, Mario] Univ Catania, GF Ingrassia Dept, Neurosci Sect, Via Santa Sofia 78, I-95123 Catania, Italy.
   [Malaguarnera, Michele] Univ Catania, Res Ctr Great Senescence, Catania, Italy.
   [Arcidiacono, Antonio] Univ Catania, Biometec Dept, Via Santa Sofia 78, I-95123 Catania, Italy.
   [Vecchio, Ignazio; Scuderi, Rosario] Univ Catania, Dept Clin & Expt Med, Catania, Italy.
RP Rampello, L (corresponding author), Univ Catania, GF Ingrassia Dept, Neurosci Sect, Via Santa Sofia 78, I-95123 Catania, Italy.
RI Zappia, Mario/AAB-7800-2019; Malaguarnera, Michele/A-1376-2019
OI Malaguarnera, Michele/0000-0002-7145-6377; chisari, clara
   grazia/0000-0003-1607-543X
FU University of Catania, Department. " G.F. Ingrassia" [21040104/2014]
FX This work was supported by the University of Catania, trough financing
   No 21040104/2014, Department. " G.F. Ingrassia".
CR Abbott CA, 2011, DIABETES CARE, V34, P2220, DOI 10.2337/dc11-1108
   Bierhaus A, 2009, DIABETOLOGIA, V52, P2251, DOI 10.1007/s00125-009-1458-9
   Bischoff C, 1996, ELECTROMYOGR MOTOR C, V101, P528, DOI 10.1016/S0013-4694(96)96553-4
   Boulton AJM, 2004, NEW ENGL J MED, V351, P48, DOI 10.1056/NEJMcp032966
   Callaghan BC, 2012, LANCET NEUROL, V11, P521, DOI 10.1016/S1474-4422(12)70065-0
   Chisari CG, 2015, ACTA MEDICA MEDITERR, V31, P1217
   Chisari CG, 2014, ACTA MEDICA MEDITERR, V30, P249
   Chisari G, 2015, ACTA MEDICA MEDITERR, V31, P1057
   Chisari G, 2013, ACTA MEDICA MEDITERR, V29, P369
   Gregg EW, 2004, DIABETES CARE, V27, P1591, DOI 10.2337/diacare.27.7.1591
   Johannsen L, 2001, J Clin Neuromuscul Dis, V3, P47, DOI 10.1097/00131402-200112000-00001
   Miralles-Garcia Jose M, 2010, Endocrinol Nutr, V57, P414, DOI 10.1016/j.endonu.2010.05.006
   Pop-Busui R, 2017, DIABETES CARE, V40, P136, DOI 10.2337/dc16-2042
   Rampello L., 2011, 20 WORLD C NEUR FREE, P133
   Rampello L, 2016, J NEUROL SCI, V369, P354, DOI 10.1016/j.jns.2016.08.048
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P133
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P127
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P139
   Steven S, 2016, DIABETES CARE, V39, P808, DOI 10.2337/dc15-1942
   Van Acker K, 2009, DIABETES METAB, V35, P206, DOI 10.1016/j.diabet.2008.11.004
   Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019
   Vincent AM, 2011, NAT REV NEUROL, V7, P573, DOI 10.1038/nrneurol.2011.137
   Vinik AI, 2016, NEW ENGL J MED, V374, P1455, DOI 10.1056/NEJMcp1503948
   Warren B, 2017, LANCET DIABETES ENDO, V5, P34, DOI 10.1016/S2213-8587(16)30321-7
   WATKINS PJ, 1997, TXB DIABETES
NR 25
TC 1
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 691
EP 696
DI 10.19193/0393-6384_2018_3_106
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000011
DA 2022-07-14
ER

PT J
AU Rampello, L
   Patti, F
   Rampello, L
   Arcidiacono, A
   Zappia, M
AF Rampello, Luigi
   Patti, Francesco
   Rampello, Liborio
   Arcidiacono, Antonio
   Zappia, Mario
TI A CASE OF MULTIPLE AUTOIMMUNITY COMPLICATED BY SIADH
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Autoimmunity; Vasculitis- CNS Vasculitides-Multiorgan dysimmune
   syndrome-SIADH-Immunosuppressors
ID CENTRAL-NERVOUS-SYSTEM; PRIMARY ANGIITIS; VASCULITIS
AB Central nervous system (CNS) vasculitides are rare, often severe diseases, difficult to diagnose for the lack of specific symptoms and with a poor outcome. We report a case of CNS vasculitis in a 57-year-old patient suffering from multiorgan dysimmune syndrome characterised by celiac disease, ulcerative colitis and diabetes mellitus. Cognitive deterioration, gait impairment and balance loss were the main clinical findings, and the patient was able to walk in 3 years. Moreover, inappropriate secretion of adiuretin syndrome occurred, making the patient's treatment more complex. Methylprednisolone and monthly intravenous pulse of cyclophosphamide boosters were administered; plasma-exchange, intravenous immunoglobulins and rituximab were sequentially used with no benefit.
C1 Univ Catania, GF Ingrassia Dept, Neurosci Sect, Via Santa Sofia 78, I-95123 Catania, Italy.
   Univ Catania, Biometec Dept, Via Santa Sofia 78, I-95123 Catania, Italy.
RP Rampello, L (corresponding author), Univ Catania, Via Santa Sofia 78, I-95123 Catania, Italy.
RI Zappia, Mario/AAB-7800-2019
OI patti, francesco/0000-0002-6923-0846
FU University of Catania, GF Ingrassia Department [21040104]
FX The authors have contributed equally to the elaboration and writing of
   the manuscript with a financing of the University of Catania No
   21040104, GF Ingrassia Department
CR Benseler SM, 2006, ARTHRITIS RHEUM-US, V54, P1291, DOI 10.1002/art.21766
   Calabrese LH, 1997, ARTHRITIS RHEUM, V40, P1189, DOI 10.1002/1529-0131(199707)40:7<1189::AID-ART2>3.0.CO;2-4
   CALABRESE LH, 1988, MEDICINE, V67, P20, DOI 10.1097/00005792-198801000-00002
   Campi A, 2001, NEURORADIOLOGY, V43, P599, DOI 10.1007/s002340100561
   Crowley Rachel K, 2006, Expert Rev Endocrinol Metab, V1, P537, DOI 10.1586/17446651.1.4.537
   Cuesta M, 2016, BEST PRACT RES CL EN, V30, P175, DOI 10.1016/j.beem.2016.02.009
   CUPPS TR, 1983, AM J MED, V74, P97, DOI 10.1016/0002-9343(83)91125-7
   Holle JU, 2011, CURR OPIN RHEUMATOL, V23, P7, DOI 10.1097/BOR.0b013e32834115f9
   Kadkhodayan Y, 2004, RADIOLOGY, V233, P878, DOI 10.1148/radiol.2333031621
   Pistone G, 2002, ARCH GERONTOL GERIAT, P279
   Polizzi A, 2001, CLIN NEUROL NEUROSUR, V103, P151, DOI 10.1016/S0303-8467(01)00132-9
   Rampello L, 2016, J NEUROL SCI, V369, P354, DOI 10.1016/j.jns.2016.08.048
   Rampello L, 2012, CLIN NEUROL NEUROSUR, V114, P751, DOI 10.1016/j.clineuro.2011.12.027
   Runkle I, 2013, MED CLIN-BARCELONA, V141
   Runkle I, 2014, NEFROLOGIA, V34, P439, DOI 10.3265/Nefrologia.pre2014.Apr.12220
   Salvarani C, 2007, ANN NEUROL, V62, P442, DOI 10.1002/ana.21226
   Salvarani C, 2012, LANCET, V380, P767, DOI 10.1016/S0140-6736(12)60069-5
   Twilt M, 2012, NAT REV RHEUMATOL, V8, P97, DOI 10.1038/nrrheum.2011.197
   Verbalis JG, 2013, AM J MED, V126, pS5, DOI 10.1016/j.amjmed.2013.07.006
NR 19
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1131
EP 1135
DI 10.19193/0393-6384_2018_4_174
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500037
DA 2022-07-14
ER

PT J
AU Rampello, L
   Patti, F
   Rampello, L
   Arcidiacono, A
   D'Amico, E
   Zappia, M
AF Rampello, Luigi
   Patti, Francesco
   Rampello, Liborio
   Arcidiacono, Antonio
   D'Amico, Emanuele
   Zappia, Mario
TI PRIMARY CEREBRAL VASCULITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE primary CNS vasculitis; PACNS; CNS primary angiitis; CNS vasculitides;
   vasculitis
ID CENTRAL-NERVOUS-SYSTEM; NONINFECTIOUS GRANULOMATOUS-ANGIITIS;
   ZOSTER-VIRUS VASCULOPATHIES; CHURG-STRAUSS-SYNDROME;
   LUPUS-ERYTHEMATOSUS; VASOCONSTRICTION SYNDROMES; NEUROLOGICAL
   INVOLVEMENT; WEGENERS-GRANULOMATOSIS; INFECTION; MANIFESTATIONS
AB Vasculitides are rare conditions affecting vessels of different type and caliber. They are characterized by inflammation of the blood vessel walls and vascular damage causing alterations in blood flow. The resulting clinical syndromes mostly result from tissue ischemia, vascular damage and inflammation affecting one or more organs or systems. Primary isolated vasculitic involvement of the central nervous system (primary CNS vasculitis) is a rare form characterized by inflammation of the blood vessels in the brain and medulla without evidence of vasculitis symptoms outside the CNS.
C1 Univ Catania, GF Ingrassia Dept, Neurosci Sect, Via Santa Sofia 78, I-95123 Catania, Italy.
   Univ Catania, Biometec Dept, Via Santa Sofia 78, I-95123 Catania, Italy.
RP Rampello, L (corresponding author), Univ Catania, Via Santa Sofia 78, I-95123 Catania, Italy.
RI Zappia, Mario/AAB-7800-2019; D'Amico, Emanuele/N-5568-2019
OI D'Amico, Emanuele/0000-0001-7494-9057; patti,
   francesco/0000-0002-6923-0846
FU University of Catania, Department. "G.F. Ingrassia" [21040104]
FX This work was supported by the University of Catania, trough financing
   No 21040104, Department. "G.F. Ingrassia".
CR Al-Araji A, 2009, LANCET NEUROL, V8, P192, DOI 10.1016/S1474-4422(09)70015-8
   Alrawi A, 1999, NEUROLOGY, V53, P858, DOI 10.1212/WNL.53.4.858
   Appenzeller S, 2008, CLIN REV ALLERG IMMU, V34, P361, DOI 10.1007/s12016-007-8060-z
   Barinagarrementeria F, 1998, STROKE, V29, P123, DOI 10.1161/01.STR.29.1.123
   Benseler SM, 2006, ARTHRITIS RHEUM-US, V54, P1291, DOI 10.1002/art.21766
   Bilge I, 2005, PEDIATR NEPHROL, V20, P529, DOI 10.1007/s00467-004-1736-1
   Birnbaum J, 2009, ARCH NEUROL-CHICAGO, V66, P704, DOI 10.1001/archneurol.2009.76
   Bleck TP, 1999, NEUROL CLIN, V17, P801, DOI 10.1016/S0733-8619(05)70167-5
   Bley TA, 2007, AM J NEURORADIOL, V28, P1722, DOI 10.3174/ajnr.A0638
   Cacoub P, 2005, AIDS, V19, pS128, DOI 10.1097/01.aids.0000192081.33938.2f
   Calabrese LH, 2007, ANN INTERN MED, V146, P34, DOI 10.7326/0003-4819-146-1-200701020-00007
   Calabrese LH, 1997, ARTHRITIS RHEUM, V40, P1189, DOI 10.1002/1529-0131(199707)40:7<1189::AID-ART2>3.0.CO;2-4
   CALABRESE LH, 1988, MEDICINE, V67, P20, DOI 10.1097/00005792-198801000-00002
   Chitravas N, 2011, ANN NEUROL, V70, P437, DOI 10.1002/ana.22454
   CRAVIOTO H, 1959, NEUROLOGY, V9, P599, DOI 10.1212/WNL.9.9.599
   CUPPS TR, 1983, AM J MED, V74, P97, DOI 10.1016/0002-9343(83)91125-7
   Ducros A, 2007, BRAIN, V130, P3091, DOI 10.1093/brain/awm256
   Ducros Anne, 2009, Pract Neurol, V9, P256, DOI 10.1136/jnnp.2009.187856
   ELLIS SG, 1979, SEMIN ARTHRITIS RHEU, V8, P212, DOI 10.1016/S0049-0172(79)80009-8
   Engelter ST, 2002, ARCH NEUROL-CHICAGO, V59, P1480, DOI 10.1001/archneur.59.9.1480
   FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660
   Gan C, 2015, J CLIN NEUROSCI, V22, P1528, DOI 10.1016/j.jocn.2015.03.030
   Garge SS, 2014, ANN INDIAN ACAD NEUR, V17, P444, DOI 10.4103/0972-2327.144035
   Ghinoi A, 2010, CLIN EXP RHEUMATOL, V28, P759
   Gilden D, 2009, LANCET NEUROL, V8, P731, DOI 10.1016/S1474-4422(09)70134-6
   GOLDEN MP, 1994, MEDICINE, V73, P246, DOI 10.1097/00005792-199409000-00003
   Goncalves C, 2004, An Pediatr (Barc), V60, P188
   Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003
   Hajj-Ali RA, 2014, J AUTOIMMUN, V48-49, P149, DOI 10.1016/j.jaut.2014.01.007
   HANLY JG, 1992, J RHEUMATOL, V19, P732
   Harbitz F, 1922, AM J MED SCI, V163, P250, DOI 10.1097/00000441-192202000-00010
   HARRISON PE, 1976, J NEUROL SCI, V29, P335, DOI 10.1016/0022-510X(76)90182-9
   Heinrich A, 2003, EUR NEUROL, V50, P109, DOI 10.1159/000072510
   Holle JU, 2011, CURR OPIN RHEUMATOL, V23, P7, DOI 10.1097/BOR.0b013e32834115f9
   Lie J T, 1991, Curr Opin Rheumatol, V3, P36, DOI 10.1097/00002281-199102000-00008
   MARRA CM, 1995, CURR OPIN NEUROL, V8, P164
   Melica G, 2009, J MED VIROL, V81, P578, DOI 10.1002/jmv.21462
   Miller DV, 2009, AM J SURG PATHOL, V33, P35, DOI 10.1097/PAS.0b013e318181e097
   Nagashima T, 2000, NEUROPATHOLOGY, V20, P309, DOI 10.1046/j.1440-1789.2000.00352.x
   Nagel MA, 2008, NEUROLOGY, V70, P853, DOI 10.1212/01.wnl.0000304747.38502.e8
   NEWMAN W, 1952, T AM NEUROL ASSOC, P114
   NISHINO H, 1993, ANN NEUROL, V33, P4, DOI 10.1002/ana.410330103
   Oran I, 1999, NEURORADIOLOGY, V41, P436, DOI 10.1007/s002340050779
   Ovetchkine P, 2002, SCAND J INFECT DIS, V34, P307, DOI 10.1080/00365540110077452
   PARISI JE, 1994, SEMIN NEUROL, V14, P341, DOI 10.1055/s-2008-1041093
   Ramos-Casals M, 2008, MEDICINE, V87, P210, DOI 10.1097/MD.0b013e318181e6af
   Ringleb PA, 2005, RHEUMATOLOGY, V44, P1012, DOI 10.1093/rheumatology/keh664
   Saliou G, 2008, RHEUMATOLOGY, V47, P107, DOI 10.1093/rheumatology/kem264
   Salvarani C, 2008, ARTHRIT RHEUM-ARTHR, V59, P291, DOI 10.1002/art.23337
   Salvarani C, 2007, ANN NEUROL, V62, P442, DOI 10.1002/ana.21226
   Salvarani C, 2012, LANCET, V380, P767, DOI 10.1016/S0140-6736(12)60069-5
   SANDHU R, 1979, ARCH NEUROL-CHICAGO, V36, P433, DOI 10.1001/archneur.1979.00500430063009
   Sangha Kim M. D., 2015, GEN HOSP PSYCHIAT, V37
   SEHGAL M, 1995, MAYO CLIN PROC, V70, P337, DOI 10.4065/70.4.337
   Sen ES, 2010, RHEUMATOLOGY, V49, P806, DOI 10.1093/rheumatology/kep453
   Singhal AB, 2011, ARCH NEUROL-CHICAGO, V68, P1005, DOI 10.1001/archneurol.2011.68
   Starke J R, 1999, Semin Pediatr Neurol, V6, P318, DOI 10.1016/S1071-9091(99)80029-1
   Tabarki B, 2001, PEDIATR NEUROL, V25, P239, DOI 10.1016/S0887-8994(01)00290-9
   Twilt M, 2012, NAT REV RHEUMATOL, V8, P97, DOI 10.1038/nrrheum.2011.197
   VOLLMER TL, 1993, ARCH NEUROL-CHICAGO, V50, P925, DOI 10.1001/archneur.1993.00540090032007
   Younger DS, 2004, CURR OPIN NEUROL, V17, P317, DOI 10.1097/00019052-200406000-00014
   Zeller V, 2004, PRESSE MED, V33, P1385, DOI 10.1016/S0755-4982(04)98937-3
NR 62
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1137
EP 1142
DI 10.19193/0393-6384_2018_4_175
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500038
DA 2022-07-14
ER

PT J
AU Rao, XP
   Shi, XJ
   Chii, XL
   Wan, MY
AF Rao, Xiaopang
   Shi, Xiujuan
   Chii, Xiaolin
   Wan, Meiyan
TI BONE MINERAL DENSITY AT DIFFERENT LOCATIONS IN TYPE 2 DIABETES MELLITUS
   AND ANALYSIS OF FRACTURE SITES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Type 2 diabetes mellitus; bone mineral density; osteoporosis; fracture
ID POSTMENOPAUSAL WOMEN; HIP-FRACTURES; RISK; OSTEOPOROSIS; MEN; AGE
AB This study investigated changes in bone mineral density (BMD) at different locations in 125 patients with type 2 diabetes mellitus (T2DM) and 240 healthy controls between 2012 and 2015. BMD was assessed using dual-energy X-ray absorptiometry. BMD at L2 in men with T2DM was lower than in controls, and the difference was statistically significant (P<0.05). BMD in women with T2DM was lower at Wards triangle and the femoral neck than in controls, and the difference was statistically significant (P<0.05). The prevalence of osteoporosis was higher in women with T2DM (55.20%) and women without T2DM (29.16%) than in men with T2DM (28.80%) and men without T2DM (21.66%), and the difference was statistically significant (P<0.05). The prevalence of osteoporosis at L2 and L1-4 (5.40% and 16%) in men with T2DM was higher than that in men without T2DM (1.66% and 9.85%), and the difference was statistically significant (P<0.05). The prevalence of osteoporosis at Wards angle, the femoral neck, and the femur (20%, 12.80%, and 42.40%) in women with T2DM was higher than that in women without T2DM (3.33%, 5%, and 17.91%), and the difference was statistically significant (P< 0.05). The preferred examination sites for early diagnosis of osteoporosis in men and women with T2DM are Ward's triangle and L2, which are consistent with common osteoporotic fracture sites.
C1 [Rao, Xiaopang; Shi, Xiujuan; Chii, Xiaolin] Chengyang Peoples Hosp Qingdao, Dept Endocrinol, Qingdao 266109, Peoples R China.
   [Wan, Meiyan] Qingdao Municipal Hosp, Dept Nephrol, 1 JiaoZhou Rd ShiBei Dist, Qingdao 266100, Peoples R China.
RP Wan, MY (corresponding author), Qingdao Municipal Hosp, Dept Nephrol, 1 JiaoZhou Rd ShiBei Dist, Qingdao 266100, Peoples R China.
EM cnmeiyanwan@163.com
FU Chengyang District, Qingdao, Shandong Province Science and Technology
   Bureau [2016-WJZD121]
FX The author was funded by research grants from Chengyang District,
   Qingdao, Shandong Province Science and Technology Bureau (2016-WJZD121).
CR Anaforoglu I, 2009, J DIABETES COMPLICAT, V23, P12, DOI 10.1016/j.jdiacomp.2007.06.004
   Bhattoa HP, 2013, CLIN RHEUMATOL, V32, P1161, DOI 10.1007/s10067-013-2254-y
   Botushanov Nikolay P, 2009, Folia Med (Plovdiv), V51, P12
   Dominguez L J, 2004, Reumatismo, V56, P235
   Fan Y, 2016, OSTEOPOROSIS INT, V27, P219, DOI 10.1007/s00198-015-3279-7
   Gupta R, 2009, J CLIN DENSITOM, V12, P54, DOI 10.1016/j.jocd.2008.09.003
   Kobayashi N, 2015, J BONE MINER METAB, V33, P455, DOI 10.1007/s00774-014-0610-x
   Liu EY, 2003, DIABETES CARE, V26, P2365, DOI 10.2337/diacare.26.8.2365
   Isidro ML, 2010, CURR DIABETES REV, V6, P144, DOI 10.2174/157339910791162970
   Martinez-Laguna D, 2015, OSTEOPOROSIS INT, V26, P827, DOI 10.1007/s00198-014-2986-9
   Nicodemus KK, 2001, DIABETES CARE, V24, P1192, DOI 10.2337/diacare.24.7.1192
   Schwartz AV, 2005, J BONE MINER RES, V20, P596, DOI 10.1359/JBMR.041219
   Sealand R, 2013, CURR DIABETES REP, V13, P411, DOI 10.1007/s11892-013-0376-x
   Shan PF, 2011, J ENDOCRINOL INVEST, V34, P190, DOI [10.1007/BF03347065, 10.3275/7239]
   Sosa M, 2009, AGING CLIN EXP RES, V21, P27, DOI 10.1007/BF03324895
   Suzuki K, 2000, DIABETES RES CLIN PR, V48, P185, DOI 10.1016/S0168-8227(00)00119-4
   World Health Organization, 2004, WHO SCI GROUP ASS OS
   World Health Organization, 1985, TECH REP SER, V727
   Yaturu S, 2009, J DIABETES, V1, P246, DOI 10.1111/j.1753-0407.2009.00049.x
   Yaturu S, 2009, MED SCI MONITOR, V15, pCR5
NR 20
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1239
EP 1243
DI 10.19193/0393-6384_2018_5_190
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700012
DA 2022-07-14
ER

PT J
AU Rebegea, L
   Stefan, AM
   Firescu, D
   Miron, D
   Romila, A
AF Rebegea, Laura
   Stefan, Ana-Maria
   Firescu, Dorel
   Miron, Dumitra
   Romila, Aurelia
TI PARANEOPLASTICPEMPHIGUS ASSOCIATED WITH A HYPOPHARYNX SQUAMOUS CELL
   CARCINOMA. CASE REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE paraneoplastic pemphigus; rare; hypopharynx squamous cell carcinoma
ID PEMPHIGUS; NEOPLASIA; DISEASE; CANCER
AB Introduction: Paraneoplastic pemphigus (PNP) is a rare autoimmune disease of the skin associated with neoplasm. It is mostly associated with lymphoproliferative disorders (nearly 84% of all cases are found in hematologic neoplasms). The underlying pathogenesis is believed to be triggered by altered immune system in response to underlying neoplasm. The manifestations can predate, occur at the same time or after the diagnosis of cancer. Males between 40 and 70 years are most frequently affected. The prognosis of PNP is generally poor, and the disease is often fatal. The occurrence of PNP with squamous cell carcinoma is rare. We have chosen to present this case because PNP is a very rare paraneoplastic manifestation (in literature less than 500 cases were described), having poor prognosis, anddue to the fact that its association withhypopharynx squamous cell carcinoma is not commonly seen.
   Case presentation: We present the case of a 67-year-old male with squamous cell carcinoma of the hypopharynxassociated with PNP. The patient treatment performed was external beam radiotherapy, concomitant with chemotherapy. A skin biopsy was performed and it revealed pemphigoid lesions.
   Conclusions: This kind of case is rare because the PNP is rarely associated with a hypopharynx carcinoma and also because the particularities regarding diagnosis and challenging treatment. After the oncological treatment, the evolution was favorable, with amelioration of symptomatology, pemphigoid lesions andtumorregression. Unfortunately, the patient was not present at the visit 6months after treatment, being lost to follow-up.
C1 [Rebegea, Laura] Sf Ap Andrei Emergency Clin Hosp, Dept Radiotherapy, Galati, Romania.
   [Rebegea, Laura; Romila, Aurelia] Dunarea Jos Univ Galati, Fac Med & Pharm, Med Clin Dept, Galati, Romania.
   [Stefan, Ana-Maria] Prof Dr AlexandruTrestioreanu Oncol Inst, Radiotherapy Clin, Bucharest, Romania.
   [Firescu, Dorel] Sf Ap Andrei Emergency Clin Hosp, Surg Clin 2, Galati, Romania.
   [Firescu, Dorel] Dunarea Jos Univ Galati, Fac Med & Pharm, Surg Clin Dept, Galati, Romania.
   [Miron, Dumitra] Sf Ap Andrei Emergency Clin Hosp, Pathol Anat Dept, Galati, Romania.
   [Romila, Aurelia] Sf Ap Andrei Emergency Clin Hosp, Geriatr Dept, Galati, Romania.
RP Firescu, D (corresponding author), Sf Ap Andrei Emergency Clin Hosp, Surg Clin 2, Galati, Romania.; Firescu, D (corresponding author), Dunarea Jos Univ Galati, Fac Med & Pharm, Surg Clin Dept, Galati, Romania.
EM dorelfirescu@yahoo.com
RI Firescu, Dorel/AAB-2808-2019
CR Anhalt GJ, 2004, J INVEST DERM SYMP P, V9, P29, DOI 10.1111/j.1087-0024.2004.00832.x
   ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503
   Anhalt GJ, 1997, ADVDERMATOL, P1277
   Anhalt GJ, 2012, FITZPATRICKS DERMATO, V1, P600
   CAMISA C, 1993, ARCH DERMATOL, V129, P883, DOI 10.1001/archderm.129.7.883
   Cho JH, 2013, CANCER RES TREAT, V45, P70, DOI 10.4143/crt.2013.45.1.70
   Cummins DL, 2007, J AM ACAD DERMATOL, V56, P153, DOI 10.1016/j.jaad.2006.06.007
   Czernik A, 2011, INT J DERMATOL, V50, P905, DOI 10.1111/j.1365-4632.2011.04868.x
   Ferlito A, 2007, EUR ARCH OTO-RHINO-L, V264, P211, DOI 10.1007/s00405-006-0217-5
   Fried A, 1993, J AM ACAD DERMATOL
   Habif Thomas P., 2004, CLIN DERMATOL, P559
   Healy W J, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2014-208677
   Kaplan I, 2004, ORAL ONCOL, V40, P553, DOI 10.1016/j.oraloncology.2003.09.020
   Lee M S, 1995, Australas J Dermatol, V36, P206, DOI 10.1111/j.1440-0960.1995.tb00976.x
   Leger S, 2012, ARCH DERMATOL, V148, P1165, DOI 10.1001/archdermatol.2012.1830
   Mahajan Vikram K., 2012, CASE REPORTS DERMATO
   Mathew Deepu George, 2010, J Oral Maxillofac Pathol, V14, P41, DOI 10.4103/0973-029X.72499
   Mayo Clinic. Mayo Medical Laboratories, TEST CAT DESM 1 DSG1
   Odell W, 2000, CANC MED, P1436
   Paolino G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122532
   Pelosof LC, 2010, MAYO CLIN PROC, V85, P838, DOI 10.4065/mcp.2010.0099
   Toro C, 2010, ORAL ONCOL, V46, P14, DOI 10.1016/j.oraloncology.2009.09.007
   Wang YZ, 2016, CHINESE MED J-PEKING, V129, P1501, DOI 10.4103/0366-6999.183422
   Webster G, 2013, BRAZ J OTORHINOLAR, V79, P258, DOI 10.5935/1808-8694.20130045
   Wieczorek M, 2016, CLIN COSMET INVESTI, V9, P291, DOI 10.2147/CCID.S100802
   Wong K C, 2000, Australas J Dermatol, V41, P178, DOI 10.1046/j.1440-0960.2000.00434.x
   Zhu XJ, 2007, J DERMATOL, V34, P503, DOI 10.1111/j.1346-8138.2007.00322.x
   Zimmermann J, 2010, J DTSCH DERMATOL GES, V8, P598, DOI 10.1111/j.1610-0387.2010.07380.x
NR 28
TC 6
Z9 6
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1265
EP 1270
DI 10.19193/0393-6384_2018_5_195
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700017
DA 2022-07-14
ER

PT J
AU Romila, A
   Mocanu, ID
   Chetrone, M
   Lungu, M
   Tutunaru, D
   Calin, A
AF Romila, Aurelia
   Mocanu, Iulian-Dan
   Chetrone, Monica
   Lungu, Mihaela
   Tutunaru, Dana
   Calin, Alina
TI LEFT COMMON CAROTID ARTERY RUPTURED MYCOTIC ANEURYSM WITH ISCHAEMIC
   STROKE IN A PATIENT WITH MYELODYSPLASTIC SYNDROME. A CASE REPORT AND
   LITERATURE REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE ruptured mycotic common carotid aneurysm; stroke; sepsis; myelodysplasia
AB Introduction: A left common carotid artery mycotic aneurysm in a patient with myelodysplastic syndrome was diagnosed due to acute onset of an ischemic stroke in left carotid artery territory, with right palsy and generalized seizure, followed by painful swelling of the left latero-cervical region and sepsis state after a few hours. CT-scan of the neck confirmed a pseudo-aneurysm of the left internal carotid artery. The surgical intervention detected a ruptured aneurysm with sepsis state, with methicilin resistent Staphylococcus aureus-MRSA and Gram negative germs.
C1 [Romila, Aurelia; Lungu, Mihaela; Tutunaru, Dana] Dunarea Jos Univ Galati, Fac Med & Pharm, 35 Al I Cuza St Galati, Galati, Romania.
   [Romila, Aurelia] Emergency Clin Cty Hosp Galati, Med Pharmaceut Res Ctr, Geriatr Dept, Galati, Romania.
   [Mocanu, Iulian-Dan] Emergency Clin Cty Hosp Galati, Vasc Surg Dept, Galati, Romania.
   [Chetrone, Monica] Emergency Clin Cty Hosp, Galati, Romania.
   [Lungu, Mihaela] Emergency Clin Cty Hosp Galati, Neurol Dept, Galati, Romania.
   [Tutunaru, Dana] Med Pharmaceut Res Ctr, Clin Lab Dept, Galati, Romania.
   [Calin, Alina] Dunarea Jos, Fac Med & Pharm, Galati, Romania.
   [Calin, Alina] Clin Obstret & Gynecol Dept, Galati, Romania.
RP Lungu, M (corresponding author), Dunarea Jos Univ Galati, Fac Med & Pharm, 35 Al I Cuza St Galati, Galati, Romania.; Lungu, M (corresponding author), Clin Emergency Hosp Galati, Neurol Dept, 177 Brailei St, Galati, Romania.
EM mihaelalungu17@yahoo.com
RI LUNGU, MIHAELA/AAD-3727-2019
OI LUNGU, MIHAELA/0000-0002-2807-7742
CR [Anonymous], 2014, ADAMS VICTORS PRINCI, P853
   Forbes TL, 2008, CAN J SURG, V51, pE11
   Pearson SE, 2005, ARCH OTOLARYNGOL, V131, P454, DOI 10.1001/archotol.131.5.454
   Pirvu A, 2013, ANN VASC SURG, V27, P826, DOI 10.1016/j.avsg.2012.10.025
   Raghuram AR, 2008, INDIAN J THORAC CARD, V24, P145, DOI 10.1007/s12055-008-0023-3
   Raso Jair, 2011, Surg Neurol Int, V2, P86, DOI 10.4103/2152-7806.82328
   Shah R S, 1991, J Postgrad Med, V37, P225
   Shah R.S., 1991, J POSTGRAD MED, V37, p228A
   Simon R.W., 2006, EXTRA, V12, P63
NR 9
TC 3
Z9 4
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 449
EP 452
DI 10.19193/0393-6384_2018_2_71
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400025
DA 2022-07-14
ER

PT J
AU Rosa, R
   D'Andria, A
   Napolitano, F
AF Rosa, Roberta
   D'Andria, Antonio
   Napolitano, Felicia
TI INNOVATIVE STRATEGIES IN THE AUTISM SPECTRUM SYNDROME
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Biodanza SRT; Autism Spectrum Syndrome; Inclusion; Special Didactics
AB Introduction: Recent evidence suggests that systemic-relational approaches to corporeal mediation such as Biodanza SRT turn out to be innovative strategies in educational-didactic proposals for people with Autism Spectrum Syndrome.
   Case presentation: Through the enhancement of corporeity and the integration of music, emotions and movement lived in groups, the Biodanza SRT system induces motor, relational and emotional experiences, by stimulating the possible communication and relationship, the emotional self regulation and the autonomy capabilities, healthy lifestyles and behavioral skills that can be spent in everyday life.
   Conclusion: Biodanza SRT is an important opportunity for the development of functional skills in areas that are most undermined by the autistic disorder: that of communication, social interaction, interests and behavior in general; it represents an innovative and effective strategy that determines the increase of psychological, motor, emotional and relational well-being by improving the Quality of Life (QoL).
C1 [Rosa, Roberta; D'Andria, Antonio; Napolitano, Felicia] Parthenope Univ, Via Medina 40, Naples, Italy.
RP Rosa, R (corresponding author), Parthenope Univ, Via Medina 40, Naples, Italy.
EM roberta.rosa@uniparthenope.it
CR Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   Gallese V, 2016, EMPATIA SEMPRE INCAR
   Garaudy R, 1985, DANZARE LA VITA
   Ghedin E., 2016, J SPECIAL ED INCLUSI, V2, P204
   Giannelli M. T, 2015, HLTH EFFECTS DERIVED
   Montesano P, 2016, VALORIZZAZIONE CORPO, pXIV
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   R. Rosa R, 2016, OFFICIAL J ITALIAN S, V36
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Riva D, 2000, GIORNALE NEUROPSICHI, V20, P170
   Salvitti C, 2000, PRATICA ATTIVITA MOT
   Stueck M, 2012, BIOPSYCHOLOGICAL BAS, P1
   Tafuri D., 2017, SPORT SCI, V10, P70
   Toro Araneda R, 2012, CIMEB TEXTX, VI
   Toro Araneda R, 2012, CIMEB TESTI, VI
   Toro Araneda R., 2007, BIODANZA MUSICA MOVI
   Toro R., 1997, ALFABETO VITA POETIC
NR 24
TC 0
Z9 0
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1487
EP 1491
DI 10.19193/0393-6384_2018_3s_226
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400003
DA 2022-07-14
ER

PT J
AU Rosa, R
   de Vita, T
   Napolitano, F
AF Rosa, Roberta
   de Vita, Tiziana
   Napolitano, Felicia
TI THE "BIODANZA SRT" PROPOSAL IN NEURODEGENERATIVE DISEASES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Autism; Pet-Therapy; Motor Disorder
ID PREMOTOR CORTEX; RECOGNITION
AB Introduction: Recent evidence suggests that therapeutic dance may be an appropriate form of physical activity for some individuals with Neurodegenerative Diseases. Rolando Toro's Biodanza System (SRT) is a therapeutic strategy of human development and growth that integrates movement, music and emotions to induce motor, relational and emotional experiences.
   Case presentation: By drawing on Neuroscientific research, the authors describe therapeutic aspects and the use of "Biodanza SRT" in clinical cases of Neurodegenerative Diseases. By involving people on a physical, mental, emotional, and social level, the aim is to create new movement patterns integrating the individual's emotional and motor components, in order to generate adaptive responses aimed at strengthening the self-esteem and self-efficacy of the communication-relational skills.
   Conclusion: "Biodanza SRT" represents an innovative and effective strategy that, in short terms, allows for the increase of psychological, general motor, and emotional-relational well-being, and the consequent improvement of Quality of Life (QoL).
C1 [Rosa, Roberta; de Vita, Tiziana; Napolitano, Felicia] Parthenope Univ, Via Medina 40, Naples, Italy.
RP Rosa, R (corresponding author), Parthenope Univ, Via Medina 40, Naples, Italy.
EM roberta.rosa@uniparthenope.it
CR Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593
   Ghedin E., 2016, J SPECIAL ED INCLUSI, V2, P204
   Kiepe MS, 2012, ART PSYCHOTHER, V39, P404, DOI 10.1016/j.aip.2012.06.001
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0
   Rogers C, 2007, RELAZIONE EFFICACE N
   Rosa R., OFFICIAL J ITALIAN N, V36
   Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2
   Stueck M., 2012, BIOPSYCHOLOGICAL BAS, P1
   Tafuri D., 2017, SPORT SCI, V10, P70
   Toro Acuna GC, 2013, IBF RETE CIMEB RETE
   Toro Araneda R, 2012, TEORIA BIODANZA RACC, VI
   van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558
NR 23
TC 0
Z9 0
U1 5
U2 12
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1507
EP 1511
DI 10.19193/0393-6384_2018_3s_230
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400007
DA 2022-07-14
ER

PT J
AU Rossella, D
   Gianluca, L
   Antonella, A
   Giuseppe, C
AF Rossella, De Luca
   Gianluca, Lo Coco
   Antonella, Ardizzone
   Giuseppe, Cicero
TI PSYCHOLOGICAL DISTRESS AND QUALITY OF LIFE IN OSTOMY PATIENTS WITH
   COLORECTAL CANCER: A SYSTEMATIC REVIEW OF THE LITERATURE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Quality of Life; stomy; anxiety; depression; distress; body image
ID RECTAL-CANCER; INTESTINAL STOMA; IMPACT; METAANALYSES; RADIOTHERAPY;
   DOCETAXEL; EFFICACY
AB Introduction: This research examine the literature related to the psychological state and the quality of life in patients with colorectal cancer. In particular, this study investigates the alterations in patients who have undergone ostomy procedures (colostomy and/or ileostomy).
   Materials and methods: A systematic research was been carried out through the electronic databases PubMed and Psychinfo. After having identified 1289 scientific articles, a convenient sample of 12 studies were included in the research. Overall, all studies taken into analyses have shown how enterostomy affects the quality of life of stoma patients both after the formation of the stoma and the follow-up.
   Results: 12 studies examined have demonstrated that several factors influence the quality of life and psychological state. One of the major results was relate to changes in body appearance considered as a strong predictor of various psychological problems including anxiety, depression and distress.
   Conclusion: These results give healthcare professionals the opportunity to have a wider and clearer view on all aspects related to the quality of life of all patients affected by enterostomy and colorectal cancer.
C1 [Rossella, De Luca; Antonella, Ardizzone; Giuseppe, Cicero] Univ Palermo, Dept Surg Oncol & Oral Sci, Palermo, Italy.
   [Gianluca, Lo Coco] Univ Palermo, Dept Psychol, Palermo, Italy.
RP Giuseppe, C (corresponding author), Univ Palermo, Dept Surg Oncol & Oral Sci, Palermo Med Oncol, Via Vespro 129, I-90127 Palermo, Italy.
EM giuseppe.cicero@unipa.it
OI Lo Coco, Gianluca/0000-0001-9027-1899
CR Bjeldbak-Olesen M, 2013, DAN MED J, V60
   Brown SR, 2014, ANN SURG, V259, P916, DOI 10.1097/SLA.0000000000000407
   Cicero G, 2017, J GENET COUNS, V26, P999, DOI 10.1007/s10897-017-0072-0
   Cicero G, 2018, ONCOTARGET THERAPY
   Cicero G, 2017, ONCOLOGY-BASEL, V93, P354, DOI 10.1159/000479112
   Cicero G, 2017, ANTI-CANCER DRUG, V28, P1047, DOI 10.1097/CAD.0000000000000549
   Cicero G, 2017, ANTICANCER RES, V37, P5187, DOI 10.21873/anticanres.11941
   Cicero G, 2017, ANTICANCER RES, V37, P1475, DOI 10.21873/anticanres.11472
   Cicero G, 2017, ONCOLOGY-BASEL, V92, P94, DOI 10.1159/000452491
   Danielsen AK, 2013, COLORECTAL DIS, V15, pE276, DOI 10.1111/codi.12197
   Danielsen AK, 2013, J CLIN NURS, V22, P1343, DOI 10.1111/jocn.12011
   Danielsen AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090354
   Danielsen AK, 2013, INT J COLORECTAL DIS, V28, P1603, DOI 10.1007/s00384-013-1749-y
   De Luca R, 2018, ONCOLOGY-BASEL, V94, P161, DOI 10.1159/000485102
   Karabulut HK, 2014, J CLIN NURS, V23, P2800, DOI 10.1111/jocn.12541
   Laforest A, 2012, COLORECTAL DIS, V14, P1231, DOI 10.1111/j.1463-1318.2012.02956.x
   Lim SH, 2015, J ADV NURS, V71, P1310, DOI 10.1111/jan.12595
   Lo Re G, 2016, RADIOL MED, V121, P763, DOI 10.1007/s11547-016-0664-z
   Marijnen CAM, 2005, J CLIN ONCOL, V23, P1847, DOI 10.1200/JCO.2005.05.256
   Meraviglia S, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1347742
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Neuman HB, 2011, ANN SURG ONCOL, V18, P1397, DOI 10.1245/s10434-010-1446-9
   Orsini RG, 2013, EJSO-EUR J SURG ONC, V39, P164, DOI 10.1016/j.ejso.2012.10.005
   Page MJ, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0663-8
   Dazio EMR, 2009, REV LAT-AM ENFERM, V17, P664, DOI 10.1590/S0104-11692009000500011
   Santini D, 2017, ANN ONCOL, V28, P2906, DOI 10.1093/annonc/mdw551
   Sharpea L, 2011, J PSYCHOSOM RES, V70, P95
   Vonk-Klaassen SM, 2016, QUAL LIFE RES, V25, P125, DOI 10.1007/s11136-015-1050-3
   Wiltink LM, 2014, EUR J CANCER, V50, P2390, DOI 10.1016/j.ejca.2014.06.020
NR 30
TC 3
Z9 4
U1 2
U2 32
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1357
EP 1363
DI 10.19193/0393-6384_2018_5_208
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700030
DA 2022-07-14
ER

PT J
AU Ruberto, M
   Gallai, B
   Tripi, G
   Lavano, F
   Salerno, M
   Lavano, SM
   Romano, P
   Russo, D
   Marotta, R
   Franco, S
   Picciocchi, E
   Geraci, D
   Chisari, MG
   Marsala, G
   Polito, AN
   Sorrentino, M
   Russo, D
   Magliulo, RM
   D'oro, L
   Di Folco, A
   Parisi, L
   Testa, D
   Murabito, P
   Giugliano, P
   Cerroni, F
AF Ruberto, Maria
   Gallai, Beatrice
   Tripi, Gabriele
   Lavano, Francesco
   Salerno, Margherita
   Lavano, Serena Marianna
   Romano, Palmira
   Russo, Daniela
   Marotta, Rosa
   Franco, Sabrina
   Picciocchi, Elisabetta
   Geraci, Diego
   Chisari, Mario Giuseppe
   Marsala, Gabriella
   Polito, Anna Nunzia
   Sorrentino, Michele
   Russo, Daniela
   Magliulo, Rosaria Martina
   D'oro, Lucrezia
   Di Folco, Annabella
   Parisi, Lucia
   Testa, Davide
   Murabito, Paolo
   Giugliano, Pasquale
   Cerroni, Francesco
TI RETRACTED: CORPUS CALLOSUM AGENESIA A MINIREVIEW (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review; Retracted Publication
DE corpus callosum; agenesia; cerebral abnormalities
ID MONOSYMPTOMATIC NOCTURNAL ENURESIS; SLEEP-APNEA SYNDROME;
   BEHAVIORAL-DISORDERS; KETOGENIC DIET; HYPERTHERMIC REACTIONS; CHILDHOOD
   MIGRAINE; PARENTAL STRESS; MATERNAL STRESS; OREXIN SYSTEM; CHILDREN
AB The corpus callosum (CC) is the largest of the fiber bundles present in the human brain, and its name derives from its hard consistency caused by the presence of myelinated fibers. It represents the largest and most voluminous brain commissure and a white matter station. CC alterations may be identified in many neurodevelopmental disorders.
C1 [Ruberto, Maria] CDR Santa Maria del Pozzo, Somma Vesuviana, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Lavano, Francesco; Lavano, Serena Marianna; Marotta, Rosa] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Russo, Daniela; Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Di Folco, Annabella; Parisi, Lucia; Testa, Davide] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Franco, Sabrina; Geraci, Diego] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, I-95123 Catania, Italy.
   [Picciocchi, Elisabetta] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Chisari, Mario Giuseppe] INPS, Catania, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Osped Riuniti Foggia, Struttura Complessa Farm, Foggia, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp, NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
   [Magliulo, Rosaria Martina] Ctr Scoliosi SRL, Bari, Italy.
   [D'oro, Lucrezia; Di Folco, Annabella] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
   [Giugliano, Pasquale] UOC Med Legale, Azienda Osped St Anna San & Sebastiano di Caserta, Viterbo, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
RP Parisi, L (corresponding author), Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Murabito, Paolo/0000-0002-2662-1898; Cerroni,
   Francesco/0000-0003-3024-5482; Marotta, Rosa/0000-0003-0515-5952
CR AIELLO I, 1994, ITAL J NEUROL SCI, V15, P497, DOI 10.1007/BF02334611
   Anderson NG, 2006, PEDIATRICS, V118, P951, DOI 10.1542/peds.2006-0553
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto M, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00295
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00188
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Delcan J, 2004, PRENATAL DIAG, V24, P635, DOI 10.1002/pd.955
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1181, DOI 10.19193/0393-6384_2017_2s_184
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1197, DOI 10.19193/0393-6384_2017_2s_186
   Gallai B, 2017, ACTA MEDICA MEDITERR, V33, P1205, DOI 10.19193/0393-6384_2017_2s_187
   Jarre A, 2017, RADIOLOGIA-MADRID, V59, P226, DOI 10.1016/j.rx.2017.01.002
   Labadi B, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00094
   Maldonato MN, 2018, ACTA MEDICA MEDITERR, V34, P357, DOI 10.19193/0393-6384_2018_2_56
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P769, DOI 10.19193/0393-6384_2017_5_113
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P729, DOI 10.19193/0393-6384_2017_5_107
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P737, DOI 10.19193/0393-6384_2017_5_108
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSL, V8
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P1279, DOI 10.19193/0393-6384_2017_2s_197
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Pacheco Sheila Cristina da Silva, 2014, Rev. paul. pediatr., V32, P252, DOI 10.1590/0103-0582201432317
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Pascoe L, 2015, J INT NEUROPSYCH SOC, V21, P610, DOI 10.1017/S1355617715000715
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P349, DOI 10.19193/0393-6384_2018_2_55
   Testa D, 2017, AGING CLIN EXP RES, V29, pS191, DOI 10.1007/s40520-016-0647-x
   Testa D, 2016, OPEN MED-WARSAW, V11, P208, DOI 10.1515/med-2016-0040
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 94
TC 0
Z9 0
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2115
EP 2123
DI 10.19193/0393-6384_2018_4s_326
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900006
DA 2022-07-14
ER

PT J
AU Ruberto, M
   Gallai, B
   Tripi, G
   Lavano, F
   Salerno, M
   Lavano, SM
   Romano, P
   Russo, D
   Marotta, R
   Franco, S
   Picciocchi, E
   Geraci, D
   Chisari, MG
   Marsala, G
   Polito, AN
   Sorrentino, M
   Magliulo, RM
   D'oro, L
   Di Folco, A
   Parisi, L
   Testa, D
   Murabito, P
   Cerroni, F
AF Ruberto, Maria
   Gallai, Beatrice
   Tripi, Gabriele
   Lavano, Francesco
   Salerno, Margherita
   Lavano, Serena Marianna
   Romano, Palmira
   Russo, Daniela
   Marotta, Rosa
   Franco, Sabrina
   Picciocchi, Elisabetta
   Geraci, Diego
   Chisari, Mario Giuseppe
   Marsala, Gabriella
   Polito, Anna Nunzia
   Sorrentino, Michele
   Magliulo, Rosaria Martina
   D'oro, Lucrezia
   Di Folco, Annabella
   Parisi, Lucia
   Testa, Davide
   Murabito, Paolo
   Cerroni, Francesco
TI NEUROPSYCHOMOTRICITY IN WATER: A NEW REHABILITATIVE TOOL FOR
   NERUODEVELOPMENTAL DISORDERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE neuropsychomotricity; pediatric rehabilitation; water
ID CHILDHOOD ABSENCE EPILEPSY; PRIMARY NOCTURNAL ENURESIS; HYPERTHERMIC
   REACTIONS; OXIDATIVE STRESS; HEME OXYGENASE-1; OBESE CHILDREN;
   OPEN-LABEL; MIGRAINE; SLEEP; ADOLESCENTS
AB Neuropsychomotricity in water is a rehabilitative practice that avails itself just of the liquid element, as a mediator of relationships: in water yes they upset all dynamics, be they relational, of equilibrium, of movement and perception, due to the fact that proprioceptive sensations, created by bodily contact with water, they are different than those generated by contact with air.
C1 [Ruberto, Maria] CDR Santa Maria del Pozzo, Somma Vesuviana, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, Italy.
   [Lavano, Francesco; Lavano, Serena Marianna; Marotta, Rosa] Magna Graecia Univ Catanzaro, Dept Hlth Sci 5, Catanzaro, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Di Folco, Annabella; Parisi, Lucia; Testa, Davide] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Franco, Sabrina; Geraci, Diego] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, I-95123 Catania, Italy.
   [Picciocchi, Elisabetta] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa dei Fiori Acerra, Naples, Italy.
   [Chisari, Mario Giuseppe] INPS, Catania, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Osped Riuniti Foggia, Struttura Complessa Farm, Foggia, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp, NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
   [Magliulo, Rosaria Martina] Ctr Studi Scoliosi SRL, Naples, Italy.
   [D'oro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
RP Parisi, L (corresponding author), Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Cerroni, Francesco/0000-0003-3024-5482; Marotta,
   Rosa/0000-0003-0515-5952; Murabito, Paolo/0000-0002-2662-1898
CR Albenzio M, 2013, J DAIRY SCI, V96, P2781, DOI 10.3168/jds.2012-6218
   Albenzio M, 2017, NUTRIENTS IN DAIRY AND THEIR IMPLICATIONS FOR HEALTH AND DISEASE, P435, DOI 10.1016/B978-0-12-809762-5.00034-6
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Berges J, 1966, Rev Neuropsychiatr Infant, V14, P239
   Buhr M, 1992, Kinderarztl Prax, V60, P168
   Cappellini A C, 2008, Minerva Pediatr, V60, P277
   Caroprese M, 2012, SMALL RUMINANT RES, V102, P177, DOI 10.1016/j.smallrumres.2011.07.010
   Caroprese M, 2010, J DAIRY SCI, V93, P2395, DOI 10.3168/jds.2009-2604
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   DE FRANCO F, 1960, G Psichiatr Neuropatol, V88, P1049
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2017, EUR J PHYS REHAB MED, V53, P643, DOI 10.23736/S1973-9087.16.04037-5
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Gallelli Luca, 2017, Microrna, V6, P152, DOI 10.2174/2211536606666170913152821
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Li Volti G, 2004, BIOCHEM BIOPH RES CO, V315, P517, DOI 10.1016/j.bbrc.2004.01.090
   Loranger N, 1992, Pediatr Nurs, V18, P571
   Matricardi S, 2018, ACTA NEUROL SCAND, V137, P575, DOI 10.1111/ane.12902
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSL, V8
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Rizzo M, 2015, J CLIN ENDOCR METAB, V100, P603, DOI 10.1210/jc.2014-2291
   Salamone F, 2012, WORLD J GASTROENTERO, V18, P3862, DOI 10.3748/wjg.v18.i29.3862
   Santillo A, 2009, INT DAIRY J, V19, P655, DOI 10.1016/j.idairyj.2009.06.011
   Santillo A, 2009, J DAIRY SCI, V92, P1330, DOI 10.3168/jds.2008-1598
   Smirni D, 2018, J NERV MENT DIS, V206, P628, DOI 10.1097/NMD.0000000000000853
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Testa D, 2017, AGING CLIN EXP RES, V29, pS191, DOI 10.1007/s40520-016-0647-x
   Testa D, 2016, OPEN MED-WARSAW, V11, P208, DOI 10.1515/med-2016-0040
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2018, ACTA NEUROL SCAND, V138, P523, DOI 10.1111/ane.13006
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Viggiano E, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00150
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 99
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2151
EP 2159
DI 10.19193/0393-6384_2018_4s_330
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900010
DA 2022-07-14
ER

PT J
AU Rui, L
   Zhang, GJ
   Bie, FJ
   Min, M
   Yi, M
AF Rui, Liao
   Zhang Guijuan
   Bie Fengjie
   Min, Ma
   Yi, Ma
TI EUGENOL SUPPRESSES THE DEVELOPMENT OF ESTROGEN RECEPTOR-POSITIVE
   PRECANCEROUS BREAST LESIONS AND REGULATES ESTROGEN RECEPTOR-RELATED
   PROTEINS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Eugenol; estrogen receptor-positive; precancerous lesions of breast
   cancer; antitumor therapy; prevention
ID GLYCOGEN-SYNTHASE KINASE-3; CANCER-CELLS; GPER; TAMOXIFEN; PATHWAY;
   DISEASE; ACTIVATION
AB Introdution: The breast precancerous lesions is a necessary stage of breast cancer, and most of drugs for the treatment o breast precancerous lesions have a lot of adverse reactions, so finding a new drug effects on precancerous lesions of breast cancer has important significance. Eugenol has therapeutic effect on tumor, However, the mechanism of the treatment is not clear, the purpose of this study is to evaluate eugenol anti-tumor effect on ER positive precancerous lesions of breast cancer.
   Material and methods: 40 female SD rats were randomized into 5 groups, 8 in each. The groups were named Blank control group, Model group, Tamoxifen group, The low dose of Eugenol cream group (0.5mg) and The high dose of Eugenol cream group (1mg) respectively. The rats with breast precancerous lesions were induced by 7,12-dimethylbenz(a)anthracene (DMBA) combined with estrogen and progesterone injection. Drug interventions by tamoxifen(TAM) ointment and Eugenol cream were also launched during the model formation. The rats were executed after 70d. In MCF-10AT cell lines, we use 180 mu M eugenol to treat the cell lines, then observed 24 hours. And then the correlated indexes are detected by Western-blot and elisa.
   Results: 1mg eugenol significantly delayed the pathology process of rat breast tissue models in precancerous lesions of breast cancer, meanwhile, 1mg eugenol reduced the level of serum estradiol(E2) and the reduce rate was 36%, increased progesterone(P) and the increase rate was 26%, in addition, the protein levels of ER alpha, GPER, p-AKT, GSK3-alpha, GSK3-beta, p70s6k were decreased in the rat models and the decreased rates were respectively 31%, 53%, 57%, 58%, 56%, 93%, as well as MCF-10AT cell lines were treated with 180 mu M eugenol, the decreased rates were respectively 35%, 60%, 63%, 57%, 42%, 68% (P < 0.01). However, in rat models the expressions of PTEN and ER beta protein were increased and the increase rates were 76%, 58% (P < 0.05), in MCF-10AT cell lines the increase rates of the expressions of PTEN and ER beta protein were 46%, 177%.
   Discussion: eugenol is effective in the treatment of ER positive precancerous lesions of breast cancer, indicating that eugenol may be a new effective drug in treating ER positive precancerous lesions of breast cancer.
C1 [Rui, Liao; Zhang Guijuan] Jinan Univ, Affiliated Hosp 1, Guangzhou 510632, Guangdong, Peoples R China.
   [Bie Fengjie; Min, Ma] Jinan Univ, Sch Tradit Chinese Med, Guangzhou 510632, Guangdong, Peoples R China.
   [Rui, Liao] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Yi, Ma] Jinan Univ, Bioengn Inst, Guangzhou 510632, Guangdong, Peoples R China.
RP Min, M (corresponding author), Jinan Univ, Sch Tradit Chinese Med, Guangzhou 510632, Guangdong, Peoples R China.
EM 1019312292@qq.com
FU National Natural Science Foundation Project of China [81173265,
   81473688, 81373314, 81673979]; Science and Technology Planning Project
   of Guangdong Province, China [2014A020210015, 2013B090500105,
   2014A020212672]; Education Program of China for New Century Excellent
   Talents [NCET-13-0827]; Traditional Chinese Medicine Administration
   Project of Guangdong Province, China [20141070]; Natural Science
   Foundation of Guangdong Province [2015A030313333, 2015A030313345,
   2016A030313114]; Science and Technology Support Program of Guangzhou,
   China [2014J4100104, 201707010245]; Fundamental Research Funds for the
   Central Universities [21615412, 21615464]; Guangzhou Municipal
   Enterprise Research and Development Institutions Construction Project
   [201503010064]; Cooperation Ombudsman Workstation Project in Industry,
   Education and Research of Guangdong Province, China [2013B090900010]
FX The current work was supported by National Natural Science Foundation
   Project of China (no. 81173265, 81473688, 81373314 and 81673979); The
   Science and Technology Planning Project of Guangdong Province, China
   (no. 2014A020210015, 2013B090500105 and 2014A020212672); Education
   Program of China for New Century Excellent Talents (no. NCET-13-0827);
   Traditional Chinese Medicine Administration Project of Guangdong
   Province, China (no. 20141070); The Natural Science Foundation of
   Guangdong Province (no. 2015A030313333, 2015A030313345 and
   2016A030313114); Science and Technology Support Program of Guangzhou,
   China (no. 2014J4100104 and 201707010245); The Fundamental Research
   Funds for the Central Universities (no. 21615412 and 21615464).
   Guangzhou Municipal Enterprise Research and Development Institutions
   Construction Project (No. 201503010064), the Cooperation Ombudsman
   Workstation Project in Industry, Education and Research of Guangdong
   Province, China (No. 2013B090900010).
CR Al-Sharif I, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-600
   Ali S, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00045
   Azoulay-Alfaguter I, 2015, ONCOGENE, V34, P4613, DOI 10.1038/onc.2014.390
   Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067
   Barough MS, 2015, IRAN J CANCER PREV, V8, DOI 10.17795/ijcp-4193
   Bartella V, 2016, CELL SIGNAL, V28, P61, DOI 10.1016/j.cellsig.2015.11.010
   Baxi SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048402
   Bocker W, 2002, VERH DEUT G, V86, P116
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen ZJ, 2016, MOL ONCOLOGY
   Chiang KC, 2015, DRUG DES DEV THER, V9, P4631, DOI 10.2147/DDDT.S86184
   Dembowy J, 2015, ONCOGENE, V34, P3514, DOI 10.1038/onc.2014.279
   DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303
   Fox EM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3449
   Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295
   Jones ME, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3206
   Kesharwani RK, 2015, APPL BIOCHEM BIOTECH, V176, P1996, DOI 10.1007/s12010-015-1696-x
   Kim H. S., 2013, PLOS ONE, V8
   Li DH, 2012, ADV MATER RES-SWITZ, V554-556, P1725, DOI 10.4028/www.scientific.net/AMR.554-556.1725
   Lim J, 2015, J NEUROCHEM, V133, P544, DOI 10.1111/jnc.13085
   Lin YL, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0163-3
   Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122
   Prossnitz ER, 2009, PROSTAG OTH LIPID M, V89, P89, DOI 10.1016/j.prostaglandins.2009.05.001
   Pupo M, 2016, METHODS MOL BIOL, V1366, P471, DOI 10.1007/978-1-4939-3127-9_37
   Rigiracciolo DC, 2016, ONCOTARGET, V7, P94, DOI 10.18632/oncotarget.6475
   Sarwa KK, 2014, CURR DRUG DELIV, V11, P332, DOI 10.2174/1567201811666140115113127
   Segatto I, 2013, MOL CANCER RES, V11, DOI 10.1158/1557-3125.ADVBC-B056
   Segatto I, 2014, MOL ONCOL, V8, P766, DOI 10.1016/j.molonc.2014.02.006
   Tokunaga E, 2006, INT J CANCER, V118, P284, DOI 10.1002/ijc.21358
   Wang C, 2012, AM J TRANSL RES, V4, P390
   Wang S, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0668-y
   Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470-2045(07)70385-6
   Wu JJ, 2014, EXP CELL RES, V328, P351, DOI 10.1016/j.yexcr.2014.08.030
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yarla NS, 2016, SEMINARS CANC BIOL
   Zhang GJ, 2012, ADV MATER RES-SWITZ, V554-556, P1789, DOI 10.4028/www.scientific.net/AMR.554-556.1789
   Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112
NR 37
TC 0
Z9 0
U1 0
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1821
EP 1827
DI 10.19193/0393-6384_2018_6_280
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400031
DA 2022-07-14
ER

PT J
AU Sahin, N
   Gurses, VV
   Baydil, B
   Akgul, MS
   Feka, K
   Iovane, A
   Messina, G
AF Sahin, Nese
   Gurses, Veli Volkan
   Baydil, Bilgehan
   Akgul, Mustafa Sakir
   Feka, Kaltrina
   Iovane, Angelo
   Messina, Giuseppe
TI THE EFFECT OF COMPREHENSIVE WARM UP (FIFA 11+PROGRAM) ON MOTOR ABILITIES
   IN YOUNG BASKETBALL PLAYERS: A PILOT STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE physical fitness; performance; agility; FIFA 11+; injury prevention
ID INJURY SURVEILLANCE SYSTEM; 11 TRAINING-PROGRAM; FOOTBALL PLAYERS;
   DESCRIPTIVE EPIDEMIOLOGY; PREVENTING INJURIES; STRATEGIES; PERFORMANCE;
   MECHANISMS; STRENGTH; IMPACT
AB Aim: Recent findings indicated that dedicated warm up activities may significantly affect performance and prevent injuries. Furthermore, since it is known that comprehensive warm up program helps in prevention injuries, the purpose of this study was to investigate the effects of a comprehensive warm-up program (F-MARC The 11+) on performance and injuries in young basketball players. While knowing the specifics and possible injuries of basketball game, the prevention of injuries must be considered as an important issue.
   Methods: Twenty children (mean +/- SD: age 10,7 +/- 0,3 yr; height 149,20 +/- 7.51, weight 47,61 +/- 12,30 kg, percentage of body fat: 14,44 +/- 7,68 %) were recruited from two local basketball clubs to participate in this study. Players were randomly selected and assigned to either group: experimental (Exp. n = 10) or a control (Con. n = 10), respectively. They were trained 3 days per week (2,1 +/- 0,6 years of experience), for 10 weeks in a row.
   The experimental group followed the F-MARC 11+ program for 20 minutes during warm up phase in each training season for ten weeks while control group performed their regular warm up routine. Both groups performed vertical jumps and pro agility tests at the beginning and at the end of the tenth-week training sessions. Moreover, nonparametric Wilcoxon signed rank tests were performed to compare the pre and post test scores.
   Results: The agility pre-test result was found 6,358 +/- 0, 27 seconds and post-test was found 6,121 +/- 0, 34 seconds. A significant difference was found between agility test values (p<0,05)
   Discussion: Comprehensive warm-up program leads to a significant change in agility in the present study. Therefore, this is a desirable result since basketball is characterized by many quick movements such as sudden speed-ups, stops and turns. Eventually, previous studies indicated that the FIFA 11+ program resulted to be an important way to warm up properly before training sessions.
   Conclusion: Based on the results of this study we may conclude that "The F-MARC 11+" comprehensive warm-up is an appropriate and effective tool for improving basketball-specific performance such as agility in young basketball players.
C1 [Sahin, Nese] Ankara Univ, Fac Sport Sci, Ankara, Turkey.
   [Gurses, Veli Volkan; Baydil, Bilgehan; Akgul, Mustafa Sakir] Kastamonu Univ, Sch Phys Educ & Sport, Kastamonu, Turkey.
   [Feka, Kaltrina] Univ Palermo, PhD Program Hlth Promot & Cognit Sci, Sport & Exercise Sci Res Unit, Palermo, Italy.
   [Iovane, Angelo; Messina, Giuseppe] Univ Palermo, Dept Psychol Pedag & Educ Sci, Sport & Exercise Sci Res Unit, Palermo, Italy.
RP Messina, G (corresponding author), Via Giovanni Pascoli 6, I-90144 Palermo, Italy.
EM giuseppe.messina17@unipa.it
RI AKGÜL, Mustafa Şakir/AAT-8696-2020; Messina, Giuseppe/N-7298-2019
OI AKGÜL, Mustafa Şakir/0000-0002-9696-6541; Messina,
   Giuseppe/0000-0003-2774-4950; Feka, Kaltrina/0000-0003-1293-7995
CR Adirim TA, 2006, CURR PAEDIAT, V16, P205, DOI DOI 10.1016/j.cupe.2006.03.001
   Agel J, 2007, J ATHL TRAINING, V42, P202
   Alentorn-Geli E, 2009, KNEE SURG SPORT TR A, V17, P705, DOI 10.1007/s00167-009-0813-1
   Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341
   Battaglia G, 2016, ACTA MEDICA MEDITERR, V32, P1589, DOI 10.19193/0393-6384_2016_5_135
   Bianco A, 2014, CANCER MED-US, V3, P385, DOI 10.1002/cam4.193
   Brito J, 2010, ISOKINET EXERC SCI, V18, P211, DOI 10.3233/IES-2010-0386
   Chimera NJ, 2004, J ATHL TRAINING, V39, P24
   Condello G, 2016, INT J SPORT PHYSIOL, V11, P96, DOI 10.1123/ijspp.2014-0458
   Cowley HR, 2006, J ATHL TRAINING, V41, P67
   Dick R, 2007, J ATHL TRAINING, V42, P194
   Enoksen E, 2009, J SPORT SCI, V27, P77, DOI 10.1080/02640410802448723
   Neto MG, 2017, CLIN REHABIL, V31, P651, DOI 10.1177/0269215516675906
   Kilding AE, 2008, J SPORT SCI MED, V7, P320
   Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899
   Lockie RG, 2016, SPORTS, V4, DOI 10.3390/sports4030041
   Longo UG, 2012, AM J SPORT MED, V40, P996, DOI 10.1177/0363546512438761
   Meeuwisse WH, 2003, AM J SPORT MED, V31, P379, DOI 10.1177/03635465030310030901
   Pasanen K, 2009, BRIT J SPORT MED, V43, P1073, DOI 10.1136/bjsm.2009.061747
   Patti A, 2016, J PHYS THER SCI, V28, P72, DOI 10.1589/jpts.28.72
   Sahin N, 2015, J PHYS THER SCI, V27, P437, DOI 10.1589/jpts.27.437
   Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]
   Steffen K, 2013, BRIT J SPORT MED, V47, P480, DOI 10.1136/bjsports-2012-091887
   Vanderlei Franciele Marques, 2013, Int Arch Med, V6, P5, DOI 10.1186/1755-7682-6-5
NR 24
TC 1
Z9 1
U1 2
U2 12
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 703
EP 707
DI 10.19193/0393-6384_2018_3_108
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000013
DA 2022-07-14
ER

PT J
AU Sahin, SK
   Elboga, G
   Kilic, OHT
   Sahin, AZ
   Unal, A
   Altindag, A
AF Sahin, Sengul Kocamer
   Elboga, Gulcin
   Kilic, Osman Hasan Tahsin
   Sahin, Ahmet Ziya
   Unal, Ahmet
   Altindag, Abdurrahman
TI METABOLIC SYNDROME IN PATIENTS WITH SCHIZOAFFECTIVE DISORDER AND
   RELATIONSHIP WITH THE ANTIPSYCHOTICS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Schizoaffective disorder; metabolic syndrome; antipsychotic; systemic
   inflammation; dyslipidemia
ID PREVALENCE; SCHIZOPHRENIA; ABNORMALITIES; ADULTS; RISK
AB Introduction: Metabolic syndrome is highly prevalent in patients with schizophrenia. The use of atypical antipsychotics also increases the risk of metabolic syndrome. This study aimed to evaluate the association between schizoaffective disorder and risk of incident metabolic syndrome and the relationship with the drugs used.
   Materials and methods: This cross-sectional study included patients diagnosed with schizoaffective disorder. The study group consisted of 77 outpatients aged 18 to 65 years, prescribed any antipsychotic medication between September 2013 and August 2014. Metabolic syndrome was defined using the criteria of the National Cholesterol Education Program - Adult Treatment Protocol and the National Cholesterol Education Program - Adapted Adult Treatment Protocol.
   Results: Metabolic syndrome was found in 33.8% according to National Cholesterol Education Program - Adult Treatment Protocol diagnostic criteria, 36.4% according to National Cholesterol Education Program - Adapted Adult Treatment Protocol diagnostic criteria of the patients. When we grouped patients treated with typical antipsychotic, atypical antipsychotics and typical & atypical antipsychotics in combination, there was no significant difference for prevalence of metabolic syndrome among any groups. Metabolic syndrome prevalence was significantly higher in study subjects using antidepressants in combination with antipsychotics.
   Conclusions: The results suggest that metabolic syndrome risk is common among patients with schizoaffective disorder. Our data shows that systemic inflammation plays a key role in both schizoaffective disorder and metabolic syndrome so chronic comorbid disorders should be treated concurrently and all risk factors like that weight loss, regular physical activity, smoking cessation should be eliminated by modifying life style.
C1 [Sahin, Sengul Kocamer] Adana State Hosp, Dept Psychiat, Adana, Turkey.
   [Elboga, Gulcin; Unal, Ahmet; Altindag, Abdurrahman] Gaziantep Univ, Med Fac, Dept Psychiat, Gaziantep, Turkey.
   [Kilic, Osman Hasan Tahsin] Zonguldak Ataturk State Hosp, Dept Psychiat, Zonguldak, Gaziantep, Turkey.
   [Sahin, Ahmet Ziya] Adana Askim Tufekci State Hosp, Dept Internal Med, Adana, Turkey.
RP Elboga, G (corresponding author), Gaziantep Univ, Med Fac, Dept Psychiat, Sahinbey, Gaziantep, Turkey.
RI kılıç, osman/AAK-2864-2020; Elboga, Gulcin/AAG-6587-2020; Altindag,
   Abdurrahman/AAG-6463-2020; Ünal, Ahmet/ABH-9455-2020; Şahin,
   Şengül/AAI-2398-2019
OI Altindag, Abdurrahman/0000-0001-5531-4419; Ünal,
   Ahmet/0000-0002-8612-528X; Şahin, Şengül/0000-0002-5371-3907
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI [DOI 10.1176/APPI.BOOKS.9780890420249.DSM-IV-TR, 10.1176/appi.books.9780890420249.dsm-iv-tr]
   Babic D, 2010, PSYCHIAT DANUB, V22, P75
   Basu R, 2004, BIPOLAR DISORD, V6, P314, DOI 10.1111/j.1399-5618.2004.00126.x
   Bermudes RA, 2006, PSYCHOSOMATICS, V47, P491, DOI 10.1176/appi.psy.47.6.491
   Bobes J, 2012, EUR PSYCHIAT, V27, P267, DOI 10.1016/j.eurpsy.2010.09.001
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Correll CU, 2007, SCHIZOPHR RES, V89, P91, DOI 10.1016/j.schres.2006.08.017
   Dortland AKBV, 2010, ACTA PSYCHIAT SCAND, V122, P30, DOI 10.1111/j.1600-0447.2010.01565.x
   Elboga G, 2017, ACTA MEDICA MEDITERR, V33, P863, DOI 10.19193/0393-6384_2017_5_128
   Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
   Gundogan K, 2006, TURKIYEKLINIKLERI J, V2, P18
   Heiskanen T, 2003, J CLIN PSYCHIAT, V64, P575, DOI 10.4088/JCP.v64n0513
   Jacob Rajesh, 2008, Indian J Med Sci, V62, P23
   Kantrowitz JT, 2011, CNS DRUGS, V25, P317, DOI 10.2165/11587630-000000000-00000
   Kim Sung-Hwan, 2010, Korean Journal of Internal Medicine, V25, P168, DOI 10.3904/kjim.2010.25.2.168
   Lee JS, 2017, PSYCHIAT INVEST, V14, P44, DOI 10.4306/pi.2017.14.1.44
   McEvoy JP, 2005, SCHIZOPHR RES, V80, P19, DOI 10.1016/j.schres.2005.07.014
   McIntyre RS, 2006, EXPERT OPIN DRUG SAF, V5, P523, DOI 10.1517/14740338.5.4.523
   Mitchell AJ, 2013, SCHIZOPHRENIA BULL, V39, P295, DOI 10.1093/schbul/sbs082
   Mottillo S, 2010, J AM COLL CARDIOL, V56, P1113, DOI 10.1016/j.jacc.2010.05.034
   NASRALLAH HA, 2004, J CLIN PSYCHOPHARM, V24, P7, DOI DOI 10.1097/01.JCP.0000142282.62336.E9
   Padhy S, 2015, TURK PSIKIYATR DERG, V26, P131
   Pasdar Y, 2017, ACTA MEDICA MEDITERR, V33, P715, DOI 10.19193/0393-6384_2017_4_106
   Perala J, 2007, ARCH GEN PSYCHIAT, V64, P19, DOI 10.1001/archpsyc.64.1.19
   Straker D, 2005, AM J PSYCHIAT, V162, P1217, DOI 10.1176/appi.ajp.162.6.1217
   Van Gaal LF, 2006, EUR NEUROPSYCHOPHARM, V16, pS142, DOI 10.1016/j.euroneuro.2006.06.005
   Yogaratnam J, 2013, East Asian Arch Psychiatry, V23, P21
NR 27
TC 1
Z9 1
U1 0
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 133
EP 137
DI 10.19193/0393-6384_2018_1_22
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600022
DA 2022-07-14
ER

PT J
AU Sak, T
   Yokus, O
   Gedik, H
AF Sak, Tuncer
   Yokus, Osman
   Gedik, Habip
TI SERUM IMMUNOGLOBULIN VALUES AND THE DEVELOPMENT OF INVASIVE FUNGAL
   INFECTIONS IN THE HEMATOLOGICAL PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Immunglobulins; fungal infections; immunoglobulin G; galactomannan; HRCT
ID IMMUNOCOMPROMISED PATIENTS; PULMONARY ASPERGILLOSIS; CANCER-PATIENTS;
   DIAGNOSIS; THERAPY; DISEASES
AB Purpose: The aim of this study was to investigate whether lower serum immunoglobulins, especially IgG, increase the development of fitngal infection in patients with hematological malignancy.
   Material and methods: Patients, who were hospitalized due to hematological maligancies at Ministry of Health Istanbul Training and Research Hospital, between April 2015 and January 2017, in henunology and internal medicine clinics and diagnosed with a fungal infection in compatible with a galactomannan positivity as well as frosted glass opacities and nodular infiltrates on high resolution computed tomography (HRCT) and chest X-ray, with or without a yielded microbiological culture, were evaluated in this retrospective case - control study.
   Results: A total of 22 patients with hematological malignancies (HM) and invasive fungal infections (IFI; cases group) were compared with 22 patients with HM without IFI (control group) in the study. The IgG level in the cases group was significantly lower than the control group (p: 0.044). The mean IgA and M values in the cases group and control group did not differ significantly (p > 0.05). The mean Galactomannan value in the cases group was significantly higher than the control group (p 0.041).
   Conclusion: Serum IgG levels were found to be lower in patients with invasive fungal infection during the treatment of hematologic malignancy than in patients with hematological malignancy and without invasive fungal infection. There needs a randomized-control study to describe the relationship between low serum immunglobulin values in patients with hematological malignancy and development of invasive fungal infection.
C1 [Sak, Tuncer] Istanbul Training & Res Hosp, Minist Hlth, Dept Internal Dis, Istanbul, Turkey.
   [Yokus, Osman] Istanbul Training & Res Hosp, Minist Hlth, Dept Hematol, Istanbul, Turkey.
   [Gedik, Habip] Bakirkoy Sadi Konuk Training & Res Hosp, Minist Hlth, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
RP Gedik, H (corresponding author), Bakirkoy Sadi Konuk Training & Res Hosp, Minist Hlth, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
EM habipgedik@yahoo.com
RI Gedik, Habip/ABI-3946-2020; Yokus, Osman/ABF-5160-2020
OI Gedik, Habip/0000-0002-8406-2254; 
CR Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335
   Bal ZS, 2015, MYCOSES, V58, P225, DOI 10.1111/myc.12303
   Bergeron A, 2012, BLOOD, V119, P1831, DOI 10.1182/blood-2011-04-351601
   Caillot D, 2001, J CLIN ONCOL, V19, P253, DOI 10.1200/JCO.2001.19.1.253
   Casadevall A, 2012, CELL HOST MICROBE, V11, P447, DOI 10.1016/j.chom.2012.04.004
   Coelho LE, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1462-x
   Cumbo Thomas A, 2004, J Natl Compr Canc Netw, V2, P455
   DROMER F, 1987, INFECT IMMUN, V55, P742, DOI 10.1128/IAI.55.3.742-748.1987
   Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073
   GIGLIOTTI F, 1988, J CLIN INVEST, V81, P1666, DOI 10.1172/JCI113503
   GUPTA S, 1987, AM J MED, V82, P129, DOI 10.1016/0002-9343(87)90388-3
   Hachem RY, 2009, J CLIN MICROBIOL, V47, P129, DOI 10.1128/JCM.00506-08
   Link H, ANN HEMATOL S2, V2033, pS105
   Maertens J, 2004, BRIT J HAEMATOL, V126, P852, DOI 10.1111/j.1365-2141.2004.05140.x
   Male D, 2006, IMMUNOLOGY, P59
   Maschmeyer G, 2003, ANN HEMATOL, V82, pS118, DOI 10.1007/s00277-003-0765-3
   Maschmeyer G, 2008, INT J ANTIMICROB AG, V31, P193, DOI 10.1016/j.ijantimicag.2007.06.014
   Peng Xin-Guo, 2015, Asian Pac J Cancer Prev, V16, P3137
   Souza CA, 2006, J THORAC IMAG, V21, P184
   van Spriel AB, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000338
   Yu Jin, 2010, Zhonghua Yi Xue Za Zhi, V90, P371
NR 21
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1975
EP 1980
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400059
DA 2022-07-14
ER

PT J
AU Savran, Y
   Mengi, T
   Yilmaz, B
   Tokur, ME
   Ergan, B
   Yaka, E
   Comert, B
AF Savran, Yusuf
   Mengi, Tugce
   Yilmaz, Baris
   Tokur, Murat E.
   Ergan, Begum
   Yaka, Erdem
   Comert, Bilgin
TI CAN NEUTROPHIL-LYMPHOCYTE RATIO PREDICT DISEASE SEVERITY AND MORTALITY
   IN SEPSIS AND SEPTIC SHOCK PATIENTS?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE critical care; mortality; rteutrophil-lymphocyte ratio; sepsis; septic
   shock; severity
ID COUNT RATIO; ASSOCIATION; DIAGNOSIS
AB Introduction: Sepsis and septic shock are the most serious clinical conditions in intensive care units with increased mortality rates. Efforts on improving treatment modalities and survival is still the most hot topic worldwide. One of the key points is finding out a reliable and cost-effective marker that can predict prognosis. The neutrophil-lymphocyte ratio (NLR) has been shown to be associated with prognosis in various clinical situations. The aim of this study was to investigate the relationship of NLR at admission and disease severity and 28-day mortality in sepsis and septic shock patients.
   Materials and methods: Patients over 18 years of age admitted to Medical Intensive Care Unit (ICU) with the diagnosis of sepsis and septic shock between January 1st ,2010 and January 1st ,2016 were enrolled retrospectively. NLR at ICU admission of each patient was calculated from whole blood test results.
   Results: A total of 314 patients, 159 men and 155 women, were included in the study. 185 patients (58.9%) were diagnosed as sepsis and 129 patients (41.1%) as septic shock. NLR was significantly higher in the septic shock group (sepsis: 14.7, septic shock: 21.5) (p<0.05). 118 patients (37.6%) survived, and 196 (62.4%) died. While APACHE II scores (survivors: 21; non-survivors: 25) and expected mortality rates (survivors: 38%; non-survivors: 53%) were significantly different between two groups (p<0,05), no significant relationship between NLR and mortality could be detected (p>0.05).
   Conclusion: In our study, there was no significant relationship between NLR and mortality but, NLR was related to severity of sepsis. We suggest NLR should be used in detecting severity of sepsis besides APACHE and SOFA scores which will increase physicians' awareness during the management of therapy.
C1 [Savran, Yusuf] Dokuz Eylul Univ, Fac Med, Dept Internal Med, Izmir, Turkey.
   [Mengi, Tugce; Yaka, Erdem] Dokuz Eylul Univ, Fac Med, Dept Neurol, Izmir, Turkey.
   [Yilmaz, Baris] Dokuz Eylul Univ, Fac Med, Dept Pulmonol, Izmir, Turkey.
   [Tokur, Murat E.] Dokuz Eylul Univ, Fac Med, Dept Anesthesiol, Izmir, Turkey.
   [Ergan, Begum] Dokuz Eylul Univ, Fac Med, Dept Pulmonol & Intens Care, Izmir, Turkey.
   [Comert, Bilgin] Dokuz Eylul Univ, Fac Med, Dept Internal Med & Intens Care, Izmir, Turkey.
RP Savran, Y (corresponding author), Dokuz Eylul Univ, Fac Med, Dept Internal Med, Izmir, Turkey.
EM yusuf.savran@deu.edu.tr
RI Mengi, Tuğçe/AAA-4505-2022; Cömert, Bilgin/P-3030-2019; Savran,
   Yusuf/AAI-1796-2019; Ergan, Begum/U-8276-2017
OI Cömert, Bilgin/0000-0002-2148-5356; Ergan, Begum/0000-0003-2920-9214
CR Benites-Zapata VA, 2015, AM J CARDIOL, V115, P57, DOI 10.1016/j.amjcard.2014.10.008
   de Jager CPC, 2010, CRIT CARE, V14, DOI 10.1186/cc9309
   Gurol G, 2015, J MICROBIOL BIOTECHN, V25, P521, DOI 10.4014/jmb.1408.08060
   Hwang SY, 2017, AM J EMERG MED, V35, P234, DOI 10.1016/j.ajem.2016.10.055
   Korkmaz P, 2017, J CLIN ANAL MED, V8, P211, DOI 10.4328/JCAM.4816
   Liu X, 2016, MEDIAT INFLAMM, V2016, DOI DOI 10.1155/2016/8191254
   Lowsby R, 2015, EMERG MED J, V32, P531, DOI 10.1136/emermed-2014-204071
   OKASHAH AS, 2014, RES OPIN ANESTH INTE, V0002, P00039
   Park JJ, 2013, AM J CARDIOL, V111, P636, DOI 10.1016/j.amjcard.2012.11.012
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Riche F, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1144-x
   Salciccioli JD, 2015, CRIT CARE, V19, DOI 10.1186/s13054-014-0731-6
   Sandquist M, 2014, EXPERT REV CLIN IMMU, V10, P1349, DOI 10.1586/1744666X.2014.949675
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Terradas R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042860
   Vincent JL, 2013, EXPERT REV ANTI-INFE, V11, P265, DOI [10.1586/eri.13.9, 10.1586/ERI.13.9]
   Yodying H, 2016, ANN SURG ONCOL, V23, P646, DOI 10.1245/s10434-015-4869-5
   Zhang HB, 2016, EXP THER MED, V12, P2215, DOI 10.3892/etm.2016.3583
NR 18
TC 2
Z9 2
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 877
EP 882
DI 10.19193/0393-6384_2018_3_134
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000038
DA 2022-07-14
ER

PT J
AU Scoppa, F
   Pirino, A
   Belloni, G
   Gallamini, M
   Messina, G
   Iovane, A
AF Scoppa, Fabio
   Pirino, Alessio
   Belloni, Gabriele
   Gallamini, Michele
   Messina, Giuseppe
   Iovane, Angelo
TI POSTURAL AND AUTONOMIC MODIFICATIONS FOLLOWING OSTEOPATHIC MANIPULATIVE
   TREATMENT (OMT): COMPARISON BETWEEN TWO TECHNIQUES. A PILOT STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE static baropodometry; balance; posture; Osteopathic Manipulative
   Treatment (OMT)
ID SWAY-DENSITY; BALANCE; FALLS; STABILIZATION
AB Objective: With reference to OMT principles consistent mention is made of the capability of stimulating Autonomic Responses through both Ortho-and Para-Sympathetic channels. Several studies have been performed to demonstrate this kind of interaction. The purpose of this pilot study was twofold: 1) Compare different OMTs that supposedly interact either with Ortho-or Para-Sympathetic branches of the Autonomic System; 2) Ascertain whether there is a relationship between Autonomic Balance and Quiet Upright Stance Balance.
   Results: A Sample of 51 young healthy students underwent to a series of four assessment tests for both functions over a 5 hr period.
   Conclusion: The time plot of the main parameters afforded by the Heart Rate Variability (HRV) Instrumental Assessment and by the Romberg Test performed on a Force Platform actually confirmed that different OMTs challenge different Autonomic components and can achieve different responses in quiet upright stance balance control.
C1 [Scoppa, Fabio; Belloni, Gabriele] Sapienza Univ Rome, Fac Med & Dent Surg, Posturol, Rome, Italy.
   [Scoppa, Fabio; Belloni, Gabriele] Chinesis IFOP Osteopathy Sch, Rome, Italy.
   [Pirino, Alessio] Univ Sassari, Dept Biomed Sci, Sassari, Italy.
   [Messina, Giuseppe; Iovane, Angelo] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
RP Messina, G (corresponding author), Via Giovanni Pascoli 6, I-90144 Palermo, Italy.
EM 17@unipa.it
RI Messina, Giuseppe/N-7298-2019; PIRINO, ALESSIO/ABG-2384-2020
OI Messina, Giuseppe/0000-0003-2774-4950; PIRINO,
   ALESSIO/0000-0001-5369-7284
CR AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045
   Baratto L, 2002, MOTOR CONTROL, V6, P246, DOI 10.1123/mcj.6.3.246
   Bianco A, 2014, AGING CLIN EXP RES, V26, P147, DOI 10.1007/s40520-013-0144-4
   Burns L, 2000, J OSTEOPATH MED, V100, P249, DOI 10.7556/jaoa.2000.100.4.249
   Camm AJ, 1996, EUR HEART J, V17, P354
   Fornari M, 2017, J AM OSTEOPATH ASSOC, V117, P559, DOI 10.7556/jaoa.2017.110
   Giles PD, 2013, J ALTERN COMPLEM MED, V19, P92, DOI 10.1089/acm.2011.0031
   Gurfinkel V, 2006, J NEUROPHYSIOL, V96, P2678, DOI 10.1152/jn.00406.2006
   Gurfinkel Victor S, 2011, J Vis Exp, DOI 10.3791/3677
   Henley Charles E, 2008, Osteopath Med Prim Care, V2, P7, DOI 10.1186/1750-4732-2-7
   Jacono M, 2004, MOTOR CONTROL, V8, P292, DOI 10.1123/mcj.8.3.292
   Jakel A, 2011, J AM OSTEOPATH ASSOC, V111, P685
   Kang HG, 2013, GAIT POSTURE, V38, P757, DOI 10.1016/j.gaitpost.2013.03.022
   Kapteyn T S, 1983, Agressologie, V24, P321
   Lopez D, 2011, J AM OSTEOPATH ASSOC, V111, P382, DOI 10.7556/jaoa.2011.111.6.382
   Martines F, 2016, EUR ARCH OTO-RHINO-L, V273, P1419, DOI 10.1007/s00405-015-3714-6
   Martines F, 2015, ACTA MEDICA MEDITERR, V31, P907
   Messina Giuseppe, 2017, Eur J Transl Myol, V27, P6363, DOI 10.4081/ejtm.2017.6363
   Milnes K, 2007, INT J OSTEOPATH MED, V10, P8, DOI 10.1016/j.ijosm.2007.01.003
   Noll DR, 2013, J AM OSTEOPATH ASSOC, V113, P17
   Northup GW, 1945, J AM OSTEOPATH ASSOC, V100, P647
   Pagani M, 1984, J HYPERTENS        S, V2, pS383
   Parvan K, 2013, MED BALTIM, V2, P295, DOI DOI 10.1097/MD.0000000000002414
   Patti A., 2015, J BIOLOGICAL RES, V88, P113
   Patti A, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070806
   Patti A, 2017, WORK, V57, P23, DOI 10.3233/WOR-172539
   Ruffini N, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00272
   Salvago P, 2017, INT J AUDIOL, V56, P148, DOI 10.1080/14992027.2016.1236418
   Scoppa F, 2017 ACTA MED MEDITE
   Scoppa F, 2013, GAIT POSTURE, V37, P290, DOI 10.1016/j.gaitpost.2012.07.009
   Waitley DD, 1948, J AM OSTEOPATH ASSOC, V100, P653
   Younes M, 2017, CHIROPR MAN THER, V25, DOI 10.1186/s12998-017-0167-6
NR 32
TC 1
Z9 1
U1 2
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 431
EP 436
DI 10.19193/0393-6384_2018_2_68
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400022
DA 2022-07-14
ER

PT J
AU Sekerci, YG
AF Sekerci, Yasemin Gumus
TI RETRACTED: EFFECT OF MOTIVATIONAL INTERVIEWING ON EXERCISE BEHAVIOR IN
   WOMEN WITH TYPE 2 DIABETES MELLITUS (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE Type 2 diabetes mellitus; exercise; motivational interviewing;
   self-efficacy
ID PHYSICAL-ACTIVITY; SELF-EFFICACY; INTERVENTION; MANAGEMENT;
   ASSOCIATIONS; METAANALYSIS; ADULTS
AB Introduction: The aim of this study was to investigate the impact of motivational interviewing (MI) on exercise behavior in women with type 2 diabetes mellitus (DM).
   Materials and methods: The sample of this experimental study consisted of 63 women with type 2 DM registered to in family health centers in Turkey. The data were collected using the description form and the Exercise Self-Efficacy Scale (ESES). Mean fasting glucose levels, mean nonfasting glucose levels, mean hemoglobin A1c (HbA1c) values and number of hypoglycemic attacks were compared to the initially, 6th month, and 12th month in study.
   Results: During the study period, a statistically significant decrease in mean fasting glucose levels, mean nonfasting glucose levels, mean HbA1c values, and number of hypoglycemic attacks were observed (p < 0.05). The scores for ESES and weekly duration of exercise (minute) of the experimental group increased during follow-up in women with type 2 DM receiving MI about exercise. While 26% of the women with type 2 DM had regular health check-ups before the motivation activity, during the MI, regular followup ratio improved and increased up to 81%.
   Conclusion: This study showed that MI might provide significant improvement in the glisemic control and exercise behavior of women with type 2 DM. The frequency of regular health checkups for women throughout MI has increased. It is suggested that for the effectiveness of MI compare or combine it with other interventional methods.
C1 [Sekerci, Yasemin Gumus] Mustafa Kemal Univ, Hatay Sch Hlth, Dept Publ Hlth Nursing, Antakya, Turkey.
RP Sekerci, YG (corresponding author), Mustafa Kemal Univ, Antakya, Turkey.
EM y.gumus36@hotmail.com
CR Adam J, 2014, JNP-J NURSE PRACT, V10, P42, DOI 10.1016/j.nurpra.2014.07.033
   Al-Hassan MA, 2017, J DIABETES, V9, P93, DOI 10.1111/1753-0407.12389
   American Diabetes Association, 2017, Diabetes Care, V40, pS44
   Bianco A, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-224
   Bjornstad Petter, 2015, Curr Pediatr Rep, V3, P177
   Burke BL, 2003, J CONSULT CLIN PSYCH, V71, P843, DOI 10.1037/0022-006X.71.5.843
   Bweir S, 2009, DIABETOL METAB SYNDR, V1, DOI 10.1186/1758-5996-1-27
   Chen SM, 2012, INT J NURS STUD, V49, P637, DOI 10.1016/j.ijnurstu.2011.11.011
   Colucci A, 2011, Minerva Gastroenterol Dietol, V57, P241
   Dutton GR, 2009, J BEHAV MED, V32, P270, DOI 10.1007/s10865-009-9200-0
   Haffner SM, 2006, AM J CARDIOL, V97, p3A, DOI 10.1016/j.amjcard.2005.11.010
   Hardcastle SJ, 2013, INT J BEHAV NUTR PHY, V10, DOI 10.1186/1479-5868-10-40
   Holten MK, 2004, DIABETES, V53, P294, DOI 10.2337/diabetes.53.2.294
   Jones A, 2014, PRIM CARE DIABETES, V8, P91, DOI 10.1016/j.pcd.2014.01.009
   Kantarova D, 2015, EPIDEMIOL MIKROBI IM, V64, P121
   Kartal A., 2014, J NURS FAC, P1
   Kelley GA, 2007, PUBLIC HEALTH, V121, P643, DOI 10.1016/j.puhe.2007.02.014
   Kim C, 2008, DIABETES EDUCATOR, V34, P719, DOI 10.1177/0145721708321005
   Kirk A, 2003, DIABETES CARE, V26, P1186, DOI 10.2337/diacare.26.4.1186
   Kocyigit C, 2017, INT J DIABETES DEV C, V37, P165, DOI 10.1007/s13410-016-0470-0
   Kushnir V, 2016, J ADDICT DIS, V35, P58, DOI 10.1080/10550887.2016.1107315
   Lindwall M, 2017, INT J BEHAV NUTR PHY, V14, DOI 10.1186/s12966-017-0464-4
   MARCUS BH, 1992, RES Q EXERCISE SPORT, V63, P60, DOI 10.1080/02701367.1992.10607557
   Mason AE, 2016, J BEHAV MED, V39, P201, DOI 10.1007/s10865-015-9692-8
   Paoli A, 2012, AM J CARDIOL, V109, P305, DOI 10.1016/j.amjcard.2011.10.011
   Scheen AJ, 1998, DIABETES METAB, V24, P116
   Sekerci YG, 2017, INT J MED RES HEALTH, V6, P95
   Stanger C, 2013, J PEDIATR PSYCHOL, V38, P629, DOI 10.1093/jpepsy/jst032
   Tse MMY, 2013, J CLIN NURS, V22, P1843, DOI 10.1111/j.1365-2702.2012.04317.x
   Yin JM, 2016, J DIABETES, V8, P109, DOI 10.1111/1753-0407.12262
NR 30
TC 0
Z9 0
U1 1
U2 12
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 383
EP 389
DI 10.19193/0393-6384_2018_2_60
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400014
DA 2022-07-14
ER

PT J
AU Sessa, F
   Franco, S
   Picciocchi, E
   Geraci, D
   Chisari, MG
   Marsala, G
   Polito, AN
   Sorrentino, M
   Tripi, G
   Salerno, M
   Russo, D
   Lavano, SM
   Cerroni, F
   Romano, P
   Gallai, B
   Marotta, R
   Lavano, F
   Magliulo, RM
   D'oro, L
   Di Folco, A
   Parisi, L
   Testa, D
   Murabito, P
   Montana, A
   Giugliano, P
   Salerno, M
AF Sessa, Francesco
   Franco, Sabrina
   Picciocchi, Elisabetta
   Geraci, Diego
   Chisari, Mario Giuseppe
   Marsala, Gabriella
   Polito, Anna Nunzia
   Sorrentino, Michele
   Tripi, Gabriele
   Salerno, Margherita
   Russo, Daniela
   Lavano, Serena Marianna
   Cerroni, Francesco
   Romano, Palmira
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Francesco
   Magliulo, Rosaria Martina
   D'oro, Lucrezia
   Di Folco, Annabella
   Parisi, Lucia
   Testa, Davide
   Murabito, Paolo
   Montana, Angelo
   Giugliano, Pasquale
   Salerno, Monica
TI ADDICTIONS SUBSTANCE FREE DURING LIFESPAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Digital Natives; addiction; techonology
ID MONOSYMPTOMATIC NOCTURNAL ENURESIS; CHILDHOOD ABSENCE EPILEPSY;
   SLEEP-APNEA SYNDROME; QUALITY-OF-LIFE; HYPERTHERMIC REACTIONS; HEME
   OXYGENASE-1; CHILDREN; MIGRAINE; ADOLESCENTS; WEIGHT
AB The addictions substance free is an umbrella definition comprises internet addiction, sexual addiction, gambling pathological, workholism, videogames and computer addiction. Actually, the technological addictions is frequent in young adolescents. The term Digital Natives indicates the children born in an information system of learning and communication different from that of the generations previous. This temporal range was strongly characterized by growing presence of technological communication tools in daily life. The effects of hyper-exposition to technological tools tend to create a relational virtuality without a body is born, therefore, already within the family ties and during adolescence he moved to the digital socialization network. The technological object it interacts between the adolescent and the world of peers and adults, becoming the facilitator object that as the psychotropic substance, it conveys new modes of communication
C1 [Sessa, Francesco; Salerno, Monica] Univ Foggia, Dept Clin & Expt Med, Viale Pinto 1, I-71122 Foggia, Italy.
   [Franco, Sabrina; Geraci, Diego; Montana, Angelo] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, I-95123 Catania, Italy.
   [Picciocchi, Elisabetta] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Chisari, Mario Giuseppe] INPS, Catania, Italy.
   [Marsala, Gabriella] Azienda Ospedaliero Univ, Osped Riuniti Foggia, Struttura Complessa Farm, Foggia, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Sorrentino, Michele] NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp, Castel Volturno, CE, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Di Folco, Annabella; Parisi, Lucia; Testa, Davide] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Lavano, Serena Marianna; Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Magliulo, Rosaria Martina] Ctr Studi Scoliosi SRL, Naples, Italy.
   [D'oro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
   [Giugliano, Pasquale] UOC Med Legale, Syracuse, Italy.
   [Giugliano, Pasquale] Azienda Osped St Anna & San Sebastiano Caserta, Caserta, Italy.
RP Salerno, M (corresponding author), Univ Foggia, Dept Clin & Expt Med, Viale Pinto 1, I-71122 Foggia, Italy.
RI Marotta, Rosa/AAG-1453-2020; SALERNO, MONICA/AAC-1321-2019; Sessa,
   Francesco/G-1754-2018
OI SALERNO, MONICA/0000-0002-6410-3960; Sessa,
   Francesco/0000-0003-0357-8791; Murabito, Paolo/0000-0002-2662-1898;
   Marotta, Rosa/0000-0003-0515-5952
CR Albenzio M, 2018, J DAIRY SCI, V101, P4842, DOI 10.3168/jds.2017-13104
   Albenzio M, 2016, J DAIRY SCI, V99, P5032, DOI 10.3168/jds.2015-10704
   Albenzio M, 2017, NUTRIENTS IN DAIRY AND THEIR IMPLICATIONS FOR HEALTH AND DISEASE, P435, DOI 10.1016/B978-0-12-809762-5.00034-6
   Carey SE, 2015, DRUG ALCOHOL DEPEN, V155, P175, DOI 10.1016/j.drugalcdep.2015.07.671
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSL, V8
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Crocq Marc-Antoine, 2007, Dialogues Clin Neurosci, V9, P355
   De Luca V, 2008, PSYCHIAT INVEST, V5
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Gigante E, 2018, ACTA MEDICA MEDITERR, V34, P1295, DOI 10.19193/0393-6384_2018_5_199
   Jouroukhin Y, 2019, BIOL PSYCHIAT, V85, P891, DOI 10.1016/j.biopsych.2018.07.024
   Kang SH, 2018, IRAN J PUBLIC HEALTH, V47, P1047
   King DL, 2013, AUST NZ J PSYCHIAT, V47, P875, DOI 10.1177/0004867413495925
   Larkin M, 2002, ADDICT RES THEORY, V10, P281, DOI 10.1080/16066350211866
   Li Volti G, 2004, BIOCHEM BIOPH RES CO, V315, P517, DOI 10.1016/j.bbrc.2004.01.090
   Lupica CR, 2018, LEARN MEMORY, V25, P435, DOI 10.1101/lm.046748.117
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSL, V8
   Moscatelli F, 2016, PLOS ONE, V24
   Moscatelli F, 2015, BIOL MED, V7
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Rizzo M, 2015, J CLIN ENDOCR METAB, V100, P603, DOI 10.1210/jc.2014-2291
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Salamone F, 2012, WORLD J GASTROENTERO, V18, P3862, DOI 10.3748/wjg.v18.i29.3862
   Salgado-Mendialdua V, 2018, BIOCHEM PHARMACOL, V157, P159, DOI 10.1016/j.bcp.2018.08.026
   Sami H, 2018, PSYCHIAT RES, V267, P327, DOI 10.1016/j.psychres.2018.03.067
   Shaffer HJ, 2004, HARVARD REV PSYCHIAT, V12, P367, DOI 10.1080/10673220490905705
   Singer M, 2012, ADDICTION, V107, P1747, DOI 10.1111/j.1360-0443.2012.03879.x
   Smirni D, 2018, J NERV MENT DIS, V206, P628, DOI 10.1097/NMD.0000000000000853
   Smirni D, 2018, NEUROL SCI, V39, P885, DOI 10.1007/s10072-018-3297-2
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P1271, DOI 10.19193/0393-6384_2018_5_196
   Throuvala MA, 2018, CURR NEUROPHARMACOL
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2005, INT J CARDIOL, V104, P152, DOI 10.1016/j.ijcard.2004.10.051
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Viggiano E, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00150
NR 99
TC 6
Z9 6
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2081
EP 2087
DI 10.19193/0393-6384_2018_4s_322
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900002
DA 2022-07-14
ER

PT J
AU Sessa, F
   Franco, S
   Picciocchi, E
   Geraci, D
   Chisari, MG
   Marsala, G
   Polito, AN
   Sorrentino, M
   Tripi, G
   Salerno, M
   Russo, D
   Lavano, SM
   Cerroni, F
   Romano, P
   Gallai, B
   Marotta, R
   Lavano, F
   Magliulo, RM
   D'Oro, L
   Di Folco, A
   Parisi, L
   Testa, D
   Murabito, P
   Salerno, M
AF Sessa, Francesco
   Franco, Sabrina
   Picciocchi, Elisabetta
   Geraci, Diego
   Chisari, Mario Giuseppe
   Marsala, Gabriella
   Polito, Anna Nunzia
   Sorrentino, Michele
   Tripi, Gabriele
   Salerno, Margherita
   Russo, Daniela
   Lavano, Serena Marianna
   Cerroni, Francesco
   Romano, Palmira
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Francesco
   Magliulo, Rosaria Martina
   D'Oro, Lucrezia
   Di Folco, Annabella
   Parisi, Lucia
   Testa, Davide
   Murabito, Paolo
   Salerno, Monica
TI FORENSIC CONSIDERATIONS ON VIOLENT PARASOMNIAS DURING LIFESPAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE NREM parasomnias; sleep; consciousness; guiltiness
ID HYPERTHERMIC REACTIONS; NOCTURNAL ENURESIS; HEME OXYGENASE-1; SLEEP;
   BEHAVIOR; CHILDREN; SYSTEM; SLEEPWALKING; DISORDERS; EVENTS
AB Nocturnal parasomnias are a group of sleep complex manifestation that don't alter the sleep macrostructure, but when persistent during adulthood may be assume violent aspects with relevant forensic implications about the guiltiness.
C1 [Sessa, Francesco; Picciocchi, Elisabetta; Salerno, Monica] Univ Foggia, Dept Clin & Expt Med, Viale Pinto 1, I-71122 Foggia, Italy.
   [Franco, Sabrina; Geraci, Diego] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, I-95123 Catania, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa dei Fiori Acerra, Naples, Italy.
   [Chisari, Mario Giuseppe] INPS, Catania, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Osped Riuniti Foggia, Struttura Complessa Farm, Foggia, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Sorrentino, Michele] Pineta Grande Hosp Castel Volturno, NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Di Folco, Annabella; Parisi, Lucia; Testa, Davide] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Lavano, Serena Marianna; Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Magliulo, Rosaria Martina] Ctr Studi Scoliosi SRL, Naples, Italy.
   [D'Oro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
RP Salerno, M (corresponding author), Univ Foggia, Dept Clin & Expt Med, Viale Pinto 1, I-71122 Foggia, Italy.
RI Sessa, Francesco/G-1754-2018; SALERNO, MONICA/AAC-1321-2019; Marotta,
   Rosa/AAG-1453-2020
OI Sessa, Francesco/0000-0003-0357-8791; SALERNO,
   MONICA/0000-0002-6410-3960; Murabito, Paolo/0000-0002-2662-1898;
   Marotta, Rosa/0000-0003-0515-5952; Cerroni,
   Francesco/0000-0003-3024-5482
CR Albenzio M, 2018, J DAIRY SCI, V101, P4842, DOI 10.3168/jds.2017-13104
   Albenzio M, 2016, J DAIRY SCI, V99, P5032, DOI 10.3168/jds.2015-10704
   Albenzio M, 2013, J DAIRY SCI, V96, P2781, DOI 10.3168/jds.2012-6218
   Albenzio M, 2017, NUTRIENTS IN DAIRY AND THEIR IMPLICATIONS FOR HEALTH AND DISEASE, P435, DOI 10.1016/B978-0-12-809762-5.00034-6
   Bisulli F, 2011, SLEEP MED, V12, pS27, DOI 10.1016/j.sleep.2011.10.008
   Bugalho P, 2017, J NEURAL TRANSM, V124, P1183, DOI 10.1007/s00702-017-1759-y
   Caroprese M, 2010, J DAIRY SCI, V93, P2395, DOI 10.3168/jds.2009-2604
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Carpprese M, 2012, SMALL RUMINANT RES
   Chieffi S, 2017, FRONT PHYSL, V8
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Fantini ML, 2012, CURR TREAT OPTION NE, V14, P438, DOI 10.1007/s11940-012-0187-4
   Ferini-Strambi L, 2016, PARKINSONISM RELAT D, V22, pS69, DOI 10.1016/j.parkreldis.2015.09.002
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Geddes MR, 2016, CORTEX, V74, P96, DOI 10.1016/j.cortex.2015.10.015
   Gigante E, 2018, ACTA MEDICA MEDITERR, V34, P1295, DOI 10.19193/0393-6384_2018_5_199
   Jiang HY, 2017, MOL NEUROBIOL, V54, P2997, DOI 10.1007/s12035-016-9831-4
   Kotagal S, 2015, SLEEP MED CLIN, V10, P163, DOI 10.1016/j.jsmc.2015.02.004
   Li Volti G, 2004, BIOCHEM BIOPH RES CO, V315, P517, DOI 10.1016/j.bbrc.2004.01.090
   Mahowald Mark W, 2011, Handb Clin Neurol, V99, P1149, DOI 10.1016/B978-0-444-52007-4.00026-6
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   McKenna D, 2017, MOVEMENT DISORD, V32, P636, DOI 10.1002/mds.27003
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSL, V8
   Moscatelli F, 2016, PLOS ONE, V24
   Moscatelli F, 2015, BIOL MED, V7
   Ohayon MM, 2010, SLEEP MED, V11, P941, DOI 10.1016/j.sleep.2010.02.016
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Rizzo M, 2015, J CLIN ENDOCR METAB, V100, P603, DOI 10.1210/jc.2014-2291
   Salamone F, 2012, WORLD J GASTROENTERO, V18, P3862, DOI 10.3748/wjg.v18.i29.3862
   Santillo A, 2009, INT DAIRY J, V19, P655, DOI 10.1016/j.idairyj.2009.06.011
   Santillo A, 2009, J DAIRY SCI, V92, P1330, DOI 10.3168/jds.2008-1598
   Smirni D, 2019, NEUROL SCI, V40, P97, DOI 10.1007/s10072-018-3587-8
   Sperandeo R, 2018, ACTA MEDICA MEDITERR, V34, P1271, DOI 10.19193/0393-6384_2018_5_196
   Stallman Helen M, 2017, Aust Fam Physician, V46, P590
   Szucs A, 2014, MED HYPOTHESES, V83, P47, DOI 10.1016/j.mehy.2014.04.012
   Tassinari CA, 2009, REV NEUROL-FRANCE, V165, P762, DOI 10.1016/j.neurol.2009.08.002
   Testa D, 2017, AGING CLIN EXP RES, V29, pS191, DOI 10.1007/s40520-016-0647-x
   Testa D, 2016, OPEN MED-WARSAW, V11, P208, DOI 10.1515/med-2016-0040
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2005, INT J CARDIOL, V104, P152, DOI 10.1016/j.ijcard.2004.10.051
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Turillazzi E, 2013, FORENSIC SCI INT, V231, P142, DOI 10.1016/j.forsciint.2013.04.006
   Umanath S, 2011, J HIST NEUROSCI, V20, P253, DOI 10.1080/0964704X.2010.513475
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   van Gastel A, 2014, Tijdschr Psychiatr, V56, P123
   Viana BD, 2009, REV BRAS PSIQUIATR, V31, P281
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano E, NEUROPSYCHIATR DIS, V10
   Viggiano E, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00150
NR 82
TC 6
Z9 6
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2135
EP 2142
DI 10.19193/0393-6384_2018_4s_328
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900008
DA 2022-07-14
ER

PT J
AU Shang, Y
   Tan, F
AF Shang, Yu
   Tan, Feng
TI CORRELATION BETWEEN PROGNOSIS OF MEMBRANOUS NEPHROPATHY PATIENTS AND
   EXPRESSIONS OF CXCL16 AND PODOCIN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Membranous nephropathy; Podocin; CXCL16; Prognosis
ID LIGAND 16; PATHWAY; DISEASE
AB Objective: To study the effect of expressions of CXC chemokine ligand 16 (CXCL16) and glomerular podocyte slit membrane protein (podocin) on prognosis of patients with membranous nephropathy (MN).
   Methods: A total of 102 MN patients admitted from March 2015 to December 2017 were selected and divided into prognosis-good group (event-free survival) and prognosis-poor group (severe complications or death) based on analysis of their prognosis. After comparing clinical features from the two groups, predictive values of CXCL16 and podocin expressions for poor prognosis were determined by ROC curve method, and the independent risk factors for MN prognosis were determined by logistic regression analysis model.
   Results: Twenty-seven (27) (26.47 %) patients presented with poor prognosis, while 75 patients (73.53 %) had good prognosis. In the prognosis-good group, serum creatinine level (>= 186 mu mol/L), 24-h urine protein (> 3.5g), tubular-interstitial injury area (>= 25 %), and proportion of patients in stage III-IV were lower than corresponding values in prognosis-poor group. However, in prognosis-poor group, serum CXCL16 level and glomerular podocin expression were significantly higher (p < 0.05). The areas under curve of CXCL16 and podocin were 0.828 and 0.791, respectively. The independent risk factors for poor MN prognosis included serum creatinine, 24-h urine protein, severity of tubular-interstitial injury; increase in, and pathological staging of serum CXCL16 level (stage III-IV), and decrease in glomerular podocin expression (p < 0.05).
   Conclusion: The expressions of serum CXCL16 and glomerular podocin are independent risk factors and show high predictive value for poor MN prognosis. Thus, they can be used as important clinical indexes for evaluating the conditions of patients.
C1 [Shang, Yu] Xian Med Univ, Sch Clin Med, Xian 710021, Shanxi, Peoples R China.
   [Tan, Feng] Fourth Peoples Hosp Shanxi Prov, Dept Nephrol, Xian 710043, Shanxi, Peoples R China.
RP Shang, Y (corresponding author), Xian Med Univ, Sch Clin Med, Xian 710021, Shanxi, Peoples R China.
EM vu1205@163.com
CR Academic Committee of Nephrology Research Institute of Chinese People's Liberation Army, 2004, CHIN J NEPHROL DIAL, V13, P558
   Adamski V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071468
   Chandrasekar B, 2004, J BIOL CHEM, V279, P3188, DOI 10.1074/jbc.M311660200
   Elewa U, 2016, KIDNEY BLOOD PRESS R, V41, P663, DOI 10.1159/000447935
   Francis JM, 2016, AM J KIDNEY DIS, V68, P138, DOI 10.1053/j.ajkd.2016.01.030
   Hu ZB, 2016, INT J MED SCI, V13, P858, DOI 10.7150/ijms.16724
   Kumar S, 2016, IUBMB LIFE, V68, P578, DOI 10.1002/iub.1515
   Lang K, 2015, EUR J CANCER, V51, pS86, DOI 10.1016/S0959-8049(16)30258-1
   Lang K, 2017, ONCOTARGET, V8, P104946, DOI 10.18632/oncotarget.20737
   Liang H, 2016, ONCOTARGET, V7, P31652, DOI 10.18632/oncotarget.9386
   Liu WJ, 2017, AM J NEPHROL, V46, P64, DOI 10.1159/000478031
   Lu L, 2015, RENAL FAILURE, V37, P1329, DOI 10.3109/0886022X.2015.1067129
   Qi XM, 2016, INFLAMM RES, V65, P103, DOI 10.1007/s00011-015-0893-y
   Rinschen MM, 2016, HUM MOL GENET, V25, P1328, DOI 10.1093/hmg/ddw016
   Rinschen MM, 2015, PROTEOMICS, V15, P1326, DOI 10.1002/pmic.201400235
   Ruggenenti P, 2017, NAT REV NEPHROL, V13, P563, DOI 10.1038/nrneph.2017.92
   Schay G, 2018, BIOPHYS J, V114, p60A, DOI 10.1016/j.bpj.2017.11.379
   Tomas NM, 2016, J CLIN INVEST, V126, P2519, DOI 10.1172/JCI85265
   Von LI, 2016, CYTOKINE, V8, P89
   Wei SY, 2016, AM J NEPHROL, V43, P129, DOI 10.1159/000445361
   Wu JB, 2018, J CELL PHYSIOL, V233, P3648, DOI 10.1002/jcp.26228
   Yu XW, 2016, ONCOL REP, V35, P1557, DOI 10.3892/or.2015.4520
NR 22
TC 0
Z9 0
U1 1
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1405
EP 1410
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700036
DA 2022-07-14
ER

PT J
AU Shao, J
   Gu, SL
   Liu, GL
   Zhang, SH
   Ye, XJ
   Zhao, J
   Shen, C
AF Shao, Jing
   Gu, Shengli
   Liu, Gailing
   Zhang, Shaohui
   Ye, Xiaojing
   Zhao, Jing
   Shen, Cui
TI THE DIAGNOSIS AND TREATMENT OF 12 CASES OF INTRACRANIAL ANEURYSM WITH
   ACUTE SUBDURAL HEMATOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE intracranial aneurysm; acute subdural hematoma; diagnosis and treatment
   and clinical effect
ID SUBARACHNOID HEMORRHAGE
AB Objective: Study and analyze the clinical effect after diagnosis and treatment of patients of intracranial aneurysm with acute subdural hematoma
   Method: Select the 12 cases of intracranial aneurysm with acute subdural hematoma admitted from January 2011 to January 2016 by the Hospital among which there are five male patients and seven female patients from 41 years old to 72 years old with the average age of 53.26 +/- 5.03. During preoperative Hunt-Hess grading, there are three cases of Grade III, seven cases of Grade IV and two cases of Grade V. The preoperative diagnosis shows that all the patients have aneurysm rupture. After CT of initial diagnosis, 11 cases show subdural hematoma and only one case (Case 11) shows subdural hematoma after CT of initial diagnosis but turns out to be multiple intracranial aneurysms after the digital shadow angiography; disturbance of consciousness suddenly occurred during the operation and the emergency operation is given before CT reexamination and emergency intubation; in the operation, it is proved that there is subdural hematoma and temporal lobe intracranial hematoma. All the 11 patients will accept Phase I hematoma clearance, aneurysm occlusion and craniotomy of subdural hematoma. The hippocrepiform incision at central line of forehead will be adopted for two cases of pericallosal aneurysm and the middle approach will be adopted for craniotomy (Case 2 and Case 5); the extensive pterional approach shall be adopted for the other nine cases.
   Results: For the 11 cases with aneurysm occlusion, the CT angiography shows that the aneurysm is completely occluded from operation to discharge and the hematoma is thoroughly cleared. In GOS assessment for 12 patients in the study, three cases have a good recovery, five cases are moderate disability, three cases are severe disability and one case is dead.
   Conclusion: The clinic occurrence rate of intracranial aneurysm with acute subdural hematoma is relatively low, but the occurrence is rapid and the disease progresses quickly, so the condition is severe; after admission, in case of decline, accurate diagnosis early aneurysm occlusion and hematoma clearance, the clinical effect for the patients after treatment can be effectively improved.
C1 [Shao, Jing; Gu, Shengli] Cent Hosp Shanghai Zhabei Dist, Neurol Dept, 619 Zhonghua Rd, Shanghai 200070, Peoples R China.
   [Liu, Gailing] Shanghai T Lukes Hosp, Neurol Dept, Shanghai, Peoples R China.
   [Zhang, Shaohui] Shanghai St Lukes Hosp, Rehabil Dept, Shanghai, Peoples R China.
   [Ye, Xiaojing; Zhao, Jing; Shen, Cui] Shanghai City Changning Dist Xianxia Community Hl, Gen Practice, Shanghai, Peoples R China.
RP Gu, SL (corresponding author), 619 Zhonghua Rd, Shanghai 200070, Peoples R China.
EM hh18888@126.com
CR Awe OO, 2011, NEUROSURGERY, V68, P753, DOI 10.1227/NEU.0b013e318207a9fb
   CHEN Shaojun, 2014, CHIN J CLIN NEUROSUR, V19, P145
   [丁新民 Ding Xinming], 2012, [中华神经外科杂志, Chinese Journal of Neurosurgery], V28, P45
   GuoZhifei Zhao Bing, 2016, ANHUI MED PHARM J, V20, P1521
   [梁明礼 Liang Mingli], 2015, [中华神经医学杂志, Chinese Journal of Neuromedicine], V14, P572
   [刘峥 Liu Zheng], 2012, [中华神经外科杂志, Chinese Journal of Neurosurgery], V28, P665
   Marbacher S, 2012, INT J VASC MED, V2012, DOI 10.1155/2012/753596
   Mrfka Manuel, 2013, J Emerg Med, V44, pe369, DOI 10.1016/j.jemermed.2012.11.073
   Qingrong Fan, 2014, CHINESE J POSTGRADUA, V37, P16
   Rui Zhang, 2016, CHINESE J PRACTICAL, V19, P11
   Schuss P, 2013, J NEUROSURG, V118, P984, DOI 10.3171/2012.11.JNS121435
   Westerlaan HE, 2011, RADIOLOGY, V258, P134, DOI 10.1148/radiol.10092373
   [张五中 Zhang Wuzhong], 2014, [中华神经医学杂志, Chinese Journal of Neuromedicine], V13, P405
NR 13
TC 0
Z9 0
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1233
EP 1238
DI 10.19193/0393-6384_2018_5_189
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700011
DA 2022-07-14
ER

PT J
AU Shen, L
   Xu, YM
   Zhu, YL
   Zhong, CJ
AF Shen, Liang
   Xu, Yi-Ming
   Zhu, Yu-Ling
   Zhong, Chong-Jun
TI MIR-222 ENHANCES HUMAN ESOPHAGEAL SQUAMOUS CELL CARCINOMA CELL LINE TE11
   GROWTH VIA REGULATING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE microRNA-222; proliferation; ESCC; p27
ID CANCER CELLS; MICRORNAS; EXPRESSION; PROLIFERATION
AB Increasing evidence suggests that the abnormal expression of microRNAs involved in human esophageal carcinogenesis. It is still unknown whether and how miRNA-222 played a part in esophageal cancer. Herein, we aimed to investigate the roles of miR-222 in esophageal cancer cells, particularly in regulating response to proliferation. Esophageal squamous cell carcinoma cell line, TE11 cells, was transfected with miR-222 mimic, inhibitor or their negative controls. Cell Counting Kit-8 (CCK-8) and EdU incorporation assay were used to analyze Cell proliferation. MiR-222 and expression levels of its putative target genes (p27 and p57) were detected using qRT-PCR and Western blot. Our results showed that overexpression of miR-222 enhanced TE11 cell proliferation, and expression level of p27Kip1 was negatively moderated by miR-222 up-regulation at post-transcriptional level. Finally, we transfected miR-222 inhibitor and p27 si-RNA into TE11 cells, and found that proliferation-suppressing effects of miR-222 inhibitor on TE11 cells could be partially reversed by silencing p27, indicating that p27 is a target gene of miR-222 during TE11 cell proliferation. Our data suggests that miR-222 overexpression controls TE11 cell growth by down-regulating p27. Inhibition of miR-222 might be a potential therapeutic strategy for esophageal cancer.
C1 [Shen, Liang; Xu, Yi-Ming; Zhu, Yu-Ling; Zhong, Chong-Jun] Nantong Univ, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, 6 Haierxiang Bei Rd, Nantong 226001, Peoples R China.
RP Zhong, CJ (corresponding author), Nantong Univ, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, 6 Haierxiang Bei Rd, Nantong 226001, Peoples R China.
EM zhongcjnt001@126.com
FU The Science and Technology Guiding Program of Nantong [YYZ17035]
FX This work was supported by the grants from The Science and Technology
   Guiding Program of Nantong (Project No: YYZ17035 to L. Shen).
CR Akao Y, 2011, CANCER LETT, V300, P197, DOI 10.1016/j.canlet.2010.10.006
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06
   Chen WX, 2013, TUMOR BIOL, V34, P1361, DOI 10.1007/s13277-013-0750-y
   Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178
   Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200
   Garofalo M, 2012, CURRENT MOL MED, V12, P185
   Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019
   Han Li-Hui, 2015, Asian Pac J Cancer Prev, V16, P2245
   He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102
   Hiyama T, 2010, INT J CANCER, V121, P1643
   Hwang MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066502
   Liu JG, 2012, EUR J CARDIO-THORAC, V41, pE7, DOI 10.1093/ejcts/ezr240
   Matsuzaki J, 2015, J CLIN MED, V4, P1566, DOI 10.3390/jcm4081566
   Matsuzaki J, 2013, GASTROENTEROLOGY, V145, P1300, DOI 10.1053/j.gastro.2013.08.008
   Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209
   Quintavalle C, 2012, ONCOGENE, V31, P858, DOI 10.1038/onc.2011.280
   Sage CL, 2014, EMBO J, V26, P3699
   Shibuya H, 2010, ONCOLOGY-BASEL, V79, P313, DOI 10.1159/000323283
   Tili E, 2011, P NATL ACAD SCI USA, V108, P4908, DOI 10.1073/pnas.1101795108
   Yamashita R, 2015, CANCER MED-US, V4, P551, DOI 10.1002/cam4.412
   Yang ZH, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-31
   Zhang S, 2015, AER ADV ENG RES, V15, P1
   Zhang YQ, 2009, WORLD J SURG, V33, P698, DOI 10.1007/s00268-008-9833-0
   Zhao YY, 2015, J CANCER, V6, P1230, DOI 10.7150/jca.12546
   Zhong CJ, 2015, INT J CLIN EXP MED, V8, P5534
   Zhou JF, 2010, ONCOL REP, V23, P121, DOI 10.3892/or_00000613
NR 27
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1311
EP 1316
DI 10.19193/0393-6384_2018_5_201
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700023
DA 2022-07-14
ER

PT J
AU Shi, WJ
   Tian, KW
   Ye, Y
   Yan, JX
   Chen, K
AF Shi, Wen-Jia
   Tian, Ke-Wei
   Ye, Ye
   Yan, Jia-Xiang
   Chen, Ke
TI CORRELATION BETWEEN RHEUMATOID ARTHRITIS CAUSED BY LIVER AND KIDNEY YIN
   DEFICIENCY AND OSTEOPOROSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Rheumatoid arthritis; Bone metabolism; Osteoporosis; Liver; Kidney
AB Purpose: To investigate the occurrence of osteoporosis in rheumatoid arthritis patients with liver and kidney yin deficiency and to predict the occurrence and hazards of secondary osteoporosis.
   Method: A total of 64 RA patients presented with liver and kidney yin deficiency were selected for this study. They were divided into three groups: control (12 patients), osteopania (22 patients), and osteoporosis (30 patients). The patients were subjected to routine blood analysis and estimations of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factors (IgARF, IgMRF, IgGRF), cyclic citrulinated peptide antibody (CCP antibody), bone metabolism index and bone mineral density (BMD).
   Results: Patients in the osteoporosis group presented with RA of the damp-heat blockage type. The BMD was correlated with the CCP antibody, and patients with osteoporosis had relatively high CCP antibody levels. The hemoglobin concentration was correlated with BMD, and it was higher in the control group. There was a negative correlation between the acute inflammation index and the parathyroid hormone (PTH) level. There was also a negative correlation between IgMRF, CCP antibody, PTH and hip BMD levels. Patients above 65 years had double risks of hip osteoporosis, relative to others. The occurrence of osteoporosis on lumbar vertebra and hip in patients with abnormal erythrocyte sedimentation rate was about 10 times higher than those with normal ESR. Patients with high CCP antibody titer had 7 times higher occurrence of lumbar vertebra osteoporosis, and more than 9 times higher occurrence of hip osteoporosis, relative to the control group.
   Conclusion: Age, ESR and CCP antibody levels are closely related to BMD, and are predisposing factors to secondary osteoporosis. Rheumatoid arthritis (RA) patients above 65 years who present with liver and kidney yin deficiency have high ESR and CCP antibody level and low hemoglobin concentrations.
C1 [Shi, Wen-Jia; Tian, Ke-Wei; Ye, Ye; Yan, Jia-Xiang; Chen, Ke] Orthoped Hosp Henan Prov, Dept Hip Injury & Dis, Luoyang 471000, Henan, Peoples R China.
RP Chen, K (corresponding author), Orthoped Hosp Henan Prov, Dept Hip Injury & Dis, Luoyang 471000, Henan, Peoples R China.
EM ro1322@163.com
CR Murillo YA, 2015, REUMATOL CLIN, V11, P68, DOI 10.1016/j.reuma.2014.03.006
   Bultink IEM, 2012, CURR RHEUMATOL REP, V14, P224, DOI 10.1007/s11926-012-0252-8
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Coulthard LG, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3278
   Hou Lei, 2014, Zhongguo Zhong Xi Yi Jie He Za Zhi, V34, P279
   Liu Jing, 2016, Zhongguo Zhong Yao Za Zhi, V41, P1940, DOI 10.4268/cjcmm20161030
   Mosaad YM, 2014, HUM IMMUNOL, V75, P452, DOI 10.1016/j.humimm.2014.02.009
   Sujic R, 2016, MATURITAS, V88, P70, DOI 10.1016/j.maturitas.2016.03.021
   Zhao Z, 2009, SHAANXI J TRADIT CHI, V30, P434
NR 9
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1437
EP 1440
DI 10.19193/0393-6384_2018_5_218
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700040
DA 2022-07-14
ER

PT J
AU Simsek, Y
   Satar, S
   Sahin, GK
   Gulen, M
AF Simsek, Yeliz
   Satar, Salim
   Sahin, Gonca Koksaldi
   Gulen, Muge
TI EVALUATION OF RHABDOMYOLYSIS ACCORDING TO CREATININE PHOSPHOKINASE (CPK)
   VALUES IN POISONING PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Rhabdomyolysis; Creatinine Phosphokinase; Poisoning Severity Score
ID ACUTE-RENAL-FAILURE; SEVERITY SCORE; RISK
AB Introduction: We evaluated the poisoning cases who admitted to the emergency department and had Creatinine Phosphokinase (CPK) levels up to normal range (>200 U/L). We aimed to contribute to the identification of prognostic factors in rhabdomyolysis.
   Materials and methods: Our study is retrospective. 71 adult patients were included in the study. Their demographic characteristics, systemic examinations, electrocardiogram (ECG) and laboratory parameters were recorded from patient files. Poisoning Severity Score (PSS) was used for determining the degree of intoxication. 25 (35%) of 71 patients had CPK levels above 1000 U/L, and these patients were included in the rhabdomyolysis group. Spearman correlation, Mann-Whitney and Kruskal-Wallis and Chi-square test were used for statistical analysis.
   Results: 70% of 71 patients were male and, mean age was 32.3+/-12.2. The most commonly taken drugs were antidepressants +/- anksiolitik (29.4%). Central nervous system symptoms were found the most common symptoms. Sinus tachycardia was found the most frequent ECG abnormalities. Mean of CPK levels of 71 patients was 2699.4+/-6693.1. We found statistically significant correlation between CPK levels and Alanine aminotransferase (ALT) (p = 0.037), PSS (p = 0.000). ALT (p = 0.026) and PSS (p = 0.001) were also found statistically significant differences in rhabdomyolysis group.
   Conclusions: In our study, there were correlation between CPK and PSS, ALT. In ALT levels and PSS score were statistically significant differences in rhabdomyolysis group. According to our study; poisoning patients who have taken psychiatric.
C1 [Simsek, Yeliz; Satar, Salim; Sahin, Gonca Koksaldi; Gulen, Muge] Numune Educ & Res Hosp, Emergency Dept, Adana, Turkey.
RP Simsek, Y (corresponding author), Numune Educ & Res Hosp Adana, Emergency Dept, Adana, Turkey.
EM ylzberk@yahoo.com
CR Arefi Mohammad, 2014, Nephrourol Mon, V6, pe11910, DOI 10.5812/numonthly.11910
   Bagley WH, 2007, INTERN EMERG MED, V2, P210, DOI 10.1007/s11739-007-0060-8
   Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
   Bywaters EGL, 1998, J AM SOC NEPHROL, V9, P322
   Cervellin G, 2010, CLIN CHEM LAB MED, V48, P749, DOI 10.1515/CCLM.2010.151
   Chen CY, 2013, AM J EMERG MED, V31, P1062, DOI 10.1016/j.ajem.2013.03.047
   Davies JOJ, 2008, QJM-INT J MED, V101, P371, DOI 10.1093/qjmed/hcn014
   Eizadi-Mood N, 2012, J PAK MED ASSOC, V62, pS67
   Fernandez WG, 2005, AM J EMERG MED, V23, P1, DOI 10.1016/j.ajem.2004.09.025
   Guis S, 2005, JOINT BONE SPINE, V72, P382, DOI 10.1016/j.jbspin.2004.04.010
   Huerta-Alardin AL, 2005, CRIT CARE, V9, P158, DOI 10.1186/cc2978
   Packard Kathleen, 2014, J Pharm Pract, V27, P501, DOI 10.1177/0897190013516509
   Persson HE, 1998, J TOXICOL-CLIN TOXIC, V36, P205, DOI 10.3109/15563659809028940
   Safari S, 2016, CLIN EXP NEPHROL, V20, P153, DOI 10.1007/s10157-015-1204-1
   Sam KG, 2009, J FORENSIC LEG MED, V16, P239, DOI 10.1016/j.jflm.2008.12.004
   Talaie H, 2007, HUM EXP TOXICOL, V26, P557, DOI 10.1177/0960327107078667
   Torres PA, 2015, OCHSNER J, V15, P58
   Yakistiran S, 2010, TURK J CLIN LAB, V1, P17
NR 18
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 21
EP 25
DI 10.19193/0393-6384_2018_1_3
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600003
DA 2022-07-14
ER

PT J
AU Sirin, MC
   Goktas, S
AF Sirin, Mumtaz Cem
   Goktas, Safak
TI DETERMINATION OF THE PREVALENCE OF VIRAL, BACTERIAL AND FUNGAL PATHOGENS
   CAUSING MENINGITIS BY USING MULTIPLEX REAL-TIME POLYMERASE CHAIN
   REACTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE cerebrospinal fluid; meningitis; multiplex PCR; prevalence
ID CENTRAL-NERVOUS-SYSTEM; INFLUENZAE TYPE-B; STREPTOCOCCUS-PNEUMONIAE;
   NEISSERIA-MENINGITIDIS; ASEPTIC-MENINGITIS; PCR; DIAGNOSIS; INFECTIONS;
   ENTEROVIRUSES; CULTURE
AB Introduction: This retrospective cross-sectional study was conducted to determine the prevalence of viral, bacterial, and fungal pathogens by using a multiplex real-time PCR assay in patients with suspected meningitis in Istanbul, Turkey.
   Materials and methods: A total of 204 cerebrospinal fluid specimens were analyzed by using MeningoFinder 2Smart (PathoFinder BV, The Netherlands) and Rotor-Gene 6000 real-time PCR system (Qiagen, Germany).
   Results: At least one pathogen was detected in 55 (27%) of all specimens. Overall, 57 pathogens were detected, and 30 (52.63%) of them were viruses, 26 (45.62%) were bacteria and 1 (1.75%) was fungus. In two cases, two pathogens (Epstein-Barr virus and Streptococcus agalactiae, Measles virus and Streptococcus pneumoniae) were found together. The detected pathogens were Haemophilus influenzae (n=14), Human herpesvirus 6 (n=13), Cytomegalovirus (n=9), S. pneumoniae (n=6), Epstein-Barr virus (n=5), S. agalactia (n=4), Parechovirus (n=1), Human herpesvirus 7 (n=1), Measles virus (n=1), Listeria monocytogenes (n=1), Borrelia burgdorferi/miyamatoi (n=1) and Cryptococcus neoformans (n=1). S. pneumoniae was the most common pathogen in 0-4year-old age subgroup, H. influenzae in 5-15-year-old age subgroup and in 16-64-year-old age subgroup, and Cytomegalovirus in >= 65-year-old age subgroup. Viral infections occurred predominantly in the autumn (11/30, 36.6%) and summer (9/30, 30%) whereas bacterial infections in the autumn (10/26, 38.5%) and winter (8/26, 30.8%).
   Conclusion: Herpesviruses and H. influenzae were found to be the major viral and bacterial causes of meningitis in the study. Our findings would contribute to the knowledge base on the epidemiology of meningitis in Istanbul.
C1 [Sirin, Mumtaz Cem] Suleyman Demirel Univ, Fac Med, Dept Med Microbiol, Isparta, Turkey.
   [Goktas, Safak] Dept Infect Dis & Clin Microbiol, Gelisim Med Labs, Istanbul, Turkey.
RP Sirin, MC (corresponding author), Suleyman Demirel Univ, Fac Med, Dept Med Microbiol, Cunur Isparta, Turkey.
RI Şirin, Mümtaz Cem/AGN-8051-2022
OI Şirin, Mümtaz Cem/0000-0002-7349-3438
CR Aberle SW, 2002, J CLIN VIROL, V25, pS79, DOI 10.1016/S1386-6532(02)00037-9
   Amin M, 2016, KAOHSIUNG J MED SCI, V32, P501, DOI 10.1016/j.kjms.2016.08.009
   Bamberger DM, 2010, AM FAM PHYSICIAN, V82, P1491
   Baspinar EO, 2017, BRAZ J MICROBIOL, V48, P232, DOI 10.1016/j.bjm.2016.06.014
   Ceyhan M, 2014, HUM VACC IMMUNOTHER, V10, P2706, DOI 10.4161/hv.29678
   Demiroglu YZ, 2010, TURK KLIN TIP BILIM, V30, P218, DOI 10.5336/medsci.2008-8623
   Duman Y, 2012, DICLE MED J, V39, P70
   Gaeta A, 2009, NEW MICROBIOL, V32, P333
   Saraiva MDG, 2015, REV SOC BRAS MED TRO, V48, P79, DOI 10.1590/0037-8682-0116-2014
   Gultepe B, 2015, ABANT MED J ABANT MED J, V4, P125
   Khater Walaa Shawky, 2016, Int J Microbiol, V2016, P4197187, DOI 10.1155/2016/4197187
   Kleines M, 2014, DIAGN MICR INFEC DIS, V80, P207, DOI 10.1016/j.diagmicrobio.2014.07.010
   Mace SE, 2008, EMERG MED CLIN N AM, V26, P281, DOI 10.1016/j.emc.2008.02.002
   Noordhoek GT, 2008, J CLIN VIROL, V41, P75, DOI 10.1016/j.jcv.2007.09.011
   Parisi SG, 2016, INT J INFECT DIS, V44, P8, DOI 10.1016/j.ijid.2016.01.012
   Mendoza LP, 2007, J INFECTION, V54, P589, DOI 10.1016/j.jinf.2006.11.013
   Putz K, 2013, PRIMARY CARE, V40, P707, DOI 10.1016/j.pop.2013.06.001
   Vidal LRR, 2011, ARQ NEURO-PSIQUIAT, V69, P475, DOI 10.1590/S0004-282X2011000400013
   Somand D, 2009, EMERG MED CLIN N AM, V27, P89, DOI 10.1016/j.emc.2008.07.004
   Tapiainen T, 2007, VACCINE, V25, P5793, DOI 10.1016/j.vaccine.2007.04.058
   Traore Y, 2009, CLIN INFECT DIS, V48, pS181, DOI 10.1086/596498
   Tuppeny M, 2013, CRIT CARE NURS CLIN, V25, P363, DOI 10.1016/j.ccell.2013.04.003
   Turel O, 2013, BALK MED J, V30, P80, DOI 10.5152/balkanmedj.2012.092
   Wieczorek M, 2016, POL J MICROBIOL, V65, P231, DOI 10.5604/17331331.1204485
   Wolffs PFG, 2009, J CLIN MICROBIOL, V47, P2620, DOI 10.1128/JCM.02436-08
   Wu HM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-26
   Zhou LF, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13020193
NR 27
TC 1
Z9 1
U1 2
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 127
EP 132
DI 10.19193/0393-6384_2018_1_21
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600021
DA 2022-07-14
ER

PT J
AU Solak, I
   Duran, C
   Demirtepe, I
   Pekgor, S
   Eryilmaz, MA
AF Solak, Ibrahim
   Duran, Cevdet
   Demirtepe, Ibrahim
   Pekgor, Selma
   Eryilmaz, Mehmet Ali
TI THE EFFECTS OF SHORT-TERM SMOKING CESSATION ON METABOLIC SYNDROME
   PARAMETERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Cigarette; metabolic syndrome; smoking cessation
ID CIGARETTE-SMOKING; DIABETES-MELLITUS; FAT DISTRIBUTION; WEIGHT CONCERNS;
   BLOOD-PRESSURE; BODY-WEIGHT; ASSOCIATION; OBESITY; RISK; MEN
AB Objective: Smoking cigarettes and metabolic syndrome (MetS) are among preventable health problems. On the other hand, smoking cessation may also lead to gaining weight and MetS. Here, we aimed to investigate the effects of short-term smoking cessation on MetS parameters.
   Materials and methods:The study was performed in 150 subjects willing to cease cigarette smoking. Varenicline or bupropion was started to the subjects ceasing smoking as a supportive treatment, and current diet exercises were continued. MetS incidence was evaluated before and at week 12 with the National Cholesterol Education Program, Adult Treatment Panel (NCEP ATP III).
   Results: Of 150 subjects, 74 continued smoking cessation at week 12. Compared to the baseline values, it was seen that body weight (p<0.001), waist circumference (WC) (p<0.001), body mass index (BM) (p<0.001) and high density lipoprotein (HDL)-cholesterol (p<0.001) levels increased at the 12th week. However, blood pressure (BP), blood glucose and triglyceride (TG) levels remained unchanged. Presence of MetS was found 8.1% at the baseline and 17.6% at the end of the study (p=0.118). Of all subjects, while present in 43.2% at initial, WC criteria for MetS, then, increased to 54.1% at week 12 (p=0.039). Although present in 68.9% of subjects at the baseline, HDL-cholesterol criteria decreased to 50.0% at week 12 (p=0.001).
   Conclusions: Although an increase was observed in WC, body weight and BMI, we observed no changes in MetS frequency within 12-week period. Administration of appropriate calorie-restricting diet and exercise may prevent weight gain and MetS to develop after smoking cessation.
C1 [Solak, Ibrahim; Demirtepe, Ibrahim; Pekgor, Selma] Univ Hlth Sci, Konya Hlth Applicat & Res Ctr, Dept Family Med, Konya, Turkey.
   [Duran, Cevdet] Usak Univ, Div Endocrinol & Internal Med, Med Sch, Usak, Turkey.
   [Eryilmaz, Mehmet Ali] Univ Hlth Sci, Konya Hlth Applicat & Res Ctr, Dept Gen Surg, Konya, Turkey.
   [Eryilmaz, Mehmet Ali] Univ Hlth Sci, Konya Hlth Applicat & Res Ctr, Family Med Clin, Konya, Turkey.
RP Solak, I (corresponding author), Univ Hlth Sci, Konya Hlth Applicat & Res Ctr, Dept Family Med, Konya, Turkey.
EM isolaktr@yahoo.com
RI Solak, Ibrahim/F-2225-2019; Duran, Cevdet/AAB-6174-2020; pekgör,
   selma/ABB-6440-2020
OI Solak, Ibrahim/0000-0001-5311-0631; pekgör, selma/0000-0001-9907-1842
FU Konya Training and Research Hospital
FX The study was funded by the research fund of Konya Training and Research
   Hospital. Authors thank Numan Duran for language editing.
CR Al-Safi Saafan A, 2005, Eur J Cardiovasc Nurs, V4, P286, DOI 10.1016/j.ejcnurse.2005.03.004
   Bush T, 2016, OBESITY, V24, P1834, DOI 10.1002/oby.21582
   Canoy D, 2005, OBES RES, V13, P1466, DOI 10.1038/oby.2005.177
   Chiolero A, 2008, AM J CLIN NUTR, V87, P801, DOI 10.1093/ajcn/87.4.801
   Clark MM, 2004, ADDICT BEHAV, V29, P1637, DOI 10.1016/j.addbeh.2004.02.034
   DALLOSSO HM, 1984, INT J OBESITY, V8, P365
   FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q
   FAGERSTROM K O, 1990, Ear Nose and Throat Journal, V69, P763
   Filozof C, 2004, Obes Rev, V5, P95, DOI 10.1111/j.1467-789X.2004.00131.x
   FLEGAL KM, 1995, NEW ENGL J MED, V333, P1165, DOI 10.1056/NEJM199511023331801
   Geslain-Biquez C, 2003, DIABETES METAB, V29, P226, DOI 10.1016/S1262-3636(07)70031-9
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Heggen E, 2017, NUTR METAB CARDIOVAS, V27, P335, DOI 10.1016/j.numecd.2016.12.011
   Hishida A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-263
   HOFSTETTER A, 1986, NEW ENGL J MED, V314, P79, DOI 10.1056/NEJM198601093140204
   Ishizaka N, 2005, ATHEROSCLEROSIS, V181, P381, DOI 10.1016/j.atherosclerosis.2005.01.026
   Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683
   Jee SH, 2002, OBES RES, V10, P891, DOI 10.1038/oby.2002.122
   Kar D, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0475-5
   Karthikeyan VJ, 2007, J HUM HYPERTENS, V21, P911, DOI 10.1038/sj.jhh.1002300
   Keten HS, 2015, ACTA MEDICA MEDITERR, V31, P899
   Khan HA, 2007, CLIN EXP MED, V7, P24, DOI 10.1007/s10238-007-0121-3
   Kim BJ, 2009, DIABETES CARE, V32, P1314, DOI 10.2337/dc09-0060
   Kim JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045815
   Lee DH, 2001, HYPERTENSION, V37, P194, DOI 10.1161/01.HYP.37.2.194
   Manson JE, 2000, AM J MED, V109, P538, DOI 10.1016/S0002-9343(00)00568-4
   Matsushita Y, 2011, OBESITY, V19, P647, DOI 10.1038/oby.2010.237
   Meyers AW, 1997, J CONSULT CLIN PSYCH, V65, P448, DOI 10.1037/0022-006X.65.3.448
   MOFFATT RJ, 1991, METABOLISM, V40, P465, DOI 10.1016/0026-0495(91)90225-L
   Oh SW, 2005, DIABETES CARE, V28, P2064, DOI 10.2337/diacare.28.8.2064
   Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008
   Primatesta P, 2001, HYPERTENSION, V37, P187, DOI 10.1161/01.HYP.37.2.187
   STAMFORD BA, 1986, AM J CLIN NUTR, V43, P486, DOI 10.1093/ajcn/43.4.486
   STUBBE I, 1982, BMJ-BRIT MED J, V284, P1511, DOI 10.1136/bmj.284.6328.1511
   Sung YT, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3961756
   Uysal M Atilla, 2004, Tuberk Toraks, V52, P115
   Wada T, 2007, INTERNAL MED, V46, P1079, DOI 10.2169/internalmedicine.46.0026
   Wang YF, 2005, AM J CLIN NUTR, V81, P555
   Waverley BL, NON TRADITIONAL REF
   Will JC, 2001, INT J EPIDEMIOL, V30, P540, DOI 10.1093/ije/30.3.540
   Woynillowicz AK, 2012, TOXICOL APPL PHARM, V265, P122, DOI 10.1016/j.taap.2012.08.020
NR 41
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 2037
EP 2044
DI 10.19193/0393-6384_2018_6_318
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400069
DA 2022-07-14
ER

PT J
AU Song, AY
   Zhang, JH
   Liu, ZY
   Zhao, Q
   Gao, P
   Wei, QQ
   Zhu, S
AF Song, Aiyang
   Zhang, Jiahui
   Liu, Zhaoying
   Zhao, Qi
   Gao, Ping
   Wei, Qianqian
   Zhu, Song
TI INFLUENCE OF LONG-TERM WATER IMMERSION ON THE COEFFICIENT OF THERMAL
   EXPANSION OF COMPOSITE RESINS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Dental Materials; Coefficient of thermal expansion; Aging
ID DENTAL COMPOSITES; RESTORATIVE MATERIALS; SHRINKAGE; POLYMERIZATION;
   SOLUBILITY; SORPTION; MONOMER
AB Introduction: Light-cured composite resins have been widely used as dental restoratives. The purpose of this study was to investigate the change of coefficient of thermal expansion (CTE) of low-shrinkage composite resins after long-term water immersion.
   Materials and methods: Immersed in distilled water at 37. for 24 h, 1 month, 3 months and 6 months, the CTE of six kinds of composite resin were measured with a thermomechanical analyzer (TMA). The measured data were statistically analyzed. Additionally, the surface morphology of the composite resins were evaluated after long-term water immersion.
   Results: After water immersion, the CTE increased initially, then reduced or remained stable with changing temperature and time.
   Conclusion: The change of the CTE is closely related to the composition of the composite resin. The CTE of epoxide and prepolymerized filler in low-shrinkage composite resin is relatively stable, and the CTE of high-content filler nanometer resin is the closest to the thermal expansion coefficient of tooth structure.
C1 [Song, Aiyang; Zhang, Jiahui; Liu, Zhaoying; Zhao, Qi; Gao, Ping; Wei, Qianqian; Zhu, Song] Jilin Univ, Sch & Hosp Stomatol, Changchun, Jilin, Peoples R China.
RP Zhu, S (corresponding author), 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
EM zhusong1965@163.com
FU National Natural Science Foundation of China (NSFC) [81371185]
FX This study was financially supported by the National Natural Science
   Foundation of China (NSFC, Grant No. 81371185).
CR Alnazzawi A, 2012, DENT MATER, V28, P1240, DOI 10.1016/j.dental.2012.09.004
   Boaro LC, 2013, DENT MATER, V29, P398, DOI 10.1016/j.dental.2013.01.006
   Bottenberg P, 2007, J DENT, V35, P163, DOI 10.1016/j.jdent.2006.07.002
   BULLARD RH, 1988, J AM DENT ASSOC, V116, P871, DOI 10.14219/jada.archive.1988.0291
   de Moraes Rafael Ratto, 2008, J Prosthodont, V17, P323, DOI 10.1111/j.1532-849X.2007.00295.x
   Dos Santos PA, 2010, MICROSC RES TECHNIQ, V73, P176, DOI 10.1002/jemt.20769
   Emami N, 2003, EUR J ORAL SCI, V111, P536, DOI 10.1111/j.0909-8836.2003.00082.x
   Finer Y, 2004, J BIOMED MATER RES A, V69A, P233, DOI 10.1002/jbm.a.30000
   Fu J, 2014, INT J MOL SCI, V15, P2400, DOI 10.3390/ijms15022400
   Ilie N, 2007, DENT MATER J, V26, P149, DOI 10.4012/dmj.26.149
   Irie M, 2002, DENT MATER, V18, P203, DOI 10.1016/S0109-5641(01)00083-5
   Janda R, 2007, J BIOMED MATER RES B, V82B, P545, DOI 10.1002/jbm.b.30760
   Moszner N, 2008, DENT MATER, V24, P851, DOI 10.1016/j.dental.2007.10.004
   Münchow Eliseu A., 2014, Braz. Dent. J., V25, P321, DOI 10.1590/0103-6440201300058
   Papadogiannis D, 2011, DENT MATER J, V30, P350, DOI 10.4012/dmj.2010-181
   Park CA, 2007, J MATER SCI-MATER M, V18, P1549, DOI 10.1007/s10856-007-3023-8
   Peutzfeldt A, 2005, J DENT RES, V84, P659, DOI 10.1177/154405910508400715
   Schneider Luis Felipe J, 2011, J Oral Sci, V53, P413
   Sideridou I, 2004, BIOMATERIALS, V25, P3087, DOI 10.1016/j.biomaterials.2003.09.078
   Sideridou ID, 2015, DENT MATER, V31, P154, DOI 10.1016/j.dental.2014.11.008
   Trujillo-Lemon M, 2006, J POLYM SCI POL CHEM, V44, P3921, DOI 10.1002/pola.21493
   Turssi CP, 2002, J ORAL REHABIL, V29, P864, DOI 10.1046/j.1365-2842.2002.00926.x
   Vouvoudi EC, 2016, J TAIBAH UNIV MED SC, V11, P63, DOI 10.1016/j.jtumed.2015.11.009
   Wei YJ, 2011, DENT MATER, V27, P259, DOI 10.1016/j.dental.2010.10.015
   Weinmann W, 2005, DENT MATER, V21, P68, DOI 10.1016/j.dental.2004.10.007
   XU HC, 1989, AUST DENT J, V34, P530
NR 26
TC 0
Z9 0
U1 0
U2 20
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 989
EP 995
DI 10.19193/0393-6384_2018_4_150
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500013
DA 2022-07-14
ER

PT J
AU Sorrentino, M
   Tripi, G
   Salerno, M
   Russo, D
   Lavano, SM
   Cerroni, F
   Romano, P
   Gallai, B
   Marotta, R
   Lavano, F
   Magliulo, RM
   D'Oro, L
   Di Folco, A
   Testa, D
   Marsala, G
   Montana, A
   Franco, S
   Geraci, D
   Chisari, MG
   Picciocchi, E
   Polito, AN
   Murabito, P
   Ruberto, M
   Parisi, L
AF Sorrentino, Michele
   Tripi, Gabriele
   Salerno, Margherita
   Russo, Daniela
   Lavano, Serena Marianna
   Cerroni, Francesco
   Romano, Palmira
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Francesco
   Magliulo, Rosaria Martina
   D'Oro, Lucrezia
   Di Folco, Annabella
   Testa, Davide
   Marsala, Gabriella
   Montana, Angelo
   Franco, Sabrina
   Geraci, Diego
   Chisari, Mario Giuseppe
   Picciocchi, Elisabetta
   Polito, Anna Nunzia
   Murabito, Paolo
   Ruberto, Maria
   Parisi, Lucia
TI BEHAVIORAL ASPECTS IN CHILDREN'S BROTHERS AFFECTED BY AUTISM SPECTRUM
   DISORDERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Autism spectrum disorders; siblings; behavior
ID MONOSYMPTOMATIC NOCTURNAL ENURESIS; CHILDHOOD ABSENCE EPILEPSY;
   SLEEP-APNEA SYNDROME; QUALITY-OF-LIFE; HYPERTHERMIC REACTIONS;
   DEPRESSIVE SYMPTOMS; OBESE CHILDREN; OPEN-LABEL; MIGRAINE; WEIGHT
AB Introduction: Autistic Spectrum Disorder (ASD) is a permanent and complex disability arising within the first three years of life characterized by a socio-communicative disorder and by fixed interests and repetitive behaviors. The present pilot study aims to evaluate behavioral aspects in a small population of siblings of ASD children.
   Material and methods: Population: 5 school-aged children (2 males, 3 females) (mean age 9.235 +/- 2.041) were enrolled, as siblings of ASD children, and for comparison, 12 healthy (7 males, 5 females) children (average age 9,528 +/- 3,351). All subjects underwent evaluation of the behavioral with Child Behavior Checklist (CBCL) scale.
   Results: The two groups were statistically comparable by age (p = 0.86) and gender distribution (p = 0.87). From the behavioral point of view evaluated with the CBCL scale, siblings of ASD have a higher degree of overall problem (Total problems) compared to control children (p=0.003), in addition they have significantly higher scores in the subscales of behavior examined (Anxious/Depressed, Withdrawn, Somatic Complaints, Social, Thought, Attention, Delinquent, Aggressive) as well as a greater share of disturbances both internalizing (p=0.004) and externalizing (p = 0.007) (Table 1).
   Conclusions: The present preliminary data confirm the need for a global management of the entire family structure for the correct management of Autistic Disorders.
C1 [Sorrentino, Michele] Pineta Grande Hosp, NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
   [Tripi, Gabriele; Ruberto, Maria] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Russo, Daniela] Ctr Riabilitaz La Filanda LARS, Sarno, Italy.
   [Di Folco, Annabella; Testa, Davide; Parisi, Lucia] Univ Palermo, Dept Psychol Educ Sci & Human Movement, Palermo, Italy.
   [Lavano, Serena Marianna; Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Cerroni, Francesco] Ctr Manzoni Srl, Naples, Italy.
   [Romano, Palmira] Ctr Riabilitaz LARS, Sarno, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Magliulo, Rosaria Martina] Ctr Scoliosi SRL, Naples, Italy.
   [D'Oro, Lucrezia] Ctr Ambulatoriale Santo Stefano, Pesaro, Italy.
   [Marsala, Gabriella] Osped Riuniti Foggia, Azienda Osped Univ, Struttura Complessa Farm, Foggia, Italy.
   [Montana, Angelo; Franco, Sabrina; Geraci, Diego] Univ Catania, Dept Med Surg & Adv Technol Sci GF Ingrassia, Catania, Italy.
   [Chisari, Mario Giuseppe] INPS, Catania, Italy.
   [Picciocchi, Elisabetta] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Polito, Anna Nunzia] Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
   [Murabito, Paolo] Univ Catania, Catania, Italy.
   CRD Santa Maria Pozzo, Somma Vesuviana, Italy.
RP Sorrentino, M (corresponding author), Pineta Grande Hosp, NICU Preterm & High Risk Newborn Neurodev Follow, Castel Volturno, CE, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Cerroni, Francesco/0000-0003-3024-5482; Marotta,
   Rosa/0000-0003-0515-5952; Murabito, Paolo/0000-0002-2662-1898
CR Achenbach T M, 2000, Pediatr Rev, V21, P265, DOI 10.1542/pir.21-8-265
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Bontinck C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193367
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSL, V8
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2017, EUR J PHYS REHAB MED, V53, P643, DOI 10.23736/S1973-9087.16.04037-5
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Filliter JH, 2015, J ABNORM CHILD PSYCH, V43, P567, DOI 10.1007/s10802-014-9921-6
   Finan LJ, 2018, DEV PSYCHOL, V54, P1555, DOI 10.1037/dev0000543
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Gallelli Luca, 2017, Microrna, V6, P152, DOI 10.2174/2211536606666170913152821
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Matricardi S, 2018, ACTA NEUROL SCAND, V137, P575, DOI 10.1111/ane.12902
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00261
   Messina A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, FRONT PHYSL, V8
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Moscatelli F, 2016, PLOS ONE, V24
   Moscatelli F, 2015, BIOL MED, V7
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisula E, 2015, INT J MOL SCI, V16, P13217, DOI 10.3390/ijms160613217
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Sin J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010540.pub2
   Smirni D, 2018, J NERV MENT DIS, V206, P628, DOI 10.1097/NMD.0000000000000853
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2005, INT J CARDIOL, V104, P152, DOI 10.1016/j.ijcard.2004.10.051
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2018, ACTA NEUROL SCAND, V138, P523, DOI 10.1111/ane.13006
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 99
TC 0
Z9 0
U1 2
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 4
BP 2097
EP 2105
DI 10.19193/0393-6384_2018_4s_324
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA4LD
UT WOS:000450232900004
DA 2022-07-14
ER

PT J
AU Sperandeo, R
   Maldonato, MN
   Messina, A
   Cozzolino, P
   Monda, M
   Cerroni, F
   Romano, P
   Salerno, M
   Maltese, A
   Roccella, M
   Parisi, L
   Tripi, G
   Moscatelli, F
   Sessa, F
   Salerno, M
   Cibelli, G
   Messina, G
   Monda, V
   Chieffi, S
   Villano, I
   Monda, E
   Ruberto, M
   Marsala, G
   Marotta, RR
   Velenzano, A
AF Sperandeo, Raffaele
   Maldonato, Mauro N.
   Messina, Antonietta
   Cozzolino, Pasquale
   Monda, Marcellino
   Cerroni, Francesco
   Romano, Palmira
   Salerno, Margherita
   Maltese, Agata
   Roccella, Michele
   Parisi, Lucia
   Tripi, Gabriele
   Moscatelli, Fiorenzo
   Sessa, Francesco
   Salerno, Monica
   Cibelli, Giuseppe
   Messina, Giovanni
   Monda, Vincenzo
   Chieffi, Sergio
   Villano, Ines
   Monda, Emanuele
   Ruberto, Maria
   Marsala, Gabriella
   Marotta, Rosa R.
   Velenzano, Anna
TI OREXIN SYSTEM: NETWORK MULTI-TASKING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Orexin; Obesity; emotional stress; narcolepsy
ID RESTING ENERGY-EXPENDITURE; SLEEP-APNEA SYNDROME; HYPOCRETIN/OREXIN
   NEURONS; CHILDHOOD MIGRAINE; RAT-BRAIN; CHILDREN; RECEPTOR; EXPRESSION;
   NARCOLEPSY; AURA
AB Orexin system regulates sleep/wake states and its deficiency result in narcolepsy thus indicating the crucial role of orexins in maintaining wakefulness. There are two types of orexin peptides: the orexin-A (OXA or hypocretin 1) and orexin-B (OXB or hypocretin 2). The Majority of the central nervous system orexin peptides are synthesized in neurons located in the lateral and back hypothalamus and send projections throughout the brain regions Orexin neurons are "multi-tasking" hence regulating also energy homeostasis, reward systems and feeding behaviour through connection with hypothalamic nuclei and through responsiveness to leptine and glucose. It has recently been found a connection with lymbic system suggesting a further possible role of orexins in regulating emotions. All the studies conducted confirm that orexin system regulates vigilance states, energy homeostasis, reward system, and emotions. These crucial role might be the target to develope treatments of narcolepsy, obesity, emotional stress, and drug addiction.
C1 [Sperandeo, Raffaele] Univ Campania, Dept Expt Med, Sect Human Physiol, Naples, Italy.
   [Sperandeo, Raffaele] Univ Campania, Unit Dietet & Sport Med, Naples, Italy.
   [Maldonato, Mauro N.; Messina, Antonietta; Monda, Marcellino] Univ Basilicata, Dept Human Sci, Potenza, Italy.
   [Cozzolino, Pasquale] SiPGI Postgrad Sch Integrated Gestalt Psychothera, DM 12 10 2007, Naples, Italy.
   [Cerroni, Francesco; Romano, Palmira] Univ Campania Luigi Vanvitelli, Dept Mental Hlth Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Naples, Italy.
   [Marotta, Rosa R.] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Salerno, Margherita; Maltese, Agata; Roccella, Michele; Parisi, Lucia; Tripi, Gabriele] Univ Palermo, Dept Psychol & Pedag Sci, Child Neuropsychiat, Palermo, Italy.
   [Moscatelli, Fiorenzo; Sessa, Francesco; Salerno, Monica; Cibelli, Giuseppe; Messina, Giovanni; Velenzano, Anna] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Monda, Vincenzo; Chieffi, Sergio; Villano, Ines; Monda, Emanuele] Univ Campania Luigi Vanvitelli, Dept Expt Med, Sect Human Physiol, Naples, Italy.
   [Monda, Vincenzo; Chieffi, Sergio; Villano, Ines; Monda, Emanuele] Univ Campania Luigi Vanvitelli, Unit Dietet & Sports Med, Naples, Italy.
   [Ruberto, Maria] Ctr CRD, Naples, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Struttura Complessa Farm, Foggia, Italy.
RP Velenzano, A (corresponding author), Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
EM anna.valenzano@unifg.it
RI Monda, Emanuele/AAQ-6457-2020; MESSINA, ANTONIETTA/K-9366-2016; Messina,
   Antonietta/AHH-2383-2022; Moscatelli, Fiorenzo/ABC-9536-2020; Sessa,
   Francesco/G-1754-2018; Cibelli, Giuseppe/AAC-2635-2019; Messina,
   Giovanni/AAE-8668-2022; Marotta, Rosa/AAG-1453-2020; SALERNO,
   MONICA/AAC-1321-2019; MALDONATO, NELSON MAURO/AAG-3791-2021
OI Monda, Emanuele/0000-0001-9304-988X; Messina,
   Antonietta/0000-0001-8343-432X; Sessa, Francesco/0000-0003-0357-8791;
   Messina, Giovanni/0000-0002-0011-867X; SALERNO,
   MONICA/0000-0002-6410-3960; MALDONATO, NELSON MAURO/0000-0002-6401-2305;
   Moscatelli, Fiorenzo/0000-0003-1274-0332; Sperandeo,
   Raffaele/0000-0002-8892-179X; VILLANO, INES/0000-0002-1755-358X; Monda,
   Marcellino/0000-0002-7184-218X; Marotta, Rosa/0000-0003-0515-5952;
   Monda, Vincenzo/0000-0002-6083-5814; TRIPI,
   Gabriele/0000-0001-7088-9325; Cerroni, Francesco/0000-0003-3024-5482;
   CIBELLI, GIUSEPPE/0000-0002-5371-2584
CR Avola R, 2004, CLIN EXP HYPERTENS, V26, P323, DOI 10.1081/CEH-120034137
   Bramanti V, 2012, NEUROCHEM RES, V37, P2795, DOI 10.1007/s11064-012-0873-3
   Capovilla G, 2004, EPILEPSIA, V45, P887, DOI 10.1111/j.0013-9580.2004.457erratum.x
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2017, FRONT PSYCHIATRY, P8
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Cerretani D, 2011, PHARMACOL RES, V64, P517, DOI 10.1016/j.phrs.2011.08.002
   Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00231
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Cianci P, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0857-x
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito T, 2016, DRUG DES DEV THER, V10, P2939, DOI 10.2147/DDDT.S106440
   Fiorelli A, 2017, ANN THORAC SURG, V103, P216, DOI 10.1016/j.athoracsur.2016.10.055
   Forlano I, 2011, ANN ITAL CHIR, V82, P405
   Liu ZW, 2007, J NEUROPHYSIOL, V97, P837, DOI 10.1152/jn.00873.2006
   Maldonato M., 2015, ARCHIPELAGO CONSCIOU
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/639280
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G, 2015, BIOL MED
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Asian J Sports Med, V7, pe26841, DOI 10.5812/asjsm.26841
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16
   Monda M, 2008, CLIN NUTR, V27, P657, DOI 10.1016/j.clnu.2008.04.005
   Monda M, 2008, PEPTIDES, V29, P120, DOI 10.1016/j.peptides.2007.10.016
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Nambu T, 1999, BRAIN RES, V827, P243, DOI 10.1016/S0006-8993(99)01336-0
   Neri V, PANCREAS, V38
   Neri V, 2013, ANN ITAL CHIR, V84, P47
   Neri V, 2009, ANN ITAL CHIR, V80, P363
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perez-Leighton CE, 2012, AM J PHYSIOL-ENDOC M, V303, pE865, DOI 10.1152/ajpendo.00119.2012
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pomara C, 2012, CURR MED CHEM, V19, P5647, DOI 10.2174/092986712803988811
   Pomara C, 2008, CLIN TOXICOL, V46, P322, DOI 10.1080/15563650701419011
   Pomara C, 2016, J CELL PHYSIOL, V231, P1385, DOI 10.1002/jcp.25272
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Precenzano F, 2017, ACTA MEDICA MEDITERR, P33
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Rainero Innocenzo, 2008, Expert Rev Neurother, V8, P409, DOI 10.1586/14737175.8.3.409
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6
   Salomone F, 2014, TRANSL RES, V163, P593, DOI 10.1016/j.trsl.2013.12.001
   Saper CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6
   Shiuchi T, 2009, CELL METAB, V10, P466, DOI 10.1016/j.cmet.2009.09.013
   Sperandeo R, 7 IEEE INT C COGN IN
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1
   Trivedi P, 1998, FEBS LETT, V438, P71, DOI 10.1016/S0014-5793(98)01266-6
   Tsunematsu T, 2008, J NEUROSCI, V28, P228, DOI 10.1523/JNEUROSCI.3490-07.2008
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2013, FORENSIC SCI INT, V231, P142, DOI 10.1016/j.forsciint.2013.04.006
   Turillazzi E, 2010, HISTOL HISTOPATHOL, V25, P1539, DOI 10.14670/HH-25.1539
   Turillazzi E, 2008, VIRCHOWS ARCH, V453, P209, DOI 10.1007/s00428-008-0632-7
   Vacchiano G, 2012, J ROY ARMY MED CORPS, V158, P338, DOI 10.1136/jramc-158-04-15
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Vyshka G, 2014, BMJ CASE REP
   Williams RH, 2007, P NATL ACAD SCI USA, V104, P10685, DOI 10.1073/pnas.0702676104
   Xie XM, 2006, J PHYSIOL-LONDON, V574, P399, DOI 10.1113/jphysiol.2006.108266
   Yang LY, 2013, J NEUROSCI, V33, P5275, DOI 10.1523/JNEUROSCI.3200-12.2013
   Zhao X, 2014, PEPTIDES, V54, P140, DOI 10.1016/j.peptides.2013.11.019
NR 86
TC 22
Z9 23
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 349
EP 356
DI 10.19193/0393-6384_2018_2_55
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400009
DA 2022-07-14
ER

PT J
AU Sperandeo, R
   Picciocchi, E
   Valenzano, A
   Cibelli, G
   Ruberto, V
   Moretto, E
   Monda, V
   Messina, A
   Dell'Orco, S
   Di Sarno, AD
   Marsala, G
   Polito, AN
   Longobardi, T
   Maldonato, NM
AF Sperandeo, Raffaele
   Picciocchi, Elisabetta
   Valenzano, Anna
   Cibelli, Giuseppe
   Ruberto, Valentina
   Moretto, Enrico
   Monda, Vincenzo
   Messina, Antonietta
   Dell'Orco, Silvia
   Di Sarno, Alfonso Davide
   Marsala, Gabriella
   Polito, Anna Nunzia
   Longobardi, Teresa
   Maldonato, Nelson Mauro
TI EXPLORING THE RELATIONSHIPS BETWEEN EXECUTIVE FUNCTIONS AND PERSONALITY
   DIMENSIONS IN THE LIGHT OF "EMBODIED COGNITION" THEORY: A STUDY ON A
   SAMPLE OF 130 SUBJECTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Executive Functions; personality; prefrontal cortical areas
ID HYPERTHERMIC REACTIONS; INHIBITOR DEVELOPMENT; CHILDHOOD MIGRAINE;
   CEREBRAL INJECTION; ITALIAN PATIENTS; STRESS; MUTATION; GENE;
   MICROSCOPY; SYMPTOMS
AB The Executive Functions and the dimensions of the personality seem to have numerous points of convergence both on the psychological and neurobiological sides. Current studies interpret this relationship as a linear concatenation that starts from a damage of the prefrontal cortical areas, produces a deficit of the executive functions and finally evolves towards the development of pathological character traits. In an "enacted cognition" perspective, the relationship between executive functions and personality should be interpreted according to a circular causality model that appears ecologically more realistic and adequate to empirical data.
   The present study evaluates executive functions and personality dimensions in a sample of 130 subjects using the Frontal Assessment Battery, the Temperament and Character Inventory, respectively.
   The results show that subjects with low empathic and emotional propensities, detected through 9 items of Temperament and Character Inventory, while not presenting any kind of disturbances, show Executive Functions that are not efficient or even inadequate.
   These data are not easily explained according to the classic linear model and seem to confirm the circular perspective proposed by the "embodied cognition" theory. However, an expansion of the sample is essential to obtain confirmation of the data that emerged.
C1 [Sperandeo, Raffaele; Moretto, Enrico; Di Sarno, Alfonso Davide; Longobardi, Teresa] SiPGI Postgrad Sch Integrated Gestalt Psychothera, DM 12-10-2007,Via V Veneto 240, I-80058 Naples, Italy.
   [Picciocchi, Elisabetta; Valenzano, Anna; Cibelli, Giuseppe; Ruberto, Valentina] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Picciocchi, Elisabetta] Casa Cura Villa Fiori Acerra, Naples, Italy.
   [Monda, Vincenzo; Messina, Antonietta] Univ Campania, Dept Expt Med, Sect Human Physiol, Naples, Italy.
   [Monda, Vincenzo; Messina, Antonietta] Univ Campania, Unit Dietet & Sport Med, Naples, Italy.
   [Dell'Orco, Silvia; Maldonato, Nelson Mauro] Univ Basilicata, Dept Human Sci, Potenza, Italy.
   [Marsala, Gabriella] Osped Riuniti Foggia, Azienda Osped Univ, Foggia, Italy.
   [Polito, Anna Nunzia] Osped Riuniti Foggia, Complex Struct Neuropsychiat Childhood Adolescenc, Foggia, Italy.
RP Sperandeo, R (corresponding author), SiPGI Postgrad Sch Integrated Gestalt Psychothera, DM 12-10-2007,Via V Veneto 240, I-80058 Naples, Italy.
EM raffaele.sperandeo@gmail.com
RI Messina, Antonietta/AHH-2383-2022; MESSINA, ANTONIETTA/K-9366-2016;
   Cibelli, Giuseppe/AAC-2635-2019; MALDONATO, NELSON MAURO/AAG-3791-2021;
   Moretto, Enrico/AFV-4935-2022
OI Messina, Antonietta/0000-0001-8343-432X; MALDONATO, NELSON
   MAURO/0000-0002-6401-2305; MORETTO, ENRICO/0000-0002-1726-7866;
   Sperandeo, Raffaele/0000-0002-8892-179X; CIBELLI,
   GIUSEPPE/0000-0002-5371-2584; Monda, Vincenzo/0000-0002-6083-5814
CR Albenzio M, 2013, J DAIRY SCI, V96, P2781, DOI 10.3168/jds.2012-6218
   Appollonio I, 2005, NEUROL SCI, V26, P108, DOI 10.1007/s10072-005-0443-4
   Bafunno V, 2012, HAEMOPHILIA, V18, P1003, DOI 10.1111/j.1365-2516.2012.02882.x
   Bafunno V, 2010, HAEMOPHILIA, V16, P469, DOI 10.1111/j.1365-2516.2009.02150.x
   Bafunno V, 2014, THROMB RES, V134, P1135, DOI 10.1016/j.thromres.2014.08.028
   Bafunno V, 2013, J ALLERGY CLIN IMMUN, V132, P748, DOI 10.1016/j.jaci.2013.04.006
   Bramanti V, 2016, J NEUROSCI RES, V94, P90, DOI 10.1002/jnr.23678
   Bukvic N, 2010, AM J MED GENET A, V152A, P1730, DOI 10.1002/ajmg.a.33437
   Burgess P., 2003, HDB CLIN NEUROPSYCHO, P302
   Canestraro M, 2010, CANCER GENET CYTOGEN, V199, P110, DOI 10.1016/j.cancergencyto.2010.02.010
   Cantone D, 2012, REV LATINOAM PSICOPA, V15, P42, DOI 10.1590/S1415-47142012000100004
   Caroprese M, 2012, SMALL RUMINANT RES, V102, P177, DOI 10.1016/j.smallrumres.2011.07.010
   Caroprese M, 2010, J DAIRY SCI, V93, P2395, DOI 10.3168/jds.2009-2604
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Caruana F., 2016, CERVELLO AZIONE INTR
   Cerretani D, 2011, PHARMACOL RES, V64, P517, DOI 10.1016/j.phrs.2011.08.002
   Chieffi S, 2017, FRONT PHYSIOL, P8
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Cloninger C.R., 1994, TEMPERAMENT CHARACTE
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2014, CHEMOSPHERE, V94, P62, DOI 10.1016/j.chemosphere.2013.09.013
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Fossati A, 2007, COMPR PSYCHIAT, V48, P380, DOI 10.1016/j.comppsych.2007.02.003
   Galimberti S, 2007, J CHEMOTHERAPY, V19, P315, DOI 10.1179/joc.2007.19.3.315
   Hart Susan, 2008, BRAIN ATTACHMENT PER
   JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026
   Kagan J., 2011, TRAMA VITA COME GENI
   Le Doux J, 2002, IL SE SINAPTICO
   Maldonato M., 2011, WORLD FUTURE, V67, P569, DOI [10.1080/02604027.2011.615591, DOI 10.1080/02604027.2011.615591]
   Maldonato M, 2018, SMART INNOV SYST TEC, V69, P369, DOI 10.1007/978-3-319-56904-8_35
   Maldonato M, 2016, INTEL SYST REF LIBR, V106, P13, DOI 10.1007/978-3-319-31053-4_3
   Maldonato NM, 2017, WORLD FUTURES, P1
   Mandolesi L., 2012, NEUROSCIENZE ATTIVIT
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Meares Russell., 2012, DISSOCIATION MODEL B
   Messina G, 2015, AFRICAN J PSYCHIAT S, V18
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BIOL MED, V7
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda M, 2008, PEPTIDES, V29, P120, DOI 10.1016/j.peptides.2007.10.016
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda V, 2017, FRONT PHYSIOL, P8
   Moscatelli F, 2015, BIOL MED, V7
   Moscatelli F, 2016, PLOS ONE, V11
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Pellegrino PL, 2007, AM J CARDIOL, V99, P1737, DOI 10.1016/j.amjcard.2007.01.056
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Petito A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156601
   Petrides M, 2005, PHILOS T ROY SOC B, V360, P781, DOI 10.1098/rstb.2005.1631
   Piacentino D, 2015, CURR NEUROPHARMACOL, V13, P101, DOI 10.2174/1570159X13666141210222725
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Pomara C, 2009, RADIOL MED, V114, P1367, DOI 10.1007/s11547-009-0435-1
   Pomara C, 2008, CLIN TOXICOL, V46, P322, DOI 10.1080/15563650701419011
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santacroce R, 2008, BLOOD COAGUL FIBRIN, V19, P197, DOI 10.1097/MBC.0b013e3282f234ab
   Santacroce R, 2009, GENET TEST MOL BIOMA, V13, P573, DOI 10.1089/gtmb.2009.0015
   Santillo A, 2009, INT DAIRY J, V19, P655, DOI 10.1016/j.idairyj.2009.06.011
   Santillo A, 2009, J DAIRY SCI, V92, P1330, DOI 10.3168/jds.2008-1598
   Sevi A, 2003, APPL ANIM BEHAV SCI, V83, P41, DOI 10.1016/S0168-1591(03)00088-1
   Sperandeo R, 2017, 27 IT WORKSH NEUR NE
   Sperandeo R, 2016, SMART INNOV SYST TEC, V54, P293, DOI 10.1007/978-3-319-33747-0_29
   Sperandeo R, 2017, INT CONF COGN INFO, P63, DOI 10.1109/CogInfoCom.2017.8268217
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   Sperandeo R, 2016, INT CONF COGN INFO, P43, DOI 10.1109/CogInfoCom.2016.7804522
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2005, INT J CARDIOL, V104, P152, DOI 10.1016/j.ijcard.2004.10.051
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2008, INT J LEGAL MED, V122, P173, DOI 10.1007/s00414-007-0208-0
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Turillazzi E, 2013, FORENSIC SCI INT, V231, P142, DOI 10.1016/j.forsciint.2013.04.006
   Turillazzi E, 2008, VIRCHOWS ARCH, V453, P209, DOI 10.1007/s00428-008-0632-7
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 91
TC 16
Z9 16
U1 1
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1271
EP 1279
DI 10.19193/0393-6384_2018_5_196
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700018
DA 2022-07-14
ER

PT J
AU Spinato, G
   Cazzato, G
   Ferlito, S
   Tirelli, G
   Rizzo, PB
   Da Mosto, MC
   Galletti, B
   Tonoli, G
   Politi, D
   Conti, A
   Campione, G
   Di Luca, M
   Gatto, A
   Piovesana, M
   Serra, A
AF Spinato, Giacomo
   Cazzato, Giorgio
   Ferlito, Salvatore
   Tirelli, Giancarlo
   Rizzo, Paolo Boscolo
   Da Mosto, Maria Cristina
   Galletti, Bruno
   Tonoli, Giovanni
   Politi, Doriano
   Conti, Angelo
   Campione, Gianluca
   Di Luca, Milena
   Gatto, Annalisa
   Piovesana, Marco
   Serra, Agostino
TI THERAPEUTICAL INNOVATIONS AND MEDICAL RESPONSIBILITY: WHAT'S NEW IN
   OTO-LARYNGOLOGY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE law Gelli Bianco; legally valid consent; therapeutical innovation;
   molecular biology; new technologies; professional responsibility
ID VOICE REHABILITATION; HEAD
AB On one hand the incessant and constant technological and instrumental progress in the medical field has allowed to increase knowledge and to reach new objectives. On the other hand, however, it has also raised the risk linked to professional responsibility, regarding informed consent and law 24/2017 of the Italian Republic, better known as Gelli Bianco. In this work an analysis of relevant literature will be presented, followed by a study on the role of new devices on responsibility profiles in otolaryngology. According to the analysis of the Italian law and considering the weaknesses of the above mentioned guidelines, pending legal administrative clarifications, we believe an operational protocol can be proposed in case of application of therapeutical innovations, especially about experimental introductions. Consequently, in our opinion, the risk of incrimination persists in case of use of innovative procedures in the absence of a formal shared opinion expressed in guidelines or in good practices, which still need a satisfactory definition.
C1 [Spinato, Giacomo; Tonoli, Giovanni] Rovigo Prov Hosp, Ear Nose & Throat Dept, I-45100 Rovigo, Italy.
   [Cazzato, Giorgio; Politi, Doriano] Mestre Hosp, Prov Ear Nose & Throat Dept Venice, I-30174 Venice, Italy.
   [Ferlito, Salvatore; Conti, Angelo; Campione, Gianluca; Di Luca, Milena; Serra, Agostino] Univ Catania, Ear Nose & Throat Dept, I-95125 Catania, Italy.
   [Tirelli, Giancarlo; Gatto, Annalisa; Piovesana, Marco] Univ Trieste, Cattinara Hosp, Ear Nose & Throat Dept, I-34149 Trieste, Italy.
   [Rizzo, Paolo Boscolo; Da Mosto, Maria Cristina] Univ Padua, Treviso Prov Hosp, Dept Neurosci, Ear Nose & Throat Clin, I-35122 Padua, Italy.
   [Rizzo, Paolo Boscolo; Da Mosto, Maria Cristina] Univ Padua, Treviso Prov Hosp, Reg Ctr Head & Neck Canc, I-35122 Padua, Italy.
   [Galletti, Bruno] Univ Messina, Dept Otolaryngol, Messina, Italy.
RP Spinato, G (corresponding author), Rovigo Prov Hosp, Ear Nose & Throat Dept, I-45100 Rovigo, Italy.
EM giacomo.spinato@aulss5.veneto.it
RI salvatore, ferlito/AAB-5788-2021; tirelli, giancarlo/G-3118-2012
OI salvatore, ferlito/0000-0001-7136-9698; tirelli,
   giancarlo/0000-0002-7871-2011; Cocuzza, Salvatore/0000-0002-6135-0958;
   BOSCOLO RIZZO, PAOLO/0000-0002-4635-7959; Spinato,
   Giacomo/0000-0001-5295-5077
CR [Anonymous], 1997, EUR TREAT SER, V164
   Ausoni S, 2016, CANCER METAST REV, V35, P413, DOI 10.1007/s10555-016-9625-1
   Barbash GI, 2010, NEW ENGL J MED, V363, P701, DOI 10.1056/NEJMp1006602
   Boscolo-Rizzo P, 2015, EUR ARCH OTO-RHINO-L, V272, P3491, DOI 10.1007/s00405-014-3369-8
   Boscolo-Rizzo P, 2015, ORAL ONCOL, V51, P500, DOI 10.1016/j.oraloncology.2015.02.100
   Caltabiano R, 2012, EUR REV MED PHARMACO, V16, P1891
   Caltabiano R, 2008, PATHOLOGICA, V100, P185
   Cherry J, 2000, J LARYNGOL OTOL, V114, P737
   Cocuzza S, 2014, J VOICE, V28, P245, DOI 10.1016/j.jvoice.2013.08.008
   Cocuzza S, 2013, EUR ARCH OTO-RHINO-L, V270, P1879, DOI 10.1007/s00405-013-2430-3
   Da Mosto MC, 2013, ANN SURG ONCOL, V20, P250, DOI 10.1245/s10434-012-2520-2
   Dawes PJD, 1999, CLIN OTOLARYNGOL, V24, P198, DOI 10.1046/j.1365-2273.1999.00244.x
   De Nicola E, 1947, CONSTITUTION ITALIAN
   Ferri E, 2013, INT J SURG ONCOL, V2013, DOI 10.1155/2013/369345
   Gallina S, 2015, ACTA OTORHINOLARYNGO, V35, P15
   Germonpre P, 2016, B-ENT, V12, P87
   Giacomarra V, 2013, EUR ARCH OTO-RHINO-L, V270, P2975, DOI 10.1007/s00405-013-2625-7
   Institute of Medicine, 2011, CLIN PRACT GUID WE C
   Jouanneau E., 2011, ADV ENDOSCOPIC SURG
   Karpishchenko S. A., 2016, Vestnik Otorinolaringologii, P14, DOI 10.17116/otorino201681414-18
   Mallardi V, 2005, Acta Otorhinolaryngol Ital, V25, P312
   Manna A., 2005, CARDIOLOGIA AMBULATO, V3, P152
   McCloy R, 2001, BRIT MED J, V323, P912, DOI 10.1136/bmj.323.7318.912
   Meisel A, 1996, ARCH INTERN MED, V156, P2521, DOI 10.1001/archinte.156.22.2521
   Mercante G, 2013, ACTA OTORHINOLARYNGO, V33, P230
   Montevecchi F, 2017, INT J MED ROBOT COMP, V13, DOI 10.1002/rcs.1763
   Mosher HP, 1913, LARYNGOSCOPE, V23, P881
   National Federations of Medical Doctors, 2014, COD MED ETH
   Petrie K J, 2002, BMJ, V324
   Serra A, 2017, ACTA OTORHINOLARYNGO, V37, P175, DOI 10.14639/0392-100X-1291
   Serra A, 2015, ACTA OTORHINOLARYNGO, V35, P412, DOI 10.14639/0392-100X-680
   Serra A, 2017, ONCOTARGET, V8, P38962, DOI 10.18632/oncotarget.17161
   Serra A, 2017, INT J PEDIATR OTORHI, V97, P245, DOI 10.1016/j.ijporl.2017.04.021
   Serra A, 2016, PROG NUTR, V18, P334
   Serra A, 2016, EUR ARCH OTO-RHINO-L, V273, P4359, DOI 10.1007/s00405-016-4177-0
   Sokol AJ, 2002, J LEGAL MED, V23, P449, DOI 10.1080/01947640290050300
   Tahir A., 2015, INT J OTOLARYNGOLOGY, V4, P137
   Thiagarajan Balasubramanian, 2014, OTOLARYNGOLOGY ONLIN, V4
   Tirelli G., 2013, AM J RHINOLOGY ALLER
   Umani Ronchi G, 2004, CONSENT PROFESSIONAL
NR 40
TC 7
Z9 7
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 307
EP 312
DI 10.19193/0393-6384_2018_2_49
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400003
DA 2022-07-14
ER

PT J
AU Stolic, RV
   Trajkovic, GZ
   Pavlovic, V
   Matijasevic, IR
   Jaksic, MD
   Mirkovic, ZM
   Smilic, L
   Milinic, SB
   Odalovic, D
   Vasic, A
   Stolic, BZ
AF Stolic, Radojica V.
   Trajkovic, Goran Z.
   Pavlovic, Vedrana
   Matijasevic, Ivana R.
   Jaksic, Masa D.
   Mirkovic, Zlatica M.
   Smilic, Ljiljana
   Milinic, Srbislava B.
   Odalovic, Dragica
   Vasic, Aleksandar
   Stolic, Boban Z.
TI EFFECTS OF STRENGTH TRAINING PROGRAM ON MUSCLE MASS IN PATIENTS ON
   HEMODIALYSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Physical exercise; Intensity of exercise; Muscle mass; Hemodialysis
ID STAGE RENAL-DISEASE; RANDOMIZED CONTROLLED-TRIAL; EXERCISE; DIALYSIS;
   KIDNEY; ESRD; REHABILITATION; EFFICACY; REMOVAL
AB Background: Physical rehabilitation is an important segment in the treatment of hemodialysis patients as they often have numerous comorbidities, functional constraints and severe disabilities resulting from physical inactivity.
   Aim: To determine the effect of strength training program on muscle mass in patients on hemodialysis.
   Methodology: The study runs organized in the Center for Hemodialysis, Kosovska Mitrovica, Serbia for the duration of 8 weeks. It involved 25 patients, 18 (72%) men and 7 (28%) women, of average age 52.9 +/- 14 years, who had received chronic hemodialysis for 3 x 3-4 hours, for at least 3 months using commercially available dialysers. During the first two hemodialyses, twice a week for 15-20 minutes, exercises were performed with a load to increase muscle mass of the upper and lower extremities together with isometric muscle contractions to strengthen the quadriceps, as well as a lateral flexion of the spinal column. Measurements were made before and after exercise. Routine laboratory analyses, oxygen saturation, demographic, anthropometric and clinical characteristics of the subjects were also evaluated.
   Results: After exercise oxygen saturation (p = 0.04) and venous pressure (p = 0.009) were significantly lower than preexercise values. Muscle strength of the fist (p = 0.001), the upper arm (p = 0.005) and forearms (p <0.001) also differed significantly before and after exercise. After exercise lower extremity muscles were significantly stronger, both in relation to the left and right muscles of the shin and thighs. Left side (p = 0.002) and right-side = (p = 0.017) spinal column flexion was significantly higher after exercise.
   Conclusion: The study confirmed the positive effect of strength training program on the size of the exercising muscles, lateral flexion of the spinal column and venous pressure.
C1 [Stolic, Radojica V.] Univ Kragujevac, Fac Med Sci, Dept Internal Med, Kragujevac, Serbia.
   [Trajkovic, Goran Z.; Pavlovic, Vedrana] Univ Belgrade, Inst Med Stat & Informat, Fac Med, Belgrade, Serbia.
   [Matijasevic, Ivana R.; Jaksic, Masa D.; Mirkovic, Zlatica M.; Smilic, Ljiljana; Milinic, Srbislava B.; Odalovic, Dragica; Vasic, Aleksandar; Stolic, Boban Z.] Univ Pristina Kosovska Mitrovica, Fac Med, Pristina K Mitrovica, Serbia.
RP Stolic, BZ (corresponding author), Fac Med Sci, Svetozar Markovic 69, Kragujevac 34000, Serbia.
EM radojica.stolic@med.pr.ac.rs
RI Stolic, Radojica/AAH-7049-2021
OI Stolic, Radojica/0000-0002-6215-9258
FU Ministry of Education and Science of Serbia [III41010]
FX The authors disclose receipt of the following financial support for the
   research, authorship, and/or publication of this article. This research
   was partly supported by the Ministry of Education and Science of Serbia,
   Grant III41010.
CR Afshar R, 2010, Indian J Nephrol, V20, P185, DOI 10.4103/0971-4065.73442
   Anding K, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008709
   Aucella F, 2014, KIDNEY BLOOD PRESS R, V39, P97, DOI 10.1159/000355783
   Campistol JM, 2002, KIDNEY INT, V62, P1901, DOI 10.1046/j.1523-1755.2002.00614.x
   Capitanini A, 2014, KIDNEY BLOOD PRESS R, V39, P129, DOI 10.1159/000355787
   Cappy C S, 1999, J Ren Nutr, V9, P63
   Cheema B, 2007, AM J KIDNEY DIS, V50, P574, DOI 10.1053/j.ajkd.2007.07.005
   Daugirdas JT, 2010, KIDNEY INT, V77, P637, DOI 10.1038/ki.2009.525
   Daul A E, 2004, Clin Nephrol, V61 Suppl 1, pS26
   DeBisschop E, 1997, KIDNEY INT, V51, P1182, DOI 10.1038/ki.1997.161
   Deligiannis A, 1999, INT J CARDIOL, V70, P253, DOI 10.1016/S0167-5273(99)00090-X
   DePaul V, 2002, AM J KIDNEY DIS, V40, P1219, DOI 10.1053/ajkd.2002.36887
   Intiso D, 2014, KIDNEY BLOOD PRESS R, V39, P180, DOI 10.1159/000355795
   Johansen KL, 2007, J AM SOC NEPHROL, V18, P1845, DOI 10.1681/ASN.2007010009
   KEMPENEERS G, 1990, AM J KIDNEY DIS, V16, P57, DOI 10.1016/S0272-6386(12)80786-4
   Kouidi EJ, 2001, SPORTS MED, V31, P651, DOI 10.2165/00007256-200131090-00002
   Kutner N, 2008, CLIN J AM SOC NEPHRO, V3, P111, DOI 10.2215/CJN.02990707
   Kutner NG, 2012, INT ENCY REHABILITAT
   LEVY NB, 1990, INT J PSYCHIAT MED, V20, P325, DOI 10.2190/T5TH-9UJY-A3MW-M1PR
   Mahrova A, PROF HIROMICHI SUZUK, DOI [10.5772/53058, DOI 10.5772/53058]
   Miller BW, 2002, AM J KIDNEY DIS, V39, P828, DOI 10.1053/ajkd.2002.32004
   Mitrou GI, 2013, SEMIN DIALYSIS, V26, P604, DOI 10.1111/sdi.12112
   Mohseni Raheleh, 2013, Oman Med J, V28, P345, DOI 10.5001/omj.2013.99
   Paoli A, 2012, AM J CARDIOL, V109, P305, DOI 10.1016/j.amjcard.2011.10.011
   Parsons TL, 2006, ARCH PHYS MED REHAB, V87, P680, DOI 10.1016/j.apmr.2005.12.044
   Parsons TL, 2004, CLIN NEPHROL, V61, P261
   Ridley J, 1999, CANNT J, V9, P20
   Silva SF, 2013, J BRAS NEFROL, V35, DOI [10.5935/0101-2800.20130028, DOI 10.5935/0101-2800.20130028.]
   Vaithilingam I, 2004, AM J KIDNEY DIS, V43, P85, DOI 10.1053/j.ajkd.2003.09.016
   Yurdalan US, 2013, PHYSIOTHERAPY PATIEN
NR 30
TC 0
Z9 0
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1551
EP 1556
DI 10.19193/0393-6384_2018_3s_239
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400015
DA 2022-07-14
ER

PT J
AU Su, L
   Li, YH
   Shi, HY
   Huo, R
   Liu, ML
   Li, ZG
   Li, Q
   Yu, Q
   Hu, L
AF Su, Lei
   Li, Yanhong
   Shi, Hongyun
   Huo, Ran
   Liu, Miaoling
   Li, Zhigang
   Li, Qian
   Yu, Qian
   Hu, Ling
TI PET/CT FUSION TECHNOLOGY IN LYMPH NODE STAGING AND RADIOTHERAPY
   ARRANGEMENT FOR PATIENTS OF NSCLC
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE radiotherapy; non-small-cell lung; carcinoma; positron-emission
   tomography; computed tomography
AB Background: Computed tomography (CT)/positron emission tomography (PET) may decide on nodal staging so as to improve radiotherapy arrangement for patients of non-small cell lung cancer (NSCLC). However, if PET/CT can reduce the variability of interobserver in the target amount delineation remains to be answered. The present study assesses how accurate PET/CT is in identification of nodal metastasis as well as nodal staging and its impact on the radiotherapy amount delineation to patients of NSCLC.
   Methods: In total, 27 patients with NSCLC were recruited and scanned with PET/CT. Sets of PETS as well as CT data could be delivered to the treatment planning system (TPS), followed by the fusing of CT and PET images using TPS. Two radiation oncologists on CT and PET/CT images were employed to contour gross tumor volume (GTV). The contours were outlined together with two radiation oncologists, thus producing a final consensus.
   Results: Tumor-node-metastasis categories changed on 8/27 patients (30%) on the basis of PET/CT. Radiation on PET and CT integration images led to changes in treatment arrangements on 12/20 patients (60%). In addition, PET/CT produced significant accuracy for nodal staging than CT. The negative and positive predictive values, sensitivity, specificity, and accuracy of PET/CT to detect nodal metastasis were 74.3%, 89.3%, 51.5%, 95.8%, and 87.3% and the corresponding CT data were respectively 45.5%, 87.1%, 45.5%, 87.1%, and 79.2%. PET/CT confers significantly higher specificity, positive predictive value as well as accuracy of CT in detecting nodal metastasis.
   Conclusions: PET/CT fusion images may influence treatment arrangement. PET/CT is much more precise than CT in nodal staging, and is more detailed and precise than CT in finding nodal metastasis but is less sensitive with a higher false-negative rate.
C1 [Su, Lei; Li, Yanhong; Shi, Hongyun; Huo, Ran; Liu, Miaoling; Li, Zhigang; Li, Qian] Hebei Univ, Affiliated Hosp, Dept Radiol, Baoding 071000, Peoples R China.
   [Yu, Qian] Hebei Univ, Affiliated Hosp, VIP Ward, Baoding 071000, Peoples R China.
   [Hu, Ling] Hebei Univ, Affiliated Hosp, Dept Oncol, Baoding 071000, Peoples R China.
RP Hu, L (corresponding author), Hebei Univ, Affiliated Hosp, Dept Oncol, Baoding 071000, Peoples R China.
EM 57461548@qq.com
CR De Ruysscher D, 2005, INT J RADIAT ONCOL, V62, P988, DOI 10.1016/j.ijrobp.2004.12.019
   Nestle Ursula, 2002, Mol Imaging Biol, V4, P257, DOI 10.1016/S1536-1632(02)00005-7
NR 2
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 479
EP 484
DI 10.19193/0393-6384_2018_2_77
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400031
DA 2022-07-14
ER

PT J
AU Su, MH
   Yang, DD
   Zhang, SL
AF Su Meihua
   Yang Duoduo
   Zhang Shuilian
TI PREVENTIVE EFFECT OF CRANBERRY CONSUMPTION AGAINST DNA DAMAGE AFTER
   EXHAUSTIVE EXERCISE IN ATHLETE MEN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Cranberry; DNA damage; single cell gel electrophoresis (SCGE);
   exhaustive exercise; Lipid oxidation
ID PLASMA ANTIOXIDANT CAPACITY; ESCHERICHIA-COLI; COMET ASSAY; METABOLIC
   SYNDROME; LIPID OXIDATION; STRAND BREAKS; MUSCLE; JUICE; REPAIR;
   FLAVONOIDS
AB This study was performed to determine Effect of short-term cranberry consumption on DNA damage after exhaustive exercise in athlete men. Twenty male athletes in a randomized and double-blind design were allocated in two equal supplement and placebo groups (take cranberry soft chews 500mg for 14 days). After supplementation, all participants were participated in bruce test. The blood samples were taken in three phases (before and after the supplementation and after the exercise). This experiment used single cell gel electrophoresis including modified comet assay (with FPG and ENDO III enzymes) to detect the oxidative DNA damage induced by exhaustive exercise in athlete blood cells, and the product 8-hydroxy-2-deoxyguanosine (8-OHdG) of oxdation of DNA, also, the level of MDA, BUN and CK in athlete plasma were observed. The normal data (Mean +/- SD) were analyzed by repeated measure ANOVA, Tukey and independent t-test (P <= 0.05). The results showed that a 14-day cranberry consumption hadn't significant effect on the damage index of modified comet assay (with FPG and ENDO III enzymes) and the level of 8-OHdG and also the level of MDA, BUN and CK in plasma at rest status (P>0.05). However, exercise-induced decrease of 8-OHdG and the value of comet assay and the plasma level of MDA, BUN and CK in the cranberry group were significantly more in comparison with those in the placebo group (P<0.01). Result of the study indicates that 14-day cranberry consumption can reduce the production of lipid oxidation and oxidative DNA damage during exhaustive exercise.
C1 [Su Meihua; Zhang Shuilian] Minnan Normal Univ, Sch Phys Educ, Zhangzhou 363000, Fujian, Peoples R China.
   [Yang Duoduo] Guizhou Univ Engn Sci, Coll PE & Hlth Sci, Guiyang 551700, Guizhou, Peoples R China.
RP Su, MH (corresponding author), Minnan Normal Univ, Sch Phys Educ, Zhangzhou 363000, Fujian, Peoples R China.
EM sumh1234@163.com
FU Educational Commission Fujian Province China [2005-B11504]
FX This work was supported by Educational Commission Fujian Province China
   of Grant No. 2005-B11504.
CR Asagoshi K, 2000, BIOCHEMISTRY-US, V39, P11389, DOI 10.1021/bi000422l
   Asami S, 1998, BIOCHEM BIOPH RES CO, V243, P678, DOI 10.1006/bbrc.1998.8166
   Basu A, 2012, J AGR FOOD CHEM, V60, P5687, DOI 10.1021/jf203488k
   Basu A, 2011, NUTR RES, V31, P190, DOI 10.1016/j.nutres.2011.02.003
   Best BP, 2009, REJUV RES, V12, P199, DOI 10.1089/rej.2009.0847
   Boffi FM, 2007, BAG, J. basic appl. genet., V18, P1
   CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673
   Child RB, 1998, MED SCI SPORT EXER, V30, P1603, DOI 10.1097/00005768-199811000-00008
   Collins A, 2002, MUTAGENESIS, V17, P489, DOI 10.1093/mutage/17.6.489
   COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6
   Demirbag Recep, 2006, Anadolu Kardiyol Derg, V6, P135
   Dusinska M, 2008, MUTAGENESIS, V23, P191, DOI 10.1093/mutage/gen007
   Farhadi H., 2013, EUR J EXP BIOL, V3, P455
   Fuhrman B, 2001, CURR OPIN LIPIDOL, V12, P41, DOI 10.1097/00041433-200102000-00008
   Gandhi G, 2009, INT J HUM GENET, V9, P69, DOI 10.1080/09723757.2009.11886061
   Godard T, 1999, MUTAT RES-GEN TOX EN, V444, P103, DOI 10.1016/S1383-5718(99)00100-X
   Gupta P, 2016, FOOD FUNCT, V7, P2655, DOI [10.1039/c6fo00109b, 10.1039/C6FO00109B]
   Ikeda M, 2008, INT J SPORTS MED, V29, P27
   Kathirvel P, 2009, FOOD CHEM, V115, P924, DOI 10.1016/j.foodchem.2009.01.007
   Kowalska K, 2016, J FUNCT FOODS, V20, P171, DOI 10.1016/j.jff.2015.11.001
   Kowalska K, 2015, FOOD CHEM, V185, P383, DOI 10.1016/j.foodchem.2015.03.152
   LINDSAY WA, 1980, AM J VET RES, V41, P1919
   Mastaloudis A, 2004, FREE RADICAL BIO MED, V36, P966, DOI 10.1016/j.freeradbiomed.2004.01.012
   Moller P, 2001, FASEB J, V15, P1181, DOI 10.1096/fj.00-0703com
   Nadin SB, 2001, J HISTOCHEM CYTOCHEM, V49, P1183, DOI 10.1177/002215540104900912
   Powers SK, 2008, PHYSIOL REV, V88, P1243, DOI 10.1152/physrev.00031.2007
   Ruel G, 2005, METABOLISM, V54, P856, DOI 10.1016/j.metabol.2005.01.031
   Selman C, 2002, ARCH BIOCHEM BIOPHYS, V401, P255, DOI 10.1016/S0003-9861(02)00050-4
   Stobnicka A., 2010, Postepy Fitoterapii, V11, P170
   Stuart JA, 2004, FASEB J, V18, P595, DOI 10.1096/fj.03-0890fje
   Sun J, 2002, J AGR FOOD CHEM, V50, P7449, DOI 10.1021/jf0207530
   Tomic S, 2012, ARCH MED SCI, V8, P886, DOI 10.5114/aoms.2012.31620
   Tsai K, 2001, FREE RADICAL BIO MED, V31, P1465, DOI 10.1016/S0891-5849(01)00729-8
   Vasileiou I, 2013, NUTR RES, V33, P595, DOI 10.1016/j.nutres.2013.05.018
   Vattem DA, 2005, PROCESS BIOCHEM, V40, P2225, DOI 10.1016/j.procbio.2004.09.001
   Wang S, 2011, FOOD RES INT, V44, P14, DOI 10.1016/j.foodres.2010.09.028
   Zhang K, 2004, J AGR FOOD CHEM, V52, P222, DOI 10.1021/jf035073r
NR 37
TC 2
Z9 2
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 499
EP 506
DI 10.19193/0393-6384_2018_2_81
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400034
DA 2022-07-14
ER

PT J
AU Sun, LP
   Wang, SX
   Dong, Z
   Zhang, XX
AF Sun, Liping
   Wang, Shixuan
   Dong, Zheng
   Zhang, Xinzhou
TI THE MTOR PATHWAY IN KIDNEY INJURY AND POLYCYSTIC KIDNEY DISEASE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE mTOR; AKI; PKD; regulator
ID CELL-CYCLE PROGRESSION; MOLECULAR-MECHANISMS; SIGNAL INTEGRATION;
   MAMMALIAN PROTEIN; T-CELLS; RAPAMYCIN; GROWTH; COMPLEX; AUTOPHAGY;
   TARGET
AB Mechanistic target of rapamycin (mTOR) protein is a conserved serine/threonine kinase that is essential in many signaling pathways. It forms, with different protein components, two distinct protein complexes, mTOR complex 1 and 2. mTOR signaling has been studied under physiological and pathological conditions of the kidney, such as kidney injury/repair and polycystic kidney disease (PKD). mTOR inhibition with rapamycin has been reported to affect the disease progress and be beneficial in animal models. Here, we briefly overview recent advances of mTOR signaling pathway in studying kidney injury/repair and PKD, and try to elucidate further studies.
C1 [Sun, Liping; Zhang, Xinzhou] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Nephrol, Shenzhen 518020, Peoples R China.
   [Wang, Shixuan; Dong, Zheng] Augusta Univ, Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA.
   [Wang, Shixuan; Dong, Zheng] Charlie Norwood VA Med Ctr, Augusta, GA 30912 USA.
RP Zhang, XX (corresponding author), Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Div Nephrol, Shenzhen 518020, Peoples R China.
EM slp08@126.com
OI Wang, Shixuan/0000-0002-3088-0745
FU Science and Technology Planning Project of Guangdong Province, China
   [2014A020212472]; Science and Technology Planning Project of shenzhen,
   China [JCYJ20150403101146288]; Health Bureau Health Scientific Research
   Projects of shenzhen, China [201501003]
FX The study was supported in part by grants from Science and Technology
   Planning Project of Guangdong Province, China (2014A020212472), Science
   and Technology Planning Project of shenzhen, China
   (JCYJ20150403101146288), Health Bureau Health Scientific Research
   Projects of shenzhen, China (201501003).
CR Agarwal S, 2015, J BIOL CHEM, V290, P27473, DOI 10.1074/jbc.M115.665133
   Boletta A, 2003, TRENDS CELL BIOL, V13, P484, DOI 10.1016/S0962-8924(03)00169-7
   Bond P, 2017, NUTR METAB, V14, DOI 10.1186/s12986-017-0166-6
   Bonegio R, 2002, CURR OPIN NEPHROL HY, V11, P301, DOI 10.1097/00041552-200205000-00006
   Bonventre JV., 2003, J AM SOC NEPHROLOGY
   BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328
   BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0
   CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012
   Cam M, 2014, J BIOL CHEM, V289, P4083, DOI 10.1074/jbc.M113.530303
   Carson RP, 2013, HUM MOL GENET, V22, P140, DOI 10.1093/hmg/dds414
   Chen GC, 2016, J IMMUNOL, V197, P3917, DOI 10.4049/jimmunol.1601251
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200
   Demetriades C, 2014, CELL, V156, P786, DOI 10.1016/j.cell.2014.01.024
   Dibble CC, 2013, NAT CELL BIOL, V15, P555, DOI 10.1038/ncb2763
   Fantus D, 2016, NAT REV NEPHROL, V12, P587, DOI 10.1038/nrneph.2016.108
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802
   Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004
   Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003
   Grantham JJ, 2011, NAT REV NEPHROL, V7, P556, DOI 10.1038/nrneph.2011.109
   Hasty P, 2013, CELL CYCLE, V12, P20, DOI 10.4161/cc.22912
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hsu CY, 2012, J AM SOC NEPHROL, V23, P967, DOI 10.1681/ASN.2012030222
   Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217
   Huang KZ, 2014, SEMIN CELL DEV BIOL, V36, P79, DOI 10.1016/j.semcdb.2014.09.011
   Huber TB, 2012, AUTOPHAGY, V8, P1009, DOI 10.4161/auto.19821
   Huber TB, 2011, KIDNEY INT, V79, P502, DOI 10.1038/ki.2010.457
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50
   Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363
   Kinsey GR, 2014, CURR OPIN NEPHROL HY, V23, P9, DOI 10.1097/01.mnh.0000436695.29173.de
   Kuehn EW, 2002, AM J PHYSIOL-RENAL, V283, pF1326, DOI 10.1152/ajprenal.00166.2002
   KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F
   Kurbegovic A, 2016, AM J PHYSIOL-RENAL, V311, pF740, DOI 10.1152/ajprenal.00167.2016
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058
   Leonhard WN, 2015, J AM SOC NEPHROL, V26, P1322, DOI 10.1681/ASN.2013080864
   Li JZ, 2014, KIDNEY INT, V86, P86, DOI 10.1038/ki.2013.559
   Lieberthal W, 2008, KIDNEY INT, V74, P555, DOI 10.1038/ki.2008.325
   Lieberthal W, 2009, J AM SOC NEPHROL, V20, P2493, DOI 10.1681/ASN.2008111186
   Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6
   Low SH, 2006, DEV CELL, V10, P57, DOI 10.1016/j.devcel.2005.12.005
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672
   Mazhab-Jafari MT, 2012, STRUCTURE, V20, P1528, DOI 10.1016/j.str.2012.06.013
   Mori H, 2009, BIOCHEM BIOPH RES CO, V384, P471, DOI 10.1016/j.bbrc.2009.04.136
   Pampliega O, 2016, CURR OPIN CELL BIOL, V39, P1, DOI 10.1016/j.ceb.2016.01.008
   Prasad S, 2009, AM J PATHOL, V175, P1493, DOI 10.2353/ajpath.2009.090227
   Rai P, 2013, AM J PHYSIOL-RENAL, V305, pF343, DOI 10.1152/ajprenal.00135.2013
   Ricoult SJH, 2013, EMBO REP, V14, P242, DOI 10.1038/embor.2013.5
   Perez JCR, 2011, NEFROLOGIA, V31, P251, DOI 10.3265/Nefrologia.pre2011.Apr.10947
   SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sas KM, 2015, AM J PHYSIOL-RENAL, V309, pF79, DOI 10.1152/ajprenal.00652.2014
   Satake A, 2008, KIDNEY INT, V73, P308, DOI 10.1038/sj.ki.5002690
   Schmitt R, 2012, AM J TRANSPLANT, V12, P2892, DOI 10.1111/j.1600-6143.2012.04214.x
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Sharif-Naeini R, 2009, CELL, V139, P587, DOI 10.1016/j.cell.2009.08.045
   Sharma N, 2013, J AM SOC NEPHROL, V24, P456, DOI 10.1681/ASN.2012020154
   Sherpa Rinzhin T, 2016, Int Educ Res J, V2, P91
   Showkat Mehvish, 2014, Mol Biol Int, V2014, P686984, DOI 10.1155/2014/686984
   Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995
   Suhara T, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0865-4
   Takacs Z, 2016, NAT CELL BIOL, V18, P591, DOI 10.1038/ncb3366
   Takakura A, 2009, HUM MOL GENET, V18, P2523, DOI 10.1093/hmg/ddp147
   Tanner GA, 2002, KIDNEY INT, V62, P1947, DOI 10.1046/j.1523-1755.2002.00689.x
   Torras J, 2009, NEPHROL DIAL TRANSPL, V24, P3632, DOI 10.1093/ndt/gfp367
   Torres VE, 2010, CLIN J AM SOC NEPHRO, V5, P1312, DOI 10.2215/CJN.01360210
   Ueda N, 2000, AM J MED, V108, P403, DOI 10.1016/S0002-9343(00)00311-9
   Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122
   Yang L, 2015, J CLIN INVEST, V125, P1620, DOI 10.1172/JCI75417
   Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64
   Yin WQ, 2016, J AM SOC NEPHROL, V27, P1943, DOI 10.1681/ASN.2015050500
   Yin YC, 2016, CELL RES, V26, P46, DOI 10.1038/cr.2015.133
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
   Zuk A, 2016, ANNU REV MED, V67, P293, DOI 10.1146/annurev-med-050214-013407
NR 80
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 739
EP 747
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000019
DA 2022-07-14
ER

PT J
AU Tafuri, D
   Di Palma, D
   Molisso, V
AF Tafuri, Domenico
   Di Palma, Davide
   Molisso, Vittoria
TI DOPING: EDUCATION AND PREVENTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Doping; Addiction; Education; Knowledge; Prevention
AB Education and prevention represent, in the complex world of doping, a fundamental aspect for it allow us identifying its characteristics and, at the same time, acting on the origins of this phenomenon, by working on aspects that are facilitators, co-responsible and involved in it. Doping refers to the use of substances or drugs that an athlete takes to improve his performance. Being it a phenomenon of great complexity, it requires a deep and exhaustive analysis, which cannot ignore the convergence and confluence of different aspects that, on the one hand, show and explain the reason why this phenomenon exists and, on the other, are elements that support the education and prevention of this large and extended field.
C1 [Tafuri, Domenico; Di Palma, Davide; Molisso, Vittoria] Parthenope Univ, Via Medina 40, Naples, Italy.
RP Di Palma, D (corresponding author), Parthenope Univ Naples, Naples, Italy.
EM davide.dipalma@uniparthenope.it
OI Di Palma, Davide/0000-0001-8224-5797
CR Andolfi M, 2009, MANUALE PSICOLOGIA R
   Ascione A, 2018, ACTA MEDICA MEDITERR, V34, P1261, DOI 10.19193/0393-6384_2018_5_194
   Aurilio R, 2015, TERAPIA SISTEMICO RE
   Bateson G., 1984, MENTE E NATURA
   Bateson Gregory, 1976, VERSO UNECOLOGIA MEN
   Belfiore P, 2018, ACTA MEDICA MEDITERR, V34, P1257, DOI 10.19193/0393-6384_2018_5_193
   Cisotto L., 2015, PSICOPEDAGOGIA DIDAT
   Di Palma D, 2018, ACTA MEDICA MEDITERR, V34, P1253, DOI 10.19193/0393-6384_2018_5_192
   LEVY P, 1996, INTELLIGENZA COLLETT
   Levy P., 1990, TECNOLOGIE INTELLIGE
   Malagoli Togliatti M, 2014, DALLINDIVIDUO SISTEM
   Murgia M, 2014, MIGLIORARE PRESTAZIO
   Orio F, 2016, MINERVA ENDOCRINOL, V41, P509
   Palma D. di, 2018, Journal of Physical Education and Sport, V18, P473
   Palma D. di, 2017, Sport Science, V10, P36
   Palma D. di, 2017, Sport Science, V10, P18
   Palma D. di, 2016, Journal of Physical Education and Sport, V16, P785
   Palma D. di, 2016, Sport Science, V9, P24
   Petralia MC, 2018, ACTA MEDICA MEDITERR, V34, P107, DOI 10.19193/0393-6384_2018_1_18
   Pontecorvo C., 1995, CONTESTI SOCIALI APP, P155
   Prokop L, 1970, J Sports Med Phys Fitness, V10, P45
   Raiola G, 2017, SPORT SCI, V10, P51
   Raiola G., 2016, SPORT SCI, V9, P49
   Reale G, 2001, IL PENSIERO ANTICO, P83
   Tafuri D., 2017, SPORT SCI, V10, P70
NR 25
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1499
EP 1502
DI 10.19193/0393-6384_2018_3s_228
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400005
DA 2022-07-14
ER

PT J
AU Taghvaei, T
   Akha, O
   Mouodi, M
   Fakheri, HT
   Kashi, Z
   Maleki, I
   Mohammadpour, R
AF Taghvaei, Tarang
   Akha, Ozra
   Mouodi, Marjan
   Fakheri, Hafez Tirgar
   Kashi, Zahra
   Maleki, Iradj
   Mohammadpour, Rezaali
TI EFFECTS OF VITAMIN D SUPPLEMENTATION ON PATIENTS WITH NON-ALCOHOLIC
   FATTY LIVER DISEASE (NAFLD)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Fibroscan; Liver fibrosis; Liver steatosis; NAFLD; Vitamin D; CAP score
ID INSULIN-RESISTANCE; GENERAL-POPULATION; METABOLIC SYNDROME;
   HYPOVITAMINOSIS-D; RISK-FACTORS; PREVALENCE; FIBROSIS
AB Background and Objective: Previous evidences have suggested a potentially causal relationship between vitamin D deficiency (VDD) and nonalcoholic fatty liver disease (NAFLD). Considering the effects of vitamin D, it is possible that vitamin D supplement in NAFLD patients with VDD may have significant biochemical and histological benefits.
   Materials and methods: This study aimed at evaluating the effectiveness of vitamin D supplementation on NAFLD patients. Patients with increased liver enzymes with NAFLD diagnosis were enrolled. This clinical trial was conducted in two groups of 20 patients. In control group, only lifestyle modification was performed, but the case group received 50,000 IU vitamin D3 weekly for 12 weeks alongside lifestyle modification.
   Results: Fibroscan was used to assess the liver fibrosis and steatosis before and after the intervention. The levels of vitamin D and liver enzymes were also assessed in six months. Mean BMI and serum liver enzymes decreased significantly in two groups (p<0.05). At the end of the study a significant improvement was observed in steatosis in both groups when the results were compared with their baseline measures (p<0.05), however, no significant differences were observed between the two groups in steatosis when measured by CAP parameter.
   Discussion and conclusion: There was no significant improvement in the severity of fibrosis measured by kpa between two groups (p>0.05). A significant improvement was observed in case group in the fibrosis severity. Vitamin D may improve the degree of steatosis and severity of fibrosis in NAFLD patients and be useful in preventing fibrosis.
C1 [Taghvaei, Tarang] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Gut & Liver Res Ctr, Dept Gastroenterol, Sari, Iran.
   [Akha, Ozra] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Diabet Res Ctr, Dept Endocrinol, Sari, Iran.
   [Mouodi, Marjan] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Internal Med, Sari, Iran.
   [Fakheri, Hafez Tirgar; Maleki, Iradj] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Gut & Liver Res Ctr, Sari, Mazandaran, Iran.
   [Kashi, Zahra] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Diabet Res Ctr, Endocrinol, Sari, Iran.
   [Mohammadpour, Rezaali] Mazandaran Univ Med Sci, Stat & Epidemiol, Sari, Mazandaran, Iran.
RP Akha, O (corresponding author), Mazandaran Univ Med Sci, Diabet Res Ctr, Sari, Iran.
RI Maleki, Iradj/AAY-4649-2020; Taghvaei, Tarang/AAE-5110-2021;
   Mohammadpour, Reza Ali/F-4279-2017; Fakheri, Hafez Tirgar/G-7638-2017
OI Maleki, Iradj/0000-0003-2395-8118; Mohammadpour, Reza
   Ali/0000-0003-2353-5027; Fakheri, Hafez Tirgar/0000-0002-0579-6111
FU Mazandaran University of Medical Sciences, Sari, Iran
FX This study was supported by Mazandaran University of Medical Sciences,
   Sari, Iran.
CR Adams LA, 2005, CAN MED ASSOC J, V172, P899, DOI 10.1503/cmaj.045232
   Angelico F, 2005, J CLIN ENDOCR METAB, V90, P1578, DOI 10.1210/jc.2004-1024
   Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496
   Barchetta I, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-85
   Chiu KC, 2004, AM J CLIN NUTR, V79, P820
   Dalhoff K, 2003, BRIT J CANCER, V89, P252, DOI 10.1038/sj.bjc.6601104
   Dasarathy J, 2014, LIVER INT, V34, pE118, DOI 10.1111/liv.12312
   Eliades M, 2013, ALIMENT PHARM THER, V38, P246, DOI 10.1111/apt.12377
   Fan JG, 2005, J HEPATOL, V43, P508, DOI 10.1016/j.jhep.2005.02.042
   Jablonski KL, 2013, NUTR METAB CARDIOVAS, V23, P792, DOI 10.1016/j.numecd.2012.12.006
   Kasapoglu B, 2013, CLIN MED, V13, P576, DOI 10.7861/clinmedicine.13-6-576
   Kitson MT, 2012, J HEPATOL, V57, P897, DOI 10.1016/j.jhep.2012.04.033
   Kwok RM, 2013, HEPATOLOGY, V58, P1166, DOI 10.1002/hep.26390
   Nakano T, 2011, J HEPATOL, V55, P415, DOI 10.1016/j.jhep.2010.11.028
   NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142
   Pittas AG, 2010, ANN INTERN MED, V152, P307, DOI 10.7326/0003-4819-152-5-201003020-00009
   Preiss D, 2008, CLIN SCI, V115, P141, DOI 10.1042/CS20070402
   Rhee EJ, 2013, ENDOCR J, V60, P743, DOI 10.1507/endocrj.EJ12-0387
   Song BJ, 2013, LIVER INT, V33, P653, DOI 10.1111/liv.12147
   Stein EM, 2009, CLIN ENDOCRINOL, V71, P176, DOI 10.1111/j.1365-2265.2008.03470.x
   Taghvaei T, 2013, J MAZANDARAN U MED S, V23, P164
   Ueno T, 1997, J HEPATOL, V27, P103, DOI 10.1016/S0168-8278(97)80287-5
   van der Poorten D, 2008, CLIN LIVER DIS, V12, P805, DOI 10.1016/j.cld.2008.07.003
   Wong GL-H, 2013, GASTROENTEROL REP
NR 24
TC 5
Z9 5
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 415
EP 422
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400020
DA 2022-07-14
ER

PT J
AU Taheri, M
   Noroozi, R
   Sayad, A
   Ghafouri-Fard, S
   Omrani, MD
AF Taheri, Mohammad
   Noroozi, Rezvan
   Sayad, Arezou
   Ghafouri-Fard, Soudeh
   Omrani, Mir Davood
TI INTEGRIN SUBUNIT ALPHA 4 (ITGA4) VARIANT IS ASSOCIATED WITH
   RELAPSING-REMITTING MULTIPLE SCLEROSIS IN AN IRANIAN POPULATION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE multiple sclerosis; ITGA4; integrin; polymorphism
ID TARGET GENES; NATALIZUMAB; THERAPY; SUSCEPTIBILITY; POLYMORPHISMS
AB Introduction: Multiple sclerosis (MS) is an inflammatory demyelinating disorder of central nervous system (CNS). As a multifactorial disorder, several genetics and environmental factors contribute in its pathogenesis. Among them are genetic variants in the integrin subunit alpha 4 (ITGA4) gene. The encoded protein has been shown to assist in migration of leukocytes across the blood brain barrier participating in the pathogenesis of neuroinflammatory disorders.
   Materials and methods: The current case-control association study enrolled 410 unrelated MS patients and 477 healthy matched controls. The rs1143676 within ITGA4 gene, which leads to an arginine to glutamine transversion, was genotyped in all study participants using tetra-primer amplification refractory mutation system PCR (T-ARMS-PCR).
   Results: The rs1143676 polymorphism showed significant differences in allele and genotype frequencies between the MS patients and healthy subjects. In addition, genotypes were risk associated in dominant and codominant models.
   Conclusion: The rs1143676 polymorphism is associated with MS risk in Iranian population. Future studies are needed to evaluate its significance in MS pathogenesis in other populations. These results are in agreement with the supposed biological role of ITGA4 in immune cell trafficking in the CNS.
C1 [Taheri, Mohammad; Sayad, Arezou; Ghafouri-Fard, Soudeh; Omrani, Mir Davood] Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran.
   [Taheri, Mohammad] Shahid Beheshti Univ Med Sci, Urogenital Stem Cell Res, Tehran, Iran.
   [Noroozi, Rezvan] Shahid Beheshti Univ Med Sci, Phytochem Res Ctr, Tehran, Iran.
RP Ghafouri-Fard, S; Omrani, MD (corresponding author), Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran.
EM s.ghafourifard@sbmu.ac.ir; davood_omrani@yahoo.co.uk
RI Sayad, Arezou/AAX-1349-2021; Noroozi, Rezvan/AAG-2134-2020;
   Ghafouri-Fard, Soudeh/O-7994-2019
OI Noroozi, Rezvan/0000-0003-2294-171X; Ghafouri-Fard,
   Soudeh/0000-0002-0223-499X
FU Shahid Beheshti University of Medical Sciences
FX The current study was supported by a grant from Shahid Beheshti
   University of Medical Sciences.
CR Andreoli V, 2007, J NEUROIMMUNOL, V189, P125, DOI 10.1016/j.jneuroim.2007.06.015
   Bennett JL, 2006, NEUROL RES, V28, P291, DOI 10.1179/016164106X98189
   Collins A., 2012, OPEN BIOINFORM J, V6, DOI [10.2174/1875036201206010055, DOI 10.2174/1875036201206010055]
   Dardiotis E, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000350
   Durmanova V, 2015, FOLIA BIOL-PRAGUE, V61, P8
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Mazdeh M, 2016, PHARMACOGENOMICS, V17, P489, DOI 10.2217/pgs.16.2
   Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696
   O'Doherty C, 2007, J NEUROIMMUNOL, V189, P151, DOI 10.1016/j.jneuroim.2007.07.006
   Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366
   Satoh JI, 2013, GENE REGUL SYST BIO, V7, P139, DOI 10.4137/GRSB.S13204
   Sayad A, 2017, NEUROL SCI, V38, P1093, DOI 10.1007/s10072-017-2935-4
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Steinman L, 2005, NAT REV DRUG DISCOV, V4, P510, DOI 10.1038/nrd1752
   Taheri M, 2017, CYTOKINE, V96, P138, DOI 10.1016/j.cyto.2017.04.007
   Ward LD, 2016, NUCLEIC ACIDS RES, V44, pD877, DOI 10.1093/nar/gkv1340
NR 17
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 83
EP 86
DI 10.19193/0393-6384_2018_1_14
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600014
DA 2022-07-14
ER

PT J
AU Taheri, M
   Noroozi, R
   Sayad, A
   Ghafouri-Fard, S
   Omrani, MD
AF Taheri, Mohammad
   Noroozi, Rezvan
   Sayad, Arezou
   Ghafouri-Fard, Soudeh
   Omrani, Mir Davood
TI ASSOCIATION STUDY OF CASITAS B-LINEAGE LYMPHOMA PROTO-ONCOGENE B (CBLB)
   GENE VARIANT AND MULTIPLE SCLEROSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Multiple sclerosis; polymorphism; CBLB
ID RISK ALLELES; ACTIVATION
AB Introduction: Multiple sclerosis is a complex inflammatory demyelinating disorder of central nervous system (CNS). Several genetic loci have been shown to be linked with this disorder. Among them is the Casitas B-lineage lymphoma proto-oncogene b (CBLB) gene whose protein product participates as a negative regulator of adaptive immune responses. In the current study we aimed at evaluation of the association between the rs12487066 single nucleotide polymorphism (SNP) within CBLB gene and MS in a population of Iranian patients.
   Materials and methods: We designed a case-control association study registering 410 unrelated patients with sporadic MS and 428 healthy matched controls. Genotyping of rs12487066 was performed using tetra-primer amplification refractory mutation system PCR (T-ARMS-PCR).
   Results: No statistically significant difference was observed in allele and genotype frequencies between the MS patients and healthy subjects.
   Conclusion: Although the rs12487066 SNP has been shown to be associated with MS in other populations, our study suggest that this SNP is not linked with MS in Iranian population.
C1 [Taheri, Mohammad; Sayad, Arezou; Ghafouri-Fard, Soudeh; Omrani, Mir Davood] Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran.
   [Taheri, Mohammad] Shahid Beheshti Univ Med Sci, Urogenital Stem Cell Res, Tehran, Iran.
   [Noroozi, Rezvan] Shahid Beheshti Univ Med Sci, Phytochem Res Ctr, Tehran, Iran.
RP Ghafouri-Fard, S; Omrani, MD (corresponding author), Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran.
EM s.ghafourifard@sbmu.ac.ir; davood_omrani@yahoo.co.uk
RI Noroozi, Rezvan/AAG-2134-2020; Sayad, Arezou/AAX-1349-2021;
   Ghafouri-Fard, Soudeh/O-7994-2019
OI Noroozi, Rezvan/0000-0003-2294-171X; Ghafouri-Fard,
   Soudeh/0000-0002-0223-499X
FU Shahid Beheshti University of Medical Sciences, Tehran, Iran
FX The current study was supported by a grant from Shahid Beheshti
   University of Medical Sciences, Tehran, Iran. We are thankful to all
   study participants.
CR Andreoli V, 2007, J NEUROIMMUNOL, V189, P125, DOI 10.1016/j.jneuroim.2007.06.015
   Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770
   Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235
   Collins A., 2012, OPEN BIOINFORM J, V6, DOI [10.2174/1875036201206010055, DOI 10.2174/1875036201206010055]
   D'Netto MJ, 2009, NEUROLOGY, V72, P1984, DOI 10.1212/WNL.0b013e3181a92c25
   Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   Mazdeh M, 2016, PHARMACOGENOMICS, V17, P489, DOI 10.2217/pgs.16.2
   Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366
   Qiao GL, 2007, J IMMUNOL, V179, P4473, DOI 10.4049/jimmunol.179.7.4473
   Sanna S, 2010, NAT GENET, V42, P495, DOI 10.1038/ng.584
   Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251
   Sayad A, 2017, NEUROL SCI, V38, P1093, DOI 10.1007/s10072-017-2935-4
   Schmitz ML, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.276pe38
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Sturner KH, 2014, J IMMUNOL, V193, P4439, DOI 10.4049/jimmunol.1303077
   Taheri M, 2017, CYTOKINE, V96, P138, DOI 10.1016/j.cyto.2017.04.007
NR 17
TC 2
Z9 2
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 87
EP 90
DI 10.19193/0393-6384_2018_1_15
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600015
DA 2022-07-14
ER

PT J
AU Taheri, M
   Irandoust, K
   Sadeghi, A
   Yari, S
AF Taheri, Morteza
   Irandoust, Khadijeh
   Sadeghi, Abbas
   Yari, Shokoofe
TI THE EFFECT OF OMEGA-3 FATTY ACID SUPPLEMENT AND AEROBIC EXERCISE ON
   LIPID PROFILE AND DEPRESSION IN OBESE WOMEN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Omega 3; Lipid profiles; Exercise; Depression
ID BODY-COMPOSITION; RISK-FACTORS; CHOLESTEROL; CHILDREN; ADULTS; TRIAL;
   ACID; MEN
AB Background: Elevated blood lipids and its associated psychological concerns, including depression, are some of the most harmful aspects of obesity, which has made the need for its prevention and treatment more obvious to researchers and authorities.
   Objectives: This study sought to evaluate the effect of 8 weeks of omeg-3 supplementation combined with aerobic exercise on blood lipid profile and depression in obese women.
   Materials and methods: 32 inactive obese women with mild to moderate depression with the age range of 25-40 years were selected and then randomly divided into four groups of (n=8): aerobic exercise + omega-3 supplement; omega-3 supplement, aerobic exercise, and control. The aerobic exercise protocol included warming up; main program and cooling down phases lasted for 8 consecutive weeks (5 days/week). The daily intake of omega-3 supplement was 2,000 milligrams. Lipid profiles and the Depression were measured before and after 8 weeks of exercise intervention and supplementation.
   Results: There was a significant decrease in total cholesterol and LDL in aerobic exercise, aerobic exercise + omega-3, and omega-3 groups and there was a significant increase in HDL in the three groups (p=0.05). Compared to the omega-3 supplement group, aerobic exercise group and aerobic exercise+omega-3 supplement group had lower total cholesterol and LDL levels and higher HDL after intervention (p=0.05). In addition, in all three experimental groups, depression showed a significant improvement (p=0.05). The aerobic exercise group and the aerobic+omega-3 supplement group showed a more significant improvement compared to the omega-3 supplement group in terms of depression (p=0.05).
   Conclusion: Given the findings of this study, aerobic exercise and omega-3 supplement simultaneously improve the blood lipids and depression in women. Since blood lipids are improved in the prevention of obesity and related diseases, including depression, omega-3 consumption and aerobic exercise in interaction are recommended for women.
C1 [Taheri, Morteza; Irandoust, Khadijeh; Sadeghi, Abbas] Imam Khomeini Int Univ, Dept Sport Sci, Fac Social Sci, Qazvin, Iran.
   [Yari, Shokoofe] Imam Khomeini Int Univ, Dept Sport Sci, Fac Social Sci, Exercise Physiol, Qazvin, Iran.
RP Taheri, M (corresponding author), Imam Khomeini Int Univ, Dept Sport Sci, Fac Social Sci, Qazvin, Iran.
EM taheri_morteza@yahoo.com
RI Taheri, Morteza/N-5170-2016; irandoust, khadijeh/ABH-3519-2021
OI Taheri, Morteza/0000-0001-8031-3792; 
CR Altena TS, 2006, MED SCI SPORT EXER, V38, P367, DOI 10.1249/01.mss.0000185088.33669.fd
   Amini M, 2018, INT J SPORT STUD HLT
   Bianco A, 2010, J SPORT MED PHYS FIT, V50, P159
   Budania S, 2014, MED J DY PATIL U, V7, P543
   Colussi Gianluca, 2007, Recent Pat Cardiovasc Drug Discov, V2, P13, DOI 10.2174/157489007779606158
   Dangardt F, 2010, ATHEROSCLEROSIS, V212, P580, DOI 10.1016/j.atherosclerosis.2010.06.046
   Dunn AL, 2002, CONTROL CLIN TRIALS, V23, P584, DOI 10.1016/S0197-2456(02)00226-X
   Hesar KM, 2013, IRANIAN J ENDOCRINOL, V14, P472
   Irandoost K, 2015, SALMAND, V10, P48
   Irandoust K, 2017, PHYS PHYSL LITERACY
   Irandoust K, 2017, ASIAN J SPORTS MED, V8
   Irandoust K, 2015, J PHYS THER SCI, V27, P433, DOI 10.1589/jpts.27.433
   Jafari M, 2017, INT J SPORT STUD HLT
   Jee SH, 2011, EUR HEART J, V32, P2773, DOI 10.1093/eurheartj/ehr229
   Jensky-Squires NE, 2008, BRIT J NUTR, V100, P859, DOI 10.1017/S0007114508925460
   Kannan U, 2014, J CLIN DIAGN RES, V8, pBC8, DOI 10.7860/JCDR/2014/8519.4611
   Kong A, 2012, J ACAD NUTR DIET, V112, P1428, DOI 10.1016/j.jand.2012.05.014
   Lee HC, 2014, J PHYS THER SCI, V26, P1675, DOI 10.1589/jpts.26.1675
   Liperoti R, 2009, CURR PHARM DESIGN, V15, P4165, DOI 10.2174/138161209789909683
   Maes M, 1997, ACTA PSYCHIAT SCAND, V95, P212, DOI 10.1111/j.1600-0447.1997.tb09622.x
   Mann S, 2014, SPORTS MED, V44, P211, DOI 10.1007/s40279-013-0110-5
   Mohammadpour A, 2015, J PHARM CARE, V1, P25
   Noorian F., 2017, ACTA MED MEDITERRANE, V33
   Olusi SO, 1996, BIOL PSYCHIAT, V40, P1128, DOI 10.1016/S0006-3223(95)00599-4
   Paoli A, 2015, MAR DRUGS, V13, P996, DOI 10.3390/md13020996
   Paoli A, 2012, AM J CARDIOL, V109, P305, DOI 10.1016/j.amjcard.2011.10.011
   Rahman A., 2015, INVESTIGATION PREVAL, V2015, P12
   Rogers PJ, 2008, BRIT J NUTR, V99, P421, DOI 10.1017/S0007114507801097
   Ruljancic N, 2011, PROG NEURO-PSYCHOPH, V35, P1261, DOI 10.1016/j.pnpbp.2011.02.007
   Sarshar N, 2006, OFOGH E DANESH J GON, V12, P38
   Sayyah M, 2011, BIOSCI BIOTECH RES A, V8, P367, DOI DOI 10.13005/bbra/875
   Schachter H M, 2005, Evid Rep Technol Assess (Summ), P1
   Shibata H, 1999, J Epidemiol, V9, P261
   Simopoulos Artemis P, 2007, Curr Sports Med Rep, V6, P230, DOI 10.1007/s11932-007-0037-4
   Sneddon AA, 2008, OBESITY, V16, P1019, DOI 10.1038/oby.2008.41
   Surette ME, 2008, CAN MED ASSOC J, V178, P177, DOI 10.1503/cmaj.071356
   Zorba E, 2011, J SPORT MED PHYS FIT, V51, P664
NR 37
TC 1
Z9 1
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 865
EP 870
DI 10.19193/0393-6384_2018_3_132
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000036
DA 2022-07-14
ER

PT J
AU Tan, B
   Yang, ZB
   Ren, KD
   Zhang, XJ
   Peng, J
   Luo, XJ
AF Tan, Bin
   Yang, Zhong-Bao
   Ren, Kai-Di
   Zhang, Xiao-Jie
   Peng, Jun
   Luo, Xiu-Ju
TI ROLE OF ALDH2 IN PROTECTION OF NG108-15 NEURAL CELLS AGAINST
   HYPOXIA/REOXYGENATION-INDUCED INJURY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE mitochondrial aldehyde dehydrogenase (ALDH2); NG108-15 cells;
   hypoxia/reoxygenation; 4-Hydroxynonenal
ID MITOCHONDRIAL ALDEHYDE DEHYDROGENASE; OXIDATIVE STRESS; ISCHEMIC-STROKE;
   HEART; DAMAGE; BRAIN
AB Introduction: Recent studies uncovered that toxic aldehydes accumulation under neurological diseases such as ischemic stroke was involved in neural cell death and that mitochondrial aldehyde dehydrogenase (ALDH2) plays a key role in clearance of toxic aldehydes. This study aims to explore whether ALDH2 is able to protect NG108-15 neural cells from hypoxia/reoxygenation (H/R) induced injury through prevention of toxic aldehydes accumulation.
   Materials and methods: NG108-15 cells were subjected to 5h of hypoxia (H) followed by 20h of reoxygenation (R) to establish H/R injury model. The cells were randomly divided into 6 groups as follows: the control group; the H/R group; the Alda-1 (5 mu M), the Alda-1 (10 mu M) or the Alda-1 (30 mu M) plus H/R group; and the vehicle plus H/R group. To verify the function of ALDH2, the NG10815 cells were subjected to 4-HNE (50 mu M) for 24 h. At the end, culture medium and cells were collected for analysis of cellular apoptosis, lactate dehydrogenase (LDH) release, reactive oxygen species (ROS), 4-hydroxynonenal (4-HNE) and malondialdehye(MDA) levels, and ALDH2 expression, respectively.
   Results: It showed an increase in cell necrosis and apoptosis concomitant with down-regulation of ALDH2 expression and activity while accumulation of toxic aldehydes including 4-Hydroxynonenal (4-HNE) and malondialdehyde (MDA) in the H/R group. Administration of ALDH2 activator (Alda-1) reduced H/R-induced NG108-15 cells injury accompanied by a reverse in ALDH2 activation and toxic aldehydes accumulation. 4-HNE treatment increased cell necrosis and apoptosis concomitant with down-regulation of ALDH2 expression and activity while an increase in ROS production, all these effects were reversed in the presence of ALDH2 activator.
   Conclusions: ALDH2 is able to protect neural cells from H/R-induced injury through prevention of toxic aldehydes accumulation and it might serve as a molecular target for the development of novel drugs to treat neurological diseases such as stroke.
C1 [Tan, Bin; Yang, Zhong-Bao; Peng, Jun] Xiang Nan Univ, Dept Pharmacol, Chenzhou 423000, Peoples R China.
   [Tan, Bin; Ren, Kai-Di; Zhang, Xiao-Jie; Peng, Jun] Cent S Univ, Xiangya Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410078, Hunan, Peoples R China.
   [Yang, Zhong-Bao] HuNan Normal Univ, Affiliated Changsha Hosp, Dept Pharm, Changsha 410006, Hunan, Peoples R China.
   [Luo, Xiu-Ju] Cent S Univ, Xiangya Sch Med, Dept Lab Med, Changsha 410013, Hunan, Peoples R China.
RP Peng, J (corresponding author), Xiang Nan Univ, Dept Pharmacol, Chenzhou 423000, Peoples R China.
EM junpeng@csu.edu.cn
RI peng, jun/AAA-6751-2022
OI peng, jun/0000-0001-7536-3613
FU National Nature Science Foundation of China [81373409, 81573430,
   81603107]; Hunan Provincial Natural Science Foundation of China
   [2015JJ2156]
FX This work was supported by National Nature Science Foundation of China
   (No. 81373409 to Jun Peng, No. 81573430 to Xiu-Ju Luo, No. 81603107 to
   Zhong-Bao Yang), Hunan Provincial Natural Science Foundation of China
   (No. 2015JJ2156 to Xiu-Ju Luo).
CR Arai H, 2014, SUBCELL BIOCHEM, V77, P103, DOI 10.1007/978-94-007-7920-4_9
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Brown DI, 2015, CIRC RES, V116, P531, DOI 10.1161/CIRCRESAHA.116.303584
   Calamaras TD, 2015, FREE RADICAL BIO MED, V82, P137, DOI 10.1016/j.freeradbiomed.2015.01.007
   Chen CH, 2008, SCIENCE, V321, P1493, DOI 10.1126/science.1158554
   Chen CH, 2014, PHYSIOL REV, V94, P1, DOI 10.1152/physrev.00017.2013
   Chen CH, 2010, CARDIOVASC RES, V88, P51, DOI 10.1093/cvr/cvq192
   Fu SH, 2014, N-S ARCH PHARMACOL, V387, P87, DOI 10.1007/s00210-013-0922-8
   He L, 2012, EUR J PHARMACOL, V678, P32, DOI 10.1016/j.ejphar.2011.12.042
   Luo XJ, 2014, CURR DRUG TARGETS, V15, P948, DOI 10.2174/1389450115666140828142401
   Mali VR, 2014, FREE RADICAL RES, V48, P251, DOI 10.3109/10715762.2013.864761
   Manzanero S, 2013, NEUROCHEM INT, V62, P712, DOI 10.1016/j.neuint.2012.11.009
   Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040
   Puyal J, 2013, PROG NEUROBIOL, V105, P24, DOI 10.1016/j.pneurobio.2013.03.002
   Rodrigo R, 2013, CNS NEUROL DISORD-DR, V12, P698
   Shoeb M, 2014, CURR MED CHEM, V21, P230
   Sultana R, 2013, FREE RADICAL BIO MED, V62, P157, DOI 10.1016/j.freeradbiomed.2012.09.027
   Thompson JW, 2012, CURR NEUROPHARMACOL, V10, P354, DOI 10.2174/157015912804143577
   Venderova K, 2012, COLD SPRING HARB PER, V2
   Zhong HQ, 2015, REDOX BIOL, V4, P193, DOI 10.1016/j.redox.2014.12.011
NR 20
TC 0
Z9 0
U1 0
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 145
EP 152
DI 10.19193/0393-6384_2018_1_24
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600024
DA 2022-07-14
ER

PT J
AU Tan, R
   Tang, NN
   Zhang, Y
   Mei, YJ
   Sun, LD
AF Tan, Rui
   Tang, Nina
   Zhang, Yuan
   Mei, Yijie
   Sun, Ledong
TI EFFECT OF IMIQUIMOD IN THE TREATMENT OF BASAL CELL CARCINOMA AND ON
   EXPRESSION OF VEGF MRNA IN THE PERIPHERAL BLOOD
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Imiquimod; Basal cell carcinoma; VEGF
ID ENDOTHELIAL GROWTH-FACTORS; MICROVESSEL DENSITY; ANGIOGENESIS;
   INHIBITOR; PATHWAY; BIOLOGY
AB Objective: Study the clinical efficacy of imiquimod for basal cell carcinoma and the effect on expression of VEGF mRNA to explore the underlying mechanism of imiquimod for basal cell carcinoma.
   Materials and methods: Use 5% imiquimod cream for 8 weeks regularly, and detect the expression of VEGF in peripheral blood of VEGF mRNA by real-time fluorescence quantitative PCR in before and after treatment groups.
   Results: The clinical efficacy of imiquimod for basal cell carcinoma was significant; the expression levels of VEGF mRNA in before/after treatment group were significantly higher than those of normal group (p<0.05); In the meantime, the expression level in after treatment group were obvious lower than that in before group(p<0.05).
   Conclusion: The therapeutic effect of imiquimod for basal cell carcinoma may be related to the decreased expression of VEGF mRNA in the peripheral blood.
C1 [Tan, Rui; Tang, Nina; Zhang, Yuan; Mei, Yijie; Sun, Ledong] Southern Med Univ, Zhujiang Hosp, Dept Dermatol, 253 Ind Rd, Guangzhou 510282, Guangdong, Peoples R China.
RP Sun, LD (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Dermatol, 253 Ind Rd, Guangzhou 510282, Guangdong, Peoples R China.
EM sunledong126@126.com
CR Anwar U, 2006, PLAST RECONSTR SURG, V117, p6E, DOI 10.1097/01.prs.0000194908.32762.e6
   Carbone A, 2011, EUR J DERMATOL, V21, P608, DOI 10.1684/ejd.2011.1319
   Gabhann FM, 2008, MICROCIRCULATION, V15, P715, DOI 10.1080/10739680802095964
   Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4
   Hesling C, 2004, BRIT J DERMATOL, V150, P761, DOI 10.1111/j.0007-0963.2004.05898.x
   Imai Y, 2015, J IMMUNOL, V195, P421, DOI 10.4049/jimmunol.1500448
   Jiang HH, 2012, MED RECAPITULATE, V18, P299
   Jimeno A, 2013, CLIN CANCER RES, V19, P2766, DOI 10.1158/1078-0432.CCR-12-3654
   Leng FF, 2017, ACTA MEDICA MEDITERR, V33, P1085, DOI 10.19193/0393-6384_2017_6_172
   Li Vincent W, 2008, J Drugs Dermatol, V7, ps17
   Majewski S, 2005, INT J DERMATOL, V44, P14, DOI 10.1111/j.1365-4632.2004.02318.x
   Nagarajan S, 2002, CANCER RES, V62, P2869
   Oh CK, 2003, J DERMATOL, V30, P306, DOI 10.1111/j.1346-8138.2003.tb00392.x
   Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713
   Sobjanek M, 2014, ARCH DERMATOL RES, V306, P539, DOI 10.1007/s00403-014-1471-9
   Sterry W, 2002, BRIT J DERMATOL, V147, P1227, DOI 10.1046/j.1365-2133.2002.05069.x
   Tang S, 2016, AUSTRALAS J DERMATOL
   Tokluoglu S, 2017, ACTA MEDICA MEDITERR, V33, P145, DOI 10.19193/0393-6384_2017_1_022
   Vuletic MS, 2014, J BUON, V19, P780
   Wang XY, 2011, CLIN EXP DERMATOL, V36, P69, DOI 10.1111/j.1365-2230.2010.03860.x
   Wu CS, 2014, DNA CELL BIOL, V33, P652, DOI 10.1089/dna.2014.2366
   Yla-Herttuala S, 2007, J AM COLL CARDIOL, V49, P1015, DOI 10.1016/j.jacc.2006.09.053
   Zhong CG, 2014, EXPRESSION CYCLIND1
   彭军, 2007, [中华皮肤科杂志, Chinese Journa of Dermatology], V40, P160
NR 24
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1351
EP 1355
DI 10.19193/0393-6384_2018_5_207
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700029
DA 2022-07-14
ER

PT J
AU Tartaglia, N
   Iadarola, R
   Di Lascia, A
   Fersini, A
   Ambrosi, A
AF Tartaglia, Nicola
   Iadarola, Roberta
   Di Lascia, Alessandra
   Fersini, Alberto
   Ambrosi, Antonio
TI UNUSUAL COMPLICATION IN THYROID SURGERY. CASE REPORT AND LITERATURE
   REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Total thyroidectomy; Tracheal injury; Tracheal surgery; Tracheal
   lesion-Tracheostomy-Tracheal laceration
ID ASTROGLIAL CELL-PROLIFERATION; ACUTE BILIARY PANCREATITIS; TRACHEAL
   NECROSIS; CHILDREN; EXPRESSION; RUPTURE; DIFFERENTIATION; POPULATION;
   LEUKEMIA; EFFICACY
AB Background and Objective: Complication rates from total thyroidectomy are low, at present mortality for this procedure is around 0% and overall complication rate is less than 3%. Major complication includes wound infection, hematoma, recurrent laryngeal nerve palsy, hypoparathyroidism. Tracheal injury associated with thyroidectomy is rare, but when it occurs it can be very dangerous. Tracheal perforation is generally not considered a complication as such, but rather atechnical occurrence during surgery that requires expeditious attention. Tracheal perforation, if encountered, needs to be managed appropriately incenters of expertise for high volume of thyroidectomy.
C1 [Tartaglia, Nicola; Iadarola, Roberta; Di Lascia, Alessandra; Fersini, Alberto; Ambrosi, Antonio] Univ Foggia, Dept Med & Surg Sci, Luigi Pinto St 1, I-71122 Foggia, Italy.
RP Tartaglia, N (corresponding author), Univ Foggia, Dept Med & Surg Sci, Luigi Pinto St 1, I-71122 Foggia, Italy.
EM nicola.tartaglia@unifg.it
RI Tartaglia, Nicola/AAJ-9264-2020; tartaglia, nicola/AAD-7321-2019
OI Tartaglia, Nicola/0000-0001-6845-7080; tartaglia,
   nicola/0000-0001-6845-7080
CR Albano GD, 2017, ACTA MEDICA MEDITERR, V33, P939
   Albenzio M, 2009, J DAIRY SCI, V92, P79, DOI 10.3168/jds.2008-1439
   Albenzio M, 2013, J DAIRY SCI, V96, P2781, DOI 10.3168/jds.2012-6218
   Avola R, 2004, CLIN EXP HYPERTENS, V26, P323, DOI 10.1081/CEH-120034137
   Bertolaccini L, 2012, INTERACT CARDIOV TH, V14, P500, DOI 10.1093/icvts/ivr126
   Bonaventure A, 2017, LANCET HAEMATOL, V4, pE202, DOI 10.1016/S2352-3026(17)30052-2
   Bramanti V, 2012, NEUROCHEM RES, V37, P2795, DOI 10.1007/s11064-012-0873-3
   Bramanti V, 2016, J NEUROSCI RES, V94, P90, DOI 10.1002/jnr.23678
   Caroprese M, 2010, J DAIRY SCI, V93, P2395, DOI 10.3168/jds.2009-2604
   Caroprese M, 2009, J DAIRY SCI, V92, P2796, DOI 10.3168/jds.2008-1809
   Carotenuto M, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00295
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carter YM, 2012, ENDOCR PRACT, V18, P720, DOI [10.4158/EP12014.OR, 10.4158/EP11344.CR]
   Cerame Giuseppe, 2008, Ig Sanita Pubbl, V64, P469
   Chauhan A, 2009, J POSTGRAD MED, V55, P193, DOI 10.4103/0022-3859.57401
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Cianci P, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0857-x
   Conzo G, 2012, ANN ITAL CHIR, V83, P259
   Conzo G, 2012, ANN ITAL CHIR, V83, P55
   Damrose EJ, 2009, AURIS NASUS LARYNX, V36, P113, DOI 10.1016/j.anl.2008.03.007
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Escott Alistair B, 2016, Ear Nose Throat J, V95, pE14
   Esposito M, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00680
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Forlano I, 2011, ANN ITAL CHIR, V82, P405
   Giallongo C, 2011, ACTA HAEMATOL-BASEL, V126, P205, DOI 10.1159/000329911
   Golger A, 2002, CAN J SURG, V45, P463
   Gosnell JE, 2006, BRIT J SURG, V93, P55, DOI 10.1002/bjs.5136
   Han XW, 2016, J VASC INTERV RADIOL, V27, P1758, DOI 10.1016/j.jvir.2016.04.017
   Heavrin BS, 2012, J EMERG MED, V43, pE259, DOI 10.1016/j.jemermed.2011.03.031
   Jacqmin Sebastien, 2005, J Anesth, V19, P347, DOI 10.1007/s00540-005-0330-4
   Lombardi C P, 2007, Minerva Chir, V62, P395
   Maglietta F, 2017, ACTA MEDICA MEDITERR, V33, P947, DOI 10.19193/0393-6384_2017_6_149
   Mazzucco W, 2012, ARCH ENVIRON OCCUP H, V67, P91, DOI 10.1080/19338244.2011.578683
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BENEFICIAL EFFECTS C, DOI [10.4172/0974-8369.1000, DOI 10.4172/0974-8369.1000]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Asian J Sports Med, V7, pe26841, DOI 10.5812/asjsm.26841
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2018, MOL NEUROBIOL, V55, P6362, DOI 10.1007/s12035-017-0865-z
   Monda V, 2017, DIABETES METAB SYNDR, V10, DOI 10.2147/DMSO.S148392
   Neri V, 2013, ANN ITAL CHIR, V84, P47
   Neri V, 2009, ANN ITAL CHIR, V80, P363
   Neri V, 2009, PANCREAS, V38, P717, DOI 10.1097/MPA.0b013e3181a83087
   Nishihara E, 2005, THYROID, V15, P1183, DOI 10.1089/thy.2005.15.1183
   Palmieri Giovanni Messina Filomena, 2015, BIOL MED
   Pieri M, 2016, J FORENSIC LEG MED, V38, P93, DOI 10.1016/j.jflm.2015.12.002
   Pomara C, 2008, CLIN TOXICOL, V46, P322, DOI 10.1080/15563650701419011
   Pomara C, 2016, J CELL PHYSIOL, V231, P1385, DOI 10.1002/jcp.25272
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Precenzano F, 2017, ACTA MEDICA MEDITERR, P33
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Rosato L, 2012, MINERVA CHIR, V67, P271
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Salomone F, 2014, TRANSL RES, V163, P593, DOI 10.1016/j.trsl.2013.12.001
   Sanna S, 2014, G CHIR, V35, P65, DOI 10.11138/gchir/2014.35.3.065
   Sperandeo R, 2018, NEUROPSYCH DIS TREAT, V14, P11, DOI 10.2147/NDT.S146250
   To Edward W H, 2002, Ear Nose Throat J, V81, P738
   Tramuto F, 2012, J COMMUN HEALTH, V37, P547, DOI 10.1007/s10900-011-9477-0
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Vacchiano G, 2012, J ROY ARMY MED CORPS, V158, P338, DOI 10.1136/jramc-158-04-15
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 76
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 423
EP 429
DI 10.19193/0393-6384_2018_2_66
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400021
DA 2022-07-14
ER

PT J
AU Tekin, A
   Atis, G
   Yasar, S
   Goktay, F
   Aytekin, S
AF Tekin, Atilla
   Atis, Guldehan
   Yasar, Sirin
   Goktay, Fatih
   Aytekin, Sema
TI THE RELATIONSHIP OF TYPE D PERSONALITY AND QUALITY OF LIFE IN PATIENTS
   WITH PSORIASIS: A CROSS-SECTIONAL STUDY IN TURKISH POPULATION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE psoriasis; Type D personality; quality of life; stress
ID D DISTRESSED PERSONALITY; DEPRESSION; STRESS; DERMATOLOGY; ANXIETY;
   TURKEY; HEALTH
AB Introduction: Psychosomatic diseases are related to higher level of psychologic stress. Type D personality is characterized with high level of negative affect and social inhibition.
   Aims: The aim of this study is to investigate of relationship between Type D personality and quality of life in patients with psoriasis.
   Materials and methods: 71 patients with psoriasis who admitted to our dermatology out-patient clinics and 60 healthy controls were enrolled into the study. The sociodemographic form, Hospital Anxiety and Depression Scale, Type D Personality Scale and Dermatology Life Quality Index were adiministrated to the participants.
   Results: The negative correlations were found between Type D personality subscales (negative affect and social inhibition) and quality of life (respectively r=-.412 and r=-.510). Additionally, higher levels of negative affect and social inhibition correlated with PASI scores in patients with psoriasis (respectively r=.275 and r=.347).
   Conclusion: Type D personality can be negatively affect the quality of life and severity of disease in patients with psoriasis.
C1 [Tekin, Atilla] Halic Univ, Dept Psychol, TR-34400 Istanbul, Turkey.
   [Atis, Guldehan; Yasar, Sirin; Goktay, Fatih; Aytekin, Sema] Univ Hlth Sci, Haydarpasa Numune Training & Res Hosp, Istanbul, Turkey.
RP Tekin, A (corresponding author), Halic Univ, Dept Psychol, TR-34400 Istanbul, Turkey.
RI Yasar, Sirin/AAL-3175-2020; Aytekin, Sema/AAS-8763-2021; göktay,
   fatih/AAO-9758-2020; Aytekin, Sema/ABG-9414-2021; Tekin,
   Atilla/AAD-3659-2022; Tekin, Atilla/AAA-4800-2022
OI Yasar, Sirin/0000-0002-4110-1874; GOKTAY, Fatih/0000-0002-2380-7697
CR Alcelik A, 2012, J MOOD DISORD, V2, P1, DOI 10.5455/jmood.20120307062608
   Altunay IK, 2014, AM J CLIN DERMATOL, V15, P365, DOI 10.1007/s40257-014-0075-7
   Atakan N, 2016, J DERMATOL, V43, P298, DOI 10.1111/1346-8138.13081
   Aydemir O., 1997, TURK J PSYCHIAT, V8, P280
   Basinska MA, 2013, POSTEP DERM ALERGOL, V30, P381, DOI 10.5114/pdia.2013.39437
   Denollet J, 2005, PSYCHOSOM MED, V67, P89, DOI 10.1097/01.psy.0000149256.81953.49
   Denollet J, 2009, AM J CARDIOL, V103, P399, DOI 10.1016/j.amjcard.2008.09.096
   Evers AWM, 2010, BRIT J DERMATOL, V163, P986, DOI 10.1111/j.1365-2133.2010.09984.x
   Finlay AY, 1998, SEMIN CUTAN MED SURG, V17, P291, DOI 10.1016/S1085-5629(98)80026-6
   Hunter HJA, 2013, BRIT J DERMATOL, V169, P965, DOI 10.1111/bjd.12478
   Molina-Leyva A, 2015, J EUR ACAD DERMATOL, V29, P1710, DOI 10.1111/jdv.12960
   Mols F, 2012, J AFFECT DISORDERS, V136, P26, DOI 10.1016/j.jad.2011.08.034
   Ozturkcan S, 2006, INT J DERMATOL, V45, P1300, DOI 10.1111/j.1365-4632.2006.02881.x
   Pedersen SS, 2003, EUR J CARDIOV PREV R, V10, P241, DOI 10.1097/00149831-200308000-00005
   Schiffer AA, 2008, EUR J HEART FAIL, V10, P802, DOI 10.1016/j.ejheart.2008.06.012
   Schmitt JM, 2007, DERMATOLOGY, V215, P17, DOI 10.1159/000102029
   Smith IG, 2015, BRAIN BEHAV IMMUN, V49, P18, DOI 10.1016/j.bbi.2015.02.025
   Stewart TJ, 2018, INT J DERMATOL, V57, P1275, DOI 10.1111/ijd.13956
   Tee SI, 2016, J EUR ACAD DERMATOL, V30, P1159, DOI 10.1111/jdv.13615
   Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 21
TC 2
Z9 2
U1 1
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1009
EP 1013
DI 10.19193/0393-6384_2018_4_153
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500016
DA 2022-07-14
ER

PT J
AU Teng, JY
   Fan, HC
   Zhang, T
AF Teng, Jiangyan
   Fan, Houcui
   Zhang, Tao
TI ANALYSIS ON FACTORS INFLUENCING THE DEATH OF PATIENTS WITH DUAL
   INFECTIONS OF MYCOBACTERIUM TUBERCULOSIS AND HIV DURING
   ANTI-TUBERCULOSIS TREATMENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Tuberculosis infection; HIV; dual infection; fatal cause
ID MOLECULAR-STRUCTURES; ADENOCARCINOMA; DRUGS
AB Objective: This paper analyzes the specific factors that lead to death in the course of anti-tuberculosis treatment of patients with double infections of mycobacterium tuberculosis and HIV, consequently providing guidance for future clinical treatment.
   Methods: The 276 patients with mycobacterium tuberculosis and HIV treated in our hospital from March 2014 to December 2016 were enrolled in this study. A prospective & retrospective analysis was conducted to estimate probability of death during the course of treatment and summarizes the factors leading to death.
   Results: During the treatment period, 29 patients died, with odds of 10.51%. Statistical analysis showed that mortality was significantly lower in patients receiving antiviral therapy than those who did not (P < 0.05). In addition, the probability of death occurrence could be reduced with early antiviral therapy. Based on HIV infection route, it could be noted that the mortality of intravenous drug users was significantly higher than patients with sexually transmitted infections (P < 0.05). This could be observed from infection type of mycobacterium tuberculosis, whereby mortality of patients with smear positive pulmonary tuberculosis infection was substantially higher than those with smear negative pulmonary tuberculosis and patients with extrapulmonary tuberculosis alone (P < 0.05). Meanwhile the mortality of patients with CD4 + T lymphocyte level> 350 cells/mu l was significantly higher than patients with other cases (P < 0.05).
   Conclusion: HIV infection route, severity of tuberculosis, antiviral therapy and early treatment are the significant relevant factors that affect the death of patients infected with mycobacterium tuberculosis and HIV in the course of anti-tuberculosis treatment. These factors demand severe attention besides symptomatic treatment should be comprehended in all clinical institution to ensure patients' wellbeing.
C1 [Teng, Jiangyan; Fan, Houcui; Zhang, Tao] Linyi Peoples Hosp, Linyi 276034, Peoples R China.
RP Zhang, T (corresponding author), Linyi Peoples Hosp, Linyi 276034, Peoples R China.
CR Cahill T., 2015, ASIAN PAC J SURG ONC, V1, P47
   Duan Huamei, 2015, CONTINUING MED ED, V12, P70
   Galavi HR, 2016, PAK J PHARM SCI, V29, P2397
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P127, DOI 10.1016/j.sjbs.2016.09.005
   Ghoneum M, 2015, ASIAN PAC J SURG ONC, V1, P73
   Liu XH, 2017, BIOMED RES-INDIA, V28, P2990
   Manosroi A, 2016, SAUDI J BIOL SCI, V23, P248, DOI 10.1016/j.sjbs.2015.03.008
   Othman N, 2015, ASIAN PAC J SURG ONC, V1, P141
   Sandri A. B. A., 2015, ASIAN PAC J SURG ONC, V1, P113
   Sultana SSP, 2017, ARAB J CHEM, V10, P448, DOI 10.1016/j.arabjc.2017.01.017
   Xu Lin, 2015, Modern Preventive Medicine, V42, P3587
   Xue Xiao, 2011, CHINESE J ANNTITUBER, V33, P380
   Yormaz B, 2017, ACTA MEDICA MEDITERR, V33, P627, DOI 10.19193/0393-6384_2017_4_093
   Zhang J, 2016, SAUDI PHARM J, V24, P312, DOI 10.1016/j.jsps.2016.04.003
   Zhou Lin, 2010, CHINESE J ANTITUBERC, V10, P539
   Zhou Lin, 2011 NAT AC C P, V201, P1
   Zhou Lin, 2011, CHINESE J ANTITUBERC, V33, P734
NR 20
TC 2
Z9 2
U1 1
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 267
EP 271
DI 10.19193/0393-6384_2018_1s_44
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100009
DA 2022-07-14
ER

PT J
AU Teng, X
   Zhang, ZB
   Ding, LZ
   Zhang, JS
   Yuan, C
   Yang, MZ
AF Teng, Xiao
   Zhang, Zhaobo
   Ding, Lingzhi
   Zhang, Jingsheng
   Yuan, Chi
   Yang, Meizi
TI POSTERIOR LUMBAR SPINE FUSION VERSUS INTERSPINOUS PROCESS DECOMPRESSION
   IN THE TREATMENT OF PATIENTS WITH THE SINGLE-LEVEL DEGENERATIVE LUMBAR
   SPINE DISORDERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Single segment; Degenerative lumbar spinedisease; Posterior lumbar spine
   fusion; Interspinous process decompression; Clinical effect
AB Objective: We treated patients suffering from degenerative lumbar spine disorder with minimally invasive and traditional open transforaminal lumbar interbody fusion to evaluate clinical efficacy of patients through influences on imageological examination and the whole recovery.
   Method: We selected 120 cases of patients suffering from single-level degenerative lumbar spine disorder and treated in our hospital from January, 2012 to January, 2016, and all patients received complete follow-up visit. Before treatment, all patients were averagely divided into two groups based on number table method. Minimally invasive transforaminal interbody fusion (MIS-TLIF) was used for treatment on 60 cases in Group A, while traditional transforaminal interbody fusion (TLIF) was used for treatment on remaining 60 cases in Group B.
   Results: With comparison on operation duration, in-operation blood volume and post-operation drainage volume between two groups of patients, the operation duration of Group A is obviously longer than that of Group B, while the in-operation blood volume and post-operation drainage volume of Group A are distinctly less than these of Group B, and the difference has statistical significance (p<0.05). The VAS score on lumbago and leg pain at 1 week and 8 weeks of post-operation for Group A is significantly lower than that for Group B, and the difference has statistical significance (p<0.05); the VAS score on lumbago and leg pain in six months of post-operation for Group A is slightly lower than that for Group B, and the difference has statistical significance (p<0.05). The ODI functional disability scores under follow-up visit in 2 months, 4 months and 6 months of post-operation for both Group A and Group B are distinctly lower than these of pre-operation, and JOA score is obviously higher than that of pre-operation, so the difference has statistical significance (p<0.05).
   Conclusion: the clinical effect of minimally invasive transforaminal lumbar interbody fusions to treat single-level degenerative lumbar spine disorder is much better and the vertebral fusion rate is higher, while the minimally invasive technique needs to be completed in the working aisle for its narrowness.
C1 [Teng, Xiao; Zhang, Zhaobo; Ding, Lingzhi; Zhang, Jingsheng; Yuan, Chi; Yang, Meizi] Taizhou Cent Hosp, Dept Orthoped, Taizhou City 318000, Zhejiang, Peoples R China.
RP Zhang, ZB (corresponding author), Taizhou Cent Hosp, 999 East China Sea Rd, Taizhou City 318000, Zhejiang, Peoples R China.
EM hh18888@126.com
CR Bo Xiao, 2013, J MED COLL PLA, V34, P446
   [陈文昊 Chen Wenhao], 2015, [中国临床解剖学杂志, Chinese Journal of Clinical Anatomy], V33, P593
   Chen Zhigang, 2016, J PRACTICAL ORTHOPED, V22, P155
   Cheng Mengmeng, 2015, SHANDONG MED J, V55, P34
   Cincu Rafael, 2015, Asian J Neurosurg, V10, P75, DOI 10.4103/1793-5482.145120
   Gao Mingzhong, 2013, CHINA J POSTGRADUATE, V36, P25
   Hao Yonghong, 2011, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V25, P87
   Kasliwal MK, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.05.049
   Li Qingchu, 2011, CHINJSPINE SPINAL CO, V24, P303
   Mao Keya, 2012, CHINJSPINE SPINAL CO, V21, P113
   Masevnin S, 2015, ASIAN SPINE J, V9, P239, DOI 10.4184/asj.2015.9.2.239
   Mobbs RJ, 2011, J CLIN NEUROSCI, V18, P741, DOI 10.1016/j.jocn.2010.09.019
   Qi Qihua, 2015, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V29, P1253
   Richter A, 2010, EUR SPINE J, V19, P283, DOI 10.1007/s00586-009-1229-9
   Rui Zhang, 2011, ORTHOPEDIC J CHINA, V20, P2125
   Soleimanha M, 2014, ARCH BONE JT SURG-AB, V2, P163
   Wu RH, 2010, SPINE, V35, P2273, DOI 10.1097/BRS.0b013e3181cd42cc
   Yang Jin, 2013, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V27, P262
   [周亮 Zhou Liang], 2013, [解放军医学杂志, Medical Journal of Chinese People's Liberation Army], V38, P972
   Zhou Liang, 2014, ORTHOPEDIC J CHINA, V22, P770
   冯永洪, 2011, [广东医学, Guangdong Medical Journal], V32, P2147
NR 21
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1429
EP 1435
DI 10.19193/0393-6384_2018_5_217
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700039
DA 2022-07-14
ER

PT J
AU Tian, CF
   Su, BY
   Tong, YH
   Zhao, XH
   Wang, Y
   Li, SB
   Gao, BL
AF Tian, Chun-Feng
   Su, Bai-Yu
   Tong, Yu-Hong
   Zhao, Xu-Hong
   Wang, Yan
   Li, Shun-Bao
   Gao, Bu-Lang
TI PROTECTIVE EFFECTS OF STATINS ON RENAL FUNCTION IN PATIENTS WITH CAROTID
   ATHEROSCLEROTIC PLAQUES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Carotid atherosclerotic plague; Stains; Renal Function; Cystatin C; C
   reactive protein
ID CHRONIC KIDNEY-DISEASE; CORONARY-HEART-DISEASE; CUSHINGS-SYNDROME;
   ATORVASTATIN THERAPY; REDUCTASE INHIBITOR; SIMVASTATIN; TRIAL;
   INFLAMMATION; CHOLESTEROL
AB Purpose: To investigate the effects of statins on renal function in atherosclerotic patients.
   Materials and methods: Two-hundred-forty patients with carotid atherosclerotic plaques were enrolled and randomly divided into four groups. Group A had atorvastatin 10 mg/d, group B had simvastatin 20 mg/d, group C had rosuvastatin 5 mg/d and group D had lovastatin 20 mg/d before sleep once daily for four months. The alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL), Cystatin C (Cys C), high sensitive C reactive protein (hsCRP), blood urea nitrogen (BUN) and serum creatinine (SCr) were tested before medication, 4 and 15 weeks of follow-up.
   Results: No significant (P>0.05) differences existed in the demographic data among the four groups. Significant (P<0.05) decreases in TG, TC, LDL, hsCRP and Cys C but significant (P<0.05) increases were found in HDL at weeks 4 and 15 compared with before medication (Table 2-3). No significant (P>0.05) differences existed in the ALT, AST and BUN at different time points. The SCr was significantly (P<0.05) decreased at week 15 compared with before medication. No significant (P>0.05) decrease was in the BUN after medication, but significant (P<0.05) decrease in the SCr at week 15 and in the Cys C, hsCRP, TC and LDL at weeks 4 and 15 (Table 4-5). However, no significant (P>0.05) difference existed in these parameters in the four groups.
   Conclusion: Statins have a potential protective effect on renal function besides reducing serum lipids and inflammatory factors.
C1 [Tian, Chun-Feng; Su, Bai-Yu; Tong, Yu-Hong; Zhao, Xu-Hong; Gao, Bu-Lang] Shijiazhuang First Hosp, 36 Fanxi Rd, Shijiazhuang 050011, Hebei, Peoples R China.
   [Wang, Yan] Baoding New Dist Hosp, Baoding, Peoples R China.
   [Li, Shun-Bao] Baoding First Cent Hosp, Baoding, Peoples R China.
RP Gao, BL (corresponding author), Shijiazhuang First Hosp, 36 Fanxi Rd, Shijiazhuang 050011, Hebei, Peoples R China.
CR Agarwal R, 2006, AM J CARDIOL, V97, P748, DOI 10.1016/j.amjcard.2005.09.110
   Baigent C, 2011, LANCET, V377, P2181, DOI 10.1016/S0140-6736(11)60739-3
   Choudhry NK, 2011, J AM COLL CARDIOL, V57, P784, DOI 10.1016/j.jacc.2010.07.059
   Cieszynski L, 2016, ENDOKRYNOL POL, V67, P458, DOI 10.5603/EP.a2016.0055
   Ding SF, 2008, AM J MED SCI, V336, P27, DOI 10.1097/MAJ.0b013e31815b60a1
   Duan SB, 2013, CLIN NEPHROL, V80, P349, DOI 10.5414/CN107829
   Hiro T, 2009, J AM COLL CARDIOL, V54, P293, DOI 10.1016/j.jacc.2009.04.033
   Hirohata A, 2010, J AM COLL CARDIOL, V55, P976, DOI 10.1016/j.jacc.2009.09.062
   Kadoglou NPE, 2010, J VASC SURG, V51, P114, DOI 10.1016/j.jvs.2009.07.119
   Kalaitzidis RG, 2011, AM J NEPHROL, V34, P195, DOI 10.1159/000330355
   Kobayashi T, 2014, BIOCHEM BIOPH RES CO, V445, P412, DOI 10.1016/j.bbrc.2014.02.021
   Komukai K, 2014, J AM COLL CARDIOL, V64, P2207, DOI 10.1016/j.jacc.2014.08.045
   Koren MJ, 2009, AM J KIDNEY DIS, V53, P741, DOI 10.1053/j.ajkd.2008.11.025
   Lian Penghu, 2015, Zhonghua Yi Xue Za Zhi, V95, P929
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Mason RP, 2008, DRUGS, V68, P885, DOI 10.2165/00003495-200868070-00001
   Newell-Price J, 2006, LANCET, V367, P1605, DOI 10.1016/S0140-6736(06)68699-6
   ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126
   Garcia LP, 2012, AN SIST SANIT NAVAR, V35, P461, DOI 10.4321/s1137-66272012000300012
   ROSS EJ, 1982, LANCET, V2, P646
   Sahebkar A, 2013, METABOLISM, V62, P1876, DOI 10.1016/j.metabol.2013.08.017
   Seliger SL, 2002, KIDNEY INT, V61, P297, DOI 10.1046/j.1523-1755.2002.00109.x
   Seljeflot I, 2002, ATHEROSCLEROSIS, V162, P179, DOI 10.1016/S0021-9150(01)00696-7
   Sharma ST, 2015, CLIN EPIDEMIOL, V7, P281, DOI 10.2147/CLEP.S44336
   Shepherd J, 2008, J AM COLL CARDIOL, V51, P1448, DOI 10.1016/j.jacc.2007.11.072
   Shoji T, 2002, KIDNEY INT, V61, P2187, DOI 10.1046/j.1523-1755.2002.00372.x
   STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P3617, DOI 10.1210/jc.80.12.3617
   Yang L, 2010, SAUDI MED J, V31, P578
NR 28
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1003
EP 1007
DI 10.19193/0393-6384_2018_4_152
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500015
DA 2022-07-14
ER

PT J
AU Tocco, A
   Privitera, G
   Raffaele, L
   Salamone, V
   Scoglio, C
   Milazzotto, R
   Marletta, D
   Cuttone, G
   Cirrone, GAP
   Russo, A
   Avitabile, T
   Spatola, C
AF Tocco, Alessandra
   Privitera, Giuseppe
   Raffaele, Luigi
   Salamone, Vincenzo
   Scoglio, Claudio
   Milazzotto, Roberto
   Marletta, Dario
   Cuttone, Giacomo
   Cirrone, Giuseppe Antonio Pablo
   Russo, Andrea
   Avitabile, Teresio
   Spatola, Corrado
TI POROCARCINOMA OF THE EYELID TREATED WITH PROTON BEAM RADIOTHERAPY: CASE
   REPORT AND LITERATURE REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Eyelid porocarcinoma; eccrine; radiotherapy; proton therapy
AB Introduction: Porocarcinoma is a rare sort of skin cancer developing from eccrine sweat glands, with a very rare location to the eyelid. Surgery is the unique form of treatment reported in the literature. We use radiotherapy for a case of an almost centenary man who suffered from an histologically proven porocarcinoma at the level of the left inferior eyelid.
   Materials and methods: We made a treatment plan comparison between photon-beam and proton-beam radiotherapy and chose the latter due to the favourable dose distribution of charged particles. Irradiation was delivered through an extreme hypofractionation
   Results: A rapid complete response was obtained. No relevant effects have been reported and visual function is maintained.
   Conclusions: This is the first case of use of proton-beam radiotherapy for the treatment of eyelid porocarcinoma. We believe that protontherapy can become a valid alternative to surgery for this type of cancer.
C1 [Tocco, Alessandra; Privitera, Giuseppe; Raffaele, Luigi; Salamone, Vincenzo; Scoglio, Claudio; Milazzotto, Roberto; Marletta, Dario; Spatola, Corrado] VE Catania, UO Radiodiagnost & Radioterapia Policlin, Catania, Italy.
   [Cuttone, Giacomo; Cirrone, Giuseppe Antonio Pablo] LNS Catania, INFN, Catania, Italy.
   [Russo, Andrea; Avitabile, Teresio] VE Catania, UO Oftalmol Policlin, Catania, Italy.
RP Tocco, A (corresponding author), VE Catania, UO Radiodiagnost & Radioterapia Policlin, Catania, Italy.
EM aluccia82@hotmail.it
RI Avitabile, Teresio/AAC-6076-2022; Cirrone, Giuseppe/AAF-7101-2021;
   raffaele, luigi/ABG-4082-2020
OI Cirrone, Giuseppe/0000-0001-5733-9281; Milazzotto, Roberto
   Massimo/0000-0003-3282-2204
CR Boynton JR, 1997, OPHTHALMOLOGY, V104, P1626, DOI 10.1016/S0161-6420(97)30072-4
   Chua PY, 2015, SEMIN OPHTHALMOL, V30, P443, DOI 10.3109/08820538.2013.874475
   Cirrone GAP, 2017, FRONTIERS ONCOLOGY, V1
   Salih AM, 2017, ANN MED SURG, V20, P74, DOI 10.1016/j.amsu.2017.06.027
   Spatola C, 2008, RIV MED, V14
   Spatola Corrado, 2018, Future Oncol, V14, P17, DOI 10.2217/fon-2017-0280
   Spatola C, 2016, FUTURE ONCOL, V12, P73, DOI 10.2217/fon-2016-0331
   Spatola C, 2016, FUTURE ONCOL, V12, P67, DOI 10.2217/fon-2016-0330
NR 8
TC 2
Z9 2
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 709
EP 712
DI 10.19193/0393-6384_2018_3_109
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000014
DA 2022-07-14
ER

PT J
AU Tozun, M
   Turhan, E
   Babaoglu, AB
AF Tozun, Mustafa
   Turhan, Ebru
   Babaoglu, Asya Banu
TI BETA THALASSEMIA TRAIT IN TURKEY AND THE MIDDLE EAST: A META-ANALYSIS OF
   PREVALENCE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE beta thal trait; prevalence; meta-analysis
ID SICKLE-CELL-DISEASE; PREMARITAL HEMOGLOBINOPATHY; SAUDI-ARABIA; ANEMIA
   TRAIT; REGION; PROVINCE; PROGRAM; PREVENTION; FREQUENCY; IRAN
AB Introduction:Beta thalassemia (beta thal) is a genetic blood disorder, which is endemic in especially Mediterranean countries. Hemoglobinopathy Control Programs are conducted in endemic areas, in order to reduce the number of risky newborns with thalassemia. The study's aim was to present the results of a Meta-analysis of the prevalence of beta thalassemia trait (beta thal trait) in Turkey and the Middle East Islamic countries since 2000.
   Materials and methods: This study is a meta-analysis of prevalence. A meta-analysis was conducted on results of studies about the prevalence of beta that trait from Turkey's provinces and from the other Middle East Islamic countries. Meta-analysis of prevalence was studied with MetaXL. Random effects model was used to evaluate heterogeneity. Prevalence was presented with low and high Confidence Interval 95% (LCI and HCI), and weight (%). Pooled prevalence, I-squared and Cochran's Q (homogeneity test), and Chi-square p were presented.
   Results: Pooled prevalence was 2.6%. In Turkey, provinces from the Mediterranean and Aegean region have high prevalence of beta thal trait, generally. Pakistan has a high prevalence of beta thal trait, conversely, Iran national data reported a low prevalence of beta thal trait.
   Conclusion: Meta-analysis including in Turkey and the Middle East Islamic countries show a prevalence of beta that trait between 0.2% to 7.9%. Iran's national data presented the lowest prevalence of beta thal trait. Geographical features were considered as the main cause of heterogeneity. Premarital screening programs should be conducted in endemic countries.
C1 [Tozun, Mustafa; Turhan, Ebru; Babaoglu, Asya Banu] Izmir Katip Celebi Univ, Med Fac, Publ Hlth Dept, Izmir, Turkey.
RP Tozun, M (corresponding author), Izmir Katip Celebi Univ, Med Fac, Publ Hlth Dept, Izmir, Turkey.
EM mtzn76@gmail.com
RI Turhan, Ebru/AAR-2220-2021; Babaoglu, Asya Banu/AAB-7783-2021
OI Babaoglu, Asya Banu/0000-0002-1259-1288; Turhan,
   Ebru/0000-0003-2387-3253
CR Acemoglu H, 2008, PUBLIC HEALTH, V122, P620, DOI 10.1016/j.puhe.2007.09.007
   Al-Allawi N. A., 2010, Eastern Mediterranean Health Journal, V16, P381
   Al-Allawi NA, 2008, DOHUK MED J, V2, P71
   Al-Allawi NAS, 2013, J MED SCREEN, V20, P171, DOI 10.1177/0969141313508105
   Al-Awamy BH, 2000, SAUDI MED J, V21, P8
   Al-Suliman A, 2006, ANN SAUDI MED, V26, P14, DOI 10.5144/0256-4947.2006.14
   AlHamdan NA, 2007, GENET MED, V9, P372, DOI 10.1097/GIM.0b013e318065a9e8
   Almutawa F, 2009, J BAHRAIN MED SOC, V21, P217
   Altikat S, 2016, SAS J MED, V2, P1
   Arica SG, 2012, INT J COLLAB RES INT, V4, P145
   Belhoul KM, 2013, HEMOGLOBIN, V37, P359, DOI 10.3109/03630269.2013.791627
   Bolaman Z, 2001, Turk J Haematol, V18, P85
   Canatan D, 2006, COMMUNITY GENET, V9, P124, DOI 10.1159/000091493
   Cao A, 2010, GENET MED, V12, P61, DOI [10.1186/1750-1172-5-11, 10.1038/gim.2016.173, 10.1097/GIM.0b013e3181cd68ed]
   Colah R, 2010, EXPERT REV HEMATOL, V3, P103, DOI 10.1586/EHM.09.74
   Cousens NE, 2010, EUR J HUM GENET, V18, P1077, DOI 10.1038/ejhg.2010.90
   El-Tayeb EN, 2007, GENETIC COUNSELING G, V19, P211
   Genc A, 2012, HEMOGLOBIN, V36, P131, DOI 10.3109/03630269.2012.658128
   Ghotbi N., 2005, Eastern Mediterranean Health Journal, V11, P308
   Guler E, 2007, J PEDIAT HEMATOL ONC, V29, P783, DOI 10.1097/MPH.0b013e318159a570
   Guler E, 2010, PEDIATR HEMAT ONCOL, V27, P608, DOI 10.3109/08880018.2010.503772
   Hashemizadeh H, 2013, IRAN J PEDIATR HEMAT, V3, P29
   Hassan M K, 2003, East Mediterr Health J, V9, P45
   Incebiyik A, 2014, HEMOGLOBIN, V38, P402, DOI 10.3109/03630269.2014.978008
   Iqbal M, 2012, J RAWAL MED COLL, V16, P73
   Jameel T, 2017, PAK J MED SCI, V33, P665, DOI 10.12669/pjms.333.12098
   Karakukcu C, 2012, J PEDIAT HEMATOL ONC, V34, pE49, DOI 10.1097/MPH.0b013e3182370bdf
   Karimi M, 2007, J MED SCREEN, V14, P62, DOI 10.1258/096914107781261882
   Keskin A, 2000, ACTA HAEMATOL-BASEL, V104, P31, DOI 10.1159/000041066
   Khodaei GH, 2013, INT J PEDIATR-MASSHA, V1, P45
   Memish ZA, 2011, J EPIDEMIOL GLOB HEA, V1, P61, DOI 10.1016/j.jegh.2011.06.002
   Moher D., 2015, SYSTEM REV, V4, P1, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1]
   Oktay G, 2016, J CLIN ANAL MED, V7, P6, DOI 10.4328/JCAM.2427
   Saffi M, 2015, PUBLIC HEALTH GENOM, V18, P193, DOI 10.1159/000430837
   Salama Rasha Aziz Attia, 2016, [Journal of Genetic Medicine, 대한의학유전학회지], V13, P26
   Samavat A, 2014, BMJ-BRIT MED J, V329, P1134
   Sarper N, 2009, TURK J HEMATOL, V26, P62
   Shariq M, 2014, J MED SCREEN, V21, P163, DOI 10.1177/0969141314541434
   Tadmouri GO, 2001, HEMOGLOBIN, V25, P227, DOI 10.1081/HEM-100104031
   Tarazi I, 2007, INT J LAB HEMATOL, V29, P111, DOI 10.1111/j.1751-553X.2006.00836.x
   Tosun Fatma, 2006, Turk J Haematol, V23, P84
   Uludag A, 2016, BALK J MED GENET, V19, P29, DOI 10.1515/bjmg-2016-0004
   Ulutas KT, 2014, TURK J BIOCHEM, V39, P357, DOI 10.5505/tjb.2014.90217
   Uysal A, 2013, PEDIATR HEMAT ONCOL, V30, P46, DOI 10.3109/08880018.2012.742604
   Zeinalian M, 2013, SCI J IRANIAN BLOOD, V10, P20
   Zeinalian M, 2013, J COMMUN GENET, V4, P517, DOI 10.1007/s12687-013-0142-4
NR 46
TC 2
Z9 2
U1 1
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1731
EP 1738
DI 10.19193/0393-6384_2018_6_265
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400016
DA 2022-07-14
ER

PT J
AU Turkoglu, SA
   Ogun, MN
   Karabork, S
   Yildiz, N
   Yildiz, S
AF Turkoglu, Sule Aydin
   Ogun, Muhammed Nur
   Karabork, Seyda
   Yildiz, Nebil
   Yildiz, Serpil
TI THE ASSOCIATION OF ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH MULTIPLE
   SCLEROSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Multiple Sclerosis; Antiphospholipid syndrome; Antiphospholipid
   antibodies; Anticardiolipin antibodies; Lupus anticoagulant
ID HUGHES SYNDROME; CLASSIFICATION; DISORDERS; DIAGNOSIS; DISEASE; LUPUS;
   APS
AB Aim: Antiphospholipid syndrome (APS) is one of the most common acquired causes of arterial and venous thrombosis. The diagnosis is made based on the presence of antiphospholipid antibodies (APA), anticardiolipin antibodies (aCLA), lupus anticoagulant (LA), and anti-beta 2-glycoprotein I antibody levels and clinical criteria. Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system. From time to time, MS and APS can cause diagnostic confusion for clinical and cranial involvement. We aimed to investigate the frequency of APA in patients with and without MS after being admitted for a differential diagnosis of MS.
   Materials and methods: The laboratory values for vasculitis/MS differential diagnosis for the last 14 months were analyzed in this retrospective cross-sectional study. The patients were categorized into those who were diagnosed as having MS and those who were not (MS-like) based on the McDonald criteria. The patients' APA IgG and IgM antibodies, aCLA IgG and IgM, and LA values were recorded. Correlation regarding the Expanded Disability Status Scale (EDSS) scores of the patients with MS was investigated. P<0.05 was considered statistically significant.
   Results: Of 125 patients, 42 had MS and 83 had MS-like illnesses. LA was found negative in 21 (50%) patients and positive in 21 (50%) patients in the MS group. LA was found negative in 26 (31%) patients and positive in 57 (69%) patients in the MS-like group. The difference between the groups was statistically significant (p=0.04). There were positive APA values in 1 patient, and positive aCLA values in 3 patients in the MS group, and positive APA values in 3 patients, and positive aCLA values in 4 patients in the MS-like group. This difference between the groups was not statistically significant (p=0.9). There was no correlation found between EDSS and LA in the patients with MS.
   Conclusion: The prevalence of antiphospholipid antibodies in MS is a controversial topic. Our study had a higher prevalence of LA in the patients with MS than in the normal population but lower than in the MS-like group. APS should be taken into consideration in the differential diagnosis of patients with MS-like conditions.
C1 [Turkoglu, Sule Aydin; Ogun, Muhammed Nur; Yildiz, Nebil; Yildiz, Serpil] Abant Izzet Baysal Univ, Med Fac, Dept Neurol, Bolu, Turkey.
   [Karabork, Seyda] Abant Izzet Baysal Univ, Med Fac, Dept Microbiol, Bolu, Turkey.
RP Turkoglu, SA (corresponding author), Abant Izzet Baysal Univ Hosp, Dept Neurol, TR-14280 Bolu, Turkey.
RI yildiz, nebil/AAO-2341-2020
OI yildiz, nebil/0000-0002-1845-0902
CR Akdemir N, 2017, NOROPSIKIYATRI ARS, V54, P11, DOI 10.5152/npa.2016.12451
   Cervera R, 2012, AUTOIMMUN REV, V11, P581, DOI 10.1016/j.autrev.2011.10.017
   Checa CM, 2013, BEST PRACT RES CL RH, V27, P405, DOI 10.1016/j.berh.2013.07.010
   de Amorim LCD, 2017, LUPUS, V26, P529, DOI 10.1177/0961203316688784
   Espinosa G, 2015, NAT REV RHEUMATOL, V11, P586, DOI 10.1038/nrrheum.2015.88
   Etemadifar M, 2013, J RES MED SCI, V18, P616
   Etemadifar M, 2013, IRAN J NEUROL, V12, P172
   Fernandez-Fernandez FJ, 2006, EUR J INTERN MED, V17, P500, DOI 10.1016/j.ejim.2006.02.018
   Ferreira S, 2005, RHEUMATOLOGY, V44, P434, DOI 10.1093/rheumatology/keh532
   Gomez-Puerta JA, 2014, J AUTOIMMUN, V48-49, P20, DOI 10.1016/j.jaut.2014.01.006
   Horstman LL, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-3
   Huang WJ, 2017, EXP THER MED, V13, P3163, DOI 10.3892/etm.2017.4410
   Hughes GRV, 2003, POSTGRAD MED J, V79, P81, DOI 10.1136/pmj.79.928.81
   Ijdo JW, 1999, LUPUS, V8, P109, DOI 10.1191/096120399678847461
   Ilgen U, 2017, LUPUS
   Kirichuk V, 2002, Z NEVROLOGII PSIKHIA, P34
   Koudriavtseva T, 2014, NEUROL SCI, V35, P1737, DOI 10.1007/s10072-014-1823-4
   Koudriavtseva T, 2014, J NEUROL, V261, P2028, DOI 10.1007/s00415-014-7506-5
   Merashli M, 2017, SEMINARS ARTHRITIS R
   Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
   Nalbant S., 2007, TURK IC HASTALIKLARI, V14, P83
   Ruiz-Irastorza G, 2011, LUPUS, V20, P206, DOI 10.1177/0961203310395803
   SCOTT TF, 1994, ARCH INTERN MED, V154, P917, DOI 10.1001/archinte.154.8.917
   Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313
   Uthman I, 2015, LUPUS, V24, P115, DOI 10.1177/0961203314555539
   Vilisaar J, 2005, MULT SCLER J, V11, P378, DOI 10.1191/1352458505ms1208oa
   Yelnik CM, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-016-0568-x
NR 27
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 637
EP 641
DI 10.19193/0393-6384_2018_3_98
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000003
DA 2022-07-14
ER

PT J
AU Valiani, M
   Mansourian, M
   Ashtari, F
AF Valiani, Mahboubeh
   Mansourian, Marjan
   Ashtari, Fereshteh
TI THE EFFECT OF AURICULOTHERAPY ON STRESS, ANXIETY, AND DEPRESSION IN MS
   PATIENTS: A DOUBLE BLIND RANDOMIZED CLINICAL CONTROL TRIAL (PARALLEL
   DESIGN)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE multiple sclerosis; auriculotherapy; stress; anxiety; depression; Iran
ID MULTIPLE-SCLEROSIS; ACUPUNCTURE; RELAPSE; SLEEP; RISK
AB Background: MS is one of the central nervous system diseases, which is of relatively high prevalence among neurological diseases. Multiple studies have shown that stressful life is associated with an increased risk of MS. The aim of this study is to investigate the impact of using the auriculotherapy technique on stress, anxiety, and depression in MS patients.
   Materials and methods: This study was a double blind randomized clinical trial in two groups. The sample size was estimated to be 64 subjects in each group. The Center for MS at Kashani hospital in the Province of Isfahan was the location of research. DASS-21 questionnaire were completed before, after and one month after intervention. The auriculotherapy technique began in the intervention group and at the end of each session, herbal vaccaria seeds were fixed at three main points on the ear, for at least 3 days. All the tests were carried out using the SPSS19 software at an error level of 5%.
   Results: The results showed that the mean score of stress, anxiety and depression decreased in the auriculotherapy group compared with that in the placebo group. The analysis of variance showed significant differences between the two groups after intervention and one month later ( P <0.05). Whereas the stress, anxiety and depression score had not undergone any significant changes before intervention in two groups (P>0.05).
   Conclusion: Auriculotherapy as a safe and effective technique reduced stress, anxiety, and depression in MS patients.
C1 [Valiani, Mahboubeh; Ashtari, Fereshteh] Isfahan Univ Med Sci, Isfahan Neurosci Res Ctr, Alzahra Res Inst, Esfahan, Iran.
   [Mansourian, Marjan] Isfahan Univ Med Sci, Hlth Sch, Dept Biostat, Esfahan, Iran.
RP Ashtari, F (corresponding author), Isfahan Univ Med Sci, Isfahan Neurosci Res Ctr, Alzahra Res Inst, Esfahan, Iran.
EM f_ashtari@med.mui.ac.ir
RI Mansourian, Marjan/AAX-1011-2020; ashtari, fereshteh/N-1243-2018
OI Mansourian, Marjan/0000-0002-7217-0282
FU Isfahan University of Medical Sciences; Neuroscience Research Center of
   Isfahan University of Medical Sciences
FX This paper is the result of a part of a doctoral thesis titled "An
   investigation on the effect of auriculotherapy on pain and stress in
   patients suffering from multiple sclerosis", which is sponsored by the
   deputy of research at Isfahan University of Medical Sciences and the
   Neuroscience Research Center of this University. And no doubt, it was
   not possible to conduct this study without coordination from the
   management at Ayatollah Kashani Hospital and cooperation of the
   respectable MS patients.
CR Abolfazli R, 2014, J NEUROL SCI
   Artemiadis AK, 2011, NEUROEPIDEMIOLOGY, V36, P109, DOI 10.1159/000323953
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Beate Stritmatte, 2011, PRECISE POCKET ATLAS
   Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544
   Dossett ML, 2014, AM J GASTROENTEROL, V109, P1705, DOI 10.1038/ajg.2014.108
   Douglas C, 2008, J NEUROSCI NURS, V40, P158, DOI 10.1097/01376517-200806000-00006
   Fathi Ashtiani Ali, 2009, PSYCHOL PERSONALITY
   Food & Drug Department of Ministry of Health, 2011, TREATM MED ED IR OFF, P256
   Funai F. E., MANAGEMENT NORMAL LA, P5
   Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106
   Hung Yu Ng E., 2010, FERTIL STERIL, V90, P1
   Karpatkin HI, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/972935
   Laden Ansari, 2013, EAR ACUPUNCTURE
   Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907
   Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560
   Mantis LL, 2013, J NEUROL NEUROSUR PS, V84, P420, DOI [DOI 10.1136/JNNP-2012-303291, 10.1136/jnnp-2012-303291]
   Masoud Etemadifar, 2010, HLTH PROMOTION MULTI, P14
   Murray ED, 2012, J BRADLEYS NEUROLOGY, V6th
   Nakahara J, 2012, CLIN REV ALLERG IMMU, V42, P26, DOI 10.1007/s12016-011-8287-6
   Namjooyan Foroogh, 2014, J Tradit Complement Med, V4, P145, DOI 10.4103/2225-4110.136543
   Nandagopal M., 2006, 2014 MCMASTER UNIVER
   National Institute for Clinical Excellence, 2013, NICE CLIN GUIDELINE8
   Nociti V, 2017, J NEUROL SCI, V372, P387, DOI 10.1016/j.jns.2016.10.040
   Oleson Terry, 2014, CHINESE W SYSTEMS EA, P212
   Olsson M, 2008, HEALTH CARE WOMEN IN, V29, P416, DOI 10.1080/07399330701876646
   Quispe-Cabanillas JG, 2012, IMPACT ELECTIVE ACUP
   Riise T, 2011, NEUROLOGY, V76, P1866, DOI 10.1212/WNL.0b013e31821d74c5
   Rosti-Otajarvi E, 2014, J NEUROL SCI, V338, P156, DOI 10.1016/j.jns.2013.12.039
   Sahraian MA, 2017, EUR NEUROL, V77, P258, DOI 10.1159/000470904
   Siamak Samani, 2007, J SOCIAL HUMAN SCI S, V26, P65
   Silverberg JI, 2014, DERMATITIS, V25, P246, DOI 10.1097/DER.0000000000000072
   Skokou M, 2012, ISRN NEUROLOGY, V2012, P6
   SmithCa, 2009, COMPLEMENTARY ALTERN, P2
   Snooks M. K., 2010, HEALTH PSYCHOL, P183
   Valiani M, 2014, IRAN J REPROD MED, V12, P47
   Valiani Mahboobeh, 2009, STRESS MANAGEMENT SK, P11
   Wang SM, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.04.028
   Wang Yao-Kuang, 2013, Gastroenterol Res Pract, V2013, P983653, DOI 10.1155/2013/983653
   Wang ZJ, 2017, J PSYCHIATR RES, V84, P18, DOI 10.1016/j.jpsychires.2016.09.014
   Xiang Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174872
   Zhang Y, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1693-4
NR 42
TC 2
Z9 3
U1 1
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 2
BP 561
EP 567
DI 10.19193/0393-6384_2018_2s_89
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7SD
UT WOS:000429274400003
DA 2022-07-14
ER

PT J
AU Vanne, D
   Vanni, P
   Mannelli, I
   Vanne, S
AF Vanne, Duccio
   Vanni, Paolo
   Mannelli, Iacopo
   Vanne, Simone
TI ELENA, DUCHESS OF AOSTA, INSPECTOR GENERAL OF THE RED CROSS VOLUNTEER
   NURSES IN THE GREAT WAR - WORLD WAR 1
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Italian Red Cross; Word War 1; Elena of France; San Giorgio of Nogaro;
   Accanto agli Eroi. Italian volunteer nurses
AB It is our conviction that the history of the Red Cross is part of the history of medicine. The nursing activity of H.R.H. Elena of France during the Great War is a fine example of the medical emergency history. In May 1915, the Duchess of Aosta became Inspector General of the volunteer nurses of the Italian Red Cross. Her diary "Accanto agli eroi" (Side by Side with the Heros) is an exhaustive text that accurately describes those dramatic events. For her activity in the Great War we can refer to her as our Florence Nightingale.
C1 [Vanne, Duccio] Univ Florence, Hist Med, Hlth Sci Dept, Florence, Italy.
   [Vanni, Paolo] Univ Florence, Med Chem, Italian Red Cross Silver Medal, Florence, Italy.
   [Vanne, Simone] Empoli Hosp Florence, Emergency Dept, Florence, Italy.
RP Vanni, P (corresponding author), Reg Toscana, Ufficio Storico CRI, Via Massoni 21, I-50139 Florence, Italy.
OI Vanni, Simone/0000-0002-1201-5715
CR [Anonymous], 1919, P MED C HELD INV COM
   Baldo D., 2010, STUDENTI AL FRONTE, P59
   Bartoloni S., 2003, ITALIANE GUERRA LASS, P1
   D'Aosta Elena, 1930, ACCANTO EROI CROCE R, P1
   Diana E., 2011, ATT CONV NAZ FIR 9 1
   Dunant H., 2005, MEMOIRES TEXT ESTABL, V1071
   Dunant H., 2010, PUBLIC GENEVA LIB, V1-11
   Dunant H., 2008, SOUVENIR SOLFERINO
   Gaspari P., 2008, CROCEROSSINE NELLA G, P218
   Guthrie D., 1958, HIST MED
   Major RH, 1959, HIST MED
   Ottaviani R, 2011, J MED BIOGR, V19, P117, DOI 10.1258/jmb.2010.010036
   Ottaviani R., 2011, MENSCHENLIEBE HEILT, P55
   Ottaviani Raimonda, 2003, Vesalius, V9, P20
   Pazzini A., 1974, STORIA ARTE SANITARI, VI-II
   Premuda L., 1960, STORIA MED
   Vanni D, 2008, J Med Biogr, V16, P195, DOI 10.1258/jmb.2008.008021
   Vanni D., 2014, MED STORIA ANNO 14, V6, P68
   Vanni D., 2017, ATT CONV NAZ STOR SA
   Vanni D., INTERNAL EMERGENCY M
   Vanni P., 2013, STORIA CROCE ROSSA I, P805
   Walker K., 1957, STORY MED
   Zanobio B., 1997, STORIA MED
   [No title captured]
NR 24
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 713
EP 718
DI 10.19193/0393-6384_2018_3_110
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000015
DA 2022-07-14
ER

PT J
AU Vanni, D
   Guerin, E
   Mannelli, I
AF Vanni, Duccio
   Guerin, Elisabeth
   Mannelli, Iacopo
TI A POSSIBLE (IF NOT PROBABLE) DIFFERENT INTERPRETATION OF KUHN'S PROFILE
   OF HENRY DUNANT (1828-1910), THE REAL FOUNDER OF THE INTERNATIONAL RED
   CROSS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE International Red Cross; Henry Dunant; Roland Kuhn; historical
   psychiatric reading
AB In 1985, the famous Swiss psychiatrist, Roland Kuhn (1912-2005), explained his psychiatric reading of Henry Dunant (1828-1910), the real founder of the International Red Cross, in a specific paper. Our historical analysis obout his article shows at least five criticism that can be made against Kuhn's interpretation of Dunant profile. All reasons of our historical criticism are described and discussed.
C1 [Vanni, Duccio] Univ Florence, Hlth Sci Dept, Hist Med, Florence, Italy.
   [Guerin, Elisabeth] Univ Florence, SCIFOPSI LILSI, Florence, Italy.
   [Mannelli, Iacopo] IOT, Cent Emergency Headquarters 118, Nursing Sci, Florence, Italy.
RP Vanni, D (corresponding author), Univ Florence, Hlth Sci Dept, Hist Med, Florence, Italy.
EM duccio.vanni@unifi.it
CR Baccolo M.G., 2007, ATT FOND G RONCH ANN, P787
   Dunant H., 2010, QUADERNI H DUNANT, V1-10
   DUNANT H., 2008, SOUVENIR SOLFERINO R
   Dunant H., 2010, QUADERNI H DUNANT, V11
   Dunant H., 1994, L AVENIR SANGLANT
   Dunant H., 2005, MEMOIRES, P1071
   Durand R., 1989, SOURCES IDEE CROIX R
   Kuhn R., 1988, ACT C H DUN GEN 3 4, P111
   Kuhn R., 1993, PSICHIATRIA TERRITOR, V10, P3
   Ottaviani R, 2011, J MED BIOGR, V19, P117, DOI 10.1258/jmb.2010.010036
   Ottaviani R., 2011, MENSCHENLIEBE HEILT, P55
   Ottaviani Raimonda, 2003, Vesalius, V9, P20
   Vanni D, 2008, J Med Biogr, V16, P195, DOI 10.1258/jmb.2008.008021
   Vanni D., 2014, MED STORIA ANNO 14, V6, P68
   Vanni D., 2017, GENESI CROCE ROSSA M, P548
   Vanni D., INTERNAL EMERGENCY M
   Vanni P., 2013, STORIA CROCE ROSSA I, P805
NR 17
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1345
EP 1349
DI 10.19193/0393-6384_2018_5_206
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700028
DA 2022-07-14
ER

PT J
AU Vanni, D
   Vanni, P
   Vanni, S
AF Vanni, Duccio
   Vanni, Paolo
   Vanni, Simone
TI GREAT WAR: MILITARY MEDICAL CARE AND ITALIAN RED CROSS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Battles of the Isonzo; Military Healthcar; Italian Red Cross; Diseases
   of war; causes of death
AB After a brief description of the great war the authors deal with medical assistance, military health activities and the Red Cross. The tragic aspects of a vast medical assistance, yet always insufficient compared to the magnitude of the tragedy, are described.
C1 [Vanni, Duccio] Univ Florence, Hist Med, Florence, Italy.
   [Vanni, Paolo] Florence Univ, Florence, Italy.
   [Vanni, Simone] Empolis Hosp, Emergency Dept, Empoli Firenze, Italy.
RP Vanni, P (corresponding author), Florence Univ, Florence, Italy.
EM paolo.vanni@unifi.it
RI Vanni, Simone/GLR-6148-2022
OI Vanni, Simone/0000-0002-1201-5715
CR Baldo D., 2010, STUDENTI AL FRONTE, P59
   Barbero A., 2017, CAPORETTO
   Belogi R., 1990, CRI BERGAMO, V1-3
   Bocchetti F., 1924, LIBRO ORO MEDICI ITA
   Gadda C.-E., 2002, GIORNALE GUERRA PRIG
   Gaspari P., 2008, CROCEROSSINE NELLA G, P218
   Losi A., 2015, ALBO ONORE CADUTI GR
   Lusssu E., 1996, ANNO SULL ALTIPIANO
   Santoro A., 2017, CONV NAZ STOR SAN MI, P431
   Vanne D, 2018, ACTA MEDICA MEDITERR, V34, P713, DOI 10.19193/0393-6384_2018_3_110
   Vanni D, 2018, INTERN EMERG MED, V13, P301, DOI 10.1007/s11739-017-1775-9
NR 11
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1863
EP 1867
DI 10.19193/0393-6384_2018_6_288
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400039
DA 2022-07-14
ER

PT J
AU Varol, AC
AF Varol, Aydan Cevik
TI EVALUATION OF NUTRITIONAL STATUS WITH MUST SCREENING TEST AND COMPARISON
   OF RESULTS WITH LABORATORY PARAMETERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Nutritional status; MUST; laboratory parameters
ID OLDER-ADULTS; MALNUTRITION; TOOLS; RISK
AB Introduction: The follow-up of malnourished patients is recommended by many international organizations. The Malnutrition Universal Screening Tool (MUST) is recommended for determining the malnutrition status of adult individuals. This test is easy to use, and its results are consistent with laboratory data. The purpose of this study is to assess the malnutrition status of patients receiving home health care by using MUST together with laboratory data.
   Material and methods: This study was conducted between 2013 and 2014 and included 178 patients aged 65 years or older who received home health care. According to the MUST evaluation form, a score of 23.5-30 was considered normal; 17-23.5 was considered to indicate malnutrition risk; and <17 was considered to indicate malnutrition. One-way ANOVA was used for descriptive statistical analysis, and Tukey's honest significant difference (HSD) test was used for determining differences between groups. Pearson's chi-square test, Yates' continuity correction test, Fisher's exact test and the Fisher-Freeman-Halton test were used for comparison of qualitative data. The significance level was set at p < 0.05, with a 95% confidence interval.
   Results: The average age of the subjects participating in the study was 81.19 +/- 8.22 years, and the study group comprised 32% male and 68% female participants. The body mass index values showed that 67.4% of the patients were obese. According to the MUST scores, 12.4% were at moderate risk and 14.6% were at high risk of malnutrition. Over the last 3 months, 16.9% of the patients had lost more than 3 kg of body weight, and 44.9% were dealing with psychological stress or acute illness. In this study population, 33% of the patients could eat their meals without assistance. Further, 45.5% had severe dementia or depression, and 94.9% were on more than three prescription drugs per day. The total protein, albumin, iron, TDBC, ferritin and B12 folic acid levels differed significantly according to the MUST scores (p<0.01), as did the CRP, hemoglobin, cholesterol, HDL, AST and ALT levels (p < 0.05).
   Conclusions: The results indicate that malnutrition is fairly common in geriatric patients who need health care at home. These patients should therefore extensive laboratory tests and physical examinations for assessing anamnesis and physical and mental functions, and should also undergo screening, specifically for the risk of malnutrition.
C1 [Varol, Aydan Cevik] Community Hlth Ctr, Tekirdag, Turkey.
RP Varol, AC (corresponding author), Community Hlth Ctr, Tekirdag, Turkey.
EM dracevik@gmail.com
RI Varol, Aydan Çevik/AAS-5377-2021
CR [Anonymous], 2005, J AM DIET ASSOC, V105, P1955, DOI 10.1016/j.jada.2005.10.004
   Crogan NL, 2003, J GERONTOL A-BIOL, V58, P159
   Demirel U., 2012, Firat Tip Dergisi, V17, P63
   Elia M., 2000, GUIDELINES DETECTION
   Green SM, 2006, J ADV NURS, V54, P477, DOI 10.1111/j.1365-2648.2006.03841.x
   Guigoz Y, 2006, J NUTR HEALTH AGING, V10, P466
   Jahoor F, 2005, AM J CLIN NUTR, V82, P792, DOI 10.1093/ajcn/82.4.792
   Johson LE, 2004, CURRENT GERIATRIC TR, P391
   Kaiser MJ, 2010, J AM GERIATR SOC, V58, P1734, DOI 10.1111/j.1532-5415.2010.03016.x
   Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0
   Norman K, 2008, CLIN NUTR, V27, P5, DOI 10.1016/j.clnu.2007.10.007
   Rakicioglu N, 2013, YASLILIK DONEMINDE M, P115
   Raslan M, 2010, NUTRITION, V26, P721, DOI 10.1016/j.nut.2009.07.010
   Seiler WO, 2001, NUTRITION, V17, P496, DOI 10.1016/S0899-9007(01)00558-5
   Soeters PB, 2008, CLIN NUTR, V27, P706, DOI 10.1016/j.clnu.2008.07.009
   Soini H, 2004, EUR J CLIN NUTR, V58, P64, DOI 10.1038/sj.ejcn.1601748
   Stratton RJ, 2005, AGEING RES REV, V4, P422, DOI 10.1016/j.arr.2005.03.005
   Ulger Z, 2010, CLIN NUTR, V29, P507, DOI 10.1016/j.clnu.2010.01.006
   Velasco C, 2011, EUR J CLIN NUTR, V65, P269, DOI 10.1038/ejcn.2010.243
   Weijs PJM, 2008, CLIN NUTR, V27, P150, DOI 10.1016/j.clnu.2007.09.001
NR 20
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 169
EP 174
DI 10.19193/0393-6384_2018_1_28
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600028
DA 2022-07-14
ER

PT J
AU Vasileva, DG
   Runev, NM
   Manov, EI
   Naydenov, SN
   Petrova-Nikolova, DS
   Pencheva-Genova, VP
   Apostolova, MD
AF Vasileva, Daniela Georgieva
   Runev, Nikolay Margaritov
   Manov, Emil Ivanov
   Naydenov, Stefan Naydenov
   Petrova-Nikolova, Daniela Stoychkova
   Pencheva-Genova, Ventsislava Pencheva
   Apostolova, Margarita Dimitrova
TI SHOULD WE MEASURE COPEPTIN LEVELS IN PATIENTS WITH PRE-METABOLIC AND
   METABOLIC SYNDROME?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Copeptin; Metabolic syndrome; Pre-metabolic syndrome; Vasopressin;
   Cardio-metabolic risk
ID PLASMA COPEPTIN; INSULIN-RESISTANCE; MARKER; VASOPRESSIN; COHORT; RISK;
   MEN
AB Introduction: Copeptin has been established as a stable and sensitive biomarker of arginine vasopressin precursor level. Its increased values are associated with higher risk for cardiovascular disorders and related with Metabolic syndrome (MS). However, the data about the role of copeptin in Pre-metabolic syndrome (PreMS) are scarce. The aim of the study was to compare the copeptin levels in patients with MS, PreMS and in healthy controls and to evaluate the possible correlations between copeptin and cardio-metabolic (CM) factors.
   Materials and methods: Altogether 82 subjects were investigated and divided in 3 groups: MS (n=33; mean age 57,7 +/- 11,7 years), PreMS (n=26; 56,5 +/- 13,78 years) and controls (n=23; 37,4 +/- 13,56 years). In all patients the following measurements were performed: copeptin concentrations, waist size, body mass index (BMI), lipid profile, fasting blood glucose (FBG).
   Results: Copeptin levels were found to be significantly higher in both, MS and PreMS groups: 24,56 +/- 10,05 pmol/l and 18,74 +/- 6,4 pmol/l, respectively, versus controls (16,28 +/- 9,16 pmol/l) and its values increased with age in both genders. However, there was no significant difference between the measured copeptin levels in MS and PreMS patients (p>0,017, NS, non-Gaussian distribution). Significant correlations of copeptin values with low density lipoproteins, FBG and presence of diabetes mellitus type 2 (DM T2) were obtained in MS group only (in PreMS, p=NS), whereas no relations were found between copeptin and waist size in these two groups.
   Conclusion: Our results confirmed the reported data for increased copeptin levels in MS, which correlated with the well established risk factors - arterial hypertension, dyslipidemia, increased BMI, diabetes mellitus. In PreMS patients copeptin concentrations were comparable to those with MS, suggesting that PreMS could also be associated with increased CM risk by common pathogenetic mechanism, but independently of the abdominal obesity.
C1 [Vasileva, Daniela Georgieva; Runev, Nikolay Margaritov; Manov, Emil Ivanov; Naydenov, Stefan Naydenov] Med Univ, UMHAT Aleksandrovska, Med Fac, Clin Cardiol,Dept Propedeut Internal Med, Sofia, Bulgaria.
   [Petrova-Nikolova, Daniela Stoychkova; Pencheva-Genova, Ventsislava Pencheva] Med Univ, UMHAT Alexandrovska, Dept Internal Med, Clin Pulmol, Sofia, Bulgaria.
   [Apostolova, Margarita Dimitrova] Bulgarian Acad Sci, Inst Mol Biol Roumen Tsanev, Sofia, Bulgaria.
RP Vasileva, DG (corresponding author), Med Univ, UMHAT Aleksandrovska, Med Fac, Clin Cardiol,Dept Propedeut Internal Med, Sofia, Bulgaria.
RI Apostolova, Margarita/AAF-2940-2019
OI Apostolova, Margarita/0000-0001-7188-506X; Naydenov,
   Stefan/0000-0002-0855-7861
CR Asferg CL, 2014, DIABETIC MED, V31, P728, DOI 10.1111/dme.12411
   Cornier MA, 2008, ENDOCR REV, V29, P777, DOI 10.1210/er.2008-0024
   Enhorning S, 2013, INT J OBESITY, V37, P598, DOI 10.1038/ijo.2012.88
   Enhorning S, 2011, J CLIN ENDOCR METAB, V96, pE1065, DOI 10.1210/jc.2010-2981
   Enhorning S, 2010, CIRCULATION, V121, P2102, DOI 10.1161/CIRCULATIONAHA.109.909663
   Enhorning S, 2009, AM J CLIN NUTR, V89, P400, DOI 10.3945/ajcn.2008.26382
   Giannopoulos G, 2013, CURR TOP MED CHEM, V13, P231, DOI 10.2174/15680266113139990088
   Grundy SM, 2008, ARTERIOSCL THROM VAS, V28, P629, DOI 10.1161/ATVBAHA.107.151092
   Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038
   Rothermel J, 2016, CLIN ENDOCRINOL, V85, P868, DOI 10.1111/cen.13235
   Roussel R, 2016, J CLIN ENDOCR METAB, V101, P2432, DOI 10.1210/jc.2016-1113
   Runev N., 2015, EUR J PREV CARDIO S1, V22, pS103
   Saleem U, 2009, J CLIN ENDOCR METAB, V94, P2558, DOI 10.1210/jc.2008-2278
   Stagnaro S., 2003, BMJ-BRIT MED J, V327, P266
   Vasileva D, 2014, B CARDIOL, V1, P16
   Vasileva D, 2014, B CARDIOL S1, VXX, P42
   Vidigal FD, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/s13098-015-0003-x
   Vintila M, 2016, J Med Life, V9, P353
   Wannamethee SG, 2015, J CLIN ENDOCR METAB, V100, P3332, DOI 10.1210/JC.2015-2362
   Yin QQ, 2013, J OBSTET GYNAECOL RE, V39, P203, DOI 10.1111/j.1447-0756.2012.01907.x
NR 20
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1201
EP 1206
DI 10.19193/0393-6384_2018_5_184
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700006
DA 2022-07-14
ER

PT J
AU Wan, L
   Liu, J
   Huang, CB
   Wang, Y
   Shen, X
   Zhang, WD
   Wang, GZ
   Fan, HX
   Ge, Y
   Chen, RL
   Cao, YX
   Zong, RK
   Liu, TY
AF Wan Lei
   Liu Jian
   Huang Chuan-Bing
   Wang Yuan
   Shen Xi
   Zhang Wan-Dong
   Wang Gui-Zheng
   Fan Hai-Xia
   Ge Yao
   Chen Rui-Lian
   Cao Yun-Xiang
   Zong Rui-Kai
   Liu Tian-Yang
TI EFFECTS OF XINFENG CAPSULE ON LIPOPROTEIN METABOLISM IN ADJUVANT
   ARTHRITIS RATS BASED ON VASCULAR STRESS IMBALANCE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE adjuvant arthritis; Xinfeng capsules; lipoprotein; metabolism; vascular
   stress
ID HIGH-DENSITY-LIPOPROTEIN; RHEUMATOID-ARTHRITIS; NONRHEUMATOID ARTHRITIS;
   PULMONARY-FUNCTION; CHOLESTEROL; SERUM
AB Objective: To observe the effect of Xinfeng Capsule (XFC) on protein metabolism and cytokines in adjuvant arthritis (AA).
   Methods: 60 rats were randomly divided into normal control group (NC) group, model control group (MC) group, methotrexate (MTX), tripterygium wilfordii polyglycoside (TPT) group and XFC group. To the rats except the NC group, the right hind foot plantar intradermal injection of 0.1 ml inflammation. / G), apolipoprotein A1 (Apo-A1), Apolipoprotein B (Apo-B), apolipoprotein A1 / B (APOA1 / B), cytokines, GMP-140, CD40L were observed after 30 days of administration.
   Results: Compared with NC group, the levels of PA, ALB, A / G, APOA1, APOA1 / B and IL-10 were decreased in MC group, and the levels of GLO, IL-1 beta, ANCA, VEGF and E IL-1 beta, ANCA, VEGF, E-selectin, PAF, GMP-140 and CD40L in MTX, TPT and XFC groups were significantly lower than those in MC group (P <0.05), While the XFC group in the rise of PA, ALB, APOA1, APOA1 / B and other aspects was significantly better than other treatment groups. (P < 0.05 or P < 0.01). Compared with TPT and MTX group, the body weight of XFC group increased (P < 0.05), and the arthritis index of XFC group was significantly lower than that before treatment, VEGF, E-selectin, PAF decreased, IL-10 was significantly increased (P < 0.05).
   Conclusion: Xinfeng Capsule can reduce the arthritis of adjuvant arthritis rats and improve the body weight and regulate protein metabolism. The mechanism is that by down-regulating the expression of cytokines IL-1 beta, ANCA, VEGF, E-selectin, GMP-140, CD40L, Upregulates the expression of cytokines IL-10, inhibits inflammatory effects, enhances anti-inflammatory effects, inhibits vasculitis formation, improves microvascular circulation, regulates protein metabolism in vivo.
C1 [Wan Lei; Liu Jian; Huang Chuan-Bing; Wang Yuan; Shen Xi; Zhang Wan-Dong; Wang Gui-Zheng; Fan Hai-Xia; Ge Yao; Chen Rui-Lian; Cao Yun-Xiang; Zong Rui-Kai; Liu Tian-Yang] Anhui Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Rheumatol, Hefei 230031, Anhui, Peoples R China.
RP Liu, J (corresponding author), Anhui Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Rheumatol, Hefei 230031, Anhui, Peoples R China.
FU National Natural Science Foundation [81403388]; Anhui Provincial Natural
   Science Foundation of China [1508085QH159]; Anhui Provincial Key
   Laboratory of Modern Traditional Chinese Medicine Internal Medicine
   Application Foundation and Development Research [1606c08238]; Anhui
   University Natural Science Research Project [KJ2017A281]
FX This paper belongs to the project of the "National Natural Science
   Foundation Project (81403388). Anhui Provincial Natural Science
   Foundation of China (1508085QH159), Anhui Provincial Key Laboratory of
   Modern Traditional Chinese Medicine Internal Medicine Application
   Foundation and Development Research (1606c08238), Anhui University
   Natural Science Research Project (KJ2017A281).
CR An J, 2016, J RHEUMATOL, V43, P1989, DOI 10.3899/jrheum.160110
   Cao YX, 2011, CHIN J INTEGR MED, V17, P738, DOI 10.1007/s11655-011-0873-1
   Charles-Schoeman C, 2017, ARTHRITIS RHEUMATOL, V69, P46, DOI 10.1002/art.39833
   Govindan KPS, 2015, J PHARM BIOALLIED SC, V7, pS22, DOI 10.4103/0975-7406.155767
   Jamnitski A, 2013, J RHEUMATOL, V40, P825, DOI 10.3899/jrheum.121358
   Kahraman C, 2016, ACTA MEDICA MEDITERR, V32, P981, DOI 10.19193/0393-6384_2016_4_119
   Kim JY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164564
   Kremer JM, 2017, ARTHRITIS RHEUMATOL, V69, P943, DOI 10.1002/art.40036
   Lee JS, 2016, PROTEOM CLIN APPL, V10, P183, DOI 10.1002/prca.201500036
   Liao KP, 2017, HEART, V103, P734, DOI 10.1136/heartjnl-2016-310764
   Liao KP, 2014, ANN RHEUM DIS, V73, P1170, DOI 10.1136/annrheumdis-2012-203202
   Liao KP, 2013, ARTHRIT CARE RES, V65, P2046, DOI 10.1002/acr.22091
   Liu J, 2014, J TRADIT CHIN MED, V34, P532, DOI 10.1016/S0254-6272(15)30058-3
   Liu J, 2011, CHIN J INTEGR MED, V17, P735, DOI 10.1007/s11655-011-0872-2
   O'Neill F, 2017, HEART, V103, P766, DOI 10.1136/heartjnl-2015-308953
   Ormseth MJ, 2016, ARTHRITIS RHEUMATOL, V68, P2099, DOI 10.1002/art.39675
   Ormseth MJ, 2016, CURR OPIN LIPIDOL, V27, P67, DOI 10.1097/MOL.0000000000000256
   Russo C, 2012, ACTA MEDICA MEDITERR, V28, P201
   Schroeder LL, 2015, RHEUMATOL INT, V35, P1059, DOI 10.1007/s00296-014-3194-9
   Sodergren A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/673018
   Tian Zhang Jun, 1998, MODERN PHARM EXPT ME, P1383
   Wagan AA, 2016, PAK J MED SCI, V32, P534, DOI 10.12669/pjms.323.9779
   Wan L, 2014, J TRADIT CHIN MED, V34, P76, DOI 10.1016/S0254-6272(14)60058-3
   Wan L, 2013, J CHIN MED ASSOC, V76, P715, DOI 10.1016/j.jcma.2013.08.002
   Wang YL, 2015, J TRADIT CHIN MED, V35, P626
   Wu JJ, 2015, INT J DERMATOL, V54, pE442, DOI 10.1111/ijd.12921
   Xu SY, 2002, PHARM EXPT METHODOLO, P919
NR 27
TC 1
Z9 1
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 51
EP 57
DI 10.19193/0393-6384_2018_1_9
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600009
DA 2022-07-14
ER

PT J
AU Wan, QQ
   Wu, D
   Xiao, XZ
AF Wan, Qiquan
   wu, Di
   Xiao, Xiuzhen
TI AN ANALYSIS OF CYTOKINE GENE POLYMORPHISMS ON ACUTE REJECTION IN RENAL
   RECIPIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Gene polymorphism; panel reactive antibody; acute rejection; renal
   transplant
ID DELAYED GRAFT FUNCTION; CLINICAL RISK-FACTORS; KIDNEY-TRANSPLANTATION;
   ASSOCIATION; DONORS
AB Introduction: We sought to investigate the role of recipients TNF-beta, IL-10, IL-1 beta and IL-1 receptor antagonist (ra) gene polymorphism as well as other variables such as PRA levels and HLA mismatches in acute renal graft rejection.
   Materials and methods: TNF-beta (+252A/G), IL-10 (-592A/C), IL-1 beta (-511C/T) and IL-1ra (86bp VNTR) gene polymorphisms were investigated in 157 renal recipients for correlation with acute rejection within the first year after renal transplantation.
   Results: Patients with increased panel-reactive antibody (PRA) levels were predisposed to acute renal graft rejection (P = 0.001). After adjusting for all variables of P < 0.3, a PRA level > 10% remained significant risk factor in a multivariate logistic regression analysis (OR = 5.897, 95% CI = 1.884-18.456, P = 0.002).
   Conclusion: Increased PRA levels have more significant impacts than cytokine gene polymorphisms on the likelyhood of developing acute renal graft rejection. The necessary pre- and/or post-transplant measures to lower the PRA levels should be taken.
C1 [Wan, Qiquan; wu, Di] Cent S Univ, Xiangya Hosp 3, Dept Transplant Surg, Changsha 410013, Hunan, Peoples R China.
   [Xiao, Xiuzhen] Cent S Univ, Xiangya Hosp 3, Outpatient Dept, Nursing Unit, Changsha 410013, Hunan, Peoples R China.
RP Xiao, XZ (corresponding author), Third Xiangya Hosp, Outpatient Dept, Nursing Unit, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
OI Wu, Di/0000-0002-5622-7488
FU Third xiangya hosipital of Central South University [20170311]
FX This work was supported by grant 20170311 from the New Xiangya Talent
   Project of the Third xiangya hosipital of Central South University.
CR Alakulppi NS, 2004, TRANSPLANTATION, V78, P1422, DOI 10.1097/01.TP.0000140884.71571.BC
   Asgari E, 2010, CURR OPIN ORGAN TRAN, V15, P486, DOI 10.1097/MOT.0b013e32833b9cb7
   Azmandian J, 2012, IRAN J KIDNEY DIS, V6, P56
   Brabcova I, 2007, TRANSPLANTATION, V84, P1037, DOI 10.1097/01.tp.0000285295.39275.3b
   Ding SQ, 2016, MED SCI MONITOR, V22, P4736, DOI 10.12659/MSM.898193
   Grinyo J, 2008, TRANSPL INT, V21, P879, DOI 10.1111/j.1432-2277.2008.00679.x
   Gubensek J, 2013, TRANSPL P, V45, P1524, DOI 10.1016/j.transproceed.2012.09.123
   Krichen H, 2011, IRAN J KIDNEY DIS, V5, P187
   Mandegary A, 2013, IRAN J KIDNEY DIS, V7, P135
   Poli F, 2009, HUM IMMUNOL, V70, P631, DOI 10.1016/j.humimm.2009.06.006
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x
   Sainz J, 2008, J CLIN IMMUNOL, V28, P473, DOI 10.1007/s10875-008-9197-0
   Seyhun Y, 2012, TRANSPL P, V44, P1670, DOI 10.1016/j.transproceed.2012.05.046
   Sivtritepe R, 2017, ACTA MEDICA MEDITERR, V33, P789, DOI 10.19193/0393-6384_2017_5_116
   Wu XX, 2014, TRANSPL IMMUNOL, V30, P71, DOI 10.1016/j.trim.2013.10.009
   Yilmaz B, 2017, ACTA MEDICA MEDITERR, V33, P663, DOI 10.19193/0393-6384_2017_4_099
   Zhang J, 2007, J MOD LAB MED, V22, P81
NR 17
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 47
EP 50
DI 10.19193/0393-6384_2018_1_8
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600008
DA 2022-07-14
ER

PT J
AU Wan, QQ
   Liu, HM
   Wu, D
   Zhou, H
AF Wan, Qiquan
   Liu, Huanmiao
   Wu, Di
   Zhou, Hui
TI THE DISTRIBUTION AND DRUG-RESISTANCE OF PATHOGENS AMONG LIVER TRANSPLANT
   RECIPIENTS WITH GRAM-POSITIVE BACTEREMIAS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Liver transplantation; Gram-positive; bacteremia; drug resistance
ID BLOOD-STREAM INFECTIONS; ADULT LIVING DONOR; RISK-FACTORS; PREDOMINANT
   PATHOGENS; STAPHYLOCOCCUS; MORTALITY; EPIDEMIOLOGY; BACTERIA
AB Introduction: To study the species distribution and frequency of antimicrobial resistance among Gram-positive bacteria responsible for bacteremias in liver transplant recipients.
   Materials and methods: Blood samples were processed by the BACTEC 9120 blood culture system. Species identification was performed using the Vitek-2 system. The drug susceptibility of pathogens was performed using the ATB FUNGUS 3 system.
   Results: Sixty eight episodes of Gram-positive bacteremias occurred in 51 liver recipients between January 31, 2003 and September 1, 2014. The median time to the onset of Gram-positive bacteremias was 6 days after liver transplantation and 92.6% of Gram-positive bacteremias were early-onset. The most common site of primary infection was intra-abdominal/biliary, followed by lungs. Of these 51 liver recipients with Gram-positive bacteremias, 25 (49%) died. The most common bacteria were Staphylococcus aureus (29.4%) and Enterococcus faecium (27.9%). Of these 20 Staphylococcus aureus, 90% were methicillin-resistant. The Gram-positive bacteria were highly resistant to erythromycin, penicillin and trimethoprim-sulfamethoxazole (resistance rate > 80%) and relatively susceptible to glycopeptides and oxazolidone antibiotics (resistance rate < 10%). There were 21 (30.9%) episodes of Gram-positive bacteremias without receiving appropriate antibiotic therapy.
   Conclusion: In liver transplantation, Gram-positive bacteria led to severe bacteremias with a high mortality rate and were resistant to the majority of commonly used antibiotics.
C1 [Wan, Qiquan; Liu, Huanmiao; Wu, Di] Cent S Univ, Xiangya Hosp 3, Dept Transplant Surg, Changsha 410013, Hunan, Peoples R China.
   [Zhou, Hui] Cent S Univ, Xiangya Hosp 3, Dept Hlth Management Ctr, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
RP Zhou, H (corresponding author), Cent S Univ, Xiangya Hosp 3, Dept Hlth Management Ctr, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
OI Wu, Di/0000-0002-5622-7488
FU Third xiangya hosipital of Central South University [20170311]
FX This work was supported by grant 20170311 from the New Xiangya Talent
   Project of the Third xiangya hosipital of Central South University.
CR Bert F, 2000, CLIN INFECT DIS, V31, P1295, DOI 10.1086/317469
   Bert F, 2010, LIVER TRANSPLANT, V16, P393, DOI 10.1002/lt.21991
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3
   Iida T, 2010, LIVER TRANSPLANT, V16, P1379, DOI 10.1002/lt.22165
   Kawecki D, 2007, TRANSPL P, V39, P16
   Kim HK, 2013, INFECT CHEMOTHER, V45, P315, DOI 10.3947/ic.2013.45.3.315
   Kim SI, 2009, YONSEI MED J, V50, P112, DOI 10.3349/ymj.2009.50.1.112
   Lanza G, 2015, ACTA MEDICA MEDITERR, V31, P647
   Lee SO, 2011, LIVER TRANSPLANT, V17, P733, DOI 10.1002/lt.22296
   Liu LJ, 2014, CHINESE J CANCER RES, V26, P698, DOI 10.3978/j.issn.1000-9604.2014.12.18
   Malinis MF, 2012, TRANSPLANTATION, V93, P1045, DOI 10.1097/TP.0b013e31824bf219
   National Committee for Clinical Laboratory Standards, 2002, M27A2 NCCLS
   Ouyang W, 2015, HEPATO-GASTROENTEROL, V62, P346, DOI 10.5754/hge14092
   Rhee KW, 2012, TRANSPL P, V44, P794, DOI 10.1016/j.transproceed.2012.01.014
   Saner FH, 2008, TRANSPLANTATION, V85, P1564, DOI 10.1097/TP.0b013e31816f61a6
   Sganga G, 2012, TRANSPL P, V44, P1973, DOI 10.1016/j.transproceed.2012.06.055
   Shao MJ, 2014, TRANSPLANT REV-ORLAN, V28, P176, DOI 10.1016/j.trre.2014.02.001
   Shi SH, 2010, CHINESE MED J-PEKING, V123, P1983, DOI 10.3760/cma.j.issn.0366-6999.2010.15.006
   Shoji K, 2015, PEDIATR INFECT DIS J, V34, P1063, DOI 10.1097/INF.0000000000000811
   Singh N, 2004, LIVER TRANSPLANT, V10, P844, DOI 10.1002/lt.20214
   Wan QQ, 2013, TRANSPL P, V45, P305, DOI 10.1016/j.transproceed.2012.06.080
   Zhou JD, 2015, THER CLIN RISK MANAG, V11, P933, DOI 10.2147/TCRM.S84579
NR 22
TC 1
Z9 1
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 77
EP 81
DI 10.19193/0393-6384_2018_1_13
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600013
DA 2022-07-14
ER

PT J
AU Wang, BY
   Gong, X
   Cui, JL
   Yu, XD
   Zhang, DQ
AF Wang, B. Y.
   Gong, X.
   Cui, J. L.
   Yu, X. D.
   Zhang, D. Q.
TI TREATMENT OF TRANSFER AND REPLANTATION COMBINED WITH DORSAL INTEROSSEOUS
   FLAP FOR DESTRUCTIVE INJURY OF HAND WITH ROTATION, AVULSION AND
   AMPUTATION: A CASE REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Destructive injury; Ectopic replantation of residual finger; Reverse
   island flap of forearm dorsal interosseous artery perforator
AB Avulsion and amputation are common surgical traumas in clinical emergency treatment. The patient had the left hand twisted by agricultural machinery, resulting avulsion or amputation of limbs to varying degrees. The episode was urgent and the injury was greatly traumatic with hemorrhagic shock, and emergency surgical treatment was needed. The treatment methods vary. In our study, we used transfer and replantation combined with dorsal interosseous flap for destructive injury along with the postoperative functional recovery and exercise. The long-term postoperative follow-up of the functions of affected limb during daily life and work provided more confirmed evidence for the feasibility of this surgical mode in the application to the avulsion and amputation.
C1 [Wang, B. Y.; Gong, X.; Cui, J. L.] Jilin Univ, Hosp 1, Dept Hand & Foot Surg, Changchun 130000, Jilin, Peoples R China.
   [Yu, X. D.] Jilin Canc Hosp, Dept Anesthesiol, Changchun 130000, Jilin, Peoples R China.
   [Zhang, D. Q.] FAW Gen Hosp Jilin Prov, Dept Neurol, Changchun 130021, Jilin, Peoples R China.
RP Gong, X (corresponding author), Jilin Univ, Hosp 1, Dept Hand & Foot Surg, Changchun 130000, Jilin, Peoples R China.
CR Azzolina R, 2010, ACTA MEDICA MEDITERR, V26, P85
   Gupta A, 1997, J HAND SURG-BRIT EUR, V22B, P32, DOI 10.1016/S0266-7681(97)80010-1
NR 2
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 475
EP 478
DI 10.19193/0393-6384_2018_2_76
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400030
DA 2022-07-14
ER

PT J
AU Wang, CY
AF Wang, Changyou
TI TREATMENT OF KNEE JOINT DISCOID MENISCUS INJURY OF BASKETBALL PLAYERS
   WITH ARTHROSCOPY: ANALYSIS OF RISK FACTORS FOR POSTOPERATIVE PAIN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Arthroscopy; Knee Joint Discoid Meniscus Injury; Postoperative Pain;
   Risk Factor Analysis
AB To further improve the clinical effect of treating knee joint discoid meniscus injury with arthroscopy in basketball players, this paper analyzed the detailed effects of arthroscopy in the treatment of knee joint discoid meniscus injury and identified the risk factors for postoperative pain. 1400 basketball players who had arthroscopy treatment for knee joint discoid meniscus injury were selected as subjects. After treatment, a 12-month postoperative follow-up was implemented to observe the recovery, injury recurrence, and postoperative pain. Based on the occurrence of postoperative pain as a critical criterion, patients were divided into a painful group and a painless group to analyze the risk factors for pain. Results showed that after surgery, 1274 out of 1400 patients with knee joint discoid meniscus injury recovered well, indicating an overall effective rate of 91%. The remaining 126 patients were not effectively treated, as they suffered severe postoperative pain after surgery, with a pain occurrence rate of 9%. Through comparison of risk factors, it was found that there were significant differences between the two groups in terms of average age, load bearing time, joint soft bone injury condition, and postoperative cold compress condition (p<0.05). There were no significant differences in terms of their body weights and surgical methods (p>0.05). These findings suggested that using arthroscopy to treat knee joint discoid meniscus injury of basketball players can realize significant therapeutic effect and an increased healing rate. Some patients may be prone to risk factors for postoperative pain, to a certain degree due to their age and previous injury history. To minimize such negative impact of the surgery, target analysis of these risk factors should be conducted in future studies in order to formulate targeted clinical treatment and nursing intervention for better healing.
C1 [Wang, Changyou] Huaihua Univ, Coll Kinesiol & Hlth Sci, Huaihua 418000, Peoples R China.
RP Wang, CY (corresponding author), Huaihua Univ, Coll Kinesiol & Hlth Sci, Huaihua 418000, Peoples R China.
CR Al-Sadoon MK, 2016, SAUDI J BIOL SCI, V23, P135, DOI 10.1016/j.sjbs.2015.10.010
   Alanazi K, 2016, SAUDI J BIOL SCI, V23, P87, DOI 10.1016/j.sjbs.2015.09.008
   Balkhair KS, 2016, SAUDI J BIOL SCI, V23, pS83, DOI 10.1016/j.sjbs.2015.10.029
   Chen GM, 2016, SAUDI PHARM J, V24, P250, DOI 10.1016/j.jsps.2016.04.008
   Dai Yongli, 2012, J BENGBU MED COLL, V37, P33
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   Jiang Jian, 2011, ACTA ACAD MED, V31, P175
   [蒋涛 Jiang Tao], 2012, [中国全科医学, Chinese General Practice], V15, P1278
   Kocak MZ, 2017, BIOMED RES-INDIA, V28, P3009
   Kumar R, 2016, SAUDI J BIOL SCI, V23, P243, DOI 10.1016/j.sjbs.2015.03.006
   Li Tao, 2014, ACAD J GUANGZHOU MED, V17, P151
   Ma QZ, 2008, PROCEEDINGS OF 2008 CONFERENCE ON REGIONAL ECONOMY AND SUSTAINABLE DEVELOPMENT, P955
   Shiri F, 2016, SAUDI PHARM J, V24, P197, DOI 10.1016/j.jsps.2015.03.012
   Xu Yi, 2014, J YANGTZE U NATURAL, V11, P5
   Youssef AM, 2017, ARAB J CHEM, V10, P631, DOI 10.1016/j.arabjc.2015.02.017
   Zhu YC, 2016, PAK J PHARM SCI, V29, P2363
NR 16
TC 0
Z9 0
U1 2
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 245
EP 248
DI 10.19193/0393-6384_2018_1s_40
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100005
DA 2022-07-14
ER

PT J
AU Wang, P
   Zheng, GL
   Duan, LQ
AF Wang Ping
   Zheng Guanlin
   Duan Luqin
TI STUDY ON CORRELATION BETWEEN SERUM URIC ACID, INSULIN RESISTANCE AND
   PANCREATIC ISLET B CELL FUNCTION OF ELDERLY PATIENTS WITH TYPE 2
   DIABETES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Type 2 diabetes; uric acid; insulin resistance; pancreatic islet beta
   cell
ID MELLITUS; HYPERURICEMIA; ASSOCIATION; THICKNESS
AB Introduction: This study is designed to discuss the serum uric acid level, insulin resistance and pancreatic islet beta cell functional status of elderly patients with Type 2 diabetes (T2DM) and analyse the correlation between serum uric acid, insulin resistance and pancreatic islet beta cell function.
   Materials and methods: Elderly patients (N = 279) with T2DM admitted to the Endocrinology Department of our hospital from September 2015 to August 2017 were randomly selected. They were divided into two ,groups, the high uric acid group (n = 143) and the normal uric acid group (n = 136), according to their blood uric acid level to compare the glycosylated haemoglobin (HbAlc), serum creatinine (Scr), total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), insulin resistance index (HOMA-IR), beta cell function index (HOMA-beta) and other indices of the two ,groups. Pearson correlation analysis was adopted to summarise the correlation between serum uric acid level, HOMA-IR and HOMA-beta of the patients.
   Results: HbAlc levels and HDL levels of the high uric acid ,group were lower than those of the normal uric acid group, while other detection indices, including Scr, TC, TG, LDL and BMI were higher than those of the normal uric acid group (p < 0.05). For the elderly patients with T2DM, serum uric acid levels and HOMA-IR were in positive correlation (p < 0.05), but serum uric acid levels had no obvious correlation with HOMA-beta (p > 0.05).
   Conclusion: Uric acid level is not only one of the independent risk factors for insulin resistance but also the predictive ,factor for T2DM. Therefore, controlling uric acid levels may become an important strategy for improving insulin resistance of elderly patients with T2DM.
C1 [Wang Ping; Duan Luqin] Taian City Cent Hosp, Dept Geriatr, Tai An 271000, Shandong, Peoples R China.
   [Zheng Guanlin] Taian Publ Hlth Sch, Tai An, Shandong, Peoples R China.
RP Wang, P (corresponding author), Taian City Cent Hosp, Dept Geriatr, Tai An 271000, Shandong, Peoples R China.
EM ja1274@163.com
CR Al-Daghri NM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12085-0
   Bo S, 2001, EUR J CLIN INVEST, V31, P318, DOI 10.1046/j.1365-2362.2001.00812.x
   Bonakdaran S, 2014, CURR DIABETES REV, V10, P113, DOI 10.2174/1573399810666140228160938
   Chen YY, 2014, J MED POSTGRADUATES, V27, P221
   Deng ZX, 2016, DIABETES-METAB RES, V32, P325, DOI 10.1002/dmrr.2724
   Du L, 2017, J MOL NEUROSCI, V61, P25, DOI 10.1007/s12031-016-0848-y
   Hamamura Misako, 2017, J Clin Med Res, V9, P297, DOI 10.14740/jocmr2870w
   Liang CC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081248
   Liu P, 2015, INTERNAL MED, V54, P2129, DOI 10.2169/internalmedicine.54.4310
   Magri C, 2012, INT UROL NEPHROL, V44, P197, DOI 10.1007/s11255-011-9958-1
   Neupane Sunita, 2016, Niger Med J, V57, P119, DOI 10.4103/0300-1652.182074
   Vinuthinee-Naidu MN, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0486-3
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Zhang, 2000, CHIN J ENDOCRINOL ME, V16, P87
   Zhang J, 2014, J ENDOCRINOL INVEST, V37, P441, DOI 10.1007/s40618-013-0034-9
NR 15
TC 0
Z9 0
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1901
EP 1905
DI 10.19193/0393-6384_2018_6_295
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400046
DA 2022-07-14
ER

PT J
AU Wang, ST
   Li, J
AF Wang, Shitao
   Li, Jing
TI FINITE ELEMENT ANALYSIS OF ELITE RACE WALKERS' LIGAMENT DAMAGE AROUND
   THE ANKLE ON TALUS STABILITY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Elite; Race walker; Ankle; Ligament injury; Talus; Stability; Finite
   element
AB Objective: Through analyzing ligament damage around the ankle of elite race walkers, impact of damage on talus stability was analyzed. Methods: Through analysis of 3,200 injured race walkers from physical culture institutes and sports teams in a city, who were injured during June 2012-June 2015, the impact of ligament damage around the ankle on talus stability was analyzed, ankle injury was analyzed with spiral CT scan data, and three-dimensional aggregation model of foot and ankle was built with three-dimensional reconstruction software.
   Results: The three-dimensional finite element models of normal human foot and ankle were built. Internal and external rotation of ankle cause different effects on biomechanics of talus.
   Conclusion: Under external rotation forces, tibiotalar ligament of athletes will exert important impact on stability of ankle.
C1 [Wang, Shitao] Jilin Sport Univ, Sch Sports & Arts, Changchun 130022, Peoples R China.
   [Li, Jing] Jilin Sport Univ, Sch Sports Human Sci, Changchun 130022, Peoples R China.
RP Li, J (corresponding author), Jilin Sport Univ, Sch Sports Human Sci, Changchun 130022, Peoples R China.
EM wst-0223@163.com
FU Jilin Social Science Fund Project - Research on the health industry of
   the elderly [2017M16]
FX Jilin Social Science Fund Project - Research on the health industry of
   the elderly (No. 2017M16).
CR Belniak P, 2017, SAUDI PHARM J, V25, P365, DOI 10.1016/j.jsps.2016.09.004
   Billen J, 2017, SAUDI J BIOL SCI, V24, P830, DOI 10.1016/j.sjbs.2016.06.007
   Chonglin Yang, 2013, INT J ORTHOPAEDICS
   Dastan SD, 2015, PAK J PHARM SCI, V28, P1141
   Dingguo Xu, 2013, CHONGQING MED, V8
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P127, DOI 10.1016/j.sjbs.2016.09.005
   Haifei Dai, 2012, CHINESE J BONE JOINT, V22, P121
   Ibrahim RW, 2016, SAUDI J BIOL SCI, V23, pS45, DOI 10.1016/j.sjbs.2015.09.012
   Jin Huang, 2013, CHINESE J TRADITIONA, V31, P74
   Khans BM, 2017, PAK J PHARM SCI, V30, P793
   Pengchao Guo, 2014, CHINESE J TISSUE ENG, V8, P5056
   Qi Li, 2015, CHINESE J INTERVENTI, V6, P669
   Shen Y, 2017, POL MARIT RES, V24, P95, DOI 10.1515/pomr-2017-0110
   Shrikhande SS, 2015, SAUDI PHARM J, V23, P341, DOI 10.1016/j.jsps.2014.08.004
   Wenjiang Tang, 2013, ACUPUNCTURE RES, V6, P314
   Xiaowei Liu, 2013, PUBLIC MED FORUM MAG, V15, P2116
   Yong Yang, 2011, WINTER SPORTS, V2, P65
   Yong Zhao, 2015, CHINA J ORTHOPAEDICS, V14, P374
   Zheng Zhou, 2015, CONT MED, V22, P82
NR 19
TC 0
Z9 0
U1 2
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1575
EP 1578
DI 10.19193/0393-6384_2018_3s_244
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400020
DA 2022-07-14
ER

PT J
AU Wang, TH
   Zhang, YL
   Gu, YQ
   Zhou, CN
   Chen, J
AF Wang Tianhong
   Zhang Yanli
   Gu Youquan
   Zhou Chaoning
   Chen Jun
TI CLINICAL FEATURES AND RISK FACTORS ANALYSIS OF DELAYED ENCEPHALOPATHY
   AFTER ACUTE CARBON MONOXIDE POISONING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Delayed Encephalopathy; Acute Carbon Monoxide poisoning
ID MANAGEMENT
AB Objective: To explore clinical features and risk factors of delayed encephalopathy after acute carbon monoxide poisoning (DEACMP).
   Methods: A total of 184 ACMP patients admitted in the Department of Neurology, The First Hospital of Lanzhou University from 2008 to 2016 were recruited as study subjects. They were randomly divided into the study group (DEACMP) and the control group (non-DEACMP). Twelve (12) indices (age, sex, coma time and JSC score, COHb, WBC, CK, CK-MB, LDH, abnormal skull CT, hospitalization time, and hyperbaric oxygen therapy) of patients in the two groups were analyzed.
   Results: ACMP patients in two groups, there were 114 cases with coma time of patients in the control group was 12h or less 12h, 19 patients with 13h to 24h, 11 cases with 25h to 48h, 4 cases with over 48h. 36 delayed encephalopathy cases in 184 ACMP patients were the study group. The incidence rate was 19.56%. There were 13 cases with coma time of patients in the study group was 12h or less 12h, 11 patients with 13h to 24h, 5 cases with 25h to 48h, 7 cases with over 48h. The coma time in the study group was longer. Patients in the study group compared with the control group in ratio of male and female, there were no differences in mean age and laboratory indexes (COHb concentration and WBC), data had no statistical significance (P > 0.05). According to Japan coma scale (JSC) scoring, it was found that consciousness dysfunction when admitted into hospital in the study group was worse compared with the control group. At the same time, Cranial CT in the study group showed that patients with hypoxic hypoxia brain change, which compared with the control group, the percentage was more high, differences had statistical significance (P < 0.01). According to indexes in experiment, it showed that CK, CK-MB and LDH level significantly increased in the study group compared with the control group, differences had statistical significance (P < 0.01). Compared with the control group, hospitalization time in the study group was longer and hyperbaric oxygen treatment had been prolonged. Differences between two groups had statistical significance (P < 0.01).
   Conclusion: DEACMP patients should particularly pay attention to strengthen clinical monitor to decrease incidence of DEACMP.
C1 [Wang Tianhong; Gu Youquan; Zhou Chaoning; Chen Jun] Lanzhou Univ, Hosp 1, Dept Neurol, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.
   [Zhang Yanli] Lanzhou Univ, Hosp 1, Dept Radiol, Lanzhou, Gansu, Peoples R China.
RP Wang, TH (corresponding author), Lanzhou Univ, Hosp 1, Dept Neurol, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.
CR Fujiwara S, 2016, NEURORADIOLOGY, V58, P27, DOI 10.1007/s00234-015-1600-y
   Ge XX, 2014, CHINESE J MODERN DRU, V8, P102
   Geerts AFJ, 2009, DRUG SAFETY, V32, P1189, DOI 10.2165/11316700-000000000-00000
   Gu RJ, 1994, CHIN J PHYS THER, V17, P216
   Li J, 2015, GENET MOL RES, V14, P10384, DOI 10.4238/2015.September.1.5
   Liu JY, 1997, DIAGNOSIS TREATMENT, P386
   MARES M, 1991, CARDIOLOGY, V78, P111, DOI 10.1159/000174774
   Pepe G, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-16
   Shinohara Y, 2009, STROKE, V40, P1439, DOI 10.1161/STROKEAHA.108.535070
   Thalmeier A, 2008, INT J NEUROPSYCHOPH, V11, P217, DOI 10.1017/S1461145707007894
   Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121
   Yi L., 2014, J MED THEORY PRACTIC, V27, P186
   Yue Y, 2015, EVID-BASED COMPL ALT, V2015
   Zhao XZ, 1994, CHIN J NEUROL, V17, P216
   Zhou ZT, 2015, CHIN J PRIM MED PHAR, V22, P2028
NR 15
TC 0
Z9 0
U1 2
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1177
EP 1180
DI 10.19193/0393-6384_2018_5_180
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700002
DA 2022-07-14
ER

PT J
AU Wang, Y
   Zhang, HY
   Wang, YS
AF Wang, Yang
   Zhang, Haiyu
   Wang, Yongsheng
TI RELEVANCE BETWEEN FGFR-2 GENE POLYMORPHISM AND BREAST CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Breast cancer; fibroblast growth factor receptor 2; Gene polymorphism
ID SUSCEPTIBILITY; ASSOCIATION
AB Objective: To investigate the relevance between the second intron single nucleotide polymorphism of fibroblast growth factor receptor 2 (FGFR2) gene and the onset of breast cancer in women.
   Methods: The 132 cases of female breast cancer (breast cancer group) and 145 normal women (control group) were detected by combining polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method with agarose gel electrophoresis. The polymorphism distribution of two single nucleotide polymorphisms (rs2981579) and (rs2981582) of the second intron of FGFR2 gene was analyzed statistically.
   Results: For FGFR2 gene single nucleotide polymorphism rs2981579, the frequencies of genotype (CC, CT, TT) in breast cancer group and the control group were 31.06%, 43.18%,25.76% and 26.90%, 45.52%,27.58% respectively. The frequencies of C allele in breast cancer group and control group were 68.94% and 75.17% respectively, and the frequencies of T allele in the two groups were 31.06% and 24.83% respectively. There was no statistically significant difference in genotype and allele frequency distribution between the two groups. For FGFR2 gene single nucleotide polymorphism s2981582, the frequencies of genotype (CC, CT, TT) in breast cancer group and the control group were 37.12%, 46.97%, 15.91% and 35.86% .45.52% .18.62% respectively. The frequencies of C allele in breast cancer group and control group were 72.73% and 71.72% respectively, and the frequencies of T allele were 27.27% and 31.72% respectively. The distribution of genotype frequency and allele frequency were compared between the two groups and there was no statistically significant difference (p>0. 05).
   Conclusion: There is no significant correlation between the 2 polymorphism sites of FGFR2 intron and breast cancer.
C1 [Wang, Yang; Wang, Yongsheng] Shandong Univ, Shandong Canc Hosp, Jiyan Rd 440, Jinan 250117, Shandong, Peoples R China.
   [Wang, Yang] Weifang Peoples Hosp, Dept Galactophore Surg, Guangwen St 151, Weifang 261041, Shandong, Peoples R China.
   [Zhang, Haiyu] Weifang Peoples Hosp, Dept Antenatal Diag, Guangwen St 151, Weifang 261041, Shandong, Peoples R China.
   [Wang, Yongsheng] Shandong Acad Med Sci, Jinan 250062, Shandong, Peoples R China.
RP Wang, YS (corresponding author), Shandong Acad Med Sci, Jinan 250062, Shandong, Peoples R China.; Wang, YS (corresponding author), Shandong Univ, Shandong Canc Hosp, Breast Canc Ctr, Jiyan Rd 440, Jinan, Shandong, Peoples R China.
CR Bai AL, 2010, CANCER RES, V70, P7630, DOI 10.1158/0008-5472.CAN-10-1489
   Basse C, 2015, INT J CANCER, V137, P2785, DOI 10.1002/ijc.29347
   Boyarskikh UA, 2009, EUR J HUM GENET, V17, P1688, DOI 10.1038/ejhg.2009.98
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Garcia-Closas Montserrat, 2008, PLoS Genetics, V4, pe1000054, DOI 10.1371/journal.pgen.1000054
   Hunter DJ, NATURE GENETICS, V20, P870
   Ingersoll RG, 2001, CYTOGENET CELL GENET, V94, P121, DOI 10.1159/000048802
   Katoh M, 2010, EXPERT REV ANTICANC, V10, P1375, DOI 10.1586/ERA.10.128
   Liang J, 2008, CARCINOGENESIS, V29, P2341, DOI 10.1093/carcin/bgn235
   MichailldouI K, NATURE GENETICS, V20, P373
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pollock PM, 2007, ONCOGENE, V26, P7158, DOI 10.1038/sj.onc.1210529
   Reintjes N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060264
   Tapper W, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2213
   [赵洪猛 Zhao Hongmeng], 2010, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V37, P626
NR 15
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1717
EP 1720
DI 10.19193/0393-6384_2018_6_262
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400013
DA 2022-07-14
ER

PT J
AU Wang, YF
   Diao, HY
   Ju, LL
   Chen, L
   Yangwang
   Bian, ZL
   Shao, JG
AF Wang, Yifan
   Diao, Huayu
   Ju, Linling
   Chen, Lin
   YangWang
   Bian, Zhaolian
   Shao, Jianguo
TI THE PROTECTIVE EFFECT OF CYSTEINE-RICH PROTEIN 61 ONCAERULEIN-INDUCED
   ACUTE PANCREATITIS IN C57BL/6 MICE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE SAcute pancreatitis; CCN1; Inflammatory infiltration; Neutrophils;
   Caerulein
ID INTEGRIN ALPHA(6)BETA(1); BINDING-SITE; CYR61 CCN1; GENES;
   DIFFERENTIATION; IDENTIFICATION; CCN1/CYR61; EXPRESSION; ADHESION
AB Introduction: Acute pancreatitis (AP) is an inflammatory response with trypsin abnormal over-activation in the pancreas. The matricellular protein Cysteine-rich protein 61 (CCN1) plays important roles in several inflammation diseases. However, the role of CCN1 in acute pancreatitis remains unclear. This work was aimed at investigating the protective effect of CCN1 on acute pancreatitis and the potential mechanism.
   Materials and methods: The AP mouse model was induced by intraperitoneal injection(i.p.) of caerulein. Over-expression of CCN1 was achieved by orbital intravenous injection of CCN1 adenovirus. CCN1 mRNA and protein levels in pancreas were detected by qPCR and western blots. Pancreatic tissue damage was evaluated and confirmed by Hematoxylin and Eosin staining H.&E. and serum amylase activity analysis. Leukocyte infiltration was observed and immunohistochemically stained.
   Results: Caerulein-induced AP resulted in elevated serum amylase activity (p < 0.05). Histopathologic damage of pancreatic tissue in AP mice was significantly higher than saline group (p < 0.05). Both mRNA and protein levels of CCN1 were decreased in AP group (p < 0.05). Over-expression of CCN1 recovered CCN1 mRNA and protein levels. Pathological damage of pancreatic tissue was reduced in CCN1 over-expression AP group (p < 0.05). Over-expression of CCN1 in pancreas significantly decreases neutrophils effusion but not macrophages in CCN1 over-expression AP mice (p < 0.05).
   Conclusions: Reduction of CCN1 may be associated with caerulein-induced AP development in mice. Further studies are needed to investigate the effect of CCN1 in AP patients and the biochemical explanations for this phenomenon.
C1 [Wang, Yifan; Ju, Linling; Chen, Lin; Bian, Zhaolian; Shao, Jianguo] Nantong Third Peoples Hosp, Nantong Inst Liver Dis, Nantong 226006, Jiangsu, Peoples R China.
   [Diao, Huayu] Nanjing Univ Chinese Med, Nanjing 210023, Jiangsu, Peoples R China.
   [YangWang] Nantong Univ, Sch Med, Nantong 226006, Jiangsu, Peoples R China.
RP Shao, JG (corresponding author), Nantong Third Peoples Hosp, Nantong Inst Liver Dis, Nantong 226006, Jiangsu, Peoples R China.
EM shaojianguo4144@163.com
FU Nantong Science and Technology Bureau [MS22015105]; Natural Science
   Foundation of Jiangsu Province [BK20160420]; National Natural Science
   Foundation of China [81600449]
FX This work was supported by Nantong Science and Technology Bureau, (No.
   MS22015105); The Natural Science Foundation of Jiangsu Province (Grants
   NO. BK20160420); National Natural Science Foundation of China, (No.
   81600449).
CR Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779
   Cakir OO, 2015, INT J CLIN EXP MED, V8, P17551
   Chang CC, 2014, WORLD J GASTROENTERO, V20, P6826, DOI 10.3748/wjg.v20.i22.6826
   Chen CC, 2016, ONCOGENE, V35, P1314, DOI 10.1038/onc.2015.190
   De Waele JJ, 2014, CURR OPIN CRIT CARE, V20, P189, DOI 10.1097/MCC.0000000000000068
   Gomatos IP, 2014, EXPERT REV MOL DIAGN, V14, P333, DOI 10.1586/14737159.2014.897608
   Grazioli S, 2015, AM J PHYSIOL-LUNG C, V308, pL759, DOI 10.1152/ajplung.00190.2014
   Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441
   Hirota M, 2000, PANCREAS, V21, P141, DOI 10.1097/00006676-200008000-00006
   Imhof BA, 2016, P NATL ACAD SCI USA, V113, pE4847, DOI 10.1073/pnas.1607710113
   Jerebtsova Marina, 2009, Cardiovascular & Hematological Disorders - Drug Targets, V9, P136
   Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070
   Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090
   Krupska I, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-015-0046-y
   Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200
   Lin JP, 2012, J IMMUNOL, V188, P5776, DOI 10.4049/jimmunol.1103201
   Maity G, 2014, SCI REP-UK, V4, DOI 10.1038/srep04995
   Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002
   Modak C, 2010, BIOCHEM BIOPH RES CO, V392, P533, DOI 10.1016/j.bbrc.2010.01.057
   Norman J, 1998, AM J SURG, V175, P76, DOI 10.1016/S0002-9610(97)00240-7
   SCHMIDT J, 1992, ANN SURG, V215, P44, DOI 10.1097/00000658-199201000-00007
   Schober JM, 2003, J BIOL CHEM, V278, P25808, DOI 10.1074/jbc.M301534200
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955-2964.2006
   Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218
   Tripathi S, 2017, SCI REP-UK, V7, P1, DOI [10.1038/srep43056, 10.26700/shuri.2017.04.7.1.1]
   Wang Y, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0478-4
   Weiskirchen R, 2015, AM J PHYSIOL-LUNG C, V309, pL747, DOI 10.1152/ajplung.00239.2015
   Yang R, 2008, PHYSIOL GENOMICS, V36, P1, DOI 10.1152/physiolgenomics.90291.2008
   Yu JH, 2005, FREE RADICAL BIO MED, V39, P590, DOI 10.1016/j.freeradbiomed.2005.04.019
   Zhou DM, 2005, J APPL PHYSIOL, V98, P2344, DOI 10.1152/japplphysiol.01093.2004
NR 30
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 981
EP 988
DI 10.19193/0393-6384_2018_4_149
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500012
DA 2022-07-14
ER

PT J
AU Wang, YX
AF Wang, Yunxing
TI COMPARISON OF THERAPEUTIC EFFECTS BETWEEN MESSAGE AND MASSAGE PLUS
   OBLIQUE PULLING METHOD IN TREATING ACUTE LUMBAR MUSCLE SPRAIN OF
   SPRINTERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Massage; Oblique pulling; Acute lumber muscle sprain; Therapeutic effect
   comparison
ID OPTIMIZATION
AB Objective: to explore and compare the therapeutic effects between massage and massage plus oblique pulling method in treating acute lumbar muscle sprain of sprinters.
   Methods: to further explore the differences between these two methods and provide reference for clinical treatment, the study selected 1,200 cases of patients of acute lumber muscle sprain receiving treatment in the Hospital from August 2011 to May 2016 as the research objects, and equally divided them into the control group (600 cases) and the experimental group (600 cases) through drawing method. The patients of the control group received massage therapy and the patients of the experimental group received massage plus oblique pulling. The therapeutic effects of the two groups of patients was compared.
   Results: according to the research, the experimental group had a therapeutic response rate of 95%, and the control group had a therapeutic response rate of 83%. Compared with the control group, the experimental group had obvious advantage, meeting the condition that P < 0.05, with statistically significant difference.
   Conclusion: the massage plus oblique pulling has remarkable clinical effect in treating acute lumbar muscle sprain of sprinters, and can alleviate the patients' pain and shorten the treatment time. It is the best treatment protocol of clinical treatment. Therefore, it is suggested that we actively promote application of massage plus oblique pulling in future clinical practices.
C1 [Wang, Yunxing] Anqing Normal Univ, Sch Phys Educ, Anqing 246013, Peoples R China.
RP Wang, YX (corresponding author), Anqing Normal Univ, Sch Phys Educ, Anqing 246013, Peoples R China.
EM wyx520wyx520@163.com
CR Al-Maary KS, 2017, SAUDI J BIOL SCI, V24, P367, DOI 10.1016/j.sjbs.2016.06.006
   Cantarella G, 2015, ACTA MEDICA MEDITERR, V31, P1019
   Dash RN, 2016, SAUDI PHARM J, V24, P92, DOI 10.1016/j.jsps.2015.03.004
   Esmaeili A, 2017, PAK J PHARM SCI, V30, P473
   Ganeshpurkar A, 2017, SAUDI PHARM J, V25, P149, DOI 10.1016/j.jsps.2016.04.025
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Hertiani T, 2015, PAK J PHARM SCI, V28, P1691
   Hong Xuling, 2014, J EMERGENCY TRADITIO, V3, P494
   Ibrahim RW, 2016, SAUDI J BIOL SCI, V23, pS45, DOI 10.1016/j.sjbs.2015.09.012
   Leimin Zhou, 2015, J NEW CHINESE MED, V8, P245
   Li Sibin, 2014, CHINA MODERN DOCTOR, V11, P95
   Litong Wang, 2011, CHINESE J SPORTS MED, V8, P745
   Mi C, 2015, J COASTAL RES, P28, DOI 10.2112/SI73-006.1
   Shiri F, 2016, SAUDI PHARM J, V24, P197, DOI 10.1016/j.jsps.2015.03.012
   Yang AM, 2017, RESULTS PHYS, V7, P1046, DOI 10.1016/j.rinp.2017.02.027
   Yang X, 2015, J COASTAL RES, P448, DOI 10.2112/SI73-079.1
   Yang ZC, 2015, J COASTAL RES, P420, DOI 10.2112/SI73-074.1
   Yang Zhongliang, 2016, GUIDE CHINA MED, V7, P220
NR 18
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1599
EP 1603
DI 10.19193/0393-6384_2018_3s_249
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400025
DA 2022-07-14
ER

PT J
AU Wang, ZJ
   Wang, BF
   Leng, H
   Zhang, HJ
AF Wang Zhiju
   Wang Binfeng
   Leng Hui
   Zhang Haijun
TI CLINICAL EFFECTS OF ANTIBIOTIC-IMPREGNATED CEMENT ON THE TREATMENT OF
   TRAUMATIC SHINBONE OSTEOMYELITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Antibiotic-impregnated cement; Traumatic shinbone osteomyelitis;
   Clinical effects
AB Objective: To study the clinical effects of antibiotic-impregnated cement on the clinical treatment of traumatic shinbone osteomyelitis.
   Methods: A total of 120 patients with traumatic shinbone osteomyelitis admitted in the Department of Traumatology, Chifeng Clinical Hospital, were recruited. They were randomly divided into control group and experimental group according to random attribution method (60 cases per group). The control group was given local perfusion antibiotics, while the experimental group received antibiotic-impregnated cement. Joint function activation, trauma recovery, anti-infection indices, and total treatment effects were comprehensively evaluated.
   Results: Knee joint activation function in the experimental group was better than that in the control group, and the recovery time was shorter than in the control group (p < 0.05). In addition, trauma infection control was significantly better in the experimental group than in the control group (p < 0.05). There were 57 cases with effective treatment in the experimental group (97 % effectiveness), which differed significantly from 45 cases of effective treatment in the control group (75 % effectiveness; p < 0.05).
   Conclusion: Antibiotic-impregnated cement is very effective for the clinical treatment of traumatic shinbone osteomyelitis, and deserves clinical promotion.
C1 [Wang Zhiju; Wang Binfeng; Leng Hui; Zhang Haijun] Inner Mongolia Med Univ, Chifeng Clin Hosp, Dept Traumatol, Chifeng, Inner Mongolia, Peoples R China.
RP Wang, ZJ (corresponding author), Rehabil Ctr Pain Bone Injury, Hall First Floor North Xin Garden,Changqing St, Chifeng, Inner Mongolia, Peoples R China.
EM hdozgfdlca15023@163.com
CR Bi JW, 2016, GANSU MED J, V35, P102
   Du Quanhong, 2014, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V28, P562
   Huang Y, 2014, CHIN J MODERN OPER S, V34, P196
   Kang YZ, 2014, J CLIN RES, V31, P1832
   Li CQ, 2014, SHANDONG MED J, V54, P59
   Lu JG, 2016, J NINGXIA MED U, V38, P337
   Pan ZG, 2014, J MED THEORY PRACT, P775
   [任义军 Ren Yijun], 2013, [中华创伤骨科杂志, Chinese Journal of Orthopaedic Trauma], V15, P845
   Wang HL, 2016, YIYAOQIANYAO, V6, P293
   Zhai RS, 2011, HEILONGJIANG MED PHA, V34, P41
   Zhu YG, 2015, J CLIN REHAB TISSUE, V19, P3942, DOI [10.3969/j.issn.2095-4344.2015.25.002, DOI 10.3969/J.ISSN.2095-4344.2015.25.002]
NR 11
TC 0
Z9 1
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1101
EP 1104
DI 10.19193/0393-6384_2018_4_169
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500032
DA 2022-07-14
ER

PT J
AU Wang, ZY
AF Wang, Zhiying
TI ANALYSIS OF INFLUENTIAL FACTORS OF MEDICATION ADHERENCE OF INHALATION
   DEVICES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE chronic obstructive pulmonary disease (COPD); inhalation device;
   medication adherence; influential factor
ID ASTHMA; HEALTH
AB Introduction: The objective of this study was to investigate influential factors of medication adherence of inhalation devices in patients with chronic obstructive pulmonary disease (COPD)through the following criteria: application scores of the inhalation devices, physician effective guidance, the number of acute exacerbation, adverse drug reactions (ADRs).
   Materials and methods: A total of 130 patients with COPD who sought medical care in the hospital were recruited for the study. Questionnaire survey was performed to evaluate medication adherence of inhalation devices. The obtained data were analyzed by using a t-test, a Chi-square test, and a binary logistic regression analysis to determine the relationship of the above various factors with medication adherence. Then, the 130 patients were randomly divided into an intervention group and a control group. The intervention group was interviewed by the physician in the process of using inhalation devices. After 3 months and 6 months, observed the difference of the two groups.
   Results: The analysis indicated that there was a close relationship between medication adherence of inhalation devices and the following criteria: application score of the inhalation devices, ADRs, the number of acute exacerbations, and effective guidance of physicians. Compared with the control group, application scores of the inhalation device of the intervention group were significantly improved. The number of acute exacerbation decreased by 16%, the incidence of ADRs in the intervention group was 13.6% lower than that in the control group, and the difference was statistically significant.
   Conclusion: After physician effective guidance, the application scores of the inhalation devices were improved, the number of acute exacerbation and ADRs decreased. Physician should take intervention measures in accordance with the influential factors of medication adherence of inhalation devices to improve treatment efficacy of COPD.
C1 [Wang, Zhiying] Shaoxing Univ, Affiliated Hosp, Dept Resp, Shaoxing 312000, Zhejiang, Peoples R China.
RP Wang, ZY (corresponding author), Shaoxing Univ, Affiliated Hosp, Dept Resp, Shaoxing 312000, Zhejiang, Peoples R China.
EM wslinghu@usx.edu.cn
CR Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304
   Lasmar L, 2009, ALLERGY, V64, P784, DOI 10.1111/j.1398-9995.2008.01877.x
   Lavorini F, 2011, RESP MED, V105, P1099, DOI 10.1016/j.rmed.2011.03.012
   Makela MJ, 2013, RESP MED, V107, P1481, DOI 10.1016/j.rmed.2013.04.005
   Melani AS, 2011, RESP MED, V105, P930, DOI 10.1016/j.rmed.2011.01.005
   MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007
   Morton K, 2015, HEALTH PSYCHOL REV, V9, P205, DOI 10.1080/17437199.2014.882006
   National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94
   Resnicow K, 2016, PEDIATR CLIN N AM, V63, P539, DOI 10.1016/j.pcl.2016.02.008
   Seville PC, 2007, CRIT REV THER DRUG, V24, P307, DOI 10.1615/CritRevTherDrugCarrierSyst.v24.i4.10
   Tuccero D, 2016, PRIMARY CARE, V43, P191, DOI 10.1016/j.pop.2016.01.006
   Veprekova B, 2013, Vnitr Lek, V59, P794
   Virchow JC, 2005, CURR MED RES OPIN, V21, pS19, DOI 10.1185/030079905X61758
   Virchow JC, 2004, RESP MED, V98, pS28, DOI 10.1016/j.rmed.2004.07.012
NR 14
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1703
EP 1709
DI 10.19193/0393-6384_2018_6_260
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400011
DA 2022-07-14
ER

PT J
AU Wei, M
   Luo, XH
AF Wei, Min
   Luo, Xin-Hua
TI ANALYSIS OF EXPRESSIONS AND CLINICAL SIGNIFICANCE OF CXCR1, CXCR2 AND
   CXCL8 IN PATIENTS WITH PRIMARY HEPATIC CARCINOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Primary hepatic carcinoma; CXC chemokine receptor 1; CXC chemokine
   receptor 2; CXC chemokine ligand 8
ID PRIMARY LIVER-CANCER; HEPATOCELLULAR-CARCINOMA
AB Purpose: To investigate the expressions and significance of CXC chemokine receptor 1 (CXCR1), CXC chemokine receptor 2 (CXCR2) and CXC chemokine ligand 8 (CXCL8) in primary hepatic carcinoma (PHC).
   Methods: A total of 62 PHC patients and 62 CHB patients seen from June 2016 to December 2017 at Guizhou Provincial People's Hospital, Guiyang City were selected, and randomly divided into PHC group and CHB group. The control group consisted of 62 randomly selected healthy people (62, normal group). The mRNA expressions of CXCR1, CXCR2 and CXCL8 were determined in the three groups using real-time fluorescent quantitative method in peripheral blood mononuclear cells (PBMC). The correlation of mRNA expression of CXCL8 with those of CXCR1 and CXCR2 were analyzed by Pearson linear correlation analysis, while the predictive values of mRNA expressions of CXCL8, CXCR1 and CXCR2 for PHC were analyzed by ROC curve.
   Results: In the PHC group, the mRNA expressions of CXCR1, CXCR2 and CXCL8 were higher than in CHB group and normal group, and in the CHB group, the mRNA expressions of CXCR1 and CXCR2 were higher than those in the normal group (p < 0.05). The mRNA expression of CXCL8 was positively correlated with those of CXCRI and CXCR2 (r = 0.694, 0.704; p < 0.05). For the prediction of PHC, ROC curve model showed that the area under curve of mRNA expressions of CXCRI, CXCR2 and CXCL8 were 0.864, 0.852 and 0.887, respectively; the sensitivities were 0.871, 0.855 and 0.887 respectively; and the specificities were 0.871, 0.839 and 0.871 respectively.
   Conclusion: These results indicate that the mRNA expressions of CXCR1, CXCR2 and CXCL8 have high predictive value for PHC.
C1 [Wei, Min; Luo, Xin-Hua] Guizhou Prov Peoples Hosp, Dept Infect, Guiyang 550001, Guizhou, Peoples R China.
RP Luo, XH (corresponding author), Guizhou Prov Peoples Hosp, Dept Infect, Guiyang 550001, Guizhou, Peoples R China.
EM fe1229@163.com
CR Amrouche L, 2017, J AM SOC NEPHROL, V28, P479, DOI 10.1681/ASN.2016010045
   Broutier L, 2017, NAT MED, V23, P1424, DOI 10.1038/nm.4438
   Chassagne F, 2016, ONCOLOGY-BASEL, V91, P106, DOI 10.1159/000446398
   Chayanupatkul M, 2017, J HEPATOL, V66, P355, DOI 10.1016/j.jhep.2016.09.013
   Chinese Society of Hepatology of Chinese Medical Association, 2015, J CLIN HEPAT, V31, P1941, DOI DOI 10.3969/J.ISSN.1001-5256.2015.12.002
   Chinese Society of Liver Cancer, 2015, MED J CHIN PLA, V21, P865
   Gopal R, 2017, CELL ONCOL, V40, P219, DOI 10.1007/s13402-017-0321-0
   Hu SS, 2017, ANAT RES, V39, P185
   Joseph PRB, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170168
   Liu J, 2016, CANCER LETT, V379, P49, DOI 10.1016/j.canlet.2016.05.022
   Marrero JA, 2014, AM J GASTROENTEROL, V109, P1328, DOI 10.1038/ajg.2014.213
   Mossanen JC, 2016, HEPATOLOGY, V64, P1667, DOI 10.1002/hep.28682
   Oikawa T, 2016, HEPATOLOGY, V64, P645, DOI 10.1002/hep.28485
   Qiao Bingbing, 2018, Oncotarget, V9, P15068, DOI 10.18632/oncotarget.23492
   Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048
   Sun C, 2017, MED, V96, P7513
   Verne J, 2016, J HEPATOL, V64, pS461, DOI 10.1016/S0168-8278(16)00773-X
   Yoo S, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0973-7
   Zhu Y, 2018, CANCER SCI, V109, P710, DOI 10.1111/cas.13487
   Zou X, 2017, LIVER INT, V37, P35, DOI 10.1111/liv.13188
   别雅琴(综述), 2017, [中国肿瘤生物治疗杂志, Chinese Journal of Cancer Biotherapy], V24, P194
NR 21
TC 0
Z9 0
U1 2
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1721
EP 1726
DI 10.19193/0393-6384_2018_6_263
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400014
DA 2022-07-14
ER

PT J
AU Wei, RS
AF Wei, Ruisong
TI STUDY ON MODIFIED SYNTHESIS AND ACTIVITY OF CHALCONE COMPOUNDS BASED ON
   DRUG SPLICING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE chalcone compounds; drug splicing principle; modified synthesis
ID MOLECULAR-STRUCTURES; DERIVATIVES
AB Chalcone, a polyphenolic compound that belongs to flavonoids family, has revealed a variety of biological activities that may benefit human health such as anti-tumor cell growth. This natural compound is mainly found in the composition of Chinese herbal medicine such as safflower. Drug splicing method has been known to enhance the chalcone's activities. Thus in this paper, the reaction between ketoacetic acid and enoic acid, in the presence of silver nitrate catalyst and water, was employed for the derivation of chalcone compounds. The derived compounds have inhibitory effect on protein aggregation as well as anti-inflammatory and antibacterial activity. This method which yields 89% of final product is a new green and environmental-friendly technique for the synthesis of chalcone compounds.
C1 [Wei, Ruisong] Hechi Univ, Sch Chem & Biol Engn, Hechi 546300, Peoples R China.
RP Wei, RS (corresponding author), Hechi Univ, Sch Chem & Biol Engn, Hechi 546300, Peoples R China.
FU project of Guangxi - Study on the application of ionic liquids in the
   modification of rosin acid [0832091]
FX The research is supported by 2008 project of Guangxi - Study on the
   application of ionic liquids in the modification of rosin acid
   (0832091).
CR Arik F, 2017, ACTA MEDICA MEDITERR, V33, P592, DOI 10.19193/0393-6384_2017_4_087
   Balan K, 2017, ARAB J CHEM, V10, P732, DOI 10.1016/j.arabjc.2014.07.002
   Chen GM, 2016, SAUDI PHARM J, V24, P250, DOI 10.1016/j.jsps.2016.04.008
   Dong Jingqiu, 2007, FINE CHEM INTERMEDIA, V35, P31
   El-Jakee JK, 2016, SAUDI J BIOL SCI, V23, P48, DOI 10.1016/j.sjbs.2015.06.011
   Fan Rui, 2011, CHINESE J MED CHEM, V21, P17
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P127, DOI 10.1016/j.sjbs.2016.09.005
   Kumar KS, 2017, ARAB J CHEM, V10, pS368, DOI 10.1016/j.arabjc.2012.09.009
   Kumar SK, 2003, J MED CHEM, V46, P2813, DOI 10.1021/jm030213+
   Lawrence NJ, 2006, BIOORG MED CHEM LETT, V16, P5844, DOI 10.1016/j.bmcl.2006.08.065
   Li M, 2015, PAK J PHARM SCI, V28, P1861
   Sana T, 2016, PAK J PHARM SCI, V29, P2321
   Saxena HO, 2007, STEROIDS, V72, P892, DOI 10.1016/j.steroids.2007.07.012
   Scoppa F, 2017, ACTA MEDICA MEDITERR, V33, P707, DOI 10.19193/0393-6384_2017_4_105
   Tartar AS, 2017, ACTA MEDICA MEDITERR, V33, P699, DOI 10.19193/0393-6384_2017_4_104
   [王壮坤 WANG Zhuangkun], 2015, [合成化学, Chinese Journal of Synthetic Chemistry], V23, P202
   Wu Lei, 2008, Journal of Tropical Medicine (Guangzhou), V8, P987
   Yao HJ, 2017, BIOMED RES-INDIA, V28, P2479
   Zhang Ning, 2015, SILVER CATALYZED DOU
   Zhang Shuang, 2012, PROGR STUDY STRUCTUR, V36, P242
   Zhang Y.W., 1996, FOREIGN MED SCI SECT, V23, P218
   Zhong Qi, 1990, CHINESE J ORG CHEM, P459
NR 25
TC 4
Z9 4
U1 1
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 255
EP 259
DI 10.19193/0393-6384_2018_1s_42
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100007
DA 2022-07-14
ER

PT J
AU Xiao, W
   Zhang, XB
   Wang, Z
   Guo, XL
   He, L
   Wang, Y
AF Xiao Wei
   Zhang Xianbao
   Wang Zhen
   Guo Xiaoli
   He Ling
   Wang Yan
TI MECHANISMS OF ACUPUNCTURE INTERVENTION IN RATS OF POST-STROKE DEPRESSION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE post-stroke depression; acupuncture; neurotransmitter; neurotransmitter
   receptor
ID FILIFORM NEEDLE ACUPUNCTURE; HIPPOCAMPAL; STRESS; MODEL;
   NEUROINFLAMMATION; 5-HTTLPR; UPDATE; STROKE; LESION; PSD
AB Objective: To observe the effect of Jieyuanshen acupuncture on brain neurotransmitters in post-stroke depression (PSD) rats, and to explore the mechanism by which acupuncture improves PSD.
   Methods: Rats were randomly divided into normal, model, drug, and acupuncture groups. A post-stroke depression model was made by middle cerebral artery occlusion and chronic unpredictable mild stress. The acupuncture group was treated at Baihui, Fengfu, Shenmen and Taichong points for 20 min. The rats in the treatment group were treated with fluoxetine (2 mg/kg) once a day for 7 days. 3 courses, each course of rest between 1 day. Pathological changes in the hippocampal CA1 region were observed by light microscopy. Ultrastructural changes of the hippocampus were observed by electron microscopy. Levels of seretonin (5-HT), norepinephrine (NE), acetylcholine (Ach), gamma-aminobutyric acid (gamma-GABA) and glutamate (Glu) were measured in the cerebral cortex. 5-HT transporter (5-HTT), 5-HT1A receptor (5-HT1A R), NE alpha 2 receptor (NE alpha 2R) mRNAs and proteins were detected by RT-PCR and immunoblotting, respectively, in the hippocampus and raphe nucleus.
   Results: Compared with the model group, the acupuncture group had a lower Zea Longa score, higher sugar consumption, higher exercise level and greater number of vertical movements in the open field test (P <0.01 or P <0.05). The ultrastructural changes of hippocampal neurons were obvious and the damage to neurons was severe. There were fewer ultrastructural changes in hippocampal neurons in the acupuncture and drug groups compared with those in the model group. After treatment, levels of 5-HTT and 5HT1A R mRNA and protein in the brain tissue of PSD model rats were decreased, and levels of Ach, gamma-GABA, and Glu, and 5-HTT and 5-HT1A R mRNA and protein were significantly higher in the cortex of the acupuncture group compared with those in the untreated group (P <0.01). The mRNA and protein levels of NE alpha 2R mRNA and protein in the hippocampus, (P <0.01). The mRNA and protein levels of Ach, gamma-GABA, Glu and NE alpha 2R were decreased (P <0.01 or P <0.05).
   Conclusion: Jieyuanshen acupuncture can significantly improve the behavioral changes of post-stroke depression rats, and may up-regulate the levels of 5-HT and NE in the cerebral cortex, down-regulate the expression of Ach, gamma-GABA and Glu, and promote hippocampus, 5-HTT, 5-HT1A R, NE alpha 2R, inhibit the expression of NE alpha 2R, reduce the organic damage of hippocampus, and provide neuroprotective effect.
C1 [Xiao Wei; Zhang Xianbao; Wang Zhen; Guo Xiaoli] Anhui Univ Chinese Med, Affiliated Hosp 2, Hefei 230001, Anhui, Peoples R China.
   [He Ling] Anhui Univ Chinese Med, Hefei 230001, Anhui, Peoples R China.
   [Wang Yan] Anqing Municipal Hosp, Anqing 246000, Peoples R China.
RP Xiao, W (corresponding author), Care of Jian L, Dept Rheumatol, Anhui Univ Chinese Med, Affiliated Hosp 1, Hefei 230031, Anhui, Peoples R China.
EM liujianahzy@126.com
FU National Natural Science Foundation Project: Study on the Mechanism of
   Acupuncture Intervention on Post-stroke Depression by Using
   Neurotransmitter Receptor PCR Chip Technology [81273857]
FX Fund Project: National Natural Science Foundation Project: Study on the
   Mechanism of Acupuncture Intervention on Post-stroke Depression by Using
   Neurotransmitter Receptor PCR Chip Technology (81273857)
CR [Anonymous], 2014, J ACUPUNCTURE MOXIBU, V39, P136
   Carnes-Vendrell A, 2016, REV NEUROLOGIA, V62, P460, DOI 10.33588/rn.6210.2015473
   Das SK, 2016, NEUROSCI LETT, V612, P231, DOI 10.1016/j.neulet.2015.12.038
   Ding XH, 2016, METAB BRAIN DIS, V31, P279, DOI 10.1007/s11011-015-9748-z
   Llorca GE, 2015, NEUROLOGIA, V30, P23, DOI 10.1016/j.nrl.2012.06.008
   Fan WT, 2012, NEURAL REGEN RES, V7, P187, DOI 10.3969/j.issn.1673-5374.2012.03.005
   Feng C, 2014, J SCI WORLD, V2014, P5213
   Finkelmeyer A, 2016, PSYCHOL MED, V46, P2157, DOI 10.1017/S0033291716000702
   Ji XW, 2014, EXP THER MED, V8, P159, DOI 10.3892/etm.2014.1674
   Koizumi J., 1986, JPN J STROKE, V8, P1
   Le JJ, 2016, NEUROSCI LETT, V615, P66, DOI 10.1016/j.neulet.2016.01.004
   Li JF, 2016, J AFFECT DISORDERS, V197, P215, DOI 10.1016/j.jad.2016.03.038
   Li Y, 2015, CHINESE MED J-PEKING, V128, P2926, DOI 10.4103/0366-6999.168058
   Liu Dan, 2010, ZHONGGUO JING BAO JI, V13, P380
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Loubinoux I, 2012, J CELL MOL MED, V16, P1961, DOI 10.1111/j.1582-4934.2012.01555.x
   Manning KJ, 2016, BIOL PSYCHIAT, V80, pE1, DOI 10.1016/j.biopsych.2016.05.001
   Nabavi SF, 2015, CURR MED CHEM, V22, P343
   Qian XL, 2015, J ALTERN COMPLEM MED, V21, P748, DOI 10.1089/acm.2015.0084
   Queirazza F, 2014, J NEUROL NEUROSUR PS, V85, P241, DOI 10.1136/jnnp-2012-304149
   Robinson RG, 2016, AM J PSYCHIAT, V173, P221, DOI 10.1176/appi.ajp.2015.15030363
   Sun Yi, 2007, CHINESE J STROKE, V2, P891
   Tanahashi N, 2016, NEUROSCI LETT, V618, P99, DOI 10.1016/j.neulet.2016.02.051
   Tang MM, 2016, PHYSIOL BEHAV, V161, P166, DOI 10.1016/j.physbeh.2016.04.034
   Terroni L, 2015, NEUROPSYCH DIS TREAT, V11, P233, DOI 10.2147/NDT.S73722
   Wei CJ, 2016, INT J NEUROSCI, V126, P623, DOI 10.3109/00207454.2015.1051045
   Werheid K, 2016, GERONTOLOGY, V62, P33, DOI 10.1159/000381876
   WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358
   Wiwanitkit V, 2014, NEURAL REGEN RES, V9, P1248, DOI 10.4103/1673-5374.135320
   Xu Shuyun, 1994, PHARM EXPT METHOD, P642
   Young KD, 2016, BRAIN BEHAV IMMUN, V56, P335, DOI 10.1016/j.bbi.2016.04.007
   Zhang C, 2015, EVID-BASED COMPL ALT, V2015, P496
   Zhang JP, 2014, NEURAL REGEN RES, V9, P773, DOI 10.4103/1673-5374.131590
   Zhao Q, 2016, MOL NEUROBIOL, V53, P1699, DOI 10.1007/s12035-015-9120-7
NR 34
TC 0
Z9 0
U1 6
U2 21
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 507
EP 515
DI 10.19193/0393-6384_2018_2_82
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400035
DA 2022-07-14
ER

PT J
AU Xiao, XP
   He, X
   Jia, YF
   Ren, HL
   Xu, YS
AF Xiao, Xing-peng
   He, Xuan
   Jia, Yi-fan
   Ren, Han-lin
   Xu, Yan-shu
TI EFFICACY AND COMPARATIVE ANALYSIS OF SUFENTANIL AND FENTANYL IN
   INDUCTION OF GENERAL ANESTHESIA IN ELDER PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Sufentanil; fentanyl; hemodynatnics; stress response
ID PROPOFOL; COUGH
AB Objective:To explore the effects of sufentanil and fentanyl on hemodynamics and stress responses in induction of general anesthesia in elder patients.
   Methods: Randomly, we selected a total of 100 elder patients who would undergo general anesthesia in this hospital, and those patients were divided into two groups, i.e. the sufentanil group (n=50) and the fentanyl group (n=50). Respectively, induction in the sufentanil group and the fentanyl group was carried out with sufentanil (0.5 mu g/kg) and fentanyl (4.0 mu g/kg). Items to be observed in this study included the changes in hemodynamics and respiratory functions before induction and 1 min, 5 min and 10 min after intubation, and the variations in blood glucose and norepinephrine in venous blood that was drawn at 1 min after intubation.
   Results: From 1 min after intubation, the indicators of hemodynamics of patients in the sufentanil group were significantly lower than those in the fentanyl group and the difference had statistical significance (p<0.05), but at 10 min after intubation, no statistically significant difference was identified between two groups (p>0.05); at 1 min and 5 min after administration of drugs, respiratory depression in varying degrees was observed, while the reduction in respiratory rate in fentanyl group was more obvious than that in the sufentanil group, and the difference had statistical significance (p<0.05). However, comparison of the partial pressure of carbon dioxide (PaCO2) after intubation between two groups showed no statistically significant difference (p>0.05). At 1 min after intubation, decreases were identified in blood glucose and norepinephrine in the sufentanil group, while in the fentanyl group, these two indicators were elevated, and the differences between two groups had statistical significance (p<0.05).
   Conclusion: Sufentanil, with less inhibitory effect on respiration, can stabilize the hemodynamics, maintain the stability of circulation system and inhibit the stress response in the induction of general anesthesia for elderly patients. Thus, sufentanil is more applicable to the induction of general anesthesia.
C1 [Xiao, Xing-peng; He, Xuan; Jia, Yi-fan; Ren, Han-lin; Xu, Yan-shu] Wuhan Univ, Renmin Hosp, Dept Anaesthesiol, Wuhan 430060, Hubei, Peoples R China.
RP Xu, YS (corresponding author), Fengcheng Hosp Shanghai Fengxian Dist, Dept Anaesthesiol, 9983 Chuannan Fenggong Rd, Shanghai, Peoples R China.
CR Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801
   HAMILTON WK, 1953, ANESTHESIOLOGY, V14, P550, DOI 10.1097/00000542-195311000-00002
   HUGHES NJ, 1995, CAN J ANAESTH, V42, P744, DOI 10.1007/BF03012676
   PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623
   RIES CR, 1994, CAN J ANAESTH, V41, P414, DOI 10.1007/BF03009864
   Schricker T, 2000, ANESTH ANALG, V90, P450, DOI 10.1097/00000539-200002000-00039
   Shen JC, 2008, CURR THER RES CLIN E, V69, P480, DOI 10.1016/j.curtheres.2008.12.002
   Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6
   Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005
   Yu J, 2012, IRISH J MED SCI, V181, P517, DOI 10.1007/s11845-012-0807-8
NR 10
TC 0
Z9 0
U1 2
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 889
EP 892
DI 10.19193/0393-6384_2018_3_136
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000040
DA 2022-07-14
ER

PT J
AU Xie, K
   Yu, JG
   Sun, GY
   Li, CG
   Wang, H
   Liu, X
   Wen, Q
   Wang, SQ
AF Xie, Kun
   Yu, Jingui
   Sun, Guoyong
   Li, Chuangang
   Wang, Hui
   Liu, Xiao
   Wen, Qing
   Wang, Shuqin
TI APPLICATION OF MILD HYPOTHERMIA THERAPY COMBINED WITH 3-N-BUTYLPHTHALIDE
   IN TREATMENT OF RATS WITH CEREBRAL ISCHEMIA-REPERFUSION INJURY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE mild hypothermia; n-Butylphthalide; cerebral ischemia-reperfilsion
   injury; neuroprotection; mTOR
ID TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; ISCHEMIA/REPERFUSION INJURY;
   PARKINSONS-DISEASE; STROKE; DL-3-N-BUTYLPHTHALIDE; MICE; INFLAMMATION;
   ANTIOXIDANT; EXPRESSION
AB Objective: To investigate the neuroprotective effect of mild hypothermia (MH) combined with n-Butylphthalide (NBP) on rats ischemia-reperfusion injury model. Methods Rats were divided into Sham group, MH group, Model group, NBP group and MH+NBP group. Rats in NBP and MH+NBP group were treated with NBT for 7 days before surgery, and solvent was used in other groups. Rat global cerebral ischemia-reperfusion model was constructed using Pulsinelli four-vessel occlusion method. Content of oxidative damage and inflammation related factors were measured using corresponding kit. Neuronal cell damage was detected by Nissl staining. Western blot was used to detect expression of Bcl-2, Bax, mTOR and NF-kappa B proteins.
   Results: MDA, NO, NOS, IL-6 and IL-1 beta contents and levels of Bax, p-mTOR and p-NF-kappa B proteins were significantly increased and SOD content and expression level of Bcl-2 were significantly decreased in Model group compared with Sham group (p<0.05), while MH, NBP, and MH+NBP significantly inhibited those changes (p<0.05) and the inhibition effect of MH+NBP was the strongest. Numbers of neurons in MH, NBP, and MH+NBP were all increased compared with Model group, while this number was highest in MH+NBP group and showed no significant difference to that of Sham group.
   Conclusion: MH+NBP played a better role in inhibiting oxidation damage and inflammatory response induced by cerebral ischemia-reperfusion than MH and NBP alone. The mechanism is possibly related to the inhibited phosphorylation of mTOR and NF-kappa B proteins, increase in expression level of anti-apoptotic proteins and decrease in expression level of pro-apoptotic proteins.
C1 [Xie, Kun; Sun, Guoyong; Li, Chuangang; Liu, Xiao] Shandong Univ, Hosp 2, Dept Anesthesiol, Jinan, Shandong, Peoples R China.
   [Yu, Jingui; Wang, Shuqin] Shandong Univ, Qilu Hosp, Dept Anesthesiol, 107 Wenhua West Rd, Jinan, Shandong, Peoples R China.
   [Wang, Hui; Wen, Qing] Shandong Univ, Hosp 2, Blood Purificat Ctr, 247 Beiyuan St, Jinan, Shandong, Peoples R China.
RP Wang, SQ (corresponding author), Shandong Univ, Qilu Hosp, Dept Anesthesiol, 107 Wenhua West Rd, Jinan, Shandong, Peoples R China.; Wen, Q (corresponding author), Shandong Univ, Hosp 2, Blood Purificat Ctr, 247 Beiyuan St, Jinan, Shandong, Peoples R China.
EM 120382594@qq.com; Shuqinwang2004@163.com
CR Arrich J, 2012, HYPOTHERMIA NEUROPRO
   Chen H, 2011, ANTIOXID REDOX SIGN, V14, P1505, DOI 10.1089/ars.2010.3576
   Chen SD, 2011, INT J MOL SCI, V12, P7199, DOI 10.3390/ijms12107199
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Ghosh A, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057735, 10.1371/journal.pone.0082529]
   Gong P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035313
   Hacke W, 2012, CEREBRAL ISCHEMIA M
   Heeba GH, 2012, LIFE SCI, V90, P388, DOI 10.1016/j.lfs.2011.12.001
   Huang JZ, 2010, NEUROSCI LETT, V475, P89, DOI 10.1016/j.neulet.2010.03.053
   Kalogeris T, 2014, REDOX BIOL, V2, P702, DOI 10.1016/j.redox.2014.05.006
   Kalogeris T, 2012, INT REV CEL MOL BIO, V298, P229, DOI 10.1016/B978-0-12-394309-5.00006-7
   Kleikers PWM, 2012, J MOL MED, V90, P1391, DOI 10.1007/s00109-012-0963-3
   Malik ZA, 2011, J ETHNOPHARMACOL, V133, P729, DOI 10.1016/j.jep.2010.10.061
   O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741
   Pan J, 2007, NEURORADIOLOGY, V49, P93, DOI 10.1007/s00234-006-0183-z
   Peng Y, 2012, J ALZHEIMERS DIS, V29, P379, DOI 10.3233/JAD-2011-111577
   Sanderson TH, 2013, MOL NEUROBIOL, V47, P9, DOI 10.1007/s12035-012-8344-z
   Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959
   Shi GD, 2011, BIOCHEM BIOPH RES CO, V404, P941, DOI 10.1016/j.bbrc.2010.12.085
   Suda S, 2013, EUR J PHARMACOL, V707, P26, DOI 10.1016/j.ejphar.2013.03.020
   Sullivan PG, 1999, J NEUROSCI, V19, P6248
   Tissier R, 2013, RESUSCITATION, V84, P249, DOI 10.1016/j.resuscitation.2012.06.030
   Wang CH, 2012, NEUROSCI LETT, V529, P45, DOI 10.1016/j.neulet.2012.08.078
   WILSON CW, 1970, J FOOD SCI, V35, P766, DOI 10.1111/j.1365-2621.1970.tb01989.x
   Wong CHY, 2008, CURR MED CHEM, V15, P1
   Xiong NA, 2012, NEUROBIOL AGING, V33, P1777, DOI 10.1016/j.neurobiolaging.2011.03.007
   Zhang JT, 2002, PROGR STUDY NEUROPHA, P49
   Zhang LH, 2012, CURR NEUROVASC RES, V9, P167, DOI 10.2174/156720212801618956
   Zhang T, 2011, NEUROL RES, V33, P396, DOI 10.1179/1743132810Y.0000000006
   Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014
NR 30
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1959
EP 1965
DI 10.19193/0393-6384_2018_6_305
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400056
DA 2022-07-14
ER

PT J
AU Xie, YR
   Yu, WJ
   Yu, FY
   Bing, LL
AF Xie, Yanrong
   Yu, Wenjuan
   Yu, Fengyun
   Bing, Leilei
TI PROTECTIVE EFFECTS OF BUCKWHEAT FLAVONOIDS ON DIABETIC NEPHROPATHY RATS
   VIA PI3K/AKT SIGNALING PATHWAY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE buckwheat flavonoid; diabetic nephropathy; PI3K/Akt signaling pathway;
   FOXO1 mRNA
ID KIDNEY-DISEASE; KINASE; GENES; LIFE; FOXO
AB PI3K/Akt signaling pathway is multi-functional, and a host of reports have proved a key role in regulating renal extracellular matrix accumulation in diabetic kidney disease. The present study aimed to investigate the protective effect of buckwheat flavonoids on diabetic nephropathy via PI3K/Akt signaling pathway. In the present study, a lot of experiments were performed to validate the above assumptions, such as H&E staining, RT-PCR, western blot, blood glucose, kidney index et al. From the experimental data, we found that buckwheat flavonoids could ameliorate complications of the rats bearing diabetic nephropathy. After 4 weeks of buckwheat flavonoids administration, the mice exhibited an excellent improvement in blood glucose and kidney index, reduced morphological changes in the renal tissue and normalized the abnormal expression of FOXO1 mRNA. Treatment of buckwheat flavonoids also down-regulated p-Akt and PI3K (p85) proteins level caused by diabetic nephropathy, which indicated the involvement of PI3K/Akt signaling pathway in the diabetic nephropathy. Our results verified buckwheat flavonoids as a potential therapeutic agent evidently by improving the renal function via inhibiting PI3K/Akt signaling pathway, consequently ameliorating diabetic nephropathy.
C1 [Xie, Yanrong; Yu, Wenjuan; Yu, Fengyun; Bing, Leilei] Yantai Hosp Tradit Chinese Med, Dept Endocrinol, 39 Xingfu Rd, Yantai 264001, Shandong, Peoples R China.
RP Bing, LL (corresponding author), Yantai Hosp Tradit Chinese Med, Dept Endocrinol, 39 Xingfu Rd, Yantai 264001, Shandong, Peoples R China.
EM LeileiBing@Yeah.com
CR Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Excerpts From the United States Renal Data System, 2009, AM J KIDNEY DIS, V55, pS231
   Forouhi Nita Gandhi, 2014, Medicine (Abingdon), V42, P698
   Hall JE, 2004, ADV RENAL REPLACE TH, V11, P41, DOI 10.1053/j.arrt.2003.10.007
   Hedrick SM, 2009, NAT IMMUNOL, V10, P1057, DOI 10.1038/ni.1784
   Hu FB, 2011, DIABETES CARE, V34, P1249, DOI 10.2337/dc11-0442
   Kato M, 2006, J AM SOC NEPHROL, V17, P3325, DOI 10.1681/ASN.2006070754
   Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897
   Kennedy DO, 2014, ADV NUTR, V5, P515, DOI 10.3945/an.114.006320
   Liao CY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/840542
   Madhusudhan T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7496
   Maezawa Y, 2015, J DIABETES INVEST, V6, P3, DOI 10.1111/jdi.12255
   Nam TG, 2015, FOOD CHEM, V170, P97, DOI 10.1016/j.foodchem.2014.08.067
   Rane MJ, AM J PHYSL RENAL PHY, V201, pF49
   Ren W, 2001, METHOD FIND EXP CLIN, V23, P427, DOI 10.1358/mf.2001.23.8.662129
   Song ZX, 2014, METABOLISM, V63, P1324, DOI 10.1016/j.metabol.2014.06.013
   Tabish SA, 2007, INT J HEALTH SCI-IJH, V1, pV
   Testa R, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050310
   van der Vos KE, 2011, ANTIOXID REDOX SIGN, V14, P579, DOI 10.1089/ars.2010.3419
   Vinayagam R, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0057-7
   Yang KS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094540
   Yang Y, 2007, AM J NEPHROL, V27, P495, DOI 10.1159/000106782
   Zdychova J, 2005, PHYSIOL RES, V54, P1, DOI 10.33549/physiolres.930582
NR 23
TC 1
Z9 1
U1 4
U2 13
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 719
EP 724
DI 10.19193/0393-6384_2018_3_111
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000016
DA 2022-07-14
ER

PT J
AU Xing, CY
   Lin, RS
   Guo, AS
   Fang, YR
   Zhou, CF
   Lin, ZY
   Cai, WP
AF Xing Chunyang
   Lin Ruisheng
   Guo Aishun
   Fang Yiru
   Zhou Changfu
   Lin Zhiyong
   Cai Weiping
TI EVALUATION OF THE EXPRESSIONS AND PROGNOSTIC VALUES OF ADAM17, EGFR AND
   KI-67 IN GLIOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Glioma; ADAM17; EGFR; Ki-67; Degree of malignancy; Prognosis
AB Purpose: To investigate the expressions of depolymerization element - metal protease (ADAM17), epidermal growth factor receptor (EGFR) and cell proliferating nuclear antigen (Ki-67) in glioma and their prognostic values.
   Methods: The surgical excision specimens of 70 patients with glioma treated in the hospital from January 2011 to June 2016 were chosen as glioma group, and 20 cases of non-tumor brain tissue were chosen as control group. In glioma group, there were 25 cases of WHO grade II, 25 cases of grade III, 20 cases of grade IV, and the patients were divided into 2 groups: low-grade glioma group (grade II) and high-grade glioma group (III + IV). Immunohistochemical method was used to determine the expressions of ADAM17, EGFR and Ki-67 in the pathological specimens, and all the patients were followed up after surgery to record the survival time.
   Results: The positive expression rates of ADAM17, EGFR and Ki-67 in the control group and the brain glioma group were significantly different. Among them, the positive expressions of ADAM17, EGFR and Ki-67 in low-grade glioma group were 56.0% (14/25), 48.0% (12/25) and 20.0% (5/25), respectively, and the positive expressions of ADAM17, EGFR and Ki-67 in high-grade glioma group were 97.8% (44/45), 84.4% (38/45) and 86.7% (39/45), respectively. The positive expressions of ADAM17, EGFR and Ki-67 increased significantly with increase in malignancy (p < 0.05). All patients were followed up in order to record survival time, and it was found that within 3 years, the survival rate of ADAM1 negative and positive patients were 75.0% and 31.0%, respectively; the 3 years survival rates of EGFR negative and positive patients were 65.0% and 28.0%, respectively, and the 3 years survival rates of patients with Ki-67 negative and positive were 80.8% and 20.5%, respectively. The 3 years survival rates of ADAM1, EGFR, Ki-67 negative and positive groups were significantly different. The high expression of ADAM1, EGFR and Ki-67 suggested poor prognosis.
   Conclusion: ADAM17, EGFR and Ki-67 are closely related to the malignant degree of glioma. The three parameters are helpful in the assessment of malignancy and prognosis of the tumor.
C1 [Xing Chunyang; Lin Ruisheng; Guo Aishun; Fang Yiru; Zhou Changfu; Lin Zhiyong; Cai Weiping] Fujian Med Univ, Zhangzhou Affiliated Hosp, Dept Neurosurg, Zhangzhou 363000, Fujian, Peoples R China.
RP Cai, WP (corresponding author), Dept Neurosurg, Zhangzhou, Peoples R China.
EM 316130136@qq.com
RI xing, chunyang/AAM-8142-2021
CR Ahmed S, 2016, TURK J PATHOL, V32, P70, DOI 10.5146/tjpath.2015.01344
   Barth RF, 2016, ONCOTARGETS THER, V9, P2769, DOI 10.2147/OTT.S99242
   Bohrer Laura R, 2016, Genes Cancer, V7, P240, DOI 10.18632/genesandcancer.115
   Cioca Andreea, 2016, Asian Pac J Cancer Prev, V17, P4205
   Derks J, 2017, NEUROIMAGE-CLIN, V14, P87, DOI 10.1016/j.nicl.2017.01.007
   Field CS, 2016, IMMUNOTHERAPY-UK, V8, P387, DOI 10.2217/imt-2015-0022
   Hu TM, 2016, CHIN MED REC, V05, P21
   Li B, 2016, ONCOTARGET, V7, P63054, DOI 10.18632/oncotarget.10666
   Lorenzen I, 2016, SCI REP-UK, V6, DOI 10.1038/srep35067
   Miao C, 2015, ONCOL LETT, V10, P1716, DOI 10.3892/ol.2015.3474
   de Souza ALR, 2017, MOL IMAGING BIOL, V19, P41, DOI 10.1007/s11307-016-0980-7
   Su Changliang, 2016, RADIOLOGY PRACTICE, V31, P570
   Tant TY, 2013, CHIN J CANC PREV TRE, P840
   Wolf C, 2016, SCI REP-UK, V6, DOI 10.1038/srep39780
   Zhang Y, 2013, J CHIN ONCO, V04, P307
NR 15
TC 0
Z9 0
U1 2
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 733
EP 737
DI 10.19193/0393-6384_2018_3_113
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000018
DA 2022-07-14
ER

PT J
AU Xu, HT
   Xu, GM
   Wang, Y
   Si, LH
AF Xu, Haitao
   Xu, Guangmeng
   Wang, Yao
   Si, Lihui
TI GENE PROFILE OF COLORECTAL CANCER AND ITS IMPLICATIONS IN CANCER
   DEVELOPMENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Colorectal cancer; cDNA microarray; GO analysis; Pathway analysis
ID CELLS
AB Objective: To analyse gene expression profiles between colorectal cancer and adjacent normal tissues and preliminarily explore the potent key genes and underlying molecular mechanisms in colorectal cancer development.
   Methods: Gene expression microarray chips were used to identify genes that were differently expressed in colorectal cancer and adjacent normal tissues. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to validate microarray results. Furthermore, gene oncology (GO) and pathway analyses were conducted for clustering of these differentially expressed genes.
   Results: About 1072 genes were differentially expressed between cancer tissues and adjacent normal tissues (P <= 0.05, Fc> 2.0), in which 435 genes were upregulated and 637 genes were downregulated. Three up-regulated genes (KRT23, TGFBI, and MYC) and one downregulated gene (DPHA7) were selected and confirmed using qRT-PCR, which was consistent with that of microarray analysis. These genes were further classified into 71 groups based on their functions using GO and pathway analysis. KEGG analysis of these upregulated or downregulated genes revealed that a total of 23 signalling pathways were involved.
   Conclusion: This study preliminarily screened key genes and the signalling pathways that are closely associated with colorectal cancer development, yet subsequent gene function studies are still required to verify these findings. These four key genes, which are closely related with the development of colorectal cancer, could interfere with tumour development. Further researches may shed new lights on the pathogenesis of colorectal cancer.
C1 [Xu, Haitao; Wang, Yao] Jilin Univ, Dept Ophthalmol, Hosp 2, Jilin, Jilin, Peoples R China.
   [Xu, Guangmeng] Jilin Univ, Dept Gen Surg, Hosp 2, Jilin, Jilin, Peoples R China.
   [Si, Lihui] Jilin Univ, Dept Gynaecol & Obstet, Hosp 2, Jilin, Jilin, Peoples R China.
RP Si, LH (corresponding author), Jilin Univ, Dept Gynaecol & Obstet, Hosp 2, Jilin, Jilin, Peoples R China.
EM silihui1982@163.com
CR Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Colli LM, 2013, PLOS ONE, V26
   Fang X, 2013, BIOCHEM BIOPH RES CO, P19
   Gantt GA, 2014, COLORECTAL DIS, V16, P57, DOI 10.1111/codi.12395
   Han L, 2014, INT J MOL MED, V33, P581, DOI 10.3892/ijmm.2014.1620
   Krausova M, 2014, CELL SIGNAL, V26, P570, DOI 10.1016/j.cellsig.2013.11.032
   LaPointe LC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029059
   Liu J, 2013, ACTA BIOCH BIOPH SIN, P29
   Mao CD, 2011, CRITICAL REV EUKARYO, V21
   Naushad SM, 2014, CELL BIOCHEM BIOPHYS, V68, P397, DOI 10.1007/s12013-013-9720-7
   Nishimura Y, 2014, INT J ONCOL, V44, P412, DOI 10.3892/ijo.2013.2194
   Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9
   Takahashi Y, 2014, BRIT J CANCER, V110, P164, DOI 10.1038/bjc.2013.698
   Wang F, 2007, CHINESE J CANC
   Wang SH, 2014, MOL MED REP, V9, P973, DOI 10.3892/mmr.2014.1889
   Wang XC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052707
   Wang Y, 2014, PATHOLOGY ONCOLOGY R
   Yi JM, 2012, TUMOR BIOL, V33, P363, DOI 10.1007/s13277-011-0302-2
NR 18
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1453
EP 1459
DI 10.19193/0393-6384_2018_5_221
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700043
DA 2022-07-14
ER

PT J
AU Xu, J
   Huang, Y
   Xu, Y
   Huang, XL
   Li, L
   Zheng, M
AF Xu, Jing
   Huang, Yi
   Xu, Ying
   Huang, Xiaolin
   Li, Li
   Zheng, Min
TI EXPRESSION CHARACTERISTICS OF MIRNA-218-5P IN INVASIVE FRONTIER CELLS OF
   ORAL SQUAMOUS CELL CARCINOMA AND ITS MOLECULAR SIGNAL OF REGULATION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE oral squamous cell carcinoma; invasive frontier cells; miRNA-218-5p;
   expression; signal pathway
ID PROMOTES; CANCER
AB Introduction: To discuss expression characteristics of miRNA-218-5p in invasive frontier cells of oral squamous cell carcinoma (OSCC) and its molecular signal of regulation.
   Materials and methods: OSCC invasive frontier cell strains, specifically SCC6-M and SCC6 cancer cell strains, were dissociated from cancer tissue and acquired from other parts of tumours of OSCC patients in our hospital. miRNA-218-5p expression level in the two cell strain groups and CD44mRNA expression level in the SCC6-M cell strain after transfection by miRNA-218-5p mimics and inhibitor were compared with a negative control. CD44 protein expression levels of cell strains in two groups were detected using the Western blot method.
   Results: Relative expression levels of miRNA-218-5p in the SCC6-M cell strain was lower than that of the SCC6 cell strain (P < 0.05), while relative expression level of CD44 protein in the SCC6-M cell strain was higher than that of the SCC6 cell strain (P < 0.05). Invasion depth, invasion area and CD44mRNA expression level of the SCC6-M cell strain were all lower than those of the negative control group (P < 0.05) 24 h and 48 h after transfection by miRNA-218-5p mimics. Invasion depth, invasion area and CD44mRNA expression level of the SCC6-M cell strain were all higher than those of the negative control group (P < 0.05) 24 h and 48 h after transfection by a miRNA-218-5p inhibitor.
   Conclusion: Expression level of miRNA-218-5p in invasive frontier cells of OSCC was lower than that of other parts of the tumour. miRNA-218-5P weakens the CD44/ROCK signal pathway and inhibits tumour metastasis and invasion by inhibiting CD44 protein expression.
C1 [Xu, Jing] Wenzhou Med Univ, Zhoushan Hosp, Comprehens Breast Hlth Ctr, Zhoushan, Zhejiang, Peoples R China.
   [Huang, Yi] Sichuan Prov Peoples Hosp, Dept Stomatol, Chengdu, Sichuan, Peoples R China.
   [Xu, Ying; Huang, Xiaolin; Li, Li; Zheng, Min] Wenzhou Med Univ, Zhoushan Hosp, Dept Stomatol, Zhoushan, Zhejiang, Peoples R China.
RP Zheng, M (corresponding author), Wenzhou Med Univ, Zhoushan Hosp, Dept Stomatol, Zhoushan, Zhejiang, Peoples R China.
EM tc1276@163.com
FU National Natural Science Foundation of China [81502357]; Medical Science
   and Technology Project of Zhejiang Province [2016KYB316, 2016KYA183]
FX This paper was supported by National Natural Science Foundation of China
   Grant (No. 81502357) and Medical Science and Technology Project of
   Zhejiang Province (No. 2016KYB316 and No. 2016KYA183).
CR Chen X, 2017, STOMATOL, V37, P462
   Dasari S, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0139-9
   Duan YS, 2016, ONCOL LETT, V12, P2055, DOI 10.3892/ol.2016.4838
   He L, 2017, CLIN J MED OFF, V45, P661
   Huang Y, 2018, ONCOL REP, V39, P1338, DOI 10.3892/or.2017.6163
   Jose FG, 2018, RENEW ENERGY
   Li HC, 2018, EXP THER MED, V15, P3369, DOI 10.3892/etm.2018.5814
   Liu M, 2017, PLOS ONE, V12
   Ma F, 2017, BIOMED PHARMACOTHER, V88, P863, DOI 10.1016/j.biopha.2017.01.150
   Mauzo SH, 2016, J CLIN PATHOL, V69, P382, DOI 10.1136/jclinpath-2015-203467
   Ren ZH, 2016, ONCOL LETT, V11, P1973, DOI 10.3892/ol.2016.4207
   [石晓妮 Shi Xiaoni], 2017, [中国病理生理杂志, Chinese Journal of Pathophysiology], V33, P1869
   Shimizu S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195451
   Sun K, 2016, CLIN EXP MED, V16, P37, DOI 10.1007/s10238-015-0336-7
   Zhang SC, 2015, ARCH ORAL BIOL, V60, P1581, DOI 10.1016/j.archoralbio.2015.08.003
   Zhao Y, 2016, MOL MED REP, V14, P1901, DOI 10.3892/mmr.2016.5518
NR 16
TC 0
Z9 0
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1953
EP 1957
DI 10.19193/0393-6384_2018_6_304
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400055
DA 2022-07-14
ER

PT J
AU Xu, LY
   Wei, DS
   Liu, YP
AF Xu, Liyan
   Wei, Daishu
   Liu, Yanping
TI EFFECT OF TRANSITIONAL CARE MODEL ON REHABILITATION OF LUMBAR DISC
   HERNIATION PATIENTS FOLLOWING NON-SURGICAL TREATMENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Transitional care model; Non-surgical treatment; Lumbar disc herniation;
   Observation and analysis of rehabilitation efficacy
AB Objective: This study assesses the efficacy of transitional care model on rehabilitation for lumbar disc herniation patients following non-surgical treatment.
   Methods: A total of 600 patients with lumbar disc herniation receiving non-surgical treatment were randomly divided into two groups denoted as research and control, with 300 patients in each group. Two treatment models were applied with patients in control group adhered to normal nursing, while those under research group given transitional care model. Subsequently, the nursing efficacy of patients in both groups was investigated.
   Results: Comparisons on both groups showed that the overall treatment effectiveness in research group was substantial than that in the control group, showing compliance with P < 0.05. Recurrence rate was distinctly greater in control group (P < 0.05). while, higher overall nursing satisfaction was observed in research group with P < 0.05.
   Conclusions: Transitional care model on lumbar disc herniation patients that follows non-surgical treatment not only improves the rehabilitation efficacy, but also provide better nursing service, as well as distinctly reduce the recurrence rate.
C1 [Xu, Liyan] Linyi Mental Hlth Ctr, Linyi 276000, Peoples R China.
   [Wei, Daishu] Shan Dong Med Coll, Affiliated Hosp, Linyi 276000, Peoples R China.
   [Liu, Yanping] Linyi Peoples Hosp, Linyi 276000, Peoples R China.
RP Liu, YP (corresponding author), Linyi Peoples Hosp, Linyi 276000, Peoples R China.
EM yuanyangliu@163.com
CR Cahill G., 2015, ASIAN PAC J SURG ONC, V1, P27
   Cahill T., 2015, ASIAN PAC J SURG ONC, V1, P47
   Dobson P. R., 2015, ASIAN PAC J SURG ONC, V1, P59
   Du HG, 2016, SAUDI PHARM J, V24, P305, DOI 10.1016/j.jsps.2016.04.002
   Ghoneum M, 2015, ASIAN PAC J SURG ONC, V1, P73
   Hu QQ, 2015, HUBEI J TRADITIONAL, V22, P53
   Huang RQ, 2016, SAUDI PHARM J, V24, P341, DOI 10.1016/j.jsps.2016.04.014
   Lee SJ, 2016, SAUDI J BIOL SCI, V23, P9, DOI 10.1016/j.sjbs.2015.01.016
   Li YP, 2016, J JILIN MED COLL, V11, P444
   Pan YZ, 2016, CHINESE J MODERN DRU, V23, P227
   Xu H., 2016, WORLD LATEST MED INF, V10, P277
   Yung K. W., 2015, ASIAN PAC J SURG ONC, V1, P1
   [张冬玲 Zhang Dongling], 2014, [护理学杂志, Journal of Nursing Science], V29, P69
NR 13
TC 0
Z9 0
U1 0
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 261
EP 265
DI 10.19193/0393-6384_2018_1s_43
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100008
DA 2022-07-14
ER

PT J
AU Xu, YM
   Peng, CY
   He, ZG
   Wang, SH
   Tian, H
AF Xu, Yue-Ming
   Peng, Chun-Yu
   He, Zhi-Gang
   Wang, Shun-Hong
   Tian, Hai
TI EFFECT OF PERIOPERATIVE LUNG PROTECTIVE VENTILATION ON PATIENTS WITH
   SEPSIS IN THE ABDOMINAL CAVITY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Intraoperative lung protection ventilation; sepsis; intro-abdominal
   infection; Acute Respiratory Distress Syndrome; pulmonary complication
ID POSTOPERATIVE PULMONARY COMPLICATIONS; RESPIRATORY-DISTRESS-SYNDROME;
   TIDAL VOLUME VENTILATION; SURGERY; INFLAMMATION
AB Introduction: Severe abdominal infections often induce sepsis, and the lung is one of the organs that are frequently affected by sepsis. Many patients with sepsis caused by abdominal infections, but no clinical study on whether these patients should receive ventilation strategies has been reported. This study aims to investigate the effects of different mechanical ventilations on patients with sepsis in the abdominal cavity.
   Materials and methods: A retrospective analysis was conducted on data obtained from 296 patients with sepsis in the abdominal cavity, who were admitted in our hospital, in order to evaluate the effects of mechanical ventilations with different tidal volumes. Carbon dioxide partial pressure, oxygenation index and mean airway plateau pressure at different time points after mechanical ventilation, the tracheal extubation rate within two hours after surgery, the incidence of atelectasis within 24 hours after surgery, and mortality within 28 days after surgery were compared between the two groups.
   Results: Differences in the basic situations of patients upon entering the operating room between the two groups were not statistically significant. At 10, 30 and 60 minutes after mechanical ventilation, and at the end of the operation, differences in arterial blood pH value, oxygenation index, extubation rate within two hours after surgery, and the incidence of atelectasis within 24 after surgery between the two groups were not statistically significant (P>0.05). Ventilation was obviously excessive and airway plateau pressure was higher in group 1, while patients had mild CO2 retention in group 11; and the difference was statistically significant (P<0.05). Furthermore, differences in the incidence of acute respiratory distress syndrome and 28-day mortality between the two groups were statistically significant (P=0.04).
   Conclusion: Lung protective ventilation can reduce the incidence of acute respiratory distress syndrome and 28-day mortality.
C1 [Xu, Yue-Ming; Peng, Chun-Yu; He, Zhi-Gang; Wang, Shun-Hong; Tian, Hai] Peoples Liberat Army, Dept Anesthesiol, Hosp 324, Chongqing 400020, Peoples R China.
RP Xu, YM (corresponding author), 324 PLA Hosp, Master Dept anesthesiol, 29 East Rd Janxin, Chongqing 400020, Peoples R China.
EM xuyueming_111@163.com
CR Baudouin SV, 2006, THORAX, V61, P464, DOI 10.1136/thx.2005.057265
   Canet J, 2010, ANESTHESIOLOGY, V113, P1338, DOI 10.1097/ALN.0b013e3181fc6e0a
   de Prost N, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-28
   Del Sorbo L, 2011, CURR OPIN CRIT CARE, V17, P1, DOI 10.1097/MCC.0b013e3283427295
   Fernandez-Bustamante A, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0032-x
   Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052
   Gattinoni L, 2011, CHEST, V140, P11, DOI 10.1378/chest.11-0827
   Haitsma JJ, 2006, MINERVA ANESTESIOL, V72, P117
   Hauber HP, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-21
   Hemmes SNT, 2014, LANCET, V384, P495, DOI 10.1016/S0140-6736(14)60416-5
   Hubmayr RD, 2011, CHEST, V140, P9, DOI 10.1378/chest.11-0825
   Kallet R H, 2001, Respir Care, V46, P49
   Kiss T, 2016, ANAESTHESIST, V65, P573, DOI 10.1007/s00101-016-0198-8
   Ladha K, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3646
   LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430
   Lellouche F, 2013, INTENS CARE MED, V39, P6, DOI 10.1007/s00134-012-2728-4
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Matthias Briel, 2010, JAMA-J AM MED ASSOC, V9, P300
   Patel JM, 2016, PERIOPER MED-LONDON, V5, DOI 10.1186/s13741-016-0033-4
   Sato H, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0209-y
   Schultz MJ, 2015, CURR OPIN CRIT CARE, V21, P351, DOI 10.1097/MCC.0000000000000215
   Neto AS, 2015, ANESTHESIOLOGY, V123, P66, DOI 10.1097/ALN.0000000000000706
   Severgnini P, 2013, ANESTHESIOLOGY, V118, P1307, DOI 10.1097/ALN.0b013e31829102de
   Sigurdsson MI, 2013, ACTA ANAESTH SCAND, V57, P37, DOI 10.1111/aas.12001
   Sundar S, 2011, ANESTHESIOLOGY, V114, P1102, DOI 10.1097/ALN.0b013e318215e254
   Xiong Wei, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V36, P215
NR 26
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1697
EP 1702
DI 10.19193/0393-6384_2018_6_259
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400010
DA 2022-07-14
ER

PT J
AU Xue-Mei, X
   Dian-Ming, L
   Jun-Feng, H
   Yong, Z
   Shan, G
AF Xue-Mei, Xia
   Dian-Ming, Li
   Jun-Feng, Hu
   Yong, Zhang
   Shan, Gao
TI MECHANISMS INVOLVED IN THE EFFECT OF DOWN-REGULATED CX43 ON ACQUIRED
   RESISTANCE OF NON-SMALL CELL LUNG CANCER CELLS TO GEFITINIB (R)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Non-small cell lung cancer; CX43; Gifitinib (R); Acquired resistance
ID TYROSINE KINASE EXPRESSION; BREAST-CANCER; AXL; NEK2
AB Objective: To study the effect of down-regulated Cx43 on acquired resistance of non-small lung cancer (NSCLC) cells to Gefitinib (R), and explore its mechanisms.
   Methods: Gefitinib (R) - resistant cells strain HCC827 GR were exposed gradually to increasing concentrations of Gefitinib (R), and the IC50 value of the drug was determined by MTT assay. The Cx43 mRNA expression was measured using RT-PCR, while the protein and phosphorylated Akt (p-Akt) levels were determined with Western blot. Immunofluorescence technique was used for the analysis of the Cx43 cells.
   Results: The IC50 values of Gefitinib (R) for HCC827 and HCC827 GR were 0.075 +/- 0.013 and 10.67 +/- 0.027 mu mol/L, respectively, and differed significantly (p < 0.05). The expression levels of mRNA and protein of Cx43 in HCC827 GR were significantly lower than those of HCC827 (p < 0.05), while the protein level of p-Akt was significantly increased (p < 0.05). When LT294002, the specific inhibitor of PI3K was added to HCC827 GR, the protein expression level of p-Akt was significantly reduced (p < 0.05), while that of Cx43 was significantly increased (p < 0.01).
   Conclusion: The down-regulation of Cx43 in the cytoplasm of patients with NSCLC is associated with acquired resistance of NSCLC cells to Gefitinib (R), most likely due to the activation of PI3K / Akt signal pathway of Cx43 non-GJIC-dependent. Thus, measurement of levels of Cx43 is a useful guide during the treatment of NSCLC.
C1 [Xue-Mei, Xia; Dian-Ming, Li; Jun-Feng, Hu; Yong, Zhang; Shan, Gao] Bengbu Med Coll, Affiliated Hosp 1, Dept Resp & Crit Care Med, Bengbu, Anhui, Peoples R China.
RP Dian-Ming, L (corresponding author), Bengbu Med Coll, Affiliated Hosp 1, Dept Resp & Crit Care Med, Bengbu, Anhui, Peoples R China.
EM yxogy6@163.com
CR Cichon MA, 2014, ONCOGENE, V33, P4185, DOI 10.1038/onc.2013.388
   D'Alfonso TM, 2014, J CLIN PATHOL, V67, P690, DOI 10.1136/jclinpath-2013-202161
   Lee CH, 2014, ANN SURG ONCOL, V21, P1031, DOI 10.1245/s10434-013-3400-0
   Liu X, 2014, ONCOL REP, V31, P745, DOI 10.3892/or.2013.2910
   Neal CP, 2014, J SURG ONCOL, V110, P828, DOI 10.1002/jso.23717
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   WANG Junjie, 2016, ORAL MEDCINE, V36, P333
   Wang W.J., 2017, MOBILE INFORM SYSTEM, V2017, P1, DOI DOI 10.1080/09540105.2017.1360254
   Yue CH, 2016, MOL MED REP, V14, P1636, DOI 10.3892/mmr.2016.5424
NR 9
TC 0
Z9 0
U1 1
U2 12
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1037
EP 1040
DI 10.19193/0393-6384_2018_4_158
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500021
DA 2022-07-14
ER

PT J
AU Yalvac, ESD
   Demiroglu, M
   Gursel, S
   Aydin, E
AF Yalvac, Emine Seyma Denli
   Demiroglu, Murat
   Gursel, Sidika
   Aydin, Ebuzer
TI CALCIUM DOBESILATE VERSUS MICRONISED PURIFIED FLAVONOID FRACTION OF
   DIOSMIN IN THE TREATMENT OF CHRONIC VENOUS DISEASE: A RANDOMIZED
   PROSPECTIVE STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Chronic venous disease; Veno active drugs; Calcium dobesilate;
   Micronised purified flavonoid fraction; visual analogue scale
ID COMPRESSION STOCKINGS; CONSENSUS STATEMENT; VARICOSE-VEINS;
   RISK-FACTORS; LOWER-LIMBS; INSUFFICIENCY; DISORDERS; DIAMETER
AB Introduction: Chronic venous disease (CVD) of the lower extremities has a substantial effect on quality of life. The clinical, etiology, anatomy, pathophysiology classification (CEAP) is a frequently used classification for CVD. Patients with varicose veins are classified as CEAP class C2. Veno-active drugs (VAD) such as Calcium Dobesilate or Micronised Purified Flavonoid Fraction of Diosmin (MPFF) reduce the symptoms of pain associated with CVD. However, although the effectiveness of VAD is well established, it is controversial. The aims of the this study were to compare the efficacy of two VAD (Calcium dobesilate and MPFF in the treatment of CVD in view of the intended visual analogue scale (VAS) and duplex scanning (DS) changes such as measuring great saphenous vein (GSV) diameter.
   Materials and methods: A total of 24 patients who had no prior VAD treatment with CEAP class C2, with no family history of CVD were treated; 12 received calcium dobesilate and 12 received MPFF for 60 days. Comorbidities such as hypertension (HT) and diabetes mellitus (DM) were examined. Before and after treatment period, the patients were investigated with DS for diameter of GSV and pain complaint according to VAS were recorded.
   Results: There were no difference in treatment groups in terms of age, gender, or the comorbidities. For the whole groups, no significant differences were recorded before and after treatment regarding DS parameters. On the other hand, pain was significantly reduced for the group 1 and 2 according to VAS (respectively p=0,04,p=0,03).
   Conclusion: In this study, pain was reduced in both groups, but no improvement was observed in DS findings. The role of VAD in treatment of patients with CVD needs to be improved in the existing recommendations.
C1 [Yalvac, Emine Seyma Denli; Gursel, Sidika; Aydin, Ebuzer] Medeniyet Univ, Fac Med, Dept Cardiovasc Surg, Istanbul, Turkey.
   [Demiroglu, Murat] Medeniyet Univ, Fac Med, Dept Dept Orthoped & Traumatol, Istanbul, Turkey.
RP Demiroglu, M (corresponding author), Gortepe Egitim Ar Hastanesi, Istanbul, Turkey.
EM drmuratdemiroglu@gmail.com
RI Aydın, Ebuzer/AAR-2100-2020; Yalvac, Emine Seyma Denli/AAJ-5545-2020
OI Yalvac, Emine Seyma Denli/0000-0003-0629-660X
CR Asbeutah AM, 2014, J ULTRAS MED, V33, P803, DOI 10.7863/ultra.33.5.803
   Benigni JP, 2003, INT ANGIOL, V22, P383
   Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575
   Campbell WB, 2007, EUR J VASC ENDOVASC, V34, P741, DOI 10.1016/j.ejvs.2007.07.012
   Carpentier PH, 2004, J VASC SURG, V40, P650, DOI 10.1016/j.jvs.2004.07.025
   CASLEYSMITH JR, 1985, MICROCIRC ENDOTH LYM, V2, P385
   Criqui MH, 2007, J VASC SURG, V46, P331, DOI 10.1016/j.jvs.2007.03.052
   Eklof B, 2004, J VASC SURG, V40, P1248, DOI 10.1016/j.jvs.2004.09.027
   Heller JA, 2015, VASC MED, V20, P88, DOI 10.1177/1358863X14566224
   Jantet G, 2002, ANGIOLOGY, V53, P245, DOI 10.1177/000331970205300301
   Jeanneret C, 2014, VASA, V43, P268, DOI 10.1024/0301-1526/a000362
   Lane TRA, 2017, BRIT J SURG, V104, P1648, DOI 10.1002/bjs.10598
   Lane TRA, 2013, PHLEBOLOGY, V28, P148, DOI 10.1177/0268355513476815
   Lim CS, 2014, CAN MED ASSOC J, V186, pE391, DOI 10.1503/cmaj.131281
   Lyseng-Williamson KA, 2003, DRUGS, V63, P71, DOI 10.2165/00003495-200363010-00005
   Mahmutyazicioglu K, 2003, DIAGN INTERV RADIOL, V9, P471
   Martinez MJ, 2005, COCHRANE DB SYST REV, V20
   Mdez-Herrero A, 2007, PHLEBOLOGY, V22, P207, DOI 10.1258/026835507782101654
   Nicolaides AN, 2008, INT ANGIOL, V27, P1
   Nicolaides AN, 2000, CIRCULATION, V102, pE126, DOI 10.1161/01.CIR.102.20.e126
   Paysant J, 2008, INT ANGIOL, V27, P81
   Pinto A, 2013, CRIT ULTRASOUND J, V5, DOI 10.1186/2036-7902-5-S1-S1
   Rabe E, 2013, PHLEBOLOGY, V28, P308, DOI 10.1177/0268355512471929
   Ratchford Elizabeth V, 2017, Curr Treat Options Cardiovasc Med, V19, P16, DOI 10.1007/s11936-017-0518-6
NR 24
TC 2
Z9 2
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 657
EP 661
DI 10.19193/0393-6384_2018_3_101
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000006
DA 2022-07-14
ER

PT J
AU Yan, SG
   Seo, J
   Zhang, JY
   He, LJ
AF Yan, Shengguang
   Seo, Jaebok
   Zhang, Jinyang
   He, Lijuan
TI FACTORS CAUSING GALLSTONE EPIDEMIOLOGY AMONG UNIVERSITY FACULTY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Gallstone; Epidemiology; Predisposing factor; Investigation and analysis
AB In order to clarify occurrence rate of gallstone disease among university faculty members and analyze relevant factors causing gallstones epidemiology, in this paper 5,450 faculty members from 18 different universities in six regions were selected asm research objects, which were investigated and analyzed in health screening form June to December, 2015. The results show that among 5,450 respondents, 429 were diagnosed with gallstone, with incidence rate at 7.87%; moreover, among university faculty members, female members have a significantly higher risk of suffering from gallstones than male members, with statistical value in difference, P <0.05. Diagnosis results of gallstone patients were compared with those of respondents without gallstone, showing that serum cholesterol (TC), serum low density lipoprotein (LDL-C), serum triglyceride (TG) of gallstone patients were higher than those of respondents without gallstone, while serum high density lipoprotein cholesterol (HDL-C) of gallstone patients was significantly lower than that of respondents without gallstone. It can thus be concluded that hyperlipidemia patients are more likely to have gallstone disease. In order to improve health level of university faculty, the clinical prevention of gallstone should be strengthened, and gallstone patients should be guided to give up unhealthy living habits and do more exercise.
C1 [Yan, Shengguang] North China Univ Sci & Technol, Int Educ Ctr, Tangshan 063000, Peoples R China.
   [Seo, Jaebok] Jeonju Univ, Dept Educ, Jeollabuk Do 55069, South Korea.
   [Zhang, Jinyang] Jeonju Univ, Dept Business Adm, Jeollabuk Do 55069, South Korea.
   [He, Lijuan] Kailuan Gen Hosp, Dept Hepatobiliary Surg, Tangshan 063000, Peoples R China.
RP He, LJ (corresponding author), Kailuan Gen Hosp, Dept Hepatobiliary Surg, Tangshan 063000, Peoples R China.
EM anthonyyan2005@163.com
CR Ablet Ma Jun, 2006, CHINESE J HEPATOBILI, V23, P772
   Chaoyang Sun, 2007, J MILITARY SURG SW C, V12, P5
   Demir D, 2017, ACTA MEDICA MEDITERR, V33, P587, DOI 10.19193/0393-6384_2017_4_086
   Erkaya S, 2017, TURK J MED SCI, V47, P300, DOI 10.3906/sag-1602-137
   Fu HL, 2017, WATER-SUI, V9, DOI 10.3390/w9110846
   Fujun Lv, 2013, PROGR MODERN BIOMEDI, V18, P1323
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P1370, DOI 10.1016/j.sjbs.2016.12.016
   Jamil S, 2017, PAK J PHARM SCI, V30, P755
   Jiangwei Liu, 2013, CHINESE J CLIN ELECT, V18, P9542
   Li ZG, 2018, ENERG SOURCE PART B, V13, P137, DOI 10.1080/15567249.2017.1410593
   Min Chen, 2015, CHINESE J CLIN ELECT, V7, P1352
   Nansong Yu, 2012, CHINA MODERN DOCTOR, V16, P9
   Oz M, 2017, TURK J MED SCI, V47, P1744, DOI 10.3906/sag-1607-93
   Valiee S, 2016, ACTA MEDICA MEDITERR, V32, P1021
   Xiangdong Xu, 2013, CHINESE RURAL HLTH S, V17, P320
   Xiaomin Sun, 2011, WORLD CHINESE J DIGE, V31, P2881
   Zhang Lijuan, 2009, MED INFORM, V34, P2979
   Zhengcheng Wang, 2013, W J TRADITIONAL CHIN, V17, P67
NR 19
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1783
EP 1786
DI 10.19193/0393-6384_2018_6_273
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400024
DA 2022-07-14
ER

PT J
AU Yan, Y
   Ying, T
AF Yan, Yan
   Ying, Tian
TI GENETIC VARIATIONS AND CLINICAL ANALYSES OF P53, BCL-2 AND BAX IN ACUTE
   LEUKEMIA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Acute leukemia; P53; Bcl-2; Bax; Clinical features
ID APOPTOSIS
AB Purpose: To investigate genetic variations in p53, bcl-2 and bax in acute leukemia and their relationship with clinical features and chemotherapeutic efficacy.
   Methods: A total of 152 patients were recruited for this study, and they were divided into two groups: acute leukemia group and control group. There were 100 patients in the acute leukemia group which comprised 51 males and 49 females within the age range 17-66 years (mean age = 36.77 +/- 5.61 years). Based on the classification criteria for FAB, there were 56 cases with acute myeloid leukemia and 44 cases with acute lymphoblastic leukemia (ALL). The control group consisted of 52 patients with non-hematological malignancies within the same period. The expressions of p53, bcl-2 and bax genes in the two groups of patients were measured using immuno-histochemical staining.
   Results: The positive expressions of p53, bcl-2 and bax genes in the control group were significantly lower (p < 0.05) than those of the acute leukemia group. There were no significant differences (p > 0.05) in the expressions of these genes between the AML and ALL groups. There were significant differences in the expressions of p53, bcl-2 and bax genes between the different FAB typing of AML. No significant differences were seen in the expressions of p53, bcl-2 and bax genes between the different FAB types of ALL (p. 0.05). The effective positive expressions of p53, bcl-2 and bax genes in patients with acute leukemia were significantly lower (p < 0.05) than those of control.
   Conclusion: These results suggest that mutant p53, bcl-2 and bax participate in the onset of acute leukemia, and are associated with its clinical characteristics such as typing and chemotherapeutic efficacy. Thus, they may be used as markers in the treatment and prognosis of acute leukemia.
C1 [Yan, Yan; Ying, Tian] Capital Med Univ, Beijing Chao Yang Hosp, Dept Hematol, 8 Gong Ti South Rd, Beijing 100020, Peoples R China.
RP Yan, Y (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Dept Hematol, 8 Gong Ti South Rd, Beijing 100020, Peoples R China.
EM vc1208@163.com
CR Ai HS, 2000, LEUKEMIA, V9, P331
   Chen Yuan-zhong, 2003, Zhonghua Xue Ye Xue Za Zhi, V24, P640
   Feng ZG, 2001, J CLIN HEMATOL, V14, P54
   Fisher DE, 2001, HEMATOL ONCOL CLIN N, V15, P931, DOI 10.1016/S0889-8588(05)70258-6
   He Q, 2002, MED PHAM YUNNAN, V23, P177
   He Q, 2002, J CLIN HEMATOL, V15, P213
   He Q, 2002, J LEUKEMIA LYMPHOMA, V11, P148
   MAUNG ZT, 1994, BRIT J HAEMATOL, V88, P105, DOI 10.1111/j.1365-2141.1994.tb04984.x
   Saikumar P, 1999, AM J MED, V107, P489, DOI 10.1016/S0002-9343(99)00259-4
   Tang CH, 2005, J CLIN PHYS, V7, P887
   Thomas A, 1996, ONCOGENE, V12, P1055
   Xue WQ, 2006, FUJIAN MED J, V28, P77
   Zhang ZN, 1998, DIAGNOSIS HEMOTONOSI, P214
NR 13
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1391
EP 1395
DI 10.19193/0393-6384_2018_5_212
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700034
DA 2022-07-14
ER

PT J
AU Yan, ZG
AF Yan, Zhenggang
TI RETRACTED: EFFECT OF TOPICAL TRAUMATIC DRUG ON EXPRESSION OF IL-6 IN
   MUSCLE CELLS OF NEW ZEALAND RABBITS AFTER EXERCISE-INDUCED CHRONIC
   SKELETAL MUSCLE INJURY (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE Topical traumatic drugs; Exercise-induced chronic skeletal muscle
   injury; IL-6 expression in muscle cell
ID MOLECULAR-STRUCTURES; ALGORITHM
AB This study aimed to observe the effects of topical traumatic drug on expression of IL-6 in muscle cell of New Zealand rabbits after exercise-induced chronic skeletal muscle injury. Besides, the effect of IL-6 on restoration of injured muscle tissue was also analyzed. In view of this, the study was conducted by splitting forty-eight adult male New Zealand rabbits into three groups referred as Xiaotong strapping, voltaren and control group.. Each group was further subdivided into 4th-week and 5th-week group, each containing 8 rabbits. The animals were provoked with high-voltage and low-current stimulatorin order to initiate them to run and jump. At the end of training, different topical drugs were given to 4th-week and 5th-week voltaren and Xiaotong strapping groups. After a week of drug administration, medial head of left leg gastrocnemius muscle of these New Zealand rabbits were selected and kept in paraformaldehyde solution. The morphological changes in muscle tissue were deduced from the H&E stained and immunohistochemical images of IL-6 expression in cells. The expression of IL-6 in skeletal muscle cells showed a tendency to increase with the extension of training duration. Results obtained shows that the use of topical traumatic drugs could decrease inflammatory cytokines of exercise-induced chronic skeletal muscle injury. In addition, expression of IL-6 in muscle cell towards exercise-induced chronic skeletal muscle injury could be effectively decreased.
C1 [Yan, Zhenggang] Zhongnan Univ Econ & Law, Wuhan 430064, Hubei, Peoples R China.
RP Yan, ZG (corresponding author), Zhongnan Univ Econ & Law, Wuhan 430064, Hubei, Peoples R China.
EM 13317151696@163.com
FU University Provincial Teaching Reform Research Project in Hubei Province
   [2013160]
FX The project is supported by University Provincial Teaching Reform
   Research Project in Hubei Province (No. 2013160).
CR Chen J, 2015, J COASTAL RES, P620, DOI 10.2112/SI73-108.1
   Chen Y. X., 2013, STUDY RECOVERY MECH
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   Niu W. Y, 2016, B SPORT SCI TECHNOLO, V7
   Niu W. Y., 2013, EXPRESSION IL 6 EXER
   Wang L, 2015, J COASTAL RES, P259, DOI 10.2112/SI73-046.1
   Wang S. M, 2013, EFFECT TOPICAL TRAUM
   Xu H., 2013, EFFECT TOPICAL TRAUM
   Yang XM, 2015, J COASTAL RES, P197, DOI 10.2112/SI73-035.1
   Zhou R, 2015, J COASTAL RES, P600, DOI 10.2112/SI73-104.1
   Zhu FM, 2015, J COASTAL RES, P48, DOI 10.2112/SI73-009.1
NR 13
TC 0
Z9 0
U1 14
U2 21
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 239
EP 243
DI 10.19193/0393-6384_2018_1s_39
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100004
DA 2022-07-14
ER

PT J
AU Yang, AH
   Cai, JG
AF Yang, Aihua
   Cai, Jianguang
TI CLINICAL SIGNIFICANCE OF THORACOLUMBAR INJURY CLASSIFICATION AND
   SEVERITY SCORE IN TREATMENT OF THORACOLUMBAR FRACTURES OF VOLLEYBALL
   PLAYERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Thoracolumbar injury severity score; Volleyball; Thoracolumbar fracture;
   Therapeutic significance
AB Objective: This paper aims to evaluate specific role of thoracolumbar injury classification and severity score in treatment of volleyball-induced thoracolumbar fractures, and to provide reference for choice of clinical treatment plan.
   Methods: The 112 patients with volleyball-induced thoracolumbar fractures treated in our hospital from June 2014 to December 2015 were selected as the subjects. Thoracolumbar injury classification and severity (TLICS) score was evaluated according to the individual injury, neurological function and integrity of posterior ligament complex. The treatment plan was determined according to the score. There were 17 cases with score minus 4 points, who were treated with conservative treatment; 70 cases with score above 4 points, who were treated with surgical treatment; for those with score equal to 4 points, 16 cases received surgical treatment and 9 cases received conservative treatment according to individual circumstances. The anterior vertebral height, cobb angle and oswestry disability index (ODI) were compared before and after the treatment. And excellent rates of surgical treatment and conservative treatment were compared.
   Results: All patients were followed up for 12-24 months. As can be seen from the results, after treatment, cobb angle, anterior vertebral height were significantly improved on the average for the 112 patients, with P <0.05 in comparison before and after the treatment, so there is a statistical significance; ODI score results showed that excellent rates were 88.46% (23/26) and 90.69% (78/86) respectively for conservative treatment and surgical treatment, so the two regimens provide good therapeutic effect, with difference P> 0.05, and there is no statistical difference.
   Conclusion: Application of thoracolumbar injury classification and severity score can provide a scientific reference for choice of clinical treatment for patients with volleyball-induced thoracolumbar fractures, further improve patient's condition and ensure excellent rate of treatment.
C1 [Yang, Aihua] Changsha Univ Sci & Technol, Sch Phys Educ, Changsha 410076, Hunan, Peoples R China.
   [Cai, Jianguang] Hunan Univ Sci & Technol, Sch Sports, Xiangtan 411201, Peoples R China.
RP Cai, JG (corresponding author), Hunan Univ Sci & Technol, Sch Sports, Xiangtan 411201, Peoples R China.
EM JYKH56@126.com
FU Hunan Province Education Science "13th Five-Year" program [XJK016CTW009]
FX Hunan Province Education Science "13th Five-Year" program (No.
   XJK016CTW009).
CR Al-Ghanim KA, 2016, SAUDI J BIOL SCI, V23, P72, DOI 10.1016/j.sjbs.2015.03.012
   Al-Hazmi AS, 2016, SAUDI J BIOL SCI, V23, P288, DOI 10.1016/j.sjbs.2015.04.007
   Azra MN, 2016, SAUDI J BIOL SCI, V23, P257, DOI 10.1016/j.sjbs.2015.03.011
   Billen J, 2017, SAUDI J BIOL SCI, V24, P830, DOI 10.1016/j.sjbs.2016.06.007
   Bozkirli F, 2017, TURK J MED SCI, V47, P295, DOI 10.3906/sag-1601-113
   Gao W, 2017, J INTELL FUZZY SYST, V33, P3153, DOI 10.3233/JIFS-169367
   Garazd Y, 2017, SAUDI PHARM J, V25, P214, DOI 10.1016/j.jsps.2016.05.005
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P1355, DOI 10.1016/j.sjbs.2016.09.010
   Guo Shi-rong, 2013, Journal of China Medical University, V42, P473
   Haidar AM, 2016, SAUDI J BIOL SCI, V23, P293, DOI 10.1016/j.sjbs.2015.06.017
   Hassani H, 2017, TURK J MED SCI, V47, P1813, DOI 10.3906/sag-1508-36
   Lee SJ, 2016, SAUDI J BIOL SCI, V23, P9, DOI 10.1016/j.sjbs.2015.01.016
   Lv You, 2011, ORTHOPEDIC J CHINA, V19, P620
   [毛克亚 MAO Ke-ya], 2009, [中华创伤骨科杂志, Chinese Journal of Orthopaedic Trauma], V11, P989
   Sun Tiansheng, 2007, J SPINAL SURG, V5, P325
   Yang AM, 2017, J ALLOY COMPD, V695, P915, DOI 10.1016/j.jallcom.2016.10.188
   Yang Mingzhi, 2014, CHINA MED, V9, P862
   Zeng Zhongyou, 2015, J SPINAL SURG, V13, P294
NR 18
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 3
BP 1593
EP 1597
DI 10.19193/0393-6384_2018_3s_248
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GP7NG
UT WOS:000441088400024
DA 2022-07-14
ER

PT J
AU Yang, HX
   Gao, W
   Ma, CE
AF Yang, Hongxia
   Gao, Wei
   Ma, Chengen
TI A META-ANALYSIS OF TOLL-LIKE RECEPTOR-4 GENE POLYMORPHISM FOR
   DETERMINATION OF SUSCEPTIBILITY TO, AND SEVERITY OF ACUTE PANCREATITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Acute pancreatitis; Toll-like receptor-4; Gene polymorphism;
   Susceptibility; Meta-analysis
ID KAPPA-B P56; OMEGA-3-FATTY-ACIDS; RATS; MICE
AB Objective: To carry out meta-analysis on the association of Toll-like receptor 4 (TLR4) gene polymorphism with susceptibility to, and severity of acute pancreatitis (AP).
   Methods: Literature published from January 2014 to December 2017 on the relationship between TLR4 Asp299Gly and Thr399Ile gene polymorphisms, and AP in case-control studies were retrieved. Studies that met the inclusion criteria were analyzed statistically. Publication bias of included literature was evaluated, and sensitivity analysis and meta-analysis were performed.
   Results: A total number of 15 studies were included in the meta-analysis, including 467 AP patients and 3412 control cases. The analysis showed absence of any obvious publication bias in symmetrical funnel plots. In allele models (G/A versus C/T), TLR4 gene polymorphism increased the risk of AP (P < 0.05). Gene polymorphisms in Thr399Ile and Asp299Gly also increased the risk of AP (P < 0.05). In codominance models (GG/AA versus CC/TT), TLR4 gene polymorphism, as well as Thr399Ile and Asp299Gly gene polymorphisms increased the risk of AP (P < 0.05).
   Conclusion: Acute pancreatitis (AP) is a complex disease affected by multiple genes and factors. Polymorphisms in Thr399Ile and Asp299Gly are associated with the susceptibility and severity of AP. These results indicate that TLR4 gene mutation is implicated in the occurrence of AP.
C1 [Yang, Hongxia; Gao, Wei; Ma, Chengen] Shandong Univ, Hosp 2, Dept Intens Care Unit, Jinan 250033, Shandong, Peoples R China.
RP Ma, CE (corresponding author), Shandong Univ, Hosp 2, Dept Intens Care Unit, Jinan 250033, Shandong, Peoples R China.
EM vf1336@163.com
CR Amrani-Midoun A, 2016, INT J CARDIOL, V225, P408, DOI 10.1016/j.ijcard.2016.10.027
   [Anonymous], 2017, DATA BRIEF, V13, P287
   Barbosa EM, 2017, GENET MOL RES, V16, DOI 10.4238/gmr16029610
   Bieniek-Kobuszewska M, 2016, FUNCT INTEGR GENOMIC, V16, P705, DOI 10.1007/s10142-016-0522-z
   Bonyadi M, 2017, OPHTHALMIC GENET, V10, P1
   Caillat-Zucman S, 2017, HLA, V89, P3, DOI 10.1111/tan.12947
   Cen YY, 2016, INT IMMUNOPHARMACOL, V38, P252, DOI 10.1016/j.intimp.2016.06.007
   Chang CH, 2018, ENVIRON RES, V160, P339, DOI 10.1016/j.envres.2017.10.011
   Chen XW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04992-z
   Chukwu EE, 2017, MICROB PATHOGENESIS, V111, P232, DOI 10.1016/j.micpath.2017.08.031
   Cunha R, 2017, BLOOD, V129, P525, DOI 10.1182/blood-2016-06-722249
   Enge S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02594-3
   Gouin-Thibault I, 2017, J THROMB HAEMOST, V15, P273, DOI 10.1111/jth.13577
   Irie Y, 2017, J NEUROIMMUNE PHARM, V7, P99
   Kang R, 2016, J IMMUNOL, V196, P4331, DOI 10.4049/jimmunol.1502340
   Li G, 2016, INT J MOL MED, V38, P1313, DOI 10.3892/ijmm.2016.2707
   Li G, 2016, INT J MOL MED, V37, P99, DOI 10.3892/ijmm.2015.2410
   Li XF, 2017, NEUROL RES, V39, P367, DOI 10.1080/01616412.2017.1286541
   Liu Y, 2016, PANCREAS, V45, P755, DOI 10.1097/MPA.0000000000000565
   Liu ZY, 2016, AM J CHINESE MED, V44, P149, DOI 10.1142/S0192415X16500105
   Miri-Moghaddam Ebrahim, 2017, J Clin Exp Dent, V9, pe196, DOI 10.4317/jced.53190
   Nimptsch K, 2017, EUR J EPIDEMIOL, V32, P419, DOI 10.1007/s10654-017-0262-y
   Pan LF, 2016, J SURG RES, V206, P298, DOI 10.1016/j.jss.2016.08.011
   Reddy KKVVVS, 2017, DATA BRIEF, V12, P287, DOI 10.1016/j.dib.2017.04.010
   Roland TP, 2017, PROTIST, V168, P565, DOI 10.1016/j.protis.2017.07.006
   Toker H, 2017, CENT EUR J PUBL HEAL, V25, P157, DOI 10.21101/cejph.a4656
   Ulveling D, 2016, HEPATOLOGY, V64, P1462, DOI 10.1002/hep.28695
   Vrolyk V, 2017, VET PATHOL, V54, P129, DOI 10.1177/0300985816646432
   Wang B, 2017, PANCREAS, V46, P1267, DOI 10.1097/MPA.0000000000000935
   Wang B, 2016, WORLD J GASTROENTERO, V22, P9784, DOI 10.3748/wjg.v22.i44.9784
   Ye JC, 2016, AM J HUM GENET, V99, P1281, DOI 10.1016/j.ajhg.2016.10.001
   Zhang Y, 2016, CARDIOVASC J AFR, V27, P228, DOI 10.5830/CVJA-2016-001
   Zhou X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.342
   Zhou XJ, 2014, WORLD J GASTROENTERO, V20, P6666, DOI 10.3748/wjg.v20.i21.6666
NR 34
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1125
EP 1130
DI 10.19193/0393-6384_2018_4_173
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500036
DA 2022-07-14
ER

PT J
AU Yang, JW
   Chen, QX
AF Yang Jiwen
   Chen Qianxue
TI EXPRESSION OF KU PROTEINS IN GLIOMA AND THEIR ASSOCIATION WITH
   RADIOTHERAPY SENSITIVITY AND PROGNOSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE KU70; KU80; Glioma; Radiotherapy; Prognosis
ID RECTAL-CANCER; TEMOZOLOMIDE; THERAPY; PATHWAY; CELLS
AB Objective: To study the expression of KU 70 and KU80 proteins in glioma tissue and their correlations with radiotherapy sensitivity and prognosis.
   Methods: Glioma tissue samples (20) from patients exposed to radiotherapy in neurological surgery from January, 2014 to December, 2016 were used in the study. Ten (10) normal cerebral tissue samples served as control. Immunochemical staining was used to determine the expressions of KU70 protein and KU80 protein in glioma tissue and normal cerebral tissue. In addition, glioma nude mice models were divided into blank control group (A group), and groups exposed to different degrees of radiation (Gy) for different durations i.e. 2 Gy+24 h group (B group), 2 Gy+48 h (C group), 4 Gy+24 h (D group), 4 Gy+48 h (E group), 8 Gy+24 h (F group) and 8 Gy+48 h (G group). Immunochemical staining was used to determine the expressions of KU 70 and KU80 proteins.
   Results: Positive expressions of KU 70 protein and KU80 protein in tumor tissue were 65.0 % and 50.0 %, respectively higher than in normal cerebral tissue (p < 0.05). The expressions of these proteins were positively correlated with recent treatment effects and prognosis (p < 0.05). Results from the animal experiments showed that positive expression of KU protein had positive correlation with dose of radiation (p < 0.05), but it had no correlation with exposure time (p > 0.05).
   Conclusion: Triptolide plays anti-proliferation role in glioma cells by inhibiting the up-regulation of gene-1 expression in astrocytes.
C1 [Yang Jiwen; Chen Qianxue] Wuhan Univ Hubei, Renmin Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
RP Chen, QX (corresponding author), Wuhan Univ Hubei, Renmin Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM vwbua7@163.com
OI Chen, Qianxue/0000-0002-9413-1030
CR Chen LC, 2012, MOL MED REP, V5, P575, DOI 10.3892/mmr.2011.674
   Gasinska A, 2017, REP PRACT ONCOL RADI, V22, P368, DOI 10.1016/j.rpor.2017.07.002
   Hasegawa T, 2017, STRAHLENTHER ONKOL, V193, P29, DOI 10.1007/s00066-016-1023-7
   Komuro Y, 2003, J EXP CLIN CANC RES, V22, P223
   Li G, 2012, CHINESE J CANC PREVE, V19, P1628
   Liu C, 2015, CURR MOL MED, V15, P663, DOI 10.2174/1566524015666150831141112
   Molina S, 2016, INT J RADIAT ONCOL, V95, P965, DOI 10.1016/j.ijrobp.2016.02.015
   Pinel B, 2017, J NEURO-ONCOL, V132, P287, DOI 10.1007/s11060-016-2367-7
   Pucci S, 2017, INT J RADIAT ONCOL, V97, P381, DOI 10.1016/j.ijrobp.2016.10.018
   Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034
   Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261
   Wei W, 2015, CHINESE J ONCOLOGY P, V7, P445
   Wilson CR, 2000, BRIT J CANCER, V83, P1702, DOI 10.1054/bjoc.2000.1510
   Yang SH, 2016, WORLD J GASTROENTERO, V22, P7275, DOI 10.3748/wjg.v22.i32.7275
NR 14
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1065
EP 1069
DI 10.19193/0393-6384_2018_4_163
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500026
DA 2022-07-14
ER

PT J
AU Yang, L
   Shi, HX
   Lin, P
   Xue, HY
   Wang, YG
   Liu, XF
AF Yang, Lin
   Shi, Hong-Xia
   Lin, Peng
   Xue, Hong-Yan
   Wang, Yong-Gang
   Liu, Xiao-Feng
TI RESEARCH ON VITRO ANTI-OXIDANT AND ANTI-CANCER ACTIVITY OF CYNOMORIUM
   SONGARICUM RUPR.'S EXTRACTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Cynomorium songaricum Rupr.; Antioxidant activity; Anti-cancer activity
ID FREE-RADICALS; L.
AB Introduction: Cynomorium songaricum as a famous Traditional Chinese Medicine (TCM) material, is generally used to cure impotence, premature ejaculation, kidney-yang deficiency, and spermatorrhea. Aim of this research is to study on vitro anti-oxidant and anti-cancer activities of C. songaricum extracts to found its potential in the future medicine and nutrition.
   Materials and methods: Polysaccharides, saponins, flavonoids and tannins were extracted from Cynomorium songaricum by Ultrasonic assisted assistant. Anti-oxidant and anti-cancer activity of extracts were analyzed and compared by the method of ultraviolet spectrophotometry and MTT assay respectively.
   Results: Conclusion demonstrated that ascorbic acid had the best hydroxyl radical-scavenging assay (scavenging rate was 94.14%), the mitomycin's inhibition rate for cancer cell A549 was 59.31%, and its inhibition rate for cancer cell SMMC-7721 was 53.83%. Tannins had the highest reducing power assay(EC50=0.35) and DPPH radical-scavenging assay (IC50=0.0019) better than ascorbic acid, the highest hydroxyl radical-scavenging assay (46.44%) better than other extracts, and had the good inhibition action for cancer cell A549 (inhibition rate was 41.6%) and SMMC-7721 (inhibition rate was 13.1%). Flavonoids had good reducing power assay (EC50=0.38) and DPPH radical-scavenging assay (IC50=0.0028) which was only next to tannins, and had the best inhibition action for cancer cell A549 (inhibition rate is 45.7%) than other ectracts. Saponins had the highest inhibition action for cancer cell A549 (inhibition rate is 36.0%). Polysaccharides have good hydroxyl radical-scavenging rate (39.33%) which was only next to tannins.
   Conclusion: Four extracts of C. songaricum showed good anti-oxidant activities and certain anti-tumor activities.
C1 [Yang, Lin; Lin, Peng; Xue, Hong-Yan; Wang, Yong-Gang; Liu, Xiao-Feng] Lanzhou Univ Technol, Sch Life Sci & Engn, Gansu Educ Dept, Key Lab Screening Evaluat & Adv Proc TCM & Tibeta, Lanzhou 730050, Gansu, Peoples R China.
   [Shi, Hong-Xia] Lanzhou Inspect & Quarantine Co Ltd, 1 Yingmen Village Anning Dist, Lanzhou, Gansu, Peoples R China.
RP Yang, L (corresponding author), Lanzhou Univ Technol, Sch Life Sci & Engn, Gansu Educ Dept, Key Lab Screening Evaluat & Adv Proc TCM & Tibeta, Lanzhou 730050, Gansu, Peoples R China.
EM yanglin-401@163.com
CR Al-Duais M, 2009, EUR FOOD RES TECHNOL, V228, P813, DOI 10.1007/s00217-008-0994-8
   ARUOMA OI, 1994, FOOD CHEM TOXICOL, V32, P671, DOI 10.1016/0278-6915(94)90011-6
   Cui ZH, 2013, J ETHNOPHARMACOL, V147, P1, DOI 10.1016/j.jep.2013.01.020
   Ebadi AG, 2017, BULG CHEM COMMUN, V49, P540
   Jin SW, 2014, INT J FOOD PROP, V17, P13, DOI 10.1080/10942912.2011.587623
   Liang CH, 2009, FOOD CHEM, V116, P841, DOI 10.1016/j.foodchem.2009.03.032
   Lin P., 2013, RES CHEM COMPOSITION, P61
   [刘晓风 Liu Xiaofeng], 2013, [食品工业科技, Science & Technology of Food Industry], V34, P239
   Ma CM, 1999, CHEM PHARM BULL, V47, P141, DOI 10.1248/cpb.47.141
   Ma Lijie, 2009, Zhongguo Zhong Yao Za Zhi, V34, P1257
   MARX JL, 1987, SCIENCE, V235, P529, DOI 10.1126/science.3810154
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Shi GY, 2011, INT J BIOL MACROMOL, V48, P788, DOI 10.1016/j.ijbiomac.2011.03.001
   Siddhuraju P, 2007, FOOD CHEM, V101, P10, DOI 10.1016/j.foodchem.2006.01.004
   SMIRNOFF N, 1989, PHYTOCHEMISTRY, V28, P1057, DOI 10.1016/0031-9422(89)80182-7
   Wang JL, 2010, FOOD CHEM, V120, P443, DOI 10.1016/j.foodchem.2009.10.034
   Yan J., 2009, J CHENGDU U NATURAL, V2, P91
   Yang L., 2013, ACTA CHINESE MED PHA, V41, P76
   Zhang Ru-Xue, 2008, Zhong Yao Cai, V31, P407
   Zhao X, 2013, EXP THER MED, V5, P1083, DOI 10.3892/etm.2013.938
NR 20
TC 1
Z9 1
U1 2
U2 16
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 13
EP 19
DI 10.19193/0393-6384_2018_1_2
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600002
DA 2022-07-14
ER

PT J
AU Yang, L
   Zhou, XK
   Wang, L
   Shi, HX
   Liu, XF
   Wang, YG
AF Yang, Lin
   Zhou, Xiao-Kai
   Wang, Lei
   Shi, Hong-Xia
   Liu, Xiao-Feng
   Wang, Yong-Gang
TI ISOLATION OF ENDOPHYTIC FUNGI FROM THERMOPSIS LANCEOLATA AND THEIR
   ANTIOXIDANT ACTIVITY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Endophytic fungi; Thermopsis lanceolata; Antioxidant activity
AB Introduction: Plant endophytic fungi resources is nearly a decade of research hot spots, endogenous fungal resources development and utilization will be fruitful.
   Aim: Aim of this study is isolation of endophytic fungi strains from healthy tissues of Thermopsis lanceolata and evaluation of antioxidant activity of fermented extracts of these isolated endophytic fungi strains.
   Materials and methods: Root, stem and leaf of Thermopsis lanceolata were used to isolate endophytic fungi strains. Reducing power and DPPH free radical scavenging assays were used to evaluate the antioxidant activity of fermented extracts from isolated endophytic fungi strains from Thermopsis lanceolata. Meanwhile, Total phenolic content (TPC) of fungal extracts was tested by Folin-Ciocalteau reagent based assay.
   Results: 16 endophytic fungi strains were isolated by tissue culture from healthy root, stem and leaf of Thermopsis lanceolata; Results of antioxidant activity evaluate indicates that there are 4 samples showed a good reduction force, especially ethyl acetate extract of Tlc-R-7 has the highest reducing power, it's absorbance value reached 0.528 (ascorbic acid, 0.588). Moreover, ethyl acetate extracts had generally higher antioxidant activity than extracts of n-butanol and methanol; Result of DPPH free radical scavenging activity showed there are 3 extracts samples showed inhibition rate of more than 90%. 2 extracts showed inhibition rate of more than 85%, among them, Tlc-R-7 ethyl acetate extract has the highest inhibition rate of 93%; The results indicate that the higher the phenol content in the sample, the stronger the antioxidant capacity of the sample; Most of the higher activity extracts of the fungal was concentrated in the roots.
   Conclusion: There are abundant endophytic fungi resources in Thermopsis lanceolata, and the endophytic fermentation product has a good prospect of antioxidant drug development.
C1 [Yang, Lin; Zhou, Xiao-Kai; Wang, Lei; Liu, Xiao-Feng; Wang, Yong-Gang] Lanzhou Univ Technol, Sch Life Sci & Engn, Gansu Educ Dept, Key Lab Screening Evaluat & Adv Proc TCM & Tibeta, Lanzhou 730050, Gansu, Peoples R China.
   [Shi, Hong-Xia] Lanzhou Inspect & Quarantine Co Ltd, 1 Yingmen Village Anning Dist, Lanzhou, Gansu, Peoples R China.
RP Yang, L (corresponding author), Lanzhou Univ Technol, Sch Life Sci & Engn, Gansu Educ Dept, Key Lab Screening Evaluat & Adv Proc TCM & Tibeta, Lanzhou 730050, Gansu, Peoples R China.
EM yanglin-401@163.com
CR Cai YZ, 2004, LIFE SCI, V74, P2157, DOI 10.1016/j.lfs.2003.09.047
   CARROLL G, 1988, ECOLOGY, V69, P2, DOI 10.2307/1943154
   Chen J. S, 1987, POISONOUS PLANTS CHI, P340
   Cui JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118204
   Ebadi A. G., MEASUREMENT SOME CHE
   Faeth SH, 1997, ECOLOGY, V78, P810, DOI 10.1890/0012-9658(1997)078[0810:FEIOTL]2.0.CO;2
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Goddemir G., 2017, ACTA MEDICA MEDITERR, P157
   Gulcin I, 2007, AMINO ACIDS, V32, P431, DOI 10.1007/s00726-006-0379-x
   Halliwel B, 1989, FREE READICALS BIOL
   Halliwell B, 1995, BIOCHEM SOC SYMP, P73, DOI 10.1042/bss0610073
   HAWKSWORTH DL, 1991, MYCOL RES, V95, P641, DOI 10.1016/S0953-7562(09)80810-1
   Kelecom A, 2002, AN ACAD BRAS CIENC, V74, P151, DOI 10.1590/S0001-37652002000100012
   Lachance PA, 2001, NUTRITION, V17, P835, DOI 10.1016/S0899-9007(01)00636-0
   Liu CH, 2001, J BIOTECHNOL, V88, P277, DOI 10.1016/S0168-1656(01)00285-1
   Manila Y, 2014, ASIAN PAC J TROP MED, pS256, DOI [10.1016/S1995-7645(14)60242-X, DOI 10.1016/S1995-7645(14)60242-X]
   Mirzaei A, 2016, ACTA MEDICA MEDITERR, V32, P1329
   Ovchinnikov A. Yu, 2013, Vestnik Otorinolaringologii, P84
   Pan JH, 2008, BOT MAR, V51, P179, DOI 10.1515/BOT.2008.030
   Petrini Orlando, 1992, Natural Toxins, V1, P185, DOI 10.1002/nt.2620010306
   Rodriguez RJ, 2009, NEW PHYTOL, V182, P314, DOI 10.1111/j.1469-8137.2009.02773.x
   Sadananda TS, 2011, J MED PLANTS RES, V5, P3643
   Schulz B, 2002, MYCOL RES, V106, P996, DOI 10.1017/S0953756202006342
   Strobel GA, 2003, MICROBES INFECT, V5, P535, DOI 10.1016/S1286-4579(03)00073-X
   Zheng Xiu-Fang, 2013, Zhong Yao Cai, V36, P1555
NR 25
TC 2
Z9 2
U1 3
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 27
EP 31
DI 10.19193/0393-6384_2018_1_4
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600004
DA 2022-07-14
ER

PT J
AU Yang, T
   Lai, YH
   Cui, R
   Wang, YZ
   Liu, WH
AF Yang, Tao
   Lai, Yan-Hong
   Cui, Rui
   Wang, Yu-Zhu
   Liu, Wen-Hu
TI EMERGENCE OF HEMODIALYSIS ACCESS-INDUCED DISTAL ISCHEMIA IN THE MATURITY
   STAGE OF ARTERIOVENOUS FISTULA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hemodialysis; Arteriovenous fistula; Ischemia
ID HAND ISCHEMIA; VASCULAR ACCESS; STEAL SYNDROME; HAIDI; ULTRASOUND;
   MANAGEMENT; LIGATION; INFLOW; ARTERY
AB Objective: To investigate the relationship between time of hemodialysis access-induced distal ischemia (HAIDI) of autogenous arteriovenous fistula (AVF) in wrist after surgery, and vascular remodeling (VR) of arteriovenous fistula.
   Methods: A total of 55 out of 62 end-stage kidney disease patients were enrolled. History of smoking, diabetes history and artery calcification evaluated by X ray in forearm was recorded. Inner diameters of radial artery and cephlic vein were evaluated by ultrasound, and oxyhemoglobin saturation (SpO(2)) in extremities, as well as skin temperature in bilateral hand were re-checked. At 1 and 3 months after surgery, ischemia, SpO(2), and skin temperature were re-evaluated; radial artery and fistula vein were checked by ultrasound. Patients with or without HAIDI were divided into HAIDI and non-HAIDI group.
   Results: The occurrence of HAIDI was 16.1 % between HAIDI1 and HAIDI2a. The ischemia scores of 8 HAIDI patients who were identified HAIDI1 and HAIDI2a at 1 month after surgery showed no significant difference at 1 and 3 months after operation (p = 0.713). The onset time of ischemia was 1 similar to 90 days (median = 1 day). Skin temperature in HAIDI group was significantly lower than that in non-HAIDI group 1 month and 3 months after surgery (p < 0.05). the radial artery and cephlic vein gradually became larger. When compared with patients with or without steal phenomenon after operation, and at 3 months after operation, there was no significant difference in incidence of HAIDI (p = 0.348, 0.484), and in incidence of HAIDI in patients with or without fistula venous intimal hyperplasia (p = 0.568).
   Conclusion: After AVF, HAIDI can be seen immediately in some patients while it emerges gradually in others in the maturing stage of fistula. Changes in the diameter of radial artery and cephalic vein are not associated with HAIDI. The distal temperature is more obvious among the clinical manifestation in mild patients.
C1 [Yang, Tao; Liu, Wen-Hu] Capital Med Univ, Beijing Friendship Hosp, Dept Nephrol, Beijing 100050, Peoples R China.
   [Cui, Rui; Wang, Yu-Zhu] Peking Univ, Beijing Haidian Sect, Dept Nephrol, Beijing Haidian Hosp,Hosp 3, Beijing 100080, Peoples R China.
RP Liu, WH (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Dept Nephrol, Beijing 100050, Peoples R China.
EM ui0708@163.com
CR Bashar K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119958
   Bracale UM, 2015, ANN ITAL CHIR, V86, P239
   Huber TS, 2016, J VASC SURG, V64, P1050, DOI 10.1016/j.jvs.2016.03.449
   Ishii T, 2016, J VASC ACCESS, V17, P499, DOI 10.5301/jva.5000595
   Jennings W, 2013, J VASC SURG, V58, P1305, DOI 10.1016/j.jvs.2013.05.006
   Malik J, 2003, J NEPHROL, V16, P903
   Matoussevitch V, 2014, EUR J VASC ENDOVASC, V48, P472, DOI 10.1016/j.ejvs.2014.07.003
   Miller GA, 2008, J VASC ACCESS, V9, P58, DOI 10.1177/112972980800900110
   Modaghegh MHS, 2015, J VASC SURG, V62, P135, DOI 10.1016/j.jvs.2015.02.024
   Modaghegh MHS, 2015, J VASC ACCESS, V16, P26, DOI 10.5301/jva.5000304
   Pajek J, 2017, J VASC ACCESS, V18, pS5, DOI 10.5301/jva.5000672
   Rothuizen TC, 2013, NEPHROL DIAL TRANSPL, V28, P1085, DOI 10.1093/ndt/gft068
   Scheltinga MR, 2012, EUR J VASC ENDOVASC, V43, P218, DOI 10.1016/j.ejvs.2011.10.018
   Scheltinga MR, 2009, NEPHROL DIAL TRANSPL, V24, P3198, DOI 10.1093/ndt/gfp200
   Sidawy AN, 2008, J VASC SURG, V48, p2S, DOI 10.1016/j.jvs.2008.08.042
   Sturm M, 2017, COMPUT METHOD BIOMEC, V20, P949, DOI 10.1080/10255842.2017.1315635
   Suding PN, 2007, SEMIN VASC SURG, V20, P184, DOI 10.1053/j.semvascsurg.2007.07.009
   Vaes RHD, 2012, EUR J VASC ENDOVASC, V44, P452, DOI 10.1016/j.ejvs.2012.07.007
   Vaes RHD, 2013, J VASC SURG, V58, P446, DOI 10.1016/j.jvs.2013.01.032
   Valentine RJ, 2002, J VASC SURG, V36, P351, DOI 10.1067/mva.2002.125848
   van Hoek F, 2006, EUR J VASC ENDOVASC, V32, P710, DOI 10.1016/j.ejvs.2006.05.018
   Varble N, 2014, J VASC SURG, V59, P1410, DOI 10.1016/j.jvs.2013.04.055
   Wang Y.Z., 2014, CHINESE J BLOOD PURI, V13, P549
   Xu Yuan-kai, 2017, CHINESE J NEPHROLOGY, V33, P187
NR 24
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1085
EP 1090
DI 10.19193/0393-6384_2018_4_166
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500029
DA 2022-07-14
ER

PT J
AU Yao, LC
AF Yao, Liangcai
TI BIOMECHANICAL ANALYSIS OF TRACTION THERAPY FOR IMPROVEMENT OF WEIGHT
   LIFIERS' EARLY AND MID-ANKYLOSING SPONDYLITIS SYMPTOMS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Early and mid-ankylosing spondylitis; Traction therapy; Clinical
   efficacy; Bio-mechanical analysis
ID INDEX
AB Affected by occupational factors, weight lifters are prone to many diseases, among which, early and mid-ankylosing spondylitis has the highest incidence. Once weight lifters suffer front early and mid-ankylosing spondylitis, it will affect their economic level, and even affect their lives when serious, bringing many inconveniences to their lives. 3,000 cases of weight lifters were selected as observation objects, to be intervened with traction therapy with its clinical outcomes for early and mid-ankylosing spondylitis observed. Joint changes, degenerative changes in the lumbar spine, scoliosis generated by traction therapy were analyzed . from pathogenesis and biomechanical effects, and efficacy and role of traction therapy, for early and mid-ankylosing spondylitis were confirmed from clinical, theoretical aspects.
C1 [Yao, Liangcai] Qiqihar Univ, Sch Phys Educ, Qiqihar 161006, Peoples R China.
RP Yao, LC (corresponding author), Qiqihar Univ, Sch Phys Educ, Qiqihar 161006, Peoples R China.
EM liangcai@163.com
FU Heilongjiang provincial education department 2018 undergraduate
   innovation and entrepreneurship training program project - Libo sports
   service co. LTD. - focus on health training and development projects
   [201810232111]
FX Heilongjiang provincial education department 2018 undergraduate
   innovation and entrepreneurship training program project - Libo sports
   service co. LTD. - focus on health training and development projects
   (No. 201810232111).
CR Aldahlawi AM, 2016, SAUDI J BIOL SCI, V23, P101, DOI 10.1016/j.sjbs.2015.05.003
   Belniak P, 2017, SAUDI PHARM J, V25, P365, DOI 10.1016/j.jsps.2016.09.004
   Bo Peng, 2014, STUDY IMPACT ELECTRO
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P127, DOI 10.1016/j.sjbs.2016.09.005
   Jianbang Feng, 2009, CHINESE J TRADITIONA, V17, P68
   Liu ZL, 2017, ENERG SOURCE PART B, V12, P971, DOI 10.1080/15567249.2017.1336813
   Mellotte G. M. V., 2015, ASIAN PAC J SURG ONC, V1, P101
   Moty SGA, 2016, SAUDI PHARM J, V24, P119, DOI 10.1016/j.jsps.2013.12.016
   Ozyurek S, 2017, TURK J MED SCI, V47, P1885, DOI 10.3906/sag-1607-12
   Sandri A. B. A., 2015, ASIAN PAC J SURG ONC, V1, P113
   Sharma M, 2015, SAUDI PHARM J, V23, P675, DOI 10.1016/j.jsps.2015.02.013
   Shen YF, 2017, POL MARIT RES, V24, P102, DOI 10.1515/pomr-2017-0111
   Shikiang Zheng, 2006, STUDY J TRADITIONAL, V24, P292
   Turhan Iyidir O, 2017, TURK J MED SCI, V47, P1751, DOI 10.3906/sag-1610-139
   Wenfeng Zhang, 2010, CLIN OBSERVATION CER
   Wroblewska K, 2015, SAUDI PHARM J, V23, P407, DOI 10.1016/j.jsps.2014.11.009
   Yingli Jin, 2014, INFLUENCE NEEDLE KNI
NR 18
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1915
EP 1918
DI 10.19193/0393-6384_2018_6_297
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400048
DA 2022-07-14
ER

PT J
AU Yao, RF
   Zhu, XL
AF Yao, Renfen
   Zhu, Xiaoli
TI EFFECT OF KAP INTERVENTION ON SURFACE CLEANING AND DISINFECTION OF
   OBJECTS IN NEONATAL WARD
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE KAP intervention; surface disinfection of environmental objects;
   fluorescence labeling
AB Introduction: The knowledge level, the attitude and the faith of personnel in charge of cleaning and disinfection affect the quality of surface cleaning and disinfection of objects in hospital directly. Our research purpose is to observe the effect of knowledge, attitude and practice (KAP) intervention on surface cleaning and disinfection of objects with high-frequency contact in neonatal ward.
   Methods: The KAP intervention mode was adopted to conduct knowledge training, assessment and behavior cultivation on disinfectant workers. The fluorescence labeling method was adopted to monitor and compare the effects of workers' surface cleaning and disinfection of objects with high-frequency contact in wards before and after intervention.
   Results: The fluorescence labeling clearance rate (91.2%) of object surface in the intervention group was significantly higher than that (79.6%) in the control group, and P value was less than 0.00.
   Conclusions: KAP intervention measures can be used to improve the responsibility of disinfectant workers working in neonatal ward and make them master the standard disinfection knowledge, so as to improve the effect of surface cleaning and disinfection of objects with high-frequency contact in neonatal ward.
C1 [Yao, Renfen; Zhu, Xiaoli] Guizhou Prov Peoples Hosp, Neonatal Dept, Guiyang 550000, Guizhou, Peoples R China.
RP Zhu, XL (corresponding author), Guizhou Prov Peoples Hosp, Neonatal Dept, Guiyang 550000, Guizhou, Peoples R China.
CR [陈鸣明 Chen Mingming], 2014, [护理学杂志, Journal of Nursing Science], V29, P18
   [傅响玲 Fu Xiangling], 2016, [护理学杂志, Journal of Nursing Science], V31, P8
   Hu Bijie, 2012, BEST PRACTICE CLEANI, P15
   Huang X., 2015, CHIN J INFECT CONT, V14, P1
   Kang Lihong, 2017, CHINESE J HOSP INFEC, V27, P696
   Li YJ, 2014, SUSTAIN ENERGY TECHN, V6, P25, DOI 10.1016/j.seta.2014.01.003
   Matlow AG, 2012, AM J INFECT CONTROL, V40, P260, DOI 10.1016/j.ajic.2011.02.024
   Otter JA, 2011, INFECT CONT HOSP EP, V32, P687, DOI 10.1086/660363
   Xu Hong, 2013, CHINESE J DISINFECTI, V30
   Zhu Lanlan, 2014, CHINESE MED GUIDELIN, V12, P378
NR 10
TC 0
Z9 0
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1829
EP 1832
DI 10.19193/0393-6384_2018_6_281
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400032
DA 2022-07-14
ER

PT J
AU Ye, QF
   Zhou, W
   Wan, QQ
AF Ye, Qifa
   Zhou, Wei
   Wan, Qiquan
TI BACTERIA ISOLATED FROM KIDNEY RECIPIENTS WITH URINARY TRACT INFECTIONS:
   EPIDEMIOLOGY AND SUSCEPTIBILITY OF THE STRAINS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Kidney transplantation; Bacteria; Urinary tract infections; Antibiotic
   resistance
ID RENAL-TRANSPLANT RECIPIENTS; RISK-FACTORS; 1ST YEAR
AB Purpose: The incidence, type, and frequency of antimicrobial resistance of bacteria isolated from kidney recipients with bacterial urinary tract infections (UTIs) was evaluated.
   Methods: From 2007 to 2015, 1307 consecutive kidney recipients were studied retrospectively for patient demographics, clinical characteristics and urine culture data.
   Results: A total of 86 (6.6%) patients experienced 102 culture-proved bacterial UTI episodes. Three (3.5%) septic shocks occurred in these 86 patients and 1(1.2%) patients developed UTI-related mortality. The most frequently isolated species were Gram-negative bacteria (68.6%) with E. coli (42.2%) being the most prevalent bacterium. The Gram-negative bacteria were highly resistant to 1st-and 2nd-generation cephalosporin, monocyclic beta lactam and relatively sensitive to meropenem, amikacin and cefoperazone/sulbactam, with the resistance rates of 85.7%, 85.7%, 81.4%, 21.4%, 21.4% and 28.6%, respectively. More than half (71.4%, 50/70) of Gram-negative bacteria were caused by extended-spectrum beta-lactamase (ESBL) producing strains. All Gram-positive bacteria were susceptible to teicoplanin and linezolid whereas 12.5% of them were resistant to vancomycin.
   Conclusions: The Gram-negative bacteria were relatively susceptible to meropenem, amikacin and cefoperazone/sulbactam and most of Gram-positive bacteria were susceptible to glycopeptides and oxazolidone. The majority of Gram-negative bacteria were ESBL+ strains and vancomycin-resistant enterococci accounted for 13.6% of all enterococci.
C1 [Ye, Qifa; Zhou, Wei; Wan, Qiquan] Cent S Univ, Xiangya Hosp 3, Dept Transplantat Surg, Changsha 410013, Hunan, Peoples R China.
   [Ye, Qifa] Wuhan Univ, Zhongnan Hosp, Dept Transplantat Surg, Wuhan 430071, Hubei, Peoples R China.
RP Wan, QQ (corresponding author), Cent S Univ, Xiangya Hosp 3, Dept Transplantat Surg, Changsha 410013, Hunan, Peoples R China.
EM 13548685542@163.com
FU New Xiangya Talent Project of the Third xiangya hosipital of Central
   South University [20170311]
FX This work was supported by grant 20170311 from the New Xiangya Talent
   Project of the Third xiangya hosipital of Central South University.
CR Chuang P, 2005, CLIN TRANSPLANT, V19, P230, DOI 10.1111/j.1399-0012.2005.00327.x
   Espinar MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134737
   Golebiewska J, 2014, TRANSPL P, V46, P2748, DOI 10.1016/j.transproceed.2014.09.074
   Golebiewska J, 2011, TRANSPL P, V43, P2985, DOI 10.1016/j.transproceed.2011.07.010
   Gonen I, 2015, ACTA MEDICA MEDITERR, V29, P853
   Kilinc C, 2015, ACTA MEDICA MEDITERR, V31, P1035
   Kosmadakis G, 2013, TRANSPL P, V45, P1579, DOI 10.1016/j.transproceed.2012.10.047
   Leylabadlo Hamed Ebrahimzadeh, 2016, J Nat Sci Biol Med, V7, P179, DOI 10.4103/0976-9668.184707
   Lim JH, 2013, TRANSPL P, V45, P1584, DOI 10.1016/j.transproceed.2012.12.011
   LIPSKY BA, 1989, ANN INTERN MED, V110, P138, DOI 10.7326/0003-4819-110-2-138
   Mitra Subhashis, 2011, Curr Infect Dis Rep, V13, P579, DOI 10.1007/s11908-011-0210-z
   Naik AS, 2015, TRANSPL INT
   Papasotiriou M, 2011, RENAL FAILURE, V33, P405, DOI 10.3109/0886022X.2011.568137
   Pilmis B, 2015, INFECT DIS-NOR, V47, P714, DOI 10.3109/23744235.2015.1051107
   Ramadas P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091289
   Wan QQ, 2013, EXP CLIN TRANSPLANT, V11, P211, DOI 10.6002/ect.2012.0093
   Yabanoglu H, 2015, EXP CLIN TRANSPLANT, V13, P11, DOI 10.6002/ect.tdtd2015.O9
NR 17
TC 0
Z9 0
U1 0
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 163
EP 167
DI 10.19193/0393-6384_2018_1_27
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600027
DA 2022-07-14
ER

PT J
AU Yi, ML
   Du, JD
   Jiang, LH
   Li, Q
   Wu, JY
   Sun, CM
AF Yi, Mao-Li
   Du, Jiang-Dong
   Jiang, Li-Hua
   Li, Qian
   Wu, Jing-Ying
   Sun, Cheng-Ming
TI EMERGENCE OF NDM-1-PRODUCING ESCHERICHIA COLI IN THE SHANDONG PROVINCE
   OF CHINA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Escherichia coli; PAN-drug resistance; carbapenemases; NDM-1
ID METALLO-BETA-LACTAMASE; ACINETOBACTER-BAUMANNII; KLEBSIELLA-PNEUMONIAE;
   CARBAPENEMASES; NDM-1; PATHOGENS; ISOLATE; ISSUES; INDIA
AB Objective: The goal of this study was to investigate the drug resistance mechanism and molecular epidemiology of five strains of PAN-drug resistant Escherichia coli isolated from June 2013 to December 2013 in Yantai Yuhuangding Hospital of Shandong regional medical center.
   Method A modified Hodge test and an imipenem-EDTA phenotypic confirmatory test were performed to detect production of metallo-beta-lactamases. PCR-based surveillance was used to detect the blaNDM-1 gene. For blaNDM-1-positive isolates, antibiotic susceptibility was assessed and molecular typing was performed using PFGE. The genetic location of bla NDM-1 was determined through the analysis of PFGE profiles of S1 nuclease-digested genomic DNA and Southern blot hybridization. Plasmid transfer to E. coli recipients was investigated using filter mating and electroporation.
   Results: Five isolates harboring blaNDM-1 were identified; the strains were clonally diverse and carried blaNDM-1 on different plasmids. Plasmids carrying blaNDM-1 were successfully transferred from four of the five isolates to E. coli recipients.
   Conclusion: We describe the emergence of E. coli producing NDM-1 isolated from the Yantai Yuhuangding hospital of Shandong Province Regional Medical Center production of China. A systemic surveillance network should be established for monitoring these resistant bacteria.
C1 [Yi, Mao-Li; Du, Jiang-Dong; Jiang, Li-Hua; Li, Qian; Wu, Jing-Ying; Sun, Cheng-Ming] Yantai Yuhuangding Hosp, Dept Lab, Yantai 264000, Peoples R China.
RP Sun, CM (corresponding author), Yantai Yuhuangding Hosp, Dept Lab, Yantai 264000, Peoples R China.
EM yimaoli76@163.com
FU Science and Technology Development Plan of Shandong Province
   [2013YD18041]; Yantai Science and Technology Development Plan
   [2016WS020, 2016WS023]
FX This study was funded by a grant from the Science and Technology
   Development Plan of Shandong Province(Grant NO. 2013YD18041) and the
   Yantai Science and Technology Development Plan(Grant NO. 2016WS020 and
   Grant NO. 2016WS023)
CR Chen Y, 2011, J ANTIMICROB CHEMOTH, V66, P1255, DOI 10.1093/jac/dkr082
   Cornaglia G, 2007, INT J ANTIMICROB AG, V29, P380, DOI 10.1016/j.ijantimicag.2006.10.008
   Flateau C, 2012, EUROSURVEILLANCE, P17
   Jovcic B, 2011, ANTIMICROB AGENTS CH, V55, P3929, DOI 10.1128/AAC.00226-11
   Karthikeyan K, 2010, J ANTIMICROB CHEMOTH, V65, P2253, DOI 10.1093/jac/dkq273
   Kilinc C, 2015, ACTA MEDICA MEDITERR, V31, P1035
   Lee K, 2005, ANTIMICROB AGENTS CH, V49, P4485, DOI 10.1128/AAC.49.11.4485-4491.2005
   Miriagou V, 2010, CLIN MICROBIOL INFEC, V16, P112, DOI 10.1111/j.1469-0691.2009.03116.x
   Nordmann P, 2009, LANCET INFECT DIS, V9, P228, DOI 10.1016/S1473-3099(09)70054-4
   Poirel L, 2011, ANTIMICROB AGENTS CH, V55, P447, DOI 10.1128/AAC.01305-10
   Rolain JM, 2010, CLIN MICROBIOL INFEC, V16, P1699, DOI 10.1111/j.1469-0691.2010.03385.x
   Tzouvelekis LS, 2012, CLIN MICROBIOL REV, V25, P682, DOI 10.1128/CMR.05035-11
   Walsh TR, 2008, CURR OPIN INFECT DIS, V21, P367, DOI 10.1097/QCO.0b013e328303670b
   Wei ZQ, 2007, ANTIMICROB AGENTS CH, V51, P763, DOI 10.1128/AAC.01053-06
   Yong D, 2009, ANTIMICROB AGENTS CH, V53, P5046, DOI 10.1128/AAC.00774-09
NR 15
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 2
BP 457
EP 462
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GB7TQ
UT WOS:000429278400027
DA 2022-07-14
ER

PT J
AU Yildiz, Y
   Cakmak, S
   Calapoglu, T
   Hocoglu, ZI
   Karadeniz, EG
   Ozkasap, S
AF Yildiz, Yasin
   Cakmak, Semiha
   Calapoglu, Tugba
   Hocoglu, Zeynep I.
   Karadeniz, Elif G.
   Ozkasap, Serdar
TI MEAN PLATELET VOLUME CAN BE USED AS A HOSPITALIZATION CRITERIA IN
   PEDIATRIC PATIENTS DIAGNOSED WITH ACUTE BRONCHIOLITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Mean platelet volume; Acute bronchiolitis; C-reactive protein; White
   blood cells
ID INFLAMMATION
AB Introduction: Acute bronchiolitis is a disease generally seen in children tinder the age of 2 years and progressing with pronounced wheezing, cough, tachypnea and prolonged expirium resulting from inflammation of the bronchioles frequently caused by viral infection. Mean platelet volume (MPV) is a marker of platelet activation and function.
   Method: 204 children were included in this study in three ,groups; healthy children aged 3 - 48 months (control, group, Group 2), patients diagnosed with acute bronchiolitis in our clinic and then hospitalized (severe cases, group 1b) and patients diagnosed but not hospitalized (mild cases, Group 1a). Patients with a history of asthma, chronic disease or congenital anomaly were excluded. The clinical severity of acute bronchiolitis and the relations with WBC, CRP and MPV were compared between the groups.
   Results: Mean MPV values were 7.4 +/- 1.5 fL (4.6-10.3) in Group 2; 7.8 +/- 0.7 fL (6.5-10.1) in Group la and 8.3 +/- 1.0 fL (6.311.2) in Group 1b.While no difference was observed in terms of MPV between Group 2 and Group 1a(p=0.23), a significant difference was determined between Group 2 and Group 1b (<0.001).
   Discussion: MPV values in our study differed only in the severe patient group. In addition, no difference was observed between the mild and severe case groups in terms of other parameters apart from MPV. This finding shows that MPV values are correlated with severity of disease, that they rise significantly in moderate-severe cases and that they can therefore be used as a finding to assist clinicians in assessing the severity of the disease.
C1 [Yildiz, Yasin; Cakmak, Semiha; Calapoglu, Tugba] Recep Tayyip Erdogan Univ, Sch Med, Dept Pediat, Rize, Turkey.
   [Hocoglu, Zeynep I.; Karadeniz, Elif G.] Rize Publ Hosp, Dept Pediat, Rize, Turkey.
RP Yildiz, Y (corresponding author), Rize Training & Res Hosp, Rize, Turkey.
EM yasinyildizmd@gmail.com
RI yildiz, yasin/AAE-2806-2019; Yildiz, Yasin/AAG-7802-2021
OI Yildiz, Yasin/0000-0002-0602-7795
CR Anmolsingh R, 2016, W INDIAN MED J, DOI [10.7727/wimj.2015.364, DOI 10.7727/WIMJ.2015.364]
   Aslan A, 2004, J CHILD HLTH DIS, V47, P209
   Canpolat FE, 2009, PEDIATR INT, V51, P314, DOI 10.1111/j.1442-200X.2009.02820.x
   EVERARD ML, 1994, ARCH DIS CHILD, V71, P428, DOI 10.1136/adc.71.5.428
   Fitzgerald DA, 2004, MED J AUSTRALIA, V180, P399, DOI 10.5694/j.1326-5377.2004.tb05993.x
   Gasparyan AY, 2011, CURR PHARM DESIGN, V17, P47
   Gunes A, 2015, INT J CLIN EXP MED, V8, P11337
   Kara TT, 2015, TURKISH J PED DIS, DOI [10.12956/tjpd.2015.187, DOI 10.12956/TJPD.2015.187]
   Karadag-Oncel E, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-16
   Kutlug S, 2021, W INDIAN MED J, V69, P395, DOI 10.7727/wimj.2015.266
   Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223
   Makay B, 2009, CLIN RHEUMATOL, V28, P975, DOI 10.1007/s10067-009-1148-5
   Mannaioni PF, 1997, INFLAMM RES, V46, P4, DOI 10.1007/PL00000158
   Martinez FD, 1999, J ALLERGY CLIN IMMUN, V104, pS169, DOI 10.1016/S0091-6749(99)70058-8
   Mochizuki H, 2000, PEDIATRICS, V106, P1442, DOI 10.1542/peds.106.6.1442
   OMalley T, 1996, BLOOD COAGUL FIBRIN, V7, P431, DOI 10.1097/00001721-199606000-00001
   Park Y, 2002, PLATELETS, V13, P301, DOI 10.1080/095371002220148332
   Schoene NW, 1997, AM J CLIN NUTR, V65, P1665
   Steiner RWP, 2004, AM FAM PHYSICIAN, V69, P325
   Turkish Thoracic Society, 2009, TURKISH THORACIC J
   Yeaman MR, 1997, CLIN INFECT DIS, V25, P951, DOI 10.1086/516120
NR 21
TC 0
Z9 0
U1 2
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1997
EP 2000
DI 10.19193/0393-6384_2018_6_311
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400062
DA 2022-07-14
ER

PT J
AU Yilmaz, D
   Turker, G
   Ozturk, A
   Dikmen, Y
AF Yilmaz, Dilek
   Turker, Gurkan
   Ozturk, Aliye
   Dikmen, Yurdanur
TI AN EXAMINATION OF THE THRESHOLD LEVEL OF PRESSURE PAIN IN CASES OF
   CHRONIC PAIN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE baseline algometry; chronic pain; pressure pain threshold;
   musculoskeletal diseases
ID MYOFASCIAL TRIGGER POINT; UPPER TRAPEZIUS MUSCLE; RELIABILITY;
   SENSITIVITY; REPEATABILITY; FIBROMYALGIA; PERCEPTION; ALGOMETRY;
   VALIDITY; IMPACT
AB Introduction: The aim of this study is to determine the threshold levels of pressure pain in individuals with chronic pain and to investigate the correlation between the different variables.
   Materials and methods: The research sample consisted of 60 adult patients who were attending the algology outpatients' clinic, and who had complaints of chronic pain with a duration of at least six months relating to the musculoskeletal system. Before measuring the patients' pressure pain thresholds, they were asked to mark their severity of pain, taking into account their general pain when in motion. Later, an algometer was used to take measurements of the pressure pain threshold in the mid deltoid, mid ulna, hypothenar eminence, mid tibia, and quadriceps,femoris regions.
   Results: Results of statistical analysis showed no significant difference between the mean regional pressure pain thresholds of patients according to illness group (P > 0.05), but did show a significant difference between the mean regional pressure pain thresholds of male and female patients (P < 0.05).
   Conclusion: It was concluded in this study that there was no difference between groups of patients with complaints of chronic pain relating to different musculoskeletal diseases and regional pressure pain threshold levels, that the factor of gender affected the regional pressure pain threshold level.
C1 [Yilmaz, Dilek] Bursa Uludag Univ, Fac Hlth Sci, Dept Nursing, TR-16059 Bursa, Turkey.
   [Turker, Gurkan] Bursa Uludag Univ, Fac Med, Dept Anesthesiol & Reanimat, Bursa, Turkey.
   [Ozturk, Aliye] Bursa Uludag Univ Hosp, Dept Algol, Bursa, Turkey.
   [Dikmen, Yurdanur] Sakarya Univ, Fac Hlth Sci, Dept Nursing, Sakarya, Turkey.
RP Yilmaz, D (corresponding author), Bursa Uludag Univ, Fac Hlth Sci, Dept Nursing, TR-16059 Bursa, Turkey.
EM dilekk@uludag.edu.tr
RI TURKER, Gurkan/AAI-6642-2021; Yilmaz, Dilek/V-6292-2018
OI TURKER, YUNUS GURKAN/0000-0002-3019-581X; Yilmaz,
   Dilek/0000-0001-7269-8493
CR Abu Taleb W, 2016, J BODYW MOV THER, V20, P863, DOI 10.1016/j.jbmt.2016.02.008
   Ashina S, 2005, EUR J NEUROL, V12, P543, DOI 10.1111/j.1468-1331.2005.01023.x
   Aslan FE, 2014, NATURE CONTROL PAIN, P67
   Aydin D, 2016, J CLIN NURS, V25, P2328, DOI 10.1111/jocn.13321
   Aytar A, 2014, J MUSCULOSKELET PAIN, V22, P1
   Bernhardt O, 2007, J OROFAC PAIN, V21, P29
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Cashley D, 2015, INT MUSCULOSKELETAL, V37, P72
   Dawson A, 2009, J ORAL REHABIL, V36, P271, DOI 10.1111/j.1365-2842.2009.01943.x
   Garcia Esmeralda, 2007, Psychol Health Med, V12, P567, DOI 10.1080/13548500701203433
   Gelinas C, 2016, INTENS CRIT CARE NUR, V34, P1, DOI 10.1016/j.iccn.2016.03.001
   Gunnarsson HEM, 2016, SCAND J PAIN, V13, P1, DOI 10.1016/j.sjpain.2016.05.032
   Incel NA, 2002, RHEUMATOL INT, V22, P148, DOI 10.1007/s00296-002-0211-1
   Kall LB, 2008, J REHABIL MED, V40, P171, DOI 10.2340/16501977-0163
   Kersten P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099485
   Ko SJ, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/3052954
   Koo TK, 2013, J MANIP PHYSIOL THER, V36, P84, DOI 10.1016/j.jmpt.2013.01.001
   Lautenbacher S, 2005, PAIN, V115, P410, DOI 10.1016/j.pain.2005.03.025
   Lee YC, 2009, ARTHRIT CARE RES, P3
   Lin CH, 2014, AM J PHYS MED REHAB, V93, P299, DOI 10.1097/PHM.0000000000000003
   Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025
   Mantyselka P, 2001, PAIN, V89, P175, DOI 10.1016/S0304-3959(00)00361-4
   Maquet D, 2004, EUR J PAIN, V8, P111, DOI 10.1016/S1090-3801(03)00082-X
   Montenegro MLLS, 2012, BRAZ J MED BIOL RES, V45, P578, DOI 10.1590/S0100-879X2012007500064
   Ospina MB, 2013, PAIN RES MANAG, V18, pE129, DOI 10.1155/2013/120784
   Park G, 2011, ANN REHABIL MED-ARM, V35, P412, DOI 10.5535/arm.2011.35.3.412
   Pickering G, 2002, GERONTOLOGY, V48, P112, DOI 10.1159/000048937
   Starkweather AR, 2016, APPL NURS RES, V29, P237, DOI 10.1016/j.apnr.2015.03.013
   Thongbuang S, 2014, J MED TECHN PHY THER, V26, P313
   Tornero-Caballero MC, 2016, PAIN MED, V17, P1923, DOI 10.1093/pm/pnw090
   Tough EA, 2007, CLIN J PAIN, V23, P278, DOI 10.1097/AJP.0b013e31802fda7c
   Tsai CT, 2010, AM J PHYS MED REHAB, V89, P133, DOI 10.1097/PHM.0b013e3181a5b1bc
   Ung A, 2016, BRIT J PAIN, V10, P8, DOI 10.1177/2049463715583142
   Vaughan B, 2007, INT J OSTEOPATH MED, V10, P24, DOI 10.1016/j.ijosm.2006.12.003
   Vladimirova N, 2015, ARTHRITIS, DOI 10.1155/2015/434109
   Ylinen J, 2007, MANUAL THER, V12, P192, DOI 10.1016/j.math.2006.06.010
   Yucel A, 2014, NATURE CONTROL PAIN, P35
   Ziaeifar M, 2014, J BODYW MOV THER, V18, P298, DOI 10.1016/j.jbmt.2013.11.004
NR 38
TC 0
Z9 0
U1 2
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1647
EP 1653
DI 10.19193/0393-6384_2018_6_254
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400005
DA 2022-07-14
ER

PT J
AU Yin, M
   Wang, ZY
   Xiao, W
AF Yin, Ming
   Wang, Zhongyang
   Xiao, Wei
TI THE SIGNIFICANCE OF ULTRASOUND-GUIDED LAUROMACROGOL INJECTION TO
   HEPATOCELLULAR CARCINOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Lauromacrogol; HCC; ultrasound-guided
ID ETHANOL INJECTION; CIRRHOSIS; ABLATION; LESIONS
AB Introduction: Ultrasound-guided lauromacrogol injection (UGLI) has been widely utilized in patients with various ailments such as cystic lesions, piles, varicose veins, and so on. Herein, we utilized HepG2-bearing mice model to explore the efficacy and feasibility of UGLI on hepatocellular carcinoma (HCC).
   Material and methods: 26 BALB/c mice were inoculated subcutaneously with hepatoma HepG2 cells in right armpit. When subcutaneous tumor nodules developed, animals were respectively administered with intratumoral injection of lauromacrogol, ethanol or saline under ultrasound guidance. Ten days after treatment, tumor weight, histopathological as well as inflammatory infiltration extent and liver function variance were investigated.
   Results: Our datum demonstrated that lauromacrogol and ethanol nearly played equivalent tissue ablation effect on the hepatoma nodules as compared with saline. However, mice pretreated with lauromacrogol exhibited with less tissue inflammatory infiltration, liver injury.
   Conclusion: These results revealed that on the basis of nearly equivalent antitumor effect, lauromacrogol harbored less tissue impairment and side-effects, deserving further clinic promotion.
C1 [Yin, Ming; Wang, Zhongyang; Xiao, Wei] Jiangsu Taizhou Peoples Hosp, Ultrason Unit, Taizhou 225300, Peoples R China.
RP Wang, ZY (corresponding author), Jiangsu Taizhou Peoples Hosp, Ultrason Unit, Taizhou 225300, Peoples R China.
EM zhongyangwangdoc@163.com
CR Acharya SK, 2014, J CLIN EXP HEPATOL, V4, pS27, DOI 10.1016/j.jceh.2014.05.013
   Alazawi W, 2010, ALIMENT PHARM THER, V32, P344, DOI 10.1111/j.1365-2036.2010.04370.x
   CASTELLS A, 1993, HEPATOLOGY, V18, P1121
   Curley SA, 2000, ANN SURG, V232, P381, DOI 10.1097/00000658-200009000-00010
   Huang H, 2015, INT J HYPERTHER, V31, P40, DOI 10.3109/02656736.2014.999017
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kang TW, 2015, LIVER CANCER, V4, P176, DOI 10.1159/000367740
   Kosugi C, 2004, WORLD J SURG, V28, P29, DOI 10.1007/s00268-003-7003-y
   Kukura V, 2010, COLLEGIUM ANTROPOL, V34, P37
   Liccioni A, 2014, DIGEST DIS, V32, P554, DOI 10.1159/000360501
   LIVRAGHI T, 1995, RADIOLOGY, V197, P101, DOI 10.1148/radiology.197.1.7568806
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   Mancuso A, 2015, DIGEST LIVER DIS, V47, P324, DOI 10.1016/j.dld.2015.01.001
   Mohandas KM, 2007, J GASTROENTEROL, V26, P261
   Nakaji S, 2015, ENDOSCOPY, V47, pE558, DOI 10.1055/s-0034-1393394
   Sato D, 2012, EUR J VASC ENDOVASC, V44, P73, DOI 10.1016/j.ejvs.2012.04.001
   Szary N, 2015, BIOMOLECULES, V5, P3295, DOI 10.3390/biom5043295
   Wang ZK, 2015, GASTROINTEST ENDOSC, V81, P1274, DOI 10.1016/j.gie.2014.08.013
   Xue J, 2015, PAK J PHARM SCI, V28, P697
   Zhong JH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000396
   Zimmet Steven E, 2003, Tech Vasc Interv Radiol, V6, P116, DOI 10.1053/S1089-2516(03)00044-1
NR 21
TC 1
Z9 1
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1331
EP 1335
DI 10.19193/0393-6384_2018_5_204
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700026
DA 2022-07-14
ER

PT J
AU Yu, HX
   Wang, X
   Gu, WW
   Lin, J
   Yan, GJ
AF Yu, Hong-Xing
   Wang, Xiao
   Gu, Wei-Wei
   Lin, Jie
   Yan, Guang-Jun
TI ANALYSIS OF CLINICAL EFFICACY OF INTERVENTIONAL THERAPY ON LOW EXTREMITY
   THROMBOANGIITIS OBLITERANS PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Interventional therapy; low extremity thromboangiitis obliterans;
   clinical research
ID PERIPHERAL ARTERIAL-DISEASE; BUERGERS-DISEASE
AB Objective: To investigate the clinical efficacy of interventional therapy on low extremity thromboangiitis obliterans in clinical practice.
   Methods: We selected 100 low extremity thromboangiitis obliterans patients who went to this hospital for treatment between January 2016 and December 2017 as subjects, and, divided them randomly into two groups, i.e. the treatment group (n=50) and the control group (n=50). Patients in the control group received the conventional conservative treatment, while those in the treatment group received the interventional therapy, and clinical efficacy was compared.
   Results: After treatment, ameliorations in varying degrees were seen in blood flow volume, blood flow velocity, ankle-brachial index, transcutaneous oxygen pressure, inner diameter of arteria dorsalis pedis in patients of two groups, but effectiveness rate in the treatment ,group was better than that in the control group (p<0.051. Meanwhile, incidence rate of the patients in the treatment group was significantly lower than that in the control group (p<0.05).
   Conclusion: In clinical treatment of low extremity thromboangiitis obliterans, interventional therapy can improve the condition of patients, increase the total effectiveness of clinical treatment and decrease the incidence rate of complications, which, thus, is worthy being promoted in clinical practice.
C1 [Yu, Hong-Xing; Lin, Jie; Yan, Guang-Jun] Jilin Univ, Japan Union Hosp, Dept Vasc Surg, 126 Xiantai Ave, Changchun 130033, Jilin, Peoples R China.
   [Wang, Xiao] Liaocheng Peoples Hosp, Dept Vasc Surg, Liaocheng 252004, Shandong, Peoples R China.
   [Gu, Wei-Wei] Jilin Univ, Japan Union Hosp, Dept Hepatobiliary & Pancreat Surg, Changchun 130033, Jilin, Peoples R China.
RP Yan, GJ (corresponding author), Jilin Univ, Japan Union Hosp, Dept Vasc Surg, 126 Xiantai Ave, Changchun 130033, Jilin, Peoples R China.
EM yanguangjvn@163.com
CR Czarnacki Maciej, 2004, Przegl Lek, V61, P1346
   Dean Steven M, 2002, J Am Board Fam Pract, V15, P55
   Jacomella V, 2013, EUR J VASC ENDOVASC, V45, P497, DOI 10.1016/j.ejvs.2013.01.026
   Lazarides M K, 2006, Int J Low Extrem Wounds, V5, P89, DOI 10.1177/1534734606288817
   Maldonado FJM, 2009, ANGIOLOGY, V60, P725, DOI 10.1177/0003319708327787
   Nesargikar PN, 2009, INT J SURG, V7, P145, DOI 10.1016/j.ijsu.2009.01.004
   Ohta T, 2004, J VASC SURG, V39, P176, DOI 10.1016/j.jvs.2003.08.006
   Olin JW, 2006, CURR OPIN RHEUMATOL, V18, P18, DOI 10.1097/01.bor.0000198000.58073.aa
   Raghavendra GKG, 2012, INDIAN J SURG, V74, P298, DOI 10.1007/s12262-011-0364-9
   Parra JAT, 2010, ANN VASC SURG, V24, DOI 10.1016/j.avsg.2010.03.011
   Watts SW, 2010, AM J PHYSIOL-REG I, V298, pR254, DOI 10.1152/ajpregu.00584.2009
   Yoshimuta T, 2009, CAN J CARDIOL, V25, P365, DOI 10.1016/S0828-282X(09)70099-6
   Zhao FL, 2010, PHYTOTHER RES, V24, pS209, DOI 10.1002/ptr.3092
NR 13
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1851
EP 1855
DI 10.19193/0393-6384_2018_6_286
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400037
DA 2022-07-14
ER

PT J
AU Yu, WJ
   Xie, YR
   Bing, LL
   Yu, FY
AF Yu, Wenjuan
   Xie, Yanrong
   Bing, Leilei
   Yu, Fengyun
TI RUTIN IMPROVED INSULIN RESISTANCE INDUCED BY HIGH FAT DIET IN MICE LIVER
   VIA REGULATION OF MAPK SIGNALING PATHWAY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE MAPK pathway; PPAR-alpha; inflammatory cytokines; oxidative stress;
   HOMA-IR; Adipo-IR
ID NONALCOHOLIC STEATOHEPATITIS; MECHANISMS; GROWTH; MOUSE
AB Objective: In view of the pharmacological properties of rutin and the pathogenesis of insulin resistance, the aim of our study was to investigate the effect of rutin on insulin resistance induced by high fat diet in mice liver.
   Method: C57BL/6J mice were randomly divided into 5 groups: blank control group (ctrl), high fat diet group (HFD), low, medium and high concentration of rutin intervention group (Rutin-L, Rutin-M, Rutin-H). Mice in ctrl group were fed with normal diet, and mice in HFD and rutin intervention groups were both fed with high fat diet. Then different dose of rutin treated was in Rutin-L, Rutin-M and Rutin-Hgroups while saline was used in ctrl and HFD groups. Histopathological changes of the liver were observed by hematoxylin and eosin stain (H&E) staining. Blood and liver biochemical indicators were measured through non-esterified fatty acid (NEFA) and insulin detection kit. HOMA-IR and adipo-IR were calculated from the belowed equation. RT-PCR was used to detect the expression of insulin resistance-related genes, such as PPAR-alpha, IR, IRS-1 and SREBP-1c mRNA. The expression of oxidative stress, inflammatory factors and MAPK pathway related factors in liver tissue were detected by Western-blot test.
   Result: The results indicated that rutin decreased HOMA-IR and Adipo-IR significantly (p<0.05). The medium and high doserutin treatment could inhibit the abnormal expression of IR, IRS-1, PPAR-a and SREBP-1c mRNA. In addition, the western blot results suggested that expression of HO-1, Nrf2, GSS and SOD2 were down-regulated while KEAP1 was up-regulated by rutin against insulin resistance. Also, some inflammatory factors (TNF-alpha, IL-1, IL-6) were inhibited by rutin treatment. Meanwhile, P-JNK and p-ERK expression in the regualtion of MAPK signal pathways was also reduced markedly after rutin administration (p<0.05).
   Conclusion: Therefore, these finding suggested that rutin can improve the insulin resistance induced by high fat diet by the way of MAPK signaling pathway, and thus could be a potential agent against insulin resisitance.
C1 [Yu, Wenjuan; Xie, Yanrong; Bing, Leilei; Yu, Fengyun] Yantai Hosp Tradit Chinese Med, Dept Endocrinol, 39 Xingfu Rd, Yantai 264001, Shandong, Peoples R China.
RP Yu, FY (corresponding author), Yantai Hosp Tradit Chinese Med, Dept Endocrinol, 39 Xingfu Rd, Yantai 264001, Shandong, Peoples R China.
EM yfyun0976@126.com
CR Bosco D, 2011, J CELL MOL MED, V15, P1807, DOI 10.1111/j.1582-4934.2011.01318.x
   Boucher J, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a009191
   Carmiel-Haggai M, 2004, FASEB J, V18, P136, DOI 10.1096/fj.04-2291fje
   Chua LS, 2013, J ETHNOPHARMACOL, V150, P805, DOI 10.1016/j.jep.2013.10.036
   Day CP, 2002, GUT, V50, P585, DOI 10.1136/gut.50.5.585
   de la Monte SM, 2009, CURR OPIN INVEST DR, V10, P1049
   Ferre P, 2010, DIABETES OBES METAB, V12, P83, DOI 10.1111/j.1463-1326.2010.01275.x
   Guo SD, 2014, J ENDOCRINOL, V220, pT1, DOI 10.1530/JOE-13-0327
   Josse AR, 2011, J NUTR, V141, P1626, DOI 10.3945/jn.111.141028
   Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482
   Khan RA, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-178
   KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397
   Li TY, 2016, FOOD FUNCT, V7, P1147, DOI 10.1039/c5fo01036e
   Liu CD, 2014, GEN COMP ENDOCR, V197, P82, DOI 10.1016/j.ygcen.2013.12.006
   Meigs James B, 2003, Curr Diab Rep, V3, P73, DOI 10.1007/s11892-003-0057-2
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215
   Samuel VT, 2012, CELL, V148, P852, DOI 10.1016/j.cell.2012.02.017
   Siddle K, 2011, J MOL ENDOCRINOL, V47, pR1, DOI 10.1530/JME-11-0022
   Sikder K, 2014, FOOD FUNCT, V5, P1294, DOI 10.1039/c3fo60526d
   Silbernagel G, 2011, BRIT J NUTR, V106, P79, DOI 10.1017/S000711451000574X
   Su KY, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-21
   Winzell MS, 2004, DIABETES, V53, pS215, DOI 10.2337/diabetes.53.suppl_3.S215
   Yin F, 2014, ANTIOXID REDOX SIGN, V20, P353, DOI 10.1089/ars.2012.4774
   Zhang HF, 2013, FOOD CHEM TOXICOL, V55, P70, DOI 10.1016/j.fct.2012.12.043
NR 25
TC 2
Z9 2
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 677
EP 683
DI 10.19193/0393-6384_2018_3_104
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000009
DA 2022-07-14
ER

PT J
AU Zeng, GX
   Wang, C
   Tian, M
   He, LL
   Wang, M
   Li, X
AF Zeng Guoxiang
   Wang Cheng
   Tian Mi
   He Lili
   Wang Mei
   Li Xin
TI STUDIES ON THE MOLECULAR MECHANISMS INVOLVED IN SLOW VIRUS-INDUCED MUC16
   GENE EFFECT ON CELL INVASION AND METASTASIS IN GALLBLADDER CARCINOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Mucoprotein; Gallbladder carcinoma; Proliferation; Invasion; PI3K/Akt
   signal pathway
ID ADENOCARCINOMA; CHOLANGIOCARCINOMA; MUC16/CA125; EXPRESSION; PROGNOSIS;
   GROWTH; MUCIN; P53
AB Introduction: To study the effect of lentivirus-induced mucin16 (MUC16) gene on cell invasion and metastasis in gallbladder carcinoma, and the molecular mechanisms involved.
   Methods: Gallbladder cell-Shandong (GBC-SD) of over-expression MUC16 and empty viral plasmid-transfected cells were produced through slow virus transfection system. The effect of MUC16 on proliferation of GBC-SC cells in vitro was determined using 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Scratch test and Transnell chambers were used to measure the effect of MUC16 over-expression on in vitro cell migration and invasion. The effect of MUC16 overexpression on GBC-SD cell adhesion was determined with adhesion test, while real time-polymerase chain reaction (RT-PCR) was used to ascertain the pathway involved in MUC16-induced regulation of GBC-SD cell biology.
   Results: The growth rate of MUC16 over-expression cells was significantly higher than that of the control group (p < 0.05). MUC16 over-expression increased the migration, scratch recovery, and extracellular matrix ( ECM) adhesion abilities of GBC-SD cells in vitro. MUC16 significantly enhanced the expression of matrix metalloproteinase-2 (MMP2) and MMP7 mRNAs, relative to control (p < 0.05).
   Conclusion: MUC16 enhances the proliferation, invasion and migration of gallbladder carcinoma cells in vitro by activating the PI3K/Akt signal pathway.
C1 [Zeng Guoxiang] Peoples Hosp Hanchuan City, Dept Gen Surg, Hanchuan 431600, Hubei, Peoples R China.
   [Wang Cheng; He Lili; Wang Mei; Li Xin] Second Peoples Hosp Jingmen Hubei Prov, Dept Gen Surg, Jingmen, Hubei, Peoples R China.
   [Tian Mi] Jingmen Publ Secur Bur, Forens Identificat Inst, Jingmen, Hubei, Peoples R China.
RP Li, X (corresponding author), Second Peoples Hosp Jingmen Hubei Prov, Dept Gen Surg, Jingmen, Hubei, Peoples R China.
EM ph1349@163.com
CR Chen CY, 2002, HEPATO-GASTROENTEROL, V49, P616
   Cotton S, 2017, MOL ONCOL, V11, P895, DOI 10.1002/1878-0261.12035
   Ghosh M, 2005, EJSO-EUR J SURG ONC, V31, P891, DOI 10.1016/j.ejso.2005.03.008
   Higashi M, 2012, PATHOBIOLOGY, V79, P101, DOI 10.1159/000335164
   Johnson Mahlon D, 2016, Surg Neurol Int, V7, pS1049, DOI 10.4103/2152-7806.196367
   Kim SM, 2012, KOREAN J PATHOL, V46, P429, DOI 10.4132/KoreanJPathol.2012.46.5.429
   Lakshmanan I, 2017, CLIN CANCER RES, V23, P3906, DOI 10.1158/1078-0432.CCR-16-2530
   Liang C, 2017, MOL CANCER RES, V15, P201, DOI 10.1158/1541-7786.MCR-16-0296
   Niculescu Z, 2016, ROM J MORPHOL EMBRYO, V57, P1165
   Sun K K, 2018, J CELLULAR BIOCH, V119
   Takagawa M, 2005, DIGEST DIS SCI, V50, P1410, DOI 10.1007/s10620-005-2854-8
   Taniguchi T, 2017, J BIOL CHEM, V292, P11079, DOI 10.1074/jbc.M116.770123
   Wong LL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08574-x
   Wu SY, 2016, AM J TRANSL RES, V8, P5433
   You Y, 2014, CANCER CONTROL, V21, P247, DOI 10.1177/107327481402100312
   Zhu T, 2016, J PRACTICAL ONCOLOGY, V30, P568
NR 16
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1641
EP 1646
DI 10.19193/0393-6384_2018_6_253
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400004
DA 2022-07-14
ER

PT J
AU Zeng, YW
   Zhang, M
   Huang, DD
   Zheng, YH
AF Zeng, Yu-wei
   Zhang, Ming
   Huang, Dan-dan
   Zheng, Yong-hong
TI OBSERVATION OF EFFICACY OF COMBINED MEDICATION OF BISOPROLOL AND
   IRBESARTAN ON CHRONIC CONGESTIVE HEART FAILURE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE bisoprolol; irbesartan; chronic congestive heart failure; efficacy
ID EJECTION FRACTION; MILRINONE; HEMODYNAMICS
AB Objective: To investigate the clinical efficacy of combined medication of bisoprolol and irbesartan on chronic congestive heart failure.
   Methods: A total of 98 patients with chronic congestive heart failure who were admitted to this hospital for treatment between June 2015 and May 2017 were selected as the subjects, and randomly divided into two groups, i.e. the control group and the observation group. For patients in the control group, they underwent regular treatment, while those in the observation group, they additionally received the combined medication of bisoprolol and irbesartan. Then the ameliorations in heart functions were compared between two groups through changes in measurements of blood pressure, heart fate, left ventricular ejection fraction (LVEF), endsystolic and -diastolic volumes.
   Results: After treatment, indicators of patients in two groups were all ameliorated significantly in these two groups, while the amelioration in the observation group was much better than that in the control group (p<0.05). In terms of the effectiveness, the effective rate in the observation was as high as 93.9%, significantly higher than 77.6% in the control group (p<0.05).
   Conclusion: Combined medication of bisoprolol and irbesartan manifest significant effectiveness in treatment of chronic congestive heart failure through ameliorating the indicators of heart function. In addition, this strategy can increase the effectiveness of treatment, which is conducive to the health of patients, and deserves to be promoted in clinical practice.
C1 [Zeng, Yu-wei] Chongqing Med Univ, Affiliated Hosp 1, Chongqin, Peoples R China.
   [Zhang, Ming] Xian Med Univ, Dept Cardiol, Affiliated Hosp 2, Xian, Shanxi, Peoples R China.
   [Huang, Dan-dan] North Sichuan Med Coll, Preeclin Sch, Nanchong, Sichuan, Peoples R China.
RP Zheng, YH (corresponding author), Fujian Med Univ, Fujian Prov Clin Coll, 134 Dongda Rd, Fuzhou, Fujian, Peoples R China.; Zheng, YH (corresponding author), Fujian Prov Hosp, Dept Cardiol, 134 Dongda Rd, Fuzhou, Fujian, Peoples R China.
CR AlHabib KF, 2015, ANGIOLOGY, V66, P837, DOI 10.1177/0003319714563138
   Hyldebrandt JA, 2015, AM J PHYSIOL-HEART C, V309, pH860, DOI 10.1152/ajpheart.00384.2015
   Kaye DM, 2016, J AM COLL CARDIOL, V67, P2554, DOI 10.1016/j.jacc.2016.03.539
   Ku H, 2017, YONSEI MED J, V58, P944, DOI 10.3349/ymj.2017.58.5.944
   Li Y, 2014, ACTA PHARMACOL SIN, V35, P1257, DOI 10.1038/aps.2014.75
   Nanayakkara S, 2017, INTERN MED J, V47, P973, DOI 10.1111/imj.13503
   Pitt B, 2017, CLIN PHARMACOL THER, V102, P389, DOI 10.1002/cpt.746
   Seno A, 2016, HYPERTENSION, V68, P678, DOI 10.1161/HYPERTENSIONAHA.116.07371
   Si LJ, 2015, J CARDIOVASC PHARM, V66, P558, DOI 10.1097/FJC.0000000000000304
   Toukhsati Samia R, 2015, Card Fail Rev, V1, P128, DOI 10.15420/cfr.2015.1.2.128
NR 10
TC 0
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 827
EP 830
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000030
DA 2022-07-14
ER

PT J
AU Zeraatkar, K
   Ahmadi, M
   Sahraian, MA
AF Zeraatkar, Kimia
   Ahmadi, Maryam
   Sahraian, Mohammad Ali
TI DASHBOARD OF MULTIPLE SCLEROSIS SURVEILLANCE REGISTRY: DEVELOPING ITS
   KEY PERFORMANCE INDICATORS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Multiple sclerosis; Registry; Big data; Dashboards; Key performance
   indicators
ID HEALTH-CARE; ANALYTICS; BIOBANK; IRAN
AB Introduction: Multiple sclerosis (MS) registries with longitudinally collected data have the potential to produce big data over time. Business intelligence visual analytics tools like dashboards can be used to navigate, manipulate, and convert such big data into actionable knowledge. The combined use of clinical dashboards with MS registries can provide near real-time surveillance to improve patient outcomes when appropriately configured. The first step for dashboard development is to determine its key performance indicators (KPIs).
   Method: This qualitative study was conducted in 2017. Interviews with neurologists for requirement analysis was performed after studying the MS registries' aims and indicators in leading countries. The face and content validity and also reliability of the questionnaire were assessed by expert's opinions and Cronbach's alpha, respectively. In order to make a consensus about dashboard KPIs, Delphi technique was applied.
   Results: A set of 45 KPIs was developed for the MS surveillance registry dashboard and categorized into three layers-country layer, regional layer, and patient layer-with 7, 28, and 10 indicators, respectively, in each layer.
   Conclusion: The first step to develop the MS surveillance registry dashboard is to determine its key performance indicators. KPIs serve as a mind map for collecting key data for dashboard visualization. These indicators provide a framework for performance measurement and create the basis for quality assurance and quality improvement of MS care.
C1 [Zeraatkar, Kimia; Ahmadi, Maryam] Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Dept Hlth Informat Technol, Hlth Informat Management, Tehran, Iran.
   [Sahraian, Mohammad Ali] Univ Tehran Med Sci, Neurosci Inst, Business Inst MS Res Ctr, Neurol, Tehran, Iran.
   [Sahraian, Mohammad Ali] Univ Tehran Med Sci, Neurosci Inst, Business Inst MS Res Ctr, Tehran, Iran.
RP Ahmadi, M (corresponding author), Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Dept Hlth Informat Technol, Hlth Informat Management, Tehran, Iran.
RI , maryam/AAP-6423-2021; zeraatkar, kimia/ACN-7271-2022
OI , maryam/0000-0003-0765-9556; zeraatkar, kimia/0000-0003-1563-9213
FU Iran University of Medical Sciences [IUMS/SHMIS-2015/16]
FX This study was part of a PhD thesis supported by Iran University of
   Medical Sciences (IUMS/SHMIS-2015/16). The authors would like to thank
   all of the participants.
CR Arsenault C, 2017, B WORLD HEALTH ORGAN, V95, P128, DOI 10.2471/BLT.16.178079
   Bronnum-Hansen H, 2011, SCAND J PUBLIC HEALT, V39, P62, DOI 10.1177/1403494810390729
   Browne P, 2014, NEUROLOGY, V83, P1022, DOI 10.1212/WNL.0000000000000768
   Cheng CKY, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1658
   Culpepper WJ, 2015, J REHABIL RES DEV, V52, P263, DOI 10.1682/JRRD.2014.07.0172
   Eskandarieh S, 2017, IRAN J PUBLIC HEALTH, V46, P699
   Etemadifar M, 2013, EUR NEUROL, V70, P356, DOI 10.1159/000355140
   Flachenecker P, 2014, EUR NEUROL, V72, P95, DOI [10.1159/000360285, 10.1159/000367622]
   Gliklich RE., 2020, REGISTRIES EVALUATIN, V4th
   Gohil Kunj, 2015, P T, V40, P604
   Guthrie JL, 2017, J AM MED INFORM ASSN, V24, pE136, DOI 10.1093/jamia/ocw130
   Hillert J, 2015, ACTA NEUROL SCAND, V132, P11, DOI 10.1111/ane.12425
   Jinpon P., 2011, WALAILAK J SCI TECHN, V8, P97
   Khan N, 2014, SCI WORLD J, DOI 10.1155/2014/712826
   Koch-Henriksen N, 2015, ACTA NEUROL SCAND, V132, P4, DOI 10.1111/ane.12424
   Lo YS, 2014, COMPUT METH PROG BIO, V117, P351, DOI 10.1016/j.cmpb.2014.07.006
   Magyari M, 2016, CLIN EPIDEMIOL, V8, P549, DOI 10.2147/CLEP.S99500
   Myhr KM, 2015, ACTA NEUROL SCAND, V132, P24, DOI 10.1111/ane.12427
   Myhr KM, 2012, ACTA NEUROL SCAND, V126, P1, DOI 10.1111/ane.12039
   Myhr KM, 2012, ACTA NEUROL SCAND, V126, P20, DOI 10.1111/ane.12030
   Patrick R, 2017, JAIDS-J ACQ IMM DEF, V75, pS397, DOI 10.1097/qai.0000000000001417
   Robertson H, 2017, STUD HEALTH TECHNOL, V239, P126, DOI 10.3233/978-1-61499-783-2-126
   Rosewell A, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1910-0
   Ryan K, 2016, WMJ, V115, P224
   Simpao AF, 2015, BRIT J ANAESTH, V115, P350, DOI 10.1093/bja/aeu552
   The Canadian Institute for Health Information (CIHI), CAN MULT SCLER MON S
   Wilbanks BA, 2014, CIN-COMPUT INFORM NU, V32, P545, DOI 10.1097/CIN.0000000000000106
NR 27
TC 1
Z9 1
U1 1
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1305
EP 1310
DI 10.19193/0393-6384_2018_5_200
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700022
DA 2022-07-14
ER

PT J
AU Zhan, GL
   Li, CH
   Zhao, LY
   Li, T
AF Zhan, Guilai
   Li, Chenhu
   Zhao, Liyu
   Li, Ting
TI EFFECTS OF COMMUNITY MENTAL HEALTH SERVICE ON MENTAL HEALTH STATUS OF
   ELDERLY COMMUNITY RESIDENTS IN SHANGHAI, CHINA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Mental Health Service; Health Status; Elderly; Community; Scales
AB The aim of this study was to investigate the effects of community mental health services on the mental health status of elderly community residents in China. Elderly residents (n = 2,000; >= 60 years) were randomly selected based on recommendations by the residents' committee and family doctors and assigned to either an observational or control group. The Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), and General Well-Being Schedule (GWB) were used to evaluate the mental health of the subjects at baseline and at the end of months 6 and 12, respectively. The analysis of the PHQ-9, GAD-7, GWB scores in the observation group found that PHQ-9 and GAD-7 scores gradually decreased, GWB score gradually increased and the change had statistically significant differences (F = 1603.272, 653.680, 2158.862; P < 0.001 for all). After 12 months, compared the control group, the scores of subscale in GWB satisfaction and interest in life, worries about health, depressed versus cheerful mood, and relaxation versus tension (anxiety) were significantly better (P < 0.001). Community mental health service could effectively improve the mental health status of aged community residents, and prolonged community mental health service could result in better outcomes.
C1 [Zhan, Guilai; Li, Chenhu; Zhao, Liyu; Li, Ting] Mental Hlth Ctr Xuhui Dist, Shanghai 200232, Peoples R China.
RP Zhan, GL (corresponding author), Mental Hlth Ctr Xuhui Dist, Shanghai 200232, Peoples R China.
EM zgltd2004@sina.com
FU Key Medical Project of Xuhui District, Shanghai, China [SHXH201113]
FX This study was supported by the Key Medical Project of Xuhui District,
   Shanghai, China (SHXH201113).
CR Jia ZB, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-172
   Karatzias A, 2006, QUAL LIFE RES, V15, P1143, DOI 10.1007/s11136-006-0064-2
   Muramatsu N, 2010, SOC SCI MED, V70, P1050, DOI 10.1016/j.socscimed.2009.12.005
   Pirkola S, 2009, LANCET, V373, P147, DOI 10.1016/S0140-6736(08)61848-6
   Pollack D, 2003, COMMUNITY MENT HLT J, V39, P377, DOI 10.1023/A:1025829101530
   Shin YH, 1996, J KOREAN ACAD NURS, V26, P743, DOI DOI 10.4040/JNAS.1996.26.4.743
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Wang XiaoJuan, 2006, China Vegetables, P35
   Xiangdong C, 2012, CHINESE J HLTH PSYCH, V24, P1
   Xie J, 2014, SICHUANMENTAL HLTH, V27, P363
   Yao K., 2011, MED PHILOS, V32, P37
   남일성, 2014, Korean Journal of Health Promotion, V14, P112, DOI 10.15384/kjhp.2014.14.3.112
NR 12
TC 0
Z9 0
U1 3
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 967
EP 973
DI 10.19193/0393-6384_2018_4_147
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500010
DA 2022-07-14
ER

PT J
AU Zhang, LG
   Zhang, Y
   Wang, PM
AF Zhang Laigen
   Zhang Yan
   Wang Peimin
TI EFFECT OF COMBINATION OF YANYU TONGLUO PLASTER AND CELECOXIB CAPSULE ON
   TREATMENT OF KNEE OSTEOARTHRITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Yanyu tongluo plaster; Celecoxib capsule; Knee osteoarthritis; SDF-1;
   Irisn
AB Objective: To investigate the effect of combination of Yanyu tongluo plaster and celecoxib capsule on treating knee osteoarthriand its impact on serum and knee joint fluid levels of irisin and SDF-1.
   Methods: Knee osteoarthritis patients (numbering 400) admitted to the Department of Orthopaedics and Traumatology, Affiliated Hospital of Nanjing University from January 2013 to January 2016 were recruited into the study. They were ramlornly assigned to either control group or observation group (2001group). All patients received celecoxib, but those in the observation group were given Yanyu tongluo plaster. Treatment effectiveness, improvement of specific clinical manifestations, and levels of knee join fluid SDF-1 and serum irisin were assayed in the two groups using enzyme-linked immunosorbent assay (EL1SA).
   Results: Total clinical effectiveness in the observation group (91.5%) was much higher than that of the control group (75.5%, p < 0.05). There were no significant differences in Lysholm scores and VAS scores between the two groups before treatment (p > 0.05) However; after treatment, the Lysholm scores of two groups increased significantly, but values in the observation group were significantly higher than corresponding values in the control group (p < 0.05). Moreover; the VAS scores of two groups decreased significantly, but VAS scores in the cthservaticm group was much less than VAS scores in the Control group (p < 0.05). No significant differences existed serum SDF-1 and irisin or knee joint fluid between the two groups before treatment. After treatment, serum SDF-1 and knee joint fluid in the two groups decreased significantly, but these parameters were significantly lower in the observation group than in the control group (p < 0.05). Similarly, serum irisin and knee joint fluid of two groups were significantly increased after treatment but their levels in the observation group were much higher than those in the control group (p <'0.05).
   Conclusion: The combination of Yanyu tongluo plaster and celecoxib may play a positive role in treating knee osteoarthritis through regulation of serum SDF-1 and irisin or knee joint fluid. This finding merits further exploration with a view to adopting them for clinical application.
C1 [Zhang Laigen; Wang Peimin] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Orthoped & Traumatol, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhang Yan] Nanjing Normal Univ, Sch Publ Adm, Nanjing 210029, Jiangsu, Peoples R China.
RP Wang, PM (corresponding author), Nanjing Normal Univ, Sch Publ Adm, Nanjing 210029, Jiangsu, Peoples R China.
EM nqgze5@163.com
CR Akhtar N, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3368
   Chen J, 2014, J CANCER RES THER, V10, P56, DOI 10.4103/0973-1482.139761
   Chinese Orthopaedic Society, 2007, CHIN J ORTHOP, V27, P793, DOI DOI 10.3760/J.ISSN:0253-2352.2007.10.016
   Colaianni G, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/902186
   He XJ, 2013, J BEIJING U TRAD CHI, V20, P9
   Li DM, 2016, SHANGHAI J TRAD CHIN, V50, P60
   Liu YN, 2011, CLIN J CHIN MED, V3, P39
   Ma YF, 2014, HEIBEI MED, V20, P690
   Ministry of Health P. R. China, 1993, CLIN GUID NEW DRUGS, P210
   Wang RQ, 2016, CLINR ES PRACT, V1, P129
   Wang XZ, 2015, SHANGHAI J TRAD CHIN, V49, P7
   Wu XK, 2016, ZHEJIANG J TRADIT CH, V51, P63
   Yu GS, 2012, HEIBEI J TRAD CHIN M, V34, P775
   Zhao BL, 2011, HEBEI J TRAD CHIN ME, V33, P551
   王书雅, 2014, [中华内科杂志, Chinese Journal of Internal Medicine], V53, P327
NR 15
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 847
EP 851
DI 10.19193/0393-6384_2018_3_128
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000033
DA 2022-07-14
ER

PT J
AU Zhang, L
   Chang, JH
   Liu, LY
   Fu, Q
   Liu, CZ
AF Zhang, Lin
   Chang, Jin-Hua
   Liu, Li-Yan
   Fu, Qiang
   Liu, Cui-Zhe
TI A RAPID UPLC-MS/MS METHOD FOR SIMULTANEOUS DETERMINATION OF FIVE
   ANTHRAQUINONES IN RAT PLASMA: APPLICATION TO A PHARMACOKINETIC STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Rhubarb anthraquinones; rat plasma; pharmacokinetics; UPLC-MS/MS
ID TANDEM MASS-SPECTROMETRY; SIMULTANEOUS QUANTIFICATION;
   LIQUID-CHROMATOGRAPHY; DECOCTION; RHEIN; COMPONENTS; BERBERINE;
   BAICALIN; EXTRACT; SYSTEM
AB Introduction: A rapid and simple UPLC-MS/MS method was established and validated for simultaneous determination of aloe-emodin, rhein, emodin, chrysophanol and physcion in rat plasma.
   Materials and methods: After sample preparation by a simple protein precipitation, the mass detection was conducted in multiple reaction monitoring using an API 6500 triple quadruple in negative-ion mode with an electrospray ionization interface. Gradient elution was performed with a mobile phase composed of acetonitrile and water containing 0.1% formic acid at a flow rate of 0.6 mL/min.
   Results: The retention time of emodin, aloe-emodin, chrysophanol, physcion, rhein and IS was at 1.54, 1.04, 1.67, 1.69, 1.09 and 1.59 min, respectively.
   Conclusion: This method exhibited acceptable precision, accuracy, recoveries, matrix effect and carry-over effect, which was superior to previous methods in analysis time and sample throughput.
C1 [Zhang, Lin; Chang, Jin-Hua; Liu, Li-Yan; Liu, Cui-Zhe] Chengde Med Coll, Hebei Prov Key Lab Res & Dev Chinese Med, Chengde 067000, Hebei, Peoples R China.
   Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China.
RP Liu, CZ (corresponding author), Chengde Med Coll, Hebei Prov Key Lab Res & Dev Chinese Med, Chengde 067000, Hebei, Peoples R China.
EM liucuizhexy@163.com
FU National Natural Science Foundation of China [81073146, 81341143]; Key
   Discipline Construction Projects of Higher School; Hebei Province
   Natural Science Foundation of China [H2014406036]; Science and
   Technology Research Key Project of Higher School in Hebei Province
   [ZH2012050]; Science and Technology Research Youth Fund Project of
   Higher School in Hebei Province [QN2013020]; Hundred of Excellent
   Creative Talents Support Plan of Higher School in Hebei Province (II)
   [BR2-103]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 81073146 and No. 81341143); Key Discipline
   Construction Projects of Higher School; Hebei Province Natural Science
   Foundation of China (No. H2014406036); Science and Technology Research
   Key Project of Higher School in Hebei Province (No. ZH2012050); Science
   and Technology Research Youth Fund Project of Higher School in Hebei
   Province (No. QN2013020); and A Hundred of Excellent Creative Talents
   Support Plan of Higher School in Hebei Province (II) (No. BR2-103).
CR F.a.D.A. U.S. Department of Health and Human Services Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM), 2018, PHYS ACT GUID AM
   Feng SX, 2013, PHYTOTHER RES, V27, P1489, DOI 10.1002/ptr.4890
   Gong XH, 2014, EUROPEAN J DRUG META
   Hou ML, 2014, MOLECULES, V19, P4058, DOI 10.3390/molecules19044058
   Huang P, 2012, BIOANALYSIS, V4, P1205, DOI [10.4155/BIO.12.81, 10.4155/bio.12.81]
   Liu X, 2015, J CHROMATOGR B, V980, P88, DOI 10.1016/j.jchromb.2014.11.025
   Shi YB, 2014, J INTEGR MED-JIM, V12, P455, DOI 10.1016/S2095-4964(14)60037-6
   Wang Y, 2015, J SEP SCI, V38, P1100, DOI 10.1002/jssc.201401197
   Wang ZG, 2013, J ETHNOPHARMACOL, V145, P442, DOI 10.1016/j.jep.2012.11.008
   Wu WJ, 2014, CHEM-BIOL INTERACT, V219, P18, DOI 10.1016/j.cbi.2014.05.006
   Wu WJ, 2014, BIOMED CHROMATOGR, V28, P564, DOI 10.1002/bmc.3070
   Xu YP, 2013, J CHROMATOGR B, V932, P92, DOI 10.1016/j.jchromb.2013.06.011
   Zhang L, 2015, FITOTERAPIA, V104, P86, DOI 10.1016/j.fitote.2015.05.018
   Zhang Q, 2014, J PHARMACEUT BIOMED, V92, P35, DOI 10.1016/j.jpba.2013.12.038
   Zhao JL, 2013, J PHARMACOL SCI, V122, P118, DOI 10.1254/jphs.13037FP
   Zhu HY, 2014, J CHROMATOGR B, V960, P116, DOI 10.1016/j.jchromb.2014.04.031
NR 16
TC 1
Z9 1
U1 1
U2 18
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 1
BP 175
EP 180
DI 10.19193/0393-6384_2018_1_29
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AH
UT WOS:000424878600029
DA 2022-07-14
ER

PT J
AU Zhang, W
   Ji, Y
   Huang, CH
   Ying, J
   Ye, ZQ
   Qin, GY
   Zhao, NQ
AF Zhang, Wei
   Ji, Yuan
   Huang, Caihong
   Ying, Jun
   Ye, Zhengqiang
   Qin, Guoyou
   Zhao, Naiqing
TI EVALUATION OF THE ASSOCIATION BETWEEN THE PATHOGENESIS OF TYPE 2
   DIABETES AND GENOME-WIDE COPY NUMBER VARIATIONS USING THE LASSO METHOD
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Type 2 diabetes; copy number variation; Genome-wide association; LASSO
ID ARRAY; GENE; VARIANTS; IDENTIFICATION; INSIGHTS; DATABASE; GLUCOSE;
   OBESITY
AB Objective: Type 2 diabetes (T2D) is a complex disease caused by the combination of genetic factors and environmental factors. To date, although many loci, including genes and single nucleotide polymorphisms (SNPs), have been identified as risk variants of T2D, only approximately 10% of its heritability can be explained. In the current study, we proposed a data processing and analysis procedure to more accurately evaluate the association of the pathogenesis of T2D with copy number variations (CNVs).
   Methods: The data in our study came from the WTCCC (Wellcome Trust Case Control Consortium) genome-wide CNV database. Individual CNVs were identified by SW-ARRAY and CBS algorithms and genotyped with a global threshold method. Overlapped CNVs among all samples were split into smaller but more accurate CNV segments (CNVSegs) after the CNV call; then, LASSO-based logistic regression models with 10-fold cross-validations were performed 100 times to examine the association of CNVSegs with T2D. The AUC (area under the curve) in every model was summarized to preliminarily verify the classification ability of the models.
   Results: After quality control, 1,813 T2D cases and 2,777 controls were enrolled in the study. A total of 65,163 CNVs were identified, of which 25,512 were identified in the T2D group and 39,651 were identified in the healthy control group. A total of 22,279 CNVSegs were constructed after pre-processing the raw CNV data. By means of fitting 1,000 logistic regression models with the LASSO method, 26 CNVSegs were identified as T2D-associated CNVSegs according to pre-defined criteria (Frequency > 85% & Length > = 50 bp). Twenty-seven protein-coding genes were found to be overlapped with the CNVSegs, of which 11 were verified to be relevant to T2D, obesity or metabolic syndrome based on current published evidence. The average AUC of all models was 0.611 with the maximum being 0.683.
   Conclusions: Our study explored T2D-associated CNVSegs by LASSO-logistic regression models from the perspective of the whole genome for a more complete understanding of the genetic mechanisms of T2D. Further studies are necessary to verify the influence of the susceptibility loci on the pathogenesis or progression of T2D among different populations.
C1 [Zhang, Wei; Qin, Guoyou; Zhao, Naiqing] Fudan Univ, Sch Publ Hlth, Dept Biostat, Shanghai 200032, Peoples R China.
   [Zhang, Wei; Ying, Jun] Fudan Univ, Fudan Univ Lib, Shanghai 200032, Peoples R China.
   [Ji, Yuan] Northshore Univ HealthSyst, Evanston, IL 60201 USA.
   [Ji, Yuan] Univ Chicago, Med & Biol Sci, Chicago, IL 60637 USA.
   [Huang, Caihong] Xuhui Cent Hosp, Shanghai 200032, Peoples R China.
   [Ye, Zhengqiang] Fudan Univ, Eye & ENT Hosp, Shanghai 200032, Peoples R China.
RP Qin, GY; Zhao, NQ (corresponding author), Fudan Univ, Sch Publ Hlth, Dept Biostat, Shanghai 200032, Peoples R China.
EM gyqin@fudan.edu.cn; nqzhao@fudan.edu.cn
FU NIH [2R01 CA132897]
FX YJ's research is partly supported by NIH 2R01 CA132897.
CR Aerts E, 2016, OBESITY, V24, P970, DOI 10.1002/oby.21435
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bae JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019091
   Baeza-Raja B, 2012, P NATL ACAD SCI USA, V109, P5838, DOI 10.1073/pnas.1103638109
   Bao MX, 2006, CHIN J CLIN REHABIL, V10, P140
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Crespo-Facorro B., 2014, INT J NEUROPSYCHOPHA, V18
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Fukuda T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164131
   Grarup N, 2014, DIABETOLOGIA, V57, P1528, DOI 10.1007/s00125-014-3270-4
   Herder C, 2011, EUR J CLIN INVEST, V41, P679, DOI 10.1111/j.1365-2362.2010.02454.x
   Jeon JP, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-426
   Kato N, 2013, J DIABETES INVEST, V4, P233, DOI 10.1111/jdi.12067
   Lee HS, 2014, GENOMICS, V104, P113, DOI 10.1016/j.ygeno.2014.05.004
   MacDonald JR, 2014, NUCLEIC ACIDS RES, V42, pD986, DOI 10.1093/nar/gkt958
   Meigs JB, 2000, DIABETES, V49, P2201, DOI 10.2337/diabetes.49.12.2201
   Morris AP, 2012, NAT GENET, V44, P981, DOI 10.1038/ng.2383
   Murea Mariana, 2012, Rev Diabet Stud, V9, P6, DOI 10.1900/RDS.2012.9.6
   Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008
   Pinto D, 2011, NAT BIOTECHNOL, V29, P512, DOI 10.1038/nbt.1852
   Plengvidhya N, 2012, GENE, V506, P383, DOI 10.1016/j.gene.2012.06.094
   Price TS, 2005, NUCLEIC ACIDS RES, V33, P3455, DOI 10.1093/nar/gki643
   Pundir S, 2017, METHODS MOL BIOL, V1558, P41, DOI 10.1007/978-1-4939-6783-4_2
   Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Sanghera DK, 2012, J DIABETES METAB, V3, DOI 10.4172/2155-6156.1000198
   Sedova L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152708
   Slattery ML, 2011, MUTAT RES-FUND MOL M, V706, P13, DOI 10.1016/j.mrfmmm.2010.10.005
   Smushkin G, 2010, CURR OPIN CLIN NUTR, V13, P471, DOI 10.1097/MCO.0b013e32833a558d
   Tews D, 2014, MOL CELL ENDOCRINOL, V395, P41, DOI 10.1016/j.mce.2014.07.011
   Tyner C, 2017, NUCLEIC ACIDS RES, V45, pD626, DOI 10.1093/nar/gkw1134
   Wang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092504
   World Health Organization, 1999, DEF DIAGN CLASS DI 1
   Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157
   Zhao XN, 2013, P NATL ACAD SCI USA, V110, P11023, DOI 10.1073/pnas.1217727110
NR 37
TC 0
Z9 0
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 4
BP 1143
EP 1149
DI 10.19193/0393-6384_2018_4_176
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ1AT
UT WOS:000434986500039
DA 2022-07-14
ER

PT J
AU Zhang, ZS
   Shen, YM
AF Zhang, Zhishang
   Shen, Yumei
TI EFFECTS OF VARIABLE VELOCITY AND RESISTANCE MUSCLE STRENGTH TRAINING
   EXERCISE WITH SODIUM HYALURONATE ON REHABILITATION EFFICACY OFPATIENTS
   WITH KNEE OSTEOARTHRITIS CAUSED BY TENNIS TRAINING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Variable velocity and resistance muscle strength training exercise;
   Sodium hyaluronate; Knee osteoarthritis; Rehabilitation efficacy
AB Objective: This study was to investigate the effects of variable velocity and resistance muscle strength training exercise with sodium hyaluronate onrehabilitation efficacy ofpatients with knee osteoarthritis caused by tennis training.
   Methods: The total of 1200 knee osteoarthritis patients caused by tennis training were divided equally into three groups: the observation group (variable velocity and resistance muscle strength training exercise with sodium hyaluronatetherapy), the control group (merely sodium hyaluronate injection therapy), and the physiotherapy group (paraffinotherapy, drug-iontophoresis with pulse magnetic fieldand high frequency electro microwave therapy). The efficacies of three groups were then compared.
   Results: The pain of the knee joint, the function of knee joint and low-limb muscle force were clearly improved in all three groups after the treatment for5 weeks. There was a remarkable difference between among three groups as comparedto the the data before the treatment (P < 0.05). Efficacy in the observation group was significantly better than that of the control group and the physiotherapy groupwithstatistical significance in the inter-group difference (P < 0.05).
   Conclusions: The therapy withvariable velocity and resistance muscle strength training exercise and the aid ofsodium hyaluronate reveals a fairly good effect on knee osteoarthritis caused by tennis training, which is worthy forwide application and promotion in the future.
C1 [Zhang, Zhishang] Guangdong Med Univ, Dongguan 523808, Peoples R China.
   [Shen, Yumei] Dongguan Polytech, Dongguan 523808, Peoples R China.
RP Shen, YM (corresponding author), Dongguan Polytech, Dongguan 523808, Peoples R China.
FU Research project of Guangdong Sports Bureau of Practical reserarch on
   functional training of competitive tennis in Guangding Province
   [GDSS2016110]
FX Research project of Guangdong Sports Bureau of 2016-2017- Practical
   reserarch on functional training of competitive tennis in Guangding
   Province (No. GDSS2016110)
CR Al-Sadoon MK, 2016, SAUDI J BIOL SCI, V23, P135, DOI 10.1016/j.sjbs.2015.10.010
   Alanazi K, 2016, SAUDI J BIOL SCI, V23, P87, DOI 10.1016/j.sjbs.2015.09.008
   Balkhair KS, 2016, SAUDI J BIOL SCI, V23, pS83, DOI 10.1016/j.sjbs.2015.10.029
   Chen GM, 2016, SAUDI PHARM J, V24, P250, DOI 10.1016/j.jsps.2016.04.008
   Dai Yongli, 2012, J BENGBU MED COLL, V37, P33
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   Jiang Jian, 2011, ACTA ACAD MED, V31, P175
   [蒋涛 Jiang Tao], 2012, [中国全科医学, Chinese General Practice], V15, P1278
   Kocak MZ, 2017, BIOMED RES-INDIA, V28, P3009
   Kumar R, 2016, SAUDI J BIOL SCI, V23, P243, DOI 10.1016/j.sjbs.2015.03.006
   Li Tao, 2014, ACAD J GUANGZHOU MED, V17, P151
   Ma QZ, 2008, PROCEEDINGS OF 2008 CONFERENCE ON REGIONAL ECONOMY AND SUSTAINABLE DEVELOPMENT, P955
   Shiri F, 2016, SAUDI PHARM J, V24, P197, DOI 10.1016/j.jsps.2015.03.012
   Xu Yi, 2014, J YANGTZE U NATURAL, V11, P5
   Youssef AM, 2017, ARAB J CHEM, V10, P631, DOI 10.1016/j.arabjc.2015.02.017
   Zhu YC, 2016, PAK J PHARM SCI, V29, P2363
NR 16
TC 0
Z9 0
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 249
EP 253
DI 10.19193/0393-6384_2018_1s_41
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100006
DA 2022-07-14
ER

PT J
AU Zhao, XT
   Cheng, C
   Bian, C
   Zhao, X
AF Zhao, Xi-Tong
   Cheng, Chu
   Bian, Ce
   Zhao, Xia
TI A META-ANALYSIS OF THE RELATIONSHIP BETWEEN PROTEIN EXPRESSION OF
   HEDGEHOG SIGNALING PATHWAY AND INFECTION OF HUMAN PAPILLOMAVIRUS TYPE 16
   IN CERVICAL CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hedgehog; Human papillomavirus type 16; Cervical cancer; Meta-analysis
AB Objective: To systematically estimate the relationship between protein expression of Hedgehog (Hh) signaling pathway and human papillomavirus type 16 (HPV16) infection in cervical cancer.
   Methods: Literature published from 2001 to date on the relationship between protein expression of Hh signaling pathway and HPV16 infection in cervical cancer was retrieved from databases such as PubMed, Embase, Medline, CNKI and Wanfang. The data were screened and collated independently by two evaluators. Thereafter, the data were subjected to meta-analysis using RevMan5.2 analysis software after the evaluation of risk of bias.
   Results: Ten published works were included in this study. These consisted of 520 cases of cervical intra-epithelial neoplasia (CIN) and 642 cases of cervical carcinoma (CC). The meta-analysis showed that in the Hh signaling pathway, the expression of sonic hedgehog (Shh) protein in CC group was significantly higher than that in CIN group (OR = 0.22; 95 % CI = 0.16, 0.31; P < 0.00001); the positive expression of HPV16 in CC group was higher than that in CIN group (OR = 0.26; 95 % CI: 0.16, 0.43; P < 0.00001), and the positive expression of Shh protein in HPV16 positive group was higher than that in HPV16 negative group (OR = 4.95; 95 % CI: 2.34, 10.43; P < 0.00001).
   Conclusion: The protein expression of Hh signaling pathway is enhanced in cervical cancer and is positively correlated with HPV16 infection.
C1 [Zhao, Xi-Tong; Cheng, Chu; Bian, Ce; Zhao, Xia] West China Second Hosp, Dept Gynecol & Obstet, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu 610041, Sichuan, Peoples R China.
RP Zhao, X (corresponding author), West China Second Hosp, Dept Gynecol & Obstet, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu 610041, Sichuan, Peoples R China.
EM ft1329@163.com
CR [程鹏 Cheng Peng], 2015, [中华医院感染学杂志, Chinese Journal of Nosocomiology], V25, P3307
   Cuzick J, 2000, BRIT J CANCER, V82, P1348, DOI 10.1054/bjoc.1999.1103
   Fan XF, 2013, J MED RES, V42, P146
   Hammer A, 2016, INT J CANCER, V138, P2795, DOI 10.1002/ijc.29959
   Hu XL, 2016, J MED RES, V10, P19
   Jiang M, 2016, IMHGN, V22, P329
   Li HS, 2013, CHIN J GERONTOL, V4, P1836
   Lv DF, 2016, CHIN J HLTH LAB TECH, V26, P78
   Nan J, 2016, Zhonghua Liu Xing Bing Xue Za Zhi, V37, P852, DOI 10.3760/cma.j.issn.0254-6450.2016.06.022
   Samarzija I, 2012, BIOCHEM BIOPH RES CO, V425, P64, DOI 10.1016/j.bbrc.2012.07.051
   Skinner SR, 2016, EXPERT REV VACCINES, V15, P367, DOI 10.1586/14760584.2016.1124763
   Tie WW, 2017, CHIN MOD DOCTOR, V55, P66
   Vishnoi K, 2016, SCI REP-UK, V6, DOI 10.1038/srep34377
   Wang Y, 2006, NINGXIA MED J, V28, P883
   Wei MX, 2016, CHIN J CANC PREV TRE, V23, P198
   Xuan Yan-hua, 2009, Chinese Journal of Pathology, V38, P178, DOI 10.3760/cma.j.issn.0529-5807.2009.03.010
   Yang N, 2016, P CLIN MED, V253, P168
   ZHU Fang-pci, 2016, MODERN ONCOLOGY, V24, P149
   Zhu MY, 2015, CHIN J REPROD, V26, P518
NR 19
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1441
EP 1445
DI 10.19193/0393-6384_2018_5_219
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700041
DA 2022-07-14
ER

PT J
AU Zhu, HJ
   Ding, XM
   Xu, J
   Su, H
   Yan, J
AF Zhu, Hongjun
   Ding, Xiaomei
   Xu, Jian
   Su, Hao
   Yan, Ji
TI CORRELATION BETWEEN FRAGMENTED QRS COMPLEXES AND REPERFUSION AFTER ACUTE
   ST-ELEVATION MYOCARDIAL INFARCTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Fragmented QRS complexes; ST-elevation myocardial infarction;
   Percutaneous coronary intervention
ID CORONARY INTERVENTION; MORTALITY; PROGNOSIS
AB Objective: This study aimed to assess the correlation between fragmented QRS (fQRS) and myocardial reperfusion, and to explore the application value of fQRS in evaluating myocardial perfusion.
   Method: A total of 122 patients with acute ST-elevation myocardial infarction (STEMI) who received emergency percutaneous coronary intervention (PCI) were included. fQRS analysis was performed using 12-lead surface electrocardiogram (ECG) on the next day after surgery. Those results were combined with TIMI flow grade and TIMI myocardial perfusion (TMP) scoring for the infarcted artery immediately after PCI. Ultrasonic cardiogram (UCG) was performed one week after surgery.
   Results: Based on the results of surface ECG, fQRS was more frequent among patients with lower TMP scores. Compared with patients without fQRS, thrombolysis in myocardial infarction (TIMI) scores and ejection fraction (EF) of the coronary artery decreased significantly in patients with fQRS (P<0.05). Correlation analysis indicated that fQRS was negatively correlated with EF of the left ventricle; TMP scores and good myocardial reperfusion was negatively correlated with fQRS.
   Conclusion: fQRS is closely associated with myocardial ischemia in patients with acute myocardial infarction, and can be used as a simple and non-invasive method for the evaluation of myocardial reperfusion.
C1 [Zhu, Hongjun; Ding, Xiaomei; Xu, Jian; Su, Hao; Yan, Ji] Anhui Med Univ, Dept Cardiovasc Internal Med, Anhui Prov Hosp, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China.
RP Ding, XM (corresponding author), Anhui Med Univ, Dept Cardiovasc Internal Med, Anhui Prov Hosp, 17 Lujiang Rd, Hefei 230001, Anhui, Peoples R China.
EM dingxiaomei-1209@163.com
FU Foundation from the health department of Anhui province [1501ld04017]
FX This work was funded by a Foundation from the health department of Anhui
   province (No: 1501ld04017)
CR Akgul O, 2015, ANN NONINVAS ELECTRO, V20, P263, DOI 10.1111/anec.12179
   Basar N, 2011, J INVEST MED, V59, P931, DOI 10.2310/JIM.0b013e318214ebaf
   Bozbeyoglu E, 2016, ANN NONINVAS ELECTRO, V21, P352, DOI 10.1111/anec.12314
   Das MK, 2006, CIRCULATION, V113, P2495, DOI 10.1161/CIRCULATIONAHA.105.595892
   Das MK, 2008, CIRC-ARRHYTHMIA ELEC, V1, P258, DOI 10.1161/CIRCEP.107.763284
   Eyuboglu M, 2016, ARQ BRAS CARDIOL, V107, P299, DOI 10.5935/abc.20160139
   Gong BJ, 2016, ANN NONINVAS ELECTRO, V21, P404, DOI 10.1111/anec.12325
   Karabulut A, 2012, CORONARY ARTERY DIS, V23, P68, DOI 10.1097/MCA.0b013e32834f1188
   Li M, 2016, CHINESE MED J-PEKING, V129, P518, DOI 10.4103/0366-6999.176989
NR 9
TC 1
Z9 1
U1 1
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 781
EP 784
DI 10.19193/0393-6384_2018_3_119
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000024
DA 2022-07-14
ER

PT J
AU Zhu, JT
   Chen, JL
   Tang, QX
   Cai, B
AF Zhu, Jiting
   Chen, Jianglong
   Tang, Qingxi
   Cai, Bin
TI FREQUENTLY RECURRENT CEREBRAL INFARCTION AND TROUSSEAU'S SYNDROME
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Recurrent stroke; Colon cancer; Cancer hypercoagulability; Treatment
ID CANCER; STROKE
AB Introduction: Trousseau's syndrome is a well-known malignancy-associated hypercoagulative state, leading to venous or arterial thrombosis. Stroke may be the first manifestation of the syndrome.
   Materials and methods: We report a 72-year-old Chinese male developed recurrent cerebral infarction with four events in one month, despite therapy with three kinds of antithrombotics and atorvastatin. Brain magnetic resonance imagine (MRI) showed progressive multiple infarcts, involving the anterior and posterior circulation in two hemispheres of the brain. A whole body positron emission tomography-computed tomography (PET-CT) showed sigmoid carcinoma and tumor metastasis. He was finally diagnosised with sigmoid carcinoma and Trousseau syndrome. Similar medical literatures are reviewed.
   Results: Ischemic stroke is a common brain lesion in patients with cancer and occasionally is its initial presentation. The widely accepted etiology is related to hypercoagulability though multiple mechanisms are believed to be involved. Elevated plasma levels of D-dimmer have been found in some cancer-related stroke but not all. Low-molecular-weight heparin is considered to be the first-choice agent for controlling thrombosis associated with Trousseau syndrome. Controling over the cancer may help to control the thrombosis.
   Conclusion: Malignancy should be paid more attention in cryptogenic stroke, particularly in cases of frequently recurrent cerebral infarction. The case of frequent recurrence of cerebral infarction in trousseau has rarely been reported.
C1 [Zhu, Jiting; Tang, Qingxi; Cai, Bin] Fujian Med Univ, Affiliated Hosp 1, Dept Neurol, 20 Chazhong Rd, Fuzhou 350005, Fujian, Peoples R China.
   [Zhu, Jiting; Tang, Qingxi; Cai, Bin] Fujian Med Univ, Affiliated Hosp 1, Inst Neurol, 20 Chazhong Rd, Fuzhou 350005, Fujian, Peoples R China.
   [Chen, Jianglong] Jinjiang City Hosp Tradit Chinese Med, Dept Neurol, Quanzhou, Fujian, Peoples R China.
RP Cai, B (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Dept Neurol, 20 Chazhong Rd, Fuzhou 350005, Fujian, Peoples R China.; Cai, B (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Inst Neurol, 20 Chazhong Rd, Fuzhou 350005, Fujian, Peoples R China.
EM caibin@fjmu.edu.cn
FU Natural Science Foundation of China [81171114, 81571133]; Fujian
   Provincial Medical Project for Middle-aged and Young Talents
   [2014-ZQN-ZD-18]; Fujian Provincial Natural Science Foundation
   [2015J01392]
FX This work was partly supported by grant No. 81171114 (BC), 81571133 (BC)
   of Natural Science Foundation of China, grant No. 2014-ZQN-ZD-18 (BC) of
   Fujian Provincial Medical Project for Middle-aged and Young Talents, and
   grant No. 2015J01392 (BC) of Fujian Provincial Natural Science
   Foundation.
CR el-Shami K, 2007, ONCOLOGIST, V12, P518, DOI 10.1634/theoncologist.12-5-518
   GRAUS F, 1985, MEDICINE, V64, P16, DOI 10.1097/00005792-198501000-00002
   Guo YJ, 2014, J STROKE CEREBROVASC, V23, pE249, DOI 10.1016/j.jstrokecerebrovasdis.2013.10.022
   KAKKAR AK, 1995, BRIT J SURG, V82, P1101, DOI 10.1002/bjs.1800820831
   Kim Suk Jae, 2012, PLOS ONE, V7
   Masubuchi H, 2015, RESPIR MED CASE REP, V15, P101, DOI 10.1016/j.rmcr.2015.05.001
   Schwarzbach CJ, 2012, STROKE, V43, P3029, DOI 10.1161/STROKEAHA.112.658625
   Tripodi A, 2011, CLIN CHEM, V57, P1256, DOI 10.1373/clinchem.2011.166249
   Trousseau A., 1865, LECT CLIN MED, V94, P654
   Uchiyama S., 2005, JAP J STROKE, V27, P547
   Umehara F., 2006, JAP J STROKE, V28, P306
NR 11
TC 0
Z9 0
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1727
EP 1729
DI 10.19193/0393-6384_2018_6_264
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400015
DA 2022-07-14
ER

PT J
AU Zhu, Q
   Ma, JD
   Dong, X
   Zhang, L
AF Zhu, Qiao
   Ma, Jiede
   Dong, Xian
   Zhang, Lei
TI THE PROTECTIVE EFFECT OF THE COMBINATION OF XIAOXIANXIONG DECOCTION AND
   GUIZHI FULING PILLS ON RAT VASCULAR ENDOTHELIUM POST-MYOCARDIAL
   INFARCTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Xiaoxianxiong decoction; Guizhi Fuling Pills; Myocardial infarction;
   serum lipid; endothelium function
ID ACUTE MYOCARDIAL-INFARCTION; TRADITIONAL CHINESE MEDICINE;
   CARDIOVASCULAR-DISEASE; RISK
AB The study aims to explore the potential benefit of Traditional Chinese Medicines on myocardial infarction in well-established rat model. The myocardial infarction rat was established by ligating the left anterior descending coronary arteries. The infarction was evaluated by TTC staining. Traditional Chinese Medicines Xiaoxianxiong decoction and Guizhi Fuling Pills were administrated by gavage. The left ventricular ejection fraction (LVEF) was monitored at week 2, 4 by M-Mode Sonography. The total cholesterol and triglyceride in serum were measured by biochemical auto-analyzer. The change in serous content of C-Reactive Protein (CRP), Homocysteine (Hcy), nitric oxide (NO), endothelin (ET) were determined by ELISA and endothelial nitric oxide synthase (NOS) in myocardial tissue were detected by Western Blot. We found that treatment with the combination of Xiaoxianxiong decoction and Guizhi Fuling Pills could increase the expression level of myocardial eNOS and serous NO concentration, lower the level of CRP, Hcy and ET simultaneously. A significant protective effect was observed in endothelial injury and myocardial infarction. Our results suggested combinational treatment with Xiaoxianxiong decoction and Guizhi Fuling Pills might conserve the vascular endothelium function by promotion the release of relaxing factors, inhibition of the release of contracting factors and reduction of coronary spasm and contraction.
C1 [Zhu, Qiao; Zhang, Lei] Yantai Hosp Tradit Chinese Med, Dept Cardiol, 39 Xingfu Rd, Yantai 264013, Shandong, Peoples R China.
   [Ma, Jiede; Dong, Xian] Yantai Hosp Tradit Chinese Med, Dept Heart Dis, Yantai, Shandong, Peoples R China.
RP Zhang, L (corresponding author), Yantai Hosp Tradit Chinese Med, Dept Cardiol, 39 Xingfu Rd, Yantai 264013, Shandong, Peoples R China.
EM zhanglei19811981@163.com
CR Abrams Jonathan, 1996, American Journal of Cardiology, V77, p31C, DOI 10.1016/S0002-9149(96)00186-5
   Al-Azzam SI, 2012, ACTA CARDIOL, V67, P445, DOI 10.1080/AC.67.4.2170686
   [Anonymous], 2008, Harv Heart Lett, V18, P6
   Armitage JM, 2010, JAMA-J AM MED ASSOC, V303, P2486, DOI 10.1001/jama.2010.840
   Bhatraju P, 2015, NITRIC OXIDE-BIOL CH, V50, P114, DOI 10.1016/j.niox.2015.08.007
   Cavallari Ilaria, 2017, Interv Cardiol Clin, V6, P119, DOI 10.1016/j.iccl.2016.08.008
   Chen LL, 2017, CARDIOVASC DRUG THER, V31, P9, DOI 10.1007/s10557-016-6704-z
   Dong-mei X, 2013, INT J CLIN PRACT, V67, P1254, DOI 10.1111/ijcp.12172
   Erdmann J, 2013, NATURE, V504, P432, DOI 10.1038/nature12722
   Frangogiannis NG, 2012, CARDIOVASC RES, V96, P4, DOI 10.1093/cvr/cvs265
   Gaeta R, 2014, LANCET, V383, P410, DOI 10.1016/S0140-6736(14)60148-3
   Gao E, 2010, CIRC RES, V107, P1445, DOI 10.1161/CIRCRESAHA.110.223925
   HOLMBOM B, 1993, HISTOCHEMISTRY, V99, P265, DOI 10.1007/BF00269099
   Ke Zhi-peng, 2015, Zhongguo Zhong Yao Za Zhi, V40, P999
   Kolettis TM, 2013, CARDIOL REV, V21, P249, DOI 10.1097/CRD.0b013e318283f65a
   Mehta PK, 2015, TRENDS CARDIOVAS MED, V25, P140, DOI 10.1016/j.tcm.2014.10.005
   Moran AE, 2014, GLOB HEART, V9, P3, DOI 10.1016/j.gheart.2014.03.1220
   Normile D, 2003, SCIENCE, V299, P188, DOI 10.1126/science.299.5604.188
   O'Donnell CJ, 2011, NEW ENGL J MED, V365, P2098, DOI 10.1056/NEJMra1105239
   Oliver MF, 2014, LANCET, V383, P409, DOI 10.1016/S0140-6736(14)60147-1
   RAPAPORT E, 1979, CIRCULATION, V59, P607
   Reddy K, 2015, WORLD J CARDIOL, V7, P243, DOI 10.4330/wjc.v7.i5.243
   Reed GW, 2017, LANCET, V389, P197, DOI 10.1016/S0140-6736(16)30677-8
   Rogers EJ, 2011, LANCET, V377, P2175, DOI 10.1016/S0140-6736(11)60952-5
   White HD, 2008, LANCET, V372, P570, DOI 10.1016/S0140-6736(08)61237-4
   Wu Y., 2011, JOVE-J VIS EXP, V48, pe2464
   Zhang Zhen-zhen, 2015, Zhongguo Zhong Yao Za Zhi, V40, P993
NR 27
TC 1
Z9 1
U1 5
U2 14
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 3
BP 765
EP 771
DI 10.19193/0393-6384_2018_3_117
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GJ0YH
UT WOS:000434980000022
DA 2022-07-14
ER

PT J
AU Zhu, YN
   Jin, JY
   Li, B
   Sun, W
   Zhang, DH
   Zhang, XH
AF Zhu, Yanan
   Jin, Jianying
   Li, Bing
   Sun, Wei
   Zhang, Dehua
   Zhang, Xianhuan
TI VALUE DISCUSSION ON THE APPLICATION OF CT AND ULTRASOUND IN THE
   QUANTITATIVE AND LOCALIZATION DIAGNOSIS OF BLUNT ABDOMINAL TRAUMA(BAT)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE CT; ultrasound; parenchymal organ injury; hollow organ injury;
   application value
ID VISCERAL INJURY; MANAGEMENT
AB Purpose: To investigate the diagnostic value of CT and ultrasound in BAT, and determine the sensitivity and specificity of the diagnosis of parenchymal organ injury(POI) and hollow organ injury(HOI).
   Methods: 82 patients with BAT who received surgical treatment between January 2012 and January 2016 were analyzed retrospectively. All patients had a complete CT and ultrasound results. Take the intraoperative findings and postoperative complications as clinical diagnostic criteria; they were divided into POI group and HOI group according to the site of injury. Then the sensitivity and specificity of two imaging methods on the diagnosis of POI and HOI were compared.
   Results: Among 82 patients with BAT, 81 were cured while one died, and the types of illness included gastrointestinal tract injury(27), liver damage(11), kidney damage(3), spleen injury(29), pancreatic injury(10), multiple organ damage(1) and bladder injury(1); 69 and 77 cases of BAT were clearly diagnosed by B-mode ultrasound and CT scan respectively while the accuracy rate was 84.15% and 93.90% separately. The difference of the two compared group was statistically significant (P < 0.05).
   The accuracy rate of B-mode ultrasound diagnosis of POI and HOI was 79.31% and 56.25%, respectively, while the accuracy rate of CT diagnosis of POI and HOI was 93.10% and 87.50%, respectively. The diagnostic accuracy of CT scan was significantly higher than B-mode ultrasound, the difference was statistically significant (P < 0.05).
   Conclusion: The diagnostic accuracy of CT scan was higher than B-mode ultrasound in the quantitative and localization diagnosis of BAT, For patients with stable vital signs, CT scan should be listed as the routine examination.
C1 [Zhu, Yanan; Jin, Jianying; Li, Bing; Sun, Wei; Zhang, Dehua; Zhang, Xianhuan] Taizhou Hosp, Emergency Dept, Taizhou 310003, Zhejiang, Peoples R China.
RP Jin, JY (corresponding author), Taizhou Hosp, Oncol, 150 Ximen Rd Linhai City, Taizhou 317000, Zhejiang, Peoples R China.
EM jiangyanh2014@126.com
CR Allen CJ, 2014, CURR SURG REP, V2, DOI 10.1007/s40137-014-0056-z
   [Anonymous], 2014, CARDIOVASCULAR ULTRA, V12, P1
   Dohan A, 2014, DIAGNOSTIC INTERVENT, V96, P187
   DuBose JJ, 2015, J TRAUMA ACUTE CARE, V78, P360, DOI 10.1097/TA.0000000000000521
   Fu C Y, 2014, INJURY, V46, P29
   Gun B, 2014, ULUS TRAVMA ACIL CER, V20, P376, DOI 10.5505/tjtes.2014.57639
   Hamid S, 2014, PAK J MED HEALTH SCI, V8, P959
   Hynick NH, 2014, J TRAUMA ACUTE CARE, V76, P95, DOI 10.1097/TA.0b013e3182ab0dfa
   Iqbal Yasmeen, 2014, J Ayub Med Coll Abbottabad, V26, P52
   Libo S, 2014, LECT NOTES ELECT ENG, V269, P3039
   Malbrain MLNG, 2014, ANAESTH INTENSIVE TH, V46, P406, DOI 10.5603/AIT.2014.0063
   Barragan-Campos HM, 2015, REV INVEST CLIN, V67, P140
   Marques EGSC, 2014, INT J BURNS TRAUMA, V4, P1
   Mushambi MC, 2015, ANAESTHESIA, V70, P1286, DOI 10.1111/anae.13260
   Patel KS, 2014, J COMMUNITY HOSP INT, V4, DOI 10.3402/jchimp.v4.23840
   Sahn B, 2014, J PEDIAT GASTROENTER, V60, P82
   Saremi F, 2015, AM J ROENTGENOL, V204, pW531, DOI 10.2214/AJR.14.13551
   Schreyer A G, 2015, GASTROINTESTINAL TRA, V188, P134
   Vadodariya K, 2015, PILAS, V22, P53
   Wu CY, 2015, WORLD J EMERG SURG, V10, DOI 10.1186/1749-7922-10-4
NR 20
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 5
BP 1337
EP 1343
DI 10.19193/0393-6384_2018_5_205
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GL3JV
UT WOS:000437030700027
DA 2022-07-14
ER

PT J
AU Zhuang, HR
   Wang, HJ
   Li, SQ
AF Zhuang, Huirong
   Wang, Huijuan
   Li, Shengqin
TI EFFECT OF PRE-HOSPITAL EMERGENCY CARE IN TREATMENT AND PROGNOSIS FOR THE
   PATIENTS WITH ACUTE BRAIN INJURY ASSOCIATED WITH COMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Pre-hospital emergency care; Patients with acute brain injury associated
   with coma; Treatment and cure; Prognosis
AB It discusses the clinical features of the patients with acute brain injury and coma, studies the therapeutic effect on pre-hospital emergency care and analyzed the effect of nursing measures on the prognosis of patients. In this paper 1,400 patients, who had suffered acute brain injury associated with coma, were randomly selected as research objects and divided into reference group(700 cases) and experimental group(700 cases). The reference group were adopted routine nursing measures, the other group were given pre-hospital emergency nursing plan. According to the research results, the treatment effect and time-consuming of the experimental group were better than the other one. The two groups have big differences. There has statistical significance which meet P<0.05. From the research results, we can see that the treatment for the patients who suffered acute brain injury with coma can be improved significantly in the processing combined with pre-hospital emergency nursing. At the same time, this can optimize the effect of prognosis and should be recommended for clinical application.
C1 [Zhuang, Huirong] Linyi Peoples Hosp, Operating Theatre East Med Dist, Linyi 276034, Peoples R China.
   [Wang, Huijuan] Linyi Peoples Hosp, Thorac Surg East Med Dist, Linyi 276034, Peoples R China.
   [Li, Shengqin] Linyi Peoples Hosp, Resp Med East Med Dist, Linyi 276034, Peoples R China.
RP Li, SQ (corresponding author), Linyi Peoples Hosp, Resp Med East Med Dist, Linyi 276034, Peoples R China.
EM 15053998569@163.com
CR Aldahlawi AM, 2016, SAUDI J BIOL SCI, V23, P101, DOI 10.1016/j.sjbs.2015.05.003
   Aldahmash A, 2017, SAUDI J BIOL SCI, V24, P857, DOI 10.1016/j.sjbs.2016.04.006
   Demir D, 2017, ACTA MEDICA MEDITERR, V33, P587, DOI 10.19193/0393-6384_2017_4_086
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   Hazra M, 2015, SAUDI PHARM J, V23, P429, DOI 10.1016/j.jsps.2015.01.007
   Hyun TK, 2016, SAUDI J BIOL SCI, V23, P181, DOI 10.1016/j.sjbs.2015.02.008
   Jing Qu, 2014, CHINESE FOREIGN MED, V17, P120
   Junwen Liang, 2014, J QIQIHAR MED COLL, V15, P2204
   Khyani IAM, 2017, PAK J PHARM SCI, V30, P817
   Moty SGA, 2016, SAUDI PHARM J, V24, P119, DOI 10.1016/j.jsps.2013.12.016
   Qian Liao, 2015, CHINESE J MED DEVICE, V11, P173
   Shahwar D, 2015, PAK J PHARM SCI, V28, P969
   Shen YF, 2017, POL MARIT RES, V24, P102, DOI 10.1515/pomr-2017-0111
   Shuhua Wei, 2015, HLTH PEOPLE, V24, P228
   Sun YC, 2014, BIORESOURCES, V9, P1055
   Tabrez S, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_143
   Xie YZ, 2018, SAUDI J BIOL SCI, V25, P234, DOI 10.1016/j.sjbs.2017.08.006
NR 17
TC 0
Z9 0
U1 1
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1919
EP 1922
DI 10.19193/0393-6384_2018_6_298
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400049
DA 2022-07-14
ER

PT J
AU Zhuang, X
   Yang, J
   Sun, LZ
AF Zhuang, Xin
   Yang, Jie
   Sun, Lingzhi
TI EFFECT OF ADD-SUBSTRACT OF GUIPI DECOCTION ON BLOOD PRESSURE PATIENT AND
   THE QUALITY OF LIFE UPON TREATMENT ON SENILE HYPERTENSION WITH
   DEPRESSION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE elderly hypertension with depression; addition and subtractation Guipi
   decoction; blood pressure improvement; quality of life
AB Objective: This paper aims to observe and analyze the effect of addition and subtraction ofGuipi decoction on blood pressure and the quality of life for hypertension elderly patients complicated with depression.
   Methods: Total of 120 elderly patients diagnosed with hypertension and depression were selected as the study subjects. According to different treatment regimens, the patients were randomly divided into two groups. The analysis of clinical trials involves observation and comparison between patients with addition and subtraction of Guipi Decoction (referred as study group) and reference group that received western drug therapy.
   Results: The scores of 17 Hamilton Depression Scale (HAMD17), Health Status Questionnaire (SF-36), Hamilton Anxiety Scale (HAMA) and Treatment Drug Side Effects Scale (TESS) were measured to evaluate therapeutic effect of the two groups. The results showed that the indicators of study group were significantly better than the reference group (P < 0.05). At the same time, changes of blood pressure before and after treatment were not significantly different between both the groups (P> 0.05). Nevertheless after treatment, study group showed more significant advantages (P> 0.05).
   Conclusion: Application of addition and subtraction ofGuipi decoction for the elderly patients with hypertension complicated with depression can give full play to curative effect, significantly improve the patients' blood pressure levels, while improving their quality of life by alleviating depression symptoms, so it is worthy of promotion in treatment.
C1 [Zhuang, Xin; Yang, Jie; Sun, Lingzhi] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan 250014, Shandong, Peoples R China.
RP Zhuang, X (corresponding author), Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan 250014, Shandong, Peoples R China.
EM zhuangxin1972@126.com
CR Cai Meiyun, TREATMENT LIVER QI S
   Dung DTM, 2017, ARAB J CHEM, V10, P465, DOI 10.1016/j.arabjc.2015.10.007
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P1370, DOI 10.1016/j.sjbs.2016.12.016
   Guo Jingyin, 2016, REVELATION HYPERTENS
   Haidar AM, 2016, SAUDI J BIOL SCI, V23, P293, DOI 10.1016/j.sjbs.2015.06.017
   Kumar R, 2016, SAUDI J BIOL SCI, V23, P243, DOI 10.1016/j.sjbs.2015.03.006
   Li Haicong, 2016, CHINES J INTEGRATED, V22, P172
   Li Qiubing, 2016, CHINA J TRAD CHIN ME, V10, P3076
   Lungu M, 2017, ACTA MEDICA MEDITERR, V33, P369, DOI 10.19193/0393-6384_2017_3_053
   Nidhi, 2016, SAUDI PHARM J, V24, P458, DOI 10.1016/j.jsps.2014.10.001
   Qin HP, 2016, SAUDI PHARM J, V24, P265, DOI 10.1016/j.jsps.2016.04.015
   Selim SA, 2016, SAUDI J BIOL SCI, V23, P282, DOI 10.1016/j.sjbs.2015.11.004
   Vinoth R, 2017, BIOMED RES-INDIA, V28, P3194
   Wang C, 2016, PAK J PHARM SCI, V29, P2151
   Zhang Zhifang, 2013, REVELATION HYPERTENS
NR 17
TC 1
Z9 1
U1 0
U2 17
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
SI 1
BP 273
EP 277
DI 10.19193/0393-6384_2018_1s_45
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AM
UT WOS:000424879100010
DA 2022-07-14
ER

PT J
AU Zou, YL
   Cao, JX
   Huang, YY
   He, J
   Liu, CT
   Zhang, P
   Li, QQ
AF Zou, Yongli
   Cao, Jixia
   Huang, Yuying
   He, Jia
   Liu, Chunting
   Zhang, Ping
   Li, Qingqing
TI ON BUILDING AN INFORMATION-BASED INFORMATION SEAT ARRANGEMENT SYSTEM FOR
   PEDIATRICS INFUSION CENTER THROUGH 6-SIGMA THEORY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE 6-sigma; pediatrics infusion center; nursing safety; information-based
AB Purpose: this paper intends to divide areas and make seat arrangements for child patient in the pediatrics infusion center, so as to satisfy patients' treatment demand with limit space as well as improve the infusion hall environment.
   Method: Our hospital's pediatrics infusion center has applied 6-sigma method into the information network to divide areas and make seat arrangements for child patient subject to vein treatment.
   Result: patients' treatment demands have been satisfied with limited space; meanwhile, dean and orderly environment has been obtained in the infusion center and nursing service procedures have been optimized.
   Conclusion: the information-based seat arrangement through 6-sigma method by the pediatrics infusion center is able to ease burden on nurse, improve diagnose and treatment environment, effectively guarantee patients' nursing safety, reduce occurrence rate of nursing dispute, and improve satisfactory from emergency patients, his/her relatives, and nurse.
C1 [Zou, Yongli; Huang, Yuying; He, Jia; Liu, Chunting; Zhang, Ping; Li, Qingqing] Guizhou Prov Peoples Hosp, Pediat Emergency Dept, Guiyang 550002, Guizhou, Peoples R China.
   [Cao, Jixia] Mil Transportat Univ, Mil Transportat Commanding Dept, Tianjin 300161, Peoples R China.
RP Huang, YY (corresponding author), Guizhou Prov Peoples Hosp, Pediat Emergency Dept, Guiyang 550002, Guizhou, Peoples R China.
FU Science and Technology Fund of Guizhou Province [2015LH7112]
FX This research was funded by the Science and Technology Fund of Guizhou
   Province (No. 2015LH7112).
CR [Anonymous], 2011, ROAD EXCELLENCE INT
   Bin Liu, 2013, CHINA HLTH INFORM MA
   Guangyao Chang, 2013, KEY TECHNOLOGY RES B
   Jinhua Gao, 2011, NAT AC VEIN INF TREA, V8, P191
   Xiaohong Xu, 2013, MODERN NURSE, Vsecond, P171
   Zou YL, 2016, ACTA MEDICA MEDITERR, V32, P1177
NR 6
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2018
VL 34
IS 6
BP 1847
EP 1850
DI 10.19193/0393-6384_2018_6_285
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GX5TR
UT WOS:000447814400036
DA 2022-07-14
ER

PT J
AU Afsar, CU
   Karabulut, M
   Karabulut, S
   Alis, H
   Binboga, S
   Bilgin, E
   Aykan, NF
AF Afsar, Cigdem Usul
   Karabulut, Mehmet
   Karabulut, Senem
   Alis, Halil
   Binboga, Sinan
   Bilgin, Elif
   Aykan, Nuri Faruk
TI CIRCULATING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1/CCL-2) AS A
   POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE MCP-1; CCL2; diagnostic; serum; pancreatic cancer
ID TUMOR-ASSOCIATED MACROPHAGES; CHEMOTACTIC PROTEIN-1; SERUM CCL2; CANCER;
   EXPRESSION; MCP-1; IMMUNOSUPPRESSION; CHEMOTHERAPY; COMBINATION; GROWTH
AB Introduction: Pancreatic cancer is a highly lethal malignancy. Chemokines may control the macrophage infiltrate found in many solid tumors. Monocyte chemoattractant protein-1 (MCP-1/CCL2) plays a key role in the recruitment and activation of monocytes during inflammation. MCP-1 is a small chemotactic protein that has been found in several kinds of tumor tissue samples and functions as a key regulator of cancer progression. This study was conducted to investigate the serum levels of MCP-1 in patients with pancreatic adenocarcinoma (PA) and the relationship with tumor progression and known prognostic parameters.
   Materials and methods: Thirty-five patients with PA were investigated. Serum samples were obtained on first admission before any treatment. Both serum MCP-1 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age and sex matched 32 healthy controls were included in the analysis.
   Results: The median age at diagnosis was 61 years, range 38-84 years; 21 patients were men. The tumor was located in the head of the pancreas in 24 (69%) patients. The most common metastatic site was liver in 20 patients with metastasis (n= 18, 90%). Forty-four percent of 18 metastatic patients who received palliative chemotherapy (CTx) were CTx-responsive. The median follow-up time was 24 weeks (range: 1-191 weeks). At the end of the observation period, twelve (34%) patients experienced disease progression and twenty-three patients (66%) were dead. Median progression-free survival and overall survival of the whole group were 13.7 +/- 2.3 weeks (95% confidence interval (CI) = 9-18 weeks) and 48.0 +/- 12.8 weeks (95% CI = 23-73 weeks), respectively. The baseline serum MCP-1 levels were significantly higher in patients with PA than in the control group (p=0.02). Moreover, serum MCP-1 levels were significantly higher in the patients with low albumin ant platelet levels (p=0.04 and p=0.05, respectively). However, serum MCP-1 assays had no prognostic roles on outcome.
   Conclusion: MCP-1 is an auspicious biomarker which plays a functional role in PA. Although serum levels of MCP-1 were found to have diagnostic value, no predictive and prognostic value was determined in PA patients.
C1 [Afsar, Cigdem Usul] Istanbul Educ & Res Hosp, Clin Med Oncol, Istanbul, Turkey.
   [Karabulut, Mehmet; Alis, Halil; Binboga, Sinan] Istanbul Bakirkoy Dr Sadi Konuk Educ & Res Hosp, Clin Gen Surg, Istanbul, Turkey.
   [Karabulut, Senem; Aykan, Nuri Faruk] Istanbul Univ, Inst Oncol, Dept Med Oncol, Istanbul, Turkey.
   [Bilgin, Elif] Istanbul Univ, Inst Oncol, Dept Basic Oncol, Istanbul, Turkey.
RP Afsar, CU (corresponding author), Istanbul Educ & Res Hosp, Kasap Ilyas Mah,Org Abdurrahman Nafiz Gurman Cad, Istanbul, Turkey.
RI karabulut, senem/AAT-3594-2020; Afsar, Cigdem Usul/C-3436-2015; Aykan,
   Nuri Faruk/I-6425-2019; Alis, Halil/AAJ-6721-2020; Afsar, Cigdem
   Usul/AAA-6103-2021; Doğru, Elif Bilgin/A-6543-2018
OI Afsar, Cigdem Usul/0000-0002-3764-7639; Aykan, Nuri
   Faruk/0000-0002-5472-3218; Afsar, Cigdem Usul/0000-0002-3764-7639;
   Doğru, Elif Bilgin/0000-0003-0077-7939
CR Broek IV, 2003, BRIT J CANCER, V88, P855, DOI 10.1038/sj.bjc.6600833
   BROWN Z, 1992, KIDNEY INT, V42, P95, DOI 10.1038/ki.1992.266
   CHENSUE SW, 1995, AM J PATHOL, V146, P130
   Christiansen T, 2005, INT J OBESITY, V29, P146, DOI 10.1038/sj.ijo.0802839
   Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175
   Conti I, 2004, SEMIN CANCER BIOL, V14, P149, DOI 10.1016/j.semcancer.2003.10.009
   CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Ding L, 2014, TUMOR BIOL, V35, P10539, DOI 10.1007/s13277-014-2306-1
   Flora G, 2005, EXP NEUROL, V191, P2, DOI 10.1016/j.expneurol.2004.06.007
   Flores-Villanueva PO, 2005, J EXP MED, V202, P1649, DOI 10.1084/jem.20050126
   Furukawa S, 2013, ANTICANCER RES, V33, P4785
   Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270
   Kamei N, 2006, J BIOL CHEM, V281, P26602, DOI 10.1074/jbc.M601284200
   Karpus WJ, 1997, J IMMUNOL, V158, P4129
   Koide N, 2004, AM J GASTROENTEROL, V99, P1667, DOI 10.1111/j.1572-0241.2004.30733.x
   Kudo-Saito C, 2013, CLIN EXP METASTAS, V30, P393, DOI 10.1007/s10585-012-9545-6
   LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8
   Long KB, 2016, CANCER DISCOV, V6, P400, DOI 10.1158/2159-8290.CD-15-1032
   Lu X, 2011, EUR J CANCER, V47, P339, DOI 10.1016/j.ejca.2010.09.025
   Lu Y, 2006, PROSTATE, V66, P1311, DOI 10.1002/pros.20464
   Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731
   Monti P, 2003, CANCER RES, V63, P7451
   NAKASHIMA E, 1995, PHARM RES-DORDR, V12, P1598, DOI 10.1023/A:1016276613684
   Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4
   Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928
   Sanford DE, 2013, CLIN CANCER RES, V19, P3404, DOI 10.1158/1078-0432.CCR-13-0525
   SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI [10.3322/caac.21254, 10.1001/jamaoto.2014.2530, 10.3322/caac.21208, 10.1136/bmj.g1502]
   STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912
   Sullivan J, 2011, J ONCOL, V2011, DOI 10.1155/2011/518394
   Szczepanik AM, 2015, POL ARCH MED WEWN, V125, P443, DOI 10.20452/pamw.2886
   Tas F, 2016, CANCER CHEMOTH PHARM, V77, P127, DOI 10.1007/s00280-015-2886-5
   Valkovic T, 2002, VIRCHOWS ARCH, V440, P583, DOI 10.1007/s004280100458
   Wang J, 2006, ONCOGENE, V25, P7201, DOI 10.1038/sj.onc.1209703
   Wu JH, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472-6890-13-15
NR 36
TC 2
Z9 2
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 501
EP 507
DI 10.19193/0393-6384_2017_3_075
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200023
DA 2022-07-14
ER

PT J
AU Ahmadabadi, F
   Barak, M
   Mashayekhi, A
   Zareakbari, M
   Jafari, N
   Najafi, N
AF Ahmadabadi, Farzad
   Barak, Manouchehr
   Mashayekhi, Afshin
   Zareakbari, Mahnaz
   Jafari, Narjes
   Najafi, Nahid
TI THE EFFECTIVENESS OF THE ORAL VITAMIN B6 ON THE BEHAVIORAL SIDE EFFECTS
   OF PHENOBARBITAL IN CHILDREN 2 TO 15 YEARS OLD WITH SEIZURES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE vitamin B6; phenobarbital; behavioral disorders; seizures
ID DOUBLE-BLIND; EPILEPSY; CROSSOVER
AB Objectives: Behavioral problems are considered as the side effects of phenobarbital consumption in children. Thus, the aim of this research is studying the effect of vitamin B6 on behavioral disorders due to use of phenobarbital in patients with seizure.
   Patients and methods: In this study, 77 patients (Children with Seizures) were studied and divided to needs to be removed two groups. Phenobarbital along with vitamin B6, and phenobarbital along with a placebo were separately prescribed to the two groups for three months, and behavioral changes were recorded and the data were collected and provided for the statistical software.
   Results: In the first three months, no significant difference was observed between the two groups, and in the second three months, the average value of hyperactivity behavior removed significantly decreased. In the drug group in the first three months and placebo group in the second three months, hyperactivity and aggressive behaviors significantly reduced moreover, With respect to all three behaviors, the placebo group in the first three months and drug group in the second three months the Were not significantly different.
   Conclusion: vitamin B6 can be effective in the reduction of hyperactivity behavior in the children.
C1 [Ahmadabadi, Farzad; Barak, Manouchehr; Zareakbari, Mahnaz] Ardabil Univ Med Sci, Ardebil, Iran.
   [Mashayekhi, Afshin] Istanbul Univ, Istanbul, Turkey.
   [Jafari, Narjes] Shahid Beheshti Univ Med Sci, Tehran, Iran.
   [Najafi, Nahid] Univ Tehran Med Sci, Tehran, Iran.
RP Zareakbari, M (corresponding author), Ardabil Univ Med Sci, Ardebil, Iran.
EM 507akbari@gmail.com
RI jafari, narjes/AAC-3521-2020; ahmadabadi, farzad/N-7930-2017
OI jafari, narjes/0000-0002-7423-3814; ahmadabadi,
   farzad/0000-0002-8738-4398; Barak, Manuchehr/0000-0003-2350-4829
FU Ardabil University of Medical Sciences
FX Authors also gratefully acknowledge the Ardabil University of Medical
   Sciences for the financial supports for this research.
CR BERNSTEIN AL, 1990, ANN NY ACAD SCI, V585, P250, DOI 10.1111/j.1749-6632.1990.tb28058.x
   Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z
   Conners CK, 1997, CONNERS RATING SCALE
   Daoud AS, 2002, EPILEPSIA, V43, P740, DOI 10.1046/j.1528-1157.2002.32501.x
   Datta SS, 2005, SEIZURE-EUR J EPILEP, V14, P190, DOI 10.1016/j.seizure.2005.01.007
   Davis G.P., 2009, BEHAV EFFECTS LEVETI
   Deuel R.K., 2000, ARCH NEUROL-CHICAGO, V57, P1377
   Dunn D.W., 1999, BEHAV ISSUES PEDIATR
   Feingold BF., 1975, WHY YOUR CHILD IS HY
   Gaby S.K., 1990, VITAMIN INTAKE HLTH
   Gelder M., 2006, SHORTER OXFORD TXB P
   ILOEJE SO, 1992, J TROP PEDIATRICS, V38, P235, DOI 10.1093/tropej/38.5.235
   Jennings M.T., 1995, ARCH NEUROL-CHICAGO, V52, P745
   Jones Tonia, 2007, Int J Med Sci, V4, P110
   Kalachnik J., 2001, NADD B, V4, P49
   Kelsey JL., 1996, METHODS OBSERVATIONA
   Larsson K, 2006, EUR J PAEDIATR NEURO, V10, P107, DOI 10.1016/j.ejpn.2006.02.005
   Lerman-Sagie T, 1999, J CHILD NEUROL, V14, P820, DOI 10.1177/088307389901401210
   Lerner V, 2007, J CLIN PSYCHIAT, V68, P1648, DOI 10.4088/JCP.v68n1103
   Leung Alexander K C, 2007, J Pediatr Health Care, V21, P250, DOI 10.1016/j.pedhc.2006.10.006
   Major P, 2008, EPILEPSY BEHAV, V13, P557, DOI 10.1016/j.yebeh.2008.07.004
   Masuko AH, 2003, ARQ NEURO-PSIQUIAT, V61, P897, DOI 10.1590/S0004-282X2003000600001
   Menkes JH, 2006, CHILD NEUROLOGY
   Millar J.S., 2006, AM FAMILY PHYS, V73
   Nelson WE., 2007, NELSON TXB PEDIAT, V18th
   Nimaga K, 2002, B WORLD HEALTH ORGAN, V80, P532
   Pal DK, 1998, LANCET, V351, P19, DOI 10.1016/S0140-6736(97)06250-8
   RIMLAND B, 1978, AM J PSYCHIAT, V135, P472, DOI 10.1176/ajp.135.4.472
   Shils ME, 2006, MODERN NUTR HLTH DIS
   Tong Y, 2014, INTRACTABLE RARE DIS, V3, P52, DOI 10.5582/irdr.2014.01005
   Zhang LL, 2011, EPILEPTIC DISORD, V13, P349, DOI 10.1684/epd.2011.0444
NR 31
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 895
EP 900
DI 10.19193/0393-6384_2017_6_142
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500001
DA 2022-07-14
ER

PT J
AU Ahmadi, M
AF Ahmadi, Maryan
TI DIMENSIONS AND ASSESSMENT METHODS OF DATA QUALITY IN HEALTH INFORMATION
   SYSTEMS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE data quality; information quality; dimension; health information system;
   assessment; evaluation
ID NATIONAL-CANCER-REGISTRY; CLINICAL-RESEARCH; PATIENT SAFETY; CARE;
   IMPROVEMENT; MANAGEMENT; FRAMEWORK; PROGRAM; SURGERY; CONTEXT
AB Introduction: Data quality in health information systems (HIS) plays a principal role in decision-making, planning, and rendering of needed knowledge of health care specialists. The purpose of this study was to identify the methods and dimensions of data quality assessment in the HIS.
   Method: A review of literature discussing data quality dimensions and assessment methodology for HIS was performed. The relevant publications were identified in major databases. Data quality dimensions and its assessment methods were extracted by using content analysis method.
   Results: The dimensions and methods of data were observed to be most frequently assessed. Among a total of 50 dimensions of data quality, 11 are categorized as the main dimensions. Completeness, timeliness, and accuracy were the three most-used dimensions and element presence, gold standard, and log review were the most-used methods for assessing these dimensions, respectively. The major quantitative assessment methods were descriptive surveys, whereas the main qualitative assessment methods were interview and documentation review.
   Conclusion: There is currently little consistency or potential generalizability in the dimensions and methods used to assess HIS data quality. Generally, qualitative and quantitative methods were used to assess data quality in the reviewed publications. Thus, because of the inconsistency in dimensions' definition and assessment methods, categorization of data quality dimensions in the format of the limited main dimensions and identification of its assessments methods seemed necessary.
C1 [Ahmadi, Maryan] Iran Univ Med Sci, Sch Hlth Management & Med Informat Sci, 6 Rashid Yasemi st,Vali e asr Ave, Tehran, Iran.
RP Ahmadi, M (corresponding author), Iran Univ Med Sci, Sch Hlth Management & Med Informat Sci, 6 Rashid Yasemi st,Vali e asr Ave, Tehran, Iran.
EM m_ahmadi24@yahoo.com
RI , maryam/AAP-6423-2021; Alipour, Jahanpour/J-9360-2017; alipour,
   jahanpour/Q-7958-2017
OI , maryam/0000-0003-0765-9556; Alipour, Jahanpour/0000-0002-8139-1140;
   alipour, jahanpour/0000-0002-8139-1140
FU Iran University of Medical Sciences
FX This study was funded by the Iran University of Medical Sciences.
CR Adeleke IT, 2012, J AM MED INFORM ASSN, V19, P1039, DOI 10.1136/amiajnl-2012-000823
   Ahmadi M., 2010, HAKIM RES J, V13, P185
   Almutiry O, 2013, IADIS INT C E SOC LI
   Almutiry O., 2013, INF SOC I SOC 2013 I
   Amiresmaili M, 2013, HEALTH INF MANAG J, V10, P3
   Anderson JG, 2006, INT J MED INFORM, V75, P809, DOI 10.1016/j.ijmedinf.2006.05.043
   Azizi A, 2011, HEALTH INF MANAG J, V8, P556
   Azizi A, 2011, SURVEY SATISFACTION, V8, P571
   Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847
   Batini Carlo, 2009, ACM Computing Surveys, V41, DOI 10.1145/1541880.1541883
   Batini C., 2006, DATA QUALITY CONCEPT
   Bray F, 2009, EUR J CANCER, V45, P747, DOI 10.1016/j.ejca.2008.11.032
   Bronnert June, 2012, J AHIMA, V83, P62
   Byrd JB, 2013, AM HEART J, V165, P434, DOI 10.1016/j.ahj.2012.12.009
   Byrd LW, 2013, SYST SCI HICSS 2013
   Chen H, 2014, INT J ENV RES PUB HE, V11, P5170, DOI 10.3390/ijerph110505170
   Cho KW, 2015, HEALTHC INFORM RES, V21, P43, DOI 10.4258/hir.2015.21.1.43
   Choi W, 2013, HEALTHC INFORM RES, V19, P110, DOI 10.4258/hir.2013.19.2.110
   Dentler K, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-32
   Dewan R, 2008, HAW INT C SYST SCI P
   Farahbakhsh M, 2008, HEALTH INF MANAG J, V5, P131
   Garrib A, 2008, SAMJ S AFR MED J, V98, P549
   Gattiker TF, 2005, MIS QUART, V29, P559
   Gimbel S, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-12
   Gong Y, 2015, SAF HLTH, V1, P7, DOI DOI 10.1186/2056-5917-1-7
   Hajavi A, 2006, J HLTH ADM, V9, P7
   Hendrickson BK, 2015, J PUBLIC HEALTH MAN, V21, P288, DOI 10.1097/PHH.0000000000000045
   Hewson-Conroy KM, 2012, ANAESTH INTENS CARE, V40, P675, DOI 10.1177/0310057X1204000414
   Igira F., 2008, J HLTH INFORM DEV CO, V2, P24
   Jebraeily M, 2015, J URMIA NURSING MIDW, V12, P982
   Kahn MG, 2012, MED CARE, V50, pS21, DOI 10.1097/MLR.0b013e318257dd67
   Kerr K., 2000, DEV DATA QUALITY FRA
   Koronios A, 2010, P 1 INT C E BUS INT
   Krzych LJ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-212
   Lean S, 2012, HLTH INF NZ C 7 9 NO
   Lee YW, 2002, INFORM MANAGE-AMSTER, V40, P133, DOI 10.1016/S0378-7206(02)00043-5
   Lippeveld T, 2000, DESIGN IMPLEMENTATIO
   Long J, 2001, P 6 INT C INF QUAL
   Mahdavi N., 2012, Iranian Journal of Epidemiology, V8, P1
   Michel-Verkerke MB, 2012, INT J MED INFORM, V81, P662, DOI 10.1016/j.ijmedinf.2012.07.006
   MOBASHERI M, 2014, LIFE SCI J, V11, P425
   Modirian M, 2014, ARCH IRAN MED, V17, P193, DOI 0141703/AIM.0010
   Mohammed SA, 2013, J EVAL CLIN PRACT, V19, P379, DOI 10.1111/j.1365-2753.2012.01839.x
   Moradi Lakeh M, 2006, IRANIAN J DIABETES L, V5, P377
   Ndira SP, 2008, METHOD INFORM MED, V47, P489, DOI 10.3414/ME0511
   Nelson RR, 2005, J MANAGE INFORM SYST, V21, P199, DOI 10.1080/07421222.2005.11045823
   Nennecke AL, 2009, ACTA ONCOL, V48, P34, DOI 10.1080/02841860802199808
   Nisingizwe MP, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25829
   Parkin DM, 2009, EUR J CANCER, V45, P756, DOI 10.1016/j.ejca.2008.11.033
   Pinto-Valverde JM, 2013, T INT C HLTH INF TEC, P198
   Pipino L, 2011, P 17 AM C INF SYST A
   Pipino L.L., 2002, COMMUN ACM, V45, P211, DOI [DOI 10.1145/505248.506010, 10.1145/505248.506010]
   Puttkammer N, 2015, ANN GLOB HEALTH, V81, P196, DOI DOI 10.1016/j.aogh.2015.02.952
   Redman TC, 1998, COMMUN ACM, V41, P79, DOI 10.1145/269012.269025
   Riain CO, 2005, IADIS VIRT MULT COMP
   Rodrigues J., 2009, HLTH INFORM SYSTEMS
   Rodriguez CCG, 2011, P 1 HLTH AMB INF SYS
   Rousseau MC, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-2
   Salati M, 2011, EUR J CARDIO-THORAC, V40, P91, DOI 10.1016/j.ejcts.2010.11.004
   Shahmoradi L, 2007, J HLTH ADM, V10, P15
   Shimakawa Y, 2013, INT J CANCER, V132, P658, DOI 10.1002/ijc.27646
   Shrivastava S, 2014, INT J HLTH SYSTEM DI, V2, P127, DOI [10.4103/2347-9019.139073, DOI 10.4103/2347-9019.139073]
   Stewart JC, 2001, HEALTH POLICY PLANN, V16, P248, DOI 10.1093/heapol/16.3.248
   Strong DM, 1997, COMMUN ACM, V40, P103, DOI 10.1145/253769.253804
   TEPERI J, 1993, J EPIDEMIOL COMMUN H, V47, P242, DOI 10.1136/jech.47.3.242
   Tierney WM, 2001, INT J MED INFORM, V62, P1, DOI 10.1016/S1386-5056(01)00127-7
   Tomic K, 2015, EUR J CANCER, V51, P101, DOI 10.1016/j.ejca.2014.10.025
   Toulabi T., 2012, CRITICAL CARE NURSIN, V5, P53
   Vafaee A, 2010, J RES HEALTH SCI, V10, P47
   Wager K, 2013, HLTH CARE INFORM SYS
   Wang R. Y., 1996, Journal of Management Information Systems, V12, P5
   Weiskopf NG, 2013, J AM MED INFORM ASSN, V20, P144, DOI 10.1136/amiajnl-2011-000681
   WHO,, 2008, TOOLK MON HLTH SYST
   Wong K, 2010, RADIOTHER ONCOL, V95, P339, DOI 10.1016/j.radonc.2010.03.015
   Zong W, 2017, ENTERP INF SYST-UK, V11, P434, DOI 10.1080/17517575.2015.1065513
NR 75
TC 9
Z9 9
U1 4
U2 36
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 313
EP 320
DI 10.19193/0393-6384_2017_2_047
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700022
DA 2022-07-14
ER

PT J
AU Ahmadi, MRH
   Javedani, M
   Ghiasi, B
   Ghavam, S
AF Ahmadi, Mohammad Reza Hafezi
   Javedani, Mojgan
   Ghiasi, Bahare
   Ghavam, Samiramis
TI INVESTIGATION OF THE RELATIONSHIP BETWEEN PHASE ANGLE AND
   MICRO-ALBUMINURIA IN TYPE 2 DIABETIC PATIENTS WITH A HISTORY OF MORE
   THAN 5 YEARS OF THE DISEASE IN ILAM PROVINCE, IRAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE phase angle; micro-albuminuria; diabetes; Ilam
AB Introduction: Phase angle is the ratio between cell mass and fat-free tissue and a cell health indicator which is measurable through bio-impedance analysis with 50 KHZ alternating current and can be interpreted as a voltage and a wave-form current. Diabetes mellitus contains a group of metabolic disorders that are in common in terms of appearance characteristic of hyperglycemia. Micro-albuminuria of urine albumin amounts 30-300mg/24h and the higher values are for diagnostic diabetic nephropathy. The aim of this study was to determine the relationship between Phase angle and micro-albuminuria in type 2 diabetic patients with a history of more than 5 years of the disease in the city of Ilam.
   Materials and methods: This is an analytical-practical case-control study and statistical society includes two case and control groups with an average age 52.06 +/- 6.69 years in case group and 50.02 +/- 5.42 years in the control group. The sample size in each group has been designated equal to 50 and data analysis is performed using SPSS and parametric and Non-parametric statistical methods and the related tests.
   Conclusion: The average Ph. A was obtained equal to 5.87 +/- 1.42 in the case group and 7.29 +/- 0.355 in the control group which statistically significant relationship exists between the two groups in Ph. A value (P<0.000). Average micro-albuminuria was 67.32 +/- 75.92 in the case group and 0.276 +/- 0.147 in the control group which there was a significant relationship statistically between the amount of micro-albuminuria within the both groups (P< 0.000).
   Discussion: By investigation of the relationship between ph. Angle and micro-albuminuria in diabetic patients it can be concluded that the amount Ph. A reduces with the increase of micro-albuminuria and by increasing micro-albuminuria, the variables of overall body water volume, intracellular water and extracellular water relatively increase and fat mass relatively decreases.
C1 [Ahmadi, Mohammad Reza Hafezi] Ilam Univ Med Sci, Dept Pathol, Ilam, Iran.
   [Javedani, Mojgan] Iran Univ Med Sci, Shahid Akbarabadi Hosp, Res & Clin Ctr Gynecol & Fertil, Tehran, Iran.
   [Ghiasi, Bahare] Ilam Univ Med Sci, Dept Nephrol, Ilam, Iran.
   [Ghavam, Samiramis] Ilam Univ Med Sci, Dept Cardiol, Ilam, Iran.
RP Ghavam, S (corresponding author), Ilam Univ Med Sci, Fac Med, Dept Cardiol, Ilam, Iran.
RI hafeziahmadi, mohammadreza/D-4095-2017; hafeziahmadi,
   mohammadreza/AHE-7465-2022
OI hafeziahmadi, mohammadreza/0000-0002-8085-9856; hafeziahmadi,
   mohammadreza/0000-0002-8085-9856
CR Abedi G, 2012, INT J COLLAB RES INT, V4, P103
   Futrakul N, 2009, RENAL FAILURE, V31, P140, DOI 10.1080/08860220802595948
   Han TS, 1998, DIABETIC MED, V15, P129, DOI 10.1002/(SICI)1096-9136(199802)15:2<129::AID-DIA535>3.3.CO;2-U
   Harrison, 2008, PRINCIPLES INTERNAL
   Kyle UG, 2001, NUTRITION, V17, P534, DOI 10.1016/S0899-9007(01)00555-X
   Maryam Ghaffari, ONLINE VERSION IRANI
   Shah S. N, 2007, J ASSOC PHYSICIAN I, V32, P1057
   Stolarczyk L M, 1999, Diabetes Technol Ther, V1, P289, DOI 10.1089/152091599317206
   Sugure D.D., 1999, POSTGRAD MED J, V58, P680, DOI [10.1136/pgmj.58.685.680, DOI 10.1136/PGMJ.58.685.680]
NR 9
TC 5
Z9 5
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 351
EP 357
DI 10.19193/0393-6384_2017_2_052
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700027
DA 2022-07-14
ER

PT J
AU Akhayeva, A
   Scosarev, I
   Gupenova, D
   Kengetaeva, T
   Moraru, D
   Pestre, ASA
   Chesca, A
   Toma, SI
AF Akhayeva, Ardak
   Scosarev, Ivan
   Gupenova, Dana
   Kengetaeva, Tattigul
   Moraru, Dan
   Pestre, Sorina Anamaria A.
   Chesca, Antonella
   Toma, Sebastian Ionut
TI COMPARATIVE ANALYSIS OF INFLAMMATORY BIOMARKERS IN THE DEVELOPMENT OF
   THE SEVERITY OF COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Inflammatory biomarkers; community-acquired pneumonia; children; IL-6;
   TNF-alpha; PCT
ID BACTERIAL; PROCALCITONIN
AB Objective: Conduct a comparative analysis of inflammatory biomarkers in the development of severity in community-acquired pneumonia
   Material and method: In a prospective cohort study under the supervision of 110 children at the age of 5 to 14 years, of them 90 children with community-acquired pneumonia and 20 children from the control group, undergoing treatment in the respiratory department of Children's Hospital of Karaganda, in which 43.64% were girls (95% CI 31.51% -56, 33%) and boys 57.27% (95% CI 34.91% - 59.88%). The diagnosis of pneumonia was verified on the basis of standards ICD - 10 (10th revision of the International Statistical Classification of Diseases) for diagnosis and treatment of pneumonia in children. General clinical examination was carried out in accordance with the protocols of examination of children with this pathology approved in the Republic of Kazakhstan, with the inclusion of: a bacteriological method of investigation, studies of TNF-alpha, IL-6 and PCT in serum by enzyme immunoassay.
   Statistical processing of the obtained results of the difference in quantitative traits marker concentrations was carried out using a nonparametric Mann-Whitney's U test
   Conclusion: The results of our study indicate that as the severity of pneumonia increases, the titers of pro-inflammatory cytokines and procalcitonin in the blood serum of patients increase. The results of the study in patients with bacterial and viral pneumonia, proinflammatory cytokines (TNF-alpha, IL-6) and procalcitonin can be used as predictors to predict the severity of pneumonia.
C1 [Akhayeva, Ardak; Gupenova, Dana; Kengetaeva, Tattigul] Karaganda State Med Univ, Karaganda, Kazakhstan.
   [Moraru, Dan; Chesca, Antonella] Transilvania Univ Brasov, Fac Med, Brasov, Romania.
   [Scosarev, Ivan] Clin Hosp Pneumophthisiol Brasov, Brasov, Romania.
   [Chesca, Antonella; Toma, Sebastian Ionut] Clin Hosp Psychiat & Neurol Brasov, Brasov, Romania.
RP Chesca, A (corresponding author), Transilvania Univ Brasov, Fac Med, Brasov, Romania.; Chesca, A (corresponding author), Clin Hosp Psychiat & Neurol Brasov, Brasov, Romania.
CR Don M, 2009, PEDIATR INT, V51, P91, DOI 10.1111/j.1442-200X.2008.02678.x
   Dubos F, 2008, ARCH PEDIAT ADOL MED, V162, P1157, DOI 10.1001/archpedi.162.12.1157
   Hoshina T, 2014, J INFECT CHEMOTHER, V20, P616, DOI 10.1016/j.jiac.2014.06.003
   Leroy S., 2010, EUR SOC PAED INF DIS
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Moulin F, 2001, ARCH DIS CHILD, V84, P332, DOI 10.1136/adc.84.4.332
   Qin Q, 2015, INDIAN J PEDIATR, V82, P745, DOI 10.1007/s12098-015-1785-4
NR 7
TC 0
Z9 0
U1 2
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1221
EP 1224
DI 10.19193/0393-6384_2017_2s_189
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700006
DA 2022-07-14
ER

PT J
AU Akil, F
   Ayral, M
   Yollu, U
   Toprak, SF
   Yilmaz, M
   Yener, HM
AF Akil, Ferit
   Ayral, Muhammed
   Yollu, Umur
   Toprak, Serdar Ferit
   Yilmaz, Mehmet
   Yener, H. Murat
TI SMOKING; AS A RISK AND PROGNOSTIC FACTOR FOR SUDDEN SENSORINEURAL
   HEARING LOSS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Sudden hearing loss; smoking; risk factors; prognosis; tinnitus
ID CARDIOVASCULAR RISK; EXPERIENCE; POPULATION; ETIOLOGY; STEROIDS
AB Introduction: Sudden sensorineural hearing loss is commonly defined as sudden hearing impairement of more than 30 dB across three contiguous frequencies in less than 3 days and affects an estimated 5 to 20 per 100,000 people in a year. About the effect of cigaratte smoking on treatment results of idiopathic sudden sensorineural hearing loss, although there are only a limited information in several studies, as it is found that there is no study to investigate effects of smoking in various frequencies in means of decibel difference. We specifically evaluated hearing loss in different frequencies by examining the differences pre and post therapy between smokers and non smokers. This study is thought to be a first in this field.
   Material and methods: This is a prospective study. Patients with pathology in magnetic resonance imaging, diagnosed vascular disease and diabetes mellitus, and patients over 65 years of age or under 18 years of age, patients who admitted to the hospital after 4 days and who received medical treatment before were excluded. Total of 72 patients were included in the study and divided into two groups as smokers and non-smokers. Whether patients had or didn't have vertigo, degree of tinnitus, audiogram characteristics, 250 Hz, 500 Hz, 1000 Hz, 4000 Hz, 8000 Hz hearing tresholds and pure tone averages were recorded before and after treatment.
   Results: No statistically significant difference found between groups in terms of age, sex differences, treatment start time, presence of vertigo and the degree of tinnitus. No significant between-group differences found in pre-treatment hearing tresholds, post-treatment hearing tresholds and hearing gains after treatment.
   Conclusion: The effect of the smoking on recovery for each different frequency of hearing tresholds was not studied before. According to our results we are sharing the opinion that says smoking is not a risk factor or prognostic factor for sudden hearing loss. This can also be said for each different frequencies of hearing treshold.
C1 [Akil, Ferit] Diyarbakir Selahaddin Eyyubi Publ Hosp, Otolaryngol Clin, Diyarbakir, Turkey.
   [Ayral, Muhammed; Toprak, Serdar Ferit] Diyarbakir Gazi Yasargil Educ & Res Hosp, Otolaryngol Dept, Diyarbakir, Turkey.
   [Yollu, Umur] Gumushane Publ Hosp, Otolaryngol Clin, Gumushane, Turkey.
   [Yilmaz, Mehmet; Yener, H. Murat] Istanbul Univ, Otolaryngol Dept, Cerrahpasa Med Fac, Istanbul, Turkey.
RP Yollu, U (corresponding author), Gumushane Devlet Hastanesi, KBB Poliklin, TR-29000 Merkez Gumushane, Turkey.
RI YILMAZ, Mehmet Birhan/Y-1372-2019; yener, murat/AAK-4605-2020
OI YILMAZ, Mehmet Birhan/0000-0002-8169-8628; yener, h
   murat/0000-0002-0932-2773; AKINER, Umur/0000-0002-4058-5707
CR Agarwal L, 2009, COCHRANE DB SYST REV, V4
   Aimoni C, 2010, AUDIOL NEURO-OTOL, V15, P111, DOI 10.1159/000231636
   Aksoy Songul, 2007, Int Tinnitus J, V13, P94
   Brors D, 2008, LARYNGO RHINO OTOL, V87, P400, DOI 10.1055/s-2007-995466
   BYL FM, 1984, LARYNGOSCOPE, V94, P647
   Cadoni G, 2005, J OTOLARYNGOL, V34, P395, DOI 10.2310/7070.2005.34606
   Cadoni G, 2004, ACTA OTO-LARYNGOL, V124, P608, DOI 10.1080/00016480410016216
   Dispenza F, 2013, AM J OTOLARYNG, V34, P296, DOI 10.1016/j.amjoto.2012.12.010
   Fitzgerald DC, 1998, AM J NEURORADIOL, V19, P1433
   Freund K M, 1993, Ann Epidemiol, V3, P417, DOI 10.1016/1047-2797(93)90070-K
   FRIEDRICH G, 1985, LARYNG RHINOL OTOL V, V64, P62, DOI 10.1055/s-2007-1008088
   Hughes GB, 1996, OTOLARYNG CLIN N AM, V29, P393
   JAMROZIK K, 1994, STROKE, V25, P51, DOI 10.1161/01.STR.25.1.51
   Lin RJ, 2012, LARYNGOSCOPE, V122, P624, DOI 10.1002/lary.22480
   Linke R, 1998, LARYNGO RHINO OTOL, V77, P48, DOI 10.1055/s-2007-996930
   MATSCHKE RG, 1991, ACTA OTO-LARYNGOL, P69
   MATTOX DE, 1977, ANN OTO RHINOL LARYN, V86, P463, DOI 10.1177/000348947708600406
   MATTOX DE, 1989, AM J OTOL, V10, P242
   Mosnier I, 2011, AUDIOL NEURO-OTOL, V16, P55, DOI 10.1159/000312640
   Nakamura M, 2001, J Epidemiol, V11, P81
   Nakashima Tsutomu, 1997, Auris Nasus Larynx, V24, P265, DOI 10.1016/S0385-8146(96)00024-7
   PREYER S, 1992, HNO, V40, P79
   Rudack C, 2006, THROMB HAEMOSTASIS, V95, P454, DOI 10.1160/TH05-08-0554
   Samim E, 2004, EUR ARCH OTO-RHINO-L, V261, P187, DOI 10.1007/s00405-003-0659-y
   SCHMOLKE B, 1990, HNO, V38, P440
   SIMMONS FB, 1973, LARYNGOSCOPE, V83, P1221, DOI 10.1288/00005537-197308000-00005
   Suckfull M, 1999, LARYNGO RHINO OTOL, V78, P4, DOI 10.1055/s-2007-996818
   Vakkalanka S, 2000, AM J OTOL, V21, P764
   WELLESCHIK B, 1987, HNO, V35, P119
   Weng TW, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-95
   WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772
NR 31
TC 0
Z9 0
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1093
EP 1098
DI 10.19193/0393-6384_2017_6_173
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500032
DA 2022-07-14
ER

PT J
AU Akisin, YA
   Karagoz, ZN
   Turan, M
   Akar, N
AF Akisin, Yasemin Ardicoglu
   Karagoz, Zeynep Nur
   Turan, Mustafa
   Akar, Nejat
TI THE ROLE OF PLATELET-TO-LYMPHOCYTE RATIO IN THE DIAGNOSIS OF INFECTIOUS
   MONONUCLEOSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Infectious Mononucleosis; Epstein-Barr Virus; Platelet; Lymphocyte
ID NEUTROPHIL
AB Introduction: We investigated the use of Platelet-to-Lymphocyte Ratio (PLR) which can be calculated by using platelet and lymphocyte counts from total blood count, for the diagnosis of infectious mononucleosis (IM).
   Materials and methods: Out of 116 patients, 24 of them were diagnosed as IM with regard to serological tests and accepted as patient group. 40 healthy subjects were taken as control group. PLR values of the patient and control groups were calculated and cutoff values were determined using ROC Curve analysis.
   Results: According to the study data, sensitivity and specificity of PLR value in diagnosing IM is 50% and 95%, respectively.
   Conclusion: We concluded that low values of PLR can be used to give an idea about the existence of IM. However, high values of PLR may necessitate more evaluation for other differential diagnosis.
C1 [Akisin, Yasemin Ardicoglu] TOBB ETU, Fac Med, Biochem, Ankara, Turkey.
   [Karagoz, Zeynep Nur] TOBB ETU, Fac Med, Ankara, Turkey.
   [Turan, Mustafa] TOBB ETU, Fac Med, Dept Med Educ, Ankara, Turkey.
   [Akar, Nejat] TOBB ETU, Fac Med, Dept Pediat, Ankara, Turkey.
RP Akisin, YA (corresponding author), TOBB ETU Hosp, Yasam Cad 5 Sogutozu, TR-06510 Ankara, Turkey.
RI Turan, Mustafa/AAD-1569-2022; Akar, Nejat/H-2949-2019; Turan,
   Mustafa/U-5499-2017
OI Turan, Mustafa/0000-0003-4782-8596
CR Akboga MK, 2015, ANGIOLOGY
   Aktar F, 2016, ITAL J PEDIATR, V42, DOI 10.1186/s13052-016-0211-5
   Alan S, 2015, KAOHSIUNG J MED SCI, V31, P626, DOI 10.1016/j.kjms.2015.10.010
   Bolis V, 2016, J PEDIAT-BRAZIL, V92, P113, DOI 10.1016/j.jped.2015.06.007
   Chung JH, 2015, LARYNGOSCOPE, V125, P257, DOI 10.1002/lary.25204
   Gayret OB, 2016, IRAN J PEDIATR, V26, DOI 10.5812/ijp.8191
   Kemal Y, 2014, ASIAN PAC J CANCER P, V15, P2651, DOI 10.7314/APJCP.2014.15.6.2651
   Kundi H, 2016, ANATOL J CARDIOL
   Langsenlehner T, 2015, UROLOGIC ONCOLOGY, DOI [10.1016/j.urolonc, DOI 10.1016/J.UROLONC]
   Valachis A, 2012, VIRUS ADAPT TREAT, V4, P23, DOI [10.2147/VAAT.S17837, DOI 10.2147/VAAT.S17837]
   You J., 2016, ONCOTARGET
   Zencir C, 2015, KAOHSIUNG J MED SCI, V31, P632, DOI 10.1016/j.kjms.2015.10.004
NR 12
TC 0
Z9 0
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1081
EP 1084
DI 10.19193/0393-6384_2017_6_171
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500030
DA 2022-07-14
ER

PT J
AU Akpinar, O
   Karakaya, Z
AF Akpinar, Onur
   Karakaya, Zeynep
TI PROGNOSTIC VALUE OF TROPONIN T IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN
   EMERGENCY DEPARTMENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Troponin T; Stroke; Emergency service
ID BRAIN NATRIURETIC PEPTIDE; MYOCARDIAL-INFARCTION; ELEVATED TROPONIN;
   RISK; MORTALITY
AB Introduction: It's well known that elevated troponin levels have prognostic value in stroke patients. Mostly these patients are old with concurrent cardiac and/or renal diseases. The aim of the present study was to evaluate elevated troponin levels in stroke patients who presented to Emergency Department (ED) with no known cardiac or renal diseases at time of admission.
   Materials and methods: This study group included 64 consecutive patients who were admitted to the ED with acute ischemic stroke. Patients with cardiac and/or renal disease history, severe bradyarrhythmia or tachyarrhythmia, atrial fibrillation and/or pathologic Q wave in electrocardiograph and high serum creatinine levels were excluded.
   Results: Of 64 patients, 11 had inconclusive troponin T levels above 0.014 ng/mL. Twelve patients died during the follow-up in hospital period. We have shown that patients who had high troponin T levels in ED had poor prognosis.
   Conclusions: In ED, high troponin T levels had effect on in-hospital mortality in stroke patients who did not have any known cardiac or renal problems.
C1 [Akpinar, Onur] Near East Univ, Dept Cardiol, Nicosia, Kktc, Cyprus.
   [Karakaya, Zeynep] Katip Celebi Univ, Izmir Ataturk Educ & Res Hosp, Emergency Med Serv, Izmir, Turkey.
RP Akpinar, O (corresponding author), Near East Univ, Fac Med, Dept Cardiol, Nicosia, Cyprus.
CR Aakre CA, 2014, STROKE, V45, P426, DOI 10.1161/STROKEAHA.113.002585
   Darki A, 2013, J STROKE CEREBROVASC, V22, P959, DOI 10.1016/j.jstrokecerebrovasdis.2011.12.004
   Dixit S, 2000, ARCH INTERN MED, V160, P3153, DOI 10.1001/archinte.160.20.3153
   Ertas F, 2013, TURK KARDIYOL DERN A, V41, P99, DOI 10.5543/tkda.2013.18488
   Etgen T, 2005, STROKE, V36, P270, DOI 10.1161/01.STR.0000151364.19066.a1
   Guo Xiaobi, 2006, Exp Clin Cardiol, V11, P298
   Hajdinjak E, 2012, J INT MED RES, V40, P768, DOI 10.1177/147323001204000243
   James P, 2000, BRIT MED J, V320, P1502, DOI 10.1136/bmj.320.7248.1502
   Jensen JK, 2007, AM J CARDIOL, V99, P867, DOI 10.1016/j.amjcard.2006.10.052
   Jensen JK, 2007, AM J CARDIOL, V99, P108, DOI 10.1016/j.amjcard.2006.07.071
   Kerr G, 2009, CEREBROVASC DIS, V28, P220, DOI 10.1159/000226773
   Mueller M, 2013, CIRC J, V77, P1653, DOI 10.1253/circj.CJ-13-0706
   NORRIS JW, 1979, STROKE, V10, P548, DOI 10.1161/01.STR.10.5.548
   Ralea IC, 2009, J STROKE CEREBROVASC, V18, P167, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.008
   Sandhu R, 2008, AM J CARDIOL, V102, P632, DOI 10.1016/j.amjcard.2008.04.036
   Twerenbold R, 2012, EUR HEART J, V33, P579, DOI 10.1093/eurheartj/ehr492
   Van de Graaff EV, 2006, STROKE, V37, P2546, DOI 10.1161/01.STR.0000240495.99425.0f
NR 17
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 757
EP 761
DI 10.19193/0393-6384_2017_5_111
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000005
DA 2022-07-14
ER

PT J
AU Aktas, T
   Aktas, F
   Ozmen, C
   Ozmen, Z
   Kaya, T
   Demir, O
AF Aktas, Turan
   Aktas, Fatma
   Ozmen, Cansel
   Ozmen, Zafer
   Kaya, Turan
   Demir, Osman
TI MEAN PLATELET VOLUME (MPV): A NEW PREDICTOR OF PULMONARY FINDINGS AND
   SURVIVAL IN CCHF PATIENTS?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Crimean-Congo Hemorrhagic Fever; Mean Platelet Volume; Chest X-ray;
   Paranchymal Infiltration; Pleural Effusion
ID CONGO HEMORRHAGIC-FEVER
AB Background: Crimean-Congo Hemorrhagic Fever (CCHF) is a viral zoonotic disease caused by infection with Nairoviruses in the Bunyaviridae family. The virus is transmitted to people by vectors such as ticks. Despite how little is known about the disease's pathophysiology, management of the clinical period, and developments in treatment, it is known that proinflammatory parameters and cytokines are important in the pathophysiology and clinical follow-up of viral hemorrhagic diseases with fever. Among these, the number of platelets, neutrophils, and lymphocytes is important in diagnosis and clinical follow-up. There is a lot of information concerning how low platelet number is directly related to mortality and survival. Mean platelet volume (MPV) is a parameter showing platelet activation and function; therefore, it is a significant finding showing platelet maturation. For that reason, it can be claimed that platelet activation plays an important role in CCHF.
   Materials and methods: A total of 209 patients who were diagnosed as CCHF between May 2010 and September 2015 and whose lungs were examined during admission were retrospectively involved in the study. The patients' demographic features, clinical findings and follow-ups, laboratory findings, radiological examinations of lung, and surveys were retrospectively examined.
   Results: The 209 cases involved in the study consisted of 127 male (60.8%) and 82 female (39.2%) patients. Mean age was as 52 +/- 18 years. Ferritin, procalcitonin, and CRP, which are related to inflammation, were high compared to the normal reference range, too. Mean platelets and leukocytes in hemogram were 56.200/mu L +/- 44.800 and 3.070/mu L +/- 2.930, respectively. Average MPV values in nonsurvival and survival groups were 11.50 fL +/- 2.74 fL and 10.44 fL +/- 2.40 fL, respectively.
   Conclusions: The comparison of MPV between the survival and nonsurvival groups was found to be statistically significant (p<0.05) in CCHF. MPV can be used as a new and important clinical follow-up parameter for clinical observation of patients diagnosed with CCHF in terms of both survival and radiological findings.
C1 [Aktas, Turan] Gaziosmanpasa Univ, Sch Med, Pulmonar Med Dept, Tokat, Turkey.
   [Aktas, Fatma; Ozmen, Zafer] Gaziosmanpasa Univ, Sch Med, Dept Radiol, Tokat, Turkey.
   [Ozmen, Cansel] Gaziosmanpasa Univ, Sch Med, Dept Clin Biochem, Tokat, Turkey.
   [Kaya, Turan] Tokat State Hosp, Infect & Clin Microbiol Dept, Tokat, Turkey.
   [Demir, Osman] Gaziosmanpasa Univ, Sch Med, Dept Stat, Tokat, Turkey.
RP Aktas, T (corresponding author), Gaziosmanpasa Univ, Sch Med, Dept Pulm Med, Tokat, Turkey.
CR Baize S, 2002, CLIN EXP IMMUNOL, V128, P163, DOI 10.1046/j.1365-2249.2002.01800.x
   Bancroft AJ, 2000, PLATELETS, V11, P379
   Ekiz F, 2013, CLIN APPL THROMB-HEM, V19, P441, DOI 10.1177/1076029612440035
   Ergonul O, 2006, CLIN MICROBIOL INFEC, V12, P551, DOI 10.1111/j.1469-0691.2006.01445.x
   Ergonul O, 2006, LANCET INFECT DIS, V6, P203, DOI 10.1016/S1473-3099(06)70435-2
   Gasparyan AY, 2011, CURR PHARM DESIGN, V17, P47
   Gozutok F., 2015, ACTA MED ANAT, V3, P5
   Inci A, 2015, J CLIN ANAL MED, V6, P1, DOI 10.4328/JCAM.2271
   Mardani M, 2007, ARCH IRAN MED, V10, P204
   Oncu Serkan, 2013, Virologica Sinica, V28, P193, DOI 10.1007/s12250-013-3327-4
   Park Y, 2002, PLATELETS, V13, P301, DOI 10.1080/095371002220148332
   Parlak E., 2015, JMID, V5, P51
   SWANEPOEL R, 1989, REV INFECT DIS, V11, pS794
   Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283
NR 14
TC 2
Z9 2
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 183
EP 190
DI 10.19193/0393-6384_2017_2_026
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700001
DA 2022-07-14
ER

PT J
AU Akyol, M
   Kara, M
   Alacacioglu, A
   Demir, L
   Ellidokuz, H
   Kucukzeybek, Y
   Yildiz, Y
   Bayoglu, V
   Yildiz, I
   Salman, T
   Varol, U
   Kucukzeybek, B
   Oflazoglu, U
   Taskaynatan, H
   Gumus, Z
   Tarhan, MO
AF Akyol, Murat
   Kara, Mete
   Alacacioglu, Ahmet
   Demir, Leyla
   Ellidokuz, Hulya
   Kucukzeybek, Yuksel
   Yildiz, Yasar
   Bayoglu, Vedat
   Yildiz, Ibrahim
   Salman, Tarik
   Varol, Umut
   Kucukzeybek, Betul
   Oflazoglu, Utku
   Taskaynatan, Halil
   Gumus, Zehra
   Tarhan, Mustafa Oktay
TI THE EFFECTS OF ADJUVANT CHEMOTHERAPY ON SERUM ADMA AND ENDOTHELIN-1
   LEVELS IN EARLY STAGE BREAST CANCER PATIENTS ( IZMIR ONCOLOGY GROUP
   (IZOG) STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ADMA; Endothelin-1; early stage breast cancer; adjuvant chemotherapy
ID NITRIC-OXIDE SYNTHASE; BODY-COMPOSITION CHANGE; WEIGHT-GAIN; ASYMMETRIC
   DIMETHYLARGININE; ENERGY-BALANCE; WOMEN; DIMETHYLAMINOHYDROLASE;
   SURVIVAL; DYSFUNCTION; DOXORUBICIN
AB Objective: We aimed to investigate changes in body composition, serum asymmetric dimethyl arginine (ADMA) and endothelin-1(ET-1) levels before and after adjuvant chemotherapy in early breast cancer patients.
   Methods: Seventy-two patients with early breast cancer who admitted to our outpatient clinic were included in the study. Before and after chemotherapy, the anthropometric measurements and bioelectrical impedance analysis with TANITA device, body compositions, serum ADMA and ET-1 levels were recorded.
   Results: There was a statistically significant increase of serum ADMA levels (112.10 +/- 52.24 ng/ml vs. 206.34 +/- 128.02 ng/ml, p<0.001) after chemotherapy. On the other hand, the decrease of serum ET-1 levels was not statistically significant (2.19 +/- 6.65 vs. 1.68 +/- 3.71, p=0.57). ADMA levels was similar in both of the groups treated with anthracycline or anthracycline plus taxane regimens. There was no relationship between serum ADMA levels and disease stage/grade, hormone or nodal status. The changes in body composition and antropometric measurements were not statistically significant.
   Conclusion: The increased serum levels of ADMA could be caused by the oxidative stress, apoptosis and endothelial dysfunction secondary to chemotherapy and the decreased estrogen levels. The decrease in serum ET-1 levels might be due to the inhibition of cell proliferation and angiogenesis due to adjuvant chemotherapy.
C1 [Akyol, Murat] Manisa State Hosp, Dept Med Oncol, Manisa, Turkey.
   [Kara, Mete; Alacacioglu, Ahmet; Kucukzeybek, Yuksel; Yildiz, Yasar; Bayoglu, Vedat; Yildiz, Ibrahim; Salman, Tarik; Varol, Umut; Oflazoglu, Utku; Taskaynatan, Halil; Gumus, Zehra] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey.
   [Demir, Leyla] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Biochem, Izmir, Turkey.
   [Ellidokuz, Hulya; Tarhan, Mustafa Oktay] Dokuz Eylul Univ, Inst Oncol, Izmir, Turkey.
   [Kucukzeybek, Betul] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey.
RP Alacacioglu, A (corresponding author), Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Med Oncol Clin, TR-35360 Izmir, Turkey.
RI akyol, murat/AAV-5418-2021; DEMİR, LEYLA/ABH-5523-2020; Yildiz,
   Ibrahim/AAF-9885-2019; Ellidokuz, Hülya/Q-4049-2019; yildiz,
   ibrahim/C-9144-2014
OI akyol, murat/0000-0003-0886-3559; Ellidokuz, Hülya/0000-0001-8503-061X; 
CR Abe O, 2005, LANCET, V366, P2087
   Alacacioglu A, 2010, J BUON, V15, P572
   Aslani A, 1999, BREAST CANCER RES TR, V57, P285, DOI 10.1023/A:1006220510597
   Bagnato Anna, 2004, J Transl Med, V2, P16, DOI 10.1186/1479-5876-2-16
   Bhalla A, 2009, EUR J CLIN INVEST, V39, P74, DOI 10.1111/j.1365-2362.2009.02123.x
   BRISTOW MR, 1978, AM J MED, V65, P823, DOI 10.1016/0002-9343(78)90802-1
   CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327
   CHLEBOWSKI RT, 1986, BREAST CANCER RES TR, V7, P23, DOI 10.1007/BF01886732
   Churchill E, 2008, ANNU REV PHARMACOL, V48, P569, DOI 10.1146/annurev.pharmtox.48.121806.154902
   COBBS CS, 1995, CANCER RES, V55, P727
   Conklin KA, 2000, NUTR CANCER, V37, P1, DOI 10.1207/S15327914NC3701_1
   Demark-Wahnefried W, 2001, J CLIN ONCOL, V19, P2381, DOI 10.1200/JCO.2001.19.9.2381
   Demark-Wahnefried W, 2008, CLIN BREAST CANCER, V8, P70, DOI 10.3816/CBC.2008.n.005
   DEMARKWAHNEFRIED W, 1993, J CLIN ONCOL, V11, P1418, DOI 10.1200/JCO.1993.11.7.1418
   DemarkWahnefried W, 1997, J AM DIET ASSOC, V97, P519, DOI 10.1016/S0002-8223(97)00133-8
   Dirican A, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0905-8
   Fleming I, 2005, CARDIOVASC RES, V65, P897, DOI 10.1016/j.cardiores.2004.11.003
   Freedman RJ, 2004, J CLIN ENDOCR METAB, V89, P2248, DOI 10.1210/jc.2003-031874
   Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587
   Goodwin PJ, 1999, J CLIN ONCOL, V17, P120, DOI 10.1200/JCO.1999.17.1.120
   Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750
   HEASMAN KZ, 1985, BREAST CANCER RES TR, V5, P195, DOI 10.1007/BF01805994
   Holden DP, 2003, CIRCULATION, V108, P1575, DOI 10.1161/01.CIR.0000091083.61609.DF
   Hung CH, 2015, TOXICOL SCI, V145, P59, DOI 10.1093/toxsci/kfv017
   Ingram C, 2004, CANCER NURS, V27, P483
   INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863
   KAYE DM, 1994, CLIN EXP PHARMACOL P, V21, P709, DOI 10.1111/j.1440-1681.1994.tb02574.x
   Kostourou V, 2002, BRIT J CANCER, V87, P673, DOI 10.1038/sj.bjc.6600518
   Kroenke CH, 2005, J CLIN ONCOL, V23, P1370, DOI 10.1200/JCO.2005.01.079
   Krzyzanowska K, 2004, J CLIN ENDOCR METAB, V89, P6277, DOI 10.1210/jc.2004-0672
   Kutynec CL, 1999, J AM DIET ASSOC, V99, P1222, DOI 10.1016/S0002-8223(99)00301-6
   Leiper J, 2002, P NATL ACAD SCI USA, V99, P13527, DOI 10.1073/pnas.212269799
   Levine MN, 2006, NEW ENGL J MED, V355, P1920, DOI 10.1056/NEJMe068204
   Li H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.345
   LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205
   MUKHOPADHYAY M G, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P254
   Murata T, 2001, LIFE SCI, V69, P2685, DOI 10.1016/S0024-3205(01)01352-2
   Patnaik JL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2901
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI [10.3322/caac.21254, 10.1001/jamaoto.2014.2530, 10.3322/caac.21208, 10.1136/bmj.g1502]
   Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709
   Szuba A, 2008, LEUKEMIA LYMPHOMA, V49, P2316, DOI 10.1080/10428190802510323
   THOMSEN LL, 1994, CANCER RES, V54, P1352
   Tsai KL, 2011, MOL NUTR FOOD RES, V55, pS227, DOI 10.1002/mnfr.201100147
   Tsuda K, 2004, CIRCULATION, V109, pE35, DOI 10.1161/01.CIR.0000115213.34702.58
   Vallance P, 2004, ARTERIOSCL THROM VAS, V24, P1023, DOI 10.1161/01.ATV.0000128897.54893.26
   VALLANCE P, 1992, J CARDIOVASC PHARM, V20, pS60, DOI 10.1097/00005344-199204002-00018
   Vassilakopoulou M, 2010, VASC PHARMACOL, V53, P115, DOI 10.1016/j.vph.2010.05.002
   Villela Nivaldo Ribeiro, 2006, Clinics, V61, P53, DOI 10.1590/S1807-59322006000100010
   Wulfing P, 2004, BRIT J CANCER, V91, P434, DOI 10.1038/sj.bjc.6601889
   Wulfing P, 2003, CLIN CANCER RES, V9, P4125
NR 50
TC 1
Z9 1
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 557
EP 564
DI 10.19193/0393-6384_2017_4_081
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700002
DA 2022-07-14
ER

PT J
AU Albano, GD
   Sessa, F
   Messina, A
   Monda, V
   Bertozzi, G
   Maglietta, F
   Giugliano, P
   Vacchiano, G
   Gabriella, M
   Salerno, M
AF Albano, Giuseppe Davide
   Sessa, Francesco
   Messina, Antonietta
   Monda, Vincenzo
   Bertozzi, Giuseppe
   Maglietta, Francesca
   Giugliano, Pasquale
   Vacchiano, Giuseppe
   Gabriella, Marsala
   Salerno, Monica
TI AAS AND ORGANS DAMAGE: A FOCUS ON NANDROLONE EFFECTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE anabolic androgenic steroids; nandrolone decanoate; athletes; testis;
   organ damage
ID ANABOLIC-ANDROGENIC STEROIDS; PRADER-WILLI-SYNDROME; TESTOSTERONE
   BIOSYNTHESIS; LEYDIG-CELLS; SELF-CONCEPT; CHILDREN; MIGRAINE; EXERCISE;
   MULTICENTER; EXPRESSION
AB AAS are being used widespread in order to improve athlete's performance, due to its capacity to improve muscle mass and strength, furthermore, recent studies showed a diffuse abuse by adolescents for libido reasons and appearance. Nandrolone is one of the most abused AAS in the world, it has a similar structure and chemical characteristic compared to testosterone. It interacts with different receptors in our body, such as estrogen, progesterone and testosterone, that's why Nandrolone side effects affect the whole human body. Differents proteins and genes are involved in testosterone biosynthesis of testosterone, with different regulatory pathways. In this review we focused on nandrolone related male reproductive system damage, in order to show the heavy consequences of AAS abuse. Nandrolone regulates MMP-2 and it could lead to spermatogenesis impairment. Oxidative stress and increase of Ros production could play a leading role in Nandrolone related infertility. Different oncogenic pathways are activated by Nandrolone and more studies need to be done to clear up correlations between this molecule and cancer. Leydig cell testosterone production is influenced by Nandrolone, moreover it was demonstrated to be a dose-dipendent mechanism, despite multiple proteins and genes involved in this process were discovered, other regulatory proteins, genes and pathways, need to be studied in deep.
C1 [Albano, Giuseppe Davide; Sessa, Francesco; Bertozzi, Giuseppe; Maglietta, Francesca; Salerno, Monica] Univ Foggia, Sect Forens Pathol, Clin & Expt Med Dept, Osped Colonnello DAvanzo, Viale Aviatori 1, I-71100 Foggia, Italy.
   [Messina, Antonietta; Monda, Vincenzo] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.
   [Giugliano, Pasquale] UOC, Legal Med, St Anna & San Sebastiano Hosp, Palasciano St, Caserta, Italy.
   [Vacchiano, Giuseppe] Sannio Univ, UOC, Dept Law Econ & Math Methods, Benevento, Italy.
   [Gabriella, Marsala] Azienda Osped Univ, Struttura Complessa Farm, Osped Riuniti Foggia, Foggia, Italy.
RP Salerno, M (corresponding author), Univ Foggia, Sect Forens Pathol, Clin & Expt Med Dept, Osped Colonnello DAvanzo, Viale Aviatori 1, I-71100 Foggia, Italy.
RI Messina, Antonietta/AHH-2383-2022; Sessa, Francesco/G-1754-2018;
   Bertozzi, Giuseppe/AAS-9882-2020; MESSINA, ANTONIETTA/K-9366-2016;
   SALERNO, MONICA/AAC-1321-2019
OI Messina, Antonietta/0000-0001-8343-432X; Sessa,
   Francesco/0000-0003-0357-8791; Bertozzi, Giuseppe/0000-0002-8179-1072;
   SALERNO, MONICA/0000-0002-6410-3960; Monda,
   Vincenzo/0000-0002-6083-5814; Giugliano, Pasquale/0000-0002-3633-8893;
   Maglietta, Francesca/0000-0001-7240-5902
CR ALEN M, 1987, AM J SPORT MED, V15, P357, DOI 10.1177/036354658701500411
   Bafunno V, 2012, HAEMOPHILIA, V18, P1003, DOI 10.1111/j.1365-2516.2012.02882.x
   Bafunno V, 2014, THROMB RES, V134, P1135, DOI 10.1016/j.thromres.2014.08.028
   Barone R, 2017, J CELL MOL MED, V21, P1636, DOI 10.1111/jcmm.13092
   Barone R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079686
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Chaves EA, 2006, J STEROID BIOCHEM, V99, P223, DOI 10.1016/j.jsbmb.2006.01.004
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Chimento A, 2012, J CELL PHYSIOL, V227, P2079, DOI 10.1002/jcp.22936
   Clark AS, 1997, HORM BEHAV, V31, P35, DOI 10.1006/hbeh.1997.1355
   D'Errico S, 2011, MINI-REV MED CHEM, V11, P446, DOI 10.2174/138955711795445934
   Dohle GR, 2003, WORLD J UROL, V21, P341, DOI 10.1007/s00345-003-0365-9
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Evans NA, 2004, AM J SPORT MED, V32, P534, DOI 10.1177/0363546503262202
   Fineschi V, 2006, INT J LEGAL MED, V120, P293, DOI 10.1007/s00414-006-0104-z
   Fineschi V, 2010, FORENSIC SCI INT, V194, P1, DOI 10.1016/j.forsciint.2009.10.025
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Frati P, 2015, CURR NEUROPHARMACOL, V13, P146, DOI 10.2174/1570159X13666141210225414
   Garevik N, 2011, J STEROID BIOCHEM, V127, P295, DOI 10.1016/j.jsbmb.2011.08.005
   Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070
   Kostic TS, 2011, TOXICOL SCI, V121, P397, DOI 10.1093/toxsci/kfr063
   Ledda C, 2017, MOL MED REP, V15, P3350, DOI 10.3892/mmr.2017.6380
   Liu PY, 2003, ENDOCR REV, V24, P313, DOI 10.1210/er.2003-0005
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina G, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00137
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F., 2015, BIOL MED PARIS, V7, pS3008, DOI [10.4172/0974-8369.1000S3008, DOI 10.4172/0974-8369.1000S3008]
   Neri M, 2015, CURR VASC PHARMACOL, V13, P26, DOI 10.2174/15701611113119990003
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pomara C, 2005, INT J LEGAL MED, V119, P153, DOI 10.1007/s00414-004-0513-9
   Pomara C, 2012, CURR MED CHEM, V19, P5647, DOI 10.2174/092986712803988811
   Pomara C, 2009, RADIOL MED, V114, P1367, DOI 10.1007/s11547-009-0435-1
   Pomara C, 2016, J CELL PHYSIOL, V231, P1385, DOI 10.1002/jcp.25272
   Riezzo I, 2011, CURR PHARM BIOTECHNO, V12, P275, DOI 10.2174/138920111794295792
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Rone MB, 2012, MOL ENDOCRINOL, V26, P1868, DOI 10.1210/me.2012-1159
   SAARTOK T, 1984, ENDOCRINOLOGY, V114, P2100, DOI 10.1210/endo-114-6-2100
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Santamaria S., 2016, BIOL MED, V8, DOI 10.4172/0974-8369.1000263
   Shokri S, 2010, BASIC CLIN PHARMACOL, V106, P324, DOI 10.1111/j.1742-7843.2009.00495.x
   Stocco DM, 2005, MOL ENDOCRINOL, V19, P2647, DOI 10.1210/me.2004-0532
   Tahtamouni L. H., 2010, Jordan Journal of Biological Sciences (JJBS), V3, P165
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Turillazzi E, 2011, MINI-REV MED CHEM, V11, P374, DOI 10.2174/138955711795445925
   Turillazzi E, 2016, J CELL MOL MED, V20, P601, DOI 10.1111/jcmm.12748
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   van Amsterdam J, 2010, REGUL TOXICOL PHARM, V57, P117, DOI 10.1016/j.yrtph.2010.02.001
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   VORNBERGER W, 1994, ENDOCRINOLOGY, V134, P2307, DOI 10.1210/en.134.5.2307
NR 68
TC 13
Z9 13
U1 1
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 939
EP 946
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500007
DA 2022-07-14
ER

PT J
AU Ali, FB
   Heidari, F
AF Ali, Fakheri Barat
   Heidari, Forouzan
TI TRANSFORMATION OF MANITOL 1-PHOSPHATE DEHYDROGENASE (MTLD) GENE INTO
   CANOLA (BRASSICA NAPUS L.) TO IMPROVE SALINITY TOLERANCE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Genetic engineering; Manitol; Hypocotyls; mtlD gene; Salinity stress;
   canola
ID AGROBACTERIUM-MEDIATED TRANSFORMATION; STRESS TOLERANCE; SALT TOLERANCE;
   TRANSGENIC PLANTS; MOLECULAR-BIOLOGY; ABIOTIC STRESS; WATER-STRESS; CROP
   PLANTS; MANNITOL; CELERY
AB Abiotic stresses such as salinity are one of the important factors that limit crops production worldwide. One suitable method for inducing salinity resistance is osmolytes production increase in plants. In this study, biosynthetic gene which produces osmolyte manitol (mtlD gene) was transferred to Brassica napus L. to increase salinity tolerance. AGLO1 strain of Agrobacterium tumefaciens carrying pBH21 transformation vector, containing mtlD and nptII (transformed plant selectable marker) gene were used for transformation of SLM046 cultivar of B. napus L. Hypocotyl explants were utilized for regeneration of canola plants. PCR analysis of transgenic plants depicted a resemblance in the observed band size and expected band of 500 and 680 bp for the nptII and mtlD genes, respectively. Extracted DNA of transgenic plants, just the same as extracted plasmid containing mtlD gene, revealed a colored blot on a positively charged nylon membrane, while wild-type plants revealed no colored blot. Transformation efficiency was 4.7%. Tolerance threshold against NaCl in wild type and transgenic seeds germination were 250 and 350 mM of NaCl. Thus, Gene transformation into B. napus L. led to the synthesis of mannitol 1-phosphate dehydrogenase that improves its salinity tolerance ability.
C1 [Ali, Fakheri Barat; Heidari, Forouzan] Univ Zabol, Fac Agr, Dept Plant Breeding & Biotechnol, Zabol, Iran.
RP Ali, FB (corresponding author), Univ Zabol, Fac Agr, Dept Plant Breeding & Biotechnol, Zabol, Iran.
EM fakheri@uoz.ac.ir
CR Aarnikunnas J, 2006, THESIS
   Abebe T, 2003, PLANT PHYSIOL, V131, P1748, DOI 10.1104/pp.102.003616
   Alcazar R, 2006, BIOTECHNOL LETT, V28, P1867, DOI 10.1007/s10529-006-9179-3
   BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951
   Bohnert HJ, 1996, TRENDS BIOTECHNOL, V14, P89, DOI 10.1016/0167-7799(96)80929-2
   Bohnert HJ, 1999, MOL MECH SALINITY TO
   Cardoza V, 2004, IN VITRO CELL DEV-PL, V40, P542, DOI 10.1079/IVP2004568
   Cardoza V, 2003, PLANT CELL REP, V21, P599, DOI 10.1007/s00299-002-0560-y
   Chiang YJ, 2005, J AM SOC HORTIC SCI, V130, P605, DOI 10.21273/JASHS.130.4.605
   Cushman JC, 2000, CURR OPIN PLANT BIOL, V3, P117, DOI 10.1016/S1369-5266(99)00052-7
   DEBLOCK M, 1989, PLANT PHYSIOL, V91, P694, DOI 10.1104/pp.91.2.694
   Dellaporta SL., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]
   EVERARD JD, 1994, PLANT PHYSIOL, V106, P281, DOI 10.1104/pp.106.1.281
   Flowers TJ, 1995, AUST J PLANT PHYSIOL, V22, P875, DOI 10.1071/PP9950875
   FRANZINI E, 1994, ARCH BIOCHEM BIOPHYS, V309, P261, DOI 10.1006/abbi.1994.1111
   GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053
   HALLIWELL B, 1988, METHOD BIOCHEM ANAL, V33, P59
   HANSON AD, 1994, P NATL ACAD SCI USA, V91, P306, DOI 10.1073/pnas.91.1.306
   Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463
   Hu L, 2005, TREE PHYSIOL, V25, P1273, DOI 10.1093/treephys/25.10.1273
   Huang J, 2000, PLANT PHYSIOL, V122, P747, DOI 10.1104/pp.122.3.747
   Jonoubi P, 2005, BIOL PLANTARUM, V49, P175, DOI 10.1007/s10535-005-5180-2
   Karakas B, 1997, PLANT CELL ENVIRON, V20, P609, DOI 10.1111/j.1365-3040.1997.00132.x
   Loescher Wayne H., 2000, VVolume 9, P275
   LOESCHER WH, 1992, PLANT PHYSIOL, V98, P1396, DOI 10.1104/pp.98.4.1396
   LOESCHER WH, 1987, PHYSIOL PLANTARUM, V70, P553, DOI 10.1111/j.1399-3054.1987.tb02857.x
   Maheswari M, 2010, BIOL PLANTARUM, V54, P647, DOI 10.1007/s10535-010-0115-y
   Mashayekhi M, 2008, AFR J BIOTECHNOL, V7, P4459
   McDonald B.E., 2011, CANOLA OIL NUTR PROP
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   PHARR DM, 1995, HORTSCIENCE, V30, P1182, DOI 10.21273/HORTSCI.30.6.1182
   Prabhavathi V, 2002, MOL BREEDING, V9, P137, DOI 10.1023/A:1026765026493
   Prasad KVSK, 2000, MOL BREEDING, V6, P489, DOI 10.1023/A:1026542109965
   Punja ZK, 2001, CAN J PLANT PATHOL, V23, P216
   Rahnama H, 2011, ACTA PHYSIOL PLANT, V33, P1521, DOI 10.1007/s11738-010-0690-8
   Ruperez P, 2003, EUR FOOD RES TECHNOL, V216, P224, DOI 10.1007/s00217-003-0663-x
   Sakamoto A, 2000, J EXP BOT, V51, P81, DOI 10.1093/jexbot/51.342.81
   Sambrook J., 2001, MOL CLONING LAB MANU
   Shen B, 1997, PLANT PHYSIOL, V115, P527, DOI 10.1104/pp.115.2.527
   Shen B, 1997, PLANT PHYSIOL, V113, P1177, DOI 10.1104/pp.113.4.1177
   SMIRNOFF N, 1989, PHYTOCHEMISTRY, V28, P1057, DOI 10.1016/0031-9422(89)80182-7
   Soetaert W, 1999, METH BIOTEC, V10, P261
   Srivastava S, 2004, PLANT CELL PHYSIOL, V45, P1320, DOI 10.1093/pcp/pch137
   Stoop JMH, 1996, TRENDS PLANT SCI, V1, P139, DOI 10.1016/S1360-1385(96)80048-3
   Su Jin, 1999, Scientia Agricultura Sinica, V32, P101
   TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508
   Tester M, 2010, SCIENCE, V327, P818, DOI 10.1126/science.1183700
   THOMAS JC, 1995, PLANT CELL ENVIRON, V18, P801, DOI 10.1111/j.1365-3040.1995.tb00584.x
   Wang HZ, 2000, CHINESE SCI BULL, V45, P1685, DOI 10.1007/BF02898987
   Yeo A, 1998, J EXP BOT, V49, P915, DOI 10.1093/jexbot/49.323.915
   Zamski E, 2001, PLANT MOL BIOL, V47, P621, DOI 10.1023/A:1012395121920
   Zebarjadi Alireza, 2006, Iranian Journal of Biotechnology, V4, P79
   Zhang HX, 2001, P NATL ACAD SCI USA, V98, P12832, DOI 10.1073/pnas.231476498
   Zhang JX, 1999, J EXP BOT, V50, P291, DOI 10.1093/jexbot/50.332.291
   Zhang Y, 2005, AUST J AGR RES, V56, P353, DOI 10.1071/AR04175
   Zhu JK, 2000, PLANT PHYSIOL, V124, P941, DOI 10.1104/pp.124.3.941
NR 56
TC 1
Z9 1
U1 1
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 935
EP 943
DI 10.19193/0393-6384_2017_1s_140
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000009
DA 2022-07-14
ER

PT J
AU Aliverti, M
   Pezzoni, B
   Gorini, I
   Martini, M
   Vecchio, I
   Tornali, C
AF Aliverti, Massimo
   Pezzoni, B.
   Gorini, Ilaria
   Martini, Mariano
   Vecchio, Ignazio
   Tornali, Cristina
TI NEUROSYPHILIS IN ITALIAN PSYCHIATRY OF THE LATE 19(TH) CENTURY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Neurosyphilis; progressive paralysis; tabes dorsalis; psychiatry
AB Based on Italian and international literature, the authors have studied nineteenth-century research into neurosyphilis in its main syndromic manifestations: tabes dorsalis and progressive paralysis. By examining some psychiatry handbooks of the time, it was possible to recover ample information about the symptomatology and the description of the clinical course of the illness. Moreover, the relationship between syphilis and mental illness became a conceptual paradigm which psychiatrists applied to other mental disorders as well. Our paper has brought to light the medical debates of the late 19th century.
C1 [Aliverti, Massimo] Univ Insubria Varese, Varese, Italy.
   [Vecchio, Ignazio] Univ Catania, Dept Clin & Expt Med, Catania, Italy.
   [Pezzoni, B.; Gorini, Ilaria] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.
   [Tornali, Cristina] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Martini, Mariano] Univ Genoa, Sect Hist Med & Eth, Dept Hlth Sci DISSAL, Genoa, Italy.
RP Vecchio, I (corresponding author), Univ Catania, Policlin, Via Santa Sofia 78, Catania, Italy.
RI Tornali, Cristina/M-5187-2017
OI Tornali, Cristina/0000-0002-1722-5498; Vecchio,
   Ignazio/0000-0001-5942-1908
CR Breda A, 1889, MANUALE PRATICO MALA
   Giacchi O, 1871, SCROFOLA SIFILIDE CE, pXXIII
   Gorini I., 2013, RIV STORIA MED GENNA, VXXIII, P85
   La Loggia G, 1880, IL PISANI, VI, P35
   Martini M, 2016, ACTA MED-HIST ADRIAT, V14, P73
   Morselli E., 1898, MANUALE SEMEIOTICA M
   Pinel S, 1858, ANN MED-PSYCHOL, VXIV, P581
   Vecchio I, 2014, ACTA MEDICA MEDITERR, V30, P755
   Verga A, 1897, STUDI ANATOMICI CRAN, pIII
NR 9
TC 1
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 465
EP 470
DI 10.19193/0393-6384_2017_3_068
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200016
DA 2022-07-14
ER

PT J
AU Aliverti, M
   Gorini, I
   Borgo, M
   Licata, M
   Martini, M
   Vecchio, I
   Tornali, C
AF Aliverti, Massimo
   Gorini, Ilaria
   Borgo, Melania
   Licata, Marta
   Martini, Mariano
   Vecchio, Ignazio
   Tornali, Cristina
TI ON TWO ITALIAN PUBLICATIONS BY THE CUBAN ANTHROPOLOGIST FERNANDO ORTIZ
   (1881-1969)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Fernando Ortiz; criminal anthropology; criminal superstitions
AB Fernando Ortiz was a Cuban anthropologist as well as one of the most prominent figures in 20th-century Latin-American culture. His interests spanned from law to criminology, from anthropology to sociology, from psychology to ethnomedicine, and from folklore to musicology. In this paper, we will focus on two essays that he wrote in Italian, "Criminality of the Black in Cuba" and "Criminal superstitions in Cuba". Noteworthy is the relationship between Ortiz and the Italian school of criminology. He spent several years in Genoa where he met Cesare Lombroso, one of the leading figures of the "positive school". Ortiz drew inspiration from Cesare Lombroso and contextualised these ideas in Cuban society.
C1 [Aliverti, Massimo] Univ Insubria, Varese, Italy.
   [Gorini, Ilaria; Borgo, Melania; Licata, Marta] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.
   [Vecchio, Ignazio] Univ Catania, Dept Clin & Expt Med, Catania, Italy.
   [Tornali, Cristina] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Licata, Marta] Univ Genoa, Sect Hist Med & Eth, Dept Hlth Sci DISSAL, Genoa, Italy.
RP Vecchio, I (corresponding author), Univ Catania, Policlin, Via Santa Sofia 78, Catania, Italy.
RI ; Tornali, Cristina/M-5187-2017
OI Vecchio, Ignazio/0000-0001-5942-1908; Tornali,
   Cristina/0000-0002-1722-5498
CR Aliverti M., 2001, RIV ITALIANA SCI TRA, V1, P7
   Borgo M, 2017, ACTA MEDICA MEDITERR, V33, P95, DOI 10.19193/0393-6384_2017_1_015
   Iznaga Diana, 1989, TRANSCULTURACION FER
   Licata M, 2016, ACTA MEDICA MEDITERR, V32, P1569, DOI 10.19193/0393-6384_2016_5_131
   Matos Arevalos Jose, 1999, HIST FERNANDO ORTIZ
   Ortiz F, 1998, MISCELANEA 2 STUDIES
   Riva V, 1982, ESTATE VARADERO ORTI
NR 7
TC 2
Z9 2
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 471
EP 474
DI 10.19193/0393-6384_2017_3_069
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200017
DA 2022-07-14
ER

PT J
AU Amini, M
   Vaseie, M
   Ansari, I
AF Amini, Maryam
   Vaseie, Mohammad
   Ansari, Iman
TI THE EVALUATION OF NOSOCOMIAL URINARY TRACT INFECTIONS AND ANTIMICROBIAL
   RESISTANCE IN ICU PATIENTS, TEHRAN, IRAN, 2012-2016
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE nosocomial infections; urinary tract infections; antibiotic resistance;
   intensive care unit
AB Background and objectives: Given the importance of nosocomial infections, especially urinary tract infections, on mortality, morbidity and disability of patients and unfortunately increasing antibiotic resistance that makes up the most important part of treatment of the affected patients, the present study evaluated the pattern of antibiotic resistance and the prevalence of bacterial pathogen of nosocomial urinary infections in the intensive care unit of Mostafa Khomeini hospital during the 2012 to 2016.
   Materials and methods: This cross-sectional study was conducted on 194 patients hospitalized in the intensive care unit with positive urine cultures. Information on age, sex, length of hospital stay, underlying diseases, cause of hospitalization and duration of urinary catheter use were recorded for each patient in a check list. After identifying the nature of the bacteria, antibiogram was performed by disk diffusion method and the results were compared with standard tables to record the results as sensitive, moderately sensitive and resistant.
   Results: Gram-negative bacilli are responsible for urinary tract infections, including strains of E. coli, Acinetobacter, Pseudomonas spp., Klebsiellaspp and Proteus spp., with a frequency of 77.3% and gram positive cocci, including Enterococcus and Staphylococcusspecies with a frequency of 22.7%. The least antibiotic-resistant against gram-positive pathogens was related to ciprofloxacin and ceftazidime and against gram-negative bacilli was related to nitrofurantoin and ciprofloxacin.
   Conclusion: The results of the present study showed that the resistance antibiotic pattern changes over time; thus, performing urine culture and antibiogram test is essential before beginning treatment and choosing the appropriate antibiotic, in order to prevent antibiotic resistance.
C1 [Amini, Maryam] Shahed Univ, Med Fac, Dept Infect Dis & Trop Med, Tehran, Iran.
   [Vaseie, Mohammad] Univ Tehran Med Sci, Imam Khomeini Hosp, Med Fac, Tehran, Iran.
   [Ansari, Iman] Shahed Univ, Med Fac, Tehran, Iran.
RP Amini, M (corresponding author), Shahed Univ, Med Fac, Dept Infect Dis & Trop Med, Tehran, Iran.
EM mmamini55602@gmail.com
RI Ansari, Iman/B-7096-2018; Vaseie, Mohammad/AAH-2434-2019
OI Ansari, Iman/0000-0001-9597-653X; 
CR Akram Mohammed, 2007, Ann Clin Microbiol Antimicrob, V6, P4, DOI 10.1186/1476-0711-6-4
   Al-Helali NS, 2004, INFECT CONT HOSP EP, V25, P1004, DOI 10.1086/502336
   Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4
   Arabestani MR, 2014, PAJOUHAN SCI J, V12, P20
   BagheriNejad S, 2011, B WORLD HEALTH ORGAN, V89
   Bilvayea S, 2015, J CLIN RES PARAMEDSC, V4, P255
   Dahle KW, 2012, J PEDIATR INFECT DIS, V1, P333, DOI 10.1093/jpids/pis055
   Esmaeili R, 2014, J ILAM U MED SCI, V21, P281
   Farazi A. A., 2015, Qom University of Medical Sciences Journal, V9, P37
   Finkelstein R, 2000, J HOSP INFECT, V44, P200, DOI 10.1053/jhin.1999.0682
   Foxman B, 2002, AM J MED, V113, p5S
   Ghorbanalizadehgan M, 2008, J ILAM U MED SCI, V16, P1
   Goldman L, 2012, GOLDMANS CECILMEDICI
   Gould IM, 2000, CLIN MICROBIOL INFEC, V6, P442, DOI 10.1046/j.1469-0691.2000.00139.x
   Hajibagheri K, 2006, KORDESTAN J MED SCI, V10, P44
   Jarsiah P., 2014, Journal of Mazandaran University of Medical Sciences, V24, P77
   Jombo G T A, 2006, Niger J Med, V15, P230
   Kumamoto Yoshiaki, 2006, Japanese Journal of Antibiotics, V59, P217
   Kurutepe S, 2005, JPN J INFECT DIS, V58, P159
   Longo DL, 2012, HARRISONS PRINCIPLE
   Masinde A, 2009, Tanzan J Health Res, V11, P154
   Mobaien AR, 2012, J ZANJAN U MED SCI, V20, P94
   Mohammadimehr M., 2009, IRAN J MED MICROBIOL, V3, P47
   Molazade A, 2014, PAR J MED SCI, V12, P22
   Moravej A, 2013, J FASA U MED SCI, V2, P254
   Nazari R, 2010, J MASHAD FACULTY NUR, V10, P31
   Petty WC, 2009, J PERIANESTH NURS, V24, P250, DOI 10.1016/j.jopan.2009.05.101
   Qorbanalizadehgan M, 2007, IJIDTM J, V11, P69
   Rafati MR., 2015, J MAZANDARAN U MED S, V25, P122
   Sharif MR, 2014, IJIDTM J, V19, P47
   Sharifian M, 2006, IRANIAN SCI MICROBIO, V4, P13
   Thongpiyapoom Somchit, 2004, Journal of the Medical Association of Thailand, V87, P819
NR 32
TC 3
Z9 3
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 945
EP 952
DI 10.19193/0393-6384_2017_1s_141
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000010
DA 2022-07-14
ER

PT J
AU Arcangeli, M
   Feola, A
   Marsella, LT
AF Arcangeli, Mauro
   Feola, Alessandro
   Marsella, Luigi T.
TI MALIGNANT HYPERTHERMIA: A CASE REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE malignant hyperthermia; anesthesia; skeletal muscles; volatile
   anesthetic
ID GUIDELINES; ANESTHESIA
AB Malignant hyperthermia manifests clinically as a hypermetabolic crisis when a malignant hyperthermia-susceptible individual is exposed to a volatile anesthetic such as halothane, isoflurane, enflurane, sevoflurane, or desflurane or depolarizing muscular blockers such as succinylcholine. The condition shows autosomal dominant inheritance with reduced penetrance, and is mostly associated with mutations resulting in abnormal ryanodine receptor type 1 or, more rarely, dihydropyridine receptors. Exposure to triggering agents may lead to unregulated passage of calcium from the sarcoplasmic reticulum into the intracellular space, resulting in an acute malignant hyperthermia crisis. Mortality from malignant hyperthermia in the United States was 16.9% in 2001 and 6.5% in 2005, but it is characterized by high morbidity. Therapy is based on suspension of the triggering agent and administration of dantrolene. Diagnosis is possible by biopsy using in vitro contraction tests or DNA screening for malignant hyperthermia. The authors present a case of malignant hyperthermia during myocardial revascularization through off-pump coronary artery bypass graft.
C1 [Arcangeli, Mauro] Univ Aquila, Dept Life Hlth & Environm Sci, Laquila, Italy.
   [Feola, Alessandro; Marsella, Luigi T.] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy.
RP Feola, A (corresponding author), Via Montpellier 1, I-00133 Rome, Italy.
RI Feola, Alessandro/AAI-4601-2020
OI Feola, Alessandro/0000-0002-9666-2636; Marsella, Luigi
   Tonino/0000-0002-7005-7526; ARCANGELI, Mauro/0000-0002-2665-7372
CR Bendixen D, 1997, ACTA ANAESTH SCAND, V41, P480, DOI 10.1111/j.1399-6576.1997.tb04727.x
   Brady JE, 2009, ANESTH ANALG, V109, P1162, DOI 10.1213/ane.0b013e3181ac1548
   Brandom BW, 2015, ADV ANESTHESIA, V33, P113, DOI DOI 10.1016/J.AAN.2015.07.007
   Glahn KPE, 2010, BRIT J ANAESTH, V105, P417, DOI 10.1093/bja/aeq243
   Halsall PJ, 2005, ANAEST INTENS CARE M, V6, P192, DOI 10.1383/anes.6.6.192.65782
   Hopkins PM, 2015, BRIT J ANAESTH, V115, P531, DOI 10.1093/bja/aev225
   Kollmann-Camaiora A, 2017, REV ESP ANEST REANIM, V64, P32, DOI 10.1016/j.redar.2016.06.004
   Larach MG, 2008, ANESTHESIOLOGY, V108, P603, DOI 10.1097/ALN.0b013e318167aee2
   Rosenberg H, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0310-1
   Rosero EB, 2009, ANESTHESIOLOGY, V110, P89, DOI 10.1097/ALN.0b013e318190bb08
NR 10
TC 2
Z9 2
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 807
EP 809
DI 10.19193/0393-6384_2017_5_119
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000013
DA 2022-07-14
ER

PT J
AU Arik, F
   Arik, BE
   Ozer, O
   Kalan, U
   Uyaniker, N
   Cetinkaya, A
AF Arik, Ferhat
   Arik, Bade Erturk
   Ozer, Ozerhan
   Kalan, Ugur
   Uyaniker, Nur
   Cetinkaya, Ali
TI FATAL INTOXICATION WITH COLCHICINE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Low dose; Colchicine; Intoxication; Fatal; Hemodialysis
ID PHARMACOLOGY
AB Introduction: Colchicine is a medication with anti-inflammatory properties, which is used in gouty arthritis, familial Mediterranean fever (FMF) and consequently developing amyloidosis. Colchicine poisoning is associated with a bad outcome and can be fatal. Deaths generally occur because of hypovolemic shock and cardiovascular collapse or secondary to rapidly progressive multiorgan failure.
   Case presentation: The present study is about a 20-year-old female patient who had taken 20 tablets of 0.5 mg/tb colchicine (0.2 mg/kg) for suicidal purpose. The treatments applied at each stage are explained with details.
   Conclusion: Colchicine has a narrow therapeutic index and no clear-cut distinction between non-toxic, toxic, and lethal doses. In our case, the patient who had taken low-dose colchicine (0.2 mg/kg) died despite of all the treatments. Death with a such low dose is rare.
C1 [Arik, Ferhat; Ozer, Ozerhan; Kalan, Ugur; Cetinkaya, Ali] Kayseri Training & Res Hosp, Dept Internal Med, TR-38030 Kayseri, Turkey.
   [Arik, Bade Erturk] Erciyes Univ, Fac Med, Dept Family Phys, Kayseri, Turkey.
   [Uyaniker, Nur] TSGI Engn & Construct Co, Dept Qual, Izmir, Turkey.
RP Arik, F (corresponding author), Kayseri Training & Res Hosp, Dept Internal Med, TR-38030 Kayseri, Turkey.
RI ÖZER, ÖZERHAN/O-6794-2015
OI ÖZER, ÖZERHAN/0000-0001-5855-5509
CR ACHTERT G, 1989, EUR J DRUG METAB PH, V14, P317, DOI 10.1007/BF03190118
   Adler Y, 1998, CIRCULATION, V97, P2183, DOI 10.1161/01.CIR.97.21.2183
   [Anonymous], 1974, BR MED J, V1, P446
   Atas B, 2004, HUM EXP TOXICOL, V23, P353, DOI 10.1191/0960327104ht457sc
   Ben-Chetrit E, 1998, SEMIN ARTHRITIS RHEU, V28, P48, DOI 10.1016/S0049-0172(98)80028-0
   Bhat A, 2009, ANN NY ACAD SCI, V1173, P766, DOI 10.1111/j.1749-6632.2009.04674.x
   Borron SW, 1996, HUM EXP TOXICOL, V15, P885, DOI 10.1177/096032719601501104
   Brncic N, 2001, CROAT MED J, V42, P673
   Erden A, 2013, THER CLIN RISK MANAG, V9, P505, DOI 10.2147/TCRM.S54558
   Finkelstein Y, 2010, CLIN TOXICOL, V48, P407, DOI 10.3109/15563650.2010.495348
   Guven AG, 2002, PEDIATRICS, V109, P971, DOI 10.1542/peds.109.5.971
   Hood Robert L., 1994, Journal of Emergency Medicine, V12, P171, DOI 10.1016/0736-4679(94)90695-5
   Jouffroy R, 2013, INTENS CARE MED, V39, P1163, DOI 10.1007/s00134-013-2911-2
   MURRAY SS, 1983, MAYO CLIN PROC, V58, P528
   PUTTERMAN C, 1991, SEMIN ARTHRITIS RHEU, V21, P143, DOI 10.1016/0049-0172(91)90003-I
   ROCHDI I, 1994, EUR J CLIN PHARMACOL, V46, P351
   ROUAN SKE, 1990, AM J PATHOL, V137, P779
   WALLACE SL, 1970, AM J MED, V48, P443, DOI 10.1016/0002-9343(70)90043-4
   ZEMER D, 1986, NEW ENGL J MED, V314, P1001, DOI 10.1056/NEJM198604173141601
NR 19
TC 3
Z9 3
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 592
EP 596
DI 10.19193/0393-6384_2017_4_087
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700008
DA 2022-07-14
ER

PT J
AU Asila, ALJ
   Liao, J
   Deng, YJ
   Liu, ZF
   Meng, QC
   Song, YC
   Fang, R
AF Asila, Ailijiang
   Liao Jun
   Deng Yingjie
   Liu Zhenfeng
   Meng Qingcai
   Song Yucheng
   Fang Rui
TI RELEVANCE BETWEEN EXERCISE-INDUCED SKELETAL MUSCLE INJURY AND SKELETAL
   MUSCLE CELL APOPTOSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Micro Exercise-Induced Skeletal Muscle Injury; Skeletal Muscle Cell
   Apoptosis; Relevance
AB It is essential to understand the relation between bone cell apoptosis and exercise-induced skeletal muscle injury in order to achieve an effective prevention treatment for exercise-induced bone crisis injury. Therefore, this paper reveals the clinical datas on retrospective analysis of skeletal muscle cell apoptosis of 1000 patients with micro exercise-induced skeletal muscle injury. The results obtained demonstrated a close correlation between physiological environment, micro exercise-induced skeletal muscle injury due to sports and skeletal muscle cell apoptosis. Hence, study on relevance between micro exercise-induced skeletal muscle injury and skeletal muscle cell apoptosis is of important significance for prevention and treatment of exercise-induced injury.
C1 [Asila, Ailijiang; Liao Jun; Deng Yingjie; Liu Zhenfeng; Meng Qingcai; Song Yucheng; Fang Rui] Chinese Med Hosp Xinjiang, Dept Orthopaed, Urumqi, Uygur Autonomou, Peoples R China.
RP Fang, R (corresponding author), Chinese Med Hosp Xinjiang, Dept Orthopaed, Urumqi, Uygur Autonomou, Peoples R China.
EM dfksedw@163.com
FU National Natural Science Foundation of China [81160460]
FX National Natural Science Foundation of China (grant 81160460).
CR Apostolakis E. D. D., 2015, ASIAN PAC J SURG ONC, V1, P191
   Breitenbuecher F, 2015, ASIAN PAC J SURG ONC, V1, P181
   Chen Gan, 2012, LIFE SCI RES, V02, P102
   Chen J, 2015, J COASTAL RES, P620, DOI 10.2112/SI73-108.1
   El-Jakee JK, 2016, SAUDI J BIOL SCI, V23, P48, DOI 10.1016/j.sjbs.2015.06.011
   Halici U, 2015, ACTA MEDICA MEDITERR, V31, P807
   Khalifa AYZ, 2016, SAUDI J BIOL SCI, V23, P79, DOI 10.1016/j.sjbs.2015.06.008
   Li Chen, 2014, J TAISHAN MED COLL, V04, P241
   Li Weiping, 2013, CHINESE J APPL PHYSL, V05, P452
   Luo XW, 2015, J COASTAL RES, P315, DOI 10.2112/SI73-055.1
   Manosroi A, 2016, SAUDI J BIOL SCI, V23, P248, DOI 10.1016/j.sjbs.2015.03.008
   Song W, 2013, J NANOMATER, V2013, P1
   Song Weihong, 2013, J HUNAN I HUMANITIES, V02, P58
   Tibpromma S, 2016, SAUDI J BIOL SCI, V23, P1, DOI 10.1016/j.sjbs.2015.01.018
   Yang SY, 2016, SAUDI PHARM J, V24, P245, DOI 10.1016/j.jsps.2016.04.006
   Yu Xinkai, 2013, PROGR ANATOMICAL SCI, V03, P298
   Zheng Haiyan, 2012, MODERN J INTEGRATED, V25, P2842
NR 17
TC 0
Z9 0
U1 6
U2 17
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 3
BP 1329
EP 1332
DI 10.19193/0393-6384_2017_3s_207
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AC
UT WOS:000424878100009
DA 2022-07-14
ER

PT J
AU Atalay, H
   Boyuk, B
   Guzel, S
   Altay, M
   Kiziler, AR
   Aydemir, B
AF Atalay, Hande
   Boyuk, Banu
   Guzel, Savas
   Altay, Murat
   Kiziler, Ali Riza
   Aydemir, Birsen
TI SERUM TRACE ELEMENTS IN TYPE 2 DIABETES MELLITUS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Diabetes; trace elements; HbA1C
ID MAGNESIUM-DEFICIENCY; INSULIN-RESISTANCE; OXIDATIVE STRESS; ZINC;
   COPPER; HYPOMAGNESEMIA; PATHOGENESIS; METABOLISM; MANGANESE; FERRITIN
AB Studies suggested that imbalances of several trace elements may play an important role in normal glucose and insulin metabolism. The aim of the present study was to evaluate changes in serum levels of copper, zinc, iron, and magnesium in patients with type 2 diabetes mellitus (T2DM) and their effect on glycemic control.
   Sixty female patients with T2DM and seventeen healthy subjects were enrolled in this study. Fasting plasma samples were obtained from the patient and control groups. Trace elements were studied using an atomic absorption spectrometer. Correlation analyses of trace elements with metabolic parameters were analyzed using Spearman's Rho correlation coefficient.
   T2DM patients had a significantly high fasting plasma glucose, glycated hemoglobin (HbA1C), and microalbuminuria levels (p< 0.05). Serum magnesium levels were significantly lower in patients with T2DM compared with the healthy controls (2.0 +/- 0.2 ng/mL vs. 2.3 +/- 0.2 ng/mL, p< 0.05). Serum copper levels showed a negative correlation with diabetes duration (r= -0.338, p= 0.011), and iron levels were negatively correlated with body mass index and C-reactive protein (r= -0.407, p= 0.009; r= -0.390, p= 0.017). Serum magnesium levels indicated a correlation with HbA1C and creatinine clearance (r= -0.371, p= 0.049; r= -0.462, p= 0.023), but no significant correlation was found with any of the other variables and zinc levels.
   The present study found low levels of magnesium, iron, copper, and zinc in women with T2DM, which supports a close relationship of the above trace elements with glucose metabolism. Low magnesium levels has been linked to poor glycemic control in T2DM; therefore, magnesium deficiency should be prevented in patients with diabetes.
C1 [Atalay, Hande] Gebze Fatih Govt Hosp, Internal Med Dept, Kocaeli, Turkey.
   [Boyuk, Banu; Altay, Murat] Gaziosmanpasa Taksim Educ & Res Hosp, Dept Internal Med, Istanbul, Turkey.
   [Guzel, Savas] Namik Kemal Univ, Dept Biochem, Tekirdag, Turkey.
   [Kiziler, Ali Riza] Namik Kemal Univ, Dept Biophys, Tekirdag, Turkey.
   [Aydemir, Birsen] Sakarya Univ, Dept Biophys, Med Fac, Adapazari, Turkey.
RP Atalay, H (corresponding author), Gebze Fatih Govt Hosp, Internal Med Dept, Kocaeli, Turkey.
RI erman, hande/AAP-6507-2021; erman, hande/AAZ-7697-2021; Boyuk,
   Banu/GLN-8251-2022; BOYUK, BANU/ABA-7026-2021
OI erman, hande/0000-0001-7213-9624; erman, hande/0000-0001-7213-9624;
   Boyuk, Banu/0000-0001-7794-4411; 
CR Bao B, 2010, AM J CLIN NUTR, V91, P1634, DOI 10.3945/ajcn.2009.28836
   Barbagallo M, 2007, ARCH BIOCHEM BIOPHYS, V458, P40, DOI 10.1016/j.abb.2006.05.007
   BENNETT PH, 1994, JOSLINS DIABETES MEL, P193
   Canturk Z, 2003, ENDOCR RES, V29, P299, DOI 10.1081/ERC-120025037
   Chutia Happy, 2015, J Lab Physicians, V7, P75, DOI 10.4103/0974-2727.163131
   Cohen A M, 1986, Pancreas, V1, P309, DOI 10.1097/00006676-198607000-00003
   Friederich M, 2009, CURR DIABETES REV, V5, P120, DOI 10.2174/157339909788166800
   Hadjistavri LS, 2010, MED SCI MONITOR, V16, pCR307
   Jansen J, 2009, J NUTR BIOCHEM, V20, P399, DOI 10.1016/j.jnutbio.2009.01.009
   Kazi TG, 2008, BIOL TRACE ELEM RES, V122, P1, DOI 10.1007/s12011-007-8062-y
   Kelleher SL, 2011, ADV NUTR, V2, P101, DOI 10.3945/an.110.000232
   Khan AR, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/2251-6581-13-16
   Kisters K, 2000, TRACE ELEM ELECTROLY, V17, P67
   MA J, 1995, J CLIN EPIDEMIOL, V48, P927, DOI 10.1016/0895-4356(94)00200-A
   Makhlough A, 2015, NEPHROUROL MON, V7, DOI DOI 10.5812/NUMONTH-LY.28576
   Fernandez-Real JM, 2015, DIABETES CARE, V38, P2169, DOI 10.2337/dc14-3082
   MCNAIR P, 1978, DIABETES, V27, P1075, DOI 10.2337/diabetes.27.11.1075
   Miao X, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/425854
   Miller JM, 2005, CLIN NEPHROL, V64, P248
   MOORADIAN AD, 1994, DIABETES CARE, V17, P464, DOI 10.2337/diacare.17.5.464
   NADLER JL, 1993, HYPERTENSION, V21, P1024, DOI 10.1161/01.HYP.21.6.1024
   NOTO R, 1983, ACTA DIABETOL LAT, V20, P81, DOI 10.1007/BF02629133
   PAOLISSO G, 1986, DIABETOLOGIA, V29, P644, DOI 10.1007/BF00869264
   Pham PCT, 2005, CLIN NEPHROL, V63, P429
   Pham PCT, 2007, CLIN J AM SOC NEPHRO, V2, P366, DOI 10.2215/CJN.02960906
   PIDDUCK HG, 1970, DIABETES, V19, P234, DOI 10.2337/diab.19.4.234
   Prabodh S, 2011, BIOL TRACE ELEM RES, V142, P29, DOI 10.1007/s12011-010-8750-x
   Ranasinghe P, 2015, DARU, V23, DOI 10.1186/s40199-015-0127-4
   Sales CH, 2011, CLIN NUTR, V30, P359, DOI 10.1016/j.clnu.2010.12.011
   Schulze MB, 2007, ARCH INTERN MED, V167, P956, DOI 10.1001/archinte.167.9.956
   Sheu WHH, 2003, CLIN ENDOCRINOL, V58, P380, DOI 10.1046/j.1365-2265.2003.01729.x
   Tilbrook Louise, 2004, Ann Clin Biochem, V41, P255
   Viktorinova A, 2009, METABOLISM, V58, P1477, DOI 10.1016/j.metabol.2009.04.035
   Vincent AM, 2004, ENDOCR REV, V25, P612, DOI 10.1210/er.2003-0019
   WALTER RM, 1991, DIABETES CARE, V14, P1050, DOI 10.2337/diacare.14.11.1050
   Walti MK, 2003, AM J CLIN NUTR, V78, P448
   Zargar AH, 1998, POSTGRAD MED J, V74, P665, DOI 10.1136/pgmj.74.877.665
NR 37
TC 4
Z9 4
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 795
EP 800
DI 10.19193/0393-6384_2017_5_117
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000011
DA 2022-07-14
ER

PT J
AU Ayaz, S
   Gultekin, SS
   Dilli, A
   Ayaz, UY
AF Ayaz, Sevin
   Gultekin, Salih Sinan
   Dilli, Alper
   Ayaz, Umit Yasar
TI BONE MINERAL DENSITY DISCORDANCES IN FEMALES: A COMPARISON OF
   PREMENOPAUSAL AND NON-GERIATRIC POSTMENOPAUSAL ADULT POPULATIONS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Bone Density; Femur Neck; Lumbar Vertebrae; Postmenopause
ID ESTROGEN DEFICIENCY; UNITARY MODEL; LUMBAR SPINE; FEMORAL-NECK;
   OSTEOPOROSIS; WOMEN; PREVALENCE; DXA; HIP; PATHOGENESIS
AB Introduction: Bone mineral density (BMD) discordance between lumbar and femoral T-scores can cause difficulties in the interpretation of dual x-ray absorptiometry (DXA) results. We aimed to compare BMD discordance in premenopausal and non-geriatric (early) postmenopausal women.
   Materials and methods: Lumbar spine (L1-4) and femoral neck BMD measurements of premenopausal (n = 236/944) and postmenopausal (n = 708/944) women were performed by DXA. For both groups the mean age, BMD, T-scores, BMI, osteopeniaosteoporosis rates, concordance-discordance rates and the rates of the regions with lower T-scores were obtained and compared.
   Results: Osteopenia and osteoporosis were more frequent in postmenopausal women than in premenopausal women (P < 0.05). Minor discordance rates were 26.3% (n = 62/236) in premenopausal women and 42.4% (n = 300/708) in postmenopausal ones (P < 0.05), whereas major discordance rates were 0% (n = 0/236) and 2.5% (n = 18/708), respectively (P < 0.05). In discordant cases of postmenopausal group, the rate of lumbar regions with lower T-scores was statistically higher than those of premenopausal group (P < 0.05). The majority (63.5%, n = 202/318) of postmenopausal women with T-score discordances had lower lumbar T-scores.
   Conclusion: Because of higher prevalence of discordance in non-geriatric postmenopausal women, we recommend together lumbar and femoral BMD measurements for the diagnosis of osteopenia and osteoporosis.
C1 [Ayaz, Sevin] Toros Univ, Vocat Sch, Dept Nucl Med, Mersin State Hosp,Dept Med Imaging Tech, Mersin, Turkey.
   [Gultekin, Salih Sinan] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Nucl Med, Ankara, Turkey.
   [Dilli, Alper] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Radiol, Ankara, Turkey.
   [Ayaz, Umit Yasar] Mersin Womens & Childrens Hosp, Dept Radiol, Mersin, Turkey.
RP Ayaz, S (corresponding author), Toros Univ, Vocat Sch, Dept Med Imaging Tech, Bahcelievler Campus,1857 Str,12 Yenisehir, TR-33140 Mersin, Turkey.
RI AYAZ, Sevin COŞAR/F-5759-2019; Gültekin, Salih Sinan/L-4198-2019
OI Gültekin, Salih Sinan/0000-0003-2458-3530
CR Abrahamsen B, 1997, J BONE MINER RES, V12, P1471, DOI 10.1359/jbmr.1997.12.9.1471
   Arlot ME, 1997, J BONE MINER RES, V12, P683, DOI 10.1359/jbmr.1997.12.4.683
   Ayaz S, 2017, J CLIN ANAL MED, V8, P19, DOI 10.4328/JCAM.4578
   Barrera G, 2004, NUTRITION, V20, P769, DOI 10.1016/j.nut.2004.05.014
   Boonen S, 1996, Am J Orthop (Belle Mead NJ), V25, P198
   Cai ZJ, 1999, WHO TECH REP SER, V887, P1
   Cakmak B, 2012, TURK OSTEOPOROZ DERG, V18, P86, DOI 10.4274/Tod.27146
   Chen HY, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/213234
   Clo A, 2015, NEW MICROBIOL, V38, P345
   Costa-Paiva Lúcia, 2003, Rev. Bras. Ginecol. Obstet., V25, P507, DOI 10.1590/S0100-72032003000700007
   Dahnert W., 2007, RADIOLOGY REV MANUAL, P4
   EASTELL R, 1989, J CLIN INVEST, V83, P168, DOI 10.1172/JCI113854
   ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402
   Fountoulis G, 2016, INT J ENDOCRINOL, V2016, DOI 10.1155/2016/6169721
   Gultekin SS, 2015, J CLIN ANAL MED, V6, P541, DOI 10.4328/JCAM.2232
   Iranpour D, 2014, HELL J NUCL MED, V17, P111, DOI 10.1967/s002449910138
   Karaguzel G, 2010, REV ENDOCR METAB DIS, V11, P237, DOI 10.1007/s11154-010-9154-0
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   KOHRT WM, 1995, J BONE MINER RES, V10, P1303, DOI 10.1002/jbmr.5650100906
   Lo SST, 2015, HONG KONG MED J, V21, P536, DOI 10.12809/hkmj154527
   Lu YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep25206
   Meiyanti, 2010, UNIVERSA MED, V29, P169
   Moayyeri A, 2005, BMC ENDOCR DISORD, V5, P1
   Mounach A, 2009, SEMIN ARTHRITIS RHEU, V38, P467, DOI 10.1016/j.semarthrit.2008.04.001
   O'Connor KM, 2016, MED CLIN N AM, V100, P807, DOI 10.1016/j.mcna.2016.03.016
   Ozdemir O, 2015, TURK OSTEOPOROZ DERG, V21, P105, DOI 10.4274/tod.22448
   PECK WA, 1993, AM J MED, V94, P646
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Schnabel M, 2005, ZBL CHIR, V130, P469, DOI 10.1055/s-2005-836871
   Seok H, 2014, J BONE MINER METAB, V32, P405, DOI 10.1007/s00774-013-0512-3
   Singh Meeta, 2012, J Midlife Health, V3, P76, DOI 10.4103/0976-7800.104457
   TSAI KS, 1984, J CLIN INVEST, V73, P1668, DOI 10.1172/JCI111373
   WHO Scientific Group, 1996, WHO TECHN REP SER, V866
   Woodson G, 2000, J CLIN DENSITOM, V3, P319, DOI 10.1385/JCD:3:4:319
   World Health Organization Study Group, 1994, WHO TECHN REP SER, V843
   Xu C, 2014, ACTA MEDICA MEDITERR, V30, P1397
   Younes Mohamed, 2014, Tunis Med, V92, P1
   Zebaze R, 2010, OSTEOPOROSIS IN MEN: THE EFFECTS OF GENDER ON SKELETAL HEALTH, 2ND EDITION, P167, DOI 10.1016/B978-0-12-374602-3.00013-4
NR 40
TC 0
Z9 0
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 683
EP 690
DI 10.19193/0393-6384_2017_4_102
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700023
DA 2022-07-14
ER

PT J
AU Aykas, F
   Avci, D
   Arik, F
   Cetinkaya, A
   Kolagasi, O
   Ozen, M
   Oguz, A
   Unal, A
   Uslu, E
   Arik, BE
AF Aykas, Fatma
   Avci, Deniz
   Arik, Ferhat
   Cetinkaya, Ali
   Kolagasi, Oykun
   Ozen, Mustafa
   Oguz, Arzu
   Unal, Aydin
   Uslu, Emine
   Arik, Bade Erturk
TI THERE IS A RELATION BETWEEN BLOOD SUBGROUPS AND INSULIN RESISTANCE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE insulin resistance; ABO blood subgroups; Rh system; HOMA-IR
ID DIABETES-MELLITUS; ADIPOSE-TISSUE; GROUP-AB; OBESITY; RISK; DISEASE;
   CANCER
AB Objective: Effects of concomitance of genetic factors with diabetes mellitus have been researched for a long time. We investigated relationship between insulin resistance and ABO/Rh blood group systems, which has not been investigated before.
   Material and method: In the present study, medical files of patients who applied to outpatient clinics of Endocrinology and Metabolism, Internal Medicine and Diabetes at Kayseri Training and Research Hospital between dates September 2010 and March 2015, and who had been studied for, but not diagnosed with diabetes mellitus, were retrospectively evaluated. Among patients, those with HOMA-IR >= 2.5 were accepted as having insulin resistance, and enrolled in the study. Patient whose blood groups were recorded in the hospital records or blood groups were determined later during control visits. The control group composed of healthy individuals who applied to the same hospital.
   Results: When compared with the control group, blood type A was significantly higher in patients with insulin resistance (p=0.022). The adjusted p value was 0.264 when Bonferroni correction was used. Blood type O group was also determined less significantly higher in patients with insulin resistance (p=0.055). The adjusted p value was 0.060. No significant difference was determined in blood types B and AB (p=0.49 and 0.12, respectively). Blood type A Rh (+) was 45.2% in patients with IR whereas 37.2% in the control group (p=0.030, adj. p=0.360). Blood type 0 Rh (+) was significantly higher in the control group (p< 0.001, adj. p< 0.001).
   Conclusion: These data suggest that individuals with blood type A are more directly related with insulin resistance, while those with type O are less directly related with insulin resistance in Turkish population.
C1 [Aykas, Fatma; Kolagasi, Oykun] Antalya Training & Res Hosp, Dept Hematol, Antalya, Turkey.
   [Avci, Deniz; Arik, Ferhat; Cetinkaya, Ali; Ozen, Mustafa; Oguz, Arzu; Uslu, Emine] Kayseri Training & Res Hosp, Dept Internal Med, Kayseri, Turkey.
   [Unal, Aydin] Univ Erciyes, Dept Nephrol, Kayseri, Turkey.
   [Arik, Bade Erturk] Univ Erciyes, Dept Family Practice, Kayseri, Turkey.
RP Arik, F (corresponding author), Kayseri Training & Res Hosp, Dept Internal Med, Kayseri, Turkey.
RI Oguz, Arzu/W-8004-2019
OI Oguz, Arzu/0000-0001-6512-6534
CR Anstee DJ, 2010, BLOOD, V115, P4635, DOI 10.1182/blood-2010-01-261859
   Bener A, 2014, NIGER J CLIN PRACT, V17, P565, DOI 10.4103/1119-3077.141418
   Fagherazzi G, 2015, DIABETOLOGIA, V58, P519, DOI 10.1007/s00125-014-3472-9
   Franchini M, 2014, THROMB HAEMOSTASIS, V112, P1103, DOI 10.1160/TH14-05-0457
   Gates MA, 2011, INT J CANCER, V128, P482, DOI 10.1002/ijc.25339
   Hiltunen LM, 2009, THROMB RES, V124, P167, DOI 10.1016/j.thromres.2008.11.012
   HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936
   Jassim W. E., 2012, Eastern Mediterranean Health Journal, V18, P888
   KANAZAWA Y, 1983, Tohoku Journal of Experimental Medicine, V141, P295
   Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200
   Ohno Y, 2015, INT J CLIN EXP MED, V8, P2642
   Okon U A, 2008, Niger J Physiol Sci, V23, P1
   Patel PS, 2013, J OBES, V2013, DOI 10.1155/2013/616193
   Pourafkari L, 2015, PERFUSION
   Qureshi MA, J COLL
   Sahi MD, 2011, S AFR FAM PRACT, V53, P568, DOI 10.1080/20786204.2011.10874154
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Tahir, 2012, ANN PAK I MED SCI, V8, P134
   Tsukumo DML, 2007, DIABETES, V56, P1986, DOI 10.2337/db06-1595
   Wang DS, 2012, INT J CANCER, V131, P461, DOI 10.1002/ijc.26376
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Zhang CP, 2015, DIABETES-METAB RES, V31, P627, DOI 10.1002/dmrr.2650
NR 22
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 987
EP 990
DI 10.19193/0393-6384_2017_6_156
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500015
DA 2022-07-14
ER

PT J
AU Azizpour, M
   Moosazadeh, M
   Esmaeili, R
AF Azizpour, Mahtabeh
   Moosazadeh, Mahmood
   Esmaeili, Ravanbakhsh
TI USE OF PHYSICAL RESTRAINTS IN INTENSIVE CARE UNIT: A SYSTEMATIC REVIEW
   STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Systematic review; intensive care units; physical restraint
ID UNPLANNED EXTUBATION; PREVALENCE; MULTICENTER; DELIRIUM; RISK;
   PREDICTORS; SEDATION
AB Background and purpose: Use of physical restraints is a common clinical practice in different conditions and hospital wards including Intensive Care Units (ICU). Given the importance of the use of physical restraints in the ICUs, the present systematic review was conducted in order to determine the prevalence of physical restraint use in the ICUs.
   Materials and methods: Related papers on restraint use in the ICUs published from 2000 to 2016 were included in this study by searching the national and international scientific databases. Based on Farsi and English keywords searching, and applying inclusion and exclusion criteria, final 22 papers from 17 countries were selected for the meta-analysis. The data were analyzed by using Stata Software Version 12.0. The index of heterogeneity among different studies was determined using Cochran (Q) and I2 tests.
   Results: The present systematic review study includes 22 related articles. The prevalence of physical restrains use varied from 7% in the study by Elliott with a sample size of 569 patients in general ICUs in Australia to 87% in Curry's study with a sample of 26 patients in a surgical ICU in the United States. According to the results of the meta-analysis, the prevalence of physical restrains use was estimated to be 46.7% (CI 95%: 34.7-58.6) in the ICUs.
   Conclusion: As there is a widespread use of physical restraints in the ICU, it is necessary that hospital managers plan appropriately to reduce the use of physical restraints and whereby its complications and to increase adequately the knowledge, attitudes of ICU nurses towards physical restraint of patients and its affecting factors so that they adhere to the guidelines of this method of care properly.
C1 [Azizpour, Mahtabeh] Mazandaran Univ Med Sci, Student Res Comm, Sari, Iran.
   [Moosazadeh, Mahmood] Mazandaran Univ Med Sci, Hlth Sci Res Ctr, Sari, Iran.
   [Esmaeili, Ravanbakhsh] Univ Med Sci, Orthoped Res Ctr Mazandaran, Nasibeh Sch Nursing & Midwifery, Sari, Iran.
RP Esmaeili, R (corresponding author), Mazandaran Univ Med Sci, Med Surg Nursing Dept, Nasibeh Sch Nursing & Midwifery, Vesal Shirazi St, Sari, Iran.
RI moosazadeh, mahmood/F-3730-2017
OI moosazadeh, mahmood/0000-0002-5452-514X
CR Benbenbishty Julie, 2010, Intensive Crit Care Nurs, V26, P241, DOI 10.1016/j.iccn.2010.08.003
   Burry LD, 2014, CAN J ANESTH, V61, P619, DOI 10.1007/s12630-014-0174-1
   Chang LY, 2008, AM J CRIT CARE, V17, P408
   Choi E, 2003, J CLIN NURS, V12, P651, DOI 10.1046/j.1365-2702.2003.00789.x
   Curry K, 2008, AM J CRIT CARE, V17, P45
   De Jonghe B, 2013, INTENS CARE MED, V39, P31, DOI 10.1007/s00134-012-2715-9
   Egerod I, 2013, NURS CRIT CARE, V18, P166, DOI 10.1111/nicc.12003
   Elliott D, 2013, CRIT CARE RESUSC, V15, P213
   Evans D, 2003, J ADV NURS, V41, P274, DOI 10.1046/j.1365-2648.2003.02501.x
   Happ MB, 2004, AM J CRIT CARE, V13, P210, DOI 10.4037/ajcc2004.13.3.210
   Hofso Kristin, 2007, Intensive Crit Care Nurs, V23, P249, DOI 10.1016/j.iccn.2007.04.003
   Hooseinrezaee H, 2015, J NURS EDUC, V4, P31
   Huang HT, 2009, J NURS RES, V17, P241, DOI 10.1097/JNR.0b013e3181c1215d
   Ismaeil MF, 2014, EGYPT J CHEST DIS TU, V63, P219, DOI 10.1016/j.ejcdt.2013.09.023
   Jiang H, 2015, NURS ETHICS, V22, P652, DOI 10.1177/0969733014557118
   Kabirzadeh A, 2005, J MAZANDARAN U MED S, V16, P138
   Kandeel NA, 2013, NURS HEALTH SCI, V15, P79, DOI 10.1111/nhs.12000
   Kruger C, 2013, INT J NURS STUD, V50, P1599, DOI 10.1016/j.ijnurstu.2013.05.005
   Kuzniewicz MW, 2008, CHEST, V133, P1319, DOI 10.1378/chest.07-3061
   Lai CK, 2011, REHABILITATION REP, V9
   Langley Gayle, 2011, Intensive Crit Care Nurs, V27, P67, DOI 10.1016/j.iccn.2010.12.001
   Liu JJ, 2009, HEART LUNG, V38, P208, DOI 10.1016/j.hrtlng.2008.06.002
   Lucidarme O, 2010, CRIT CARE, V14, DOI 10.1186/cc8954
   Luk E, 2014, CRITICAL CARE, V18, P46
   Maccioli GA, 2003, CRIT CARE MED, V31, P2665, DOI 10.1097/01.CCM.0000095463.72353.AD
   Martin B, 2005, AM J CRIT CARE, V14, P133, DOI 10.4037/ajcc2005.14.2.133
   Martin IV, 2011, ENFERMERIA INTENSIVA, V23, P164
   Mehta S, 2015, CRIT CARE MED, V43, P557, DOI 10.1097/CCM.0000000000000727
   Micek ST, 2005, CRIT CARE MED, V33, P1260, DOI 10.1097/01.CCM.0000164540.58515.BF
   Ming Y, 2007, 18 INT NURS RES C FO
   Minnick AF, 1998, J NURS ADMIN, V28, P19, DOI 10.1097/00005110-199811000-00007
   Minnick AF, 2007, J NURS SCHOLARSHIP, V39, P30, DOI 10.1111/j.1547-5069.2007.00140.x
   Mohr WK, 2003, CAN J PSYCHIAT, V48, P330, DOI 10.1177/070674370304800509
   Moradimajd P., 2015, IRAN J CRIT CARE NUR, V8, P173
   Nirmalan M, 2004, BRIT J ANAESTH, V92, P789, DOI 10.1093/bja/aeh138
   Ozdemir L, 2009, CONTEMP NURSE, V34, P119
   Pashaee S, 2014, PREVENTIVE CARE NURS, V4, P65
   Poodineh Moghadam M., 2015, J NURS EDUC, V4, P9
   Rose L, 2016, J CRIT CARE, V31, P31, DOI 10.1016/j.jcrc.2015.09.011
   Taha NM, 2013, J NURSING CARE, V135, P2013
   Tanios MA, 2010, RESP CARE, V55, P561
   van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892
   Yeh Shu-Hui, 2004, J Nurs Res, V12, P246
   Zencirci AD, 2012, USE PHYS RESTRAINTS
NR 44
TC 9
Z9 10
U1 6
U2 42
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 129
EP 136
DI 10.19193/0393-6384_2017_1_020
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800020
DA 2022-07-14
ER

PT J
AU Babenko, D
   Turmuhambetova, A
   Sandle, T
   Pestrea, SA
   Moraru, D
   Chesca, A
AF Babenko, Dmitriy
   Turmuhambetova, Anar
   Sandle, Tim
   Pestrea, Sorina Anamaria
   Moraru, Dan
   Chesca, Antonella
TI IN SILICO COMPARISON OF DIFFERENT TYPES OF MLVA WITH PFGE BASED ON
   PSEUDOMONAS AERUGINOSA GENOMES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE MLVA; PFGE; Pseudomonas aeruginosa; In Silico; Simpson index; Adjusted
   Rand index; Adjusted Wallace coefficient
ID FIELD GEL-ELECTROPHORESIS; CYSTIC-FIBROSIS; TYPING METHODS;
   DISCRIMINATORY POWER; POLYMORPHISM; SEQUENCE
AB Introduction: Pseudomonas aeruginosa is an important pathogen in nosocomial infections and developed typing techniques are essential allowing researchers to understanding hospital epidemiology. Monitoring the emergence and transmission of Pseudomonas aeruginosa strains permits the elucidation of the source of infection and routes of bacterial transmission. The aim of the present study was an in silico comparison of Pulsed-field gel electrophoresis with different schemes of Multiple Locus Variable-number Tandem Repeat Analysis in terms of discriminatory power and concordance.
   Materials and methods: 58 P.aeruginosa whole genomes have been analyzed in silico to determine SpeI-digested PFGE type and subspecies types using different MLVA methods. Resolution power, strength and direction of the concordance between typing methods have been estimated by calculation of the Simpson's index, the adjusted Rand and the adjusted Wallace coefficients.
   Results: The Simpson's indices of diversity were 1.0 for PFGE and from 0.995 to 0.999 for MLVA schemes with 6-19 markers. The congruence between PFGE and different MLVA methods measured by the adjusted Rand index were from 0.306 to 0.665 on cluster level for PFGE and type level for MLVA. The congruence was slightly higher at the clonal cluster level-from 0.46 to 0.694.
   Conclusion: Our in silico study for comparing different MLVA schemes with PFGE, based on Pseudomonas aeruginosa genomes showed, on the one hand, the same high level of discriminatory power of PFGE and MLVA even with 6 tandems markers; nonetheless, on the other hand, there was moderate/poor congruence (no more 70%) between PFGE and MLVA schemes on cluster level.
C1 [Babenko, Dmitriy; Turmuhambetova, Anar] Karaganda State Med Univ, Karaganda, Kazakhstan.
   [Sandle, Tim] Univ Manchester, Manchester, Lancs, England.
   [Pestrea, Sorina Anamaria] Clin Hosp Psychiat & Neurol Brasov, Brasov, Romania.
   [Moraru, Dan; Chesca, Antonella] Clin Hosp Pneumophtysiol Brasov, Brasov, Romania.
   [Chesca, Antonella] Transilvania Univ Brasov, Brasov, Romania.
RP Chesca, A (corresponding author), Clin Hosp Pneumophtysiol Brasov, Brasov, Romania.
RI Babenko, Dmitriy/AAW-9907-2020; Sandle, Tim/D-4572-2015
OI Sandle, Tim/0000-0002-8304-8274
CR Carrico JA, 2006, J CLIN MICROBIOL, V44, P2524, DOI 10.1128/JCM.02536-05
   Di Cagno R, 2010, INT J FOOD MICROBIOL, V143, P246, DOI 10.1016/j.ijfoodmicro.2010.08.018
   DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409
   Doleans-Jordheim A, 2009, EUR J CLIN MICROBIOL, V28, P1105, DOI 10.1007/s10096-009-0755-z
   Edelstein MV, 2013, LANCET INFECT DIS, V13, P867, DOI 10.1016/S1473-3099(13)70168-3
   Galili T., 2014, DENDEXTEND EXTENDING
   GRUNDMANN H, 1995, J CLIN MICROBIOL, V33, P528, DOI 10.1128/JCM.33.3.528-534.1995
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Maatallah M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082069
   Morales G, 2004, J BACTERIOL, V186, P4228, DOI 10.1128/JB.186.13.4228-4237.2004
   NEI M, 1983, J MOL EVOL, V19, P153, DOI 10.1007/BF02300753
   Onteniente L, 2003, J CLIN MICROBIOL, V41, P4991, DOI 10.1128/JCM.41.11.4991-4997.2003
   Revets H, 1996, ACTA CLIN BELG, V51, P222, DOI 10.1080/22953337.1996.11718514
   Roy PH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008842
   Sabat AJ, 2013, EUROSURVEILLANCE, V18, P17
   Sayers EW, 2016, METHODS MOL BIOL, V1374, P1, DOI 10.1007/978-1-4939-3167-5_1
   Servant Nicolas, 2014, EMA EASY MICROARRAY
   Silbert S, 2004, INFECT CONT HOSP EP, V25, P847, DOI 10.1086/502307
   Sobral D, 2012, EUR J CLIN MICROBIOL, V31, P2247, DOI 10.1007/s10096-012-1562-5
   Speijer H, 1999, J CLIN MICROBIOL, V37, P3654, DOI 10.1128/JCM.37.11.3654-3661.1999
   Spencker FB, 2000, CLIN MICROBIOL INFEC, V6, P600, DOI 10.1046/j.1469-0691.2000.00171.x
   Struelens M. J., 1996, Clin Microbiol Infect, V2, P2, DOI 10.1111/j.1469-0691.1996.tb00193.x
   Talon D, 1996, J HOSP INFECT, V32, P135, DOI 10.1016/S0195-6701(96)90055-9
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995
   Turton JF, 2010, CLIN MICROBIOL INFEC, V16, P1111, DOI 10.1111/j.1469-0691.2009.03049.x
   van Belkum A, 2007, CLIN MICROBIOL INFEC, V13, P1, DOI 10.1111/j.1469-0691.2007.01786.x
   Vu-Thien H, 2007, J CLIN MICROBIOL, V45, P3175, DOI 10.1128/JCM.00702-07
NR 27
TC 4
Z9 4
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 607
EP 612
DI 10.19193/0393-6384_2017_4_090
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700011
DA 2022-07-14
ER

PT J
AU Bacarea, A
   Romila, A
   Petrisor, DV
   Costea, GC
   Bui, L
   Bacarea, V
AF Bacarea, Anca
   Romila, Aurelia
   Petrisor, Dana Valentina
   Costea, George Claudiu
   Bui, Lucia
   Bacarea, Vladimir
TI OCCUPATIONAL WORK EXPOSURE TO HEPATITIS B VIRUS INFECTION IN THE
   EMERGENCY COUNTY CLINICAL HOSPITAL, TIRGU MURES, ROMANIA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE hepatitis B viral infection; HBsAg; HBsAb; health care workers;
   occupational work exposure
ID HEALTH-CARE WORKERS; BODY-FLUIDS; BLOOD; RISKS
AB Introduction: One of the ways of transmission of hepatitis B viral infection is occupational exposure and health care workers (HCWs) are exposed to the risk of acquiring HBV infection. The aim of our study is to assess the occupational exposure to HBV infection, in the HCWs of the Emergency County Clinical Hospital Tirgu Mures, Romania.
   Materials and methods: The study was conducted retrospectively on a sample of 524 HCWs, between January 2010 and December 2014, who accidentally came into contact with blood or other body fluids from patients admitted in the Emergency County Clinical Hospital Tirgu Mures, Romania. We persuaded the source patients for the following markers: HBsAg, HCVAb and the HCWs for the following markers: HBsAg, HBsAb, HCVAb, HIVAb. Depending on the tests results and after subjects has given their consent for vaccination and counseling, vaccination was planned at 1 month, 3 months and 6 months.
   Results: The annual rate of HBV infections occurring in health care workers ranged from 0.78% to 2.88%. The highest proportion of occupational work exposure occurred among physicians (41.6%) and nurses (32.44%). The HCWs working in surgical departments, reported the highest occupational work exposure (44.85%). The adherence to follow-up decreased significantly from the 1 month scheduled serological testing, to the 3 and 6 months testing (p< 0.0001).
   Conclusion: Educational programs, implementation and adherence to more safety precautions for HCWs will help to decrease the frequency of occupational work exposure. Administration of hepatitis B vaccine to HCWs early in their careers can prevent HBV infection associated with occupational work exposure.
C1 [Bacarea, Anca; Costea, George Claudiu] Univ Med & Pharm, Dept Pathophysiol, Targu Mures, Romania.
   [Romila, Aurelia] Univ Dunarea de Jos, Fac Med, Dept Clin Med, 1 Vadu Sacalelor St,Bl Pescarus,Ap 8, Galati, Romania.
   [Romila, Aurelia] Galati Cty Hosp, Clin Geriatr Dept, Targu Mures, Romania.
   [Petrisor, Dana Valentina; Bacarea, Vladimir] Univ Med & Pharm, Med Res Methodol Dept, Targu Mures, Romania.
   [Bui, Lucia] Emergency Cty Hosp, Surveillance & Control Nosocomial Infect Dept, Targu Mures, Romania.
RP Romila, A (corresponding author), Univ Dunarea de Jos, Fac Med, Dept Clin Med, 1 Vadu Sacalelor St,Bl Pescarus,Ap 8, Galati, Romania.
RI Bacarea, Anca/AAW-9459-2020
CR [Anonymous], 2011, COUNTRY MISSION ROMA
   Batra V, 2015, ANN GASTROENTEROL, V28, P276
   Blachier M, 2013, J HEPATOL, V58, P593, DOI 10.1016/j.jhep.2012.12.005
   Butsashvili M, 2012, OCCUP MED-OXFORD, V62, P620, DOI 10.1093/occmed/kqs121
   Coppola N, 2016, WORLD J HEPATOL, V8, P273, DOI 10.4254/wjh.v8.i5.273
   Dement JM, 2004, AM J IND MED, V46, P637, DOI 10.1002/ajim.20106
   Gheorghe L, 2013, EUR J GASTROEN HEPAT, V25, P56, DOI 10.1097/MEG.0b013e328358b0bb
   Homoud AHA, 2014, J INFECT PUBLIC HEAL, V7, P257, DOI 10.1016/j.jiph.2013.08.004
   Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Marcellin P, 2009, J HEPATOL, V50, P227, DOI 10.1016/j.jhep.2008.10.001
   Markovc-Denic L, 2013, SRP ARK CELOK LEK, V141, P789, DOI 10.2298/SARH1312789M
   McMahon BJ, 2005, SEMIN LIVER DIS, V25, P3, DOI 10.1055/s-2005-915644
   Minuk G Y, 2005, HPB (Oxford), V7, P56, DOI 10.1080/13651820410016633
   Nardone A, 2009, EPIDEMIOL INFECT, V137, P961, DOI 10.1017/S0950268808001672
   Rice BD, 2015, OCCUP MED-OXFORD, V65, P210, DOI 10.1093/occmed/kqu206
   Schillie S, 2013, MMWR RECOMM REP, V62, P1
   Vieira D, 2015, ANN OCCUP HYG, V59, P566, DOI 10.1093/annhyg/meu117
NR 18
TC 1
Z9 1
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 17
EP 21
DI 10.19193/0393-6384_2017_1_002
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800002
DA 2022-07-14
ER

PT J
AU Bagheri, A
   Mahvi, AH
   Nabizadeh, R
   Dehghani, MH
   Mahmoudi, B
   Akbari-Adergani, B
   Yaghmaeian, K
AF Bagheri, Amin
   Mahvi, Amir Hossein
   Nabizadeh, Ramin
   Dehghani, Mohammad Hadi
   Mahmoudi, Babak
   Akbari-Adergani, Behrouz
   Yaghmaeian, Kamyar
TI RAPID DESTRUCTION OF THE NON-STEROIDAL ANTI-INFLAMMATORY DRUG DICLOFENAC
   USING ADVANCED NANO-FENTON PROCESS IN AQUEOUS SOLUTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Diclofenac; Pollutant; Advanced Nano-Fenton; water
ID TREATMENT PLANTS; WATER; PHARMACEUTICALS; DEGRADATION; CARBAMAZEPINE;
   RESIDUES; REMOVAL
AB Introduction: Pharmaceuticals have been attracting the attention of many researchers and are considered as a xenobiotic and emerging pollutant in the environment. Diclofenac(DCF) as a non-steroidal pharmaceutical has been detected in water and wastewater samples more than other compounds due to high consumption and limited biodegradability. The disastrous event of a reduction in the number of vultures due to kidney damage following feeding on the corpse of domestic animals contaminated with DCF and the high bioaccumulation capacity of this drug in the tissue of organisms indicate the significance of this compound as a potential contaminant.
   Materials and methods: In this study, advanced Nano-Fenton process (ANF) was applied to remove DCF from aqueous solutions. The full factorial design was applied using R software (3.1.0) to optimize variables. DCF residual concentration was determined by high-pressure liquid chromatography device and the degree of mineralization was determined through TOC analysis.
   Results: The mean DCF removal efficiency under different operational conditions and at the time of 1-10 min was obtained to be about 83%. With the increase in the time and H/F along with the reduction in initial concentration of the drug, the response variable (DCF removal) increased.
   Conclusion: Our research showed that ANF can be considered as a quick and efficient process for the removal of DCF from wastewater with a significant amount of mineralization.
C1 [Bagheri, Amin; Mahvi, Amir Hossein; Nabizadeh, Ramin; Dehghani, Mohammad Hadi; Mahmoudi, Babak; Yaghmaeian, Kamyar] Univ Tehran Med Sci, Sch Publ Hlth, Dept Environm Hlth Engn, Tehran, Iran.
   [Mahvi, Amir Hossein; Yaghmaeian, Kamyar] Univ Tehran Med Sci, Inst Environm Res, Ctr Water Qual Res, Tehran, Iran.
   [Dehghani, Mohammad Hadi] Univ Tehran Med Sci, Inst Environm Res, Ctr Solid Waste Res, Tehran, Iran.
   [Nabizadeh, Ramin] Univ Tehran Med Sci, Inst Environm Res, Ctr Air Pollut Res, Tehran, Iran.
RP Yaghmaeian, K (corresponding author), Univ Tehran Med Sci, Sch Publ Hlth, Dept Environm Hlth Engn, Tehran, Iran.; Yaghmaeian, K (corresponding author), Univ Tehran Med Sci, Inst Environm Res, Ctr Water Qual Res, Tehran, Iran.
EM kam.yaghmaeian@gmail.com
RI Akbari-adergani, Behrouz/M-4260-2018
OI dehghani, mohammad hadi/0000-0001-7516-8885; nabizadeh,
   ramin/0000-0002-6798-7474
FU Center for Water Quality Research, Institute for Environmental Research,
   Tehran University of Medical Sciences, Tehran, Iran [94-01-46-28790]
FX This research has been financially supported by the grant (Project No:
   94-01-46-28790) from the Center for Water Quality Research, Institute
   for Environmental Research, Tehran University of Medical Sciences,
   Tehran, Iran.
CR Acuna V, 2015, SCI TOTAL ENVIRON, V503, P133, DOI 10.1016/j.scitotenv.2014.05.067
   Agarwal S, 2016, J MOL LIQ, V221, P1237, DOI 10.1016/j.molliq.2016.04.076
   Andreozzi R, 2003, CHEMOSPHERE, V50, P1319, DOI 10.1016/S0045-6535(02)00769-5
   Andreozzi R, 2002, WATER RES, V36, P2869, DOI 10.1016/S0043-1354(01)00500-0
   Babuponnusami A, 2014, J ENVIRON CHEM ENG, V2, P557, DOI 10.1016/j.jece.2013.10.011
   Bae S, 2013, APPL CATAL B-ENVIRON, V134, P93, DOI 10.1016/j.apcatb.2012.12.031
   Chakma S, 2013, AICHE J, V59, P4303, DOI 10.1002/aic.14150
   Clesceri L.S., 2005, STANDARD METHODSFOR
   Karami MA, 2016, BULG CHEM COMMUN, V48, P43
   Klavarioti M, 2009, ENVIRON INT, V35, P402, DOI 10.1016/j.envint.2008.07.009
   Kummerer K, 2009, J ENVIRON MANAGE, V90, P2354, DOI 10.1016/j.jenvman.2009.01.023
   Naddeo V, 2009, ULTRASON SONOCHEM, V16, P790, DOI 10.1016/j.ultsonch.2009.03.003
   Naghan DJ, 2015, BULG CHEM COMMUN, V47, P14
   Oaks JL, 2004, NATURE, V427, P630, DOI 10.1038/nature02317
   Su CC, 2013, J TAIWAN INST CHEM E, V44, P310, DOI 10.1016/j.jtice.2012.11.009
   Taggart MA, 2007, ENVIRON INT, V33, P759, DOI 10.1016/j.envint.2007.02.010
   Ternes TA, 1998, WATER RES, V32, P3245, DOI 10.1016/S0043-1354(98)00099-2
   Weng CH, 2013, SEP PURIF TECHNOL, V117, P75, DOI 10.1016/j.seppur.2013.03.047
   Xu LJ, 2011, J HAZARD MATER, V186, P256, DOI 10.1016/j.jhazmat.2010.10.116
   Zhang YJ, 2008, CHEMOSPHERE, V73, P1151, DOI 10.1016/j.chemosphere.2008.07.086
NR 20
TC 6
Z9 6
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 879
EP 883
DI 10.19193/0393-6384_2017_5_131
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000025
DA 2022-07-14
ER

PT J
AU Balkan, A
   Guelsen, MT
   Kaya, B
AF Balkan, Ayhan
   Guelsen, Murat Taner
   Kaya, Buenyamin
TI SERUM MICRORNA-26, MICRORNA-122 AND MICRORNA-192 EXPRESSIONS IN
   HEPATOCELLULAR CARCINOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hepatocellular carcinoma; microRNA-26; microRNA-122; microRNA-192
ID HEPATITIS-B-VIRUS; CIRCULATING MICRORNAS; ALPHA-FETOPROTEIN; CANCER;
   IDENTIFICATION; METASTASIS; BIOMARKERS; DIAGNOSE; PLASMA
AB Introduction: There is not yet an ideal biomarker to detect hepatocellular carcinoma (HCC) in early stage. MicroRNA (miRNA) dysregulation in HCC results in inhibition of cellular apoptosis, increased angiogenesis, invasion and development of metastasis. The aim of the present study was to evaluate the efficacy of serum miRNA-26, miRNA-122 and miRNA-192 levels in diagnosis of HCC compared to other prognostic criteria.
   Materials and methods: The study included newly diagnosed HCC patients (n=42) and patients with non-alcoholic fatty liver disease (NAFLD) as controls (n=45). We measured serum miRNA-26, miRNA-122 and miRNA-192 levels for each patient.
   Results: Serum levels of miRNA-26 were significantly lower in HCC patients (29.03) than those in control group (30.34) (p<0.001). There was no significant difference in serum levels of miRNA-122 between the two groups (p=0.181). MiRNA-192 was not expressed as assessed by the real-time PCR method. For diagnosis of HCC, cut-off value was set at 29.38 for miR-26. With this cut-off value, sensitivity was 71.4%, and specificity was 82.2%, while positive and negative predictive values were 78.9% and 75.5%, respectively (p<0.0001). We also compared the miRNA-26 and miRNA-122 levels of patients with other diagnostic, clinical and prognostic data, which are significant for HCC. No statistically significant correlation was found between alpha-fetoprotein (AFP) and miRNA122 and miRNA-26 gene expressions.
   Conclusions: Serum levels of miRNA-26 may contribute to early diagnosis of HCC when used together with other diagnostic, clinical and prognostic markers.
C1 [Balkan, Ayhan; Guelsen, Murat Taner] Gazi Univ, Fac Med, Dept Gastroenterol, Gaziantep TR-27310, Turkey.
   [Kaya, Buenyamin] Gazi Univ, Fac Med, Dept Internal Med, Gaziantep TR-27310, Turkey.
RP Balkan, A (corresponding author), Gazi Univ, Fac Med, Dept Gastroenterol, Gaziantep TR-27310, Turkey.
FU Scientific Research Fund by Gaziantep University [BAP- TF.UT.16.07]
FX All authors thank to Scientific Research Fund by Gaziantep University
   for their financial support (Project no. BAP- TF.UT.16.07).
CR Badvie S, 2000, POSTGRAD MED J, V76, P4, DOI 10.1136/pmj.76.891.4
   Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031
   Carr BI, 2007, DIGEST DIS SCI, V52, P776, DOI 10.1007/s10620-006-9541-2
   Cortez MA, 2009, EXPERT OPIN BIOL TH, V9, P703, DOI [10.1517/14712590902932889, 10.1517/14712590902932889 ]
   Dienstag JL, 2012, HARRISONS PRINCIPLES, V18e
   Durand F, 2001, J HEPATOL, V35, P254, DOI 10.1016/S0168-8278(01)00108-8
   European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kojima K, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1345
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Liu SP, 2012, J HEPATOL, V56, P389, DOI 10.1016/j.jhep.2011.08.008
   Liu Z, 2008, INT J MOL SCI, V9, P978, DOI 10.3390/ijms9060978
   Okuda K, 1992, PRIMARY LIVER CANC J, P3
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013
   Piluso A, 2015, HEPATOL INT, V9, P586, DOI 10.1007/s12072-015-9658-5
   Qi P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028486
   Sanyal AJ, 2010, ONCOLOGIST, V15, P14, DOI 10.1634/theoncologist.2010-S4-14
   Sun J, 2013, SCI WORLD J, DOI 10.1155/2013/924206
   Takizawa D, 2007, DIGEST DIS SCI, V52, P3290, DOI 10.1007/s10620-007-9808-2
   Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806
   Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106
   Wang Y, 2016, TUMOUR BIOL
   Wu W, 2007, INT J CANCER, V120, P953, DOI 10.1002/ijc.22454
   Xu JA, 2011, MOL CARCINOGEN, V50, P136, DOI 10.1002/mc.20712
   Yuen MF, 2004, HEPATOLOGY, V39, P1694, DOI 10.1002/hep.20240
   Zhou J, 2011, J CLIN ONCOL, V29, P4781, DOI 10.1200/JCO.2011.38.2697
   Zinkin NT, 2008, CLIN CANCER RES, V14, P470, DOI 10.1158/1078-0432.CCR-07-0586
NR 29
TC 2
Z9 2
U1 1
U2 13
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 165
EP 172
DI 10.19193/0393-6384_2017_1_025
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800025
DA 2022-07-14
ER

PT J
AU Bilgili, B
   Cizmeci, Z
   Erkilinc, M
   Kural, A
   Tanriverdi, B
   Bilgili, MG
AF Bilgili, Beliz
   Cizmeci, Zeynep
   Erkilinc, Mehmet
   Kural, Alev
   Tanriverdi, Bulent
   Bilgili, Mustafa Gokhan
TI BACTERIAL BURDEN OF THYROID SHIELDS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Thyroid shields; Microorganisms; Infection risk; Disinfection
ID CONTAMINATION; INFECTION
AB Introduction: The aim of this study was to assess the role of thyroid shield as an infection source in operation room and to evaluate the effectiveness of the sterilization method that is routinely used in the institution.
   Materials and methods: Samples were obtained from the front faces of 14 thyroid shields using swabs humidified with sterile normal saline. After sampling, shields were cleansed, disinfected and sampling was repeated after 5 minutes. Microorganisms growing in the media were passaged and typed individually and their sensitivity to antibiotics was determined. Growing microorganisms in cultures were compared.
   Results: At least one pathogenic bacterium was isolated from 13 of the 14 thyroid shields sampled prior to their disinfection. Corynebacterium spp. and methicillin-resistant Staphylococcus epidermidis were most frequently isolated. More than one pathogenic bacterium was isolated from four thyroid shields, and methicillin-resistant microorganisms were isolated from eight thyroid shields. After disinfection, bacterial growth was observed only on two thyroid shields.
   Conclusion: Thyroid shields are liable to bacterial colonization. In surgical procedures performed under fluoroscopic guidance, appropriate disinfection of thyroid shields before every use is an efficient method for reducing bacterial burden.
C1 [Bilgili, Beliz] Marmara Univ, Sch Med, Anesthesiol & Reanimat Dept, Istanbul, Turkey.
   [Cizmeci, Zeynep; Tanriverdi, Bulent; Bilgili, Mustafa Gokhan] Bakirkoy Dr Sadi Konuk Res & Training Hosp, Microbiol Dept, Istanbul, Turkey.
   [Erkilinc, Mehmet] Bakirkoy Dr Sadi Konuk Res & Training Hosp, Orthopaed & Traumatol Dept, Zuhuratbaba Mh Tevfik Saglam 11, Istanbul, Turkey.
   [Kural, Alev] Bakirkoy Dr Sadi Konuk Res & Training Hosp, Biochem Dept, Istanbul, Turkey.
RP Bilgili, MG (corresponding author), Bakirkoy Dr Sadi Konuk Res & Training Hosp, Orthopaed & Traumatol Dept, Zuhuratbaba Mh Tevfik Saglam 11, Istanbul, Turkey.
RI bilgili, mustafa g/M-2923-2014; Bilgili, Beliz/M-7867-2017
OI bilgili, mustafa g/0000-0002-5301-6407; Bilgili,
   Beliz/0000-0003-3466-0771
CR Bible JE, 2009, CLIN ORTHOP RELAT R, V467, P825, DOI 10.1007/s11999-008-0341-1
   Elsayed S, 2005, J TRAUMA INJURY INFE, V59, P542
   Feierabend S, 2015, J ORTHOP TRAUMA, V29, P18, DOI 10.1097/BOT.0000000000000161
   Grogan BF, 2011, ORTHOPEDICS, V34, pE765, DOI 10.3928/01477447-20110922-09
   Guinto CH, 2002, AM J INFECT CONTROL, V30, P499, DOI 10.1067/mic.2002.126427
   HOWORTH FH, 1985, LANCET, V1, P386
   Mills SJC, 2000, AUST NZ J SURG, V70, P837, DOI 10.1046/j.1440-1622.2000.01999.x
   Neely AN, 2005, AM J INFECT CONTROL, V33, P233, DOI 10.1016/j.ajic.2005.03.002
   Pally E, 2013, CAN J SURG, V56, P109, DOI 10.1503/cjs.015311
   Rutala WA, 2006, INFECT CONT HOSP EP, V27, P372, DOI 10.1086/503340
NR 10
TC 2
Z9 2
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1059
EP 1061
DI 10.19193/0393-6384_2017_6_167
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500026
DA 2022-07-14
ER

PT J
AU Borgo, M
   Martini, M
   Bragazzi, NL
   Paluan, F
   Gorini, I
   Vecchio, I
   Licata, M
AF Borgo, Melania
   Martini, Mariano
   Bragazzi, Nicola Luigi
   Paluan, Filippo
   Gorini, Ilaria
   Vecchio, Ignazio
   Licata, Marta
TI CORPUS LOQUENS: THE SPEAKING BODY AND ABELE DE BLASIO (1858-1945)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Abele De Blasio; criminal anthropology; cultural anthropology; social
   pathology
AB This article provides a comprehensive overview of the work of Abele De Blasio (1858-1945), a pol-yhedral and eclectic figure of physician who cultivated a wide range of interests, from cultural an-thropology and ethnology to botanics, chemistry and dentistry. In particular, De Blasio is recog-nized as one of the founders and one of the most important representatives of Italian criminal an-thropology, thanks to his thorough knowledge and historical culture. He challenged the strict bio-medical paradigm of the period and combined a scientific and rigorous approach with a humanistic Weltanschauung, conjugating disciplines, such as archeology and psychopathology with biology, in such a way to give birth to a unique, innovative interdisciplinary approach. He applied this method, for example, when investigating deviant behaviors or when analyzing populations' customs and hab-its. He also studied trepanation and he considered analyzing the skull as the best way to investigate the different aspects of human life.
C1 [Borgo, Melania; Gorini, Ilaria; Licata, Marta] Univ Insubria Varese, Dept Biotechnol & Life Sci, O Rossi 9, I-21100 Varese, Italy.
   [Martini, Mariano] Univ Genoa, Dept Hlth Sci DISSAL, Sect Hist Med & Eth, Largo R Benzi,10 Pad 3, I-16132 Genoa, Italy.
   [Bragazzi, Nicola Luigi] Univ Genoa, Dept Hlth Sci DISSAL, Via Antonio Pastore 1, I-16132 Genoa, Italy.
   [Paluan, Filippo] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Via Giustiniani 2, I-35128 Padua, Italy.
   [Vecchio, Ignazio] Univ Catania, Dept Clin & Expt Med, I-95124 Catania, Italy.
RP Martini, M (corresponding author), Univ Genoa, Dept Hlth Sci DISSAL, Sect Hist Med & Eth, Largo R Benzi,10 Pad 3, I-16132 Genoa, Italy.
RI Bragazzi, Nicola Luigi/G-1672-2011
OI Bragazzi, Nicola Luigi/0000-0001-8409-868X; Vecchio,
   Ignazio/0000-0001-5942-1908
CR De Blasio A, 1900, RIV PSICHIAT FORENSE, V3, P169
   De Blasio A, 1901, RIV PSICHIAT FORENSE, V4, P117
   De Blasio A., 1902, RIV PSICHIATRIA FORE, V5, P41
   De Blasio A., 1900, RIV PSICHIATRIA FORE, V3, P293
   De Blasio A, 1901, RIV PSICHIAT FORENSE, V4, P285
   De Blasio A., 1902, RIV PSICHIAT FORENSE, P173
   DeBlasio A, 1900, RIV PSICHIAT FORENSE, V3, P394
   Jelardi A, 2004, GIUSEPPE MOSCATI SCU
   Premuda L, 1971, METODO CONOSCENZA IP
   Stronati M, 2009, QUADERNI FIORENTINI
NR 10
TC 12
Z9 12
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 95
EP 100
DI 10.19193/0393-6384_2017_1_015
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800015
DA 2022-07-14
ER

PT J
AU Bovand, T
   Vatanpour, H
   Mousavi, Z
AF Bovand, Tannaz
   Vatanpour, Hossein
   Mousavi, Zahra
TI THE PROTECTIVE EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR (GCSF) ON
   PHENOBARBITAL TOXICITY IN MOUSE FETUS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE GCSF; Phenobarbital; prevention; mice fetuswith language disorders
ID ANTIEPILEPTIC DRUGS; TERATOGENICITY; PREGNANCY; MICE; PHENYTOIN;
   THERAPY; TUMOR; TRIAL; CSF
AB Introduction: GCSF is a drug That is prescribed for growing the stimulation either in some of immune system diseases or anticoncern drug users. In this study, the researchers reflected on the GCSF's effects on different organs in pregnant mice. Then, using safe doses for mother and fetus, it was applied either as a growing stimulator or a neutralizer factor for negative effects of such teratogenicity drugs as Phenobarbital. Using Phenobarbital during pregnancy can increase the possibility of abnormalities in infants like cleft palate, heart abnormalities and weight reduction in birthday. The purpose of this research is Studying the possible protective effect of GCSF against teratogenic effects of Phenobarbital in mice fetus.
   Method: 120 mg/kg of Phenobarbital within GCSF in different doses was injected to the mice on 9th day of gestation. Their fetuses were then brought out of uterus on 15th day of gestation and were examined by microscopic and macroscopic methods.
   Findings: Although it was observed that 1.63 mu g/mL of GCSF amended the cleft palate in mice fetus (P<0.05), other doses of GCSF (3.25, 7.75, 12, 15 mu g/mL) yielded no difference in the cleft palate occurrence or its amendment in mice fetus.
   Results: The results of the present study showed that GCSF may have the teratogenicity effects of Phenobarbital in cleft palate and will prevent its occurrence.
C1 [Bovand, Tannaz; Mousavi, Zahra] Islamic Azad Univ, Pharmaceut Sci Branch, Fac Pharm, Dept Pharmacol & Toxicol,IAUPS, Tehran, Iran.
   [Vatanpour, Hossein] Med Sci Univ Shahid Beheshti, Sch Pharm, Toxicol & Pharmacol Dept, Tehran, Iran.
RP Vatanpour, H (corresponding author), Med Sci Univ Shahid Beheshti, Sch Pharm, Toxicol & Pharmacol Dept, Tehran, Iran.
RI Mousavi, Zahra/AAO-3117-2021
OI Mousavi, Zahra/0000-0001-6524-491X
FU Toxicology and Pharmacology Lab., School of Pharmacy, Medical Science
   University of Shahid Beheshti, Tehran, Iran
FX The authors thank the Toxicology and Pharmacology Lab., School of
   Pharmacy, Medical Science University of Shahid Beheshti, Tehran, Iran
   for supporting this project. Thanks to Akbar Shirini, Baharak Mohammad
   Zadeh Asl, Saba Vatanpour for their many helpful comments on this paper.
CR Afshar M., 2002, RAZI J MED SCI, V8, P523
   Andermann E., 1982, EPILEPSY PREGNANCY C, P235
   CHAOUAT G, 1990, J REPROD FERTIL, V89, P447
   Clark DA, 1999, AM J REPROD IMMUNOL, V41, P233
   Finnell RH, 1995, TERATOLOGY, V52, P324, DOI 10.1002/tera.1420520603
   Finnell RH, 1997, DRUG TOXICITY EMBRYO, P121
   Fleming A, 1998, SCIENCE, V280, P2107, DOI 10.1126/science.280.5372.2107
   Gorivodsky M, 1999, CLIN EXP IMMUNOL, V117, P540
   Heidari M., 2000, CLONING EXPRESSION I
   HERNANDEZDIAZ S, 2001, OBSTET GYNECOLOGICAL, V56, P257
   HOLDER M, 1990, MONATSSCHR KINDERH, V138, P34
   LAWRENCE A, 1963, BRIT MED J, P1267
   Liles WC, 1997, TRANSFUSION, V37, P182, DOI 10.1046/j.1537-2995.1997.37297203521.x
   Marino VJ, 2001, CYTOKINE, V16, P41, DOI 10.1006/cyto.2001.0943
   NAU H, 1995, LIFE SCI, V57, P53, DOI 10.1016/0024-3205(95)00242-X
   NETA R, 1988, J IMMUNOL, V140, P108
   Neta R, 1989, PROGR CLIN BIOL RES, V352, P471
   OSTER W, 1989, BLOOD, V73, P64
   REYNOLDS EH, 1973, LANCET, V1, P1376
   RUEDY J, 1984, CAN FAM PHYSICIAN, V30, P2133
   Saddler TW, 2004, LANGMANS MED EMBRYOL, P91
   Savion S, 1999, TERATOGEN CARCIN MUT, V19, P171, DOI 10.1002/(SICI)1520-6866(1999)19:3<171::AID-TCM1>3.0.CO;2-S
   Shyu WC, 2006, CAN MED ASSOC J, V174, P927, DOI 10.1503/cmaj.051322
   SULLIVAN FM, 1975, TOXICOL APPL PHARM, V34, P271, DOI 10.1016/0041-008X(75)90032-0
   THAKKER J C, 1991, Indian Pediatrics, V28, P73
   Tiboni GM, 2005, PEDIATR RES, V58, P94, DOI 10.1203/01.PDR.0000166754.24957.73
   TORCHINSKY A, 1994, CLIN EXP IMMUNOL, V98, P513
   Wegmann T, 1989, TRANSPLANTATION P
   WEGMANN TG, 1990, CURR OPIN IMMUNOL, V2, P765, DOI 10.1016/0952-7915(90)90048-L
   Winn LM, 1999, FREE RADICAL BIO MED, V26, P266, DOI 10.1016/S0891-5849(98)00193-2
   Yamano T, 2007, JPN J CLIN ONCOL, V37, P793, DOI 10.1093/jjco/hym094
   Yerby M., 2001, NEW ANTIEPILEPTIC DR
   Yerby MS, 2008, INT REV NEUROBIOL, V83, P181, DOI 10.1016/S0074-7742(08)00010-X
   Zhang XM, 2012, NUTR NEUROSCI, V15, P55, DOI 10.1179/1476830511Y.0000000025
NR 34
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 3
BP 1351
EP 1359
DI 10.19193/0393-6384_2017_3s_211
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AC
UT WOS:000424878100013
DA 2022-07-14
ER

PT J
AU Bragazzi, NL
   Martini, M
   Igwe, SC
   Vecchio, I
   Barberis, I
   Tornali, C
   Licata, M
   Borromeo, F
   Cardinale, AE
   Adawi, M
   Brigo, F
AF Bragazzi, Nicola Luigi
   Martini, Mariano
   Igwe, Stanley C.
   Vecchio, Ignazio
   Barberis, Ilaria
   Tornali, Cristina
   Licata, Marta
   Borromeo, Federica
   Cardinale, Adelfio Elio
   Adawi, Mohammad
   Brigo, Francesco
TI HAS THE ICE BUCKET CHALLENGE REALLY INCREASED PEOPLE'S AWARENESS OF
   AMYOTROPHIC LATERAL SCLEROSIS? INSIGHTS AND ETHICAL IMPLICATIONS FROM
   GOOGLE TRENDS AND WIKIPEDIA: A 2 YEARS-FOLLOW UP
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE amyotrophic lateral sclerosis; awareness campaign; big data; Ice Bucket
   Challenge
ID MEDIA
AB Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is the most common form of motor neuron diseases (MNDs), causing the death of neurons controlling voluntary muscles. In order to increase public awareness and to promote fundraising, a charity activity known as the "Ice Bucket Challenge" (IBC), initially started only as a joke, was launched in July and August 2014, by Pete Frates, ex Boston College baseball player and himself suffering from ALS. Immediately, it became "viral" among social media and social network users, worldwide. We used Google Trends (GT) and accessed to Wikipedia page to document interest towards ALS 2 years after the IBC. In coincidence with the IBC initiative, a peak in web queries could be noticed, as well as a burst in daily accesses to Wikipedia page. However, this increase in web activities (+450% for GT) was characterized by a brief memory and a short half-life: before and after IBC initiative, GT-based RSVs were 18.2 +/- 1.7% and 17.8 +/- 1.9%, respectively. Despite alleged claims of the effectiveness of social networks-based campaigns, apart from money donation and a temporarily burst of web queries and accesses to specialized web-sites, before and after the IBC the level of web-related activities has remained practically constant. The direct involvement of scientists and stakeholders, besides that of celebrities and famous people, would be of crucial importance. Only in this way, initiatives such as the IBC could turn from mere entertaining events even though money-attracting into real educational moments. Otherwise, they would be other missed opportunities.
C1 [Bragazzi, Nicola Luigi; Barberis, Ilaria] Univ Genoa, Sch Publ Hlth, Dept Hlth Sci, Genoa, Italy.
   [Martini, Mariano] Univ Genoa, Sect Hist Med & Eth, Dept Hlth Sci, Genoa, Italy.
   [Igwe, Stanley C.] Fed Teaching Hosp, Dept Neuropsychiat, Abakaliki, Ebonyi State, Nigeria.
   [Vecchio, Ignazio] Univ Catania, Dept Clin & Expt Med, Catania, Italy.
   [Tornali, Cristina] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Licata, Marta; Borromeo, Federica] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.
   [Cardinale, Adelfio Elio] Italian Soc Hist Med, Varennes, PQ, Canada.
   [Adawi, Mohammad] Bar Ilan Univ Safed, Israel Fac Med Galilee, Dept Internal Med, Ziv Med Ctr Safed, Safed, Hazafon, Israel.
   [Brigo, Francesco] Franz Tappeiner Hosp, Dept Neurol, Merano, Italy.
RP Martini, M (corresponding author), Univ Genoa, Dept Hlth Sci DISSAL, Largo R Benzi 10,Pad 3, I-16132 Genoa, Italy.
RI PAN, ZEQIANG/X-6341-2018; Adawi, Mohammad/ABG-4428-2021; Bragazzi,
   Nicola Luigi/G-1672-2011; Brigo, Francesco/H-6513-2013; Tornali,
   Cristina/M-5187-2017
OI Bragazzi, Nicola Luigi/0000-0001-8409-868X; Vecchio,
   Ignazio/0000-0001-5942-1908; Brigo, Francesco/0000-0003-0928-1577;
   Tornali, Cristina/0000-0002-1722-5498
CR Al-Chalabi A, 2016, LANCET NEUROL, V15, P1182, DOI 10.1016/S1474-4422(16)30199-5
   [Anonymous], 2015, 2015 ANN REP IC BUCK
   Bendezu-Quispe G, 2015, REV NEUROLOGIA, V60, P240, DOI 10.33588/rn.6005.2014471
   Carri MT, 2014, NATURE, V515, P343, DOI 10.1038/515343e
   Gualano MR, 2016, PUBLIC HEALTH, V140, P276, DOI 10.1016/j.puhe.2016.05.026
   Hancock J, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00430
   HOBSON EV, 2016, NAT REV NEUROL, V12, DOI DOI 10.1038/NRNEU-R0L.2016.111.[
   Landen Rachel, 2014, Mod Healthc, V44, P12
   Mckee K, 2015, NEUROHOSPITALIST, V5, P182, DOI 10.1177/1941874415573024
   Morgan S, 2016, BR MED B
   Ni MY, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g7185
   Nuti SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109583
   Ram S, 2016, ANN NEUROSCI, V23, P209, DOI 10.1159/000449481
   Rampello L, 2011, ACTA MEDICA MEDITERR, V27, P149
   Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207
   Song PP, 2014, INTRACTABLE RARE DIS, V3, P94, DOI 10.5582/irdr.2014.01015
   Tracy HM, 2016, CEREBRUM
   Vaidya M, 2014, NAT MED, V20, P1080, DOI 10.1038/nm1014-1080
   van der Linden S, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-016-0041
   Wicks P, 2014, AMYOTROPH LAT SCL FR, V15, P479, DOI 10.3109/21678421.2014.984725
NR 20
TC 1
Z9 1
U1 3
U2 21
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 875
EP 878
DI 10.19193/0393-6384_2017_5_130
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000024
DA 2022-07-14
ER

PT J
AU Bulgan, C
   Ersoz, G
   Bingul, BM
   Mengutay, S
   Aydin, M
AF Bulgan, Cigdem
   Ersoz, Gulfem
   Bingul, Bergun Meric
   Mengutay, Sami
   Aydin, Mensure
TI THREE-DIMENSIONAL ANGULAR KINEMATICS OF 200M FLAT-WATER SPRINT KAYAKING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Biomechanics; Kayak Ergometer; 200m Kayaking
ID BIOMECHANICAL ASSESSMENT; PERFORMANCE; KAYAKERS; STROKE; PADDLE
AB The aim of this study was to identify the angular kinematic variables of the catch and aerial phases, affecting success in kayaking techniques on ergometer for 200m. Twelve kayakers from Turkish National Team (9 males, mean age: 20 +/- 3,6 years; mean height: 178,5 +/- 4,6cm; mean mass: 78 +/- 9,06kg; mean training age: 6,3 +/- 2.7years and 3 females, mean age: 18 +/- 1,7years; mean height: 169,3 +/- 9,07cm; mean mass: 57,9 +/- 12,4kg; mean training age: 2,3 +/- 0.7years) were participated to this study as voluntarily. Kayakers performed 200m paddling performances and these performances were recorded to the computer directly. All kinematic variables from catch phase and aerial phase of the start and end of the performance were calculated by using SIMI Reality Motion System GmbH (Version 8.5.7) program and evaluated by SPSS 18.0 (SPSS Inc., Chicago, IL, USA). Findings of the study showed that, significant differences were found in knee joint angular movement in exit phase and elbow angular velocity in aerial phase (p<0.05). In conclusion, it should be noted that the creation of a chain movements from the lower limbs; kayakers should stay away from inconsistent angular movements and keep the body posture stable with correct angular position to get an economic stroke.
C1 [Bulgan, Cigdem; Mengutay, Sami] Halic Univ, Sch Phys Educ & Sports, TSYD Campus,Levent Cad 51, TR-34350 Istanbul, Turkey.
   [Ersoz, Gulfem] Ankara Univ, Fac Sports Sci, Ankara, Turkey.
   [Bingul, Bergun Meric; Aydin, Mensure] Kocaeli Univ, Sch Phys Educ & Sports, Kocaeli, Turkey.
RP Bulgan, C (corresponding author), Halic Univ, Sch Phys Educ & Sports, TSYD Campus,Levent Cad 51, TR-34350 Istanbul, Turkey.
RI Bulgan, Cigdem/AAH-3432-2020; Ersöz, Gülfem/AAD-5880-2020
OI Ersöz, Gülfem/0000-0001-8813-3032; MERIC BINGUL,
   BERGUN/0000-0002-4001-9617
FU Turkish Canoe Federation
FX Thanks to the Turkish Canoe Federation for their support.
CR Abdel-Aziz Y., 1971, P S CLOS RANG PHOT U, P1
   Alacid Fernando, 2015, Coll Antropol, V39, P119
   Baudouin A, 2002, BRIT J SPORT MED, V36, P396, DOI 10.1136/bjsm.36.6.396
   Cautino S, 2008, BIOMECHANICS KAYAK E
   Fleming N, 2012, J SPORT SCI MED, V11, P430
   Fleming N, 2012, J SPORT SCI MED, V11, P16
   Hofmijster MJ, 2007, J SPORT SCI, V25, P403, DOI 10.1080/02640410600718046
   KENDAL SJ, 1992, INT J SPORT BIOMECH, V8, P233, DOI 10.1123/ijsb.8.3.233
   Lee C.H., 2012, INT J BIOSCI BIOTECH, V4, P41
   Lok YK, 2013, P 3 MAL POSTGR C SYD, P216
   Lovell C, 2001, J SPORT REHABIL, V10, P3
   McDonnell LK, 2012, SPORT BIOMECH, V11, P507, DOI 10.1080/14763141.2012.724701
   Michael JS, 2012, J SPORT SCI, V30, P661, DOI 10.1080/02640414.2012.655303
   Michael JS, 2009, SPORT BIOMECH, V8, P167, DOI 10.1080/14763140902745019
   Nilsson JE, 2016, INT J SPORT PHYSIOL, V11, P22, DOI 10.1123/ijspp.2014-0030
   Rottenbacher C, 2011, P 20 C IT ASS THEOR
   Sturm D, 2010, ISBS P 28 INT S BIOM, P712
   Wainwright B, 2016, ISBS C P ARCH, V33, P1
   Wassinger CA, 2011, SPORT BIOMECH, V10, P98, DOI 10.1080/14763141.2011.569563
NR 19
TC 2
Z9 2
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 291
EP 294
DI 10.19193/0393-6384_2017_2_043
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700018
DA 2022-07-14
ER

PT J
AU Bulgan, C
AF Bulgan, Cigdem
TI ANGULAR KINEMATICS OF THE DEEP SQUAT TEST IN FUNCTIONAL MOVEMENT SCREEN
   (TM) ACCORDING TO THE SCORING SYSTEM
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Angular Kinematics; Deep Squat; FMS; Screening
ID INTERRATER RELIABILITY; BIOMECHANICAL ANALYSIS; PERFORMANCE; PLAYERS;
   SCORES; ASSOCIATION; OVERWEIGHT; STABILITY; CHILDREN
AB The aim of this study was to determine to angular kinematic differences of the Functional Movement Screen (FMS) TM deep squat test according to the classifications. 23 university students (age 22.43 +/- 1.53yrs; height 177.26 +/- 6.09cm and weight 70.21 +/- 12.40kg) participated to this study voluntarily. Participants performed a deep squat test three times according to Cook's guidelines for Functional Movement Screening. They get scored by a clinician as 1, 2 or 3. During the test performance, 3D angular kinematic data was collected by 8 high speed Oqus 7+ cameras which were connected directly to the computer. Left and right knee, hip and shoulder angles; trunk flexion angle; hip, calf segmental angles, dowel angle in frontal axis; and also thigh segmental angle in horizontal axis were assessed to examine differences between the three scoring groups by using Qualisys Track Manager (QTM) Version 2.12.
   SPSS 18.0 (SPSS Inc., Chicago, IL, USA) program was used for the differences by Kruskal Wallis test. As a result of the study, the significant difference were found at right and left knee angle between groups (p<0.05). Also in horizontal plane, right and left thigh were significantly difference between groups (p<0.05) too. There were no significant differences found in other parameters. (p>0.05). As a conclusion, in squat movement, as the limitation of motion increases, the hip and knee angles were getting higher and because there was a knee excursion in the horizantal plane, the mechanics of movement distorted.
C1 [Bulgan, Cigdem] Halic Univ, Sch Phys Educ & Sports, TSYD Campus,Levent Cad 51, TR-34350 Istanbul, Turkey.
RP Bulgan, C (corresponding author), Halic Univ, Sch Phys Educ & Sports, TSYD Campus,Levent Cad 51, TR-34350 Istanbul, Turkey.
RI Bulgan, Cigdem/AAH-3432-2020
CR Beach TAC, 2014, APPL ERGON, V45, P482, DOI 10.1016/j.apergo.2013.06.009
   Bushman TT, 2015, J STRENGTH COND RES, V29, pS65, DOI 10.1519/JSC.0000000000001040
   Butler RJ, 2010, SPORT BIOMECH, V9, P270, DOI 10.1080/14763141.2010.539623
   Chorba Rita S, 2010, N Am J Sports Phys Ther, V5, P47
   Clifton DR, 2013, J STRENGTH COND RES, V27, P966, DOI 10.1519/JSC.0b013e318260b723
   Conlon JK, 2013, THESIS
   Cook G, FUNCTIONAL MOVEMENT
   Cook G., 2010, MOVEMENT FUNCTIONAL, VFirst
   Cook Gray, 2006, N Am J Sports Phys Ther, V1, P62
   Duncan MJ, 2013, BMC SPORTS SCI MED R, V5, DOI 10.1186/2052-1847-5-11
   El-Tohamy AM, 2016, TRENDS APPL SCI RES, V11, P19, DOI DOI 10.3923/tasr.2016.19.25
   Escamilla RF, 2001, MED SCI SPORT EXER, V33, P984, DOI 10.1097/00005768-200106000-00019
   Fernandez WG, 2007, ACAD EMERG MED, V14, P641, DOI 10.1111/j.1553-2712.2007.tb01851.x
   Fox D, 2014, PHYS THER SPORT, V15, P194, DOI 10.1016/j.ptsp.2013.11.004
   Frost DM, 2012, J STRENGTH COND RES, V26, P1620, DOI 10.1519/JSC.0b013e318234ec59
   Hemmerich A, 2006, J ORTHOP RES, V24, P770, DOI 10.1002/jor.20114
   Kiesel K, 2011, SCAND J MED SCI SPOR, V21, P287, DOI 10.1111/j.1600-0838.2009.01038.x
   Koehle MS, 2016, J STRENGTH COND RES, V30, P540, DOI 10.1519/JSC.0000000000001092
   Krause DA, 2015, INT J SPORTS PHYS TH, V10, P37
   Liao T, 2017, APPL FUNCTIONAL MOVE, P189
   Lockie RG, 2015, BIOL SPORT, V32, P41, DOI 10.5604/20831862.1127281
   McCunn R, 2016, SPORTS MED, V46, P763, DOI 10.1007/s40279-015-0453-1
   McMillian DJ, 2016, J STRENGTH COND RES, V30, P973, DOI 10.1519/JSC.0000000000001190
   Mills JD, 2005, PHYS THER SPORT, V6, P60, DOI 10.1016/j.ptsp.2005.02.006
   Minick KI, 2010, J STRENGTH COND RES, V24, P479, DOI 10.1519/JSC.0b013e3181c09c04
   Okada T, 2011, J STRENGTH COND RES, V25, P252, DOI 10.1519/JSC.0b013e3181b22b3e
   Paoli A, 2015, CLIN PHYSIOL FUNCT I, V35, P1, DOI 10.1111/cpf.12136
   Parenteau E, 2014, PHYS THER SPORT, V15, P169, DOI 10.1016/j.ptsp.2013.10.001
   Shultz R, 2013, J ATHL TRAINING, V48, P331, DOI 10.4085/1062-6050-48.2.11
   Waldron M, 2016, J STRENGTH COND RES, V30, P910, DOI 10.1519/JSC.0000000000000270
NR 30
TC 1
Z9 1
U1 1
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 651
EP 656
DI 10.19193/0393-6384_2017_4_097
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700018
DA 2022-07-14
ER

PT J
AU Bursa, D
   Paciorek, M
   Porowski, D
   Bednarska, A
AF Bursa, Dominik
   Paciorek, Marcin
   Porowski, Dawid
   Bednarska, Agnieszka
TI PATIENT WITH UNDETERMINED FULMINANT SYSTEMIC INFLAMMATORY RESPONSE
   SYNDROME: CLINICAL IMPLICATIONS FROM CASE REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE sepsis; systemic inflammatory response syndrome; hemophagocytic
   limphohistiocytosis; macrophage activation syndrome; adult-onset Still's
   disease; red man syndrome
ID MACROPHAGE ACTIVATION SYNDROME; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS;
   SEPTIC SHOCK
AB Introduction: Severe systemic inflammatory response syndrome (SIRS) is commonly related to sepsis but rare autoimmunological or hematological diseases can provide similar conditions: adult-onset Still's disease (AOSD), systemic lupus erythematous (SLE), hemophagocytic limphohistiocytosis (HLH), macrophage activation syndrome (MAS). These diseases cause cytokine storm and trigger extreme hyperferritinemia, thus they are called hyperferritinemic syndromes.
   Case presentation: We present a case of a 55-year-old female who had fever, rash and arthralgia. She was admitted to the Hospital of Infectious Diseases in Warsaw with SIRS initially attributed to bacterial infection and suspicion of sepsis. During diagnostic management the patient developed overwhelming SIRS with hyperferritinemia. Broad-spectral antibiotics with short course of steroids were administered for the suspected autoimmunological syndrome. The response to treatment was quick. None syndromes met diagnostic criteria. After vancomycin infusion the second exacerbation appeared with acute kidney injury. Methylprednisolone pulses provided improvement. The patient met HLH criteria a few days after the second exacerbation. Slow, complete remission was achieved with immunosuppressive therapy (steroids and methotrexate). MAS was recognized due to AOSD.
   Conclusion: The clinical presentation of patients with SIRS is nonspecific. They require thorough assessment because similar symptoms may occur in other several non-infectious conditions, such as autoimmune or hematological disorders.
C1 [Bursa, Dominik; Paciorek, Marcin; Porowski, Dawid; Bednarska, Agnieszka] Med Univ Warsaw, Dept Adults Infect Dis, Warsaw, Poland.
   [Bursa, Dominik; Paciorek, Marcin; Porowski, Dawid; Bednarska, Agnieszka] Hosp Infect Dis, Warsaw, Poland.
RP Bursa, D (corresponding author), 7-6 Lecha St, PL-05400 Otwock, Poland.
FU Research Development Foundation in Hospital for Infectious Diseases,
   Warsaw, Poland
FX Paper is partially supported by Research Development Foundation in
   Hospital for Infectious Diseases, Warsaw, Poland
CR Cooper GS, 2009, J AUTOIMMUN, V33, P197, DOI 10.1016/j.jaut.2009.09.008
   Deane S, 2010, INT ARCH ALLERGY IMM, V153, P109, DOI 10.1159/000312628
   Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI [10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]
   Efthimiou P, 2014, CLIN RHEUMATOL, V33, P305, DOI 10.1007/s10067-014-2487-4
   Gerfaud-Valentin M, 2014, AUTOIMMUN REV, V13, P708, DOI 10.1016/j.autrev.2014.01.058
   Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039
   Janka GE, 2012, ANNU REV MED, V63, P233, DOI 10.1146/annurev-med-041610-134208
   Janka GE, 2007, BLOOD REV, V21, P245, DOI 10.1016/j.blre.2007.05.001
   Olgar S, 2007, J RHEUMATOL, V34, P2491
   Raschke RA, 2011, CHEST, V140, P933, DOI 10.1378/chest.11-0619
   Rosado FGN, 2013, AM J CLIN PATHOL, V139, P713, DOI 10.1309/AJCP4ZDKJ4ICOUAT
   Rosario C, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-185
   YAMAGUCHI M, 1992, J RHEUMATOL, V19, P424
NR 13
TC 1
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 569
EP 573
DI 10.19193/0393-6384_2017_4_083
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700004
DA 2022-07-14
ER

PT J
AU Cai, JG
   Tang, H
   Yang, AH
AF Cai, Jianguang
   Tang, Hui
   Yang, Aihua
TI INFLUENCE OF THE AEROBIC EXERCISE ON THE BIOLOGICAL AGE OF THE ELDERLY
   MALES WITH DIFFERENT AGING DEGREES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Aerobic exercise; aging degrees; elderly males; biological age;
   influence
ID MOLECULAR-STRUCTURES; MECHANISM; BEARING
AB Objective: To observe and analyze the influence of aerobic exercise on the biological age of the elderly males with differentaging degrees.
   Methods: A total of 100 retired elderly males were enrolled in this study. All the elderly males performed the incremental load aerobic exercise using cycle ergometer. The physiological parameters of the candidates such as the biological age, body shape, cardiovascular and pulmonary function were measured before and after the exercise. Based on the gap between the biological age and the actual age, the 100 cases of elderly males were divided into pro-senescence group (50 cases) and delaying senescence group (50 cases) for comparative study.
   Results: Before the aerobic exercise was carried out, the elderly males possessed larger biological age as compared to their actualage, however, the difference was not statistically significant (P> 0.05). The elderly males who completed the aerobic exercise showed smaller biological age than the actual age, with P< 0.05. Moreover, the pro-senescence group had a larger biological age than their actual age before they performedaerobic exercise. However, after the aerobic exercise was executed, the result indicates that their biological age was close to their actual age but was lower than that of their actual age before accomplishing the aerobic exercise was accomplished (P < 0.05). On the other hand, the biological age of delaying senescence group was smaller than the actual age. In comparison to the biological age of candidates before experienced the aerobic exercise, the biological age of the candidates after aerobic exercise was lower. After aerobic exercise, when P> 0.05, the pro-senescence group exhibited smaller waist and larger waist-to-hip ratio; as P < 0.05, the pro-senescence group showed a smaller skin fold thickness of the upper arm and their physiological function index changed significantly. Furthermore, with P < 0.05, the systolic blood pressure and diastolic blood pressure among the cardiovascular and pulmonary function of the two groups decreased, and at the same time, the vital capacity increased,.
   Conclusion: Aerobic exercise can exert positive impact on the biological age, physiological function and body shape of the elderly males with different aging degree, and delay their senescence.
C1 [Cai, Jianguang; Tang, Hui] Hunan Univ Sci & Technol, Sch Sports, Xiangtan 411201, Peoples R China.
   [Yang, Aihua] Changsha Univ Sci & Technol, Dept Phys Educ, Changsha 410114, Hunan, Peoples R China.
RP Cai, JG (corresponding author), Hunan Univ Sci & Technol, Sch Sports, Xiangtan 411201, Peoples R China.
EM Pumancai@163.com
FU Natural Science Foundation of Hunan province [2015JJ2052]
FX Natural Science Foundation of Hunan province. (Grant No. 2015JJ2052)
CR Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Ge S, 2016, SAUDI JOURNAL OF BIO
   Kilic B, 2017, ACTA MEDICA MEDITERR, V33, P335, DOI 10.19193/0393-6384_2017_2_050
   Li Aihua, 2007, CHINESE J TISSUE ENG, V13, P7739
   Li H., J COASTAL RE
   Li W, 2015, J COASTAL RES, P453, DOI 10.2112/SI73-080.1
   Li XL, 2015, J COASTAL RES, P516, DOI 10.2112/SI73-090.1
   Liang Meiyang, 2015, EFFECTS AEROBIC EXER
   Liu Wenfeng, 2014, STUDY CARBONYL STRES
   Luo XY, 2017, BIOMED RES-INDIA, V28, P2952
   Meng XL, 2016, SAUDI PHARM J, V24, P286, DOI 10.1016/j.jsps.2016.04.021
   Swieca M, 2015, SAUDI J BIOL SCI, V22, P409, DOI 10.1016/j.sjbs.2014.12.007
   Wu K, 2015, J COASTAL RES, P554, DOI 10.2112/SI73-096.1
   Yang JW, 2017, BIOMED RES-INDIA, V28, P3869
   Yang X, 2015, J COASTAL RES, P448, DOI 10.2112/SI73-079.1
   Zhang H, 2016, PAK J PHARM SCI, V29, P1681
   Zhang Su, 2014, CHINESE J MODERN MED, V22, P71
   Zhu Lihua, 2016, HUNAN J TRADITIONAL, V13, P95
NR 19
TC 0
Z9 0
U1 2
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 3
BP 1345
EP 1349
DI 10.19193/0393-6384_2017_3s_210
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AC
UT WOS:000424878100012
DA 2022-07-14
ER

PT J
AU Cakmur, H
   Anuk, T
AF Cakmur, Hulya
   Anuk, Turgut
TI FREQUENCY AWARENESS AND MANAGEMENT OF OBESITY AMONG HEALTHCARE PROVIDERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE awareness; education; health personnel; obesity
ID RISK-FACTORS; BODY-MASS; OVERWEIGHT; WEIGHT; PREVALENCE; NURSES; ADULTS
AB Introduction: Obesity is a growing public health problem all over the world. To create a healthy generation and for health promotion, obesity must be more emphasised among healthcare providers and policy makers. The aim of this study was to evaluate the frequency, awareness and self-management of obesity among healthcare providers. This study also evaluated whether sociodemographic factors influence obesity and obesity awareness and management among the participants.
   Material and methods: The study was cross-sectional; the research was conducted with 493 healthcare providers. The study group ranged in age from 18-57 years. The survey questions were prepared using the World Health Organisation (WHO) STEP wise approach to noncommunicable disease risk factor surveillance.
   Results: The frequency of obesity among healthcare providers was 14.9%. Obesity risks were 3.361 fold (95% CI, 1.996-5.727) higher in older age groups than younger. There was no significant relationship identified between obesity and gender. A relatively low educational level meant a 2.688-fold (95% CI, 1.590-4.546) increase in the risk of obesity. The obesity rate was significantly higher in married participants and significantly lower in childless participants. The frequency of obesity by occupation was 16% for doctors, 1% for nurses, 13% for permanent medical staff, and 22% for medical information technology staff. A higher rate of eating a regular balanced diet was observed in doctors. It was observed that cigarette smoking increased the risk of obesity 1.852-fold (95% CI, 1.282.2.973).
   Conclusion: Although obesity awareness was low among all healthcare providers, the frequency of obesity was lower than the general population in this study group.
C1 [Cakmur, Hulya] Kafkas Univ, Sch Med, Dept Family Med, Kars, Turkey.
   [Anuk, Turgut] Kafkas Univ, Dept Gen Surg, Sch Med, Kars, Turkey.
RP Cakmur, H (corresponding author), Kafkas Univ, Sch Med, Dept Family Med, Kars, Turkey.
CR [Anonymous], 2016, WHO STEP WISE APPROA
   Cakmur H., 2017, ADIPOSITY EPIDEMIOLO, P12
   Dombrowski SU, 2010, OBESITY FACTS, V3, P377, DOI 10.1159/000323076
   Florez KR, 2015, J ACAD NUTR DIET, V115, P1102, DOI 10.1016/j.jand.2015.01.001
   Garaulet M, 2010, INT J OBESITY, V34, P1667, DOI 10.1038/ijo.2010.118
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1
   Iwuala SO, 2015, PAN AFR MED J, V22, DOI 10.11604/pamj.2015.22.1.5586
   Katz Sara, 2005, BMC Med Educ, V5, P4, DOI 10.1186/1472-6920-5-4
   Kyle RG, 2016, INT J NURS STUD, V53, P126, DOI 10.1016/j.ijnurstu.2015.10.015
   Makowske M, 2005, NUTR J, V4, DOI 10.1186/1475-2891-4-2
   Metcalf B, 2005, OBES SURG, V15, P183, DOI 10.1381/0960892053268381
   Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76
   Oguz A, 2008, TURK KARDIYOL DERN A, V36, P302
   Paoli A, 2015, CLIN PHYSIOL FUNCT I, V35, P1, DOI 10.1111/cpf.12136
   Rurik I, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-156
   Satman I, 2002, TURDEP GROUP D CARE, V25, P1551
   Thaikruea L, 2016, PREVALENCE NORMAL WE
   TurkStat, 2016, STAT DEM
   While AE, 2015, LONDON J PRIM CARE, V7, P112, DOI 10.1080/17571472.2015.1113716
   Willis LH, 2012, J APPL PHYSIOL, V113, P1831, DOI 10.1152/japplphysiol.01370.2011
   Withrow D, 2011, OBES REV, V12, P131, DOI 10.1111/j.1467-789X.2009.00712.x
   Wolf AM, 2008, DIABETES OBES METAB, V10, P1248, DOI 10.1111/j.1463-1326.2008.00895.x
   Wolin KY, 2009, OBESITY
   World Health Organization, GLOB STRAT DIET PHYS
   World Health Organization Expert Committee on Physical Status, 1995, WHO TECHN SUPP SER, V854
   Zhu DQ, 2011, OBES REV, V12, P459, DOI 10.1111/j.1467-789X.2010.00821.x
NR 26
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1073
EP 1079
DI 10.19193/0393-6384_2017_6_170
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500029
DA 2022-07-14
ER

PT J
AU Celebi, A
   Gurler, M
   Koc, DO
   Ozdemir, AA
   Ekizoglu, I
   Altay, M
   Degirmencioglu, S
AF Celebi, Aslan
   Gurler, Mujgan
   Koc, Deniz Ogutmen
   Ozdemir, Ali Abbas
   Ekizoglu, Ismail
   Altay, Murat
   Degirmencioglu, Serife
TI SERUM VISFATIN LEVELS IN PATIENTS WITH SUBCLINICAL AND NEWLY DIAGNOSED
   TYPE 2 DIABETES MELLITUS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Subclinical diabetes mellitus; type 2 diabetes mellitus; visfatin
ID PLASMA VISFATIN; VISCERAL FAT; OBESITY; ADIPOKINES
AB Introduction: The present study aimed to compare serum visfatin levels among subjects with subclinical diabetes/pre-diabetes (impaired fasting glucose [IFG] alone and IFG+impaired glucose tolerance [IGT]), subjects with newly diagnosed type 2 diabetes mellitus (DM), and healthy nondiabeticnormoglycemic controls and to evaluate the relation of serum visfatin levels with some metabolic parameters and insulin resistance.
   Materials and methods: The study was conducted in 80 subjects, of whom 52 (65%) were female and 28 (35%) were male. The subjects were divided into 4 groups as control, IFG, IFG+IGT, and newly diagnosed type 2 DM groups, containing 20 subjects in each. Waist and hip circumferences, age, gender, body mass index, and demographic characteristics were recorded in each group. The levels of fasting plasma glucose, fasting serum insulin, C-peptide, cortisol, glycosylated hemoglobin (HbA1c), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglyceride were measured and insulin/C-peptide ratio and the homeostasis model assessment-insulin resistance (HOMA-IR) were calculated and compared among the groups.
   Results: In line with glucose metabolism disorder, significant increases were observed in the insulin, C-peptide, insulin/C-peptide ratio, HbA1c (%), HOMA-IR values, cardiovascular risk parameters (total cholesterol, LDL-C, VLDL-C, triglyceride), and visfatin levels in the subclinical diabetes and diabetes groups as compared to the control group.
   Conclusion: Visfatin could be considered among therapeutic agents used in the prevention of diabetes and in the prevention or reduction of its critical complications.
C1 [Celebi, Aslan; Koc, Deniz Ogutmen; Ozdemir, Ali Abbas; Ekizoglu, Ismail; Altay, Murat] GaziosmanpasaTaksim Educ & Res Hosp, Dept Internal Med, Istanbul, Turkey.
   [Gurler, Mujgan] Metin Sabanci Baltalimani Bone Dis Educ & Res Hos, Dept Internal Med, Istanbul, Turkey.
   [Degirmencioglu, Serife] Demre State Hosp, Dept Internal Med, Antalya, Turkey.
RP Celebi, A (corresponding author), GaziosmanpasaTaksim Educ & Res Hosp, 120 Gaziosmanpasa, Istanbul, Turkey.
OI Ozdemir, Ali/0000-0002-8087-9654
CR Abdul-Ghani MA, 2006, DIABETES CARE, V29, P1130, DOI 10.2337/dc05-2179
   Altuntas Y., 2001, YONUYLE DIABETES MEL, P839
   Bluher M, 2014, MOL METAB, V3, P230, DOI 10.1016/j.molmet.2014.01.005
   Coelho M, 2013, ARCH MED SCI, V9, P191, DOI 10.5114/aoms.2013.33181
   Dogru T, 2007, DIABETES RES CLIN PR, V76, P24, DOI 10.1016/j.diabres.2006.07.031
   Emral R, 2006, TURKIYEKLINIKLERI J, V26, P409
   Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Goncalves N, 2015, FUTURE MED CHEM, V7, P139, DOI [10.4155/fmc.14.147, 10.4155/FMC.14.147]
   Gunawardana SC, 2014, WORLD J DIABETES, V5, P420, DOI 10.4239/wjd.v5.i4.420
   Kuzuya T, 2002, DIABETES RES CLIN PR, V55, P65, DOI 10.1016/S0168-8227(01)00365-5
   Levy JC, 1998, DIABETES CARE, V21, P2191, DOI 10.2337/diacare.21.12.2191
   Rabe K, 2008, MOL MED, V14, P741, DOI 10.2119/2008-00058.Rabe
   Sandeep S, 2007, METABOLISM, V56, P565, DOI 10.1016/j.metabol.2006.12.005
   Sethi JK, 2005, TRENDS MOL MED, V11, P344, DOI 10.1016/j.molmed.2005.06.010
   Takebayashi K, 2007, METABOLISM, V56, P451, DOI 10.1016/j.metabol.2006.12.001
   Twigg SM, 2007, MED J AUSTRALIA, V186, P461, DOI 10.5694/j.1326-5377.2007.tb00998.x
   Zou CH, 2008, J NUTR BIOCHEM, V19, P277, DOI 10.1016/j.jnutbio.2007.06.006
NR 18
TC 0
Z9 0
U1 1
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 197
EP 201
DI 10.19193/0393-6384_2017_2_028
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700003
DA 2022-07-14
ER

PT J
AU Cetinkaya, G
   Sahin, FN
   Tyariz, K
AF Cetinkaya, Guney
   Sahin, F. Nese
   Tyariz, Kisme
TI LEISURE SATISFACTION LEVEL OF ACTIVE AND PASSIVE PARTICIPATION IN
   OUTDOOR RECREATION ACTIVITIES AND ITS RELATIONSHIP WITH PUBLIC HEALTH
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Outdoor recreation; leisure satisfaction; participation in outdoor
   recreation activities
ID PHYSICAL-ACTIVITY; RISK
AB Introduction: The aim of this study was to determine the leisure satisfaction scores according to participation in outdoor recreation activities.
   Material and methods: Participants of this study consisted of 101 men and 97 women with the total of 198 people (X age = 29.68 +/- 9.79) who volunteered for the study. Leisure satisfaction was measured with "Leisure Satisfaction Scale (LSS)" developed by Beard and Raghed (1980) and the Turkish validity and reliability of the scale was measured by Karli et al. (2008). Additionally a " personal information form" was adopted in order to collect data concerning the demographic information and outdoor recreation participation of the sample. Independent samples t test was used to determine the differences of leisure satisfaction levels of participants according to their active or passive participation in these activities.
   Results: According to the findings, significant differences were obtained in leisure satisfaction scores (total(3.723)= 196, p= 0.000) and in four sub-dimensions of the scale which were Psychological (t1(4.191)= 196, p= 0.000), Educational (t2(2,373)= 159.7, p= 0.019), Relaxing (t3(2.852)= 196, p= 0.005) and Physiological (t4(4.442)= 196, p= 0.000) according to active or passive participation in outdoor recreation activities.
   Conclusion: In conclusion, the findings of this study present that leisure satisfaction scores are affected by active and passive participation in outdoor recreation activities. As a result, the findings of this study demonstrate that leisure satisfaction differs according to active/passive participation in outdoor activities. Participating in outdoor activities in an active manner may enhance individuals' levels of leisure satisfaction.
C1 [Cetinkaya, Guney; Sahin, F. Nese; Tyariz, Kisme] Ankara Univ, Fac Sport Sci, Ankara, Turkey.
RP Sahin, FN (corresponding author), Ankara Univ, Fac Sport Sci, Ankara, Turkey.
RI Rajendran, Renuchitra/AAO-4033-2020; Çetinkaya, Güney/AAG-8657-2019;
   SAHIN, FATMA NESE/AAG-9096-2020; Çetinkaya, Güney/B-9050-2016
OI Çetinkaya, Güney/0000-0002-1757-5105; SAHIN, FATMA
   NESE/0000-0002-8777-5807; 
CR Aksoy Y., 2011, ISTANBUL TICARET UNI, V10, P81
   Aras D, 2016, ACTA MEDICA MEDITERR, V32, P223
   Ardahan F., 2010, SPOR BILIMLERI DERGI, V21, P129
   Aydin I., 2014, ANATOLIA TURIZM ARAS, V25, P118
   Baker DA, 2006, SOC INDIC RES, V75, P395, DOI 10.1007/s11205-004-5298-1
   BEARD JG, 1980, J LEISURE RES, V12, P20, DOI 10.1080/00222216.1980.11969416
   Bedimo-Rung AL, 2005, AM J PREV MED, V28, P159, DOI 10.1016/j.amepre.2004.10.024
   Bell S, 2008, DESIGN OUTDOOR RECRE, DOI [DOI 10.4324/9780203928110, 10.4324/9780203928110]
   Bianco A, 2014, CANCER MED-US, V3, P385, DOI 10.1002/cam4.193
   Bodin M, 2003, PSYCHOL SPORT EXERC, V4, P141, DOI 10.1016/S1469-0292(01)00038-3
   BROWN BA, 1993, SOCIOL SPORT J, V10, P1, DOI 10.1123/ssj.10.1.1
   Chick G, 2008 M SOC CROSS CUL
   Chick G, 1994, EXPRESSIVE VALUES RU
   Chick G, 2015, LEISURE SCI, V37, P232, DOI 10.1080/01490400.2014.967897
   Collins S, 2007, J FOREST, V105, P371
   Coon JT, 2011, ENVIRON SCI TECHNOL, V45, P1761, DOI 10.1021/es102947t
   Cordell H. K., 2008, Forest History Today, P4
   Dahmann N, 2010, HEALTH PLACE, V16, P431, DOI 10.1016/j.healthplace.2009.11.005
   Dobbs R., 2014, OVERCOMING OBESITY I
   Feskanich D, 2002, JAMA-J AM MED ASSOC, V288, P2300, DOI 10.1001/jama.288.18.2300
   Godbey GC, 2005, AM J PREV MED, V28, P150, DOI 10.1016/j.amepre.2004.10.027
   Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]
   Henderson K. A., 2002, Journal of Park and Recreation Administration, V20, P130
   Ho J.T.S., 1996, INT J EDUC MANAG, V10, P41, DOI [https://doi.org/10.1108/09513549610105353, DOI 10.1108/09513549610105353]
   Hug SM, 2009, HEALTH PLACE, V15, P971, DOI 10.1016/j.healthplace.2009.03.002
   Iwasaki Y, 2001, CAN J PUBLIC HEALTH, V92, P214, DOI 10.1007/BF03404309
   Karakucuk S., 2008, REKREASYON BOS ZAMAN
   Karli U., 2008, HACET J SPORT SCI, V19, P80
   Leitzmann MF, 1999, NEW ENGL J MED, V341, P777, DOI 10.1056/NEJM199909093411101
   Librett J., 2007, J PHYS ACT HLTH S1, V4, P1
   Librett John, 2007, J Phys Act Health, V4 Suppl 1, pS1
   Maller C, 2006, HEALTH PROMOT INT, V21, P45, DOI 10.1093/heapro/dai032
   Mannell R. C., 2007, World Leisure Journal, V49, P114
   Mieczkowski Z., 1990, WORLD TREND TOURISM
   Mitchell R, 2013, SOC SCI MED, V91, P130, DOI 10.1016/j.socscimed.2012.04.012
   Onder S., 2003, ZIRAAT FAKULTESI DER, V17, P31
   Onsekiz D, 2008, SOSYAL BILIMLER ENST, V24, P69
   Outdoor Industry Association, 2012, OUTD RECR EC
   Overholt J., 2012, ILLUMINARE STUDENT J, V10, P3
   Paoli A, 2015, IRAN J PUBLIC HEALTH, V44, P602
   Pretty J, 2005, INT J ENVIRON HEAL R, V15, P319, DOI 10.1080/09603120500155963
   Reconomics, 2014, EC IMP OUTD RECR
   Rocha CA, 2017, EXPOS HEALTH, V9, P169, DOI 10.1007/s12403-016-0230-x
   Rosenberger RS, 2009, J PARK RECREAT ADM, V27, P8
   Spangler KJ, 2007, J PHYS ACT HEALTH, V4, P64
   Talay I, 2010, COGRAFI BILIMLER DER, V8, P147
   The UK's Faculty of Public Health, 2016, WHY PUBL MENT HLTH M
   Wenger N K, 1995, Clin Pract Guidel Quick Ref Guide Clin, P1
NR 48
TC 3
Z9 3
U1 1
U2 21
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 191
EP 196
DI 10.19193/0393-6384_2017_2_027
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700002
DA 2022-07-14
ER

PT J
AU Chaibi, R
   Drine, S
   Ferchichi, A
AF Chaibi, Rafika
   Drine, Sawsen
   Ferchichi, Ali
TI CHEMICAL STUDY AND BIOLOGICAL ACTIVITIES OF VARIOUS EXTRACTS FROM
   LAWSONIA INERMIS (HENNA) SEEDS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Lawsonia inermis (L); antioxidant; cytotoxic; cholinesterase;
   anti-inflammatory; phenolics
ID ANTIOXIDANT; LEAVES; L.; ANTIBACTERIAL
AB Objectives: In this study we attempted to determine chemical composition, antioxidant, anti-inflammatory, anti-cholinesterase and cytotoxic activities of extracts with different polarities (hexane, chloroform and methanol) obtained from Lawsonia inermis seeds and compared to those in controls.
   Methods: Seeds of Lawsonia inermis were extracted successively in a Soxhlet system. The quantification of total phenolics of each extract was determined by the Folin-Ciocalteu method. The antioxidant scavenging activity was studied using 1, 1-diphenyl-2picrylhydrazyl free radical (DPPH)/2,20-azinobis-3-ethylbenzothiazoline-6-sulphonate (ABTS) assays. Ascorbic acid was used as a standard. The anti-inflammatory activity of Lawsonia inermis seeds was determined on Soybean lipoxygenase. Cholinesterase (ChE) inhibitory activities were measured using Galanthamine as a positive control. The Cytotoxicity of each extract was estimated on human breast cancer cells (HTC-116) by the MTT (3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.
   Conclusion: The methanolic seed extract from Lawsonia inermis presented a very good antioxidant activity, a stronger 5-lipoxygenase and moderate acetylcholinesterase (AChE) activities. The strongest activity of Henna seed against human breast cancer cells (HTC-116) were obtained for the chloroform extract (IC50 = 45 mg/L). Our findings suggested that Lawsonia inermis seed could be a potential source of active molecule.
C1 [Chaibi, Rafika; Drine, Sawsen; Ferchichi, Ali] Inst Arid Reg, Lab Arid Land & Oases Cropping, Medenine, Tunisia.
RP Chaibi, R (corresponding author), Inst Arid Reg, Lab Arid Land & Oases Cropping, Medenine, Tunisia.
EM chercheur_rafika@yahoo.com
FU Research Deputy of Kermanshah University of Medical Sciences [92423]
FX Hereby, the authors would like to express their gratitude to the
   Research Center for Environmental Determinants of Health, School of
   Public Health, for reviewing the project and also to the Research Deputy
   of Kermanshah University of Medical Sciences for approving and funding
   the research (No. 92423).
CR Abdelgadir E. H., 2010, Journal of Pharmacology and Toxicology, V5, P324, DOI 10.3923/jpt.2010.324.333
   Abdelmalek W., 2014, INT J PHARM PHARM SC, V6
   Adams LS, 2006, J AGR FOOD CHEM, V54, P980, DOI 10.1021/jf052005r
   Agunu A., 2011, PLANTA MED, V77, P30
   Basak P, 2014, INT J PHARM RES SCHO, V3, P2014
   Bekir J, 2013, FOOD CHEM TOXICOL, V55, P470, DOI 10.1016/j.fct.2013.01.036
   Ben Hsouna A, 2011, FOOD CHEM, V125, P193, DOI 10.1016/j.foodchem.2010.08.060
   Boubaya A, 2011, AFR J BIOTECHNOL, V10, P4980
   Chaibi R., 2015, Journal of Natural Products (India), V8, P85
   Dhaouadi K, 2015, IND CROP PROD, V77, P544, DOI 10.1016/j.indcrop.2015.09.037
   Dorman HJD, 2004, J AGR FOOD CHEM, V52, P762, DOI 10.1021/jf034908v
   Endrini S., 2007, Journal of Medical Sciences (Pakistan), V7, P1098
   Gozubuyuk GS, 2014, J MYCOL MED, V24, P313, DOI 10.1016/j.mycmed.2014.07.002
   Handa G, 1997, INDIAN J CHEM B, V36, P252
   Jeyaseelan E. Christy, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P798, DOI 10.1016/S2221-1691(12)60232-9
   Khlifi D, 2013, IND CROP PROD, V45, P240, DOI 10.1016/j.indcrop.2012.12.030
   Megdiche K., 2012, FOOD CHEM, V139, P1073
   Mina B., 2012, INT J CURRENT PHARM, V3, P54
   Moloudizargari Milad, 2013, Pharmacogn Rev, V7, P199, DOI 10.4103/0973-7847.120524
   Mudi SY, 2011, J MED PLANTS RES, V5, P5123
   Ogunbinu AO, 2007, J ESSENT OIL BEAR PL, V10, P184, DOI 10.1080/0972060X.2007.10643540
   Philip J. P., 2011, J TROP MED, P457
   Philip J. P., 2013, INT J PHARM SCI, V5, p[2, 617]
   Singh DK, 2015, IND CROP PROD, V65, P269, DOI 10.1016/j.indcrop.2014.11.025
   Surveswaran S, 2007, FOOD CHEM, V102, P938, DOI 10.1016/j.foodchem.2006.06.033
   Trigui M, 2013, CROP PROT, V45, P83, DOI 10.1016/j.cropro.2012.11.014
NR 26
TC 1
Z9 2
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 981
EP 986
DI 10.19193/0393-6384_2017_6_155
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500014
DA 2022-07-14
ER

PT J
AU Chelouti, H
   Bouzid, K
   Khelil, M
AF Chelouti, Hiba
   Bouzid, Kamel
   Khelil, Malika
TI NO ASSOCIATION BETWEEN NAT1*15 AND BREAST CANCER, AND INTERACTION WITH
   RED MEAT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Genetic polymorphism; N-acetyltransferase 1; Red meat; Risk factor
ID CIGARETTE-SMOKING; HUMAN N-ACETYLTRANSFERASE-1; HETEROCYCLIC AMINES;
   COOKED FOODS; RISK; ACETYLTRANSFERASE; NAT1; CARCINOGENESIS;
   POLYMORPHISMS; ACETYLATION
AB Introduction: Breast cancer is a complex disease characterized by the accumulation and combination of multiple genetic and environmental factors. Indeed, many studies have suggested that among powerful pre-carcinogens involved in breast carcinogenesis derived from aromatic and heterocyclic amines. These are either directly detoxified or converted into carcinogens by N-acetyltransferases-1 and 2. Both highly polymorphic isoenzymes are involved in the increased susceptibility to breast cancer. The objective of our work was to examine the effects of N-acetyltransferase 1*15 (NAT1*15) polymorphism and its relationship with red meat consumption and cigarettes smoking, on breast cancer risk.
   Materiel and methods: The C and T alleles were identified by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism analysis for 60 Algerian patients with BC and 60 women controls.
   Results: There was no association between NAT1*15 polymorphisms and Breast cancer. However, the red meat intake increased susceptibility to the disease (p=0.017, OR=5.537).
   Conclusion: Our results suggest that NAT1* 15 polymorphisms would not be involved in the pathogenesis of breast cancer. However, the red meat intake would be a risk factor for breast cancer in our population. This risk can be attributed to the high fat contained in the red meat.
C1 [Chelouti, Hiba; Khelil, Malika] Univ Sci & Technol Houari Boumed, Fac Sci Biol, Dept Biol Cellulaire & Mol, BP 32 El Alia, Algiers 16111, Algeria.
   [Bouzid, Kamel] CHU Mustapha Bacha, Ctr Pierre & Marie Curie, Serv Oncol, Algiers, Algeria.
RP Khelil, M (corresponding author), Univ Sci & Technol Houari Boumed, Fac Sci Biol, Dept Biol Cellulaire & Mol, BP 32 El Alia, Algiers 16111, Algeria.
CR Boukouvala S, 2005, DRUG METAB REV, V37, P511, DOI 10.1080/03602530500251204
   Bruhn C, 1999, BIOCHEM PHARMACOL, V58, P1759, DOI 10.1016/S0006-2952(99)00269-5
   Cho EY, 2006, ARCH INTERN MED, V166, P2253, DOI 10.1001/archinte.166.20.2253
   Deitz AC, 1997, ANAL BIOCHEM, V253, P219, DOI 10.1006/abio.1997.2379
   Felton JS, 2002, ENVIRON MOL MUTAGEN, V39, P112, DOI 10.1002/em.10070
   Gammon MD, 2004, ENVIRON RES, V96, P176, DOI 10.1016/j.envres.2003.08.009
   Gaudet MM, 2013, JNCI-J NATL CANCER I, V105, P515, DOI 10.1093/jnci/djt023
   GOODMAN MT, 1992, CANCER EPIDEM BIOMAR, V1, P269
   Grant DM, 1997, MUTAT RES-FUND MOL M, V376, P61, DOI 10.1016/S0027-5107(97)00026-2
   Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7
   Hein DW, 2006, MOL CARCINOGEN, V45, P230, DOI 10.1002/mc.20164
   HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2
   Hirvonen A, 1999, IARC Sci Publ, P251
   Hughes NC, 1998, PHARMACOGENETICS, V8, P55, DOI 10.1097/00008571-199802000-00008
   LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39
   MATOS EL, 1991, NEOPLASMA, V38, P357
   Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269
   Miller SA, 1988, NUCLEIC ACIDS RES, V16, P883, DOI [DOI 10.1093/NAR/16.3.1215, 10.1093/nar/16.3.1215]
   Millikan RC, 1998, CANCER EPIDEM BIOMAR, V7, P371
   NAGAO M, 1994, CANCER, V74, P1063, DOI 10.1002/1097-0142(19940801)74:3+<1063::AID-CNCR2820741514>3.0.CO;2-2
   PALMER JR, 1993, EPIDEMIOL REV, V15, P145, DOI 10.1093/oxfordjournals.epirev.a036098
   Shirai T, 1995, Princess Takamatsu Symp, V23, P232
   VATSIS KP, 1993, ARCH BIOCHEM BIOPHYS, V301, P71, DOI 10.1006/abbi.1993.1116
   VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001
   WEBER WW, 1985, PHARMACOL REV, V37, P25
   Xue F, 2011, ARCH INTERN MED, V171, P125, DOI 10.1001/archinternmed.2010.503
   Zheng W, 1998, JNCI-J NATL CANCER I, V90, P1724, DOI 10.1093/jnci/90.22.1724
   Zheng W, 1999, CANCER EPIDEM BIOMAR, V8, P233
   Zhu Y, 2008, PHARMACOGENOMICS J, V8, P339, DOI 10.1038/sj.tpj.6500483
NR 29
TC 1
Z9 1
U1 1
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 89
EP 93
DI 10.19193/0393-6384_2017_1_014
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800014
DA 2022-07-14
ER

PT J
AU Chisari, EM
   Lo Castro, T
   Grasso, A
   Chisari, CG
   Di Nuovo, S
   Chisari, G
AF Chisari, Eleonora Margherita
   Lo Castro, Tiziana
   Grasso, Antonino
   Chisari, Clara Grazia
   Di Nuovo, Santo
   Chisari, Giuseppe
TI FUNCTIONAL STRESS AND MICROBIOTA EYE IN SUBJECTS WITH TYPE 2 DIABETES: A
   MULTIFACTORIAL APPROACH
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE functional stress; the eye surface; microbiota; type 2 diabetics
ID PEGYLATED INTERFERON; OCULAR SURFACE; GUT MICROBIOTA; RISK-FACTORS;
   DISEASE; DEPRESSION; PROBIOTICS; ANXIETY
AB The authors studied functional stress in subjects with type 2 diabetes with alterations of the ocular surface. 30 diabetic patients were admitted to the study (9 males and 21 females, mean age 67 +/- 5 years), with signs and symptoms of discomfort and /or dry eye (burning, foreign body sensation, dryness and itching), with Schirmer I less than 10 mm, with break-up time test (BUT) lower at 8 seconds according to Van Bijsterveld 1 criteria. A test "measuring perceived stress" (MSP) was performed on all patients to assess the aspects of self-perceived stress aspects, "feeling stressed" derives from a widespread tool in the international arena, the Mesuredu Stress Psychologique (MSP). 30 healthy patients, workers, operators no video displays as controls were also enrolled. The analysis of individual cluster showed a statistically significant difference between the two groups with regards to only the Cluster 1 and 2 (p = 0.03 and p = 0.04 respectively). Multivariate analysis that pose as outside as the main the presence or absence of clinically significant stress, found that, controlling for age and sex, the number of shifts and the presence of positive Schirmer test are two risk factors for the development stress. Alteration of the ocular surface in diabetics can easily trigger the chronic process of functional stress changes with the microbiota of the ocular surface.
C1 [Chisari, Eleonora Margherita; Lo Castro, Tiziana; Di Nuovo, Santo] Univ Catania, Dept Educ, I-95124 Catania, Italy.
   [Grasso, Antonino] Univ Catania, Dept Gen Surg & Surg Med Specialties, I-95124 Catania, Italy.
   [Chisari, Clara Grazia] Univ Catania, Dept Neurosci, I-95124 Catania, Italy.
   [Chisari, Giuseppe] Univ Catania, Dept Biomed & Biotechnol Sci, I-95124 Catania, Italy.
RP Chisari, G (corresponding author), Univ Catania, Dept Biomed & Biotechnol Sci, Sez Microbiol, I-95124 Catania, Italy.
RI Di Nuovo, Santo/K-7760-2019
OI Di Nuovo, Santo/0000-0001-6086-7624; chisari, clara
   grazia/0000-0003-1607-543X; CHISARI, Giuseppe/0000-0002-0492-2171
CR Agarwal N, 2015, EXPERT REV OPHTHALMO, V10, P145, DOI 10.1586/17469899.2015.1003544
   Brewitt H, 2001, SURV OPHTHALMOL, V45, pS199, DOI 10.1016/S0039-6257(00)00202-2
   Chisari CG, 2015, ACTA MEDICA MEDITERR, V31, P1217
   Chisari CG, 2014, ACTA MEDICA MEDITERR, V30, P249
   Chisari EM, 2016, ACTA MEDICA MEDITERR, V32, P1577
   Chisari G, 2016, ACTA MEDICA MEDITERR, V32, P865, DOI 10.19193/0393-6384_2016_4_102
   Chisari G, 2015, ACTA MEDICA MEDITERR, V31, P1057
   Chisari G, 2013, ACTA MEDICA MEDITERR, V29, P369
   Chisari G, 2011, ACTA MEDICA MEDITERR, V27, P73
   Chisari G, 2008, CURR CLIN PHARMACOL, V3, P153, DOI 10.2174/157488408785747692
   Di Nuovo S, 2007, PSICOLOGIA TURISMO P, P89
   Di Nuovo S., 2005, COME FUNZIONANO PSIC
   Ferreira CM, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/689492
   FizPerez FJ, 2011, COLPIRE STRESS COPIN
   Frazzetto P, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-S1-S14
   Galor A, 2015, MINI-REV MED CHEM, V16, P241
   Kaido M, 2012, CORNEA, V31, P1009, DOI 10.1097/ICO.0b013e31823f8cfc
   Llansola M, 2015, NEW HORIZ TRANSL MED, V2, P39, DOI 10.1016/j.nhtm.2014.11.057
   Llansola M, 2015, NEUROCHEM INT, V88, P15, DOI 10.1016/j.neuint.2014.10.011
   Magnano M, 2012, ACTA MEDICA MEDITERR, V28, P231
   Malaguarnera G, 2016, AGING CLIN EXP  1107
   Malaguarnera G, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1115-z
   Malaguarnera G, 2015, CLIN OPHTHALMOL, V9, P1437, DOI 10.2147/OPTH.S77538
   Malaguarnera G, 2014, WORLD J GASTROENTERO, V20, P16639, DOI 10.3748/wjg.v20.i44.16639
   Malaguarnera G, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.11608
   Malaguarnera G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/191497
   Malaguarnera G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/943505
   Malaguarnera M, 2015, AM J TRANSL RES, V7, P2510
   Malaguarnera M, 2013, ACTA MEDICA MEDITERR, V29, P791
   Malaguarnera M, 2012, J CANCER RES THER, V8, P520, DOI 10.4103/0973-1482.106527
   Miljanovic B, 2007, AM J OPHTHALMOL, V143, P409, DOI 10.1016/j.ajo.2006.11.060
   Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P225
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P219
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P133
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P127
   Russo C, 2012, ACTA MEDICA MEDITERR, V28, P201
   Schiffman RM, 2003, OPHTHALMOLOGY, V110, P1412, DOI 10.1016/S0161-6420(03)00462-7
   Sekirov I, 2010, PHYSIOL REV, V90, P859, DOI 10.1152/physrev.00045.2009
   Sheppard John D, 2003, Manag Care, V12, P20
   Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165
   Vrieze A, 2010, DIABETOLOGIA, V53, P606, DOI 10.1007/s00125-010-1662-7
   Yilmaz U, 2015, PAK J MED SCI, V31, P626, DOI 10.12669/pjms.313.7091
   Yoon Kyung-Chul, 2004, Korean J Ophthalmol, V18, P168
   Zanchi S., 2008, RISORSA UOMO, VXIV, P263
NR 45
TC 4
Z9 5
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 9
EP 16
DI 10.19193/0393-6384_2017_1_001
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800001
DA 2022-07-14
ER

PT J
AU Chisari, G
   Chisari, EM
   Maria, BA
   Grasso, A
   Chisari, CG
AF Chisari, Giuseppe
   Chisari, Eleonora Margherita
   Maria, Borzi Antonio
   Grasso, Antonino
   Chisari, Clara Grazia
TI AMNIOTIC MEMBRANE USE IN TYPE 2 DIABETES PATIENTS WITH CHRONIC ULCERS:
   MICROBIOLOGICAL EVALUATION AND THERAPEUTIC BENEFITS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE amniotic membrane AM; bacteria; type II diabetes
ID OCULAR SURFACE; PEGYLATED INTERFERON; RISK-FACTORS; TRANSPLANTATION;
   SUPPLEMENTATION; PROTEINS; DISEASE
AB Amniotic membrane AM, as a natural biomaterial, has many advantages, such as low immunogenicity and rich extracellular matrix components, which make it a promising source for vascular tissue engineering. This study evaluated the efficacy and impact of amniotic membrane skin in patients (diabetes) with chronic ulcer lesions "hard to heel". 56 patients with type II diabetes (32 F-24 M mean age 57 +/- 5 years) with chronic ulcers were admitted to our department. Patients were treated with human amniotic membrane was prepared using fresh human placenta. At 4 weeks grafting were found the following data: 57.1% scar in full and the remaining 42.9% partial resolution. Histological evaluation of the grafts explanted shown a single layer of skin cells compact enough.
   The results show that the amniotic membrane has a good regulatory activities and its clinical efficacy is confirmed by direct activity in wound skin and an indirect selection in the normal bacterial flora of the skin.
C1 [Chisari, Giuseppe] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Chisari, Eleonora Margherita] Univ Catania, Dept Educ, Catania, Italy.
   [Maria, Borzi Antonio] Univ Catania, Res Ctr Great Senescence, Catania, Italy.
   [Grasso, Antonino; Chisari, Clara Grazia] Univ Catania, Dept Med Surg Sci & Adv Technol GF Ingrassia, Catania, Italy.
RP Chisari, EM (corresponding author), Univ Catania, Dept Educ, Catania, Italy.
RI Borzì, Antonio Maria/X-8685-2018
OI Borzì, Antonio Maria/0000-0001-6984-308X; chisari, clara
   grazia/0000-0003-1607-543X
CR Agarwal N, 2015, EXPERT REV OPHTHALMO, V10, P145, DOI 10.1586/17469899.2015.1003544
   Akinbi HT, 2004, AM J OBSTET GYNECOL, V191, P2090, DOI 10.1016/j.ajog.2004.05.002
   Azuara-Blanco A, 1999, BRIT J OPHTHALMOL, V83, P399, DOI 10.1136/bjo.83.4.399
   Cabrera-Pastor A, 2016, SCI REP-UK, V6, DOI 10.1038/srep33124
   Chisari CG, 2015, ACTA MEDICA MEDITERR, V31, P1217
   Chisari CG, 2014, ACTA MEDICA MEDITERR, V30, P249
   Chisari EM, 2017, ACTA MEDICA MEDITERR, V10, P384
   Chisari EM, 2016, ACTA MEDICA MEDITERR, V32, P1577
   Chisari G, 2016, ACTA MEDICA MEDITERR, V32, P865, DOI 10.19193/0393-6384_2016_4_102
   Chisari G, 2015, ACTA MEDICA MEDITERR, V31, P1057
   Chisari G, 2013, ACTA MEDICA MEDITERR, V29, P369
   Chisari G, 2011, ACTA MEDICA MEDITERR, V27, P73
   Chisari G, 2008, CURR CLIN PHARMACOL, V3, P153, DOI 10.2174/157488408785747692
   COLOCHO G, 1974, ARCH SURG-CHICAGO, V109, P370
   Davis S., 1910, J HOPKINS MED J, V15, P307
   Frazzetto P, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-S1-S14
   Ghanassia E, 2008, DIABETES CARE, V31, P1288, DOI 10.2337/dc07-2145
   Grasso A, 2016, ACTA VULVOLOGICA
   Hao YX, 2000, CORNEA, V19, P348, DOI 10.1097/00003226-200005000-00018
   Khanolkar MP, 2008, QJM-INT J MED, V101, P685, DOI 10.1093/qjmed/hcn027
   Lavery LA, 2006, DIABETES CARE, V29, P1288, DOI 10.2337/dc05-2425
   Lo V, 2009, INT J DERMATOL, V48, P935, DOI 10.1111/j.1365-4632.2009.04173.x
   Malaguarnera G, 2016, AGING CLIN EXP RES
   Malaguarnera G, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1115-z
   Malaguarnera G, 2015, CLIN OPHTHALMOL, V9, P1437, DOI 10.2147/OPTH.S77538
   Malaguarnera G, 2014, WORLD J GASTROENTERO, V20, P16639, DOI 10.3748/wjg.v20.i44.16639
   Malaguarnera G, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.11608
   Malaguarnera G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/191497
   Malaguarnera G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/943505
   Malaguarnera M, 2015, AM J TRANSL RES, V7, P2510
   Malaguarnera M, 2013, ACTA MEDICA MEDITERR, V29, P791
   Malaguarnera M, 2011, WORLD J GASTROENTERO, V17, P4414, DOI 10.3748/wjg.v17.i39.4414
   Malaguarnera M, 2011, HEPAT MON, V11, P92
   Mamede AC, 2012, CELL TISSUE RES, V349, P447, DOI 10.1007/s00441-012-1424-6
   Meller D, 2011, DTSCH ARZTEBL INT, V108, P243, DOI 10.3238/arztebl.2011.0243
   Niknejad H, 2008, EUR CELLS MATER, V15, P88
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P225
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P219
   Rampello L, 2012, ACTA MEDICA MEDITERR, V28, P127
   Sabella N, 1913, MED REC NY, V83, P478, DOI DOI 10.1177/001452461302401011
   Stock SJ, 2007, AM J OBSTET GYNECOL, V196, P255, DOI 10.1016/j.ajog.2006.10.908
   Zhang Y, 2004, EXP HEMATOL, V32, P657, DOI 10.1016/j.exphem.2004.04.001
NR 42
TC 9
Z9 10
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 431
EP 435
DI 10.19193/0393-6384_2017_3_063
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200011
DA 2022-07-14
ER

PT J
AU Coco, M
   Ramaci, T
   Sagone, E
   Sardo, MG
   Brachina, P
   Buscemi, B
   Coco, LSG
   Papotto, G
   Papotto, GMF
   Di Gregorio, G
   Petralia, MC
   Buscemi, A
   Perciavalle, V
AF Coco, Marinella
   Ramaci, Tiziana
   Sagone, Elisabetta
   Sardo, Milena Galati
   Brachina, Paola
   Buscemi, Barbara
   Coco, Lucio Salvatore Giovanni
   Papotto, Giacomo
   Papotto, Giulio Maria Federico
   Di Gregorio, Giulia
   Petralia, Maria Cristina
   Buscemi, Andrea
   Perciavalle, Valentina
TI BRAIN AND MEMORY: A PILOT STUDY ON THE EXPERIENCE OF REBIRTH AND THE
   PRESENT LIFE QUALITY OF ADULT SUBJECTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE memory; rebirth; pregnancy; adults; lifestyle
ID ADOLESCENTS
AB It is commonly thought that you cannot remember anything about one's birth, what happened inside the maternal womb and on childbirth. Experimental investigations have, however, highlighted the existence of a fetal memory, as the fetus would seem to be able to memorize and learn prematurely. However, these are unconscious memories, which are not easily retrievable and expressible.
   The purpose of this study was to verify whether and how pregnancy and birth patterns affect the lifestyle of an adult subject.
   50 volunteer students of the Degree Course in Psychological Sciences and Techniques of the University of Catania took part in the research. The sample was subjected to the regression technique, and then a nine-question questionnaire was given out to be filled in anonymously. Only 15 out of 50 subjects returned it completed.
   The results obtained have shown how the experience of rebirth influences the quality of present life.
   One observes how the experience of regression is significantly correlated with the perception of one's self and how subjects can retrieve memories of unconscious feelings that experience has led them to live, which may partly account for one's personality.
C1 [Coco, Marinella; Buscemi, Barbara; Buscemi, Andrea] Horus Cooperat Social, Ragusa, Italy.
   [Ramaci, Tiziana] Univ Kore, Enna, Italy.
   [Sagone, Elisabetta; Perciavalle, Valentina] Univ Catania, Dept Educ Sci, Catania, Italy.
   [Sardo, Milena Galati; Brachina, Paola; Coco, Lucio Salvatore Giovanni; Papotto, Giacomo; Papotto, Giulio Maria Federico; Di Gregorio, Giulia] Univ Catania, Catania, Italy.
   [Petralia, Maria Cristina] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
RP Coco, M (corresponding author), Horus Cooperat Social, Ragusa, Italy.
EM marinella.coco@gmail.com
RI Coco, Marinella/AAC-8750-2020; papotto, giacomo/AAP-3068-2021; RAMACI,
   TIZIANA/AAD-3672-2019; Sagone, Elisabetta/AAC-1483-2022; Petralia,
   Maria/AAE-6337-2019
OI papotto, giacomo/0000-0001-8103-8075; RAMACI,
   TIZIANA/0000-0002-0745-2013; Petralia, Maria
   Cristina/0000-0002-9643-1045; SAGONE, Elisabetta/0000-0001-5283-4603
CR Buscemi A, 2016, ACTA MEDICA MEDITERR, V32, P953, DOI 10.19193/0393-6384_2016_4_115
   Caraci F, 2014, CNS NEUROL DISORD-DR, V13, P173, DOI 10.2174/18715273113129990103
   Castellano S, 2015, CLIN GERONTOLOGIST, V38, P103, DOI 10.1080/07317115.2014.990599
   Chamberlain D., 1998, BAMBINI RICORDANO NA
   Conel JL, 1939, POSTNATAL DEV HUMAN
   De Pasquale C, 2016, WORLD J TRANSPLANT, V24, P736
   De Pasquale C, 2016, ANN GEN PSYCHIATR, P15
   FALIN LI, 1961, ACTA ANAT, V44, P188
   Friedhoff AJ, PRENATAL NEUROTRANSM, P519
   Garcia D, 2017, PEERJ, V5, DOI 10.7717/peerj.2868
   HUTTUNEN MO, 1978, ARCH GEN PSYCHIAT, V35, P429
   Imbasciati A., 1998, NASCITA COSTRUZIONE
   Kershman J., 1939, ARCH NEUROL PSYCHIAT
   Lagercrantz H, 2002, NEWBORN BRAIN: NEUROSCIENCE AND CLINICAL APPLICATIONS, P139
   Musumeci G, 2012, ACTA HISTOCHEM, V114, P805, DOI 10.1016/j.acthis.2012.02.001
   Musumeci G, 2012, KNEE SURG SPORT TR A, V20, P216, DOI 10.1007/s00167-011-1630-x
   Pellerone M, 2017, CLIN NEUROPSYCHIATR, V14, P141
   Pellerone M, 2017, PSYCHOL RES BEHAV MA, V10, P69, DOI 10.2147/PRBM.S128313
   Perciavalle V, 2016, PHYSICIAN SPORTSMED, V44, P403, DOI 10.1080/00913847.2016.1222852
   Sagone E, 2013, PROCD SOC BEHV, V82, P131, DOI 10.1016/j.sbspro.2013.06.236
   Santisi G, 2014, PROCD SOC BEHV, V116, P1227, DOI 10.1016/j.sbspro.2014.01.373
   Specchiale A, 2013, ACTA MEDICA MEDITERR, V29, P407
   Ulfig N, 2003, ANN NY ACAD SCI, V985, P22
NR 23
TC 4
Z9 4
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 901
EP 904
DI 10.19193/0393-6384_2017_6_143
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500002
DA 2022-07-14
ER

PT J
AU Cui, H
AF Cui, Hao
TI CLINICAL VALUE OF EMERGENCY CT EXAMINATION IN TAEKWONDO ATHLETES' KNEE
   FRACTURE AND LIGAMENT INJURY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Taekwondo Athletes; Emergency CT Examination; Knee Fracture; Ligament
   Injury; Clinical Application
AB Knee fracture and ligament injury are very common in the competition and training of taekwondo athletes. In this study, specific causes of athletes' knee fracture and ligament injury were explored, the application of emergency CT examination in taekwondo athletes' knee fracture and ligament injury was analyzed through a specific examination method, in order to verify the practical value of emergency CT examination in the clinic. 1400 taekwondo athletes with knee fracture and ligament injury were randomly selected as subjects, clinical data were retrospectively analyzed, with patients' X-ray examination results, clinical and surgical results compared. Results showed that 1,000 out of 1,400 patients had fracture. 1200 cases (why 1200 ? only 1000 had fracture ?) of knee fracture were diagnosed by CT examination, with 10 false negative cases; 500 cases of fracture were detected by X-ray examination, 900 cases of ligament injury were diagnosed by CT examination with 50 false negative cases; 170 cases of medial collateral ligament injury were determined by X-ray with indirect signs. Based on the above findings we can conclude that CT examination had advantages when compared to X-ray examination, as it was more sensitive than X-ray examination in incomplete ligament injury diagnosis. For the diagnosis of complete laceration of ligament, X-ray examination should be combined with clinical data to obtain a more accurate diagnosis.
C1 [Cui, Hao] DaLian Maritime Univ, Dept Phys Educ, Dalian 116026, Peoples R China.
RP Cui, H (corresponding author), DaLian Maritime Univ, Dept Phys Educ, Dalian 116026, Peoples R China.
EM haocui2016@126.com
CR Cantarella G, 2015, ACTA MEDICA MEDITERR, V31, P1019
   Gao W, 2017, SAUDI PHARM J, V25, P580, DOI 10.1016/j.jsps.2017.04.027
   Ge S, 2016, SAUDI JOURNAL OF BIO
   Khan M, 2017, ARAB J CHEM, V10, P708, DOI 10.1016/j.arabjc.2017.01.003
   Li Chengming, 2011, CONT MED, V14, P114
   Olya M. H., 2014, ADV IND ENG MANAGE, V3, P35, DOI [10.7508/AIEM-V3-N4-35-44, DOI 10.7508/AIEM-V3-N4-35-44]
   Peng Botao, 2016, CHINESE J CT MRI, V03, P127
   Qi HC, 2012, J COMPUT THEOR NANOS, V9, P1525, DOI 10.1166/jctn.2012.2237
   Qiu H, 2015, PAK J PHARM SCI, V28, P1845
   Shao Lixi, 2014, J MODERN MED HLTH, V13, P2003
   Wang Y, 2015, ACTA MEDICA MEDITERR, V31, P981
   Yang SY, 2016, SAUDI PHARM J, V24, P245, DOI 10.1016/j.jsps.2016.04.006
   Yang X, 2015, J COASTAL RES, P448, DOI 10.2112/SI73-079.1
   Yang ZC, 2015, J COASTAL RES, P420, DOI 10.2112/SI73-074.1
   Yao Yong, 2013, J MED IMAGING, V11, P1775
   Zhang YL, 2016, SAUDI J BIOL SCI, V23, P237, DOI 10.1016/j.sjbs.2015.02.013
NR 16
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 3
BP 1317
EP 1320
DI 10.19193/0393-6384_2017_3s_204
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AC
UT WOS:000424878100006
DA 2022-07-14
ER

PT J
AU Demir, D
   Tosun, A
   Kahraman, N
   Ozsin, KK
   Sanri, US
   Kocaslan, A
   Korkmaz, UT
   Goncu, MT
AF Demir, Deniz
   Tosun, Ali
   Kahraman, Nail
   Ozsin, Kadir Kaan
   Sanri, Umut Serhat
   Kocaslan, Aydemir
   Korkmaz, Ufuk Turan
   Goncu, Mehmet Tugrul
TI TECHNIQUE OF CIRCULAR NARROWING WITH A POLYTETRAFLUOROETHYLENE GRAFT IN
   PATIENTS WITH HIGH-FLOW ARTERIOVENOUS FISTULA: MID-TERM RESULTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE High-flow rate; flow reduction; arteriovenous fistula; circular
   narrowing technique; polytetrafluoroethylene graft
ID VASCULAR ACCESS; STEAL SYNDROME; HEMODIALYSIS; REDUCTION; ANEURYSMS
AB Introduction: An arteriovenous fistula with a high- flow rate adversely affects the hemodialysis treatment of the patients. There are several methods that help to decrease the high- flow rate. This study aims to investigate the effects of circular narrowing technique on lowering the flow rate with a polytetrafluoroethylene graft for the treatment of patients with a high- flow arteriovenous fistula and to present our shortand mid- term results.
   Materials and methods: Seven patients with a fistula flow rate of above 1200 ml/min were retrospectively analyzed. All patients were operated on under local anesthesia and underwent a circular narrowing procedure with a polytetrafluoroethylene graft. Additional aneurysmectomy was performed on the patients with aneurysms. Fistula flow rates were recorded at baseline and following the procedure.
   Results: Postoperative thrill was observed in all patients. The mean preoperative flow rate of arteriovenous fistula was 1428 +/- 230 ml/min. At three to six months following the procedure, it was 655 +/- 98 ml/min. Two patients suffered from pain in the arm at rest preoperatively and the pain resolved postoperatively. All patients continued to receive hemodialysis through the native fistula on a regular basis in the postoperative period.
   Conclusion: Our study results suggest that the circular narrowing technique with a polytetrafluoroethylene graft is an effective modality that can be easily used in patients with high- flow arteriovenous fistulas.
C1 [Demir, Deniz; Kahraman, Nail; Ozsin, Kadir Kaan; Sanri, Umut Serhat; Goncu, Mehmet Tugrul] Bursa Yuksek Ihtisas Training & Res Hosp, Dept, Cardiovasc Surg, Bursa, Turkey.
   [Tosun, Ali] Sanliurfa Mehmet Akif Inan State Hosp, Radiol Dept, Sanliurfa, Turkey.
   [Kocaslan, Aydemir] Harran Univ, Cardiovasc Surg Dept, Sanliurfa, Turkey.
   [Korkmaz, Ufuk Turan] Abant Izzet Baysal Univ, Cardiovasc Surg Dept, Bolu, Turkey.
RP Demir, D (corresponding author), Bursa Yuksek Ihtisas Training & Res Hosp, Cardiovasc Surg Dept, Bursa, Turkey.
RI korkmaz, ufuk turan kürşat/A-3747-2019; Özsin, Kadir Kaan/GLU-3668-2022;
   SANRI, UMUT SERHAT/AAH-3493-2019; KAHRAMAN, Nail/C-6828-2019; Özsin,
   Kadir Kaan/O-8581-2019
OI korkmaz, ufuk turan kürşat/0000-0002-6107-2943; Özsin, Kadir
   Kaan/0000-0001-5933-9322; SANRI, UMUT SERHAT/0000-0003-4008-4336;
   KAHRAMAN, Nail/0000-0001-9343-0947; Özsin, Kadir
   Kaan/0000-0001-5933-9322
CR Bachleda P, 2011, ANN ACAD MED SINGAP, V40, P136
   BRESCIA MJ, 1966, NEW ENGL J MED, V275, P1089, DOI 10.1056/NEJM196611172752002
   DeCaprio J D, 1997, Cardiovasc Surg, V5, P648, DOI 10.1016/S0967-2109(97)00072-0
   Demir D, 2014, CASE STUDY CASE REP, V4, P17
   Goel N, 2006, KIDNEY INT, V70, P765, DOI 10.1038/sj.ki.5001554
   Miller GA, 2012, SEMIN NEPHROL, V32, P545, DOI 10.1016/j.semnephrol.2012.10.005
   Pasklinsky G, 2011, J VASC SURG, V53, P1291, DOI 10.1016/j.jvs.2010.11.100
   Santoro A, 2006, J NEPHROL, V19, P259
   Schneider CG, 2006, J VASC SURG, V43, P402, DOI 10.1016/j.jvs.2005.11.047
   Sigala F, 2014, J VASC ACCESS, V15, P370, DOI 10.5301/jva.5000224
   Tellioglu G, 2008, TRANSPL P, V40, P87, DOI 10.1016/j.transproceed.2007.11.059
   Zamani P, 2009, VASC MED, V14, P371, DOI 10.1177/1358863X09102293
   Zanow J, 2006, J VASC SURG, V44, P1273, DOI 10.1016/j.jvs.2006.08.010
NR 13
TC 7
Z9 7
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 587
EP 591
DI 10.19193/0393-6384_2017_4_086
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700007
DA 2022-07-14
ER

PT J
AU Diaconu, S
   Cambrea, SC
   Petcu, CL
   Rugina, S
AF Diaconu, Simona
   Cambrea, Simona Claudia
   Petcu, Cristian Lucian
   Rugina, Sorin
TI ASPECTS OF NOSOCOMIAL GASTROENTERITIS WITH ROTAVIRUS IN CHILDREN
   HOSPITALIZED IN CONSTANTA-ROMANIA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE acute gastroenteritis; rotavirus; nosocomial infection; children
ID EASTERN-EUROPE; BURDEN; COUNTRIES; DIARRHEA; DISEASE
AB Background: The infection with rotavirus is a frecquent cause of accute diarrheal disease in infants and young children anywhere in the world.
   Objective: The aim of this study was to evaluate the clinical characteristics and the severity of nosocomial gastroenteritis with rotavirus.
   Material and methods: We conducted a descriptive, observational, non-interventional, prospective and retrospective study (2011-2012), performed on two groups of patients patients with acute rotavirus gastroenteritis and nosocomial rotavirus gastroenteritis hospitalized in the pediatric ward of the Clinical Infectious Diseases Hospital of Constanta. The diagnostic was confirmed by a positive test for determining latex agglutination rotavirus in faeces.
   Results: From 505 cases of rotaviral gastroenteritis, 98 were nosocomial infections (19.4%). There were no statistical significant difference between the two groups-with or without nosocomial infection regarding the average age (p=0.64), the number of vomiting per day (p=0.34). There were statistical significant differences between two studied groups regarding the number of stools per day (p=0.001), the value of maximum temperature (p=0.001), the duration of hospitalization (p=0.001).
   Conclusions: Our study highlighted that nosocomial rotaviral gastroenteritis in children presented more severe symptoms and prolonged hospitalisations.
C1 [Diaconu, Simona; Cambrea, Simona Claudia; Petcu, Cristian Lucian; Rugina, Sorin] Clin Infect Dis Hosp, Constanta, Romania.
   [Cambrea, Simona Claudia; Petcu, Cristian Lucian; Rugina, Sorin] Ovidius Univ, Fac Med, Constanta, Romania.
RP Cambrea, SC (corresponding author), 100 Ferdinad Ave, Constanta 900709, Romania.
EM cambrea.claudia@gmail.com
RI Cambrea, Simona Claudia/W-2103-2017; Petcu, Lucian
   Cristian/AAE-4100-2022; Rugina, Sorin/U-5168-2019
OI Cambrea, Simona Claudia/0000-0003-4898-8938; 
CR Anca Ioana Alina, 2014, Germs, V4, P30, DOI 10.11599/germs.2014.1053
   Dennehy PH, 1998, PEDIATR RES, V43, P143
   Festini F, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-235
   Giaquinto C, 2007, J INFECT DIS, V195, pS26, DOI 10.1086/516717
   Gleizes O, 2006, PEDIATR INFECT DIS J, V25, pS12, DOI 10.1097/01.inf.0000197563.03895.91
   Ion-Nedelcu N, 2013, REV ROMANA BOLI INFE, VXVI, P25
   Lazar S, 2016, REV ROMANA BOLI INFE, VXIV, P129
   Lesanu G, 2013, PEDIATR INFECT DIS J, V32, P89, DOI 10.1097/INF.0b013e3182706152
   Marin L, 2014, THESIS, P24
   Meszner Z, 2008, PEDIATR INFECT DIS J, V27, pS33, DOI 10.1097/INF.0b013e31815eee3b
   Ogilvie I, 2011, HUM VACCINES, V7, P523, DOI 10.4161/hv.7.5.14819
   Parashar UD, 1998, EMERG INFECT DIS, V4, P561, DOI 10.3201/eid0404.980406
   Parashar UD, 2006, EMERG INFECT DIS, V12, P304
   Pickering LK, 2003, RED BOOK 2003 REPORT, P534
   Ulmeanu Coriolan, 2009, Bacteriol Virusol Parazitol Epidemiol, V54, P41
   Unal N, 2016, ACTA MEDICA MEDITERR, V32, P81
   Gutierrez-Gimeno MV, 2010, PEDIATR INFECT DIS J, V29, P23, DOI 10.1097/INF.0b013e3181b3603a
NR 17
TC 10
Z9 10
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1289
EP 1293
DI 10.19193/0393-6384_2017_2s_198
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700015
DA 2022-07-14
ER

PT J
AU Duzalan, OB
   Pakyuz, SC
AF Duzalan, Ozlem Bulantekin
   Pakyuz, Sezgi Cinar
TI SCALE DEVELOPMENT: DIETARY KNOWLEDGE AND BEHAVIORS ASSESSMENT IN
   HEMODIALYSIS PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE hemodialysis; validity; reliability; nutrition
ID PRACTICE PATTERNS; ADHERENCE; RECOMMENDATIONS; CONSEQUENCES;
   RESTRICTIONS; NONADHERENCE; MORTALITY; DOPPS
AB Aim: The aim of the study was to develop a valid and reliable instrument for dietary knowledge and behaviors assessment in hemodialysis patients.
   Methods: This study follows a psychometric methodological design. The content validity was evaluated using a Lawshe's technique with ten experts in the field of hemodialysis. The confirmatory factor analysis, and explanatory factor analysis were used for scale validity in the study. Internal consistency analysis, item discrimination indices, and the test-retest technique were used for scale reliability. The study sample included 302 chronic hemodialysis patients.
   Results: Scale for Dietary Knowledge in Hemodialysis Patients (SDKHP), is a three-point Likert scale and consisting of 18 items. Cronbach's alpha reliability coefficient of the scale was 0.86. The Scale for Dietary Behaviors in Hemodialysis Patients (SDBHP) is a five-point Likert scale and consisting of 13 items. Cronbach's alpha reliability coefficient of the scale was 0.73.
   Conclusions: SDKHP and SDBHP are valid and reliable measurement tools for assessing the level of dietary knowledge and the dietary behaviors in hemodialysis patients, respectively for use by nurses and other health professionals.
C1 [Duzalan, Ozlem Bulantekin] Cankiri Karatekin Univ, Sch Hlth, Dept Nursing, Cankiri, Turkey.
   [Pakyuz, Sezgi Cinar] Celal Bayar Univ, Manisa Sch Hlth, Dept Nursing, Manisa, Turkey.
RP Duzalan, OB (corresponding author), Cankiri Karatekin Univ, Sch Hlth, Dept Nursing, Cankiri, Turkey.
CR Afrasiabifar A, 2013, IRAN RED CRESCENT ME, V15, P566, DOI 10.5812/ircmj.12024
   Buyukozturk, 2008, SOSYAL BILIMLER ICIN
   Cicolini G, 2012, J ADV NURS, V68, P2410, DOI 10.1111/j.1365-2648.2011.05935.x
   COLE DA, 1987, J CONSULT CLIN PSYCH, V55, P584, DOI 10.1037/0022-006X.55.4.584
   Cosar AA, 2016, JPN J NURS SCI, V13, P174, DOI 10.1111/jjns.12083
   Denhaerynd K, 2007, AM J CRIT CARE, V16, P222
   Durose CL, 2004, J AM DIET ASSOC, V104, P35, DOI 10.1016/j.jada.2003.10.016
   Efe D, 2015, JPN J NURS SCI, V12, P113, DOI 10.1111/jjns.12055
   GOZUM S, 2003, HEMSIRELIKTE ARASTIR, V5, P3
   Hecking E, 2004, NEPHROL DIAL TRANSPL, V19, P100, DOI 10.1093/ndt/gfg418
   Kim Youngmee, 2010, Nephrol Nurs J, V37, P377
   Kline R.B, 2011, PRINCIPLES PRACTICE
   Lee SH, 2002, INT J NURS STUD, V39, P695, DOI 10.1016/S0020-7489(02)00007-X
   Oka M, 1999, Clin Nurs Res, V8, P302, DOI 10.1177/10547739922158322
   Onbe H, 2013, J RENAL CARE, V39, P90, DOI 10.1111/j.1755-6686.2013.12011.x
   Ozdamar K., 2002, PAKET PROGRAMLAR ILE, P511
   Pace Rory Caswell, 2007, Nephrol Nurs J, V34, P557
   Patel SS, 2002, AM J KIDNEY DIS, V40, P1013, DOI 10.1053/ajkd.2002.36336
   Polit DF, 2007, RES NURS HEALTH, V30, P459, DOI 10.1002/nur.20199
   Rushe H, 1998, J PSYCHOSOM RES, V45, P149, DOI 10.1016/S0022-3999(97)00228-6
   Saran R, 2003, KIDNEY INT, V64, P254, DOI 10.1046/j.1523-1755.2003.00064.x
   Sezer S, 2002, RENAL FAILURE, V24, P37, DOI 10.1081/JDI-120002659
   Tezbasaran A., 1997, GUIDE LIKERT SCALE D
   Welch JL, 2013, RES NURS HEALTH, V36, P284, DOI 10.1002/nur.21539
   Welch JL, 2001, J ADV NURS, V33, P200, DOI 10.1046/j.1365-2648.2001.01654.x
   Yurdugul H., 2005, MEASUREMENT THEORY R
NR 26
TC 2
Z9 2
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 457
EP 463
DI 10.19193/0393-6384_2017_3_067
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200015
DA 2022-07-14
ER

PT J
AU Duzer, S
   Aydemir, Y
   Sakallioglu, O
   Akyigit, A
   Polat, C
   Cetiner, H
AF Duzer, Sertac
   Aydemir, Yavuz
   Sakallioglu, Oner
   Akyigit, Abdulvahap
   Polat, Cahit
   Cetiner, Hasan
TI SIGNIFICANCE OF PARANASAL SINUS APLASIA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Paranasal; sinus; aplasia; anomaly
ID SPHENOID SINUS; AGENESIS; MAXILLARY
AB Introduction: Paranasal sinus aplasia is a rare condition mostly affecting the frontal and sphenoid sinuses and more rarely the maxillary sinuses.
   Material and methods: The present study retrospectively evaluated axial and coronal 1 mm thick CT scans of paranasal sinuses in 1502 cases. The patients without aeration of the frontal bone and ethmoidal cells above the supraorbital margin (horizontal line) and patients without aerated cells extending beyond the medial wall of the orbit (vertical line) were considered to have frontal sinus aplasia
   Results: Of 1502 patients with an age range between 16 and 73 years, 819 were females and 683 were males. Of these patients, 42 (0.27%) had bilateral frontal sinus aplasia and 53 (0.35%) had unilateral frontal sinus aplasia. Only two patients had sphenoid sinus aplasia and one patient had maxillary sinus aplasia.
   Conclusion: Paranasal sinuses represent great structural variations. Fractures, mucocele, primary ciliary dyskinesia, infections, and some syndromes may affect the development of PNSs. Aplasia of PNSs can point to clinically significant diseases and it must be kept in mind and explored during planning for surgical intervention to the sinuses in order to prevent complications. Computed tomography is a useful method in delineating a detailed anatomy of PNSs and detecting anomalies and pathological conditions.
C1 [Duzer, Sertac; Sakallioglu, Oner; Akyigit, Abdulvahap; Polat, Cahit; Cetiner, Hasan] Elazig Training & Res Hosp, Dept Otorhinolaryngol, TR-23200 Elazig, Turkey.
   [Aydemir, Yavuz] Elazig Training & Res Hosp, Dept Radiol, Elazig, Turkey.
RP Duzer, S (corresponding author), Elazig Training & Res Hosp, Dept Otorhinolaryngol, TR-23200 Elazig, Turkey.
RI CETINER, HASAN/AAQ-6824-2020; DUZER, SERTAC/AAK-1078-2020; Akyigit,
   Abdulvahap/W-2984-2018
OI DUZER, SERTAC/0000-0003-2988-6223; Akyigit,
   Abdulvahap/0000-0002-2192-155X; POLAT, CAHIT/0000-0001-9838-6906
CR Anik I, 2005, CLIN ANAT, V18, P217, DOI 10.1002/ca.20096
   Antoniades K, 1996, ORL J OTO-RHINO-LARY, V58, P347, DOI 10.1159/000276868
   Aydinlioglu A, 2004, CLIN ANAT, V17, P618, DOI 10.1002/ca.20026
   Aydmlioglu A, 2003, YONSEI MED J, V44, P215
   Baykara M., 2002, TURK J MED SCI, V32, P273
   Cakur Binali, 2011, Int J Med Sci, V8, P278
   Choudhary S, 2015, INT J ANAT RES, V3, P1620, DOI [10.16965/ijar.2015.237, DOI 10.16965/IJAR.2015.237]
   Eggesbo HB, 2001, ACTA RADIOL, V42, P482, DOI 10.1080/028418501127347214
   HANSON CL, 1980, AM J PHYS ANTHROPOL, V53, P251, DOI 10.1002/ajpa.1330530209
   Jafari-Pozve Nasim, 2014, Dent Res J (Isfahan), V11, P615
   Keskin G, 2002, SURG RADIOL ANAT, V24, P324, DOI 10.1007/s00276-002-0028-3
   Khanduri S, 2015, INDIAN J OTOLARYNGOL, V67, P434, DOI 10.1007/s12070-015-0877-9
   Korkmaz H, 2013, ALLERGY RHINOL, V4, pE105, DOI 10.2500/ar.2013.4.0056
   Martines F, 2016, BRAZ J OTORHINOLAR, V82, P215, DOI 10.1016/j.bjorl.2015.04.002
   Martines Francesco, 2014, J Med Case Rep, V8, P282, DOI 10.1186/1752-1947-8-282
   Pifferi M, 2011, EUR RESPIR J, V37, P566, DOI 10.1183/09031936.00068810
   Pifferi M, 2009, THORAX, V64, P1077, DOI 10.1136/thx.2008.110940
   REICHS KJ, 1993, FORENSIC SCI INT, V61, P141, DOI 10.1016/0379-0738(93)90222-V
   Ribeiro F de A, 2000, Ear Nose Throat J, V79, P26
   Som PM, 2003, ANATOMY PHYSL, P98
   Sonbay D, 2010, B-ENT, V6, P167
   Thiagarajan B, 2012, ONLINE J OTOLARYNGOL, V2
   Vitali M, 2017, J NEUROSURG SCI, DOI 10.23736/S0390-5616.17.03987-X
   White SC., 2009, ORAL RADIOL, V6th ed, P520
NR 24
TC 3
Z9 3
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 637
EP 640
DI 10.19193/0393-6384_2017_4_094
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700015
DA 2022-07-14
ER

PT J
AU Eksi, F
AF Eksi, Fahriye
TI INVESTIGATION OF ANTIBIOTIC RESISTANCE GENES AND PANTON-VALENTINE
   LEUCOCIDIN IN STAPHYLOCOCCUS AUREUS STRAINS ISOLATED FROM VARIOUS
   CLINICAL SAMPLES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE S. aureus; MRSA; Resistance genes; MecA; PVL
ID INDUCIBLE CLINDAMYCIN RESISTANCE; LEUKOCIDIN GENES; SCCMEC TYPES; MECA;
   CEFOXITIN; PCR
AB Introduction: Staphylococcus aureus is the etiological factor of one of the most widespread infections. This study aimed to investigate the relationship between antibiotic resistance and the presence of Panton-Valentine leucocidin (PVL) in S. aureus strains.
   Materials and methods: The methicillin resistance of the various strains was measured using a cefoxitin disc diffusion test. Presence of the ermA, ermC, mecA, tetK, tetM, gyrA, parC, aacA, and vanA genes and PVL (lukF/lukS) was investigated using the hybridization method following a multiplex polymerase chain reaction (PCR).
   Results: In this study, 63.5% of the 96 strains were identified as methicillin-sensitive S. aureus (MSSA) and 36.5% as methicillin-resistant S. aureus (MRSA). In 15.6% of the S. aureus strains, only ermA was detected; in 10.4%, only ermC; in 2.1%, both ermA and ermC; in 36.5%, only mecA; in 11.5%, only tetK; in 18.8%, only tetM; in 1.0%, both tetK and M; in 1.0%, only the gyrA mutation; in 7.3%, only the parC mutation; in 14.6%, both gyrA and parC mutations; in 31.3%, aacA; in 5.2%, the PVL gene. The VanA gene was not detected in any strain.
   Conclusion: According to our analysis, there may be S. aureus strains that carry but do not express known resistance genes, so other genes that may be responsible for resistance should be researched.
C1 [Eksi, Fahriye] Gaziantep Univ, Fac Med, Dept Med Microbiol, Univ Bulvari, TR-27310 Gaziantep, Turkey.
RP Eksi, F (corresponding author), Gaziantep Univ, Fac Med, Dept Med Microbiol, Univ Bulvari, TR-27310 Gaziantep, Turkey.
FU Gaziantep University Scientific Research Projects Administration
   Department Commission Directorate [TF.13.13]
FX This study, Project No. TF.13.13, was supported by the Gaziantep
   University Scientific Research Projects Administration Department
   Commission Directorate.
CR Anand KB, 2009, INDIAN J MED MICROBI, V27, P27
   Aridogan A, 2004, TURK MIKROBIYOL CEM, V34, P20
   Aydeniz Ozansoy F, 2015, MIKROBIYOL BUL, V49, P1
   Bannerman TL., 2003, MANUAL CLIN MICROBIO, P284
   Bhutia Kunsang O, 2012, Int J Appl Basic Med Res, V2, P84, DOI 10.4103/2229-516X.106348
   Boyle-Vavra S, 2007, LAB INVEST, V87, P3, DOI 10.1038/labinvest.3700501
   Cetin ES, 2008, INT J ANTIMICROB AG, V31, P364, DOI 10.1016/j.ijantimicag.2007.11.014
   Chini V, 2006, CLIN MICROBIOL INFEC, V12, P29, DOI 10.1111/j.1469-0691.2005.01295.x
   CLSI, 2013, M100S23 CLSI, V33
   Deresinski S, 2005, CLIN INFECT DIS, V40, P562, DOI 10.1086/427701
   Deurenberg RH, 2007, CLIN MICROBIOL INFEC, V13, P222, DOI 10.1111/j.1469-0691.2006.01573.x
   Duman Y, 2009, J TURGUT OZAL MED CT, V16, P145
   Duman Y, 2013, MIKROBIYOL BUL, V47, P389
   Dundar V, 2008, BASKI ISTANBUL NOBEL, P2065
   Emaneini M, 2013, Ann Burns Fire Disasters, V26, P76
   Fernandes CJ, 2007, J CLIN MICROBIOL, V45, P4018, DOI 10.1128/JCM.01158-07
   Gulmez D, 2012, MIKROBIYOL BUL, V46, P341
   Hauschild T, 2008, FOLIA HISTOCHEM CYTO, V46, P225, DOI 10.2478/v10042-008-0034-3
   Holfelder M, 2006, CLIN MICROBIOL INFEC, V12, P1163, DOI 10.1111/j.1469-0691.2006.01547.x
   Hooper DC, 2002, LANCET INFECT DIS, V2, P530, DOI 10.1016/S1473-3099(02)00369-9
   Juyal D, 2013, J CLIN DIAGN RES, V7, P61, DOI DOI 10.7860/JCDR/2012/4877.2671
   Karahan ZC, 2008, MICROB DRUG RESIST, V14, P203, DOI 10.1089/mdr.2008.0811
   Kilic A, 2008, ANTON LEEUW INT J G, V94, P607, DOI 10.1007/s10482-008-9278-3
   Kurutepe S., 2007, Infeksiyon Dergisi = Turkish Journal of Infection, V21, P187
   Kwak YG, 2013, J ANTIMICROB CHEMOTH, V68, P2766, DOI 10.1093/jac/dkt286
   Lodise Thomas P., 2003, Clinical Infectious Diseases, V36, P1418, DOI 10.1086/375057
   Mathews AA, 2010, INDIAN J PATHOL MICR, V53, P79, DOI 10.4103/0377-4929.59189
   Ozkul H, 2007, MIKROBIYOL BUL, V41, P357
   Olowe Olugbenga Adekunle, 2013, Infect Drug Resist, V6, P87, DOI 10.2147/IDR.S48809
   Queipo-Ortuno MI, 2008, CLIN VACCINE IMMUNOL, V15, P293, DOI 10.1128/CVI.00270-07
   Rasheed JK, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P1248
   Reischl U, 2015, GMS Z FORDERUNG QUAL, V6, P1
   Sakoulas G, 2001, J CLIN MICROBIOL, V39, P3946, DOI 10.1128/JCM.39.11.3946-3951.2001
   Skov R, 2014, J ANTIMICROB CHEMOTH, V69, P133, DOI 10.1093/jac/dkt341
   Stegger M, 2012, CLIN MICROBIOL INFEC, V18, P395, DOI 10.1111/j.1469-0691.2011.03715.x
   Swenson JM, 2005, J CLIN MICROBIOL, V43, P3818, DOI 10.1128/JCM.43.8.3818-3823.2005
   Vandendriessche S, 2011, J ANTIMICROB CHEMOTH, V66, P2455, DOI 10.1093/jac/dkr348
   Vandenesch F, 2003, EMERG INFECT DIS, V9, P978
   Zelazny AM, 2005, J CLIN MICROBIOL, V43, P2613, DOI 10.1128/JCM.43.6.2613-2615.2005
NR 39
TC 5
Z9 5
U1 1
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 341
EP 349
DI 10.19193/0393-6384_2017_2_051
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700026
DA 2022-07-14
ER

PT J
AU Elboga, G
   Sahin, SK
   Sahin, AZ
   Altindag, A
AF Elboga, Gulcin
   Sahin, Sengul Kocamer
   Sahin, Ahmet Ziya
   Altindag, Abdurrahman
TI SERUM LEVELS OF INFLAMMATORY BIOMARKERS IN SCHIZOAFFECTIVE DISORDERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Schizoaffective disorder; IL-2; IL-4; IL-6; TNF-alpha; hs-CRP
ID BIPOLAR DISORDER; SCHIZOPHRENIA; ALPHA; IL-6; POPULATION; DEPRESSION;
   SYMPTOMS; MARKERS; DISEASE
AB Introduction: A growing body of evidence suggests that inflammatory markers elevate in schizophrenia, bipolar disorder, major depression. The purpose of this study is to evaluate the association between schizoaffective disorder and serum levels of IL-2, IL-4, IL-6, TNF-alpha, hs-CRP, including the comparison between the affective episodes of the disease.
   Materials and methods: The study group consisted of 40 patients with bipolar type schizoaffective disorder as defined by DSM-IV criteria and 39 healthy control subjects. IL-2, IL-4, IL-6, TNF-alpha and hsCRP serum levels were examined by ELISA. Their clinical symptoms were rated using the Hamilton Depression Rating Scale and Young Mania Rating Scale. Univariate analysis of covariance controlled for possible confounders was used to compare cytokines and hsCRP levels among the groups.
   Results: hsCRP levels were significantly higher in patients compared to controls and IL-4 levels were significantly lower in patients compared to controls. hsCRP levels were significantly higher during the depressive phase, and IL-4 levels were significantly lower during the manic phase in patients compared to controls. No statistically significant differences were found in IL-2, IL-6, TNF-alpha.
   Conclusion: The results suggest that inflammatory dysregulation is associated with the schizoaffective disorder, and these changes may be related to affective phases of the bipolar type schizoaffective disorder.
C1 [Elboga, Gulcin; Altindag, Abdurrahman] Gaziantep Univ, Med Fac, Dept Psychiat, Sahinbey, Gaziantep, Turkey.
   [Sahin, Sengul Kocamer] Adana State Hosp, Dept Psychiat, Adana, Turkey.
   [Sahin, Ahmet Ziya] Adana Askim Tufekei State Hosp, Dept Internal Med, Adana, Turkey.
RP Elboga, G (corresponding author), Gaziantep Univ, Med Fac, Dept Psychiat, Sahinbey, Gaziantep, Turkey.
RI Sahin, Ahmet Ziyaettin/AAI-1994-2021; Elboga, Gulcin/AAG-6587-2020;
   Şahin, Ahmet Ziyaettin/A-8069-2012; Şahin, Şengül/AAI-2398-2019;
   Altindag, Abdurrahman/AAG-6463-2020
OI Sahin, Ahmet Ziyaettin/0000-0003-1060-6746; Şahin, Ahmet
   Ziyaettin/0000-0003-1060-6746; Şahin, Şengül/0000-0002-5371-3907;
   Altindag, Abdurrahman/0000-0001-5531-4419
FU Gaziantep University Scientific Research Project Department [TF.12.32]
FX Gaziantep University Scientific Research Project Department supports
   this study. (Project no: TF.12.32)
CR Altamura AC, 2013, PROG NEURO-PSYCHOPH, V42, P63, DOI 10.1016/j.pnpbp.2012.08.015
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI [DOI 10.1176/APPI.BOOKS.9780890420249.DSM-IV-TR, 10.1176/appi.books.9780890420249.dsm-iv-tr]
   Bauer S, 2007, NAT REV NEUROSCI, V8, P221, DOI 10.1038/nrn2054
   Bernstein HG, 2009, EXPERT REV NEUROTHER, V9, P1059, DOI [10.1586/ern.09.59, 10.1586/ERN.09.59]
   Bhatia M S, 1992, Indian J Med Sci, V46, P239
   Binbay T, 2012, TURK PSIKIYATR DERG, V23, P149, DOI 10.5080/u6783
   Brietzke E, 2009, J AFFECT DISORDERS, V116, P214, DOI 10.1016/j.jad.2008.12.001
   Campbell IL, 2005, BRAIN RES REV, V48, P166, DOI 10.1016/j.brainresrev.2004.12.006
   Chase Kayla A., 2016, BMC PSYCHIATRY, V16, P152
   Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297
   Drexhage RC, 2003, BRAIN BEHAV IMMUNOLO, V25, P1206
   Frydecka D, 2015, EUR ARCH PSY CLIN N, V265, P449, DOI 10.1007/s00406-014-0533-5
   GATTAZ WF, 1992, SCHIZOPHR RES, V6, P237, DOI 10.1016/0920-9964(92)90006-Q
   Goldstein BI, 2009, J CLIN PSYCHIAT, V70, P1078, DOI 10.4088/JCP.08r04505
   Hope S, 2011, J PSYCHIATR RES, V45, P1608, DOI 10.1016/j.jpsychires.2011.08.003
   Hope S, 2009, BIPOLAR DISORD, V11, P726, DOI 10.1111/j.1399-5618.2009.00757.x
   Howren MB, 2009, PSYCHOSOM MED, V71, P171, DOI 10.1097/PSY.0b013e3181907c1b
   Kim YK, 2000, SCHIZOPHR RES, V44, P165, DOI 10.1016/S0920-9964(99)00171-1
   Kuloglu M, 2011, KLIN PSIKOFARMAKOL B, V21, P193, DOI 10.5455/bcp.20110418011851
   Kunz M, 2011, REV BRAS PSIQUIATR, V33, P268, DOI 10.1590/S1516-44462011000300010
   Li ZX, 2017, ACTA MEDICA MEDITERR, V33, P41, DOI 10.19193/0393-6384_2017_1_006
   Lowe GDO, 2005, J THROMB HAEMOST, V3, P1618, DOI 10.1111/j.1538-7836.2005.01416.x
   Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029
   Miller BJ, 2011, BIOL PSYCHIAT, V70, P663, DOI 10.1016/j.biopsych.2011.04.013
   Modabbernia A, 2013, BIOL PSYCHIAT, V15, P4754
   O'Brien SM, 2008, PSYCHIAT RES, V160, P256, DOI 10.1016/j.psychres.2007.11.014
   Ortiz-Dominguez A, 2007, BIPOLAR DISORD, V9, P596, DOI 10.1111/j.1399-5618.2007.00493.x
   Padhy S, 2015, TURK PSIKIYATR DERG, V26, P131
   Petitto JM, 1997, J NEUROIMMUNOL, V73, P183, DOI 10.1016/S0165-5728(96)00196-8
   Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315
   Suvisaari J, 2011, PSYCHIAT RES, V189, P305, DOI 10.1016/j.psychres.2011.07.006
   WOODROOFE MN, 1995, NEUROLOGY, V45, pS6, DOI 10.1212/WNL.45.6_Suppl_6.S6
   Zhang XY, 2004, J CLIN PSYCHIAT, V65, P940
NR 33
TC 3
Z9 3
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 863
EP 868
DI 10.19193/0393-6384_2017_5_128
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000022
DA 2022-07-14
ER

PT J
AU Elham, R
   Shahnaz, A
   Niloofar, M
   Afsaneh, G
   Zohreh, Z
AF Elham, Rahmani
   Shahnaz, Ahmadi
   Niloofar, Motamed
   Afsaneh, Ghasemi
   Zohreh, Zamani
TI COMPARISON BETWEEN THE EFFICACY OF SHORT-TERM AND FIXED PROTOCOLS OF
   GNRH ANTAGONIST IN IVF CYCLES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE infertility; IVF; gonadotropins; follicular phase
ID OVARIAN STIMULATION; HORMONE ANTAGONIST; AGONIST; PREGNANCY
AB Background: Aim of this study is to compare the short-term effect of GnRH antagonist in follicular phase with fixed protocol of GnRH antagonist in IVF cycles in infertile women.
   Materials and methods: The present study was conducted on 60 patients. Patients were divided into two groups of 30, based on random table of Excel. The target group received 0.25 mg per day subcutaneous Cetrorelix on days 1, 2 and 3, which was injected on the fourth day of menstruation and for the control group, fixed Cetrorelix, was started on the 6th day of cycle and continued until HCG injection. Both groups received 300 IU gonadotropin for four days that was adjusted based on the ultrasound results. Then gonadotropin consumption, number of oocytes and pregnancy rates were clinically compared.
   Results: In the present study, there was no difference between the case and control group regarding pregnancy rate (P value = 0.54). Cetrorelix dose used and the total number of days of treatment were significantly different between the two groups (P value = 0.0001) and the target group used higher dose of Cetrorelix but had a lower duration of therapy. The two groups were not significantly different in the primary outcome, including chemical and clinical pregnancy (P value = 0.58) (P value = 0.68).
   Conclusion: It was demonstrated in the present study that short-term and fixed use of GnRH antagonist in the follicular phase was not different and the short-term protocol decreases the length of treatment and increases the costs.
C1 [Elham, Rahmani] Bushehr Univ Med Sci, Dept Gynecol Obstet, Bushehr, Iran.
   [Shahnaz, Ahmadi; Afsaneh, Ghasemi] Iran Univ Med Sci, Dept Gynecol Obstet, Tehran, Iran.
   [Niloofar, Motamed] Bushehr Univ Med Sci, Community, Bushehr, Iran.
   [Zohreh, Zamani] Bushehr Univ Med Sci, Bushehr, Iran.
RP Shahnaz, A (corresponding author), Iran Univ Med Sci, Dept Gynecol Obstet, Tehran, Iran.
EM Ahmadishahnaz2005@yahoo.com
RI Rahmani, Elham/S-4222-2017; Motamed, Niloofar/F-3355-2017
OI Motamed, Niloofar/0000-0001-5291-1680; Rahmani,
   Elham/0000-0001-8392-7685; ahmadi, shahnaz/0000-0002-2136-4474
CR Al-Inany H, 2007, REPROD BIOMED ONLINE, V14, P640, DOI 10.1016/S1472-6483(10)61059-0
   Albano C, 2000, HUM REPROD, V15, P526, DOI 10.1093/humrep/15.3.526
   Blockeel C, 2011, FERTIL STERIL, V95, P1714, DOI 10.1016/j.fertnstert.2011.01.028
   Davar R, 2013, ARCH GYNECOL OBSTET, V287, P149, DOI 10.1007/s00404-012-2522-0
   Eftekhar Maryam, 2014, Iran J Reprod Med, V12, P513
   Eftekhar M, 2012, IRAN J REPROD MED, V10, P297
   Fanchin R, 2003, HUM REPROD, V18, P2698, DOI 10.1093/humrep/deg516
   Firouzabadi RD, 2014, ARCH GYNECOL OBSTET, V289, P201, DOI 10.1007/s00404-013-2959-9
   Frankfurter D, 2007, FERTIL STERIL, V88, P1442, DOI 10.1016/j.fertnstert.2007.01.022
   Griesinger G, 2011, REPROD BIOMED ONLINE, V23, P457, DOI 10.1016/j.rbmo.2011.06.016
   Khalaf M, 2010, REPROD BIOMED ONLINE, V21, P56, DOI 10.1016/j.rbmo.2010.03.017
   Malmusi S, 2005, FERTIL STERIL, V84, P402, DOI 10.1016/j.fertnstert.2005.01.139
   Moraloglu O, 2008, ADV THER, V25, P266, DOI 10.1007/s12325-008-0028-8
   Rackow BW, 2008, FERTIL STERIL, V89, P1234, DOI [10.1016/j.fertnstert.2007.04.060, 10.1016/j.fertnstert.2007.12.030]
   Younis JS, 2010, FERTIL STERIL, V94, P1350, DOI 10.1016/j.fertnstert.2009.08.033
NR 15
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 785
EP 788
DI 10.19193/0393-6384_2017_5_115
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000009
DA 2022-07-14
ER

PT J
AU Erdogan, S
   Yildirim, A
   Bakan, N
   Yazar, AS
   Guven, S
AF Erdogan, Seher
   Yildirim, Ahmet
   Bakan, Nurten
   Yazar, Ahmet Sami
   Guven, Sirin
TI STATUS EPILEPTICUS, METABOLIC ACIDOSIS, RHABDOMYOLYSIS: ACUTE ISONIAZIDE
   INTOXICATION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Status epilepticus; acidosis; intoxication
AB Isoniazide is one of the most commonly used medications for the prophylaxis and treatment of childhood tuberculosis. Intake of isoniazide at high doses may cause recurrent convulsions resistant to anticonvulsants, high anion gap metabolic acidosis, lactic acidosis, coma, and rhabdomyolysis in a dose-dependent manner; it may lead to death in untreated cases. Herein, we report a 16-year-old patient who was admitted to emergency department for acute isoniazide intoxication characterized by recurrent seizures, rhabdomyolysis, and metabolic acidosis. Convulsions were taken under control with Midazolam infusion. The patient was hydrated for rhabdomyolysis and alkalinization treatment was given. Pyridoxin which is a spsesific antidot was given intravenously and the patient has been treated successfully. INH-mediated intoxications has recently been on the rise especially in the young. Therefore, the intravenous form of pyridoxine should be found in every emergency department.
C1 [Erdogan, Seher] Umraniye Res & Training Hosp, Dept Pediat Crit Care, Istanbul, Turkey.
   [Yildirim, Ahmet; Bakan, Nurten] Umraniye Res & Training Hosp, Dept Anaesthesia & Intens Care Med, Istanbul, Turkey.
   [Yazar, Ahmet Sami; Guven, Sirin] Umraniye Res & Training Hosp, Dept Pediat, Istanbul, Turkey.
RP Erdogan, S (corresponding author), Umraniye Res & Training Hosp, Adem Yavuz Cad 1, TR-34764 Istanbul, Turkey.
RI guven, sirin/AAL-2290-2020
CR Chen HY, 2016, BRIT J CLIN PHARMACO, V81, P412, DOI 10.1111/bcp.12720
   Gokhale Yojana A, 2009, J Assoc Physicians India, V57, P70
   Howland MA, 2010, GOLDFRANKS TOXICOLOG, P845
   Minns AB, 2010, PEDIATR EMERG CARE, V26, P380, DOI 10.1097/PEC.0b013e3181db24b6
   Okutur S. K., 2006, TURK J MED SCI, V36, P397
   Panganiban LR, 2001, J TOXICOL-CLIN TOXIC, V39, P143, DOI 10.1081/CLT-100103830
   Skinner K, 2015, HEMODIAL INT, V19, pE37, DOI 10.1111/hdi.12293
   Uzman S, 2013, TUBERK TORAK, V61, P50, DOI 10.5578/tt.1897
NR 8
TC 0
Z9 0
U1 1
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1063
EP 1065
DI 10.19193/0393-6384_2017_6_168
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500027
DA 2022-07-14
ER

PT J
AU Eroglu, M
   Ozkul, F
   Erbag, G
   Temiz, A
   Altun, B
   Arik, K
   Sen, H
   Binnetoglu, E
   Asik, M
AF Eroglu, Mustafa
   Ozkul, Faruk
   Erbag, Gokhan
   Temiz, Ahmet
   Altun, Burak
   Arik, Kasim
   Sen, Hacer
   Binnetoglu, Emine
   Asik, Mehmet
TI EVALUATION OF EPICARDIAL FAT TISSUE THICKNESS AND CAROTID INTIMA MEDIA
   THICKNESS IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM AFTER
   PARATHYROIDECTOMY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE epicardial fat tissue (EFT); carotid intima-media thickness (CIMT)
ID CORONARY-ARTERY-DISEASE; MILD PRIMARY HYPERPARATHYROIDISM; DEATH;
   ABNORMALITIES; POPULATION; DIAGNOSIS; STIFFNESS; RISK
AB Introduction: It has been shown that epicardial fat tissue (EFT) thickness in primary hyperparathyroidism (PHPT) is increased and that this is closely associated with cardiovascular disease and atherosclerosis. However, EFT thickness in patients with hyperparathyroidism who were treated with parathyroidectomy has not yet been studied. In this study we aimed to examine whether carotid intima-media thickness (CIMT) and EFT thickness would be affected after treatment of PHPT by parathyroidectomy.
   Materials and methods: 27 patients with PHPT who were diagnosed with a parathyroidectomy indication and 39 healthy volunteers were included in the study. For all patients with PHPT, anthropometric measurements were made before and 12 months after parathyroidectomy, and EFT thickness, CIMT, serum parathormone (PTH), calcium and lipid levels were measured.
   Results: It was observed that preoperative CIMT and EFT thickness in patients with PHPT were significantly higher than the control group (for both p<0.001). Although hyperparathyroidism and hypercalcemia of the patients improved after parathyroidectomy, no significant change in the thickness of CIMT or EFT was determined.
   Conclusions: CIMT and EFT thickness seem to be good cardiovascular indicators for diagnosis of patients with PHPT. Nevertheless, this study raises the question of the reliability of a decrease in these parameters in patient follow-up. It is therefore necessary to be more careful in evaluating these parameters after treatment of patients with PHPT.
C1 [Eroglu, Mustafa; Asik, Mehmet] Canakkale Onsekiz Mart Univ, Fac Med, Dept Endocrinol & Metab, Canakkale, Turkey.
   [Eroglu, Mustafa; Asik, Mehmet] Canakkale Onsekiz Mart Univ, Fac Med, Dept Gen Surg, Canakkale, Turkey.
   [Erbag, Gokhan] Canakkale Onsekiz Mart Univ, Fac Med, Dept Gen Med, Canakkale, Turkey.
   [Temiz, Ahmet; Altun, Burak] Canakkale Onsekiz Mart Univ, Fac Med, Dept Cardiol, Canakale, Turkey.
RP Eroglu, M (corresponding author), Canakkale Onsekiz Mart Univ, Fac Med, Dept Endocrinol & Metab, Canakkale, Turkey.
RI şen, hacer/AAC-2469-2021; Eroğlu, Mustafa/AAC-1081-2020
OI Eroğlu, Mustafa/0000-0002-7526-7151; Asik, mehmet/0000-0002-0716-0221
CR Andersson P, 2004, EUR HEART J, V25, P1776, DOI 10.1016/j.ehj.2004.07.010
   Arcadi T, 2014, INT J CARDIOL, V176, P988
   Asik M, 2014, ENDOCR PRACT, V20, P26, DOI 10.4158/EP13140.OR
   Asik M, 2013, CLIN ENDOCRINOL, V79, P571, DOI 10.1111/cen.12176
   Barletta G, 2000, J CLIN ENDOCR METAB, V85, P1815, DOI 10.1210/jc.85.5.1815
   Binnetoglu E, 2014, WIEN KLIN WOCHENSCHR, V126, P485, DOI 10.1007/s00508-014-0570-0
   Cansu GB, 2016, CLIN ENDOCRINOL, V84, P39, DOI 10.1111/cen.12952
   DOMINICZAK AF, 1990, CLIN SCI, V78, P127, DOI 10.1042/cs0780127
   Fallo F, 2003, J CLIN ENDOCR METAB, V88, P2096, DOI 10.1210/jc.2002-021837
   HEATH DA, 1989, ENDOCRIN METAB CLIN, V18, P631, DOI 10.1016/S0889-8529(18)30357-8
   Hedback G, 1998, EUR J CLIN INVEST, V28, P271
   HEDBACK G, 1991, WORLD J SURG, V15, P399, DOI 10.1007/BF01658740
   HEDBACK G, 1990, WORLD J SURG, V14, P829, DOI 10.1007/BF01670531
   Holaj R, 2003, CAN J CARDIOL, V19, P670
   Jeong JW, 2007, CIRC J, V71, P536, DOI 10.1253/circj.71.536
   Kablak-Ziembicka A, 2004, HEART, V90, P1286, DOI 10.1136/hrt.2003.025080
   Kosch M, 2001, CLIN NEPHROL, V55, P303
   Kosch M, 2000, AM J HYPERTENS, V13, P759, DOI 10.1016/S0895-7061(00)00248-X
   Lumachi F, 2006, IN VIVO, V20, P887
   Natale F, 2009, EUR J ECHOCARDIOGR, V10, P549, DOI 10.1093/ejechocard/jep002
   Nilsson IL, 1999, SURGERY, V126, P1049, DOI 10.1067/msy.2099.101422
   Piovesan A, 1999, CLIN ENDOCRINOL, V50, P321, DOI 10.1046/j.1365-2265.1999.00651.x
   Ruda JM, 2005, OTOLARYNG HEAD NECK, V132, P359, DOI 10.1016/j.otohns.2004.10.005
   Seyrek N, 2003, RENAL FAILURE, V25, P1011, DOI 10.1081/JDI-120026036
   Silverberg SJ, 2000, J CLIN ENDOCR METAB, V85, P3513
   STEFENELLI T, 1993, AM J MED, V95, P197, DOI 10.1016/0002-9343(93)90260-V
   Tanindi A, 2015, CORONARY ARTERY DIS, V26, P686, DOI 10.1097/MCA.0000000000000296
   Tuna MM, 2015, CLIN ENDOCRINOL, V83, P951, DOI 10.1111/cen.12666
   Walker MD, 2009, J CLIN ENDOCR METAB, V94, P3849, DOI 10.1210/jc.2009-1086
   Wermers RA, 1998, AM J MED, V104, P115, DOI 10.1016/S0002-9343(97)00270-2
NR 30
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 77
EP 81
DI 10.19193/0393-6384_2017_1_012
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800012
DA 2022-07-14
ER

PT J
AU Ersan, S
   Liv, F
   Tanrisev, M
   Colak, H
   Yilmaz, B
   Alp, A
AF Ersan, Sibel
   Liv, Fatma
   Tanrisev, Mehmet
   Colak, Hulya
   Yilmaz, Banu
   Alp, Alper
TI HEMODIALYSIS PATIENTS' KNOWLEDGE AND AWARENESS ABOUT DIETARY SODIUM:
   THERE IS STILL NEED FOR AWARENESS RAISING INTERVENTIONS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE chronic kidney disease; hemodialysis patients; nutrition; salt
ID SALT INTAKE; NONCOMPLIANCE
AB Introduction: Hemodialysis patients are particularly susceptible to the adverse effects of salt because of impaired ability to excrete sodium. The patients who restrict dietary sodium intake have better cardiovascular outcomes and quality of life. The purpose of this study was to assess dietary knowledge of patients about dietary sodium and medical complications of noncompliance.
   Materials and methods: An interviewer-administered questionnaire about knowledge of dietary sodium, and medical complications of dietary noncompliance was applied to hemodialysis patients.
   Results: Although 85.3% of patients reported that high sodium intake was associated with high blood pressure, interdialytic weight gain were more than 5.7% in 81.6% of patients. There was no statistically significant difference between genders, educational, and economic status of patients and interdialytic weight gain. Overall knowledge scores were poor, moderate, and high in 16%, 56%, and 28% of patients, respectively. The awareness score of risks of noncompliance was high in only 24% of patients. The knowledge scores showed significant weak positive correlation with educational level (spearman's rho (rs)=0.17, p=0.03). There was no correlation with knowledge levels and interdialytic weight gains (rs=-0.13, p=0.11). The awareness did not differ with educational level, and age (rs=-0.01, p=0.84, and rs=0.13, p=0.10, respectively).
   Conclusion: Majority of the patients have not still perceived the constituents of salt-free diet despite the implementation of the governmental salt reduction program. More impressive dietetic and psycho-educational techniques to promote dietary changes and compliance should be implemented.
C1 [Ersan, Sibel; Liv, Fatma; Tanrisev, Mehmet; Colak, Hulya; Yilmaz, Banu; Alp, Alper] Izmir Tepecik Res & Training Hosp, Dept Nephrol, Izmir, Turkey.
RP Ersan, S (corresponding author), Izmir Tepecik Res & Training Hosp, Dept Nephrol, Izmir, Turkey.
RI ERSAN, SİBEL/ABF-1542-2021; Alp, Alper/AAK-2766-2020; Colak,
   Hulya/AAB-1979-2021
OI ERSAN, SİBEL/0000-0002-9381-5262; Alp, Alper/0000-0002-2864-361X; 
CR Agondi RD, 2011, J RENAL NUTR, V21, P160, DOI 10.1053/j.jrn.2010.03.007
   Baines LS, 2000, NEPHRON, V85, P1, DOI 10.1159/000045622
   CHAN CY, 1994, DIALYSIS TRANSPLANT, V23, P184
   CUMMINGS KM, 1982, MED CARE, V20, P567, DOI 10.1097/00005650-198206000-00003
   Durose CL, 2004, J AM DIET ASSOC, V104, P35, DOI 10.1016/j.jada.2003.10.016
   Erdem Y, 2010, BLOOD PRESSURE, V19, P313, DOI 10.3109/08037051003802541
   Hecking M, 2013, AM J NEPHROL, V38, P78, DOI 10.1159/000353104
   Lee SH, 2002, INT J NURS STUD, V39, P695, DOI 10.1016/S0020-7489(02)00007-X
   Mason H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084445
   Park KA, 2008, J RENAL NUTR, V18, P415, DOI 10.1053/j.jrn.2008.04.004
   Saran R, 2003, KIDNEY INT, V64, P254, DOI 10.1046/j.1523-1755.2003.00064.x
   Shepherd R, 2002, P NUTR SOC, V61, P267, DOI 10.1079/PNS2002147
   Strazzullo P, 2012, NUTR METAB CARDIOVAS, V22, P161, DOI 10.1016/j.numecd.2011.10.004
   Suckling RJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006763.pub2
   Topbas E, 2015, J REN CARE
   Welch JL, 2005, INT J NURS STUD, V42, P597, DOI 10.1016/j.ijnurstu.2004.09.015
   Wiser NA, 1997, J RENAL NUTR, V7, P187, DOI DOI 10.1016/S1051-2276(97)90017-0
NR 17
TC 2
Z9 2
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 217
EP 222
DI 10.19193/0393-6384_2017_2_032
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700007
DA 2022-07-14
ER

PT J
AU Feola, A
   Della Pietra, B
AF Feola, Alessandro
   Della Pietra, Bruno
TI ACUTE LIVER FAILURE CAUSED BY PARACETAMOL TOXICITY: A CASE REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE acute liver failure; paracetamol; acetaminophen; adverse drug reaction;
   liver injury; poisoning
ID FULMINANT HEPATIC-FAILURE; MANAGEMENT; ETIOLOGY
AB This was a case of acute liver failure caused by paracetamol toxicity. The patient was a 54-year-old woman who self-medicated with paracetamol to treat a fever. She was admitted to hospital after 3 days of nausea, vomiting, and jaundice. After excluding viral hepatitis, diagnosis leaned towards hepatitis secondary to paracetamol, which was later confirmed by serum paracetamol levels (69.4 mg/L). Despite acetylcysteine therapy, the patient died after a few hours. Upon macroscopic examination at autopsy, diffuse congestion of the hepatic parenchyma with alterations to the normal structure and diffuse parenchymal necrosis were observed. Upon microscopic examination of hepatic tissue, features of hepatic centrilobular necrosis were present. From data reported in the literature, findings obtained from the clinical history and the anatomopathological evidence suggested that the death of the patient was attributable to accidental paracetamol poisoning.
C1 [Feola, Alessandro] Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.
   [Della Pietra, Bruno] Univ Naples 2, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy.
RP Feola, A (corresponding author), Via Montpellier 1, I-00133 Rome, Italy.
EM alessandro.feola@icloud.com
RI Feola, Alessandro/AAI-4601-2020
OI Feola, Alessandro/0000-0002-9666-2636; Della Pietra,
   Bruno/0000-0002-1832-5618
CR Bernal W, 2010, LANCET, V376, P190, DOI 10.1016/S0140-6736(10)60274-7
   Dargan PI, 2003, TRENDS PHARMACOL SCI, V24, P154, DOI 10.1016/S0165-6147(03)00053-1
   Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9
   Gotthardt D, 2007, NEPHROL DIAL TRANSPL, V22, P5, DOI 10.1093/ndt/gfm650
   Gyamlani GG, 2002, CRIT CARE, V6, P155, DOI 10.1186/cc1475
   Heard KJ, 2008, NEW ENGL J MED, V359, P285, DOI 10.1056/NEJMct0708278
   Hussaini SH, 2007, EXPERT OPIN DRUG SAF, V6, P673, DOI 10.1517/14740338.6.6.673
   Ichai P, 2008, LIVER TRANSPLANT, V14, pS67, DOI 10.1002/lt.21612
   Ichai P, 2011, CLIN RES HEPATOL GAS, V35, P610, DOI 10.1016/j.clinre.2011.03.010
   Jaeschke H, 2012, LIVER INT, V32, P8, DOI 10.1111/j.1478-3231.2011.02501.x
   Kasper LD, 2015, HARRISONS PRINCIPLES
   Mas A, 1997, LANCET, V349, P1081, DOI 10.1016/S0140-6736(96)08054-3
   Moffat A.C., 2011, PHARM BODY FLUIDS PO
   Williams CD, 2010, TOXICOL APPL PHARM, V247, P169, DOI 10.1016/j.taap.2010.07.004
NR 14
TC 4
Z9 4
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 55
EP 58
DI 10.19193/0393-6384_2017_1_008
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800008
DA 2022-07-14
ER

PT J
AU Fu, YG
   Hu, DJ
   Wang, L
AF Fu, Yugui
   Hu, Dejian
   Wang, Li
TI ANTI-ALLERGIC ACTIVITY OF ETHANOL EXTRACT OF CHINESE PETASITES
   TATEWAKIANUS KITAM IN PREVENTIVE TREATMENT OF ALLERGIC RHINITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE butterbur extract; anti-allergic activity; histamine; leukotrienes
ID MAST-CELL; ALTERNATIVE MEDICINE; LEUKOTRIENE B-4; NASAL-MUCOSA; ASTHMA;
   INFLAMMATION; NEUTROPHILS; EXPRESSION; IDENTIFICATION; COMPLEMENTARY
AB Objective: This study aims to evaluate potential protective effects of the ethanol extract of Chinese Petasites tatewakianus Kitam (PTK) on rats with induced AR.
   Methods: Sprague-Dawley rats were sensitized and randomly allocated into two groups: control (n = 10) and PTK (n = 10). One hr prior to intra-nasal challenge with the antigen, rats received either the PTK or saline vehicle per os. Nasal symptoms and quality of life were compared between the rats in the two groups over the course of 20 min post-challenge. Nasal fluids and in serum were collected 1 hr after the antigen challenge and then evaluated for the levels of several key inflammatory mediators. Lipid mediator production was also evaluated ex vivo using PBMC (peripheral blood mononuclear cells) and granulocytes from the sensitized rats.
   Results: The results showed that a single administration of PTK extract resulted in significantly decreased histamine and LTs levels (LTB4 and cysteinyl-LTs) in the blood and nasal fluids of the rats. Further, the synthesis of cysteinyl-LTs and LTB4 were all significantly inhibited ex vivo by the PTK extract. Overall, the treatment with PTK extract significantly alleviated the nasal symptoms and improved the quality-of-life of the challenged hosts.
   Conclusion: Taken together, these results indicated to us that PTK extract was effective in treating AR, in part, by decreasing levels of nasal inflammatory mediators and the synthesis of LTs and, in doing so, ameliorated allergy symptoms and improved the quality of life of the antigen-challenged sensitized hosts.
C1 [Fu, Yugui] Linyi Peoples Hosp, Dept Otolaryngol, Linyi 276003, Peoples R China.
   [Hu, Dejian] Weifang Peoples Hosp, Dept Pharm, Weifang 261000, Peoples R China.
   [Wang, Li] Qingdao Univ, Dept Otolaryngol, Affiliated Yantai Yuhuangding Hosp, Yantai 264000, Peoples R China.
RP Wang, L (corresponding author), Qingdao Univ, Dept Otolaryngol, Affiliated Yantai Yuhuangding Hosp, Yantai 264000, Peoples R China.
CR Anderson N, 2009, TOXICOL SCI, V112, P507, DOI 10.1093/toxsci/kfp216
   BRADDING P, 1993, J IMMUNOL, V151, P3853
   Busse WW, 1996, CLIN EXP ALLERGY, V26, P868, DOI 10.1046/j.1365-2222.1996.d01-390.x
   Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100
   Chen Chien-Fu, 2001, Journal of Microbiology Immunology and Infection, V34, P57
   CHERIASAMMARI S, 1995, CLIN EXP ALLERGY, V25, P729, DOI 10.1111/j.1365-2222.1995.tb00010.x
   Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x
   Dong XW, 2010, FITOTERAPIA, V81, P153, DOI 10.1016/j.fitote.2009.08.013
   Ferguson BJ, 2004, OTOLARYNG HEAD NECK, V130, P617, DOI 10.1016/j.otohns.2004.02.001
   FRETLAND DJ, 1995, INFLAMMATION, V19, P333, DOI 10.1007/BF01534391
   Gelfand EW, 2004, J ALLERGY CLIN IMMUN, V114, pS135, DOI 10.1016/j.jaci.2004.08.043
   Guo R, 2007, ANN ALLERG ASTHMA IM, V99, P483, DOI 10.1016/S1081-1206(10)60375-4
   Hugg T, 2008, EUR J EPIDEMIOL, V23, P123, DOI 10.1007/s10654-007-9217-z
   Inoue T, 2001, BIOL PHARM BULL, V24, P92, DOI 10.1248/bpb.24.92
   Kang HG, 2010, J VET SCI, V11, P51, DOI 10.4142/jvs.2010.11.1.51
   Klimek L, 1999, J ALLERGY CLIN IMMUN, V103, P47, DOI 10.1016/S0091-6749(99)70524-5
   Knapp H R, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P279
   KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506
   LEWIS RA, 1990, NEW ENGL J MED, V323, P645
   Man LX, 2009, CURR OPIN OTOLARYNGO, V17, P226, DOI 10.1097/MOO.0b013e3283295791
   Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809
   Nelson Edmund A. S., 2007, Hong Kong Medical Journal, V13, P114
   Passalacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P1054, DOI 10.1016/j.jaci.2005.12.1308
   PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x
   SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274
   Shimoda H, 2006, J AGR FOOD CHEM, V54, P2915, DOI 10.1021/jf052994o
   SIMON HU, 1994, J IMMUNOL, V153, P364
   Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071
   Sugimoto Y, 2000, IMMUNOPHARMACOLOGY, V48, P1, DOI 10.1016/S0162-3109(00)00173-9
   Thomet OAR, 2002, INT IMMUNOPHARMACOL, V2, P997, DOI 10.1016/S1567-5769(02)00046-2
   Thomet OAR, 2001, CLIN EXP ALLERGY, V31, P1310, DOI 10.1046/j.1365-2222.2001.01158.x
   TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133
   VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170
   Wang MC, 2014, J AGR FOOD CHEM, V62, P9362, DOI 10.1021/jf5034224
   YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868
NR 35
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1129
EP 1135
DI 10.19193/0393-6384_2017_6_177
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500036
DA 2022-07-14
ER

PT J
AU Gallai, B
   Valentini, V
   Barbanera, F
   Marotta, R
   Lavano, F
   Lavano, SM
   Maltese, A
   Tripi, G
   Romano, P
   Salerno, M
AF Gallai, Beatrice
   Valentini, Vittoria
   Barbanera, Francesca
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Maltese, Agata
   Tripi, Gabriele
   Romano, Palmira
   Salerno, Margherita
TI BEHAVIOURAL DISORDERS IN CHILDREN AND ADOLESCENTS: A CONCEPTUAL REVIEW
   ABOUT THE THERAPEUTIC ALLIANCE WITH FAMILY AND SCHOOL
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Behavioural disorders; Family alliance; therapeutic program
ID AUTISM SPECTRUM DISORDERS; CHILDHOOD ABSENCE EPILEPSY; PRIMARY NOCTURNAL
   ENURESIS; PRIMARY CILIARY DYSKINESIA; PRADER-WILLI-SYNDROME; SLEEP-APNEA
   SYNDROME; WEIGHT-LOSS PROGRAM; QUALITY-OF-LIFE; PARENTAL STRESS;
   MATERNAL STRESS
AB Aim: In disruptive behavioral disorders, given the wide range of symptomatic manifestations and the complexity of the socio-familiar contexts in which they develop, it is now proven that more visible and more stable results can be achieved over time through multimodal and multidimensional interventions. These are accomplished through the integration of psychotherapeutic interventions for the child and parents, counseling interventions for all the various practitioners who come into contact with the child in school, sports, and social settings, through the possibility of organizing multiple settings in patient can be followed by several health professionals such as child and adolescent neuropsychiatrist, neuropsychomotricist, occupation therapist, psychologist.
C1 [Gallai, Beatrice; Valentini, Vittoria; Barbanera, Francesca] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Romano, Palmira] Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Romano, Palmira] Univ Campania Luigi Vanvitelli, Naples, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI TRIPI, Gabriele/0000-0001-7088-9325; Marotta, Rosa/0000-0003-0515-5952
CR Ahmadi MRH, 2017, ACTA MEDICA MEDITERR, V33, P351, DOI 10.19193/0393-6384_2017_2_052
   Balkan A, 2017, ACTA MEDICA MEDITERR, V33, P165, DOI 10.19193/0393-6384_2017_1_025
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chelouti H, 2017, ACTA MEDICA MEDITERR, V33, P89, DOI 10.19193/0393-6384_2017_1_014
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Eksi F, 2017, ACTA MEDICA MEDITERR, V33, P341, DOI 10.19193/0393-6384_2017_2_051
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Feola A, 2017, ACTA MEDICA MEDITERR, V33, P55, DOI 10.19193/0393-6384_2017_1_008
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Gokdemir GS, 2017, ACTA MEDICA MEDITERR, V33, P157, DOI 10.19193/0393-6384_2017_1_024
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Karagoz H, 2017, ACTA MEDICA MEDITERR, V33, P205, DOI 10.19193/0393-6384_2017_2_030
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisano S, 2017, J CHILD ADOL PSYCHOP, V27, P844, DOI 10.1089/cap.2016.0203
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Shirazi SAM, 2017, ACTA MEDICA MEDITERR, V33, P267, DOI 10.19193/0393-6384_2017_2_039
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Yilmazel G, 2017, ACTA MEDICA MEDITERR, V33, P329, DOI 10.19193/0393-6384_2017_2_049
NR 91
TC 10
Z9 10
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1181
EP 1188
DI 10.19193/0393-6384_2017_2s_184
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700002
DA 2022-07-14
ER

PT J
AU Gallai, B
   Valentini, V
   Barbanera, F
   Marotta, R
   Lavano, F
   Lavano, SM
   Maltese, A
   Tripi, G
   Romano, P
   Salerno, M
   Di Folco, A
AF Gallai, Beatrice
   Valentini, Vittoria
   Barbanera, Francesca
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Maltese, Agata
   Tripi, Gabriele
   Romano, Palmira
   Salerno, Margherita
   Di Folco, Annabella
TI THE PSYCHOTERAPEUTIC INTERVENTIONS AND STRATEGIES FOR CHILDREN AND
   ADOLESCENTS WITH BEHAVIOURAL DISORDERS: THE INCREDIBLE YEARS TREATMENT
   PROGRAM
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Behavioural disorders; psychotherapeutic interventions; parents;
   teachers
ID AUTISM SPECTRUM DISORDERS; CHILDHOOD ABSENCE EPILEPSY; PRIMARY NOCTURNAL
   ENURESIS; PRIMARY CILIARY DYSKINESIA; PRADER-WILLI-SYNDROME; SLEEP-APNEA
   SYNDROME; WEIGHT-LOSS PROGRAM; PARENTAL STRESS; MATERNAL STRESS; OBESE
   CHILDREN
AB The psychotherapeutic interventions disposable and considered the key role in behavioral therapy are the Incredible Years, the evidence-based parenting support.
C1 [Gallai, Beatrice; Valentini, Vittoria; Barbanera, Francesca] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Barbanera, Francesca] Univ Perugia, Azienda Sanitaria Locale Umbria 1, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Romano, Palmira] Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Romano, Palmira] Univ Campania Luigi Vanvitelli, Naples, Italy.
   [Salerno, Margherita; Di Folco, Annabella] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI TRIPI, Gabriele/0000-0001-7088-9325; Marotta, Rosa/0000-0003-0515-5952
CR Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00983
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisano S, 2017, J CHILD ADOL PSYCHOP, V27, P844, DOI 10.1089/cap.2016.0203
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Sofulu F, 2017, ACTA MEDICA MEDITERR, V33, P107, DOI 10.19193/0393-6384_2017_1_017
   Taravati F, 2017, ACTA MEDICA MEDITERR, V33, P271, DOI 10.19193/0393-6384_2017_2_040
   Tokluoglu S, 2017, ACTA MEDICA MEDITERR, V33, P145, DOI 10.19193/0393-6384_2017_1_022
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Xu YM, 2017, ACTA MEDICA MEDITERR, V33, P231, DOI 10.19193/0393-6384_2017_2_034
   Yildirim MS, 2017, ACTA MEDICA MEDITERR, V33, P83, DOI 10.19193/0393-6384_2017_1_013
   Yilmazel G, 2017, ACTA MEDICA MEDITERR, V33, P329, DOI 10.19193/0393-6384_2017_2_049
NR 90
TC 3
Z9 3
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1189
EP 1196
DI 10.19193/0393-6384_2017_2s_185
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700003
DA 2022-07-14
ER

PT J
AU Gallai, B
   Valentini, V
   Barbanera, F
   Marotta, R
   Lavano, F
   Lavano, SM
   Maltese, A
   Tripi, G
   Romano, P
   Salerno, M
AF Gallai, Beatrice
   Valentini, Vittoria
   Barbanera, Francesca
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Maltese, Agata
   Tripi, Gabriele
   Romano, Palmira
   Salerno, Margherita
TI REVIEW ABOUT COMORBIDITIES OF BEHAVIOURAL DISORDERS IN CHILDREN AND
   ADOLESCENTS: THE FOCUS ON ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Behavioural disorders; comorbidities; ADHD
ID AUTISM SPECTRUM DISORDERS; CALLOUS UNEMOTIONAL TRAITS; CHILDHOOD ABSENCE
   EPILEPSY; PRIMARY NOCTURNAL ENURESIS; PRIMARY CILIARY DYSKINESIA;
   PRADER-WILLI-SYNDROME; SLEEP-APNEA SYNDROME; WEIGHT-LOSS PROGRAM;
   QUALITY-OF-LIFE; PARENTAL STRESS
AB Disruptive behavior disorders (DBD) present high comorbidity rate mainly for opposite-defiant disorders that are frequent among children, adolescents and adults affected by with attention deficit and hyperactivity disorder (ADHD), probably as result of common temperamental risk factors such as attention, distraction, impulsivity. ADHD tend to manifest in about 50% of individuals diagnosed as disruptive behavioral disorders.
C1 [Gallai, Beatrice; Valentini, Vittoria; Barbanera, Francesca] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Romano, Palmira] Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Romano, Palmira] Univ Campania Luigi Vanvitelli, Naples, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; TRIPI, Gabriele/0000-0001-7088-9325
CR Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chisari G, 2016, ACTA MEDICA MEDITERR, V32, P865, DOI 10.19193/0393-6384_2016_4_102
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Masi G, 2016, PSYCHIAT RES, V238, P8, DOI 10.1016/j.psychres.2016.02.010
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Muratori P, 2017, J AFFECT DISORDERS, V208, P110, DOI 10.1016/j.jad.2016.08.052
   Muratori P, 2016, COMPR PSYCHIAT, V69, P202, DOI 10.1016/j.comppsych.2016.06.002
   Muratori P, 2016, PSYCHIAT RES, V236, P35, DOI 10.1016/j.psychres.2016.01.003
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_147
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisano S, 2017, J CHILD ADOL PSYCHOP, V27, P844, DOI 10.1089/cap.2016.0203
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Wen SW, 2016, ACTA MEDICA MEDITERR, V32, P303
NR 88
TC 11
Z9 11
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1197
EP 1203
DI 10.19193/0393-6384_2017_2s_186
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700004
DA 2022-07-14
ER

PT J
AU Gallai, B
   Valentini, V
   Barbanera, F
   Marotta, R
   Lavano, F
   Lavano, SM
   Maltese, A
   Tripi, G
   Romano, P
   Salerno, M
   Di Folco, A
AF Gallai, Beatrice
   Valentini, Vittoria
   Barbanera, Francesca
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Maltese, Agata
   Tripi, Gabriele
   Romano, Palmira
   Salerno, Margherita
   Di Folco, Annabella
TI THE BEHAVIORAL PARENTING INTERVENTIONS (BPT) FOR SUPPORT AND MANDATORY
   INTEGRATIVE THERAPY FOR CHILDREN AND ADOLESCENTS AFFECTED BY DISRUPTIVE
   BEHAVIOURAL DISORDERS: A BRIEF REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Behavioural disorders; therapeutic alliance; parental involving
ID AUTISM SPECTRUM DISORDERS; CHILDHOOD ABSENCE EPILEPSY; PRIMARY NOCTURNAL
   ENURESIS; PRIMARY CILIARY DYSKINESIA; PRADER-WILLI-SYNDROME; SLEEP-APNEA
   SYNDROME; WEIGHT-LOSS PROGRAM; QUALITY-OF-LIFE; MATERNAL STRESS; OBESE
   CHILDREN
AB The behavioral parenting interventions (BPT), commonly abbreviated as parent training, is a program conducted by an expert with the specific purpose of improving or modifying parental practices in order to promote the child's well-being, increasing parenting skills in the daily management of the child, problem solving and reducing the level of parenting and family stress.
   BPT presents many positive effects on children or adolescents affected by neurodevelopmental disorder such as ADHD, autism and cognitive dysfunction but BPT appears to improve also other proximal outcomes such as parenting competence and parenting stress
C1 [Gallai, Beatrice; Valentini, Vittoria; Barbanera, Francesca] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Romano, Palmira] Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Romano, Palmira] Univ Campania Luigi Vanvitelli, Naples, Italy.
   [Salerno, Margherita; Di Folco, Annabella] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI TRIPI, Gabriele/0000-0001-7088-9325; Marotta, Rosa/0000-0003-0515-5952
CR Azizpour M, 2017, ACTA MEDICA MEDITERR, V33, P129, DOI 10.19193/0393-6384_2017_1_020
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Huang HT, 2017, ACTA MEDICA MEDITERR, V33, P223, DOI 10.19193/0393-6384_2017_2_033
   Ibrahim S, 2017, ACTA MEDICA MEDITERR, V33, P65, DOI 10.19193/0393-6384_2017_1_010
   Li ZX, 2017, ACTA MEDICA MEDITERR, V33, P41, DOI 10.19193/0393-6384_2017_1_006
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P667, DOI 10.19193/03936384_2017_4_100
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P675, DOI 10.19193/0393-6384_2017_4_101
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P641, DOI 10.19193/0393-6384_2017_4_095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Natanzi MM, 2017, ACTA MEDICA MEDITERR, V33, P295, DOI 10.19193/0393-6384_2017_2_044
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Diaz-Narvaez VP, 2017, ACTA MEDICA MEDITERR, V33, P115, DOI 10.19193/0393-6384_2017_1_018
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisano S, 2017, J CHILD ADOL PSYCHOP, V27, P844, DOI 10.1089/cap.2016.0203
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Sahin N, 2017, ACTA MEDICA MEDITERR, V33, P245, DOI 10.19193/0393-6384_2017_2_036
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Taravati F, 2017, ACTA MEDICA MEDITERR, V33, P271, DOI 10.19193/0393-6384_2017_2_040
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Yildirim MS, 2017, ACTA MEDICA MEDITERR, V33, P83, DOI 10.19193/0393-6384_2017_1_013
NR 93
TC 11
Z9 11
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1205
EP 1212
DI 10.19193/0393-6384_2017_2s_187
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700005
DA 2022-07-14
ER

PT J
AU Ghorbani, M
   Gohari, A
   Sakhteman, A
   Rezaei, Z
AF Ghorbani, Mahdieh
   Gohari, Ali
   Sakhteman, Amirhossein
   Rezaei, Zahra
TI IN SILICO ANALYSIS OF DRUG RESISTANCE IN HIV-REVERSE TRANSCRIPTASE
   INHIBITORS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE HIV-I; Cross-docking simulations; reverse transcriptase; drug resistance
ID DOCKING; DERIVATIVES; MUTATIONS; PROTEASE
AB AIDS/HIV is the third cause of mortality by infectious diseases in the world. Drug resistance is the major clinical problem for the treatment of virus- infected individuals. The role of Reverse Transcriptase (RT) enzyme is vital in the life cycle of HIV virus. In this work, the role of single point mutations of reverse transcriptase on drug resistance has been studied based in silico methods. Through this study, the most important single point mutations of transcriptase enzyme have been simulated. Consequently, cross-docking simulations were used to compare binding energies of native and mutated enzymes with some known inhibitors. The purpose of the study was to find some structural features which are responsible for drug resistance against this target. Presence of phosphate groups showed to increase the chance of drug resistance while hydrazinecarboxamide substructure was beneficial to decrease less drug resistance.
C1 [Ghorbani, Mahdieh; Sakhteman, Amirhossein; Rezaei, Zahra] Shiraz Univ Med Sci, Sch Pharm, Dept Med Chem, Shiraz, Iran.
   [Gohari, Ali] Shiraz Univ Med Sci, Sch Med, Dept Biochem, Shiraz, Iran.
RP Sakhteman, A (corresponding author), Shiraz Univ Med Sci, Sch Pharm, Dept Med Chem, Shiraz, Iran.
RI Sakhteman, Amirhossein/L-6685-2016; sakhteman, amirhossein/T-4285-2017
OI Sakhteman, Amirhossein/0000-0002-1922-6523; sakhteman,
   amirhossein/0000-0002-1922-6523
FU Shiraz university of medical sciences [8714]
FX This work was financially supported by Shiraz university of medical
   sciences (grant number: 8714)
CR Alcaro S, 2010, CURR MED CHEM, V17, P290, DOI 10.2174/092986710790192695
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cortez KJ, 2011, VIRUSES-BASEL, V3, P347, DOI 10.3390/v3040347
   Daeyaert F, 2004, PROTEINS, V54, P526, DOI 10.1002/prot.10599
   De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jcv.2004.02.009
   Gaulton A., 2011, NUCL ACIDS RES
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Khoddami M, 2015, J MOL MODEL, V21, DOI 10.1007/s00894-015-2579-3
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   Mammano F, 2000, J VIROL, V74, P8524, DOI 10.1128/JVI.74.18.8524-8531.2000
   Menendez-Arias L, 2008, VIRUS RES, V134, P124, DOI 10.1016/j.virusres.2007.12.015
   NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Ragno R, 2005, J MED CHEM, V48, P200, DOI 10.1021/jm0493921
   Ranise A, 2003, J MED CHEM, V46, P768, DOI 10.1021/jm0209984
   Sakhteman A, 2016, J MOL MODEL, V22, DOI 10.1007/s00894-016-3091-0
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Seal A, 2011, BIOINFORMATION, V5, P430, DOI 10.6026/97320630005430
   Shafer RW, 2007, AIDS, V21, P215, DOI 10.1097/QAD.0b013e328011e691
   Titmuss SJ, 1999, BIOORGAN MED CHEM, V7, P1163, DOI 10.1016/S0968-0896(99)00012-7
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Usach I, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18567
   Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q
   Wapling J, 2005, J VIROL, V79, P10247, DOI 10.1128/JVI.79.16.10247-10257.2005
   Eswar Narayanan, 2006, Curr Protoc Bioinformatics, VChapter 5, pUnit, DOI [10.1002/cpps.20, 10.1002/cpbi.3, 10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15]
   Zhou ZG, 2002, PROTEINS, V49, P529, DOI 10.1002/prot.10233
NR 28
TC 0
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 745
EP 749
DI 10.19193/0393-6384_2017_5_109
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000003
DA 2022-07-14
ER

PT J
AU Giuseppe, V
   Benedetto, TL
   Fabio, T
   Maria, P
   Pascale, B
   Francesco, M
   Serafino, R
AF Giuseppe, Vacchiano
   Benedetto, Tecchia Livio
   Fabio, Tortora
   Maria, Pieri
   Pascale, Basilicata
   Francesco, Massoni
   Serafino, Ricci
TI SPINAL EPIDURAL HEMATOMA FOLLOWING CARDIO AORTIC SURGERY: ANY
   CORRELATION POSSIBLE?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Spinal epidural hematoma; cardio aortic surgery; medicolegal correlation
ID MITRAL-VALVE SURGERY; CORD-INJURY; EXTRADURAL HEMATOMA; PARAPLEGIA;
   RISK; DECOMPRESSION; DIAGNOSIS; ANEURYSM
AB The Authors report a case of acute spinal epidural hematoma after the descending aorta repair for thoracic-abdominal aortic dissection with Sulzer-Vascutek straight prosthetic implant. Left anterolateral thoracotomy in the fourth intercostal space was done.
   After aneurysmectomy and straight aortic prosthetic implant a significant bleeding was observed.
   It needed clamping of the straight aortic prosthesis and redoing of the distal anastomosis 2 cm down stream.
   In II postoperative day the patient presented a spinal epidural hematoma with paraplegia.
   The Authors analize the genesis dell'ematoma, riportano a literature review e richiamano la necessita di adeguate manovre e di opportune procedure per evitare l'insorgere di questo grave danno midollare.
C1 [Francesco, Massoni; Serafino, Ricci] Sapienza Univ, Dept Anat Histol Legal Med & Orthoped, Viale Regina Elena 336, I-00161 Rome, Italy.
   [Benedetto, Tecchia Livio] Univ Naples Federico II, Dept Cardiol Cardiosurg & Cardiovasc Emergency, Naples, Italy.
   [Fabio, Tortora] Univ Campania Luigi Vanvitelli, Dept Med Surg Clin & Expt Internal Med, Naples, Italy.
   [Maria, Pieri; Pascale, Basilicata] Univ Naples Federico II, Legal Med Sect, Dept Adv Biomed Sci, Naples, Italy.
   [Giuseppe, Vacchiano] Univ Sannio, Dept Law Econ & Math Methods, Benevento, Italy.
RP Serafino, R (corresponding author), Sapienza Univ, Dept Anat Histol Legal Med & Orthoped, Viale Regina Elena 336, I-00161 Rome, Italy.
RI Pieri, Maria/AGV-7017-2022
OI pieri, maria/0000-0002-4184-5718
CR American Spinal Injury Association, 2006, STAND NEUR CLASS SPI
   Archer T, 2014, NEUROTOX RES, V26, P400, DOI 10.1007/s12640-014-9473-0
   Arriada-Mendicoa N, 2003, REV NEUROLOGIA, V36, P530, DOI 10.33588/rn.3606.2002409
   Babayev R, 2016, CHILD NERV SYST, V32, P181, DOI 10.1007/s00381-015-2768-5
   Bang J, 2011, KOREAN J ANESTHESIOL, V61, P524, DOI 10.4097/kjae.2011.61.6.524
   BATELLIER J, 1989, ANN CHIR, V43, P210
   Biglioli P, 2002, J THORAC CARDIOV SUR, V124, P407, DOI 10.1067/mtc.2002.122138
   Cabana F, 2000, REV CHIR ORTHOP, V86, P335
   Chimenti P, 2013, J SPINAL CORD MED, V36, P213, DOI 10.1179/2045772312Y.0000000070
   Cramer DE, 2009, J SPINAL DISORD TECH, V22, P565, DOI 10.1097/BSD.0b013e318193452a
   Dai LY, 2004, J TRAUMA, V56, P348, DOI 10.1097/01.TA.0000035089.51187.43
   Fehlings MG, 2006, SPINE, V31, pS28, DOI 10.1097/01.brs.0000217973.11402.7f
   Geisbusch S, 2014, J THORAC CARDIOV SUR, V147, P220, DOI 10.1016/j.jtcvs.2013.09.022
   Glotzbecker MP, 2010, SPINE, V35, pE413, DOI 10.1097/BRS.0b013e3181d9bb77
   Hasuwa Kyoko, 2009, Masui, V58, P456
   Hayashi I, 2011, SURG TODAY, V41, P704, DOI 10.1007/s00595-010-4315-z
   Heiner JD, 2009, AM J EMERG MED, V27, P1023, DOI 10.1016/j.ajem.2008.12.031
   Hemmerling TM, 2013, ANN CARD ANAESTH, V16, P169, DOI 10.4103/0971-9784.114237
   Henry JB, 2012, SPINAL CORD, V50, P655, DOI 10.1038/sc.2012.48
   Holmes JF, 2001, ACAD EMERG MED, V8, P866, DOI 10.1111/j.1553-2712.2001.tb01146.x
   Imanaka K, 2000, INTENS CARE MED, V26, P826, DOI 10.1007/s001340051262
   Kao FC, 2015, EUR SPINE J, V24, P348, DOI 10.1007/s00586-014-3297-8
   Karlekar A, 2015, J CARDIOTHOR VASC AN, V29, P139, DOI 10.1053/j.jvca.2013.07.012
   Kin H, 2016, GEN THORAC CARDIOVAS, V64, P153, DOI 10.1007/s11748-014-0401-2
   Kou J, 2002, SPINE, V27, P1670, DOI 10.1097/00007632-200208010-00016
   Kreppel D, 2003, NEUROSURG REV, V26, P1, DOI 10.1007/s10143-002-0224-y
   La Rosa G, 2004, SPINAL CORD, V42, P503, DOI 10.1038/sj.sc.3101627
   Landoni G, 2015, BRIT J ANAESTH, V115, P25, DOI 10.1093/bja/aev201
   Levi AD, 2006, SPINE, V31, P451, DOI 10.1097/01.brs.0000199927.78531.b5
   Liu Z, 2008, SURG NEUROL, V69, P253, DOI 10.1016/j.surneu.2007.02.019
   Martin Christopher T, 2010, Spine J, V10, pe21, DOI 10.1016/j.spinee.2010.02.011
   Massoni F, 2014, ACTA MEDICA MEDITERR, V30, P77
   Miyairi T, 2001, J THORAC CARDIOV SUR, V122, P1240, DOI 10.1067/mtc.2001.116937
   Moufarrij NA, 2016, J NEUROSURG, V125, P982, DOI 10.3171/2015.8.JNS15396
   National Spinal Cord Injury Statistical Center, SPIN CORD INJ FACTS
   Okitsu K, 2017, J CARDIOTHOR VASC AN, V31, P453, DOI 10.1053/j.jvca.2016.06.002
   Papadopoulos SM, 2002, J TRAUMA, V52, P323, DOI 10.1097/00005373-200202000-00019
   Patil Vijaysinh Namdeo, 2016, Indian Heart J, V68 Suppl 2, pS22, DOI 10.1016/j.ihj.2016.05.012
   PEREZGUERRA F, 1985, ANN THORAC SURG, V39, P282, DOI 10.1016/S0003-4975(10)62599-4
   Raj R, 2016, WORLD NEUROSURG, V93, P55, DOI 10.1016/j.wneu.2016.05.072
   Villaescusa JR, 2017, GERIATR ORTHOP SURG, V8, P18, DOI 10.1177/2151458516681633
   Roberts SAG, 2013, BRIT J NEUROSURG, V27, P696, DOI 10.3109/02688697.2013.776669
   Rosen DA, 2004, ANESTH ANALG, V98, P966, DOI 10.1213/01.ANE.0000103267.37895.5B
   Schroeder GD, 2015, J SPINAL DISORD TECH, V28, P313, DOI 10.1097/BSD.0000000000000329
   Shroll J, 2014, A A CASE REP, V2, P75, DOI 10.1213/XAA.0000000000000001
   Tsai TT, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-0891-4
   Uribe Juan, 2003, Spine J, V3, P125, DOI 10.1016/S1529-9430(02)00535-1
   Vitarelli A, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000071
   Vyskha G, 2014, SEVERE FLACCID PARAP, P5, DOI [10.1136/bcr-2013-202071, DOI 10.1136/BCR-2013-202071]
   Yamada K, 2015, SPINE, V40, P1046, DOI 10.1097/BRS.0000000000000876
   Yi-Da T, 2016, AM J EMERG MED, V34
   Yin GD, 2014, ACTA ORTHOP TRAUMATO, V48, P437, DOI 10.3944/AOTT.2014.13.0133
NR 52
TC 1
Z9 1
U1 1
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1163
EP 1169
DI 10.19193/0393-6384_2017_6_182
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500041
DA 2022-07-14
ER

PT J
AU Gokdemir, GS
   Gokdemir, MT
   Karakilcik, AZ
AF Goekdemir, Guel Sahika
   Gokdemir, Mehmet Tahir
   Karakilcik, Ali Ziya
TI TOTAL OXIDATIVE STRESS, TOTAL ANTIOXIDANT STATUS AND ERYTHROCYTES STATUS
   IN PATIENTS WITH ACUTE ISCHEMIC STROKE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Total Oxidative stress; Total antioxidant status; Erythrocytes indices;
   Acute ischemic stroke; Emergency department
ID TRAUMATIC BRAIN-INJURY; HEAD-INJURY; GLUTATHIONE; PATHOPHYSIOLOGY;
   RADICALS; DISEASE; RISK
AB Objectives: In this prospective study, we attempted to determine the initial oxidative-antioxidative status using a new automated measurement method. Serum total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI) levels and erythrocyte status in patients with acute ischemic stroke (AIS) were detect and compared to those in controls.
   Methods: In total, 51 patients with AIS and 49 sex-and-age matched healthy participant as controls were enrolled the study. With the new automated extent practice developed by Erel, Serum TOS, TAS and OSI was measured. In addition serum erythrocytes level were measured.
   Results: Subjects suffering AIS had higher TOS and OSI level than those control subjects. In contrast the TAS level were moderate higher in the controls than patients. In addition serum Mean corpuscular volume (MCV) and Red cell distribution width (RDW) levels were higher in patients with AIS in accordance with the controls.
   Conclusions: Patients with AIS are subjected to oxidative stress and thus, erythrocyte indices have a significant impact on this type of patients. However, further studies are needed to confirm this relationship.
C1 [Goekdemir, Guel Sahika; Karakilcik, Ali Ziya] Harran Univ, Sch Med, Dept Physiol, Sanliurfa, Turkey.
   [Gokdemir, Mehmet Tahir] Harran Univ, Sch Med, Emergency Med, Sanliurfa, Turkey.
RP Gokdemir, MT (corresponding author), Harran Univ, Sch Med, Emergency Med, Sanliurfa, Turkey.
CR Aygul R, 2006, J INT MED RES, V34, P413, DOI 10.1177/147323000603400411
   Cherubini A, 2005, FREE RADICAL BIO MED, V39, P841, DOI 10.1016/j.freeradbiomed.2005.06.025
   Cojocaru Inimioara Mihaela, 2013, Rom J Intern Med, V51, P97
   Cooper AJL, 1997, BIOL CHEM, V378, P793
   Demirkaya S, 2001, EUR J NEUROL, V8, P43, DOI 10.1046/j.1468-1331.2001.00166.x
   Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0
   Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X
   El Kossi MMH, 2000, STROKE, V31, P1889, DOI 10.1161/01.STR.31.8.1889
   Erel O, 2004, CLIN BIOCHEM, V37, P112, DOI 10.1016/j.clinbiochem.2003.10.014
   Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008
   Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154
   Fukui S, 2002, FREE RADICAL BIO MED, V32, P289, DOI 10.1016/S0891-5849(01)00804-8
   Ghaffari S, 2008, ANTIOXID REDOX SIGN, V10, P1923, DOI 10.1089/ars.2008.2142
   Gokdemir MT, 2012, J INT MED RES, V40, P167, DOI 10.1177/147323001204000117
   Gokdemir MT, 2013, ANATOL J CARDIOL, V13, P131, DOI 10.5152/akd.2013.037
   Hackam DG, 2003, JAMA-J AM MED ASSOC, V290, P932, DOI 10.1001/jama.290.7.932
   Hohl A, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.06.007
   Kaya H, 2013, HONG KONG J EMERG ME, V20, P225, DOI 10.1177/102490791302000406
   Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871
   Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106
   Moustafa RR, 2008, BRIT J PHARMACOL, V153, pS44, DOI 10.1038/sj.bjp.0707530
   Nayak C, 2007, CLIN CHEM LAB MED, V45, P629, DOI 10.1515/CCLM.2007.123
   Nayak CD, 2008, NEUROL INDIA, V56, P31, DOI 10.4103/0028-3886.39309
   Osborn MF, 2014, J STROKE CEREBROVASC, V23, P1477, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.017
   Skjelbakken T, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001109
   SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393
   Sogut O, 2012, TURK J MED SCI, V42, P1010, DOI 10.3906/sag-1109-35
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   Woodruff TM, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-11
   Zimmermann C, 2004, EUR NEUROL, V51, P157, DOI 10.1159/000077662
NR 30
TC 2
Z9 2
U1 1
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 157
EP 163
DI 10.19193/0393-6384_2017_1_024
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800024
DA 2022-07-14
ER

PT J
AU Gonen, M
   Aytac, E
   Mungen, B
AF Gonen, Murat
   Aytac, Emrah
   Mungen, Bulent
TI CHILDHOOD OCCIPITAL EPILEPSY OF GASTAUT: A LONG-TERM PROSPECTIVE STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Occipital epilepsy; Gastaut; Prospective study
AB Aim: Childhood occipital epilepsy of Gastaut is a pure occipital epileptic syndrome that is usually accepted to have benign course. Information about the disease is mostly based on retrospective studies and its prognosis is not clearly defined. We investigated the electro-clinical course and prognostic features of the disease in this prospective study in which clinical follow-up and treatment were standardized as much as possible.
   Materials and methods: In the study, patients (10 females, 9 males) were followed-up for an average of 9.47 +/- 5.47 years (range: 2-17). The seizures were ceased in 16 (84.2%) patients, and remission was achieved in 12 (63.2%). The seizures continued in 3 patients (15.8%) despite mono-or poly-therapy. When we compared the cases with (12 patients) or without remission (7 patients), the age at disease onset was lower in cases without remission (7 +/- 5.44 years) compared to those with remission (12.08 +/- 2.71 years), (p=0.014). Likewise, the total number of seizures experienced before remission was higher in cases without remission (27 +/- 41.04) (median: 12 range: 10-120) compared to those with (6.25 +/- 7.84) (median: 4 range: 2-30) (p=0.003).
   Results: In patients with abnormal EEG at baseline, EEG recordings were normalized in those with remission (100%) but remained to be abnormal in those couldn't achieve remission. Of 5 cases with normal EEG recording from onset to end of follow-up period, remission was achieved in 4 cases but not in one case.
   Conclusion: Our result indicated that consistently normal EEG recordings or abnormal EEG recordings that normalized during follow-up strongly suggest good prognosis. In addition, we concluded that smaller number of seizures experienced before remission and a relative older age, given the age of onset of the disease, can be indicators of good prognosis.
C1 [Gonen, Murat; Aytac, Emrah; Mungen, Bulent] Firat Univ, Neurol Clin, Fac Med, Elazig, Turkey.
RP Aytac, E (corresponding author), Firat Univ, Neurol Clin, Fac Med, Elazig, Turkey.
RI AYTAC, EMRAH/X-1420-2018; GÖNEN, Murat/AAA-1811-2021
CR [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x
   Caraballo RH, 2008, EPILEPSIA, V49, P288, DOI 10.1111/j.1528-1167.2007.01322.x
   Incecik F, 2015, J NEUROSCI RURAL PRA, V6, P300, DOI 10.4103/0976-3147.158741
   Panayiotopoulos CP., 2005, EPILEPSIES SEIZURES, P249
   Verrotti A, 2016, EUR J NEUROL, V23, P241, DOI 10.1111/ene.12840
   Wakamoto H, 2011, PEDIATR NEUROL, V44, P183, DOI 10.1016/j.pediatrneurol.2010.10.005
NR 7
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1175
EP 1179
DI 10.19193/0393-6384_2017_2s_183
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700001
DA 2022-07-14
ER

PT J
AU Gorini, I
   Vecchio, I
   Badino, P
AF Gorini, Ilaria
   Vecchio, Ignazio
   Badino, Paola
TI THE "EMERGENCY ARCHAEOLOGY" AND THE OSTEOARCHAEOLOGICAL STUDIES. THE
   NORTHWEST LOMBARDY RESEARCH ON FUNERARY SITES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Letter
ID MEDIEVAL SKELETONS
C1 [Gorini, Ilaria; Badino, Paola] Univ Insubria, Dept Biotechnol & Life Sci, Ctr Res Osteoarchaeol & Paleopathol, Varese, Italy.
   [Vecchio, Ignazio] Univ Catania, Dept Clin & Expt Med, Catania, Italy.
RP Badino, P (corresponding author), Univ Insubria, Dept Biotechnol & Life Sci, Ctr Res Osteoarchaeol & Paleopathol, Varese, Italy.
OI Vecchio, Ignazio/0000-0001-5942-1908
CR Lazzati AMB, 2016, INT J OSTEOARCHAEOL, V26, P670, DOI 10.1002/oa.2458
   Licata M, 2016, SKELETAL RADIOL, V45, P323, DOI 10.1007/s00256-015-2266-6
   Licata M, 2014, ACTA MEDICA MEDITERR, V30, P555
   Licata M, 2014, INJURY, V45, P457, DOI 10.1016/j.injury.2013.10.013
   Ubelaker SH, 1989, HUMAN SKELETAL REMAI
NR 5
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 965
EP 966
DI 10.19193/0393-6384_2017_6_152
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500011
DA 2022-07-14
ER

PT J
AU Gul, OO
   Pekgoz, M
   Gullulu, S
   Cander, S
   Tutuncu, A
   Seker, I
   Sag, S
   Acikgoz, E
   Sarandol, E
   Ersoy, C
AF Gul, Ozen Oz
   Pekgoz, Murat
   Gullulu, Sumeyye
   Cander, Soner
   Tutuncu, Ahmet
   Seker, Ismail
   Sag, Saim
   Acikgoz, Ebru
   Sarandol, Emre
   Ersoy, Canan
TI CORRELATES OF VISCERAL AND SUBCUTANEOUS FAT THICKNESS IN NON-DIABETIC
   OBESE AND MORBIDLY OBESE PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Obesity; visceral fat; subcutaneous fat; visfatin; resistin; insulin
   resistance
ID EPICARDIAL ADIPOSE-TISSUE; CORONARY-ARTERY-DISEASE; INTIMA-MEDIA
   THICKNESS; PLASMA RESISTIN LEVELS; INSULIN-RESISTANCE; INFLAMMATORY
   MEDIATORS; VISFATIN LEVELS; HEART-DISEASE; ATHEROSCLEROSIS; EXPRESSION
AB Background: To determine the correlates of visceral and subcutaneous fat thickness in non-diabetic obese and morbidly obese patients
   Methods: A total of 31 obese female outpatients composed of morbidly obese (n=16, BMI of >= 40kg/m(2)) and obese (n=15, BMI of 30-39.9kg/m(2)) patients were included in the present study. Data on age, anthropometrics, blood biochemistry, HOMA-IR, carotid intima-media thickness (CIMT) were recorded in each subject as were plasma resistin (mu g/L) and visfatin (mu g/ml) levels, epicardial, subcutaneous and abdominal fat thickness (mm). Correlates of visceral and subcutaneous fat thickness were determined via linear regression models with inclusion of severity of obesity, insulin resistance, plasma resistin and visfatin levels and CIMT as variables.
   Results: Epicardial fat thickness (mm) was 3.1(1.0-10.20) and 8.8(2.60-13.0), CIMT (mm) was 5.8(4.7-8.9) and 5.9(4-8.6), abdominal fat thickness (mm) was 10.8(7.8-16.1) and 13.2(8.7-16.5), subcutaneous fat thickness(mm) was 43.8(28.4-62.9) and 57.4(39.5-72.7), plasma resistin levels (mu g/L) were 8.5(4.7-38.1) and 10.8(0.7-26.4) and plasma visfatin levels (mu g/ml) were 55.5(5.1-209.5) and 78.2(4.7-228) in obese and morbidly obese patients, respectively. Linear regression analysis revealed that being morbidly obese was likely to increase epicardial fat thickness by 4.33mm(p=0.004) compared with obesity, while for each 1 unit increase in HOMA levels, subcutaneous fat thickness was likely to decrease by 1.16mm(p=0.009).
   Conclusion: In conclusion, our findings revealed that neither plasma levels for resistin and visfatin nor CIMT correlated with visceral or subcutaneous fat thickness in non-diabetic obese females, while increase in subcutaneous and epicardial fat thickness values were noted with decrease in HOMA-IR and the presence of morbid obesity, respectively.
C1 [Gul, Ozen Oz; Cander, Soner; Ersoy, Canan] Uludag Univ, Med Sch, Dept Endocrinol & Metab, TR-16059 Gorukle, Bursa, Turkey.
   [Pekgoz, Murat] Uludag Univ, Med Sch, Dept Internal Med, Bursa, Turkey.
   [Gullulu, Sumeyye; Tutuncu, Ahmet; Sag, Saim] Uludag Univ, Med Sch, Dept Cardiol, Bursa, Turkey.
   [Seker, Ismail] Bilson Radiol Ctr, Bursa, Turkey.
   [Acikgoz, Ebru; Sarandol, Emre] Uludag Univ, Med Sch, Biochem, Bursa, Turkey.
RP Gul, OO (corresponding author), Uludag Univ, Med Sch, Dept Endocrinol & Metab, TR-16059 Gorukle, Bursa, Turkey.
RI Ersoy, Canan/AAH-8861-2021; Gul, Ozen Oz/AAI-1005-2021; SARANDÖL,
   EMRE/ABE-1716-2020; sag, saim/AAW-9185-2020
OI SARANDÖL, EMRE/0000-0002-2593-7196; sag, saim/0000-0001-8404-8252
CR Baker AR, 2006, CARDIOVASC DIABETOL, V5, DOI 10.1186/1475-2840-5-1
   Berndt J, 2005, DIABETES, V54, P2911, DOI 10.2337/diabetes.54.10.2911
   Cakir E, 2013, ATHEROSCLEROSIS, V226, P291, DOI 10.1016/j.atherosclerosis.2012.11.004
   Chen CC, 2005, METABOLISM, V54, P471, DOI 10.1016/j.metabol.2004.10.015
   Cheng KH, 2008, INT J OBESITY, V32, P268, DOI 10.1038/sj.ijo.0803726
   Choi KM, 2008, EUR J ENDOCRINOL, V158, P203, DOI 10.1530/EJE-07-0633
   Dahl TB, 2007, CIRCULATION, V115, P972, DOI 10.1161/CIRCULATIONAHA.106.665893
   Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243
   Hamdy O, 2006, CURR DIABETES REV, V2, P367, DOI 10.2174/1573399810602040367
   Hammarstedt A, 2006, J CLIN ENDOCR METAB, V91, P1181, DOI 10.1210/jc.2005-1395
   Hofso D, 2009, EUR J ENDOCRINOL, V161, P451, DOI 10.1530/EJE-09-0421
   Iacobellis G, 2005, NAT CLIN PRACT CARD, V2, P536, DOI 10.1038/ncpcardio0319
   Iacobellis G, 2005, CYTOKINE, V29, P251, DOI 10.1016/j.cyto.2004.11.002
   Iacobellis G, 2007, AM J CARDIOL, V99, P1470, DOI 10.1016/j.amjcard.2006.12.082
   Iacobellis G, 2011, INT J CARDIOL, V146, P452, DOI 10.1016/j.ijcard.2010.10.117
   Ingelsson E, 2007, DIABETES CARE, V30, P1278, DOI 10.2337/dc06-2353
   Jeong JW, 2007, CIRC J, V71, P536, DOI 10.1253/circj.71.536
   Kang ES, 2011, EUR J ENDOCRINOL, V164, P911, DOI 10.1530/EJE-11-0052
   Kim BJ, 2013, INT J CARDIOL, V167, P2234, DOI 10.1016/j.ijcard.2012.06.013
   Lakka TA, 2001, ATHEROSCLEROSIS, V154, P497, DOI 10.1016/S0021-9150(00)00514-1
   Malavazos AE, 2008, NUTR METAB CARDIOVAS, V18, P523, DOI 10.1016/j.numecd.2007.09.001
   Mathieu P, 2010, CLIN PHARMACOL THER, V87, P407, DOI 10.1038/clpt.2009.311
   Matsuzawa Y, 1995, OBES RES, V3, pS645, DOI 10.1002/j.1550-8528.1995.tb00481.x
   Mazurek T, 2003, CIRCULATION, V108, P2460, DOI 10.1161/01.CIR.0000099542.57313.C5
   Norata GD, 2007, EUR J ENDOCRINOL, V156, P279, DOI 10.1530/eje.1.02338
   PEIRIS AN, 1989, ANN INTERN MED, V110, P867, DOI 10.7326/0003-4819-110-11-867
   Pischon T, 2005, OBES RES, V13, P1764, DOI 10.1038/oby.2005.215
   Sanches PD, 2012, ARQ BRAS CARDIOL, V99, P892
   Shimamoto Y, 2013, INT HEART J, V54, P273, DOI 10.1536/ihj.54.273
   Silha JV, 2003, EUR J ENDOCRINOL, V149, P331, DOI 10.1530/eje.0.1490331
   Soo-Kyung K, 2007, EUR J ENDOCRINOL, V157, P167, DOI 10.1530/EJE-07-0043
   Sucharda P, 2010, Vnitr Lek, V56, P289
   Tan BK, 2006, J CLIN ENDOCR METAB, V91, P5022, DOI 10.1210/jc.2006-0936
   Ukkola O, 2002, EUR J ENDOCRINOL, V147, P571, DOI 10.1530/eje.0.1470571
NR 34
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1017
EP 1023
DI 10.19193/0393-6384_2017_6_161
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500020
DA 2022-07-14
ER

PT J
AU Gunes, AE
   Aktas, S
AF Gunes, Ali Erdal
   Aktas, Samil
TI A REVIEW OF HYPERBARIC OXYGEN THERAPY FOR AVASCULAR NECROSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE Hyperbaric Oxygenation; Avascular Necrosis of Bone; Aseptic Necrosis of
   Bone; Femur Head Necrosis.
ID FEMORAL-HEAD; OSTEONECROSIS
AB Introduction: Avascular necrosis (AN) is the death of trabecular bone and bone marrow. Hyperbaric oxygen (HBO) treatment in the early stages of AN of the femoral head alleviates intraosseous pressure by increasing the tissue oxygen pressure, increases microcirculation by arranging the venous drainage, so is recommended for that patients' treatment plan. Recently, many clinical trials and experimental studies were conducted about the effects of HBO on AN.
   Aim: Current treatment modalities partially address a need for adequate remedy to this disease. Prosthetic surgery performed on patients due to AN may cause some medical problems in long term follow up. HBO treatment can bring a new modality option for AN. There is no much data on the efficacy of HBO therapy on disease healing and delay of implementation of prosthetic implants. The aim of this review was to evaluate and summarize the evidence for application of HBO as a treatment for AN.
   Methods: The study included 10 randomized studies found in databases including PubMed/MedLine, Science Direct, Web of Science, and Cochrane Central Register of Controlled Trials Databases. The keywords "hyperbaric* oxygen therapy" or "hyperbaric* oxygen treatment" and "avascular necrosis" or "aseptic necrosis" or "femoral head necrosis" were used, and no time frame was selected.
   Results: The studies covered in our work consisted of experimental, clinical, and case series assessments. Three were controlled, experimental studies, and seven were clinical trials, which are generally considered more valuable due to their power and study design. Studies were evaluated in three category title; primary outcomes, stage of disease and effectiveness. HBO therapy has been shown to be effective in all three categories.
   Conclusion: The incidence of patients with AN is increasing majorly due to some external factors, steroid and trauma. Although the existed literature is qualified, the number of articles about the effects of HBO on AN are still quite few in the electronic database. In order to evidently state the efficacy of HBO in AN, well designed, comprehensive, randomized studies are required.
C1 [Gunes, Ali Erdal] Harran Univ, Sch Med, Underwater & Hyperbar Med Dept, Sanliurfa, Turkey.
   [Aktas, Samil] Istanbul Univ, Istanbul Sch Med, Underwater & Hyperbar Med Dept, Istanbul, Turkey.
RP Gunes, AE (corresponding author), Harran Univ, Sch Med, Dept Underwater & Hyperbar Med, Yenisehir Campus, TR-63300 Sanliurfa, Turkey.
RI Aktaş, Şamil/AAD-6656-2020; GUNES, ALI ERDAL/ABF-3292-2020
CR ASHER MA, 1968, CLIN ORTHOP RELAT R, P48
   Bassett CA, 1961, INFLUENCE OXYGEN CON, P460
   Camporesi EM, 2010, J ARTHROPLASTY, V25, P118, DOI 10.1016/j.arth.2010.05.005
   Capone A, 2011, HIP INT, V21, P211, DOI 10.5301/HIP.2011.6492
   Ficat P, 1983, REV CHIRURG ORTHOPED, V70, P253
   Gesell LB, 2008, HYPERBARIC OXYGEN TH
   Hsu SL, 2010, ARCH ORTHOP TRAUM SU, V130, P23, DOI 10.1007/s00402-009-0918-5
   HUNGERFORD DS, 1980, ORTHOPADE, V9, P245
   HUNT TK, 1972, SURG GYNECOL OBSTETR, V135, P561
   Huri G, 2011, GOZTEPE TIP DERGISI, V26, P108
   Jones Jr JP, 1991, EFFECT HYPERBARIC OX
   KATAOKA Y, 1992, ACTA ORTHOP SCAND, V63, P527, DOI 10.3109/17453679209154729
   Levin D, 1999, EXP MOL PATHOL, V67, P99, DOI 10.1006/exmp.1999.2273
   MARCUS ND, 1973, J BONE JOINT SURG AM, VA 55, P1351, DOI 10.2106/00004623-197355070-00002
   MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0
   Mazieres B., 1994, RHEUMATOLOGY, V2, P1877
   NYLANDER G, 1985, PLAST RECONSTR SURG, V76, P596, DOI 10.1097/00006534-198510000-00021
   Peskin B, 2001, UNDERSEA HYPERBAR M, V28, P187
   Reis ND, 2003, J BONE JOINT SURG BR, V85B, P371, DOI 10.1302/0301-620X.85B3.13237
   Scherer A, 2000, ROFO-FORTSCHR RONTG, V172, P798, DOI 10.1055/s-2000-7903
   Schroer W C, 1994, Orthop Rev, V23, P487
   Solacoff D., 1993, ORTHOP, V17, P1085
   STRAUSS M, 1999, HYPERBARIC MED PRACT, P912
   Thom SR, 2009, J APPL PHYSIOL, V106, P988, DOI 10.1152/japplphysiol.91004.2008
   Wang C, 2014, EXP THER MED, V8, P700, DOI 10.3892/etm.2014.1811
   Yoo MC, 2008, CLIN ORTHOP RELAT R, V466, P1133, DOI 10.1007/s11999-008-0204-9
   Zhao FC, 2010, INT ORTHOP, V34, P799, DOI 10.1007/s00264-009-0829-7
NR 27
TC 0
Z9 0
U1 1
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 29
EP 34
DI 10.19193/0393-6384_2017_1_004
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800004
DA 2022-07-14
ER

PT J
AU Gunes, AE
   Eren, MA
   Karakas, EY
   Demir, M
   Aslan, HK
   Sabuncu, T
AF Gunes, Ali Erdal
   Eren, Mehmet Ali
   Karakas, Emel Yigit
   Demir, Mehmet
   Aslan, Huseyin Kara
   Sabuncu, Tevfik
TI RELATION WITH MEAN PLATELET VOLUME AND DIABETIC FOOT ULCERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Diabetes Mellitus; Diabetic Foot Ulcer; Mean Platelet Volume
ID MELLITUS
AB Aims: Diabetes Mellitus (DM) is a global health problem with multiple and major complication. Diabetic foot ulcer (DFU) is one of those that 15% of diabetic patients experience with DFU during their lifetime. Mean platelet volume (MPV) is a marker of platelet activation and function. It means that increase of MPV release of highly reactive platelets from stores and related with thrombotic disease and atherosclerosis. The aim of this study is corresponding elevated MPV on lead to the ulcers.
   Methods: We included consecutive 28 patients with Type 2 diabetes and non-gangrenous DFU and matched 28 patients with Type 2 diabetes and without foot ulcers as well as 28 healthy volunteers for age and sex. Diagnostic criteria for diabetic foot ulcers were the presence of systemic signs of infection, purulent wound secretion or at least two local findings of inflammation (e.g., redness, warmth, induration, pain or tenderness).
   Results: Hemoglobin level of DFU group was lower than healthy control group (p=0.001). MPV levels were higher in DFU group when compared to diabetic or healthy control groups (p=0.03 and p<0.001, respectively). MPV was higher in diabetic group with DFU when compared to both diabetic and healthy control groups.
   Discussion: The atherosclerotic process and disorders of vascular circulation in the course of DFU may explain the high MPV in patients with DFU.
   Conclusions: All of these underlying pathogenic disorders may influence the volume of platelets or high MPV -as a marker of more thrombogenic and active platelets- may contribute the development of DFU.
C1 [Gunes, Ali Erdal] Harran Univ, Sch Med, Underwater & Hyperbar Med Dept, Osmanbey Campus, TR-63300 Sanliurfa, Turkey.
   [Eren, Mehmet Ali; Aslan, Huseyin Kara; Sabuncu, Tevfik] Harran Univ, Sch Med, Endocrinol Dept, Sanliurfa, Turkey.
   [Karakas, Emel Yigit; Demir, Mehmet] Harran Univ, Sch Med, Internal Med Dept, Sanliurfa, Turkey.
RP Gunes, AE (corresponding author), Harran Univ, Sch Med, Underwater & Hyperbar Med Dept, Osmanbey Campus, TR-63300 Sanliurfa, Turkey.
RI GUNES, ALI ERDAL/ABF-3292-2020; Sabuncu, Tevfik/ABF-5291-2020; eren,
   mehmet ali/ABH-7279-2020
OI Sabuncu, Tevfik/0000-0001-6504-5355; 
CR Agrawal J, 2016, DIABETES METAB SYNDR
   Akinsegun A, 2014, PAN AFR MED J, V18, DOI 10.11604/pamj.2014.18.42.3651
   Antonopoulos AS, 2015, DIABETES CARE
   Fard AS, 2007, INT J CLIN PRACT, V61, P1931, DOI 10.1111/j.1742-1241.2007.01534.x
   Gasparyan AY, 2011, CURR PHARM DESIGN, V17, P47
   Jindal S, 2011, HEMATOLOGY, V16, P86, DOI 10.1179/102453311X12902908412110
   Kodiatte Thomas Alex, 2012, J Lab Physicians, V4, P5, DOI 10.4103/0974-2727.98662
   Leone Sebastiano, 2012, Infez Med, V20 Suppl 1, P8
   LEVIN M, 1991, CLIN DIABETES MELLIT, P504
   Papanas N, 2004, PLATELETS, V15, P475, DOI 10.1080/0953710042000267707
   Park Y, 2002, PLATELETS, V13, P301, DOI 10.1080/095371002220148332
   Sansanayudh N, 2014, INT J CARDIOL, V175, P433, DOI 10.1016/j.ijcard.2014.06.028
   THOMPSON CB, 1983, J LAB CLIN MED, V101, P205
   Tuttolomondo A, 2015, WORLD J ORTHOP, V6, P62, DOI 10.5312/wjo.v6.i1.62
   Unubol M, 2012, PLATELETS, V23, P475, DOI 10.3109/09537104.2011.634934
   Xiao WJ, 2014, J DIABETES, V6, P298, DOI 10.1111/1753-0407.12104
   Yazdanpanah L, 2015, WORLD J DIABETES, V6, P37, DOI 10.4239/wjd.v6.i1.37
   Yuksel Kalkan G, 2014, ANADOLU KARDIYOL DER, DOI [10.5152/akd.2014.5576, DOI 10.5152/AKD.2014.5576]
NR 18
TC 5
Z9 5
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 401
EP 404
DI 10.19193/0393-6384_2017_3_058
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200006
DA 2022-07-14
ER

PT J
AU Guo, TW
   Wang, L
AF Guo, Taiwei
   Wang, Lei
TI BIOMECHANICAL RESEARCH TOWARDS THE IMPACT OF BADMINTON PLAYERS' LUMBAR
   SPONDYLOLYSIS ON UPPER SPINE STABILITY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Badminton Player; Lumbar; Spondylolysis; Upper Spinal Stability;
   Biomechanics
AB Introduction: Lumbar spondylolysis is a common injury in badminton players' career. The occurrence of lumbar spondylolysis will affect athletes' competitive level, physical and mental health, which requires attention in daily care and treatment.
   Methods: In this paper, badminton players' lumbar spondylolysis was analyzed based on biomechanical research method. Besides, three-dimensional activity range of upper spine in biological model and lumbar spondylolysis upper spinal stability was studied and discussed, with the aim to provide a practical reference for trauma therapy of badminton players' lumbar spondylolysis. In this study, 3000 cases of adults' fresh lumbar specimens were selected and the cut off L5 bilateral spondylolysis formed as the test model. The specimen was applied with flexion, extension, lateral bending and rotation of 10 Nm torque before (normal) and after modeling (lumbar spondylolysis group) via three-dimensional movement experimental mechanism of the spine.
   Results: From the results obtained, the flexion, extension and rotation for upper spine (L4) spondylolysis group specimens was 12.70 degrees, 4.80 degrees and 3.71 degrees respectively while the average values for normal group model were 10.40 degrees, 3.70 degrees and 2.78 degrees respectively. Comparison of both the test data demonstrated significant statistical difference. The results were higher in lumbar spondylolysis group with the value of 22.1%, 29.4% and 33.8% respectively. However there is no significant difference between the average value of flexion activities for spondylolysis group (7.74 degrees) and normal group (7.67 degrees) Spondylolysis spine (1.5) motion range of flexion, extension and rotation gave values of 12.69 degrees, 6.29 degrees, 4.10 degrees, while average value of normal group was 10.12 degrees, 5.19 degrees, 3.01 degrees respectively, with significant differences between the groups, reflecting P value less than 0.01. Spondylolysis group values increased by 25.4%, 44.1% and 36.4% while range of flexion activities for spondylolysis group was 6.12 degrees and 6.06 degrees for normal group. The difference between the groups was not obvious therefore it's not statistically significant.
   Conclusions: From the above studies, specific conclusion is that lumbar spondylolysis will adversely affect the badminton players' upper spine stability. It should also take be noted that, some of the badminton players might suffer from instability of upper spine in flexion, extension and rotation, which has a negative impact on athletes' competitive level and career.
C1 [Guo, Taiwei; Wang, Lei] Yangzhou Univ, Sch Phys Educ, Yangzhou 225009, Jiangsu, Peoples R China.
RP Guo, TW (corresponding author), Yangzhou Univ, Sch Phys Educ, Yangzhou 225009, Jiangsu, Peoples R China.
EM licewhet@163.com
CR Al-Sadoon MK, 2016, SAUDI J BIOL SCI, V23, P135, DOI 10.1016/j.sjbs.2015.10.010
   Aldahlawi AM, 2016, SAUDI J BIOL SCI, V23, P101, DOI 10.1016/j.sjbs.2015.05.003
   Aldea M, 2016, ASIAN PAC J SURG ONC, V2, P163
   Arisoy A, 2015, ACTA MEDICA MEDITERR, V31, P343
   August DA, 2016, ASIAN PAC J SURG ONC, V2, P153
   Diaconu C, 2015, ACTA MEDICA MEDITERR, V31, P339
   Gong RD, 2016, SAUDI PHARM J, V24, P254, DOI 10.1016/j.jsps.2016.04.010
   Li DL, 2015, WOOD RES-SLOVAKIA, V60, P755
   Ma Y, 2015, J COASTAL RES, P496, DOI 10.2112/SI73-087.1
   Vafi M, 2017, ARAB J CHEM, V10, P739, DOI 10.1016/j.arabjc.2014.07.003
   Wroblewska K, 2015, SAUDI PHARM J, V23, P407, DOI 10.1016/j.jsps.2014.11.009
   Xue Q, 2014, PAK J PHARM SCI, V27, P975
NR 12
TC 0
Z9 0
U1 1
U2 17
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 3
BP 1325
EP 1328
DI 10.19193/0393-6384_2017_3s_206
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AC
UT WOS:000424878100008
DA 2022-07-14
ER

PT J
AU Guven, R
   Aykal, G
   Gungor, F
   Akyol, KC
   Bayar, N
AF Guven, Ramazan
   Aykal, Guzin
   Gungor, Faruk
   Akyol, K. Can
   Bayar, Nermin
TI WHICH PATIENTS HAVE AN ASSOCIATION BETWEEN HBA1C LEVEL AND SEVERITY OF
   CORONARY ARTERY DISEASE: DIABETIC OR NON-DIABETIC?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE coronary artery disease; diabetes mellitus; HbA1c; gensini
ID ACUTE MYOCARDIAL-INFARCTION; GLYCATED HEMOGLOBIN; CARDIOVASCULAR RISK;
   ADMISSION GLUCOSE; HEART-DISEASE; MELLITUS; MORTALITY; COMPLICATIONS;
   GLYCEMIA; INSULIN
AB Introduction: Diabetes mellitus (DM) has long been recognized as a major risk factor for coronary artery diseases (CAD). Although Hemoglobin A1c (HbA1c) has been widely used as a marker for predicting the severity of DM, there are controversial reports in the literature regarding its association with the severity of CAD. The aim of our study was to determine the association between HbA1c levels and severity of CAD in both diagnosed and undiagnosed diabetic patients with admission hyperglycemia.
   Materials and methods: The files of the patients who were admitted to the emergency department of a regional training and research hospital from 2014 to 2015 due to acute coronary syndrome and whose diagnosis was confirmed by coronary angiography and HbA1c levels were analyzed were reviewed retrospectively. Those patients whose HbA1c levels were measured were divided into two groups: diagnosed diabetes (DD) or undiagnosed diabetes (UDD). Gensini score was measured for all patients and the correlation between elevated HbA1c levels and severity of coronary artery disease was subjected to statistical analysis.
   Results: Out of 168 patients who met the inclusion criteria, 85.1% (n=143) were male, while 14.9% (n=25) were female. The mean age was 46.6 +/- 6.5 years. HbA1c was found to have a significantly positive correlation with the Gensini score in DD group (n=77), whereas no significant correlation was found between HbA1c and the Gensini score in UDD group (n=91) (p <0.001; correlation coefficient: 0.656, p=0.207; correlation coefficient: 0.251, respectively). Linear regression analysis revealed that HbA1c was a significant predictor for gensini score (p<0.001; a: 0.632).
   Conclusion: HbA1c can be used as a predictor for the evaluation of diabetic patients with CAD. Moreover, HbA1c was not found to have a significant association with the severity of CAD in undiagnosed diabetic CAD patients with admission hyperglycemia.
C1 [Guven, Ramazan] Bitlis State Hosp, Dept Emergency Med, Bitlis, Turkey.
   [Aykal, Guzin] Antalya Training & Res Hosp, Dept Biochem, Antalya, Turkey.
   [Gungor, Faruk; Akyol, K. Can] Antalya Training & Res Hosp, Dept Emergency Med, Antalya, Turkey.
   [Bayar, Nermin] Antalya Training & Res Hosp, Dept Cardiol, Antalya, Turkey.
RP Guven, R (corresponding author), Bitlis State Hosp, Dept Emergency Med, Bitlis, Turkey.
RI Aykal, Güzin/AED-4990-2022; Kucukseymen, Selcuk/Q-4135-2018
OI Kucukseymen, Selcuk/0000-0002-9757-3088
CR Ayhan SS, 2012, ENDOKRYNOL POL, V63, P367
   Dziewierz A, 2009, AM J CARDIOL, V103, P954, DOI 10.1016/j.amjcard.2008.12.008
   Ertem AG, 2013, TURK KARDIYOL DERN A, V41, P389, DOI 10.5543/tkda.2013.95666
   Garg N, 2014, MAYO CLIN PROC, V89, P908, DOI 10.1016/j.mayocp.2014.03.017
   GENSINI GG, 1983, AM J CARDIOL, V51, P606, DOI 10.1016/S0002-9149(83)80105-2
   Ghaffari Samad, 2015, Ther Adv Cardiovasc Dis, V9, P305, DOI 10.1177/1753944715585500
   Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404
   Hong LF, 2014, LIPIDS HLTH DIS, V13, P1
   Kautzky-Willer A, 2016, ENDOCR REV, V37, P278, DOI 10.1210/er.2015-1137
   Khaw KT, 2006, CURR OPIN LIPIDOL, V17, P637, DOI 10.1097/MOL.0b013e3280106b95
   Kosiborod M, 2005, CIRCULATION, V111, P3078, DOI 10.1161/CIRCULATIONAHA.104.517839
   Liu Y, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-98
   Malmberg K, 2005, EUR HEART J, V26, P650, DOI 10.1093/eurheartj/ehi199
   Marik PE, 2013, CRIT CARE MED, V41, pE93, DOI 10.1097/CCM.0b013e318283d124
   MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323
   Meigs JB, 2002, DIABETES CARE, V25, P1313, DOI 10.2337/diacare.25.8.1313
   Naito R, 2014, J CARDIOL, V63, P106, DOI 10.1016/j.jjcc.2013.07.009
   Selvin E, 2010, NEW ENGL J MED, V362, P800, DOI 10.1056/NEJMoa0908359
   Sloan FA, 2008, ARCH INTERN MED, V168, P192, DOI 10.1001/archinternmed.2007.35
   Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405
   Wang W, 2011, PANCREAS, V40, P206, DOI 10.1097/MPA.0b013e31820032ae
   WHO, 2016, GLOB REP PSOR
NR 22
TC 1
Z9 1
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 123
EP 127
DI 10.19193/0393-6384_2017_1_019
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800019
DA 2022-07-14
ER

PT J
AU Han, CLM
   Yang, SL
   Chen, AP
   Zhang, ZC
   Liu, Y
   Zhang, YL
   Li, SZ
   Wang, L
AF Han, Chaolumen
   Yang, Silu
   Chen, Aiping
   Zhang, Zhichen
   Liu, Yue
   Zhang, Yunling
   Li, Shuzhen
   Wang, Le
TI AN ANALYSIS OF THE POST-STROKE COGNITIVE IMPAIRMENT COMBINATION LAW OF
   TRADITIONAL CHINESE MEDICINE SYMPTOM BASED ON THE COMPLEX SYSTEM ENTROPY
   CLUSTERING METHOD
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE stroke; cognitive impairment; TCM symptom; complex system entropy
   clustering
AB Objective: To analyze the TCM symptom manifestations of patients with post-stroke cognitive impairment and explore the combination law of its core symptoms. Method: through the collaboration of multi centers, 1451 patients with mild cognitive impairment and mild dementia are incorporated, of which, 838 cases are with mild cognitive impairment and 613 cases mild dementia. After filtering, the occurrence rate of symptoms which is over 10% are retained and inputted to the traditional Chinese medicine inheritance auxiliary platform through standardized "four diagnostic information". And then there will be an analysis of the rules of symptoms based on complex system entropy clustering method which is software-integrated. Result: after the analysis based on entropy clustering method, it is found that there are 8 symptom collective groups for mild cognitive impairment and 9 symptom collective groups for mild dementia. The syndrome factor combinations that can be extracted are kidney deficiency, qi deficiency and blood stasis, spleen and kidney deficiency, phlegm stasis; kidney deficiency, phlegm stasis, qi deficiency and blood stasis, spleen and kidney deficiency, phlegm stasis and yin deficiency resulting in vigorous fire. Conclusion: syndrome factors of post-stroke cognitive impairment are qi deficiency, blood stasis, phlegm, yang deficiency, yin deficiency and fire. Kidney deficiency, qi deficiency and blood stasis, spleen and kidney deficiency, phlegm stasis and yin deficiency resulting in vigorous fire are typical symptoms of post-stroke cognitive impairment. Number of patients with yin deficiency resulting in vigorous fire, will increase as their disease aggravated.
C1 [Han, Chaolumen; Yang, Silu; Chen, Aiping; Li, Shuzhen] Beijing Univ Chinese Med, Beisanhuan East Rd, Beijing 100029, Peoples R China.
   [Zhang, Zhichen; Liu, Yue; Zhang, Yunling; Wang, Le] Beijing Univ Chinese Med, Dongfang Hosp, Beijing 100078, Peoples R China.
RP Li, SZ (corresponding author), Beijing Univ Chinese Med, Beisanhuan East Rd, Beijing 100029, Peoples R China.; Wang, L (corresponding author), Beijing Univ Chinese Med, Dongfang Hosp, Beijing 100078, Peoples R China.
EM shuzhenli2011@163.com; 13661172704@139.com
FU Special Research Project of TCM [201007002, 201407100]; Beijing Science
   and Technology Planning Project [Z111107056811040]; Innovation Team of
   Beijing University of Chinese Medicine [2011 - CXTD- 23]; Capital
   Clinical Character Application Research [Z131107002213151]
FX This work was supported by Special Research Project of TCM 2010 and 2014
   (No. 201007002 & No. 201407100), Beijing Science and Technology Planning
   Project 2011 (No. Z111107056811040); Innovation Team of Beijing
   University of Chinese Medicine (No. 2011 - CXTD- 23), and Capital
   Clinical Character Application Research 2013 (No. Z131107002213151).
CR [陈宝鑫 Chen Baoxin], 2012, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V27, P374
   Chen J., 2008, THESIS
   Diagnosis and Treatment Group of Acute Ischemic Stroke Cerebrovascular Disease Group Neurology chapter Chinese Medical Association, 2010, CHINESE J FRONTIERS, V04
   LING CQ, 2004, J CHIN INTEGR MED, V2, P86
   Liu Y, 2015, BEIJING J TRADIT CHI, V02, P83
   Liu YQ., 2015, THESIS CHINESE ACAD, P1
   [刘玥 Liu Yue], 2015, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V30, P1723
   Lu P, 2012, CHIN J EXP TRADIT ME, V18, P1
   Ma B, 2006, J LIAONING U TRADIT, V12, P1561
   Niu HM, 2014, BEIJING J TRADIT CHI, V07, P488
   SHI L., 2014, THESIS
   [石玉如 SHI Yuru], 2006, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V29, P350
   Tang SH, 2009, SHI JIE KE XUE JI SH, V11, P225
   [王天芳 Wang Tianfang], 2005, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V28, P19
   Yang, 2013, THESIS
   Yang HJ, 2009, J BIOL SYST, V17, P329, DOI 10.1142/S0218339009002971
   Ye YA, 2015, WORLD CHIN MED, V10, P1293
   Yu XJ, 2015, CHIN J CHIN MED, V30, P222
   [张志斌 Zhang Zhibin], 2005, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V28, P1
   Zhao JZ, 1985, SYNDROME DIFFERENTIA
   Zhao RL, 2007, CHIN J STROKE, V06, P513
   Zhao Y, 2007, THESIS, P4
   郭蕾, 2003, [北京中医药大学学报, Journal of Beijing University of Traditional Chinese Medicine], V26, P5
   李海霞, 2007, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V13, P627
NR 24
TC 0
Z9 0
U1 2
U2 14
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 509
EP 515
DI 10.19193/0393-6384_2017_3_076
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200024
DA 2022-07-14
ER

PT J
AU Hasni, R
   Ali, A
AF Hasni, Roslan
   Ali, Akbar
TI SOME REMARKS ON "THE FORGOTTEN TOPOLOGICAL INDEX OF SOME DRUG
   STRUCTURES"
SO ACTA MEDICA MEDITERRANEA
LA English
DT Editorial Material
ID VERTEX
C1 [Hasni, Roslan] Univ Malaysia Terengganu, Sch Informat & Appl Math, Kuala Terengganu 21030, Terengganu, Malaysia.
   [Ali, Akbar] Univ Management & Technol, Sch Sci, Sialkot, Pakistan.
RP Ali, A (corresponding author), Univ Management & Technol, Sch Sci, Sialkot, Pakistan.
EM akbarali.maths@gmail.com
RI Abdullah, Roslan Hasni @/AAT-1187-2020; Ali, Akbar/S-3344-2016
OI Ali, Akbar/0000-0001-8160-4196; Hasni, Roslan/0000-0003-3695-2145
CR Deng HY, 2011, COMPUT MATH APPL, V61, P3017, DOI 10.1016/j.camwa.2011.03.089
   Farahani MR., 2013, J CHEM ACTA, V2, P70
   Gao W, 2016, ACTA MEDICA MEDITERR, V32, P579
   Hollas B, 2005, MATCH-COMMUN MATH CO, V54, P177
   Rostami M, 2012, DIG J NANOMATER BIOS, V7, P247
   Shetty BS, 2012, DIG J NANOMATER BIOS, V7, P1097
   Vukicevic D, 2010, CROAT CHEM ACTA, V83, P243
NR 7
TC 1
Z9 1
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 203
EP 204
DI 10.19193/0393-6384_2017_2_029
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700004
DA 2022-07-14
ER

PT J
AU Heidarabadi, NN
   Safdari, R
   Saeidi, MG
   Kolivand, P
   Tahmasbian, S
   Hakemi, L
AF Heidarabadi, Nasrolah Nasr
   Safdari, Reza
   Saeidi, Marjan Ghazi
   Kolivand, Pirhossein
   Tahmasbian, Shahram
   Hakemi, Laleh
TI A REVIEW OF DEVELOPED INFORMATION SYSTEMS FOR PAIN MANAGEMENT IN
   PATIENTS WITH SPINAL CORD INJURY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE pain; spinal cord injury; expert systems; clinical decision support
   systems (CDS System)
ID CLINICAL DECISION-SUPPORT
AB Introduction: Pain is one of the most disabling problems in people with Spinal Cord Injury. An interdisciplinary pain management team includes healthcare providers from different disciplines, each of them specialized in various characteristics of pain, and all should be coordinated so that the optimum results will be achieved. Information technology has been used in various domains of medicine. The aim of this study was to review relevant articles and find out power and weak points in pain management developed information systems and technologies used in these systems in the spinal cord injury population.
   Research method: A literature review was established to search developed information systems for pain management of patient with spinal cord injury, e-journals collections, and printed journals, books, dissertations, and theses for relevant articles. The search strategy interchangeably used the terms of "spinal cord injury", "pain management system", "expert system" and "clinical decision support system" combined with Boolean operator "AND". Search results (n=184) were adjusted for duplications, screened based on their abstract relevancy and full-text availability (n=93) and then assessed for eligibility (n=47). Eligible articles were included if they had explicitly focused on information systems for pain management, finally, 18 relevant articles included in the study.
   Results: Reviewing 18 articles published in English from 2007 to 2016 showed that computerized CDS systems may minimize pain mismanagements by nearly 60%, decrease hospital stay, and optimize co-morbidities' management. The results of the system showed an accuracy of about 78% for the diagnosis of the type of pain in patients with SCI. Different studies indicated positive role of the systems to increase accuracy and improve physician's decision making.
   Discussion: Use of Information Systems in medicine aid medical practitioners for better management. To produce such a device, it is necessary to choose methods and algorithms for classification, such as neural network, support vector machine, genetic algorithms, rule-based systems, decision tree, and so forth.
   Conclusion: Medical informatics like "Developed Information Systems" should become a powerful member of the team. Although Research on "Developed Information Systems" in chronic pain management is limited. Using medical informatics in medicine would result in 1-minimizing clinical errors (pharmaceutical and diagnostics), 2-optimizing care effectiveness, 3-saving the time, and 4-jump to novel ideas and knowledge in the field of medicine.
C1 [Heidarabadi, Nasrolah Nasr; Safdari, Reza; Saeidi, Marjan Ghazi] Univ Tehran Med Sci, Sch Allied Med Sci, Hlth Informat Management Dept, Tehran, Iran.
   [Heidarabadi, Nasrolah Nasr; Kolivand, Pirhossein; Hakemi, Laleh] Khatam Ol Anbia Hosp, Shefa Neurosci Res Ctr, Tehran, Iran.
   [Tahmasbian, Shahram] Univ Med Sci, ShahreKord Med Sci Coll, Shahrekord, Iran.
RP Safdari, R; Saeidi, MG (corresponding author), Univ Tehran Med Sci, Sch Allied Med Sci, Hlth Informat Management Dept, Tehran, Iran.
EM nasr.a128@gmail.com
RI Safdari, Reza/AAK-7482-2021; ghazisaeedi, marjan/AAL-4111-2021
OI ghazisaeedi, marjan/0000-0002-2400-209X; Kolivand,
   PirHossein/0000-0002-0532-4130; Safdari, Reza/0000-0002-4982-337X
CR Abas H. I., 2011, 2011 International Conference on Semantic Technology and Information Retrieval (STAIR 2011), P106, DOI 10.1109/STAIR.2011.5995773
   [Anonymous], 2015, SPINAL CORD INJURIES
   Ariaei M, 2012, HLTH INF MANAG  0512, P711
   Asefzadeh S, 2007, CHALLENGES EVALUATIO, P11
   Ashburn MA, 1999, LANCET, V353, P1865, DOI 10.1016/S0140-6736(99)04088-X
   Baig MM, 2013, J MED SYST, V37, DOI 10.1007/s10916-012-9898-z
   Basheer IA, 2000, J MICROBIOL METH, V43, P3, DOI 10.1016/S0167-7012(00)00201-3
   Bassols A, 1999, PAIN, V83, P9, DOI 10.1016/S0304-3959(99)00069-X
   Bertsche T, 2009, PAIN, V147, P20, DOI 10.1016/j.pain.2009.07.009
   Bonica JJ., 2010, BONICAS MANAGEMENT P
   Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103
   Campagnolo D.I., 2011, SPINAL CORD MED
   Carter J, 2014, PROF CASE MANAG, V19, P126, DOI 10.1097/NCM.0000000000000029
   Cho I, 2010, INT J MED INFORM, V79, P611, DOI 10.1016/j.ijmedinf.2010.06.002
   Gatchel RJ, 2014, AM PSYCHOL, V69, P119, DOI 10.1037/a0035514
   Gerard MN, 2008, J AM MED INFORM ASSN, V15, P776, DOI 10.1197/jamia.M2698
   Glaser JP., 2005, MANAGING HLTH CARE I
   Hecht T, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0094-9
   Hsiao JL, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-16
   Johnson R, 2011, BR J CARD NURS, V6
   Khalifa M, 2014, PROCEDIA COMPUT SCI, V37, P422, DOI 10.1016/j.procs.2014.08.063
   Lee S, 2013, CIN-COMPUT INFORM NU, V31, P477, DOI 10.1097/01.NCN.0000432127.99644.25
   Lippeveld T, 2000, DESIGN IMPLEMENTATIO
   Malaekeh SR, 2013, CLIN DECISION SUPPOR
   Maldonado H., 2015, 2015 12 INT C EL ENG, P1
   Midboe AM, 2011, TRANSL BEHAV MED, V1, P35, DOI 10.1007/s13142-011-0022-6
   Musen MA., 2014, BIOMEDICAL INFORM, P643, DOI [DOI 10.1007/978-1-4471-4474-8_22, 10.1007/978-1-4471-4474-8_22, 10.1007/978-1-4471-4474-8_22.]
   Nair Kalpana Maria, 2015, J Innov Health Inform, V22, P329, DOI 10.14236/jhi.v22i3.149
   NasrHeydarabadi Nasrolah, 2016, NEUROSCIENCE J SHEFA
   Neill DB, 2013, IEEE INTELL SYST, V28, P92, DOI 10.1109/MIS.2013.51
   OBrien, 2000, INTRO INFORM SYSTEMS
   Ohmann C, 1996, ARTIF INTELL MED, V8, P23, DOI 10.1016/0933-3657(95)00018-6
   OSHEROFF JA, CLIN DECISION SUPPOR
   Osheroff JA, 2007, J AM MED INFORM ASSN, V14, P141, DOI 10.1197/jamia.M2334
   Peiris D, 2014, JMIR RES PROTOC, V3, DOI 10.2196/resprot.3071
   Pombo N, 2014, ARTIF INTELL MED, V60, P1, DOI 10.1016/j.artmed.2013.11.005
   Roshanov PS, 2011, IMPLEMENT SCI, V6, DOI [10.1186/1748-5908-6-88, 10.1186/1748-5908-6-92]
   Roth EJ, 1994, SPINAL CORD INJURY M, P141
   Siddall PJ, 1997, SPINAL CORD, V35, P69, DOI 10.1038/sj.sc.3100365
   Singh P., 2013, INDIAN J PUBLIC HLTH, V4, P185
   Sleed M, 2005, PAIN, V119, P183, DOI 10.1016/j.pain.2005.09.028
   Smith MY, 2007, PAIN MED, V8, pS155, DOI 10.1111/j.1526-4637.2007.00278.x
   Soer R, 2016, DESIGN WEB BASED CLI
   Sternbach R. A., 1986, CLIN J PAIN, V2, P49, DOI [10.1097/00002508-198602010-00008, DOI 10.1097/00002508-198602010-00008]
   Teich JM, 2005, J AM MED INFORM ASSN, V12, P365, DOI 10.1197/jamia.M1822
   Trafton J, 2010, PAIN MED, V11, P575, DOI 10.1111/j.1526-4637.2010.00818.x
   Turk DC, 2004, ARTHRITIS RES THER, V6, P151, DOI 10.1186/ar1196
   Turk Dennis C., 1997, P253
   Verma SK, 2013, INT SOC OPTICS PHOTO
   Verma SK, 2014, PROC SPIE, V9039, DOI 10.1117/12.2044434
   Westgren N, 1998, ARCH PHYS MED REHAB, V79, P1433, DOI 10.1016/S0003-9993(98)90240-4
   Wyatt JC, 2003, INT J MED INFORM, V69, P251, DOI 10.1016/S1386-5056(02)00108-9
NR 52
TC 3
Z9 3
U1 0
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 237
EP 243
DI 10.19193/0393-6384_2017_2_035
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700010
DA 2022-07-14
ER

PT J
AU Hou, SX
   Lu, YM
   Huang, DM
   Luo, XH
   Wang, ZX
   Zhang, JC
   Xu, WP
AF Hou, Shuxin
   Lu, Yingmin
   Huang, Damin
   Luo, Xiaohan
   Wang, Zhaoxia
   Zhang, Jinchun
   Xu, Weiping
TI CORRELATION OF ATRIAL FIBRILLATION WITH RENIN-ANGIOTENSIN-ALDOSTERONE
   SYSTEM GENE POLYMORPHISM
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Atrial fibrillation; renin-angiotensin-aldosterone system; gene
   polymorphism
ID ESSENTIAL-HYPERTENSION; CONVERTING ENZYME; ASSOCIATION; STROKE; RISK;
   ABLATION; CHINESE; DISEASE; M235T; I/D
AB Background: This study aimed to investigate renin-angiotensin-aldosterone system gene polymorphism in atrial fibrillation (AF) patients.
   Materials and methods: 82 AF patients diagnosed in this survey were included for investigation, and 82 subjects without AF served as controls.
   Results: There were 3 genotypes of AGT M235T in the subjects investigated: MM genotype (7.32% vs. 13.41%), MT (26.83% vs. 35.37%) and TT (65.85% vs. 51.22%). The TT genotype frequency and T allele frequency in AF group were significantly higher than in control group (P<0.05). Logistic regression analysis showed T allele increased the risk for AF by 1.57 times (P<0.05). There were 3 genotypes of ACE AluID in the subjects investigated: II genotype (17.07% vs. 46.34%), ID genotype (51.22% vs. 34.15%) and DD genotype (31.71% vs. 19.51%). The DD genotype frequency and D allele frequency in AF group were markedly higher than in control group (P<0.05). Logistic regression analysis showed D allele increased the risk for AF by 2.42 folds (OR=2.42, P<0.05). CYP112B2344C/T showed TT, TC and CC genotypes, and their frequencies were 64.63%, 25.61% and 9.76%, respectively in AF group and 58.54%, 29.27% and 12.20%, respectively in control group. Allele T frequency was 77.44% and 73.17% in AF group and control group, respectively, and allele C frequency was 22.56% and 26.83% in AF group and control group, respectively. No significant differences were observed in the allele C and T frequencies between two groups (P> 0.05). CYP112B2-344CT gene polymorphism had no relationship with AF.
   Conclusion: In AF adults of Chongming, AGT-M235T, angiotensin converting enzyme (ACE) AluID and CYP112B2 -344CT genes show polymorphisms, T allele of AGT-M235T gene and D allele of ACE AluID gene may increase the risk for AF, and CYP112B2-344CT gene polymorphism has no relationship with AF.
C1 [Hou, Shuxin; Lu, Yingmin; Huang, Damin; Luo, Xiaohan; Wang, Zhaoxia; Zhang, Jinchun; Xu, Weiping] Shanghai Jiao Tong Univ, Dept Cardiol, XinHua Chongming Hosp, Sch Med, 25 Nanmengang Rd, Shanghai 202150, Peoples R China.
RP Lu, YM; Xu, WP (corresponding author), Shanghai Jiao Tong Univ, Dept Cardiol, XinHua Chongming Hosp, Sch Med, 25 Nanmengang Rd, Shanghai 202150, Peoples R China.
RI Xu, Yongping/AAH-3987-2020
OI Xu, Yongping/0000-0002-3946-9223
FU Yingmin Lu Foundation of the Committee of Shanghai Municipal Health and
   Family Planning [20124241]
FX This study was supported by the Yingmin Lu Foundation of the Committee
   of Shanghai Municipal Health and Family Planning (No. 20124241).
CR Al-Hazzani A, 2014, J BIOL RES-THESSALON, V21, DOI 10.1186/2241-5793-21-8
   Ayada C, 2015, INT J CLIN EXP MED, V8, P4521
   Bao H, 2015, INT J CLIN EXP MED, V8, P12914
   Campbell CY, 2010, AM J NEPHROL, V32, P156, DOI 10.1159/000315866
   Chen H.Z., 2009, PRACTICAL INTERNAL M
   Chen JF, 2015, INT J CLIN EXP MED, V8, P9162
   Disertori M, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-28
   Kaplan I, 2014, MED SCI MONITOR, V20, P1745, DOI 10.12659/MSM.892140
   Li WX, 2014, J RENIN-ANGIO-ALDO S, V15, P150, DOI 10.1177/1470320312466928
   Lu WH, 2015, INT J CLIN EXP MED, V8, P5513
   Mentz RJ, 2013, INT J CARDIOL, V167, P1677, DOI 10.1016/j.ijcard.2012.10.007
   Mondry Adrian, 2005, BMC Nephrol, V6, P1, DOI 10.1186/1471-2369-6-1
   Orenes-Pinero E, 2011, J RENIN-ANGIO-ALDO S, V12, P521, DOI 10.1177/1470320311405247
   Pi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068842
   Steinberg BA, 2015, EUR HEART J, V36, P288, DOI 10.1093/eurheartj/ehu359
   Tada H, 2014, STROKE, V45, P2856, DOI 10.1161/STROKEAHA.114.006072
   Topal NP, 2011, J RENIN-ANGIO-ALDO S, V12, P549, DOI 10.1177/1470320311399605
   Tucker NR, 2014, CIRC RES, V114, P1469, DOI 10.1161/CIRCRESAHA.114.302225
   Woods CE, 2014, CIRC RES, V114, P1532, DOI 10.1161/CIRCRESAHA.114.302362
   Workman AJ, 2011, PHARMACOL THERAPEUT, V131, P221, DOI 10.1016/j.pharmthera.2011.02.002
   XIa LZ, 2013, J AEROSPA MED, V24, P1450
   Xiao XP, 2012, INT J CARDIOVAS DIS, V39, P68
   Yang Bo, 2012, Shengwu Jiagong Guocheng, V10, P7, DOI 10.3969/j.issn.1672-3678.2012.04.002
   Yang JK, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0073053, 10.1371/journal.pone.0053939]
   Yao J, 2012, GENET TEST MOL BIOMA, V16, P1343, DOI 10.1089/gtmb.2012.0149
   Zakrzewski-Jakubiak M, 2008, BRIT J CLIN PHARMACO, V65, P742, DOI 10.1111/j.1365-2125.2007.03091.x
   Zhang XL, 2012, EXP THER MED, V4, P741, DOI 10.3892/etm.2012.650
   Zhang Y, 2013, CHIN J EVI BASE CARD, P664
   Zhao LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124978
   Zhou Zi-qiang, 2004, Zhonghua Nei Ke Za Zhi, V43, P491
   Zoni-Berisso M, 2014, CLIN EPIDEMIOL, V6, P213, DOI 10.2147/CLEP.S47385
   王成, 2013, [中国老年学杂志, Chinese Journal of Gerontology], V33, P4441
NR 32
TC 1
Z9 1
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 275
EP 283
DI 10.19193/0393-6384_2017_2_041
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700016
DA 2022-07-14
ER

PT J
AU Huang, HT
   Wang, F
   Ding, SG
   Lu, CX
   Zhong, CJ
AF Huang, Hai-Tao
   Wang, Fei
   Ding, Sheng-guang
   Lu, Chen-xi
   Zhong, Chong-jun
TI EXPRESSION LEVELS OF NET1, KAI1/CD82 PROTEINS AND D2-40 LABELED
   LYMPHATIC VESSEL INVASION (LVI) IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
   (ESCC) AND THEIR CORRELATION WITH CLINICOPATHOLOGICAL FACTORS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE esophageal squamous cell carcinoma; NET1; KAI1/CD82; LVI; Metastasis
ID INDEPENDENT PROGNOSTIC-FACTOR; CLINICAL-SIGNIFICANCE;
   MONOCLONAL-ANTIBODY; RHO-GTPASES; METASTASIS; MARKER; RISK
AB Objectives: Esophageal squamous cell carcinoma (ESCC) is associated with abnormal expression of multiple genes. Neuroepithelial transforming gene 1 (NET1) is a carcinogenic gene, overexpressed in several cancers. The tumor suppressor gene CD82, which encodes the protein KAI1, is down regulated in cancers. Lymphatic vessel invasion (LVI) is closely associated with metastasis. We investigated the expression levels of NET1, KAI1/CD82, LVI and their correlation with clinicopathological factors in ESCC.
   Methods: Immunohistochemistry and Western Blot were used to detect NET1, KAI1/CD82 expression levels in the para-carcinoma tissue and ESCC. LVI detected by D2-40 immunohistochemical staining. The relationships between the protein expression levels, positive LVI and clinicopathologic data were analyzed. Eighty-five patients, who had a primary resection of esophageal cancer, were analyzed by univariate and multivariate logistic regression, and univariate and multivariate survival analysis.
   Results: NET1 expression levels in cervical cancer were significantly higher than in the para-carcinoma tissue, (P<0.05). KAI1/CD82 expression was markedly lower in ESCC than in the para-carcinoma tissue (P<0.05). NET1 high expression and positive LVI were positively correlated while KAI1/CD82 expression was negatively correlated with invasion, lymph node metastasis, and clinical stage. They were all independent prognostic factors for lymph node metastasis. Kaplan-Meier analysis revealed that NET1 high expression and positive LVI was negatively correlated with overall survival (OS), while KAI1/CD82 expression was positively correlated with OS. Low KAI1/CD82 expression, high expression of NET1, positive LVI was associated with a poor prognosis in ESCC. Multivariate Cox regression analysis indicated that the positive LVI were independent predictors for OS in ESCC.
   Conclusions: NET1 high expression, positive LVI and KAI1/CD82 negative expression were all independent prognostic factors for lymph node metastasis in ESCC. Positive LVI was also an independent prognostic factor for OS. Combined detection of these factors may be of significant value in predicting the prognosis and metastasis in ESCC patients.
C1 [Huang, Hai-Tao; Wang, Fei; Ding, Sheng-guang; Lu, Chen-xi; Zhong, Chong-jun] Nantong First Peoples Hosp, Dept Thorac & Cardiovasc Surg, Nantong 226001, Jiangsu, Peoples R China.
RP Zhong, CJ (corresponding author), Nantong Univ, Affiliated Hosp 2, 6 North Haier Lane Rd, Nantong 226001, Peoples R China.
FU Nantong Health Authority [WQ2014020]
FX Foundation: supported by the Youth Fund Project of Nantong Health
   Authority; (project number: WQ2014020)
CR Bai Bing, 2013, Cancer Biology Medicine, V10, P81, DOI 10.7497/j.issn.2095-3941.2013.02.003
   Bennett G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-50
   Carr HS, 2013, MOL CELL BIOL, V33, P622, DOI 10.1128/MCB.00980-12
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Arnal MJD, 2015, WORLD J GASTROENTERO, V21, P7933, DOI 10.3748/wjg.v21.i26.7933
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Freedman ND, 2007, AM J EPIDEMIOL, V165, P1424, DOI 10.1093/aje/kwm051
   Gilcrease MZ, 2009, CANCER EPIDEM BIOMAR, V18, P80, DOI 10.1158/1055-9965.EPI-08-0842
   Guo C, 2009, HEPATOB PANCREAT DIS, V8, P389
   Huang HT, 2015, ACTA MEDICA MEDITERR, V31, P73
   Imamura Y, 2012, J SURG ONCOL, V105, P277, DOI 10.1002/jso.22079
   Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721
   Knoener M, 2012, DIS MARKERS, V32, P337, DOI [10.1155/2012/737132, 10.3233/DMA-2012-0896]
   Kozlowski M, 2011, FOLIA HISTOCHEM CYTO, V49, P90, DOI 10.5603/FHC.2011.0013
   Lahiff C, 2014, BRIT J SURG, V101, P55, DOI 10.1002/bjs.9373
   Leyden J, 2006, BRIT J CANCER, V94, P1204, DOI 10.1038/sj.bjc.6603054
   Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z
   Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010
   Shen SQ, 2008, MED ONCOL, V25, P341, DOI 10.1007/s12032-008-9042-6
   Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031
   Tu YY, 2010, JPN J CLIN ONCOL, V40, P388, DOI 10.1093/jjco/hyp186
   Wu Q, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0411-0
NR 22
TC 2
Z9 2
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 223
EP 229
DI 10.19193/0393-6384_2017_2_033
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700008
DA 2022-07-14
ER

PT J
AU Huang, HT
   Wang, F
   Ding, SG
   Zhong, CJ
AF Huang, Hai-Tao
   Wang, Fei
   Ding, Shengguang
   Zhong, Chong-Jun
TI PROGNOSTIC SIGNIFICANCE OF KAI1/CD82 AND ITS RELATION TO D2-40 LABELED
   LYMPHATIC VESSEL INVASION (LVI) AND LYMPHATIC VESSEL DENSITY (LVD) IN
   ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE esophageal squamous cell carcinoma; KAI1/CD82; LVI; LVD; Metastasis
ID METASTASIS SUPPRESSOR; MONOCLONAL-ANTIBODY; CANCER INVASION; EXPRESSION;
   MARKER; CD82/KAI-1; CD82
AB Objectives: The KAI1/CD82 appears to inhibit multiple steps of cancer metastatic. D2-40 labeled LVI and LVD are also closely associated with cancer metastasis. We investigated the expression levels of KAI1/CD82, D2-40 labeled LVI and LVD and their correlation with clinicopathological factors in ESCC.
   Methods: Immunohistochemistry and Western Blot were used to detect KAI1/CD82 expression levels in the peritumoral tissue and ESCC. LVI and LVD detected by D2-40 immunohistochemical staining. The relationships between the KAI1/CD82 expression levels, LVI and LVD were analyzed. The prognosis of ESCC was analyzed by Kaplan-Meier survival analysis and Cox's proportional hazards model.
   Results: KAI1/CD82 expression was markedly lower in ESCC than in the para-carcinoma tissue (P< 0.05). Positive peritumoral LVI and high mean peritumoral LVD were positively correlated while KAI1/CD82 expression was negatively correlated with tumor invasion, lymph node metastasis, and clinical stage. Kaplan-Meier analysis revealed that high mean peritumoral LVD and positive LVI was negatively correlated with overall survival (OS) and disease-free survival (DFS) time, while KAI1/CD82 expression was positively correlated with OS and DFS time. Low KAI1/CD82 expression, high mean peritumoral LVD, positive LVI was associated with a poor prognosis in ESCC. Multivariate Cox regression analysis indicated that the positive LVI and KAI1/CD82 positive expression were independent predictors for OS in ESCC. Positive LVI and high mean peritumoral LVD were independent predictors for DFS in ESCC
   Conclusions: KAI1/CD82 expression, LVI and LVD were significantly correlated with some clinicopathological factors of ESCC including lymph node metastasis, differentiation, and clinical stage. Combined detection of these factors may be of significant value in predicting the prognosis and metastasis in ESCC patients.
C1 [Huang, Hai-Tao; Wang, Fei; Ding, Shengguang; Zhong, Chong-Jun] Nantong First Peoples Hosp, Dept Thorac & Cardiovasc Surg, Nantong 226001, Jiangsu, Peoples R China.
RP Zhong, CJ (corresponding author), Nantong Univ, Affiliated Hosp 2, 6 North Haier Lane Rd, Nantong 226001, Peoples R China.
FU Youth Fund Project of Nantong Health Authority [WQ2014020]
FX Foundation: supported by the Youth Fund Project of Nantong Health
   Authority (project number: WQ2014020)
CR Abe M, 2008, CANCER LETT, V266, P163, DOI 10.1016/j.canlet.2008.02.058
   Bai Bing, 2013, Cancer Biology Medicine, V10, P81, DOI 10.7497/j.issn.2095-3941.2013.02.003
   Bari R, 2009, AM J PATHOL, V174, P647, DOI 10.2353/ajpath.2009.080685
   Bass R, 2005, J BIOL CHEM, V280, P14811, DOI 10.1074/jbc.M414189200
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Gombos Z, 2005, CLIN CANCER RES, V11, P8364, DOI 10.1158/1078-0432.CCR-05-1238
   Guo C, 2009, HEPATOB PANCREAT DIS, V8, P389
   Imamura Y, 2012, J SURG ONCOL, V105, P277, DOI 10.1002/jso.22079
   Inoue A, 2008, PATHOL INT, V58, P611, DOI 10.1111/j.1440-1827.2008.02279.x
   Ito Masahiro, 2007, Breast Cancer, V14, P381, DOI 10.2325/jbcs.14.381
   Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5
   JIANG WG, 1994, BRIT J SURG, V81, P1576, DOI 10.1002/bjs.1800811107
   Knoener M, 2012, DIS MARKERS, V32, P337, DOI [10.1155/2012/737132, 10.3233/DMA-2012-0896]
   Kozlowski M, 2011, FOLIA HISTOCHEM CYTO, V49, P90, DOI 10.5603/FHC.2011.0013
   Minardi D, 2011, HUM PATHOL, V42, P1596, DOI 10.1016/j.humpath.2010.12.020
   Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z
   Mori D, 2007, MODERN PATHOL, V20, P694, DOI 10.1038/modpathol.3800786
   Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7
   Todeschini AR, 2007, J BIOL CHEM, V282, P8123, DOI 10.1074/jbc.M611407200
   Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031
   Wang J, 2014, WORLD J GASTROENTERO, V20, P18397, DOI 10.3748/wjg.v20.i48.18397
   Wang XL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-299
   Waterman TA, 2004, ANN THORAC SURG, V78, P1161, DOI 10.1016/j.athoracsur.2004.04.045
   WU Q, 2015, DIAGN PATHOL, V10
NR 24
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 967
EP 974
DI 10.19193/0393-6384_2017_6_153
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500012
DA 2022-07-14
ER

PT J
AU Ibrahim, S
   Bulgurlu, SS
   Demirtunc, R
AF Ibrahim, Solak
   Bulgurlu, S. S.
   Demirtunc, R.
TI THE RELATION BETWEEN HBA1C AND URINE ALBUMIN EXCRETION IN TYPE 2
   DIABETES MELLITUS PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hemoglobin A1c; Urine Albumin Excretion; Type 2 Diabetes Mellitus;
   Nephropathy; Microalbuminuria
ID RENAL-FUNCTION; MICROALBUMINURIA; RISK
AB Introduction: Hyperglycemia and duration of diabetes are known risk factors for diabetic nephropathy, and the presence of microalbuminuria is a strong indicator of nephropathy. We aimed to examine the relation between Hemoglobin A1c (HbA1c) and urine albumin excretion (UAE) in this study.
   Material and methods: The association between HbA1c and UAE was evaluated in 57 patients with diabetes mellitus, who had at least 8 years of disease history and 5 years of follow-up.
   Result: Hb1Ac levels were above the target levels, and UAE levels were significantly increased with duration of disease, which was also associated with diabetic nephropathy.
   Conclusion: According to the findings of this study, severe glucose control may inhibit progression of diabetic nephropathy.
C1 [Ibrahim, Solak] Hlth Sci Univ, Konya Educ & Res Hosp, Dept Family Practice, Konya, Turkey.
   [Bulgurlu, S. S.] Hlth Sci Univ, Haydarpasa Numune Educ & Res Hosp, Dept Family Practice, Istanbul, Turkey.
   [Demirtunc, R.] Hlth Sci Univ, Haydarpasa Numune Educ & Res Hosp, Clin Internal Dis, Istanbul, Turkey.
RP Ibrahim, S (corresponding author), Hlth Sci Univ, Konya Educ & Res Hosp, Dept Family Practice, Konya, Turkey.
RI Solak, Ibrahim/F-2225-2019
OI Solak, Ibrahim/0000-0001-5311-0631
CR Alzaid AA, 1996, DIABETES CARE, V19, P79, DOI 10.2337/diacare.19.1.79
   BENNETT PH, 1995, AM J KIDNEY DIS, V25, P107
   Caramori MLA, 1999, DIABETES CARE, V22, P1512, DOI 10.2337/diacare.22.9.1512
   DCCT Res Grp, 1986, DIABETES, V35, P530
   DEFRONZO RA, 1995, DIABETES REV, V3, P510
   EUCID, 2008, FIN REP EUR COR IND
   Forsblom CM, 1998, DIABETES CARE, V21, P1932, DOI 10.2337/diacare.21.11.1932
   GAMBARA V, 1993, J AM SOC NEPHROL, V3, P1458
   Garg JP, 2002, VASC MED, V7, P35, DOI 10.1191/1358863x02vm412ra
   Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
   Holl RW, 1999, DIABETES CARE, V22, P1555, DOI 10.2337/diacare.22.9.1555
   Hostetner TH, 1991, PRINCIPLES PRACTICE, P460
   International Diabetes Federation, 2013, DIABETES ATLAS, V6th
   Klausen K, 2004, CIRCULATION, V110, P32, DOI 10.1161/01.CIR.0000133312.96477.48
   KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902
   Mojiminiyi OA, 2003, J DIABETES COMPLICAT, V17, P160, DOI 10.1016/S1056-8727(02)00177-0
   Morello CM, 2006, AM J HEALTH-SYST PH, V63, P1325, DOI 10.2146/ajhp050430
   Pickup J, 1997, TXB DIABETES
   Pickup J, 1997, TXB DIABETES
   Pittrow D., 2006, DIABETOLOGIE STOFFWE, V1
   Ritz E, 1999, NEW ENGL J MED, V341, P1127, DOI 10.1056/NEJM199910073411506
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
NR 22
TC 2
Z9 2
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 65
EP 69
DI 10.19193/0393-6384_2017_1_010
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800010
DA 2022-07-14
ER

PT J
AU Ilhan, E
   Ureyen, O
   Alpdogan, O
   Senlikci, A
   Alay, D
   Gokcelli, U
   Meral, UM
AF Ilhan, Enver
   Ureyen, Orhan
   Alpdogan, Ozcan
   Senlikci, Abdullah
   Alay, Demet
   Gokcelli, Ugur
   Meral, Ulvi Mehmet
TI IS MOLECULAR SUBTYPES OF BREAST CANCER RELATED WITH AXILLARY
   INVOLVEMENT? A RETROSPECTIVE STUDY OF 86 CASES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Breast Cancer; Molecular Subtype; Lymph Node Metastasis
ID EXPRESSION; CARCINOMA; IMMUNOHISTOCHEMISTRY; PORTRAITS; CONSENSUS;
   PATTERNS; FEATURES; TUMORS; P53
AB Introduction: Gene expression analysis has identified several molecular subtypes of breast cancer. This classification of subtypes is important for the treatment and prognosis of the disease. The relationship between molecular subtypes of breast cancer and axillary involvement remains controversial. The purpose of this study is to examine whether there is a relationship between molecular subtypes and axillary involvement in breast cancer, and whether such relationshipis useful in the decision of surgical interventions for the axilla.
   Materials and methods: Medical records of 86 patients with breast cancer were examined retrospectively. Data were collected on the following independent variables: age, gender, menopausal status, neoadjuvant treatment, tumor size, axillary involvement, TNM stage, histologic type and grade, estrogen receptor(ER), progesterone receptor (PR), HER-2 status, and the presence of p53 and Ki-67 gene expression. Patients in this cohort were grouped according to their molecular subtypes of the breast cancers as defined by the St. Gallen International Expert Consensus 2013. The relationship between molecular subtypes and nodal involvement was investigated and compared in terms of independent variables. In addition, Luminal A and Luminal B subtypes were compared with each other.
   Results: There were 20 (23.2%), 47(54.6%), 8(9.3%), and 4(4.6%) patients in the Luminal A, Luminal B, HER-2 (+), and Triple Negative(TN) groups, respectively. p53 gene expression was different in the TN group when compared with that in the Luminal A and B groups(p<0.05). There were no significant differences in any other independent variables among the molecular subtype groups. Overall, 40 (46.4%) patients had nodal involvement. Age, molecular subtypes of cancer, histologic grade, and hormone receptor status had no discernible effect on nodal involvement. Tumor stage correlated with nodal involvement(p<0.05).
   Conclusion: We were not able to find an association between nodal involvement and molecular subtypes of breast cancer in this study. Therefore, the prediction of axillary involvement based on the identification of molecular subtypes of breast cancer may not be possible, according to these results.
C1 [Ilhan, Enver; Ureyen, Orhan; Alpdogan, Ozcan; Senlikci, Abdullah; Alay, Demet; Gokcelli, Ugur] Bozyaka Res & Training Hosp, Dept Gen Surg, Izmir, Turkey.
   [Meral, Ulvi Mehmet] Izmir Mil Hosp, Gen Surg, Izmir, Turkey.
RP Ureyen, O (corresponding author), Bozyaka Res & Training Hosp, Dept Gen Surg, Izmir, Turkey.
RI Ureyen, Orhan/AGI-3233-2022; Senlikci, Abdullah/AAI-8432-2020
OI Ureyen, Orhan/0000-0002-7820-9088; 
CR Ahn HJ, 2015, J BREAST CANCER, V18, P149, DOI 10.4048/jbc.2015.18.2.149
   Coates AS, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3348
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Howland NK, 2013, J SURG RES, V185, P697, DOI 10.1016/j.jss.2013.06.048
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Ilhan E, 2009, BREAST CARE, V4, P308, DOI 10.1159/000230912
   Jones T, 2013, ANN SURG ONCOL, V20, P2866, DOI 10.1245/s10434-013-2994-6
   Kornegoor R, 2012, MODERN PATHOL, V25, P398, DOI 10.1038/modpathol.2011.174
   Lee JH, 2010, CANCER RES TREAT, V42, P30, DOI 10.4143/crt.2010.42.1.30
   Lyman GH, 2014, J CLIN ONCOL, V32, P1365, DOI 10.1200/JCO.2013.54.1177
   Morrison DH, 2012, BRIT J CANCER, V107, P382, DOI 10.1038/bjc.2012.219
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rao R, 2013, JAMA-J AM MED ASSOC, V310, P1385, DOI 10.1001/jama.2013.277804
   Reyal F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020297
   Sawaki M, 2014, ONCOL LETT, V8, P1707, DOI 10.3892/ol.2014.2333
   Si CS, 2014, INT J CLIN EXP PATHO, V7, P6800
   SILVERSTEIN MJ, 1995, J AM COLL SURGEONS, V180, P700
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Wang GS, 2012, MOL MED REP, V6, P779, DOI 10.3892/mmr.2012.981
   Yemelyanova A, 2011, MODERN PATHOL, V24, P1248, DOI 10.1038/modpathol.2011.85
   Yoshihara E, 2013, BREAST, V22, P357, DOI 10.1016/j.breast.2012.09.003
NR 23
TC 3
Z9 3
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 393
EP 398
DI 10.19193/0393-6384_2017_3_056
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200004
DA 2022-07-14
ER

PT J
AU Inci, A
   Sarici, IS
   Caliskan, G
   Kalayci, MU
AF Inci, Ayse
   Sarici, Inanc Samil
   Caliskan, Gurkan
   Kalayci, Mustafa Uygar
TI INVESTIGATION OF FREQUENCY OF HBSAG, ANTI HBS, ANTI HCV AND ANTI HIV IN
   REFUGEE PATIENTS FROM SYRIA WHO ADMIT TO A TRAINING AND RESEARCH
   HOSPITAL DEPARTMENT OF SURGERY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hepatitis B; Hepatitis C; Human immunodeficiency virus; Surgery; Syrian
   refugee
ID HEPATITIS-B; PREVALENCE
AB Introduction: Hepatitis B and C and HIV cause severe health problems in worldwide. Controlled and/or unrecorded migrations which have been occurring as a result of Syrian war, leads to death of many people, increase poverty, make dissemination of diseases easier and increase health problems.
   Materials and methods: Data of Syrian refugee patients who were being surgical treatment and follow-up in Kanuni Sultan Suleyman Training and Research Hospital Department of Surgery (General Surgery, urology, gynecologic oncology, orthopedics and intensive care units) and for whom ELISA (HBsAg, Anti-HBs, Anti-HCV and anti-HIV) was performed between January and December 2015 were retrospectively evaluated from computerized records.
   Results: Three hundred Syrian refugee patients who were included in the study were evaluated. One hundred fifty six (52%) patients were female and 144 (48%) were male. The most common age distribution range was found between 16-30. One hundred twenty five (41.6%) patients in general surgery, 78 (26%) patients in orthopedics, 55 (18.4%) patients in urology and 42 (14%) patients in gynecological oncology underwent surgery. HBsAg positivity was found in 9 (3%), anti-HCV was found positivity in 7 (2.3%) and anti-HBs positivity was found in 73 (26.6%) patients. Anti-HIV positivity was found in none of these patients.
   Conclusion: Increasing number of uncontrolled and unrecorded Syrian refugees causes lots of social and health problems. We recommended that is important to know frequency of hepatitis in both refugee and local society. According to our study; hepatitis and HIV screening recommended for Syrian refugees in their medical treatments due to the migration from regions where the disease is widespread. Our data will be beneficial for relevant physicians in terms of provide predictions concerning about follow-up of this patient group which will going on surgical intervention.
C1 [Inci, Ayse] Kanuni Sultan Suleyman Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
   [Sarici, Inanc Samil; Kalayci, Mustafa Uygar] Kanuni Sultan Suleyman Training & Res Hosp, Dept Gen Surg, Istanbul, Turkey.
   [Caliskan, Gurkan] Kanuni Sultan Suleyman Training & Res Hosp, Dept Orthoped Traumatol, Istanbul, Turkey.
RP Sarici, IS (corresponding author), 4 Bolge Atakent Mahallesi Toki Menekse Evleri C2-, Halkali Istanbul, Turkey.
RI Sarici, Inanc Samil/V-8868-2017
CR Antaki N, 2010, EPIDEMIOL INFECT, V138, P40, DOI 10.1017/S0950268809990288
   BICEROGLU SU, 2012, EGE TIP DERGISI, V51, P233
   Cavus E, 2015, IKSST DERG, V7, P22
   Gammouh OS, 2015, PREV CHRONIC DIS, V12, DOI 10.5888/pcd12.140424
   Hughes E, 2016, LANCET PSYCHIAT, V3, P40, DOI 10.1016/S2215-0366(15)00357-0
   Huster Karin M. J., 2014, Yale Journal of Biology and Medicine, V87, P269
   Ibrahim N., 2014, HEPATITIS B AWARENES, V2014
   Karim M, 2008, SYR EPIDEMIOL B, V2, P10
   Kose S., 2011, Turk Hijyen ve Deneysel Biyoloji Dergisi, V68, P191, DOI 10.5505/TurkHijyen.2011.44154
   Muselmani W, 2014, J INFECT DEV COUNTR, V8, P1013, DOI 10.3855/jidc.3827
   Othman BM, 2002, SAUDI MED J, V23, P393
   Sayan M, 2014, J INT AIDS SOC, V17, P158, DOI 10.7448/IAS.17.4.19750
   Sever ON, 2015, ACU SAGLIK BIL DERG, P216
   Tosun S, 2006, VIRAL HEPATIT DERGIS, V11, P117
   Toy M, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-337
   Yacoub R, 2010, J GLOB INFECT DIS, V2, P28, DOI 10.4103/0974-777X.59247
NR 16
TC 2
Z9 2
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 59
EP 63
DI 10.19193/0393-6384_2017_1_009
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800009
DA 2022-07-14
ER

PT J
AU Jambarsang, S
   Baghban, AA
   Zayeri, F
   Nazari, SSH
   Nikfarjam, A
   Moradi, A
AF Jambarsang, Sara
   Baghban, Alireza Akbarzadeh
   Zayeri, Farid
   Nazari, Seyed Saeed Hashemi
   Nikfarjam, Ali
   Moradi, Ali
TI CD4 CELL CHANGE RATES IN HIV-INFECTED PATIENTS AFTER HIGHLY ACTIVE
   ANTIRETROVIRAL THERAPY: RETROSPECTIVE COHORT STUDY 1999-2014
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE HIV; highly active antiretroviral therapy; CD4 Lymphocyte Count; Markov
   model
ID CLINICAL-TRIALS; CHRONIC DISEASE; AIDS; COUNTS; LESS
AB Background and purpose: Determination if treatment of HIV-infected patients subject to highly active antiretroviral therapy resulted in decreased viral replication and increased CD4 cell counts. The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART. The objective was to identify the effect of HAART on the transition rate between CD4 cell states based on a multi-state Markov model.
   Methodology: This was an observational cohort study of 305 HIV-positive patients between 1999 and 2014 who were divided into two groups. One group of 179 patients had not received antiretroviral therapy and one group of 126 patients had received HAART. Both had been referred to the Iranian Research Center for HIV/AIDS.
   Results: HIV-positive patients on HAART showed half the hazard of progression to death than those in the non-HAART group. The rate of recovery from state 2 of CD4 cells to state 1 in the HAART group was significantly greater than in the non-HAART group at HR = 2.5 95% CI: 1.38, 4.70). The probability of recovery after 36 months from each state was estimated using Markov model.
   Conclusion: It was found that the effect of HAART on the rate of recovery was significant only for patients that begin therapy from a CD4 value of >200 cells/ml. As treatment continued from three to five years, the probability of reconstitution of CD4 cells from <200 cells/ml to a normal nadir increased from 0.53 to 0.61. Our findings have important implications for clinical management and should be taken into account in future treatment guidelines.
C1 [Jambarsang, Sara; Zayeri, Farid] Shahid Beheshti Univ Med Sci, Fac Paramed Sci, Dept Biostat, Tehran, Iran.
   [Baghban, Alireza Akbarzadeh] Shahid Beheshti Univ Med Sci, Sch Rehabil, Dept Basic Sci, Prote Res Ctr, Tehran, Iran.
   [Zayeri, Farid] Shahid Beheshti Univ Med Sci, Fac Paramed Sci, Prote Res Ctr, Tehran, Iran.
   [Nazari, Seyed Saeed Hashemi] Shahid Beheshti Univ Med Sci, Sch Publ Hlth, Dept Epidemiol, Epidemiol, Tehran, Iran.
   [Nikfarjam, Ali] Univ Tehran Med Sci, Hlth, Tehran, Iran.
   [Moradi, Ali] Hamadan Univ Med Sci, Asadabad Hlth & Treatment Network, Hamadan, Iran.
RP Baghban, AA (corresponding author), Shahid Beheshti Univ Med Sci, Sch Rehabil, Dept Basic Sci, Prote Res Ctr, Tehran, Iran.
EM s.jambarsang@sbmu.ac.ir
RI Zayeri, Farid/ABA-5531-2020; Jambarsang, Sara/S-2637-2017
OI Zayeri, Farid/0000-0002-7791-8122; Jambarsang, Sara/0000-0002-8295-7812
CR Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   King JT, 2003, MED DECIS MAKING, V23, P9, DOI 10.1177/0272989X02239652
   LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563
   Miranda A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000826
   Palmisano L, 2011, ANN I SUPER SANITA, V47, P44, DOI 10.4415/ANN_11_01_10
   Robbins GK, 2009, CLIN INFECT DIS, V48, P350, DOI 10.1086/595888
   Scandlyn J, 2000, WESTERN J MED, V172, P130, DOI 10.1136/ewjm.172.2.130
   Schneider Eileen, 2008, Morbidity and Mortality Weekly Report, V57, P1
   Setegn T, 2015, AIDS RES TREAT, V2015, DOI 10.1155/2015/148769
   Smith CJ, 2004, J INFECT DIS, V190, P1860, DOI 10.1086/425075
   Spruance SL, 2004, ANTIMICROB AGENTS CH, V48, P2787, DOI 10.1128/AAC.48.8.2787-2792.2004
   Vrisekoop N, 2008, J IMMUNOL, V181, P1573, DOI 10.4049/jimmunol.181.2.1573
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
NR 16
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 927
EP 930
DI 10.19193/0393-6384_2017_1s_138
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000007
DA 2022-07-14
ER

PT J
AU Jenaabadi, H
AF Jenaabadi, Hossein
TI A COMPARISON OF COGNITIVE EMOTION REGULATION STRATEGIES AND EMOTIONAL
   SCHEMAS BETWEEN MOTHERS OF CHILDREN WITH MENTAL DISORDERS AND MOTHERS OF
   PHYSICALLY AND MENTALLY DISABLED CHILDREN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Cognitive Emotion Regulation; Emotional Schemas; Mental Disorders;
   Disabled Children; Mental and Physical Disability
ID PARENTS
AB Introduction: This study aimed to evaluate cognitive emotion regulation strategies and emotional schemas in mothers of children with mental disorders and mothers of physically and mentally disabled children.
   Methods and Materials: The method of this study was descriptive followed by a casual-comparative design. The statistical population of this study included all mothers of children with mental disorders and mothers of physically and mentally disabled children in Zahedan. The statistical sample consisted of 63 mothers of children with mental disorders, including emotional disorders, disruptive behavior disorders, and developmental disorders, selected using the random sampling method. The sample was matched with 63 mothers of physically and mentally disabled children chosen among clients admitted to rehabilitation centers and clinics in Zahedan. These two groups filled out the Garnefski, Kraaij, and Spinhoven Cognitive Emotion Regulation Questionnaire and the Leahy Emotional Schemas Scale. The obtained data was analyzed using the multivariate analysis of variance (MANOVA).
   Results: The results indicated that compared to the mothers of disabled children, the mothers of children with mental disorders obtained higher scores on self-blame, catastrophizing, and other-blame (the subscales of maladaptive cognitive emotion regulation strategies), putting into perspective (the subscale of adaptive cognitive emotion regulation strategies), emotional self-awareness, expression of feelings, not being controlled, comprehensibility, simplistic view of emotions, and acceptance of feelings (the subscales of emotional schemas).
   Conclusion: It can be concluded that using these improper strategies can put these mothers at the risk of mental issues and conflicts. Therefore, through training efficient emotional schemas and adaptive cognitive emotion regulation strategies, these mothers can be aided to improve their conditions.
C1 [Jenaabadi, Hossein] Univ Sistan & Baluchestan, Fac Educ Sci & Psychol, Dept Educ Sci, Zahedan, Iran.
RP Jenaabadi, H (corresponding author), Univ Sistan & Baluchestan, Fac Educ Sci & Psychol, Dept Educ Sci, Zahedan, Iran.
EM hjenaabadi@ped.usb.ac.ir
OI Jenaabadi, Hossein/0000-0002-4373-9353
CR Ahmadi KH, 2013, J BEHAV SCI, V6, P331
   Aldao A, 2010, CLIN PSYCHOL REV, V30, P217, DOI 10.1016/j.cpr.2009.11.004
   Aminzadeh A, 2011, J REHABIL, V18, P37
   Bargh J.A., 2007, HDB EMOTION REGULATI, P429, DOI DOI 10.3109/00048674.2010.496359
   Baxter AC, 2007, J AUTISM DEV DISORD, V37, P976, DOI 10.1007/s10803-006-0217-8
   BHAVNAGRI NP, 1999, EARLY EDUC DEV, V10, P551
   Campbell-Sills L., 2007, HDB EMOTION REGULATI, P542
   Cordova JV, 2005, J SOC CLIN PSYCHOL, V24, P218, DOI 10.1521/jscp.24.2.218.62270
   Darvishi M, 2015, J ARAK U MED SCI, V18, P32
   Dowdell E B, 1995, J Psychosoc Nurs Ment Health Serv, V33, P27
   Garnefski N, 2004, PERS INDIV DIFFER, V36, P267, DOI 10.1016/S0191-8869(03)00083-7
   Garnefski N, 2003, J YOUTH ADOLESCENCE, V32, P401, DOI 10.1023/A:1025994200559
   Gross JJ, 2007, HDB EMOTION REGULATI, V2007, P3, DOI DOI 10.'1080/00140130600971135
   Hames A, 1998, CHILD CARE HLTH DEV, V24, P157
   Hankin, 2001, DRUG BENEFIT TRENDS, V13, P15
   Hasani J, 2014, J CLIN PSYCHOL, V6, P91
   Hasani J., 2011, J CLIN PSYCHOL, V2, P73
   Jamilian H R, 2014, Glob J Health Sci, V6, P116, DOI 10.5539/gjhs.v6n7p116
   Karimi HR, 2004, REHABILITATION SERVI
   Khanzade M., 2012, J CLIN PSYCHOL, V11, P91
   KOEGEL RL, 1992, J AUTISM DEV DISORD, V22, P205, DOI 10.1007/BF01058151
   Leahy R. L., 2009, COGNITIVE BEHAV THER, V2, P187
   Loeb ME, 2008, ALTER, V2, P32, DOI 10.1016/j.alter.2007.06.001
   Mashhadi A, 2011, JCP, V8, P29
   McKay M., 2007, DIALECTICAL BEHAV TH
   Rosenzweig JM, 2002, SOC WORK, V47, P415, DOI 10.1093/sw/47.4.415
   Roskam I, 2008, J COUNS DEV, V86, P132, DOI 10.1002/j.1556-6678.2008.tb00490.x
   Sanders JL, 1997, CHILD FAM BEHAV THER, V19, P15, DOI 10.1300/J019v19n04_02
   Tompson NS, 2009, PARENTAL PERCEPTION
   Xie HY, 2005, PSYCHIAT SERV, V56, P1282, DOI 10.1176/appi.ps.56.10.1282
   Yoselyani GH, 2012, J SCH PSYCHOL, V1, P114
   Zamani N, 2014, SCI J ILAM U MED SCI, V20, P45
   Zamani N, 2013, J RES HLTH, V123, P22
NR 33
TC 0
Z9 0
U1 0
U2 12
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 887
EP 894
DI 10.19193/0393-6384_2017_1s_132
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000001
DA 2022-07-14
ER

PT J
AU Ji, WB
   Wang, WZ
   Xu, XJ
   Mi, YC
   Fu, X
   Chen, YE
   Yang, S
   Tao, D
   Xu, W
   Xu, C
AF Ji, Wen-Bin
   Wang, Wei-Zhen
   Xu, Xin-Jian
   Mi, Yu-Cheng
   Fu, Xin
   Chen, Yi-Er
   Yang, Song
   Tao, Dan
   Xu, Wen
   Xu, Chao
TI ARTERIAL EMBOLIZATION IN TREATMENT OF HEPATIC ARTERY PSEUDOANEURYSM
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Artery embolization; Hepatic angiography; Pseudoaneurysm
ID LAPAROSCOPIC PARTIAL NEPHRECTOMY; RENAL-ARTERY; LIVER-TRANSPLANTATION;
   RUPTURE; HEMORRHAGE; ANEURYSM; TRAUMA
AB Introduction: Hepatic artery pseudoaneurysm (HAPA) was a rare but lethal disease. Surgery, recommended as the main choice for the management of HAPA in the past, often associated with high rates of bleeding recurrence and mortality. Recently, transcatheter arterial embolization (TAE) has been gradually applied in the treatment of HAPA. However, these studies were mostly case reports and with less efficacy evaluation, the main purpose of this study was to provide more evidence of TAE on the effect of HAPA.
   Materials and methods: Six HAPA patients with recurrent gastrointestinal or abdominal bleeding were enrolled in this study. Digital subtraction angiography and embolization treatment were performed, and the treatment efficacy was investigated. Of 6 patients, 4 had intrahepatic HAPA and 2 had extrahepatic HAPA.
   Results: Two patients had major postoperative bleeding after traumatic hepatic rupture repair, and 4 had surgical postoperative bleeding. Five patients had no secondary bleeding after the first embolization; 1 intrahepatic HAPA patient exhibited major bleeding 10 days after intrahepatic embolization, but bleeding stopped after the second embolization. One patient died of liver failure 1 day after the embolization.
   Conclusions: Angiographic diagnosis and arterial coil embolization achieved a good result of HAPA treatment, which indicated that TAE was a safe and feasible treatment of HAPA.
C1 [Ji, Wen-Bin; Xu, Xin-Jian; Mi, Yu-Cheng] Wenzhou Med Univ, Affiliated Taizhou Hosp, Dept Radiol, Taizhou 317000, Peoples R China.
   [Wang, Wei-Zhen] Wenzhou Med Univ, Affiliated Taizhou Hosp, Dept Vasc Surg, Taizhou 317000, Peoples R China.
   [Fu, Xin; Chen, Yi-Er; Yang, Song; Tao, Dan; Xu, Wen; Xu, Chao] Wenzhou Med Univ, Affiliated Taizhou Hosp, Vasc Intervent Ctr, Taizhou 317000, Peoples R China.
RP Ji, WB (corresponding author), Wenzhou Med Univ, Affiliated Taizhou Hosp, Dept Radiol, Taizhou 317000, Peoples R China.
CR Albani JM, 2003, UROLOGY, V62, P227, DOI 10.1016/S0090-4295(03)00364-9
   Amico EC, 2014, PANCREATOLOGY, V14, P144, DOI 10.1016/j.pan.2013.12.003
   Arroua F, 2010, PROG UROL, V20, P472, DOI 10.1016/j.purol.2009.10.004
   Asai K, 2014, SURG TODAY, V44, P160, DOI 10.1007/s00595-012-0314-6
   Asayama Naoki, 2014, Nihon Shokakibyo Gakkai Zasshi, V111, P931
   Baggio E, 2004, ANN VASC SURG, V18, P93, DOI 10.1007/s10016-003-0042-x
   Bardes JM, 2011, J TRAUMA, V71, P783, DOI 10.1097/TA.0b013e31822b095a
   Cohenpour M, 2007, CLIN RADIOL, V62, P1104, DOI 10.1016/j.crad.2007.06.004
   COUNTRYMAN D, 1983, AM SURGEON, V49, P51
   Farrell TM, 1996, J TRAUMA, V41, P1067, DOI 10.1097/00005373-199612000-00025
   HALL CL, 1987, BRIT MED J, V294, P1526, DOI 10.1136/bmj.294.6586.1526
   Hidas G, 2005, ISR MED ASSOC J, V7, P410
   Jebara VA, 1998, J VASC SURG, V27, P362, DOI 10.1016/S0741-5214(98)70368-4
   Karatzas T, 1997, TRANSPLANT P, V29, P2853, DOI 10.1016/S0041-1345(97)00706-9
   Kasirajan K, 2001, J ENDOVASC THER, V8, P150, DOI 10.1583/1545-1550(2001)008<0150:EMOVAA>2.0.CO;2
   Lukes DJ, 2006, TRANSPL P, V38, P2671, DOI 10.1016/j.transproceed.2006.07.029
   Netsch C, 2010, WORLD J UROL, V28, P519, DOI 10.1007/s00345-010-0572-0
   Panaro F, 2013, ANN VASC SURG, V27, P1088, DOI 10.1016/j.avsg.2013.01.007
   Povo-Martin IJ, 2010, ACTAS UROL ESP, V34, P647, DOI 10.1016/j.acuro.2009.12.011
   Prabhu A, 2012, GASTROENTEROLOGY, V142, P1422, DOI 10.1053/j.gastro.2011.12.014
   Reber PU, 1998, J AM COLL SURGEONS, V186, P325, DOI 10.1016/S1072-7515(98)00032-5
   Reiter DA, 2013, J EMERG MED, V44, P100, DOI 10.1016/j.jemermed.2011.08.021
   Rencuzogullari A, 2014, INT J SURG CASE REP, V5, P142, DOI 10.1016/j.ijscr.2014.01.005
   Shakhssalim N, 2010, UROL J, V7, P12
   Tessier DJ, 2003, ANN VASC SURG, V17, P663, DOI 10.1007/s10016-003-0075-1
   Treiber U, 2003, UROLOGE A, V42, P547, DOI 10.1007/s00120-002-0256-5
   Weissbart S, 2009, CAN J UROL, V16, P4687
   Zorn KC, 2007, J ENDOUROL, V21, P763, DOI 10.1089/end.2006.0332
NR 28
TC 4
Z9 4
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 449
EP 455
DI 10.19193/0393-6384_2017_3_066
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200014
DA 2022-07-14
ER

PT J
AU Jiang, GP
AF Jiang Guiping
TI EFFECT OF MASSAGE AND MOVING CUP MANIPULATION'S COMBINED THERAPY IN
   TREATING CLOSED SOFT TISSUE INJURY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Sport Massage; Moving Cup Manipulation; Martial Arts Athlete; Closed
   Soft Tissue; Injury
AB Purpose: Combined therapy of massage and moving cup manipulation was applied on martial arts athletes that sustained closed soft tissue injury. Detailed analysis of this therapy revealed that such combined therapy can be an effective treatment for injuries such as closed soft tissue injury.
   Methods: Documentary analysis and questionnaire methods were used in this study. A total of 2600 martial arts athletes who sustained closed soft tissue injury between Feb 2013 and Feb 2016 were selected as research subjects. The athletes underwent the proposed combined therapy of massage and moving cup manipulation treatment and the curative effect is analyzed.
   Results: Closed soft tissue injury is a common injury sustained during training and competition of martial arts sport. Combined therapy of massage and moving cup manipulation can effectively relieve soft tissue injury and prolong the athletes' career.
   Conclusion: Prior to training sessions and competitions, athletes should warm-up to avoid severe injuries and stay healthy.
C1 [Jiang Guiping] Harbin Univ, Sch Phys Educ, Harbin 150086, Heilongjiang, Peoples R China.
RP Jiang, GP (corresponding author), Harbin Univ, Sch Phys Educ, Harbin 150086, Heilongjiang, Peoples R China.
EM guiping_jiang_2016@163.com
CR Ali MA, 2016, SAUDI J BIOL SCI, V23, P229, DOI 10.1016/j.sjbs.2015.02.010
   Azra MN, 2016, SAUDI J BIOL SCI, V23, P257, DOI 10.1016/j.sjbs.2015.03.011
   Fang Yuan, 2015, FREE COMBAT SPORTS F
   Huang Zhenhua, 2011, FREE COMBAT MARTIAL, V4, P66
   Kalpana D, 2016, SAUDI J BIOL SCI, V23, P24, DOI 10.1016/j.sjbs.2015.02.004
   Lin Z, 2015, J PURE APPL MICROBIO, V9
   Liu XH, 2017, BIOMED RES-INDIA, V28, P2990
   Ma Chuanju, 2014, CONT SPORTS TECHNOLO, V14, P21
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P667, DOI 10.19193/03936384_2017_4_100
   Mohammad AM, 2017, ARAB J CHEM, V10, P683, DOI 10.1016/j.arabjc.2014.12.016
   Ren Lihong, 2011, COMBAT SPORT SPORT F, V13, P92
   Srivalli KMR, 2016, SAUDI PHARM J, V24, P386, DOI 10.1016/j.jsps.2014.04.007
   Tibpromma S, 2016, SAUDI J BIOL SCI, V23, P1, DOI 10.1016/j.sjbs.2015.01.018
   Wang Y, 2015, CLUSTER COMPUT, V18, P507, DOI 10.1007/s10586-015-0428-x
   Zhang JW, 2015, J COASTAL RES, P228, DOI 10.2112/SI73-040.1
   Zhou R, 2015, J COASTAL RES, P600, DOI 10.2112/SI73-104.1
NR 16
TC 0
Z9 0
U1 1
U2 12
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 3
BP 1305
EP 1308
DI 10.19193/0393-6384_2017_3s_201
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AC
UT WOS:000424878100003
DA 2022-07-14
ER

PT J
AU Jiang, SY
AF Jiang, Suyi
TI PROPHYLACTIC EFFECT OF STRENGTH TRAINING METHOD ON HURDLE ANKLE INJURY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Strength Training; Hurdle Movement; Ankle Injury; Prophylactic Effect
AB Objective: Questionnaire on athletes' ankle injury in hurdle sport with focus on strength training method is done. The findings can provide necessary guidance for training & rehabilitation of athletes.
   Method: 2500 cases of hurdle athletes from different teams with ankle injury from June 2013 to June 2015 were reviewed. The causes of these injuries were analyzed and appropriate prevention as well as treatments were determined. These findings can help in preventing severe injuries during training and improve teaching methods in hurdle sport.
   Results: Necessary rehabilitation programs with strength training method can prevent these ankle injuries as well as improve recovery, physical fitness and training quality of the athletes.
   Discussion: In the process of ankle injury's repair, hurdler athletes' strength training should be improved. Hurdle athletes, coaches and medical staff should implement science based training to prevent ankle injuries during training and competitions.
C1 [Jiang, Suyi] Hohai Univ, Dept Phys Educ, Nanjing 210098, Jiangsu, Peoples R China.
RP Jiang, SY (corresponding author), Hohai Univ, Dept Phys Educ, Nanjing 210098, Jiangsu, Peoples R China.
EM dfheju@163.com
CR Gao W, 2012, J CHANGCHUN U SCI TE, V11, P95
   Gao W, 2017, SAUDI PHARM J, V25, P548, DOI 10.1016/j.jsps.2017.04.021
   Gao W, 2017, SAUDI J BIOL SCI, V24, P132, DOI 10.1016/j.sjbs.2016.09.001
   He Qing, 2010, MOVEMENT, V13, P11
   Hussain S, 2017, PAK J PHARM SCI, V30, P773
   Li Guojun, 2012, SHANXI SPORTS SCI TE, V6, P17
   Liu Y, 2017, BIOMED RES-INDIA, V28, P2975
   Lu JQ, 2016, SAUDI J BIOL SCI, V23, pS22, DOI 10.1016/j.sjbs.2015.06.012
   Lv Feng, 2013, TRAINING CHARACTERIS, V30
   Ragab MH, 2016, SAUDI PHARM J, V24, P429, DOI 10.1016/j.jsps.2014.06.009
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Xu Chen, 2015, TRACK FIELD, V21, P23
   Xu Shuli, 2011, J CHENGDU SPORT U, V35, P78
   Yang Wenxue, 2011, J BEIJING SPORT U, V22, P109
   Yu J, 2014, J NANOMATER, V2014, DOI 10.1155/2014/313674
   Yu Jing, 2014, J NANJING I PHYS ED, V25, P75
   Zhang Yaoshan, 2012, CONT SPORTS TECHNOLO, V9
NR 17
TC 0
Z9 0
U1 3
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 3
BP 1301
EP 1304
DI 10.19193/0393-6384_2017_3s_200
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AC
UT WOS:000424878100002
DA 2022-07-14
ER

PT J
AU Jiang, ZC
   Hong, WD
AF Jiang, Zhengcai
   Hong, Wandong
TI 5-ASA IS NO USE FOR PREVENTION OF DIARRHEA DUE TO ACUTE RADIATION
   ENTERITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE 5-aminosalicylic acid; Radiation Enteritis; Diarrhea
ID DOUBLE-BLIND; TRIAL
AB Introduction: It was controversial that whether the use of 5-ASA was associated with a decrease in the incidence of diarrhea due to radiation therapy. Materials and methods: A comprehensive search of several databases was carried out. A random-effect model was used to pool the data. Results: Five randomized controlled trials were enrolled. Compared with placebo, the use of 5-ASA was not associated with a decrease in the incidence of diarrhea (OR= 0.97; 95% CI: 0.62, 1.52) or severe diarrhea (OR= 0.71; 95% CI: 0.19, 2.58) Conclusion: 5-ASA did not decrease the incidence of diarrhea due to radiation therapy.
C1 [Jiang, Zhengcai] Wenzhou Med Univ, Dept Surg, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China.
   [Hong, Wandong] Wenzhou Med Univ, Dept Gastroenterol & Hepatol, Affiliated Hosp 1, 2 Fu Xue Rd, Wenzhou 325000, Zhejiang, Peoples R China.
RP Hong, WD (corresponding author), Wenzhou Med Univ, Dept Gastroenterol & Hepatol, Affiliated Hosp 1, 2 Fu Xue Rd, Wenzhou 325000, Zhejiang, Peoples R China.
CR Baughan C A, 1993, Clin Oncol (R Coll Radiol), V5, P19, DOI 10.1016/S0936-6555(05)80689-2
   Jahraus CD, 2005, INT J RADIAT ONCOL, V63, P1483, DOI 10.1016/j.ijrobp.2005.04.032
   Kilic D, 2000, RADIOTHER ONCOL, V57, P125, DOI 10.1016/S0167-8140(00)00254-1
   Martenson JA, 1996, INT J RADIAT ONCOL, V35, P299, DOI 10.1016/0360-3016(96)00016-8
   Resbeut M, 1997, RADIOTHER ONCOL, V44, P59, DOI 10.1016/S0167-8140(97)00064-9
NR 5
TC 0
Z9 0
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 399
EP 400
DI 10.19193/0393-6384_2017_3_057
PG 2
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200005
DA 2022-07-14
ER

PT J
AU Kalantari, N
   Taghynejad, M
   Gholamalizadeh, M
   Torkaman, M
   Doaei, S
   Oraz, N
AF Kalantari, Naser
   Taghynejad, Maryam
   Gholamalizadeh, Maryam
   Torkaman, Mahdie
   Doaei, Saeid
   Oraz, Nadia
TI FOOD GROUP INTAKE AND CD4 CELL COUNTS IN HIV INFECTED PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE AIDS; food group intake; CD4 cell counts; Nutritional status
AB Introduction: AIDS or acquired immune deficiency syndrome is a type of disease in the immune system due to infection by immune deficiency virus (HIV). This disease is classified based on the number of CD4 (cluster of differentiation 4) cells in blood.
   Objectives: The aim of this study was to investigate relationship between food group intake and improvement in health status of AIDS patients in Tehran, Iran.
   Methods: 123 persons with AIDS were selected randomly at four behavioral health specialist centers in Tehran. The personal information was collected by general information questionnaires, and information about food group intake for each person and his family was collected by household food group intake security valid questionnaire; also CD4 cell counts was obtained from medical records of each patient. The relationship between food insecurity and CD4 cells count in patients with HIV infection was evaluated by linear regression method.
   Results: 83 percent of the participants in this study had inadequate intake of meat group and 67.5 percent of them had inadequate intake of fruits and vegetables group. Inadequate intake of food group was significantly related to CD4 cell counts (P= 0.001).
   Conclusion: The results suggest that food group intake of AIDS patients is related to CD4 cell counts; and improvement in the nutritional state of AIDS patients may help to prevent deterioration of their condition.
C1 [Kalantari, Naser] Shahid Beheshti Univ Med Sci, Dept Nutr & Food Sci, Tehran, Iran.
   [Taghynejad, Maryam; Doaei, Saeid] Shahid Beheshti Univ Med Sci, Natl Nutr & Food Technol Res Inst, Fac Nutr Sci & Food Technol, Students Res Comm, Tehran, Iran.
   [Gholamalizadeh, Maryam] Shahid Beheshti Univ Med Sci, Canc Res Ctr, Students Res Comm, Tehran, Iran.
   [Torkaman, Mahdie] Islamic Azad Univ, Sci & Res Branch, Dept Chem Engn, Tehran, Iran.
   [Oraz, Nadia] Tarbit Modares Univ, Food Sci & Technol Dept, Tehran, Iran.
RP Doaei, S (corresponding author), Shahid Beheshti Univ Med Sci, Natl Nutr & Food Technol Res Inst, Fac Nutr Sci & Food Technol, Students Res Comm, Tehran, Iran.
RI kalantari, naser/AAA-2857-2022; Doaei, Saeid/X-6425-2018
OI Doaei, Saeid/0000-0002-2532-7478
FU Students' Research Committee of Shahid Beheshti University of Medical
   Sciences [5730]
FX This study was funded by the Students' Research Committee of Shahid
   Beheshti University of Medical Sciences (grant #5730). We acknowledge
   all the staff Behavioral consulting centers of Tehran and the
   participants for their excellent cooperation.
CR Alimoradi1 Zainab, 1393, J SHAHID BEHESHTI SC, V87, P63
   Anema A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061277
   Hossieni F, 2010, J EPIDEMIOL, V83, P2
   Normen L, 2005, J NUTR, V135, P820, DOI 10.1093/jn/135.4.820
   Rahmati F, 2011, PAYRSH J, V2, P205
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Sharp PM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006841
   Tsai AC, 2011, SOC SCI MED, V73, P1717, DOI 10.1016/j.socscimed.2011.09.026
   US Center for Disease Control and Prevention, 2021, END HIV EP COMM INV
   Wang E, 2011, JGIM, V5, P1012
   Weiser SD, 2011, AM J CLIN NUTR, V94, p1729S, DOI 10.3945/ajcn.111.012070
   Weiser SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010340
   World Health Organization (WHO), 2014, MAT NEWB CHILD AD HL
NR 13
TC 1
Z9 1
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 151
EP 155
DI 10.19193/0393-6384_2017_1_023
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800023
DA 2022-07-14
ER

PT J
AU Karabulut, M
   Afsar, CU
   Karabulut, S
   Peker, KD
   Gemici, E
   Dagoglu, N
   Karaman, S
   Yasasever, CT
   Tas, F
AF Karabulut, Mehmet
   Afsar, Cigdem Usul
   Karabulut, Senem
   Peker, Kivanc Derya
   Gemici, Eyup
   Dagoglu, Nergiz
   Karaman, Sule
   Yasasever, Ceren Tilgen
   Tas, Faruk
TI SERUM INTERLEUKIN-32 (IL-32) LEVELS MAY HAVE DIAGNOSTIC AND PROGNOSTIC
   ROLES IN PATIENTS WITH PANCREATIC ADENOCARCINOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE IL-32; diagnostic; pancreatic adenocancer; prognostic; serum
ID NF-KAPPA-B; TUMOR PROGRESSION; CARCINOMA-CELLS; CANCER; EXPRESSION;
   GROWTH; MIGRATION; SUSCEPTIBILITY; POLYMORPHISMS; INFLAMMATION
AB Background: Pancreatic adenocarcinoma (PA) is a very lethal malignancy. Different parameters have been found to be predictive and prognostic. This study was conducted to investigate the serum levels of interleukin-32 (IL-32) in patients with PA and the relationship with tumor progression and known prognostic parameters.
   Materials and methods: Thirty-three patients with PA were investigated. Blood samples were obtained from patients with PA at first admission, one month after surgery and two weeks before adjuvant or palliative treatment. Age and sex matched 30 healthy controls were included in the analysis. Serum IL-32 levels were determined using enzyme-linked immunosorbent assay (ELISA).
   Results: The median age at diagnosis was 59 years, range 32-84 years; 20 (61%) patients were men. The tumor was located in the head of the pancreas in 21 (63%) patients. The most common metastatic site was liver in 23 patients with metastasis (n = 19, 83%). The median follow-up time was 26.0 weeks (range: 1.0-184.0 weeks). At the end of the observation period, thirty-two patients (97%) were dead. Thirty-nine percent of 23 metastatic patients who received palliative chemotherapy (CTx) were CTx-responsive. Median overall survival (OS) of the whole group was 41.3 +/- 8.3 weeks [95% confidence interval (CI) = 25-58 weeks]. The baseline serum IL-32 levels were significantly higher in patients with PA than in the control group (p=0.04). Serum IL-32 levels were significantly higher in the patients with liver metastatic disease (p=0.05). Moreover, patients with elevated serum IL-32 concentrations had significantly favorable OS compared with those with lower levels (median 47.2 vs 32.7 weeks, respectively, p = 0.05).
   Conclusion: Despite new therapies; the prognosis of PA is still poor. There is need to find new parameters. Serum levels of IL-32 may be a good diagnostic and prognostic marker for PA according to our data.
C1 [Karabulut, Mehmet; Peker, Kivanc Derya; Gemici, Eyup] Istanbul Bakirkoy Dr Sadi Konuk Educ & Res Hosp, Clin Gen Surg, Istanbul, Turkey.
   [Afsar, Cigdem Usul] Acibadem Bakirkoy Hosp, Clin Med Oncol, Istanbul, Turkey.
   [Karabulut, Senem] Istanbul Bakirkoy Dr Sadi Konuk Educ & Res Hosp, Clin Med Oncol, Istanbul, Turkey.
   [Dagoglu, Nergiz; Karaman, Sule] Istanbul Univ, Inst Oncol, Dept Radiat Oncol, Istanbul, Turkey.
   [Yasasever, Ceren Tilgen] Istanbul Univ, Inst Oncol, Dept Basic Oncol, Istanbul, Turkey.
   [Tas, Faruk] Istanbul Univ, Inst Oncol, Dept Med Oncol, Istanbul, Turkey.
RP Afsar, CU (corresponding author), Acibadem Bakirkoy Hosp, Clin Med Oncol, Istanbul, Turkey.
RI Dagoglu, Nergiz/AAE-7450-2020; Tas, Faruk/AAF-8751-2019; Karaman,
   Sule/AAS-5135-2020; karabulut, senem/AAT-3594-2020; Yasasever, Ceren
   Tilgen/A-6547-2018; Peker, Kivanc Derya Derya/D-8801-2015; Afsar, Cigdem
   Usul/C-3436-2015; Gemici, Eyüp/ABC-5796-2020; Afsar, Cigdem
   Usul/AAA-6103-2021
OI Karaman, Sule/0000-0002-4810-4453; Yasasever, Ceren
   Tilgen/0000-0002-8732-4117; Peker, Kivanc Derya
   Derya/0000-0002-8887-3505; Afsar, Cigdem Usul/0000-0002-3764-7639;
   Afsar, Cigdem Usul/0000-0002-3764-7639
CR Bellone G, 2006, CANCER IMMUNOL IMMUN, V55, P684, DOI 10.1007/s00262-005-0047-0
   Ben-Baruch A, 2006, SEMIN CANCER BIOL, V16, P38, DOI 10.1016/j.semcancer.2005.07.006
   Egberts JH, 2008, CANCER RES, V68, P1443, DOI 10.1158/0008-5472.CAN-07-5704
   Erturk K, 2016, TUMOR BIOL, V37, P405, DOI 10.1007/s13277-015-3829-9
   Farrow B, 2002, SURG ONCOL, V10, P153, DOI 10.1016/S0960-7404(02)00015-4
   Hong JT, 2017, PHARMACOL THERAPEUT, V174, P127, DOI 10.1016/j.pharmthera.2017.02.025
   Ishigami S, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0472-4
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kang YH, 2012, CANCER LETT, V318, P226, DOI 10.1016/j.canlet.2011.12.023
   Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003
   Kollmar O, 2006, ANN SURG ONCOL, V13, P263, DOI 10.1245/ASO.2006.03.096
   Leach SD, 2015, J EXP MED, V212, P284, DOI 10.1084/jem.2123insight1
   Lee HJ, 2012, ONCOL LETT, V3, P490, DOI 10.3892/ol.2011.511
   Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009
   Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87
   Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006
   McCawley LJ, 2001, CURR BIOL, V11, pR25, DOI 10.1016/S0960-9822(00)00038-5
   Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860
   Netea MG, 2005, P NATL ACAD SCI USA, V102, P16309, DOI 10.1073/pnas.0508237102
   Nishida A, 2009, J BIOL CHEM, V284, P17868, DOI 10.1074/jbc.M900368200
   Okada S, 1998, JPN J CLIN ONCOL, V28, P12, DOI 10.1093/jjco/28.1.12
   Paniccia A, 2015, CHINESE J CANCER RES, V27, P376, DOI 10.3978/j.issn.1000-9604.2015.05.01
   Park JS, 2013, CELL ONCOL, V36, P493, DOI 10.1007/s13402-013-0154-4
   Poch B, 2007, LANGENBECK ARCH SURG, V392, P353, DOI 10.1007/s00423-006-0140-7
   Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021
   Seo EH, 2008, J MICROBIOL BIOTECHN, V18, P1606
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI [10.3322/caac.21254, 10.1001/jamaoto.2014.2530, 10.3322/caac.21208, 10.1136/bmj.g1502]
   Sorrentino C, 2009, AM J RESP CRIT CARE, V180, P769, DOI 10.1164/rccm.200903-0400OC
   Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180
   Sunaga N, 2012, INT J CANCER, V130, P1733, DOI 10.1002/ijc.26164
   Tjomsland V, 2011, NEOPLASIA, V13, P664, DOI 10.1593/neo.11332
   Tsai CY, 2014, CLIN CANCER RES, V20, P2276, DOI 10.1158/1078-0432.CCR-13-1221
   Wang SM, 2015, ONCOL LETT, V9, P305, DOI 10.3892/ol.2014.2641
   Wang YW, 2017, BIOMARKERS, V22, P165, DOI 10.1080/1354750X.2016.1252956
   Wu HH, 2015, J EXP MED, V212, P333, DOI 10.1084/jem.20141702
   Yousif NG, 2013, CYTOKINE, V61, P223, DOI 10.1016/j.cyto.2012.09.022
   Yu XZ, 2015, TUMOR BIOL, V36, P5265, DOI 10.1007/s13277-015-3186-8
   Zeng QL, 2014, CYTOKINE, V65, P24, DOI 10.1016/j.cyto.2013.09.017
   Zhang Y, 2015, REV RECENT CLIN TRIA, V10, P317, DOI 10.2174/1574887110666150916142537
NR 39
TC 1
Z9 1
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 613
EP 619
DI 10.19193/0393-6384_2017_4_091
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700012
DA 2022-07-14
ER

PT J
AU Karaca, F
   Afsar, CU
   Almali, N
   Karabulut, S
   Karabulut, M
   Keskin, S
   Akbulut, S
AF Karaca, Feryal
   Afsar, Cigdem Usul
   Almali, Necat
   Karabulut, Senem
   Karabulut, Mehmet
   Keskin, Siddik
   Akbulut, Serkan
TI THE EFFECT OF PRETREATMENT NEUTROPHIL/LEUCOCYTE RATIO ON SURVIVAL IN
   PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL CANCER RECEIVING
   CHEMORADIOTHERAPY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE esophageal cancer; survival; chemotherapy; radiotherapy; neutrophil
ID DEFINITIVE CHEMORADIOTHERAPY; GASTRIC CANCERS; TRIAL; CHEMOTHERAPY;
   CARCINOMA; SURGERY; CISPLATIN; RISK
AB Introduction: Esophageal cancer (EC) is a highly lethal malignancy. The majority of esophageal cancers are squamous cell or adenocarcinomas. Although the incidence of squamous cell carcinoma (SCC) is decreasing in the United States, the incidence of adenocarcinoma arising out of Barrett's esophagus is rising dramatically, although less so in the last few years. Treatment in locally advanced EC (LA-EC) must be multidisciplinary. There are only few factors which affects the prognosis. Our aim was to investigate the prognostic and predictive roles of pretreatment neutrophil/leucocyte (neu/leu) ratios in LA-EC patients receiving chemoradiotherapy (CRT).
   Materials and methods: Sixty patients with non-metastatic EC (youngest 31 years old) who applied to our hospital between 2011 and 2015 were included in this study. Neu/leu ratios were calculated before CRT and after CRT. The Kaplan-Meier method was used for estimating the survival function from lifetime data. In addition, Cox regression model was also used to explore the relationship between the survival of a patient and several explanatory variables.
   Results: There was statistical significance between neu/leu ratio before CRT and OS (p=0.047). One unit increase in neu/leu ratio, increases the probability of being alive 2.725 times (1/0.367). There was statistical significance between neu/leu ratio before CRT and progression-free survival (PFS) (p=0.046). One unit increase in neu/leu ratio, increases the probability of no relapse 3.559 (1/0.281) times. This means that the patients with higher neu/leu ratio before CRT have a lower risk of relapse.
   Discussion and conclusion: Multimodal therapeutic strategies combining chemotherapy, radiation therapy and surgery have been shown to be feasible and to have a positive impact on outcomes by decreasing the risk of locoregional recurrence and often by increasing overall survival. The overall survival (OS) and disease-free survival (DFS) of patients is too short in patients with LA-EC. Our study shows that patients with LA-EC who had higher pretreatment neu/leu ratios have better OS and PFS.
C1 [Karaca, Feryal] Adana Numune Educ & Res Hosp, Dept Radiat Oncol, Adana, Turkey.
   [Afsar, Cigdem Usul] Acibadem Bakirkoy Hosp, Dept Med Oncol, Istanbul, Turkey.
   [Almali, Necat] Van YuzuncuYil Univ, Med Fac, Dept Gen Surg, Van, Turkey.
   [Karabulut, Senem] Bakirkoy Dr Sadi Konuk Educ & Res Hosp, Clin Med Oncol, Istanbul, Turkey.
   [Karabulut, Mehmet] Bakirkoy Dr Sadi Konuk Educ & Res Hosp, Dept Gen Surg, Istanbul, Turkey.
   [Keskin, Siddik] Van YuzuncuYil Univ, Med Fac, Dept Biostat, Van, Turkey.
   [Akbulut, Serkan] Adana Numune Educ & Res Hosp, Dept Gen Surg, Adana, Turkey.
RP Afsar, CU (corresponding author), Acibadem Bakirkoy Hosp, Dept Med Oncol, Istanbul, Turkey.
RI Afsar, Cigdem Usul/AAA-6103-2021; Akbulut, Serkan/T-5710-2018;
   karabulut, senem/AAT-3594-2020; Afsar, Cigdem Usul/C-3436-2015
OI Afsar, Cigdem Usul/0000-0002-3764-7639; Akbulut,
   Serkan/0000-0002-2043-2754; Afsar, Cigdem Usul/0000-0002-3764-7639
CR Allum WH, 2009, J CLIN ONCOL, V27, P5062, DOI 10.1200/JCO.2009.22.2083
   [Anonymous], 2014, ANN SURG, DOI DOI 10.1097/SLA.0000000000000666.
   Conroy T, 2014, LANCET ONCOL, V15, P305, DOI 10.1016/S1470-2045(14)70028-2
   Di Fiore F, 2007, AM J GASTROENTEROL, V102, P2557, DOI 10.1111/j.1572-0241.2007.01437.x
   Engel LS, 2003, J NATL CANCER I, V95, P1404, DOI 10.1093/jnci/djg047
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Gebski V, 2007, LANCET ONCOL, V8, P226, DOI 10.1016/S1470-2045(07)70039-6
   Gholipour C, 2008, DIS ESOPHAGUS, V21, P322, DOI 10.1111/j.1442-2050.2007.00776.x
   Huang LJ, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-180
   Kelsen DP, 2007, J CLIN ONCOL, V25, P3719, DOI 10.1200/JCO.2006.10.4760
   Khushalani NI, 2008, MAYO CLIN PROC, V83, P712
   LEICHMAN L, 1991, SEMIN ONCOL, V18, P64
   Nozoe T, 2001, AM J SURG, V182, P197, DOI 10.1016/S0002-9610(01)00684-5
   Shan L, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-76
   Sobin L. H., 2009, UICC TNM CLASSIFICAT
   Staal EFWC, 2010, BRIT J SURG, V97, P1482, DOI 10.1002/bjs.7175
   Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616
   Wang CY, 2009, RADIOTHER ONCOL, V92, P270, DOI 10.1016/j.radonc.2009.01.002
   Xu YP, 2013, ONCOL LETT, V5, P185, DOI 10.3892/ol.2012.1007
   Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597
   Yeh HL, 2012, FORMOS J SURG, V45, P172, DOI 10.1016/j.fjs.2012.10.001
   Zingg U, 2010, J GASTROINTEST SURG, V14, P462, DOI 10.1007/s11605-009-1113-2
NR 22
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 905
EP 911
DI 10.19193/0393-6384_2017_6_144
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500003
DA 2022-07-14
ER

PT J
AU Karagoz, H
   Erden, A
   Ozer, O
   Cetinkaya, A
   Avci, D
   Gencer, V
   Arik, F
   Kalan, U
   Gorkem, H
   Karaman, H
   Karaman, A
AF Karagoz, Hatice
   Erden, Abdulsamet
   Ozer, Ozerhan
   Cetinkaya, Ali
   Avci, Deniz
   Gencer, Vedat
   Arik, Ferhat
   Kalan, Ugur
   Gorkem, Hasan
   Karaman, Hatice
   Karaman, Ahmet
TI THE ROLE OF BLOOD GROUPS IN NON-ALCOHOLIC FATTY LIVER DISEASE AND
   NON-ALCOHOLIC STEATOHEPATITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ABO; Blood Groups; Non-alcoholic Fatty Liver Disease; Non-alcoholic
   Steatohepatitis
ID PREECLAMPSIA; RISK; SEVERITY; FEATURES; FIBROSIS
AB Introduction: Non-alcoholic fatty liver disease is defined as the accumulation of fat in the liver in the absence of excessive alcohol consumption or other known pathologies and is a spectrum of disease ranging from steatosis (fat infiltration into the liver) to steatohepatitis. Non-alcoholic steatohepatitis is a more severe form of Non-alcoholic fatty liver disease which is characterised by steatosis, lobular inflammation, ballooning, and fibrosis in liver biopsies. In this study, we aimed to investigate any possible relationship between the ABO/Rh blood group system and Non-alcoholic fatty liver disease /Non-alcoholic steatohepatitis, in Turkey.
   Materials and methods: A total of 179 patients with hepatosteatosis from Kayseri Training and Research Hospital between the years 2002-2012 were included in the study. The distributions of blood groups of the patients with Non-alcoholic fatty liver disease were compared with the distribution of blood groups of 17.314 healthy donors. The patients were examined for any association between ABO/Rh blood groups and Non-alcoholic fatty liver disease /Non-alcoholic steatohepatitis, and also for an association between ABO/Rh blood groups and grading.
   Results: Group AB was found to be higher in patients with Non-alcoholic fatty liver disease compared to the control group (p=0.04). The percentage of patients with steatohepatitis was significantly higher in group AB than non-AB blood group (p=0.024). The percentage of patients with steatohepatitis was significantly higher in group grade 3 Non-alcoholic fatty liver disease patients than other two -grade 1 and grade 2 Non-alcoholic fatty liver disease -groups (<0.001).
   Conclusion: To our knowledge, this is the first analysis in the literature that investigates the association between the ABO blood groups and Non-alcoholic fatty liver disease /Non-alcoholic steatohepatitis. This epidemiological study can not explain the mechanism behind the blood group effect but may be a light for future studies.
C1 [Karagoz, Hatice; Karaman, Ahmet] Acibadem Kayseri Hosp, Dept Internal Med, Kayseri, Turkey.
   [Erden, Abdulsamet; Ozer, Ozerhan; Cetinkaya, Ali; Avci, Deniz; Gencer, Vedat; Arik, Ferhat; Kalan, Ugur; Gorkem, Hasan] Kayseri Training & Res Hosp, Dept Internal Med, Kayseri, Turkey.
   [Karaman, Hatice] Kayseri Training & Res Hosp, Dept Clin Pathol, Kayseri, Turkey.
RP Erden, A (corresponding author), Kayseri Training & Res Hosp, Dept Internal Med, Kayseri, Turkey.
RI Karaman, Hatice/AAX-1803-2021; Erden, Abdulsamet/W-2397-2019; ÖZER,
   ÖZERHAN/O-6794-2015; KARAMAN, HATİCE/AAW-2604-2021; Karagöz,
   Hatice/AAP-8029-2020
OI ÖZER, ÖZERHAN/0000-0001-5855-5509; KARAMAN, HATİCE/0000-0002-5250-5663; 
CR Adams LA, 2005, DIABETIC MED, V22, P1129, DOI 10.1111/j.1464-5491.2005.01748.x
   ALSARRAF M, 1974, CANCER-AM CANCER SOC, V33, P574, DOI 10.1002/1097-0142(197402)33:2<574::AID-CNCR2820330237>3.0.CO;2-A
   Anderson EL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140908
   Chandra T, 2012, IRAN J PEDIATR HEMAT, V2, P140
   Corrado RL, 2014, MED CLIN N AM, V98, P55, DOI 10.1016/j.mcna.2013.09.001
   Farhud DD, 2013, IRAN J PUBLIC HEALTH, V42, P1
   Flegel WA, 2013, BLOOD TRANSFUS-ITALY, V11, P6, DOI 10.2450/2012.0250-12
   HAMLYN AN, 1974, GUT, V15, P480, DOI 10.1136/gut.15.6.480
   Hiltunen LM, 2009, THROMB RES, V124, P167, DOI 10.1016/j.thromres.2008.11.012
   JICK H, 1969, LANCET, V1, P539
   Kamil M, 2010, LIBYAN J MED, V5, DOI 10.3402/ljm.v5i0.4847
   Karagoz H, 2015, THER CLIN RISK MANAG, V11, P1613, DOI 10.2147/TCRM.S92294
   Larsen TB, 2005, J THROMB HAEMOST, V3, P300, DOI 10.1111/j.1538-7836.2005.01195.x
   Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
   MAY D, 1973, BMJ-BRIT MED J, V4, P738, DOI 10.1136/bmj.4.5894.738
   MELENDEZ M, 1979, GUT, V20, P288, DOI 10.1136/gut.20.4.288
   Morelli VM, 2005, J THROMB HAEMOST, V3, P183, DOI 10.1111/j.1538-7836.2004.01071.x
   Salomone F, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/153276
   SANKALE M, 1968, PATHOL BIOL, V16, P1071
   Shavakhi A, 2012, J RES MED SCI, V17, P466
   SPINILLO A, 1995, J HUM HYPERTENS, V9, P623
   Stal P, 2015, WORLD J GASTROENTERO, V21, P11077, DOI 10.3748/wjg.v21.i39.11077
   Torres DM, 2012, CLIN GASTROENTEROL H, V10, P837, DOI 10.1016/j.cgh.2012.03.011
   Yang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131664
   ZUCKERMAN A. J., 1966, J MED GENET, V3, P33, DOI 10.1136/jmg.3.1.33
NR 25
TC 2
Z9 2
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 205
EP 210
DI 10.19193/0393-6384_2017_2_030
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700005
DA 2022-07-14
ER

PT J
AU Karakas, D
   Demiroglu, M
AF Karakas, Dursun
   Demiroglu, Murat
TI RARE COMPLICATION AFTER HIP ARTHROSCOPY; GLAUCOMA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Open angle glaucoma; glaucoma crisis; glaucoma after extraocular
   surgery; hip arthroscopy
ID ANGLE-CLOSURE GLAUCOMA; CATARACT; SURGERY
AB Introduction: In the related literature glaucoma appears as a rare complication of general anestesia and several drugs such as adrenergic, both anticholinergic and cholinergic, antidepressant and antianxiety, sulfa-based, and anticoagulant agents. Glaucoma crisis is also a rare complication observed after extraocular surgery.
   Material methods: The patient is 55 years-old, female without preexisting eye complaints. We evaluated the open angle glaucoma crisis developing after hip arthroscopy performed due to right hip labrum tear. The onset of post-arthroscopic symptoms was at 24 hours. The ophtalmological consultation revealed an indication for ocular surgery.
   Discussion: Glaucoma crisis may ocur due to any reason in all extraocular surgeries. Permanent vision loss can be prevented with early diagnosis and treatment. Glaucoma should be considered in patients having postoperative headache, visual disorder, nausea and other eye complaints so that an ophtalmological consultation should follow to enable an immediate treatment.
C1 [Karakas, Dursun] Gisbir Special Hosp, Orthopaed Div, Istanbul, Turkey.
   [Demiroglu, Murat] IstanbulGoztepe Training Hosp, Orthopaed, Istanbul, Turkey.
RP Karakas, D (corresponding author), Care of Caddesi E, Goztepe Arastirma Hastanesi, Istanbul, Turkey.
CR [Anonymous], 1970, BR J OPHTHALMOL, V54, P161
   Ates Halil, 1999, International Ophthalmology, V23, P129, DOI 10.1023/A:1010667502014
   ELDOR J, 1989, ISRAEL J MED SCI, V25, P652
   FAZIO DT, 1985, ARCH OPHTHALMOL-CHIC, V103, P360
   Friedman DS, 2002, OPHTHALMOLOGY, V109, P1902, DOI 10.1016/S0161-6420(02)01267-8
   INOMATA H, 1984, JPN J OPHTHALMOL, V28, P339
   Jampel HD, 2002, OPHTHALMOLOGY, V109, P2215, DOI 10.1016/S0161-6420(02)01439-2
   MAPSTONE R, 1976, BRIT J OPHTHALMOL, V60, P120, DOI 10.1136/bjo.60.2.120
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROSENBERG M, 1981, J ORAL SURG, V39, P945
   Salmon JF, 1999, PROG RETIN EYE RES, V18, P121, DOI 10.1016/S1350-9462(98)00007-X
   VANBUSKI.EM, 1973, AM J OPHTHALMOL, V76, P632, DOI 10.1016/0002-9394(73)90555-2
NR 12
TC 1
Z9 1
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 811
EP 813
DI 10.19193/0393-6384_2017_5_120
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000014
DA 2022-07-14
ER

PT J
AU Khodaii, Z
   Ghaderian, SMH
   Natanzi, MM
AF Khodaii, Zohreh
   Ghaderian, Sayyed Mohammad Hossein
   Natanzi, Mahboobeh Mehrabani
TI PROBIOTIC BACTERIA AGAINST HALITOSIS PRODUCING BACTERIA, IN THE PRESENCE
   OF THE HEP 2 CELLS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Streptococcus mutans; Lactobacillus routeri; probiotic bacteria; HEp-2
   cell
ID LACTOBACILLUS-RHAMNOSUS GG; ORAL MICROBIOME; IN-VITRO; ADHESION; CARIES
AB Background and aim: Streptococcus mutans (S. mutans) is a Gram-positive, bacterium commonly found in the human oral cavity. S. mutans is a significant contributor to tooth decay. The potential application of probiotic bacteria for control and prevention of oral diseases has been the focus of the attention for various health researchers.
   Material and methods: In this study, primarily, we examined the antibacterial activity of Lactobacillus routeri (L. routeri) against S. mutans using the spot agar test. Secondly, the ability of L. routeri to inhibit the adhesion of pathogenic S. mutans to human epidermoid laryngeal (HEp-2) cell line was tested using coincubation assay. In co incubation experiment, both bacteria were added to HEp-2 cells simultaneously and the number of adhered pathogen was counted in the presence and absent of probiotic bacteria.
   Results: The result showed that, the presence of L. routeri decreased S. mutans adhesion by 4-folds.
   Conclusion: In conclusion, probiotic bacteria may prevent colonization of oral cavity by odours producing bacteria: S. mutans.
C1 [Khodaii, Zohreh; Natanzi, Mahboobeh Mehrabani] Alborz Univ Med Sci, Dietary Supplements & Probiot Res Ctr, Karaj, Iran.
   [Khodaii, Zohreh; Natanzi, Mahboobeh Mehrabani] Alborz Univ Med Sci, Dept Biochem Genet & Nutr, Fac Med, Karaj, Iran.
   [Ghaderian, Sayyed Mohammad Hossein] Shahid Beheshti Univ Med Sci, Dept Med Genet, Fac Med, Tehran, Iran.
RP Natanzi, MM (corresponding author), Eshteraki Blvd Baghestan, Karaj 9779453, Iran.
EM Mahboobehmehrabani@yahoo.com
RI ghaderian, sayyed mohammad hossein/O-5566-2019; mehrabani natanzi,
   mahboobeh/O-3489-2017; Khodaii, Zohreh/S-4983-2017
OI ghaderian, sayyed mohammad hossein/0000-0002-2534-071X; mehrabani
   natanzi, mahboobeh/0000-0001-8879-5984; Khodaii,
   Zohreh/0000-0002-8858-1983
CR Bowen WH, 2011, CARIES RES, V45, P69, DOI 10.1159/000324598
   Chaiyasut C, 2012, AFR J MICROBIOL RES, V6, P1658, DOI 10.5897/AJMR10.135
   Chang YC, 2001, ORAL SURG ORAL MED O, V92, P446, DOI 10.1067/moe.2001.116812
   FARZIANPOUR F, 2014, AM J AGR BIOL SCI, V9, P147, DOI DOI 10.3844/AJAB-SSP.2014.147.152
   Hasslof P, 2010, BMC ORAL HEALTH, V10, DOI 10.1186/1472-6831-10-18
   Jenkinson HF, 2011, ENVIRON MICROBIOL, V13, P3077, DOI 10.1111/j.1462-2920.2011.02573.x
   Lebeer S, 2010, BENEF MICROBES, V1, P335, DOI 10.3920/BM2010.0032
   Mehrabani M, 2013, INT J ENTRIC PATHOG, V1, P54
   Nase L, 2001, CARIES RES, V35, P412, DOI 10.1159/000047484
   Organization WH, 2001, HLTH NUTR PROP PROB
   Ouwehand AC, 1999, FEMS MICROBIOL LETT, V177, P35, DOI 10.1111/j.1574-6968.1999.tb13710.x
   Sadoun D., 2014, INT J APPL MICROBIOL, V2, P52
   Smith EG, 2012, J DENT RES, V91, P133, DOI 10.1177/0022034511415415
   Takahashi N, 2011, J DENT RES, V90, P294, DOI 10.1177/0022034510379602
   Twetman S, 2012, Adv Dent Res, V24, P98, DOI 10.1177/0022034512449465
   Wade WG, 2013, PHARMACOL RES, V69, P137, DOI 10.1016/j.phrs.2012.11.006
   Wu CC, 2015, MOL ORAL MICROBIOL, V30, P16, DOI 10.1111/omi.12063
   Yanine N, 2013, CLIN ORAL INVEST, V17, P1627, DOI 10.1007/s00784-013-0990-7
NR 18
TC 3
Z9 3
U1 1
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 301
EP 304
DI 10.19193/0393-6384_2017_2_045
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700020
DA 2022-07-14
ER

PT J
AU Kilic, B
   Demiroglu, M
   Ozkan, FU
   Soylemez, MS
   Turkmen, I
   Saglam, Y
   Ozkan, K
AF Kilic, Bulent
   Demiroglu, Murat
   Ozkan, Feyza Unlu
   Soylemez, Mehmet Salih
   Turkmen, Ismail
   Saglam, Yavuz
   Ozkan, Korhan
TI OSTEOARTHRITIS: CAN IT BE REVERSED? A NEW BIOLOGICAL TREATMENT TECHNIQUE
   FOR TREATING PATIENTS WITH MODERATE TO ADVANCED GONARTHROSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Gonarthrosis; Subchondral drilling; Bone Marrow injection;
   Osteophytectomy
ID KNEE OSTEOARTHRITIS; SUBCHONDRAL BONE; JOINT LAVAGE; RISK-FACTORS;
   CARTILAGE; TKA; HIP
AB Osteoarthritis of the knee is leading cause of disability in the elderly, all times. Although there are pharmacological and nonpharmacological treatment methods, these are generally insufficient to alleviate pain and the disability in advanced cases Although total knee arthroplasty improves quality of life and provides a generally high level of patient satisfaction for treatment of advanced gonarthrosis, it is not always without complications. Herein we present a new technique consisting of patellofemoral joint irrigation, simple osteophytectomy if needed, lateral patellar retinaculum release, subchondral drilling of the proximal tibia, percutaneous medial collateral ligament release, intra-articular injection of proximal tibial bone marrow, and the results of this treatment applied under local anesthesia in 20 knees of 13 patients. The mean VAS (Visual Analogue Scale) was 8.20 +/- 0.68 prior to treatment and 3.33 +/- 0.72 after treatment; the values were 18.67 +/- 3.34 and 4.10 +/- 3.15 for leg measurements, 7.80 +/- 0.77 and 1.07 +/- 0.96 for pain, 5.07 +/- 2.28 and 1.80 +/- 1.42 for walking, and 5.80 +/- 0.92 and 1.23 +/- 0.92 for daily living activities, respectively. All decreases were statistically significant (p = 0.001 for p < 0.01 in all cases). Biological treatment solutions to gonarthrosis without using foreign materials could decrease the need for prosthetic surgery and its related complications, as well as the need for further attempts at revision. In this study we presented a new biologic treatment for gonarthrosis.
C1 [Kilic, Bulent] Istanbul Gelisim Univ, Dept Hlth Sci, Istanbul, Turkey.
   [Demiroglu, Murat] Istanbul Medeniyet Univ, Goztepe Training & Res Hosp, Dept Orthopaed & Traumatol, Istanbul, Turkey.
   [Ozkan, Feyza Unlu] Fatih Sultan Mehmet Training & Res Hosp, Dept Phys Therapy & Rehabil, Istanbul, Turkey.
   [Soylemez, Mehmet Salih] Bingol State Hosp, Dept Orthopaed & Traumatol, Bingol, Turkey.
   [Turkmen, Ismail] Beykoz State Hosp, Dept Orthopaed & Traumatol, Istanbul, Turkey.
   [Saglam, Yavuz] Biruni Univ, Dept Orthopaed & Traumatol, Fac Med, Istanbul, Turkey.
   [Ozkan, Korhan] Istanbul Medeniyet Univ, Dept Orthopaed & Traumatol, Fac Med, Istanbul, Turkey.
RP Kilic, B (corresponding author), Istanbul Gelisim Univ, Dept Hlth Sci, Istanbul, Turkey.
CR ARNOLDI CC, 1975, J BONE JOINT SURG BR, V57, P360, DOI 10.1302/0301-620X.57B3.360
   ARNOLDI CC, 1994, ACTA ORTHOP SCAND, V65, P5
   Bhosale AM, 2008, BRIT MED BULL, V87, P77, DOI 10.1093/bmb/ldn025
   Bozic KJ, 2014, J BONE JOINT SURG AM, V96A, P640, DOI 10.2106/JBJS.L.01639
   Brandt KD, 2003, OSTEOARTHRITIS
   Davies-Tuck ML, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2911
   de Rezende MU, 2015, ACTA ORTOP BRAS, V23, P162, DOI 10.1590/1413-785220152302145885
   Farnworth L, 2000, ORTHOPEDICS, V23, P146
   Hauser RA, 2013, CLIN MED INSIGHTS-AR, V6, P65, DOI 10.4137/CMAMD.S10951
   Healy WL, 2013, CLIN ORTHOP RELAT R, V471, P215, DOI 10.1007/s11999-012-2489-y
   Higuera CA, 2011, CLIN ORTHOP RELAT R, V469, P1391, DOI 10.1007/s11999-011-1804-3
   Imhof H, 1997, SKELETAL RADIOL, V26, P398, DOI 10.1007/s002560050254
   Iorio R, 2014, CLIN ORTHOP RELAT R, V472, P194, DOI 10.1007/s11999-013-2980-0
   Koh IJ, 2014, CLIN ORTHOP RELAT R, V472, P316, DOI 10.1007/s11999-013-3252-8
   LEQUESNE MG, 1987, SCAND J RHEUMATOL, P85
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Lyu SR, 2008, J BONE JOINT SURG BR, V90B, P1186, DOI 10.1302/0301-620X.90B9.20584
   Moskowitz RW, 2001, OSTEOARTHRITIS DIAGN
   Murphy L, 2012, ORTHOP NURS, V31, P85, DOI 10.1097/NOR.0b013e31824fcd42
   Pan J, 2009, J ORTHOP RES, V27, P1347, DOI 10.1002/jor.20883
   Piedade SR, 2013, KNEE SURG SPORT TR A, V21, P2737, DOI 10.1007/s00167-012-2139-7
   Prakash D, 2002, KNEE, V9, P7, DOI 10.1016/S0968-0160(01)00133-8
   Ravaud P, 1999, ARTHRITIS RHEUM-US, V42, P475, DOI 10.1002/1529-0131(199904)42:3<475::AID-ANR12>3.0.CO;2-S
   Simkin P.A., 2004, NOVART FDN SYMP, V260, P186
   Simkin PA., 2004, NOVART FDN SYMP, V260, P277
   Simkin Peter A, 2004, Novartis Found Symp, V260, P179
   Siow WM, 2013, CLIN ORTHOP RELAT R, V471, P1451, DOI 10.1007/s11999-012-2776-7
   Tanamas SK, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2971
   WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405
   Wluka A, 2007, OSTEOARTHR CARTILAGE, V15, P1437, DOI 10.1016/j.joca.2007.04.010
NR 30
TC 3
Z9 3
U1 2
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 335
EP 340
DI 10.19193/0393-6384_2017_2_050
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700025
DA 2022-07-14
ER

PT J
AU Koca, R
   Eyigor, M
   Osma, U
   Eyigor, H
   Yilmaz, MD
   Selcuk, OT
   Renda, L
   Gultekin, M
AF Koca, Rahime
   Eyigor, Mete
   Osma, Ustun
   Eyigor, Hulya
   Yilmaz, Mustafa Deniz
   Selcuk, Omer Tarik
   Renda, Levent
   Gultekin, Meral
TI SIGNIFICANCE OF INTERLEUKIN-17A AND INTERLEUKIN-23 IN CHRONIC
   RHINOSINUSITIS WITH NASAL POLYPS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Chronic rhinosinusitis; nasal polyposis; IL-17A; IL-23; serum; nasal
   lavage; ELISA
ID EXPRESSION; IL-17; IL-23; SINUSITIS; CYTOKINE; DISTINCT; CHILDREN
AB Introduction: Several previous studies have investigated the significance of interleukin 17 (IL-17) in the pathogenesis of chronic rhinosinusitis with nasal polyposis; however, the importance of IL-23 has not been studied. We investigated the significance of IL-17 and IL-23 in the pathogenesis of by chronic rhinosinusitis with nasal polyposis measuring the levels of these proinflammatory cytokines in serum and nasal lavage samples.
   Materials and methods: Twenty-five patients aged >18 years with chronic rhinosinusitis with nasal polyposis and a control group with 25 healthy subjects were included the study. The levels of IL-17 and IL-23 were measured in the serum and nasal lavage fluids using enzyme-linked immunosorbent assays.
   Results: The average serum level of IL-17 was 10.2 pg/ml in the study group, and it was 5.0 pg/ml in the control group. The average nasal lavage level of IL-17 was 16.8 pg/ml in the study group compared with 1.0 pg/ml in the control group. There were no statistically significant differences between the groups in the serum levels of IL-17 or IL-23; however, a significant difference between the two groups was found in the lavage fluid levels of IL-17 (p < 0.001).
   Conclusion: We found a significant difference in the nasal lavage fluid levels of IL-17, which demonstrates the importance of local inflammation. This supports the hypothesis that IL-17 is significant in the pathogenesis of nasal polyposis.
C1 [Koca, Rahime; Osma, Ustun; Yilmaz, Mustafa Deniz; Selcuk, Omer Tarik; Renda, Levent] Antalya Educ & Res Hosp, Dept ENT Head & Neck Surg, Antalya, Turkey.
   [Eyigor, Mete; Eyigor, Hulya; Gultekin, Meral] Akdeniz Univ, Fac Med, Dept Med Microbiol, Antalya, Turkey.
RP Selcuk, OT (corresponding author), Antalya Educ & Res Hosp, ENT Dept, Antalya, Turkey.
RI Selcuk, Omer/AAJ-3450-2021; Eyigor, Mete/C-1251-2016
OI Selcuk, Omer/0000-0002-7364-7599; 
FU Antalya Education and Research Hospital
FX The study was funded by Antalya Education and Research
   Hospital<SUP>1</SUP>
CR Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1
   Beadling C, 2006, ARCH IMMUNOL THER EX, V54, P15, DOI 10.1007/s00005-006-0002-6
   Bernstein JM, 1995, OTOLARYNG HEAD NECK, V113, P724, DOI 10.1016/S0194-5998(95)70012-9
   Ciprandi G, 2009, ALLERGY, V64, P1375, DOI 10.1111/j.1398-9995.2009.02010.x
   [杜进涛 Du Jintao], 2010, [四川大学学报. 医学版, Journal of Sichuan University. Medical Science Edition], V41, P235
   Fokkens W, 2007, RHINOLOGY S20, V45, P1
   GEORGITIS JW, 1995, INT ARCH ALLERGY IMM, V106, P416, DOI 10.1159/000236875
   HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E
   Hu XD, 2013, J INT MED RES, V41, P777, DOI 10.1177/0300060513478089
   Jacobi HH, 1999, J ALLERGY CLIN IMMUN, V103, P768, DOI 10.1016/S0091-6749(99)70418-5
   Jiang XD, 2011, AM J RHINOL ALLERGY, V25, pE171, DOI 10.2500/ajra.2011.25.3645
   Liu SJ, 2007, J LEUKOCYTE BIOL, V82, P354, DOI 10.1189/jlb.0207111
   Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183
   Makihara S, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.014
   Martines F, 2016, BRAZ J OTORHINOLAR, V82, P215, DOI 10.1016/j.bjorl.2015.04.002
   Martines Francesco, 2014, J Med Case Rep, V8, P282, DOI 10.1186/1752-1947-8-282
   McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698
   Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029
   Molet SM, 2003, LARYNGOSCOPE, V113, P1803, DOI 10.1097/00005537-200310000-00027
   Mucia M, 2015, ACTA MEDICA MEDITERR, V31, P419
   Ono N, 2012, ALLERGY RHINOL, V3, pE50, DOI 10.2500/ar.2012.3.0030
   Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4
   Saitoh T, 2010, INT ARCH ALLERGY IMM, V151, P8, DOI 10.1159/000232566
   Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401
   Shen Y, 2011, SCAND J IMMUNOL, V74, P176, DOI 10.1111/j.1365-3083.2011.02546.x
   Steinke JW, 2004, AM J RESP CELL MOL, V30, P212, DOI 10.1165/rcmb.2003-0071OC
   Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018
   Wakashin H, 2009, INT ARCH ALLERGY IMM, V149, P108, DOI 10.1159/000211382
   Wang M, 2013, CLIN EXP ALLERGY, V43, P956, DOI 10.1111/cea.12123
   Wang X, 2006, ANN OTO RHINOL LARYN, V115, P450, DOI 10.1177/000348940611500609
NR 30
TC 2
Z9 2
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 211
EP 216
DI 10.19193/0393-6384_2017_2_031
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700006
DA 2022-07-14
ER

PT J
AU Komurcu, O
   Avci, A
   Gulen, M
   Ozer, AI
   Kocer, M
   Ulger, H
   Satar, S
AF Komurcu, Ozkan
   Avci, Akkan
   Gulen, Muge
   Ozer, Ali Ilker
   Kocer, Mursel
   Ulger, Huseyin
   Satar, Salim
TI THE PROGNOSTIC ROLE OF MPV AND RDW IN PATIENTS WITH SPONTANEOUS
   INTRACEREBRAL HEMORRHAGE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE MPV; RDW; Haemorrhagic Stroke; Emergency Service
ID CELL DISTRIBUTION WIDTH; MORTALITY; DISEASE; STROKE; RISK; RECEPTOR
AB Aim: Having serious complications and high morbidity and mortality rate, stroke, which can result from ischemic and haemorrhagic causes, is a significant emergency case that requires early diagnosis and treatment. The aim of this study is to identify whether their is a significant relationship between mean value of platelet volume obtained from complete blood cell count of the patients diagnosed with haemorrhagic stroke, corpuscular distribution volume value and bleeding volume value identified in the computed tomography scans of the head.
   Material and method: The sample of the study consisted of all patients aged above 18 and diagnosed with haemorrhagic stroke who applied to Emergency Unit at Adana Numune Education and Research Hospital between 1, June 2014 and 30, July 2016.
   Results: The sample included 86 patients with haemorrhagic stroke. The sample consisted of 58 % (n=50) male and 41,9 % (n=36) female. The mean value for the patients' ages was 60,4 +/- 16,5. Among the patients, 60,5 % (n=52) of them were observed to have applied to the emergency service with sudden clouding of consciousness. A high majority of patients these (79,5 %) were later exitus. The mean value of red cells distribution volume of the patients with exitus was significantly higher than those of surviving patients' (p<0,05). Parenchymal bleeding was observed to exist in 55,8 % (n=48) of the patients. The mortality rate for the patients with high bleeding volume was higher.
   Conclusion: Impaired consciousness, existence of hypertension, high corpuscular distribution and bleeding volume can be among the factors affecting mortality.
C1 [Komurcu, Ozkan] Sehit Kamil State Hosp, Emergency Med Serv, Gaziantep, Turkey.
   [Avci, Akkan; Gulen, Muge; Ozer, Ali Ilker; Ulger, Huseyin; Satar, Salim] Health Sci Univ, Adana Numune Training & Res Hosp, Adana, Turkey.
   [Kocer, Mursel] Balikligol State Hosp, Emergency Serv, Sanliurfa, Turkey.
RP Avci, A (corresponding author), Hlth Sci Univ, Adana Numune Training & Res Hosp, Dept Emergency Med, TR-01240 Adana, Turkey.
CR Akca ASD, 2012, TURK J GERIATR, V15, P151
   Ali SS, 2000, HYPERTENSION COMPANI, P110
   Altintas O, 2017, TURK NEUROSURG, V27, P368, DOI 10.5137/1019-5149.JTN.16136-15.1
   Ani C, 2009, J NEUROL SCI, V277, P103, DOI 10.1016/j.jns.2008.10.024
   Cheung RTF, 2003, STROKE, V34, P1717, DOI 10.1161/01.STR.0000078657.22835.B9
   Cigsar G, 2015, KAFKAS J MED SCI, V5, P6
   DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796
   Eroglu A, 2012, TURK NOROSIRURJI DER, V22, P167
   FIESCHI C, 1988, STROKE, V19, P192, DOI 10.1161/01.STR.19.2.192
   Fukuta H, 2009, INT HEART J, V50, P301, DOI 10.1536/ihj.50.301
   Garcia JH, 1994, INTRACEREBRAL HEMORR, P45
   Gul HL, 2006, THESIS
   Gurol ME., 2010, KLIN GELISIM DERGISI, V23, P19
   Hommel M., 2014, CEREBROVASC DIS, P778
   Kim JA, 1996, BIOCHEM BIOPH RES CO, V27, P58
   Kiyan S, 2009, EURASIAN J EMERG MED, V8, P15, DOI 10.4170/JAEM.2009.46330
   Lopez-Farre A, 2001, NEPHROL DIAL TRANSPL, V16, P45, DOI 10.1093/ndt/16.suppl_1.45
   Mayda DF, 2010, J STROKE CEREBROVASC, V19, P66
   Mozaffarian D, 2016, CIRCULATION, V133, P447, DOI 10.1161/CIR.0000000000000366
   MULLEY GP, 1983, THROMB HAEMOSTASIS, V50, P524
   Naidech AM, 2009, ANN NEUROL, V65, P352, DOI 10.1002/ana.21618
   Nickenig G, 2002, CIRCULATION, V105, P393, DOI 10.1161/hc0302.102618
   NIIZUMA H, 1988, STROKE, V19, P987, DOI 10.1161/01.STR.19.8.987
   Ogihara T, 2002, HYPERTENSION, V40, P872, DOI 10.1161/01.HYP.0000040262.48405.A8
   Ozdemir G, 2002, INTRASEREBRAL HEMORA, P151
   Patel KV, 2010, J GERONTOL A-BIOL, V65, P258, DOI 10.1093/gerona/glp163
   Perlstein TS, 2009, ARCH INTERN MED, V169, P588, DOI 10.1001/archinternmed.2009.55
   Pierce CN, 2005, PERFUSION-UK, V20, P83, DOI 10.1191/0267659105pf793oa
   Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907
   Serebruany VL, 1998, STROKE, V29, P235, DOI 10.1161/01.STR.29.1.235
   STEINER I, 1984, STROKE, V15, P279, DOI 10.1161/01.STR.15.2.279
   Takahashi O, 2006, QJM-INT J MED, V99, P743, DOI 10.1093/qjmed/hcl107
   Unger T, 2002, AM J CARDIOL, V89, p3A
   Uyarel H, 2012, INT J CARDIOL, V154, P351, DOI 10.1016/j.ijcard.2011.10.126
   Wolf PA, 2000, CIRCULATION, V102, P75
   Yilmaz M, 2011, J CLIN EXP INVEST, V2, P404
   Ziai Wendy C, 2003, J Stroke Cerebrovasc Dis, V12, P201, DOI 10.1016/S1052-3057(03)00075-2
NR 37
TC 3
Z9 3
U1 2
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 527
EP 533
DI 10.19193/0393-6384_2017_3_078
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200026
DA 2022-07-14
ER

PT J
AU Kou, GN
   Zhao, Z
   Dong, XY
   Zhang, Y
   Guo, LY
   Zhou, ZQ
AF Kou, Guangning
   Zhao, ZiYan
   Dong, Xin-Ying
   Zhang, Ying
   Guo, Li-Ya
   Zhou, Zhi-Qin
TI EFFECTS OF CITRUS FRUITS ON BLOOD LIPID LEVELS: A SYSTEMATIC REVIEW AND
   META-ANALYSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE citrus fruits; total cholesterol; triglycerides; high-density
   lipoprotein-cholesterol; low-density lipoprotein-cholesterol;
   meta-analysis
ID GAMMA-GLUTAMYL-TRANSFERASE; METABOLIC SYNDROME; OXIDATIVE STRESS; ORANGE
   JUICE; VITAMIN-C; DISEASE; CHOLESTEROL; FLAVONOIDS; CANCER; RISK
AB Background: For management of hyperlipidemia and cardiovascular diseases, total fruit consumption that is increased is used. However, it is still not known if different subtypes like the citruses can play a role that is preventative. The response of the treatment and its magnitude is associated with the citrus in the improvement of the Total Cholesterol (TC), the Tri-glycerides (TG), the High Density Lipoprotein-Cholesterol (HDL-C), and the Low Density Lipoprotein-Cholesterol (LDL-C) which has not, until now been quantified systematically.
   Method: The core objective of our analysis is t reviewing and conducting of the quantitative analyses of these studies which are evaluated for the effects of the ingestion of citrus into the blood lipid parameters. There are pertinent studies that are identified using a systematically proceeded PubMed search, and also the EMBASE of the China National Knowledge Infrastructure and the Cochrane Library until March 2017. The quality of study has been assessed by means of using a modified Jadad scale. These results were viewed on the basis of mean differences (WMD) with a confidence interval (CI) of 95% by making use of an unplanned impacts model.
   Results: Randomized controlled testing with 7 in number having 282 participants had been included. According to the analysis a citrus fruit intake was significant in reducing TC (-5.18 mg/dL, 95% CI:-10.21 to -0.14, p=0.04) and LDL-C (-7.64 mg/dL, 95% CI:-12.27 to -3.01, p=0.001) in the participants, but the other lipid indexes were not significantly altered.
   Conclusion: The results showed that in taking the citric fruitescan reduce the TC and the LDL-C and the effect and the size were moderate remaining ineffective on the HDL-C and the TG levels.
C1 [Zhao, ZiYan; Dong, Xin-Ying; Zhou, Zhi-Qin] Southwest Univ, Coll Hort & Landscape Architecture, Chongqing, Peoples R China.
   [Kou, Guangning; Zhao, ZiYan; Dong, Xin-Ying; Zhou, Zhi-Qin] Chongqing Southwest Inst Fruits Nutr, Chongqing, Peoples R China.
   [Zhang, Ying] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Guo, Li-Ya] Southwest Univ, Coll Sport Sci & Educ, Chongqing, Peoples R China.
RP Zhou, ZQ (corresponding author), Southwest Univ, Coll Hort & Landscape Architecture, Chongqing, Peoples R China.; Zhou, ZQ (corresponding author), Chongqing Southwest Inst Fruits Nutr, Chongqing, Peoples R China.
EM zhouzhiqin@swu.edu.cn
FU Chongqing programme [2017-4-4]; National Risk Assessment Program for
   Agricultural Products Quality and Safety [GJFP201601501]; Fundamental
   Research Funds for the Central Universities [XDJK2017D087]
FX The work had its financial assistance from Chongqing programme to
   produce citrus fruit which mature lately (No. 2017-4-4); National Risk
   Assessment Program for Agricultural Products Quality and Safety
   (GJFP201601501); Fundamental Research Funds for the Central Universities
   (XDJK2017D087).
CR Abdel-Maksoud M, 2008, J CARDIOVASC PHARM, V51, P331, DOI 10.1097/FJC.0b013e318165e2e7
   Amiot MJ, 2016, OBES REV, V17, P573, DOI 10.1111/obr.12409
   Aptekmann NP, 2010, MATURITAS, V67, P343, DOI 10.1016/j.maturitas.2010.07.009
   Arabbi PR, 2004, J AGR FOOD CHEM, V52, P1124, DOI 10.1021/jf0499525
   Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12
   Cesar TB, 2010, NUTR RES, V30, P689, DOI 10.1016/j.nutres.2010.09.006
   Chambial S, 2013, INDIAN J CLIN BIOCHE, V28, P314, DOI 10.1007/s12291-013-0375-3
   Charleux JL, 1996, NUTR REV, V54, pS109, DOI 10.1111/j.1753-4887.1996.tb03829.x
   Charlton-Menys V, 2008, EXP PHYSIOL, V93, P27, DOI 10.1113/expphysiol.2007.035147
   Chen X., 2011, FOOD SCI TECNOLOGY, V36, P66
   Chun OK, 2007, J NUTR, V137, P1244, DOI 10.1093/jn/137.5.1244
   Dahlof Bjorn, 2010, Am J Cardiol, V105, p3A, DOI 10.1016/j.amjcard.2009.10.007
   Dourado GKZS, 2015, FOOD NUTR RES, V59, DOI 10.3402/fnr.v59.28147
   Ghouri N, 2010, HEPATOLOGY, V52, P1156, DOI 10.1002/hep.23789
   Gokbel H., 2006, EUR J GEN MED, V3, P126
   Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002
   Higgins J., 2009, COCHRANE COLLABORATI
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holt EM, 2009, J AM DIET ASSOC, V109, P414, DOI 10.1016/j.jada.2008.11.036
   Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991
   Kelley DS, 2015, J FUNCT FOODS, V12, P271, DOI 10.1016/j.jff.2014.11.026
   Kim J, 2013, FOOD FUNCT, V4, P258, DOI 10.1039/c2fo30209h
   Kontush A, 2006, NAT CLIN PRACT CARD, V3, P144, DOI 10.1038/ncpcardio0500
   Kris-Etherton PM, 2002, AM J MED, V113, P71, DOI 10.1016/S0002-9343(01)00995-0
   Kurowska EM, 2000, AM J CLIN NUTR, V72, P1095
   Kurowska EM, 2004, LIPIDS, V39, P143, DOI 10.1007/s11745-004-1212-8
   Liu S, 2000, AM J CLIN NUTR, V72, P922
   Manthey JA, 2001, CURR MED CHEM, V8, P135, DOI 10.2174/0929867013373723
   McRae MP, 2008, J CHIROPR MED, V7, P48, DOI 10.1016/j.jcme.2008.01.002
   Morand C, 2011, AM J CLIN NUTR, V93, P73, DOI 10.3945/ajcn.110.004945
   Mulero J, 2012, CLIN NUTR, V31, P372, DOI 10.1016/j.clnu.2011.11.014
   NRC. National Research Council, 2005, DIET REF INT EN CARB
   Onakpoya I, 2017, CRIT REV FOOD SCI, V57, P602, DOI 10.1080/10408398.2014.901292
   Oremus M, 2001, DEMENT GERIATR COGN, V12, P232, DOI 10.1159/000051263
   Robertson L, 2007, J INTERN MED, V262, P659, DOI 10.1111/j.1365-2796.2007.01861.x
   Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046
   Roza JM, 2007, ALTERN THER HEALTH M, V13, P44
   Ruhl CE, 2009, GASTROENTEROLOGY, V136, P477, DOI 10.1053/j.gastro.2008.10.052
   Sabharwal AK, 2008, MOL CELL BIOCHEM, V309, P125, DOI 10.1007/s11010-007-9650-z
   Simpson EJ, 2016, FOOD FUNCT, V7, P1884, DOI [10.1039/C6FO00039H, 10.1039/c6fo00039h]
   Targher G, 2010, CLIN CHEM LAB MED, V48, P147, DOI 10.1515/CCLM.2010.031
   Tchoua U, 2010, ATHEROSCLEROSIS, V209, P430, DOI 10.1016/j.atherosclerosis.2009.10.002
   Tundis R, 2014, CRIT REV FOOD SCI, V54, P225, DOI 10.1080/10408398.2011.581400
NR 43
TC 2
Z9 2
U1 1
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1143
EP 1150
DI 10.19193/0393-6384_2017_6_179
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500038
DA 2022-07-14
ER

PT J
AU Kuscu, F
   Komur, S
   Caglayik, DY
   Ulu, A
   Inal, AS
   Kurtaran, B
   Tasova, Y
   Aksu, HSZ
   Ozkul, A
AF Kuscu, Ferit
   Komur, Suheyla
   Caglayik, Dilek Yagci
   Ulu, Aslihan
   Inal, Ayse Seza
   Kurtaran, Behice
   Tasova, Yesim
   Aksu, Hasan Salih Zeki
   Ozkul, Aykut
TI IS CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS TOPOTYPE IMPORTANT IN THE
   POSSIBILITY OF NOSOCOMIAL TRANSMISSION?
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Crimean-Congo hemorrhagic fever; nosocomial transmission; Phylogenetic
   analysis
ID M-RNA SEGMENT; RIBAVIRIN PROPHYLAXIS; OUTBREAK
AB Introduction: Crimean-Congo hemorrhagic fever (CCHF) is a viral zoonotic disease which is mainly transmitted by tick bite. Contact with blood or body secretions of viremic humans or animals is also among the other modes of transmission. In this study, the serological states in terms of CCHF tested in healthcare workers (HCW) who had had contact with two fatal patients with a diagnosis of CCHF. The relation of the transmission possibility with the phylogenetic analysis of the virus were evaluated.
   Materials and methods: CCHF IgM and IgG were investigated with ELISA one month after contact with index cases in HCW. The contact levels and states of use of personal protective equipment (PPE) were evaluated. Phylogenetic analysis with sequence analysis based on partial sequences of NP coding region was performed for CCHF viruses detected in the index cases.
   Results: CCHF IgM and IgG were found negative in any of 20 healthcare workers some of whom had a history of high-risk contact. The sequence analysis revealed that the viruses found in both patients were identical. Phylogenetic evaluation showed that both viruses have high homology with the viruses which were determined previously in the endemic area in Turkey.
   Conclusion: As in our study, detection of virus topotype with sequence analysis in studies about nosocomial transmission will help to determine if there is a difference between virus subtypes in terms of transmission.
C1 [Kuscu, Ferit; Komur, Suheyla; Ulu, Aslihan; Inal, Ayse Seza; Kurtaran, Behice; Tasova, Yesim; Aksu, Hasan Salih Zeki] Cukurova Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Adana, Turkey.
   [Caglayik, Dilek Yagci] Publ Hlth Inst Turkey, Natl Arbovirus & Viral Zoonoses Reference & Res L, Ankara, Turkey.
   [Caglayik, Dilek Yagci] Marmara Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
   [Ozkul, Aykut] Ankara Univ, Fac Vet Med, Dept Virol, Ankara, Turkey.
RP Kuscu, F (corresponding author), Cukurova Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Adana, Turkey.
RI Kuscu, Ferit/L-2974-2016; Inal, Ayse Seza/B-7367-2016; Taşova,
   Yeşim/H-5871-2018; kömür, süheyla/E-9639-2018; Candevir,
   Aslihan/A-8016-2015; Çağlayık, Dilek Yağcı/AAD-5747-2020; Ozkul,
   Aykut/A-1973-2016; Kurtaran, Behice/E-9577-2018
OI Kuscu, Ferit/0000-0001-5662-8305; Inal, Ayse Seza/0000-0002-1182-7164;
   Candevir, Aslihan/0000-0001-9340-516X; Çağlayık, Dilek
   Yağcı/0000-0003-3473-8073; Ozkul, Aykut/0000-0001-5008-9443; Kurtaran,
   Behice/0000-0002-2081-4664
CR Ahmed AA, 2005, J GEN VIROL, V86, P3327, DOI 10.1099/vir.0.81175-0
   Bente DA, 2010, J VIROL, V84, P11089, DOI 10.1128/JVI.01383-10
   BURNEY MI, 1980, AM J TROP MED HYG, V29, P941, DOI 10.4269/ajtmh.1980.29.941
   Celikbas AK, 2014, EMERG INFECT DIS, V20, P477, DOI 10.3201/eid2003.131353
   Centers for Disease Control (CDC), 1988, MMWR Suppl, V37, P1
   Charrel RN, 2004, CLIN MICROBIOL INFEC, V10, P1040, DOI 10.1111/j.1469-0691.2004.01022.x
   Ergonul O, 2006, LANCET INFECT DIS, V6, P203, DOI 10.1016/S1473-3099(06)70435-2
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Gozel MG, 2013, INT J INFECT DIS, V17, pE1046, DOI 10.1016/j.ijid.2013.05.005
   Guner R, 2014, VECTOR-BORNE ZOONOT, V14, P601, DOI 10.1089/vbz.2013.1546
   Haferkamp S, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-42
   JUKES T H, 1969, P21
   Leblebicioglu H, 2016, ANTIVIR RES, V126, P21, DOI 10.1016/j.antiviral.2015.12.003
   Morikawa S, 2007, COMP IMMUNOL MICROB, V30, P375, DOI 10.1016/j.cimid.2007.07.001
   Oncu Serkan, 2013, Virologica Sinica, V28, P193, DOI 10.1007/s12250-013-3327-4
   Ozdarendeli A, 2008, ARCH VIROL, V153, P37, DOI 10.1007/s00705-007-1056-4
   Ozkaya E, 2010, VIRUS RES, V149, P64, DOI 10.1016/j.virusres.2009.12.014
   Papa A, 2005, J MED VIROL, V75, P466, DOI 10.1002/jmv.20290
   Papa A, 2011, SCAND J INFECT DIS, V43, P225, DOI 10.3109/00365548.2010.540036
   Pshenichnaya NY, 2015, INT J INFECT DIS, V33, P120, DOI 10.1016/j.ijid.2014.12.047
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454
   SULEIMAN MNEH, 1980, LANCET, V2, P939
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/mst197, 10.1093/oxfordjournals.molbev.a040023]
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101
   TIGNOR GH, 1993, ANTIVIR RES, V22, P309, DOI 10.1016/0166-3542(93)90040-P
   Tutuncu EE, 2009, SCAND J INFECT DIS, V41, P377, DOI 10.1080/00365540902882434
   VANEEDEN PJ, 1985, S AFR MED J, V68, P711
   Vorou R, 2007, CURR OPIN INFECT DIS, V20, P495, DOI 10.1097/QCO.0b013e3282a56a0a
   Whitehouse CA, 2004, ANTIVIR RES, V64, P145, DOI 10.1016/j.antiviral.2004.08.001
NR 29
TC 3
Z9 3
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 575
EP 580
DI 10.19193/0393-6384_2017_4_084
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700005
DA 2022-07-14
ER

PT J
AU La Marra, M
   Valenzano, A
   Ruberto, M
   Perrella, R
   Iavarone, A
   Chieffi, S
   Monda, V
   Albano, GD
   Sessa, F
   Marsala, G
   Centofanti, D
   Salerno, M
   Triggiani, AI
   Messina, A
   Caviglia, G
AF La Marra, Marco
   Valenzano, Anna
   Ruberto, Maria
   Perrella, Raffaella
   Iavarone, Alessandro
   Chieffi, Sergio
   Monda, Vincenzo
   Albano, Giuseppe Davide
   Sessa, Francesco
   Marsala, Gabriella
   Centofanti, Domenico
   Salerno, Monica
   Triggiani, Antonio Ivano
   Messina, Antonietta
   Caviglia, Giorgio
TI RETRACTED: THE EFFECTS OF OVERWEIGHT AND OBESITY ON COGNITIVE FUNCTIONS
   AND PSYCHOLOGICAL WELL-BEING (Retracted article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE Obesity; cognitive decline; mood disorders
ID BODY-MASS INDEX; BLOOD-BRAIN-BARRIER; C-REACTIVE PROTEIN; FOLLOW-UP;
   ALZHEIMER-TYPE; INSULIN-RESISTANCE; RISK-FACTORS; DEMENTIA; DEPRESSION;
   CHILDREN
AB Recent findings showed that obesity represent a risk factor to developingbrain illness such as cognitive impairments and psychopathological disorders. Weight increase additively afflicts brain structure of cognitively impaired patients but is linked with poor brain volumes even in healthysubjects. Further, several studies show that subjects with psychiatric disorders are more likely than general population to be obese. Hovewer, the process by which weight gain injures cognitive abilities and psychological well-being remain unclear. In this review we analyze the relationships between obesity andbrain illness and underline the role played by covariates to determine this link.
C1 [La Marra, Marco; Chieffi, Sergio; Monda, Vincenzo; Messina, Antonietta] Univ Campania Luigi Vanvitelli, Sect Human Physiol, Dept Expt Med, Naples, Italy.
   [Valenzano, Anna; Albano, Giuseppe Davide; Sessa, Francesco; Salerno, Monica; Triggiani, Antonio Ivano] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Ruberto, Maria] Univ Campania Luigi Vanvitelli, Dept Med Surg & Dent Specialties, Naples, Italy.
   [Perrella, Raffaella; Caviglia, Giorgio] Univ Campania Luigi Vanvitelli, Dept Psychol, Naples, Italy.
   [Iavarone, Alessandro] AORN Osped Colli, CTO Hosp, Neurol & Stroke Unit, Naples, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Osped Riuniti Foggia, Struttura Complessa Farm, Foggia, Italy.
   [Centofanti, Domenico] Natl Assoc Nutr Sci Specialists, Rome, Italy.
   [Centofanti, Domenico] Italian Soc Aesthet Med, Rome, Italy.
RP Messina, A (corresponding author), Univ Campania Luigi Vanvitelli, Sect Human Physiol, Dept Expt Med, Naples, Italy.; Triggiani, AI (corresponding author), Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
EM ivanotriggiani@gmail.com; ivanotriggiani@gmail.com
RI Messina, Antonietta/AHH-2383-2022; Sessa, Francesco/G-1754-2018;
   SALERNO, MONICA/AAC-1321-2019; MESSINA, ANTONIETTA/K-9366-2016;
   Triggiani, Antonio Ivano/M-6252-2015
OI Messina, Antonietta/0000-0001-8343-432X; Sessa,
   Francesco/0000-0003-0357-8791; SALERNO, MONICA/0000-0002-6410-3960; la
   marra, marco/0000-0001-7488-8493
CR Aksoy A, 2016, ACTA MEDICA MEDITERR, V32, P707, DOI 10.19193/0393-6384_2016_3_78
   Amann B, 2009, J AFFECT DISORDERS, V118, P155, DOI 10.1016/j.jad.2009.01.020
   Amieva H, 2005, BRAIN, V128, P1093, DOI 10.1093/brain/awh451
   Atik D, 2016, ACTA MEDICA MEDITERR, V32, P933, DOI 10.19193/0393-6384_2016_4_112
   Balkan A, 2016, ACTA MEDICA MEDITERR, V32, P669, DOI 10.19193/0393-6384_2016_3_73
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Beydoun MA, 2008, OBES REV, V9, P204, DOI 10.1111/j.1467-789X.2008.00473.x
   BLACK DW, 1992, AM J PSYCHIAT, V149, P227
   Caballero B, 2007, EPIDEMIOL REV, V29, P1, DOI 10.1093/epirev/mxm012
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Cerretani D, 2011, PHARMACOL RES, V64, P517, DOI 10.1016/j.phrs.2011.08.002
   Chieffi S, 2011, CURR TOP PEPT PROTEI, V12, P71
   Chieffi S, 2011, CURR TOPICS PEPTIDE, V12, P65
   Chieffi S, 2013, HORIZON NEUROSCIENCE, V13
   Chieffi S., 2016, JOUNRAL PSYCHIAT, V19, P388, DOI [10.4172/2378-5756.1000388, DOI 10.4172/2378-5756.1000388]
   Chieffi S, 2015, J PSYCHIAT, V18, P297, DOI DOI 10.4172/2378-5756.1000297
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Debette S, 2011, NEUROLOGY, V77, P461, DOI 10.1212/WNL.0b013e318227b227
   den Heijer T, 2010, BRAIN, V133, P1163, DOI 10.1093/brain/awq048
   Elias MF, 2000, ARCH NEUROL-CHICAGO, V57, P808, DOI 10.1001/archneur.57.6.808
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Fewlass DC, 2004, FASEB J, V18, P1870, DOI 10.1096/fj.04-2572com
   Frisardi V, 2010, AGEING RES REV, V9, P399, DOI 10.1016/j.arr.2010.04.007
   Gao JL, 2016, ACTA MEDICA MEDITERR, V32, P551
   Gazdzinski S, 2008, ANN NEUROL, V63, P652, DOI 10.1002/ana.21377
   Ghasemzadeh I, 2016, ACTA MEDICA MEDITERR, V32, P2013
   Glinski J, 2001, OBES SURG, V11, P581, DOI 10.1381/09608920160557057
   Goodman E, 2002, PEDIATRICS, V110, P497, DOI 10.1542/peds.110.3.497
   Gorospe EC, 2007, AGE AGEING, V36, P23, DOI 10.1093/ageing/afl123
   Grimley Evans J, 2003, COCHRANE DATABASE SY, V1
   Gunstad J, 2008, BRAIN RES, V1230, P233, DOI 10.1016/j.brainres.2008.07.045
   Gustafson D, 2004, NEUROLOGY, V63, P1876, DOI 10.1212/01.WNL.0000141850.47773.5F
   Gustafson D, 2003, ARCH INTERN MED, V163, P1524, DOI 10.1001/archinte.163.13.1524
   Hajloo N, 2016, ACTA MEDICA MEDITERR, V32, P1099
   Harvey J, 2006, PROG LIPID RES, V45, P369, DOI 10.1016/j.plipres.2006.03.001
   Hassing LB, 2009, INT J OBESITY, V33, P893, DOI 10.1038/ijo.2009.104
   Ho AJ, 2010, NEUROBIOL AGING, V31, P1326, DOI 10.1016/j.neurobiolaging.2010.04.006
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Iavarone A, 2007, J AUTISM DEV DISORD, V37, P775, DOI 10.1007/s10803-006-0190-2
   Jagust W, 2005, ARCH NEUROL-CHICAGO, V62, P1545, DOI 10.1001/archneur.62.10.1545
   Jahangiri A, 2013, OBESITY, V21, P993, DOI 10.1002/oby.20126
   Jahdi F, 2016, ACTA MEDICA MEDITERR, V32, P1273
   Jalili Z, 2016, ACTA MEDICA MEDITERR, V32, P1971
   Kolotkin RL, 2003, OBES SURG, V13, P371, DOI 10.1381/096089203765887688
   Lan YH, 2016, ACTA MEDICA MEDITERR, V32, P1159
   Lee YH, 2009, NEUROENDOCRINOLOGY, V90, P383, DOI 10.1159/000235555
   Luchsinger JA, 2007, ARCH NEUROL-CHICAGO, V64, P392, DOI 10.1001/archneur.64.3.392
   Maddi SR, 2001, OBES SURG, V11, P680, DOI 10.1381/09608920160558605
   Messina G, 2011, CURR TOPICS PEPTIDE, V12, P77
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Miller AA, 2014, BRAIN BEHAV IMMUN, V42, P10, DOI 10.1016/j.bbi.2014.04.001
   Mitchell NS, 2011, PSYCHIAT CLIN N AM, V34, P717, DOI 10.1016/j.psc.2011.08.005
   Moroz N, 2008, J ALZHEIMERS DIS, V15, P29
   Morrison CD, 2009, BBA-MOL BASIS DIS, V1792, P401, DOI 10.1016/j.bbadis.2008.12.004
   Moscatelli F, 2015, BIOL MED
   Mrak RE, 2009, CLIN NEUROPATHOL, V28, P40
   Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8
   Nguyen JCD, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00375
   Nicosia L, 2016, ACTA MEDICA MEDITERR, V32, P1567, DOI 10.19193/0393-6384_2016_5_130
   Nodari RJ, 2016, ACTA MEDICA MEDITERR, V32, P1015, DOI 10.19193/0393-6384_2016_4_125
   Odegaard JI, 2013, SCIENCE, V339, P172, DOI 10.1126/science.1230721
   Onyike CU, 2003, AM J EPIDEMIOL, V158, P1139, DOI 10.1093/aje/kwg275
   Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921
   Pannacciulli N, 2006, NEUROIMAGE, V31, P1419, DOI 10.1016/j.neuroimage.2006.01.047
   Papageorgiou GM, 2002, OBES SURG, V12, P534, DOI 10.1381/096089202762252307
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870
   Ramos JM, 2016, ACTA MEDICA MEDITERR, V32, P273
   Richardson LP, 2003, ARCH PEDIAT ADOL MED, V157, P739, DOI 10.1001/archpedi.157.8.739
   Rosengren A, 2005, ARCH INTERN MED, V165, P321, DOI 10.1001/archinte.165.3.321
   Salomone F, 2013, STEM CELL RES, V11, P1037, DOI 10.1016/j.scr.2013.07.003
   Serrano-Pozo A, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006189
   Shahrbabaki PM, 2016, ACTA MEDICA MEDITERR, V32, P873
   Shen H, 2016, ACTA MEDICA MEDITERR, V32, P57
   Silay K, 2016, ACTA MEDICA MEDITERR, V32, P123
   Skoog I, 1998, NEUROLOGY, V50, P966, DOI 10.1212/WNL.50.4.966
   Song JU, 2016, ACTA MEDICA MEDITERR, V32, P447
   Taki Y, 2008, OBESITY, V16, P119, DOI 10.1038/oby.2007.4
   Tibullo D, 2013, CURR PHARM DESIGN, V19, P2765, DOI 10.2174/1381612811319150012
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2008, INT J LEGAL MED, V122, P173, DOI 10.1007/s00414-007-0208-0
   Turillazzi E, 2008, VIRCHOWS ARCH, V453, P209, DOI 10.1007/s00428-008-0632-7
   Uluocak N, 2016, ACTA MEDICA MEDITERR, V32, P1029, DOI 10.19193/0393-6384_2016_4_127
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Volti GL, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-62
   Wang QX, 2016, ACTA MEDICA MEDITERR, V32, P501
   Ward MA, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-23
   Whitmer RA, 2008, NEUROLOGY, V71, P1057, DOI 10.1212/01.wnl.0000306313.89165.ef
   World Health Organization, 2011, OB OV FACTSHEET
   Yaffe K, 2007, CURR ALZHEIMER RES, V4, P123, DOI 10.2174/156720507780362191
   Yazdanbakhsh K, 2016, ACTA MEDICA MEDITERR, V32, P2001
   Yu M, 2016, ACTA MEDICA MEDITERR, V32, P1767, DOI 10.19193/0393-6384_2016_6_161
   Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972
NR 100
TC 0
Z9 0
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1225
EP 1231
DI 10.19193/0393-6384_2017_2s_190
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700007
DA 2022-07-14
ER

PT J
AU Lafci, A
   Gokcinar, D
   Ornek, D
   Yilmaz, S
   Dikmen, B
   Un, C
   Kilci, O
   Dag, O
AF Lafci, Ayse
   Gokcinar, Derya
   Ornek, Dilsen
   Yilmaz, Sibel
   Dikmen, Bayazit
   Un, Canan
   Kilci, Oya
   Dag, Osman
TI ADDITION OF FENTANYL TO LEVOBUPIVACAINE DECREASES POSTOPERATIVE PAIN
   DURING ARTHROSCOPIC SHOULDER SURGERY UNDER INTERSCALENE BRACHIAL PLEXUS
   BLOCK
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Arthroscopy; interscalene block; analgesia; fentanyl; addition
ID FEMORAL NERVE BLOCK; LOCAL-ANESTHETICS; CONTROLLED-TRIAL; ANALGESIA;
   ROPIVACAINE; ARTHROPLASTY; PROLONGS
AB Background and Aim: Interscalene brachial plexus block is a common technique used for perioperative pain management in patients undergoing shoulder surgery. This study aimed to determine the analgesic efficacy and hemodynamic effects of the addition of fentanyl to levobupivacaine interscalene brachial plexus block for shoulder surgery.
   Material and methods: This study included 39 patients scheduled to undergo arthroscopic shoulder surgery under general anesthesia. Intraoperative blood pressure (BP) and heart rate (HR) were measured. Patients in group A were administered 10 mL of 2% prilocaine + 13 mL of 0.25% levobupivacaine + 7 mL of 0.09% NaCl, and those in group B were administered 10 mL of 2% prilocaine + 13 mL of 0.25% levobupivacaine + 1 mL of fentanyl (50 mu g) + 6 mL of 0.09% NaCl. Mean arterial BP and HR were recorded before, and then 1, 3, 5, 10, 15, and 20 min after surgical incision. Visual analog scale (VAS) pain score was assessed preoperatively, and 1, 3, 6, 12, and 24 h postsurgery.
   Results: Group A and Group B did not differ significantly in terms of mean arterial BP, and HR did not differ significantly between the 2 groups at any time point. Postoperative VAS pain scores were significantly lower in group B than in group A 1, 3, and 6 h postsurgery.
   Conclusion: Interscalene brachial plexus block performed with the addition of fentanyl improves postoperative pain control.
C1 [Lafci, Ayse; Gokcinar, Derya; Ornek, Dilsen; Dikmen, Bayazit; Un, Canan; Kilci, Oya] Ankara Numune Training & Res Hosp, Dept Anesthesiol, Talatpasa Bulvari 5, TR-06100 Ankara, Turkey.
   [Yilmaz, Sibel] Bursa Cekirge Devlet Hastanesi, Dept Anesthesiol, Bursa, Turkey.
   [Dag, Osman] Hacettepe Univ, Fac Med, Dept Biostat, Ankara, Turkey.
RP Gokcinar, D (corresponding author), Ankara Numune Training & Res Hosp, Dept Anesthesiol, Talatpasa Bulvari 5, TR-06100 Ankara, Turkey.
RI Dag, Osman/S-5379-2016; KILCI, OYA/AAA-2554-2022; Gokcinar,
   Derya/AAC-7710-2019
OI Dag, Osman/0000-0002-1750-8789; Ornek, Dilsen/0000-0002-3300-4839;
   Gokcinar, Derya/0000-0002-0870-2168
CR Alemanno F, 2012, MINERVA ANESTESIOL, V78, P291
   Burlacu Crina L, 2008, Ther Clin Risk Manag, V4, P381
   Casati A, 2003, ANESTH ANALG, V96, P253, DOI 10.1097/00000539-200301000-00051
   Fanelli G, 2001, ACTA ANAESTH SCAND, V45, P590, DOI 10.1034/j.1399-6576.2001.045005590.x
   FLETCHER D, 1994, REGION ANESTH, V19, P183
   Heo BH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004771
   Karakaya D, 2001, REGION ANESTH PAIN M, V26, P434, DOI 10.1053/rapm.2001.24675
   KARDASH K, 1995, REGION ANESTH, V20, P311
   Kean J, 2006, J BONE JOINT SURG BR, V88B, P1173, DOI 10.1302/0301-620X.88B9.17412
   Lee HY, 2012, KOREAN J ANESTHESIOL, V62, P30, DOI 10.4097/kjae.2012.62.1.30
   MACLEAN D, 1988, BRIT J ANAESTH, V60, P136, DOI 10.1093/bja/60.2.136
   Magistris L, 2000, EUR J ANAESTH, V17, P348, DOI 10.1046/j.1365-2346.2000.00685.x
   Nishikawa K, 2000, ANESTH ANALG, V91, P384, DOI 10.1097/00000539-200008000-00028
   Saryazdi Hamid, 2015, Adv Biomed Res, V4, P232, DOI 10.4103/2277-9175.167901
   Sert H, 2011, RENAL FAILURE, V33, P280, DOI 10.3109/0886022X.2011.560502
   Sindjelic RP, 2010, ANESTH ANALG, V111, P234, DOI 10.1213/ANE.0b013e3181e1e9ab
   Tripathi Archana, 2016, J Anaesthesiol Clin Pharmacol, V32, P344, DOI 10.4103/0970-9185.188819
   Tsikas D, 2015, BRIT J CLIN PHARMACO, V79, P1030, DOI 10.1111/bcp.12568
NR 18
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 827
EP 831
DI 10.19193/0393-6384_2017_5_123
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000017
DA 2022-07-14
ER

PT J
AU Lan, LX
   Zhou, Q
   Yang, XH
AF Lan, Lixin
   Zhou, Quan
   Yang, Xiaohui
TI PREPARATION OF VINORELBINE TARTRATE THERMOSENSITIVE LIPOSOMES AND
   MEASUREMENT OF ITS ENCAPSULATION EFFICIENCY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE vinorelbine tartrate; thermosensitive liposomes; preparation and
   encapsulation efficiency
AB Objective: This paper aims to explore the preparation of vinorelbine tartrate (VRT) thermosensitive liposomes and determine its encapsulation efficiency.
   Methods: Preparation of VRT thermosensitive liposomes was carried out by pH gradient method. The VRT content in liposomes was determined by high performance liquid chromatograph (HPLC). Separation of liposomes and free drugs was done with microcolumn centrifugation method. The influence on type of dextrangel and elution solvent as well as eluted volume of vinorelbine tartrate and free drug was closely observed.
   Results: The average particle size and average content of vinorelbine tartrate were (94.8 +/- 1.5) nm, (1.84 +/- 0.04) mg/mL respectively. The dextrangel G-25 was used for preparation of microcolumn, in which 4 cm was the best column height. The elution solvent used was PBS buffer and gradient elution volume method was employed in separation of liposomes and free drugs. The encapsulation efficiency of three batches vinorelbine tartrate were recorded as (95.76 +/- 1.43)%, (91.13 +/- 1.24)% and (94.13 +/- 2.05)%, with respective elution recovery rate at (98.5 +/- 2.41)%, (93.6 +/- 1.85)% and 96.8 +/- 1.67)%.
   Conclusion: Preparation of vinorelbine tartrate is relatively a stable process technology with large drug loading, which resulted in high encapsulation efficiency. Moreover, there are accurate and convenient methods for measurements of content and encapsulation efficiency.
C1 [Lan, Lixin; Zhou, Quan; Yang, Xiaohui] Hunan Chem Vocat Technol Coll, Dept Pharmaceut & Biol Engn, Zhuzhou 412004, Peoples R China.
RP Lan, LX (corresponding author), Hunan Chem Vocat Technol Coll, Dept Pharmaceut & Biol Engn, Zhuzhou 412004, Peoples R China.
EM pgpp44@126.com
CR Ali MA, 2016, SAUDI J BIOL SCI, V23, P229, DOI 10.1016/j.sjbs.2015.02.010
   Attari Z, 2016, SAUDI PHARM J, V24, P57, DOI 10.1016/j.jsps.2015.03.008
   Dash RN, 2016, SAUDI PHARM J, V24, P92, DOI 10.1016/j.jsps.2015.03.004
   Ge SB, 2017, SAUDI J BIOL SCI, V24, P127, DOI 10.1016/j.sjbs.2016.09.005
   Gong Wei, 2014, PHARM J CHINESE PEOP, V11, P107
   Gong Wei, 2014, CHINESE PHARM J, V23, P1036
   Huang Hesong, 2010, CHINESE PHARM J, V24, P1250
   Ji WB, 2017, ACTA MEDICA MEDITERR, V33, P449, DOI 10.19193/0393-6384_2017_3_066
   Murtaza G, 2016, SAUDI PHARM J, V24, P220, DOI 10.1016/j.jsps.2015.03.009
   Ofori-Kwakye K, 2016, SAUDI PHARM J, V24, P82, DOI 10.1016/j.jsps.2015.03.005
   Shiri F, 2016, SAUDI PHARM J, V24, P197, DOI 10.1016/j.jsps.2015.03.012
   Singh G, 2017, ARAB J CHEM, V10, P523, DOI 10.1016/j.arabjc.2015.07.017
   Xie Xiangyang, 2015, HERALD MED, V11, P379
   Yan JM, 2017, BIOMED RES-INDIA, V28, P2997
   Yang Q, 2016, PAK J PHARM SCI, V29, P2163
   Zhang Hongmei, 2014, CHINESE J PHARM, V12, P244
NR 16
TC 1
Z9 1
U1 2
U2 12
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 3
BP 1339
EP 1343
DI 10.19193/0393-6384_2017_3s_209
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AC
UT WOS:000424878100011
DA 2022-07-14
ER

PT J
AU Lavoipierre, V
   Kerbaj, J
   Million, M
   Brouqui, P
AF Lavoipierre, Virginie
   Kerbaj, Jad
   Million, Matthieu
   Brouqui, Philippe
TI HEPATIC MILIARY IN A 36-YEAR-OLD TYPE II DIABETIC, HFE (H63D)
   HETEROZYGOUS PATIENT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Yersinia enterocolitica; hepatic abscesses; hepatic miliary; HFE;
   diabetes mellitus
ID YERSINIA-ENTEROCOLITICA; HEMOCHROMATOSIS; INFECTION; ABSCESSES
AB Introduction: Yersinia enterocolitica is a frequent bacterial cause of gastroenteritis. Extra-intestinal complications are uncommon. We report a case of Yersinia enterocolitica hepatic miliary, leading to diabetes mellitus diagnosis.
   Case presentation: A 36-year-old patient with medical history of untreated mild chronic ulcerative colitis was admitted for persisting fever, pharyngitis and headache without abdominal symptom. Blood tests showed inflammatory syndrome, mild cytolysis and multiple hepatic micro-abscesses were found on abdominal computed tomography. Blood culture returned positive for Yersinia enterocolitica. Patient received five days of intravenous ceftriaxone and gentamicin, then ciprofloxacin for six weeks with good clinical and biological outcome. Patient was also diagnosed with type 2 diabetes. As ferritin level was high, we looked for mutation of HFE gene: patient had heterozygous H63D mutation.
   Conclusion: This case report aims at showing an unusual manifestation of Yersinia enterocolitica infection and underlines the importance of type 2 diabetes rather than iron overload as underlying condition.
C1 [Lavoipierre, Virginie; Kerbaj, Jad; Million, Matthieu; Brouqui, Philippe] Inst Hosp Univ Mediterranee Infect, AP HM, CHU Nord, Pole Malad Infect,Serv Malad Infect, F-13015 Marseille, France.
   [Lavoipierre, Virginie; Kerbaj, Jad; Million, Matthieu; Brouqui, Philippe] Aix Marseille Univ, URMITE, UM63, CNRS 7278,IRD 198,Inserm 1095, F-13005 Marseille, France.
   [Million, Matthieu; Brouqui, Philippe] Inst Hosp Univ Mediterranee Infect, 27 Blvd Jean Moulin, F-13005 Marseille, France.
RP Brouqui, P (corresponding author), Inst Hosp Univ Mediterranee Infect, 27 Blvd Jean Moulin, F-13005 Marseille, France.
RI Brouqui, Philippe/P-5771-2016; Million, Matthieu/F-7693-2011
OI Million, Matthieu/0000-0002-5556-6947
CR Benbrika S, 2005, REV MED INTERNE, V26, P151, DOI 10.1016/j.revmed.2004.05.011
   Bergmann TK, 2001, SCAND J GASTROENTERO, V36, P891, DOI 10.1080/003655201750313450
   Bottone EJ, 1997, CLIN MICROBIOL REV, V10, P257, DOI 10.1128/CMR.10.2.257
   Bottone EJ, 1999, MICROBES INFECT, V1, P323, DOI 10.1016/S1286-4579(99)80028-8
   Carniel E, 1996, J BACTERIOL, V178, P6743, DOI 10.1128/jb.178.23.6743-6751.1996
   Charkraborty A, 2015, PUBLIC HLTH REP, V130, P269
   Dima V F, 1999, Roum Arch Microbiol Immunol, V58, P157
   MILLER VL, 1989, INFECT IMMUN, V57, P121, DOI 10.1128/IAI.57.1.121-131.1989
   Piroth L, 1997, REV MED INTERNE, V18, P932, DOI 10.1016/S0248-8663(97)80112-9
   Rong Y, 2012, AM J EPIDEMIOL, V176, P461, DOI 10.1093/aje/kws126
   TAUXE RV, 1987, LANCET, V1, P1129
   Thomson NR, 2006, PLOS GENET, V2, P2039, DOI 10.1371/journal.pgen.0020206
   Watson GT, 2013, AM J MED, V126, P578, DOI 10.1016/j.amjmed.2013.03.006
   Zaloumis SG, 2015, J GASTROEN HEPATOL, V30, P719, DOI 10.1111/jgh.12804
NR 14
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 959
EP 963
DI 10.19193/0393-6384_2017_6_151
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500010
DA 2022-07-14
ER

PT J
AU Lei, W
   Ping, LS
   Mou, XD
   Jun, L
AF Lei, Wei
   Ping, Liao Su
   Mou, Xing Dan
   Jun, Liu
TI THE EFFECTS OF GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) ON
   FUNCTIONAL REGENERATION OF TRANSECTED FEMORAL NERVE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Femoral nerve injury; Glial cell line-Derived Neurotrophic Factor
   (GDNF); Nerve Regeneration; Functional recovery
ID BINDING NGF-BETA; COLLAGEN SCAFFOLDS; LARYNGEAL MUSCLES; SCHWANN-CELLS;
   REPAIR; CONDUIT; EXPRESSION; PROMOTION; LAMININ; RATS
AB Femoral nerve injury is still a challenge because of the lack of effective treatments. In this research, a new drug delivery system is built, which contains a tube of polylactic acid-trimethylene carbonate (PA-TC) equipped with Glial cell line-Derived Neurotrophic Factor (GDNF) and examined its capability to facilitate functional recovery in femoral nerve injury. At the bottom of the transected femoral nerve in rats, a tube injected with GDNF will be installed. Assessment of functional recovery will be made at the fourth, the eight, and twelfth weeks after injury. Compared with animals remedied by antilogous nerve grafting (p < 0.05), those animals treated with the PA-TC tube loaded with GDNF showed improvement of recovery in muscle action potentials and regenerated fiber area. As a result, we can conclude that drug delivery system which induced nerve regeneration following femoral nerve transaction takes better effects than which induced by antilogous nerve grafting. It is possible to have great potential to be applied in nerve regeneration of femoral nerve transection injury.
C1 [Lei, Wei; Ping, Liao Su; Mou, Xing Dan; Jun, Liu] Huazhong Univ Sci & Technol, Pu Ai Hosp, Dept Hand Surg, Wuhan, Hubei, Peoples R China.
RP Lei, W (corresponding author), Huazhong Univ Sci & Technol, Pu Ai Hosp, Dept Hand Surg, Wuhan, Hubei, Peoples R China.
EM eeplore@163.com
CR Agrawal CM, 1997, J BIOMED MATER RES, V38, P105, DOI 10.1002/(SICI)1097-4636(199722)38:2<105::AID-JBM4>3.0.CO;2-U
   Bozkurt A, 2016, BIOMATERIALS, V75, P112, DOI 10.1016/j.biomaterials.2015.10.009
   Cao JN, 2013, BIOMATERIALS, V34, P1302, DOI 10.1016/j.biomaterials.2012.10.031
   Cao JI, 2011, BIOMATERIALS, V32, P3939, DOI 10.1016/j.biomaterials.2011.02.020
   Chen PR, 2004, BIOMATERIALS, V25, P5667, DOI 10.1016/j.biomaterials.2004.01.052
   Chen YY, 2005, J NEUROPATH EXP NEUR, V64, P613, DOI 10.1097/01.jnen.0000171650.94341.46
   Ciaramitaro P, 2010, J PERIPHER NERV SYST, V15, P120, DOI 10.1111/j.1529-8027.2010.00260.x
   de Boer R, 2011, MICROSURG, V31, P293, DOI 10.1002/micr.20869
   Ding T, 2011, REGEN MED, V6, P437, DOI [10.2217/RME.11.39, 10.2217/rme.11.39]
   Gu XS, 2011, PROG NEUROBIOL, V93, P204, DOI 10.1016/j.pneurobio.2010.11.002
   Ha SW, 2009, CHEM COMMUN, P2881, DOI 10.1039/b902195g
   Hadlock T, 2000, TISSUE ENG, V6, P119, DOI 10.1089/107632700320748
   Hernandez-Morato I, 2014, LARYNGOSCOPE, V124, P2750, DOI 10.1002/lary.24759
   Immerman I, 2014, BULL HOSP JT DIS, V72, P43
   Iorio JA, 2016, CURR REV MUSCULOSKE, V9, P290, DOI 10.1007/s12178-016-9350-y
   Li BC, 2010, J BIOMED MATER RES A, V94A, P769, DOI 10.1002/jbm.a.32727
   Lin H, 2006, J BIOMED MATER RES A, V79A, P591, DOI 10.1002/jbm.a.30862
   Luo ZT, 2014, CHEM COMMUN, V50, P5143, DOI 10.1039/c3cc47512c
   Pattammattel A, 2015, RSC ADV, V5, P59364, DOI 10.1039/c5ra10306a
   Petis S, 2015, CAN J SURG, V58, P128, DOI 10.1503/cjs.007214
   Pierucci A, 2008, TISSUE ENG PT A, V14, P595, DOI 10.1089/tea.2007.0271
   Sun WJ, 2007, J BIOMED MATER RES A, V83A, P1054, DOI 10.1002/jbm.a.31417
   Sun WJ, 2010, J BIOMED MATER RES A, V92A, P887, DOI 10.1002/jbm.a.32445
   Sun WJ, 2009, BIOMATERIALS, V30, P4649, DOI 10.1016/j.biomaterials.2009.05.037
   Sun WJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006180
   Vega-Cordova X, 2010, LARYNGOSCOPE, V120, P1591, DOI 10.1002/lary.21026
   Wood MD, 2013, BIOTECHNOL BIOENG, V110, P1272, DOI 10.1002/bit.24800
   Xu YQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147184
   Yang XN, 2013, BIOMATERIALS, V34, P5606, DOI 10.1016/j.biomaterials.2013.04.018
   Yin P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141973
   Yuan JJ, 2015, J MATER SCI-MATER M, V26, DOI 10.1007/s10856-015-5437-z
NR 31
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1117
EP 1122
DI 10.19193/0393-6384_2017_6_175
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500034
DA 2022-07-14
ER

PT J
AU Leng, FF
   Luo, W
   Jing, YJ
   Li, YL
   Wei, QW
   Yang, MJ
   Wang, YG
   Ebadi, AG
AF Leng, Feifan
   Luo, Wen
   Jing, Yanjun
   Li, Yuanli
   Wei, Qingwei
   Yang, Mingjun
   Wang, Yonggang
   Ebadi, Abdol Ghaffar
TI BIOINFORMATICS ANALYSIS OF FERREDOXIN FROM ACIDITHIOBACILLUS
   FERROOXIDANS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Acidithiobacillus ferrooxidans; Bioinformatics analysis; Electron
   transfer; Interaction network; Tertiary structure
ID FERREDOXIN/THIOREDOXIN SYSTEM; IRON; IDENTIFICATION; PROTEINS; CLUSTER
AB Introduction: Ferredoxin was one of important proteins in Acidithiobacillus ferrooxidans, functioned as electron transfer agents in many important biological reactions. As a crucial protein involved in iron oxidation-reduction and electron transfer, thorough investigation of ferredoxin was of great significance. Aim of the study is to study the structure and function of ferredoxin laid a theoretical foundation for understanding energy accumulation, metabolism and electron transfer of Acidithiobacillus ferrooxidans.
   Materials and methods: Eleven kinds of ferredoxin sequences were downloaded from the NCBI database. Aspects concluding basic physicochemical properties, conserved domain, protein modification, subcellular localization, advanced structures prediction, homology and protein interaction network were predicted on the application of combination of software and online tools.
   Results: The results showed that all proteins were electrically neutral in acidic solution except ACK80487.1. Minority of the proteins (three to eleven) were hydrophilic protein. Majority of the proteins were unstable with exceptions of ACK79455.1 & ACK80389.1. The cytoplasm was the place where they played a part. Through the comprehensive forecast, four proteins were involved in nitrogen fixation reaction; two proteins mainly participated in iron sulfur-cluster assembly; four from eleven took effect in oxidation and reduction reactions; the rest one play a major role in nucleic acid reaction.
   Conclusion: The basic physicochemical properties, the secondary structure and tertiary structure of protein, subcellular localization, signal peptide and transmembrane domain analysis showed the protein was characterized by diversity and implied the complexity of electron transfer and energy mechanism of Acidithiobacillus ferrooxidans
C1 [Leng, Feifan; Luo, Wen; Jing, Yanjun; Li, Yuanli; Wei, Qingwei; Yang, Mingjun; Wang, Yonggang] Lanzhou Univ Technol, Sch Life Sci & Engn, Lanzhou 730050, Gansu, Peoples R China.
   [Ebadi, Abdol Ghaffar] Islamic Azad Univ, Jouybar Branch, Dept Agr, Jouybar, Iran.
RP Leng, FF; Wang, YG (corresponding author), Lanzhou Univ Technol, Sch Life Sci & Engn, Lanzhou 730050, Gansu, Peoples R China.
RI Ebadi, Abdol Ghaffar/AAV-9463-2021
OI Ebadi, Abdol Ghaffar/0000-0003-4472-5866
FU Chinese National Natural Science Foundation [31460032, 81660581]
FX The authors would like to give thanks to the participants, coordinators
   and administrators for their support during the study. This work was
   supported by Chinese National Natural Science Foundation (No. 31460032,
   81660581)
CR Andreozzi S, 2016, METAB ENG, V35, P148, DOI 10.1016/j.ymben.2016.01.009
   Arroyuelo A, 2016, J COMPUT AID MOL DES, V30, P619, DOI 10.1007/s10822-016-9944-x
   BACHOFEN R, 1964, P NATL ACAD SCI USA, V51, P690, DOI 10.1073/pnas.51.4.690
   Badawi M.M., 2016, AM J INFECT DIS MICR, V4, P61, DOI DOI 10.12691/AJIDM-4-3-3
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Buchanan BB, 2002, PHOTOSYNTH RES, V73, P215, DOI 10.1023/A:1020407432008
   Elisabeth G, 1999, PROTEOMICS PROTOCOLS, V112, P531, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]
   Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903
   Gupta Ramneek, 2002, Pac Symp Biocomput, P310
   Kulbe H, 2016, ONCOTARGET, V7, P15648, DOI 10.18632/oncotarget.7255
   Kumari A, 2002, MINER ENG, V15, P103, DOI 10.1016/S0892-6875(01)00209-6
   Lill R, 2009, NATURE, V460, P831, DOI 10.1038/nature08301
   Liu W, 2013, BIOTECHNOL APPL BIOC, V60, P623, DOI 10.1002/bab.1110
   Mason LJ, 2002, MINER ENG, V15, P795, DOI 10.1016/S0892-6875(02)00118-8
   Payen L, 2015, ANAL BIOANAL CHEM, V407, P6721, DOI 10.1007/s00216-015-8829-5
   Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701
   Reinders J, 2007, BIOMOL ENG, V24, P169, DOI 10.1016/j.bioeng.2007.03.002
   Schurmann P, 2008, ANTIOXID REDOX SIGN, V10, P1235, DOI 10.1089/ars.2007.1931
   Schut GJ, 2009, J BACTERIOL, V191, P4451, DOI 10.1128/JB.01582-08
   Vilella F, 2004, COMP FUNCT GENOM, V5, P328, DOI 10.1002/cfg.406
   Xu XM, 2011, ANTIOXID REDOX SIGN, V15, P271, DOI 10.1089/ars.2010.3259
   Yalcin A., 2012, J FACULTY VET MED, V31, P29
   Yan R, 2015, BBA-PROTEINS PROTEOM, V1854, P1113, DOI 10.1016/j.bbapap.2015.02.002
   Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264
NR 24
TC 3
Z9 3
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1085
EP 1091
DI 10.19193/0393-6384_2017_6_172
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500031
DA 2022-07-14
ER

PT J
AU Li, ZX
   Mi, DH
   Wen, ZZ
AF Li, Zhaoxia
   Mi, Denghai
   Wen, Zhizhen
TI A SYSTEMATIC REVIEW OF THE ASSOCIATION BETWEEN THE INFLAMMATORY
   CYTOKINES POLYMORPHISMS AND CANCER- RELATED FATIGUE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE cancer-related fatigue; inflammatory cytokines; polymorphisms
ID QUALITY-OF-LIFE; SINGLE-NUCLEOTIDE POLYMORPHISMS; BREAST-CANCER;
   LUNG-CANCER; GENE POLYMORPHISMS; SLEEP DISTURBANCE; PROSTATE-CANCER;
   SYMPTOM BURDEN; DEPRESSED MOOD; PAIN SEVERITY
AB Background: Fatigue, which is one of the most common symptoms of cancer, can seriously affect the quality of life and subsequent treatment of patients with cancer. After reviewing the existing literature systematically, we discussed the association between inflammatory cytokine polymorphisms and cancer-related fatigue (CRF).
   Methods: We conducted a search on the association of inflammatory cytokine polymorphisms and cancer-related fatigue in PubMed, ISI Web of Science, the Cochrane Central Register of Controlled Trials, Embase, the Chinese Biomedical Literature Database (CBM), the Chinese Journal Full-text Database (CJFD) and the Wanfang Database. Studies were selected using specific inclusion and exclusion criteria. We finished the manuscript followed the checklist of PRISMA statement.
   Results: We identified 15 studies in the published literature that specifically assessed the association between fatigue and inflammatory cytokine polymorphisms in cancer patients. There were 13 studies exploring positive associations between inflammatory cytokine polymorphisms and CRF. Because of the heterogeneity of these studies in terms of cancer type, cancer-related fatigue measures, diagnosis of CRF, and selection of controls, it was difficult to merge correlation estimates between inflammatory cytokine polymorphisms and cancer-related fatigue for a quantitative review and clear results. Nevertheless, the present review evaluated the gaps of knowledge in this topic to advance CRF research.
   Conclusion: Future efforts should define CRF and select appropriate questionnaires for CRF measures and controls. Publications in this field have focused on single race (e. g. the white) and a few cancer type(e. g. breast and lung cancer). Therefore, additional studies should be performed in other races and cancer types to obtain more convincing evidence. Meanwhile, the development of clear definition and unified questionnaires of CRF is an important avenue for future research.
C1 [Li, Zhaoxia; Mi, Denghai] Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China.
   [Li, Zhaoxia; Mi, Denghai; Wen, Zhizhen] Second Hosp Gansu Prov, Lanzhou, Peoples R China.
RP Mi, DH (corresponding author), Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China.
CR Aouizerat BE, 2015, J PAIN SYMPTOM MANAG, V50, P599, DOI 10.1016/j.jpainsymman.2015.05.008
   Aouizerat BE, 2009, BIOL RES NURS, V11, P27, DOI 10.1177/1099800409333871
   Barsevick A, 2010, QUAL LIFE RES, V19, P1419, DOI 10.1007/s11136-010-9757-7
   Berger AM, 2010, J NATL COMPR CANC NE, V8, P904, DOI 10.6004/jnccn.2010.0067
   Bower JE, 2007, BRAIN BEHAV IMMUN, V21, P251, DOI 10.1016/j.bbi.2006.08.001
   Bower JE, 2013, J CLIN ONCOL, V31, P1656, DOI 10.1200/JCO.2012.46.2143
   Bower JE, 2009, CLIN CANCER RES, V15, P5534, DOI 10.1158/1078-0432.CCR-08-2584
   Carlo-Stella N, 2006, CLIN EXP RHEUMATOL, V24, P179
   Collado-Hidalgo A, 2008, BRAIN BEHAV IMMUN, V22, P1197, DOI 10.1016/j.bbi.2008.05.009
   Curt G A, 2000, Oncologist, V5, P353, DOI 10.1634/theoncologist.5-5-353
   Dhruva A, 2015, BIOL RES NURS, V17, P175, DOI 10.1177/1099800414534313
   Donovan KA, 2013, PSYCHO-ONCOLOGY, V22, P737, DOI 10.1002/pon.3085
   Doong SH, 2015, BIOL RES NURS, V17, P237, DOI 10.1177/1099800414550394
   Fernandez-de-las-Penas C, 2012, BREAST CANCER RES TR, V133, P405, DOI 10.1007/s10549-011-1757-y
   Filler K, 2016, SUPPORT CARE CANCER, V24, P5, DOI 10.1007/s00520-015-2965-5
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   Fung A, 2012, BRAIN RES, V1446, P144, DOI 10.1016/j.brainres.2012.01.061
   Hassan MI, 2003, CYTOKINE, V21, P10, DOI 10.1016/S1043-4666(02)00489-1
   Helmig S, 2011, CYTOKINE, V53, P306, DOI 10.1016/j.cyto.2010.11.018
   Hewlett S, 2011, ARTHRIT CARE RES, V63, pS263, DOI 10.1002/acr.20579
   Jim HSL, 2012, BRAIN BEHAV IMMUN, V26, P1030, DOI 10.1016/j.bbi.2012.03.001
   Kober KM, 2016, J PAIN SYMPTOM MANAG, V52, P695, DOI 10.1016/j.jpainsymman.2016.04.014
   Lyon DE, 2011, J NURS SCHOLARSHIP, V43, P274, DOI 10.1111/j.1547-5069.2011.01406.x
   Miaskowski C, 2010, J PAIN SYMPTOM MANAG, V40, P531, DOI 10.1016/j.jpainsymman.2009.12.006
   Mills PJ, 2005, BIOL PSYCHOL, V69, P85, DOI 10.1016/j.biopsycho.2004.11.007
   Mitchell SA, 2010, PM&R, V2, P364, DOI 10.1016/j.pmrj.2010.03.024
   Neefjes ECW, 2013, ONCOLOGIST, V18, P1135, DOI 10.1634/theoncologist.2013-0076
   Olson K, 2002, QUAL HEALTH RES, V12, P655, DOI 10.1177/104973202129120160
   Piraino B, 2012, BRAIN BEHAV IMMUN, V26, P552, DOI 10.1016/j.bbi.2011.12.009
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Rausch SM, 2010, CANCER-AM CANCER SOC, V116, P4103, DOI 10.1002/cncr.25255
   Reinertsen KV, 2011, BRAIN BEHAV IMMUN, V25, P1376, DOI 10.1016/j.bbi.2011.04.001
   Reyes-Gibby CC, 2008, LANCET ONCOL, V9, P777, DOI 10.1016/S1470-2045(08)70197-9
   Reyes-Gibby CC, 2007, CANCER EPIDEM BIOMAR, V16, P2745, DOI 10.1158/1055-9965.EPI-07-0651
   Reyes-Gibby CC, 2013, SUPPORT CARE CANCER, V21, P3117, DOI 10.1007/s00520-013-1885-5
   Reyes-Gibby CC, 2013, J PAIN SYMPTOM MANAG, V46, P161, DOI 10.1016/j.jpainsymman.2012.07.019
   Reyes-Gibby CC, 2009, CANCER EPIDEM BIOMAR, V18, P2636, DOI 10.1158/1055-9965.EPI-09-0426
   Saligan LN, 2012, BRAIN BEHAV IMMUN, V26, P830, DOI 10.1016/j.bbi.2012.05.004
   Schubert C, 2007, BRAIN BEHAV IMMUN, V21, P413, DOI 10.1016/j.bbi.2006.11.004
   Seyidova-Khoshknabi D, 2011, AM J HOSP PALLIAT ME, V28, P119, DOI 10.1177/1049909110381590
   Shi QL, 2015, CANCER-AM CANCER SOC, V121, P1138, DOI 10.1002/cncr.29154
   Sloan JA, 2012, J CLIN ONCOL, V30, P1699, DOI 10.1200/JCO.2010.34.5629
   Vallance K, 2010, EUR J CANCER, V46, P1848, DOI 10.1016/j.ejca.2010.03.026
   Wang XS, 2015, GYNECOL ONCOL, V136, P446, DOI 10.1016/j.ygyno.2014.10.013
   Weis J, 2011, EXPERT REV PHARM OUT, V11, P441, DOI [10.1586/erp.11.44, 10.1586/ERP.11.44]
   Zhu Y, 2004, CANCER RES, V64, P2251, DOI 10.1158/0008-5472.CAN-03-2800
NR 46
TC 6
Z9 6
U1 2
U2 15
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 41
EP 47
DI 10.19193/0393-6384_2017_1_006
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800006
DA 2022-07-14
ER

PT J
AU Li, ZX
   Zhou, G
   Mi, DH
   Ma, B
   Chen, L
AF Li, Zhaoxia
   Zhou, Gang
   Mi, Denghai
   Ma, Bin
   Chen, Li
TI THE ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR-ALPHA-308G/A POLYMORPHISM
   AND HEPATOCELLULAR CARCINOMA RISK: AN UPDATED META-ANALYSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE HCC; TNF-alpha; polymorphism; meta-analysis
ID ALPHA GENE POLYMORPHISMS; B-VIRUS INFECTION; CHRONIC HEPATITIS-B;
   TNF-ALPHA; IFN-GAMMA; CYTOKINE; PROGRESSION; TGF-BETA-1; CLEARANCE;
   GENOTYPES
AB Objective: To determine more precise estimations for the relationship between TNF-a-308 polymorphism and the risk for HCC through a meta-analysis of the available data.
   Materials and methods: We conducted a search for case-control studies on the association of TNF-a-308 polymorphism with susceptibility to HCC in PubMed, ISI Web of Science, Cochrane Central Register of Controlled Trials, Embase, Chinese Biomedical Literature Database (CBM), Chinese Journal Full-text Database (CJFD) and Wanfang Database. Odds ratios (OR) with 95% confidence intervals (95% CI) were calculated to estimate the strength of the association between TNF-a-308 polymorphism and the risk for HCC.
   Results: 24 studies were identified, including 4,331 HCC patients and 7,254 controls. Our results demonstrated a significant association between TNF-a-308 polymorphism and HCC risk in all genetic models while the control group was HCC-free. Howeve, when removing the data about healthy control, the pooled ORs were significantly decreased in the additive model (AA versus GG) and the allele model (G versus A), even no significant differences were observed in the rest genetic models. In an analysis stratified by ethnicity, increased risks were observed in both Asian and Caucasian populations.
   Conclusion: This meta-analysis suggests that TNF-a-308 GG genotype might decrease the risk of HCC development, specifically among both Asian and Caucasian populations. However, these results should be interpreted with caution because of heterogeneity of control populations. Well-designed studies with appropriate controls, larger sample sizes and more in-depth data are required to confirm this conclusion.
C1 [Li, Zhaoxia; Mi, Denghai] Lanzhou Univ, Clin Med Coll 1, Lanzhou, Gansu, Peoples R China.
   [Li, Zhaoxia; Mi, Denghai] Second Hosp Gansu Prov, Lanzhou, Gansu, Peoples R China.
   [Zhou, Gang] Hosp Gansu Prov, Lanzhou, Gansu, Peoples R China.
   [Ma, Bin] Lanzhou Univ, Sch Basic Sci, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China.
   [Chen, Li] Gansu Univ Tradit Chinese Med, Coll Publ Hlth, Lanzhou, Gansu, Peoples R China.
RP Mi, DH (corresponding author), 222 Tianshui Rd, Lanzhou, Gansu, Peoples R China.
FU Gansu province health department [GSWSKY-2014-14]
FX This work was supported by the funding plan from the Gansu province
   health department (grant numbers: GSWSKY-2014-14).
CR Abraham LJ, 1999, J LEUKOCYTE BIOL, V66, P562, DOI 10.1002/jlb.66.4.562
   Akkiz H, 2009, CANCER EPIDEMIOL, V33, P261, DOI 10.1016/j.canep.2009.06.001
   Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3
   Ben-Ari Z, 2003, AM J GASTROENTEROL, V98, P144, DOI 10.1111/j.1572-0241.2003.07179.x
   Berhane N, 2012, MOL BIOL REP, V39, P11125, DOI 10.1007/s11033-012-2020-2
   Chen CC, 2005, INT J EPIDEMIOL, V34, P1310, DOI 10.1093/ije/dyi191
   Chen XM, 2011, INT J BIOL MARKER, V26, P181, DOI 10.5301/JBM.2011.8580
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Feng H, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0199-3
   Garrity-Park MM, 2008, AM J GASTROENTEROL, V103, P407, DOI 10.1111/j.1572-0241.2007.01572.x
   Giacalone A, 2011, OMICS, V15, P193, DOI 10.1089/omi.2010.0095
   Flores-Ramos LG, 2013, GENET MOL RES, V12, P5680, DOI 10.4238/2013.November.18.17
   Guo YM, 2010, HEPATO-GASTROENTEROL, V57, P926
   Hajeer AH, 2001, HUM IMMUNOL, V62, P1191, DOI 10.1016/S0198-8859(01)00322-6
   Hajeer AH, 2000, MICROSC RES TECHNIQ, V50, P216, DOI 10.1002/1097-0029(20000801)50:3<216::AID-JEMT5>3.0.CO;2-Q
   Heneghan Michael A, 2003, Int J Gastrointest Cancer, V34, P19
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hol SY, 2004, CANCER CAUSE CONTROL, V15, P657, DOI 10.1023/B:CACO.0000036173.99930.75
   Jeng JE, 2007, NEOPLASIA, V9, P987, DOI 10.1593/neo.07781
   Jeng JE, 2009, MEDICINE, V88, P349, DOI 10.1097/MD.0b013e3181c10477
   Jin YJ, 2015, J CLIN GASTROENTEROL, V49, pE76, DOI 10.1097/MCG.0000000000000261
   Kummee P, 2007, J VIRAL HEPATITIS, V14, P841, DOI 10.1111/j.1365-2893.2007.00880.x
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Migita K, 2005, J HEPATOL, V42, P505, DOI 10.1016/j.jhep.2004.11.026
   Ng M H L, 2012, Hong Kong Med J, V18 Suppl 6, P37
   Niro GA, 2005, LIVER INT, V25, P1175, DOI 10.1111/j.1478-3231.2005.01166.x
   Ognjanovic S, 2009, CARCINOGENESIS, V30, P758, DOI 10.1093/carcin/bgn286
   Qin H, 2010, J INT MED RES, V38, P760, DOI 10.1177/147323001003800304
   Radwan MI, 2012, CYTOKINE, V60, P271, DOI 10.1016/j.cyto.2012.05.010
   Sakamoto T, 2008, CANCER LETT, V271, P98, DOI 10.1016/j.canlet.2008.05.036
   Saxena R, 2014, MOL CELL BIOCHEM, V385, P297, DOI 10.1007/s11010-013-1838-9
   Sghaier I, 2015, GENE, V568, P140, DOI 10.1016/j.gene.2015.05.029
   Shi HZ, 2012, ASIAN PAC J CANCER P, V13, P6217, DOI 10.7314/APJCP.2012.13.12.6217
   Shi ZR, 2011, GENET TEST MOL BIOMA, V15, P569, DOI 10.1089/gtmb.2011.0008
   SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149
   Song SF, 2009, J GUANGDONG PHARM CO, V25, P196
   Stankovioc MM, 2009, NEOPLASMA, V56, P348, DOI 10.4149/neo_2009_04_348
   Sugimoto M, 2007, J GASTROEN HEPATOL, V22, P51, DOI 10.1111/j.1440-1746.2006.04442.x
   Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3
   Talaat RM, 2012, CHIN J CANCER, V31, P29, DOI 10.5732/cjc.011.10258
   Teixeira AC, 2013, HUM IMMUNOL, V74, P1024, DOI 10.1016/j.humimm.2013.04.029
   Wang BB, 2010, PATHOLOGY, V42, P674, DOI 10.3109/00313025.2010.523696
   Wang Y, 2003, HEPATOLOGY, V37, P65, DOI 10.1053/jhep.2003.50017
   Wei YG, 2011, DIGEST DIS SCI, V56, P2227, DOI 10.1007/s10620-011-1617-y
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   Yang MD, 2015, ANTICANCER RES, V35, P5417
   Yang Y, 2012, EXP THER MED, V3, P513, DOI 10.3892/etm.2011.418
   Yang Y, 2011, J CANCER RES CLIN, V137, P947, DOI 10.1007/s00432-010-0959-8
NR 49
TC 2
Z9 2
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1007
EP 1015
DI 10.19193/0393-6384_2017_6_160
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500019
DA 2022-07-14
ER

PT J
AU Liao, J
   Deng, YJ
   Ailijiang, ASL
   Liu, ZF
   Meng, QC
   Xiang, WY
   Yu, HC
   Fang, R
AF Liao, Jun
   Deng, Yingjie
   Ailijiang, Asila
   Liu, Zhenfeng
   Meng, Qingcai
   Xiang, Wenyuan
   Yu, Haicheng
   Fang, Rui
TI SHOULDER ARTHROSCOPIC ANCHOR IMPLANTATION AND FIXATION FOR SHOULDER
   JOINT BANKART INJURY CAUSED BY SWIMMING
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Shoulder Arthroscopy; Anchor Implantation and Fixation; Shoulder Joint
   Bankart Injury; Clinical Efficacy
ID STRESS; WATER
AB This study attempted to better understand the clinical efficacy of shoulder arthroscopic anchor implantation and fixation for shoulder joint bankart injury patients, in order to provide a scientific basis guiding the clinical treatment of related diseases. We collected the clinical data of a total of 1025 cases of patients with shoulder joint bankart injury caused by swimming and treated in twenty medical units from January 2014 to December 2015 for a retrospective analysis. All patients voluntarily accepted shoulder arthroscopic anchor implantation and fixation. To further clarify for the effect of treatment, shoulder injury pain degree and athletic ability level of patients before and after treatment were statistically compared. Also, by 6 months' follow-up, stability of the treatment effect was evaluated. The results showed that shoulder arthroscopic anchor implantation and fixation enjoyed very significant effect for shoulder joint bankart injury caused by swimming, with significant improvements in shoulder function scores and pain scores after treatment. Differences before and after treatment were statistically significant (p < 0.05); in addition, after 3 months of treatment, 991 cases of patients had a stable efficacy, without recurring injury and with effective treatment rate at 96.68%; 34 cases of patients had recurrence of shoulder injury, with a recurrence rate at 3.32%. As can be seen from the treatment results, shoulder arthroscopic anchor implantation and fixation showed a significant treatment effect for shoulder joint bankart injury caused by swimming, which can effectively help patients restore joint function, reduce pain in patients, with a high application value and good therapeutic effect.
C1 [Liao, Jun; Deng, Yingjie; Ailijiang, Asila; Liu, Zhenfeng; Meng, Qingcai; Xiang, Wenyuan; Yu, Haicheng; Fang, Rui] Chinese Med Hosp Xinjiang, Dept Orthopaed, Uygur Autonomous Region, Urumqi, Peoples R China.
RP Fang, R (corresponding author), Chinese Med Hosp Xinjiang, Dept Orthopaed, Uygur Autonomous Region, Urumqi, Peoples R China.
EM jndkhkiu@163.com
FU National Natural Science Foundation of China [81160460];  [ZYYBZ2013]
FX National Natural Science Foundation of China (grant 81160460).;
   Postdoctoral Research Fund (No. ZYYBZ2013).
CR Attari Z, 2016, SAUDI PHARM J, V24, P57, DOI 10.1016/j.jsps.2015.03.008
   Cam R, 2015, ACTA MEDICA MEDITERR, V31, P1075
   Dawood KM, 2017, ARAB J CHEM, V10, P473, DOI 10.1016/j.arabjc.2013.06.004
   Halici U, 2015, ACTA MEDICA MEDITERR, V31, P807
   Kumar R, 2016, SAUDI J BIOL SCI, V23, P243, DOI 10.1016/j.sjbs.2015.03.006
   Kuppusamy P, 2016, SAUDI PHARM J, V24, P473, DOI 10.1016/j.jsps.2014.11.013
   Li M, 2015, PAK J PHARM SCI, V28, P1861
   Mohan D, 2016, SAUDI J BIOL SCI, V23, P122, DOI 10.1016/j.sjbs.2015.01.013
   Moussa TAA, 2016, SAUDI J BIOL SCI, V23, P397, DOI 10.1016/j.sjbs.2015.04.013
   Ofori-Kwakye K, 2016, SAUDI PHARM J, V24, P82, DOI 10.1016/j.jsps.2015.03.005
   Sandri A. B. A., 2015, ASIAN PAC J SURG ONC, V1, P113
   Smithers BM, 2015, ASIAN PAC J SURG ONC, V1, P125
   Yang X, 2015, J COASTAL RES, P448, DOI 10.2112/SI73-079.1
   Yang ZC, 2015, J COASTAL RES, P420, DOI 10.2112/SI73-074.1
NR 14
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 3
BP 1309
EP 1312
DI 10.19193/0393-6384_2017_3s_202
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV9AC
UT WOS:000424878100004
DA 2022-07-14
ER

PT J
AU Lo Sasso, B
   Agnello, L
   Florena, AM
   Pappalardo, E
   Milano, S
   Butera, D
   Scazzone, C
   Bivona, G
   Giannone, AG
   Bellia, C
   Ciaccio, M
AF Lo Sasso, Bruna
   Agnello, Luisa
   Florena, Ada Maria
   Pappalardo, Emanuela
   Milano, Salvatore
   Butera, Daniela
   Scazzone, Concetta
   Bivona, Giulia
   Giannone, Antonino Giulio
   Bellia, Chiara
   Ciaccio, Marcello
TI THE CERVICAL FRACTURE AS FIRST SYMPTOM OF MULTIPLE MYELOMA: A CASE
   REPORT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE monoclonal gammopathy; bone lesion; osteolysis; bortezomib; cervical
   spine
ID BINDING LECTIN; POLYMORPHISMS
AB Introduction: Multiple Myeloma (MM) is a clonal disorder characterized by proliferation and accumulation of malignant plasma cells in the bone marrow. Bone disease occurs in approximately 80% of patients with newly diagnosed MM. The cervical spine is the least common site of disease involvement.
   Case presentation: A 60-year-old female patient was referred to the Department of Neurosurgery for bone pain. A magnetic resonance imaging (MRI) scan showed a pathological fracture of the sixth cervical vertebra (C6). The laboratory tests and the bone marrow examination led to a diagnosis of IgA x MM (Durie Salmon stage IIIA). The patient underwent a cervical arthrodesis and started systemic Bortezomib-Thalidomide-Dexamethasone (VTD) combination chemotherapy. During chemiotherapic treatment the patient underwent a vertebroplasty of L4-L5. After 4 VTD cycles, the patient was dismissed showing a very good partial remission (VGPR). Later the patient subjected herself to hematopoietic stem cell transplantation (HSCT) obtaining a complete remission.
   Discussion: We report a clinical case of MM in which the fracture of cervical spine represents the clinical onset. Indeed this clinical presentation is not common in this type of monoclonal gammopathy. This case underlines the importance of suspecting MM in all cases of compromised bone.
C1 [Lo Sasso, Bruna; Agnello, Luisa; Butera, Daniela; Scazzone, Concetta; Bivona, Giulia; Bellia, Chiara; Ciaccio, Marcello] Univ Palermo, Dipartimento Biopatol & Biotecnol Med, Sez Biochim Clin & Med Mol Clin, Palermo, Italy.
   [Florena, Ada Maria; Giannone, Antonino Giulio; Ciaccio, Marcello] Univ Palermo, Dipartimento Sci Promoz Salute & Materno Infantil, Palermo, Italy.
   [Pappalardo, Emanuela; Milano, Salvatore; Ciaccio, Marcello] Azienda Osped Univ Policlin P Giaccone Palermo, Dipartimento Diagnost Lab, CoreLab, UOC Med Lab, Via Vespro Palermo, Palermo, Italy.
RP Ciaccio, M (corresponding author), Univ Palermo, Policlin Univ, Dipartimento Biopatol & Biotecnol Med, Sez Biochim Clin & Med Mol Clin, Via Vespro,129, I-90127 Palermo, Italy.
RI Bellia, Chiara/AAO-3725-2020; Giannone, Antonino Giulio/K-2713-2018;
   scazzone, concetta/J-9541-2018
OI Bellia, Chiara/0000-0003-0611-9363; Giannone, Antonino
   Giulio/0000-0002-1219-627X; scazzone, concetta/0000-0001-7424-8066;
   BIVONA, Giulia/0000-0003-1723-3305
CR Agnello L, 2016, NEUROL SCI, V37, P261, DOI 10.1007/s10072-015-2401-0
   Agnello L, 2016, CLIN BIOCHEM, V49, P47, DOI 10.1016/j.clinbiochem.2015.09.008
   Caruso A, 2014, PHARMACOGN PERS MED, V7, P117, DOI 10.2147/PGPM.S55548
   Dispenzieri A, 2009, LEUKEMIA, V23, P215, DOI 10.1038/leu.2008.307
   Frigui M, 2011, RHEUMATOL REP, V3, P22, DOI 10.4081/rr.2011.e5
   Fuchida S, 2012, INT J HEMATOL, V96, P664, DOI 10.1007/s12185-012-1164-0
   Mehta GR, 2014, DM-DIS MON, V60, P483, DOI 10.1016/j.disamonth.2014.08.002
   Molle I, 2006, EUR J HAEMATOL, V77, P19, DOI 10.1111/j.1600-0609.2006.00669.x
   Novo G, 2015, ANN CLIN LAB SCI, V45, P382
   Petta S, 2012, J VIRAL HEPATITIS, V19, P465, DOI 10.1111/j.1365-2893.2011.01557.x
   Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5
   Rollig C, 2015, LANCET, V385, P2197, DOI 10.1016/S0140-6736(14)60493-1
   Tomaiuolo R, 2012, AGING CELL, V11, P394, DOI 10.1111/j.1474-9726.2012.00793.x
   Tosi P., 2013, SCI CAIRO, V2013
   Zhou WW, 2015, ONCOL LETT, V10, P1171, DOI 10.3892/ol.2015.3294
NR 15
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 535
EP 538
DI 10.19193/0393-6384_2017_3_079
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200027
DA 2022-07-14
ER

PT J
AU Lungu, M
   Romila, A
   Nechita, A
   Tutunaru, D
   Bacarea, A
AF Lungu, Mihaela
   Romila, Aurelia
   Nechita, Aurel
   Tutunaru, Dana
   Bacarea, Anca
TI NEUROLOGICAL MANIFESTATIONS IN THYROIDITIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE thyroiditis; neuropsychiatric manifestations
AB Introduction: A five years prospective study was conducted with the aim to observe the neurological manifestations in acute, subacute and chronic thyroiditis.
   Materials and methods: A study on 26 patients was carried out over the span of 5 years. Clinical and paraclinical examinations were carried out every three months. The paraclinical exam included hormone dosing, ultrasound exams, thyroid scintigraphy, biopsies, brain computed tomography and blood biochemistry tests.
   Results: A large amount of detailed data was collected over a relatively long span of time.
   Conclusions: The collected data largely corresponds to the reference literature. It is often the case that patients first address the neurologist, who has to diagnose the thyroid disease and its neurological manifestations.
C1 [Lungu, Mihaela; Nechita, Aurel; Tutunaru, Dana] Dunarea de Jos Univ Galati, Fac Med & Pharm, Galati, Romania.
   [Lungu, Mihaela] Emergency Clin Hosp, Neurol Dept, Galati, Romania.
   [Romila, Aurelia] Dunarea de Jos Univ Galati, Fac Med & Pharm, Ctr Res Med Pharmaceut, Galati, Romania.
   [Romila, Aurelia] Emergency Cty Hosp, Geriatr Dept, Galati, Romania.
   [Nechita, Aurel] Emergency Hosp Pediat, Pediat Dept, Galati, Romania.
   [Bacarea, Anca] Univ Med & Pharm Targu Mures, Pathophysiol Dept, Targu Mures, Romania.
RP Romila, A (corresponding author), Univ Med & Pharm Dunarea de Jos, Geriatr Dept, Vadu Sacalelor 1,Bl Pescarus,Ap 8, Galati, Romania.
RI LUNGU, MIHAELA/AAD-3727-2019; Bacarea, Anca/AAW-9459-2020
OI LUNGU, MIHAELA/0000-0002-2807-7742; 
CR Aminoff M. J., 1999, CLIN NEUROLOGY
   [Anonymous], 2014, ADAMS VICTORS PRINCI, p[1155, 1358, 1450]
   Duyff RF, 2000, J NEUROL NEUROSUR PS, V68, P750, DOI 10.1136/jnnp.68.6.750
   DYCK PJ, 1970, J NEUROPATH EXP NEUR, V29, P631, DOI 10.1097/00005072-197010000-00008
   Hufschmidt A, 2002, INTEGRAL NEUROLOGY S
   Isselbacher K.J., 1995, MED PRINCIPLES, P599
   Weatherall D.J., 2000, MED TREATY NEUROLOGY, P419
   Zbranca E, 1999, ENDOCRINOLOGY GUIDE, p[26, 69]
NR 8
TC 15
Z9 15
U1 0
U2 13
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 369
EP 376
DI 10.19193/0393-6384_2017_3_053
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200001
DA 2022-07-14
ER

PT J
AU Lungu, M
   Romila, A
   Nechita, A
   Tutunaru, D
   Caraban, BM
AF Lungu, Mihaela
   Romila, Aurelia
   Nechita, Aurel
   Tutunaru, Dana
   Caraban, Bogdan Marian
TI NEUROLOGICAL MANIFESTATIONS IN NON-AUTOIMMUNE HYPERTHYROIDISM GOITER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE non-autoimmune hyperthyroidism goiter; neurological manifestations
AB Introduction: A prospective study was conducted over the span of 5 years, with the aim to observe the neurological manifestations in non-autoimmune hyperthyroidism goiter.
   Materials and methods: In a study group of 106 cases of hyperthyroidism including various etiologies, were included 60 cases of non-autoimmune hyperthyroidism goiter, representing 56.60% of the cases of hyperthyroidism followed. Clinical and paraclinical examinations were carried out every three months. The paraclinical exam included hormone dosing, ultrasound exams, thyroid scintigraphy, biopsies, brain computed tomography and blood biochemistry tests.
   Results: A large amount of detailed data was collected over a relatively long span of time.
   Conclusions: The collected data largely corresponds to the reference literature. It is often the case that patients first address the neurologist, who has to diagnose the thyroid disease and its neurological manifestations.
C1 [Lungu, Mihaela; Nechita, Aurel; Tutunaru, Dana] Dunarea de Jos Univ Galati, Fac Med & Pharm, Galati, Romania.
   [Lungu, Mihaela] Emergency Clin Hosp, Neurol Dept, Galati, Romania.
   [Romila, Aurelia] Dunarea de Jos Univ Galati, Fac Med & Pharm, Ctr Res Med Pharmaceut, Galati, Romania.
   [Romila, Aurelia] Emergency Cty Hosp, Geriatr Dept, Galati, Romania.
   [Nechita, Aurel] Emergency Hosp Pediat, Pediat Dept, Galati, Romania.
   [Caraban, Bogdan Marian] Ovidius Univ Constanta, Fac Med, Plast Surg Dept, Constanta, Romania.
RP Romila, A (corresponding author), Univ Med & Pharm Dunarea de Jos, Geriatr Dept, Vadu Sacalelor 1,Bl Pescarus,Ap 8, Galati, Romania.
RI LUNGU, MIHAELA/AAD-3727-2019
OI LUNGU, MIHAELA/0000-0002-2807-7742
CR Aminoff M. J., 1999, CLIN NEUROLOGY
   [Anonymous], 2014, ADAMS VICTORS PRINCI, p[1155, 1358, 1450]
   Duyff RF, 2000, J NEUROL NEUROSUR PS, V68, P750, DOI 10.1136/jnnp.68.6.750
   DYCK PJ, 1970, J NEUROPATH EXP NEUR, V29, P631, DOI 10.1097/00005072-197010000-00008
   Goh SY, 2004, CLIN ENDOCRINOL, V60, P600, DOI 10.1111/j.1365-2265.2004.02033.x
   Isselbacher K.J., 1995, MED PRINCIPLES, P599
   ROQUER J, 1993, ACTA NEUROL SCAND, V88, P149
   Serratrice G., 2007, NEUROMUSCULAR PATHOL
   Uldry R-A., 1991, NEUROLOGICAL COMPLIC
   VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537
   Zbranca E., 1999, ENDOCRINOLOGY, p[26, 69]
NR 11
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 377
EP 384
DI 10.19193/0393-6384_2017_3_054
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200002
DA 2022-07-14
ER

PT J
AU Lungu, M
   Romila, A
   Nechita, A
   Tutunaru, D
   Marian, CB
AF Lungu, Mihaela
   Romila, Aurelia
   Nechita, Aurel
   Tutunaru, Dana
   Marian, Caraban Bogdan
TI NEUROLOGICAL MANIFESTATIONS IN THYROID TUMORS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE thyroid tumors; neurological manifestations
AB Introduction: Thyroid nodules, defined as a localized swelling of the thyroid gland may be the clinical manifestation of some order of thyroid tumors, either benign - adenomas, teratomas or malignant - carcinomas, lymphomas, sarcomas, secondary metastatic tumors.
   Materials and methods: A personal five years' clinical prospective study conducted on patients with thyroid tumor nodules hospitalized in the neurology and endocrinology departments of Emergency Hospital Galati, targeted the neurological manifestations associated to thyroid tumor pathology, referring to the frequency, clinical aspect and therapeutic response to neurological determinations from thyroid tumors. Clinical and paraclinical examinations were carried out every three months. The paraclinical exam included hormone dosing, ultrasound exams, thyroid scintigraphy, biopsies, brain computed tomography and blood biochemistry tests.
   Results: A large amount of detailed data was collected over a relatively long span of time.
   Conclusions: The collected data largely corresponds to the reference literature. It is often the case that patients first address the neurologist, who has to diagnose the thyroid disease and its neurological manifestations.
C1 [Lungu, Mihaela; Nechita, Aurel; Tutunaru, Dana] Dunarea de Jos Univ Galati, Fac Med & Pharm, Galati, Romania.
   [Lungu, Mihaela] Emergency Clin Hosp, Neurol Dept, Galati, Romania.
   [Romila, Aurelia] Dunarea de Jos Univ Galati, Fac Med & Pharm, Ctr Res Med Pharmaceut, Galati, Romania.
   [Romila, Aurelia] Emergency Cty Hosp, Geriatr Dept, Galati, Romania.
   [Nechita, Aurel] Emergency Hosp Pediat, Pediat Dept, Galati, Romania.
   [Marian, Caraban Bogdan] Ovidius Univ Constanta, Fac Med, Plast Surg Dept, Constanta, Romania.
RP Romila, A (corresponding author), Univ Med & Pharm Dunarea de Jos, Geriatr Dept, Vadu Sacalelor 1,Bl Pescarus,Ap 8, Galati, Romania.
RI LUNGU, MIHAELA/AAD-3727-2019
OI LUNGU, MIHAELA/0000-0002-2807-7742
CR Aminoff M. J., 1999, CLIN NEUROLOGY
   [Anonymous], 2014, ADAMS VICTORS PRINCI, p[1155, 1358, 1450]
   DYCK PJ, 1970, J NEUROPATH EXP NEUR, V29, P631, DOI 10.1097/00005072-197010000-00008
   Hufschmidt A, 2002, NEUROLOGIE INTEGRALA
   Isselbacher K.J., 1995, PRINCIPII MED INT, P599
   Zbranca E., 1999, ENDOCRINOLOGIE GHID, p[26, 69]
NR 6
TC 1
Z9 1
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 385
EP 392
DI 10.19193/0393-6384_2017_3_055
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200003
DA 2022-07-14
ER

PT J
AU Macin, S
   Akyon, Y
AF Macin, Salih
   Akyon, Yakut
TI PHENOTYPIC AND GENOTYPIC VIRULENCE FACTORS IN PSEUDOMONAS AERUGINOSA
   STRAINS ACCORDING TO PIGMENT PRESENCE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE antibiotic resistance; pigment; Pseudomonas aeruginosa; virulence
ID ANTIBIOTIC-RESISTANCE; CYSTIC-FIBROSIS; FITNESS; TRACT
AB Introduction: Pseudomonas aeruginosa is an aerobic, motile, non-spore forming, straight or slightly curved, gram-negative bacilli and it can grow at 42 degrees C. The incidence of P. aeruginosa has been increased in recent years and its virulence factors are various. The aim of this study was to compare the differences of the virulence factors in pigmented and non-pigmented P. aeruginosa isolates.
   Materials and methods: Isolates of patients that were identified as P. aeruginosa were included into the study. Strains of patients (n: 100) were divided into two groups according to pigment production. Antibiotic susceptibility tests of all strains were performed by disk diffusion method. DNase, protease, elastase, hemolysis and motility tests were performed as phenotypic tests. The presence of several virulence-associated genes encoding exotoxins T (exoT), S (exoS), U (exoU) and Y (exoY) and quorum sensing mediators (rhlA and rhlB) were assessed by Real-time PCR method for genotypic identification. The relationship between pigment production, antibiotic resistance and virulence factors were examined.
   Results: There was no significant difference between pigmented and non-pigmented isolates when elastolytic activity and mucus production were compared. Pigmented isolates produced significantly more (p<0.05) protease and hemolysis activity. Motility was present in pigmented isolates more frequently than in non-pigmented isolates. DNase activity was significant in pigmented isolates then non-pigmented isolates (p<0.05). Antibiotic resistance was present more frequently in non-pigmented isolates than pigmented isolates. Pigmented isolates had more frequently and significant more (p<0.05) virulence-associated genes rhlB, exoS, exoY (p<0.05).
   Conclusion: The results of this study suggest that both phenotypic and genotypic virulence factors may be associated with the pigment production in P. aeruginosa. Pigment production is easy to determine, which might be a good starting point to identify the virulence status of an isolate.
C1 [Macin, Salih] Sirnak State Hosp, Microbiol Lab, Sirnak, Turkey.
   [Akyon, Yakut] Hacettepe Univ, Fac Med, Dept Med Microbiol, Ankara, Turkey.
RP Macin, S (corresponding author), Sirnak State Hosp, Microbiol Lab, Sirnak, Turkey.
RI Macin, Salih/H-4850-2017; YILMAZ, YAKUT AKYON/I-8298-2013; Macin,
   Salih/P-2881-2019
OI Macin, Salih/0000-0002-1871-3629; YILMAZ, YAKUT
   AKYON/0000-0002-0919-5508; 
FU Hacettepe University Scientific Research Fund [17388665/285]
FX We thank Onur Karatuna for providing P. aeruginosa PAO-1, PAO-JP2 and
   PAO-JP3 strains. This work was supported by a project grant (Project no:
   17388665/285) from the Hacettepe University Scientific Research Fund.
CR BURKE V, 1991, PATHOLOGY, V23, P145, DOI 10.3109/00313029109060814
   Caldwell CC, 2009, AM J PATHOL, V175, P2473, DOI 10.2353/ajpath.2009.090166
   Ciragil Pinar, 2004, Mikrobiyoloji Bulteni, V38, P341
   Clinical and Laboratory Standards Institute, 2014, STAND ANT SUSC TEST
   Davis R, 2016, J MED MICROBIOL, V65, P261, DOI 10.1099/jmm.0.000229
   DORING G, 1983, J INFECT DIS, V147, P744, DOI 10.1093/infdis/147.4.744
   Finlayson EA, 2011, W INDIAN MED J, V60, P24
   HEDBERG M, 1969, AM J CLIN PATHOL, V52, P631
   Jayaseelan S, 2014, WORLD J MICROB BIOT, V30, P1159, DOI 10.1007/s11274-013-1552-5
   Karatuna O, 2010, CLIN MICROBIOL INFEC, V16, P1770, DOI 10.1111/j.1469-0691.2010.03177.x
   Liu GY, 2009, TRENDS MICROBIOL, V17, P406, DOI 10.1016/j.tim.2009.06.006
   Livermore DM, 2002, CLIN INFECT DIS, V34, P634, DOI 10.1086/338782
   Meyer JM, 2000, ARCH MICROBIOL, V174, P135, DOI 10.1007/s002030000188
   Palleroni NJ, 2003, MICROBIOL-SGM, V149, P1, DOI 10.1099/mic.0.25952-0
   Petermann SR, 2001, CLIN DIAGN LAB IMMUN, V8, P632, DOI 10.1128/CDLI.8.3.632-636.2001
   Senturk S, 2012, J INFECT DEV COUNTR, V6, P501
   SPEERT DP, 1993, J INFECT DIS, V167, P226, DOI 10.1093/infdis/167.1.226
   Sun ZZ, 2013, CELL PHYSIOL BIOCHEM, V31, P347, DOI 10.1159/000343372
   Van Delden C, 1998, EMERG INFECT DIS, V4, P551, DOI 10.3201/eid0404.980405
   Yayan J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139836
NR 20
TC 1
Z9 1
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1033
EP 1038
DI 10.19193/0393-6384_2017_6_163
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500022
DA 2022-07-14
ER

PT J
AU Maglietta, F
   Sessa, F
   Albano, GD
   Bertozzi, G
   Giugliano, P
   Vacchiano, G
   Marsala, G
   Salerno, M
AF Maglietta, Francesca
   Sessa, Francesco
   Albano, Giuseppe Davide
   Bertozzi, Giuseppe
   Giugliano, Pasquale
   Vacchiano, Giuseppe
   Marsala, Gabriella
   Salerno, Monica
TI ITALIAN MAFIA: A FOCUS ON APULIA MAFIA WITH A LITERATURE REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Italian mafia; Garganic Mafia; Apulia; Sacra Corona Unita; Lupara
   Bianca; Shotgun
ID LASER-SCANNING MICROSCOPY; SELF-CONCEPT; CHILDREN; MIGRAINE;
   INCAPRETTAMENTO; MULTICENTER; SLEEP; AURA; ABNORMALITIES; CHILDHOOD
AB The goal of this paper is a systematic literary review that analyzes the differences between the main Apulia's Mafia organizations and their distinctive murder methods. In homicides committed by criminal organization, the method used intends to be an admonition to other persons. We analyze the criminal organization named "Mafia of Gargano", that is a promontory of Apulia Region, in South-East of Italy. We analyze its homicidal mode, the type of weapon used in murders, the drawn body sites and the action recurrence. Previously named "Faida" of Gargano, the "Garganic Mafia" was certified by legal court as an inveterate mafia system only in 2009. In fact, in the Garganic area an archaic and violent mafia arise for theft of animals; subsequently, the most profitable activities of these clans became drug and weapons trafficking. The "Garganic Mafia" is an extremely traditional Mafia, like "Camorra", with particularly practices of cadaver concealment. Very often, utilizing natural conformation of Gargano promontory, the criminals throw away the bodies into natural canyons. In this manner, the cadavers are discovered after many years accidentally: this method was classified as "Lupara Bianca". Another kind of Apulia's Mafia is the so called "Sacra Corona Unita" (SCU). Originally it was founded by the Camorra's boss but it's inspired by Calabrian 'Ndrangheta: both these mafia associations was found in south of Italy, Camorra in Campania Region and 'Ndragheta in Calabria Region. In the murders committed by the SCU was frequent the recourse to deception to attract the victim, the use of the gun and the method of "Lupara Bianca" with the burning of the body. As previously described, the kind of the murder represents the signature of the mafia organization. These finding are very useful for investigations, helping to identify crime's motivations and the correlation with suspects.
C1 [Maglietta, Francesca; Sessa, Francesco; Albano, Giuseppe Davide; Bertozzi, Giuseppe; Salerno, Monica] Univ Foggia, Sect Forens Pathol, Clin & Expt Med Dept, DAvanzo Hosp, Viale Aviatori 1, Foggia, Italy.
   [Giugliano, Pasquale] UOC, St Anna & San Sebastiano Hosp, Legal Med, Palasciano St, Caserta, Italy.
   [Vacchiano, Giuseppe] Sannio Univ, Dept Law Econ Math Methods, UOC, Benevento, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Struttura Complessa Farm, Osped Riuniti Foggia, Foggia, Italy.
RP Salerno, M (corresponding author), Univ Foggia, Sect Forens Pathol, Clin & Expt Med Dept, Osped Colonnello DAvanzo, Viale Aviatori 1, I-71100 Foggia, Italy.
RI Sessa, Francesco/G-1754-2018; Bertozzi, Giuseppe/AAS-9882-2020; SALERNO,
   MONICA/AAC-1321-2019
OI Sessa, Francesco/0000-0003-0357-8791; Bertozzi,
   Giuseppe/0000-0002-8179-1072; SALERNO, MONICA/0000-0002-6410-3960;
   Maglietta, Francesca/0000-0001-7240-5902; Giugliano,
   Pasquale/0000-0002-3633-8893
CR Baraybar JP, 2006, J FORENSIC SCI, V51, P103, DOI 10.1111/j.1556-4029.2005.00035.x
   Barone R, 2017, J CELL MOL MED, V21, P1636, DOI 10.1111/jcmm.13092
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00188
   Council of Europe, 1999, REP ORG CRIM SIT COU, P70
   D'Errico S, 2011, AM J FOREN MED PATH, V32, P44, DOI 10.1097/PAF.0b013e3181efbbf2
   De Donno A, 2009, J FORENSIC SCI, V54, P895, DOI 10.1111/j.1556-4029.2009.01068.x
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Fenton TW, 2005, J FORENSIC SCI, V50, P274
   Fineschi V, 1998, AM J FOREN MED PATH, V19, P87, DOI 10.1097/00000433-199803000-00017
   Focardi M, 2014, AM J FOREN MED PATH, V35, P83, DOI 10.1097/PAF.0000000000000074
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Harding BE, 2011, AM J FOREN MED PATH, V32, P208, DOI 10.1097/PAF.0b013e318221ba71
   Ledda C, 2017, MOL MED REP, V15, P3350, DOI 10.3892/mmr.2017.6380
   Marselli R, 1997, INT REV LAW ECON, V17, P89, DOI 10.1016/S0144-8188(96)00060-9
   MASCIANDARO D, 1999, RIV INT SCI SOC, V107, P85
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00137
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Neri M, 2007, INT J LEGAL MED, V121, P287, DOI 10.1007/s00414-006-0110-1
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pollanen MS, 2003, AM J FOREN MED PATH, V24, P51, DOI 10.1097/00000433-200303000-00010
   Pomara C, 2015, RADIOL MED, V120, P802, DOI 10.1007/s11547-015-0549-6
   Pomara C, 2009, RADIOL MED, V114, P1367, DOI 10.1007/s11547-009-0435-1
   Pomara C, 2008, AM J FOREN MED PATH, V29, P72, DOI 10.1097/PAF.0b013e31816520bf
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Pomara C, 2010, AM J FOREN MED PATH, V31, P264, DOI 10.1097/PAF.0b013e3181dfc9b4
   Porta D, 2013, AM J FOREN MED PATH, V34, P195, DOI 10.1097/PAF.0b013e318288759a
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Santamaria S., 2016, BIOL MED, V8, DOI 10.4172/0974-8369.1000263
   Seccia D., 2011, MAFIA INNOMINABILE
   Turillazzi E, 2008, INT J LEGAL MED, V122, P173, DOI 10.1007/s00414-007-0208-0
   Turillazzi E, 2013, FORENSIC SCI INT, V231, P142, DOI 10.1016/j.forsciint.2013.04.006
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
NR 47
TC 7
Z9 7
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 947
EP 952
DI 10.19193/0393-6384_2017_6_149
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500008
DA 2022-07-14
ER

PT J
AU Mahmoodipour, H
   Baserisalehi, M
   Emami, A
AF Mahmoodipour, Hamid
   Baserisalehi, Majid
   Emami, Amir
TI MOLECULAR DETECTION OF VIRULENCE GENES INVOLVED IN ADHERENCE,
   COLONIZATION, INVASION AND CYTOTOXIN PRODUCTION IN CAMPYLOBACTER JEJUNI
   AND CAMPYLOBACTER COLI ISOLATED FROM POULTRY, COW AND SHEEP FAECES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Virulence; Campylobacter; Molecular epidemiology; Detection; Genes
ID ANTIMICROBIAL SUSCEPTIBILITY; PREVALENCE; MEAT
AB Aims: This study was conducted to determine the prevalence of different virulence genes in isolates recovered from poultry, cow, and sheep faeces samples in Behbahan, Khuzestan province, Iran.
   Methods and results: The presence of cadF, ciaB, racR, cdtA, cdtB, cdtC, and pldA virulence genes among 36 Campylobacter jejuni and 14 Campylobacter coli isolates was detected by polymerase chain reaction. The isolates were screened for the presence of seven virulence genes-namely cadF, racR, ciaB, cdtA, cdtB, cdtC, and pldA-which are responsible for adherence, colonization, invasion, and cytotoxin production in Campylobacter jejuni and Campylobacter coli. The isolates showed wide variation in the presence of these genes. The prevalence of cadF, ciaB, racR, cdtA, cdtB, cdtC, and pldA virulence genes in poultry were 74.36%, 76.92%, 84.61%, 69.23%, 84.62%, 84.62%, and 76.92%, respectively. The prevalence of cadF, ciaB, racR, cdtA, cdtB, cdtC, and pldA virulence genes in cow were 55.56%, 55.56%, 100%, 77.78%, 88.89%, 88.89%, and 88.89%, respectively. The prevalence of cadF, ciaB, racR, cdtA, cdtB, cdtC, and pldA virulence genes in sheep were 0%, 100%, 100%, 0%, 100%, 50%, and 100%, respectively.
   Conclusions: A high prevalence of ciaB, racR, cdtB, cdtC, and pldA genes was found. Significance and Impact of the Study: The high prevalence of ciaB, racR, cdtB, cdtC, and pldA genes demonstrated that these putative pathogenic determinants are widespread among Campylobacter isolates from poultry, cow, and sheep. The results emphasized that Campylobacter strains in poultry, cow, and sheep have potential pathogenic properties for humans.
C1 [Mahmoodipour, Hamid] Islamic Azad Univ, Fars Sci & Res Branch, Dept Microbiol, Fars, Iran.
   [Mahmoodipour, Hamid] Islamic Azad Univ, Shiraz Branch, Dept Microbiol, Shiraz, Iran.
   [Baserisalehi, Majid] Islamic Azad Univ, Kazeroun Branch, Dept Microbiol, Kazeroun, Iran.
   [Emami, Amir] Shiraz Univ Med Sci, Dept Burn & Wound Healing, Res Ctr, Shiraz, Iran.
RP Baserisalehi, M (corresponding author), Islamic Azad Univ, Kazeroun Branch, Dept Microbiol, Kazeroun, Iran.
EM majidbaseri@hotmail.com
RI Emami, Amir/H-1024-2016; mahmoodipour, hamid/N-5737-2015
OI Emami, Amir/0000-0002-4510-1820; baserisalehi,
   majid/0000-0003-2194-4257; mahmoodipour, hamid/0000-0003-4581-7519
CR [Anonymous], 2015, EFSA J
   Atabay HI, 1997, J APPL MICROBIOL, V83, P619, DOI 10.1046/j.1365-2672.1997.00277.x
   Baserisalehi M, 2004, J APPL MICROBIOL, V97, P853, DOI 10.1111/j.1365-2672.2004.02375.x
   Bhavsar S, 2007, INTERNET J MICROBIOL, V3
   Bolton DJ, 2015, FOOD MICROBIOL, V48, P99, DOI 10.1016/j.fm.2014.11.017
   Bras AM, 1999, J BACTERIOL, V181, P3298
   Casabonne C., 2016, INT J INFECT, V3, P1
   Cochran WG, 2007, SAMPLING TECHNIQUES, P72
   de Boer P, 2002, MOL MICROBIOL, V44, P351, DOI 10.1046/j.1365-2958.2002.02930.x
   Epps SVR, 2013, INT J ENV RES PUB HE, V10, P6292, DOI 10.3390/ijerph10126292
   Khoshbakht R, 2013, FOODBORNE PATHOG DIS, V10, P764, DOI 10.1089/fpd.2013.1489
   Koolman L, 2015, FOODBORNE PATHOG DIS, V12, P424, DOI 10.1089/fpd.2014.1883
   Lane DJ, 1991, NUCL ACID TECHNIQUES
   Lapierre L, 2016, MICROB DRUG RESIST, V22, P432, DOI 10.1089/mdr.2015.0055
   Linton D, 1997, J CLIN MICROBIOL, V35, P2568, DOI 10.1128/JCM.35.10.2568-2572.1997
   Monteville MR, 2003, MICROBIOL-SGM, V149, P153, DOI 10.1099/mic.0.25820-0
   Rizal A., 2010, INT J FOOD SAF, V12, P29
   Rozynek E, 2005, J MED MICROBIOL, V54, P615, DOI 10.1099/jmm.0.45988-0
   van der Stel AX, 2015, ENVIRON MICROBIOL, V17, P1049, DOI 10.1111/1462-2920.12476
   Zhang TF, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0132-2
   Zhong X, 2016, FOOD CONTROL, V62, P10, DOI 10.1016/j.foodcont.2015.09.032
   Ziprin RL, 2001, AVIAN DIS, V45, P549, DOI 10.2307/1592894
NR 22
TC 1
Z9 1
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 763
EP 768
DI 10.19193/0393-6384_2017_5_112
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000006
DA 2022-07-14
ER

PT J
AU Maleki, MR
   Kafil, HS
   Harzandi, N
   Moaddab, SR
AF Maleki, Mehdi Roshdi
   Kafil, Hossein Samadi
   Harzandi, Naser
   Moaddab, Seyyed Reza
TI THE INTRODUCTION OF 3+1 IMPORTANT METHOD FOR THE ISOLATION OF
   ENVIRONMENTAL MYCOBACTERIA FROM DRINKING WATERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE isolation; environmental mycobacteria; drinking water
ID NONTUBERCULOUS MYCOBACTERIA; DISEASE; DECONTAMINATION; SYSTEMS; AVIUM
AB Water is one of the important reservoirs of environmental mycobacteria ( EM). The resistance against chlorine and biofilm formation is among the important factors involved in colonization of these bacteria in water. Environmental mycobacteria cause different types of diseases especially pulmonary diseases due to their transfer to humans. The isolation and identification of these bacteria and the knowledge of how species are spread out as well as the identification of the dominant species in different geographical regions are necessary to be paid attention to because of differences in strategies for treating diseases caused by them. Different methods for isolating environmental mycobacteria have been employed by different researchers, but no standard method has been suggested for this isolation yet. Therefore, in the present study, in addition to introducing an ideal protocol, other studies related to the isolation of these bacteria from water resources were investigated, among which three top methods were selected and introduced. In addition, effective factors such as the type and concentration of disinfectants, the type of water processing, the type of culture medium, their pH, and incubation temperature involved in isolating bacteria are mentioned. Conclusion: using the filtration method instead of centrifuge one, using disinfectant of the cetylpyridinium chloride (CPC) instead of other disinfectants, using the Lowenstein-Jensen culture medium with an acidic pH, incubation in temperature of 30 degrees C and incubation duration are among factors affecting in the isolation of environmental mycobacteria from the water sample.
C1 [Maleki, Mehdi Roshdi; Harzandi, Naser] Islamic Azad Univ, Karaj Branch, Dept Microbiol, Coll Sci, Alborz, Iran.
   [Kafil, Hossein Samadi] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
   [Moaddab, Seyyed Reza] Tabriz Univ Med Sci, Fac Paramed, Dept Lab Sci, Tabriz, Iran.
RP Moaddab, SR (corresponding author), Tabriz Univ Med Sci, Fac Paramed, Dept Lab Sci, Tabriz, Iran.
RI Samadi Kafil, Hossein/AAX-2888-2021; Kafil, Hossein Samadi/B-5855-2012;
   Maleki, Mehdi Roshdi/AAN-2526-2021
OI Kafil, Hossein Samadi/0000-0001-6026-8795; Maleki, Mehdi
   Roshdi/0000-0002-3846-4770
CR Asgharzadeh M, 2008, ANN MICROBIOL, V58, P333, DOI 10.1007/BF03175339
   COLLINS CH, 1984, J APPL BACTERIOL, V57, P193, DOI 10.1111/j.1365-2672.1984.tb01384.x
   Falkinham JO, 2011, EMERG INFECT DIS, V17, P419, DOI 10.3201/eid1703.101510
   Feazel LM, 2009, P NATL ACAD SCI USA, V106, P16393, DOI 10.1073/pnas.0908446106
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST
   Iivanainen E, 1997, J APPL MICROBIOL, V82, P121
   Johnson MM, 2014, J THORAC DIS, V6, P210, DOI 10.3978/j.issn.2072-1439.2013.12.24
   Le Dantec C, 2002, APPL ENVIRON MICROB, V68, P5318, DOI 10.1128/AEM.68.11.5318-5325.2002
   Leylabadlo HE, 2016, TUBERC RESPIR DIS, V79, P134, DOI 10.4046/trd.2016.79.3.134
   Parashar D, 2009, INDIAN J MED RES, V129, P424
   Peres RL, 2009, INT J TUBERC LUNG D, V13, P1572
   SCHULZEROBBECKE R, 1991, J MICROBIOL METH, V14, P177, DOI 10.1016/0167-7012(91)90021-H
   Sebakova H, 2008, CAN J MICROBIOL, V54, P891, DOI [10.1139/W08-080, 10.1139/w08-080]
   Thomson R, 2008, APPL ENVIRON MICROB, V74, P3094, DOI 10.1128/AEM.02009-07
   van Ingen J, 2009, CLIN MICROBIOL INFEC, V15, P888, DOI 10.1111/j.1469-0691.2009.03013.x
   Vasconcellos SEG, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-80
   Whiley H, 2012, J APPL MICROBIOL, V113, P223, DOI 10.1111/j.1365-2672.2012.05298.x
   Whiley H, 2012, MYCOBACTERIUM AVIUM, P223
NR 18
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 909
EP 913
DI 10.19193/0393-6384_2017_1s_135
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000004
DA 2022-07-14
ER

PT J
AU Maltese, A
   Salerno, M
   Tripi, G
   Romano, P
   Ricciardi, A
   Folco, A
   Di Filippo, T
   Parisi, L
AF Maltese, Agata
   Salerno, Margherita
   Tripi, Gabriele
   Romano, Palmira
   Ricciardi, Annaclaudia
   Folco, AnnabellaDi
   Di Filippo, Teresa
   Parisi, Lucia
TI THE ANGELMAN SYNDROME: A BRIEF REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Angelman syndrome; behavioural abnormalities; mental retardation; UBE3A;
   EEG abnormalities
ID AUTISM SPECTRUM DISORDERS; PRIMARY NOCTURNAL ENURESIS; SLEEP-APNEA
   SYNDROME; CHILDHOOD ABSENCE EPILEPSY; PRIMARY CILIARY DYSKINESIA;
   PRADER-WILLI-SYNDROME; WEIGHT-LOSS PROGRAM; QUALITY-OF-LIFE; PARENTAL
   STRESS; MATERNAL STRESS
AB Angelman's Syndrome (AS) was described for the first time by Harry Angelman in the 1960s, based on obervation of three child patients with similar physical and behavioral features such as severe intellectual impairment, lack of language, motor disorders and happy behaviour. Many years later the typical patients' features were identified as linked to genetic abnormalities mainly characterized by neurological symptoms. Life expectancy is good although the symptoms tend to be stable and severe.
C1 [Maltese, Agata; Folco, AnnabellaDi; Di Filippo, Teresa; Parisi, Lucia] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Romano, Palmira; Ricciardi, Annaclaudia] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, CE, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Bird LM, 2014, APPL CLIN GENET, V7, P93, DOI 10.2147/TACG.S57386
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Fairbrother LC, 2015, AM J MED GENET A, V167, P1565, DOI 10.1002/ajmg.a.37058
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P491, DOI 10.19193/0393-6384_2017_3_073
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P481, DOI 10.19193/0393-6384_2017_3_071
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 84
TC 6
Z9 6
U1 3
U2 14
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 667
EP 673
DI 10.19193/03936384_2017_4_100
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700021
DA 2022-07-14
ER

PT J
AU Maltese, A
   Salerno, M
   Tripi, G
   Romano, P
   Ricciardi, A
   Sessa, G
   Di Folco, A
   Di Filippo, T
   Parisi, L
AF Maltese, Agata
   Salerno, Margherita
   Tripi, Gabriele
   Romano, Palmira
   Ricciardi, Annaclaudia
   Sessa, Giulia
   Di Folco, Annabella
   Di Filippo, Teresa
   Parisi, Lucia
TI REHABILITATIVE TREATMENT PROPOSALS IN PEDIATRIC NON-VERBAL SYNDROME
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Nonverbal learning disability; NVLD; visuospatial abilities;
   rehabilitation; evidence based medicine (EBM)
ID AUTISM SPECTRUM DISORDERS; PRIMARY NOCTURNAL ENURESIS; SLEEP-APNEA
   SYNDROME; QUALITY-OF-LIFE; CHILDHOOD ABSENCE EPILEPSY; PRIMARY CILIARY
   DYSKINESIA; PRADER-WILLI-SYNDROME; WEIGHT-LOSS PROGRAM; PARENTAL STRESS;
   MATERNAL STRESS
AB Nonverbal learning disability (NVLD) can be defined as a specific learning disorder peculiar for deficits in non-verbal area, such as visuospatial and visuo-constructive difficulties, fine motor coordination impairments, and poor mathematics achievement, associated with well-developed language skills. aim of the present work is suggesting rehabilitative proposal for management treatment of NVLD in pediatric age tailored on children and based on EBM.
C1 [Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa; Parisi, Lucia] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Romano, Palmira; Ricciardi, Annaclaudia; Sessa, Giulia] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, CE, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Alesi M, 2014, NEUROPSYCH DIS TREAT, V10, P479, DOI 10.2147/NDT.S58455
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio M. F., 2013, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V172, P705
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   La Grutta S, 2007, Minerva Pediatr, V59, P745
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P491, DOI 10.19193/0393-6384_2017_3_073
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P481, DOI 10.19193/0393-6384_2017_3_071
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2015, MENT ILLN, V7, P32, DOI 10.4081/mi.2015.5988
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Semrud-Clikeman M, 2014, J AUTISM DEV DISORD, V44, P331, DOI 10.1007/s10803-013-1871-2
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 98
TC 3
Z9 3
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 675
EP 682
DI 10.19193/0393-6384_2017_4_101
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700022
DA 2022-07-14
ER

PT J
AU Maltese, A
   Salerno, M
   Tripi, G
   Romano, P
   Ricciardi, A
   Di Folco, A
   Di Filippo, T
   Parisi, L
AF Maltese, Agata
   Salerno, Margherita
   Tripi, Gabriele
   Romano, Palmira
   Ricciardi, Annaclaudia
   Di Folco, Annabella
   Di Filippo, Teresa
   Parisi, Lucia
TI INTERNALIZING PROBLEMS ARE RELATED TO SLEEP PATTERNS DISORDERED IN
   CHILDREN AFFECTED BY PRIMARY HEADACHE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Primary headaches; internalizing problems; sleep disorders
ID AUTISM SPECTRUM DISORDERS; PRIMARY NOCTURNAL ENURESIS; QUALITY-OF-LIFE;
   CHILDHOOD ABSENCE EPILEPSY; PRIMARY CILIARY DYSKINESIA;
   PRADER-WILLI-SYNDROME; WEIGHT-LOSS PROGRAM; APNEA SYNDROME; PARENTAL
   STRESS; MATERNAL STRESS
AB Introduction: Migraine is a common disorder in children and adolescents, associated with various disorders such as emotions, behavioral problems, and sleep disturbances.
   Aim of the study is to verify the relationship between psychological problems of cephalalgic patients and sleep disturbances. Materials and methods: 64 subjects (27 females), aged 8-12 years (mean 9.4 years, SD +/- 1.03) with primary headache were enrolled. CBCL 6-18 scale and the SDSC scale were used for behavioral screening and for assessing sleep habits.
   Results: According to the ICHD-III criteria, the distribution of the headache subtype was as follows: headaches without aura (71.87%), headache episodes typical of tension (7.81%) and chronic headache (7.81%) (Figure 1).
   CBCL assessment (total problem element) showed an interesting relationship with sleep disorders such as DIMS, DA and SWTD (respectively r = .37, p = 0.019; r = .39, p = 0.015; r = 37, p = 0.019).
   Discussion: MwA children revealed a specific behavioral phenotype characterized by internalization problems. Among migraine subjects, prevalent sleep disorders include difficulty falling asleep, increased night-time awakening, decreased sleep duration, and excessive daytime sleepiness.
C1 [Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa; Parisi, Lucia] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Romano, Palmira; Ricciardi, Annaclaudia] Univ Campania Luigi Vanvitelli, Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Alesi M, 2014, NEUROPSYCH DIS TREAT, V10, P479, DOI 10.2147/NDT.S58455
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio M. F., 2013, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V172, P705
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   La Grutta S, 2007, Minerva Pediatr, V59, P745
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P491, DOI 10.19193/0393-6384_2017_3_073
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P481, DOI 10.19193/0393-6384_2017_3_071
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2015, MENT ILLN, V7, P32, DOI 10.4081/mi.2015.5988
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 94
TC 4
Z9 4
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 729
EP 735
DI 10.19193/0393-6384_2017_5_107
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000001
DA 2022-07-14
ER

PT J
AU Maltese, A
   Salerno, M
   Romano, P
   Ricciardi, A
   Di Filippo, T
   Tripi, G
AF Maltese, Agata
   Salerno, Margherita
   Romano, Palmira
   Ricciardi, Annaclaudia
   Di Filippo, Teresa
   Tripi, Gabriele
TI KETOGENIC DIET AS ANTIEPILEPTIC THERAPY: ADMINISTRATION AND FORMULAS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ketogenic diet; epilepsy; cholesterol; free fatty acids; administration;
   formulas
ID AUTISM SPECTRUM DISORDERS; PRIMARY NOCTURNAL ENURESIS; SLEEP-APNEA
   SYNDROME; QUALITY-OF-LIFE; CHILDHOOD ABSENCE EPILEPSY; PRIMARY CILIARY
   DYSKINESIA; PRADER-WILLI-SYNDROME; WEIGHT-LOSS PROGRAM; PARENTAL STRESS;
   MATERNAL STRESS
AB In 1921 Wilder defined classical cholesterol diet providing the patient with a daily calorie intake of less than 20% compared to age-related requirements. The main macronutrient is represented by saturated and long chain unsaturated fatty acids, in the ratio of 4:1 to carbohydrates and proteins (4 grams of lipids per gram of carbohydrates and proteins). One of the first therapeutic protocols proposed is that of John Hopkins that the onset of the diet should take place in a hospital environment to assess the patient's response in a controlled situation.
C1 [Maltese, Agata; Di Filippo, Teresa] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Romano, Palmira; Ricciardi, Annaclaudia] Univ Campania Luigi Vanvitelli, Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Alesi M, 2014, NEUROPSYCH DIS TREAT, V10, P479, DOI 10.2147/NDT.S58455
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio M. F., 2013, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V172, P705
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   La Grutta S, 2007, Minerva Pediatr, V59, P745
   La Grutta S, 2006, Minerva Pediatr, V58, P513
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P491, DOI 10.19193/0393-6384_2017_3_073
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P481, DOI 10.19193/0393-6384_2017_3_071
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2015, MENT ILLN, V7, P32, DOI 10.4081/mi.2015.5988
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisano S, 2017, J CHILD ADOL PSYCHOP, V27, P844, DOI 10.1089/cap.2016.0203
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 95
TC 2
Z9 2
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 737
EP 744
DI 10.19193/0393-6384_2017_5_108
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000002
DA 2022-07-14
ER

PT J
AU Maltese, A
   Salerno, M
   Romano, P
   Ricciardi, A
   Di Filippo, T
   Tripi, G
AF Maltese, Agata
   Salerno, Margherita
   Romano, Palmira
   Ricciardi, Annaclaudia
   Di Filippo, Teresa
   Tripi, Gabriele
TI KETOGENIC DIET AS ANTIEPILEPTIC THERAPY: HISTORICAL PERSPECTIVE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ketogenic diet; epilepsy; cholesterol; free fatty acids
ID AUTISM SPECTRUM DISORDERS; PRIMARY NOCTURNAL ENURESIS; SLEEP-APNEA
   SYNDROME; QUALITY-OF-LIFE; CHILDHOOD ABSENCE EPILEPSY; PRIMARY CILIARY
   DYSKINESIA; PRADER-WILLI-SYNDROME; WEIGHT-LOSS PROGRAM; PARENTAL STRESS;
   MATERNAL STRESS
AB Ketogenic diet (KD) is a high-lipid diet, adequate for protein content but low in carbohydrates content. Caloric intake is calculated on the basis of the ideal patient's needs, reduced by about 20%, and is about 90% of lipids present in 3:1 or 4: 1 ratio with proteins and carbohydrates. KD is considered the most ancient antiepileptic therapy, actually proposed also for migraine therapy.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Romano, Palmira; Ricciardi, Annaclaudia] Univ Campania Luigi Vanvitelli, Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Alesi M, 2014, NEUROPSYCH DIS TREAT, V10, P479, DOI 10.2147/NDT.S58455
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio M. F., 2013, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V172, P705
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   La Grutta S, 2007, Minerva Pediatr, V59, P745
   La Grutta S, 2006, Minerva Pediatr, V58, P513
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P491, DOI 10.19193/0393-6384_2017_3_073
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P481, DOI 10.19193/0393-6384_2017_3_071
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2015, MENT ILLN, V7, P32, DOI 10.4081/mi.2015.5988
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisano S, 2017, J CHILD ADOL PSYCHOP, V27, P844, DOI 10.1089/cap.2016.0203
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 95
TC 3
Z9 3
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 769
EP 775
DI 10.19193/0393-6384_2017_5_113
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000007
DA 2022-07-14
ER

PT J
AU Maltese, A
   Salerno, M
   Romano, P
   Ricciardi, A
   Di Filippo, T
   Tripi, G
AF Maltese, Agata
   Salerno, Margherita
   Romano, Palmira
   Ricciardi, Annaclaudia
   Di Filippo, Teresa
   Tripi, Gabriele
TI KETOGENIC DIET AS ANTIEPILEPTIC THERAPY: NEUROTRASMISSION EFFECTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ketogenic diet; epilepsy; cholesterol; free fatty acids
ID AUTISM SPECTRUM DISORDERS; PRIMARY NOCTURNAL ENURESIS; SLEEP-APNEA
   SYNDROME; QUALITY-OF-LIFE; CHILDHOOD ABSENCE EPILEPSY; PRIMARY CILIARY
   DYSKINESIA; PRADER-WILLI-SYNDROME; WEIGHT-LOSS PROGRAM; PARENTAL STRESS;
   MATERNAL STRESS
AB The Ketogenic diet (KD) presents many effects on neurostrasmitters pathways.
   KD may act on potassium channels sensitive to ATP (KATP), inhibiting rapamycin pathway in mammalians or glutamatergic synaptic transmission or mediated by peptide hormones.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Romano, Palmira; Ricciardi, Annaclaudia] Univ Campania Luigi Vanvitelli, Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Alesi M, 2014, NEUROPSYCH DIS TREAT, V10, P479, DOI 10.2147/NDT.S58455
   Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79
   Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Epifanio M. F., 2013, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V172, P705
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   La Grutta S, 2007, Minerva Pediatr, V59, P745
   La Grutta S, 2006, Minerva Pediatr, V58, P513
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G, 2014, J ANESTH CLIN RES, V5, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395.]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P491, DOI 10.19193/0393-6384_2017_3_073
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P481, DOI 10.19193/0393-6384_2017_3_071
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2015, MENT ILLN, V7, P32, DOI 10.4081/mi.2015.5988
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pisano S, 2017, J CHILD ADOL PSYCHOP, V27, P844, DOI 10.1089/cap.2016.0203
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 95
TC 19
Z9 19
U1 0
U2 8
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 777
EP 783
DI 10.19193/0393-6384_2017_5_114
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000008
DA 2022-07-14
ER

PT J
AU Maltese, A
   Romano, P
   D'Oro, L
   Gallai, B
   Marotta, R
   Lavano, F
   Lavano, SM
   Tripi, G
   Salerno, M
AF Maltese, Agata
   Romano, Palmira
   D'Oro, Lucrezia
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Tripi, Gabriele
   Salerno, Margherita
TI RETRACTED: ANGER IN CHILDREN: A MINIREVIEW (Retracted article. See vol.
   34, 2018)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review; Retracted Publication
DE anger; children; emotional control; drawings
ID MIGRAINE; SLEEP; AURA; CARE; IRAN; KERMANSHAH; HOSPITALS; SYNERGISM;
   ENURESIS; EFFICACY
AB Aggressive behavior is a peculiar characteristic of most animal species playing an important role in species preservation and two types have been identified: interspecific and intraspecific aggression. The interspecific refers purely to the instinct of predation, while the intraspecific is the purpose for species preservation. Anger has been found in very young children between the ages of four and seven, is manifested through vocalizations, expressions and global movements affecting the entire body of the child: it is a means of communication privileged to express themselves and communicate. Anger must be considered a positive event, even if it may frighten it has a positive effect: transforming an event that could only be destructive and useless in a constructive process, and channeling the child's anger toward a specific goal.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Romano, Palmira] Ctr LARS, Sarno, Italy.
   [D'Oro, Lucrezia] Ctr Relax, Benevento, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco; Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI TRIPI, Gabriele/0000-0001-7088-9325; Marotta, Rosa/0000-0003-0515-5952
CR Acar YA, 2016, ACTA MEDICA MEDITERR, V32, P75
   Akdam H, 2016, ACTA MEDICA MEDITERR, V32, P685, DOI 10.19193/0393-6384_2016_3_75
   Behnamipour S, 2016, ACTA MEDICA MEDITERR, V32, P1549
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Chisari G, 2016, ACTA MEDICA MEDITERR, V32, P865, DOI 10.19193/0393-6384_2016_4_102
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Crittenden PM, 2017, CLIN CHILD PSYCHOL P, V22, P436, DOI 10.1177/1359104517716214
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Di Serio F, 2016, ACTA MEDICA MEDITERR, V32, P1911, DOI 10.19193/0393-6384_2016_6_182
   Eksi F, 2017, ACTA MEDICA MEDITERR, V33, P341, DOI 10.19193/0393-6384_2017_2_051
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Eraslan A, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_153
   Es MU, 2016, ACTA MEDICA MEDITERR, V32, P911, DOI 10.19193/0393-6384_2016_4_109
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Fariba F, 2016, ACTA MEDICA MEDITERR, V32, P2101
   Feghhi F, 2016, ACTA MEDICA MEDITERR, V32, P1011
   George C, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01594
   Jalili Z, 2016, ACTA MEDICA MEDITERR, V32, P915
   Karakas D, 2017, ACTA MEDICA MEDITERR, V33, P811, DOI 10.19193/0393-6384_2017_5_120
   Kargin NC, 2016, ACTA MEDICA MEDITERR, V32, P317
   Khodaii Z, 2017, ACTA MEDICA MEDITERR, V33, P301, DOI 10.19193/0393-6384_2017_2_045
   Kilic B, 2017, ACTA MEDICA MEDITERR, V33, P335, DOI 10.19193/0393-6384_2017_2_050
   Kirisci O, 2016, ACTA MEDICA MEDITERR, V32, P1805, DOI 10.19193/0393-6384_2016_6_167
   Li HC, 2016, ACTA MEDICA MEDITERR, V32, P519
   Li Y, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_148
   Li ZX, 2017, ACTA MEDICA MEDITERR, V33, P41, DOI 10.19193/0393-6384_2017_1_006
   Licata M, 2016, ACTA MEDICA MEDITERR, V32, P1569, DOI 10.19193/0393-6384_2016_5_131
   Lin ZH, 2016, ACTA MEDICA MEDITERR, V32, P575
   Liu TG, 2016, ACTA MEDICA MEDITERR, V32, P877, DOI 10.19193/0393-6384_2016_4_104
   Ma H, 2016, ACTA MEDICA MEDITERR, V32, P1155
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P667, DOI 10.19193/03936384_2017_4_100
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P675, DOI 10.19193/0393-6384_2017_4_101
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P641, DOI 10.19193/0393-6384_2017_4_095
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P645, DOI 10.19193/0393-6384_2017_4_096
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Mohammadnejad E, 2016, ACTA MEDICA MEDITERR, V32, P1295
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Motlagh AH, 2016, ACTA MEDICA MEDITERR, V32, P2065
   Nankaly A, 2016, ACTA MEDICA MEDITERR, V32, P953
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Pekel NB, 2017, ACTA MEDICA MEDITERR, V33, P101, DOI 10.19193/0393-6384_2017_1_016
   Perciavalle V, 2016, ACTA MEDICA MEDITERR, V32, P23
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Pirsaheb M, 2016, ACTA MEDICA MEDITERR, V32, P967
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rasouli AS, 2016, ACTA MEDICA MEDITERR, V32, P1063
   Refahi S, 2016, ACTA MEDICA MEDITERR, V32, P1207
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salehi M, 2016, ACTA MEDICA MEDITERR, V32, P1933
   Salehi N, 2016, ACTA MEDICA MEDITERR, V32, P1965
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Valiee S, 2016, ACTA MEDICA MEDITERR, V32, P1021
   van Rosmalen L, 2016, HIST PSYCHOL, V19, P22, DOI 10.1037/hop0000015
   Vazirinejad R, 2016, ACTA MEDICA MEDITERR, V32, P987, DOI 10.19193/0393-6384_2016_4_120
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Wang GP, 2016, ACTA MEDICA MEDITERR, V32, P599
   Wang H, 2016, ACTA MEDICA MEDITERR, V32, P547
   Wen SJ, 2016, ACTA MEDICA MEDITERR, V32, P481
   Wen SW, 2016, ACTA MEDICA MEDITERR, V32, P303
   Yoon H., 2016, ACTA MEDICA MEDITERR, V32, P1697, DOI DOI 10.19193/0393-6384_5_152
   Zohreyi T, 2016, ACTA MEDICA MEDITERR, V32, P1257
NR 84
TC 1
Z9 1
U1 3
U2 17
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1233
EP 1240
DI 10.19193/0393-6384_2017_2s_191
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700008
DA 2022-07-14
ER

PT J
AU Maltese, A
   Gallai, B
   Romano, P
   D'Oro, L
   Marotta, R
   Lavano, F
   Lavano, SM
   Tripi, G
   Salerno, M
AF Maltese, Agata
   Gallai, Beatrice
   Romano, Palmira
   D'Oro, Lucrezia
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Tripi, Gabriele
   Salerno, Margherita
TI RETRACTED: MOTION SICKNESS IN CHILDHOOD MIGRAINE (Retracted article. See
   vol. 34, 2018)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE childhood migraine; periodic syndromes; Abdominal Migraine; Motion
   Sickness; Cyclic Vomiting; Growing Pains
ID BENIGN PAROXYSMAL VERTIGO; RESTLESS-LEGS-SYNDROME; PEDIATRIC MIGRAINE;
   CHILDREN; AURA; SLEEP; ANXIETY; HEADACHE; EFFICACY; THERAPY
AB Background: Migraine is a chronic, progressive, and debilitating disorder that has an impact on the lives of millions of individuals. The origins of the disability can be traced into childhood and adolescence for most adult migraine sufferers. The group of periodic syndromes consists in symptoms related to migraine, thought to be migraine equivalent or precursors. Aim of this study is to assess the role of MS as risk factors for childhood migraine.
   Materials and methods: 441 subjects (211 Females) aged 6-13 years (mean 9.20; SD 2.42), consecutively referred between October 2007 to March 2009 for primary headaches to pediatric Centers for Headache in Childhood. Control group consisted of 365 subjects (175 F) aged 7-13 years (mean 9.08; SD 3.02).
   Results: Two groups were not different for age (F=0.390; p=0.539) and sex ratio (Chi-square=0.002; p=0.966). Headache percentage distribution was the following: MoA 38.32%, MA 11.11%, FETTH 16.78%, CTTH 20.63%. Logistic regression shows a greater OR for CVS and MS associated for migraine group (MoA and MA patients), respectively 8.28 (IC95% 2.35 - 29.16) for CVS and 5.22 (IC95% 3.5 - 7.77); moreover, CVS cause a consistent increase in OR of 3.69 (IC95% 2.21 - 6.17) also for headache group (CTTH and FETTH patients).
   Discussion: Periodic syndromes could be considered the natural precursors of migraine almost but not only in children, as reported in some studies in adulthood.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Romano, Palmira] Ctr LARS, Sarno, Italy.
   [D'Oro, Lucrezia] Ctr Relax, Benevento, Italy.
   [Marotta, Rosa; Lavano, Francesco; Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI TRIPI, Gabriele/0000-0001-7088-9325; Marotta, Rosa/0000-0003-0515-5952
CR Al-Twaijri WA, 2002, PEDIATR NEUROL, V26, P365, DOI 10.1016/S0887-8994(01)00416-7
   Ambrosini A, 2003, BRAIN, V126, P2009, DOI 10.1093/brain/awg206
   Balaban CD, 1999, CURR OPIN NEUROL, V12, P29, DOI 10.1097/00019052-199902000-00005
   Barlow CF, 1984, EXPRESSION CHILDHOOD, P46
   BASSER LS, 1964, BRAIN, V87, P141, DOI 10.1093/brain/87.1.141
   Bigal ME, 2008, CURR OPIN NEUROL, V21, P301, DOI 10.1097/WCO.0b013e328300c6f5
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Chieffi S., 2015, J PSYCHIAT, V18, DOI [10.4172/1994-8220.1000228, DOI 10.4172/1994-8220.1000228]
   Chugani DC, 1999, NEUROLOGY, V53, P1473, DOI 10.1212/WNL.53.7.1473
   Cole JA, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-26
   Cologno D, 2008, NEUROL SCI, V29, pS166, DOI 10.1007/s10072-008-0915-4
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   d'Onofrio F, 2006, EUR J NEUROL, V13, P85, DOI 10.1111/j.1468-1331.2006.01129.x
   d'Onofrio F, 2008, NEUROL SCI, V29, pS169, DOI 10.1007/s10072-008-0916-3
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito T, 2006, J THERM BIOL, V31, P527, DOI 10.1016/j.jtherbio.2006.07.002
   FENICHEL GM, 1967, J PEDIATR-US, V71, P114, DOI 10.1016/S0022-3476(67)80239-7
   LANZI G, 1983, CEPHALALGIA, V3, P115, DOI 10.1046/j.1468-2982.1983.0302115.x
   Lewis DW, 2009, NEUROL CLIN, V27, P481, DOI 10.1016/j.ncl.2008.11.003
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Marcus DA, 2006, MED SCI MONITOR, V12, pPI1
   Marcus D, 2007, HEADACHE, V47, P607, DOI 10.1111/j.1526-4610.2007.00762.x
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BENEFICIAL EFFECTS C, DOI [10.4172/0974-8369.1000, DOI 10.4172/0974-8369.1000]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2015, BIOL MED
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Panconesi A, 1997, CEPHALALGIA, V17, P3, DOI 10.1046/j.1468-2982.1997.1701003.x
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Sabayan B, 2007, MED HYPOTHESES, V69, P64, DOI 10.1016/j.mehy.2006.10.060
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Shevell M., 1998, CONT PEDIAT, V15, P71
   Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x
   Teggi R, 2009, HEADACHE, V49, P435, DOI 10.1111/j.1526-4610.2009.01338.x
   Tietjen GE, 2007, HEADACHE, V47, P857, DOI 10.1111/j.1526-4610.2007.00814.x
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Vendrame M, 2008, PEDIATR NEUROL, V39, P6, DOI 10.1016/j.pediatrneurol.2008.03.007
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Wang CT, 2009, HEADACHE, V49, P426, DOI 10.1111/j.1526-4610.2008.01283.x
   Yates BJ, 1998, BRAIN RES BULL, V47, P395, DOI 10.1016/S0361-9230(98)00092-6
NR 65
TC 1
Z9 1
U1 2
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1241
EP 1247
DI 10.19193/0393-6384_2017_2s_192
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700009
DA 2022-07-14
ER

PT J
AU Maltese, A
   Gallai, B
   Marotta, R
   Lavano, F
   Lavano, SM
   Tripi, G
   Romano, P
   D'Oro, L
   Salerno, M
AF Maltese, Agata
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Tripi, Gabriele
   Romano, Palmira
   D'Oro, Lucrezia
   Salerno, Margherita
TI RETRACTED: NEUROSCIENCES AND ATTACHMENT THEORY: A BRIEF REVIEW
   (Retracted article. See vol. 34, 2018)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review; Retracted Publication
DE attachment theory; neurosciences; fMRI; cortisol
ID SLEEP-APNEA SYNDROME; CHILDREN; MIGRAINE; AURA; THERAPY; PROGNOSIS;
   EFFICACY; ANXIETY; DISEASE; RESISTANCE
AB The attachment theory was proposed and elaborated by John Bowlby.
   Over the last ten years the attachment theory has attracted considerable interest in the field of mental health as it emphasizes how relationships that are established in the earliest stages of development have an impact on man in an indefinable and lifelong manner.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Romano, Palmira] Ctr LARS, Sarno, Italy.
   [D'Oro, Lucrezia] Ctr Relax, Benevento, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI TRIPI, Gabriele/0000-0001-7088-9325; Marotta, Rosa/0000-0003-0515-5952
CR Aktas T, 2017, ACTA MEDICA MEDITERR, V33, P183, DOI 10.19193/0393-6384_2017_2_026
   Ali FB, 2017, ACTA MEDICA MEDITERR, V33, P935, DOI 10.19193/0393-6384_2017_1s_140
   Aliverti M, 2017, ACTA MEDICA MEDITERR, V33, P471, DOI 10.19193/0393-6384_2017_3_069
   Amini M, 2017, ACTA MEDICA MEDITERR, V33, P945, DOI 10.19193/0393-6384_2017_1s_141
   Atik D, 2016, ACTA MEDICA MEDITERR, V32, P933, DOI 10.19193/0393-6384_2016_4_112
   Aydin B, 2016, ACTA MEDICA MEDITERR, V32, P457
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Celik M, 2016, ACTA MEDICA MEDITERR, V32, P691, DOI 10.19193/0393-6384_2016_3_76
   Chisari EM, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_133
   Ciftci F, 2016, ACTA MEDICA MEDITERR, V32, P967, DOI 10.19193/0393-6384_2016_4_117
   Cocuzza S, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_134
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Crittenden PM, 2017, CLIN CHILD PSYCHOL P, V22, P436, DOI 10.1177/1359104517716214
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Dong GZ, 2016, ACTA MEDICA MEDITERR, V32, P103
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito G, 2017, BEHAV BRAIN RES, V325, P87, DOI 10.1016/j.bbr.2017.03.025
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Farahani ZB, 2016, ACTA MEDICA MEDITERR, V32, P1071
   Feng Y, 2016, ACTA MEDICA MEDITERR, V32, P505
   George C, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01594
   Gerardo B, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_137
   Gunaydin ZY, 2016, ACTA MEDICA MEDITERR, V32, P143
   Jamebozorg Z, 2016, ACTA MEDICA MEDITERR, V32, P1939
   Jamebozorg Z, 2016, ACTA MEDICA MEDITERR, V32, P1103
   Jiang W, 2016, ACTA MEDICA MEDITERR, V32, P535
   Karakilic E, 2016, ACTA MEDICA MEDITERR, V32, P1791, DOI 10.19193/0393-6384_2016_6_165
   Kardes S, 2016, ACTA MEDICA MEDITERR, V32, P947, DOI 10.19193/0393-6384_2016_4_114
   Kohan S, 2016, ACTA MEDICA MEDITERR, V32, P1503
   Koylu O, 2016, ACTA MEDICA MEDITERR, V32, P291
   Li WM, 2016, ACTA MEDICA MEDITERR, V32, P511
   Ma YS, 2016, ACTA MEDICA MEDITERR, V32, P485
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P675, DOI 10.19193/0393-6384_2017_4_101
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Mirjalili MR, 2016, ACTA MEDICA MEDITERR, V32, P1203
   Mirzaei N, 2016, ACTA MEDICA MEDITERR, V32, P1471
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Nedeljkovic-Arsenovic O, 2016, ACTA MEDICA MEDITERR, V32, P443
   Niu TL, 2016, ACTA MEDICA MEDITERR, V32, P871, DOI 10.19193/0393-6384_2016_4_103
   Nobari SM, 2016, ACTA MEDICA MEDITERR, V32, P1077
   Obrenovic-Kircanski B, 2016, ACTA MEDICA MEDITERR, V32, P63
   Oruc A, 2016, ACTA MEDICA MEDITERR, V32, P325
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Pekel NB, 2017, ACTA MEDICA MEDITERR, V33, P101, DOI 10.19193/0393-6384_2017_1_016
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Pirodda A, 2016, ACTA MEDICA MEDITERR, V32, P863, DOI 10.19193/0393-6384_2016_4_101
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Sastre-Heres AJ, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_151
   Shahram S, 2016, ACTA MEDICA MEDITERR, V32, P999
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   van Rosmalen L, 2016, HIST PSYCHOL, V19, P22, DOI 10.1037/hop0000015
   Vecchio I, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_132
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Wan L, 2016, ACTA MEDICA MEDITERR, V32, P1129
   Yang SY, 2016, ACTA MEDICA MEDITERR, V32, P1123
   Yazdi B, 2016, ACTA MEDICA MEDITERR, V32, P1029
   Zadeh FH, 2016, ACTA MEDICA MEDITERR, V32, P2055
NR 78
TC 2
Z9 2
U1 5
U2 25
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1249
EP 1255
DI 10.19193/0393-6384_2017_2s_193
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700010
DA 2022-07-14
ER

PT J
AU Maltese, A
   Gallai, B
   Marotta, R
   Lavano, F
   Lavano, SM
   Tripi, G
   Romano, P
   D'Oro, L
   Salerno, M
AF Maltese, Agata
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Tripi, Gabriele
   Romano, Palmira
   D'Oro, Lucrezia
   Salerno, Margherita
TI THE SYNACTIVE THEORY OF DEVELOPMENT: THE KEYWORD FOR NEURODEVELOPMENTAL
   DISORDERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Synactive Theory of Development; autonomic nervous system; sleep
ID AUTISM SPECTRUM DISORDERS; SLEEP-APNEA SYNDROME; CHILDHOOD ABSENCE
   EPILEPSY; KETOGENIC DIET; SELF-CONCEPT; CHILDREN; MIGRAINE; AURA;
   DEPRESSION; THERAPY
AB The synactive theory of development may be considered the keyword for neurodevelopmental disorders, considering that each one presents constantly autonomic troubles such as sleep disorders, feeding problems.
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco; Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Romano, Palmira; D'Oro, Lucrezia] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; TRIPI, Gabriele/0000-0001-7088-9325
CR Als H, 1986, PHYS OCCUPATIONAL TH, V6, P3, DOI DOI 10.1080/J006V06N03_02
   Asgary MR, 2016, ACTA MEDICA MEDITERR, V32, P1243
   Barghamadi Z, 2016, ACTA MEDICA MEDITERR, V32, P2069
   Bembich S, 2017, J PERINAT NEONAT NUR, V31, P67, DOI 10.1097/JPN.0000000000000228
   Bosnak V, 2016, ACTA MEDICA MEDITERR, V32, P997, DOI 10.19193/0393-6384_2016_4_122
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Chieffi S., 2015, J PSYCHIAT, V18, DOI [10.4172/1994-8220.1000228, DOI 10.4172/1994-8220.1000228]
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito T, 2006, J THERM BIOL, V31, P527, DOI 10.1016/j.jtherbio.2006.07.002
   Giardina S, 2016, ACTA MEDICA MEDITERR, V32, P1739, DOI 10.19193/0393-6384_2016_6_157
   Gibbins Sharyn, 2008, Adv Neonatal Care, V8, P141, DOI 10.1097/01.ANC.0000324337.01970.76
   Guclu A, 2016, ACTA MEDICA MEDITERR, V32, P1843, DOI 10.19193/0393-6384_2016_6_172
   Hazavehei SMM, 2016, ACTA MEDICA MEDITERR, V32, P995
   Kefeli A., 2016, ACTA MEDICA MEDITERR, V32, P1609, DOI 10.19193/0393-6384_2016_5_139
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P777, DOI 10.19193/0393-6384_2017_5_114
   Maltese A, 2017, ACTA MEDICA MEDITERR, V33, P769, DOI 10.19193/0393-6384_2017_5_113
   Martini R, 2016, AM J OCCUP THER, V70
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BENEFICIAL EFFECTS C, DOI [10.4172/0974-8369.1000, DOI 10.4172/0974-8369.1000]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda V, 2017, ACTA MEDICA MEDITERR, V33, P581, DOI 10.19193/0393-6384_2017_4_085
   Moscatelli F, 2015, BIOL MED
   Moscatelli F, 2017, ACTA MEDICA MEDITERR, V33, P423, DOI 10.19193/0393-6384_2017_3_062
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Ozcelik KC, 2016, ACTA MEDICA MEDITERR, V32, P209
   Ozkaya I, 2016, ACTA MEDICA MEDITERR, V32, P255
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P491, DOI 10.19193/0393-6384_2017_3_073
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Pektas SD, 2016, ACTA MEDICA MEDITERR, V32, P1785, DOI 10.19193/0393-6384_2016_6_164
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Pickler Rita H, 2004, Neonatal Intensive Care, V17, P31
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Rezaei S, 2016, ACTA MEDICA MEDITERR, V32, P1449
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Roan C, 2017, PHYS OCCUP THER PEDI, V37, P283, DOI 10.1080/01942638.2016.1185503
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Salerno M, 2017, ACTA MEDICA MEDITERR, V33, P621, DOI 10.19193/0393-6384_2017_4_092
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Shahtaheri E, 2016, ACTA MEDICA MEDITERR, V32, P2047
   Shamansouri S, 2016, ACTA MEDICA MEDITERR, V32, P2107
   Ulusoy MO, 2016, ACTA MEDICA MEDITERR, V32, P925, DOI 10.19193/0393-6384_2016_4_111
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Vardar E, 2016, ACTA MEDICA MEDITERR, V32, P753, DOI 10.19193/0393-6384_2016_3_85
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
NR 71
TC 9
Z9 9
U1 3
U2 11
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1257
EP 1263
DI 10.19193/0393-6384_2017_2s_194
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700011
DA 2022-07-14
ER

PT J
AU Maltese, A
   Gallai, B
   Romano, P
   D'Oro, L
   Marotta, R
   Lavano, F
   Lavano, SM
   Tripi, G
   Salerno, M
AF Maltese, Agata
   Gallai, Beatrice
   Romano, Palmira
   D'Oro, Lucrezia
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Tripi, Gabriele
   Salerno, Margherita
TI RETRACTED: THE DYNAMIC MATURATIVE MODEL FOR ATTACHMENT (Retracted
   article. See vol. 34, 2018)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE dynamic maturative model; attachment style; intersubjectivity
ID CHILDREN; MIGRAINE; PLATELET; DISEASE; SLEEP; AURA; STRATEGIES;
   EFFICACY; POSITION; THERAPY
AB The Dynamic- Maturation Model (DMM) was developed by Patricia Crittenden (1-4), which focused its studies on attachment to different ethnic, socio-cultural and dangers as families in which episodes of Maltreatment and abuse or families with high psychosocial risk. Crittenden proposes new protocols of the Strange Situation (SS) and the Adult Attachment Interview (AAI) based on a coding and classification system derived from the model proposed by Ainsworth, but modified and enriched with that of Main, Goldwyn and Hesse. The SS procedure, adopted for children aged between 10 and 18 months, is valid until all preschool age, assuming This way the name of the Preschool Assessment of Attachment (PAA).
C1 [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Romano, Palmira] Ctr LARS, Sarno, Italy.
   [D'Oro, Lucrezia] Ctr Relax, Benevento, Italy.
   [Marotta, Rosa; Lavano, Francesco; Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; TRIPI, Gabriele/0000-0001-7088-9325
CR Ariyurek SY, 2016, ACTA MEDICA MEDITERR, V32, P367
   Bayhan Z, 2016, ACTA MEDICA MEDITERR, V32, P111
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Chieffi S., 2015, J PSYCHIAT, V18, DOI [10.4172/1994-8220.1000228, DOI 10.4172/1994-8220.1000228]
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   Crittenden PM, 2017, CLIN CHILD PSYCHOL P, V22, P436, DOI 10.1177/1359104517716214
   Crittenden PM, 2017, CLIN CHILD PSYCHOL P, V22, P358, DOI 10.1177/1359104517704027
   Crittenden PM, 1999, MONOGR SOC RES CHILD, V64, P145
   Dahaz S, 2016, ACTA MEDICA MEDITERR, V32, P1039
   Dogru S, 2016, ACTA MEDICA MEDITERR, V32, P791, DOI 10.19193/0393-6384_2016_3_91
   Erken E, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_138
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito T, 2006, J THERM BIOL, V31, P527, DOI 10.1016/j.jtherbio.2006.07.002
   Fariba F, 2016, ACTA MEDICA MEDITERR, V32, P863
   Gulmez C, 2016, ACTA MEDICA MEDITERR, V32, P361
   Gunduz O, 2016, ACTA MEDICA MEDITERR, V32, P805, DOI 10.19193/0393-6384_2016_3_94
   Hamissi JH, 2016, ACTA MEDICA MEDITERR, V32, P1335
   Jamshidi F, 2016, ACTA MEDICA MEDITERR, V32, P1311
   Jiang S, 2016, ACTA MEDICA MEDITERR, V32, P539
   Lan YH, 2016, ACTA MEDICA MEDITERR, V32, P1137
   Li HY, 2016, ACTA MEDICA MEDITERR, V32, P1117
   Mao YL, 2016, ACTA MEDICA MEDITERR, V32, P837, DOI 10.19193/0393-6384_2016_3_99
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Mehrabi S, 2016, ACTA MEDICA MEDITERR, V32, P2079
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G, 2015, BENEFICIAL EFFECTS C, DOI [10.4172/0974-8369.1000, DOI 10.4172/0974-8369.1000]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Mohammadlou M, 2016, ACTA MEDICA MEDITERR, V32, P1265
   Moscatelli F, 2015, BIOL MED
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Murat B, 2016, ACTA MEDICA MEDITERR, V32, P843, DOI 10.19193/0393-6384_2016_3_100
   Nader S, 2016, ACTA MEDICA MEDITERR, V32, P1007
   Norbech PCB, 2013, J PERS ASSESS, V95, P571, DOI 10.1080/00223891.2013.823441
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Piskipasa N, 2016, ACTA MEDICA MEDITERR, V32, P203
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Savran Y, 2016, ACTA MEDICA MEDITERR, V32, P17
   Song R, 2016, ACTA MEDICA MEDITERR, V32, P593
   Taheri B, 2016, ACTA MEDICA MEDITERR, V32, P1055
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Yang J, 2016, ACTA MEDICA MEDITERR, V32, P543
   Yuan SM, 2016, ACTA MEDICA MEDITERR, V32, P355
NR 61
TC 2
Z9 2
U1 4
U2 15
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1265
EP 1270
DI 10.19193/0393-6384_2017_2s_195
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700012
DA 2022-07-14
ER

PT J
AU Mamur, A
   Kayhan, M
   Oztas, D
AF Mamur, Ahmet
   Kayhan, Mehmet
   Oztas, Dilek
TI EVALUATION OF METABOLIC PANEL AND HEPATITIS MARKERS OF TYPE 2 DIABETES
   MELLITUS PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Type 2 DM; Hepatitis B; Hepatitis C
ID VACCINATION; INFECTION; INFLUENZA; IMPACT
AB Purpose: Our aim is to evaluate the hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (AntiHBs) and AntiHCV negativity and positivity rates which can be investigated in the primary care in Type 2 Diabetes Mellitus (DM) patients in this study.
   Material and method: The recordings of patients who were diagnosed with type 2 diabetes and whose hepatitis serology was recorded in Eskisehir Tepebasi District Yeni Family Health Center's information management system program between the dates of 01.01.2016 - 31.12.2016 were evaluated retrospectively. Age, gender, comorbid diseases of patients were noted. Hepatitis serology and routine blood test results in the last 3 months were taken from the database. SPSS 21 program was used for statistical analyze.
   Results: A total of 300 patients were reached. 182 (60.7%) of the patients were female and 118 (39.3%) were male. The mean age of the patients was 58.66 +/- 11.44 years. When the patients were questioned regarding treatment method of diabetes, it was found out that 205 patients (68.3%) received only oral antidiabetic (OAD), 54 patients (18.0%) received insulin with OAD, and 41 patients (13.7%) received only insulin therapy. Of the 300 patients in the study group, 16 (5.3%) were hepatitis B surface antigen (HBsAg) positive, 62 (20.7%) were hepatitis B surface antibody (AntiHBs) positive and 7 (2.3%) were AntiHCV positive.
   Conclusion: Vaccination rates of patients can be increased by spending more time on counseling about vaccination and by emphasizing possible problems they may face if not vaccinated.
C1 [Mamur, Ahmet] Eskisehir Publ Hlth Management, Eskisehir, Turkey.
   [Kayhan, Mehmet] Yeni Family Hlth Care Ctr, Eskisehir, Turkey.
   [Oztas, Dilek] Yildirim Beyazit Univ, Dept Publ Hlth, Ankara, Turkey.
RP Mamur, A (corresponding author), Eskisehir Publ Hlth Management, Eskisehir, Turkey.
RI kayhan, mehmet/W-1631-2017
OI kayhan, mehmet/0000-0001-7493-5165
CR [Anonymous], 2014, DIABETES CARE, V37, pS5, DOI 10.2337/dc14-S005
   Arslan E. I., 2016, AWARENESS HEPATITIS, V27
   Barut HS, 2009, KLIMIK J, V22, P38
   Bridges CB, 2013, MMWR-MORBID MORTAL W, V62, P9
   Cacoub P, 2000, MEDICINE, V79, P47, DOI 10.1097/00005792-200001000-00005
   Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P1709
   Citil R, 2010, ERCIYES MED J, V32, P111
   Fabrizi F, 2011, ALIMENT PHARM THER, V33, P815, DOI 10.1111/j.1365-2036.2011.04589.x
   Hoerger TJ, 2013, DIABETES CARE, V36, P63, DOI 10.2337/dc12-0759
   Huang JF, 2007, AM J GASTROENTEROL, V102, P1237, DOI 10.1111/j.1572-0241.2007.01181.x
   Hung CH, 2011, INT J CANCER, V128, P2344, DOI 10.1002/ijc.25585
   MCKINNEY WP, 1989, AM J PUBLIC HEALTH, V79, P1422, DOI 10.2105/AJPH.79.10.1422
   Meisinger C, 2002, ARCH INTERN MED, V162, P82, DOI 10.1001/archinte.162.1.82
   Noto H, 2006, J DIABETES COMPLICAT, V20, P113, DOI 10.1016/j.jdiacomp.2006.01.001
   Pala T, 2004, TURKISH J ENDOCRINOL, V3, P91
   Reilly Meredith L, 2012, J Diabetes Sci Technol, V6, P858
   Satman I, 2013, HUM VACC IMMUNOTHER, V9, P2618, DOI 10.4161/hv.25826
   Satman I, 2013, EUR J EPIDEMIOL, V28, P169, DOI 10.1007/s10654-013-9771-5
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Thompson Nicola D, 2009, J Diabetes Sci Technol, V3, P283
NR 20
TC 0
Z9 0
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1003
EP 1006
DI 10.19193/0393-6384_2017_6_158
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500018
DA 2022-07-14
ER

PT J
AU Massimino, S
   Rinella, S
   Cicarelli, C
   Guarnera, M
   Di Corrado, D
AF Massimino, Simona
   Rinella, Sergio
   Cicarelli, Cristina
   Guarnera, Maria
   Di Corrado, Donatella
TI PSYCHOLOGICAL FEATURES OF YOUNG GIRLS PRACTISING WATER SPORTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE water sport; women; development; emotion; self-esteem
ID BLOOD LACTATE; WORKING-MEMORY; MOOD STATES; IN-VITRO; EXCITABILITY;
   PERFORMANCE; EXPRESSION; PROFILE; VIVO
AB Introduction: This study aims to investigate the characteristics of those who practice two water sports during development, such as water polo and synchronized swimming, through assessment of emotional states, self-esteem, personological features and visual-spatial skills, such as perceptual organization and visual memory.
   Materials and methods: A total of 24 young female athletes (Age: mean, m = 11.47 year; +/- 0.61 Standard Deviation, SD; Height: m = 143.75 centimeters, +/- 6.13SD; Weight: m = 39.22 kilograms, +/- 3.83SD) practicing team water sports at a competitive level from at least one year participated in the research; 11 of them were part of a synchronized swimming team and 13 of a water polo squad. To carry out the present study, in order to assess personality, self-esteem, mood and visual-spatial skills of sample, the following psychological assessment tests were used: 1) Big Five Questionnaire for Children, 2) Multidimensional Self-esteem Test, 3) Profile of Mood States-Adolescent, and 4) Rey-Osterrieth Complex Figure Test. The study was performed at the sports center "Torre del Grifo Village" (Mascalucia, Italy).
   Results: The study has showed, in both groups of athletes, the presence of personological features oriented to establish friendly and cooperative relations; what it makes us conclude that within the two teams there are positive relationships between athletes, also aimed at achieving the common goal, and that the group component is crucial. It is also seen that in the synchronized swimming team the individual dimension emerges strongly, in terms of athletic competition spirit.
   Conclusion: The comparison between the two groups showed that the water polo seems to encourage the development of visual-spatial skills, compared to synchronized swimmers. It is due to better performance in the memory copy of Rey-Osterrieth Complex Figure, by the water polo athletes.
C1 [Massimino, Simona; Rinella, Sergio; Cicarelli, Cristina] Univ Catania, Sect Physiol, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Guarnera, Maria; Di Corrado, Donatella] Kore Univ, Dept Human & Social Sci, Enna, Italy.
RP Di Corrado, D (corresponding author), Univ KORE Enna, Dept Sport Sci, I-94100 Enna, Italy.
RI Di Corrado, Donatella/H-3726-2019; Rinella, Sergio/AAB-5946-2021; Di
   Corrado, Donatella/K-3757-2019; Rinella, Sergio/ADM-1130-2022
OI Di Corrado, Donatella/0000-0001-8223-6671; Rinella,
   Sergio/0000-0002-9368-7088
CR Allport G., 1961, PATTERN GROWTH PERSO
   Barbaranelli C, 2003, PERS INDIV DIFFER, V34, P645, DOI 10.1016/S0191-8869(02)00051-X
   Barbaranelli C, 1998, BIG FIVEQUESTIONNAIR
   BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497
   Bracken B.A, 2003, TEST TMA VALUTAZIONE
   Cei A, 1998, PSICOLOGIA SPORT
   Chatard JC, 1999, EUR J APPL PHYSIOL, V79, P479, DOI 10.1007/s004210050540
   Coco M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002978
   Coco M, 2014, SOMATOSENS MOT RES, V31, P35, DOI 10.3109/08990220.2013.834816
   Coco M, 2013, SOMATOSENS MOT RES, V30, P90, DOI 10.3109/08990220.2013.769949
   Coco M, 2009, BRAIN RES, V1302, P205, DOI 10.1016/j.brainres.2009.09.032
   Di Corrado D, 2014, MOL MED REP, V9, P2441, DOI 10.3892/mmr.2014.2115
   Donia M, 2012, ONCOL REP, V28, P682, DOI 10.3892/or.2012.1840
   Eagleton JR, 2007, PERCEPT MOTOR SKILL, V105, P265, DOI 10.2466/PMS.105.5.265-275
   Fagone P, 2013, J NEUROIMMUNOL, V261, P82, DOI 10.1016/j.jneuroim.2013.04.013
   Fagone P, 2013, BASIC CLIN PHARMACOL, V112, P63, DOI 10.1111/j.1742-7843.2012.00923.x
   Furley P, 2010, PERCEPT MOTOR SKILL, V110, P801, DOI 10.2466/PMS.110.3.801-808
   GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8
   HOLLANDER AP, 1994, MED SPORT SCI, V39, P178
   Maxwell J. P., 2007, PSYCHOL ANGER, P203
   Melchiorri G, 2010, J STRENGTH COND RES, V24, P2647, DOI 10.1519/JSC.0b013e3181e3486b
   Mijatovic S, 2010, FREE RADICAL BIO MED, V48, P1090, DOI 10.1016/j.freeradbiomed.2010.01.026
   Musumeci G, 2013, INT J MOL SCI, V14, P15767, DOI 10.3390/ijms140815767
   Perciavalle V, 2015, NEUROL SCI, V36, P2129, DOI 10.1007/s10072-015-2329-4
   Perciavalle V, 2015, NEUROL SCI, V36, P1597, DOI 10.1007/s10072-015-2210-5
   Perciavalle V, 2014, PERCEPT MOTOR SKILL, V118, P940, DOI 10.2466/19.50.PMS.118k27w8
   Perciavalle V, 2014, PERCEPT MOTOR SKILL, V118, P733, DOI 10.2466/29.30.PMS.118k22w1
   Perciavalle V, 2014, SOMATOSENS MOT RES, V31, P1, DOI 10.3109/08990220.2013.796924
   Perciavalle V, 2013, MOL MED REP, V7, P1733, DOI 10.3892/mmr.2013.1426
   PRAPAVESSIS H, 1992, AUSTR J SCI MED SPOR, V24, P12
   Proios M., 2012, International Quarterly of Sport Science, P10
   Rey A., 1959, NEUROL SCI, V22, P443
   Slutzky CB, 2009, PSYCHOL SPORT EXERC, V10, P381, DOI 10.1016/j.psychsport.2008.09.006
   Tenenbaum G, 2008, MIL PSYCHOL, V20, pS11, DOI 10.1080/08995600701804772
   Terry PC, 1999, J SPORT SCI, V17, P861, DOI 10.1080/026404199365425
   Terry PC, 2003, PSYCHOL SPORT EXERC, V4, P125, DOI 10.1016/S1469-0292(01)00035-8
   TERRY PC, 1996, J SPORTS SCI, V14, P49
   Watanabe K, 2005, BRAIN DEV-JPN, V27, P564, DOI 10.1016/j.braindev.2005.02.007
   Williams AM, 2005, HUM MOVEMENT SCI, V24, P283, DOI 10.1016/j.humov.2005.06.002
   Yamamura C, 1999, INT J SPORTS MED, V20, P246, DOI 10.1055/s-2007-971125
NR 40
TC 0
Z9 0
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 657
EP 662
DI 10.19193/0393-6384_2017_4_098
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700019
DA 2022-07-14
ER

PT J
AU Maugeri, R
   Giammalva, GR
   Cicero, G
   de Luca, R
   Guli, C
   Graziano, F
   Basile, L
   Giugno, A
   Iacopino, DG
AF Maugeri, Rosario
   Giammalva, Giuseppe Roberto
   Cicero, Giuseppe
   de Luca, Rossella
   Guli, Carlo
   Graziano, Francesca
   Basile, Luigi
   Giugno, Antonella
   Iacopino, Domenico Gerardo
TI UNUSUAL CASE OF DORSAL VERTEBRAL METASTASES FROM A MALE BREAST CANCER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE male breast cancer; therapy; metastatic breast cancer; dorsal vertebral
   metastatic; surgery
ID V-GAMMA-9V-DELTA-2 T-CELLS; IMMUNOTHERAPY; INTERLEUKIN-2; ZOLEDRONATE;
   SPINE
AB Introduction: Breast cancer is a malignant neoplasm arising from mammary glands and is a rare entity in the male patient. Spine is a common site for skeletal metastases.
   Case presentation: A 53-years-old male was admitted to our Neurosurgical unit because of an untreatable dorsal pain. He had been treated 3 years before for breast cancer. A dorsal Magnetic Resonance Imaging (MRI) evidenced pathological masses at T8 level. A total body Computed Tomography (CT) scan revealed lungs and liver metastases. After a multidisciplinary consult, a posterior T8 decompression, a radiofrequency thermoablation in T8 vertebral body followed by screws and rods fixation (T7-T9) was performed. Post-operative course was uneventful and the patient experienced a significant improvement of dorsal pain. Cycles of adjuvant chemo-radiotherapy followed. After 8 months, patient is still alive and in good general conditions but a spine MRI revealed a rapid and widespread diffusion of ostelytic metastases.
   Conclusion: Despite the high incidence of breast cancer metastases to the spine, very few clinical reports (just eight, whose only one treated surgically) in the literature deal specifically with metastases from male breast cancer, which is rarer and with a worst prognosis than female counterpart. In spite of the poor course, surgery still plays a role in treating these kind of malignancies and in improving quality of life.
C1 [Maugeri, Rosario; Giammalva, Giuseppe Roberto; Guli, Carlo; Graziano, Francesca; Basile, Luigi; Giugno, Antonella; Iacopino, Domenico Gerardo] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Sch Med, Neurosurg Clin, Palermo, Italy.
   [Cicero, Giuseppe; de Luca, Rossella] Univ Palermo, Dept Surg Oncol & Oral Sci, DICHIRONS, Policlin Paolo Giaccone, Palermo, Italy.
   [Cicero, Giuseppe; de Luca, Rossella] Univ Palermo, Palermo, Italy.
RP Cicero, G (corresponding author), Univ Palermo, Dept Surg Oncol & Oral Sci, Med Oncol, Via Vespro 129, I-90127 Palermo, Italy.
RI graziano, francesca/AAP-6443-2020; Giammalva, Giuseppe
   Roberto/R-7941-2016; Iacopino, Domenico/C-1539-2013
OI Giammalva, Giuseppe Roberto/0000-0001-6309-8963; Iacopino,
   Domenico/0000-0003-1685-5209; Graziano, Francesca/0000-0001-8754-6572;
   De Luca, Rossella/0000-0001-7116-3366
CR Berman AT, 2013, CLIN BREAST CANCER, V13, P88, DOI 10.1016/j.clbc.2012.11.001
   Botelho Ricardo Vieira, 2013, Open Orthop J, V7, P286, DOI 10.2174/1874325001307010286
   Caccamo N, 2008, CURR MED CHEM, V15, P1147, DOI 10.2174/092986708784310468
   Choi D, 2010, EUR SPINE J, V19, P215, DOI 10.1007/s00586-009-1252-x
   Cicero G, 2017, J GENET COUNS, V26, P999, DOI 10.1007/s10897-017-0072-0
   Cicero G, 2017, ANTICANCER RES, V37, P1475, DOI 10.21873/anticanres.11472
   Cicero G, 2017, ONCOLOGY-BASEL, V92, P94, DOI 10.1159/000452491
   De Luca R, 2016, ACTA MEDICA MEDITERR, V32, P1827
   De Luca R, 2016, ACTA MEDICA MEDITERR, V32, P1835
   de Oliveira MF, 2015, ARQ NEURO-PSIQUIAT, V73, P330, DOI 10.1590/0004-282X20150003
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008-5472.CAN-07-0199
   Fontanella C, 2015, CLIN EXP METASTAS, V32, P819, DOI 10.1007/s10585-015-9743-0
   Grasso G, 2007, SPINAL CORD, V45, P793, DOI 10.1038/sj.sc.3102105
   Graziano Francesca, 2016, Surg Neurol Int, V7, pS77, DOI 10.4103/2152-7806.174894
   Grenader T, 2007, BREAST J, V13, P410, DOI 10.1111/j.1524-4741.2007.00450.x
   Lopez-O'Rourke VJ, 2009, SPINE, V34, pE586, DOI 10.1097/BRS.0b013e3181aa2687
   Korde LA, 2010, J CLIN ONCOL, V28, P2114, DOI 10.1200/JCO.2009.25.5729
   Kuba S, 2016, BREAST CANCER-TOKYO, V23, P945, DOI 10.1007/s12282-016-0679-2
   La Torre D, 2009, NEUROSURGERY, V64, P1082, DOI 10.1227/01.NEU.0000345946.35786.92
   Maugeri R, 2017, ACTA NEUROCHIR SUPPL, V124, P81, DOI 10.1007/978-3-319-39546-3_13
   Maugeri R, 2015, INTERDISCIP NEUROSUR, V2, P160, DOI 10.1016/j.inat.2015.07.002
   Maugeri R, 2016, WORLD NEUROSURG, V95, P611, DOI 10.1016/j.wneu.2016.06.128
   Maugeri R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071029
   Meraviglia S, 2010, CLIN EXP IMMUNOL, V161, P290, DOI 10.1111/j.1365-2249.2010.04167.x
   Meraviglia S, 2010, ONCOL REV, V4, P211, DOI 10.1007/s12156-010-0054-z
   Sanguinetti A, 2016, Int J Surg Case Rep, V20S, P8, DOI 10.1016/j.ijscr.2016.02.004
   de Souza PVS, 2015, NEUROLOGY, V85, P1183, DOI 10.1212/WNL.0000000000001977
   Shehadi JA, 2007, EUR SPINE J, V16, P1179, DOI 10.1007/s00586-007-0357-3
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016
   Weiss JR, 2005, CANCER EPIDEM BIOMAR, V14, P20, DOI 10.1158/1055-9965.EPI-05-0414
NR 31
TC 3
Z9 3
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1157
EP 1161
DI 10.19193/0393-6384_2017_6_181
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500040
DA 2022-07-14
ER

PT J
AU Mert, D
   Yilmaz, GR
   Ceken, S
   Iskender, G
   Yenigun, A
   Ertek, M
AF Mert, Duygu
   Yilmaz, Gul Ruhsar
   Ceken, Sabahat
   Iskender, Gulsen
   Yenigun, Ayla
   Ertek, Mustafa
TI EVALUATION OF EPIDEMIOLOGICAL CHARACTERISTICS, RISK FACTORS AND
   ANTIFUNGAL SENSITIVITY OF CANDIDEMIA CASES IN A TERTIARY-CARE HOSPITAL
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Candidemia; epidemiology; risk factors; antifungal susceptibility
ID BLOOD-STREAM INFECTION; INVASIVE CANDIDIASIS; SPECIES DISTRIBUTION; FKS
   MUTATIONS; SUSCEPTIBILITY; SURVEILLANCE; MORTALITY; GLABRATA;
   MULTICENTER; OUTCOMES
AB Introduction: Blood circulation infections due to Candida species have an increasing prevalence among nosocomial infections. These infections cause significant morbidity and mortality. In this study, it is aimed to evaluate the epidemiologic features, risk factors and antifungal susceptibility of candidemia cases in a tertiary-care hospital.
   Materials and methods: Between January 1, 2012 and March 1, 2016, the data of patients with candidemia were recorded in a previously prepared form in a tertiary-care hospital. In the same period, cases without candidemia were taken as control group. Candidemia cases and control group were compared in terms of epidemiological characteristics and possible risk factors. SPSS 16.0 program was used for statistical analysis.
   Results: The mean age of 60 patients diagnosed with candidemia was 57.3 +/- 18.3, 37 (61.7%) were males and 23 (38.3%) were females. The mean age of the 60 patients in the control group was 58.6 +/- 16.6, 35 (58.3%) were male and 25 (41.7%) were female. The most common isolated Candida species were C. albicans (48,3%), C. glabrata (13,3%), C. parapsilosis (10,0%), C. crusei (8% 3), C. tropicalis (8,3%), Candida spp. (5%), C. lipolytica (1.7%) and C. famota (1.7%). Amphotericin B resistance rate was 10.40% for C. albicans, 9.7% for non-albicans, fluconazole resistance rate was 3.5% for C. albicans, 19.4% for non-albicans, voriconazole resistance rate was 7,00% for C. albicans. No resistance was found in non-albicans species. There was no resistance to caspofungin, itraconazole and micafungin. According to the results of antifungal susceptibility, there was no increased resistance among Candida species compared to previous years. Conclusions: In this study, total parenteral nutrition and the use of piperacillin-tazobactam, meropenem and imipenem were the most frequent risk factors for Candida-associated bloodstream infections. The most frequently isolated species was Candida albicans. The proportion of total non-albicans species was high as a result.
C1 [Mert, Duygu; Yilmaz, Gul Ruhsar; Ceken, Sabahat; Iskender, Gulsen; Ertek, Mustafa] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Infect Dis & Clin Microbiol Clin, Ankara, Turkey.
   [Yenigun, Ayla] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Med Microbiol Lab, Ankara, Turkey.
RP Mert, D (corresponding author), Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Infect Dis & Clin Microbiol Clin, Ankara, Turkey.
RI ceken, sabahat/ABA-5328-2020
CR Alexander BD, 2013, CLIN INFECT DIS, V56, P1724, DOI 10.1093/cid/cit136
   Bassetti M, 2014, INTENS CARE MED, V40, P839, DOI 10.1007/s00134-014-3310-z
   Bassetti M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024198
   Castanheira M, 2014, ANTIMICROB AGENTS CH, V58, P577, DOI 10.1128/AAC.01674-13
   Chen PY, 2014, J MICROBIOL IMMUNOL, V47, P95, DOI 10.1016/j.jmii.2012.08.025
   Chow JK, 2008, CRIT CARE MED, V36, P1993, DOI 10.1097/CCM.0b013e31816fc4cd
   Cleveland AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120452
   Diekema DJ, 2002, J CLIN MICROBIOL, V40, P1298, DOI 10.1128/JCM.40.4.1298-1302.2002
   Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192
   Eggimann P, 2003, LANCET INFECT DIS, V3, P685, DOI 10.1016/S1473-3099(03)00801-6
   Erdem F, 2012, MIKROBIYOL BUL, V46, P637
   Garnacho-Montero J, 2010, ANTIMICROB AGENTS CH, V54, P3149, DOI 10.1128/AAC.00479-10
   Hachem R, 2008, CANCER, V112, P2493, DOI 10.1002/cncr.23466
   Kocak BY, 2011, MIKROBIYOL BUL, V45, P489
   Kullberg BJ, 2015, NEW ENGL J MED, V373, P1445, DOI 10.1056/NEJMra1315399
   Leroy O, 2009, CRIT CARE MED, V37, P1612, DOI 10.1097/CCM.0b013e31819efac0
   Lyon GM, 2010, J CLIN MICROBIOL, V48, P1270, DOI 10.1128/JCM.02363-09
   Ma CF, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-337
   Marchetti O, 2004, CLIN INFECT DIS, V38, P311, DOI 10.1086/380637
   Ostrosky-Zeichner L, 2003, EUR J CLIN MICROBIOL, V22, P651, DOI 10.1007/s10096-003-1014-3
   Oxman DA, 2010, J ANTIMICROB CHEMOTH, V65, P1460, DOI 10.1093/jac/dkq136
   Rajendran R, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00915
   Tadec L, 2016, MYCOSES, V59, P296, DOI 10.1111/myc.12470
   Wang TY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003834
   WEY SB, 1989, ARCH INTERN MED, V149, P2349, DOI 10.1001/archinte.149.10.2349
   Yang ZT, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-241
NR 26
TC 1
Z9 1
U1 2
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 815
EP 820
DI 10.19193/0393-6384_2017_5_121
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000015
DA 2022-07-14
ER

PT J
AU Messina, A
   Monda, V
   Nigro, E
   Valenzano, AA
   Villano, I
   Ruberto, M
   Monda, G
   Ascione, A
   Chieffi, S
   Cibelli, G
   Messina, G
   Monda, M
AF Messina, Antonietta
   Monda, Vincenzo
   Nigro, Ersilia
   Valenzano, Anna A.
   Villano, Ines
   Ruberto, Maria
   Monda, Giuseppe
   Ascione, Antonio
   Chieffi, Sergio
   Cibelli, Giuseppe
   Messina, Giovanni
   Monda, Marcellino
TI AN ALLIED HEALTH: THE PASTA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Mediterranean Diet; Pasta; Prevention; Health and Wellness
ID CAROTID-ARTERY OCCLUSION; PIAL MICROVASCULAR RESPONSES; MEDITERRANEAN
   DIET; LINE BISECTION; HEART-RATE; RAT; REPERFUSION; MICROCIRCULATION;
   INTERFERENCE; QUALITY
AB The Mediterranean diet has been recognized historical and cultural heritage of great importance, nutritional and culinary excellence to scratch. In the Mediterranean diet 50-60% of kilocalories should come from carbohydrates, 25-30% from lipids and the remaining 10-15% from protein, the dough thus represents the main source of complex carbohydrates, ideal energy source is essential for the daily activities ensuring the good health state. The beneficial properties and the nutritional values of pasta are numerous Pasta is a ally of the diet: satiating has great power and is an excellent solution for stress. It also contains vitamins of the B group essential for the proper functioning of the nervous system, the starch paste is free glucose, which promotes the synthesis of serotonin, which gives well-being. Some studies have shown that, among the carbohydrates, the pasta has the lowest glycemic index not therefore increases the levels of C-reactive protein, which proved to be correlated with cardiovascular risk does not increase the risk of hypertension because it contains very little sodium and fiber, the latter fundamental in the prevention of cancer.
C1 [Messina, Antonietta; Monda, Vincenzo; Villano, Ines; Monda, Giuseppe; Chieffi, Sergio; Cibelli, Giuseppe; Messina, Giovanni; Monda, Marcellino] Univ Campania, Dept Expt Med, Sect Human Physiol, Naples, Italy.
   [Messina, Antonietta; Monda, Vincenzo; Villano, Ines; Monda, Giuseppe; Chieffi, Sergio; Cibelli, Giuseppe; Messina, Giovanni; Monda, Marcellino] Univ Campania, Unit Dietet & Sport Med, Naples, Italy.
   [Nigro, Ersilia; Messina, Giovanni] CEINGE Biotecnol Avanzate Scarl, Naples, Italy.
   [Valenzano, Anna A.] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Ascione, Antonio] Univ Naples Parthenope, Dept Motor Sci & Wellness, Naples, Italy.
   [Ruberto, Maria] Univ Campania Luigi Vanvitelli, Dept Med Surg & Dent Specialties, Naples, Italy.
RP Messina, A (corresponding author), Univ Naples 2, Dept Expt Med, Sect Human Physiol, Via Costantinopoli 16, I-80138 Naples, Italy.; Messina, A (corresponding author), Univ Naples 2, Clin Dietet Serv, Via Costantinopoli 16, I-80138 Naples, Italy.
RI Messina, Antonietta/AHH-2383-2022; Cibelli, Giuseppe/AAC-2635-2019;
   MESSINA, ANTONIETTA/K-9366-2016; Ascione, Antonio/I-9473-2018; Messina,
   Giovanni/AAE-8668-2022
OI Messina, Antonietta/0000-0001-8343-432X; Ascione,
   Antonio/0000-0003-4466-1807; Messina, Giovanni/0000-0002-0011-867X;
   Nigro, Ersilia/0000-0001-5637-1685; Monda,
   Marcellino/0000-0002-7184-218X; Monda, Vincenzo/0000-0002-6083-5814;
   VILLANO, INES/0000-0002-1755-358X; CIBELLI, GIUSEPPE/0000-0002-5371-2584
FU Pastificio Di Martino Gaetano F. lli Spa
FX Thanks to Pastificio Di Martino Gaetano & F. lli Spa for non-conditioned
   financial support for research projects in Nutrition Physiology.
CR Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Esposito T, 2006, J THERM BIOL, V31, P527, DOI 10.1016/j.jtherbio.2006.07.002
   Muros JJ, 2017, NUTRITION, V35, P87, DOI 10.1016/j.nut.2016.11.002
   Lapi D, 2013, ARCH ITAL BIOL, V151, P11, DOI 10.4449/aib.v151i1.1470
   Lapi D, 2013, J VASC RES, V50, P332, DOI 10.1159/000353295
   Lapi D, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00099
   Lapi D, 2015, MICROCIRCULATION, V22, P79, DOI 10.1111/micc.12175
   Lapi D, 2013, CLIN HEMORHEOL MICRO, V54, P415, DOI 10.3233/CH-131763
   Lapi D, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00032
   Lapi D, 2011, J PINEAL RES, V51, P136, DOI 10.1111/j.1600-079X.2011.00870.x
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G., 2014, J ANESTH CLIN RES, V5, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina G, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00137
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3831972
   Padalino L, 2016, CARBOHYD POLYM, V153, P229, DOI 10.1016/j.carbpol.2016.07.102
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Tong TYN, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0677-4
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
NR 30
TC 6
Z9 6
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 641
EP 644
DI 10.19193/0393-6384_2017_4_095
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700016
DA 2022-07-14
ER

PT J
AU Messina, A
   Monda, V
   Avola, R
   Moscatelli, F
   Valenzano, AA
   Villano, I
   Ruberto, M
   Monda, E
   La Marra, M
   Tafuri, D
   Chieffi, S
   Cibelli, G
   Monda, M
   Messina, G
AF Messina, Antonietta
   Monda, Vincenzo
   Avola, Roberto
   Moscatelli, Fiorenzo
   Valenzano, Anna A.
   Villano, Ines
   Ruberto, Maria
   Monda, Emanuele
   La Marra, Marco
   Tafuri, Domenico
   Chieffi, Sergio
   Cibelli, Giuseppe
   Monda, Marcellino
   Messina, Giovanni
TI ROLE OF THE OREXIN SYSTEM ON AROUSAL, ATTENTION, FEEDING BEHAVIOUR AND
   SLEEP DISORDERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE orexin; hypocretin; arousal; attention; sleep; narcolepsy
ID HYPERTHERMIC REACTIONS; HEART-RATE; CEREBRAL INJECTION; ARTERY
   OCCLUSION; INTERFERENCE; DISTRACTOR; BISECTION
AB The orexin-A/hypocretin-1 and orexin-B/hypocretin-2 are neuropeptides synthesized by a cluster of neurons in the lateral hypothalamus. Orexins play an significant role in regulating arousal and attention. The term "arousal" refers to a person's general state of alertness or excitation, both physiological and psychological. Arousal levels ranges on a continuum from drowsiness through alertness to excitement. Orexin plays an important role in the regulation of feeding behaviour. The orexin stimulates food intake and reduces the metabolic rate, increasing and maintaining the body's energy reserves. Orexins play also a fundamental role in the regulation of the sleep-wake cycle by increasing arousal levels and maintaining wakefulness. Its deficit can cause narcolepsy. Key to the diagnosis of narcolepsy is the combination of a common symptom, excessive daytime sleepiness, and an uncommon symptom, cataplexy, i.e. a sudden and transient episode of muscle weakness
C1 [Messina, Antonietta; Monda, Vincenzo; Villano, Ines; Monda, Emanuele; La Marra, Marco; Chieffi, Sergio; Cibelli, Giuseppe; Monda, Marcellino; Messina, Giovanni] Univ Campania, Dept Expt Med, Sect Human Physiol, Naples, Italy.
   [Messina, Antonietta; Monda, Vincenzo; Villano, Ines; Monda, Emanuele; La Marra, Marco; Chieffi, Sergio; Cibelli, Giuseppe; Monda, Marcellino; Messina, Giovanni] Univ Campania, Unit Dietet & Sport Med, Naples, Italy.
   [Avola, Roberto; Messina, Giovanni] Univ Catania, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Moscatelli, Fiorenzo; Valenzano, Anna A.] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Tafuri, Domenico] Univ Naples Parthenope, Dept Motor Sci & Wellness, Naples, Italy.
   [Ruberto, Maria] Univ Campania Luigi Vanvitelli, Dept Med Surg & Dent Specialties, Naples, Italy.
RP Messina, A (corresponding author), Univ Naples 2, Dept Expt Med, Sect Human Physiol, Via Costantinopoli 16, I-80138 Naples, Italy.; Messina, A (corresponding author), Univ Naples 2, Clin Dietet Serv, Via Costantinopoli 16, I-80138 Naples, Italy.
RI Messina, Antonietta/AHH-2383-2022; Cibelli, Giuseppe/AAC-2635-2019;
   Monda, Emanuele/AAQ-6457-2020; Moscatelli, Fiorenzo/ABC-9536-2020;
   Messina, Giovanni/AAE-8668-2022; MESSINA, ANTONIETTA/K-9366-2016
OI Messina, Antonietta/0000-0001-8343-432X; Monda,
   Emanuele/0000-0001-9304-988X; Messina, Giovanni/0000-0002-0011-867X;
   VILLANO, INES/0000-0002-1755-358X; Monda,
   Marcellino/0000-0002-7184-218X; Monda, Vincenzo/0000-0002-6083-5814; la
   marra, marco/0000-0001-7488-8493; Moscatelli,
   Fiorenzo/0000-0003-1274-0332; CIBELLI, GIUSEPPE/0000-0002-5371-2584
CR Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Chieffi S, 2004, EXP BRAIN RES, V158, P421, DOI 10.1007/s00221-004-1916-z
   Chieffi S., 2015, J PSYCHIAT, V18, DOI [10.4172/1994-8220.1000228, DOI 10.4172/1994-8220.1000228]
   Chieffi S, 2008, EXP BRAIN RES, V189, P129, DOI 10.1007/s00221-008-1458-x
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Chieffi S, 2012, EXP BRAIN RES, V219, P489, DOI 10.1007/s00221-012-3106-8
   Chieffi S, 2009, BEHAV BRAIN RES, V203, P200, DOI 10.1016/j.bbr.2009.05.003
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Esposito M, 2014, CHEMOSPHERE, V94, P62, DOI 10.1016/j.chemosphere.2013.09.013
   Esposito T, 2006, J THERM BIOL, V31, P527, DOI 10.1016/j.jtherbio.2006.07.002
   Franco R, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-48
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Iavarone A, 2007, J AUTISM DEV DISORD, V37, P775, DOI 10.1007/s10803-006-0190-2
   Lapi D, 2013, ARCH ITAL BIOL, V151, P11, DOI 10.4449/aib.v151i1.1470
   Lapi D, 2013, J VASC RES, V50, P332, DOI 10.1159/000353295
   Lapi D, 2015, MICROCIRCULATION, V22, P79, DOI 10.1111/micc.12175
   Lapi D, 2013, CLIN HEMORHEOL MICRO, V54, P415, DOI 10.3233/CH-131763
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/639280
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2008, CLIN NUTR, V27, P657, DOI 10.1016/j.clnu.2008.04.005
   Monda M, 2008, PEPTIDES, V29, P120, DOI 10.1016/j.peptides.2007.10.016
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2015, BIOL MED
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
NR 50
TC 20
Z9 20
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 645
EP 649
DI 10.19193/0393-6384_2017_4_096
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700017
DA 2022-07-14
ER

PT J
AU Messina, A
   Russo, G
   Monda, V
   Valenzano, A
   Villano, I
   Ascione, A
   Moscatelli, F
   Crescenzo, R
   Catizzone, AR
   Panico, A
   Fulgione, E
   Piombino, L
   Dorato, D
   Cavaliere, G
   Trinchese, G
   Cibelli, G
   Bartolettic, E
   Messina, G
AF Messina, Antonietta
   Russo, Gianluca
   Monda, Vincenzo
   Valenzano, Anna
   Villano, Ines
   Ascione, Antonio
   Moscatelli, Fiorenzo
   Crescenzo, Romoaldo
   Catizzone, Anna Rosa
   Panico, Annalisa
   Fulgione, Elisabetta
   Piombino, Laura
   Dorato, Dario
   Cavaliere, Gina
   Trinchese, Giovanna
   Cibelli, Giuseppe
   Bartolettic, Emanuele
   Messina, Giovanni
TI RETRACTED: EFFECT OF RADIOFREQUENCY ON SYMPATHETIC NERVOUS SYSTEM
   FUNCTIONING (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE radiofrequency devices; sympathetic nervous system; thermogenesis;
   resting energy expenditure; eating behavior
ID HYPERTHERMIC REACTIONS; CEREBRAL INJECTION; CHILDREN; ENERGY;
   INTERFERENCE; POPULATION; MIGRAINE; INCREASE; EXPOSURE; STANDARD
AB Radiofrequency devices for aesthetic applications such as body and face skin tightening, cellulite reduction, rhytids and body contouring treatments are becoming increasingly popular in clinics worldwide due to their demonstrated efficacy and safety combined with a relative lack of complications and down-time. Heating of body tissues by radiofrequency (RF) energy is a mechanism for therapeutic. Such effects may be produced by local changes in tissue temperature (for example, thermally induced changes in regional blood flow) and others may be systemic effects due to the additional thermal load on the body. An elevated core temperature increases metabolism and certain other functions such as heart rate, respiration rate, and nerve conduction velocity
   The aim of this study was to determine whether healthy subjects, non-obese, undergoing treatment with radiofrequency could see changes in REE and SNA, GSR. Twenty healthy adult female, took part in the study. The study protocol consisted of the treatment of twenty minutes of radiofrequency in the abdominal region. Participants in the study were presented in the morning at 8 am fasting for at least 12 h, underwent measurement of REE, HRV and GSR 60 minutes prior to treatment, immediately after treatment, and 120 minutes after treatment.
   Radiofrequency induced significant increases of REE, sympathetic activity, and GSR. This result is also useful in the interpretation of the relationship between the sympathetic nervous system and food intake in young subjects. It has demonstrated a significant influence of sympathetic activity on eating behavior, also through an increase in thermogenesis.
C1 [Messina, Antonietta; Monda, Vincenzo; Villano, Ines] Univ Campania Luigi Vanvitelli, Dept Expt Med, Caserta, Italy.
   [Russo, Gianluca] Univ Foggia, Italian Soc Nonablat Radiofrequency, Foggia, Italy.
   [Valenzano, Anna; Moscatelli, Fiorenzo; Cibelli, Giuseppe; Messina, Giovanni] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Ascione, Antonio] Univ Naples Parthenope, Dept Motor Sci & Wellness, Naples, Italy.
   [Crescenzo, Romoaldo; Catizzone, Anna Rosa; Panico, Annalisa; Fulgione, Elisabetta; Piombino, Laura; Dorato, Dario] Univ Naples Federico II, Italian Soc Aesthet Med, Naples, Italy.
   [Cavaliere, Gina; Trinchese, Giovanna] Univ Naples Federico II, Dept Biol, Naples, Italy.
RP Messina, A (corresponding author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Caserta, Italy.
EM antonietta.messina@unicampania.it
RI Cibelli, Giuseppe/AAC-2635-2019; Messina, Antonietta/AHH-2383-2022;
   Ascione, Antonio/I-9473-2018; Moscatelli, Fiorenzo/ABC-9536-2020;
   MESSINA, ANTONIETTA/K-9366-2016; Giovanna, Trinchese/AAC-5995-2022
OI Messina, Antonietta/0000-0001-8343-432X; Ascione,
   Antonio/0000-0003-4466-1807; Giovanna, Trinchese/0000-0002-4096-6876;
   Monda, Vincenzo/0000-0002-6083-5814; CIBELLI,
   GIUSEPPE/0000-0002-5371-2584; VILLANO, INES/0000-0002-1755-358X;
   Moscatelli, Fiorenzo/0000-0003-1274-0332
CR Acar YA, 2016, ACTA MEDICA MEDITERR, V32, P75
   Adair ER, 2003, BIOELECTROMAGNETICS, V24, P489, DOI 10.1002/bem.10128
   Adair ER, 2001, BIOELECTROMAGNETICS, V22, P429, DOI 10.1002/bem.70
   Antonino A, 2016, ACTA MEDICA MEDITERR, V32, P385
   Aurilio C, 2015, AFRICAN J PSYCHIAT, V18, DOI 10.4172/2378-5756.1000307.
   Behnamipour S, 2016, ACTA MEDICA MEDITERR, V32, P1549
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Chieffi S., 2015, J PSYCHIAT, V18, DOI [10.4172/1994-8220.1000228, DOI 10.4172/1994-8220.1000228]
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   De Fusco C, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4045238
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Di Serio F, 2016, ACTA MEDICA MEDITERR, V32, P1911, DOI 10.19193/0393-6384_2016_6_182
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, CHEMOSPHERE, V94, P62, DOI 10.1016/j.chemosphere.2013.09.013
   Esposito T, 2006, J THERM BIOL, V31, P527, DOI 10.1016/j.jtherbio.2006.07.002
   Fahrenberg J., 2000, ENG PSYCHOPHYSIOLOGY, P111
   Fariba F, 2016, ACTA MEDICA MEDITERR, V32, P2101
   Fiorelli A, 2017, ANN THORAC SURG, V103, P216, DOI 10.1016/j.athoracsur.2016.10.055
   Hirsch J, 2003, OBES RES, V11, P2, DOI 10.1038/oby.2003.2
   Li HC, 2016, ACTA MEDICA MEDITERR, V32, P519
   Licata M, 2016, ACTA MEDICA MEDITERR, V32, P1569, DOI 10.19193/0393-6384_2016_5_131
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/639280
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G, 2014, AFRICAN J PSYCHIAT, V17, DOI 10.4172/Psychiatry.1000172.
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Asian J Sports Med, V7, pe26841, DOI 10.5812/asjsm.26841
   Messina G, 2016, NEUROPSYCH DIS TREAT, V12, P3193
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Mohammadnejad E, 2016, ACTA MEDICA MEDITERR, V32, P1295
   Monda M, 2008, CLIN NUTR, V27, P657, DOI 10.1016/j.clnu.2008.04.005
   Monda M, 2008, PEPTIDES, V29, P120, DOI 10.1016/j.peptides.2007.10.016
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V., 2016, BIOL MED, V8, DOI [10.4172/0974-8369.1000306, DOI 10.4172/0974-8369.1000306]
   Moscatelli F, 2015, BIOL MED
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Nankaly A, 2016, ACTA MEDICA MEDITERR, V32, P953
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Pirsaheb M, 2016, ACTA MEDICA MEDITERR, V32, P967
   Refahi S, 2016, ACTA MEDICA MEDITERR, V32, P1207
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Santamaria S., 2016, BIOL MED, V8, DOI 10.4172/0974-8369.1000263
   Senol S, 2016, ACTA MEDICA MEDITERR, V32, P1773, DOI 10.19193/0393-6384_2016_6_162
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Wang GP, 2016, ACTA MEDICA MEDITERR, V32, P599
   Wang H, 2016, ACTA MEDICA MEDITERR, V32, P547
   Yoon H., 2016, ACTA MEDICA MEDITERR, V32, P1697, DOI DOI 10.19193/0393-6384_5_152
NR 69
TC 23
Z9 23
U1 1
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 833
EP 840
DI 10.19193/0393-6384_2017_5_124
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000018
DA 2022-07-14
ER

PT J
AU Milanova, MH
   Naydenov, SN
   Runev, NM
   Manov, EI
AF Milanova, Maria Hristova
   Naydenov, Stefan Naydenov
   Runev, Nikolay Margaritov
   Manov, Emil Ivanov
TI IMPACT OF SOME MODIFIABLE CARDIOVASCULAR RISK FACTORS ON THE EARLY
   PROGNOSIS AFTER ACUTE MYOCARDIAL INFARCTION
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE hypertension; dyslipidemia; diabetes; smoking; infarction; mortality
ID CIGARETTE-SMOKING; HEART-DISEASE; PREVENTION; MORTALITY
AB Introduction: Arterial hypertension (HTN), dyslipidemias, diabetes mellitus (DM) and smoking are accepted to be major modifiable risk factors (RF) for cardiovascular morbidity and mortality worldwide. Nevertheless their role for the prognosis of patients early after an acute cardiovascular event has not been fully elucidated. The aim of our study was to evaluate the impact of HTN, dyslipidemia, DM and smoking on the early prognosis of patients with acute myocardial infarction (AMI).
   Materials and methods: We included 682 consecutive patients with AMI, mean age 66.6 +/- 12.9 years. Detailed information was collected about the cardiovascular RF of the patients, concomitant diseases, demographic and socio-economic data.
   Results: Acute myocardial infarction with persistent ST-elevation was diagnosed in 344 (50.4%) patients. Arterial hypertension was present in 589 (86.4%), dyslipidemia -347 (50.9%), active smoking -178 (26.1%), type 2 DM -171 (25.1%). In-hospital mortality was 13.6% (n= 89): 14.1% (n= 46) for ST-elevation AMI and 12.7% (n= 38) for non-ST-elevation AMI, p= N. S. The impact of the analyzed RF on the early prognosis, demonstrated by the odds ratio (OR) for lethal outcome was as follows: HTN -OR = 3.19, p< 0.0001, DM -OR = 2.20, p = 0.003, dyslipidemia -OR = 1.80, p= 0.03, active smoking -OR = 0.35, p = 0.005.
   Conclusion: Prevalence of HTN, dyslipidemia, type 2 DM and active smoking in patients with AMI in our study was high with HTN being the most influential RF in regard to the early post-infarction prognosis. While the first three RF were associated with increased early mortality, surprisingly active smoking reduced the risk for unfavourable outcome.
C1 [Milanova, Maria Hristova] UMBALSM NI Pirogov, Clin Cardiol, Sofia, Bulgaria.
   [Naydenov, Stefan Naydenov; Runev, Nikolay Margaritov; Manov, Emil Ivanov] Med Univ Sofia, Dept Internal Dis Prof St Kirkovich, 1 Georgi Sofiyski Str, Sofia 1431, Bulgaria.
RP Naydenov, SN (corresponding author), Med Univ Sofia, Dept Internal Dis Prof St Kirkovich, 1 Georgi Sofiyski Str, Sofia 1431, Bulgaria.
OI Naydenov, Stefan/0000-0002-0855-7861
CR Albert MA, 2006, CIRCULATION, V114, P2619, DOI 10.1161/CIRCULATIONAHA.106.660043
   Bardaji A, 2013, REV ESP CARDIOL, V66, P923, DOI 10.1016/j.rec.2013.07.008
   Dhutia Harshil, 2015, Practitioner, V259, P15
   Doolan Daniel M, 2008, Prog Cardiovasc Nurs, V23, P119, DOI 10.1111/j.1751-7117.2008.00001.x
   Fritz J, 2015, ATHEROSCLEROSIS, V243, P86, DOI 10.1016/j.atherosclerosis.2015.08.048
   Hobbs FDR, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0507-0
   Huisman M, 2005, PREV MED, V40, P756, DOI 10.1016/j.ypmed.2004.09.022
   Kang SH, 2013, NICOTINE TOB RES, V15, P1230, DOI 10.1093/ntr/nts248
   Kotseva K, 2010, EUR J CARDIOV PREV R, V17, P530, DOI 10.1097/HJR.0b013e3283383f30
   McEvoy JW, 2015, ARTERIOSCL THROM VAS, V35, P1002, DOI 10.1161/ATVBAHA.114.304960
   Mucha Lisa, 2006, Gend Med, V3, P279, DOI 10.1016/S1550-8579(06)80216-0
   Naydenov S, 2013, BULGARIAN J CARDIOLO, V2, P15
   Naydenov S, 2014, J CARDIOVASC DIS DIA, V2, P2
   Nichols M, 2014, EUR HEART J, V35, P2950, DOI 10.1093/eurheartj/ehu299
   Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106
   Pimentel AD, 2015, NUTRITION, V31, P827, DOI 10.1016/j.nut.2014.12.024
   Prescott E, 1998, BMJ-BRIT MED J, V316, P1043
   Smith SC, 2012, J AM COLL CARDIOL, V60, P2343, DOI 10.1016/j.jacc.2012.08.962
   Stefan N, 2014, J AM COLL CARDIOL, V63, P2748, DOI 10.1016/j.jacc.2014.01.079
   Vassilaki M, 2015, PREV MED, V81, P326, DOI 10.1016/j.ypmed.2015.09.024
   Yngve A, 2012, PUBLIC HEALTH NUTR, V15, P567, DOI 10.1017/S1368980012000675
NR 21
TC 3
Z9 3
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 821
EP 825
DI 10.19193/0393-6384_2017_5_122
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000016
DA 2022-07-14
ER

PT J
AU Mohamadizadeh, L
   Makvandi, B
   Pasha, R
   Bakhtiarpour, S
   Hafezi, F
AF Mohamadizadeh, Ladan
   Makvandi, Behnam
   Pasha, Reza
   Bakhtiarpour, Saeid
   Hafezi, Fariba
TI COMPARING OF THE EFFECT OF DIALECTICAL BEHAVIOR THERAPY (DBT) AND SCHEMA
   THERAPY (ST) ON REDUCING MOOD ACTIVITY AND SUICIDAL THOUGHTS IN PATIENTS
   WITH BORDERLINE PERSONALITY DISORDER
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE dialectical behavior therapy; schema therapy; mood activity; suicidal
   thoughts; borderline personality disorder
ID DEPRESSION
AB Introduction: Borderline personality disorder is known as the most common personality disorder in the field of psychiatry. The aim of this study was to compare the effect of dialectical behavior therapy and schema therapy on mood activity and suicidal thoughts in patients with borderline personality disorder in the city of Qazvin.
   Materials and methods: This study in terms of purpose is an applied one and in terms of the method of data collection, can be regarded as pre-experimental and post-experimental semi-experimental study with the control group. The study population included all patients with borderline personality disorder and mood activity and suicidal thoughts who referred to Bou-Ali Hospital in the city of Ghazvin. The sample consisted of 36 students, who were selected by convenience sampling. Of these, 24 patients were randomly divided into two groups, two experimental group including12 people, and a control group consisting 12 patients. In this study, The Millon Clinical Multiaxial Inventory, The beck Depression Inventory and Scale suicide imagination Mach (SSIM) were used. Patients with the borderline personality disorder who belonged to the experimental group were under intervention for 16 section which takes long 90 minutes sessions in eight consecutive weeks under the controls. Research data was analyzed using multivariate and single factor analysis of covariance, and T-experimental was analyzed for the independent groups.
   Results: The results showed that there was a significant difference between dialectical behavior therapy and schema therapy with regard to their effect on mood activity and suicidal thoughts at (0.05>P). The results of the Independent t-experimental also showed that there was no significant difference between dialectical behavior therapy and schema therapy in patients with the borderline personality disorder in terms of the Suicidal thoughts variable at (0.05>P), but there was a significant difference between schema therapy and dialectical behavior therapy in patients with the borderline personality disorder in terms of the mood activity variable at (0.01>P).
   Discussion and conclusion: So, we could conclude that dialectical behavior therapy and schema therapy should be effective in reducing mood activity and suicidal thoughts in patients with borderline personality disorder.
C1 [Mohamadizadeh, Ladan] Islamic Azad Univ, Khuzestan Sci & Res Branch, Dept Psychol, Ahvaz, Iran.
   [Makvandi, Behnam; Pasha, Reza; Bakhtiarpour, Saeid; Hafezi, Fariba] Islamic Azad Univ, Ahvaz Branch, Dept Psychol, Ahvaz, Iran.
RP Makvandi, B (corresponding author), Islamic Azad Univ, Ahvaz Branch, Dept Psychol, Ahvaz, Iran.
RI makvandi, behnam/AAN-4246-2021
OI mohamadizadeh, ladan/0000-0001-6250-2709
CR Abolghasemi A, 2012, J CLIN PSYCHOL, V42, P29
   Aghayusefi A, 2015, Q J RES ADDICT, V9, P79
   Alizadeh A, 2013, J PSYCHONURSE, V1, P62
   American Psychiatric Association, 2000, DIAGNOSTIC STAT MANU
   [Anonymous], 2001, PRACT GUID TREATM PA
   Arntz A, 2015, BEHAV RES THER, V74, P60, DOI 10.1016/j.brat.2015.09.002
   Barlow DH, 2002, ABNORMAL PSYCHOL INT
   Barnicot K, 2016, J BEHAV THER EXP PSY, V52, P147, DOI 10.1016/j.jbtep.2016.04.006
   Beck A.T., 1996, BECK DEPRESSION INVE
   Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13
   Dickhaut V, 2014, J BEHAV THER EXP PSY, V45, P242, DOI 10.1016/j.jbtep.2013.11.004
   Khajeh Mogehi N., THESIS
   Kianpoor M, 2016, ACTA MEDICA MEDITERR, V32, P1493
   Kiehn B, 2002, OVERVIEW DIALECTICAL
   Kroger C, 2010, J BEHAV THER EXP PSY, V41, P381, DOI 10.1016/j.jbtep.2010.04.001
   Lynch TR, 2007, INT J GERIATR PSYCH, V22, P131, DOI 10.1002/gps.1703
   Miller PA, 2007, DIALECTICAL BEHAV TH
   Millon T, 1977, J PERSO ASSESSMENT, V68, P62
   Millon T., 1994, MILLON CLINICALMULTI
   Mohan MR, 2009, INT J BUS PERFORM MA, V11, P1, DOI 10.1504/IJBPM.2009.023798
   Moosaviasl SA, 2014, YASUJ UNI MED SCI J, V19, P89
   Sempertegui GA, 2013, CLIN PSYCHOL REV, V33, P426, DOI 10.1016/j.cpr.2012.11.006
   Soloff PH, 2000, PSYCHIAT CLIN N AM, V23, P169, DOI 10.1016/S0193-953X(05)70150-7
   Stepp SD, 2008, J PERS DISORD, V22, P549, DOI 10.1521/pedi.2008.22.6.549
   Zamani N, 2014, SCI J ILAM U MED SCI, V20, P45
   Zamani N, 2012, J HAMEDAN ISLAMIC AZ, V5, P123
NR 26
TC 4
Z9 4
U1 0
U2 25
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1025
EP 1031
DI 10.19193/0393-6384_2017_6_162
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500021
DA 2022-07-14
ER

PT J
AU Monda, V
   Nigro, E
   Ruberto, M
   Monda, G
   Valenzano, A
   Triggiani, AI
   Moscatelli, F
   Monda, E
   Villano, I
   Roccella, M
   Parisi, L
   Messina, A
AF Monda, Vincenzo
   Nigro, Ersilia
   Ruberto, Maria
   Monda, Giuseppe
   Valenzano, Anna
   Triggiani, Antonio I.
   Moscatelli, Fiorenzo
   Monda, Emanuele
   Villano, Ines
   Roccella, Michele
   Parisi, Lucia
   Messina, Antonietta
TI SYNERGISM OR COMPETITION BETWEEN ZINC AND CHROMIUM DIETARY LEVELS ON
   INSULIN ACTION MECHANISM. A METHOD TO INVESTIGATE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE zinc; chromium; dietary supplementation; glucose
ID HYPERTHERMIC REACTIONS; CEREBRAL INJECTION; NOCTURNAL ENURESIS;
   CHILDREN; MIGRAINE; INTERFERENCE; ADOLESCENTS; POPULATION; STRESS; SLEEP
AB Introduction: The action of zinc and chromium on the metabolism of carbohydrates and, consequently, on lipids and protein metabolism improves, on the one hand, the receptor membrane efficiency and, on the other hand, plays an important role in the regulation of secretion and insulin activity. Aim of the study is to gather preliminary data on the efficacy of treatment with zinc or chromium on impairment glucose tolerance.
   Materials and methods: Subjects: All patients from a dietician examination had levels of blood sugar limits (35 men and 58 women; age 39-61 years). Diet food: intake of all nutrients was measured in weekly diary. The supplementation of chromium or zinc has been carried out - in a random way.
   Statistical analysis: Data are expressed as mean +/- SD or percentage changes from baseline.
   Results: Blood glucose trigger levels of our patients (especially the elderly) was closely linked to the intake of chromium with diet rather than to zinc intake. The effect of dietary supplementation of chromium based on the contribution of some foods has a beneficial effect on the glucose tolerance test (0.5 g glucose / kg body weight) (Fig. 1-A) and on the basal blood glucose levels (Fig. 1-B). In particular, the basal level of glucose in the serum decreases after 1 month of treatment, and this is still true after 6 months.
   Discussion: The effect of dietary chromium supplementation has a beneficial effect on the glucose tolerance test and fasting plasma glucose. The presence of zinc was less than chromium, but competes with the same chromium to the glucose tolerance test. The baseline serum glucose level decreases although it is still less than the amount detected in subjects treated with chromium.
   We can speculate that zinc and chromium may present a competitive effect on the absorption of insulin secretion and insulin receptor.
C1 [Monda, Vincenzo; Monda, Giuseppe; Monda, Emanuele; Villano, Ines; Messina, Antonietta] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.
   [Nigro, Ersilia] CEINGE Biotecnol Avanzate Scarl, Naples, Italy.
   [Ruberto, Maria] Univ Campania Luigi Vanvitelli, Dept Med Surg & Dent Specialties, Naples, Italy.
   Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Valenzano, Anna; Triggiani, Antonio I.; Moscatelli, Fiorenzo] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
RP Messina, A (corresponding author), Univ Naples 2, Dept Expt Med, Sect Human Physiol, Via Costantinopoli 16, I-80138 Naples, Italy.; Messina, A (corresponding author), Univ Naples 2, Clin Dietet Serv, Via Costantinopoli 16, I-80138 Naples, Italy.
RI Monda, Emanuele/AAQ-6457-2020; Triggiani, Antonio Ivano/M-6252-2015;
   MESSINA, ANTONIETTA/K-9366-2016; Messina, Antonietta/AHH-2383-2022;
   triggiani, antonio ivano/Q-4701-2019; Moscatelli, Fiorenzo/ABC-9536-2020
OI Monda, Emanuele/0000-0001-9304-988X; Messina,
   Antonietta/0000-0001-8343-432X; triggiani, antonio
   ivano/0000-0003-3291-9452; Moscatelli, Fiorenzo/0000-0003-1274-0332;
   Nigro, Ersilia/0000-0001-5637-1685; VILLANO, INES/0000-0002-1755-358X;
   Monda, Vincenzo/0000-0002-6083-5814
CR Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Chieffi S., 2015, J PSYCHIAT, V18, DOI [10.4172/1994-8220.1000228, DOI 10.4172/1994-8220.1000228]
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2014, CHEMOSPHERE, V94, P62, DOI 10.1016/j.chemosphere.2013.09.013
   Esposito T, 2006, J THERM BIOL, V31, P527, DOI 10.1016/j.jtherbio.2006.07.002
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/639280
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2008, CLIN NUTR, V27, P657, DOI 10.1016/j.clnu.2008.04.005
   Monda M, 2008, PEPTIDES, V29, P120, DOI 10.1016/j.peptides.2007.10.016
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Moscatelli F, 2015, BIOL MED
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
NR 47
TC 21
Z9 21
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 581
EP 585
DI 10.19193/0393-6384_2017_4_085
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700006
DA 2022-07-14
ER

PT J
AU Monda, V
   Anna, V
   Ruberto, M
   Villano, I
   Russo, V
   La Marra, M
   Pastore, B
   Giuseppe, C
   Salerno, M
   Albano, GD
   Sessa, F
   Marsala, G
   Messina, A
AF Monda, Vincenzo
   Anna, Valenzano
   Ruberto, Maria
   Villano, Ines
   Russo, Vincenzo
   La Marra, Marco
   Pastore, Bianca
   Giuseppe, Cibelli
   Salerno, Monica
   Albano, Giseppe D.
   Sessa, Francesco
   Marsala, Gabriella
   Messina, Antonietta
TI PHYSIOLOGICAL POSTURAL STABILIZATION WITH RUGRAN PLANTAR IN ATHLETES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Plantar; posture; foot; static pedobarographic
ID LASER-SCANNING MICROSCOPY; TESTOSTERONE BIOSYNTHESIS; MICROVASCULAR
   RESPONSES; PRESSURE DISTRIBUTION; LINE BISECTION; PES CAVUS; CHILDREN;
   MIGRAINE; STABILITY; AURA
AB The foot is a complex structure with many articulations and multiple degrees of freedom that play an important role in static posture and dynamic activities. The evolutionary development of the arch of the foot was coincident with the greater demands placed on the foot as humans began to run. The movement and stability of the arch is controlled by intrinsic and extrinsic muscles.
   The aim of the present study was to investigate if a medical device (plantar), called RUGRAN, can enhance muscle rehabilitation in pain syndromes muscle-tendon for the correction and stabilization postural. The static pedobarographic evaluation revealed significantly higher values in terms of forefoot peak pressure, total plantar force and total contact area in subject without RUGARN plantar, compared to subjects with RUGARN plantar. To the best of our knowledge this is the first study that analyzed the pedobarographic improvements in subjects with the RUGARN plantar. The static pedobarographic results observed while the subjects were standing revealed no difference of force distribution and contact area between forefoot and rearfoot and this finding did not support the hypothesis that the centre of the body shifts to forward because of excessive adipose tissue causing excessive forefoot loading.
C1 [Monda, Vincenzo; Villano, Ines; La Marra, Marco; Pastore, Bianca; Messina, Antonietta] Univ Naples 2, Dept Expt Med, Naples, Italy.
   [Anna, Valenzano; Giuseppe, Cibelli; Salerno, Monica; Albano, Giseppe D.; Sessa, Francesco] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Ruberto, Maria] Univ Campania Luigi Vanvitelli, Dept Med Surg & Dent Specialties, Caserta, Italy.
   [Russo, Vincenzo] FMSI, Via Campi Sportivi, Rome, Italy.
   [Marsala, Gabriella] Azienda Osped Univ, Osped Riuniti Foggia, Struttura Complessa Farm, Foggia, Italy.
RP Messina, A (corresponding author), Univ Naples 2, Dept Expt Med, Naples, Italy.
EM antonietta.messina@unicampania.it
RI Sessa, Francesco/G-1754-2018; SALERNO, MONICA/AAC-1321-2019; MESSINA,
   ANTONIETTA/K-9366-2016; Messina, Antonietta/AHH-2383-2022
OI Sessa, Francesco/0000-0003-0357-8791; SALERNO,
   MONICA/0000-0002-6410-3960; Messina, Antonietta/0000-0001-8343-432X;
   VILLANO, INES/0000-0002-1755-358X; Monda, Vincenzo/0000-0002-6083-5814;
   la marra, marco/0000-0001-7488-8493
CR Barone R, 2017, J CELL MOL MED, V21, P1636, DOI 10.1111/jcmm.13092
   Barone R, 2017, J CELL PHYSIOL, V232, P1086, DOI 10.1002/jcp.25511
   Bergmann A., 2017, J MANIPULATIVE PHYSL
   Brunelli M, 2012, ARCH ITAL BIOL, V150, P231, DOI 10.4449/aib.v150i4.1420
   Burns J, 2005, CLIN BIOMECH, V20, P877, DOI 10.1016/j.clinbiomech.2005.03.006
   Busardo FP, 2015, INT J MOL SCI, V16, P6557, DOI 10.3390/ijms16036557
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Cerretani D, 2011, PHARMACOL RES, V64, P517, DOI 10.1016/j.phrs.2011.08.002
   Chieffi S., 2015, J PSYCHIAT, V18, DOI [10.4172/1994-8220.1000228, DOI 10.4172/1994-8220.1000228]
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Femery V, 2002, CLIN BIOMECH, V17, P406, DOI 10.1016/S0021-9290(02)00063-5
   FRANCO AH, 1987, PHYS THER, V67, P688, DOI 10.1093/ptj/67.5.688
   Franettovich MM, 2007, J AM PODIAT MED ASSN, V97, P115, DOI 10.7547/0970115
   FRANK JS, 1990, PHYS THER, V70, P855, DOI 10.1093/ptj/70.12.855
   Frati P, 2013, CURR PHARM BIOTECHNO, V14, P1157, DOI 10.2174/1389201015666140430101639
   Frati P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt333
   Gao S, 2011, ENTROPY-SWITZ, V13, P936, DOI 10.3390/e13050936
   Gravante G, 2003, CLIN BIOMECH, V18, P780, DOI 10.1016/S0268-0033(03)00123-2
   HENNIG EM, 1994, FOOT ANKLE, V15, P35, DOI 10.1177/107110079401500107
   Hillman SJ, 2016, MED ENG PHYS, V38, P485, DOI 10.1016/j.medengphy.2016.01.008
   Hong YL, 2012, J SCI MED SPORT, V15, P554, DOI 10.1016/j.jsams.2012.01.004
   Hue O, 2007, GAIT POSTURE, V26, P32, DOI 10.1016/j.gaitpost.2006.07.005
   Khoury M, 2013, FOOT ANKLE INT, V34, P593, DOI 10.1177/1071100713477613
   Lapi D, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00099
   Lapi D, 2013, CLIN HEMORHEOL MICRO, V53, P303, DOI 10.3233/CH-2012-1552
   Lapi D, 2011, J PINEAL RES, V51, P136, DOI 10.1111/j.1600-079X.2011.00870.x
   Lee J.-W., 2010, GRAVITY QUANTUM ENTA, V7
   Massion J., 2004, PROGR BRAIN RES
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   McKeon PO, 2015, CLIN SPORT MED, V34, P347, DOI 10.1016/j.csm.2014.12.002
   Mei Z., 2016, MED BIOL ENG COMPUTI
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2014, J ANESTH CLIN RES, V5, P2
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, J PSYCHIAT, V18, P1, DOI [10.4172/2378-5756.100028, DOI 10.4172/2378-5756.100028]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Moscatelli F, 2015, BIOL MED
   Moscatelli F, 2016, NEUROL SCI, V37, P1947, DOI 10.1007/s10072-016-2693-8
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Pastorelli F, 2013, CLIN CASES MINER BON, V10, P96, DOI 10.11138/ccmbm/2013.10.2.096
   Paterno MV, 2010, AM J SPORT MED, V38, P1968, DOI 10.1177/0363546510376053
   Carpes FP, 2008, J BODYW MOV THER, V12, P22, DOI 10.1016/j.jbmt.2007.05.001
   Pomara C, 2016, J CELL PHYSIOL, V231, P1385, DOI 10.1002/jcp.25272
   Pomara C, 2015, LEGAL MED-TOKYO, V17, P192, DOI 10.1016/j.legalmed.2014.12.008
   Puttaswamaiah R., 2007, FOOT, V17, P3, DOI DOI 10.1016/J.FOOT.2006.07.005
   Ribeiro AP, 2011, CLIN BIOMECH, V26, P194, DOI 10.1016/j.clinbiomech.2010.08.004
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Salomone F, 2013, STEM CELL RES, V11, P1037, DOI 10.1016/j.scr.2013.07.003
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Shimba T, 1984, J BIOMECHANICS, V17
   Statler TK, 2005, J AM PODIAT MED ASSN, V95, P42, DOI 10.7547/0950042
   Tasseel-Ponche S, 2015, NEUROPHYSIOL CLIN, V45, P327, DOI 10.1016/j.neucli.2015.09.003
   Taylor NF, 2007, AUST J PHYSIOTHER, V53, P7, DOI 10.1016/S0004-9514(07)70057-0
   Tibullo D, 2013, CURR PHARM DESIGN, V19, P2765, DOI 10.2174/1381612811319150012
   Triggiani A. I., 2015, CLIN PHYSL FUNCTIONA
   Turillazzi E, 2008, FORENSIC SCI INT, V179, pE5, DOI 10.1016/j.forsciint.2008.03.021
   Turillazzi E, 2008, PATHOL RES PRACT, V204, P259, DOI 10.1016/j.prp.2007.12.010
   Turillazzi E, 2008, INT J LEGAL MED, V122, P173, DOI 10.1007/s00414-007-0208-0
   Turillazzi E, 2008, VIRCHOWS ARCH, V453, P209, DOI 10.1007/s00428-008-0632-7
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Varrassi G, 2016, J PSYCHIAT, V19
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Volti GL, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-62
NR 77
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1271
EP 1278
DI 10.19193/0393-6384_2017_2s_196
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700013
DA 2022-07-14
ER

PT J
AU Monda, V
   Ruberto, M
   Villano, I
   Valenzano, A
   Ricciardi, A
   Gallai, B
   Marotta, R
   Lavano, F
   Lavano, SM
   Maltese, A
   Tripi, G
   Romano, P
   Salerno, M
AF Monda, Vincenzo
   Ruberto, Maria
   Villano, Ines
   Valenzano, Anna
   Ricciardi, Annaclaudia
   Gallai, Beatrice
   Marotta, Rosa
   Lavano, Francesco
   Lavano, Serena Marianna
   Maltese, Agata
   Tripi, Gabriele
   Romano, Palmira
   Salerno, Margherita
TI A MINIREVIEW ABOUT SPORTING PRACTICE IN EPILEPTIC CHILDREN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE exercise; synaptic-plasticity; hippocampus; epilepsy
ID SLEEP-APNEA SYNDROME; CHILDHOOD ABSENCE EPILEPSY; PRIMARY NOCTURNAL
   ENURESIS; PRIMARY CILIARY DYSKINESIA; PRADER-WILLI-SYNDROME; WEIGHT-LOSS
   PROGRAM; QUALITY-OF-LIFE; PARENTAL STRESS; MATERNAL STRESS;
   NERVOUS-SYSTEM
AB Movement is important for neuropsycho-physical development, ensuring the correct growth and giving many benefits from childhood to adulthood. Motor activity plays a pivotal role in psychological, educational and social terms: sport practice induces harmonious physical development with common important benefits independently from sport type and each sport imposes rules respect that children learns to know and respect step by step improving the social skills and cognitive abilities. Sport has a very important role in the growth of children and adolescents. Sport and physical activity work as a moral laboratory to practice decision-making and problem-solving skills, as well as teamwork and cooperation. In many pathological conditions, the sport practice is strongly discouraged, as in epileptic patients for the negative consequences on their physical condition and psychic. In general, several studies reported that physical activity has positive influence on seizure frequency and severity. As a result, attitudes regarding sports and epilepsy have changed considerably in the last decades and presently, the risk of convulsive seizures during sports practice is minimal in case of well-managed epilepsy. Evaluating the control of convulsive disease is therefore a key point to allow sports in the children and adolescents.
C1 [Monda, Vincenzo; Villano, Ines] Univ Campania Luigi Vanvitelli, Sect Human Physiol, Dept Expt Med, Caserta, Italy.
   [Monda, Vincenzo; Villano, Ines] Univ Campania Luigi Vanvitelli, Unit Dietet & Sport Med, Caserta, Italy.
   [Ruberto, Maria] Univ Campania Luigi Vanvitelli, Dept Med Surg & Dent Specialties, Caserta, Italy.
   [Valenzano, Anna] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Ricciardi, Annaclaudia; Romano, Palmira] Univ Campania Luigi Vanvitelli, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Ricciardi, Annaclaudia; Romano, Palmira] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Phys & Prevent Med, Caserta, Italy.
   [Gallai, Beatrice] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy.
   [Marotta, Rosa; Lavano, Francesco; Lavano, Serena Marianna] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
   [Maltese, Agata] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RP Salerno, M (corresponding author), Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
RI Marotta, Rosa/AAG-1453-2020
OI Marotta, Rosa/0000-0003-0515-5952; Monda, Vincenzo/0000-0002-6083-5814;
   VILLANO, INES/0000-0002-1755-358X; TRIPI, Gabriele/0000-0001-7088-9325
CR Capovilla G, 2003, EPILEPSIA, V44, P1085, DOI 10.1046/j.1528-1157.2003.55402.x
   Carotenuto M, 2006, SLEEP MED, V7, P357, DOI 10.1016/j.sleep.2006.01.005
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto Marco, 2005, J Headache Pain, V6, P268
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2015, CURRENT TOPICS PEPTI, V16, P49
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00357
   Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00231
   Chieffi S, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00983
   Chieffi S, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00188
   Chieffi S, 2017, EXP BRAIN RES, V235, P1511, DOI 10.1007/s00221-017-4919-2
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Coaccioli S., 2016, THE J, V19, DOI [10.4172/2378-5756.1000369, DOI 10.4172/2378-5756.1000369]
   Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x
   Coppola G, 2004, BRAIN DEV-JPN, V26, P26, DOI 10.1016/S0387-7604(03)00090-1
   D'Agostino D, 2016, ACTA MEDICA MEDITERR, V32, P1905, DOI 10.19193/0393-6384_2016_6_181
   De Fusco C, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4045238
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Elia M, 2008, NEUROLOGY, V71, P997, DOI 10.1212/01.wnl.0000326592.37105.88
   Elia M, 2012, BRAIN DEV-JPN, V34, P873, DOI 10.1016/j.braindev.2012.03.005
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2011, NEUROL SCI, V32, P79, DOI 10.1007/s10072-010-0411-5
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Esposito T, 2016, DRUG DES DEV THER, V10, P2939, DOI 10.2147/DDDT.S106440
   Fiorelli A, 2017, ANN THORAC SURG, V103, P216, DOI 10.1016/j.athoracsur.2016.10.055
   Gallelli L, 2014, HEADACHE, V54, P313, DOI 10.1111/head.12162
   Guzzetta A, 2011, DEV MED CHILD NEUROL, V53, P46, DOI 10.1111/j.1469-8749.2011.04065.x
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Hashemian K, 2016, ACTA MEDICA MEDITERR, V32, P1051
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Mazzeo F, 2016, BIOL MED PARIS, V8, P1, DOI [10.4172/0974-8369.1000294, DOI 10.4172/0974-8369.1000294]
   Messina A, 2017, ACTA MEDICA MEDITERR, V33, P833, DOI 10.19193/0393-6384_2017_5_124
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina Giovanni, 2016, Asian J Sports Med, V7, pe26841, DOI 10.5812/asjsm.26841
   Messina G, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00137
   Messina G, 2016, NEUROPSYCH DIS TREAT, V12, P3193
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Monda V., 2016, BIOL MED, V8, DOI [10.4172/0974-8369.1000306, DOI 10.4172/0974-8369.1000306]
   Monda V, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3831972
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2016, NEUROL SCI, V37, P1947, DOI 10.1007/s10072-016-2693-8
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P495, DOI 10.19193/0393-6384_2017_3_074
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P485, DOI 10.19193/0393-6384_2017_3_072
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Parisi P, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-57
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Piombino L., 2016, BIOL MED, V8, DOI [10.4172/0974-8369.1000298, DOI 10.4172/0974-8369.1000298]
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P405, DOI 10.19193/0393-6384_2017_3_059
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, DOI 10.19193/0393-6384_2016_5_146
   Salehi N, 2016, ACTA MEDICA MEDITERR, V32, P927
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Santamaria S., 2016, BIOL MED, V8, DOI 10.4172/0974-8369.1000263
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Verrotti A, 2013, EUR J NEUROL, V20, P394, DOI 10.1111/j.1468-1331.2012.03771.x
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Verrotti A, 2015, J NEUROL, V262, P116, DOI 10.1007/s00415-014-7542-1
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
   Yilmaz M, 2016, ACTA MEDICA MEDITERR, V32, P785, DOI 10.19193/0393-6384_2016_3_90
NR 98
TC 10
Z9 10
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 2
BP 1279
EP 1287
DI 10.19193/0393-6384_2017_2s_197
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZY
UT WOS:000424877700014
DA 2022-07-14
ER

PT J
AU Montinari, MR
   Minelli, S
AF Montinari, Maria Rosa
   Minelli, Sergio
TI THE HISTORY OF THE SALENTO'S MENTAL HOSPITAL AND THE USE OF SOMATIC
   THERAPIES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Salento's mental hospital; history; somatic therapies; Electroconvulsive
   Therapy (ECT)
ID CLOZAPINE-RESISTANT SCHIZOPHRENIA; ELECTRIC CONVULSION THERAPY;
   ELECTROCONVULSIVE-THERAPY; AUGMENTATION
AB In this article, we are going to retrace the history of the Salento's Mental Hospital, one of the largest psychiatric facilities in Southern Italy and we whilst addressing the use of somatic therapies in this institution.
   The Provincial Mental Hospital of Terra d'Otranto, established since 1897, started operation in 1901, under the direction of Dr. Giovanni Libertini. In 1931, after the advent of fascism, with the split of the Lecce Province into three provinces (Lecce, Brindisi and Taranto), The Mental Hospital turned into a hospital consortium, called The Interprovincial Psychiatric Hospital of Salento (OPIS) and subsequently, from 1985 to 1998, The Psychiatric Hospital "Giovanni Libertini".
   At The Interprovincial Psychiatric Hospital of Salento (O.P.I.S.) somatic therapies, and in particular Electroconvulsive Therapy (ECT), were widely used. Afterwards, in the 1950s, with the advent of psychotropic drugs (neuroleptics, antidepressants, MAO inhibitors tricyclics, benzodiazepines), the success of somatic therapies and in particular of ECT decreased significantly.
   The recent renewed interest in somatic therapies - again considered in the most advanced scientific studies and used in a large number of renowned hospitals and universities - is linked to the considerable deepening of the biological knowledge of such therapies and to drug resistance of many psychiatric illnesses.
   Therefore, we considered it opportune to historically analyze the use of somatic therapies in one of the most important psychiatric institutions of Southern Italy.
C1 [Montinari, Maria Rosa] Univ Salento, Dept Biol & Environm Sci & Technol, Lecce, Italy.
   [Minelli, Sergio] ASL Lecce, DSS 52, Lecce, Italy.
RP Montinari, MR (corresponding author), Univ Salento, Dept Biol & Environm Sci & Technol, Lecce, Italy.
RI MINELLI, SERGIO/AAQ-6902-2020
OI MINELLI, SERGIO/0000-0002-6259-8883
CR Abrams R., 2002, ELECTROCONVULSIVE TH
   ACCORNERO F, 1988, CONVULSIVE THER, V4, P40
   Alfonso L., 2009, DALLO SPIRITO SANTO, P157
   [Anonymous], 1800, Lond Med J, V6, P120
   Cerletti Ugo, 1940, RIV SPERIMENTALE FRE, V64, P209
   De Falco C., 2013, COMPLESSI MANICOMIAL, p[292, 390]
   Fernandez JW, 2014, J PSYCHIATR PRACT, V20, P308, DOI 10.1097/01.pra.0000452569.92449.76
   FINK M, 1984, AM J PSYCHIAT, V141, P1034
   Grover S, 2017, PSYCHIAT RES, V249, P349, DOI 10.1016/j.psychres.2017.01.042
   Kalinowsky L, 1939, LANCET, V2, P1232
   KALINOWSKY L, 1982, ELECTROCONVULSIVE TH, P1
   Kim HS, 2017, PSYCHIAT INVEST, V14, P58, DOI 10.4306/pi.2017.14.1.58
   Lally J, 2016, SCHIZOPHR RES, V171, P215, DOI 10.1016/j.schres.2016.01.024
   LANCASTER NP, 1958, J MENT SCI, V104, P221, DOI 10.1192/bjp.104.434.221
   Mazzeo A., 1981, FOLYA NEUROPSICHIATR, VXXIV, P242
   Ottosson J. O., 2004, ETHICS ELECTROCONVUL
   Pagano P., 2010, RIV PSICOLOGIA CLIN, P52
   Passione R., 2006, SCRITTI SULL ELETTRO
   Payne NA, 2009, J PSYCHIATR PRACT, V15, P346, DOI 10.1097/01.pra.0000361277.65468.ef
   Petrides G, 2015, AM J PSYCHIAT, V172, P52, DOI 10.1176/appi.ajp.2014.13060787
   PRUDIC J, 2005, COMPREHENSIVE TXB PS, V2
   SENTER NW, 1984, AM J SOC PSYCHIAT, V4, P11
   Shorter E., 2007, SHOCK THERAPY HIST E
   Sinisi L., 1994, CRONACA RACCONTATA I
   WEST ED, 1981, BRIT MED J, V282, P355, DOI 10.1136/bmj.282.6261.355
   WHITROW M, 1990, MED HIST, V34, P294, DOI 10.1017/S0025727300052431
NR 26
TC 1
Z9 1
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1051
EP 1057
DI 10.19193/0393-6384_2017_6_166
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500025
DA 2022-07-14
ER

PT J
AU Morovvati, MR
   Abbassian, A
   Rezaei, M
   Fattahian, R
   Farzaei, MH
   Morovati, S
   Sahihi, Z
AF Morovvati, Mohammad Reza
   Abbassian, Alireza
   Rezaei, Mansuor
   Fattahian, Reza
   Farzaei, Mohammad Hosein
   Morovati, Saadi
   Sahihi, Zhila
TI COMPARING THE EFFECT OF ERGH ALNASA PHLEBOTOMY WITH DICLOFENAC TABLETS
   ON PAINS SPREAD TO THE LOWER LIMB: A RANDOMIZED CLINICAL TRIAL
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE ERGH ALNASA phlebotomy; Diclofenac; pain; lower limb
ID SCIATICA; RISK
AB Introduction: Nowadays Musculo-skeletal pains are increasing and treatment of them has imposed different costs on patients, beside new medicine, some solutions in Iranian traditional medicine like ERGH ALNASA phlebotomy have been presented for reducing these pains. The purpose of doing this study has been also to compare the effect of ERGH ALNASA phlebotomy with Diclofenac tablets on the pains spread to the lower limbs.
   Methodology: This randomized clinical trial was done in 2014-2015, patients were divided into phlebotomy and drug groups in the form of randomized allocation and without blinding, drug group was under classic treatment with Diclofenac tablets and phlebotomy group was under ERGH ALNASA phlebotomy treatment. Patients, backache was assessed by using of VAS, life quality and Roland-Morris disability questionnaires, for data analysis, Kruskal-Wallis, Chi-square, Kolmogorov-Smirnov and Mann-Whiney tests were also used.
   Findings: 100 patients entered to phlebotomy, 49 persons were women and 51 persons were men with the age average of 43.57 +/- 11.04 years. VAS scale or the pain severity in the drug group was more than phlebotomy group meaningfully one hour (P<0.001), two weeks (P<0.001) and four weeks (P<0.001) after the start of study. Morris-Roland scale in the phlebotomy group was more than drug group meaningfully (P<0.001). The scales of physical health (P<0.001) and mental health of life quality (P<0.001) after phlebotomy in the phlebotomy group was more than drug group meaningfully.
   Results: Decrease in serum hemoglobulin, hematocrit, systolic blood pressure and diastolic blood pressure, as well as increase in pulse rate after cesarean section was significantly more dramatic in those received lower dose of oxytocin. The need of extra medication, atony and blood transfusion requirement were observed in 18%, 5.5%, and 3.5% of those treated with low dose oxytocin. There were absecent in patients treated with.
   Conclusion: ERGH ALNASA phlebotomy in comparison with Diclofenac has better effect on the pains spread to the lower limb in terms of reduction of the pain severity, rehabilitation and life quality of patients.
C1 [Morovvati, Mohammad Reza; Abbassian, Alireza] Univ Tehran Med Sci, Sch Tradit Med, Dept Tradit Med, Tehran, Iran.
   [Rezaei, Mansuor; Fattahian, Reza] Kermanshah Univ Med Sci, Kermanshah, Iran.
   [Farzaei, Mohammad Hosein] Kermanshah Univ Med Sci, Med Biol Res Ctr, Kermanshah, Iran.
   [Farzaei, Mohammad Hosein] Kermanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Kermanshah, Iran.
   [Morovati, Saadi] Tabriz Univ Med Sci, Tabriz, Iran.
   [Sahihi, Zhila] Kermanshah Azad Univ, Kermanshah, Iran.
RP Morovvati, MR (corresponding author), Univ Tehran Med Sci, Sch Tradit Med, Dept Tradit Med, Tehran, Iran.
EM dr.morovati1346@gmail.com
RI Farzaei, Mohammad Hosein/M-5779-2017; Abbassian, Alireza/AAI-6694-2021
OI Farzaei, Mohammad Hosein/0000-0001-7081-6521; Abbassian,
   Alireza/0000-0002-3759-7731
CR Abbasian Alireza, 2011, THESIS
   Abbassian A, 2013, IRAN J PUBLIC HEALTH, V42, P110
   Ahmadzadeh Jafar, 2002, MED MAGAZINE ORUMIA, V13, P9
   Alikhanzade M, 2013, J SHAHREKORD U MED S, V15, P16
   Arzani Mohammadakbar, AKBARI MED, V2, P1001
   Avvecenna Hossein, 1991, GHANOON, P425
   Bahmani M, 2014, ASIAN PAC J TROP MED, V7, pS43, DOI 10.1016/S1995-7645(14)60202-9
   Bam Hassan, 2002, MAGAZINE MED SCI U B, V4, P26
   Bnnett j, 2001, CECIL TXB MED, P45
   Chashti Hakim Azamkhan, GREAT ELIXIR, V41, P52
   Deena K, 2014, INT RES J PHARM, V5, P267
   Deyo RA, 2009, J AM BOARD FAM MED, V22, P62, DOI 10.3122/jabfm.2009.01.080102
   Ebrahimzadeh MA, 2006, J MAZANDARAN U MED S, V16, P35
   Elahi Bahram, 2001, ANATOMY UPPER LOWER, P183
   Epstain A, 2002, HARRISON PRINCIPLES, P49
   Farhadi Khosro, 2008, MAGAZINE MED HLTH SC
   Hajong R, 2013, J SURG CASE REP, DOI 10.1093/jscr/rjs039
   Harrer A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013707
   Hemblen David, 2011, ORTHOPAEDICS PRINCIP, P213
   Jalali M., 2013, J GORGAN U MED SCI, V15, P29
   Katz N, 2002, J PAIN SYMPTOM MANAG, V24, pS38, DOI 10.1016/S0885-3924(02)00411-6
   Katzung Bertram, 2010, BASIC CLIN PHARM, P764
   Kermani Nafis ebne Avaz, 2008, SHARH SABAB ALAMAT, P304
   Khosronia Iraj, 2003, INVESTIGATIVE MAGAZI, P197
   Kord Afshari Gholamreza, 2009, GHOLAMREZA MANUAL AC, P22
   Minaee B, 2013, RHEUMATOL INT, V33, P3095, DOI 10.1007/s00296-012-2574-2
   Motamed Mohammadreza, 2001, MED MAGAZINE DIS REC, P53
   Nasri S., 2012, REV ANTINOCICEPTIVE, V3, P293
   Nouhi E, 2012, HORMOZGAN MED J, V15, P311
   Odom DM, 2014, CLIN THER, V36, P906, DOI 10.1016/j.clinthera.2014.04.012
   Ray WA, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c6618
   Seymour Schwartz, 2011, SURG HAND ORTHOPEDIC, P110
   Shirazi Aghili Khorasani, 2006, CORRECTION NAZEM ESM, V2, P1187
   Soltanzadeh Akbar, 2011, BRAIN NERVES MUSCLES, P442
   Somesaraie Mansour, 2001, MAGAZINE MED SCI U G, V10, P22
   Tabib Tehrani, 2014, DERALSEHHEH RES CORR, P126
   Teekachunhatean S, 2004, BMC COMPLEM ALTERN M, V4, P1
   Tehranipour M, 2010, ARAK MED U J, V13, P83
   Tehranipour M, 2013, SSU J, V21, P197
   Woodley M, 1989, MANUAL MED THERAPEUT, P48
   Xu L, 2007, INTEGR CANCER THER, V6, P208, DOI 10.1177/1534735407305705
   Yekta N Hosseini, 2012, J ISLAMIC IRANIAN TR, V3, P285
   Younes M, 2006, JOINT BONE SPINE, V73, P538, DOI 10.1016/j.jbspin.2005.10.022
NR 43
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 915
EP 920
DI 10.19193/0393-6384_2017_1s_136
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000005
DA 2022-07-14
ER

PT J
AU Moscatelli, F
   Valenzano, A
   Monda, V
   Ruberto, M
   Monda, G
   Triggiani, AI
   Monda, E
   Chieffi, S
   Villano, I
   Parisi, L
   Roccella, M
   Messina, A
AF Moscatelli, Fiorenzo
   Valenzano, Anna
   Monda, Vincenzo
   Ruberto, Maria
   Monda, Giuseppe
   Triggiani, Antonio I.
   Monda, Emanuele
   Chieffi, Sergio
   Villano, Ines
   Parisi, Lucia
   Roccella, Michele
   Messina, Antonietta
TI TRANSCRANIAL MAGNETIC STIMULATION (TMS) APPLICATION IN SPORT MEDICINE: A
   BRIEF REVIEW
SO ACTA MEDICA MEDITERRANEA
LA English
DT Review
DE TMS; transcrania magnetic stimulation; motor cerebral cortex; atlethes
ID HYPERTHERMIC REACTIONS; NOCTURNAL ENURESIS; CEREBRAL INJECTION; PARENTAL
   STRESS; CHILDREN; MIGRAINE; SLEEP; AURA; INTERFERENCE; ADOLESCENTS
AB Since 1985, transcranial magnetic stimulation (TMS) has been used for non-invasive exploration of motor control in humans and for a wide range of applications in all ages of life. This brief review examined briefly the potential interest in sport medicine.
C1 [Moscatelli, Fiorenzo; Valenzano, Anna; Monda, Giuseppe; Triggiani, Antonio I.; Monda, Emanuele] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.
   [Monda, Vincenzo; Chieffi, Sergio; Villano, Ines; Messina, Antonietta] Univ Campania Luigi Vanvitelli, Dept Expt Med, Caserta, CE, Italy.
   [Ruberto, Maria] Univ Naples 2, Dept Med Surg & Dent Specialties, Naples, Italy.
   [Parisi, Lucia; Roccella, Michele] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
RP Messina, A (corresponding author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Sect Human Physiol, Via Costantinopoli 16, I-80138 Naples, Italy.; Messina, A (corresponding author), Univ Campania Luigi Vanvitelli, Clin Dietet Serv, Via Costantinopoli 16, I-80138 Naples, Italy.
RI Moscatelli, Fiorenzo/ABC-9536-2020; triggiani, antonio
   ivano/Q-4701-2019; Messina, Antonietta/AHH-2383-2022; Triggiani, Antonio
   Ivano/M-6252-2015; MESSINA, ANTONIETTA/K-9366-2016; Monda,
   Emanuele/AAQ-6457-2020
OI triggiani, antonio ivano/0000-0003-3291-9452; Messina,
   Antonietta/0000-0001-8343-432X; Monda, Emanuele/0000-0001-9304-988X;
   Chieffi, Sergio/0000-0002-1478-784X; Moscatelli,
   Fiorenzo/0000-0003-1274-0332; VILLANO, INES/0000-0002-1755-358X; Monda,
   Vincenzo/0000-0002-6083-5814
CR Aurilio C, 2015, AFRICAN J PSYCHIAT, V18, DOI 10.4172/2378-5756.1000307.
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2014, EPILEPSY BEHAV, V35, P50, DOI 10.1016/j.yebeh.2014.03.009
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P877, DOI 10.1007/s11325-012-0697-z
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Chieffi S., 2015, J PSYCHIAT, V18, DOI [10.4172/1994-8220.1000228, DOI 10.4172/1994-8220.1000228]
   Chieffi S, 2014, EXP BRAIN RES, V232, P3659, DOI 10.1007/s00221-014-4056-0
   Chieffi S, 2014, EXP BRAIN RES, V232, P1327, DOI 10.1007/s00221-014-3851-y
   De Fusco C, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4045238
   De Luca V, 2008, PSYCHIAT INVEST, V5, P203, DOI 10.4306/pi.2008.5.4.203
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2016, EUR J PHYS REHABIL M
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2014, CHEMOSPHERE, V94, P62, DOI 10.1016/j.chemosphere.2013.09.013
   Esposito T, 2006, J THERM BIOL, V31, P527, DOI 10.1016/j.jtherbio.2006.07.002
   Fiorelli A, 2017, ANN THORAC SURG, V103, P216, DOI 10.1016/j.athoracsur.2016.10.055
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Iavarone A, 2007, J AUTISM DEV DISORD, V37, P775, DOI 10.1007/s10803-006-0190-2
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Mazzeo F., 2013, CURR TOP TOXICOL, V9, P21
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/639280
   Messina G, 2012, AUTON NEUROSCI-BASIC, V169, P102, DOI 10.1016/j.autneu.2012.05.003
   Messina G., 2015, J PSYCHIAT, V18, DOI [10.4172/2378-5756.1000280, DOI 10.4172/2378-5756.1000280]
   Messina G, 2014, AFRICAN J PSYCHIAT, V17, DOI 10.4172/Psychiatry.1000172.
   Messina G., 2014, J ANESTH CLIN RES, V5, P395, DOI [10.4172/2155-6148.1000395, DOI 10.4172/2155-6148.1000395]
   Messina G., 2015, BIOL MED, V1, P7, DOI [DOI 10.4172/0974-8369.1000S3007, 10.4172/0974-8369.1000S3007]
   Messina G., 2015, BIOL MED, V7, P1, DOI [10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000248, DOI 10.4172/0974-8369.1000240]
   Messina Giovanni, 2016, Asian J Sports Med, V7, pe26841, DOI 10.5812/asjsm.26841
   Messina G, 2016, NEUROPSYCH DIS TREAT, V12, P3193
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Messina G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00997
   Monda M, 2008, CLIN NUTR, V27, P657, DOI 10.1016/j.clnu.2008.04.005
   Monda M, 2008, PEPTIDES, V29, P120, DOI 10.1016/j.peptides.2007.10.016
   Monda M, 2007, REGUL PEPTIDES, V139, P39, DOI 10.1016/j.regpep.2006.10.002
   Monda M, 2006, NEUROPEPTIDES, V40, P357, DOI 10.1016/j.npep.2006.07.003
   Monda M, 2006, NUTR NEUROSCI, V9, P141, DOI 10.1080/10284150600903552
   Monda M, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/131024
   Monda V., 2016, BIOL MED, V8, DOI [10.4172/0974-8369.1000306, DOI 10.4172/0974-8369.1000306]
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2015, BIOL MED
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Moscatelli F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155998
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Rinaldi B, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/265967
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria S., 2016, BIOL MED, V8, DOI 10.4172/0974-8369.1000263
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Triggiani AI, 2017, CLIN PHYSIOL FUNCT I, V37, P162, DOI 10.1111/cpf.12281
   Valenzano A, 2016, INT J SPORT PHYSIOL, V11, P407, DOI 10.1123/ijspp.2015-0035
   Verrotti A, 2017, EUR J PAEDIATR NEURO, V21, P570, DOI 10.1016/j.ejpn.2017.02.002
   Viggiano A, 2010, NEUROSCIENCE, V166, P416, DOI 10.1016/j.neuroscience.2009.12.071
   Viggiano A, 2014, J SPORT SCI, V32, P46, DOI 10.1080/02640414.2013.805236
   Viggiano A, 2009, J DIABETES COMPLICAT, V23, P119, DOI 10.1016/j.jdiacomp.2007.11.009
   Viggiano E, 2016, NEUROPSYCH DIS TREAT, V12, P1705, DOI 10.2147/NDT.S107074
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 76
TC 32
Z9 33
U1 3
U2 18
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 423
EP 430
DI 10.19193/0393-6384_2017_3_062
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200010
DA 2022-07-14
ER

PT J
AU Mousavian, N
   Mojembari, AK
   Aghayousefi, A
AF Mousavian, Narges
   Mojembari, Adis Kraskian
   Aghayousefi, Alireza
TI THE EFFECTIVENESS OF COGNITIVE THERAPY IN REDUCING GLYCOSYLATED
   HEMOGLOBIN IN DIABETIC PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Type II diabetes; Cognitive therapy; Glycemic control: HbA1c
AB Introduction: Type II diabetes is an illness that is associated with the severity of the lifestyle and it has very strong behavioral and emotional component as far as some experts considered as a behavioral issue. The aim of this study was to determine the effectiveness of cognitive therapy in reducing glycated hemoglobin patients with diabetes.
   Materials and methods: The study was a quasi-experimental type and research project were the two groups of experimental group and control group, along with pre-test, post-test and follow-up. The statistical population were includes all patients with type II diabetes in the range of 25 to 45 years old age that have treated in the Ganjaviyan hospital diabetes clinic and one year of their diagnosis should past. We used an available sampling method and sample size was 40 patients and the replacement of the subjects in the intervention group and the control group was randomly. The sample of individuals was selected based on the entry-exit criteria (age 25 to 45 years old, the lack of any obvious mental disorder, the passage of one year since diagnosis of type II diabetes). Then both groups were evaluated before therapeutic intervention, in the next stage therapeutic intervention was carried out on experimental group of cognitive therapy in group method. Meetings are held weekly for 2 hours (ten sessions). The control group did not receive the therapeutic intervention in a group. So, both groups were evaluated with the use of post-test and then after three months re-evaluation was conducted as a follow-up to the amount of the effectiveness of independent variables (therapeutic intervention in a group) on the dependent variable (grades and following) will be measured.
   Results: The results of the Covariance analysis showed that cognitive therapy cause reduction of blood sugar (HbA1c) in the experimental group in the post-test and following stage.
   Conclusions: Training cognitive therapy can result in blood sugar control (HbA1c) in patients with type II diabetes. So, it is recommended that the presentation of these trainings beside other medical interventions is as a part of comprehensive treatment and care of diabetes.
C1 [Mousavian, Narges; Mojembari, Adis Kraskian] Islamic Azad Univ, Dept Psychol, Karaj Branch, Karaj, Iran.
   [Aghayousefi, Alireza] Payame Noor Univ, Dept Psychol, Tehran, Iran.
RP Mojembari, AK (corresponding author), Islamic Azad Univ, Dept Psychol, Karaj Branch, Karaj, Iran.
CR Anderewli T, 2012, CECIL ESSENTIALS INT
   Basharat A, 2010, J BEHAV SCI, V2, P21
   Hatamloo Sadabadi M, 2011, J BEHAV SCI, V5, P245
   Nichols GA, 2004, DIABETIC MED, V21, P793, DOI 10.1111/j.1464-5491.2004.01191.x
   Sadeghi Movahed F, 2011, J FUNDAM MENT HLTH, V12, P470
   Sadock BJ., 2007, KAPLAN SADOCKS SYNOP
   Seminario NA, 2009, EPILEPSY BEHAV, V15, P362, DOI 10.1016/j.yebeh.2009.05.007
   Serlachius AS, 2016, J HEALTH PSYCHOL, V21, P1157, DOI 10.1177/1359105314547940
   Thorpe C. T., 2012, DIABETES ED
   Timareh M., 2006, QUALITY LIFE DIABETI
   Tovote KA, 2014, DIABETES CARE, V37, P2427, DOI 10.2337/dc13-2918
   Unden AL, 2008, GENDER MED, V5, P162, DOI 10.1016/j.genm.2008.05.003
   van Son J, 2013, DIABETES CARE, V36, P823, DOI 10.2337/dc12-1477
   WINKLEY K, 2006, BMJ
NR 14
TC 0
Z9 0
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 253
EP 257
DI 10.19193/0393-6384_2017_2_037
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700012
DA 2022-07-14
ER

PT J
AU Naseriasl, M
   Amini, A
   Doshmangir, L
   Adham, D
   Janati, A
AF Naseriasl, Mansour
   Amini, Abolgasem
   Doshmangir, Leila
   Adham, Davoud
   Janati, Ali
TI CHALLENGES OF ESTABLISHING SPECIALTY REFERRAL SYSTEM IN IRAN'S HEALTH
   SECTOR (A QUALITATIVE STUDY)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE consultation; referral system; referral process; family physician;
   qualitative research
AB Introduction: The specialty referral process, as an essential part of primary health care, is fundamentally important for the provision of optimal health services. The goal of establishing a functional referral system has yet to be achieved in Iran. This study aimed to explore health expert's viewpoints about challenges of developing and implementing referral system in rural Iran and towns with populations under 20,000.
   Material and methods: We conducted a qualitative study through five focus group discussions (FGDs), 27 face-to-face, semi-structured interviews at national, provincial, and local levels with family physicians (FPs), clinical specialist physicians, policy-makers, and managers of insurance organizations. Key informants were selected using purposive sampling. Themes were identified using the inductive-deductive framework analysis approach. The barriers and challenges of establishing functional referral system in Iran were identified in a form of six main themes as: service delivery, health workforce, health information systems, access to essential medicines, financing, and leadership/governance.
   Results: Better care for the patients is provided when health care providers and patients work as a team to allow for a smooth patient journey through the health care system.
   Conclusion: Therefore, a comprehensive reform in FP's roles and positions, health information system, as well as strengthening the health leadership and management infrastructure is recommended.
C1 [Naseriasl, Mansour; Doshmangir, Leila; Janati, Ali] Tabriz Univ Med Sci, Sch Management & Med Informat, Dept Hlth Serv Management, Iranian Ctr Excellence Hlth Management, Tabriz, Iran.
   [Amini, Abolgasem] Tabriz Univ Med Sci, Med Educ Dept, Tabriz, Iran.
   [Adham, Davoud] Ardabil Univ Med Sci, Sch Hlth, Dept Publ Hlth, Ardebil, Iran.
RP Janati, A (corresponding author), Tabriz Univ Med Sci, Sch Management & Med Informat, Dept Hlth Serv Management, Iranian Ctr Excellence Hlth Management, Tabriz, Iran.
EM janati1382@gmail.com
RI Doshmangir, Leila/AAM-7947-2021; adham, davoud/A-5055-2019; Naseriasl,
   Mansour/AAN-2991-2020; , Leila/L-1446-2017
OI Naseriasl, Mansour/0000-0003-4789-688X; adham,
   davoud/0000-0002-9764-6363; Naseriasl, Mansour/0000-0003-0998-036X; ,
   Leila/0000-0001-5197-8437
FU Tabriz University of Medical Sciences [5/95/4762]
FX This study was financed by a grant (grant no: 5/95/4762 in January 13,
   2015 (provided by the research deputy of Tabriz University of Medical
   Sciences. The authors express their gratitude to the participants who
   shared their experiences with us.
CR Chudi IP., 2010, MED PRACT REV, V1, P9, DOI [10.5897/MPR.9000011, DOI 10.5897/MPR.9000011]
   Heimly V, 2009, STUD HEALTH TECHNOL, V150, P327, DOI 10.3233/978-1-60750-044-5-327
   Honour DR, THESIS
   Hysong SJ, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-84
   Raeisee P, 2010, HAKIM RES J, V13, P19
   Takian A, 2011, HEALTH POLICY PLANN, V26, P163, DOI 10.1093/heapol/czq036
   World Health Organization, 2010, MON BUILD BLOCKS HLT
NR 7
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 921
EP 926
DI 10.19193/0393-6384_2017_1s_137
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000006
DA 2022-07-14
ER

PT J
AU Nasrabadi, AN
   Ghiavandian, S
   Sadaghiani, S
AF Nasrabadi, Alireza Nikbakht
   Ghiavandian, Sharzad
   Sadaghiani, Safa
TI AN EXPERT AS A NOVICE A PHENOMENOLOGICAL STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Nurses; relative's care; phenomenological Study Qualitative Research;
   Iran
ID RELATIVES; CARE
AB Background: Despite the public opinion that a nurse is always a nurse, but it should also be noted that a nurse play a dual role at the time of taking care of a family member. He often bears trouble to find its true role at this time and it is seen that finding a solution in these situations is not always easy. Because, unlike the trainings and cases indicated in nursing theories, we could state that the nurses are never ready to provide a perfect care which endow them the accountability as a professional nurse to provide nursing care for their family.
   Objective: The present paper aims to describe the nurses' lived experiences of attending their relatives. The study illustrates the nature of nurses' experiences at the time of taking care of their family members.
   Methods: This study is a phenomenology research with hermeneutics approach which was implemented to describe and understand the lived experiences of nurses in attending their relatives. The study applied a combination of purposive and snow-ball sampling methods. The participants must be the holders of bachelor's degrees or higher degree in nursing, being employed or retired and possess at least one experience of attending their family member which has been hospitalized and have the ability to express and transfer information. Eventually 11 cases (and 2 men) were selected. The information data was coded 9 women after being implemented. It was then analyzed by Dickelman analysis method.
   Results: One of the main themes obtained in the study was the sense of inability to practice. The two sub-themes including doubt on adequacy of action and inefficient knowledge in practice were also presented in this study. The semantic units including feelings of uncertainty on adequacy of action, inability to apply knowledge, sense of inability, sense of uncertainty, future prediction, imagination of worst positions and doubt and indecision were mentioned in relation to sub-theme of doubt on adequacy. The semantic units of difference in performance by professional and non-professional people and negative impact of practical consciousness were introduced in relation to sub-themes of inefficient knowledge in practice.
   Discussion: The research indicated that the nurses are not prepared for the position of attending their family member and are never trained for such situations. The nurses also possess dual role in this regard: Nursing care provider and recipient of nursing care. It should be noted that both nursing training and nurse trainee programs have been neglected in this area.
C1 [Nasrabadi, Alireza Nikbakht; Ghiavandian, Sharzad; Sadaghiani, Safa] Univ Tehran Med Sci, Sch Nursing & Midwifery, Tohid St, Tehran, Iran.
RP Sadaghiani, S (corresponding author), Univ Tehran Med Sci, Sch Nursing & Midwifery, Tohid St, Tehran, Iran.
EM safasadaghiani@yahoo.com
RI Nasrabadi, Alireza Nikbakht/F-3768-2014; Sadaghiani, Safa/U-6922-2017
OI Nasrabadi, Alireza Nikbakht/0000-0002-3970-4158; Sadaghiani,
   Safa/0000-0001-9216-3090
FU Tehran University of Medical Sciences, Iran
FX The present study as a doctoral thesis entitled as "lived experiences of
   nurses to take care of family members" was scientifically and
   financially supported by Tehran University of Medical Sciences, Iran
CR Andersson M, 2010, PALLIAT SUPPORT CARE, V8, P17, DOI 10.1017/S1478951509990666
   [Anonymous], 2001, INT J NURS STUD, V38, P389
   Buckley Patricia, 2011, Intensive Crit Care Nurs, V27, P263, DOI 10.1016/j.iccn.2011.07.001
   Davidson JE, 2009, CRIT CARE NURSE, V29, P28, DOI 10.4037/ccn2009611
   Engstrom Birgitta, 2011, Intensive Crit Care Nurs, V27, P1, DOI 10.1016/j.iccn.2010.11.004
   ERIN Mccoy., 2010, J PROFESSIONAL NURSI, V27, P64
   Hakio, 2015, INTENSIVE CRITICAL C, V31, P29
   Hoye Sevald, 2010, Intensive Crit Care Nurs, V26, P24, DOI 10.1016/j.iccn.2009.10.003
   Mcclunie-trust P., 2010, NEG BOUND NURS FAM M
   McKiernan Margaret, 2010, Intensive Crit Care Nurs, V26, P254, DOI 10.1016/j.iccn.2010.06.004
   Monks J, 2014, INTENS CRIT CARE NUR, V30, P353, DOI 10.1016/j.iccn.2014.04.006
   phil Halligan., 2006, J CLIN NURS, V15, P1565
   Pryzby Barbara J, 2005, Intensive Crit Care Nurs, V21, P16, DOI 10.1016/j.iccn.2004.06.008
   Rytterstrom, 2009, INTENSIVE CRITICAL C, V46, P689
   Salmond Susan W, 2011, Intensive Crit Care Nurs, V27, P10, DOI 10.1016/j.iccn.2010.09.002
   Soderstrom IM, 2003, SCAND J CARING SCI, V17, P185, DOI 10.1046/j.1471-6712.2003.00222.x
   Susan Tressman., 2009, DELICATE BALANCE NUR, P7
   Turner-Cobb JM, 2016, PSYCHOL HEALTH MED, V21, P20, DOI 10.1080/13548506.2014.997763
   van Mol MMC, 2014, PATIENT EDUC COUNS, V95, P406, DOI 10.1016/j.pec.2014.03.019
   Verhaeghe STL, 2010, J CLIN NURS, V19, P574, DOI 10.1111/j.1365-2702.2009.02987.x
   Wong, 2014, INTENSIVE CRITICAL C, V31, P51
NR 21
TC 0
Z9 0
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 895
EP 899
DI 10.19193/0393-6384_2017_1s_133
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000002
DA 2022-07-14
ER

PT J
AU Natanzi, MM
   Ghaderian, SMH
   Khodaii, Z
AF Natanzi, Mahboobeh Mehrabani
   Ghaderian, Sayyed Mohammad Hossein
   Khodaii, Zohreh
TI IRON ABSORPTION IMPROVEMENT: AN ADDITIONAL HEALTH BENEFIT FOR CERTAIN
   PROBIOTICS, IN VITRO AND IN VIVO STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Iron bioavailability; Probiotics; Caco-2; Ferritin; In vivo; In vitro
ID LACTIC-ACID BACTERIA; PHASEOLUS-VULGARIS L.; CACO-2 CELLS; PHYTASE
   ACTIVITY; PHYTIC ACID; BIOAVAILABILITY; FERMENTATION; CALCIUM; MODEL;
   COLON
AB Probiotics has gained increasing interest from the scientific community due to their promising effects on health. However, there is a limited information about their potential on improving iron bioavailability. We aimed to to investigate the effect of phytase producing probiotic bacteria on improving iron bioavailability, in vitro and in vivo.
   In the first phase a Caco-2 model was set up and ferritin formation in the monolayer was measured after addition of a phytase producing probiotic bacteria, with or without phytic acid, to the cell line. In the second phase, an in vivo assay was conducted to evaluate the effect of probiotic on the serum iron in rats.
   Results of the in vitro and in vivo assays revealed that the probiotic bacteria, significantly improved iron absorption from the mixture of phytate and iron, when compared with the control experiments.
   The results of this study suggest that probiotic bacteria may improve the iron bioavailability of the foods with high content of phytic acid, probably due to the phytase activity in bacteria. Also, this model is suitable to study the iron bioavailability in the presence of probiotics.
C1 [Natanzi, Mahboobeh Mehrabani; Khodaii, Zohreh] Alborz Univ Med Sci, Dietary Supplements & Probiot Res Ctr, Karaj, Iran.
   [Natanzi, Mahboobeh Mehrabani; Khodaii, Zohreh] Alborz Univ Med Sci, Sch Med, Dept Biochem Genet & Nutr, Karaj, Iran.
   [Ghaderian, Sayyed Mohammad Hossein] Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.
RP Khodaii, Z (corresponding author), Alborz Univ Med Sci, Biochem Genet & Nutr Dept, Fac Med, Karaj, Iran.
EM zkhodaii@yahoo.com
RI Khodaii, Zohreh/S-4983-2017; ghaderian, sayyed mohammad
   hossein/O-5566-2019; mehrabani natanzi, mahboobeh/O-3489-2017
OI Khodaii, Zohreh/0000-0002-8858-1983; ghaderian, sayyed mohammad
   hossein/0000-0002-2534-071X; mehrabani natanzi,
   mahboobeh/0000-0001-8879-5984
FU microbiology group of Biomedical Sciences Department of the University
   of Bradford; Alborz University of Medical sciences
FX Our gratitude goes to the friendly members of the microbiology group of
   Biomedical Sciences Department of the University of Bradford and Alborz
   University of Medical sciences for sponsoring the in vivo assay. Also we
   appreciate Mr. Jamshid. S. Goodarzi's help in our laboratory
   experiments.
CR Afify AMR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025512
   Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X
   Ariza-Nieto M, 2007, J AGR FOOD CHEM, V55, P7950, DOI 10.1021/jf070023y
   Au AP, 2000, J NUTR, V130, P1329, DOI 10.1093/jn/130.5.1329
   Bergillos-Meca T, 2013, BIOL TRACE ELEM RES, V151, P307, DOI 10.1007/s12011-012-9544-0
   Bergqvist SW, 2006, BRIT J NUTR, V96, P705, DOI 10.1079/BJN20061905
   BEUTLER E, 1977, BRIT J HAEMATOL, V35, P331, DOI 10.1111/j.1365-2141.1977.tb00589.x
   Bougle D, 2002, SCAND J GASTROENTERO, V37, P1008, DOI 10.1080/003655202320378176
   Charles CV, 2011, EUR J PUBLIC HEALTH, V21, P43, DOI 10.1093/eurpub/ckp237
   Etcheverry P, 2005, INT J VITAM NUTR RES, V75, P171, DOI 10.1024/0300-9831.75.3.171
   Fairweather-Tait S, 2007, INT J VITAM NUTR RES, V77, P158, DOI 10.1024/0300-9831.77.3.158
   Fraga M, 2013, ANN MICROBIOL, V64, P1
   Giraffa G, 2010, RES MICROBIOL, V161, P480, DOI 10.1016/j.resmic.2010.03.001
   Glahn RP, 1998, J NUTR, V128, P1555, DOI 10.1093/jn/128.9.1555
   Glahn RP, 1996, J NUTR, V126, P332, DOI 10.1093/jn/126.1.332
   Haeri A, 2012, ANN MICROBIOL, V62, P339, DOI 10.1007/s13213-011-0267-9
   Hallberg L, 2000, HUM NUTR DIETICS, V10, P177
   Kim EY, 2007, J GEN APPL MICROBIOL, V53, P111, DOI 10.2323/jgam.53.111
   KOT E, 1995, J FOOD SCI, V60, P547, DOI 10.1111/j.1365-2621.1995.tb09823.x
   Lai LR, 2013, J BIOSCI BIOENG, V115, P552, DOI 10.1016/j.jbiosc.2012.11.022
   Laparra JM, 2009, J FOOD SCI, V74, pH40, DOI 10.1111/j.1750-3841.2008.01027.x
   Lin MY, 1999, J NUTR, V106, P543
   Liu CF, 2011, J SCI FOOD AGR, V91, P2284, DOI 10.1002/jsfa.4456
   Lopez HW, 2000, J AGR FOOD CHEM, V48, P2281, DOI 10.1021/jf000061g
   Sanz-Penella JM, 2012, J AGR FOOD CHEM, V60, P3190, DOI 10.1021/jf205048r
   Martinez I, 1998, FOOD RES INT, V31, P459, DOI 10.1016/S0963-9969(99)00013-7
   Pavord S, 2012, BRIT J HAEMATOL, V156, P588, DOI 10.1111/j.1365-2141.2011.09012.x
   PROBERT CJS, 1993, J EPIDEMIOL COMMUN H, V47, P331, DOI 10.1136/jech.47.4.331
   Proulx AK, 2007, J AGR FOOD CHEM, V55, P2749, DOI 10.1021/jf0630015
   Razdan K., 2012, Online Journal of Animal and Feed Research (OJAFR), V2, P369
   Reale A, 2007, J AGR FOOD CHEM, V55, P2993, DOI 10.1021/jf063507n
   Salovaara S, 2003, J AGR FOOD CHEM, V51, P7820, DOI 10.1021/jf030177n
   Saran S, 2002, NUTRITION, V18, P393, DOI 10.1016/S0899-9007(01)00790-0
   Sazawal S., 2004, ASIA PAC J CLIN NUTR, V13, pS28
   Schumann K, 1997, ARZNEIMITTEL-FORSCH, V47, P369
   Skoglund E, 1999, J AGR FOOD CHEM, V47, P1109, DOI 10.1021/jf980745c
   Songre-Ouattara LT, 2008, INT J FOOD MICROBIOL, V128, P395, DOI 10.1016/j.ijfoodmicro.2008.09.004
   Sun J, 2010, LETT APPL MICROBIOL, V50, P264, DOI 10.1111/j.1472-765X.2009.02786.x
   Tang AL, 2010, J FOOD SCI, V75, pM373, DOI 10.1111/j.1750-3841.2010.01663.x
   Zamudio M, 2001, LETT APPL MICROBIOL, V32, P181, DOI 10.1046/j.1472-765x.2001.00890.x
NR 40
TC 1
Z9 1
U1 0
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 295
EP 300
DI 10.19193/0393-6384_2017_2_044
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700019
DA 2022-07-14
ER

PT J
AU Nayir, T
   Aydin, CG
   Eroglu, A
   Tas, SK
AF Nayir, Tufan
   Aydin, Canan Gonen
   Eroglu, Ali
   Tas, Suleyman Kasim
TI DOES THE REGULAR SPORTS ACTIVITIES AFFECT VITAMIN D LEVELS AT YOUNG
   ATHLETES: A CROSS SECTIONAL STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Vitamin D; Sports; Athletes; Sports Medicine
ID HIGH PREVALENCE; D INSUFFICIENCY; CHILDREN; MUSCLE
AB Objectives: The aim of this paper is to evaluate whether making regular sports activities cause vitamin D increase status at the Turkish athletes of 17 different sport modalities.
   Methods: A total of 1126 athletes were included in the study who applied to the Baltalimani Bone Diseases Hospital Sports Medicine Polyclinic between April 2015 and 2016. There were 17 different group of athletes. Vitamin D levels of the athletes were evaluated.
   Results: 39.7% of the participants were women while 60.3% were men. There was a significant difference in height and weight between the men and women in the study group (p=0.03 and p=0.00). Athletes were classified according to years of sport start. There was no statistically significant difference between groups in terms of vitamin D levels Although beginners had low levels of vitamin D, there was no significant difference (p=0.577) when compared to other groups. There was no statistically significant difference between ALP, P, Ca and PTH values according to years of sport start in females and males.
   Conclusion: In this study, even those who are engaged in long-lasting sports have not found enough vitamin D levels.
C1 [Nayir, Tufan] Minist Hlth Turkey Republ, TR-06420 Ankara, Turkey.
   [Aydin, Canan Gonen] Baltalimani Bone Dis Training & Res Hosp, Sports Med Clin, Istanbul, Turkey.
   [Eroglu, Ali] Erenkoy Phys Therapy & Rehabil Hosp, Sports Med Clin, Istanbul, Turkey.
   [Tas, Suleyman Kasim] Baltalimani Bone Dis Training & Res Hosp, Orthoped & Traumatol Clin, Istanbul, Turkey.
RP Nayir, T (corresponding author), Minist Hlth Turkey Republ, TR-06420 Ankara, Turkey.
CR Abboud M, 2014, J STEROID BIOCHEM, V144, P232, DOI 10.1016/j.jsbmb.2013.10.020
   Al-Othman A, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-92
   Association of Endocrinology and Metabolism in Turkey, 2015, GUID DIAGN TREATM ME
   Cashman Kevin D, 2007, Novartis Found Symp, V282, P123
   Close GL, 2013, BRIT J SPORT MED, V47, P692, DOI 10.1136/bjsports-2012-091735
   Constantini NW, 2010, CLIN J SPORT MED, V20, P368, DOI 10.1097/JSM.0b013e3181f207f2
   De Ronne N, 2013, J Pharm Belg, P12
   Dong J, 2014, PERITON DIALYSIS INT, V34, P447, DOI 10.3747/pdi.2013.00001
   Foo LH, 2009, J NUTR, V139, P1002, DOI 10.3945/jn.108.102053
   Glerup H, 2000, CALCIFIED TISSUE INT, V66, P419, DOI 10.1007/s002230010085
   Ha CD, 2013, MED SCI SPORT EXER, V45, P102, DOI 10.1249/MSS.0b013e31826c6956
   Halliday TM, 2011, MED SCI SPORT EXER, V43, P335, DOI 10.1249/MSS.0b013e3181eb9d4d
   Hamilton B, 2010, SCAND J MED SCI SPOR, V20, P182, DOI 10.1111/j.1600-0838.2009.01016.x
   Henderson A, 2005, JOGNN-J OBST GYN NEO, V34, P367, DOI 10.1177/0884217505276157
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Koenig J, 2000, INT J VITAM NUTR RES, V70, P214, DOI 10.1024/0300-9831.70.5.214
   Lovell G, 2008, CLIN J SPORT MED, V18, P159, DOI 10.1097/JSM.0b013e3181650eee
   Moreno LA, 2011, ANN NUTR METAB, V59, P22, DOI 10.1159/000332070
   Morton JP, 2012, APPL PHYSIOL NUTR ME, V37, P798, DOI [10.1139/h2012-037, 10.1139/H2012-037]
   Muhairi SJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-33
   Ogan D, 2013, NUTRIENTS, V5, P1856, DOI 10.3390/nu5061856
   Ruohola JP, 2006, J BONE MINER RES, V21, P1483, DOI 10.1359/JBMR.060607
   Shady Mones M Abu, 2015, Open Access Maced J Med Sci, V3, P80, DOI 10.3889/oamjms.2015.006
   Valtuena J, 2014, NUTR HOSP, V30, P124, DOI 10.3305/nh.2014.30.1.7539
   Whiting SJ, 2011, AM J CLIN NUTR, V94, P128, DOI 10.3945/ajcn.111.013268
   Willis KS, 2008, INT J SPORT NUTR EXE, V18, P204, DOI 10.1123/ijsnem.18.2.204
NR 26
TC 1
Z9 1
U1 0
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 913
EP 919
DI 10.19193/0393-6384_2017_6_145
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500004
DA 2022-07-14
ER

PT J
AU Ocek, L
   Sener, U
   Ilgezdi, I
   Ozcelik, MM
   Zorlu, Y
AF Ocek, Levent
   Sener, Ufuk
   Ilgezdi, Irem
   Ozcelik, Metin Murat
   Zorlu, Yasar
TI ACUTE ISCHEMIC STROKE IN PATIENTS WITH CANCER: RISK FACTORS, CLINICAL
   AND IMAGING OUTCOMES
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Ischemic stroke; cancer; traditional risk factor; imaging
ID ETIOLOGY; MANIFESTATION; DEFINITIONS; MECHANISMS; DISEASE; PATTERN;
   EVENTS; NECK
AB Introduction: Cancer patients have higher risk of stroke compared with the normal population. The relationship between this increased risk and traditional vascular risk factors is not known exactly. The aims of this study were to investigate ischemic strokes, who had a history of cancer or diagnosed cancer during etiologic scanning, in terms of the cancer type, likely causes of stroke and demographic data.
   Materials and methods: In this retrospective study, the stroke patients with known cancer or diagnosed with cancer during follow-up were selected by screening the data of 1002 acute ischemic stroke patients who were followed-up in the hospital between 2012 and 2015 and demographic, clinical and imaging findings were recorded. Temporal association between cancer type, presence of metastasis, treatment administered, response to therapy, cancer and stroke, possible stroke etiology and stroke risk factors of the patients were investigated.
   Results: An association was determined between acute ischemic stroke and cancer in 58 (5.8%) of our patients. Sixty-nine percent of our patients were males and the mean age was 66.5-year. Cancers most commonly found were lung (20.7%), colorectal (15.5%) and prostate cancer (13.8%). The most frequently found risk factors for ischemic stroke were hypertension and diabetes mellitus. Twelve point one percent of the patients did not have any traditional risk factors for ischemic stroke. Eight point six percent of the patients had ischemic stroke as a presenting symptom of cancer. Sixty-eight point nine percent of the patients had supratentorial infarcts and 10.3% of them infratentorial infarcts. Supratentorial infarcts were most commonly located in the middle cerebral region, and infratentorial infarcts were located in the brainstem.
   Conclusion: Cancer patients with ischemic stroke showed different risk factors, stroke etiology and infarct localizations. Therefore, cancers need to be particularly studied in patients who do not have traditional risk factors for ischemic stroke.
C1 [Ocek, Levent] Usak Univ, Educ & Res Hosp, Clin Neurol, Fevzi Cakmak Mahallesi,Denizli Caddesi 4, Usak, Turkey.
   [Sener, Ufuk; Ilgezdi, Irem; Ozcelik, Metin Murat; Zorlu, Yasar] Tepecik Educ & Res Hosp, Clin Neurol, Izmir, Turkey.
RP Ocek, L (corresponding author), Usak Univ, Educ & Res Hosp, Clin Neurol, Fevzi Cakmak Mahallesi,Denizli Caddesi 4, Usak, Turkey.
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Baird AE, 2000, NEUROLOGY, V54, P674, DOI 10.1212/WNL.54.3.674
   Cestari DM, 2004, NEUROLOGY, V62, P2025, DOI 10.1212/01.WNL.0000129912.56486.2B
   CHATURVEDI S, 1994, STROKE, V25, P1215, DOI 10.1161/01.STR.25.6.1215
   Chen PC, 2011, STROKE, V42, P3034, DOI 10.1161/STROKEAHA.111.615534
   Dipasco PJ, 2011, J SURG ONCOL, V104, P316, DOI 10.1002/jso.21925
   Donati MB, 2009, BEST PRACT RES CL HA, V22, P3, DOI 10.1016/j.beha.2009.01.005
   Giray S, 2011, CHINESE MED J-PEKING, V124, P637, DOI 10.3760/cma.j.issn.0366-6999.2011.04.030
   GRAUS F, 1985, MEDICINE, V64, P16, DOI 10.1097/00005792-198501000-00002
   Kim SG, 2010, STROKE, V41, P798, DOI 10.1161/STROKEAHA.109.571356
   Lee EJ, 2014, INT J STROKE, V9, P406, DOI 10.1111/ijs.12124
   Lee JH, 2012, EUR NEUROL, V67, P303, DOI 10.1159/000336061
   Li CS, 2010, CLIN NEUROL NEUROSUR, V112, P682, DOI 10.1016/j.clineuro.2010.05.007
   MartinNegrier ML, 1996, STROKE, V27, P536, DOI 10.1161/01.STR.27.3.536
   Oberndorfer S, 2009, J NEUROONCOL, V94, P221
   Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001
   Schwarzbach CJ, 2012, STROKE, V43, P3029, DOI 10.1161/STROKEAHA.112.658625
   Schwarzbach CJ, 2015, CEREBROVASC DIS EXTR, V5, P139, DOI 10.1159/000439549
   Scott AS, 2009, RADIOTHER ONCOL, V90, P163, DOI 10.1016/j.radonc.2008.12.019
   Selvik HA, 2014, J STROKE CEREBROVASC, V23, P919, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.041
   Uemura J, 2010, EUR NEUROL, V64, P140, DOI 10.1159/000316764
   Varki A, 2007, BLOOD, V110, P1723, DOI 10.1182/blood-2006-10-053736
   Zhang YY, 2006, ACTA NEUROL SCAND, V114, P378, DOI 10.1111/j.1600-0404.2006.00709.x
   Zhang YY, 2007, CEREBROVASC DIS, V23, P181, DOI 10.1159/000097639
NR 24
TC 5
Z9 5
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 601
EP 606
DI 10.19193/0393-6384_2017_4_089
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700010
DA 2022-07-14
ER

PT J
AU Ozturk, I
   Kilic, B
   Demiroglu, M
   Alptekin, HA
   Yazicioglu, D
   Oguz, E
   Baran, I
   Aydin, GB
   Ozturk, S
   Orhon, ZN
AF Ozturk, Ibrahim
   Kilic, Bulent
   Demiroglu, Murat
   Alptekin, Huseyin Alp
   Yazicioglu, Dilek
   Oguz, Eylem
   Baran, Ilkay
   Aydin, Gozde Bumin
   Ozturk, Selen
   Orhon, Zeynep Nur
TI EFFECT OF DIABETES MELLITUS ON SPINAL ANESTHESIA FAILURE
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE diabetes mellitus; spinal anesthesia; failure
AB Introduction: Spinal anesthesia (SA) is a commonly performed regional anesthesia technique in current practice. Failure of SA is observed depending different causes. We aimed to search the relationship between diabetes mellitus (DM) and SA failure. We hypothesized that DM could affect the success of SA.
   Methods: A total of 1032 patients were included to the study. Spinal anesthesia failure was defined as absence of sensory block according to 'pin-prick test' examination despite injection of local anesthetics after free flow of cerebrospinal fluid (CSF) and Bromage scale 4 (able to move hip, knee and ankle).
   Results: When we analysed the demographical data between successful and failed patients, no significant differences were observed (p>0.05) And also there was no difference for surgical type, puncture level, presence of DM and glucose level (p>0.05).
   Conclusion: We concluded that DM and also demographical variables such as age, height, weight and gender were not the possible risk factors for complete failure spinal anesthesia.
C1 [Ozturk, Ibrahim; Orhon, Zeynep Nur] Medeniyet Univ, Goztepe Educ & Res Hosp, Dept Anesthesiol & Reanimat, Istanbul, Turkey.
   [Kilic, Bulent] Istanbul Gelisim Univ, Dept Hlth Sci, Orthopaed Surg, Istanbul, Turkey.
   [Demiroglu, Murat] Istanbul Medeniyet Univ, Goztepe Training & Res Hosp, Dept Orthopaed & Traumatol, Istanbul, Turkey.
   [Alptekin, Huseyin Alp; Yazicioglu, Dilek; Oguz, Eylem; Baran, Ilkay; Aydin, Gozde Bumin] Diskapi Yildirim Beyazit Educ & Res Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkey.
   [Ozturk, Selen] Dr Siyami Ersek Thorax Heart & Vasc Surg Res Hosp, Istanbul, Turkey.
RP Demiroglu, M (corresponding author), Dr Erkin Cad Goztepe Egitim Arastirma Hastanesi A, Istanbul, Turkey.
RI Ünal, Dilek/AAW-7981-2020; öztürk, ibrahim/AAH-5145-2020; Öztürk,
   Selen/AAL-6037-2021; Orhon, Zeynep Nur/AAG-4516-2019; Kılıç,
   Bülent/ABB-2651-2021; aydın, gözde bumin/AAI-7766-2021
OI Ünal, Dilek/0000-0003-1481-6820; öztürk, ibrahim/0000-0002-7346-3108; 
CR Dobler K, 1990, Reg Anaesth, V13, P101
   Echevarria M, 2008, EUR J ANAESTH, V25, P1014, DOI 10.1017/S0265021508004729
   Fettes PDW, 2009, BRIT J ANAESTH, V102, P739, DOI 10.1093/bja/aep096
   Fuzier R, 2011, REGION ANESTH PAIN M, V36, P322, DOI 10.1097/AAP.0b013e318217a68e
   Hoppe J, 2007, INT J OBSTET ANESTH, V16, P250, DOI 10.1016/j.ijoa.2006.12.005
   Kroin JS, 2012, PAIN MED, V13, P802, DOI 10.1111/j.1526-4637.2012.01396.x
   Last D, 2007, DIABETES CARE, V30, P1193, DOI 10.2337/dc06-2052
   LEVY JH, 1985, ANESTH ANALG, V64, P705
   Rukewe A, 2015, ANESTH ANALG, V121, P1301, DOI 10.1213/ANE.0000000000000868
   TARKKILA PJ, 1991, REGION ANESTH, V16, P48
NR 10
TC 1
Z9 1
U1 0
U2 0
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 417
EP 421
DI 10.19193/0393-6384_2017_3_061
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200009
DA 2022-07-14
ER

PT J
AU Parisi, L
   Faraldo, MA
   Ruberto, M
   Salerno, M
   Maltese, A
   Di Folco, A
   Messina, G
   Di Filippo, T
   Roccella, M
AF Parisi, Lucia
   Faraldo, Maria Antonietta
   Ruberto, Maria
   Salerno, Margherita
   Maltese, Agata
   Di Folco, Annabella
   Messina, Giovanni
   Di Filippo, Teresa
   Roccella, Michele
TI RETRACTED: LIFE EVENTS AND PRIMARY MONOSYMPTOMATIC NOCTURNAL ENURESIS: A
   PEDIATRIC PILOT STUDY (Retracted Article)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article; Retracted Publication
DE primary monosymptomatic nocturnal enuresis; PMNE; Coddington Life Events
   Scales; life adverse events
ID SLEEP-APNEA SYNDROME; CHILDHOOD MIGRAINE; MATERNAL STRESS; CHILDREN;
   DISORDERS; SYMPTOMS; EPILEPSY; AURA; ADOLESCENTS
AB Introduction: The association between primary monosymptomatic nocturnal enuresis (PMNE) and behavioral disorders was highlighted frequently, suggesting psychiatric origin. On the other hand, there is no difference between the incidence of mental disorders in children with PMNE and controls, although the psychological genesis could provide additional secondary forms, in which the child might react to stressful events with the resumption of involuntary urination at night, with a possible alteration of bowel control due to a high vulnerability to stressors.
   The purpose of this study is assessing the stressful events of life in a sample of children with PMNE.
   Materials and methods: 56 subjects with PMNE, (37 males and 19 females) (mean 10.87 years; SD +/- 1.68) were recruited consecutively. All subjects were evaluated for the presence of stressful events (ICU) with test Coddington Life Events Scales (CLES). The control group consists of 98 typically developing children (65 males, 33 females) (p = 0.855) (mean 11.3 years; SD +/- 1.85; p = 0.594).
   Results: Individuals with enuresis do not show a significant difference in the prevalence of stressful events than the control group (42.85% vs 41.83%; Chi-square = 0.002; p = 0,963) (table 1).
   Conclusions: These results for the first time show that PMNE can be regarded as an independent state by stress factors, suggesting that it itself represents a stress factor that can affect the proper psychological and neuropsychological development in children.
C1 [Parisi, Lucia; Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa; Roccella, Michele] Univ Palermo, Dept Psychol Pedag & Educ Sci, I-90133 Palermo, Italy.
   [Faraldo, Maria Antonietta] Univ Naples 2, Dept Mental Hlth & Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Naples, Italy.
   [Ruberto, Maria] Univ Naples 2, Dept Med Surg & Dent Specialties, Naples, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, I-90133 Palermo, Italy.
   [Messina, Giovanni] Univ Foggia, Dept Expt Med, Sect Human Physiol, Foggia, Italy.
   [Messina, Giovanni] Univ Foggia, Unit Dietet & Sports Med, Dept Clin & Expt Med, Foggia, Italy.
RP Roccella, M (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, I-90133 Palermo, Italy.
CR Amjad RN, 2016, ACTA MEDICA MEDITERR, V32, P1303
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2016, EUR J PHYS REHABIL M
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1433, DOI 10.2147/NDT.S51257
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Foumany GHE, 2015, ACTA MEDICA MEDITERR, V31, P1351
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Shams S, 2016, ACTA MEDICA MEDITERR, V32, P1555
   Zou YL, 2016, ACTA MEDICA MEDITERR, V32, P1177
NR 50
TC 15
Z9 15
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 23
EP 27
DI 10.19193/0393-6384_2017_1_003
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800003
DA 2022-07-14
ER

PT J
AU Parisi, L
   Fortunato, MR
   Salerno, M
   Maltese, A
   Di Folco, A
   Di Filippo, T
   Roccella, M
AF Parisi, Lucia
   Fortunato, Maria Rosaria
   Salerno, Margherita
   Maltese, Agata
   Di Folco, Annabella
   Di Filippo, Teresa
   Roccella, Michele
TI SENSORY PERCEPTION IN PRESCHOOL CHILDREN AFFECTED BY AUTISM SPECTRUM
   DISORDER: A PILOT STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Autism Spectrum Disorders; Preschool children; Perception; SPCR
ID SLEEP-APNEA SYNDROME; PRIMARY NOCTURNAL ENURESIS; PRIMARY CILIARY
   DYSKINESIA; CHILDHOOD MIGRAINE; MATERNAL STRESS; SELF-CONCEPT; AURA;
   SYMPTOMS; MULTICENTER; ADOLESCENTS
AB Introduction: Autism spectrum disorder (ASD) is a behavioral syndrome caused by a developmental disorder, biologically determined, with onset in the first three years of life. The areas concerned are mainly those related to social communication, social interaction and mutual functional and symbolic play.
   In the last decades, different conceptions of autism have taken, also emphasizing different sensory-perceptual abnormalities as the basis of the central features of disorder.
   This pilot study intends to address the issue of sensory perception in preschool children affected by ASD.
   Material and methods: 11 ASD children were enrolled (7 males, 4 female) aged between 2.3 years and 4.6 years, (mean age 3.29 +/- 0.72). The control group consisted of 24 typical developing children (15 males, 9 females) (mean age 3.08 +/- 0.87). All subjects underwent assessment of sensory perceptual abilities according to the Bogdashina's Sensory Profile Checklist Revised (SPCR) evaluation (43).
   Results: The two groups are comparable for age (p = 0.491) and sex distribution (p = 0.755). Table 1 shows the comparison between the two groups results in the SPCR, specifically, individuals with ASD, showed significantly higher scores on near all perception areas evaluated than healthy controls, suggesting a clear perceptual impairment in ASD subjects. Only for olfactory perception two groups were comparable.
   Conclusions: no significant differences in behavioral reaction to smell stimulation between ASD and typical developing children, and this result could be explained according to the early age of our sample that could cause high reactivity to smell stimulation also in typical developing examined children.
C1 [Parisi, Lucia; Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa; Roccella, Michele] Univ Palermo, Dept Psychol Pedag & Educ Sci, I-90133 Palermo, Italy.
   [Fortunato, Maria Rosaria] Univ Naples 2, Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, I-90133 Palermo, Italy.
RP Roccella, M (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, I-90133 Palermo, Italy.
CR Amjad RN, 2016, ACTA MEDICA MEDITERR, V32, P1303
   Bogdashina O., 2003, SENSORY PERCEPTUAL I
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Foumany GHE, 2015, ACTA MEDICA MEDITERR, V31, P1351
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Montalbano R, 2009, Minerva Pediatr, V61, P361
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Narzisi A, 2011, GIOR NEUROPSICH ETA, V31, P215
   Parisi L, 2015, MINERVA PEDIATR, V67, P369
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2015, MENT ILLN, V7, P32, DOI 10.4081/mi.2015.5988
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Shams S, 2016, ACTA MEDICA MEDITERR, V32, P1555
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Yongli Z, 2016, ACTA MEDICA MEDITERR, V32, P1177
NR 50
TC 16
Z9 16
U1 0
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 49
EP 53
DI 10.19193/0393-6384_2017_1_007
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800007
DA 2022-07-14
ER

PT J
AU Parisi, L
   Salerno, M
   Maltese, A
   Tripi, G
   Romano, P
   Di Folco, A
   Di Filippo, T
   Roccella, M
AF Parisi, Lucia
   Salerno, Margherita
   Maltese, Agata
   Tripi, Gabriele
   Romano, Palmira
   Di Folco, Annabella
   Di Filippo, Teresa
   Roccella, Michele
TI PATERNAL SHIFT-WORKING AND SLEEP DISORDERS IN CHILDREN AFFECTED BY
   PRIMARY NOCTURNAL ENURESIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Primary nocturnal enuresis; paternal shift-working; SDSC
ID QUALITY-OF-LIFE; AUTISM SPECTRUM DISORDERS; CHILDHOOD MIGRAINE; PARENTAL
   STRESS; MULTICENTER; AURA; ABNORMALITIES; ADOLESCENTS; DEPRESSION;
   EFFICACY
AB Objectives: Primary monosymptomatic nocturnal enuresis (PMNE) is a common problem in childhood and studies about the sleep habits of affected children are not conclusive. Work-family conflict (WFC) results from the incompatibility between family demands and business/workplace needs. WFC can impact parental quality with many consequences on children health. Aim of study is assessing the prevalence of sleep disturbances in enuretic children, sons of work-shifters.
   Materials and methods: 80 children (67 males) aged 5-13 years (mean 10,43; SD +/- 1,99), were consecutively referred for PMNE. Sleep habits were investigated with Sleep Disturbances Scale for Children (SDSC) and the results were compared with a control group of 255 (190 males) typical developing children (TDC) sons of no shift-workers, matched for age (mean 10.57 SD +/- 1,89; p = 0.569) and sex distribution (Chi-square= 2.416; p = 0.120).
   Results: To evaluate statically differences among mean values of two samples, the Chi-square test was performed. Logistic regression was assessed to verify the role of paternal shift-working as risk factor for sleep disorders. p <= 0.05. All sleep disturbances categories were more prevalent in PMNE children sons of shift-workers than control group (Chi-square= 43.926; p<0.001); particularly 82.5% of PMNE vs. 11.76% of TDC show pathological scores for SBD category (Chi-square = 145.592; p<0.001; OR = 35,35; IC95% = 17.71-70.57); 61.25% vs 9.41% for SWTD (Chi-square = 93; p <0.001; OR = 15.213; IC95% = 8.21-28.15); 57.5% vs 9.41% for DA (Chi-square = 82.31; p < 0.001; OR = 13.02; IC95% = 7.06-23.98); 37.5% vs 6.67% for DIMS (Chi-square = 45.476; p < 0.001; OR = 8,4; IC95% = 4.3-16.39); 26.25% vs 5.88% for SHY (Chi-square = 24.257; p < 0.001; OR = 5.69; IC95% = 2,76-11,71) and 25%c vs 5.49% for DOES (Chi-square = 23.323; p < 0.001; OR = 5,73; IC95% = 2,73-12,01).
   Conclusions: Our findings suggest that paternal shif-working plus PMNE children may be a relevant factor affecting sleep quality in affected children.
C1 [Parisi, Lucia; Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa; Roccella, Michele] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Romano, Palmira] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
RP Roccella, M (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Alesi M, 2014, NEUROPSYCH DIS TREAT, V10, P479, DOI 10.2147/NDT.S58455
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio M. F., 2013, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V172, P705
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Maltese A, 2014, MINERVA PEDIATR, V66, P7
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 48
TC 9
Z9 9
U1 0
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 481
EP 484
DI 10.19193/0393-6384_2017_3_071
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200019
DA 2022-07-14
ER

PT J
AU Parisi, L
   Salerno, M
   Maltese, A
   Tripi, G
   Romano, P
   Di Folco, A
   Di Filippo, T
   Messina, G
   Roccella, M
AF Parisi, Lucia
   Salerno, Margherita
   Maltese, Agata
   Tripi, Gabriele
   Romano, Palmira
   Di Folco, Annabella
   Di Filippo, Teresa
   Messina, Giovanni
   Roccella, Michele
TI EMOTIONAL INTELLIGENCE AND OBSTRUCTIVE SLEEP APNEA SYNDROME IN CHILDREN:
   PRELIMINARY CASE-CONTROL STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE emotional intelligence; OSAS; sleep apnea; Bar-On emotional quotient
   inventory; EQ-i: YV
ID QUALITY-OF-LIFE; PRIMARY NOCTURNAL ENURESIS; AUTISM SPECTRUM DISORDERS;
   CHILDHOOD MIGRAINE; PARENTAL STRESS; MULTICENTER; ABNORMALITIES;
   ADOLESCENTS; DEPRESSION; THERAPY
AB Introduction: Obstructive sleep apnea syndrome (OSAS) affects up to 4% of pediatric population, with many co-morbidities in the medium-long term. Functional alterations in prefrontal cortex (PFC) may explain why OSAS impacts aspects such as: executive functions, memory, motor control, attention, visual-spatial skills, learning and mood regulation. Emotional intelligence (EI) is a complex neuropsychological function that could be impaired in many clinical conditions. Aim of the study is to evaluate the difference in emotional intelligence skills among children with OSAS and healthy subjects
   Materials and methods: 29 children (16 males) mean age 9.5 +/- 1.54 years, affected by OSAS were compared with 60 typical developing children similar for gender (p = 0,871), age (p = 0,934) and socio-economic status (p = 0.714). Bar-On emotional quotient inventory, youth version (EQ-i: YV) was used in order to assess the Emotional Quotient.
   Results: Apnea/hypopnea index (AHI) results to be 8.76 +/- 3.45 with medium desaturation index (ODI) amounting to 2: 52 +/- 21.5, average saturation 92.7 +/- 4.8 %, average desaturation 4.9 %. OSAS children have significant differences in Interpersonal scales (84.95 +/- 07.03 vs. 99.61 +/- 8.96; p <0.001), Adaptability (7: 36 +/- 79.61 vs. 101.32 +/- 9.4; p <0.001), Stress Management (72.48 +/- 8.14 vs. 98.44 +/- 5.19, p <0.001), QE Total (81.28 +/- 11.03 vs. 102.14 +/- 9.62; p <0.001). Pearson correlation analysis shows an inverse relationship between QE total and ODI (p <0.01).
   Conclusion: Our findings tend to highlight the role of intermittent hypoxia in OSAS effects genesis, involving also aspects different from physical impairments.
C1 [Parisi, Lucia; Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa; Roccella, Michele] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Romano, Palmira] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
   [Messina, Giovanni] Univ Foggia, Dept Expt Med, Sect Human Physiol, Foggia, Italy.
   [Messina, Giovanni] Univ Foggia, Unit Dietet & Sports Med, Dept Clin & Expt Med, Foggia, Italy.
RP Roccella, M (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
RI Messina, Giovanni/AAE-8668-2022
OI Messina, Giovanni/0000-0002-0011-867X; TRIPI,
   Gabriele/0000-0001-7088-9325
CR Alesi M, 2014, NEUROPSYCH DIS TREAT, V10, P479, DOI 10.2147/NDT.S58455
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio M. F., 2013, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V172, P705
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Maltese A, 2014, MINERVA PEDIATR, V66, P7
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 48
TC 18
Z9 18
U1 0
U2 9
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 485
EP 489
DI 10.19193/0393-6384_2017_3_072
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200020
DA 2022-07-14
ER

PT J
AU Parisi, L
   Salerno, M
   Maltese, A
   Tripi, G
   Romano, P
   Di Folco, A
   Di Filippo, T
   Roccella, M
AF Parisi, Lucia
   Salerno, Margherita
   Maltese, Agata
   Tripi, Gabriele
   Romano, Palmira
   Di Folco, Annabella
   Di Filippo, Teresa
   Roccella, Michele
TI AUTONOMIC REGULATION IN AUTISM SPECTRUM DISORDERS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE autonomic regulation; autism spectrum disorders; SenseWear Armband
ID QUALITY-OF-LIFE; PRIMARY NOCTURNAL ENURESIS; CHILDHOOD MIGRAINE;
   PARENTAL STRESS; CHILDREN; MULTICENTER; SLEEP; AURA; ABNORMALITIES;
   ADOLESCENTS
AB Introduction: The sinactive developmental model provides suggests a different way for the brain study by observing the children behavior. In all neurodevelopmental disorders, we can observe autonomic alteration comprising sleep disorders, meal behaviour alteration and self-regulatory impairment. These alterations/impairment are very frequent in autism spectrum disorders (ASD) (1-12). Aim of the present preliminary study is the assessment of metabolic rate in children affected by ASD.
   Material s and methods: 5 males affected by ASD aged 7-10 years (mean age 6.73 +/- 3:39), were recruited. The average score at the ADOS scale was 12.24 (SD +/- 3.29). The control group consisted of 5 males typically developing children (TDC) aged 7 to 11 years (mean age 7.92 +/- 3.23).
   Autonomic/Metabolic evaluation: Free-living daily physical activity was measured using either the SenseWear Armband in order to calculate the total energy expenditure (TEE), baseline (REE) and the metabolic physical activity for prolonged periods of time. In general, the SenseWear Armband allows objective monitoring of the lifestyle including duration and sleep efficiency.
   Results: ASD subjects show values of total energy expenditure (p = 0.0047) and active energy expenditure (p = 0.044) significantly higher compared to control subjects (Table 1). In addition, ASD children have a metabolic intermediate significantly higher than healthy subjects (p=0.015). (Table 1). Finally, the ASD children show a significant reduction of sleep time (p = 0.027) (Table 1).
   Conclusion: ASD can represents a very significant risk factor for developing sleep disorders and to high energy expenditure, although further studies are needed in this respect.
C1 [Parisi, Lucia; Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa; Roccella, Michele] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Romano, Palmira] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
RP Roccella, M (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Alesi M, 2014, NEUROPSYCH DIS TREAT, V10, P479, DOI 10.2147/NDT.S58455
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio M. F., 2013, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V172, P705
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Maltese A, 2014, MINERVA PEDIATR, V66, P7
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 48
TC 11
Z9 11
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 491
EP 494
DI 10.19193/0393-6384_2017_3_073
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200021
DA 2022-07-14
ER

PT J
AU Parisi, L
   Salerno, M
   Maltese, A
   Tripi, G
   Romano, P
   Di Folco, A
   Di Filippo, T
   Roccella, M
AF Parisi, Lucia
   Salerno, Margherita
   Maltese, Agata
   Tripi, Gabriele
   Romano, Palmira
   Di Folco, Annabella
   Di Filippo, Teresa
   Roccella, Michele
TI ANXIETY LEVELS IN MOTHERS OF CHILDREN AFFECTED BY X-FRAGILE SYNDROME
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE anxiety disorder; X-fragile; scale state-trait anxiety inventory for
   adults
ID QUALITY-OF-LIFE; PRIMARY NOCTURNAL ENURESIS; AUTISM SPECTRUM DISORDERS;
   CHILDHOOD MIGRAINE; PARENTAL STRESS; MULTICENTER; SLEEP; AURA;
   ABNORMALITIES; ADOLESCENTS
AB Introduction: Anxiety is the psychological process by which the individual reacts to dangerous external stimuli, triggering responses (mediated by norepinephrine, GABA and serotonin) involving physiological reactions and cognitive strategies. Anxiety can be differentiated in state anxiety and trait anxiety. Fragile X Syndrome (FXS) is a disorder most commonly caused by a triplet repeat expansion of >200 cytosine-guanine-guanine (CGG) repeats in the 50 untranslated region of the Fragile X mental retardation 1 (FMR1) gene.
   Aim of the present study is investigating the state or trait anxiety in a sample of mothers of children affected by X-fragile.
   Materials and methods: 84 mothers (mean age 48.36 +/- 7.11) of children affected by FXS were recruited and compared with mother of 171 typical developing children (mean age 46.18 +/- 9.53). The Scale State-Trait Anxiety Inventory for Adults (STAI) was used in order to assess the anxiety levels.
   Results: All mothers of children affected by FXS showed high score of anxiety levels at the STAI evaluation (Table 1), with no differences were found between mothers of males and females children affected.
   Conclusions: Mothers of children with FXS appear to be in a state of anxiety effects and suddenly even higher than those found later in mothers of children with other chronic diseases.
C1 [Parisi, Lucia; Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa; Roccella, Michele] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, St Benoit La Foret, France.
   [Romano, Palmira] Univ Campania Luigi Vanvitelli, Dept Mental Hlth & Phys & Prevent Med, Clin Child & Adolescent Neuropsychiat, Caserta, Italy.
RP Roccella, M (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Alesi M, 2014, NEUROPSYCH DIS TREAT, V10, P479, DOI 10.2147/NDT.S58455
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2010, MED HYPOTHESES, V75, P120, DOI 10.1016/j.mehy.2010.02.004
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2011, SLEEP BREATH, V15, P221, DOI 10.1007/s11325-010-0388-6
   Chieffi S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00085
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Di Filippo T, 2012, MENT ILLN, V4, P21, DOI 10.4081/mi.2012.e5
   Epifanio M. F., 2013, GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, V172, P705
   Epifanio MS, 2015, PEDIATRIC REP, V7, P38, DOI 10.4081/pr.2015.5872
   Epifanio MS, 2013, PEDIATRIC REP, V5, P81, DOI 10.4081/pr.2013.e19
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2015, J MED FOOD, V18, P916, DOI 10.1089/jmf.2014.0113
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P141, DOI 10.2147/NDT.S55518
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, DOI 10.2147/NDT.S42182
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Franzoni E, 2015, EUR J PAEDIATR NEURO, V19, P660, DOI 10.1016/j.ejpn.2015.07.008
   Maltese A, 2014, MINERVA PEDIATR, V66, P7
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Morandi A, 2015, AM J MED GENET A, V167, P2720, DOI 10.1002/ajmg.a.37222
   Moscatelli F, 2016, SOMATOSENS MOT RES, V33, P137, DOI 10.1080/08990220.2016.1203305
   Panico A, 2017, PATIENT PREFER ADHER, V11, P423, DOI 10.2147/PPA.S119180
   Parisi L, 2012, MINERVA PEDIATR, V64, P65
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2013, MENT ILLN, V5, P26, DOI 10.4081/mi.2013.e7
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Verrotti A, 2015, PEDIATR OBES, V10, P220, DOI 10.1111/ijpo.245
   Villano I, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00010
NR 48
TC 15
Z9 15
U1 1
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 495
EP 499
DI 10.19193/0393-6384_2017_3_074
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200022
DA 2022-07-14
ER

PT J
AU Pasalar, P
AF Pasalar, Parvin
TI WOUND HEALING POTENTIAL OF AQUEOUS EXTRACT OF ELAEAGNUS ANGUSTIFOLIA
   FRUIT WITH DOWN REGULATION OF TNF-ALPHA IN RAT
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Wound healing; Elaeagnus angustifolia; TNF-alpha; Antioxidant;
   Anti-inflammatory
ID MICE; MYELOPEROXIDASE; FIBROBLASTS; FLAVONOIDS; HOSPITALS; MODEL
AB Wound healing properties of Elaeagnus angustifolia (EA) fruit has been used for a long time in traditional Iranian medicine. The present study was performed to investigate the biochemical mechanism of wound healing activity of this plant in rats. After creating full-thickness skin wounds on the back of the rats, they were randomly divided into three groups. Two groups as the treated and positive control received the extract of EA and mupirocin ointment, respectively and other group as the control group, was not subjected to any treatments. Isolated tissues from wounds were harvested for 5, 10, and 15 days and were then underwent biochemical analysis. Healing activity was assessed by the rate of wound contraction and collagen content. The in vivo antioxidant and anti-inflammatory activity was investigated to understand the mechanism of wound healing potency. The concentration levels of transforming growth factor beta 1 (TGF-beta 1) and tumor necrosis factor alpha (TNF-alpha) were determined in wound tissues by an enzyme-linked immunosorbent assay (ELISA) and a real-time RT-PCR. The results indicated a significant increase in the percentage of wound contraction and collagen content in the treated group, when compared with the control and positive control groups. Both mRNA and protein levels of the TNF-alpha were significantly reduced in the EA treated group. A significant decrease was also observed in Malondialdehyde and Myeloperoxidase content in the treated group compared to the control group. This study revealed that the EA extract accelerates cutaneous wound healing. This effect may confer its antioxidant and anti inflammatory activities. Therefore, EA extract may be useful in the current management of wound healing. ns.
C1 [Pasalar, Parvin] Univ Tehran Med Sci, Fac Med, Keshavarz Blvd, Tehran, Iran.
RP Pasalar, P (corresponding author), Univ Tehran Med Sci, Fac Med, Keshavarz Blvd, Tehran, Iran.
EM ppasalar@yahoo.com
RI Dehpour, Ahmad Reza/I-6422-2019; Mehrabani Natanzi,
   Mahboobeh/O-3489-2017; Khodaii, Zohreh/S-4983-2017
OI Dehpour, Ahmad Reza/0000-0002-8001-5565; Kamalinejad,
   Mohammad/0000-0002-5946-4913; Mehrabani Natanzi,
   Mahboobeh/0000-0001-8879-5984; Tavangar, Seyed
   Mohammad/0000-0002-4253-2385; Khodaii, Zohreh/0000-0002-8858-1983
FU Tehran University of Medical Sciences [89-01-30-10456]
FX The present study was financially supported by the Tehran University of
   Medical Sciences (Grant No. 89-01-30-10456).
CR Abedi G, 2012, HEALTHMED, V6, P126
   Abedi G, 2012, HEALTHMED, V6, P24
   Ahmad SF, 2013, PHARM BIOL, V51, P411, DOI 10.3109/13880209.2012.734315
   Al-Henhena N, HISTOLOGICAL STUDY W
   [Anonymous], 2012, ASIAN PAC J TROP BIO, DOI DOI 10.1016/S2221-1691(12)60520-6
   Avecina A, 1991, GHANOON OF MED, V2
   Beigom Taheri Jamileh, 2010, J Dent Res Dent Clin Dent Prospects, V4, P29
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Burgess C, 2008, J DRUGS DERMATOL, V7, pS2
   Charles CA, 2009, J AM ACAD DERMATOL, V60, P951, DOI 10.1016/j.jaad.2008.09.012
   DEMBINSK.W, 1973, POL J PHARMACOL PHAR, V25, P599
   Ehrlich HP, 2012, ADV WOUND CARE, V1, P3, DOI 10.1089/wound.2011.0311
   Garcia-Lafuente A, 2009, INFLAMM RES, V58, P537, DOI 10.1007/s00011-009-0037-3
   Goldberg MT, 2007, J INVEST DERMATOL, V127, P2645, DOI 10.1038/sj.jid.5700890
   Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125
   Kokane DD, 2009, J ETHNOPHARMACOL, V124, P311, DOI 10.1016/j.jep.2009.04.038
   Li J, 2007, CLIN DERMATOL, V25, P9, DOI 10.1016/j.clindermatol.2006.09.007
   Lim JS, 2010, J KOREAN MED SCI, V25, P746, DOI 10.3346/jkms.2010.25.5.746
   Liu X, 2008, BIOCHEM J, V409, P289, DOI 10.1042/BJ20070545
   Liza MS, 2010, FOOD BIOPROD PROCESS, V88, P319, DOI 10.1016/j.fbp.2009.02.001
   Mori R, 2004, AM J PATHOL, V164, P1303, DOI 10.1016/S0002-9440(10)63217-8
   Mori R, 2002, FASEB J, V16, P963, DOI 10.1096/fj.01-0776com
   Natanzi M, 2012, ACTA MED IRANICA, V50
   Nayak S, 2006, J BIOL SCI, V6, P51
   Pandian C, EVALUATION WOUND HEA
   Rasekh H. R., 1999, Journal of Pharmacy and Pharmacology, V51, P128
   Ruchi Tiwari, 2013, Pharma Science Monitor, V4, P214
   Sen CK, 2003, WOUND REPAIR REGEN, V11, P431, DOI 10.1046/j.1524-475X.2003.11607.x
   Shiba Y, 2008, CHEM RES TOXICOL, V21, P1600, DOI 10.1021/tx8000835
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Siqueira MF, 2010, DIABETOLOGIA, V53, P378, DOI 10.1007/s00125-009-1529-y
   SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841
   Song HS, 2008, KOREAN J PHYSIOL PHA, V12, P343, DOI 10.4196/kjpp.2008.12.6.343
   Wallace HJ, 1998, J INVEST DERMATOL, V110, P292, DOI 10.1046/j.1523-1747.1998.00113.x
   Zargari A., 1990, MED PLANTS, V4, P574
   Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200
NR 36
TC 0
Z9 1
U1 3
U2 6
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 305
EP 311
DI 10.19193/0393-6384_2017_2_046
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700021
DA 2022-07-14
ER

PT J
AU Pasdar, Y
   Darbandi, M
   Niazi, P
   Bagheri, A
   Mohajeri, SAR
   Norouzy, A
   Hamzeh, B
AF Pasdar, Yahya
   Darbandi, Mitra
   Niazi, Parisa
   Bagheri, Amir
   Mohajeri, Seyed Amir Reza
   Norouzy, Abdolreza
   Hamzeh, Behrooz
TI THE RISK FACTORS OF METABOLIC SYNDROME AND NUTRITIONAL STATUS IN
   PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A CASE-CONTROL STUDY IN
   KERMANSHAH, IRAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Non-Alcoholic Fatty Liver Disease; Metabolic Syndrome; Nutrition;
   Triglyceride
ID ASSOCIATION; PREVALENCE; MEN
AB Introduction: Non-alcoholic fatty liver is the most common liver disease in the world that is associated with various metabolic complications. This study was conducted to determine the risk factors of metabolic syndrome and assess the nutritional status of patients with non-alcoholic fatty liver disease (NAFLD) in Kermanshah, Iran.
   Methods: The present case-control study examined 250 patients in two groups of 125. The cases were selected through a convenience sampling of patients with NAFLD as per their positive ultrasound results and the controls were selected through a simple random sampling of those with negative ultrasound results. The data collection tools used were a demographic questionnaire and the Food Frequency Questionnaire. The NCEP/ATP-III definition of metabolic syndrome was used. Data were analyzed in Stata-11 using the Chi-square test, the t-test and the logistic regression.
   Results: Triglyceride level was significantly higher in the patients with NAFLD compared to the healthy controls (33.33% vs. 14.41%; P = 0.001). The waist-to-hip ratio was significantly lower in the control group (43.69% vs. 21.01%; P = 0.001). The prevalence of metabolic syndrome was 25.5% in the patients with NAFLD and 6.8% in the control group (P < 0.001). Protein intake (OR: 0.29, 95% CI: 0.13-0.64) and vitamin E intake (OR: 0.65, 95% CI: 0.54-0.86) had a protective effect against the incidence of NAFLD.
   Conclusion: The findings showed a high prevalence of metabolic syndrome in patients with NAFLD compared to the healthy subjects and revealed a significant relationship between fatty liver and metabolic syndrome. Ensuring an early diagnosis of NAFLD can help delay the complications of this disease, including metabolic syndrome.
C1 [Pasdar, Yahya] Kermanshah Univ Med Sci, Sch Publ Hlth, Res Ctr Environm Determinants Hlth, Kermanshah, Iran.
   [Darbandi, Mitra] Kermanshah Univ Med Sci, Student Res Comm, Kermanshah, Iran.
   [Pasdar, Yahya; Niazi, Parisa; Bagheri, Amir] Kermanshah Univ Med Sci, Sch Publ Hlth, Dept Nutr, Kermanshah, Iran.
   [Mohajeri, Seyed Amir Reza] Mashhad Univ Med Sci, Sch Med, Mashhad, Iran.
   [Norouzy, Abdolreza] Mashhad Univ Med Sci, Sch Med, Dept Nutr, Mashhad, Iran.
   [Hamzeh, Behrooz] Kermanshah Univ Med Sci, Sch Publ Hlth, Dept Publ Hlth, Kermanshah, Iran.
RP Hamzeh, B (corresponding author), Kermanshah Univ Med Sci, Sch Publ Hlth, Dept Publ Hlth, Kermanshah, Iran.
RI Bagheri, Amir/AAQ-8336-2020; Norouzy, Abdolreza/AAX-1160-2020
OI Bagheri, Amir/0000-0002-8289-3484; 
FU Research Deputy of Kermanshah University of Medical Sciences [92423]
FX Hereby, the authors would like to express their gratitude to the
   Research Center for Environmental Determinants of Health, School of
   Public Health, for reviewing the project and also to the Research Deputy
   of Kermanshah University of Medical Sciences for approving and funding
   the research (No. 92423).
CR Ahmed MH, 2012, J OBESITY, V2012
   Alavian SM, 2009, LIVER INT, V29, P159, DOI 10.1111/j.1478-3231.2008.01790.x
   Almobarak AO, 2015, ARAB J GASTROENTEROL, V16, P54, DOI 10.1016/j.ajg.2015.06.001
   Amirifar A, 2006, MODERN HUMAN KRAUS
   Carvalhana S, 2012, CURR OPIN CLIN NUTR, V15, P468, DOI 10.1097/MCO.0b013e3283566614
   Day CP, 2002, BEST PRACT RES CL GA, V16, P663, DOI 10.1053/bega.2002.0333
   Gaharwar R, 2015, J ASSOC PHYSICIAN I, V63, P13
   Georgoulis M, 2015, J HUM NUTR DIET, V28, P409, DOI 10.1111/jhn.12323
   Han Eun Na, 2015, Clin Hypertens, V21, P22, DOI 10.1186/s40885-015-0032-7
   Hong HC, 2016, CLIN ENDOCRINOL, V84, P203, DOI 10.1111/cen.12940
   Jee SH, 2012, KOREAN CIRC J, V42, P371, DOI 10.4070/kcj.2012.42.6.371
   Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289
   Kim GH, 2015, CLIN MOL HEPATOL, V21, P379, DOI 10.3350/cmh.2015.21.4.379
   Lee JH, 2014, NUTRIENTS, V6, P3303, DOI 10.3390/nu6083303
   Lonardo A, 2015, DIGEST LIVER DIS, V47, P181, DOI 10.1016/j.dld.2014.09.020
   Machado MV, 2014, EXPERT REV GASTROENT, V8, P487, DOI 10.1586/17474124.2014.903798
   Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
   McCarthy EM, 2012, J ACAD NUTR DIET, V112, P401, DOI 10.1016/j.jada.2011.10.007
   Mirmiran P, 2010, PUBLIC HEALTH NUTR, V13, P654, DOI 10.1017/S1368980009991698
   Monetti M, 2007, CELL METAB, V6, P69, DOI 10.1016/j.cmet.2007.05.005
   NAGHAVI M, 2003, ETIOLOGY DEATH 18 PR, P21
   Rotter I, 2015, INT J ENV RES PUB HE, V12, P3944, DOI 10.3390/ijerph120403944
   Ryoo JH, 2013, ATHEROSCLEROSIS, V227, P398, DOI 10.1016/j.atherosclerosis.2013.01.002
   Santomauro Mercedes, 2012, Endocrinol Nutr, V59, P346, DOI 10.1016/j.endonu.2012.05.002
   Schwenger KJP, 2014, WORLD J GASTROENTERO, V20, P1712, DOI 10.3748/wjg.v20.i7.1712
   Sohrabpour Aa, 2010, Middle East J Dig Dis, V2, P14
   Targher G, 2011, J HEPATOL, V54, P1020, DOI 10.1016/j.jhep.2010.11.007
   Toshimitsu K, 2007, NUTRITION, V23, P46, DOI 10.1016/j.nut.2006.09.004
   Yki-Jarvinen H, 2014, LANCET DIABETES ENDO, V2, P901, DOI 10.1016/S2213-8587(14)70032-4
   Younossi ZM, 2015, GLOBAL EPIDEMIOLOGY
   Zhang YH, 2015, J CHEM, V2015, P9, DOI DOI 10.3389/FNCEL.2015.00165
NR 31
TC 3
Z9 3
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 4
BP 715
EP 720
DI 10.19193/0393-6384_2017_4_106
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EX2TM
UT WOS:000403079700027
DA 2022-07-14
ER

PT J
AU Pasdar, Y
   Darbandi, M
   Niazi, P
   Bagheri, A
   Mohajeri, SAR
   Norouzy, A
   Hamzeh, B
AF Pasdar, Yahya
   Darbandi, Mitra
   Niazi, Parisa
   Bagheri, Amir
   Mohajeri, Seyed Amir Reza
   Norouzy, Abdolreza
   Hamzeh, Behrooz
TI THE RISK FACTORS OF METABOLIC SYNDROME AND NUTRITIONAL STATUS IN
   PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A CASE-CONTROL STUDY IN
   KERMANSHAH, IRAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Non-Alcoholic Fatty Liver Disease; Metabolic Syndrome; Nutrition;
   Triglyceride
ID STEATOHEPATITIS; ASSOCIATION; PREVALENCE; MEN
AB Introduction: Non-alcoholic fatty liver is the most common liver disease in the world that is associated with various metabolic complications. This study was conducted to determine the risk factors of metabolic syndrome and assess the nutritional status of patients with non-alcoholic fatty liver disease (NAFLD) in Kermanshah, Iran.
   Methods: The present case-control study examined 250 patients in two groups of 125. The cases were selected through a convenience sampling of patients with NAFLD as per their positive ultrasound results and the controls were selected through a simple random sampling of those with negative ultrasound results. The data collection tools used were a demographic questionnaire and the Food Frequency Questionnaire. The NCEP/ATP-III definition of metabolic syndrome was used. Data were analyzed in Stata-11 using the Chi-square test, the t-test and the logistic regression.
   Results: Triglyceride level was significantly higher in the patients with NAFLD compared to the healthy controls (33.33% vs. 14.41%; P= 0.001). The waist-to-hip ratio was significantly lower in the control group (43.69% vs. 21.01%; P= 0.001). The prevalence of metabolic syndrome was 25.5% in the patients with NAFLD and 6.8% in the control group (P< 0.001). Protein intake (OR: 0.29, 95% CI: 0.13-0.64) and vitamin E intake (OR: 0.65, 95% CI: 0.54-0.86) had a protective effect against the incidence of NAFLD.
   Conclusion: The findings showed a high prevalence of metabolic syndrome in patients with NAFLD compared to the healthy subjects and revealed a significant relationship between fatty liver and metabolic syndrome. Ensuring an early diagnosis of NAFLD can help delay the complications of this disease, including metabolic syndrome.
C1 [Pasdar, Yahya] Kermanshah Univ Med Sci, Sch Publ Hlth, Res Ctr Environm Determinants Hlth, Kermanshah, Iran.
   [Darbandi, Mitra] Kermanshah Univ Med Sci, Student Res Comm, Kermanshah, Iran.
   [Pasdar, Yahya; Niazi, Parisa; Bagheri, Amir] Kermanshah Univ Med Sci, Sch Publ Hlth, Dept Nutr, Kermanshah, Iran.
   [Mohajeri, Seyed Amir Reza] Mashhad Univ Med Sci, Sch Med, Mashhad, Iran.
   [Norouzy, Abdolreza] Mashhad Univ Med Sci, Sch Med, Dept Nutr, Mashhad, Iran.
   [Hamzeh, Behrooz] Kermanshah Univ Med Sci, Sch Publ Hlth, Dept Publ Hlth, Kermanshah, Iran.
RP Hamzeh, B (corresponding author), Kermanshah Univ Med Sci, Sch Publ Hlth, Dept Publ Hlth, Kermanshah, Iran.
RI Norouzy, Abdolreza/AAX-1160-2020; Bagheri, Amir/AAQ-8336-2020; Hamzeh,
   Behrooz/S-6852-2017
OI Bagheri, Amir/0000-0002-8289-3484; Hamzeh, Behrooz/0000-0002-1110-0870;
   Norouzy, Abdolreza/0000-0001-6740-5502
FU Research Deputy of Kermanshah University of Medical Sciences [92423]
FX Hereby, the authors would like to express their gratitude to the
   Research Center for Environmental Determinants of Health, School of
   Public Health, for reviewing the project and also to the Research Deputy
   of Kermanshah University of Medical Sciences for approving and funding
   the research (No. 92423).
CR Ahmed MH, 2012, J OBESITY, V2012
   Alavian SM, 2009, LIVER INT, V29, P159, DOI 10.1111/j.1478-3231.2008.01790.x
   Almobarak AO, 2015, ARAB J GASTROENTEROL, V16, P54, DOI 10.1016/j.ajg.2015.06.001
   Amirifar A, 2006, MODERN HUMAN KRAUS
   Carvalhana S, 2012, CURR OPIN CLIN NUTR, V15, P468, DOI 10.1097/MCO.0b013e3283566614
   Day CP, 2002, BEST PRACT RES CL GA, V16, P663, DOI 10.1053/bega.2002.0333
   Gaharwar R, 2015, J ASSOC PHYSICIAN I, V63, P13
   Georgoulis M, 2015, J HUM NUTR DIET, V28, P409, DOI 10.1111/jhn.12323
   Han Eun Na, 2015, Clin Hypertens, V21, P22, DOI 10.1186/s40885-015-0032-7
   Hong HC, 2016, CLIN ENDOCRINOL, V84, P203, DOI 10.1111/cen.12940
   Jee SH, 2012, KOREAN CIRC J, V42, P371, DOI 10.4070/kcj.2012.42.6.371
   Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289
   Kim GH, 2015, CLIN MOL HEPATOL, V21, P379, DOI 10.3350/cmh.2015.21.4.379
   Lee JH, 2014, NUTRIENTS, V6, P3303, DOI 10.3390/nu6083303
   Lonardo A, 2015, DIGEST LIVER DIS, V47, P181, DOI 10.1016/j.dld.2014.09.020
   Machado MV, 2014, EXPERT REV GASTROENT, V8, P487, DOI 10.1586/17474124.2014.903798
   Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161
   McCarthy EM, 2012, J ACAD NUTR DIET, V112, P401, DOI 10.1016/j.jada.2011.10.007
   Mirmiran P, 2010, PUBLIC HEALTH NUTR, V13, P654, DOI 10.1017/S1368980009991698
   Monetti M, 2007, CELL METAB, V6, P69, DOI 10.1016/j.cmet.2007.05.005
   NAGHAVI M, 2003, ETIOLOGY DEATH 18 PR, P21
   Rotter I, 2015, INT J ENV RES PUB HE, V12, P3944, DOI 10.3390/ijerph120403944
   Ryoo JH, 2013, ATHEROSCLEROSIS, V227, P398, DOI 10.1016/j.atherosclerosis.2013.01.002
   Santomauro Mercedes, 2012, Endocrinol Nutr, V59, P346, DOI 10.1016/j.endonu.2012.05.002
   Schwenger KJP, 2014, WORLD J GASTROENTERO, V20, P1712, DOI 10.3748/wjg.v20.i7.1712
   Sohrabpour Aa, 2010, Middle East J Dig Dis, V2, P14
   Targher G, 2011, J HEPATOL, V54, P1020, DOI 10.1016/j.jhep.2010.11.007
   Toshimitsu K, 2007, NUTRITION, V23, P46, DOI 10.1016/j.nut.2006.09.004
   Yki-Jarvinen H, 2014, LANCET DIABETES ENDO, V2, P901, DOI 10.1016/S2213-8587(14)70032-4
   Younossi ZM, 2015, GLOBAL EPIDEMIOLOGY
   Zhang YH, 2015, J CHEM, V2015, P9, DOI DOI 10.3389/FNCEL.2015.00165
NR 31
TC 0
Z9 0
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 953
EP 958
DI 10.19193/0393-6384_2017_6_150
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500009
DA 2022-07-14
ER

PT J
AU Diaz-Narvaez, VP
   Alonso-Palacio, LM
   Caro, SE
   Silva, M
   Arboleda-Castillo, J
   Bilbao, J
   Iglesias-Acosta, J
   Calzadilla-Nunez, A
   Utsman, R
   Cervantes, M
   Fajardo, E
AF Patricio Diaz-Narvaez, Victor
   Marina Alonso-Palacio, Luz
   Elvira Caro, Sara
   Silva, Maria
   Arboleda-Castillo, Joel
   Bilbao, Jorge
   Iglesias-Acosta, Jesus
   Calzadilla-Nunez, Aracelis
   Utsman, Robert
   Cervantes, Marcos
   Fajardo, Elizabeth
TI COMPASSIONATE CARE COMPONENT OF THE CONSTRUCT EMPATHY IN MEDICAL
   STUDENTS IN COLOMBIA AND DOMINICAN REPUBLIC
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Empathy; Compassion; Medical Schools; Colombia; Dominican Republic
ID PHYSICIAN EMPATHY; JEFFERSON SCALE; VALIDITY; GENDER; SCHOOL
AB Introduction: The development of empathy in medical students, which is essential for therapeutic effectiveness and improved patient outcomes, is not well understood. The objective of this study is to determine whether there are differences between levels of the "compassionate care" component of empathy among four medical schools in Colombia and the Dominican Republic.
   Subjets and methods: The sample consisted of medical students. This exploratory and cross-section study measured empathy levels by using the Spanish version of the Jefferson Scale of Physicians. Levels of empathy were studied and compared by a three-factor analysis of variance, Tukey multiple comparison test and discriminant analysis of the matrix components.
   Results: Differences in levels of empathy of the "compassionate care" component between universities, courses and gender were found.
   Conclusions: Variability in the values of the levels of the "compassionate care" component of empathy were observed among the factors: university, course and gender. The observed variability between and within the university populations studied cannot be explained, which can be attributed to other unknown factors that influence empathy levels.
C1 [Patricio Diaz-Narvaez, Victor] Univ San Sebastian, Fac Dent, Santiago, Chile.
   [Patricio Diaz-Narvaez, Victor] Univ Bernardo OHiggins, Hlth Fac, Santiago, Chile.
   [Marina Alonso-Palacio, Luz; Elvira Caro, Sara] Univ Norte, Div Hlth Sci, Barranquilla, Colombia.
   [Silva, Maria; Arboleda-Castillo, Joel] Univ Cent Este, San Pedro De Macoris, Dominican Rep.
   [Bilbao, Jorge] Fdn Univ San Martin, Sede Puerto Colombia, Barranquilla, Colombia.
   [Iglesias-Acosta, Jesus] Univ Libre Secc Barranquilla, Fac Hlth Sci, Barranquilla, Colombia.
   [Calzadilla-Nunez, Aracelis] Hosp Felix Bulnes Cerda, Unit Child & Adolescent Psychiat, Santiago, Chile.
   [Utsman, Robert] Univ Latinoamer Ciencia & Tecnol ULACIT, Sch Hlth Sci, Res, San Jose, Costa Rica.
   [Cervantes, Marcos] Univ Norte, Fac Social Sci, Psychol, Barranquilla, Colombia.
   [Fajardo, Elizabeth] Univ Tolima, Fac Hlth Sci, Ibague, Colombia.
RP Diaz-Narvaez, VP (corresponding author), Univ San Sebastian, Fac Odontol, Av Cumming 40, Santiago Ctr, Region Metropol, Chile.
RI Utsman, Robert/ABA-2879-2020
OI Utsman, Robert/0000-0001-6265-8236
CR Alcorta-Garza A, 2005, SALUD MENT, V28, P57
   Alonso Palacio Luz Marina, 2013, Salud, Barranquilla, V29, P22
   Beach MC, 2005, ANN FAM MED, V3, P331, DOI 10.1370/afm.328
   Bilbao JL, 2015, REV FACULTAD MED, V63, P237
   Bilbao Ramírez Jorge, 2013, Salud, Barranquilla, V29, P34
   Carrasco DE., 2012, REV ESTOMATOL HERED, V22, P145
   Chen D, 2007, J GEN INTERN MED, V22, P1434, DOI 10.1007/s11606-007-0298-x
   Decety J, 2006, THESCIENTIFICWORLDJO, V6, P1146, DOI 10.1100/tsw.2006.221
   Villegas RD, 2014, CUAD BIOET, V25, P99
   Narvaez VPD, 2014, ARCH ARGENT PEDIATR, V112, P41, DOI [10.1590/S0325-00752014000100008, 10.5546/aap.2014.eng.41]
   Diaz-Narvaez V, 2015, HEALTH-LONDON, V7, P1678
   Diaz-Narvaez V, 2009, METODOLOGIA INVESTIG
   Diaz-Narvaez VP, 2016, HEALTH, V8, P32, DOI DOI 10.4236/HEALTH.2016.81005
   Diaz-Narvaez VP, 2015, HEALTH-LONDON, V07, P1268
   Diaz-Narvaez VP, 2015, HEALTH, V7, P1527, DOI DOI 10.4236/HEALTH.2015.711166
   FALVO D, 1998, THE JOURNAL OF FAMIL, V26, P643
   Fernandez-Pinto I, 2008, AN PSICOL-SPAIN, V24, P284
   Figley CR, 2002, J CLIN PSYCHOL, V58, P1433, DOI 10.1002/jclp.10090
   Galan J. M., 2014, PSICOLOGIA ED, V20, P53, DOI [10.1016/j.pse.2014.05.007, DOI 10.1016/J.PSE.2014.05.007]
   Guarino L, 2011, UNIV PSYCHOL, V10, P197
   Haidt Jonathan, 2003, HDB AFFECTIVE SCI
   Hojat M, 2005, MED TEACH, V27, P625, DOI 10.1080/01421590500069744
   Hojat M, 2004, MED EDUC, V38, P934, DOI 10.1111/j.1365-2929.2004.01911.x
   Hojat M, 2002, MED EDUC, V36, P522, DOI 10.1046/j.1365-2923.2002.01234.x
   Hojat M, 2001, EDUC PSYCHOL MEAS, V61, P349, DOI 10.1177/00131640121971158
   Hojat M, 2009, ACAD MED, V84, P1182, DOI 10.1097/ACM.0b013e3181b17e55
   Howard M, 2013, REV ODOVTOS, V15, P21
   Kataoka HU, 2009, ACAD MED, V84, P1192, DOI 10.1097/ACM.0b013e3181b180d4
   LAMONICA EL, 1981, RES NURS HEALTH, V4, P389
   Mercadillo RE, 2011, REV DIGITAL U, V12, P3
   Mercadillo RE, 2007, SALUD MENT, V30, P1
   Moreto G, 2014, ATEN FAM, V21, P16
   Nunes P, 2000, INT J MED ED, V2, P12
   Sánchez Jiménez Laura, 2013, Educ Med Super, V27, P216
   Silva María Guadalupe, 2014, Educ Med Super, V28, P74
   Silva MG, 2013, ODONTOESTOMATOLOGIA, V15, P24
   Silva Urday H, 2013, Rev. Clin. Periodoncia Implantol. Rehabil. Oral, V6, P130
   Stephenson A, 2001, LANCET, V357, P867, DOI 10.1016/S0140-6736(00)04201-X
   Varela TB, 2012, CLAVES ODONTOLOGIA, V19, P15
   Vera C., 2014, J ORAL RES, V3, P123, DOI [10.17126/joralres.2014.029, DOI 10.17126/JORALRES.2014.029]
NR 40
TC 15
Z9 23
U1 1
U2 3
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 115
EP 121
DI 10.19193/0393-6384_2017_1_018
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800018
DA 2022-07-14
ER

PT J
AU Pekel, NB
   Yildiz, D
   Kahvecioglu, S
   Kilic, AK
   Yildiz, A
   Seferoglu, M
   Gunes, A
AF Pekel, Nilufer Buyukkoyuncu
   Yildiz, Demet
   Kahvecioglu, Serdar
   Kilic, Ahmet Kasim
   Yildiz, Abdulmecit
   Seferoglu, Meral
   Gunes, Aygul
TI RESTLESS LEGS SYNDROME AND RELATED FACTORS IN PERITONEAL DIALYSIS
   PATIENTS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Peritoneal dialysis; Restless legs syndrome; Insomnia; Depression;
   Diabetes Mellitus
ID QUALITY-OF-LIFE; HEMODIALYSIS-PATIENTS; SLEEP DISTURBANCES; INSOMNIA;
   DEPRESSION; PREVALENCE; VALIDATION; SYMPTOMS; DISEASE
AB Introduction: Restless Legs Syndrome (RLS) mostly occurs in hemodialysis (HD) patients but there are limited studies about RLS frequency in peritoneal dialysis (PD) patients. In this study patients who were undergoing PD were screened for RLS and analyzed for associated factors.
   Material and methods: The study group was consisting of 69 PD patients and 43 healty controls. Beck Depression Inventory was used to analyse for the presence of depression. Sleep disorders were assessed with the Insomnia Severity Index (ISI) and Epworth Sleepiness Scale (ESS).
   Results: Demographic characteristics of patients and the control group were similar. The rate of RLS tended to be higher in the PD group (p=0.075). There was no difference between PD and control groups in insomnia severity. Logistic regression analysis revealed the only factor independently associated with RLS to be a higher ISI score (p=0.008). Logistic regression analysis revealed the only factor independently associated with at least sub-threshold insomnia as a higher depression score (p=0.002). Being in the PD group and presence of RLS also tended to be independently associated with at least sub-threshold insomnia (p=0.051 and p=0.099, respectively). Linear regression analysis revealed the presence of RLS and a higher depression score as factors independently associated with a higher ISI score (p=0.002 and p=0.013, respectively).
   Conclusion: The rate of RLS tended to be more common in patients under PD treatment. The main risk factor for the presence of RLS was insomnia. Main risk factors for increased insomnia severity were depression and RLS.
C1 [Pekel, Nilufer Buyukkoyuncu; Yildiz, Demet; Kilic, Ahmet Kasim; Seferoglu, Meral; Gunes, Aygul] Sevket Yilmaz Training & Res Hosp, Dept Neurol, Bursa, Turkey.
   [Kahvecioglu, Serdar] Sevket Yilmaz Training & Res Hosp, Dept Nephrol, Bursa, Turkey.
   [Yildiz, Abdulmecit] Cekirge State Hosp, Dept Nephrol, Bursa, Turkey.
RP Pekel, NB (corresponding author), Bursa Sevket Yilmaz Training & Res Hosp, Dept Neurol, Mimarsinan St, TR-16340 Yildirim, Bursa, Turkey.
RI kılıç, ahmet kasım/ABI-4000-2020
OI kılıç, ahmet kasım/0000-0001-8162-391X
CR Aben I, 2002, PSYCHOSOMATICS, V43, P386, DOI 10.1176/appi.psy.43.5.386
   Abetz L, 2005, VALUE HEALTH, V8, P157, DOI 10.1111/j.1524-4733.2005.03010.x
   Al-Jahdali H, 2011, SAUDI J KIDNEY DIS T, V22, P922
   Al-Jahdali HH, 2009, SAUDI J KIDNEY DIS T, V20, P378
   Beladi-Mousavi SS, 2015, NEPHROUROL MON, V7
   Bhowmik D, 2003, SLEEP MED, V4, P143, DOI 10.1016/S1389-9457(03)00005-4
   Braatvedt Geoffrey D, 2006, N Z Med J, V119, pU1977
   Chen W, AM J KIDNEY DIS, V48, P277
   Duong U, 2011, CLIN J AM SOC NEPHRO, V6, P1041, DOI 10.2215/CJN.08921010
   Earley CJ, 2010, SLEEP MED, V11, P807, DOI 10.1016/j.sleep.2010.07.007
   EKBOM K A, 1950, Acta Med Scand Suppl, V246, P64
   Finkelstein FO, 2000, NEPHROL DIAL TRANSPL, V15, P1911, DOI 10.1093/ndt/15.12.1911
   Gagnon C, 2013, J AM BOARD FAM MED, V26, P701, DOI 10.3122/jabfm.2013.06.130064
   Garcia-Borreguero D, 2012, SLEEP MED REV, V16, P281, DOI 10.1016/j.smrv.2012.03.004
   Gigli GL, 2004, SLEEP MED, V5, P309, DOI 10.1016/j.sleep.2004.01.014
   Gonenli S., 2008, PREVALENCE DEPRESSIO
   HOUSE A, 1987, J PSYCHOSOM RES, V31, P441, DOI 10.1016/0022-3999(87)90002-X
   Hui DSC, 2002, MED SCI MONITOR, V8, P331
   Hui DSC, 2000, AM J KIDNEY DIS, V36, P783, DOI 10.1053/ajkd.2000.17664
   Iliescu EA, 2004, NEPHROL DIAL TRANSPL, V19, P95, DOI 10.1093/ndt/gfg423
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Kavanagh D, 2004, AM J KIDNEY DIS, V43, P763, DOI 10.1053/j.ajkd.2004.01.007
   Kawauchi A, 2006, CLIN NEPHROL, V66, P440
   Leger D, 2000, J SLEEP RES, V9, P35, DOI 10.1046/j.1365-2869.2000.00178.x
   Merlino G, 2006, NEPHROL DIAL TRANSPL, V21, P184, DOI 10.1093/ndt/gfi144
   Merlino G, 2012, NEUROL SCI, V33, P1311, DOI 10.1007/s10072-012-0953-9
   Nichols DA, 2003, ARCH INTERN MED, V163, P2323, DOI 10.1001/archinte.163.19.2323
   Ozcan Y, 2000, J TURGUT OZAL MED CT, V7, P333
   Patel S, 2002, CURR OPIN PULM MED, V8, P498, DOI 10.1097/00063198-200211000-00002
   Sabbatini M, 2002, NEPHROL DIAL TRANSPL, V17, P852, DOI 10.1093/ndt/17.5.852
   Szentkiralyi A, 2013, PSYCHOSOM MED, V75, P359, DOI 10.1097/PSY.0b013e31828bbbf1
   Takaki J, 2003, AM J KIDNEY DIS, V41, P833, DOI 10.1016/S0272-6386(03)00031-3
   Tarsy D, TREATMENT RESTLESS L
   WALKER S, 1995, AM J KIDNEY DIS, V26, P751, DOI 10.1016/0272-6386(95)90438-7
   WALTERS AS, 1995, MOVEMENT DISORD, V10, P634, DOI 10.1002/mds.870100517
   Yuksel S, 2009, TURK KLIN TIP BILIM, V29, P344
   Zaza G, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0051-3
NR 37
TC 2
Z9 2
U1 0
U2 7
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 101
EP 105
DI 10.19193/0393-6384_2017_1_016
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800016
DA 2022-07-14
ER

PT J
AU Picakciefe, M
   Kalemci, S
   Caylak, SD
   Sozen, H
   Caylak, Y
   Akkaya, V
   Erbas, E
   Bayat, B
   Tetiker, D
AF Picakciefe, Metin
   Kalemci, Serdar
   Caylak, Selmin Dirgen
   Sozen, Hamdi
   Caylak, Yusuf
   Akkaya, Volkan
   Erbas, Erkan
   Bayat, Bekir
   Tetiker, Derya
TI EVALUATION OF THE APPLICATIONS MADE TO TUBERCULOSIS CONTROL DISPENSARY
   BETWEEN THE YEARS 2010-2014 IN THE SOUTHWEST REGION OF TURKEY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Tuberculosis control dispensary (TCD); tuberculosis (TB); Turkey
ID DRUG-RESISTANT TUBERCULOSIS
AB Introduction: As a major public health problem in the world and our country, tuberculosis (TB) constitutes 25% of the mortalities in developing countries which can be prevented. Identification and effective treatment of TB patients in the community are important to control TB. In our country, the task of ensuring TB control was given to Tuberculosis Control Dispensaries (TCD). The purpose of this study is to evaluate the applications made to TCD Southwestern Turkey between the years of 2010-2014.
   Materials and methods: The target population of the descriptive and retrospective study where TB surveillance data was analyzed was constituted by 394 people who applied to Tuberculosis Control Dispensary in the Southwest region of Turkey between the years of 2010 and 2014.
   Results: 66.2% of the applicants were male, 37.3% were in the 40-59 age group, 68.7% were married and 9.5% did not have any social insurance. Considering the reasons of application, 93.6% of the subjects applied personally and 6.4% applied with the contact history. New patients formed 78.0% of the cases, while 15.1% of the applicants were the ones who were transferred, 5.1% had recurrent disease, 1.0% were those who returned from discontinuation of the therapy and 0.8% were the patients who applied due to treatment failure. According to the records, 0.3% of the applicants were diagnosed with HIV, 9.6% used alcohol and 20.8% smoked. 66.9% of the patients had pulmonary involvement and 44.9% had contact with at least one person. Sputum examinations were performed in 65.0% of the applicants and 55.1% were determined to be positive. 71.8% of the patients were determined to have radiological findings compatible with the disease. 45.9% of the patients were found positive as a result of the bacteriological smear. Treatments of 35.0% of the registered patients were started in TCD and the length of treatment period lasted 0-6 months. According to the results of treatment, 70.5% of the patients completed the treatment and 3.6% died. All patients were implemented directly observed treatment.
   Conclusion: Dominant male gender among those who apply to TCD, being in 40-59 age group, applications due to personal reasons, new cases, pulmonary involvements, performing of sputum examinations, positive results, implementing the treatment in a hospital and completion of treatments are the most important results of the study. In conclusion, the first-line tuberculosis control takes an important place in the tuberculosis control in our country. For a successful TB control, Tuberculosis Control Dispensaries and Community and Family Health Centers must work coordinately.
C1 [Picakciefe, Metin; Akkaya, Volkan; Erbas, Erkan] Mugla Sitki Kocman Univ, Fac Med, Dept Publ Hlth, Mugla, Turkey.
   [Kalemci, Serdar] Mugla Sitki Kocman Univ, Fac Med, Dept Chest Dis, Mugla, Turkey.
   [Caylak, Selmin Dirgen; Sozen, Hamdi] Mugla Sitki Kocman Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Mugla, Turkey.
   [Caylak, Yusuf; Bayat, Bekir; Tetiker, Derya] Mugla Prov Directorate Publ Hlth, Mugla, Turkey.
RP Picakciefe, M (corresponding author), Mugla Sitki Kocman Univ, Fac Med, Dept Publ Hlth, Mugla, Turkey.
RI Picakciefe, Metin/ABA-4544-2021
OI Picakciefe, Metin/0000-0002-2877-7714; akkaya,
   volkan/0000-0002-2753-3574
CR Abebe Gemeda, 2012, BMC Res Notes, V5, P225, DOI 10.1186/1756-0500-5-225
   Aydemir Y, 2015, TURK THORAC J, V16, P166, DOI 10.5152/ttd.2015.4664
   Baddeley A, 2013, TUBERCULOSIS COUNTRY
   Buzgan T, 2013, USITC PUBL, V884
   Cosar H, 2008, J PEDIATR INFECT, V2, P1
   Duan QH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148041
   Geldenhuys HD, 2014, EUR J CLIN MICROBIOL, V33, P2259, DOI 10.1007/s10096-014-2198-4
   Ghodbane R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04236
   HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2
   Jain A, 2008, FEMS IMMUNOL MED MIC, V53, P145, DOI 10.1111/j.1574-695X.2008.00400.x
   Kurt A., 2006, Firat Tip Dergisi, V11, P55
   Ramos JM, 2013, INT J MYCOBACT, V2, P171, DOI 10.1016/j.ijmyco.2013.04.007
   Miller AC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148910
   Murray M, 2011, Int J Tuberc Lung Dis, V15 Suppl 2, P64, DOI 10.5588/ijtld.10.0535
   OZKARA S, 2002, TORAKS DERGISI, V3, P178
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   San Pedro A, 2013, REV PANAM SALUD PUBL, V33, P294, DOI 10.1590/S1020-49892013000400009
   Unsal E, 2013, J THORAC DIS, V5, P435, DOI 10.3978/j.issn.2072-1439.2013.06.30
   Uyan AP, 2008, J CURRENT PEDIAT, V6, P26
   World Health Organization, 2013, GLOB COMP ASS HLTH S
   Zellweger JP, 2013, PANMINERVA MED, V55, P145
NR 21
TC 1
Z9 1
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 71
EP 76
DI 10.19193/0393-6384_2017_1_011
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800011
DA 2022-07-14
ER

PT J
AU Precenzano, F
   Ruberto, M
   Parisi, L
   Salerno, M
   Maltese, A
   Vagliano, C
   Messina, G
   Di Folco, A
   Di Filippo, T
   Roccella, M
AF Precenzano, Francesco
   Ruberto, Maria
   Parisi, Lucia
   Salerno, Margherita
   Maltese, Agata
   Vagliano, Clara
   Messina, Giovanni
   Di Folco, Annabella
   Di Filippo, Teresa
   Roccella, Michele
TI EXECUTIVE FUNCTIONING IN PRESCHOOL CHILDREN AFFECTED BY AUTISM SPECTRUM
   DISORDER: A PILOT STUDY (RETRACTION ARTICLE)
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Autism Spectrum Disorders; Preschool children; BRIEF-P; executive
   functions
ID SLEEP-APNEA SYNDROME; NOCTURNAL ENURESIS; CHILDHOOD MIGRAINE; MATERNAL
   STRESS; SYMPTOMS; EPILEPSY; AURA; QUESTIONNAIRE; ADOLESCENTS
AB Introduction: Autism spectrum disorders (ASD) are a complex set of neurological dysfunction and development characterized by deficits in social and non-verbal interaction.
   Few studies have explored the executive functioning in ASD preschoolers.
   The aim of this pilot study is the assessment of executive functioning in preschool children with ASD.
   Material and methods: 8 ASD children (7 males, 1 female) mean age 3.09 (SD +/- 0.83 years) were enrolled in the study and compared with a control group of 15 typically developing children (12 males, 3 females) (mean age 24.3 +/- 0.61). All subjects underwent assessment of executive functioning with the BRIEF-P test.
   Results: The two groups were matched for age (p = 0.625) and gender (p = 0.900). Table 1 shows the comparison between the two groups at the BRIEF-P, with significantly higher scores on all subscales of ASD children compared with controls.
   Conclusions: Despite the small sample examined the results of this study agree with what is already known in the literature confirm the presence of a significant deficit in executive functions of subjects with ASD emphasizing for the first time the emergence of such problems at an early stage of development, but demanding further studies to confirm this.
C1 [Precenzano, Francesco; Vagliano, Clara; Di Filippo, Teresa] Univ Naples 2, Clin Child & Adolescent Neuropsychiat, Dept Mental Hlth & Phys & Prevent Med, Naples, Italy.
   [Ruberto, Maria] Univ Naples 2, Dept Med Surg & Dent Specialties, Naples, Italy.
   [Parisi, Lucia; Maltese, Agata; Di Folco, Annabella; Roccella, Michele] Univ Palermo, Dept Psychol Pedag & Educ Sci, I-90133 Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, I-90133 Palermo, Italy.
   [Messina, Giovanni] Univ Foggia, Dept Expt Med, Sect Human Physiol, Foggia, Italy.
   [Messina, Giovanni] Univ Foggia, Unit Dietet & Sports Med, Dept Clin & Expt Med, Foggia, Italy.
RP Roccella, M (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, I-90133 Palermo, Italy.
CR Amjad RN, 2016, ACTA MEDICA MEDITERR, V32, P1303
   Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2016, EUR J PHYS REHABIL M
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P437, DOI [10.2147/NDT.543673, 10.2147/NDT.S43673]
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Foumany GHE, 2015, ACTA MEDICA MEDITERR, V31, P1351
   Garon NM, 2016, APPL NEUROPSYCH-CHIL, V5, P110, DOI 10.1080/21622965.2014.1002923
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Matricardi S, 2016, AM J MED GENET C, V172, P288, DOI 10.1002/ajmg.c.31513
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina Giovanni, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P611, DOI 10.1515/jbcpp-2015-0133
   Miano S, 2007, SLEEP MED, V9, P64, DOI 10.1016/j.sleep.2007.01.014
   Montalbano R, 2009, Minerva Pediatr, V61, P361
   Parisi L, 2015, MINERVA PEDIATR, V67, P369
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2015, MENT ILLN, V7, P32, DOI 10.4081/mi.2015.5988
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1755, DOI 10.19193/0393-6384_2016_6_159
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1749, DOI 10.19193/0393-6384_2016_6_158
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Shams S, 2016, ACTA MEDICA MEDITERR, V32, P1555
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
   Zou YL, 2016, ACTA MEDICA MEDITERR, V32, P1177
NR 50
TC 33
Z9 33
U1 3
U2 37
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 1
BP 35
EP 39
DI 10.19193/0393-6384_2017_1_005
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2PY
UT WOS:000397226800005
DA 2022-07-14
ER

PT J
AU Precenzano, F
   Ruberto, M
   Parisi, L
   Salerno, M
   Maltese, A
   Verde, D
   Tripi, G
   Romano, P
   Di Folco, A
   Di Filippo, T
   Messina, G
   Roccella, M
AF Precenzano, Francesco
   Ruberto, Maria
   Parisi, Lucia
   Salerno, Margherita
   Maltese, Agata
   Verde, Domenico
   Tripi, Gabriele
   Romano, Palmira
   Di Folco, Annabella
   Di Filippo, Teresa
   Messina, Giovanni
   Roccella, Michele
TI SLEEP HABITS IN CHILDREN AFFECTED BY AUTISM SPECTRUM DISORDERS: A
   PRELIMINARY CASE-CONTROL STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Autism Spectrum Disorders; sleep problems; DIMS; SDSC
ID MONOSYMPTOMATIC NOCTURNAL ENURESIS; PRIMARY CILIARY DYSKINESIA;
   CHILDHOOD MIGRAINE; MATERNAL STRESS; APNEA SYNDROME; SELF-CONCEPT; AURA;
   MULTICENTER; ADOLESCENTS; EFFICACY
AB Introduction: The core of autism spectrum disorders (ASD) consists of alterations of neurological functions that affect the typical developmental trajectory leading to deficits in social interaction and non-verbal behaviors. In general, ASD is diagnosed at age three and many other frequent neurological signs may be present, such as sleep disorders. The aim of study is evaluating sleep habits in a sample of ASD children.
   Material and methods: The study population consists of 65 ASD children (43 males and 22 females), aged between 2 and 11 years (mean 5.73 +/- 2.39 years). The control group consists of 114 children with typical development (68 males and 46 females), aged between 3 and 10 years (mean 5.91 +/- 2.23 years). The diagnosis of ASD was confirmed by the evaluation ADOS -2, while the evaluation of sleep habits with the SDSC tests.
   Results: The two groups were matched for age (p = 0.633) and sex distribution (p = 0.483). The ASD subjects show a significantly higher rate of sleep disorders in all categories explored by SDSC tests (Table 1).
   Discussion: The sleep of people with ASD is compromised at any age and regardless of the severity of social impairment and communication, but not the level of development.
   Still, ASD is a very important risk factor for the development of sleep disorders, although the report could also be interpreted in the opposite manner.
C1 [Precenzano, Francesco; Verde, Domenico; Romano, Palmira] Univ Naples 2, Clin Child & Adolescent Neuropsychiat, Naples, Italy.
   [Precenzano, Francesco; Verde, Domenico; Romano, Palmira] Univ Naples 2, Dept Mental Hlth & Phys & Prevent Med, Headache Ctr Children & Adolescents, Naples, Italy.
   [Ruberto, Maria] Univ Naples 2, Dept Med Surg & Dent Specialties, Naples, Italy.
   [Parisi, Lucia; Maltese, Agata; Di Folco, Annabella; Di Filippo, Teresa; Roccella, Michele] Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
   [Salerno, Margherita] Univ Palermo, Sci Mother & Child Hlth Promot, Palermo, Italy.
   [Tripi, Gabriele] Univ Palermo, Dept PROSAMI, Palermo, Italy.
   [Tripi, Gabriele] CH Chinon, Childhood Psychiat Serv Neurodev Disorders, Chinon, France.
   [Messina, Giovanni] Univ Foggia, Dept Expt Med, Sect Human Physiol, Foggia, Italy.
   [Messina, Giovanni] Univ Foggia, Unit Dietet & Sports Med, Dept Clin & Expt Med, Foggia, Italy.
RP Roccella, M (corresponding author), Univ Palermo, Dept Psychol Pedag & Educ Sci, Palermo, Italy.
OI TRIPI, Gabriele/0000-0001-7088-9325
CR Carotenuto M, 2016, ACTA PAEDIATR, V105, P1079, DOI 10.1111/apa.13472
   Carotenuto M, 2011, MINERVA PEDIATR, V63, P105
   Carotenuto M, 2009, J ENDOCRINOL INVEST, V32, P752, DOI [10.1007/BF03346531, 10.3275/6398]
   Carotenuto M, 2013, WORLD J PEDIATR, V9, P312, DOI 10.1007/s12519-013-0441-1
   Carotenuto M, 2013, NEUROL SCI, V34, P1905, DOI 10.1007/s10072-013-1403-z
   Carotenuto M, 2013, MED HYPOTHESES, V81, P306, DOI 10.1016/j.mehy.2013.04.023
   Carotenuto M, 2013, SLEEP BREATH, V17, P93, DOI 10.1007/s11325-012-0654-x
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Carotenuto M, 2012, NEUROPSYCH DIS TREAT, V8, P369, DOI [10.2147/NDT.S35974, 10.2147/NDT.535974]
   Di Filippo T, 2013, MINERVA PEDIATR, V65, P599
   Esposito M, 2014, J INTELL DISABIL RES, V58, P421, DOI 10.1111/jir.12036
   Esposito M, 2011, MINERVA PEDIATR, V63, P99
   Esposito M, 2014, NEUROPSYCH DIS TREAT, V10, P1897, DOI 10.2147/NDT.S69795
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1803, DOI 10.2147/NDT.S53853
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1513, DOI 10.2147/NDT.S52716
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1351, DOI 10.2147/NDT.S51554
   Esposito Maria, 2013, Neuropsychiatr Dis Treat, V9, P1087, DOI 10.2147/NDT.S47287
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1187, DOI 10.2147/NDT.S50458
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P1061, DOI 10.2147/NDT.S49364
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P921, DOI 10.2147/NDT.S46772
   Esposito M, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-57
   Esposito M, 2013, NEUROPSYCH DIS TREAT, V9, P351, DOI 10.2147/NDT.S42818
   Esposito M, 2012, NEUROL SCI, V33, P1365, DOI 10.1007/s10072-012-1019-8
   Esposito M, 2012, NEUROPSYCH DIS TREAT, V8, P509, DOI 10.2147/NDT.S36863
   Esposito M, 2012, EUR J PEDIATR, V171, P1599, DOI 10.1007/s00431-012-1759-8
   Esposito M, 2010, NEUROSCI LETT, V485, P89, DOI 10.1016/j.neulet.2010.08.062
   Garon NM, 2016, APPL NEUROPSYCH-CHIL, V5, P110, DOI 10.1080/21622965.2014.1002923
   Guzzetta A, 2010, DEV MED CHILD NEUROL, V52, P767, DOI 10.1111/j.1469-8749.2009.03497.x
   Messina A, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00066
   Messina G, 2016, J BASIC CLIN PHYSL P
   Miano S, 2007, SLEEP MED, V9, P64, DOI 10.1016/j.sleep.2007.01.014
   Parisi L, 2015, MINERVA PEDIATR, V67, P369
   Parisi L, 2016, ACTA MEDICA MEDITERR, V32, P1665, DOI [10.19193/0393-6384_2016_5_147, DOI 10.19193/0393-6384_]
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P49, DOI 10.19193/0393-6384_2017_1_007
   Parisi L, 2017, ACTA MEDICA MEDITERR, V33, P23, DOI 10.19193/0393-6384_2017_1_003
   Parisi L, 2015, ACTA MEDICA MEDITERR, V31, P1187
   Parisi L, 2015, MENT ILLN, V7, P32, DOI 10.4081/mi.2015.5988
   Pasquali D, 2015, ENDOCRINE, V50, P797, DOI 10.1007/s12020-015-0564-3
   Perillo L, 2014, PATIENT PREFER ADHER, V8, P353, DOI 10.2147/PPA.S58971
   Perillo L, 2013, NEUROPSYCH DIS TREAT, V9, P1231, DOI 10.2147/NDT.S49985
   Precenzano F, 2017, ACTA MEDICA MEDITERR, V33, P35, DOI 10.19193/0393-6384_2017_1_005
   Precenzano F, 2017, NEUROPSYCH DIS TREAT, V13, P253, DOI 10.2147/NDT.S119648
   Precenzano F, 2016, ACTA MEDICA MEDITERR, V32, P1761, DOI 10.19193/0393-6384_2016_6_160
   Ruberto M, 2016, ACTA MEDICA MEDITERR, V32, P1659, DOI [10.19193/0393-6384_2016_5_146, DOI 10.19193/0393-6384_]
   Santamaria F, 2014, RESPIROLOGY, V19, P570, DOI 10.1111/resp.12273
   Toldo I, 2017, EUR J PAEDIATR NEURO, V21, P507, DOI 10.1016/j.ejpn.2016.12.009
   Vecchio D, 2011, MINERVA PEDIATR, V63, P341
NR 47
TC 33
Z9 33
U1 3
U2 26
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 3
BP 405
EP 409
DI 10.19193/0393-6384_2017_3_059
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EV3BF
UT WOS:000401631200007
DA 2022-07-14
ER

PT J
AU Ranjbar, R
   Babazadeh, D
   Jonaidi-Jafari, N
AF Ranjbar, Reza
   Babazadeh, Daryoush
   Jonaidi-Jafari, Nematollah
TI PREVALENCE OF CAMPYLOBACTER JEJUNI IN ADULT PATIENTS WITH INFLAMMATORY
   BACTERIAL DIARRHEA, EAST AZERBAIJAN, IRAN
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Campylobacter; Culture; Patient; PCR; Prevalence; Lactoferrin
ID MULTIPLEX PCR; FECAL LACTOFERRIN; SPECIES-LEVEL; IDENTIFICATION;
   ENTERITIS; OUTBREAK; COLI; GASTROENTERITIS; EPIDEMIOLOGY; CULTURE
AB Introduction: The Campylobacter jejuni and Campylobacter coli are the main responsible of campylobacteriosis in intestinal diseases. Campylobacteriosis is endemic in developing countries. Present study is aimed to indicate the prevalence of Campylobacter species in adult patients in East Azerbaijan province of Iran using PCR and culture methods.
   Material and methods: 1020 stool samples (498 men and 522 women) were collected and examined from adult patients in East Azerbaijan province, Iran during June-December 2016 year. Samples obtained with inflammatory criteria like fecal leukocytes (WBC >= 5) had been selected and isolated through fecal lactoferrin detection test. The samples with WBC >= 5 and lactoferrin positive samples were selected for Campylobacter detection by culture and PCR methods. Some necessary information like age, sex, place of habituation, living with animals were asked and recorded.
   Results: Campylobacter species were obtained from 79 (35.4%) samples out of 223 by multiplex PCR which consisted of 55 C. jejuni (24.7 %), 17 C. coli (7.6 %) and 7 mixed infection with both species (3.1 %). The significant correlations were seen between the prevalence of Campylobacter and patients who lived in rural places with animals or who had a daily contact with poultry.
   Conclusion: Investigation of Campylobacter jejuni prevalence in Northwest of Iran showed this bacterium can be one of the most important pathogens in inflammatory diarrheal cases. The observed risk factors for Campylobacter diarrhea were poor sanitary monitoring and the presence of animals in habituation places.
C1 [Ranjbar, Reza] Baqiyatallah Univ Med Sci, Mol Biol Res Ctr, Tehran, Iran.
   [Babazadeh, Daryoush] Islamic Azad Univ, Tabriz Branch, Young Researchers & Elite Club, Tabriz, Iran.
   [Jonaidi-Jafari, Nematollah] Baqiyatallah Univ Med Sci, Hlth Res Ctr, Tehran, Iran.
RP Babazadeh, D (corresponding author), Islamic Azad Univ, Tabriz Branch, Young Researchers & Elite Club, Tabriz, Iran.
EM Daryoushbabazadeh@gmail.com
RI Babazadeh, Daryoush/H-8472-2019
OI Babazadeh, Daryoush/0000-0003-1118-2295
FU Molecular Biology Research Center, Baqiyatallah University of Medical
   Sciences, Tehran, Iran; Dey laboratory; Imam Reza Hospital; Tabriz
   Children's Hospital; Central Laboratory of East Azerbaijan
FX Present study is sponsored by Molecular Biology Research Center,
   Baqiyatallah University of Medical Sciences, Tehran, Iran, but the
   authors thankful to the Dey laboratory, Imam Reza Hospital, Tabriz
   Children's Hospital and Central Laboratory of East Azerbaijan for their
   support and supplying the instruments, samples and devices. We also give
   thanks to Dr. Veghar Hejazi for her wonderful scientific insights.
CR Al Amri A, 2007, J MED MICROBIOL, V56, P1350, DOI 10.1099/jmm.0.47220-0
   Altekruse SF, 1999, EMERG INFECT DIS, V5, P28, DOI 10.3201/eid0501.990104
   Bae JS, 2014, J NEUROL NEUROSUR PS, V85, P905, DOI 10.1136/jnnp-2013-306212
   Bai J, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00474
   BLASER MJ, 1983, ANN INTERN MED, V98, P360, DOI 10.7326/0003-4819-98-3-360
   BLASER MJ, 1979, ANN INTERN MED, V91, P179, DOI 10.7326/0003-4819-91-2-179
   Chen CC, 2011, WORLD J GASTROENTERO, V17, P4218, DOI 10.3748/wjg.v17.i37.4218
   Choi SW, 1996, J CLIN MICROBIOL, V34, P928, DOI 10.1128/JCM.34.4.928-932.1996
   Debruyne L, 2008, RES MICROBIOL, V159, P88, DOI 10.1016/j.resmic.2007.11.020
   El-Adawy H, 2012, POULTRY SCI, V91, P454, DOI 10.3382/ps.2010-01810
   ENGLEBERG NC, 1984, WESTERN J MED, V141, P53
   Feizabadi MM, 2007, JPN J INFECT DIS, V60, P217
   Fitzgerald C, 2015, CLIN LAB MED, V35, P289, DOI 10.1016/j.cll.2015.03.001
   Friedman C.R., 2000, CAMPYLOBACTER, P121
   Gent R N, 1999, Commun Dis Public Health, V2, P39
   Girgis S. A., 2014, International Journal of Current Microbiology and Applied Sciences, V3, P861
   Guyard-Nicodeme M, 2015, INT J FOOD MICROBIOL, V203, P8, DOI 10.1016/j.ijfoodmicro.2015.02.013
   Harzandi N, 2015, INT J ENTERIC PATHOG, V3
   Irajian GHR, 2008, KOOMESH, V9, P297
   Izadi M, 2014, J TROP MED-US, V2014, DOI 10.1155/2014/405875
   Izadi M, 2012, MICROBIOL IMMUNOL, V56, P836, DOI 10.1111/j.1348-0421.2012.00513.x
   Jonaidi-Jafari N, 2016, FOOD CONTROL, V70, P35, DOI 10.1016/j.foodcont.2016.05.018
   Kaakoush NO, 2015, CLIN MICROBIOL REV, V28, P687, DOI 10.1128/CMR.00006-15
   Kittl S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081796
   Lawson AJ, 1999, J CLIN MICROBIOL, V37, P3860, DOI 10.1128/JCM.37.12.3860-3864.1999
   Levesque S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083731
   Linton D, 1997, J CLIN MICROBIOL, V35, P2568, DOI 10.1128/JCM.35.10.2568-2572.1997
   Mobaien A., 2016, Asian Pacific Journal of Tropical Disease, V6, P957, DOI 10.1016/S2222-1808(16)61164-7
   Norouzi J, 2002, J BABOL U MED SCI, V4, P30
   Oberhelman R. A., 2000, AM SOC MICROBIOL, V2, P139
   On SLW, 2003, J CLIN MICROBIOL, V41, P330, DOI 10.1128/JCM.41.1.330-336.2003
   Pearson A. D., 1992, COMMUN DIS REP CDR R, V2, P133
   Persson S, 2005, J MED MICROBIOL, V54, P1043, DOI 10.1099/jmm.0.46203-0
   Platts-Mills JA, 2014, CURR OPIN INFECT DIS, V27, P444, DOI 10.1097/QCO.0000000000000091
   Ranjbar R, 2007, Pak J Biol Sci, V10, P1138, DOI 10.3923/pjbs.2007.1126.1129
   Ranjbar Reza, 2016, Osong Public Health Res Perspect, V7, P373, DOI 10.1016/j.phrp.2016.10.002
   Ranjbar R, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-016-0163-y
   Ranjbar R, 2014, IRAN J PUBLIC HEALTH, V43, P1657
   Ranjbar R, 2014, NEW MICROBIOL, V37, P1
   Ranjbar R, 2011, ARCH IRAN MED, V14, P339, DOI 0010
   Ranjbar R, 2011, FOODBORNE PATHOG DIS, V8, P547, DOI 10.1089/fpd.2010.0736
   Ranjbar R, 2010, ARCH IRAN MED, V13, P413, DOI 010135/AIM.008
   Rao MR, 2001, AM J EPIDEMIOL, V154, P166, DOI 10.1093/aje/154.2.166
   Rastyani S., 2015, AVICENNA J CLIN MICR, V2, DOI [10.17795/ajcmi-29791, DOI 10.17795/AJCMI-29791]
   Riaz MM, 2012, J PAK MED ASSOC, V62, P20
   Rokosz N, 2014, POSTEP HIG MED DOSW, V68, P48, DOI 10.5604/17322693.1086079
   Shahrokhabadi R., 2013, Zahedan Journal of Research in Medical Sciences, V15, P28
   Sipponen T, 2013, DIGEST DIS, V31, P336, DOI 10.1159/000354689
   Skarp CPA, 2016, CLIN MICROBIOL INFEC, V22, P103, DOI 10.1016/j.cmi.2015.11.019
   SKIRROW MB, 1990, LANCET, V336, P921, DOI 10.1016/0140-6736(90)92282-M
   Strachan NJC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079331
   TAYLOR DN, 1992, CAMPLYLOBACTER JEJUNI, P20
   Wassenaar TM, 2000, APPL ENVIRON MICROB, V66, P1, DOI 10.1128/AEM.66.1.1-9.2000
NR 53
TC 2
Z9 2
U1 0
U2 1
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 901
EP 908
DI 10.19193/0393-6384_2017_1s_134
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000003
DA 2022-07-14
ER

PT J
AU Rinella, S
   Romeo, R
   Di Corrado, D
   Massimino, S
AF Rinella, Sergio
   Romeo, Rossella
   Di Corrado, Donatella
   Massimino, Simona
TI ATTENTIONAL PROCESSES AND AFFECTIVE REGULATION ABILITY OF WOMEN
   PRACTICING HATHA YOGA
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Hatha Yoga; anxiety; stress; attention; age
ID BLOOD LACTATE LEVELS; MOOD STATES; IN-VITRO; STRESS; CELLS; PERFORMANCE;
   EXCITABILITY; PLAYERS; PROFILE; VIVO
AB Introduction: The present study aims to evaluate the attentional processes and affective regulation ability of women practicing Hatha Yoga in comparison with peoples not practicing any physical activity. We hypothesized in the Hatha Yoga practitioners, reduced anxiety and a better tone of mood, superior performances in attentional tasks and, finally, more efficient attentive functions.
   Materials and methods: The research sample includes 26 women, of whom 13 (average age 39.07 years +/- 10.53 SD) practice Hatha Yoga (Yoga group) and 13 (average age 39.23 years +/- 13.45 SD) do not practicing any sport activities (Nsport group). The following psychological assessment tests were used: Profile of Mood States (POMS), State-Trait Anxiety Inventory Form Y (STAI-Y) and Attention And Concentration Test (ACT).
   Results: Yoga group shows better control of internal tension states. None significant differences between the Yoga group and the Nsport group was observed by evaluating the anxiety, although in the Nsport group, State anxiety is associated with a lower sense of perceived energy, while in the Yoga group the State anxiety is related to a decrease of Depression. The Trait anxiety in Nsport group is associated with feelings of tension, fatigue, depression and aggression, with a consequent decrease in mood, whereas in the Yoga group none relationship between Trait anxiety and mood states was detected. Finally, concerning the sense of perceived energy, only the Yoga group showing performance improvement in the Attention and Concentration test.
   Conclusion. The practice of Hatha Yoga can be seen as a factor that can prevent and improve the quality of people's life, and although its effectiveness in treatment is still under investigation, it could be understood as a valid helper of classical treatments.
C1 [Rinella, Sergio; Romeo, Rossella; Massimino, Simona] Univ Catania, Sect Physiol, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Di Corrado, Donatella] Kore Univ, Dept Human & Social Sci, Sch Sport Sci, Enna, Italy.
RP Massimino, S (corresponding author), Univ Catania, Sect Physiol, Dept Biomed & Biotechnol Sci, Catania, Italy.
RI Di Corrado, Donatella/K-3757-2019; Rinella, Sergio/ADM-1130-2022; Di
   Corrado, Donatella/H-3726-2019; Rinella, Sergio/AAB-5946-2021
OI Rinella, Sergio/0000-0002-9368-7088; Di Corrado,
   Donatella/0000-0001-8223-6671; 
CR Borella E, 2013, DETERIORAMENTO COGNI
   Bussing A, 2012, J EVID BASED COMPLEM
   Coco M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002978
   Coco M, 2015, MOL MED REP, V11, P2135, DOI 10.3892/mmr.2014.2898
   Coco M, 2014, SOMATOSENS MOT RES, V31, P35, DOI 10.3109/08990220.2013.834816
   Coco M, 2013, SOMATOSENS MOT RES, V30, P90, DOI 10.3109/08990220.2013.769949
   Coco M, 2011, MOL MED REP, V4, P471, DOI 10.3892/mmr.2011.456
   Coco M, 2009, BRAIN RES, V1302, P205, DOI 10.1016/j.brainres.2009.09.032
   Di Corrado D, 2014, MOL MED REP, V9, P2441, DOI 10.3892/mmr.2014.2115
   Di Nuovo S., 2013, ATTENZIONE CONCENTRA
   Donia M, 2012, ONCOL REP, V28, P682, DOI 10.3892/or.2012.1840
   Eysenck MW, 2007, EMOTION, V7, P336, DOI 10.1037/1528-3542.7.2.336
   Eysenck MW, 2011, PERS INDIV DIFFER, V50, P955, DOI 10.1016/j.paid.2010.08.019
   Fagone P, 2013, J NEUROIMMUNOL, V261, P82, DOI 10.1016/j.jneuroim.2013.04.013
   Fagone P, 2013, BASIC CLIN PHARMACOL, V112, P63, DOI 10.1111/j.1742-7843.2012.00923.x
   Kabat-Zinn J, 1994, WHEREVER YOU GO THER
   Kabat-Zinn J., 2013, FULL CATASTROPHE LIV
   Khalsa SBS, 2009, APPL PSYCHOPHYS BIOF, V34, P279, DOI 10.1007/s10484-009-9103-4
   Kozasa EH, 2012, NEUROIMAGE, V59, P745, DOI 10.1016/j.neuroimage.2011.06.088
   Marchand WR, 2014, WORLD J RADIOL, V6, P471, DOI 10.4329/wjr.v6.i7.471
   McCall Marcy C, 2014, Int J Yoga, V7, P4, DOI 10.4103/0973-6131.123470
   McNair D.M., 1991, PROFILE MOOD STATES
   Michalsen A, 2005, MED SCI MONITOR, V11, pCR555
   Mijatovic S, 2010, FREE RADICAL BIO MED, V48, P1090, DOI 10.1016/j.freeradbiomed.2010.01.026
   Perciavalle V, 2017, NEUROL SCI, V38, P451, DOI 10.1007/s10072-016-2790-8
   Perciavalle V, 2015, NEUROL SCI, V36, P2129, DOI 10.1007/s10072-015-2329-4
   Perciavalle V, 2015, NEUROL SCI, V36, P1597, DOI 10.1007/s10072-015-2210-5
   Perciavalle V, 2014, PERCEPT MOTOR SKILL, V118, P940, DOI 10.2466/19.50.PMS.118k27w8
   Perciavalle V, 2014, PERCEPT MOTOR SKILL, V118, P733, DOI 10.2466/29.30.PMS.118k22w1
   Perciavalle V, 2014, SOMATOSENS MOT RES, V31, P1, DOI 10.3109/08990220.2013.796924
   Perciavalle V, 2013, MOL MED REP, V7, P1733, DOI 10.3892/mmr.2013.1426
   Sethi Jaspal Kaur, 2013, J Educ Health Promot, V2, P55, DOI 10.4103/2277-9531.119043
   Sheela, 2013, Ayu, V34, P270, DOI 10.4103/0974-8520.123117
   Spielberger CD., 1996, MANUAL STATE TRAIT A
   Taneja Davendra Kumar, 2014, Indian J Community Med, V39, P68, DOI 10.4103/0970-0218.132716
   Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104
   Tang YY, 2010, P NATL ACAD SCI USA, V107, P15649, DOI 10.1073/pnas.1011043107
   Yoshihara K, 2014, BIOPSYCHOSOC MED, V8, DOI 10.1186/1751-0759-8-1
   Yoshihara K, 2011, BIOPSYCHOSOC MED, V5, DOI 10.1186/1751-0759-5-6
NR 39
TC 0
Z9 0
U1 1
U2 2
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 6
BP 1067
EP 1072
DI 10.19193/0393-6384_2017_6_169
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FI4NW
UT WOS:000411949500028
DA 2022-07-14
ER

PT J
AU Sadaghiani, S
   Jamhiry, R
   Azad, M
   Mahmoodi, H
   Imani, E
   Nokar, R
AF Sadaghiani, Safa
   Jamhiry, Reza
   Azad, Mohsen
   Mahmoodi, Hamid
   Imani, Elham
   Nokar, Royaheidari
TI THE PSYCHOLOGICAL STRUCTURE OF STUDENTS OF NURSING AND MIDWIFERY IN
   BANDAR ABBAS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE emotional maturity; social maturity; self-esteem; Cattell's personality;
   anxiety; nursing; midwifery; paramedical; students
ID PERSONALITY; STRESS
AB Introduction: There are a lot of quick developments in this high speed world and nursing is also one of those professions which is highly affected by these developments. A vast educational pressure as well as social and economic changes is among those tensions which have influenced all people working in medical professions. To cope with these conditions, psychological factors including personality, social maturity, emotional maturity, anxiety and self-esteem are very effective.
   Methods: This study is descriptive-analytics. 113 students studied in the field of Midwifery and paramedics in the School of Nursing participanted in this study. They completed some questionnaires such as Cattell's Sixteen Factors Personality Inventory, Rao's social maturity scale, Singh and Bhargava's emotional maturity scale, Hamilton's Anxiety Rating Scale, Coopersmith's self-esteem scale and demographicinformation.
   Results: 22 male students (19.5%) and 91 female students (80.5%) participated in this study. 104 participants (92%) were single and 9 participants (8%) were married. The average age of participants was 20.92 years. 16 nursing students (14.2%), 35 evening students of nursing (31%), 15 students of by stop course of nursing (13.3%), 15 bachelor students of anesthesia (13.3%), 15 Operating Room student (13.3%), 17 students of health technology (15%) participated in the study. 40 participants (35.4%) were studying in the second semester and 73 participants (64.6%) were studying in the third semester. The following findings were achieved in this study: There is a significant reverse relationship between the traits of A and B of Cattell'spersonality and anxiety and between the trait of N and social maturity. There was a significant direct relationship between the trait of C and social and emotional maturity and self-esteem and also between the trait of G and self-esteem. There was a significant direct relationship between the trait of O and emotional maturity while this relationship is in reverse between the trait of O and social maturity and self-esteem. There was a significant reverse relationship between the trait of Q3 and emotional maturity while there was a significant direct relationship between the trait of Q3 and social maturity and self-esteem. The trait of Q4 had direct relationship with emotional maturity while it had a significant reverse relationship with social maturity and self-esteem.
   Discussion: This study showed that there was a reverse relationship between the Reserved/Warm and personal anxiety and between concrete thinking/abstract thinking and anxiety. There was also a relatively strong reverse correlation between emotional stability - reactiveness and emotional maturity. There was a direct correlation emotional stability - reactiveness and social maturity and between expedient/rule-conscious and self-esteem. Private/Forthrightand social maturity had a significant reverse correlation with each other. Self-Assured/Apprehensivehada direct relationship with emotional maturity while these traits had a reverse relationship with social maturity and self-esteem. The trait of Tolerates Disorder had a direct relationship with self-esteem. Based on our findings, it can be concluded that social maturity and high self-esteem reduce stress.
C1 [Sadaghiani, Safa] Tehran Univ Med Sci & Hlth Serv, Nursing, Tehran, Iran.
   [Jamhiry, Reza] Hormozgan Univ Med Sci, Nursing & Midwifery Sch, Dept Nursing, Bandar Abbas, Iran.
   [Azad, Mohsen] Hormozgan Univ Med Sci, Paramed Sch, Dept Biostat, Bandar Abbas, Iran.
   [Mahmoodi, Hamid] Hormozgan Univ Med Sci, Paramed Sch, Dept Languages, Bandar Abbas, Iran.
   [Imani, Elham] Hormozgan Univ Med Sci, Nursing & Midwifery Sch, Dept Nursing, Nursing, Bandar Abbas, Iran.
   [Nokar, Royaheidari] Hormozgan Univ Med Sci, Bandar Abbas Hlth Ctr, Social Pathol Majoring Prevent Addict, Bandar Abbas, Iran.
RP Jamhiry, R (corresponding author), Hormozgan Univ Med Sci, Nursing & Midwifery Sch, Dept Nursing, Bandar Abbas, Iran.
EM rezajamhiry@gmail.com
RI Mahmoodi, Hamid/AAH-4003-2021; imani, elham/J-7020-2017; Mahmoodi,
   Hamid/L-9638-2017; Sadaghiani, Safa/U-6922-2017
OI Mahmoodi, Hamid/0000-0002-4138-0463; imani, elham/0000-0003-3957-3343;
   Mahmoodi, Hamid/0000-0001-7567-653X; Azad, Mohsen/0000-0001-5843-1338;
   Sadaghiani, Safa/0000-0001-9216-3090
FU Department of Science and Technology of Hormozgan University of Medical
   Sciences and Health Services
FX The study is conducted by the financial support of the Department of
   Science and Technology of Hormozgan University of Medical Sciences and
   Health Services. We are very grateful to Ms. Ghasemi and MisNakhodaii
   who helped us in different stages of this study. We are thankful to all
   students of the Nursing, Midwifery and paramedics who participated
   widely in the study.
CR Amr A, 2011, PAN AFR MED J, V8
   Beecroft PC, 2006, J ADV NURS, V55, P736, DOI 10.1111/j.1365-2648.2006.03964.x
   Benson JE, 2011, DEV PSYCHOL, V47, P1646, DOI 10.1037/a0023833
   Dante A, 2011, NURS EDUC TODAY, V31, P59, DOI 10.1016/j.nedt.2010.03.016
   GREEN A, 1991, MED EDUC, V25, P343, DOI 10.1111/j.1365-2923.1991.tb00076.x
   Homan H. A. A. G., 2011, PSYCHOL RES, V9, P13
   Honarmand M. M., 2006, J EDUC PSYCHOL, V12, P24
   Hosseini MA, 2007, IRANIAN J MED ED, V7, P137
   Masiak J, 2014, ANN AGR ENV MED, V21, P189
   Moffat KJ, 2004, MED EDUC, V38, P482, DOI 10.1046/j.1365-2929.2004.01814.x
   Mozes T, 2005, J CHILD ADOL PSYCHOP, V15, P259, DOI 10.1089/cap.2005.15.259
   Nadi A., 2009, J APPL PSYCHOL, V3, P48
   Reynolds BM, 2011, J YOUTH ADOLESCENCE, V40, P1407, DOI 10.1007/s10964-010-9619-1
NR 13
TC 0
Z9 0
U1 0
U2 5
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
SI 1
BP 931
EP 934
DI 10.19193/0393-6384_2017_1s_139
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FV8ZR
UT WOS:000424877000008
DA 2022-07-14
ER

PT J
AU Sahin, L
   Sarihan, ME
   Parlakpinar, H
   Polat, A
   Vardi, N
AF Sahin, Levent
   Sarihan, M. Ediz
   Parlakpinar, Hakan
   Polat, Alaadin
   Vardi, Nigar
TI THE EFFECTS OF VINPOCETINE ON THE PREVENTION AND TREATMENT OF THE
   ISCHEMIA/REPERFUSION INJURY: AN EXPERIMENTAL STUDY
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Animal study; kidney; rat; reperfusion injury; vinpocetine
ID ISCHEMIA-REPERFUSION INJURY; ACUTE-RENAL-FAILURE; OXIDATIVE STRESS; RAT
   MODEL; PATHOPHYSIOLOGY; ACID
AB Object: Histopathological and biochemical effects of vinpocetine, which is an anti-inflammatory and antioxidant agent, on ischemia / reperfusion (I/R) injury were studied in an animal model.
   Material and methods: Forty Sprague Dawley rats were divided into five groups. Group1 underwent only a right nephrectomy. Group 2 was administrated vinpocetine after right nephrectomy. Group 3 initially underwent a right nephrectomy. Them, left kidney of this group was applied ischemia for 60 minutes, which was followed by reperfusion for 24 hours. Group 4 underwent same steps as group 3; but was administrated vinpocetine 10 mg/kg i.p. before I/R to the left kidney. Similarly, group 5 underwent same steps as group 3 but was administrated vinpocetine 10 mg/kg i.p. after I/R to the left kidney.
   Results: Plasma BUN and creatinine showed no significant differences between control ( Sham) group and groups that were administrated vinpocetine. Decrease in plasma urea and creatinine was detected group 5, but this finding was not present in group 4. Superoxide dismutase and glutathione reductase levels in groups 4 and 5 were significantly higher than the group 3. Parallel to this, oxidative stress index was higher in the group 3compared to groups 2, 4, and 5 (p<0.05). No significant difference was found between levels of malondialdehite in sham and vinpocetine administrated only group (p<0.005). All groups showed no differences in catalase levels and Total Antioxidant Capacity. Decreased tubular injury was present in the groups administrated vinpocetine before and after I/R. In control and vinpocetine given groups, there were some apoptosis in tubules after tested with caspase 3. Caspase 3 positivity was significantly higher in I/R group compared to control group. Vinpocetine if given after I/R was more effective to prevent apoptosis then to be administrated before I/R.
   Conclusion: This experimental study showed that vinpocetine promotes achieving better renal functions. The results of this study suggest that vinpocetine may be used in the treatment of renal I/R
C1 [Sahin, Levent; Sarihan, M. Ediz] Inonu Univ, Med Fac, Dept Emergency Med, Malatya, Turkey.
   [Parlakpinar, Hakan] Inonu Univ, Med Fac, Dept Med Pharmacol, Malatya, Turkey.
   [Polat, Alaadin] Inonu Univ, Med Fac, Dept Physiol, Malatya, Turkey.
   [Vardi, Nigar] Inonu Univ, Med Fac, Dept Histol & Embryol, Malatya, Turkey.
RP Sarihan, ME (corresponding author), Inonu Univ, Med Fac, Dept Emergency Med, Malatya, Turkey.
RI Sahin, Levent/AAR-9222-2021; Polat, Alaadin/Q-4052-2018; Parlakpınar,
   Hakan/T-6517-2018; Parlakpinar, Hakan/V-6637-2019; Polat,
   Alaadin/AAA-7171-2021; vardı, nigar/C-9549-2018
OI Sahin, Levent/0000-0003-0193-4393; Polat, Alaadin/0000-0002-6920-3856;
   Parlakpınar, Hakan/0000-0001-9497-3468; Parlakpinar,
   Hakan/0000-0001-9497-3468; Polat, Alaadin/0000-0002-6920-3856; vardı,
   nigar/0000-0003-0576-1696
CR [Anonymous], 2015, BAZI SALVIA TURLERIN
   ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.bi.59.070190.004031
   Bonventre JV, 2004, KIDNEY INT, V66, P480, DOI 10.1111/j.1523-1755.2004.761_2.x
   Bozkurt Y, 2012, KAFKAS UNIV VET FAK, V18, P823
   Cakar N, 2010, TURK YOGUN BAKIM D S, V8, P1
   Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6
   Chukanova EI, 2010, ZH NEVROL PSIKHIATR, V110, P49
   Collard CD, 2001, ANESTHESIOLOGY, V94, P1133, DOI 10.1097/00000542-200106000-00030
   Cotran R, 1994, NOBEL TIP KITABEVLER, V1, P3
   Heyman Samuel N, 2002, Curr Opin Crit Care, V8, P526, DOI 10.1097/00075198-200212000-00008
   Kalman S, 2002, J TURK SOCNEPHROL, V11, P140
   Lameire N, 2005, LANCET, V365, P417
   Nyakas C, 2009, CNS NEUROSCI THER, V15, P89, DOI 10.1111/j.1755-5949.2009.00078.x
   Ozkan G, 2012, KIDNEY BLOOD PRESS R, V35, P445, DOI 10.1159/000337926
   PALLER MS, 1994, J INVEST MED, V42, P632
   Sheridan AM, 2001, CONTRIB NEPHROL, V132, P7
   SIES H, 1991, AM J MED, V91, pS31, DOI 10.1016/0002-9343(91)90281-2
   Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207
   UDASSIN R, 1994, J SURG RES, V56, P221, DOI 10.1006/jsre.1994.1035
   Walker LM, 2001, TOXICOL SCI, V63, P143, DOI 10.1093/toxsci/63.1.143
   Welbourn CR, 2004, BRIT J SURG, V10, P160
   WELBOURN CRB, 1991, BRIT J SURG, V78, P651, DOI 10.1002/bjs.1800780607
   Yamamoto S, 2011, AM J NEPHROL, V33, P485, DOI 10.1159/000327820
   Yildiz F, 2010, RENAL FAILURE, V32, P126, DOI 10.3109/08860220903367577
   Yun Y, 2009, TRANSPL P, V41, P3597, DOI 10.1016/j.transproceed.2009.06.203
NR 25
TC 2
Z9 2
U1 0
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 5
BP 857
EP 862
DI 10.19193/0393-6384_2017_5_127
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FA9PC
UT WOS:000405777000021
DA 2022-07-14
ER

PT J
AU Sahin, N
   Yazgan, P
   Karahan, AY
   Bardak, A
   Gur, A
   Aksac, B
AF Sahin, Nilay
   Yazgan, Pelin
   Karahan, Ali Yavuz
   Bardak, Aysenur G.
   Gur, Ali
   Aksac, Buket
TI DEMOGRAPHIC AND CLINICAL CHARACTERISTICS AND FUNCTIONAL STATUS OF
   PATIENTS WITH BENIGN JOINT HYPERMOBILITY SYNDROME
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE hypermobility; pain; musculoskeletal; functional status; fibromyalgia
ID DANLOS-SYNDROME; FIBROMYALGIA; PAIN; PROPRIOCEPTION; DIAGNOSIS;
   DISTRESS; MOBILITY; CRITERIA
AB Aims: This study aimed to compare the demographic, clinical features, and psychosocial status of patients with benign joint hypermobility syndrome (BJHS) and those without BJHS who have musculoskeletal pain.
   Methods: Patients referred to the Physical Therapy and Rehabilitation outpatient clinic due to musculoskeletal system pain were divided into two groups according to the Brighton diagnostic criteria as BJHS and non-BJHS. The demographic characteristics of the patients in both groups, clinical findings with physical examination, anamnesis, physical examination, myofascial pain syndrome (MPS) or fibromyalgia syndrome (FMS) presence, pain severity with visual pain scale (VAS), Short Form-36 Health Survey (SF-36), and depression status assessed by the Beck Depression Index (BDI) were recorded.
   Results: The number of painful involvement sites was significantly higher in the BJHS group than in the control group (p< 0.000). The VAS during exercise and at rest were statistically significantly higher in the BJHS group (p< 0.000). The incidence of MPS (p< 0.000) and FMS (p=0.040) was statistically higher in the BJHS group. No statistically significant difference was found in the BDI between the groups (p=0.179). In terms of function status assessment, the BJHS group had statistically significantly lower subparameters of Short Form-36, including pain, overall health, energy, and social activities, than the control group (p=0.011, p=0.001, p=0.027, and p=0.043, respectively).
   Conclusions: Subjects with BJHS had more overlapping clinical features such as FMS and MPS with more severe and diffuse pain when compared to non-BJHS subjects. But there are no significantly differences in psychosocial status. These points should be considered when designing interventions for improving the functional status of BJHS subjects.
C1 [Sahin, Nilay] Balikesir Univ, Fac Med, Phys Med & Rehabil Dept, Balikesir, Turkey.
   [Yazgan, Pelin] Harran Univ, Phys Med & Rehabil Dept, Fac Med, Sanliurfa, Turkey.
   [Karahan, Ali Yavuz] Konya Training & Res Hosp, Phys Med & Rehabil Dept, Konya, Turkey.
   [Bardak, Aysenur G.] Phys Med & Rehabil Educ & Res Hosp, Phys Med & Rehabil Dept, Istanbul, Turkey.
   [Gur, Ali] Gaziantep Univ, Fac Med, Phys Med & Rehabil Dept, Gaziantep, Turkey.
   [Aksac, Buket] Gebze Cent Hosp, Phys Med & Rehabil Dept, Istanbul, Turkey.
RP Karahan, AY (corresponding author), State Hosp Konya, Phys Med & Rehabil Dept, Konya, Turkey.
RI karahan, ali yavuz/E-4481-2017; Gür, Ali/AAG-3242-2020
OI karahan, ali yavuz/0000-0001-8142-913X; Gür, Ali/0000-0001-9680-6268
CR Bates AV, 2015, GAIT POSTURE
   Beighton P, 2012, HYPERMOBILITY OF JOINTS, FOURTH EDITION, P1, DOI 10.1007/978-1-84882-085-2
   Birtane M, 2007, CLIN RHEUMATOL, V26, P679, DOI 10.1007/s10067-006-0359-2
   Boonstra AM, 2008, INT J REHABIL RES, V31, P165, DOI 10.1097/MRR.0b013e3282fc0f93
   BULBENA A, 1993, PSYCHIAT RES, V46, P59, DOI 10.1016/0165-1781(93)90008-5
   Cassisi G, 2014, REUMATISMO, V66, P72, DOI 10.4081/reumatismo.2014.767
   Castori M, 2011, CLIN EXP RHEUMATOL, V29, P998
   Castori M, 2013, AM J MED GENET A, V161, P2989, DOI 10.1002/ajmg.a.36315
   Dequeker J, 2001, ANN RHEUM DIS, V60, P894
   Everman D B, 1998, Pediatr Rev, V19, P111, DOI 10.1542/pir.19-4-111
   Fatoye FA, 2008, MUSCULOSKELET CARE, V6, P108, DOI 10.1002/msc.127
   Garcia-Campayo J, 2011, CURR PSYCHIAT REP, V13, P18, DOI 10.1007/s11920-010-0164-0
   Grahame R, 2000, J RHEUMATOL, V27, P1777
   Grahame R, 2000, JOINT BONE SPINE, V67, P157
   Grahame R, 2000, INT J CLIN PRACT, V54, P314
   Hakim A, 2003, BEST PRACT RES CL RH, V17, P989, DOI 10.1016/j.berh.2003.08.001
   Hisli N., 1989, J PSYCHOL, V7, P3
   Hudson N, 1995, BRIT J RHEUMATOL, V34, P1157
   Karaaslan Y, 2000, J RHEUMATOL, V27, P1774
   McGeary Donald D, 2003, Spine J, V3, P197, DOI 10.1016/S1529-9430(02)00599-5
   Memis A., 1995, J DRUG THER, V12, P102
   Pacey V, 2014, J PAEDIAT CHILD HLTH
   Pacey V, 2015, J PAEDIAT CHILD HLTH
   Qvindesland A, 1999, RHEUMATOLOGY, V38, P1014, DOI 10.1093/rheumatology/38.10.1014
   Remvig L, 2007, J RHEUMATOL, V34, P804
   Russek LN, 1999, PHYS THER, V79, P591, DOI 10.1093/ptj/79.6.591
   Sanches SHB, 2012, REV BRAS PSIQUIATR, V34, pS53, DOI 10.1590/S1516-44462012000500005
   SILVERMAN S, 1975, ANN RHEUM DIS, V34, P177, DOI 10.1136/ard.34.2.177
   Simpson MAJMR, 2006, J AM OSTEOPATH ASSOC, V106, P531
   Slmmonds JV, 2007, MANUAL THER, V12, P298, DOI 10.1016/j.math.2007.05.001
   Smith TO, 2014, DISABIL REHABIL, V36, P797, DOI 10.3109/09638288.2013.819388
   Smith TO, 2014, RHEUMATOLOGY, V53, P114, DOI 10.1093/rheumatology/ket317
   Smith TO, 2013, RHEUMATOL INT, V33, P2709, DOI 10.1007/s00296-013-2790-4
   TRAVELL J, 1992, MYOFASCIAL PAIN DYSF
   Yaylaci ET, 2014, J CLIN ANAL MED, V5, P221, DOI 10.4328/JCAM.2400
NR 35
TC 1
Z9 1
U1 2
U2 10
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2017
VL 33
IS 2
BP 245
EP 251
DI 10.19193/0393-6384_2017_2_036
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EP2RK
UT WOS:000397230700011
DA 2022-07-14
ER

EF